<DOC>
<DOCNO>WT18-B31-1</DOCNO>
<DOCOLDNO>IA027-000290-B041-171</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/index.html 143.131.194.4 19970114043931 text/html 3318
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:43:39 GMT
Last-modified: Wednesday, 08-Jan-97 22:12:50 GMT
Content-length: 3126
Content-type: text/html
</DOCHDR>
<html><head><title>Dow Jones BIS</title></head><BODY Background="images/lrgbkgd.jpg" TEXT="#ffffff" LINK="#99F300"VLINK="#99F300" ALINK="#ffffff" BGCOLOR="#000000">	<nobr>					<IMG BORDER=0 ALIGN=left SRC="images/mane2.gif">			<IMG WIDTH=338 HEIGHT=137 BORDER=0 SRC="images/djbis3.gif"></nobr><BR CLEAR="ALL"><HR SIZE=8><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=15 WIDTH=600><TR><TD  valign="top" WIDTH=200><P><FONT SIZE=+1>Each day, Dow Jones provides millions of business professionals withaccess to the accurate, in-depth information they need to stay aware and ahead ofthe competition.<p>You, too, can put the power of Dow Jones behind your business decisions. To findout how, just click on an area of interest.</FONT>		<p></TD> <TD VALIGN=TOP WIDTH=200>		<a href="bizpubs/wsj-interactive.html"> <IMG WIDTH=28 HEIGHT=28 BORDER=0		SRC="images/biz.jpg" align="left"></a><BR CLEAR=LEFT>		<a href="bizpubs/wsj-interactive.html">		<font size=4>Continually Updated Business News Publication</font></a><br>The daily electronic newspaper from Dow Jones andThe Wall Street Journal&#174;.		<FONT SIZE=2><UL><LI><a href="bizpubs/wsj-interactive.html">The Wall Street Journal<br> Interactive Edition&#174;</a></UL></FONT>		<HR>								<a href="clipping/index.html"> <IMG WIDTH=28 HEIGHT=28 BORDER=0		SRC="images/cclps.jpg"  align="left"></a><BR CLEAR=LEFT>				<a href="clipping/index.html">		<font size=4>Clipping, Tracking & Alert Services</font></a><br>		Services that help you stay on top of topics that matter to you 		and your enterprise. 		<FONT SIZE=2><UL><LI> <a href="dowvision/index.html"><I>All-new</I> DowVision&#174; <BR>from Dow Jones</a><LI> <a href="clipping/dowvision/index.html">DowVision&#174;</a><LI><a href="clipping/custom-clips/index.html">Dow Jones CustomClips&#174;</a></UL></FONT><HR>	<br><a href="http://www.dowjones.com">		<font size=4>Other Dow Jones Sites</font></a>  </TD><TD VALIGN=TOP WIDTH=200>					<a href="online-lib/index.html"> <IMG WIDTH=28 HEIGHT=28 BORDER=0		SRC="images/on-lin.jpg" align="left"></a><BR CLEAR=LEFT>				<a href="online-lib/index.html">		<font size=4>Online Research Service</font></a>		<BR> 		Fast answers to tough questions.		<FONT SIZE=2><UL><LI><a href="online-lib/index.html">Dow Jones News/Retrieval&#174;</a></UL></FONT><HR>					<a href="pie/private.html"> <IMG WIDTH=28 HEIGHT=28BORDER=0 SRC="images/perfin.jpg"  align="left"></a><BR CLEAR=LEFT>				<a href="pie/private.html">		<font size=4>Personal Finance & Investing</font></a> 		<BR>		Products and services that help you better manage your own finances.		<FONT SIZE=2><UL><LI> <a href="pie/index.html"><I>All-new</I> Dow Jones News/Retrieval: <BR>Private Investor Edition&#174;</a></UL></FONT><HR>			<a href="latest.html"> <IMG WIDTH=28 HEIGHT=28 BORDER=0SRC="images/djs.jpg"  align="left"></a><BR CLEAR=LEFT>				<a href="latest.html">		<font size=4>What's Going On at BIS</font></a> 		<BR> The latest developments at Dow Jones Business Information Services.</td></tr></table>							</body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-2</DOCNO>
<DOCOLDNO>IA027-000290-B040-146</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/bizpubs/wsj-interactive.html 143.131.194.4 19970114043357 text/html 5493
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:38:03 GMT
Last-modified: Thursday, 01-Aug-96 17:56:16 GMT
Content-length: 5302
Content-type: text/html
</DOCHDR>
<html>
<head>
    <title>Wall Street Journal Interactive Edition</title>
</head> 

<body bgcolor="#ffffff" background="images/bgdbiz.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
    <td width=80 valign=top>
        <img SRC="../images/trsp.gif">  
        <A HREF="index.html">
        <IMG valign=top  WIDTH=65 HEIGHT=65 BORDER=0 SRC="images/lrgconbiz.gif"></A>
    </td>
<td>
<BR>
		
		<P>
		
		
<CENTER>
<p>
<IMG WIDTH=281 HEIGHT=57 BORDER=0 SRC="images/interact.gif">

		<P>
		
		
		
		<b>
		The Leading Source of Continually Updated Business News on the Web,
		<br>
		from <EM>The Wall Street Journal&#174;</EM></b>


<HR SIZE=4></center>
<p>
<blockquote>



		 
		<p>
		 You're just one <a href="http://wsj.com">mouse click away</a>
		from the continually updated, interactive edition of the world's most trusted
		newspaper, <EM>The Wall Street Journal<font size=2>&#174;</FONT></EM>.


<p>
<center>
<a href="http://wsj.com/tour.htm"><img src="../images/tour.gif" border=0></a>
</center>

<b>What Is It?</b>
<br>
		<EM>The Wall Street Journal<font size=2>&#174;</FONT></EM> Interactive
		Edition provides you with the
		entire spectrum of business coverage provided by its print counterpart. You'll
		see not only the pioneering, continually updated coverage of world markets, but
		all the most important stories in technology, marketing, the law -- even sports,
		weather, an expanded presentation of the Journal's<font size=2>&#174;</FONT>
		editorial-page features and additional coverage from the Asian and European
		editions of the newspaper.
		

<p>


		With its clean layout and newspaper-like structure, the Interactive
		Edition will make it easy to find what you're looking for and to dig deeper for
		additional information and insight as required. You'll also find features that
		will make the Interactive Edition even more useful and convenient, such as its
		own version of Personal Journal<font size=2>&#174;</FONT>, which enables you to
		create your own personalized view of today's news plus the ability to build and
		monitor your own personal stock portfolio.

<p>		
<HR SIZE=3>



		<b>Key Features of <EM>The Wall Street Journal<font size=2>&#174;</FONT></EM>&nbsp;
		Interactive Edition</b>
		<br>
		<br>
		<B>* A Commitment to Quality News:</b> A full-time staff of more
		than 30 are dedicated to The Journal's<font size=2>&#174;</FONT> interactive
		publishing efforts. 
		
		<p>
		
		<b>* Constant Updates:</b> Regular updates throughout the day and
		night, seven days a week -- unlike many other online newspapers, where updates,
		if any, are pulled unedited from wire services.

		<p> 
		
		<b>* In-Depth Data:</b> The Interactive Edition offers the
		popular Briefing Books, which are
		comprehensive background reports on any of nearly 9,000 companies, available at a
		click any time a company is mentioned in a story, or any time a reader needs
		background on a company of interest. Interactive Edition editors also frequently
		post background stories or packages on stories in the news. What's more, a
		complete archive of the past 14 days of stories published in the Journal<font
		size=2>&#174;</FONT> is available.

		<p>
		
		
		<b>* Global Reach:</b> The Interactive Edition is a true global product, with
		uniform content and pricing throughout the world. It includes coverage of
		international business and markets that exceeds news generally available in the
		U.S. newsprint Journal.
		
		<p>


		
		<b>* Personalization and Efficiency:</b> Using a "Personal Journal<font
		size=2>&#174;</FONT>" section, readers can create a profile based on their own
		investments, industries, or companies of interest, and have quick access to the
		latest pertinent news and stock quotes anytime, day or night.

<p>
<HR SIZE=3>

		<b>Try it FREE</b>

	<br>


		<a href="http://wsj.com"> Visit our site</a> today and register as a
		subscriber to the Interactive Edition. Your first two weeks are free and you can cancel during that time if you're not completely satisfied and pay nothing.

	<p>

		Companies can also <a href="http://info.wsj.com/mediakit/">learn more about advertising</a> in the Interactive Edition.
<p>


<center>
<table width=60% border=5 cellpadding=10>
		<tr>
		<td>
		
		<center>See what the <a href="wsj-pressquote.html"><b>press</b></a> is saying about<BR> 
		The Wall Street Journal Interactive Edition. </center>
</td>
		</tr>
		</table></center>
<p>
				
					<br>

<b>How much will the Interactive Edition cost?</b>
<br>
 $49 a year or $29 a year if you're a subscriber to any print edition of The Wall Street Journal.
<P>




</blockquote>

									<CENTER>
								
<br>
				
				<a href="../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../bizpubs/index.html">Newspapers</a> |
					<a href="../clipping/index.html">Alert Services</a> |
					<a href="../online-lib/index.html">Research</a>   |
					<a href="../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../index.html">Home</a> 

				</font>
				
				
				
				</center>
				


</TD></TR>
    
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-3</DOCNO>
<DOCOLDNO>IA027-000290-B040-182</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/index.html 143.131.194.4 19970114043425 text/html 2699
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:38:32 GMT
Last-modified: Friday, 25-Oct-96 20:34:04 GMT
Content-length: 2510
Content-type: text/html
</DOCHDR>
<html><head><title>Dow Jones BIS Clipping Services</title></head><body background="images/bgdcc.gif"><p><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  <a href="index.html"><IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="images/lrgcosclip.gif"></a></td><td><p><p><CENTER><H2><FONT SIZE=+3>C</FONT>LIPPING,<FONT SIZE=+3>T</FONT>RACKING<FONT SIZE=+3>& A</FONT>LERT<FONT SIZE=+3>S</FONT>ERVICES</H2><P><HR SIZE=4></CENTER><blopckquote><ul>We offer the only place you can get the combination of the most respected business news and information on the people, companies, and topicsyou prefer, delivered direct to your desktop. 		<p>Dow Jones offers two completely customizable news services designed to fit the needs of youand your organization. 		<p>		  <a href="../dowvision/index.html"><I>All-new</I> DowVision&#174; from Dow Jones</a><BR>Your one source for the most authoritative news of the day, over the World Wide Web		<br>			<p>		  <a href="dowvision/index.html">DowVision&#174;</a>				<BR>Most popular direct-to-the-desktop news service<br>A constant stream of unparalleled business news, including the exclusive full textaccess to the combination of <em>The Wall Street Journal</em><font size=2>&#174;</FONT>, <em>The New York Times</em>, the <em>Los Angeles Times</em>, <em>The Washington Post</em>, and the <em>Financial Times</em>. 			<br>			<p>			 <a href="custom-clips/index.html">Dow Jones CustomClips&#174;</a>				<BR>Your industry expert<br>Automatically scans of thousands of industry publications and clips thespecific topics that interest you the most.  Information is targeted,in-depth, and--coupled with DowVision<font size=2>&#174;</FONT>--provides the complete enterprise newsservice.		<P></blockquote>		<pre></pre> 								<center>								<a href="../toolbar.gif.map">								<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>					<BR>									<font size=2>					<a href="../bizpubs/index.html">Newspapers</a> |					<a href="../clipping/index.html">Alert Services</a> |					<a href="../online-lib/index.html">Research</a>   |					<a href="../pers-finance/index.html">Personal Finance</a>  |  					<a href="../latest.html">DJ In The News</a>  |					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |					<a href="../index.html">Home</a> 				</font>								</center>				</TD></tr></TABLE></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-4</DOCNO>
<DOCOLDNO>IA027-000290-B040-204</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/dowvision/index.html 143.131.194.4 19970114043438 text/html 1942
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:38:48 GMT
Last-modified: Wednesday, 30-Oct-96 21:54:07 GMT
Content-length: 1750
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE> DowVision From Dow Jones </TITLE></HEAD><BODY BGCOLOR=#FFFFFF FONT=4><CENTER><IMG SRC="IMAGES/header.gif"></CENTER><P><B>DowVision</B>, the most popular direct-to-the-desktop news service,* will soon be accessible via a browser and a connection to the Internet. Businesspeople can stay informed about customers, the competition and suppliers with the most respected news source available anywhere, featuring <I>The Wall Street Journal<font size=2>&#174;</font>, The New York Times, The Washington Post, Los Angeles Times, the Dow Jones News Service</I>, and many other newswires.<hr><H1><FONT COLOR=#800000><CENTER>Here's a Quick Tour:</CENTER></FONT></H1><br><H2><FONT COLOR=#800000><CENTER>The DowVision Home Page</CENTER></FONT></H2><img src="IMAGES/home.gif" border=0 align=center><P><P><HR><H2><FONT COLOR=#800000><CENTER>All Stories From The Top Newspapers</FONT></H2><P><img src="IMAGES/topnews.gif"></center><P><P><HR><H2><FONT COLOR=#800000><CENTER>All News Items Are Available In Full Text</FONT></H2><P><img src="IMAGES/story.gif"></CENTER><P><CENTER><H3>For more information, contact your <a href="wwsales.html">local Dow Jones representative</a>.</H3></CENTER><CENTER><H4><a href="../index.html">Back to the Dow Jones Business Information Services <BR>Home Page.</a></H4></CENTER><Pre></Pre><FONT SIZE=1>*Online Services 1995 Review Trends & Forecast, Simba Information, Inc. Wilton, CT.  **All quotations are delayed 20 minutes.  &#169 1996 Dow Jones & Company, Inc.  All rights reserved.  DowVision, The Wall Street Journal and Dow Jones News Service are marks of Dow Jones & Company, Inc. All other products mentioned are the marks of their respective owners.</FONT></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-5</DOCNO>
<DOCOLDNO>IA027-000290-B040-237</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/dowvision/index.html 143.131.194.4 19970114043459 text/html 5520
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:38:59 GMT
Last-modified: Monday, 28-Oct-96 19:16:40 GMT
Content-length: 5331
Content-type: text/html
</DOCHDR>
<html><head><title>DowVision</title></head><body bgcolor="#ffffff" background="../images/bgdcc.gif">	<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><td width=80 valign=top ><img SRC="../../images/trsp.gif">  <a href="../index.html"><IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/lrgcosclip.gif"></a></td><td><BR><CENTER><IMG WIDTH=250 HEIGHT=40 BORDER=0 SRC="images/dowvision.gif"><p><b>The most popular direct-to-the-desktop news service, delivered continuallyto every desktop on your enterprise network.</b> <br><a href="dowtour.html"><img src="../../images/tour.gif" border=0></a>	</CENTER><p><HR SIZE=4><ul><P><B>Imagine This...</B><P>				<li>There's big news about your company, or a competitor, or just about any important topic.  		<BR>		<li>Minutes after the news hits the wires, it's automatically sent to the desktop of key 		decision-makers in your organization.  		<BR>		<li>Imagine this happens every day, all day long.		<BR>		<li>Imagine your competitive advantage.  		<BR>		<li>Imagine how much more confident you will be with your decisions.		<P>It's here.  It's DowVision<font size=2>&#174;</font>.<P><HR SIZE=3><a href="../../dowvision/index.html"><img src=images/dvdjtile.gif height=120 width=100 border=0 align=left></a><BR><BR>Experience the <I>all-new</I><B> DowVision<font size=2>&#174;</font> from Dow Jones</B>. Your one source for the most authoritative news of the day, over the World Wide Web. <BR><a href="../../dowvision/index.html">Click here to take a tour</A>.<BR CLEAR="ALL">	<P><HR SIZE=3>	<B>Here's How DowVision<font size=2>&#174;</font> Works...</B>	<br>	You complete a news profile.  Indicate the companies, topics, and people	that you need to track. 			<P>	DowVision<font size=2>&#174;</font> broadcasts <a href="sources.html">the most respected sources</a>, 	including the day's <EM>Wall Street Journal&#174;, 	The New York Times</EM>,&nbsp;<EM>The Washington Post,</EM> the <EM>Los Angeles Times</EM> and <EM>Financial Times</EM>&nbsp;and 10 newswires to yourcorporate file server.  When the news you requested is found, it's instantlydelivered to your desktop.		<P>		And because your local DowVision<font size=2>&#174;</font> server stores up to six months of your DowVision<font size=2>&#174;</font> information,	you have a running bank of news from which to draw data for your meetings, reports, research and	analysis.		<P>		<BR>	<HR SIZE=3>			<b>DowVision<font size=2>&#174;</font> works within your budget</b>, offering flexible pricing plans. 	Your <a href="contact.html"> 	Dow Jones representative</a> can give you specific pricing information. For a list of sales offices, <a href="../../bissales.html">click here</a>.			<P>		With DowVision<font size=2>&#174;</font>, your company can be acting on news while your competition	is still searching for it. 		<P>		Together with <a href="../custom-clips/index.html">Dow Jones CustomClips&#174;</a>,	DowVision<font size=2>&#174;</font> is the complete enterprise news service. 	<BR>		<P><HR SIZE=3>		<B>DowVision<font size=2>&#174;</font> works for you.</B>It operates in virtually any enterprise environment, including Windows, DOS, Macintosh&#174;, OS/2&#174;, UNIX, Lotus 	Notes&#174; and Web-based platforms.	<P>		<HR SIZE=3>			<B>How will DowVision<font size=2>&#174;</font> put you in the know?</B>		<BR>		Click on your area to see an example:		<BR>		<a href="sales.html">Sales/Marketing</a>		<BR>				<a href="advertising.html">Public Relations/Investor Relations</a>		<BR>				<a href="executive.html">Executive Management</a>		<BR>			<a href="mergers.html">Strategic Planning/Mergers & Acquisitions</a>		<BR>				<a href="intelligence.html">Competitive Intelligence</a>		<BR>				<a href="mis.html">MIS</a>		<BR>				<a href="librarian.html">Information Center/Corporate Library</a>		<br>	 			<a href="accountant.html">Tax</a>		<BR>				<HR SIZE=3>		<B>Convinced?  Want more information?</B>  <a href="contact.html">Take the next step</a> and give us a 	little information about yourself and a Dow Jones representative will call 	to set up an appointment. 	<P>	<center>		<table width=50% border=5 cellpadding=10>		<tr>		<td>			See what <a href="dv-cust-quote.html"><b>			 customers</b></a> are saying about DowVision<font size=2>&#174;</font>.			<P>						See what the <a href="dv-press-quote.html"><b>			press</b></a> is saying about DowVision<font size=2>&#174;</font>.			 		</td>		</tr>		</table></center>							<BR>					</ul>					<pre>									</pre>							<center>			<br>				<a href="../../toolbar.gif.map">								<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>					<BR>									<font size=2>					<a href="../../bizpubs/index.html">Newspapers</a> |					<a href="../../clipping/index.html">Alert Services</a> |					<a href="../../online-lib/index.html">Research</a>   |					<a href="../../pers-finance/index.html">Personal Finance</a>  |  					<a href="../../latest.html">DJ In The News</a>  |					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |					<a href="../../index.html">Home</a> 				</font>								</center>				</TD></tr></TABLE></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-6</DOCNO>
<DOCOLDNO>IA027-000290-B040-267</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/custom-clips/index.html 143.131.194.4 19970114043556 text/html 4236
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:39:54 GMT
Last-modified: Wednesday, 09-Oct-96 15:05:03 GMT
Content-length: 4044
Content-type: text/html
</DOCHDR>
<html><head><title>Dow Jones Custom Clips</title></head><body bgcolor="#ffffff" background="../images/bgdcc.gif">	<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><td width=80 valign=top ><img SRC="../../images/trsp.gif">  <a href="../index.html"><IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/lrgcosclip.gif"></a></td><td><p>														<BR>		<CENTER>								<IMG BORDER=0 SRC="images/newcustclips.gif"><br>		<B>		Delivers the power of thousands of trade and industry publications <br>to your desktop.</B><br><A HREF="cctour.html"><IMG SRC="/images/tour.gif"  ALIGN=TOP border=0></a>		</CENTER><HR SIZE=4><br><BLOCKQUOTE> <P> <BR>Wouldn't it be great if you had an industry expert on hand at all times? Someone with the sole responsibility of tracking information on your industry as well as those industries that have an impact on you or your business.  <P><b>Let Dow Jones CustomClips<font size=3>&#174;</FONT> be this expert.</b><P><BR>Dow Jones CustomClips<font size=3>&#174;</FONT> scans over 1,600 trade and industry <a href="publications/publications.html">publications</a> for the news on the industries and topics most important to you.  That news is then delivered to your desktop, or to many desktops within your company, via e-mail or groupware, such as Lotus Notes&#174;. We take care of all the details! <P><HR SIZE=3>Thousands of people and corporations use Dow Jones CustomClips<font size=3>&#174;</FONT> to stay in touch with the news that affects their industry. <p><b>It's simple and easy to use!</b><BR>We work with you to set up customized topics of the news, industries, and subjects you wish to track -- it only takes a few minutes.  Articles are then automatically delivered several times a day.<P>There's affordable, flat-fee pricing for corporations. Plus, there are discounts for multiple "topics." Your <A HREF="contact.html">Dow Jones representative</A> can give you more details. For a list of sales offices, <a href="../../bissales.html">click here</a>. <P>Together with <ahref="../dowvision/index.html">DowVision&#174;</a>,Dow Jones offers a complete portfolio of enterprise news. <BR><P><P>Want more information?  <a href="contact.html">Take the next step</a> and give us a little information about yourself and a <a href="../../bissales.html">Dow Jones representative</a> will call to set up an appointment.  <P><HR SIZE=3>		<B>How would you use Dow Jones CustomClips<font size=3>&#174;</FONT>?</B>		<BR>		Click on your profession and learn how:		<BR>		<a href="sales.html">Sales/Marketing</a>		<BR>				<a href="advertising.html">Public Relations/Investor Relations</a>		<BR>				<a href="executive.html">Executive Management</a>		<BR>			<a href="mergers.html">Strategic Planning/Mergers & Acquisitions</a>		<BR>				<a href="intelligence.html">Competitive Intelligence</a>		<BR>				<a href="mis.html">MIS</a>		<BR>				<a href="librarian.html">Information Center/Corporate Library</a>		<br>	 			<a href="accountant.html">Tax</a>		<BR>				</BLOCKQUOTE><BR>		<center>		<table width=50% border=5 cellpadding=10>		<tr>		<td>			See what the <a href="cc-press-quote.html"><b>			press</b></a> is saying about Dow Jones CustomClips<font size=3>&#174;</FONT>. 			 		</td>		</tr>		</table></center>			<pre></pre> 								<center>								<a href="../../toolbar.gif.map">								<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>					<BR>									<font size=2>					<a href="../../bizpubs/index.html">Newspapers</a> |					<a href="../../clipping/index.html">Alert Services</a> |					<a href="../../online-lib/index.html">Research</a>   |					<a href="../../pers-finance/index.html">Personal Finance</a>  |  					<a href="../../latest.html">DJ In The News</a>  |					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |					<a href="../../index.html">Home</a> 				</font>								</center></TD></tr></TABLE></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-7</DOCNO>
<DOCOLDNO>IA027-000290-B040-296</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/online-lib/index.html 143.131.194.4 19970114043621 text/html 3971
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:40:26 GMT
Last-modified: Thursday, 10-Oct-96 15:45:39 GMT
Content-length: 3780
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>Dow Jones News/Retrieval</TITLE><META NAME="AUTHOR" CONTENT="Kathryn Doyle"><META NAME="GENERATOR" CONTENT="Internet Assistant for Microsoft Word 2.0z"></HEAD><BODY bgcolor="#ffffff" background="images/bgdonlin.gif"><P><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><TD width=95 valign=top><B><IMG valign=top WIDTH=65 HEIGHT=65 BORDER=0 SRC="images/lrgonlinres.gif"></B> <BR><B><IMG SRC="../images/trsp.gif"></B> </TD><TD width=500><H2><CENTER><FONT SIZE=6>O</FONT><FONT SIZE=5>NLINE </FONT><FONT SIZE=6>R</FONT><FONT SIZE=5>ESEARCH</FONT><FONT SIZE=6> S</FONT><FONT SIZE=5>ERVICE </FONT></CENTER></H2><H3><CENTER><IMG WIDTH=199 HEIGHT=59 BORDER=0 SRC="images/djnr-logo.gif"> <BR>Fast Answers to Tough Questions. </CENTER></H3><HR><A href="nrtour.html"><IMG src="../images/tour.gif" align=left border=0></A> <BR>Take a quick <A HREF="nrtour.html">tour</a><br> of the <b>NEW</b> Dow Jones News/Retrieval. <pre></pre><P><A HREF="/downl1.html"><img src="star.gif" align=right border=0></a>Dow Jones News/Retrieval<FONT SIZE=2>&#174;</FONT> is the only online service that answers your tough business questions quickly and affordably. And with its completely redesigned <A HREF="/downl1.html"><B>Windows software</B></A>, it's now also one of the easiest and most powerful ways to get to the information that matters most to you. (We also offer <A HREF="/downlmac.html">Macintosh</A> software.)<P>Specifically, Dow Jones News/Retrieval provides you with unmatched resources -- editorially and technically. What does all that mean? It means that when you sign on, you've got all this at your disposal:<P><img src="nrscreen.gif"><P>For specifics on what's included in each area on the menu -- including the more than 3,400 publications available online -- see our <A HREF="overview.html">source overview</A>.<P>Just install and take a few minutes to set up the easy-to-use software -- we'll guide you every step of the way. Then click on the area you want to visit. Searching is simple -- yet incredibly powerful. Best of all, you pay only for the information you retrieve -- no monthly fees, no hourly online charges. Want to know more? <A HREF="all.html">Read on</A> for details.<P>Or take a more direct approach and <A HREF="/downl1.html">download</A> the free Windows software now. You'll get 10 hours FREE*. (Click <A HREF="/downlmac.html">here</A> for Macintosh software.)<H4><CENTER><A HREF="all.html">Tell me more about Dow Jones News/Retrieval&#174;</A> <BR></CENTER></H4><P><DFN><SMALL>*One-time offer to new U.S. and Canadian customers only of the full Dow Jones News/Retrieval. Free time offer is per account and certain sources are excluded. There is a $29.95 start-up fee.To take advantage of this offer, you must start using the service within 90 days after you receive your password and then you must use your 10 free hours within 30 days of your first use of the service. </SMALL></DFN><P><CENTER><A href="../toolbar.gif.map"><IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></A> <BR><A href="../bizpubs/index.html">Newspapers</A><FONT SIZE=2> | <A href="../clipping/index.html">Alert Services</A> | <A href="../online-lib/index.html">Research</A> | <A href="../pers-finance/index.html">Personal Finance</A> | <A href="../latest.html">DJ In The News</A> | <A href="mailto:webmaster@nrs.dowjones.com">Write Us</A> | <A href="../index.html">Home</A> </FONT></CENTER></TD></TR></TABLE><P></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-8</DOCNO>
<DOCOLDNO>IA027-000290-B040-328</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/pie/private.html 143.131.194.4 19970114043635 text/html 775
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:40:46 GMT
Last-modified: Wednesday, 08-Jan-97 15:15:05 GMT
Content-length: 584
Content-type: text/html
</DOCHDR>
<HTML><HEAD>   <TITLE>DowJones News Retrieval Private Investor Edition</TITLE> </HEAD><BODY TEXT="#000000" BGCOLOR="#FFFFFF"><TABLE BORDER=0 CELLSPACING=2 CELLPADDING=2 WIDTH=600><TR><TD WIDTH=150></TD><TD><IMG SRC="images/DJ_PIprod_serv.gif" ALT="IMAGE" HEIGHT=75 WIDTH=450></TD></TR></TABLE><HR size="6"><A HREF="mainpage.map"><IMG SRC="mainpage.gif" BORDER=0 ISMAP></A><P><CENTER><HR size=2><A HREF="index.html">Private Investor Online Services</A>  |  <A HREF="jphone.html">JournalPhone</A>&#174;  |  <A HREF="rom.html">Software</A></CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-9</DOCNO>
<DOCOLDNO>IA027-000290-B040-359</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/pie/index.html 143.131.194.4 19970114043647 text/html 2712
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:40:57 GMT
Last-modified: Wednesday, 08-Jan-97 15:14:55 GMT
Content-length: 2520
Content-type: text/html
</DOCHDR>
<HTML><HEAD>   <TITLE>Private Investor Editions</TITLE> </HEAD><BODY TEXT="#000000" BGCOLOR="#FFFFFF" LINK="#0000FF" VLINK="#551A8B" ALINK="#0000FF"><TABLE BORDER=0 CELLSPACING=2 CELLPADDING=2 WIDTH=600><TR><TD WIDTH=150></TD><TD><IMG SRC="images/DJ_PIE.gif" ALT="IMAGE" HEIGHT=65 WIDTH=480></TD></TR></TABLE><HR size="6"><A HREF="PIE_page.map"><IMG SRC="PIE_page.gif" BORDER=0 ISMAP></A><P><CENTER><FONT size=2><A HREF="news.html">News & Quotes</A> | <A HREF="screen.html">Stock Screening</A> | <A HREF="inews.html">CustomClips&#174; for Private Investors</A> | <A HREF="publib.html">Private Investor Publications Library</A><BR><A HREF="trackna.html">Portfolio Tracking & News Alerts</A> | <A HREF="research.html">Research</A> | <A HREF="tech.html">Technical Analysis</A> | <A HREF="sports.html">Sports & Weather</A></FONT></CENTER><hr size=4>For less than a dollar a day, <B><I>Dow Jones News/Retrieval&#174; - Private Investor Edition</I></B> gives you access to the same information professional investment advisors rely on!<P><blockquote><LI> Breaking news you can trust from 11 <I>exclusive</I> Dow Jones Newswires<BR><LI> Daily and historic quotes<br><LI> Sophisticated reports and analysis<BR><LI> Searchable archive of over 200 high quality publications<BR><LI> Personal news clipping service <I>(available for a nominal monthly fee per folder)</I><BR><LI> Much, much more!<P></blockquote>The all new Private Investor Edition, v 5.0 for Windows&#174;, lets you track multiple portfolios and news on the individual securities in your portfolio. Set up your own criteria for stock screening. PLUS, you'll get access to one of the richest publication libraries designed specifically for private investors. Get 10 hours of online access weeknights from 7:01 p.m. - 6:00 a.m. (your local time), plus any time on weekends and certain holidays for one flat fee of $29.95 per month. And because you receive access to these sources outside of regular business hours, you can get them for considerably less than what professional investment advisors pay. Other restrictions apply. <A HREF="legal.html">See pricing, rules and regulations.</A><P><P><HR><CENTER><FONT SIZE=3><A HREF="downld.html">Download Now</A> | <A HREF="tour.html">Take A Tour</A> | <A HREF="pie.html">Home</A><BR><A HREF="private.html">Other Private Investor Products and Services</A><BR>Call <B>1-800-522-3567</B>, ext. 154 to subscribe, ext. 190 for more information.</FONT></CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-10</DOCNO>
<DOCOLDNO>IA027-000290-B041-11</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/latest.html 143.131.194.4 19970114043703 text/html 9623
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:41:09 GMT
Last-modified: Monday, 13-Jan-97 21:08:41 GMT
Content-length: 9434
Content-type: text/html
</DOCHDR>
<html><head><title>PR Pages</title></head><body background="images/bgddj.gif"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><td width=80 valign=top ><img SRC="images/trsp.gif">  <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="images/dowj.gif"></td><td><p><br><CENTER>	<H3><FONT SIZE=+2>T</FONT>HE<FONT SIZE=+2>L</FONT>ATEST<FONT SIZE=+2>N</FONT>EWS<FONT SIZE=+2>A</FONT>BOUT<FONT SIZE=+2>D</FONT>OW<FONT SIZE=+2>J</FONT>ONES<FONT SIZE=+2>BIS</FONT></H3><HR SIZE=4></CENTER><blockquote><H4>What's new at Dow Jones BIS? Here's the place to find out. Below you will find links to recent announcements and information regarding new products, enhancements, and more.  </H4><STRONG> Jan. 6, 1997</STRONG><BR> <A HREF="/press/releas41.html">Dow Jones Introduces Powerful Online Investor Resources for Private Investors </A><P><STRONG> Oct. 28, 1996</STRONG><BR> <A HREF="/press/releas40.html">DowVision, the Most Popular Direct-to-the-Desktop <br>Custom News Service, Now Available on the Web Directly from Dow Jones </A><P><STRONG> Oct. 16, 1996</STRONG><BR> <A HREF="/press/releas39.html">Dow Jones News/Retrieval Adds<br>Exclusive International and Business/Financial News</A><P><STRONG> Oct. 8, 1996</STRONG><BR> <A HREF="/press/releas38.html">Dow Jones Business Information Services <br>Launches Web-Based Business Directory</A><P><STRONG> Oct. 7, 1996</STRONG><BR> <A HREF="/press/releas37.html">Dow Jones Electronic ProductsWin Four Major Awards<br> for Innovation and Creativity </A><P><STRONG> Oct. 1, 1996</STRONG><BR> <A HREF="/press/releas36.html">Dow Jones' DowVision Expands Daily Newspaper Coverage</A><P><STRONG> Oct. 1, 1996</STRONG><BR> <A HREF="/press/releas35.html">Dow Jones' DowVision toProvide Customized News and Information to Cadence Design</A><P><STRONG> Sept. 16, 1996</STRONG><BR> <A HREF="/press/releas34.html">Same-Day Full Text ofThe Washington Post Available through Dow Jones Business Information Services</A><P><STRONG> Sept. 12, 1996</STRONG><BR> <A HREF="/press/releas33.html">Dow Jones Business Center(sm}Debuts on America Online</A><P><STRONG> Aug. 19, 1996</STRONG><BR> <A HREF="/press/releas32.html">Dow Jones News/Retrieval NowAvailable to Visitors of New Science, Industry and Business Library</A><P><STRONG> Aug. 16, 1996</STRONG><BR> <A HREF="/press/releas31.html">Dow Jones Personal Journal To BePreinstalled On New Line of Toshiba Notebook Computers</A><P><STRONG> Aug. 13, 1996</STRONG><BR> <A HREF="/press/releas29.html">The Wall Street Journal Interactive Edition Announces Technology & Marketing Alliance with Microsoft</A><P><STRONG> Aug. 12, 1996</STRONG><BR> <A HREF="/press/releas30.html">Dow Jones News/Retrieval Provides Continuously Updated News on Election Campaigns</A><P><STRONG> July 29, 1996</STRONG><BR> <A HREF="/press/releas28.html">The Wall Street Journal Interactive Edition Introduces E-Mart</A><P><STRONG> July 23, 1996</STRONG><BR> <A HREF="/press/releas27.html">Dow Jones Announces Distribution Agreement with Day-Timer Technologies; Personal Journal Now Included On Day-Timers CD-ROM</A><P><STRONG> July 22, 1996</STRONG><BR> <A HREF="/press/releas26.html">Photographer Annie Leibovitz Teams With The Wall Street Journal for First Internet Venture; Olympics Photos Appear on Journal's Interactive Edition</A><P><STRONG> July 15, 1996</STRONG><BR> <A HREF="/press/releas25.html">Dow Jones Business Information Names Perry to Head Distribution Strategy</A><P><STRONG> July 12, 1996</STRONG><BR> <A HREF="/press/releas24.html">The Wall Street Journal Radio Network Introduces Work & Family Show</A><P><STRONG> July 1, 1996</STRONG><BR> <A HREF="/press/releas22.html">Dow Jones and U.S. Robotics Announce Distribution Agreement For Personal Journal</A><P><STRONG> June 24, 1996</STRONG><BR> <A HREF="/press/releas23.html">The Wall Street Journal Interactive Edition Registers 500,000th Reader</A><P><STRONG> June 7, 1996</STRONG><BR> <A HREF="/press/releas21.html">Dow Jones Establishes National Alliance Program For Professional Researchers</A><P><STRONG> May 29, 1996</STRONG><BR> <A HREF="/press/releas20.html">Dow Jones Systems Engineers Win Sun Microsystems' Java Cup Contest</A><P><STRONG> May 14, 1996</STRONG><BR> <A HREF="press/releas19.html">Dow Jones Extends Leadership As Business Information Publisher; Sets New Industry Standard With Transformed Business Online Service</A><p><STRONG> May 7, 1996</STRONG><BR> <A HREF="press/releas18.html">Dow Jones' Massive Online Business Resource Doubles International Publications Offering With Quest Economics Database </A><p><STRONG>May 6, 1996</STRONG><BR> <A HREF="press/releas17.html">The Wall Street Journal Interactive Edition's First Week Brings Strong Reader Interest, Heavy Traffic</A><p><STRONG>April 29, 1996</STRONG><BR> <A HREF="press/releas16.html">The Wall Street Journal Interactive Edition Debuts Today on the World Wide Web</A><p><STRONG>February 27, 1996</STRONG><BR> <A HREF="press/releas13.html">Dow Jones and W.W. Norton introduce first-of-its-kind World Wide Web learning resource</A><p><STRONG>February 23, 1996 </STRONG><BR><A HREF="press/release1.html">Dow Jones' Massive Investor Research Service is Now Easily Accessible to Canadian Private Investors for Less Than U.S. $1.00 Per Day</A><p><STRONG>January 29, 1996</STRONG><BR><A HREF="press/release7.html">Top Business News Now Directly Available On New Compaq PCs</A><p><STRONG>January 23, 1996</STRONG><BR><A HREF="press/release4.html">Exclusive Global Business Publications Added To Dowvision<font size=2>&#174;</FONT> News Service</A><p><STRONG>January 5, 1996</STRONG><BR><A HREF="press/release8.html">Personal Journal Software Now Available Through the Internet</A><p><STRONG>December 20, 1995</STRONG><BR><A HREF="press/releas11.html">Dow Jones announces News/Retrieval for Macintosh</a><p><STRONG>November 27, 1995 </STRONG><BR><A HREF="press/releas15.html"> The Wall Street Journal Announces Customized Netscape Navigator Offering One-Step Access to Leading Internet News Source</a><p><STRONG>October  31, 1995</STRONG><BR><A HREF="press/releas12.html"> 'The world's most useful online business library' adds  full-text archives of the New York Times</A><p><STRONG>October  30, 1995</STRONG><BR> <A HREF="press/releas10.html"> Massive online business library boosted by over 65 percent</A><p><STRONG>October 18, 1995</STRONG><BR><A HREF="press/releas14.html"> The Wall Street Journal Premiers 24-Hour News Reporting in Money & Investing Update</a><p><STRONG>September 20, 1995</STRONG><BR><A HREF="press/release9.html">Now Personal Journal Delivers Itself Whenever You Want It</A><p><STRONG>September 19, 1995</STRONG><BR><A HREF="press/release5.html">The Wall Street Journal Enhances Money & Investing Update with Briefing Books</A><p><STRONG>August 29, 1995</STRONG><BR><A HREF="press/release3.html">Dow Jones Introduces CustomClips<font size=2>&#174;</FONT> for Lotus Notes<font size=2>&#174;</FONT> and Desktop Data Inc.'s Newsedge<font size=2>&#174;</FONT></A><p><STRONG>June 14, 1995 </STRONG><BR><A HREF="press/release2.html">Improved Version of Market Monitor and Tradeline Access Plan Features New, Easy-To-Use Software</A><p><STRONG>June 14, 1995</STRONG><BR><A HREF="press/release6.html">Dow Jones Introduces CD-ROM for Retirement Planning </A><hr><P><CENTER><H4>Press releases organized by product line:</H4></CENTER> <p><A HREF="press/relcat1.html">Newspapers</a><p><A HREF="press/relcat2.html">Clipping, Tracking & Alert Services</A><p><A HREF="press/relcat3.html">Online Research Service</A><p><A HREF="press/relcat4.html">Personal Finance & Investing</A><p><hr><H4>We welcome feedback or questions about the <A HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <br><A HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4></blockquote><pre></pre> 								<center>					<a href="toolbar.gif.map">								<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="images/toolbar.gif" ISMAP></a>					<BR>									<font size=2>					<a href="bizpubs/index.html">Newspapers</a> |					<a href="clipping/index.html">Alert Services</a> |					<a href="online-lib/index.html">Research</a>  |					<a href="pers-finance/index.html">Personal Finance</a>  |  					<a href="latest.html">DJ In The News</a>  |					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |					<a href="index.html">Home</a> 				</font>												</center>				</TD></tr></TABLE></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-11</DOCNO>
<DOCOLDNO>IA027-000290-B041-40</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/bizpubs/index.html 143.131.194.4 19970114043715 text/html 1954
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:41:24 GMT
Last-modified: Thursday, 03-Oct-96 15:30:28 GMT
Content-length: 1763
Content-type: text/html
</DOCHDR>
<html><head><title>Dow Jones BIS Newspapers</title></head><body background="images/bgdbiz.gif"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  <IMG valign=top  WIDTH=65 HEIGHT=65 BORDER=0 SRC="images/lrgconbiz.gif"></td><td><p><CENTER><H2><FONT SIZE=+3>C</FONT>ONTINUALLY<FONT SIZE=+3>U</FONT>PDATED<BR><FONT SIZE=+3>B</FONT>USINESS<FONT SIZE=+3>N</FONT>EWS<FONT SIZE=+3>P</FONT>UBLICATION</H2></CENTER><HR SIZE=4><blockquote><BR>Fast access to the news you trust -- from Dow Jones and <em>The Wall StreetJournal<font size=2>&#174;</FONT></em>.When you need access to accurate business news throughout the day, trust the electronic"newspaper" published by Dow Jones and <em>The Wall StreetJournal<font size=2>&#174;</FONT></em>.<P><a href="wsj-interactive.html"><em>The Wall Street Journal&#174;</em>&nbsp;Interactive Edition</a> <BR>Continuously Updated Business News on the Web,from the editors of <em>The Wall Street Journal<font size=2>&#174;</FONT></em>.<P></blockquote>	<pre></pre> 								<center>									<a href="toolbar.gif.map">								<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>					<BR>												 	<font size=2>					<a href="../bizpubs/index.html">Newspapers</a> |					<a href="../clipping/index.html">Alert Services</a> |					<a href="../online-lib/index.html">Research</a>   |					<a href="../pers-finance/index.html">Personal Finance</a>  |  					<a href="../latest.html">DJ In The News</a>  |					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |					<a href="../index.html">Home</a> 				</font>												</center>																</TD></tr></TABLE></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-12</DOCNO>
<DOCOLDNO>IA027-000290-B041-74</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/bizpubs/wsj-pressquote.html 143.131.194.4 19970114043754 text/html 2558
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:41:39 GMT
Last-modified: Thursday, 23-May-96 18:39:39 GMT
Content-length: 2367
Content-type: text/html
</DOCHDR>
<html> 

<head><title>Dow Jones</title></head> 

<body bgcolor="#ffffff" background="images/bgdbiz.gif">


<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  
<A HREF="index.html">
<IMG valign=top  WIDTH=65 HEIGHT=65 BORDER=0 SRC="images/lrgconbiz.gif"></A></td>
<td>


<center>
		
		
		<IMG WIDTH=281 HEIGHT=57 BORDER=0 SRC="images/interact.gif">
		
		
		
		<HR SIZE=4>
		
		</CENTER>
<BR>
<blockquote>



<p>

<B>Here's what the press is saying...</B>
<P>
Honorable Mention, Best Personal Financial Service<br>
<ul>-<em>Information Industry Association - Hot Shot Awards 1996</em></ul>
<p>


	"A classy sight."
<BR> 


		<UL>-<em>Fortune.</em> </UL>
		<P>

"There are the information haves and the information have-nots, the rich and the poor of the information age. The information haves will soon include those people who subscribe to The Wall Street Journal Interactive Edition."
<BR> 
		<UL>-<em>Media Week,</em> April 29, 1996</UL>
		
		<P>

	"The best online news coverage; it can improve on the hard-copy
original." <BR> 

		<UL>-<em>U.S. News & World Report.</em> </UL>
		
		<P>

	<B>Voted: <BR> One of the Top 100 Websites </B><BR> 
"With a laptop, wireless modem, and the URL for the Wall Street Journal Money & investing Update, you could become the most informed trader on the stock market floor. This slick, information-rich site gives you access to reams of company and market news, including coverage of currencies, credit markets and mutual funds."<br>

				<UL>-<em>PC Magazine.</em></UL><p>


</blockquote>


<pre>


</pre>

				<CENTER>Back To
				<A HREF="wsj-interactive.html">
				The Wall Street Journal&#174; Interactive Edition</A>
				
	<BR>
				
				
				<a href="../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../bizpubs/index.html">Newspapers</a> |
					<a href="../clipping/index.html">Alert Services</a> |
					<a href="../online-lib/index.html">Research</a>   |
					<a href="../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../index.html">Home</a> 

				</font>
				
				
				
				</center>
				
</TD>
    </TR>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-13</DOCNO>
<DOCOLDNO>IA027-000290-B041-105</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/toolbar.gif.map 143.131.194.4 19970114043828 text/html 321
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:42:35 GMT
Content-type: text/html
Content-length: 180
</DOCHDR>
<TITLE>Imagemap Error</TITLE><H1>Imagemap Error</H1>Your client did not send any coordinates. Either your client doesn't support imagemap or the map file was not accessed as a map.
</DOC>
<DOC>
<DOCNO>WT18-B31-14</DOCNO>
<DOCOLDNO>IA027-000290-B041-139</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/pers-finance/index.html 143.131.194.4 19970114043857 text/html 796
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:42:59 GMT
Last-modified: Wednesday, 08-Jan-97 22:11:26 GMT
Content-length: 605
Content-type: text/html
</DOCHDR>
<HTML><HEAD>   <TITLE>DowJones News Retrieval Private Investor Edition</TITLE> </HEAD><BODY TEXT="#000000" BGCOLOR="#FFFFFF"><TABLE BORDER=0 CELLSPACING=2 CELLPADDING=2 WIDTH=600><TR><TD WIDTH=150></TD><TD><IMG SRC="images/DJ_PIprod_serv.gif" ALT="IMAGE" HEIGHT=75 WIDTH=450></TD></TR></TABLE><HR size="6"><A HREF="mainpage.map"><IMG SRC="mainpage.gif" BORDER=0 ISMAP></A><P><CENTER><HR size=2><A HREF="../pie/index.html">Private Investor Online Services</A>  |  <A HREF="../pie/jphone.html">JournalPhone</A>&#174;  |  <A HREF="../pie/rom.html">Software</A></CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-15</DOCNO>
<DOCOLDNO>IA027-000290-B041-199</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/dowvision/wwsales.html 143.131.194.4 19970114044019 text/html 3655
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:44:13 GMT
Last-modified: Wednesday, 30-Oct-96 21:53:56 GMT
Content-length: 3463
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE> World Wide Sales Offices </TITLE></HEAD><BODY Background="IMAGES/bckgrnd.gif" FONT="4"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><td width=130></td><TD><HR><A NAME=topsy><H1>World Wide Sales Offices</H1></a><hr></td></tr></Table><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=20 WIDTH=500><TR><td width=160></td><TD VALIGN=top WIDTH=170 ALIGN=CENTER><B>UNITED STATES</B><P><A HREF=#boston><B>Boston</B></A><p><B> <A HREF=#nyc> New York City </A> </B><p><A HREF=#nj> <B>New Jersey</A> </B><p><A HREF=#dc> <B>Washington, D.C. </A> </B><p><A HREF=#ga> <B>Atlanta</A> </B><p><A HREF=#chic> <B>Chicago</A> </B><p><A HREF=#tex> <B>Dallas</A> </B><p><A HREF=#hous> <B>Houston</A> </B><p><A HREF=#sf> <B>San Francisco</A> </B><p><A HREF=#la> <B>Los Angeles</A> </B><p></TD><TD VALIGN=top WIDTH=170 ALIGN=CENTER><B>INTERNATIONAL</B><P><A HREF=#asia> <B>Asia/Pacific</B></A> <p><A HREF=#south> <B>Central/South America</B></A> <p><A HREF=#can> <B>Canada</B></A> <p><A HREF=#euro> <B>Europe/<BR>Middle East/<BR>Africa</B></A> <p></TD></tr></TABLE><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><td width=130></td><TD><HR><H2>United States </H2><A NAME=boston><B>Boston</B></A><br>617-654-6814<br>Fax: 617-654-6811<br>e-mail: bosales@cor.dowjones.com<br><P><B><A NAME=nyc>New York City</A></B><br>212-416-4208<br>Fax: 212-416-3690<br>e-mail: nysales@cor.dowjones.com	<br><P><A NAME=nj> <B>New Jersey</B></A> <br>609-520-4632<br>Fax: 609-520-4660<br>e-mail: njsales@cor.dowjones.com<br><P><A NAME=dc> <B>Washington, D.C. </B></A> <br>202-289-8500<br>Fax: 202-289-6411<br>e-mail: dcsales@cor.dowjones.com<br><P><A NAME=ga> <B>Atlanta</B></A> <br>404-240-1362<br>Fax: 404-240-1355<br>e-mail: atlsales@cor.dowjones.com<br><P><A NAME=chic> <B>Chicago</B></A> <br>312-750-4160<br>Fax: 312-750-4140<br>e-mail: chgosale@cor.dowjones.com<br><P><A NAME=tex> <B>Dallas</B></A> <br>214-951-7174<br>Fax: 214-951-7179<br>e-mail: dfwsales@cor.dowjones.com<br><P><A NAME=hous> <B>Houston</B></A> <br>713-626-8833<br>Fax: 713-626-8886<br>e-mail: housales@cor.dowjones.com<br><P><A NAME=sf> <B>San Francisco</B></A> <br>415-765-6170<br>Fax: 415-399-1732<br>e-mail: sfsales@cor.dowjones.com<br><P><A NAME=la> <B>Los Angeles</B></A> <br>213-658-3913<br>Fax: 213-658-3960<br>e-mail: lasales@cor.dowjones.com<br><P><P><HR><H2>International </H2><A NAME=asia> <B>Asia/Pacific</B></A> <br>(Hong Kong Regional Office) <br>852-2599-2279<br>Fax: 852-2506-3357<br>e-mail: bisi.sales@cor.dowjones.com<br><P><A NAME=south> <B>Central/South America</B></A> <br>(Mexico City Regional Office) <br>525-280-6094	<br>Fax: 525-280-6109<br>e-mail: bisi.sales@cor.dowjones.com<br><P><A NAME=can> <B>Canada</B></A> <br>(Toronto Regional Office) <br>416-777-5766<br>Fax: 416-777-5590<br>e-mail: torsales@cor.dowjones.com<br><BR>(Ottawa Regional Office) <br>613-232-6393<br>Fax: 613-232-1751<br>e-mail: ottsales@cor.dowjones.com<br><P><A NAME=euro> <B>Europe/Middle East/Africa </B></A> <br>(London Regional Office) <br>44-171-832-8078<br>Fax: 44-171-832-9861<br>e-mail: bisi.sales@cor.dowjones.com<br><PRE></PRE><H2><A HREF=index.html>Return to DowVision Tour.</A></H2><P><H4><a href="../index.html">Back to the Dow Jones Business Information Services <BR>Home Page.</a><BR><BR><A HREF=#topsy>Back to Top of Page</a></H4></td></tr></TABLE></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-16</DOCNO>
<DOCOLDNO>IA027-000290-B041-233</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/dowvision/dowtour.html 143.131.194.4 19970114044044 text/html 5539
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:44:54 GMT
Last-modified: Wednesday, 08-Jan-97 21:07:12 GMT
Content-length: 5347
Content-type: text/html
</DOCHDR>
<html><head><title>DowVision</title></head><body bgcolor="#ffffff" background="../images/bgdcc.gif"><TABLE Width=75% BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><td width=50 valign=top>  <a href="../index.html"><IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/lrgcosclip.gif"></a></td><td><BR><CENTER><IMG BORDER=0 SRC="images/dowvision.gif"><P><img src="../../images/tour.gif"></CENTER><UL><p>More businesspeople choose DowVision, the most popular direct-to-the-desktopnews service, than any of the others available today. Why? Take the quicktour below to find out some of the reasons. Then <a href="contact.html">click here</a> to have a representative call you.<P><HR><IMG  SRC="bullet.gif"  ALIGN=TOP><FONT SIZE=5><B>Enterprise-wide Solution </B><BR></FONT>DowVision provides the perfect enterprise-wide solution--there's no surfing orsearching. Just totally efficient delivery of the news that's vital to yourbusiness. Executives, managers and others within your organization haveinstant access to real-time news and information that keeps them informed andcompetitive. DowVision is alive and beeping--meaning thateach time news is delivered, you'll be alerted automatically. And the news isgathered from exclusive, leading business sources. In fact, DowVision is theonly single source for these leading business publications.  More on that ina minute.<br><IMG  SRC="dow1.gif"  ALIGN=TOP><P><HR><IMG  SRC="bullet.gif"  ALIGN=TOP><FONT SIZE=5><B>What You Get</B><BR></FONT>In addition to exclusive and comprehensive news coverage, you get a servicethat's incredibly reliable and easy to use. We'll work with you to getDowVision up and running. Once it's up, your users immediately accessheadlines on the news that matches your organization's profile. They justclick and read their way through the information. And they're alerted tobreaking news as it's broadcast.  It's efficient. It's easy and it'sreliable.<p><HR> <IMG  SRC="bullet.gif"  ALIGN=TOP><FONT SIZE=5><B>Exclusive Sources Plus Powerful Capabilities</B><BR></FONT>You get comprehensive, authoritative sources including <I>The Wall StreetJournal, The Wall Street Journal Europe, The Asian Wall Street Journal, TheNew York Times, The Washington Post</I>, the <I>Los Angeles Times</I> and <I>FinancialTimes</I>. (<A HREF="sources.html">Click here for a complete list.</a>) We'll work with you to create aprofile that gathers pertinent news from these and other available sources.Track anything in the business and financial arenas--companies, products,industries, people. Whatever you want.<p><HR> <IMG  SRC="bullet.gif"  ALIGN=TOP><FONT SIZE=5><B>Flexible Environments</B><BR></FONT>DowVision operates in virtually any enterprise environment--including MS-DOS,Windows, Macintosh, Unix, TCP/IP, Modems,  e-mail, the Internet or yourcompany's Intranet.  And we have alliances with several leading softwaredevelopers to make news easy to integrate into the way you currently dobusiness.<p><IMG  SRC="dow2.gif"  ALIGN=TOP><P>For more detailed information on DowVision's alliance developers, visit these sites today:<br><A HREF="http://www.desktopdata.com">Desktop Data, Inc. - NewsEDGE</a> <br><A HREF="http://www.waveo.com">WavePhore, Inc. - WavePhore Newscast</a><br><A HREF="http://www.ensemble.com/">Ensemble Information Systems - Relevant Personal Edition</a> <br><A HREF="http://www.rtinews.com">Retrieval Technologies, Inc. - News Machine</a> <br><A HREF="http://www.compassware.com/products">Compassware</a> <br><A HREF="http://www.paracel.com/demo/Current.html">Paracel</a> <br><HR><IMG  SRC="bullet.gif"  ALIGN=TOP><FONT SIZE=5><B>Predictable Pricing</B><BR></FONT>Take advantage of an affordable, budgetable pricing plan that best meets yourorganization's unique needs. There are pricing plans for small worksgroups,corporate libraries or large enterprises. These special arrangements can putDow Jones information on every desktop in your organization. Interested?<A HREF="contact.html">Click here</a> and a representative will contact you.<P><HR><IMG  SRC="bullet.gif"  ALIGN=TOP><FONT SIZE=5><B>The Perfect Partner</B><BR></FONT>Couple DowVision with its counterpart, Dow Jones CustomClips. CustomClipsallows you to add more depth and breadth to your desktop news. It's asubscription-based service that allows you to clip news of interest from morethan 1,600 leading industry and trade publications around the world. Clickhere to take a <A HREF="../../clipping/custom-clips/cctour.html">quick tour</a> of CustomClips. <P> </UL><pre></pre> <center> Back To <A HREF="index.html">DowVision</a></center> 				<center>				<a href="../../toolbar.gif.map">								<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>					<BR>									<font size=2>					<a href="../../bizpubs/index.html">Newspapers</a> |					<a href="../../clipping/index.html">Alert Services</a> |					<a href="../../online-lib/index.html">Research</a>   |					<a href="../../pers-finance/index.html">Personal Finance</a>  |  					<a href="../../latest.html">DJ In The News</a>  |					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |					<a href="../../index.html">Home</a> 				</font>				</center></TD></tr></TABLE></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-17</DOCNO>
<DOCOLDNO>IA027-000290-B041-299</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/dowvision/sources.html 143.131.194.4 19970114044141 text/html 4063
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:45:43 GMT
Last-modified: Tuesday, 22-Oct-96 20:54:06 GMT
Content-length: 3873
Content-type: text/html
</DOCHDR>
<html><head><title>DowVision Sources</title></head><body bgcolor="#ffffff" background="../images/bgdcc.gif"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><td width=80 valign=top ><img SRC="../../images/trsp.gif">  <a href="../index.html"><IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/lrgcosclip.gif"></a></td><td><br>		<CENTER>							<IMG WIDTH=200 HEIGHT=31 BORDER=0 SRC="images/dowvnsm.gif">				<p>				<H2>		Sources		</H2>		</CENTER>		<HR SIZE=4><BR><P><blockquote>DowVision<font size=2>&#174;</font> delivers breaking news from the most respected news sources! The news you get is news you can rely on when making critical business decisions.  Sources include:<P><B>Same day full-text coverage from top newspapers:</B><BR><EM>The Wall Street Journal&#174;<BR>The New York Times<BR>The Los Angeles Times<br>Financial Times<br>The Washington Post</EM><P><B>International news sources (same day full-text):</B><BR><EM>The Wall Street Journal&#174; Europe<BR>The Wall Street Journal&#174; Asia</EM><BR>Far Eastern Economic Report<BR>Financial Times<BR>Japan Economic Newswire<P><B>Five <EM>exclusive</EM> Dow Jones newswires:</B><BR>Dow Jones News Service<BR>Dow Jones International News Service<BR>Professional Investor Report<BR>Dow Jones Capital Markets Report<BR>Federal Filings <P><B>More in-depth Financial Analysis:</B><BR><EM>Barron's<BR>Investext Abstracts</EM><P><B>Four press release newswires:</B><BR>PR Newswire<BR>Business Wire<BR>Canada News Wire<BR>Canadian Corporate News<P><B>Coverage from the business sections of 54 local newspapers:</B><BR><EM>Allentown Morning Call<BR>Austin-Am. Statesman<BR>Bangor Daily News<BR>Baton-Rouge Advocate<BR>The Bergen Record<BR>Buffalo News<BR>Calgary Herald<BR>Chicago Sun-Times<BR>Chicago Tribune<BR>Cincinnati Post<BR>Cleveland Plain Dealer<BR>Commercial Appeal<BR>The Daily Oklahoman<BR>Dallas Morning News<BR>Dayton Daily News<BR>Denver Post<BR>The Evansville Courier<BR>The Financial Post<BR>Florida Times Union<BR>Ft. Lauderdale Sun Sentinel<BR>The Gazette-Montreal<BR>The Hartford Courant<BR>Houston Chronicle<BR>Indianapolis Star<BR>Kansas City Star<BR>Knoxville News-Sentinel<BR>Los Angeles Daily News<BR>Milwaukee Journal<BR>Morning News Tribune<BR>Nashville Banner<BR>News & Observer<BR>Omaha World-Herald<BR>The Orange County Register<BR>The Ottawa Citizen<BR>Patriot Ledger<BR>Pittsburgh Post-Gazette<BR>The Record<BR>Richmond Times<BR>Riverside Press<BR>Rocky Mountain News<BR>Salt Lake Tribune<BR>San Diego Union Tribune<BR>San Francisco Examiner<BR>Santa Rosa Press Democrat<BR>Seattle Times<BR>St. Louis Post<BR>St. Petersburg Times<BR>Star-Tribune-Minneapolis<BR>Times-Picayune<BR>The Toronto Star<BR>USA TODAY<BR>The Vancouver Sun<BR>Washington Times</EM><P>Some sources listed may not be available for distribution in all countries. Please speak with yourDow Jones representative for details.</blockquote>						<pre></pre>			<center>				Back To <A HREF="index.html">DowVision<font size=2>&#174;</font></A>				<br>				<a href="../../toolbar.gif.map">								<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>					<BR>									<font size=2>					<a href="../../bizpubs/index.html">Newspapers</a> |					<a href="../../clipping/index.html">Alert Services</a> |					<a href="../../online-lib/index.html">Research</a>   |					<a href="../../pers-finance/index.html">Personal Finance</a>  |  					<a href="../../latest.html">DJ In The News</a>  |					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |					<a href="../../index.html">Home</a> 				</font>												</center>				</TD></tr></TABLE></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-18</DOCNO>
<DOCOLDNO>IA027-000290-B041-326</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/dowvision/contact.html 143.131.194.4 19970114044205 text/html 5124
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:46:17 GMT
Last-modified: Thursday, 13-Jun-96 21:02:30 GMT
Content-length: 4933
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>
<body bgcolor="#ffffff" background="../images/bgdcc.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 >
<TR><td  valign=top width=80>

<img SRC="../../images/trsp.gif">  
<a href="../index.html">
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/lrgcosclip.gif"></a>
</td>
<td>



<CENTER>


		<IMG WIDTH=200 HEIGHT=31 BORDER=0 SRC="images/dowvnsm.gif">
		
		<p>
<h2>
Contact
</h2>
</CENTER>

<HR SIZE=4>
<P>

<blockquote>

<IMG WIDTH=115 HEIGHT=18 BORDER=0 SRC="images/dowvsm.gif">
		
<P>


Just fill in the blanks below and a <br>Dow Jones representative will respond promptly!
<P>





<FORM  METHOD="POST" ACTION="/cgi-bin/lead.cgi">
<INPUT NAME="Formtype" VALUE="lead_form" TYPE="hidden" size=10>

<table>
<tr><td>
	<b>Name:</b>
</td><td>
	 <INPUT TYPE ="text" NAME="name" maxlength= 30 SIZE =30>
</td></tr><tr><td>
	<b>Company Name:</b>
</td><td>
	<INPUT TYPE ="text" NAME="CompanyName" maxlength= 50 SIZE =30>
</td></tr><tr><td>
	<b>Street Address:</b>
</td><td>
     <INPUT TYPE ="text" NAME="Address1"  maxlength= 40 SIZE =30>
</td></tr>
<tr><td>
</td><td>
     <INPUT TYPE ="text" NAME="Address2"  maxlength=40 SIZE =30> 
</td></tr>

<tr><td>
	<b>City:</b>
</td><td>                 
	<INPUT TYPE ="text"NAME="City"  maxlength= 30 SIZE =30>
</td></tr><tr><td>
	<b>State:</b>
</td><td>               
	<INPUT TYPE ="text"NAME="State"  maxlength= 30 SIZE =30> 
</td></tr><tr><td> 						  
	<b>Zip/Postal Code:</b>
</td><td>
   <INPUT TYPE ="text"NAME="Zip"maxlength= 30 SIZE =30> 
</td></tr><tr><td>
<b>Country:</b>
</td><td>
<INPUT TYPE="text" NAME="Country" maxlength=30 size=30
</td></tr>
</table>




<BR>
<b>What product are you interested in?</B><br>
<Select Name ="Interested">
<OPTION SELECTED>DowVision
<Option> Dow Jones Custom Clips
<option>Dow Jones News/Retrieval
<option>All of them
</select>
<p>



<b>How would you describe your profession?</B> 
<Select Name ="Profession">
<OPTION SELECTED>Choose From List
<Option>Attorney/Counsel
<Option>Communications/Public Relations
<Option>Consultant/Analyst
<Option>Engineering
<option>Finance
<option>Human Resources/Training
<option>Executive Management
<option>Marketing/Advertising
<option>Money/Portfolio Management
<option>Product Management/Development
<option>Programming
<option>Research
<option>Sales (includes Brokerage)
<option>Strategy/Business Development
<option>Student<option>Systems Development
<option>Other
</Select>

 <P>

<B>What is your organization's primary business activity?</b>
<BR>
<Select Name ="Industry">
<Option Selected>Choose From List
<Option>Accounting
<Option>Banking
<Option>Communications/Publishing/Entertainment <option>Computers/Software/Systems
<Option>Education/Schools
<Option>Financial Services/Securities
<Option>Health Care/Hospitals
<Option>Importing/Trade
<Option>Insurance
<Option>Legal
<Option>Manufacturing
<Option>Nonprofit/Government/Associations
<OPtion>Packaged Goods/Food
<Option>Pharmaceuticals
<Option>Real Estate
<Option>Retailing
<Option>Transportation
</Select>

<P>
<b>Number of people who would probably be using <br>DowVision<font size=2>&#174;</font>:</b>  
 <INPUT TYPE = "text" NAME="number_users" maxlength= 10 SIZE =10> 
<p>

<b>Type of LAN/WAN:</b><INPUT TYPE = "text" NAME="type_lan_wan" maxlength= 25 SIZE = 10>
<p>

<STRONG>Operating/Communications Environments:</strong>
<br>
<Select Name ="operating_envir">
<OPTION SELECTED>Windows<font size=2>&#174;</font>
<Option> Lotus<font size=2>&#174;</font> Notes
<option>Macintosh<font size=2>&#174;</font>
<option>Internet E-mail
<option>Microsoft<font size=2>&#174;</font> Exchange
</select>
<p>


<P>

		<table>
		<tr><td>
		
			<b>Phone Number:</b>
		</td><td>
			
		    <INPUT TYPE = "text" NAME="Phone"  maxlength= 30 SIZE =30>
		</td></tr>
		
		<tr><td>
			<b>Fax Number:</b>
		</td><td>
		
		    <INPUT TYPE ="text"NAME="FAX"  maxlength= 30 SIZE =30>
		</td></tr>
		
		<tr><td>
		<b>E-Mail:</b>
		</td><td>
		
		
		    <INPUT TYPE = "text" NAME="Email"  maxlength= 30 SIZE =30>
		</td></tr>
		</table>

<P>

<CENTER><P><INPUT TYPE="submit" VALUE="Send Info"> <INPUT TYPE="reset" VALUE =
"Clear"></CENTER>




</form>
</blockquote>
	
<pre>
	
	
	
</pre>
	<CENTER>Back To <A HREF="index.html">DowVision<font size=2>&#174;</font></A>
	
	
	<br>			

				<a href="../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../bizpubs/index.html">Newspapers</a> |
					<a href="../../clipping/index.html">Alert Services</a> |
					<a href="../../online-lib/index.html">Research</a>   |
					<a href="../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../index.html">Home</a> 

				</font>

				
				</center>
				





</TD></tr>
</TABLE>
</body>
</html>



</DOC>
<DOC>
<DOCNO>WT18-B31-19</DOCNO>
<DOCOLDNO>IA028-000307-B019-148</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/bissales.html 143.131.194.4 19970114054427 text/html 4258
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:48:21 GMT
Last-modified: Tuesday, 03-Dec-96 15:04:19 GMT
Content-length: 4068
Content-type: text/html
</DOCHDR>
<!doctype html public "-//IETF//DTD HTML//EN"><HTML><HEAD><TITLE>Dow Jones BIS Sales Offices</TITLE><META NAME="GENERATOR" CONTENT="Internet Assistant for Word 1.00"><META NAME="AUTHOR" CONTENT="Kathryn Doyle"></HEAD><body bgcolor="#ffffff" background="/online-lib/images/bgdonlin.gif"><P><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0> <TR><TD width=80 valign=top ><IMG SRC="images/trsp.gif"> <IMG valign=top WIDTH=65 HEIGHT=65 BORDER=0 SRC="/online-lib/images/lrgonlinres.gif"></TD><TD><BR><P><CENTER><H2>Dow Jones Business Information <BR>Services Sales Offices </H2><HR><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=20 WIDTH=500><TR><TD VALIGN=top WIDTH=170 ALIGN=CENTER><B>UNITED STATES<BR>REGIONAL OFFICES</B><P><A HREF=#neweng><B>New England</B></A><p><B> <A HREF=#nreast> Northeast </A> </B><p><A HREF=#midatlan> <B>Mid-Atlantic/Southeast</A> </B><p><A HREF=#midwest> <B>Midwest </A> </B><p><A HREF=#nwest> <B>Northwest</A> </B><p><A HREF=#swest> <B>Southwest</A> </B><p></TD><TD VALIGN=top WIDTH=170 ALIGN=CENTER><B>NON-U.S.<BR>SALES OFFICES</B><P><A HREF=#headoff> <B>International<br>Head Office</B></A> <p><A HREF=#canada> <B>Canada</B></A> <p><A HREF=#eurogulf> <B>Europe/Gulf<BR>Regional Office</B></A> <p><A HREF=#asiapac> <B>Asia/Pacific<BR>Sales Office</B></A> <p><A HREF=#centsa> <B>Central/South America<BR>Sales Office</B></A> <p></TD></tr></TABLE><HR><BLOCKQUOTE></CENTER><H3>U.S. Regional Sales Offices</H3></BLOCKQUOTE><BLOCKQUOTE> <A NAME=neweng>New England</A><BR>609-520-4646</BLOCKQUOTE><BLOCKQUOTE><A NAME=nreast>Northeast </A> <BR>609-520-4661 or 609-520-4689</BLOCKQUOTE><BLOCKQUOTE><A NAME=midatlan>Mid-Atlantic/Southeast</A> <BR>202-289-8501</BLOCKQUOTE><BLOCKQUOTE><A NAME=midwest>Midwest</A> <BR>312-750-4164</BLOCKQUOTE><BLOCKQUOTE><A NAME=nwest>Northwest</A> <BR>415-765-6180</BLOCKQUOTE><BLOCKQUOTE><A NAME=swest>Southwest</A> <BR>213-658-3940</BLOCKQUOTE><hr><BLOCKQUOTE><A NAME=headoff> <H3>Non-U.S. Sales Offices</H3> </A></BLOCKQUOTE><BLOCKQUOTE><B>Head Office:</B> <BR>Dow Jones &amp; Co. <BR>Business Information Services-International, PO Box 300, Princeton,NJ 08832 USA</BLOCKQUOTE><BLOCKQUOTE>Deputy Director, BIS International: <BR>Rick Bremble, <A href="mailto:rick.bremble@cor.dowjones.com">rick.bremble@cor.dowjones.com</A>.Phone: (1) 609-520-4080 Fax: (1) 609-520-4068</BLOCKQUOTE><HR><BLOCKQUOTE><A NAME=canada><H3>Canadian Office</H3></A> Canada<br>416-777-5766</BLOCKQUOTE><HR><BLOCKQUOTE><A NAME=eurogulf> <H3>Europe/Gulf Regional Office:</H3> </A> </BLOCKQUOTE><BLOCKQUOTE>10 Fleet Place, London EC4M 7RB ENGLAND <BR>European Sales &amp; Marketing Manager: <BR>Mary McCall, <A href="mailto:mmccall@dowjones.co.uk">mmccall@dowjones.co.uk</A>.Phone: (44-171) 832-8078 Fax: (44-171) 832-9861</BLOCKQUOTE><HR><BLOCKQUOTE><A NAME=asiapac> <H3>Asia /Pacific Sales Office:</H3> </A> </BLOCKQUOTE><BLOCKQUOTE>Times Square 42/F, NatWest Tower, 1 Matheson Street, CausewayBay HONG KONG <BR>Asia/Pacific Regional Account Manager: <BR>Mark Duff, <A href="mailto:mduffnnn@reach.com">mduffnnn@reach.com</A>.Phone: (852) 2599-2222, 2599-2279 Fax: (852) 2599-2200, 2599-2499</BLOCKQUOTE><HR><BLOCKQUOTE><A NAME=centsa> <H3>Central/South America Sales Office:</H3> </A> </BLOCKQUOTE><BLOCKQUOTE>Central/South America Account Manager: <BR>John Stevens, <A href="mailto:jsteven08@reach.com">jsteven08@reach.com</A>.Phone: (525) 280-62-09 Fax: (525) 280-61-09 </BLOCKQUOTE><P><CENTER><A href="toolbar.gif.map"><IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="images/toolbar.gif" ISMAP></A><BR><FONT size=2><A href="bizpubs/index.html">Newspapers</A> | <A href="clipping/index.html">Alert Services</A>| <A href="online-lib/index.html">Research</A> | <A href="pers-finance/index.html">Personal Finance</A>| <A href="latest.html">DJ In The News</A> | <A href="mailto:webmaster@nrs.dowjones.com">Write Us</A>| <A href="index.html">Home</A> </FONT></CENTER></TD></TR></TABLE></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-20</DOCNO>
<DOCOLDNO>IA027-000290-B042-24</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/dowvision/sales.html 143.131.194.4 19970114044314 text/html 1965
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:47:20 GMT
Last-modified: Wednesday, 29-May-96 15:04:00 GMT
Content-length: 1773
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>
<body bgcolor="#ffffff" background="../images/bgdcc.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80 valign=top ><img SRC="../../images/trsp.gif">  
<a href="../index.html">
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/lrgcosclip.gif"></a></td>
<td>

<CENTER>


		<IMG WIDTH=200 HEIGHT=31 BORDER=0 SRC="images/dowvnsm.gif">
		
		<p>
</CENTER>

<HR SIZE=4>

<p><ul>

<BR>
<b>If you're in Sales/Marketing</b>, you can use DowVision<font size=2>&#174;</font> to:
<P>


<li>Understand your customers and prospects from the inside out.
<BR>

<li>Monitor their activities, product developments, and market moves to uncover new opportunities.
<BR>

<li> Develop effective, fact-based presentations that impress customers or prospects.
<BR>

<li> Use news about products, executive changes, mergers and acquisitions to uncover sales opportunities or to close a sale.
<BR>

<li> Watch the creative strategies of companies and their agencies.
<P>

</ul>


<pre>






		
</pre>
	<CENTER>Back To <A HREF="index.html">DowVision<font size=2>&#174;</font></A>
	
	<br>			
				<a href="../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../bizpubs/index.html">Newspapers</a> |
					<a href="../../clipping/index.html">Alert Services</a> |
					<a href="../../online-lib/index.html">Research</a>   |
					<a href="../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../index.html">Home</a> 

				</font>

				
				</center>
				




</TD></tr>
</TABLE>
</body>
</html>


</DOC>
<DOC>
<DOCNO>WT18-B31-21</DOCNO>
<DOCOLDNO>IA027-000290-B042-62</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/dowvision/advertising.html 143.131.194.4 19970114044345 text/html 2221
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:47:42 GMT
Last-modified: Wednesday, 29-May-96 15:03:58 GMT
Content-length: 2029
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>
<body bgcolor="#ffffff" background="../images/bgdcc.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80 valign=top ><img SRC="../../images/trsp.gif">  
<a href="../index.html">
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/lrgcosclip.gif"></a></td>
<td>

<CENTER>


		<IMG WIDTH=200 HEIGHT=31 BORDER=0 SRC="images/dowvnsm.gif">
		
		<p>
</CENTER>

<HR SIZE=4>

<p><ul>

		<b>If you're in Public Relations/Investor Relations</b>, you can use
		DowVision<font size=2>&#174;</font> to: <P>
		
		<li> Locate, comprehend and respond to what's being written about your company,
		competitors and industry using a steady stream of information from the many 
Dow Jones newswires.<BR>
		
		<li> Determine the amount of press coverage that competitors and other companies
		are co-generating via press releases, compared with independent coverage initiated by reporters. Track the pickup of corporate releases and determine how they were interpreted by the press. <BR>
		
		<li> Manage a crisis with access to the facts. <BR>
		
		<li> Construct a media timeline of events as they unfold in the press. <BR>
		
		<li> Spot trends as they are just developing so your company can get ahead of the curve. <P>

	</ul>
	
<pre>






		
</pre>
	<CENTER>Back To <A HREF="index.html">DowVision<font size=2>&#174;</font></A>
	
	
	<br>
				<a href="../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../bizpubs/index.html">Newspapers</a> |
					<a href="../../clipping/index.html">Alert Services</a> |
					<a href="../../online-lib/index.html">Research</a>   |
					<a href="../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../index.html">Home</a> 

				</font>

				
				</center>
				





</TD></tr>
</TABLE>
</body>
</html>



</DOC>
<DOC>
<DOCNO>WT18-B31-22</DOCNO>
<DOCOLDNO>IA027-000290-B042-97</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/dowvision/executive.html 143.131.194.4 19970114044417 text/html 2104
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:48:24 GMT
Last-modified: Wednesday, 29-May-96 15:03:59 GMT
Content-length: 1912
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>
<body bgcolor="#ffffff" background="../images/bgdcc.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80 valign=top ><img SRC="../../images/trsp.gif">  
<a href="../index.html">
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/lrgcosclip.gif"></a></td>
<td>

<CENTER>


		<IMG WIDTH=200 HEIGHT=31 BORDER=0 SRC="images/dowvnsm.gif">
		
		<p>
</CENTER>

<HR SIZE=4>

<p><ul>

<b>If you're in Executive Management</b>, you can use DowVision<font size=2>&#174;</font> to:
<P>


<li> Stay on top of the news and trends affecting your company and industry.
<BR>

<li> Converse with confidence about the latest developments drawing on a 
knowledge-base built on daily use of Dow Jones News Services. 
<BR>

<li> Monitor competitors and define their scope of business and objectives.
<BR>

<li> Follow developments in industries related to yours, including those of your suppliers and alliances. 
<BR>

<li> Watch critical national and international news stories unfold throughout the day. 
<BR>

<li> See how the media is covering the activities of your company or its subsidiaries.
<P>

</ul>

<pre>




		
		
</pre>
	<CENTER>Back To <A HREF="index.html">DowVision<font size=2>&#174;</font></A>
	
	
	
	
	<br>
	
	
				<a href="../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../bizpubs/index.html">Newspapers</a> |
					<a href="../../clipping/index.html">Alert Services</a> |
					<a href="../../online-lib/index.html">Research</a>   |
					<a href="../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../index.html">Home</a> 

				</font>

				</center>
				





</TD></tr>
</TABLE>
</body>
</html>



</DOC>
<DOC>
<DOCNO>WT18-B31-23</DOCNO>
<DOCOLDNO>IA027-000290-B042-125</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/dowvision/mergers.html 143.131.194.4 19970114044427 text/html 2172
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:48:38 GMT
Last-modified: Wednesday, 29-May-96 15:04:00 GMT
Content-length: 1980
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>
<body bgcolor="#ffffff" background="../images/bgdcc.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80 valign=top ><img SRC="../../images/trsp.gif">  
<a href="../index.html">
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/lrgcosclip.gif"></a></td>
<td>

<CENTER>


		<IMG WIDTH=200 HEIGHT=31 BORDER=0 SRC="images/dowvnsm.gif">
		
		<p>
</CENTER>

<HR SIZE=4>

<p><ul>

<b>If you're in Strategic Planning/Mergers & Acquisitions</b>, you
can use DowVision<font size=2>&#174;</font> to: <P>



<li> Research products and markets to set an informed strategy for future growth. <BR>

<li>Develop comprehensive profiles of key competitors or companies that are 
candidates for a merger or acquisition. Note what key analysts are saying about such companies. 
<BR>
<li>Thoroughly understand how potential partners are seen through the eyes of 
the press.
<br>

<li> Analyze the financial health of both public and hard-to-research private companies using
press and industry reports. <BR>

<li> Locate, extract and compile data on the performance of competitors. <BR>

<li> Follow the international moves of key players in the global financial markets.<P>

</ul>

<pre>






		
</pre>

	<CENTER>Back To <A HREF="index.html">DowVision<font size=2>&#174;</font></A>
	
	<br>
				<a href="../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../bizpubs/index.html">Newspapers</a> |
					<a href="../../clipping/index.html">Alert Services</a> |
					<a href="../../online-lib/index.html">Research</a>   |
					<a href="../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../index.html">Home</a> 

				</font>

				
				</center>
				






</TD></tr>
</TABLE>
</body>
</html>


</DOC>
<DOC>
<DOCNO>WT18-B31-24</DOCNO>
<DOCOLDNO>IA027-000290-B042-158</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/dowvision/intelligence.html 143.131.194.4 19970114044443 text/html 1975
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:48:54 GMT
Last-modified: Wednesday, 29-May-96 15:03:59 GMT
Content-length: 1783
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>
<body bgcolor="#ffffff" background="../images/bgdcc.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80 valign=top ><img SRC="../../images/trsp.gif">  
<a href="../index.html">
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/lrgcosclip.gif"></a></td>
<td>

<CENTER>


		<IMG WIDTH=200 HEIGHT=31 BORDER=0 SRC="images/dowvnsm.gif">
		
		<p>
</CENTER>

<HR SIZE=4>

<p><ul>

<b>If you're in Competitive Intelligence</b>, you can use DowVision<font size=2>&#174;</font> to:

<P>
		
		<li>Find out what the press is saying about your competitors, their products and
		strategies. <BR>
		
		<li>Follow new product announcements, management changes, filings at the SEC,
		potential mergers and acquisitions, and more. <BR>
		
		<li> Get the inside story on your competitors' strategies while there's still time
		to take action. <BR>
		
		<li> Look at financials, R&D expenditures and other key data that can reveal your
		competitors' latest moves. 

<P>

</ul>

	
<pre>






		
</pre>


	<CENTER>Back To <A HREF="index.html">DowVision<font size=2>&#174;</font></A>
	
	
	<br>
				<a href="../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../bizpubs/index.html">Newspapers</a> |
					<a href="../../clipping/index.html">Alert Services</a> |
					<a href="../../online-lib/index.html">Research</a>   |
					<a href="../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../index.html">Home</a> 

				</font>

				
				</center>
				





</TD></tr>
</TABLE>
</body>
</html>



</DOC>
<DOC>
<DOCNO>WT18-B31-25</DOCNO>
<DOCOLDNO>IA027-000290-B042-198</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/dowvision/mis.html 143.131.194.4 19970114044522 text/html 2042
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:49:26 GMT
Last-modified: Wednesday, 29-May-96 15:04:00 GMT
Content-length: 1850
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>
<body bgcolor="#ffffff" background="../images/bgdcc.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80 valign=top ><img SRC="../../images/trsp.gif">  
<a href="../index.html">
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/lrgcosclip.gif"></a></td>
<td>

<CENTER>


		<IMG WIDTH=200 HEIGHT=31 BORDER=0 SRC="images/dowvnsm.gif">
		
		<p>
</CENTER>

<HR SIZE=4>

<p><ul>

<b>If you're an MIS professional</b>, you can use DowVision<font size=2>&#174;</font> to:
<P>

		
		<li> Watch developments at the technology companies with whom you do business.
		<BR>
		
		<li> Stay on top of technology trends with push-button access to key newsletters.
		<BR>
		
		<li> Watch emerging technologies to avoid system obsolescence or vendor problems.
		<BR>
		
		<li>Find out how other companies are deploying new technologies to increase their competitiveness.
		<BR>
		
		<li>Shape a smart systems strategy that will survive changes in standards.
		<BR>
		
		<li> Follow daily announcements of new product releases.
		<BR>

	</ul>
<p>
				

<pre>






		
</pre>

	<CENTER>Back To <A HREF="index.html">DowVision<font size=2>&#174;</font></A>
	
	<br>
				<a href="../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../bizpubs/index.html">Newspapers</a> |
					<a href="../../clipping/index.html">Alert Services</a> |
					<a href="../../online-lib/index.html">Research</a>   |
					<a href="../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../index.html">Home</a> 

				</font>

				
				</center>
				




</TD></tr>
</TABLE>
</body>
</html>


</DOC>
<DOC>
<DOCNO>WT18-B31-26</DOCNO>
<DOCOLDNO>IA027-000290-B042-233</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/dowvision/librarian.html 143.131.194.4 19970114044545 text/html 1837
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:49:45 GMT
Last-modified: Wednesday, 29-May-96 15:04:00 GMT
Content-length: 1645
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>
<body bgcolor="#ffffff" background="../images/bgdcc.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80 valign=top ><img SRC="../../images/trsp.gif">  
<a href="../index.html">
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/lrgcosclip.gif"></a></td>
<td>

<CENTER>


		<IMG WIDTH=200 HEIGHT=31 BORDER=0 SRC="images/dowvnsm.gif">
		
		<p>
</CENTER>

<HR SIZE=4>

<p><ul>

<b>If you're an Information Center/Corporate Library professional</b>, you can use
DowVision<font size=2>&#174;</font> to: 

<P>

<li> Consult the authoritative provider for critical  real-time and same-day
business news. 

<BR>

<li> Automate the process of running key current-awareness searches for clients.
<BR>

<li> Provide a user-friendly workstation that allows your colleagues to conduct
their own basic research. 


 <P>

</ul>


				

	
<pre>






		
</pre>


	<CENTER>Back To <A HREF="index.html">DowVision<font size=2>&#174;</font></A>
	
	
	<br>
				<a href="../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../bizpubs/index.html">Newspapers</a> |
					<a href="../../clipping/index.html">Alert Services</a> |
					<a href="../../online-lib/index.html">Research</a>   |
					<a href="../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../index.html">Home</a> 

				</font>

				
				</center>
				






</TD></tr>
</TABLE>
</body>
</html>



</DOC>
<DOC>
<DOCNO>WT18-B31-27</DOCNO>
<DOCOLDNO>IA027-000290-B042-280</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/dowvision/accountant.html 143.131.194.4 19970114044616 text/html 1717
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:50:24 GMT
Last-modified: Wednesday, 29-May-96 15:03:57 GMT
Content-length: 1525
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>
<body bgcolor="#ffffff" background="../images/bgdcc.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80 valign=top ><img SRC="../../images/trsp.gif">  
<a href="../index.html">
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/lrgcosclip.gif"></a></td>
<td>

<CENTER>


		<IMG WIDTH=200 HEIGHT=31 BORDER=0 SRC="images/dowvnsm.gif">
		
		<p>
</CENTER>

<HR SIZE=4>

<p>

<ul>

<b>If you're a Tax professional</b>, you can use DowVision<font size=2>&#174;</font> to:
<P>

<li> Gather the latest regulations from the IRS, Treasury Department, Federal Reserve, and Small Business Administration as they are announced.
<BR>
<li> Follow specific developments that might affect your industry.
<BR>

</ul>
<pre>






		
</pre>


	<CENTER>Back To <A HREF="index.html">DowVision<font size=2>&#174;</font></A>
	
	
	<br>
	
				<a href="../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../bizpubs/index.html">Newspapers</a> |
					<a href="../../clipping/index.html">Alert Services</a> |
					<a href="../../online-lib/index.html">Research</a>   |
					<a href="../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../index.html">Home</a> 

				</font>

				
				
				</center>
				




</TD></tr>
</TABLE>
</body>
</html>


</DOC>
<DOC>
<DOCNO>WT18-B31-28</DOCNO>
<DOCOLDNO>IA027-000290-B042-316</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/dowvision/dv-cust-quote.html 143.131.194.4 19970114044629 text/html 2838
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:50:41 GMT
Last-modified: Wednesday, 29-May-96 15:03:58 GMT
Content-length: 2646
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>
<body bgcolor="#ffffff" background="../images/bgdcc.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80 valign=top ><img SRC="../../images/trsp.gif">  
<a href="../index.html">
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/lrgcosclip.gif"></a></td>
<td>

<BR>



<CENTER>


		<IMG WIDTH=200 HEIGHT=31 BORDER=0 SRC="images/dowvnsm.gif">
		
		<p>
</CENTER>

<HR SIZE=4>

<p><blockquote>
<b>What customers are saying...</b>



<P>
"In less than two months, [DowVision<font size=2>&#174;</font>] has become the second most popular feature
of the network -- after e-mail." 
<BR>

		<UL>-Bill O'Brien
<BR>
		Deputy Chairman
<BR>
		Coopers & Lybrand</UL>
<P>

"In addition to the Systems Marketing group, our Information Center will use
DowVision<font size=2>&#174;</font> to provide information about competitors and customers for many more
users throughout the company.  In the past, this might have been assigned to a
more costly outside consultant." <BR> 		
		<UL>-Darryl White
<BR>
		Chief Financial Officer
<BR>
		Compaq Computer Corporation</UL>
<P>

 "We've had numerous instances where DowVision<font size=2>&#174;</font> has allowed us to provide superior service to our customers -- cases where we have been alerted and been able to act faster than the competition."
<BR>
		<UL>-Craig Goldman
<BR>
		CIO
<BR>
		Chase Manhattan Bank</UL>
<P>

"DowVision<font size=2>&#174;</font> lets me research competitive news on IBM, HP, Digital and other vendors in order to maintain information on enterprise computing environments."
<BR>
		<UL>-Giovanni Caldei
<BR>
		Business Analyst and Project Manager
<BR>
		Compaq Computer Corporation
		</UL>
<P>

				See what the
				<A HREF="dv-press-quote.html"><B>
				press</B></A> is saying about DowVision<font size=2>&#174;</font>. 
 

</blockquote>

<BR>



	
	<pre>
		
		
		
		
		
		</pre>
	<CENTER>Back To <A HREF="index.html">DowVision<font size=2>&#174;</font></A>
	
	
	
	
	<br>			
				<a href="../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../bizpubs/index.html">Newspapers</a> |
					<a href="../../clipping/index.html">Alert Services</a> |
					<a href="../../online-lib/index.html">Research</a>   |
					<a href="../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../index.html">Home</a> 

				</font>

				
				
				</center>
				




</TD></tr>
</TABLE>
</body>
</html>



</DOC>
<DOC>
<DOCNO>WT18-B31-29</DOCNO>
<DOCOLDNO>IA027-000290-B042-345</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/dowvision/dv-press-quote.html 143.131.194.4 19970114044639 text/html 2008
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:50:51 GMT
Last-modified: Wednesday, 29-May-96 15:03:59 GMT
Content-length: 1816
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>
<body bgcolor="#ffffff" background="../images/bgdcc.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80 valign=top ><img SRC="../../images/trsp.gif">  
<a href="../index.html">
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/lrgcosclip.gif"></a></td>
<td>


<CENTER>	
		
		
		<IMG WIDTH=200 HEIGHT=31 BORDER=0 SRC="images/dowvnsm.gif">
		
		<p>
		
		
		</CENTER>
		
		<HR SIZE=4>
<BR>
<P>
<blockquote>

<b>Here's what the press is saying...</B>
<p>

"A big name in this group is Dow Jones' DowVision. The foundations of this service are Dow Jones' own sources: the AP-Dow Jones International News Service, Capital Markets Report, Professional Investor Report, <em>The Wall Street Journal</em>, and the Dow Jones International News Service."<br>
<ul> -<em>PC Magazine</em>, "Custom News for the Corporate Site," April 6, 1996</ul><p>

<p>

				See what
				<A HREF="dv-cust-quote.html"><B>
				customers</B></A> are saying about DowVision<font size=2>&#174;</font>. 
 

</blockquote>

<BR>



	
<pre>
</pre>
	<CENTER>Back To <A HREF="index.html">DowVision<font size=2>&#174;</font></A>
	
	
	<br>
									<a href="../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../bizpubs/index.html">Newspapers</a> |
					<a href="../../clipping/index.html">Alert Services</a> |
					<a href="../../online-lib/index.html">Research</a>   |
					<a href="../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../index.html">Home</a> 

				</font>

				
				
				</center>
				




</TD></tr>
</TABLE>
</body>
</html>



</DOC>
<DOC>
<DOCNO>WT18-B31-30</DOCNO>
<DOCOLDNO>IA027-000290-B043-169</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/custom-clips/cctour.html 143.131.194.4 19970114044859 text/html 4779
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:53:10 GMT
Last-modified: Thursday, 23-May-96 18:46:29 GMT
Content-length: 4588
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones Custom Clips</title></head>
<body bgcolor="#ffffff" background="../images/bgdcc.gif">

<TABLE Width=550 BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR>
<td width=50 valign=top>  
<a href="../index.html">
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/lrgcosclip.gif"></a></td>
<td>
<BR>



<CENTER>

<IMG BORDER=0 SRC="images/newcustclips.gif"><P>
<img src="../../images/tour.gif">
</CENTER>

<UL>

<p>

Give all the decision makers in your company access to the news and trends that affect your business. And do it automatically with Dow Jones CustomClips-via e-mail, groupware or other appropriate platforms. It's a comprehensive yet easy way to track all the news and information that matters to your organization. You pick the topics; we deliver the information. It's that simple. Follow the quick tour below to learn more and to see how Dow Jones CustomClips works.
<P>

<HR>

<IMG  SRC="bullet.gif"  ALIGN=TOP><FONT SIZE=5><B>How CustomClips Works </B><BR></FONT>
You tell us what's important to you-the companies, industries, topics, trends and people you need to follow. A Dow Jones <A HREF="/clipping/custom-clips/contact.html">representative</a> works with you to set up a news profile that matches those interests and monitors the right publications. We'll also help you set up delivery to your organization's e-mail system or LAN. Whatever works best for you. Once you're set up, relevant news is automatically delivered.<br>
<IMG SRC="cc1.gif"  WIDTH=516 HEIGHT=416 ALIGN=TOP>


<HR>

<IMG  SRC="bullet.gif"  ALIGN=TOP><FONT SIZE=5><B>The Dow Jones Difference</B><BR></FONT>
We also offer several hundred pre-created topics. These news profiles, created by Dow Jones editors, have been painstakingly tested and adjusted over time to ensure they provide comprehensive coverage-without irrelevant information making its way onto your desktop.  It's added value that only the editorial experts at Dow Jones can provide. <BR>
<IMG SRC="cc3.gif"  WIDTH=299 HEIGHT=232 ALIGN=TOP>
<p>

<HR> 

<IMG  SRC="bullet.gif"  ALIGN=TOP><FONT SIZE=5><B>Exclusive Sources </B><BR></FONT>
CustomClips delivers news from any of the 1,600 sources you want. Coverage includes a wide range of industries and includes trade journals such as <i>Communications Daily</i>, <i>Advertising Age</i>, <I>Pharmaceutical Manufacturing</I>, <I>Internet Week</I>, <I>WorldWide Energy</I> and <I>McKinsey Quarterly</I>. <A HREF="/clipping/custom-clips/publications/publications.html">Click here</a> for a complete list.<p>


<HR> 

<IMG  SRC="bullet.gif"  ALIGN=TOP><FONT SIZE=5><B>For You and For Your Enterprise</B><BR></FONT>
Dow Jones CustomClips provides precisely the information you need, whenever you need it. You decide if it's appropriate for you or for many of your colleagues to receive news delivery.<p>


<HR>

<IMG  SRC="bullet.gif"  ALIGN=TOP><FONT SIZE=5><B>Flexible Environment</B><BR></FONT>
We'll work with you to deliver CustomClips to your e-mail or other appropriate platform. We currently offer software that works with Lotus Notes, DDI NewsEdge software and other groupware applications.<br>
<IMG SRC="cc2.gif"  WIDTH=341 HEIGHT=204 ALIGN=TOP>

<P>

<HR>

<IMG  SRC="bullet.gif"  ALIGN=TOP><FONT SIZE=5><B>Competitive Pricing</B><BR></FONT>
We offer price plans that are flexible and affordable. Whether you're a one-person operation or a Fortune 500 company, we have a competitive price for you that will help empower you with this critical news delivery system. <P> 

<HR>

<IMG  SRC="bullet.gif"  ALIGN=TOP><FONT SIZE=5><B>Another Option</B><BR></FONT>
We also offer DowVision, for a more real-time broadcast news source for your enterprise. It's the most popular, direct-to-the desktop news delivery service. To take a quick tour of <A HREF="/clipping/dowvision/dowtour.html">DowVision, click here</a>.<P> 



</UL>


<pre>

</pre>
 <center> Back To <A HREF="index.html">Dow Jones CustomClips</a></center> 


				<center>
				<a href="../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../bizpubs/index.html">Newspapers</a> |
					<a href="../../clipping/index.html">Alert Services</a> |
					<a href="../../online-lib/index.html">Research</a>   |
					<a href="../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../index.html">Home</a> 

				</font>


				</center>
</TD></tr>
</TABLE>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT18-B31-31</DOCNO>
<DOCOLDNO>IA027-000290-B043-204</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/custom-clips/publications/publications.html 143.131.194.4 19970114044931 text/html 2770
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:53:28 GMT
Last-modified: Wednesday, 29-May-96 14:59:55 GMT
Content-length: 2578
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones Custom Clips Publications</title></head>

<body bgcolor="#ffffff" background="../../images/bgdcc.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td valign=top width=80>  
	<a href="../../index.html">
   <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../../images/lrgcosclip.gif"></a>
    <br>  
    <img SRC="../../../images/trsp.gif"></td> 
<td>

<br>

<center>


<A NAME="#Top Of Page"></a>

<IMG BORDER=0 SRC="images/custclips.gif">




<p>

<HR SIZE=4>

</CENTER>


<P>
<blockquote>


<b>Dow Jones CustomClips<font size=3>&#174;</FONT> pulls articles from an impressive list of trade and
industry publications. Simply click on the industries that matter most to you to
scan for the specific publications that matter most to you. </b> 

</blockquote>
<P>


<ul>			
<LI><A HREF="computers.html">Computers/Computer Technology</A>

<LI><A HREF="communications.html">Communications</A>

<LI><A HREF="construct.html">Construction</A> 

<LI><A HREF="energy.html">Energy</A>

<LI><A HREF="environment.html">Environment</A> 

<LI><A HREF="financial.html">Financial</A>	

<LI><A HREF="food.html">Food Processing</A>

<LI><A HREF="pharma.html">Pharmaceutical/Medical/Health</A>

<LI><A HREF="industechn.html">Industrial/Technology</A>

<LI><A HREF="media.html">Media</A>

<LI><A HREF="retail.html">Retail</A>

<LI><A HREF="transp.html">Transportation</A>

<LI><A HREF="political.html">Political</A>

<LI><A HREF="localnews.html">Local Newspapers</A>

<LI><A HREF="majornews.html">Major National Newspapers</A>

<LI><A HREF="generalbus.html">General Business Publications</A>

<LI><A HREF="international.html">International</A>

<LI><A HREF="business.html">Business Publications</A>

<LI><A HREF="press.html">Press Releases</A>

<LI><A HREF="general.html">General</A>


</ul>


<p>

<pre>




</pre>
 <CENTER>Back To 
			<A HREF="../index.html">Dow Jones CustomClips&#174;</A>
			
			<br>					<a href="../../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../../bizpubs/index.html">Newspapers</a> |
					<a href="../../../clipping/index.html">Alert Services</a> |
					<a href="../../../online-lib/index.html">Research</a>   |
					<a href="../../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../../index.html">Home</a> 

				</font>

				
				</center>
				




</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-32</DOCNO>
<DOCOLDNO>IA027-000290-B043-233</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/custom-clips/contact.html 143.131.194.4 19970114044945 text/html 4987
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:53:55 GMT
Last-modified: Thursday, 13-Jun-96 21:03:10 GMT
Content-length: 4796
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>
<body bgcolor="#ffffff" background="../images/bgdcc.gif">
	
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>

<TR><td width=80 valign=top ><img SRC="../../images/trsp.gif">  
<a href="../index.html">
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/lrgcosclip.gif"></a></td>
<td>

<p>
<CENTER>
<IMG WIDTH=165 HEIGHT=22 BORDER=0 SRC="images/custclips.gif">

<p>
<h2>
Contact
</H2></CENTER>





<HR SIZE=4>
<P>



<blockquote>


<IMG WIDTH=120 HEIGHT=16 BORDER=0 SRC="images/custccsm.gif">


<P>

Just fill in the blanks below and a Dow Jones representative will respond promptly!

<br>

<FORM  METHOD="POST" ACTION="/cgi-bin/lead.cgi">
<INPUT NAME="Formtype" VALUE="lead_form" TYPE="hidden" size=10>

<table>
<tr><td>
	<b>Name:</b>
</td><td>
	 <INPUT TYPE ="text" NAME="name" maxlength= 30 SIZE =30>
</td></tr><tr><td>
	<b>Company Name:</b>
</td><td>
	<INPUT TYPE ="text" NAME="CompanyName" maxlength= 50 SIZE =30>
</td></tr><tr><td>
	<b>Street Address:</b>
</td><td>
     <INPUT TYPE ="text" NAME="Address1"  maxlength= 40 SIZE =30>
</td></tr><tr><td>
</td><td>
     <INPUT TYPE ="text" NAME="Address2"  maxlength=40 SIZE =30> 
</td></tr><tr><td>
	<b>City:</b>
</td><td>                 
	<INPUT TYPE ="text"NAME="City"  maxlength= 30 SIZE =30>
</td></tr><tr><td>
	<b>State:</b>
</td><td>               
	<INPUT TYPE ="text"NAME="State"  maxlength= 30 SIZE =30> 
</td></tr><tr><td> 						  
	<b>Zip/Postal Code:</b>
</td><td>
   <INPUT TYPE ="text"NAME="Zip"maxlength= 30 SIZE =30> 
</td></tr><tr><td>
<b>Country:</b>
</td><td>
<INPUT TYPE="text" Name="Country" maxlength=30 SIZE=30>
</td></tr>
</table>
<P>

<b>What product are you interested in?</B><br> 
<Select Name ="Interested">
<OPTION SELECTED>Dow Jones Custom Clips
<Option>DowVision
<option>Dow Jones News/Retrieval
<option>All of them
</select>
<p>


<b>How would you describe your profession?</B> 
<Select Name ="Profession">
<br>
<OPTION SELECTED>Choose From List
<Option>Attorney/Counsel
<Option>Communications/Public Relations
<Option>Consultant/Analyst
<Option>Engineering
<option>Finance
<option>Human Resources/Training
<option>Executive Management
<option>Marketing/Advertising
<option>Money/Portfolio Management
<option>Product Management/Development
<option>Programming
<option>Research
<option>Sales (includes Brokerage)
<option>Strategy/Business Development
<option>Student<option>Systems Development
<option>Other
</Select>

 <P>

<B>What is your organization's primary business activity?</b>
<BR>
<Select Name = "Industry" >
<Option Selected>Choose From List
<Option>Accounting
<Option>Banking
<Option>Communications/Publishing/Entertainment <option>Computers/Software/Systems
<Option>Education/Schools
<Option>Financial Services/Securities
<Option>Health Care/Hospitals
<Option>Importing/Trade
<Option>Insurance
<Option>Legal
<Option>Manufacturing
<Option>Nonprofit/Government/Associations
<OPtion>Packaged Goods/Food
<Option>Pharmaceuticals
<Option>Real Estate
<Option>Retailing
<Option>Transportation
</Select>



<P>

<table>
<tr><td>
	<b>Phone Number: </b>
</td><td>
    <INPUT TYPE = "text" NAME="Phone"  maxlength= 30 SIZE =30>
</td></tr><tr><td>
	<b>Fax Number:</b>
</td><td>
    <INPUT TYPE ="text"NAME="Fax"  maxlength= 30 SIZE =30>
</td></tr><tr><td>
<b>E-Mail: </b>
</td><td>
    <INPUT TYPE = "text" NAME="email"  maxlength= 30 SIZE =30>
</td></tr>
</table>


<P>

<STRONG>I'm interested in:</STRONG>
<BR>
<dl>
<DT><INPUT TYPE = "checkbox" NAME="Interested_in" Value="CustomClips_only" >CustomClips<font size=3>&#174;</FONT> only
<BR>
<DT><INPUT TYPE = "checkbox" NAME="Interested_in" Value="CustomClips_and_DowVision" >CustomClips<font size=3>&#174;</FONT> & DowVision<font size=3>&#174;</FONT>
</dl>


<P>

<b>If you are interested in DowVision<font size=3>&#174;</FONT>:</b><br>   

<b>Type of LAN/WAN:</b>        
<INPUT TYPE = "text" Name="Lan_or_wan" maxlength= 30 SIZE =30>
<p>



<CENTER><P><INPUT TYPE="submit" VALUE="I Accept"> <INPUT TYPE="reset" VALUE =
"Clear">

</form>
</blockquote>

 <BR>
				<pre>
					
				</pre>
		 Back To 
			<A HREF="index.html">CustomClips&#174;</A>
			
			
			
			<br>
			
				<a href="../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../bizpubs/index.html">Newspapers</a> |
					<a href="../../clipping/index.html">Alert Services</a> |
					<a href="../../online-lib/index.html">Research</a>   |
					<a href="../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../index.html">Home</a> 

				</font>
				
				
				
				</center>
				


</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-33</DOCNO>
<DOCOLDNO>IA027-000290-B043-263</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/custom-clips/sales.html 143.131.194.4 19970114044957 text/html 2043
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:54:08 GMT
Last-modified: Thursday, 23-May-96 18:46:31 GMT
Content-length: 1852
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>

<body bgcolor="#ffffff" background="../images/bgdcc.gif">
	
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>

<TR><td width=80 valign=top ><img SRC="../../images/trsp.gif">  
<a href="../index.html">
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/lrgcosclip.gif"></a></td>
<td>

<CENTER>




<IMG WIDTH=165 HEIGHT=22 BORDER=0 SRC="images/custclips.gif">




<p>


</CENTER>

<HR SIZE=4>

<ul>


<B>If you're a Sales/Marketing Professional</B>, you can use Dow Jones CustomClips<font size=3>&#174;</FONT> to:
<P>

<li>Understand your customers and prospects from the inside out.
<BR>

<li>Monitor their activities, product developments, and market moves to uncover new opportunities.
<BR>

<li> Develop effective, fact-based presentations that impress customers or prospects.
<BR>

<li> Use news about products, executive changes, mergers and acquisitions to uncover sales opportunities or to close a sale.
<BR>

<li> Watch the creative strategies of companies and their agencies.

<P>

</ul>

<BR>

<pre>
			
			
			
			

</pre>
		 <CENTER>Back To 
			<A HREF="index.html">Dow Jones CustomClips<font size=3>&#174;</FONT></A>
			
			
			
			
			
			<br>
				
				<a href="../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../bizpubs/index.html">Newspapers</a> |
					<a href="../../clipping/index.html">Alert Services</a> |
					<a href="../../online-lib/index.html">Research</a>   |
					<a href="../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../index.html">Home</a> 

				</font>
			
				
				
				</center>
				

</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-34</DOCNO>
<DOCOLDNO>IA027-000290-B043-301</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/custom-clips/advertising.html 143.131.194.4 19970114045029 text/html 2311
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:54:28 GMT
Last-modified: Thursday, 23-May-96 18:46:28 GMT
Content-length: 2120
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>

<body bgcolor="#ffffff" background="../images/bgdcc.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>

<TR><td width=80 valign=top ><img SRC="../../images/trsp.gif">  
<a href="../index.html">
				<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/lrgcosclip.gif"></a></td>
				<td>
				
<p>
<CENTER>




<IMG WIDTH=165 HEIGHT=22 BORDER=0 SRC="images/custclips.gif">




<p>

</CENTER>

<HR SIZE=4>

<ul>

<B>If you're an Advertising/Public Relations Professional</B>, you can use Dow Jones
CustomClips<font size=3>&#174;</FONT> to: <P>

		<li> Locate, comprehend and respond to what's being written about your company,
		competitors and industry using a steady stream of information from the many 
Dow Jones newswires. <BR>
		
		<li> Determine the amount of press coverage that competitors and other companies
		are co-generating via press releases, compared with independent coverage initiated by reporters. Track the pickup of corporate releases and determine how they were interpreted by the press.<BR>
		
		<li> Manage a crisis with access to the facts. <BR>
		
		<li> Construct a media timeline of events as they unfold in the press. <BR>
		
		<li> Spot trends as they are just developing so your company can get ahead of the curve. <P>


</ul> <BR>
			<pre>
			
			
			
			
			
			
				</pre>
		 <CENTER>Back To 
			<A HREF="index.html">Dow Jones CustomClips<font size=3>&#174;</FONT></A>
			
			
			
			
			<br>
				
				<a href="../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../bizpubs/index.html">Newspapers</a> |
					<a href="../../clipping/index.html">Alert Services</a> |
					<a href="../../online-lib/index.html">Research</a>   |
					<a href="../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../index.html">Home</a> 

				</font>
				
				
				</center>
				




</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-35</DOCNO>
<DOCOLDNO>IA027-000290-B043-334</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/custom-clips/executive.html 143.131.194.4 19970114045054 text/html 2181
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:55:05 GMT
Last-modified: Thursday, 23-May-96 18:46:29 GMT
Content-length: 1990
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>

<body bgcolor="#ffffff" background="../images/bgdcc.gif">
	
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>

<TR><td width=80 valign=top ><img SRC="../../images/trsp.gif">  
<a href="../index.html">
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/lrgcosclip.gif"></a></td>
<td>
<p>
<BR>
		<CENTER>



<IMG WIDTH=165 HEIGHT=22 BORDER=0 SRC="images/custclips.gif">




<p>

</CENTER>

<HR SIZE=4>

<ul>

<B>If you're an Executive Manager</B>, you can use Dow Jones CustomClips<font size=3>&#174;</FONT> to:
<P>


<li> Stay on top of the news and trends affecting your company and industry.
<BR>

<li> Converse with confidence about the latest developments drawing on a 
knowledge-base built on daily use of Dow Jones News Services. 
<BR>

<li> Monitor competitors and define their scope of business and objectives.
<BR>

<li> Follow developments in industries related to yours, including those of your suppliers and alliances. 
<BR>

<li> Watch critical national and international news stories unfold throughout the day. 
<BR>

<li> See how the media is covering the activities of your company or its subsidiaries.

</ul>

 <BR>
			<pre>
			
			
			
			
			
			
			
				</pre>
		 <CENTER>Back To 
			<A HREF="index.html">Dow Jones CustomClips<font size=3>&#174;</FONT></A>
			
			
			
			
			<br>
			
				<a href="../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../bizpubs/index.html">Newspapers</a> |
					<a href="../../clipping/index.html">Alert Services</a> |
					<a href="../../online-lib/index.html">Research</a>   |
					<a href="../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../index.html">Home</a> 

				</font>
				
				
				</center>
				


</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-36</DOCNO>
<DOCOLDNO>IA027-000290-B043-379</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/custom-clips/mergers.html 143.131.194.4 19970114045115 text/html 2264
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:55:26 GMT
Last-modified: Thursday, 23-May-96 18:46:30 GMT
Content-length: 2073
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>

<body bgcolor="#ffffff" background="../images/bgdcc.gif">
	
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>

<TR><td width=80 valign=top ><img SRC="../../images/trsp.gif">  
<a href="../index.html">
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/lrgcosclip.gif"></a></td>
<td>
<p>

<CENTER>




<IMG WIDTH=165 HEIGHT=22 BORDER=0 SRC="images/custclips.gif">




<p>

</CENTER>

<HR SIZE=4>

<ul>

<B>If you're a Strategic Planning/Mergers & Acquisitions Professional</B>, you can use Dow Jones CustomClips<font size=3>&#174;</FONT> to:
<P>


<li> Research products and markets to set an informed strategy for future growth. <BR>

<li>Develop comprehensive profiles of key competitors or companies that are 
candidates for a merger or acquisition. Note what key analysts are saying about such companies. 
<BR>
<li>Thoroughly understand how potential partners are seen through the eyes of 
the press.
<br>

<li> Analyze the financial health of both public and hard-to-research private companies using
press and industry reports. <BR>

<li> Locate, extract and compile data on the performance of competitors. <BR>

<li> Follow the international moves of key players in the global financial markets.<P>

</ul>
 <BR>
			<pre>
			
			
			
			
			
			
				</pre>
		 <CENTER>Back To 
			<A HREF="index.html">Dow Jones CustomClips<font size=3>&#174;</FONT></A>
			
			
			
			<br>
			
				<a href="../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../bizpubs/index.html">Newspapers</a> |
					<a href="../../clipping/index.html">Alert Services</a> |
					<a href="../../online-lib/index.html">Research</a>   |
					<a href="../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../index.html">Home</a> 

				</font>
				
				
				
				</center>
				



</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-37</DOCNO>
<DOCOLDNO>IA027-000290-B043-410</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/custom-clips/intelligence.html 143.131.194.4 19970114045126 text/html 2083
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:55:38 GMT
Last-modified: Thursday, 23-May-96 18:46:30 GMT
Content-length: 1892
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>

<body bgcolor="#ffffff" background="../images/bgdcc.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>

<TR><td width=80 valign=top ><img SRC="../../images/trsp.gif">  
<a href="../index.html">
				<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/lrgcosclip.gif"></a>
				</td><td>
				
				<p>
				
				<br>

<CENTER>




<IMG WIDTH=165 HEIGHT=22 BORDER=0 SRC="images/custclips.gif">




<p>

</CENTER>

<HR SIZE=4>
<BR>
<ul>

<B>If you're a Competitive Intelligence Expert</B>, you can use Dow Jones CustomClips<font size=3>&#174;</FONT> to:
<P>

		<li>Find out what the press is saying about your competitors, their products and
		strategies. <BR>
		
		<li>Follow new product announcements, management changes, filings at the SEC,
		potential mergers and acquisitions, and more. <BR>
		
		<li> Get the inside story on your competitors' strategies while there's still time
		to take action. <BR>
		
		<li> Look at financials, R&D expenditures and other key data that can reveal your
		competitors' latest moves. 
<BR>

</ul> 

<BR>



			<pre>
			
			
			
			
			
			
			
			
				</pre>
		 <CENTER>Back To 
			<A HREF="index.html">Dow Jones CustomClips<font size=3>&#174;</FONT></A>
			
			
			<br>
				<a href="../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../bizpubs/index.html">Newspapers</a> |
					<a href="../../clipping/index.html">Alert Services</a> |
					<a href="../../online-lib/index.html">Research</a>   |
					<a href="../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../index.html">Home</a> 

				</font>
				
				</center>
				




</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-38</DOCNO>
<DOCOLDNO>IA027-000290-B043-438</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/custom-clips/mis.html 143.131.194.4 19970114045158 text/html 2099
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:55:55 GMT
Last-modified: Thursday, 23-May-96 18:46:31 GMT
Content-length: 1908
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>
<body bgcolor="#ffffff" background="../images/bgdcc.gif">
	
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>

<TR><td width=80 valign=top ><img SRC="../../images/trsp.gif">  
<a href="../index.html">
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/lrgcosclip.gif"></a></td>
<td>

<p>
<CENTER>




<IMG WIDTH=165 HEIGHT=22 BORDER=0 SRC="images/custclips.gif">




<p>

</CENTER>

<HR SIZE=4>

<ul>

<B>If you're an MIS Expert</B>, you can use Dow Jones CustomClips<font size=3>&#174;</FONT> to:
<P>

		<li> Watch developments at the technology companies with whom you do business.
		<BR>
		
		<li> Stay on top of technology trends with push-button access to key newsletters.
		<BR>
		
		<li> Watch emerging technologies to avoid system obsolescence or vendor problems.
		<BR>
		
		<li>Find out how other companies are deploying new technologies to increase their competitiveness.
		<BR>
		
		<li>Shape a smart systems strategy that will survive changes in standards.
		<BR>
		
		<li> Follow daily announcements of new product releases.
<P>

</ul>


 <BR>
			<pre>
			
			
			
			
			
			
				</pre>
		 <CENTER>Back To 
			<A HREF="index.html">Dow Jones CustomClips<font size=3>&#174;</FONT></A>
			
			
			
			<br>
				
				<a href="../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../bizpubs/index.html">Newspapers</a> |
					<a href="../../clipping/index.html">Alert Services</a> |
					<a href="../../online-lib/index.html">Research</a>   |
					<a href="../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../index.html">Home</a> 

				</font>
			
				
				</center>
				



</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-39</DOCNO>
<DOCOLDNO>IA027-000290-B043-462</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/custom-clips/librarian.html 143.131.194.4 19970114045215 text/html 1877
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:56:24 GMT
Last-modified: Thursday, 23-May-96 18:46:30 GMT
Content-length: 1686
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>

<body bgcolor="#ffffff" background="../images/bgdcc.gif">
	
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>

<TR><td width=80 valign=top ><img SRC="../../images/trsp.gif">  
<a href="../index.html">
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/lrgcosclip.gif"></a></td>
<td>

<p>

<CENTER>




<IMG WIDTH=165 HEIGHT=22 BORDER=0 SRC="images/custclips.gif">




<p>

</CENTER>

<HR SIZE=4>

<ul>

<B>If you're an Information Professional/Corporate Librarian</B>, you can use
Dow Jones CustomClips<font size=3>&#174;</FONT> to: <P>


<li> Consult the authoritative provider for critical  real-time and same-day
business news. 

<BR>

<li> Automate the process of running key current-awareness searches for clients.
<BR>

<li> Provide a user-friendly workstation that allows your colleagues to conduct
their own basic research. 

</ul> <BR>
			<pre>
			
			
			
			
			
			
				</pre>
		 <CENTER>Back To 
			<A HREF="index.html">Dow Jones CustomClips<font size=3>&#174;</FONT></A>
			
			
			
			<br>
			
			
				<a href="../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../bizpubs/index.html">Newspapers</a> |
					<a href="../../clipping/index.html">Alert Services</a> |
					<a href="../../online-lib/index.html">Research</a>   |
					<a href="../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../index.html">Home</a> 

				</font>

				</center>



</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-40</DOCNO>
<DOCOLDNO>IA027-000290-B044-33</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/custom-clips/accountant.html 143.131.194.4 19970114045308 text/html 1809
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:57:00 GMT
Last-modified: Thursday, 23-May-96 18:46:28 GMT
Content-length: 1618
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>

<body bgcolor="#ffffff" background="../images/bgdcc.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>

<TR><td width=80 valign=top ><img SRC="../../images/trsp.gif">  
<a href="../index.html">
				<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/lrgcosclip.gif"></a>
				</td><td>
				
				<p>
				
				<br>

<CENTER>




<IMG WIDTH=165 HEIGHT=22 BORDER=0 SRC="images/custclips.gif">




<p>

</CENTER>

<HR SIZE=4>

<ul>

<B>If you're an Accountant/Tax/Financial Expert</B>, you can use DowVision<font size=3>&#174;</FONT> to:
<P>


<li> Gather the latest regulations from the IRS, Treasury Department, Federal Reserve, and Small Business Administration as they are announced.
<BR>
<li> Follow specific developments that might affect your industry.
<P>

</ul>

 <BR>
			<pre>
			
			
			
			
			
			
			
				</pre>
		 <CENTER>Back To 
			<A HREF="index.html">CustomClips<font size=3>&#174;</FONT></A>
			
			
			
			
			<br>
				
				<a href="../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../bizpubs/index.html">Newspapers</a> |
					<a href="../../clipping/index.html">Alert Services</a> |
					<a href="../../online-lib/index.html">Research</a>   |
					<a href="../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../index.html">Home</a> 

				</font>
				</center>
				




</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-41</DOCNO>
<DOCOLDNO>IA027-000290-B044-72</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/custom-clips/cc-press-quote.html 143.131.194.4 19970114045328 text/html 1626
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:57:38 GMT
Last-modified: Thursday, 23-May-96 18:46:29 GMT
Content-length: 1435
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>
<body bgcolor="#ffffff" background="../images/bgdcc.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80 valign=top ><img SRC="../../images/trsp.gif">  
<a href="../index.html">
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/lrgcosclip.gif"></a></td>
<td>


<CENTER>	
		
		
		<IMG  SRC="images/newcustclips.gif">

		
		<p>
		
		
		</CENTER>
		
		<HR SIZE=4>
<BR>
<P>
<blockquote>

<b>Here's what the press is saying...</B>
<p>
"Business people who want a wide choice of sources will do well with Dow Jones' CustomClips."<br>
<ul> -<em>PC Magazine, April 6, 1996</em></ul><p>

</blockquote>

<BR>



	
<pre>
</pre>
	<CENTER>Back To <A HREF="index.html">Dow Jones CustomClips<font size=3>&#174;</FONT></A>
	
	
	<br>
									<a href="../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../bizpubs/index.html">Newspapers</a> |
					<a href="../../clipping/index.html">Alert Services</a> |
					<a href="../../online-lib/index.html">Research</a>   |
					<a href="../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../index.html">Home</a> 

				</font>

				
				
				</center>
				




</TD></tr>
</TABLE>
</body>
</html>



</DOC>
<DOC>
<DOCNO>WT18-B31-42</DOCNO>
<DOCOLDNO>IA027-000290-B044-101</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/online-lib/nrtour.html 143.131.194.4 19970114045346 text/html 6479
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:57:59 GMT
Last-modified: Tuesday, 01-Oct-96 00:42:29 GMT
Content-length: 6289
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>Dow Jones News/Retrieval</TITLE></HEAD><BODY bgcolor="#ffffff" background="images/bgdonlin.gif"><P><TABLE Width=75% BORDER=0 CELLSPACING=0 CELLPADDING=0> <TR><TD width=50 valign=top><A href="index.html"><IMG valign=top WIDTH=65 HEIGHT=65 BORDER=0 SRC="images/lrgonlinres.gif"></A><BR><IMG SRC="../images/trsp.gif"></TD><TD> <BR><CENTER><IMG BORDER=0 SRC="images/djnr-logo.gif"><P><IMG src="../images/tour.gif"><FONT SIZE=5>Available Now...</FONT><P>If you like what you see, <A HREF="/downl1.html">download</A> our Windows software or <A HREF="/downlmac.html">Macintosh</A> software now!<BR><B>Then call 1-800-369-7466 ext. 159 and get 10 free hours! </B><P></CENTER><UL>Dow Jones has gathered the most respected publications, newswires,reports and financial analyses, all in one location: Dow JonesNews/Retrieval. But that's not the only thing that will amazeyou about this unique online business information service. You'llalso be astounded at how quickly and easily you'll be able toscan this virtual universe of news and information with the newNews/Retrieval -- 5.0A for Windows. Follow the quick tour belowto see just how powerful and easy this online service is to use.Then either <A HREF="/downl1.html">download</A> the Windows software nowor just call 1-800-369-7466 ext. 159  (or 609-452-1511) to getstarted. We also offer <A HREF="/downlmac.html">Macintosh</A> software.<HR><IMG SRC="bullet.gif"  ALIGN=TEXTTOP><FONT SIZE=5><b>An AmazingResource</FONT></b><BR>Dow Jones is the exclusive combined source of <EM>The WallStreet Journal</EM>, the <EM>New York Times</EM>, the <EM>FinancialTimes</EM>, <EM>The Washington Post</EM> and the <EM>Los AngelesTimes</EM>. Search exclusive newswires for global coverage and48 of the top 50 newspapers on the day of publication. Easilyaccess information on more than 10 million public and privatecompanies and find quotes and data on every major exchange inthe world. And that's just the tip of the iceberg. Read on formore specifics.<IMG SRC="main.gif"  ALIGN=TOP><HR><IMG SRC="bullet.gif"  ALIGN=TEXTTOP><FONT SIZE=5><B>CurrentNews</FONT></b><BR><B>This Just In</B> gives you top stories of the day on businessand world events as selected by Dow Jones editors, top news fromsix industries, plus sports scores and weather forecasts. You'llbe tapping into the world's most widely read newspapers including,of course, <I>The Wall Street Journal </I>plus exclusive Dow Jones newswires.Search for the companies, industries, regions or subjects thatinterest you.<IMG SRC="currentnews.gif"  ALIGN=TOP><HR><IMG SRC="bullet.gif"  ALIGN=TEXTTOP><FONT SIZE=5><B>SearchNews and Articles</FONT></B><BR>For those times when you need more detailed background informationor want to pinpoint a specific story, use the Dow Jones PublicationsLibrary. The Library empowers you with a resource that includes60 million documents and more than 3,400 carefully selected tradeand business publications plus a search engine that's incrediblyfast and thorough. Browse the source list, even create your owncustom list. Setting up your search is easy and help is alwaysavailable if you need it.<HR><IMG SRC="bullet.gif"  ALIGN=TEXTTOP><FONT SIZE=5><B>TrackNews and Articles</FONT></B><BR>One of the best ways to manage all the available information inDow Jones News/Retrieval is Dow Jones CustomClips. Spend a momentcreating profiles and you'll automatically start to receive informationon the news most important to you from sources you choose. Youcan even use any of the 1,000 convenient pre-defined profilescreated by the search experts at Dow Jones, which gives you afast and guaranteed efficient way to follow specific companiesor industries.<IMG SRC="track.gif"  ALIGN=TOP><HR><IMG SRC="bullet.gif"  ALIGN=TEXTTOP><FONT SIZE=5><B>MoreCompany and Industry Data</FONT></B><BR>Every detail available on publicly held companies is never morethan a few mouse clicks away. Screen companies that meet the criteriayou specify, access financial and statistical information on thecompany of your choice, retrieve SEC filings. The possibilitiesare endless. And reports and profiles come from trusted servicessuch as Standard &amp; Poor's, Dun &amp; Bradstreet, Media General,Investext and Disclosure.</B><HR><IMG SRC="bullet.gif"  ALIGN=TEXTTOP><FONT SIZE=5><B>Quotes,Market Data &amp; Analyses</FONT></B><BR>Create a portfolio to track your holdings, know the value of yourinvestments or follow the performance of your competitors' allwith Dow Jones News/Retrieval. Dow Jones provides quotes and marketdata from every major exchange in the world and includes up to25 years of history. Find anything you need: stocks, bonds, mutualfunds, commodities, futures, indexes and historical Dow JonesAverages.</B><IMG SRC="portfolio.gif"  ALIGN=TOP><HR><IMG SRC="bullet.gif"  ALIGN=TEXTTOP><FONT SIZE=5><B>MoreInformation</FONT></B><BR>Need more information? Click <A href="../online-lib/djnrcontact.html">here</A>if you'd like a Dow Jones representative to contact you. Clickon <A HREF="../online-lib/overview.html">Dow Jones News/Retrieval</A>to access a complete list of what's included in the service. Ifyou'd like us to send you more information, fill out our brief<A HREF="http://bis.dowjones.com/online-lib/djnrcontact.html">form</A>.</UL><CENTER><A HREF="/downl1.html"><IMG SRC="star.gif"  BORDER=0 ALIGN=TOP></A></CENTER></UL><P><CENTER>Back To <A HREF="../online-lib/index.html">News/Retrieval</A></CENTER><P><CENTER><A href="../toolbar.gif.map"><IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></A><BR><FONT size=2><A href="../bizpubs/index.html">Newspapers</A> |<A href="../clipping/index.html">Alert Services</A> | <A href="../online-lib/index.html">Research</A>| <A href="../pers-finance/index.html">Personal Finance</A> |<A href="../latest.html">DJ In The News</A> | <A href="mailto:webmaster@nrs.dowjones.com">Write Us</A>| <A href="../index.html">Home</A> </FONT></CENTER></TD></TR></TABLE></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-43</DOCNO>
<DOCOLDNO>IA027-000290-B044-132</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/downl1.html 143.131.194.4 19970114045410 text/html 13442
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:58:13 GMT
Last-modified: Tuesday, 03-Dec-96 16:48:54 GMT
Content-length: 13251
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
<TITLE>News/Retrieval Download</TITLE>
</HEAD>
<BODY background="/images/bgdonlin.gif">
<P>
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><TD width=80 valign=top><A href="index.html"><IMG valign=top  
BORDER=0 SRC="online-lib/images/lrgonlinres.gif"></A> 



<BR>



<B><IMG SRC="../images/trsp.gif"></B> 



</TD>



<TD width=500>



<TD><CENTER><IMG BORDER=0 SRC="images/djnr-logosm.gif"></CENTER>



<H2><CENTER>Windows software download <BR>



<BR>



</CENTER></H2>







<P>



Download Dow Jones News/Retrieval, V. 5.0c for Windows <br>

or click <A HREF="/downlmac.html"> here</A> for the Macintosh software 
download. 



<P>



Just a few things before you begin:<BR>







<UL>



<LI>You need to set up your account with us before you can use the software. Call 1-
800-369-7466 ext.159. We'll sign you up for the <A HREF="/online-
lib/price.html">Standard U.S. Pricing Plan</A> or the <A HREF="/online-
lib/canprice.html">Canadian plan</A>. There's no monthly fee and you pay for only 
the information you retrieve. There's a one-time start-up fee of $29.95 and you'll get a 
free trial period to look around. We'll also send you a start-up kit that's loaded with 
information on how to maximize your access to Dow Jones News/Retrieval.



<LI>If you're outside the U.S. or Canada, contact your <A 
HREF="http://bis.dowjones.com/bissales.html">local office</A> for pricing 
information. 



<LI>Before you can download, you must read and agree to the terms of the 
Subscriber Agreement listed on the next page. You must also fill out and submit a 
very brief form online.



<LI>Then download the self-extracting software and follow the easy installation 
instructions. 



<LI> <b>Here's a tip for after your download is complete. To be sure the entire file 
was downloaded, without modem or other connection-related interruptions that can 
sometimes occur, check the file size to be sure it's complete.  It should be 
2,889,763 bytes. If you're running Windows 95, accomplish this check using 
Windows Explorer; if you're using Windows 3.1, use File Manager to locate the 
file.</b>



</UL>







<P>



To get started, <A href="#skip">click here</A>.







<HR>







<P>



<CENTER><A NAME="skip"><B>Please read this Agreement before downloading 
the software. </B></A></CENTER>



<P>



This Agreement governs your access to and use of the content (the 
&quot;Content&quot;) in the Dow Jones News/Retrieval service (the 
&quot;Service&quot;). If you download, install, or receive Dow Jones 
News/Retrieval software that you use or can be used to access the Content, this 
Agreement also applies to that software (the &quot;Software&quot;). PLEASE 
READ THIS AGREEMENT CAREFULLY BEFORE USING THE SOFTWARE OR 
THE SERVICE. BY USING THE SOFTWARE OR THE SERVICE, YOU AGREE TO 
BE BOUND BY ALL OF THE TERMS IN THIS AGREEMENT. IF YOU DO NOT 
AGREE TO BE BOUND BY ALL OF THE TERMS IN THIS AGREEMENT, DO 
NOT ACCESS THE SERVICE, AND RETURN OR DESTROY ANY SOFTWARE 
YOU HAVE RECEIVED. You may print and keep copies of this Agreement.



<P>



<B>Passwords; Unauthorized Use</B>



<P>



This Agreement, and your password, are personal to you, and you may not assign this 
Agreement or your password to anyone. You are responsible for the confidentiality of 
your password and for all charges incurred using your password. If you become aware 
of any unauthorized use of your password or if it is lost or stolen, you agree to notify 
Dow Jones Customer Service immediately.



<P>



<B>Charges and Payment; Pricing</B>



<P>



You agree to pay or to have paid, within 15 days after receipt of an invoice, all fees 
and charges for the Content, Service and Software, at the rates then in effect for your 
pricing plan, plus applicable taxes. All fees are nonrefundable. Dow Jones may 
charge late fees on overdue accounts, and you agree to pay or to have paid all costs 
(including, without limitation, attorneys' fees) Dow Jones incurs to collect any 
overdue amounts.



<P>



You acknowledge that the prices that appear when you click on the $ icon, or within 
the USAGE or INVOICE areas of the Service, are estimates only of the amount you 
will owe. You can always obtain accurate, then-current prices through GUIDE, the 
electronic user's guide. The actual amount you owe for Content and the Service will 
be the amount set forth on your invoice or billed to your credit, debit or similar 
account.



<P>



If you reside in the U.S., Canada, Puerto Rico or the U.S. Virgin Islands, and become 
a new Service subscriber on or after June 17, 1996, you will be charged according to 
the Standard Pricing Plan then in effect. References to the Information Unit Pricing 
Plan within the Service do not apply to you.



<P>



<B>Limitations on Use</B>



<P>



The Software, Content and Service are the property of Dow Jones or its licensors, 
and are protected by applicable copyright and intellectual property laws. Except as 
indicated otherwise in GUIDE or FYI, the Content may be stored in memory on your 
personal computer, manipulated, analyzed, reformatted, displayed and printed for 
your personal, noncommercial use only. Unless you obtain the express prior written 
consent of Dow Jones, you agree not to reproduce, retransmit, disseminate, 
distribute, publish, broadcast or sell any Content to anyone, including, but not 
limited to, others in your company or organization, with this one exception: You 
may, from time to time, disseminate an insubstantial portion of Content, for a 
noncommercial purpose and without charge, to a limited number of employees in the 
same company or organization, provided you include all copyright and other 
proprietary notices with such portion of the Content in the same form in which the 
notices appear in the Service. Unless you obtain the express prior written consent of 
Dow Jones, and except to the extent expressly permitted by applicable law, you also 
agree not to disassemble, decompile, reverse engineer, alter, distribute, transfer, 
reproduce, sell or license any part of the Software.



<P>



<B>Disclaimer of Warranties and Liability</B>



<P>



Due to the number of sources from which the Content is obtained, and the inherent 
hazards of electronic distribution, there may be delays, omissions or inaccuracies in 
the Content and Service. THE SOFTWARE IS PROVIDED &quot;AS IS&quot; AND 
WITHOUT ANY WARRANTIES. DOW JONES AND ITS AFFILIATES, AGENTS 
AND LICENSORS CANNOT AND DO NOT WARRANT THE ACCURACY, 
COMPLETENESS, CURRENTNESS, MERCHANTABILITY OR FITNESS FOR A 
PARTICULAR PURPOSE OF THE CONTENT, SERVICE OR SOFTWARE. 
NEITHER DOW JONES NOR ANY OF ITS AFFILIATES, AGENTS OR 
LICENSORS SHALL BE LIABLE TO YOU OR ANYONE ELSE FOR ANY LOSS 
OR INJURY CAUSED IN WHOLE OR PART BY ITS NEGLIGENCE OR 
CONTINGENCIES BEYOND ITS CONTROL IN PROCURING, COMPILING, 
INTERPRETING, EDITING, WRITING, REPORTING OR DELIVERING ANY 
CONTENT OR THE SERVICE. IN NO EVENT WILL DOW JONES, ITS 
AFFILIATES, AGENTS OR LICENSORS BE LIABLE TO YOU OR ANYONE ELSE 
FOR ANY DECISION MADE OR ACTION TAKEN BY YOU IN RELIANCE ON 
THE CONTENT, SERVICE OR SOFTWARE. DOW JONES AND ITS AFFILIATES, 
AGENTS AND LICENSORS SHALL NOT BE LIABLE TO YOU OR ANYONE 
ELSE FOR ANY DAMAGES OTHER THAN DIRECT DAMAGES (INCLUDING, 
WITHOUT LIMITATION, CONSEQUENTIAL, SPECIAL AND SIMILAR 
DAMAGES) IN CONNECTION WITH THE CONTENT, SERVICE AND 
SOFTWARE, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 
YOU AGREE THAT THE LIABILITY OF DOW JONES, ITS AFFILIATES, AGENTS 
AND LICENSORS, IF ANY, ARISING OUT OF ANY KIND OF LEGAL CLAIM 
(WHETHER IN CONTRACT, TORT OR OTHERWISE) IN ANY WAY 
CONNECTED WITH THE CONTENT, SERVICE AND SOFTWARE SHALL NOT 
EXCEED THE AGGREGATE AMOUNT PAID BY YOU TO DOW JONES FOR USE 
OF THE CONTENT OR SERVICE IN THE 12 MONTHS IMMEDIATELY 
PRECEDING THE EVENT GIVING RISE TO SUCH CLAIM. You acknowledge that 
the Content and Service may include the views, opinions and recommendations of 
third parties whose thoughts are deemed of interest, and that Dow Jones and its 
Content licensors do not endorse the views, give investment, tax or legal advice, or 
advocate the purchase or sale of any security or investment.



<P>



<B>Additional Legal Disclaimers and Changes in Terms</B>



<P>



Additional legal disclaimers and notices regarding the Content and Service are 



<P>



available, free of charge, in GUIDE, the electronic user's guide, and FYI, the 
electronic newsletter for the Service. Dow Jones also may change or add to the terms 
of this Agreement, or the fees and charges for the Content, Service or Software, at 
any time. Notice of any such changes or additions will appear in FYI. You agree to 
read GUIDE and FYI and be bound by the additional legal disclaimers and notices 
contained in GUIDE and FYI. You are urged to consult GUIDE and FYI each time 
you access the Service. By accessing Content, or using the Service or Software after 
any additional legal disclaimer or notice, or any change or addition to Agreement 
terms, fees or charges, is posted in GUIDE or FYI, you are agreeing to be bound by 
all such disclaimers, notices, changes and additions.



<P>



<B>Subscription Termination</B>



<P>



You may terminate your Service subscription at any time. Your Service subscription, 
and obligation to pay fees and charges incurred, will continue until terminated by 
Dow Jones, or until Dow Jones receives notice from you of your intention to 
terminate your Service subscription. Dow Jones may discontinue the Service, 
availability of certain Content within the Service, or their availability to you, at any 
time without notice. Dow Jones or you may terminate your right to use the Software 
at any time. Upon such termination, you agree to destroy the Software or return it to 
Dow Jones.



<P>



If any term in this Agreement is invalid or unenforceable under applicable law, the 
remaining terms in the Agreement shall remain and be deemed valid and 
enforceable. If any change or amendment to this Agreement is invalid or 
unenforceable under applicable law, the Agreement formed without such change or 
amendment shall remain and be deemed valid and enforceable. This Agreement, and 
all rights and obligations pursuant to this Agreement, shall be governed by the laws 
of the United States and State of New York, without regard to principles of conflicts 
of law. Application of the U.N. Convention on Contracts for the International Sale of 
Goods is expressly excluded.



<P>



If Dow Jones and you have manually signed a paper version of a contract governing 
your use of the Content, Service and/or Software, the terms in that manually signed, 
paper document are not amended by, and supersede, terms in this Subscription 
Agreement.<BR>







<P>



IF YOU AGREE TO BE BOUND BY ALL OF THE TERMS IN THIS AGREEMENT, 
PLEASE FILL OUT THE BRIEF FORM BELOW AND CLICK THE "SUBMIT THE 
INFORMATION" BUTTON: 







<HR>











<p><b>



Step 1: </b><br>



You must enter your name and address for our records. 



<FORM  METHOD="GET" ACTION="/cgi-bin/download.cgi">



<INPUT NAME="Formtype" VALUE="Windows" TYPE="hidden" size=10>







<table>



<tr><td>



	<b>Name:</b>



</td><td>



	 <INPUT TYPE ="text" NAME="name" maxlength= 30 SIZE =30>



</td></tr><tr><td>



	<b>Company Name:</b>



</td><td>



	<INPUT TYPE ="text" NAME="CompanyName" maxlength= 50 SIZE =30>



</td></tr><tr><td>



	<b>Street Address:</b>



</td><td>



     <INPUT TYPE ="text" NAME="Address1"  maxlength= 40 SIZE =30>



</td></tr><tr><td>



</td><td>



     <INPUT TYPE ="text" NAME="Address2"  maxlength=40 SIZE =30> 



</td></tr><tr><td>



	<b>City:</b>



</td><td>                 



	<INPUT TYPE ="text"NAME="City"  maxlength= 30 SIZE =30>



</td></tr><tr><td>



	<b>State:</b>



</td><td>               



	<INPUT TYPE ="text"NAME="State"  maxlength= 30 SIZE =30> 



</td></tr><tr><td> 						  



	<b>Zip/Postal Code:</b>



</td><td>



   <INPUT TYPE ="text"NAME="Zip"maxlength= 30 SIZE =30> 



</td></tr><tr><td>



<b>Country:</b>



</td><td>



<INPUT TYPE="text" NAME="Country" maxlength=30 SIZE=30>



</td></tr>



</table>



<P>







<B>Are you purchasing for:</b>



<BR>


<Select Name = "Purchasing_for" >



<Option>Individual



<Option>Corporation



</Select>



















<CENTER><P><INPUT TYPE="submit" VALUE="Submit the information"> 
<INPUT TYPE="reset" VALUE =



"Clear the text entry fields"></CENTER>











</form>







</blockquote>



<pre>
</pre>











				<center>



					<a href="toolbar.gif.map">



			



					<IMG WIDTH=430 HEIGHT=70 BORDER=0 
SRC="images/toolbar.gif" ISMAP></a>



					<BR>



					



				<font size=2>



					<a href="bizpubs/index.html">Newspapers</a> |



					<a href="clipping/index.html">Alert 
Services</a> |



					<a href="online-lib/index.html">Research</a>  |



					<a href="pers-finance/index.html">Personal 
Finance</a>  |  



					<a href="latest.html">DJ In The News</a>  |



					<a 
href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |



					<a href="index.html">Home</a> 







				</font>



				



				



				



				</center>



				











</TD></tr>



</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-44</DOCNO>
<DOCOLDNO>IA027-000290-B044-160</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/downlmac.html 143.131.194.4 19970114045427 text/html 12812
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:58:37 GMT
Last-modified: Friday, 06-Dec-96 21:27:56 GMT
Content-length: 12622
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
<TITLE>News/Retrieval Download</TITLE>
</HEAD>
<BODY background="/images/bgdonlin.gif">
<P>
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><TD width=80 valign=top><A href="index.html"><IMG valign=top  BORDER=0 SRC="online-lib/images/lrgonlinres.gif"></A> 
<BR>
<B><IMG SRC="../images/trsp.gif"></B> 
</TD>
<TD width=500>
<TD><CENTER><IMG BORDER=0 SRC="images/djnr-logosm.gif"></CENTER>
<H2><CENTER>Macintosh software download <BR>
<BR>
</CENTER></H2>
<P>
Download Dow Jones News/Retrieval, V. 3.2a for Macintosh
<P>
Just a few things before you begin:<BR>
<UL>
<LI>You need to set up your account with us before you can use the software. Call 1-800-369-7466 ext.159. We'll sign you up for the <A HREF="/online-lib/price.html">Standard U.S. Pricing Plan</A> or the <A HREF="/online-lib/canprice.html">Canadian plan</A>. There's no monthly fee and you pay for only the information you retrieve. There's a one-time start-up fee of $29.95 and you'll get a free trial period to look around. We'll also send you a start-up kit that's loaded with information on how to maximize your access to Dow Jones News/Retrieval.
<LI>If you're outside the U.S. or Canada, contact your <A HREF="http://bis.dowjones.com/bissales.html">local office</A> for pricing information. 
<LI>Before you can download, you must read and agree to the terms of the Subscriber Agreement listed on the next page. You must also fill out and submit a very brief form online.
<LI>Download the software and follow the easy installation instructions. (NOTE: This file is stuffed, in BinHex format. You'll need a copy of <A HREF="http://www.aladdinsys.com/VISTA/obstufex.htm">Stuffit Expander</a>, a free program, to decode it. Check your browser documentation first; Stuffit may be included with that package.)
<LI> Here's a tip for after your download is complete. To be sure the entire file was downloaded, without modem or other connection-related interruptions that can sometimes occur during, check the file size to be sure it's complete.  It should be 1,619K.
</UL>
<P>
To get started, <A href="#skip">click here</A>.
<HR>
<P>
<CENTER><A NAME="skip"><B>Please read this Agreement before downloading the software. </B></A></CENTER>
<P>
This Agreement governs your access to and use of the content (the &quot;Content&quot;) in the Dow Jones News/Retrieval service (the &quot;Service&quot;). If you download, install, or receive Dow Jones News/Retrieval software that you use or can be used to access the Content, this Agreement also applies to that software (the &quot;Software&quot;). PLEASE READ THIS AGREEMENT CAREFULLY BEFORE USING THE SOFTWARE OR THE SERVICE. BY USING THE SOFTWARE OR THE SERVICE, YOU AGREE TO BE BOUND BY ALL OF THE TERMS IN THIS AGREEMENT. IF YOU DO NOT AGREE TO BE BOUND BY ALL OF THE TERMS IN THIS AGREEMENT, DO NOT ACCESS THE SERVICE, AND RETURN OR DESTROY ANY SOFTWARE YOU HAVE RECEIVED. You may print and keep copies of this Agreement.
<P>
<B>Passwords; Unauthorized Use</B>
<P>
This Agreement, and your password, are personal to you, and you may not assign this Agreement or your password to anyone. You are responsible for the confidentiality of your password and for all charges incurred using your password. If you become aware of any unauthorized use of your password or if it is lost or stolen, you agree to notify Dow Jones Customer Service immediately.
<P>
<B>Charges and Payment; Pricing</B>
<P>
You agree to pay or to have paid, within 15 days after receipt of an invoice, all fees and charges for the Content, Service and Software, at the rates then in effect for your pricing plan, plus applicable taxes. All fees are nonrefundable. Dow Jones may charge late fees on overdue accounts, and you agree to pay or to have paid all costs (including, without limitation, attorneys' fees) Dow Jones incurs to collect any overdue amounts.
<P>
You acknowledge that the prices that appear when you click on the $ icon, or within the USAGE or INVOICE areas of the Service, are estimates only of the amount you will owe. You can always obtain accurate, then-current prices through GUIDE, the electronic user's guide. The actual amount you owe for Content and the Service will be the amount set forth on your invoice or billed to your credit, debit or similar account.
<P>
If you reside in the U.S., Canada, Puerto Rico or the U.S. Virgin Islands, and become a new Service subscriber on or after June 17, 1996, you will be charged according to the Standard Pricing Plan then in effect. References to the Information Unit Pricing Plan within the Service do not apply to you.
<P>
<B>Limitations on Use</B>
<P>
The Software, Content and Service are the property of Dow Jones or its licensors, and are protected by applicable copyright and intellectual property laws. Except as indicated otherwise in GUIDE or FYI, the Content may be stored in memory on your personal computer, manipulated, analyzed, reformatted, displayed and printed for your personal, noncommercial use only. Unless you obtain the express prior written consent of Dow Jones, you agree not to reproduce, retransmit, disseminate, distribute, publish, broadcast or sell any Content to anyone, including, but not limited to, others in your company or organization, with this one exception: You may, from time to time, disseminate an insubstantial portion of Content, for a noncommercial purpose and without charge, to a limited number of employees in the same company or organization, provided you include all copyright and other proprietary notices with such portion of the Content in the same form in which the notices appear in the Service. Unless you obtain the express prior written consent of Dow Jones, and except to the extent expressly permitted by applicable law, you also agree not to disassemble, decompile, reverse engineer, alter, distribute, transfer, reproduce, sell or license any part of the Software.
<P>
<B>Disclaimer of Warranties and Liability</B>
<P>
Due to the number of sources from which the Content is obtained, and the inherent hazards of electronic distribution, there may be delays, omissions or inaccuracies in the Content and Service. THE SOFTWARE IS PROVIDED &quot;AS IS&quot; AND WITHOUT ANY WARRANTIES. DOW JONES AND ITS AFFILIATES, AGENTS AND LICENSORS CANNOT AND DO NOT WARRANT THE ACCURACY, COMPLETENESS, CURRENTNESS, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE CONTENT, SERVICE OR SOFTWARE. NEITHER DOW JONES NOR ANY OF ITS AFFILIATES, AGENTS OR LICENSORS SHALL BE LIABLE TO YOU OR ANYONE ELSE FOR ANY LOSS OR INJURY CAUSED IN WHOLE OR PART BY ITS NEGLIGENCE OR CONTINGENCIES BEYOND ITS CONTROL IN PROCURING, COMPILING, INTERPRETING, EDITING, WRITING, REPORTING OR DELIVERING ANY CONTENT OR THE SERVICE. IN NO EVENT WILL DOW JONES, ITS AFFILIATES, AGENTS OR LICENSORS BE LIABLE TO YOU OR ANYONE ELSE FOR ANY DECISION MADE OR ACTION TAKEN BY YOU IN RELIANCE ON THE CONTENT, SERVICE OR SOFTWARE. DOW JONES AND ITS AFFILIATES, AGENTS AND LICENSORS SHALL NOT BE LIABLE TO YOU OR ANYONE ELSE FOR ANY DAMAGES OTHER THAN DIRECT DAMAGES (INCLUDING, WITHOUT LIMITATION, CONSEQUENTIAL, SPECIAL AND SIMILAR DAMAGES) IN CONNECTION WITH THE CONTENT, SERVICE AND SOFTWARE, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. YOU AGREE THAT THE LIABILITY OF DOW JONES, ITS AFFILIATES, AGENTS AND LICENSORS, IF ANY, ARISING OUT OF ANY KIND OF LEGAL CLAIM (WHETHER IN CONTRACT, TORT OR OTHERWISE) IN ANY WAY CONNECTED WITH THE CONTENT, SERVICE AND SOFTWARE SHALL NOT EXCEED THE AGGREGATE AMOUNT PAID BY YOU TO DOW JONES FOR USE OF THE CONTENT OR SERVICE IN THE 12 MONTHS IMMEDIATELY PRECEDING THE EVENT GIVING RISE TO SUCH CLAIM. You acknowledge that the Content and Service may include the views, opinions and recommendations of third parties whose thoughts are deemed of interest, and that Dow Jones and its Content licensors do not endorse the views, give investment, tax or legal advice, or advocate the purchase or sale of any security or investment.
<P>
<B>Additional Legal Disclaimers and Changes in Terms</B>
<P>
Additional legal disclaimers and notices regarding the Content and Service are 
<P>
available, free of charge, in GUIDE, the electronic user's guide, and FYI, the electronic newsletter for the Service. Dow Jones also may change or add to the terms of this Agreement, or the fees and charges for the Content, Service or Software, at any time. Notice of any such changes or additions will appear in FYI. You agree to read GUIDE and FYI and be bound by the additional legal disclaimers and notices contained in GUIDE and FYI. You are urged to consult GUIDE and FYI each time you access the Service. By accessing Content, or using the Service or Software after any additional legal disclaimer or notice, or any change or addition to Agreement terms, fees or charges, is posted in GUIDE or FYI, you are agreeing to be bound by all such disclaimers, notices, changes and additions.
<P>
<B>Subscription Termination</B>
<P>
You may terminate your Service subscription at any time. Your Service subscription, and obligation to pay fees and charges incurred, will continue until terminated by Dow Jones, or until Dow Jones receives notice from you of your intention to terminate your Service subscription. Dow Jones may discontinue the Service, availability of certain Content within the Service, or their availability to you, at any time without notice. Dow Jones or you may terminate your right to use the Software at any time. Upon such termination, you agree to destroy the Software or return it to Dow Jones.
<P>
If any term in this Agreement is invalid or unenforceable under applicable law, the remaining terms in the Agreement shall remain and be deemed valid and enforceable. If any change or amendment to this Agreement is invalid or unenforceable under applicable law, the Agreement formed without such change or amendment shall remain and be deemed valid and enforceable. This Agreement, and all rights and obligations pursuant to this Agreement, shall be governed by the laws of the United States and State of New York, without regard to principles of conflicts of law. Application of the U.N. Convention on Contracts for the International Sale of Goods is expressly excluded.
<P>
If Dow Jones and you have manually signed a paper version of a contract governing your use of the Content, Service and/or Software, the terms in that manually signed, paper document are not amended by, and supersede, terms in this Subscription Agreement.<BR>
<P>
IF YOU AGREE TO BE BOUND BY ALL OF THE TERMS IN THIS AGREEMENT, PLEASE FILL OUT THE BRIEF FORM BELOW AND CLICK THE "SUBMIT THE INFORMATION" BUTTON: 
<HR>
<p><b>
Step 1: </b><br>
You must enter your name and address for our records. 
<FORM  METHOD="GET" ACTION="/cgi-bin/nrmac.cgi">
<INPUT NAME="Formtype" VALUE="Mac" TYPE="hidden" size=10>
<table>
<tr><td>
	<b>Name:</b>
</td><td>
	 <INPUT TYPE ="text" NAME="name" maxlength= 30 SIZE =30>
</td></tr><tr><td>
	<b>Company Name:</b>
</td><td>
	<INPUT TYPE ="text" NAME="CompanyName" maxlength= 50 SIZE =30>
</td></tr><tr><td>
	<b>Street Address:</b>
</td><td>
     <INPUT TYPE ="text" NAME="Address1"  maxlength= 40 SIZE =30>
</td></tr><tr><td>
</td><td>
     <INPUT TYPE ="text" NAME="Address2"  maxlength=40 SIZE =30> 
</td></tr><tr><td>
	<b>City:</b>
</td><td>                 
	<INPUT TYPE ="text"NAME="City"  maxlength= 30 SIZE =30>
</td></tr><tr><td>
	<b>State:</b>
</td><td>               
	<INPUT TYPE ="text"NAME="State"  maxlength= 30 SIZE =30> 
</td></tr><tr><td> 						  
	<b>Zip/Postal Code:</b>
</td><td>
   <INPUT TYPE ="text"NAME="Zip"maxlength= 30 SIZE =30> 
</td></tr><tr><td>
<b>Country:</b>
</td><td>
<INPUT TYPE="text" NAME="Country" maxlength=30 SIZE=30>
</td></tr>
</table>
<P>
<B>Are you purchasing for:</b>
<BR>
<Select Name = "Purchasing_for" >
<Option>Individual
<Option>Corporation
</Select>
<CENTER><P><INPUT TYPE="submit" VALUE="Submit the information"> <INPUT TYPE="reset" VALUE =
"Clear the text entry fields"></CENTER>
</form>
</blockquote>
<pre>
</pre>
				<center>
					<a href="toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="bizpubs/index.html">Newspapers</a> |
					<a href="clipping/index.html">Alert Services</a> |
					<a href="online-lib/index.html">Research</a>  |
					<a href="pers-finance/index.html">Personal Finance</a>  |  
					<a href="latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="index.html">Home</a> 
				</font>
				
				
				
				</center>
				
</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-45</DOCNO>
<DOCOLDNO>IA027-000290-B044-199</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/online-lib/overview.html 143.131.194.4 19970114045456 text/html 2032
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:59:01 GMT
Last-modified: Thursday, 11-Jul-96 13:41:34 GMT
Content-length: 1841
Content-type: text/html
</DOCHDR>
<HTML>

<HEAD>

<TITLE>Dow Jones News/Retrieval</TITLE>

<META NAME="GENERATOR" CONTENT="Internet Assistant for Microsoft Word 2.0z">
</HEAD>
<BODY bgcolor="#ffffff" background="images/bgdonlin.gif">

<P>
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><TD width=80  valign=top><A href="index.html"><IMG valign=top WIDTH=65 HEIGHT=65 BORDER=0 SRC="images/lrgonlinres.gif"></A> 
<BR>
<B><IMG SRC="../images/trsp.gif"></B>
</TD>
<TD width=500>
<TD><CENTER><IMG BORDER=0 SRC="images/djnr-logo.gif"> </CENTER>
<H2><CENTER>Source Overview 
</CENTER></H2>

<HR SIZE=4>

Whatever you're looking for is just a few mouse clicks away with our easy-to-use software. You'll see that Dow Jones News/Retrieval is grouped into areas, as listed below. Just click on an area to read all about it -- and find out exactly what it includes.
<P>
<A HREF="currnews.html">Current News</A>
<P>
<A HREF="srchnews.html">Search News and Articles</A>
<P>
<A HREF="track.html">Track News and Articles</A>
<P>
<A HREF="company.html">Company and Industry Data</A>
<P>
<A HREF="quotes.html">Quotes &amp; Market Data</A>
<P>
<A HREF="career.html">Career and Travel</A><BR>
<BR>


<P>
<CENTER>Back To <A HREF="all.html">Tell Me More...</A></CENTER>
<P>
<CENTER><A href="../toolbar.gif.map"><IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></A> 
<BR>
<A href="../bizpubs/index.html"><FONT SIZE=2>Newspapers</FONT></A><FONT SIZE=2> | <A href="../clipping/index.html">Alert Services</A> | <A href="../online-lib/index.html">Research</A> | <A href="../pers-finance/index.html">Personal Finance</A> | <A href="../latest.html">DJ In The News</A> | <A href="mailto:webmaster@nrs.dowjones.com">Write Us</A> | <A href="../index.html">Home</A> </FONT></CENTER>
</TD></TR>

</TABLE>

<P>

</BODY>

</HTML>



</DOC>
<DOC>
<DOCNO>WT18-B31-46</DOCNO>
<DOCOLDNO>IA027-000290-B044-227</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/online-lib/all.html 143.131.194.4 19970114045536 text/html 4173
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:59:30 GMT
Last-modified: Friday, 13-Sep-96 19:13:23 GMT
Content-length: 3984
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>Dow Jones News/Retrieval</TITLE><META NAME="AUTHOR" CONTENT="Kathryn Doyle"><META NAME="GENERATOR" CONTENT="Internet Assistant for Microsoft Word 2.0z"></HEAD><BODY bgcolor="#ffffff" background="images/bgdonlin.gif"><P><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><TD width=95  valign=top><A href="index.html"><IMG valign=top WIDTH=65 HEIGHT=65 BORDER=0 SRC="images/lrgonlinres.gif"> </A><BR><B><IMG SRC="../images/trsp.gif"></B> </TD><TD width=500><TD><CENTER><IMG WIDTH=199 HEIGHT=59 BORDER=0 SRC="images/djnr-logo.gif"> </CENTER><P><CENTER><B>Fast Answers to Tough Questions.</B> </CENTER><HR><P>Install Dow Jones News/Retrieval, and seconds later, the answers are at your fingertips.<P>Sign up today and get 10 free hours. You'll get the answers to your specific business questions and the news that matters most to you. And you can take advantage of editorial expertise and quality reporting that only Dow Jones, publisher of <I>The Wall Street Journal&#174;</I>, can provide.<P>All the information you gather in those first 10 hours will be yours. All you pay is a one-time start-up charge of $29.95. After your 10 hours are over, you'll be able to search and view headlines for free. You'll never pay for hourly online charges. Pay only for the information you read, print or save. Click <A HREF="price.html">pricing</A> for a complete U.S. standard price schedule plus links to a Canadian standard price schedule and contact information for pricing in other areas around the world.<P>For more sign-up information, click <A HREF="signup.html">sign up</A>.<P>If you need assistance once you're online, <A HREF="cs.html">Customer Service representatives</A> are there when you need them. Our representatives are trained experts, who know the ins and outs of online searching. They can help you conduct successful searches, create meaningful custom news clipping folders, help configure your networks and provide ongoing support.<P>You'll wonder how you ever did business without Dow Jones News/Retrieval. <HR><P><H3 ALIGN=LEFT>Get Started Now</H3>To get started, <A HREF="/downl1.html">download</A> the free Windows software or <A HREF="/downlmac.html">Macintosh software</A> now. Then call 1-800-369-7466, ext. 159 to sign up for your account. Click <A HREF="outsideus.html">non-U.S. </A>for sign-up information outside the U.S. and Canada. Also be sure to check out the links below, which provide additional answers to all your tough questions&#133;about News/Retrieval, that is. <HR><P><H3 ALIGN=LEFT>Frequently Asked Questions</H3><A HREF="overview.html">So...exactly what's included in News/Retrieval?</A> <P><A HREF="price.html">How much does News/Retrieval cost?</A> <P><A HREF="access.html">How can I access News/Retrieval?</A> <P><A HREF="apps.html">What are some common ways I might use News/Retrieval?</A> <P><A HREF="signup.html">How can I sign up?</A> <P><A HREF="faqs.html">More Frequently Asked Questions...</A> <HR><CENTER><TABLE width=50% border=5 cellpadding=10><TR><TD>See what <A href="customer-quotes.html">customers</A> are saying about News/Retrieval&reg;.<P>See what the <A href="press-quotes.html">press</A> is saying about News/Retrieval&reg;.</TD></TR></TABLE><BR></CENTER><PRE><FONT SIZE=2>                </FONT></PRE><P><CENTER><A href="../toolbar.gif.map"><IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></A> <BR><A href="../bizpubs/index.html">Newspapers</A><FONT SIZE=2> | <A href="../clipping/index.html">Alert Services</A> | <A href="../online-lib/index.html">Research</A> | <A href="../pers-finance/index.html">Personal Finance</A> | <A href="../latest.html">DJ In The News</A> | <A href="mailto:webmaster@nrs.dowjones.com">Write Us</A> | <A href="../index.html">Home</A> </FONT></CENTER></TD></TR></TABLE><P></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-47</DOCNO>
<DOCOLDNO>IA027-000290-B044-264</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/pie/mainpage.map 143.131.194.4 19970114045558 text/html 321
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:00:06 GMT
Content-type: text/html
Content-length: 180
</DOCHDR>
<TITLE>Imagemap Error</TITLE><H1>Imagemap Error</H1>Your client did not send any coordinates. Either your client doesn't support imagemap or the map file was not accessed as a map.
</DOC>
<DOC>
<DOCNO>WT18-B31-48</DOCNO>
<DOCOLDNO>IA027-000290-B044-296</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/pie/jphone.html 143.131.194.4 19970114045628 text/html 2815
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:00:32 GMT
Last-modified: Wednesday, 08-Jan-97 15:14:56 GMT
Content-length: 2623
Content-type: text/html
</DOCHDR>
<HTML><HEAD>   <TITLE>Journal Phone</TITLE> </HEAD><BODY TEXT="#000000" BGCOLOR="#FFFFFF" LINK="#0000FF" VLINK="#551A8B" ALINK="#0000FF"><TABLE BORDER=0 CELLSPACING=2 CELLPADDING=2 WIDTH=600><TR><TD WIDTH=150></TD><TD><IMG SRC="images/DJ_PIprod_serv.gif" ALT="IMAGE" HEIGHT=75 WIDTH=450></TD></TR></TABLE><HR size="6"><IMG ALT="IMAGE" HEIGHT=369 WIDTH=569 BORDER=0 SRC="images/jrnlphn.gif"><P><CENTER><B><FONT SIZE=+3>JournalPhone&reg; 1-900-Journal</FONT></B></CENTER><P><B>For those on the go who don't have time to connect to the 'Net--JournalPhone's&#174;is the perfect solution!</B></P><P>JournalPhone&reg; offers 24-hour access to constantly updated stockquotes and market updates. You can reach JournalPhone&reg; by calling either1-900-JOURNAL or 1-800-800-4WSJ.</P><P>Calls are $.75 per minute. Quotes are subject to a 20-minute delay.Calls to 1-900-JOURNAL are billed to the telephone from which you are calling.</P><P>Calls to 1-800-800-4WSJ are charged to MasterCard, Visa or AmericanExpress. You'll be asked for your credit card number as soon as your callis answered. (You'll also be given the option of creating your own personalID number so you can avoid entering your credit card number each time youcall.)</P><P><B>STOCK MARKET REPORT<BR></B>This report, updated every 30 minutes during the trading day, providesa quick one-minute summary of the latest important developments in thestock market.</P><P><B>STOCK QUOTES<BR></B>For current quotes on any of 8000 companies, press 2. If you have aJournalPhone&reg; portfolio, press 1. You'll hear the stock's current price(delayed 20 minutes) and the net change from the previous close. To heara stock's volume and high and low trades, press * after the quote.</P><P><B>MARKET INDEXES AND MUTUAL FUNDS<BR></B>You can get updated quotes on major market indexes, andmutual fund prices updated daily, by entering index and fund symbols thesame way you enter a stock symbol.</P><P><B>JOURNALPHONE&reg; PORTFOLIO SETUP<BR></B>With a JournalPhone&reg; portfolio, you can get quotes on up to 20stocks of your choice automatically whenever you enter your personal IDnumber. This ID can also be used in place of your credit card number whenyou call 1-800-800-4WSJ.</P><P><B>TAPEWATCH</B><SUP><FONT SIZE=-2>TM<BR></FONT></SUP>Receive an update on the Tapewatch<SUP><FONT SIZE=-2>TM </FONT></SUP>column of <I>The Wall Street Journal&#174;</I>. This update features hot market, corporate and economic news of the day. </P><P><HR><CENTER><FONT SIZE=3><A HREF="private.html">Home</A></CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-49</DOCNO>
<DOCOLDNO>IA027-000290-B044-324</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/pie/rom.html 143.131.194.4 19970114045653 text/html 1209
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:00:52 GMT
Last-modified: Wednesday, 08-Jan-97 15:15:10 GMT
Content-length: 1017
Content-type: text/html
</DOCHDR>
<HTML><HEAD>   <TITLE>Software &amp; CD-ROM</TITLE></HEAD><BODY TEXT="#000000" BGCOLOR="#FFFFFF" LINK="#0000FF" VLINK="#551A8B" ALINK="#0000FF"><TABLE BORDER=0 CELLSPACING=2 CELLPADDING=2 WIDTH=600><TR><TD WIDTH=150></TD><TD><IMG SRC="images/DJ_PIprod_serv.gif" ALT="IMAGE" HEIGHT=75 WIDTH=450></TD></TR></TABLE><HR size="6"><A HREF="sftwre.map"><IMG SRC="sftwre.gif" BORDER=0 ISMAP></A><P><HR size=3><CENTER><A HREF="wow.html">Window on Wall Street&#153; from Dow Jones</A>  |  <A HREF="nirvana.html">Nirvana Data Collector</A>  |  <A HREF="plan.html">Plan Ahead&#153; for Your Financial Future CD-ROM</A></CENTER><HR size=2><P>Dow Jones Private Investor Services offers software that can help youturn raw data into an easy-to-analyze view of market and company trends.Search It, Print It and Graph It! There's also an interactive, retirementplanning CD-ROM to choose from.</P><P><HR size=3><CENTER><FONT SIZE=3><A HREF="private.html">Home</A></FONT></CENTER></P></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-50</DOCNO>
<DOCOLDNO>IA027-000290-B044-343</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/pie/PIE_page.map 143.131.194.4 19970114045707 text/html 321
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:01:16 GMT
Content-type: text/html
Content-length: 180
</DOCHDR>
<TITLE>Imagemap Error</TITLE><H1>Imagemap Error</H1>Your client did not send any coordinates. Either your client doesn't support imagemap or the map file was not accessed as a map.
</DOC>
<DOC>
<DOCNO>WT18-B31-51</DOCNO>
<DOCOLDNO>IA027-000290-B044-376</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/pie/news.html 143.131.194.4 19970114045754 text/html 3461
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:01:31 GMT
Last-modified: Wednesday, 08-Jan-97 15:15:01 GMT
Content-length: 3269
Content-type: text/html
</DOCHDR>
<HTML><HEAD>   <TITLE>News & Quotes</TITLE></HEAD><BODY TEXT="#000000" BGCOLOR="#FFFFFF" link="#0000FF"vlink="#551A8B" alink="#0000FF"><TABLE CELLPADDING=2 WIDTH="600" ><TR><TD width="150"></TD><TD WIDTH=450 VALIGN=bottom><IMG SRC="images/news_quot.gif" HEIGHT=97 WIDTH=343></TD></TR></TABLE><HR size="6" color="#800080"><TABLE CELLPADDING=5 WIDTH="600" ><TR><TD align="center" valign="top" width="150"><IMG SRC="images/pie_sideart.gif" HEIGHT=133 WIDTH=130 ALIGN=TOP></TD><TD width="450"><B><FONT SIZE=+1>NEWS: <HR WIDTH="100%"></FONT></B>The Dow Jones news organization, which publishessuch revered sources as <I>The Wall Street Journal&#174;, Barron's&#174;, SmartMoney&#174;</I> Magazine and the Dow Jones News Service&#174;, has over 1,000 reporters andeditors covering business worldwide. Dow Jones has earned a reputationfor getting the story behind the story, for revealing the motives and actionsthat other publications just don't discover. Our news gives Private Investorsthe edge in investing. And it's news you can trust.<BR><BR><B>Current News:<BR><BR></B> This Just In&#174; provides you withthe latest on business and worldwide news, as well as sports and weather!In fact, every time you sign on to the Private Investor Edition, you'llget the two top headlines of the day! Click on <A HREF="http:current.html">CurrentNews </A>for more information.<BR><BR>You can also search the exclusive Dow Jones Newswires, as well as <I>TheWall Street Journal&#174;, The New York Times, Financial Times, The WashingtonPost, Los Angeles Times</I>, press release wires, Japan Economic Newswire,Agence France Presse-Extel and business articles from other leading newspaperssimply by selecting the <A HREF="http:current.html">Current News</A> function.Search by company name, symbol, industry, business and financial news,region and governmental news. <BR><BR>Dow Jones News/Retrieval&reg; gives you the news you can count on to makesmart investment decisions.<BR><BR><B><FONT SIZE=+1>QUOTES: <HR WIDTH="100%"></FONT></B>As a Dow Jones News/Retrieval&reg;--PrivateInvestor Edition subscriber, you'll receive access to <B><I>multiple</I></B>quote information <A HREF="http:qsource.html">sources,</A> including DowJones Enhanced Current Quotes<I><SUP><FONT SIZE=-2>SM</FONT></SUP></I>,Dow Jones Quotes on Commodities, Futures and Selected Indexes<I><SUP><FONT SIZE=-2>SM</FONT></SUP></I>,Dow Jones Historical Quotes<I><SUP><FONT SIZE=-2>SM</FONT></SUP></I>, HistoricalDow Jones Averages&reg; and Snapshot Tradeline. Just click on the <A HREF="http:qandm.html">Quotes&amp; Market Data</A> function for more information (all Private InvestorEdition quotes are subject to a 20-minute delay.)<BR><BR><B>Additional Quote Services:</B> <P>Real-Time Equities Quotes --private investors can access the Dow JonesReal-Time Quotes<I><SUP><FONT SIZE=-2>SM</FONT></SUP></I> database during daytime hours for an additional fee.</P><P><BR></P></TD></TR></TABLE><P><HR><CENTER><FONT SIZE=3><A HREF="downld.html">Download Now</A> | <A HREF="tour.html">Take A Tour</A> | <A HREF="index.html">Home</A></FONT><BR>Call <B>1-800-522-3567</B>, ext. 154 to subscribe, ext. 190 for more information.</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-52</DOCNO>
<DOCOLDNO>IA027-000290-B044-404</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/pie/screen.html 143.131.194.4 19970114045824 text/html 1591
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:02:19 GMT
Last-modified: Wednesday, 08-Jan-97 15:15:11 GMT
Content-length: 1399
Content-type: text/html
</DOCHDR>
<html><head><title>Stock Screening</title></head><body bgcolor="#FFFFFF" text="#000000" link="#0000FF"vlink="#551A8B" alink="#0000FF"><table border="0" cellpadding=2 width=600>    <tr>        <td width="150"></td>        <td WIDTH=450 VALIGN=bottom><img src="images/stockscreen.gif" width="343" height="97"></td>    </tr></table><HR size="6" color="#800080"><table border="0" cellpadding="1" width="600">    <tr>        <td align="center" valign="top" width="150"><img src="images/pie_sideart.gif" width="130" height="133"></td>        <td width="450"><p>Under our <a href="coind.html">Company and Industry Data</a>        function, you can screen over 6,000 public companies that        meet your requirements, including earnings,        price/earnings ratio, price/book value, and 20 other        criteria. In fact, you can use our powerful screening        capabilities to identify a list of stocks that meet as        many criteria as you choose! Then select the Compare        Companies and Industries feature to see how your choices        stack up next to each other.</p>        </td>    </tr></table><P><HR><CENTER><FONT SIZE=3><A HREF="downld.html">Download Now</A> | <A HREF="tour.html">Take A Tour</A> | <A HREF="index.html">Home</A><BR>Call <B>1-800-522-3567</B>, ext. 154 to subscribe, ext. 190 for more information.</FONT></CENTER></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-53</DOCNO>
<DOCOLDNO>IA027-000290-B044-438</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/pie/inews.html 143.131.194.4 19970114045854 text/html 2067
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:03:00 GMT
Last-modified: Wednesday, 08-Jan-97 15:14:56 GMT
Content-length: 1875
Content-type: text/html
</DOCHDR>
<html><head><title>Custom Clips&reg; for Private Investors</title></head><body bgcolor="#FFFFFF" text="#000000" link="#0000FF"vlink="#551A8B" alink="#0000FF"><table border="0" cellpadding=3 width=600>    <tr>        <td width="150"></td>        <td WIDTH=450 VALIGN=bottom><img src="images/custclips.gif" width="343" height="97"></td>    </tr></table><HR size="6" color="#800080"><table border="0" cellpadding="1" width="600">    <tr>        <td align="center" valign="top" width="150"><img src="images/pie_sideart.gif" width="130" height="133"></td>        <td width="450"><B><FONT SIZE=+1>Tracking Investor-Related News</FONT></B><HR>The publications and other sources that are included in Dow Jones News/Retrieval&reg;--PrivateInvestor Edition are selected because of their relevance to the kinds ofdecisions investors make every day. Guiding all of these decisions is a centuryof experience in understanding --and successfully providing--news for businesspeople.<P>Now, with Dow Jones CustomClips&reg; for Private Investors, you canchoose from eight investor-related topics to track breaking news <B>for anominal fee of $2.95 per folder, per month with your paid subscription</B>--just clickon the <A HREF="http:track.html">Track News and Articles</A> function.Each time you log-on, you will receive the latest stories on these topics.Choose from Analysts' Opinions, Company and Industry Profiles, Global Investing,Initial Public Offerings, Managing Your Investments, Market Trends andForecasts, Mutual Fund Investing and Personal Finance. </P>        </td>    </tr></table><P><HR><CENTER><FONT SIZE=3><A HREF="downld.html">Download Now</A> | <A HREF="tour.html">Take A Tour</A> | <A HREF="index.html">Home</A></FONT><BR>Call <B>1-800-522-3567</B>, ext. 154 to subscribe, ext. 190 for more information.</CENTER></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-54</DOCNO>
<DOCOLDNO>IA027-000290-B045-15</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/pie/publib.html 143.131.194.4 19970114045914 text/html 2015
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:03:25 GMT
Last-modified: Wednesday, 08-Jan-97 15:15:07 GMT
Content-length: 1823
Content-type: text/html
</DOCHDR>
<html><head><title>The Private Investor Publications Library</title></head><body bgcolor="#FFFFFF" text="#000000" link="#0000FF"vlink="#551A8B" alink="#0000FF"><table cellpadding=0 cellspacing=0 width="600">    <tr>        <td width="150"></td>        <td width="450" VALIGN=bottom><img src="images/publib.gif" height=97 width=343></td>    </tr></table><hr size="6" color="#800080"><table cellpadding=0 width="600">    <tr><td align="center" valign="top" width="150"><img src="images/pie_sideart.gif" height="133" width="130" ></td><td width="450">With the <a href="search.html">Search News and Articles</a> function, you can search The Private Investor Publications Library, which is rich in content that private investors need to make smart investing decisions. This library provides you with exclusive combined access to <i>The Wall Street Journal&#174;, Barron's&#174;, Financial Times, The New York Times, Los Angeles Times</i> and over 200 other leading business and financial publications.<BR><br>Search for information on any subject, region, industry, company or person. Highlight the articles you need in national, regional and local papers, plus top business publications such as <i>Business Week, Fortune</i> and <i>Forbes</i>. Discover critical information in industry publications relevant to private investors! Save time and money by having The Private Investor Publications Library at your fingertips--all as part of your monthly fee of $29.95.<br><br><a href="pubsources.html">SOURCES</a>        </td>    </tr></table><P><HR><CENTER><FONT SIZE=3><A HREF="downld.html">Download Now</A> | <A HREF="tour.html">Take A Tour</A> | <A HREF="index.html">Home</A><BR>Call <B>1-800-522-3567</B>, ext. 154 to subscribe, ext. 190 for more information.</FONT></CENTER></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-55</DOCNO>
<DOCOLDNO>IA027-000290-B045-45</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/pie/trackna.html 143.131.194.4 19970114045937 text/html 2291
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:03:45 GMT
Last-modified: Wednesday, 08-Jan-97 15:15:17 GMT
Content-length: 2099
Content-type: text/html
</DOCHDR>
<html><head><title>Portfolio Tracking & News Alerts</title></head><body bgcolor="#FFFFFF" text="#000000" link="#0000FF"vlink="#551A8B" alink="#0000FF"><table border="0" cellpadding=2 width=600>    <tr>        <td width="150"></td>        <td WIDTH=450 VALIGN=bottom><img src="images/port_news.gif" width="343" height="97"></td>    </tr></table><HR size="6" color="#800080"><table border="0" cellpadding="2" width="600">    <tr>        <td align="center" valign="top" width="150"><img src="images/pie_sideart.gif" width="130" height="133"></td>        <td width="450">We've created a <i>multiple</i>        portfolio tracking capability in the new,        Private Investor v. 5.0 for Windows&reg; software--you can        track as many portfolios as your computer can hold!<br><br>PLUS, you can keep up-to-date on the news that <b>directly</b>        impacts you with our <b>News Alert</b> feature. A green        indicator lets you know that there's been news in the        past 24 hours on your holdings. A gray indicator tells        you that there's news from within the latest 90 days. And        Dow Jones News is news you can trust . We've been in the        business for over 100 years and publish such revered        publications as <i>The Wall Street Journal&#174;, Barron's&#174;,        SmartMoney&#174;</i> Magazine and the Dow Jones News        Service&reg;. With over 1000 reporters and editors covering        business worldwide, Dow Jones has earned a reputation for        getting the story behind the story, for revealing the        motives and actions that other publications just don't        discover. Dow Jones news helps you make smart investment        decisions.<br><br> Just click the <a href="qandm.html">Quotes & Market Data </a>function.        </td>    </tr></table><P><HR><CENTER><FONT SIZE=3><A HREF="downld.html">Download Now</A> | <A HREF="tour.html">Take A Tour</A> | <A HREF="index.html">Home</A><BR>Call <B>1-800-522-3567</B>, ext. 154 to subscribe, ext. 190 for more information.</FONT></CENTER></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-56</DOCNO>
<DOCOLDNO>IA027-000290-B045-74</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/pie/research.html 143.131.194.4 19970114050023 text/html 3544
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:04:09 GMT
Last-modified: Wednesday, 08-Jan-97 15:15:09 GMT
Content-length: 3352
Content-type: text/html
</DOCHDR>
<html><head><title>Research</title></head><body bgcolor="#FFFFFF" text="#000000" link="#0000FF"vlink="#551A8B" alink="#0000FF"><table border="0" cellpadding=2 width=600>    <tr>        <td width="150"></td>        <td WIDTH=450 VALIGN=bottom><img src="images/research.gif" width="343" height="97"></td>    </tr></table><HR size="6" color="#800080"><table border="0" cellpadding="1" width="600">    <tr>        <td align="center" valign="top" width="150"><img src="images/pie_sideart.gif" width="130" height="133"></td>        <td width="450"><P>Another distinct advantage that Dow Jones News/Retrieval&reg;-- PrivateInvestor Edition affords private investors is a massive, in-depth researchlibrary.</P><P>With our <A HREF="search.html">Search News and Articles</A> function,you can search the <A HREF="publib.html">Dow Jones Private Investor PublicationsLibrary</A> with your paid subscription. You will be able to find articles from the past sixmonths in over 200 publications on the topic you choose!</P><P>The <A HREF="coind.html">Company and Industry Data</A> function allowsyou to search <A HREF="resource.html">Corporate Ownership Watch, ZacksCorporate Earnings Estimates</A><SUP><FONT SIZE=-2>SM</FONT></SUP>, <A HREF="resource.html">Media GeneralFinancial Services, &amp; Standard &amp; Poor's Profiles and Estimates&reg;</A> with your paid subscription! You'll also be able to get informationon a company (a financial snapshot or profile), screen for companies withcriteria you determine, and compare companies and industries.</P><P>With the <A HREF="qandm.html">Quotes and Market Data</A> function, youcan see where the market has been to determine where it's going. Accesshistorical information on stocks, bonds, mutual funds, and foreign exchangerates. Find out how your stock performed today or determine your investmentsfor tomorrow with <A HREF="resource.html">Enhanced Current Quotes</A><SUP><FONT SIZE=-2>SM</FONT></SUP>,<A HREF="resource.html">Historical Equities Quotes</A><SUP><FONT SIZE=-2>SM</FONT></SUP>, <A HREF="resource.html">Snapshot Tradeline,Historical Dow Jones Averages&reg;, Quotes on Commodities, Futures andSelected Indexes</A><SUP><FONT SIZE=-2>SM</FONT></SUP>, <A HREF="resource.html">Innovest Technical AnalysisReports, Mutual Funds Performance Reports</A><SUP><FONT SIZE=-2>SM</FONT></SUP><A HREF="resource.html">and Wall $treet Week</A><SUP><FONT SIZE=-2>SM</FONT></SUP> <A HREF="resource.html">Transcripts Online.</A></P><P>Through access to The Academic American Encyclopedia&reg; you can getprofiles of people, places and things from over 32,000 articles. Thereare facts and figures on subjects such as science, technology, geography, geographic locations, sports, social sciences, population statisticsand even biographies. You can search by partial or complete title of thesubject! </P><P>Information gives you the edge in investing, and with the Private InvestorEdition's vast research tools, you can get the information you need, quicklyand accurately. </P>        </td>    </tr></table><P><HR><CENTER><FONT SIZE=3><A HREF="downld.html">Download Now</A> | <A HREF="tour.html">Take A Tour</A> | <A HREF="index.html">Home</A><BR>Call <B>1-800-522-3567</B>, ext. 154 to subscribe, ext. 190 for more information.</FONT></CENTER></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-57</DOCNO>
<DOCOLDNO>IA027-000290-B045-111</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/pie/tech.html 143.131.194.4 19970114050045 text/html 2093
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:04:57 GMT
Last-modified: Wednesday, 08-Jan-97 15:15:15 GMT
Content-length: 1901
Content-type: text/html
</DOCHDR>
<html><head><title>Technical Analysis</title></head><body bgcolor="#FFFFFF" text="#000000" link="#0000FF"vlink="#551A8B" alink="#0000FF"><table border="0" cellpadding=3 width=600>    <tr>        <td width="150"></td>        <td WIDTH=450 VALIGN=bottom><img src="images/techanal.gif" width="343" height="97"></td>    </tr></table><HR size="6" color="#800080"><table border="0" cellpadding="1" width="600">    <tr>        <td align="center" valign="top" width="150"><img src="images/pie_sideart.gif" width="130" height="133"></td>        <td width="450">As part of your subscription to Dow Jones        News/Retrieval&reg;--Private Investor Edition, you'll        receive access to: </p>        <p><b>Innovest Technical Analysis Reports</b> </p>        <p>With Innovest Technical Analysis Reports, you can        receive price and volume analysis of more than 4,500        stocks trading on the New York and American exchanges,        and the OTC. </p>        <p><b>Snapshot Tradeline</b> </p>        <p>Snapshot Tradeline gives you comprehensive snapshots        of security information and historical pricing for over        50,000 active and inactive U.S. and Canadian issues. </p>        <p>In addition to our online products, Private Investor        Services offers charting software and a data downloader! </p>        <p><b>Charting Software:<br>        <a href="wow.html">Window on WallStreet</A></b><font size="-2"><sup>TM</sup></font><a href="wow.html"><b>        for Dow Jones</b></A><p><b>Data Downloader:<br><a href="nirvana.html">Nirvana Data Collector</A></b> </p></td>    </tr></table><P><HR><CENTER><FONT SIZE=3><A HREF="downld.html">Download Now</A> | <A HREF="tour.html">Take A Tour</A> | <A HREF="index.html">Home</A><BR>Call <B>1-800-522-3567</B>, ext. 154 to subscribe, ext. 190 for more information.</FONT></CENTER></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-58</DOCNO>
<DOCOLDNO>IA027-000290-B045-134</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/pie/sports.html 143.131.194.4 19970114050113 text/html 1416
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:05:20 GMT
Last-modified: Wednesday, 08-Jan-97 15:15:13 GMT
Content-length: 1224
Content-type: text/html
</DOCHDR>
<html><head><title>Sports & Weather</title></head><body bgcolor="#FFFFFF" text="#000000" link="#0000FF"vlink="#551A8B" alink="#0000FF"><table border="0" cellpadding=3 width=600>    <tr>        <td width="150"></td>        <td WIDTH=450 VALIGN=bottom><img src="images/sport_weath.gif" width="343" height="97"></td>    </tr></table><HR size="6" color="#800080"><table border="0" cellpadding="1" width="600">    <tr>        <td align="center" valign="top" width="150"><img src="images/pie_sideart.gif" width="130" height="133"></td>        <td width="450">Now, Private Investor Edition also offers you news on sports and weather with your subscription--just click on the <a href="current.html">Current News</a> function. Take a break from researching your investments and get the latest news on your favorite teams and players! Prepare for your business trip or family vacation with the latest on weather patterns.        </td>    </tr></table><P><HR><CENTER><FONT SIZE=3><A HREF="downld.html">Download Now</A> | <A HREF="tour.html">Take A Tour</A> | <A HREF="index.html">Home</A><BR>Call <B>1-800-522-3567</B>, ext. 154 to subscribe, ext. 190 for more information.</FONT></CENTER></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-59</DOCNO>
<DOCOLDNO>IA027-000290-B045-162</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/pie/legal.html 143.131.194.4 19970114050133 text/html 3112
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:05:43 GMT
Last-modified: Thursday, 09-Jan-97 20:55:08 GMT
Content-length: 2921
Content-type: text/html
</DOCHDR>
<HTML><HEAD>   <TITLE>Pricing, Rules &amp; Regulations</TITLE></HEAD><BODY TEXT="#000000" BGCOLOR="#FFFFFF" LINK="#0000FF" VLINK="#551A8B" ALINK="#0000FF"><H2><FONT COLOR="#5b0b5a">Pricing, Rules &amp; Regulations </FONT></H2><hr size=4><P><B>Dow Jones News/Retrieval&reg;--Private Investor Edition<BR></B>Cost is $29.95 per month; fee includes up to ten hours of access. During plan hours, any time over ten hours costs $.06 per minute. Access Time: 7:01 p.m. - 6:00 a.m. (your local time) weekdays, any time on weekends and the following holidays: New Year's Day, Presidents' Day, Good Friday, Memorial Day, Independence Day, Labor Day, Thanksgiving Day, and ChristmasDay. For users accessing Private Investor Edition via a TCP/IP or Internet connection, plan hours are based on Eastern Time (ET). Subscribers in Alaska, Hawaii, and Puerto Rico are subject to additional telecommunication charges.</P><P><B>Dow Jones News/Retrieval&reg;--Technical Analyst Edition<BR></B>Cost is $39.95 per month; flat monthly fee entitles you to (5) hours of access between 7:01 p.m.- 6:00 a.m. (your local time) weekdays, any time on weekends and on thefollowing holidays: New Year's Day, Presidents' Day, Good Friday, MemorialDay, Independence Day, Labor Day, Thanksgiving Day, and Christmas Day.During plan hours, any time over (5) five hours costs $.50 per minute. Subscribers in Alaska, Hawaii,and Puerto Rico are subject to additional telecommunications surcharges.For users accessing Private Investor Edition via a TCP/IP or Internet connection, plan hours are based on Eastern Time (ET).</P><P><B>Dow Jones News/Retrieval&reg;--Technical Analyst Gold Edition<BR></B>Cost is $59.95 per month; flat montly fee entitles you to (5) hours of access to the TradelineAccess Plan and (10) hours of access to Private Investor Edition sourcesbetween 7:01 p.m. - 6:00 a.m. (your local time) weekdays, any time on weekendsand on the following holidays: New Year's Day, Presidents' Day, Good Friday,Memorial Day, Independence Day, Labor Day, Thanksgiving Day, and ChristmasDay. During plan hours, any time over (5) five hours costs $.50 per minute for Tradeline Access Plan and any time overthe ten (10) hours of Private Investor Edition sources costs $.06 per minute. Subscribers in Alaska, Hawaii, and PuertoRico are subject to additional telecommunications surcharges. The ten hoursof Dow Jones News/Retrieval&reg;--Private Investor Edition and five hoursof Tradeline Access Plan are separate and cannot be combined. For users accessing Private Investor Edition via a TCP/IP or Internet connection, plan hours are based on Eastern Time (ET). </P><P><HR><CENTER><FONT SIZE=3><A HREF="downld.html">Download Now</A> | <A HREF="tour.html">Take A Tour</A> | <A HREF="index.html">Home</A></FONT><BR>Call <B>1-800-522-3567</B>, ext. 154 to subscribe, ext. 190 for more information.</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-60</DOCNO>
<DOCOLDNO>IA027-000290-B045-197</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/pie/downld.html 143.131.194.4 19970114050206 text/html 11896
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:06:04 GMT
Last-modified: Friday, 10-Jan-97 02:28:21 GMT
Content-length: 11706
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Dow Jones News/Retrieval - Private Investor Edition - Download</TITLE></HEAD>

<BODY TEXT="#000000" BGCOLOR="#FFFFFF" LINK="#0000FF" VLINK="#551A8B" ALINK="#0000FF">

<H2><FONT COLOR="#5b0b5a">
Download Dow Jones News/Retrieval&#174;<BR>
Private Investor Edition, v. 5.0 for Windows&#174;</FONT></H2><hr size=4>

<B>Before you begin:</B>
<blockquote>
<LI> You need to set up your account with us before you can use the software. <P>

<LI> Call <B>1-800-522-3567, ext. 154</B>.  There's a monthly fee of $29.95 for 10 hours of monthly access to the sources in the Private Investor Edition (for subscribers in the contiguous U.S.) from 7:01 p.m. to 6:00 a.m. (your local time) weeknights, plus all day and night on weekends and certain holidays. Other restrictions apply.  <A HREF="legal.html">See pricing, rules and regulations.</A><P>

<LI> If you're outside the contiguous U.S., contact <A HREF="mailto:support@bis.dowjones.com">customer service</A> for pricing information.<P>

<LI> Before you can download, you must read and agree to the terms of the Subscriber Agreement listed on the next page.  You must also fill out and submit a very brief registration form online.<P>

<LI> Then download the self-extracting software and follow the easy installation instructions.<P>

<LI> <B>Here's a tip for after your download is complete.  To be sure the entire file was downloaded, without modem or other connection-related interruptions that can sometimes occur, check the file size to be sure it's complete.  It should be 2,896,596 bytes.  If you're running Windows&#174; 95, accomplish this check using Windows&#174; Explorer; if you're using Windows&#174; 3.1, use File Manager to locate the file.</B></BLOCKQUOTE>
<P>

<HR size=4>

<H3>Please read and agree to the terms and conditions of this Agreement before downloading the software.</H3>


<I>DOW JONES NEWS/RETRIEVAL&#174;-PRIVATE INVESTOR EDITION SUBSCRIPTION AGREEMENT</I><P>

This Agreement governs your access to and use of the content (the "Content") in the Dow Jones News/Retrieval&#174;-Private Investor Edition, Dow Jones News/Retrieval&#174;-Technical Analyst Edition and Dow Jones News/Retrieval&#174;-Technical Analyst Gold Edition (each a "Service"). If you download, install, or receive Dow Jones News/Retrieval&#174; software that you use or can be used to access the Content, this Agreement also applies to that software (the "Software").  PLEASE READ THIS AGREEMENT CAREFULLY BEFORE USING THE SOFTWARE OR THE SERVICE.  BY 
USING THE SOFTWARE OR THE SERVICE, YOU AGREE TO BE BOUND BY ALL OF THE TERMS IN THIS AGREEMENT.  IF YOU DO NOT AGREE TO BE BOUND BY ALL OF THE TERMS IN THIS AGREEMENT, DO NOT ACCESS THE SERVICE, AND RETURN OR DESTROY ANY SOFTWARE YOU HAVE RECEIVED.  You may print and keep copies of this Agreement.<P>

<I>Passwords; Unauthorized Use</I><BR>

This Agreement, and your password, are personal to you, and you may not assign this Agreement or your password to anyone.  You are responsible for the confidentiality of your password and for all charges incurred using your password.  If you become aware of any 
unauthorized use of your password or if it is lost or stolen, you agree to notify Dow Jones Customer Service immediately.<P>

<I>Charges and Payment; Pricing</I><BR>

You agree to pay or to have paid, within 15 days after receipt of an invoice, all fees and charges for the Content, Service and Software, at the rates then in effect for your pricing plan, plus applicable taxes.  All fees are nonrefundable.  Dow Jones may charge late fees on 
overdue accounts, and you agree to pay or to have paid all costs (including, without limitation, attorneys' fees) Dow Jones incurs to collect any overdue amounts.<P>

You acknowledge that the prices that appear when you click on the $ icon, or within the USAGE or INVOICE areas of the Service, are estimates only of the amount you will owe.  You can always obtain accurate, then-current prices through GUIDE, the electronic user's 
guide.  The actual amount you owe for Content and the Service will be the amount set forth on your invoice or billed to your credit, debit or similar account.  References to the Information Unit Pricing Plan within the Service may not apply to you.<P>

<I>Limitations on Use</I><BR>

The Software, Content and Service are the property of Dow Jones or its licensors, and are protected by applicable copyright and intellectual property laws.  Except as indicated otherwise in GUIDE or FYI, the Content may be stored in memory on your personal computer, 
manipulated, analyzed, reformatted, displayed and printed for your personal, noncommercial use only.  Unless you obtain the express prior written consent of Dow Jones, you agree not to reproduce, retransmit, disseminate, distribute, publish, broadcast or sell any Content to anyone, 
including, but not limited to, others in your company or organization, with this one exception:  You may, from time to time, disseminate an insubstantial portion of Content, for a noncommercial purpose and without charge, to a limited number of employees in the same 
company or organization, provided you include all copyright and other proprietary notices with such portion of the Content in the same form in which the notices appear in the Service.  Unless you obtain the express prior written consent of Dow Jones, and except to the extent expressly permitted by applicable law, you also agree not to disassemble, decompile, reverse engineer, alter, distribute, transfer, reproduce, sell or license any part of the Software.<P>

<I>Disclaimer of Warranties and Liability</I><BR>

Due to the number of sources from which the Content is obtained, and the inherent hazards of electronic distribution, there may be delays, omissions or inaccuracies in the Content and Service.  THE SOFTWARE IS PROVIDED "AS IS" AND WITHOUT ANY WARRANTIES.  DOW JONES AND ITS AFFILIATES, AGENTS AND LICENSORS CANNOT AND DO NOT WARRANT THE ACCURACY, COMPLETENESS, CURRENTNESS, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE CONTENT, SERVICE OR SOFTWARE.  NEITHER DOW JONES NOR ANY OF ITS AFFILIATES, AGENTS OR LICENSORS SHALL BE LIABLE TO YOU OR ANYONE ELSE FOR ANY LOSS OR INJURY CAUSED IN WHOLE OR PART BY ITS NEGLIGENCE OR CONTINGENCIES BEYOND ITS CONTROL IN PROCURING, COMPILING, INTERPRETING, EDITING, WRITING, REPORTING OR DELIVERING 
ANY CONTENT OR THE SERVICE.  IN NO EVENT WILL DOW JONES, ITS AFFILIATES, AGENTS OR LICENSORS BE LIABLE TO YOU OR ANYONE ELSE FOR ANY DECISION MADE OR ACTION TAKEN BY YOU IN RELIANCE ON THE CONTENT, SERVICE OR SOFTWARE.  DOW JONES AND ITS AFFILIATES, AGENTS AND LICENSORS SHALL NOT BE LIABLE TO YOU OR ANYONE ELSE FOR ANY DAMAGES OTHER THAN DIRECT DAMAGES (INCLUDING, WITHOUT LIMITATION, CONSEQUENTIAL, SPECIAL AND SIMILAR DAMAGES) IN CONNECTION WITH THE 
CONTENT, SERVICE AND SOFTWARE, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.  YOU AGREE THAT THE LIABILITY OF DOW JONES, ITS AFFILIATES, AGENTS AND LICENSORS, IF ANY, ARISING OUT OF ANY KIND OF LEGAL CLAIM (WHETHER IN CONTRACT, TORT OR OTHERWISE) IN ANY WAY CONNECTED WITH THE CONTENT, SERVICE AND SOFTWARE SHALL NOT EXCEED THE AGGREGATE AMOUNT PAID BY YOU TO DOW JONES FOR USE OF THE CONTENT OR SERVICE IN THE 12 MONTHS IMMEDIATELY PRECEDING THE 
EVENT GIVING RISE TO SUCH CLAIM.  You acknowledge that the Content and Service may include the views, opinions and recommendations of third parties whose thoughts are deemed of interest, and that Dow Jones and its Content licensors do not endorse the views, give investment, tax or legal advice, or advocate the purchase or sale of any security or investment.<P>

<I>Additional Restrictions, Legal Disclaimers and Changes in Terms</I><BR>

Additional restrictions that may apply to your pricing plan (e.g. Private Investor Edition subscribers), if any, and additional legal disclaimers and notices regarding the Content and Service, are available, free of charge, in GUIDE, the electronic user's guide, and FYI, the electronic newsletter for the Service.  Dow Jones also may change or add to the terms of this 
Agreement, or the fees and charges for the Content, Service or Software, at any time.  Notice of any such changes or additions will appear in FYI.  You agree to read GUIDE and FYI and be bound by the additional restrictions, legal disclaimers and notices contained in GUIDE and 
FYI.  You are urged to consult GUIDE and FYI each time you access the Service.  By accessing Content, or using the Service or Software after any additional restriction, legal disclaimer or notice, or any change or addition to Agreement terms, fees or charges, is posted in GUIDE or FYI, you are agreeing to be bound by all such restrictions, disclaimers, notices, changes and additions.<P>

<I>Subscription Termination</I><BR>

You may terminate your Service subscription at any time.  Your Service subscription, and obligation to pay fees and charges incurred, will continue until terminated by Dow Jones, or until Dow Jones receives notice from you of your intention to terminate your Service 
subscription.  Dow Jones may discontinue the Service, availability of certain Content within the Service, or their availability to you, at any time without notice.  Dow Jones or you may terminate your right to use the Software at any time.  Upon such termination, you agree to 
destroy the Software or return it to Dow Jones.<P>

If any term in this Agreement is invalid or unenforceable under applicable law, the remaining terms in the Agreement shall remain and be deemed valid and enforceable.  If any change or amendment to this Agreement is invalid or unenforceable under applicable law, the 
Agreement formed without such change or amendment shall remain and be deemed valid and enforceable.  This Agreement, and all rights and obligations pursuant to this Agreement, shall be governed by the laws of the United States and State of New York, without regard to 
principles of conflicts of law.  Application of the U.N. Convention on Contracts for the International Sale of Goods is expressly excluded.<P>

If Dow Jones and you have manually signed a paper version of a contract governing your use of the Content, Service and/or Software, the terms in that manually signed, paper document are not amended by, and supersede, terms in this Subscription Agreement.<P>

IF YOU AGREE TO BE BOUND BY ALL OF THE TERMS IN THIS AGREEMENT, PLEASE FILL OUT THE BRIEF FORM BELOW AND CLICK THE "SUBMIT THE INFORMATION" BUTTON:<P>
<HR>
<B>You must enter your name and address for our records.</B><P>
<CENTER>
<FORM  METHOD="GET" ACTION="/cgi-bin/pidwnld.cgi">
<INPUT NAME="Formtype" VALUE="PIE" TYPE="hidden" size=10>
<table>
<tr><td>
<b>Name:</b>
</td><td>
<INPUT TYPE ="text" NAME="name" maxlength= 30 SIZE =30>
</td></tr><tr><td>
<b>E-Mail Address:</b>
</td><td>
<INPUT TYPE ="text" NAME="e-mail" maxlength= 50 SIZE =30>
</td></tr><tr><td>
<b>Street Address:</b>
</td><td>
<INPUT TYPE ="text" NAME="Address1"  maxlength= 40 SIZE =30>
</td></tr><tr><td>
</td><td>
<INPUT TYPE ="text" NAME="Address2"  maxlength=40 SIZE =30> 
</td></tr><tr><td>
<b>City:</b>
</td><td>                 
<INPUT TYPE ="text"NAME="City"  maxlength= 30 SIZE =30>
</td></tr><tr><td>
<b>State:</b>
</td><td>               
<INPUT TYPE ="text"NAME="State"  maxlength= 30 SIZE =30> 
</td></tr><tr><td> 						  
<b>Zip/Postal Code:</b>
</td><td>
<INPUT TYPE ="text"NAME="Zip"maxlength= 30 SIZE =30> 
</td></tr><tr><td>
<b>Country:</b>
</td><td>
<INPUT TYPE="text" NAME="Country" maxlength=30 SIZE=30>
</td></tr>
</table>
<CENTER><P><INPUT TYPE="submit" VALUE="Submit the information"> 
<INPUT TYPE="reset" VALUE =
"Clear the text entry fields"></CENTER>
</form>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-61</DOCNO>
<DOCOLDNO>IA027-000290-B045-227</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/pie/tour.html 143.131.194.4 19970114050245 text/html 2460
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:06:36 GMT
Last-modified: Wednesday, 08-Jan-97 15:15:16 GMT
Content-length: 2268
Content-type: text/html
</DOCHDR>
<HTML><HEAD>   <TITLE>Dow Jones News/Retrieval--Private Investor Edition Tour</TITLE></HEAD><BODY TEXT="#000000" BGCOLOR="#FFFFFF" LINK="#0000FF" VLINK="#551A8B" ALINK="#0000FF"><H2><FONT COLOR="#5b0b5a">Dow Jones News/Retrieval&reg;<BR>Private InvestorEdition v. 5.0 for Windows&reg;</FONT></H2><hr size=4><CENTER><P><B><H2>Take a Tour!</H2>If you like what you see, <A HREF="http:downld.html"><BLINK>download now !</BLINK><BR></A>Then call 1-800-522-3567 ext. 154 to sign-up.</B></P></CENTER><P>What's the Secret Formula for Successful Investing? </P><P>That's what every Private Investor wants to know. What do top Wall Streetprofessionals have that gives them the edge? The answer is simple: research.</P><P>The pros not only appreciate the importance of getting their news andquotes from a highly respected source, they also use Dow Jones to thoroughlyunderstand a company before they buy or sell. They know who's buying whatstocks and why. They know what analysts have said about a company and whatthe forecasts are for each. And they have the latest financial informationand data.</P><P>Now, you too can access many of the same sources that professional investorsaround the globe turn to for reliable, accurate research. And with ourredesigned software, you'll be able to find the answers you need to makesmart investment decisions in a flash. </P><CENTER><P><B><FONT SIZE=+1>DOW JONES NEWS/RETRIEVAL&reg;--Private InvestorEdition</FONT></B></P><P>The all-new software makes it easier than ever to access the same informationthe pros use!</P></CENTER><CENTER><A HREF="mainscreen.map"><IMG SRC="mainscreen.gif" BORDER=0 ISMAP></A><BR><B>Click the buttons on the left side of the above screen for a detailed description.</B></CENTER><PRE></PRE><CENTER><P><B>Need More Information?</B> <P><A HREF="mailto:support@bis.dowjones.com">Clickhere</A> if you'd like to request more information.<P><A HREF="http:scenarios.html">Click here</A> to try our <B>investment scenarios</B>!</CENTER><PRE></PRE><P><HR><CENTER><FONT SIZE=3><A HREF="downld.html">Download Now</A> | <A HREF="index.html">Home</A><BR>Call <B>1-800-522-3567</B>, ext. 154 to subscribe, ext. 190 for more information.</FONT></CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-62</DOCNO>
<DOCOLDNO>IA027-000290-B045-251</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/pie/pie.html 143.131.194.4 19970114050325 text/html 956
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:07:14 GMT
Last-modified: Wednesday, 08-Jan-97 15:15:03 GMT
Content-length: 765
Content-type: text/html
</DOCHDR>
<HTML><HEAD>   <TITLE>Dow Jones News/Retrieval Private Investor Editions</TITLE></HEAD><BODY TEXT="#000000" BGCOLOR="#FFFFFF" LINK="#0000FF" VLINK="#551A8B" ALINK="#0000FF"><TABLE BORDER=0 CELLSPACING=2 CELLPADDING=2 WIDTH=600><TR><TD WIDTH=150></TD><TD><IMG SRC="images/DJ_PIprod_serv.gif" ALT="IMAGE" HEIGHT=75 WIDTH=450></TD></TR></TABLE><HR size="6"><A HREF="privinvst.map"><IMG SRC="privinvst.gif" BORDER=0 ISMAP></A><P><HR size=3><CENTER><FONT size=3><A HREF="index.html">Dow Jones News/Retrieval&#174; Private Investor Edition</A><BR><A HREF="tae.html">Dow Jones News/Retrieval&#174; Technical Analyst Edition</A><BR><A HREF="tag.html">Dow Jones News/Retrieval&#174; Technical Analyst Gold Edition</A></FONT></CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-63</DOCNO>
<DOCOLDNO>IA027-000290-B045-286</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/releas41.html 143.131.194.4 19970114050347 text/html 8916
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:07:53 GMT
Last-modified: Monday, 13-Jan-97 21:08:26 GMT
Content-length: 8727
Content-type: text/html
</DOCHDR>
<html><head><title>PR Pages</title></head><body  background="../images/bgddj.gif"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td><td><p><br><blockquote><center>MEDIA ADVISORY<p><b> DOW JONES INTRODUCES POWERFUL ONLINE <BR>INVESTOR RESOURCES FOR PRIVATE INVESTORS <BR>Expanded Content, New Easy-to-Use Interface <BR>Reinforce Dow Jones's Position as the Premier <BR>Provider of Online Investment Information<br></b><p></b></center><pre><B>PRINCETON, N.J., January 6, 1997 - </b>Dow Jones Business Information Services (BIS) announced today the launch of completely new versions of Dow Jones News/Retrieval&#174;-Private Investor Edition and Dow Jones News/Retrieval&#174;-Technical Analyst Edition.  Both online private investor services feature a new easy-to-use interface and expanded analytical tools and publications for serious investors to perform in-depth technical and fundamental analysis.	"Investors need more than just stock quotes and press releases, they need in-depth information from sources they can trust," said Tom Baker,executive director of consumer products, Dow Jones Business Information Services.  "These new products give private investors many of the same sources and data that professional investors use -- but at a fraction of the cost."	The new release of Dow Jones News/Retrieval-Private Investor Edition includes several major enhancements:<UL><LI>Company Screening allows investors to screen more than 6,000 companies using over 20 criteria, including earnings, PE ratios, price to book value ratios and more;<LI>Dow Jones Private Investor Publications Library gives subscribers access to the full text of more than 200 premier business publications. By entering a simple search statement, investors can find news and data on current investments or research new ideas;<LI>Portfolio Tracker with news alerts keeps investors abreast of news, quotes, portfolio value and gains or losses;<LI>Dow Jones CustomClips&#174; for Private Investors automatically delivers constantly updated news stories on pre-selected subjects from leading business and financial publications such as The Wall Street Journal&#174;, Institutional Investor and the Financial Times.</UL>	For investors who chart securities and rely on technical indicators to make investment decisions, News/Retrieval-Technical Analyst Edition provides a powerful combination of current pricing from Dow Jones and more than 20 years of historical pricing data from Tradeline.  For investors who want the benefits of both technical and fundamental analysis, News/Retrieval-Technical Analyst Gold Edition combines all the research sources and publications of the Private Investor Edition with the pricing data of the Technical Analyst Edition.	Both the Private Investor and Technical Analyst Editions include a new version of the award-winning Dow Jones News/Retrieval forWindows software application.  Both editions provide private investors with easy-to-use, highly intuitive graphical access to all the featured information and tools.  Investors need only an IBM compatible PC running Windows 3.1, Windows 95, or OS/2 2.1 or higher and a minimum 2,400 modem speed.  For in-depth content and pricing information, please see the attached information sheet.	To request the new software or to get more information, contact Dow Jones Customer Service at 1-800-522-3567, extension 164.<B>About Dow Jones</B>	Dow Jones Business Information Services, the electronic publishing arm of Dow Jones & Company, Inc., provides business and financial news and information products, including The Wall Street Journal&#174;Interactive Edition  on the World Wide Web and Dow Jones News/Retrieval&#174;,to corporations, consumers and private investors through a variety of electronic media: computer, telephone, facsimile and radio. 	Dow Jones also publishes The Wall Street Journal&#174; and its international editions, Barron's&#174; magazine and other periodicals; electronic information services, including those of Dow Jones Telerate and Dow Jones Financial News Services; and the Ottaway group of communitynewspapers.  Dow Jones also produces business television programminginternationally.  More information on Dow Jones Business Information Services and its products can be found at http://bis.dowjones.com.Dow Jones News/Retrieval, The Wall Street Journal and Barron's are registered trademarks of Dow Jones & Company, Inc.  All other productsmentioned are trademarks or service marks of their respective companies.<B>More Information About Dow Jones' Private Investor Services</B><B>News/Retrieval-Private Investor Edition</B>Subscribers can tap into high-quality, comprehensive sources and features including:<UL><LI>Ability to screen more than 6000 stocks from over 20 criteria;<LI>Full-text articles from hundreds of business publications accessed through the Dow Jones Private Investor Publications Library. Leading business and trade journals include The Economist, Bond Buyer, Institutional Investor and Electronic Information Report;<LI>Exclusive combination of the same-day, full-text articles from The Wall Street Journal&#174;, Barron's&#174;, The New York Times, Financial Times, Los Angeles Times and The Washington Post;<LI>Portfolio Tracking with news alerts;<LI>Dow Jones CustomClips&#174; for Private Investor, a news alert service that will scan top business and finance publications for news on a specific investor topic; <LI>Company financial data including security snapshots, earnings per share, earnings estimates, P/E ratio and yield; <LI>Market news from 11 exclusive Dow Jones newswires and other sources, including the Canada NewsWire, and Canadian Corporate News;<LI>Current stock and mutual fund quotes and daily historical quotes going back a full year; <LI>Monthly stock quotes back to 1979; quarterly stock data back to 1978.</UL><B>News/Retrieval-Technical Analyst Edition</B>The Technical Analyst Edition provides information especially helpful to those who track pricing trends in securities, including:<UL><LI>Dow Jones Enhanced Current Quotessm which covers common and preferred stocks, corporate and foreign bonds, mutual funds, U.S. Treasury issues, options, money markets,rights, and warrants;<LI>Tradeline's 20 years of historical pricing and dividends on over 150,000 securities;<LI>Special technical analyst reports from Tradeline.</UL><B>News/Retrieval-Technical Analyst Gold Edition</B>A powerful combination of Private Investor Edition and Technical Analyst Edition sources at a reduced price.<B>Pricing</B><U>Private Investor Edition:</U>$29.95 monthly fee includes 10 hours of online access per month;<U>Technical Analyst Edition:</U>$39.95 monthly fee includes five hours of online access to Tradeline Access Plan and Current Quotes per month;<U>Technical Analyst Gold:</U>$59.95 monthly fee includes five hours access to TAP and 10 hours of access to the Private Investor Edition per month.  Each plan permits online access between 7:01 p.m. and 6 a.m. local time onweeknights and anytime on weekends and certain holidays.  However, if the servicesare accessed through a TCP/IP connection, plan hours are 7:01 p.m. to 6 a.m. EST.When usage during these periods exceeds the hours included in the plan, additionaltime will be billed at 6 cents per minute for Private Investor Edition sources and 50cents per minute for Technical Analyst Edition sources.	There are additional charges for accessing the services from Hawaii, Alaska andPuerto Rico.CONTACT: Dow Jones, PrincetonKris LeBoutillier  609-520-4638or kris.leboutillier@cor.dowjones.com</pre><hr><a href="../latest.html">Back to the main Dow Jones in the News page.</a><hr><H4>We welcome feedback or questions about the <A HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4></blockquote><pre></pre><center><a href="../toolbar.gif.map"><IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a><BR><font size=2><a href="../bizpubs/index.html">Newspapers</a> |<a href="../clipping/index.html">Alert Services</a> |<a href="../online-lib/index.html">Research</a>  |<a href="../pers-finance/index.html">Personal Finance</a>  |  <a href="../latest.html">DJ In The News</a>  |<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |<a href="../index.html">Home</a> </font></center></TD></tr></TABLE></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-64</DOCNO>
<DOCOLDNO>IA027-000290-B045-316</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/releas40.html 143.131.194.4 19970114050424 text/html 6389
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:08:28 GMT
Last-modified: Wednesday, 30-Oct-96 14:42:48 GMT
Content-length: 6197
Content-type: text/html
</DOCHDR>
<html><head><title>PR Pages</title></head><body  background="../images/bgddj.gif"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td><td><p><br><blockquote><center>MEDIA ADVISORY<p><b>DOWVISION, THE MOST POPULAR DIRECT-TO-THE-DESKTOP<br> CUSTOM NEWS SERVICE, NOW AVAILABLE ON THE WEB <br>DIRECTLY FROM DOW JONES<br></b><p></b></center><pre><B>Washington, D.C. --  Oct. 28, 1996</B> -- Dow JonesBusiness Information Services announced today that DowVision&#174, the most popular direct-to-the-desktopcustom news service for corporations, will be available later this fall via the World Wide Web directly from DowJones. The announcement, made here at the Online World conference, is the latest development in Dow Jones' continuing commitment to make its award-winningnews and information services available on the Web.Now corporate executives, public relations professionals,information professionals, sales and marketing managers,and financial analysts can use their existing corporateInternet connections or intranets and standard browsersto keep current on competitors, industry trends, and breaking corporate news. Customers can browse thetop headlines from the leading national and internationaldaily newspapers. Company-wide or individually customizedfolders can be set up to track specific news and informationpertinent to multiple or individual users in the organization.Current quotes and market data from the same source thatfeeds the stock tables in The Wall Street Journal&#174are easily accessible, as is a 90-day archive of newsstories indexed by Dow Jones editors, which allowsaccurate and immediate searching.DowVision is the exclusive electronic source for thecombined current day's editions of The Wall StreetJournal, The New York Times, Washington Post, Los Angeles Times and Financial Times as well asthe Dow Jones News Service&#174 and Barron's&#174.In addition, DowVision is a rich source of breaking internaitonal news. Exclusive sources include TheWall Street Journal Europe, The Asian Wall StreetJournal&#174, the Far Eastern Economic Review, the Dow Jones International News Service(sm),Canada NewsWire(sm) and Canadian Corporate News(sm).DowVision from Dow Jones is the latest in a series ofDow Jones products now available on the Web, ledby the successful introduction of the award-winningWall Street Journal&#174 Interactive Edition earlierthis year, said Dorothea Coccoli Palsho, president,Dow Jones Business Information Services. "Dow-Vision from Dow Jones is another example of howour editorial staff is creating the best Web-based news products available on the market today." OtherWeb-based news and research products will beintroduced in 1997."Our research shows that custom news to the desk-top is the fastest growing segment of the businessonline market," said Clare Hart, director, enterpriseproducts, Dow Jones Business Information Services."Feedback from our customers led to the creation ofa Web-based corporate information service directlyfrom Dow Jones that was easy to use and providedquick delivery of top news from trusted sources."DowVision from Dow Jones does not require a dedi-cated server. Internet/intranet access to DowVisionis provided directly from Dow Jones via any popularWeb browser.Consistent with DowVision's current pricing model,DowVision from Dow Jones offers significant discounts as the number of users grows. For as little as $2 per seat, per month, corporate customers canput the world's premier business news, information and quotes directly on their employees' desktops,making DowVision from Dow Jones the best valuein the corporate marketplace.<B>About Dow Jones</B>Dow Jones Business Information Services is the electronic publishing arm of Dow Jones & Co., Inc. that provides business and financial news and information products, including The Wall Street Journal&#174 Interactive Edition on theWorld Wide Web and Dow Jones News/Retrieval&#174, to corporations, consumers and private investors through a variety of electronic media; computer, telephone, facsimile and radio.Dow Jones also publishes the print version of The Wall Street Journal  and its international editions, Barron's&#174 magazine and other periodicals, electronic information services, including those of Dow Jones Telerate and Dow Jones Financial NewsServices, and the Ottaway group of community newspapers. Dow Jones also produces business television programming internationally.DowVision, The Wall Street Journal, The Wall StreetJournal Interactive Edition, The Asian Wall Street Journal,Barron's and Dow Jones News Service and Telerate are all marks of Dow Jones & Co., Inc. All other products mentioned are the marks of their respective owners.<P>CONTACT: Dow Jones, PrincetonMaggie Landis, 609-520-4679mlandis@wsj.dowjones.com</pre><hr><a href="../latest.html">Back to the main Dow Jones in the News page.</a><hr><H4>We welcome feedback or questions about the <A HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4></blockquote><pre></pre> 								<center>					<a href="../toolbar.gif.map">								<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>					<BR>									<font size=2>					<a href="../bizpubs/index.html">Newspapers</a> |					<a href="../clipping/index.html">Alert Services</a> |					<a href="../online-lib/index.html">Research</a>  |					<a href="../pers-finance/index.html">Personal Finance</a>  |  					<a href="../latest.html">DJ In The News</a>  |					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |					<a href="../index.html">Home</a> 				</font>												</center>				</TD></tr></TABLE></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-65</DOCNO>
<DOCOLDNO>IA027-000290-B045-342</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/releas39.html 143.131.194.4 19970114050449 text/html 8338
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:08:54 GMT
Last-modified: Friday, 18-Oct-96 19:09:09 GMT
Content-length: 8149
Content-type: text/html
</DOCHDR>
<html><head><title>PR Pages</title></head><body  background="../images/bgddj.gif"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td><td><p><br><blockquote><center>MEDIA ADVISORY<p><b>DOW JONES NEWS/RETREVAL ADDS EXCLUSIVE <BR>INTERNATIONAL AND BUSINESS/FINANCIAL NEWS<br></b><p></b></center><pre><B>Princeton, NJ, Oct. 16, 1996</B>-- Dow JonesBusiness Information Services continues to expandits selection of exclusive sources available in DowJones News/Retrieval&#174 with the addition of four newswires. The newswires -- Dow Jones Asian Equities Report, Dow Jones Australia/New ZealandReport, Dow Jones Commodities Service, and DowJones Money Management Alert -- provide real-timebusiness and financial news focused on specificcountries, markets and investment vehicles.The Dow Jones exclusive newswires are produced solely by the company's global editorial staff of morethan 1,000 journalists who generate thousands of stories each day from 90 offices located in more than50 countries world-wide.Business professionals -- company-wide and across different industries -- can turn to these sources fromDow Jones and a host of other newswires to readbreaking news that can profoundly influence their daily business decisions. In addition to providingcurrent domestic and international news on issuesand events affecting companies around the world,Dow Jones News/Retrieval allows businessprofessionals to research issues and backgroundinformation by tapping into the deep archive of more than 60 million documents in the Dow JonesPublications Library, and by selecting from more than10 million reports on both public and privatecompanies."Businesspeople want one service that can addressall the business information needs of the professionalsthroughout their organization," says Gregory P. Gerdy,director of research products for Dow JonesBusiness Information Services. "By providing targeted information in a source as comprehensiveas Dow Jones News/Retrieval, we are making itpossible for international product managers, business development specialists and investorsto quickly and conveniently get crucial informationand fast answers to their important questions."<B>About the Newswires</B>While other services offer information that is oftendelayed or limited in scope, the new Dow Jonesnewswires provide real-time, comprehensivebusiness and financial news from Dow Jonesreporters and editors.<ul><li><B>The Dow Jones Asian Equities Report</B>covers news pertaining to stock markets and publicly traded companies in Asia. The newswireoperates 24 hours a day, seven days a week. TheIndia Report, which represents a portion of the DowJones Asian Equities Report, operates from 8 p.m.to 8 a.m. (ET), Sunday through Thursday.<li><B>The Dow Jones Australia/New ZealandReport</B> covers all financial, economic andbusiness news out of Australia and New Zealand.It operates from 4 p.m. to 4 a.m. (ET), Sundaythrough Friday. <li><B>The Dow Jones Commodities Service</B> coverscommodities markets world-wide. It includes newsaffecting precious metals, base metals, softcommodities, caseh, and futures markets. Thewire operates 24 hours a day, seven days a week.<li><B>The Dow Jones Money management Alert</B> isthe first newswire devoted exclusively to institutionalmoney management. Coverage includes all aspectsof that industry, including retail mutual funds, institutional and pension funds, variable annuitiesand publicly traded funds. It operates from 7 a.m. to7 p.m. (ET), Monday through Friday.</ul><B>New Interface Allows Subscribers to Convenientlyand Easily Access News</B>Today's announcement follows the recent launchof the newly upgraded Dow Jones News/Retrieval,which features expanded content; a redesignedinterface that is sophisticated, yet easy to use; andaffordable, transaction-based pricing. The new interface clearly displays the six service sections andallows subscribers to quickly access the news that ismost important to them.The wires can be found throughout Dow JonesNews/Retrieval: In Current News, where businessprofessionals can search the most recent 90 days ofexclusive enwswires and key newspapers; in SearchNews and Articles, where the Dow Jones PublicationsLibrary contains a vast selection of sources that provideboth current and archived information; and in TrackNews and Articles, where Dow Jones CustomClips&#174allows business professionals to set up folders andreceive news on just the topics that are of interest to them.<B>Unequalled Content of Award-WinningDow Jones News/Retrieval</B>No other online business research service provides boththe quality of content and quick, convenient access toinformation that are hallmarks of Dow JonesNews/Retrieval.Dow Jones News/Retrieval is the only online business research service that provides the combination of thesame-day full-text of The Wall Street Journal&#174, TheNew York Times, The Washington Post, Los AngelesTime and Financial times. In addition, the service includesmore than 60 million current and archived documents from more than 3,400 sources in the Dow Jones Publications Library, including newspapers, trade journal, newswires, newsletters and transcripts -- all of which can be searched using a single search statement. DowJones News/Retrieval also provides in-depth company,industry and market information.To sign up for Dow Jones News/Retrieval or toreceive assistance with the service, call Dow JonesCustomer Service at 1-800-369-7466 ext. 61.<B>About Business Information Services and Dow Jones</B>Dow Jones Business Information Services is the electronic publishing arm of Dow Jones & Co., Inc. that provides business and financial news and information products, including The Wall Street Journal&#174 Interactive Edition on theWorld Wide Web and Dow Jones News/Retrieval&#174, to corporations, consumers and private investors through a variety of electronic media; computer, telephone, facsimile and radio.Dow Jones also publishes the print version of The Wall Street Journal  and its international editions, Barron's&#174 magazine and other periodicals, electronic information services, including those of Dow Jones Telerate and Dow Jones Financial NewsServices, and the Ottaway group of community newspapers. Dow Jones also produces business television programming internationally and video news delivered to desktop computers.Dow Jones News/Retrieval, The Wall Street Journal, The Wall Street Journal Interactive Edition, Barron's and Dow Jones News Service and Telerate are all marks of Dow Jones & Co., Inc. All other products mentioned are the marks of their respective owners.<P>CONTACT: Dara Schechter, Dow Jones,  609-520-4668dara.schechter@cor.dowjones.com</pre><hr><a href="../latest.html">Back to the main Dow Jones in the News page.</a><hr><H4>We welcome feedback or questions about the <A HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4></blockquote><pre></pre> 								<center>					<a href="../toolbar.gif.map">								<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>					<BR>									<font size=2>					<a href="../bizpubs/index.html">Newspapers</a> |					<a href="../clipping/index.html">Alert Services</a> |					<a href="../online-lib/index.html">Research</a>  |					<a href="../pers-finance/index.html">Personal Finance</a>  |  					<a href="../latest.html">DJ In The News</a>  |					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |					<a href="../index.html">Home</a> 				</font>												</center>				</TD></tr></TABLE></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-66</DOCNO>
<DOCOLDNO>IA027-000290-B045-370</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/releas38.html 143.131.194.4 19970114050525 text/html 6105
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:09:36 GMT
Last-modified: Wednesday, 09-Oct-96 15:37:44 GMT
Content-length: 5913
Content-type: text/html
</DOCHDR>
<html><head><title>PR Pages</title></head><body  background="../images/bgddj.gif"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td><td><p><br><blockquote><center>MEDIA ADVISORY<p><b>DOW JONES BUSINESS INFORMATION SERVICES <BR>LAUNCHES WEB-BASED BUSINESS DIRECTORY<br></b><p></b></center><pre><B>Princeton, NJ, Oct. 8, 1996</B>-- Dow JonesBusiness Information Services announced today it has launched the Dow Jones Business Directory,a new Web-based navigation aid that providesdirect links to more than 350 quality business-and finance-related sites on the Internet, withweekly reviews of key sites.The Dow Jones Business Directory is being introduced as a feature within the Business section of <A HREF="http://www.infoseek.com">InfoSeek</A>. The availability of the Directory on InfoSeek, an Internet navigation service, marks the first of several planned distribution outlets for the new Directory, including Dow Jones Business Center(sm) on America Online, Dow Jones News/Retrieval&#174 and <A HREF="http://wsj.com">The Wall Street Journal Interactive Edition</A>.Created by editors at Dow Jones & Company, Inc.,the world's premier business information provider,the Dow Jones Business Directory allows readersto quickly and easily find important businessinformation on the World Wide Web."The Dow Jones Business Directory was developedby Dow Jones editors to provide a single place thatcan help businesspeople decide which sites wouldbe most useful to them -- eliminating the needto visit each site in order to make that determin-ation," said Tim Andrews, editor in chief of onlineservices for Dow Jones Business InformationServices. "Through the Dow Jones Business Directory, we'reproviding authoritative, well-written reviews ofvaluable business- and finance-related sites,"added Mr. Andrews. "This information anddirect links to these sites ensure that businesspeople can quickly access the business informationand data that is important to them."Robin Johnson, president and chief executiveofficer of InfoSeek, said, "InfoSeek is aninnovator of timely, personalized news on theWeb, and our award-winning search capabilitiesmake the service particularly appealing to businesspeople on the Internet. Partneringwith Dow Jones reflects both our orientation toward the business market and our appeal as a high-value content and audience aggregatoron the 'Net."The Business Directory covers five main areas:Companies, Economy, Industries, Markets andPersonal Finance; each with a number ofsubcategories. Dow Jones editors categorizeand evaluate sites using a strict set of ratingcriteria: content, speed, navigation and design.All ratings are based on a 1-10 scale and accompany the reviews.<B>About InfoSeek</B>InfoSeek Corporation (NASDAQ: SEEK) isbased in Santa Clara, CA, and provides a leading Internet navigation service. The service was recently name the number onesite in Internet advertising revenues by WebTrack and SIMBA. InfoSeek search serviceshave won a number of industry awards, including "Number One Rated Search Engine,"(PC Computing), "Top 100: Editors' Choice"(Home PC) and "Top Rated Search Engine"(Family PC). InfoSeek's World Wide Website and award-winning Internet navigationservices can be accessed at <A HREF="http://www.infoseek.com">http://www.infoseek.com</A>.<B>About Dow Jones</B>Dow Jones Business Information Services is the electronic publishing arm of Dow Jones & Co., Inc. that provides business and financial news and information products, including The Wall Street Journal&#174 Interactive Edition on theWorld Wide Web and Dow Jones News/Retrieval&#174, to corporations, consumers and private investors through a variety of electronic media; computer, telephone, facsimile and radio.Dow Jones also publishes the print version of The Wall Street Journal  and its international editions, Barron's&#174 magazine and other periodicals, electronic information services, including those of Dow Jones Telerate and Dow Jones Financial NewsServices, and the Ottaway group of community newspapers. Dow Jones also produces business television programming internationally and video news delivered to desktop computers.Dow Jones News/Retrieval, The Wall Street Journal, The Wall Street Journal Interactive Edition, Barron's and Dow Jones News Service and Telerate are all marks of Dow Jones & Co., Inc. All other products mentioned are the marks of their respective owners.<P>CONTACT: Dara Schechter, Dow Jones,  609-520-4668dara.schechter@cor.dowjones.com</pre><hr><a href="../latest.html">Back to the main Dow Jones in the News page.</a><hr><H4>We welcome feedback or questions about the <A HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4></blockquote><pre></pre> 								<center>					<a href="../toolbar.gif.map">								<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>					<BR>									<font size=2>					<a href="../bizpubs/index.html">Newspapers</a> |					<a href="../clipping/index.html">Alert Services</a> |					<a href="../online-lib/index.html">Research</a>  |					<a href="../pers-finance/index.html">Personal Finance</a>  |  					<a href="../latest.html">DJ In The News</a>  |					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |					<a href="../index.html">Home</a> 				</font>												</center>				</TD></tr></TABLE></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-67</DOCNO>
<DOCOLDNO>IA027-000290-B045-393</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/releas37.html 143.131.194.4 19970114050546 text/html 6001
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:09:57 GMT
Last-modified: Wednesday, 09-Oct-96 14:22:20 GMT
Content-length: 5809
Content-type: text/html
</DOCHDR>
<html><head><title>PR Pages</title></head><body  background="../images/bgddj.gif"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td><td><p><br><blockquote><center>MEDIA ADVISORY<p><b>DOW JONES ELECTRONIC PRODUCTS WIN<BR>FOUR MAJOR AWARDS FOR INNOVATION <BR>AND CREATIVITY<br></b><p></b></center><pre><B>Washington, D.C., Oct. 7, 1996</B>-- The Wall Street Journal&#174 Interactive Edition and Dow Jones News/Retrieval&#174 were presented three top awards here at the Information Industry Association's (IIA) HotShot Awards ceremony. In addition to today's awards,the Interactive Edition was also recently presented with an INVISION award by NewMedia Magazine.Dow Jones News/Retrieval won the top award for bestfinancial news service/corporate and The Wall StreetJournal Interactive Edition won two top IIA HotShothonors as best news service and best Web site/Professional. Tom Baker, business director for theInteractive Edition, was on hand to accept the awards.In the NewMedia INVISION Awards, The Wall StreetJournal Interactive Edition took a silver award for bestonline news information services."These awards affirm what customers have told us --that Dow Jones is providing the most innovative anduseful electronic news products and services in the market today," said Dorothea Coccoli Palsho,president, Dow Jones Business Information Services."We are honored that industry experts recognize thestrength of the Internet and online news products DowJones has to offer people in business."The IIA HotShot Awards honor the year's best and mostinnovative new online and Internet products. A panelof expert judges rated 15 different categories basedon product innovation, market need, technical quality,and uniqueness.The NewMedia INVISION Awards recognize the creativity and innovation of multimedia creators and their products. Entries came from all areas of public and private enterprise, government, education,nonprofit organizations and the arts. This year, 900entries were judged by select multimediaprofessionals, educators and journalists.The Wall Street Journal Interactive Edition featurescontinuously updated coverage of the full spectrumof business news both in the U.S. and abroad, prepared by a dedicated news staff in The WallStreet Journal's New York newsroom. Readersalso have access to more than 9,000 in-depthbackground reports on companies, a historicalarchive of articles, and convenient personalizationtools. The Interactive Edition is available on the Webat <A HREF="http://wsj.com">http://wsj.com</A>.Dow Jones News/Retrieval is the online news andinformation service designed to answer the most pressing and in-depth questions business people haveevery day. Dow Jones provides access to more than60 million articles from more than 3,400 publications,as well as 400 other sources of business and financialdata. The service includes the world's top newspapers,trade journals, newswires, financial reports, and globalmarket data. Dow Jones News/Retrieval is the onlycommercial online business research service that offers the combination of the same-day full text ofThe Wall Street Journal, The New York Times, Financial Times, Los Angeles Times, and TheWashington Post.<B>About Dow Jones</B>Dow Jones Business Information Services is the electronic publishing arm of Dow Jones & Co., Inc. that provides business and financial news and information products, including The Wall Street Journal&#174 Interactive Edition on theWorld Wide Web and Dow Jones News/Retrieval&#174, to corporations, consumers and private investors through a variety of electronic media; computer, telephone, facsimile and radio.Dow Jones also publishes the print version of The Wall Street Journal  and its international editions, Barron's&#174 magazine and other periodicals, electronic information services, including those of Dow Jones Telerate and Dow Jones Financial NewsServices, and the Ottaway group of community newspapers. Dow Jones also produces business television programming internationally and video news delivered to desktop computers.Dow Jones News/Retrieval, The Wall Street Journal, The Wall Street Journal Interactive Edition, Barron's and Dow Jones News Service and Telerate are all marks of Dow Jones & Co., Inc. All other products mentioned are the marks of their respective owners.<P>CONTACT: Dow JonesKris LeBoutillier,  609-520-4638kris.leboutillier@cor.dowjones.com</pre><hr><a href="../latest.html">Back to the main Dow Jones in the News page.</a><hr><H4>We welcome feedback or questions about the <A HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4></blockquote><pre></pre> 								<center>					<a href="../toolbar.gif.map">								<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>					<BR>									<font size=2>					<a href="../bizpubs/index.html">Newspapers</a> |					<a href="../clipping/index.html">Alert Services</a> |					<a href="../online-lib/index.html">Research</a>  |					<a href="../pers-finance/index.html">Personal Finance</a>  |  					<a href="../latest.html">DJ In The News</a>  |					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |					<a href="../index.html">Home</a> 				</font>												</center>				</TD></tr></TABLE></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-68</DOCNO>
<DOCOLDNO>IA027-000290-B046-1</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/releas36.html 143.131.194.4 19970114050623 text/html 5608
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:10:10 GMT
Last-modified: Wednesday, 09-Oct-96 14:22:12 GMT
Content-length: 5416
Content-type: text/html
</DOCHDR>
<html><head><title>PR Pages</title></head><body  background="../images/bgddj.gif"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td><td><p><br><blockquote><center>MEDIA ADVISORY<p><b>DOW JONES' DOWVISION EXPANDS<BR>DAILY NEWSPAPER COVERAGE<br></b><p></b></center><pre><B>Princeton, N.J., Oct. 1, 1996</B>--Dow Jones Business InformationServices (BIS) announced today that DowVision&#174, the most popular direct-to-the-desktop personalized news service for corporations, will broadcast same-day, full-text articles from The Washington Post and Los Angeles Times, at no additional charge.These top newspapers join the list of current-day editions of The Wall Street Journal&#174, The New York Times, and Financial Times, as well as the Dow Jones News Service&#174 and Barron's&#174 on DowVision. This exclusive combination of sources makes DowVision the most powerful and definitive source of general business news as well as the best value in custom news services.The DowVision news feed can also be customized and filtered sothat only the news that matters most to customers -- including corporate executives, public relations professionals, information professionals, product managers or financial analysts -- s delivered directly to corporate desktops."Our customers demand the highest quality news and information at a very competitive price. With DowVision, they get both," said Clare Hart, director of corporate news products, Dow Jones Business Information Services. "The Washington Post offers an inside view on the politics, personalities and legislation that shapes our nation. The Los Angeles Times provides first-hand news on the entertainment and interactive media industries. DowVision delivers this information in whatever computing environment business people use at a tremendous value.""We have business concerns around-the-globe," says David Chaplin, manager, KPMG Peat Marwick LLP. "DowVision answers our firm's need for a desktop-based news system that provides breaking industry, financial and political newsfrom around the world. Dow Jones content provides our marketing and client service professionals with the comprehensive information they need to make immediate decisions."In addition to the domestic daily newspapers and wire services, DowVision is also a rich source of breaking international news. Exclusive sources include The Wall Street Journal Europe, TheAsian Wall Street Journal&#174, the Far Eastern Economic Review, the Dow Jones International News Service(sm),Canada NewsWire(sm) and Canadian Corporate News(sm).Dow Jones has worked with a number of leading softwaredevelopment companies to create software that seamlesslyintegrates the DowVision news and information feed intodesktop application environments such as Windows&#174,Macintosh&#174, Lotus Notes&#174, e-mail and Webbrowsers.<B>About Dow Jones</B>Dow Jones Business Information Services is the electronic publishing arm of Dow Jones & Co., Inc. that provides business and financial news and information products, including The Wall Street Journal&#174 Interactive Edition and Dow Jones News/Retrieval&#174, to corporations, consumers and private investors through a variety of electronic media; computer,telephone, facsimile and radio.Dow Jones also publishes the print version of The Wall Street Journal  and its international editions, Barron's&#174 magazine and other periodicals, electronic information services, including those of Dow Jones Telerate and Dow Jones Financial NewsServices, and the Ottaway group of community newspapers. Dow Jones also produces business television programming internationally and video news delivered to desktop computers.DowVision,  Dow Jones News/Retrieval,  The Wall Street Journal, The Wall Street Journal Interactive Edition, Barron's and Dow Jones News Service and Telerate are all marks of Dow Jones & Co., Inc. All other products mentioned are the marks of their respective owners.<P>CONTACT: Dow JonesKris LeBoutillier,  609-520-4638kris.leboutillier@cor.dowjones.com</pre><hr><a href="../latest.html">Back to the main Dow Jones in the News page.</a><hr><H4>We welcome feedback or questions about the <A HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4></blockquote><pre></pre> 								<center>					<a href="../toolbar.gif.map">								<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>					<BR>									<font size=2>					<a href="../bizpubs/index.html">Newspapers</a> |					<a href="../clipping/index.html">Alert Services</a> |					<a href="../online-lib/index.html">Research</a>  |					<a href="../pers-finance/index.html">Personal Finance</a>  |  					<a href="../latest.html">DJ In The News</a>  |					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |					<a href="../index.html">Home</a> 				</font>												</center>				</TD></tr></TABLE></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-69</DOCNO>
<DOCOLDNO>IA028-000307-B012-211</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/releas35.html 143.131.194.4 19970114050644 text/html 6049
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:10:53 GMT
Last-modified: Tuesday, 24-Sep-96 18:27:21 GMT
Content-length: 5859
Content-type: text/html
</DOCHDR>
<html><head><title>PR Pages</title></head><body  background="../images/bgddj.gif"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td><td><p><br><blockquote><center>MEDIA ADVISORY<p><b>DOW JONES' DOWVISION TO PROVIDE<BR>CUSTOMIZED NEWS AND INFORMATION <br>TO CADENCE DESIGN<br></b><p></b></center><pre><B>Princeton, N.J., Sept. 19, 1996</B>--Dow Jones Business InformationServices today announced an agreement with Cadence Design Systems,Inc. to provide DowVision&#174, the most popular direct-to-the-desktopcustom news service, to Cadence's sales and marketing professionals.DowVision is the definitive source of general business news as well asthe best value in custom news services for corporate customers. TheDowVision news feed can be custom tailored and filtered so that onlythe news that matters most to the Cadence sales and marketing teamsis delivered right to their PCs."DowVision helps Cadence to make the most of its existing investmentsin internal networks by providing cost-efficient delivery of crucial, timely business news and information directly to its sales team," said Clare Hart, director of corporate news products, Dow Jones Business Information Services. "The benefit to Cadence is up-to-the-minutenews and information about customers, competitors and suppliersfrom business newswires and press release wires."Cadence Design Systems Inc. provides comprehensive services andtechnology for the product development requirements for the world'sleading electronics companies. Cadence is the largest supplier ofsoftware tools and professional services used to accelerate andmanage the design of semiconductors, computer systems, networkingand telecommunications equipment, consumer electronics, and a varietyof other electronic-based products."Cadence relies on DowVision for the latest breaking news on ourcustomers, our customers' industries, and our competitors," saidTim Herbert, director of world-wide sales operations, Cadence Design Systems. "We are building an infrastructure that assists ourworld-wide sales and delivery teams in getting better educatedabout the business issues facing customers. The better we understandour customers' businesses, the better we can service them. DowVisionhelps our team hone their competitive edge around the globe bydelivering the breaking industry news that each individual wants, from the world's trusted sources, directly to their notebook PCs."DowVision is the exclusive combined source of the current day's editionof The Wall Street Journal&#174, the Far Eastern Economic Review&#174,the Dow Jones International News Service(sm), Canada NewsWire(sm)and Canadian Corporate News(sm).Dow Jones news is delivered to Cadence 24 hours a day via <A HREF="http://www.paracel.com/demo/Current.html">Paracel Online Systems, Inc.</A> Paracel's Dallas-based newscenter managesthe development of corporate profiles, filtering, and real-time Intranet delivery of content that meets the needs and interests of the employees of Cadence.<B>About Cadence</b>With 3,000 employees and annual sales of more than a half-billiondollars, Cadence has sales offices and research facilities aroundthe world. The company is headquartered in San Jose, CA and traded on the New York Stock Exchange und erthe symbol CDN.<B>About Dow Jones</B>Dow Jones Business Information Services is the electronic publishing armof Dow Jones & Co., Inc. that provides business and financial news and information products, including The Wall Street Journal&#174 InteractiveEdition and Dow Jones News/Retrieval&#174, to corporations, consumersand private investors through a variety of electronic media; computer,telephone, facsimile and radio.Dow Jones also publishes the print version of The Wall Street Journal and its international editions, Barron's&#174 magazine and other periodicals,electronic information services, including those of Dow Jones Telerate and Dow Jones Financial News Services, and the Ottaway group of community newspapers. Dow Jones also produces business television programming internationally and video news delivered to desktop computers.Personal Journal, DowVision,  Dow Jones News/Retrieval, The Wall Street Journal, The Wall Street Journal Interactive Edition, Barron's and Dow Jones News Service and Telerate are all marks of Dow Jones & Co., Inc. All other products mentioned are the marks of their respective owners.<P>CONTACT: Dow JonesKris LeBoutillier,  609-520-4638kris.leboutillier@cor.dowjones.com</pre><hr><a href="../latest.html">Back to the main Dow Jones in the News page.</a><hr><H4>We welcome feedback or questions about the <A HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4></blockquote><pre></pre> 								<center>					<a href="../toolbar.gif.map">								<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>					<BR>									<font size=2>					<a href="../bizpubs/index.html">Newspapers</a> |					<a href="../clipping/index.html">Alert Services</a> |					<a href="../online-lib/index.html">Research</a>  |					<a href="../pers-finance/index.html">Personal Finance</a>  |  					<a href="../latest.html">DJ In The News</a>  |					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |					<a href="../index.html">Home</a> 				</font>												</center>				</TD></tr></TABLE></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-70</DOCNO>
<DOCOLDNO>IA028-000307-B012-246</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/releas34.html 143.131.194.4 19970114050659 text/html 7821
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:11:10 GMT
Last-modified: Wednesday, 18-Sep-96 13:51:32 GMT
Content-length: 7629
Content-type: text/html
</DOCHDR>
<html><head><title>PR Pages</title></head><body  background="../images/bgddj.gif"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td><td><p><br><blockquote><center>MEDIA ADVISORY<p><b>SAME-DAY FULL TEXT OF <BR>THE WASHINGTON POST AVAILABLE THROUGH<br>DOW JONES BUSINESS INFORMATION SERVICES</b><br><p></b></center><pre><B>Princeton, N.J., Sept. 16, 1996</B>--Dow Jones & Co., Inc. and TheWashington Post Company announced today an agreement to provide thesame-day full text of The Washington Post through Dow JonesNews/Retrieval&#174, Dow Jones CustomClips&#174, and DowVision&#174.This agreement reinforces Dow Jones' commitment to be the most powerfuland definitive source for general business news and information.With the addition of same-day coverage from The Washington Post, Dow Jones' services become the only electronic source offering the combinationof the same-day full text of the world's most respected newspapers: TheWall Street Journal&#174, The New York Times, Financial Times, LosAngeles Times and The Washington Post. The full text of The WashingtonPost is now available in Dow Jones News/Retrieval and Dow JonesCustomClips early morning on the day of publication and will be part of DowVision later this month."The Washington Post is the No. 1 resource for political news from our nation's capital -- and government decisions influence business decisions,"says Dorothea Coccoli Palsho, president, Dow Jones Business InformationServices. "Busy executives are hard pressed to keep up with all of the legislative activity that applies to their industries. By offering the same-day full text of The Washington Post, Dow Jones services make it possible forsubscribers to stay informed about specific legislative issues so they can make the most effective business decisions.""As a result of online availability through Dow Jones, The Washington Postwill reach an even wider business audience with the information they need,when they need it, to make sound decisions," says Ralph S. Terkowitz, vicepresident of technology of The Washington Post Company. "This relationship offers a business-to-business counterpoint to the availability of Post content through our consumer products, including <A HREF="http://www.washingtonpost.com">washingtonpost.com</A>, our newly launched World Wide Web site."<B>More About Dow Jones Products</B><br><B>Dow Jones News/Retrieval</B> is the premier business onlineservice that provides access to more than 60 million articles from more than3,400 publications, as well as 400 other sources of business and financial data. The service includes the world's top newspapers, tradejournals, newswires, financial reports, and global market data. Dow JonesNews/Retrieval's recently redesigned interface makes it easier than everfor business professionals to quickly find answers to their tough questions.With a single search statement, customers can now search -- at no charge --across the 60 million articles in the Dow Jones Publications Library.<B>DowVision</B>, the most popular direct-to-the-desktop news service,continuously delivers personalized global business news and informationto corporate desktops in virtually any computer environment. In addition to the debut of The Washington Post on DowVision later thismonth, customers can receive the same-day full text of The WallStreet Journal (and its international editions), The New York Times, Financial Times, and Los Angeles Times, plus breakinginternational news from a host of newswires, including the Dow JonesNews Service&#174.<B>Dow Jones CustomClips</B>, available through Dow JonesNews/Retrieval or as a complement to DowVision, allows users totrack news from up to 2,600 leading trade and industry sources. Users establish a profile customized to their specific needs. Onlynews and information that match this profile are delivered. The result is focused, comprehensive and in-depth coverage, 24 hoursa day.To sign up for Dow Jones services or receive assistance, callDow Jones Customer Service at 800-369-7466 or 609-452-1511.<B>The Washington Post Company's Electronic Productsand Services</B><br>The Washington Post Company has launched several electronic products and services to extend and enhance the company's information franchises. Digital Ink. Co., the electronic publishing subsidiary of TheWashington Post Company, recently debuted on the WorldWide Web with <A HREF="http://www.washingtonpost.com">washingtonpost.com</A>, a one-stop news, information and entertainment resource and <A HREF="http://www.politicsnow.com">PoliticsNow</A>, a partnership of Capital Cities/ABC Inc., everything users want to know about politics. Several other Digital Ink projects are currently in development.In addition, Newsweek and Kaplan offer many of their servicesin electronic formats. The company's Legi-Slate subsidiary isthe nation's leading online information service for congressional legislation and federal regulations.<B>About Dow Jones</B>Dow Jones Business Information Services is the electronic publishing armof Dow Jones & Co., Inc. that provides business and financial news and information products, including The Wall Street Journal&#174 InteractiveEdition and Dow Jones News/Retrieval&#174, to corporations, consumersand private investors through a variety of electronic media; computer,telephone, facsimile and radio.Dow Jones also publishes the print version of The Wall Street Journal and its international editions, Barron's&#174 magazine and other periodicals,electronic information services, including those of Dow Jones Telerate and Dow Jones Financial News Services, and the Ottaway group of community newspapers. Dow Jones also produces business television programming internationally and video news delivered to desktop computers.Dow Jones News/Retrieval, DowVision, Dow Jones CustomClips,The Wall Street Journal, The Wall Street Journal Interactive Edition, Barron's and Dow Jones News Service and Telerate are all marks of Dow Jones & Co., Inc. All other products mentioned are the marks of their respective owners.<P>CONTACT: Dow JonesDara Schecter, 609-520-4668dara.schechter@cor.dowjones.comorDigital Ink Co.Erin O'Shea, 703-469-2646osheae@washpost.com</pre><hr><a href="../latest.html">Back to the main Dow Jones in the News page.</a><hr><H4>We welcome feedback or questions about the <A HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4></blockquote><pre></pre> 								<center>					<a href="../toolbar.gif.map">								<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>					<BR>									<font size=2>					<a href="../bizpubs/index.html">Newspapers</a> |					<a href="../clipping/index.html">Alert Services</a> |					<a href="../online-lib/index.html">Research</a>  |					<a href="../pers-finance/index.html">Personal Finance</a>  |  					<a href="../latest.html">DJ In The News</a>  |					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |					<a href="../index.html">Home</a> 				</font>												</center>				</TD></tr></TABLE></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-71</DOCNO>
<DOCOLDNO>IA028-000307-B012-277</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/releas33.html 143.131.194.4 19970114050803 text/html 8265
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:11:42 GMT
Last-modified: Monday, 16-Sep-96 14:34:44 GMT
Content-length: 8076
Content-type: text/html
</DOCHDR>
<html><head><title>PR Pages</title></head><body  background="../images/bgddj.gif"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td><td><p><br><blockquote><center>MEDIA ADVISORY<p><b>DOW JONES BUSINESS CENTER<FONT SIZE=2><SUP>sm</SUP></FONT> <BR>DEBUTS ON AMERICA ONLINE<br>NEW CUSTOMIZED CONTENT AREA AVAILABLE TO <BR>AOL MEMBERS AT NO ADDITIONAL CHARGE</b><br><p></b></center><pre><B>Dulles, Va. and Princeton, N.J., Sept. 12, 1996</B>--America Online,the world's largest consumer online service, and Dow Jones BusinessInformation Services, a premier provider of electronic business and financial news, today announced the launch of the Dow Jones Business Center(sm)on America Online. The Dow Jones Business Center, which has been optimized for AOL, provides members with updated news on companies,industries, and markets all in one central location, at no extra cost to members. The Dow Jones Business Center is available on America Online in the Personal Finance Channel and via Keyword: Dow Jones.The Dow Jones Business Center features news from Dow Jones Online News(sm),a continuously updated newswire written specifically for the expanding general audience for business news online services. Through the Business Center, AOL members can follow critical business news of the day from all over the world, search for recent Dow Jones articles about particular companies, and follow developments in their own industries."Dow Jones is one of the world's most trusted sousrsces of business news, expert analysis, market updates and more," said Ted Leonsis, president of America Online Services Company. "We are pleased that Dow Jones is working with AOL to create an area specific to the needs of our growing member base. With the introduction of the Dow Jones Business Center, we're pleased to continue to offer our members an opportunity to tap into tremendously valuable information.""The Dow Jones Business Center gives business people and investorsimmediate access to the world-wide editorial resources of Dow Jones," said Dorothea Coccoli Palsho, president of Dow Jones Business InformationServices. "With AOL and the Business Center, they get quick and easy accessto the most important and relevant business news throughout the day."The Business Center provides, in a clear and well-organized format, the tools business people and investors need to succeed. Its features include:<UL><li>The Front Page -- provides the day's major news stories selected andhighlighted by Dow Jones editors with links to the full stories.<li>Economy & Nation -- offers key economic reports and the latest national political news.<li>Markets -- regularly updates the latest events in global markets, including the Dow Jones averages, bond prices, currency prices, precious metals, and other commodity prices, as well as hot stocks and analysts' comments and ratings.<li>Technology -- a specific area devoted to news about computer hardware and software and telecommunications.<li>International Section -- offers valuable coverage of Asian andEuropean business and markets.<li>Best of Dow Jones -- includes recent topical features from DowJones publications, including The Wall Street Journal&#174, Barron's&#174, and the National Business Employment Weekly&#174on personal finance, careers, travel and work and family issues.<li>Search by Topic -- offers the ability to search a database of current articles features in the Business Center</ul>Other features include a Feedback area, allowing AOL members tocommunicate with editors of the Business Center; a Dow Jones store, offering the ability to subscribe to Dow Jones products andservices, such as The Wall Street Journal&#174, Barron's&#174,the National Business Employment Weekly&#174, theWall Street Journal Guides, including "The Wall Street JournalGuide to Markets and Finance," "The Wall Street Journal Guide toPlanning Your Financial Future," and "The Wall Street Journal Guideto Understanding Personal Finance." and the CD-ROM product, "TheWall Street Journal Yearly Review of Markets and Finance."America Online's expanded Personal Finance Channel providesmembers with a wide array of personal finance information, rangingfrom stock quotes, to company research or help for smallbusinesses and individual investors. The partners that make upAOL's Personal Finance Channel place comprehensive personalfinance information just a mouse click away.The Business Center launch follows two significant and successfulproduct launches by Dow Jones Business Informaiton Services. InMay, Dow Jones launched a completely new version of Dow JonesNews/Retrieval&#174, the place where business people find fastanswers to tough questions, and The Wall Street Journal&#174Interactive Edition, the first Web-based business newspaper offeredto subscribers on a paid-subscription basis.America Online, Inc., based in Dulles, Virginia, is the largest andfastest growing provider of online services in the world, with morethan 6 million members world-wide. AOL offers its subscribers awide variety of services including electronic mail, conferencing,software, computing support, interactive magazines and newspapers,and online classes, as well as easy and affordable access to servicesof the Internet. Founded in 1985, AOL today has a global workforce of more than 5,000 people. Personal computer ownerscan obtain America Online Software at major retailers andbookstores or by calling 800/827-6364.Dow Jones Business Information Services is the electronic publishing armof Dow Jones & Co., Inc. that provides business and financial news and information products, including The Wall Street Journal&#174 InteractiveEdition and Dow Jones News/Retrieval&#174, to corporations, consumersand private investors through a variety of electronic media; computer,telephone, facsimile and radio.Dow Jones also publishes the print version of The Wall Street Journal and its international editions, Barron's&#174 magazine and other periodicals,electronic information services, including those of Dow Jones Telerate and Dow Jones Financial News Services, and the Ottaway group of community newspapers. Dow Jones also produces business television programming internationally and video news delivered to desktop computers.America Online is a registered trademark of America Online, Inc. TheDow Jones Business Center, Dow Jones News/Retrieval, The Wall Street Journal, The Wall Street Journal Interactive Edition, Barron's and Dow Jones Telerate are all registered marks of Dow Jones & Co., Inc.All other products mentioned are the marks of their respective owners.<P>CONTACT: America Online: Maria Cataldo,703-918-2156aldocat@aol.comDow Jones: Beth Brody until 9/19Maggie Landis after 9/19609-520-4679dowjones@aol.com</pre><hr><a href="../latest.html">Back to the main Dow Jones in the News page.</a><hr><H4>We welcome feedback or questions about the <A HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4></blockquote><pre></pre><center><a href="../toolbar.gif.map">	<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>	<BR>	<font size=2>		<a href="../bizpubs/index.html">Newspapers</a> |					<a href="../clipping/index.html">Alert Services</a> |					<a href="../online-lib/index.html">Research</a>  |					<a href="../pers-finance/index.html">Personal Finance</a>  |  					<a href="../latest.html">DJ In The News</a>  |					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |					<a href="../index.html">Home</a> 				</font>												</center>				</TD></tr></TABLE></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-72</DOCNO>
<DOCOLDNO>IA028-000307-B013-3</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/releas32.html 143.131.194.4 19970114050836 text/html 6430
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:12:28 GMT
Last-modified: Wednesday, 21-Aug-96 15:47:34 GMT
Content-length: 6238
Content-type: text/html
</DOCHDR>
<html><head><title>PR Pages</title></head><body  background="../images/bgddj.gif"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td><td><p><br><blockquote><center>MEDIA ADVISORY<p><b>DOW JONES NEWS/RETRIEVAL NOW AVAILABLE TO VISITORS<br> OF NEW SCIENCE, INDUSTRY AND BUSINESS LIBRARY</b><br><p></b></center><pre><B>Princeton, N.J., Aug. 19, 1996</B>--Dow Jones Business InformationServices (BIS) announced today that Dow Jones News/Retrieval&#174,the online source of business and financial information that provides fastanswers to tough questions, is now available to the public at the new,state-of-the-art Science, Industry and Business Library (SIBL) in NewYork City. SIBL, part of The New York Public Library, is the world'slargest public library devoted to science, technology, economics andbusiness.Fledgling entrepreneurs, other business professionals, and people in academia are finding that SIBL is an invaluable resource for their research needs."We're delighted to make Dow Jones News/Retrieval available at SIBL,"says Josephine K. Ottman, director of product marketing for Dow JonesBusiness Information Services. "The relationship is a natural one. Dow Jonesis on the cutting edge of electronic business research, and SIBL is leading theway among public information centers in this new era of informationtechnology. Any visitor to SIBL seeking answers to critical business questionscan go directly to Dow Jones News/Retrieval for fast access to up-to-dateand archived business and financial information."Among SIBL's computers connecting to electronic databases, one is dedicated solely to Dow Jones News/Retrieval. Individuals are asked toreserve half-hour intervals to use the service."We have a small stampede every morning to sign up," says Ann Thornton,acting assistant manager of the Science, Industry and Business Libraryfor Electronic Resources. "It's the place for one-stop shopping toobtain full-text business news and financial information. People who useDow Jones News/Retrieval find it's a very powerful and easy-to-usesearch tool. Profiles of U.S. and international companies, operatingsummaries, earnings-per-share estimates and stock quotes are just a fewexamples of the type of information people can view and then print out."<B>About Dow Jones News/Retrieval</B>Dow Jones News/Retrieval is the only online business research servicethat offers the exclusive combination of the full text of <I>The WallStreet Journal&#174, The New York Times, Financial Times, Los Angeles Times,</I> and <I>The Washington Post</I>. The service also includes more than60 million articles from more than 3,400 publications, including 48 or the top50 U.S. newspapers. Nearly 37,000 new articles are added every day, andmore than 400 other sources of business and financial data are available.Featuring a sophisticated yet intuitive interface, Dow Jones News/Retrievalmakes finding information easy, even for visitors unfamiliar with onlinenavigation. For those requiring assistance, SIBL offers weekly trainingsessions that focus on Dow Jones News/Retrieval.Access to Dow Jones News/Retrieval is free to the public at SIBL, and the service is available on a subscription basis to business professionals and other consumers in their offices and homes.To sign up for Dow Jones News/Retrieval or receive assistancewith the service, call Dow Jones Customer Service at 1-800-369-7466, ext. 61.In an effort to suport the success of SIBL, Dow Jones has becomea Corporate Partner of The New York Library, SIBL is located atMadison Avenue and 34th St. The main building of The New YorkPublic Library is at Fifth Avenue and 42nd Street.<B>About Dow Jones</B>Dow Jones Business Information Services is the electronic publishing armof Dow Jones & Co., Inc. that provides business and financial news and information products, including The Wall Street Journal&#174 InteractiveEdition and Dow Jones News/Retrieval&#174, to corporations, consumersand private investors through a variety of electronic media; computer,telephone, facsimile and radio.Dow Jones also publishes the print version of The Wall Street Journal and its international editions, Barron's&#174 magazine and other periodicals,electronic information services, including those of Dow Jones Telerate and Dow Jones Financial News Services, and the Ottaway group of community newspapers. Dow Jones also produces business television programming internationally and video news delivered to desktop computers.Dow Jones News/Retrieval, The Wall Street Journal, CustomClips,The Wall Street Journal Interactive Edition, Barron's and Dow Jones Telerate are all registered marks of Dow Jones & Co., Inc.All other products mentioned are the marks of their respective owners.<P>CONTACT: Dow Jones, PrincetonDara Schechter, 609-520-4668, ordara.schecter@cor.dowjones.com</pre><hr><a href="../latest.html">Back to the main Dow Jones in the News page.</a><hr><H4>We welcome feedback or questions about the <A HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4></blockquote><pre></pre> 								<center>					<a href="../toolbar.gif.map">								<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>					<BR>									<font size=2>					<a href="../bizpubs/index.html">Newspapers</a> |					<a href="../clipping/index.html">Alert Services</a> |					<a href="../online-lib/index.html">Research</a>  |					<a href="../pers-finance/index.html">Personal Finance</a>  |  					<a href="../latest.html">DJ In The News</a>  |					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |					<a href="../index.html">Home</a> 				</font>												</center>				</TD></tr></TABLE></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-73</DOCNO>
<DOCOLDNO>IA028-000307-B013-30</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/releas31.html 143.131.194.4 19970114050904 text/html 5686
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:13:16 GMT
Last-modified: Wednesday, 21-Aug-96 15:47:22 GMT
Content-length: 5494
Content-type: text/html
</DOCHDR>
<html><head><title>PR Pages</title></head><body  background="../images/bgddj.gif"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td><td><p><br><blockquote><center>MEDIA ADVISORY<p><b>DOW JONES PERSONAL JOURNAL TO BE PREINSTALLED <br>ON NEW LINE OF TOSHIBA NOTEBOOK COMPUTERS</b><br><b>Toshiba Tecra Computers to be bundled with first <br>electronic version of The Wall Street Journal&#174<br><p></b></center><pre><B>Princeton, N.J., Aug. 16, 1996</B>--Dow Jones Business InformationServices (BIS) today announced that its Personal Journal&#174 softwarewill be preinstalled on Toshiba's premier new Tecra 720 CDT computers."We're delighted that Personal Journal is now installed on Toshibanotebooks," said James White, Product Manager, Personal Journal. "Tecra users can now easily create their own customized Wall Street Journal so they can follow news on companies and competitors, andtrack market activity on specific stocks."Personal Journal is a continously updated, personalized electronicnewspaper that provides a quick, concise read of the business newsthat matters most to busy professionals. Published in a familiar, newspaper-like format, Personal Journal provides access to articles and news briefs published in The Wall Street Journal&#174 each day,plus wire stories, stock quotes, worldwide weather and sports.Subscribers can tailor a personal news profile to track news on up to25 companies or columns from The Wall Street Journal. Additionally,a personal portfolio tracks quotes on up to 25 stocks and mutual funds."Personal Journal is of immediate value to the Toshiba computer userwho travels frequently and works in a variety of environments but stillneeds to keep an eye on the day's business events," said Philip Osako,senior product manager, Toshiba Corp. "Adding Personal Journal toour Tecra notebooks provides the end-user with quick and easyaccess to quality electronic information and services."This latest agreement with Toshiba follows recent Personal Journaldistribution agreements with leaders in the computer industry --Day-Timers, Digital, U.S. Robotics, IBM, AST, Zenith, Compaq,CompUSA, and Sharp. Personal Journal has been installed onmore than one million PCs to date.<B>About Toshiba</B>Toshiba continues to be the leading vendor in the U.S. market for portable computers, with a 25.5 percent market share. The companyoffers portable computing solutions for consumer and business customersunder the Toshiba brand name. For a dealer referral and productliterature, call 1-800-334-3445 or visit the company's Web site at<A HREF="http://computers.toshiba.com">http://computers.toshiba.com</A>. <B>About Dow Jones</B>Dow Jones Business Information Services is the electronic publishing armof Dow Jones & Co., Inc. that provides business and financial news and information products, including The Wall Street Journal&#174 InteractiveEdition and Dow Jones News/Retrieval&#174, to corporations, consumersand private investors through a variety of electronic media; computer,telephone, facsimile and radio.Dow Jones also publishes the print version of The Wall Street Journal and its international editions, Barron's&#174 magazine and other periodicals,electronic information services, including those of Dow Jones Telerate and Dow Jones Financial News Services, and the Ottaway group of community newspapers. Dow Jones also produces business television programming internationally and video news delivered to desktop computers.Those interested in subscribing to Personal Journal may call 1-800-291-9382.Personal Journal software can be downloaded from the Internet at<A HREF="http://bis.dowjones.com/pj.html">http://bis.dowjones.com/pj.html</A>. All new subscribers receive a free two-week trial.Personal Journal, Dow Jones News/Retrieval, The Wall Street Journal,The Wall Street Journal Interactive Edition, Barron's and Dow Jones Telerate are all registered marks of Dow Jones & Co., Inc.All other products mentioned are the marks of their respective owners.<P>CONTACT: Dow Jones, PrincetonKris Leboutillier609-520-4638kris.leboutillier@cor.dowjones.com</pre><hr><a href="../latest.html">Back to the main Dow Jones in the News page.</a><hr><H4>We welcome feedback or questions about the <A HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4></blockquote><pre></pre> 								<center>					<a href="../toolbar.gif.map">								<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>					<BR>									<font size=2>					<a href="../bizpubs/index.html">Newspapers</a> |					<a href="../clipping/index.html">Alert Services</a> |					<a href="../online-lib/index.html">Research</a>  |					<a href="../pers-finance/index.html">Personal Finance</a>  |  					<a href="../latest.html">DJ In The News</a>  |					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |					<a href="../index.html">Home</a> 				</font>												</center>				</TD></tr></TABLE></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-74</DOCNO>
<DOCOLDNO>IA028-000307-B013-62</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/releas29.html 143.131.194.4 19970114050923 text/html 6028
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:13:33 GMT
Last-modified: Wednesday, 14-Aug-96 18:51:49 GMT
Content-length: 5836
Content-type: text/html
</DOCHDR>
<html><head><title>PR Pages</title></head><body  background="../images/bgddj.gif"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td><td><p><br><center>MEDIA ADVISORY<p><b>THE WALL STREET JOURNAL INTERACTIVE EDITION ANNOUNCES<br>  TECHNOLOGY AND MARKETING ALLIANCE WITH MICROSOFT</b></center><br><center> <b>Leading Web Business Publication Will Launch Enhancemements Based <br>on Internet Explorer 3.0; Microsoft Will Provide Interactive Edition<br>Subscriptions to Users of Internet Explorer</b></center><br><blockquote><pre><B>San Francisco, Calif., Aug. 13, 1996.</B>--The Wall Street Journal&#174Interactive Edition today announced a significant commitment toadvanced Web Publishing technologies from Microsoft Corp. Inaddition, as part of its marketing efforts behind the launch of InternetExplorer 3.0, Microsoft will make subscriptions to the Interactive Edition available at no charge to users of Internet Explorer through the end of 1996."We are delighted that we will be working together to help expandthe market for premium-quality publishing efforts on the Web," saidDorothea Coccoli Palsho, president, Dow Jones Business InformationServices.Microsoft&#174 Internet Explorer 3.0 is the next generation of its popular World Wide Web browser and the first to support ActiveX&#174technologies. For users, Internet Explorer provides a dynamic browsing experience for viewing content created in Java, JavaScript, NetscapePlug-ins and HTML extensions.Under this alliance, beginning today, the Interactive Edition will bring readers a range of enhancements made possible by Microsoft Internet Explorer 3.0 and ActiveX controls, including new navigation tools and shortcuts, more conveniently displayed market graphs and tables, and additional refinement of page layouts."The Interactive Edition has always been eager to use whatever technologies can make the news more convenient and appealing to readers," said Neil Budde, editor of The Wall Street Journal Interactive Edition. "The new features Internet Explorer makes possible will help keep us state of the art in presenting business information and making it useful."As part of the relationship between Microsoft and the Interactive Edition, Microsoft will offer users of Internet Explorer the ability to register for and read the Interactive Edition without subscription charge through the end of 1996. The Interactive Edition will also be included in a variety of marketing efforts for Internet Explorer."Microsoft wanted to feature the best-of-breed Web sites as part of the launch of Internet Explorer 3.0. For business news, the Interactive Edition is a clear choice," said Bill Gates, chairman and CEO of Microsoft. "We think the outstanding editorial and design qualify of the Interactive Edition will propel an even larger audience of business people to the Web."The Wall Street Journal Interactive Edition, launched in April, has quickly established itself as the leading source of business news and information on the World Wide Web, with nearly 600,000 registered readers. It features continuously updated coverage of the full spectrum of business news both in the U.S. and abroad, prepared by a dedicated news staff in The Wall Street Journal's New York newsroom. Readers also have access to more than 9,000 in-depth background reports on companies, a historical archive, and convenient personalization tools. The Interactive Edition is available on the Web at http://wsj.com.The regular subscription price for the Interactive Edition is $49 a year, or $29 a year for readers of one of The Wall Street Journal's print editions. The Interactive Edition is one of the first Web publishers to seek subscription revenues from readers, and will begin to charge new subscribers this month.<p><b>About Dow Jones</b>	Dow Jones Business Information Services, the electronic publishing arm of Dow Jones & Company, Inc., provides business and financial news and information products including The Wall Street Journal&#174; Interactive Edition on the World Wide Web and Dow Jones News/Retrieval&#174; to corporations, consumers and private investors through a variety of electronic media: computer, telephone, facsimile and radio.Dow Jones also publishes The Wall Street Journal&#174; and its international editions, Barron's&#174; magazine and other periodicals, electronic information services, including those of Dow Jones Telerate and Dow Jones Financial News Services, and the Ottaway group of community newspapers. Dow Jones also produces business television programming internationally and video news delivered to desktop computers. <p>Microsoft and ActiveX are registered trademarks or trademarks of Microsoft Corp. in the United States and/or other countries.<p></pre><hr><a href="../latest.html">Back to the main Dow Jones in the News page.</a><hr><H4>We welcome feedback or questions about the <A HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4></blockquote><center><a href="../toolbar.gif.map"><IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a><BR><font size=2><a href="../bizpubs/index.html">Newspapers</a> |<a href="../clipping/index.html">Alert Services</a> |<a href="../online-lib/index.html">Research</a>  |<a href="../pers-finance/index.html">Personal Finance</a>  |  <a href="../latest.html">DJ In The News</a>  |<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |<a href="../index.html">Home</a> </font></center></TD></tr></TABLE></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-75</DOCNO>
<DOCOLDNO>IA028-000307-B013-99</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/releas30.html 143.131.194.4 19970114050943 text/html 9128
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:13:53 GMT
Last-modified: Wednesday, 14-Aug-96 18:51:58 GMT
Content-length: 8936
Content-type: text/html
</DOCHDR>
<html><head><title>PR Pages</title></head><body  background="../images/bgddj.gif"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td><td><p><br><blockquote><center>MEDIA ADVISORY<p><b>DOW JONES NEWS/RETRIEVAL PROVIDES <br>CONTINUOUSLY UPDATED NEWS ON ELECTION CAMPAIGNS</b><br><b>Dow Jones Editors prioritize news on the issues, platforms and<br>candidates to ensure quick access to top breaking stories<br><p></b></center><pre><B>Princeton, N.J., Aug. 12, 1996</B>--Dow Jones Business InformationServices announced today that Dow Jones News/Retrieval&#174 is providing continuous comprehensive coverage of the election campaigns through Election Day, featuring news from the Republican and Democratic National Conventions and a special look at Election Day in November.Business professionals can get up-to-date drafts of Democratic and Republican election platforms; an overview of the electoral-vote outlook,including core states and likely target states for President Clinton andformer Senator Dole; national polls and emerging issues; and analyses ofpresidential, gubernatorial and congressional races. Election Day coveragein November includes comprehensive news on the presidential race, aroundup of key Senate and House races, and major contents and trends inthe nation's statehouses.Professionals like Mike Murphy, senior partner at The Murphy Pintak GautierAgency, a full-service media and consulting firm in McLean, Va., useDow Jones News/Retrieval to quickly research pressing issues and regionalmedia coverage in each part of the country. Mr. Murphy, whose politicalclients include Republican presidential nominee Bob Dole, can get breaking news on important issues like crime, taxes, education and welfare."Voters in different states may have different concerns," says Mr. Murphy. "In the Midwest, education receives extensive coverage in the press. InMichigan and Wisconsin, the media are writing about welfare. Dow Joneshelps me keep my finger on the pulse of the problems and concerns thatregional and national media are writing about -- and that helps me adviseboth corporate and political clients."Mr. Murphy notes that when a candidate -- President Clinton or formerSenator Dole, for example -- runs a television advertisement, the lengthof the ad, the text, key images and analysis are available in the Current News section of Dow Jones News/Retrieval as part of theservice's world-wide news coverage.No other online business research service provides both the qualityof content and quick, convenient access to information that are thehallmarks of Dow Jones News/Retrieval. Subscribers can turn to theservice and find a wide section of election news in a highlyorganized format, unrivaled in-depth reporting, a continuously updatedsnapshot of breaking election news prioritized by Dow Jones editors,and stories that have been indexed by a specific election code forquick retrieval.Among the key election-related sources in Dow Jones News/Retrievalare The Washington Agenda, which publishes all scheduled presidential campaign events, and <I>The Washington Post</I>, which offers important insight on the political issues of the day."Election-related news, whether it's a policy maker's opinion or standon an issue, moves financial markets and afects the decisions businessprofessionals make every day," says Tim Andrews, editor in chief ofonline services for Dow Jones Business Information Services. "DowJones editors are prioritizing breaking news and indexing electioncampaign-related stories so that subscribers to the service can quicklyobtain a wide range of crucial information on what policy makers aresaying and doing. When President Clinton comments on the minimumwage, the tax system, or trade policies, his ideas can have a profoundimpact on the way people do busines."Once subscribers explore current election news, they can go one stepfurther within Dow Jones News/Retrieval and research specific electionissues and a host of other individual subjects -- by tapping into the deeparchive of the 58 million documents in the Dow Jones PublicationsLibrary. Dow Jones News/Retrieval also provides in-depth company.industry and market information.Dow Jones News/Retrieval is the only online business research servicethat offers the exclusive combination of the full text of <I>The WallStreet Journal&#174, The Ne4w Nork Times, Financial Times, Los Angeles Times,</I> and <I>The Washington Post</I>. The Dow Jones Publications Library is a compilation of more than 58 million documents from more than 3,000 sources, including newspapers, trade journals, newswires, newsletters and transcripts -- all of which can be searched using a single search statement.<p><B>Dow Jones News/Retrieval Provides Quick Access to Information</B>Today's announcement follows the recent successful launch of thenewsly upgraded Dow Jones News/Retrieval, which features expandedcontent, a redesigned interface that is sophisticated, yet easy to use,and affordable transaction-based pricing. Now, more than everbefore, subscribers to Dow Jones News/Retrieval can convenientlyand quickly obtain crucial business news and financial information.Subscribers can find election news in both Current News and theDow Jones Publications Library. They can also set up electronic clip folders on selected election topics using Dow Jones CustomClips&#174.The Current News "This Just In...&#174" section contains top breaking election stories that are selected and edited by news editors at Dow Jones as part of world-wide news coverage. Also in Current News, subscribers can search newswires and newspapers for information on the 1996 U.S. election by simply ending the code "N/ELX." Then they can view, download or print the stories that are of interest.Search News and Articles is the section where subscribers can access the Dow Jones Publications Library. Here, business professionals can dig deep into the issues and background of the campaigns and discover information on the races in certain geographic areas. Articles are searchable by code and key words.Track News and Articles offers Dow Jones CustomClips, the newstracking service that allows Dow Jones News/Retrieval subscribers to receive customized news coverage on a wide range of topics, including those related to the 1996 elections.To sign up for Dow Jones News/Retrieval or get information about the service, call Dow Jones Customer Service at 1-800-369-7466,extension 61. <p><B>About Dow Jones</B>Dow Jones Business Information Services is the electronic publishing armof Dow Jones & Co., Inc. that provides business and financial news and information products, including The Wall Street Journal&#174 InteractiveEdition and Dow Jones News/Retrieval&#174, to corporations, consumersand private investors through a variety of electronic media; computer,telephone, facsimile and radio.Dow Jones also publishes the print version of The Wall Street Journal and its international editions, Barron's&#174 magazine and other periodicals,electronic information services, including those of Dow Jones Telerate and Dow Jones Financial News Services, and the Ottaway group of community newspapers. Dow Jones also produces business television programming internationally and video news delivered to desktop computers.Dow Jones News/Retrieval, The Wall Street Journal, CustomClips,The Wall Street Journal Interactive Edition, Barron's and Dow Jones Telerate are all registered marks of Dow Jones & Co., Inc.All other products mentioned are the marks of their respective owners.<P>CONTACT: Dow Jones, PrincetonDara Schechter, 609-520-4668, ordara.schecter@cor.dowjones.com</pre><hr><a href="../latest.html">Back to the main Dow Jones in the News page.</a><hr><H4>We welcome feedback or questions about the <A HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4></blockquote><pre></pre> 								<center>					<a href="../toolbar.gif.map">								<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>					<BR>									<font size=2>					<a href="../bizpubs/index.html">Newspapers</a> |					<a href="../clipping/index.html">Alert Services</a> |					<a href="../online-lib/index.html">Research</a>  |					<a href="../pers-finance/index.html">Personal Finance</a>  |  					<a href="../latest.html">DJ In The News</a>  |					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |					<a href="../index.html">Home</a> 				</font>												</center>				</TD></tr></TABLE></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-76</DOCNO>
<DOCOLDNO>IA028-000307-B013-129</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/releas28.html 143.131.194.4 19970114051045 text/html 4799
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:14:45 GMT
Last-modified: Monday, 12-Aug-96 18:48:04 GMT
Content-length: 4610
Content-type: text/html
</DOCHDR>
<html><head><title>PR Pages</title></head><body  background="../images/bgddj.gif"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td><td><p><br><blockquote><center>MEDIA ADVISORY<p><b>THE WALL STREET JOURNAL INTERACTIVE EDITION<br>INTRODUCES E-MART, THE INTERNET VERSION OF THE<br> WALL STREET JOURNAL'S POPULAR CLASSIFIED SECTION<p></b></center><pre><B>Princeton, N.J., July 29, 1996</B>--The Wall Street Journal&#174Interactive Edition today introduced E-Mart, an online resource that makes available highly targeted classified advertising from the print editions of The Wall Street Journal. The Interactive Edition is located on the World Wide Web at the URL: http://wsj.com"Our Web readers have consistently told us that they'd like to be able tosearch The Journal's classifieds, particularly the positions available," said Tom Baker, business director for the Interactive Edition. "Theseadvertisements are a selective and high-quality resource for businesspeople, and the interactive environment helps make them even more useful to readers."At launch, E-Mart includes six categories of ads, including severalcategories of business opportunities and The Wall Street Journal's widelyfollowed positions-available advertising. Within those categories,Interactive Edition readers can search all the ads that have appeared in all of The Journal's national and regional print editions over the past week.Readers see the full text of the original ad as it appears in print and, in the case of display advertising, all of the advertiser's original graphics and layout. Ads are published online simultaneously with their appearance in print.The Interactive Edition features continuously updated coverage of the fullspectrum of business news, including corporate news, financial markets, personal finance, technology, law, and marketing from The Wall StreetJournal's newsroom. In addition to the stories from the daily print edition of the Journal, the Interactive Edition adds its own non-stop, breaking coverage of news from more than  1,000 Dow Jones reporters based aroundthe world. Stories are  enhanced with in-depth, hyperlinked backgroundinformation and supporting documents.The regular subscription rate is $49 annually, but subscribers to the printedition of The Wall Street Journal pay a lower rate of $29 annually.<P><B>About Dow Jones</B><br>Dow Jones Business Information Services is the electronic publishing armof Dow Jones & Co., Inc. that provides business and financial news and information products, including The Wall Street Journal&#174 InteractiveEdition and Dow Jones News/Retrieval&#174, to corporations, consumersand private investors through a variety of electronic media; computer,telephone, facsimile and radio.Dow Jones also publishes the print version of The Wall Street Journal and its international editions, Barron's&#174 magazine and other periodicals,electronic information services, including those of Dow Jones Telerate and Dow Jones Financial News Services, and the Ottaway group of community newspapers. Dow Jones also produces business television programming internationally and video news delivered to desktop computers.The Wall Street Journal, Barron's The Wall Street Journal InteractiveEdition, Dow Jones News/Retrieval, Dow Jones News Service and Dow JonesInvestor Network are registered marks of Dow Jones & Co., Inc.CONTACT: Kris Leboutillier, 609-620-4638Dow Jones BISkris.leboutillier@cor.dowjones.com</pre><hr><a href="../latest.html">Back to the main Dow Jones in the News page.</a><hr><H4>We welcome feedback or questions about the <A HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4></blockquote><pre></pre> 								<center>					<a href="../toolbar.gif.map">								<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>					<BR>									<font size=2>					<a href="../bizpubs/index.html">Newspapers</a> |					<a href="../clipping/index.html">Alert Services</a> |					<a href="../online-lib/index.html">Research</a>  |					<a href="../pers-finance/index.html">Personal Finance</a>  |  					<a href="../latest.html">DJ In The News</a>  |					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |					<a href="../index.html">Home</a> 				</font>												</center>				</TD></tr></TABLE></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-77</DOCNO>
<DOCOLDNO>IA028-000307-B013-155</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/releas27.html 143.131.194.4 19970114051116 text/html 5271
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:15:09 GMT
Last-modified: Monday, 12-Aug-96 18:48:03 GMT
Content-length: 5082
Content-type: text/html
</DOCHDR>
<html><head><title>PR Pages</title></head><body  background="../images/bgddj.gif"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td><td><p><br><blockquote><center>MEDIA ADVISORY<p><b>DOW JONES ANNOUNCES DISTRIBUTION AGREEMENT WITH <br>DAY-TIMER TECHNOLOGIES; PERSONAL JOURNAL SOFTWARE<br> FROM THE WALL STREET JOURNAL INCLUDED ON NEW AWARD-WINNINGPERSONAL INFORMATION MANAGEMENT <br>CD-ROM FROM DAY-TIMERS INC.<p></b></center><pre><B>Princeton, N.J., July 23, 1996</B>--Dow Jones Business InformationServices (BIS) today announced that its Personal Journal&#174 software isnow included on Day-Timer Technologies' award-winning personal information management software. The Day-Timer Organizer Deluxe CD-ROMis available in retail stores as well as through the Day-Timer catalog.Personal Journal is a continuously updated, personalized electronicnewspaper that provides a quick, concise read of the business news thatmatters most to busy professionals. Published in a familiar, newspaper-likeformat, Personal Journal provides access to articles and news briefspublished in The Wall Street Journal&#174 each day, plus wire stories,stock quotes, worldwide weather and sports. Subscribers set up a personal news profile to track news on up to 25 companies or columns fromThe Wall Street Journal. Additionally the personal portfolio tracks quoteson up to 25 stocks and mutual funds"Busy professionals who organize their schedules with Day-Timer OrganizerDeluxe can now organize their business news with Personal Journal," saidJames White, product manager, Personal Journal. "Personal Journal nowgives Day-Timer Organizer users a simple means to get just news they needfrom The Wall Street Journal, when they need it, delivered right to their PC."The Day-Timer Organizer provides electronic scheduling, task management,address book, notebook, and expense tracking functions in tightly integrated, easily navigable modules. The software mimics the world-famous, paper-basedDay-Timer Organizer on their personal computer or network systems.This latest agreement with Day-Timer follows recent Personal Journaldistribution agreements with leaders in the computer industry -- Digital,U.S. Robotics, IBM, AST, Zenith, Compaq, CompUSA, and Sharp. PersonalJournal has been installed on more than one million PCs to date.<p><B>About Day-Timer Technologies</B>Day-Timer Technologies is a joint venture between Day-Timers, Inc., a world leader in time and information management products, andKensington Microware Limited, a designer and marketer of quality computer accessories, peripherals and software. Both companies are part of ACCO World Corporation, an operating company of AmericanBrands, Inc.<P><B>About Dow Jones</B><br>Dow Jones Business Information Services is the electronic publishing armof Dow Jones & Co., Inc. that provides business and financial news and information products, including The Wall Street Journal&#174 InteractiveEdition and Dow Jones News/Retrieval&#174, to corporations, consumersand private investors through a variety of electronic media; computer,telephone, facsimile and radio.Dow Jones also publishes The Wall Street Journal and its internationaleditions, Barron's&#174 magazine and other periodicals, electronicinformation services, including those of Dow Jones Telerate and Dow JonesFinancial News Services, and the Ottaway group of community newspapers.Dow Jones also produces business television prgramming internationallyand video news delivered to desktop computers.<p>Those interested in subscribing to Personal Journal can call1-800-291-9382 for more information.<p>Personal Journal, The Wall Street Journal, Barron's The Wall Street JournalInteractive Edition, Dow Jones News/Retrieval, Dow Jones News Service andDow Jones Investor Network are registered marks of Dow Jones & Co., Inc.<p>CONTACT: Kris Leboutillier, 609-620-4638Dow Jones BISkris.leboutillier@cor.dowjones.com</pre><hr><a href="../latest.html">Back to the main Dow Jones in the News page.</a><hr><H4>We welcome feedback or questions about the <A HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4></blockquote><pre></pre> 								<center>					<a href="../toolbar.gif.map">								<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>					<BR>									<font size=2>					<a href="../bizpubs/index.html">Newspapers</a> |					<a href="../clipping/index.html">Alert Services</a> |					<a href="../online-lib/index.html">Research</a>  |					<a href="../pers-finance/index.html">Personal Finance</a>  |  					<a href="../latest.html">DJ In The News</a>  |					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |					<a href="../index.html">Home</a> 				</font>												</center>				</TD></tr></TABLE></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-78</DOCNO>
<DOCOLDNO>IA028-000307-B013-187</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/releas26.html 143.131.194.4 19970114051138 text/html 5942
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:15:48 GMT
Last-modified: Monday, 12-Aug-96 18:48:03 GMT
Content-length: 5753
Content-type: text/html
</DOCHDR>
<html><head><title>PR Pages</title></head><body  background="../images/bgddj.gif"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td><td><p><br><blockquote><center>MEDIA ADVISORY<p><b>PHOTOGRAPHER ANNIE LEIBOVITZ TEAMS WITH <br>THE WALL STREET JOURNAL FOR FIRST INTERNET VENTURE; <br>OLYMPICS PHOTOS APPEAR ON JOURNAL'S <br>INTERACTIVE EDITION<p></b></center><pre><B>New York, July 22, 1996</B>--The Wall Street Journal&#174 InteractiveEdition today introduced an exclusive, limited-time special photo featurecalled the Virtual Gallery to celebrate the commencement of the 1996Summer Olympics in Atlanta.The Virtual Gallery introduces photos of various 1996 Olympians fromworld-renowned portrait photographer Annie Leibovitz and accompanies the release of a new Special Report called: The Olympics, The Money Games.The report investigates compelling business and financial stories behind the 26th Olympiad. Both the Virtual Gallery and the Special Report are accessible to Interactive Edition subscribers from http://wsj.com.The Interactive Edition has exclusive electronic rights to a total of 18Leibovitz photographs, which will be published shortly in her book "OlympicPortraits." The photos capture 1996 Olympians across all athletic disciplines as they prepare for the Games in various locations around the world."As we watch people continue to embrace the Web as a new way to interactwith words and images, sound and video, it is thrilling for the InteractiveEdition to be host to the first Virtual Gallery from one of the world'sleading photographers," said Jennifer Edson, creative director for The WallStreet Journal Interactive Edition."When the Interactive Edition launched on the Web back in April, the Journalcaptured a new universe of readers from the traditional print audience," Ms. Edson said. "The Interactive Edition is designed as a complementaryproduct to the print Journal and the Web's open access and unlimited realestate makes enhancing and expanding the Journal brand a natural result.While Interactive Edition subscribers are initially drawn to the site for ourunmatched business news and information, the Web allows us to enhanceour business information with other unique, compelling content."The Interactive Edition includes a continuously updated sports sectionincluding scores and game highlights. During the 1996 Atlanta games, the Interactive Edition will bring its readers frequent reports and features on the results.Dow Jones' presentation of the photos as part of the Virtual Gallery and the Interactive Edition's coverage of the games are sponsored byInternational Business Machines, Corp.Launched April 29th, the Interactive Edition features continuously updatedcoverage of the full spectrum of business news, including corporate news,financial markets, personal finance, technology, law, and marketing fromThe Wall Street Journal's newsroom. In addition to the stories from thedaily print edition of the Journal, the Interactive Edition adds its ownnon-stop, breaking coverage of news from more than 1,000 Dow Jonesreporters based around the world. Stories are enhanced with in-depth,hyperlinked background information and supporting documents. More than550,000 businesspeople from around the U.S. and around the world haveregistered as Interactive Edition readers. <p><B>About Dow Jones</B><br>Dow Jones Business Information Services is the electronic publishing armof Dow Jones & Co., Inc. that provides business and financial news and information products, including The Wall Street Journal&#174 InteractiveEdition and Dow Jones News/Retrieval&#174, to corporations, consumersand private investors through a variety of electronic media; computer,telephone, facsimile and radio.Dow Jones also publishes the print version of The Wall Street Journal andand its international editions, Barron's&#174 magazine and otherperiodicals, electronic information services, including those of Dow JonesTelerate and Dow Jones Financial News Services, and the Ottaway group of community newspapers. Dow Jones also produces business televisionprgramming internationally and video news delivered to desktop computers.The Wall Street Journal, Barron's The Wall Street Journal InteractiveEdition, Dow Jones News/Retrieval, Dow Jones News Service and Dow JonesInvestor Network are registered marks of Dow Jones & Co., Inc.<P>CONTACT: Stacia Anson/Charles SpoffordMiller/Shandwick Technologies617-536-0470sanson@miller.shandwick.comcspofford@miller.shandwick.comorKris Leboutillier, 609-620-4638Dow Jones BISkris.leboutillier@cor.dowjones.com</pre><hr><a href="../latest.html">Back to the main Dow Jones in the News page.</a><hr><H4>We welcome feedback or questions about the <A HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4></blockquote><pre></pre> 								<center>					<a href="../toolbar.gif.map">								<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>					<BR>									<font size=2>					<a href="../bizpubs/index.html">Newspapers</a> |					<a href="../clipping/index.html">Alert Services</a> |					<a href="../online-lib/index.html">Research</a>  |					<a href="../pers-finance/index.html">Personal Finance</a>  |  					<a href="../latest.html">DJ In The News</a>  |					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |					<a href="../index.html">Home</a> 				</font>												</center>				</TD></tr></TABLE></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-79</DOCNO>
<DOCOLDNO>IA028-000307-B013-208</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/releas25.html 143.131.194.4 19970114051148 text/html 4126
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:16:01 GMT
Last-modified: Monday, 12-Aug-96 18:48:02 GMT
Content-length: 3937
Content-type: text/html
</DOCHDR>
<html><head><title>PR Pages</title></head><body  background="../images/bgddj.gif"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td><td><p><br><blockquote><center>MEDIA ADVISORY<p><b>DOW JONES BUSINESS INFORMATION SERVICES NAMES PERRY TO HEAD DISTRIBUTION STRATEGY<p></b></center><pre><B>Princeton, N.J., July 15, 1996</B>--Jessica Perry has been promoted to director of distribution strategy at Dow Jones Business InformationServices in Princeton, N.J. In her new position, Ms. Perry is responsible for identifying and developing third-party relationships with onlineservices, sales agents, and network service and hardware providers for the licensing and bundling of Dow Jones Information services and products.She was previously assistant director of distribution strategy."This promotion reflects the highly visible and positive contribution Jesshas made to our business sucess, says Skip Grossman, executive director of content & distribution at Dow Jones Business Information Services. "Her special balance of teamwork, intelligence, execution and leadershipskills has invigorated our distribution efforts with third parties,niche online business services, broad-based consumer onlineservices and new players on the World Wide Web.Ms. Perry began her career as a financial writer/broadcaster at Dow Jones in 1982. Prior to joining the Dow Jones Business Information Servicesdivision in 1994 as manager, mobile products, Ms. Perry managed markettrials and research with telecommunications companies and hardwaremanufacturers from 1992-1994. From 1987-1002, Ms. Perry was marketing manager, audiotext services, responsible for direct-response print andbroadcast advertising, direct mail and promotional campaigns for audioinformation services. Ms. Perry earned Master's and Bachelor's degrees in journalism fromNorthwestern University. She is a resident of Lambertville, N.J.<P><B>About Dow Jones</B><br>Dow Jones Business Information Services is the electronic publishing arm of Dow Jones & Co., Inc. that provides business and financial news and information products, including The Wall Street Journal&#174Interactive Edition and Dow Jones News/Retrieval&#174, to corporations,consumers and private investors through a variety of electronic media; computer, telephone, facsimile and radio.Dow Jones also publishes The Wall Street Journal and its internationaleditions, Barron's&#174 magazine and other periodicals, electronicinformation services, including those of Dow Jones Telerate and Dow JonesFinancial News Services, and the Ottaway group of community newspapers.Dow Jones also produces business television prgramming internationally and video news delivered to desktop computers.<p>CONTACT: Kris Leboutillier, 609-620-4638Dow Jones BISkris.leboutillier@cor.dowjones.com</pre><hr><a href="../latest.html">Back to the main Dow Jones in the News page.</a><hr><H4>We welcome feedback or questions about the <A HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4></blockquote><pre></pre> 								<center>					<a href="../toolbar.gif.map">								<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>					<BR>									<font size=2>					<a href="../bizpubs/index.html">Newspapers</a> |					<a href="../clipping/index.html">Alert Services</a> |					<a href="../online-lib/index.html">Research</a>  |					<a href="../pers-finance/index.html">Personal Finance</a>  |  					<a href="../latest.html">DJ In The News</a>  |					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |					<a href="../index.html">Home</a> 				</font>												</center>				</TD></tr></TABLE></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-80</DOCNO>
<DOCOLDNO>IA028-000307-B013-237</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/releas24.html 143.131.194.4 19970114051202 text/html 6105
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:16:13 GMT
Last-modified: Monday, 12-Aug-96 18:48:02 GMT
Content-length: 5916
Content-type: text/html
</DOCHDR>
<html><head><title>PR Pages</title></head><body  background="../images/bgddj.gif"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td><td><p><br><blockquote><center>MEDIA ADVISORY<p><b>THE WALL STREET JOURNAL RADIO NETWORK <br>INTRODUCES WORK & FAMILY SHOW<p></b></center><pre><B>New York, July 12, 1996</B>--The Wall Street Journal Radio Network will introduce its new talk show, "Work & Family," on KSL-AM in Salt Lake City, Utah, on Saturday July 27 from 2:00-4:00 p.m. Mountain Standard Time. The two-hour call-in show features host Sue Shellenbarger, the Work & Family columns at The Wall Street Journal&#174. The topics will include surviving workplace burnout and dividing household responsibilities in dual-income families.Work & Family explores the balancing act of making time for a career, family, and responsibilities in the home."It's a wonderful opportunity to air this pilot. We're looking forward to sharing Work & Family with our listeners," says Rod Arquette, Vice President, news and programming at KSL-AM.The live show will also be aired in other cities before its national distribution beginning Saturday, Sept. 7, 1996. In May, Work & Family aired on WRC-AM 980 Radio, which serves the Washington, D.C. area."We are honored to be on the forefront of what is sure to be a radio successstory," says Jim Allen, program director at WRC-AM 980 Radio.Through listener call-ins, each Work & Family broadcast examines a specific topic, such as child-care options or burnout in the workplace, and gives solutions on thebest way to manage these difficult issues confronting today's families. Ms. Shellenbarger spends an engaging and insightful two hours offering opinions, taking calls, interviewing authorities in the field, and providing people the tools they need to juggle job and family obligations.Ms. Shellenbarger is a mother of two and stepmother of three and one of the country's leading experts on work and family issues. She has been writing or editing for The Wall Street Journal for 16 years and was also the recipient of the "Exceptional Merit Media Award" from the National Women's Political Caucusand Radcliffe College for outstanding coverage of issues of special concern to women."I believe that work and family are the two most important things in most people's lives, as they are in mine," says Ms. Shellenbarger. "During the Work & Family show, we handle issues such as finding child-care providers, caring for older family members, dividing up household responsibilities, and getting the flexibility you need from your employer in order to maintain a career and family. The goal of the program is to shed light on the real problems confronting families today, to explore the options, and to provide answers to American families."Once syndicated, Work & Family will be broadcast on Saturday mornings from 10:00 a.m.-12:00 p.m. ET. It is produced by Sal Giangrasso, managing editor at The Wall Street Journal Radio Network."The Wall Street Journal has been covering these issues for years in print. A growing interest in the work and family conflict prompted us to create an interactive show for talk radio and audiences, explains Peggy Belden, director of broadcast services at The Wall Street Journal Radio Network.The Wall Street Journal Radio Network is the national distributor of The Wall Street Journal Report&#174 and the Dow Jones Report&#174. Both provide hourly business news updates to radio stations across the country.<p><B>About Dow Jones</B><br>Dow Jones Business Information Services is the electronic publishing arm of Dow Jones & Co., Inc. that provides business and financial news and information products, including The Wall Street Journal&#174Interactive Edition and Dow Jones News/Retrieval&#174, to corporations, consumers andprivate investors through a variety of electronic media; computer, telephone, facsimile and radio.Dow Jones also publishes The Wall Street Journal and its international editions, Barron's&#174 magazine and other periodicals, electronic information services, including those of Dow Jones Telerate and Dow JonesFinancial News Services, and the Ottaway group of community newspapers. Dow Jones also producesbusiness television prgramming internationally and video news delivered to desktop computers.For more information on the Work & Family show, contact Nancy Abramson at The Wall Street Journal Radio Network, 212/416-2508 or 914/244-0655.The Wall Street Journal, The Wall Street Journal Radio Network, The Wall Street Journal Report, Dow Jones Report, The Wall Street Journal&#174 Interactive Edition, Dow Jones News/Retrieval, and Barron's are registered marks of Dow Jones & Co., Inc.<p>CONTACT: Beth Brody, 609-520-4679 or dowjonespr@aol.com</pre><hr><a href="../latest.html">Back to the main Dow Jones in the News page.</a><hr><H4>We welcome feedback or questions about the <A HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4></blockquote><pre></pre> 								<center>					<a href="../toolbar.gif.map">								<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>					<BR>									<font size=2>					<a href="../bizpubs/index.html">Newspapers</a> |					<a href="../clipping/index.html">Alert Services</a> |					<a href="../online-lib/index.html">Research</a>  |					<a href="../pers-finance/index.html">Personal Finance</a>  |  					<a href="../latest.html">DJ In The News</a>  |					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |					<a href="../index.html">Home</a> 				</font>												</center>				</TD></tr></TABLE></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-81</DOCNO>
<DOCOLDNO>IA028-000307-B013-262</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/releas22.html 143.131.194.4 19970114051311 text/html 6120
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:16:35 GMT
Last-modified: Thursday, 11-Jul-96 14:15:54 GMT
Content-length: 5929
Content-type: text/html
</DOCHDR>
<html>

<head><title>PR Pages</title></head>





<body  background="../images/bgddj.gif">



<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>

<TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  

<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td>



<td>

<p>

<br>



<center>MEDIA ADVISORY<p>

<b>DOW JONES AND U.S. ROBOTICS ANNOUNCE<br>  

DISTRIBUTION AGREEMENT FOR PERSONAL JOURNAL</b></center>



<blockquote>



<pre>

<b>U.S. Robotics to Distribute Software for Online, Customizable

Edition of The Wall Street Journal With New Sportster Modems</b><p>



Princeton, N.J., July 1, 1996--Dow Jones Business Information Services 

(BIS) and the Personal Communications Division of U.S. Robotics (USRX) 

today announced that Dow Jones' Personal Journal&#174; software is now 

included on U.S. Robotics' Connections CD-ROM provided with all 

Sportster fax modems.  The Connections CD-ROM will provide customers 

who purchase Sportster modems with easy access to Personal Journal 

software.<p>

	Personal Journal is a continuously updated, personalized electronic 

newspaper that provides a quick, concise read of the business news that 

matters most to busy professionals.  Published in a familiar, newspaper-like 

format, Personal Journal provides access to articles and news briefs 

published in The Wall Street Journal&#174; each day, plus wire stories, stock 

quotes, worldwide weather and sports.<p>

	Subscribers can customize their personal news profile to track 

news on up to 25 companies or columns from The Wall Street Journal.  

Additionally the personal portfolio tracks quotes on up to 25 stocks and 

mutual funds.<p>

</p>	"Busy professionals need to stay in touch with business news and 

financial markets but have little time to spare," said James White, product 

manager of Personal Journal.  <p>

"Personal Journal now gives the busy professional the news they need from 

The Wall Street Journal, delivered right to their PC.  It's a great complement 

to the Sportster modem."<p>

	"The addition of the Personal Journal software to our Connections 

CD-ROM is another example of our commitment to provide Sportster 

owners with an easy-to-use, feature-rich tool to access the wealth of 

information available in the online world," noted Michael Seedman, vice 

president and general manager of the Personal Communications Division.<p>

	This latest agreement with U.S. Robotics follows recent Personal 

Journal distribution agreements with leaders in the computer industry -- 

Digital, IBM, AST, Compaq, CompUSA, and Sharp.  Personal Journal has 

been installed on more than one million PCs to date.<p>

<br>

About U.S. Robotics<br>

	U.S. Robotics is one of the world's leading suppliers of products 

and systems that provide access to information. The company designs, 

manufactures, markets and supports remote access servers, enterprise 

communications systems, desktop/mobile client products, telephony 

products and modems that connect computers and other equipment over 

analog, digital and switched cellular networks, enabling users to gain access 

to, manage and share data, fax and voice information. <p>

	Its customers include Internet service providers, regional Bell 

operating companies and a wide range of other large corporations, 

businesses, institutions and individuals.  The company's 1995 sales were 

$889.3 million.  Information on the company and its products is available at 

http://usr.com.<p>

<br>

About Dow Jones<br>	

	Dow Jones Business Information Services, the electronic 

publishing arm of Dow Jones & Company, Inc., provides business and 

financial news and information products including The Wall Street Journal&#174; 

Interactive Edition on the World Wide Web and Dow Jones 

News/Retrieval&#174; to corporations, consumers and private investors through a 

variety of electronic media: computer, telephone, facsimile and radio. <p>

	Dow Jones also publishes The Wall Street Journal&#174; and its 

international editions, Barron's&#174; magazine and other periodicals, electronic 

information services, including those of Dow Jones Telerate and Dow Jones 

Financial News Services, and the Ottaway group of community 

newspapers. Dow Jones also produces business television programming 

internationally and video news delivered to desktop computers. <p>

	Those interested in subscribing to Personal Journal can call 1-800-

291-9382 for more information.  <p>

</p>	Those with Internet access can get a tour of Personal Journal and 

download software at: http://bis.dowjones.com/pj.html.<p>

<center>###</center>

Personal Journal, The Wall Street Journal, The Wall Street Journal 

Interactive Edition, Dow Jones News/Retrieval, Barron's, Dow Jones 

Telerate and Dow Jones News Service are marks of Dow Jones & 

Company, Inc.  All other products mentioned are the marks of their 

respective owners.

<p>





</pre>



<hr>



<a href="../latest.html">Back to the main Dow Jones in the News page.</a>

<hr>

<H4>We welcome feedback or questions about the <A 

HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A 

HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4>



</blockquote>



<pre>





</pre>

 

				

				<center>

					<a href="../toolbar.gif.map">

			

					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>

					<BR>

					

				<font size=2>

					<a href="../bizpubs/index.html">Newspapers</a> |

					<a href="../clipping/index.html">Alert Services</a> |

					<a href="../online-lib/index.html">Research</a>  |

					<a href="../pers-finance/index.html">Personal Finance</a>  |  

					<a href="../latest.html">DJ In The News</a>  |

					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |

					<a href="../index.html">Home</a> 



				</font>

				

				

				</center>

				



</TD></tr>

</TABLE>

</body>

</html>

</DOC>
<DOC>
<DOCNO>WT18-B31-82</DOCNO>
<DOCOLDNO>IA028-000307-B013-302</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/releas23.html 143.131.194.4 19970114051359 text/html 4094
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:17:55 GMT
Last-modified: Thursday, 11-Jul-96 14:16:30 GMT
Content-length: 3903
Content-type: text/html
</DOCHDR>
<html>
<head><title>PR Pages</title></head>


<body  background="../images/bgddj.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td>

<td>
<p>
<br>

<center>MEDIA ADVISORY<p>
<b>THE WALL STREET JOURNAL INTERACTIVE EDITION REGISTERS 500,000TH READER;<br> 12
NEW ADVERTISERS ALSO SIGN UP DURING FIRST EIGHT WEEKS OF OPERATION</b></center>

<blockquote>

<pre>
PRINCETON, N.J., June 24, 1996 -- The Wall Street Journal&#174; Interactive 
Edition the first complete resource for up-to-the-minute business news, 
analysis and financial information available from the World Wide Web, has 
passed the 500,000-reader mark.  The site is currently averaging 2,000 to 
3,000 new registrations every day.  This early, wide circulation confirms its 
premier position as one of the most popular Internet sites for business news.  
The Interactive Edition is located at the URL: http://wsj.com.<p>
	The Interactive Edition is also proving to be a powerful advertising 
tool.  Today, thirty advertisers, including Microsoft, Barclays Bank, Smith 
Barney, IBM, and AT&T are currently appearing on the Journal site.<p>
	Regular subscription rates are $49 annually, but subscribers to the 
print edition of The Wall Street Journal pay a lower rate of $29 annually.  
Registered readers will have free access until August 31.  <p>
	Launched April 29th, the Interactive Edition features continuously 
updated coverage of the full spectrum of business news, including corporate 
news, financial markets, personal finance, technology, law, and marketing 
from The Wall Street Journal's newsroom.  In addition to the stories from 
the daily print edition of The Wall Street Journal, the Interactive Edition 
adds its own non-stop, breaking coverage of news from more than 1,000 
Dow Jones reporters based around the world. Stories are enhanced with in-
depth, hyperlinked background information and supporting documents.<p>
</p>	Dow Jones Business Information Services, the electronic 
publishing arm of Dow Jones & Company, Inc., provides business news 
and information products, including The Wall Street Journal Interactive 
Edition and Dow Jones News/Retrieval&#174, to corporations, consumers and 
private investors through a variety of electronic media: computer, 
telephone, facsimile and radio.<p>
</p>	Dow Jones publishes The Wall Street Journal&#174 and its international 
editions, Barron's&#174 magazine and other periodicals, electronic business 
information services including Telerate&#174, a provider of real-time financial 
information to the international business community, Dow Jones News 
Service&#174; and other business newswires and the Ottaway group of 
community newspapers.  Dow Jones also produces business television 
programming internationally and video news delivered to desktop 
computers.<p>

<center>### </center>


</pre>

<hr>

<a href="../latest.html">Back to the main Dow Jones in the News page.</a>
<hr>
<H4>We welcome feedback or questions about the <A 
HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A 
HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4>

</blockquote>

<pre>


</pre>
 
				
				<center>
					<a href="../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../bizpubs/index.html">Newspapers</a> |
					<a href="../clipping/index.html">Alert Services</a> |
					<a href="../online-lib/index.html">Research</a>  |
					<a href="../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../index.html">Home</a> 

				</font>
				
				
				</center>
				

</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-83</DOCNO>
<DOCOLDNO>IA028-000307-B013-340</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/releas21.html 143.131.194.4 19970114051420 text/html 5837
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:18:24 GMT
Last-modified: Thursday, 13-Jun-96 15:52:33 GMT
Content-length: 5646
Content-type: text/html
</DOCHDR>
<html>
<head><title>PR Pages</title></head>


<body  background="../images/bgddj.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td>

<td>
<p>
<br>

<center>MEDIA ADVISORY<p>
<b>DOW JONES ESTABLISHES NATIONAL ALLIANCE PROGRAM<br> FOR 
PROFESSIONAL RESEARCHERS</b></center>

<blockquote>

<pre>
PRINCETON, N.J.-- June 7, 1996 -- Dow Jones Business Information 
Services (BIS) today announced the formation of the Dow Jones InfoPro 
Alliance, a program designed to recognize the special role of online research 
professionals and the long-established partnership between Dow Jones and 
the online information professional community. The InfoPro Alliance will 
provide tailored support to professional and industry groups and keep 
researchers up-to-date on new Dow Jones products and trends.<p>
	Whether they are managers of company or academic libraries, or 
independent business professionals, the searchers continuously provide 
crucial information that affects daily business decisions. They also play a 
critical role in deciding where to find the most up-to-date and comprehensive 
information, and perform the value-added research that gives their clients a 
competitive edge. Because of the information professionals' unique 
leadership position in the process of discovering, interpreting, and 
disseminating information, Dow Jones has established the InfoPro Alliance. <p>
	"We're entering a new era of information access and choice, and as 
more options become available, people will rely on professional researchers
to help them discover what is important," said Josephine K. Ottman, director 
of product marketing, Dow Jones BIS. "We have a deep commitment to these 
professionals, who have been the heart of Dow Jones News/Retrieval 
business for the past 15 years. Like all good consultants, researcher 
professionals seek ways to increase their professional standing. Our goal is to 
offer the support they need so that they can continue to reach--and exceed--
the expectations of their corporate clients."<p>

Dow Jones InfoPro Alliance Offers Benefits to Professional Researchers

	The announcement of Dow Jones InfoPro Alliance follows the recent 
successful launch of the completely new version of Dow Jones 
News/Retrieval", with expanded content, a sophisticated yet easy-to-use 
interface, and predictable, competitive pricing. Dow Jones News/Retrieval is a 
news and information service designed to answer the most pressing and in-
depth questions asked by business people every day. It is a compilation of 
more than 55 million documents and information on more than 10 million 
companies. <p>
	Dow Jones InfoPro Alliance members will be invited to attend 
quarterly product and information seminars in major cities and receive 
advance notice of key enhancements for Dow Jones products.<p>
	Members of the Alliance will also receive materials tailored to their 
needs, including the InfoPro edition of the quarterly Dow Jones newsletter, 
Dowline, and an advanced searcher guide to Dow Jones products.<p>

	A longstanding supporter of the information services profession, Dow 
Jones will continue its support of industry groups, such as the Special 
Libraries Association (SLA) -- a network of more than 14,000 corporate 
librarians -- for which Dow Jones is a patron sponsor. In addition, Dow Jones
is a vendor partner of the Association of Independent Information 
Professionals (AIIP). <p>

About BIS and Dow Jones

	Dow Jones Business Information Services is the electronic publishing 
arm of Dow Jones & Company, Inc. that provides business and financial news
and information products, including The Wall Street Journal Interactive 
Edition and Dow Jones News/Retrieval, to corporations, consumers and
private investors, through a variety of electronic media: computer, telephone, 
facsimile and radio.<p>

	Dow Jones also publishes The Wall Street Journal"  and its 
international editions: Barron's magazine and other periodicals; electronic 
information services, including those of Dow Jones Telerate, Dow Jones 
Financial News Services; and the Ottaway group of community newspapers. 
Dow Jones also produces business television programming internationally 
and video news delivered to desktop computers.<p>
	
                                                                  # # #<p>
Dow Jones News/Retrieval, The Wall Street Journal Interactive Edition, 
The Wall Street Journal , and Barron's are trademarks or service marks of
Dow Jones & Company, Inc. All other products mentioned are the marks of 
their respective companies. 

</pre>

<hr>

<a href="../latest.html">Back to the main Dow Jones in the News page.</a>
<hr>
<H4>We welcome feedback or questions about the <A 
HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A 
HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4>

</blockquote>

<pre>


</pre>
 
				
				<center>
					<a href="../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../bizpubs/index.html">Newspapers</a> |
					<a href="../clipping/index.html">Alert Services</a> |
					<a href="../online-lib/index.html">Research</a>  |
					<a href="../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../index.html">Home</a> 

				</font>
				
				
				</center>
				

</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-84</DOCNO>
<DOCOLDNO>IA028-000307-B014-2</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/releas20.html 143.131.194.4 19970114051448 text/html 4496
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:18:51 GMT
Last-modified: Thursday, 06-Jun-96 21:51:31 GMT
Content-length: 4305
Content-type: text/html
</DOCHDR>
<html>
<head><title>PR Pages</title></head>


<body  background="../images/bgddj.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td>
<td>
<p>

<br>


<blockquote>

<center>

MEDIA ADVISORY<p>

<b>DOW JONES SYSTEMS ENGINEERS WIN
SUN MICROSYSTEMS' JAVA CUP CONTEST
</b></center>

<pre>
PRINCETON, N.J. --May 29, 1996-- A software development team from Dow Jones Business 
Information Services (BIS) is being honored today by Sun Microsystems for the creation 
of an experimental, self-installing application-or applet-of Personal Journal&#174; in the Java 
Internet programming language.  The Dow Jones team is being presented the prize at 
JavaOne, the first worldwide Java Developer Conference officially sponsored by Sun 
Microsystems in San Francisco.<P>

	The prize, in the Unlimited Category, recognizes the Dow Jones team's ability to 
create an innovative and creative Web applet using Java, which  many leading software 
programmers consider an important programming language for the future of the Internet. 
The Personal Journal applet was designed specifically by Dow Jones to test the ability of 
Java to support commercial software applications.<P>

	Personal Journal is currently available commercially as a stand-alone, Windows-
based electronic online newspaper or as part of the Web-based Wall Street Journal 
Interactive Edition&#174;.  <P>

	"We are delighted that Sun has recognized members of the Personal Journal 
development team with this award," said Frank Lepelis, group vice president, systems 
development, Dow Jones BIS.  "The JavaCup demonstrates Dow Jones' ongoing effort to 
push the technology envelope by constantly testing new platforms and languages."<P>

	A group of eight Dow Jones engineers created the Java Cup Personal Journal 
applet under the guidance of Project Manager Mark Bukovec: team co-leaders James Lee 
and Rick Hall; and team members Laura Bertrand, Yaroslav Denega, Lindee Ning, Alka 
Rao, Nimesh Shah, and Ted Skolnick.<P>

	Personal Journal is a continuously updated electronic newspaper which provides a 
quick read of the business news that matters most to busy professionals.  Personal Journal 
provides access to articles and news briefs published in the print version of The Wall Street 
Journal each day, plus wire stories, stock quotes, worldwide weather and sports.<P>

	Dow Jones Business Information Services, the electronic publishing arm of Dow 
Jones & Company, Inc., provides business and financial news and information products 
including The Wall Street Journal Interactive Edition and Dow Jones News/Retrieval&#174;, to 
corporations, consumers and private investors through a variety of electronic media: 
computer, telephone, facsimile and radio. <P>

	Dow Jones also publishes The Wall Street Journal and its international editions, 
Barron's&#174; magazine and other periodicals, electronic information services, including those 
of Dow Jones Telerate and Dow Jones Financial News Services, and the Ottaway group of 
community newspapers. Dow Jones also produces business television programming 
internationally and video news delivered to desktop computers.  <P>

	Those interested in subscribing to Personal Journal may call 1-800-291-9382.  <P>


</pre>

<hr>

<a href="../latest.html">Back to the main Dow Jones in the News page.</a>
<hr>
<H4>We welcome feedback or questions about the <A 
HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A 
HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4>





</blockquote>

<pre>


</pre>
 
				
				<center>
					<a href="../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../bizpubs/index.html">Newspapers</a> |
					<a href="../clipping/index.html">Alert Services</a> |
					<a href="../online-lib/index.html">Research</a>  |
					<a href="../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../index.html">Home</a> 

				</font>
				
				
				</center>
				

</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-85</DOCNO>
<DOCOLDNO>IA028-000307-B014-40</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/releas19.html 143.131.194.4 19970114051604 text/html 35040
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:19:17 GMT
Last-modified: Thursday, 23-May-96 18:34:34 GMT
Content-length: 34848
Content-type: text/html
</DOCHDR>
<html>
<head><title>PR Pages</title></head>


<body  background="../images/bgddj.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td>
<td>
<p>

<br>


<blockquote>

<center>

MEDIA ADVISORY<p>

<b>DOW JONES EXTENDS LEADERSHIP AS BUSINESS INFORMATION PUBLISHER; SETS NEW INDUSTRY STANDARD WITH TRANSFORMED BUSINESS ONLINE SERVICE
</b></center>

<pre>
PRINCETON, N.J. --May 14, 1996-- Dow Jones announced 
today the launch of a completely new version of Dow Jones 
News/Retrieval&#174;, with expanded content, a completely redesigned, 
sophisticated, yet easy-to-use interface, and a new transaction-based 
pricing structure which offers free searching and free headlines. 
Dow Jones News/Retrieval is an online news and information 
service designed to provide fast answers to tough business 
questions, with a couple of mouse clicks, in a massive compilation 
of more than 55 million documents and information on more than 
10 million companies. <br>
	 "Business people want answers--fast," says Dorothea 
Coccoli Palsho, president of Dow Jones Business Information 
Services (BIS). "This completely new Dow Jones News/Retrieval 
gives our customers a strategic advantage through convenient access 
to logically presented information from sources they trust. We'll use 
much of what we've learned in this effort in our work on the World 
Wide Web and other distribution platforms." <br>
<p>
New Interface
	In the past, one of the biggest barriers to using conventional 
research services has been the complexity of the interface. The new 
Dow Jones service is designed so that all business people, 
regardless of their familiarity with online research services, can 
navigate easily and quickly, and be satisfied with the information 
they find. At the same time, sophisticated search commands and in-
depth content required by professional searchers remains available at 
any time; they can use the familiar, expert-level functionality that 
they have used for years. 
<p>
	"The answer to any business question is never more than a 
few mouse clicks away," says Tim Andrews, editor-in-chief of 
online services for Dow Jones BIS. "Our goal was for the service to 
be completely clear to the customer." In fact, users of the pre-launch 
version of the service have confirmed that the company has 
achieved its goal.  When surveyed, 94% found it effortless to 
navigate through and control the software.
	The new re-engineered interface is so successful at 
"surfacing" the comprehensive content contained in the Dow Jones 
service that even current Dow Jones customers were surprised. 
"Over and over, in focus groups, customers said, 'Wow-I never 
knew Dow Jones had that information! When can I have a copy of 
the new software?'" says Josie Ottman, director of product 
marketing for Dow Jones BIS. "We know we have a real winner on 
our hands."
<p>
Unequaled Content
	"Our research told us that what people wanted-whether 
they were professional searchers or business people-was fast 
answers to the tough questions that they face every day," says Ms. 
Ottman. "How do I grow my business? Should we buy that 
company? What is the risk? What is our competition up to now?  
The new interface makes it easy to answer these questions, by 
providing access to an unmatched collection of publications and data 
contained in the Dow Jones service."
	 There are more than 55 million documents contained in 
more than 3,000 sources, information on more than 10 million 
private and public companies, and quotes from every major 
financial exchange in the world. Dow Jones is the only service 
offering the combination of the same-day full text of The Wall Street 
Journal&#174;, The New York Times, Los Angeles Times, and Financial 
Times. In fact, Dow Jones offers 48 of the top 50 newspapers, with 
more full-text newspapers available than on other comparable 
services. 
	The new Dow Jones service is backed by one of the largest, 
most respected editorial organizations in the world. Dow Jones has 
over 1,000 editors and reporters working on stories as they unfold. 
In the Business Information Services division, a dedicated editorial 
team works on prioritizing, indexing, rewriting, and editing the 
stories that are incorporated into Dow Jones News/Retrieval.  
	Mick Luce, a financial analyst for PacifiCorp Financial 
Services, who has been using an early version of the new service, 
confirms that "Dow Jones News/Retrieval is the best source for 
historical and current news on companies. It's easier than any 
system I've used."
<p>
	The new version of Dow Jones News/Retrieval is organized 
into six sections: 
<ul>
<li>Current News provides continuously updated daily and 
intraday news selected by Dow Jones editors, and brings Dow 
Jones customers the most complete news and information from 
respected national, international, regional, and local newspapers 
and newswires. More than 9,000 new items are added to the 
service from the many newswires and news publications every 
day. In addition, continuously updated news on six industries is 
selected by editors from the thousands of items flowing into the 
newsroom.
<li>Search News and Articles offers one-button access to the Dow 
Jones Publications Library containing more than 55 million 
documents from more than 3,000 sources, including newswires, 
newspapers, magazines, trade journals, and transcripts-all of 
which can be searched using a single search statement. 
Business, trade and industry publications in the Dow Jones 
Publications Library, most available in full text, include leading 
trade journals on everything from advertising to wildlife, 
artificial intelligence to textiles, communications to medicine.  
Results of most searches are retrieved in five seconds or less. 
<li>Track News and Articles is a news tracking service that 
automatically alerts customers to news on companies, 
industries, and other subjects of interest throughout the day from 
more than 2,600 news, industry and trade publications. 
Subscribers to Dow Jones CustomClips&#174; can now select from 
more than 1,200 topics folders, preconfigured by Dow Jones 
online editors to track news relevant to a particular industry or 
discipline. The topics folders are an excellent way for any 
business person to investigate a new market. Subscribers can 
also create topics of their own in seconds by using keywords 
and search statements. Stories can be read on-screen or delivered 
to a subscriber via e-mail or fax.
<li>Company and Industry Data provides information on more 
than 10 million private and public companies from around the 
world. Customers can select from reports created by Dow Jones 
that present company information in varying degrees of detail. A 
new feature is the ability to screen for firms that match a 
subscriber's financial or industry criteria, then generate a 
comprehensive report. This is a powerful prospecting tool for 
salespeople, business planners, and investors.  
In addition, subscribers can choose from a number of other 
sources that have earned a reputation for providing accurate 
company and industry information, including  reports from 
Standard & Poor's, Dun & Bradstreet, Investext Analysts 
Reports, SEC filings, Disclosure, and Media General.  In-depth 
fundamentals include 10Ks, 10Qs, and annual reports. 
<li>Quotes and Market Data offers a comprehensive look at 
current, historical, and international funds, futures, commodities, 
and quotes. It provides essential information for anyone who 
monitors the markets to track competitors and 
investments. Every major exchange in the world is covered.  A 
new portfolio feature lets customers enter their holdings, check 
current pricing, and be alerted to news about their investments as 
it happens. 
<li>Career and Travel offers career management advice through 
The National Business Employment Weekly&#174; and detailed 
information about flights and lodging through the popular 
Official Airline Guide (OAG). This section also includes the 
Petersen's college selection service and a searchable 32,000-
article encyclopedia.
<p>
New pricing model
	Customer research revealed three basic requirements of 
pricing online news and information. "It had to be simple and 
predictable," says Ms. Ottman. "And searching had to be free." 
	Dow Jones is now the only online research service that does 
not charge for searching. The search and the resulting headlines are 
free. All other services charge a monthly fee, connect fee, or 
communications charges. 
	The new Dow Jones service features a transaction-based 
pricing model. "This type of structure makes it easy for customers 
to purchase just what they need when they need it," says Ms. 
Ottman. Individual articles in the Publications Library are priced at 
$2.95 per article. Experienced searchers who would rather view the 
lead paragraph or "keyword-in-context" paragraph pay only $2.00 
each. Citations are $1.00 each. There is a one-time start up fee of 
$29.95 associated with Dow Jones News/Retrieval, and after the 
first year, an annual fee. Company and Industry data provides 
company reports starting at $1.25 per report. Subscribers can screen 
to identify companies by 24 criteria, or search individual databases 
like Disclosure, where all reports on a given company are $19.95.  
Dow Jones also offers flat-fee pricing plans for enterprise accounts. 
	The new Dow Jones News/Retrieval will be available by 
early July 1996. For more information about Dow Jones 
News/Retrieval, contact  Dow Jones Customer Service at 
1-800-369-7466, extension 60, or access the company's home page 
at http://bis.dowjones.com.
	Dow Jones Business Information Services is the electronic 
publishing arm of Dow Jones & Company, Inc. that provides 
business and financial news and information products, including 
Dow Jones News/Retrieval and The Wall Street Journal Interactive 
Edition&#174;, to corporations, consumers and private investors through 
a variety of electronic media: computer, telephone, facsimile and 
radio.
<p>
	Dow Jones also publishes The Wall Street Journal&#174; and its 
international editions, Barron's&#174; magazine and other periodicals, 
electronic information services, including those of Dow Jones 
Telerate and Dow Jones Financial News Services, and the Ottaway 
group of community newspapers. Dow Jones also produces 
business television programming internationally and video news 
delivered to desktop computers. 
<center>###</center>
<p>
	CustomClips is a service of Dow Jones News/Retrieval. Dow Jones 
News/Retrieval, The Wall Street Journal, CustomClips, Barron's, World 
Equities Report, The Wall Street Journal Interactive Edition, and The 
National Business Employment Weekly are registered trademarks or service 
marks of Dow Jones & Company, Inc. All other products mentioned are the 
trademarks of their respective companies.


<hr>

PRODUCT BACKGROUNDER 


DOW JONES NEWS/RETRIEVAL&#174; SETS NEW STANDARD; 
MAKES IT EASY TO FIND FAST ANSWERS
TO THE TOUGHEST BUSINESS QUESTIONS

Dow Jones is launching a completely new version of Dow Jones 
News/Retrieval, with expanded content, a redesigned interface, and 
a customer-friendly pricing structure. Dow Jones News/Retrieval is a 
news and information service designed to answer the most pressing 
and in-depth questions asked by business people every day, with a 
couple of mouse clicks, in a massive compilation of more than 55 
million documents and information on more than 10 million 
companies. 

There's a revolution taking place in information retrieval. Dow 
Jones is leading the way with a new tool for the business 
community. Much like the desktop publishing revolution, which 
made it possible for anyone with a computer to create professional-
looking documents, the completely updated Dow Jones service 
makes it possible for business people to get fast, reliable answers to 
their toughest business questions. Information that was previously 
accessible only through services that were difficult to use and learn 
is now available to any business person with a computer and a 
modem.

What customers want 
The goal of the Dow Jones News/Retrieval editorial and product 
development team was to provide a service packed with the 
information sources business people have already come to depend 
upon-including the world's top newspapers, trade journals, 
newswires, newsletters, and financial reports--and then make that 
information easily accessible. This has been accomplished with the 
creation of the new Dow Jones News/Retrieval service.

"All day long, business people are asking questions," says Josie 
Ottman, director of product marketing for Dow Jones Business 
Information Services (BIS). "Should we purchase this company?  
Who runs the company? How are my investments doing? Has 
anyone else created a similar product? How do I find information on 
a competitor-even if it is a private company? All of these 
questions can be answered by the information contained in Dow 
Jones News/Retrieval. Our goal is to be the place where business 
people find the exact answer that they are looking for."

In order to accomplish this goal, Dow Jones spent the past year 
researching customer preferences and developing the product 
accordingly. The redesign of the Dow Jones service was led by a 
team of editors, business development professionals, designers, and 
product marketers who personally interviewed hundreds of business 
people in a broad range of industries. The team also analyzed usage 
patterns for Dow Jones News/Retrieval. 

"The message we got from customers and potential customers came 
through loud and clear," says Ms. Ottman. "They wanted a service 
with deep content, ease of use, and customer-friendly pricing. While 
other services can provide one or two of these components, only 
Dow Jones is now delivering the whole package, in a form that is 
equally attractive to professional searchers and any business person 
who needs information."

The new service: New interface, content, pricing
Dow Jones has designed a completely new interface for the service 
that rivals today's most popular online programs; has increased its 
content by more than 67% over the last year and has instituted 
transaction pricing that meets requirements for affordability and 
predictability.

Easy-to-Use Interface

One of the biggest barriers to using conventional online research 
services has been the complexity of the interface. Only the most 
highly trained professional searchers could competently navigate 
through the information and get satisfactory results from a search.

The most noticeable difference between the new Dow Jones service 
and its predecessors (and any other competing online research 
service on the market today) is the ease with which the service can 
be controlled. The new Dow Jones service is designed so that any  
business person, regardless of his or her previous experience using 
online research services, can be satisfied with the data received as 
the result of a search or in a clipping folder. 

At the same time, the searching tools employed by the Dow Jones 
service have been significantly improved, so the most experienced 
professional searcher can enter a complicated search statement and 
instantly see results. Those who want to improve their search 
statement skills are also assisted, with instructions and examples, in 
a comprehensive online context-sensitive help feature.

"Usability testing convinced us that valuable content had to be no 
more than two or three mouse clicks away," says Tim Andrews, 
editor-in-chief of online services for Dow Jones BIS. "We were 
determined to create a service that was completely intuitive. Those 
who have used pre-launch versions of the software are confirming 
that we have succeeded." When surveyed, 94% found it effortless to 
navigate through and control the software.

While online help and a printed manual will be available, every 
area of the service is accessible using the information presented on 
the screen. If someone should need more information, help and 
pricing information are a single mouse click away. 

Since all business people are only interested in answers to their 
specific questions, shortcuts to frequently used information or areas 
of the service--such as personalized news or stock portfolios-can 
be automatically created by the software and added to the toolbar at 
the top of the screen. Subscribers to Dow Jones News/Retrieval can 
build the toolbar buttons in a few seconds, using one of hundreds of 
icons provided for this purpose. The toolbars can be changed as 
subscriber needs change. 

 Another message derived from the research is that business people 
have become impatient with information that takes too long to 
access. "Business people want the facts, and they want them 
quickly," says Mr. Andrews. "While the overall Dow Jones display 
offers a logical, convenient environment, the news is accessed and 
displayed as quickly as possible, in text form. Subscribers also want 
to be able to have presentation-ready articles and reports. The new 
software provides attractive, executive-style print-outs with the 
click of a button."

One of the primary goals of the new software interface was to make 
the content obvious and accessible. Analysis of the usage patterns 
of existing Dow Jones News/Retrieval subscribers revealed that they 
typically use about 20% of the service's full capabilities. 
Subscribers start using the service to obtain a certain type of 
information, and then continue to use the service primarily to obtain 
that information, even though they might find items of interest in 
other areas of the service. 

When the new Dow Jones software was demonstrated to subscribers, 
even long-term subscribers were surprised at the range of 
information available. A common comment was, "I had no idea you 
had this-I could use this information." Dow Jones expects the 
newly designed interface to have a positive effect on usage. 

Unequaled Content 

Dow Jones News/Retrieval now gives subscribers access to more 
than 55 million documents contained in more than 3,000 sources in 
the Publications Library, plus hundreds of other databases and 
reports. Dow Jones is the only company offering the combination of 
the same-day full text of The Wall Street Journal&#174;,The New York 
Times, Los Angeles Times, and Financial Times. In fact, Dow Jones 
offers 48 of the top 50 newspapers, with more full-text newspapers 
available than on other comparable services.

"It isn't an accident that these publications have become a must-
read for business people all over the world," says Mr. Andrews. 
"They have recruited the best writers and columnists, who know 
how to get the real story on any subject, and they have an 
organizational infrastructure and culture that supports and 
encourages in-depth and insightful reporting. What we have done is 
make this knowledge and insight available to any person with a 
business question."

Dow Jones News/Retrieval is organized based on how business 
people ask questions or search for information. The sections are:
</blockquote>
<ul>
<li>Current News provides continuously updated daily and intraday 
news from the most respected national, international, regional, and 
local newswires, newspapers, and reports, including The Wall Street 
Journal, The New York Times, Los Angeles Times, Financial Times,  
press release wires, analysts' reports, economic wires, and 
international wires. Popular newswires on the service include 
exclusive Dow Jones newswires such as the Dow Jones News 
Service&#174;, Emerging Markets Report, European Corporate Report, 
and World Equities ReportSM. Other newswires include PR 
Newswire, Business Wire, Canada NewsWire, and Canadian 
Corporate News. More than 9,000 new items are added to the 
service from newswires and news publications every day. In 
addition, continuously updated news on six industries is selected by 
Dow Jones editors from the thousands of items flowing into the 
newsroom.

Subscribers have only to click on a button to see the top stories of 
the day displayed on their screen, presented  in a convenient, easy-
to-scan list. This section features a "This Just In&#174;" section for the 
latest-breaking news from around the world, prioritized, indexed, 
rewritten and/or edited by Dow Jones editors for people who need a 
quick read on the day's most important news. Choices in this section 
include Front Page news, Markets news, and news by Industry 
(Financial Services, Telecommunications, Healthcare, Computers, 
Energy, and Media). Other areas in this section are World-Wide 
News, Sports, and Weather. 

"Inclusion of press release wires give our subscribers two sides to 
every story," says Mr. Andrews. "They can see a company's raw 
spin on its information and compare that information with the 
amount and tone of the coverage received. Subscribers can see the 
difference between a company's marketing goals and its resulting 
success. Company releases also act as an early-alert service for 
investors and salespeople."

<li>Search News and Articles offers one-button access to the Dow 
Jones Publications Library containing more than 55 million 
documents from more than 3,000 sources, including newspapers, 
trade journals, newswires, newsletters, and transcripts-all of  
which can be searched using a single search statement. Results of 
most searches are retrieved in five seconds or less.

The Search News and Articles section is divided into three tabbed 
sections: Define Search, Select Sources, and View Search Results. 
To search for news and information on a particular topic, a 
subscriber simply enters a keyword or search statement, then selects 
the sources desired from a scrolling list. A range of dates or specific 
date can be entered.

The search-building folder is intuitive enough for the first-timer to 
navigate and sophisticated enough for the experienced searcher. 
Examples of searches are provided, and the tools to refine searches 
are a mouse-click away. Subscribers don't have to memorize 
commands, indexing terms, or connectors, since the software 
includes them in easy-to-find buttons and drop-down boxes. Search 
statements can be constructed offline; the software will 
automatically connect to the service when the "run search" button 
is clicked. Searches can be automatically saved, added, deleted, or 
changed for use in future sessions.

All text documents are searchable in a single search, or subscribers 
can choose from the source grouping that is best for them: Type, 
Industry, Region, or Title. Sources can be added or deleted. Source 
selections are saved from search to search and session to session, so 
subscribers don't have to rebuild source lists unless they want to.

The View Search Results tab window shows the list of headlines, 
displayed in a convenient "check-box" format. Articles can be 
saved individually or in groups. To view articles, subscribers simply 
click on the headline, and the article is displayed. The articles can 
be displayed in four different ways: Full Articles, Headline Only, 
Lead Paragraph Only, or Headline & Lead Paragraph. 

Under the new pricing plan, there is no charge for searching through 
the data and for viewing headlines. All articles can be easily printed 
and/or saved to disk. 

A wide range of search features can be tailored to meet subscriber 
requirements. "The most popular settings are provided as 'intelligent 
defaults,' which were created based on our analysis and customer 
interviews," says Mr. Andrews.

<li>Track News and Articles features the news tracking service, Dow 
Jones CustomClips&#174;, which automatically alerts subscribers to 
news on companies, industries, and other subjects of interest. 
"Unlike many other services now available, the news we deliver is 
updated continuously during the day," says Mr. Andrews. 

CustomClips is driven by a powerful clipping engine, which scans 
continuously across more than 2,600 news, industry and trade 
publications, including the top newspapers, wires, and industry 
publications. News can be delivered online or via e-mail or fax. All 
sources can be viewed by type (major business publications, 
newswires, etc.), by industry grouping, by geographical region, and 
alphabetically by title. The sources can be searched using 
keywords, industry topics, or company names. 

Subscribers to Dow Jones CustomClips can now select from more 
than 1,200 topics folders, preconfigured by Dow Jones online editors 
to track news relevant to a particular industry or discipline. The 
topics folders are an excellent way for any business person to 
investigate a new market. Subscribers can also create topics of their 
own in seconds by using keywords and search statements.

The Track News and Articles section is as easy to use as the Search 
News and Articles section, since its layout and navigational steps 
are very similar. Subscribers use the Set Up Folders, Select 
Sources, and View Results windows to set up their clipping folders 
and view results. 

For convenience, clipping folders are displayed as menu bar 
choices. Each time subscriber connects to the Dow Jones service, 
they are alerted to all news stories that have been retrieved and 
deposited into their clipping folders.

Tony Rodriquez, managing partner, Risk-Based Solutions says, "I 
go online every morning...with Dow Jones CustomClips, I get 
information on what I call a 'need-to-know-first' basis. CustomClips 
leads me to the right prospects. I can pick up the phone and make a 
call with total confidence."
 
<li>Company and Industry Data provides information on more than 10 
million private and public companies from around the world. 
Subscribers can select from reports created by Dow Jones that 
present company information in varying degrees of detail. "Our 
redesigned Company and Industry area includes the unique ability 
to screen for firms that match a subscriber's criteria-for example, 
the subscriber could be looking for companies in a specific industry, 
with a certain P/E ratio and dividend yield-and then generate a 
comprehensive report immediately that can be read online or 
printed out for review later," says Mr. Andrews. 

Reports are available through Standard & Poor's, Dun & Bradstreet, 
Investext Analysts Reports, SEC filings, Disclosure, as well as  
Media General, Zacks Corporate Earnings Estimates, Corporate 
Canada Online, Nikkei Telecom Japan News & Retrieval, 
Worldwide Corporate Reports, and the Saudi 1000. In-depth 
fundamentals include 10Ks, 10Qs, and annual reports. Insider
transactions on over 10,000 public companies are included. 

This area of the service is a powerful prospecting tool for 
salespeople, business planners, and investors. Information in this 
area can be searched by topic, keywords, and company names. 
Once a company has been identified, the subscriber can see a 
company snapshot, a profile, or a company report. 

<li> Quotes and Market Data includes current, historical, international, 
futures, and index quotes. It offers a comprehensive look at markets 
for anyone who needs to keep track of investments, industries, or 
competitors. 

The three tabbed sections are: Set Up Portfolio, View Portfolio, and 
Quotes and Market Data. An expanded portfolio feature allows 
subscribers to monitor their investments. They can enter their 
holdings, check current pricing, and be alerted to news as it 
happens. They can also tap into technical and fundamental options, 
or perform original analysis using quotes, ratios, and other market data.

Like clipping folders, Portfolios can be named and accessed through 
a toolbar icon. The portfolio can be set up using company names or 
symbols. Mutual funds can also be tracked. No other online 
information service so smoothly combines investments and the news 
that drives markets. 

In addition to monitoring specific news and quotes pertaining to an 
investment, business people also need to track market trends and 
see what the most influential analysts are saying about the market. 
They can do this by clicking on the Quotes and Market Data tab. 
Current quotes on equities, options, bonds, mutual funds and 
treasury issues are available, as well as real-time quotes listed on 
major exchanges, current and historical quotes, and historical Dow 
Jones averages. This section also contains Tradeline Global 
Security Pricing and Analysis, Innovest Technical Analysis Reports, 
the Mutual Funds Performance Report, the MMS Weekly Surveys 
of economists, traders, and money managers, and transcripts from 
the popular Wall $treet Week television show. 

<li> Career and Travel offers career management advice from The 
National Business Employment Weekly&#174; and detailed information 
about flights and lodging through the popular Official Airline Guide 
(OAG). This section also includes the Petersen's college selection 
service and a searchable 32,000-article encyclopedia. 
</ul>
<blockquote>
New, Customer-Friendly Pricing

Customer research revealed three basic requirements of pricing 
online news and information. "It has to be simple, and predictable," 
says Ms. Ottman. "And searching should be free." 

Dow Jones is the only online business research service that does not 
charge for searching. All other services charge a monthly fee, 
connect or communications charges, or searching charges. 

The new Dow Jones service features a transaction-based pricing 
model. "This type of structure makes it easy for subscribers to 
purchase just what they need, when they need it," says Ms. Ottman. 
Individual articles in the Publications Library are priced at $2.95 per 
article. Experienced searchers who would rather view the lead 
paragraph or "keyword-in-context" paragraph pay $2.00 each. 
Citations are $1.00 each. Dow Jones CustomClip folders are $19.95 
per month. There is a one-time start up fee ($29.95) associated with 
Dow Jones News/Retrieval, and after the first year, an annual fee of 
$19.95. 

Company and Industry data provides company reports starting at 
$1.25 per report. Subscribers can screen to identify companies by 24 
criteria, or search individual databases like Disclosure, where all 
reports on a given company are $19.95.  

Dow Jones also offers flat-fee enterprise site license pricing plans. 
"This is the best route for our larger corporate customers, who 
appreciate the budgetability of a flat-fee plan and want to make 
Dow Jones research tools available to everyone in their organization 
or department," says Ms. Ottman. 

The Dow Jones Difference

Dow Jones is the world's premier publisher of business news and 
information in every form of media. The company has pioneered 
new information technologies throughout its history.

In the late 19th century, it was Dow Jones that developed the 
electric ticker to deliver reports from the Dow Jones News Service. 
In the 1960s, it was Dow Jones that first began with microwave, and 
then satellite delivery of newspaper pages to multiple production 
sites. By the 1970s, long before electronic publishing was 
fashionable, Dow Jones began to build a successful database 
publishing business with Dow Jones News/Retrieval. These days, 
including the real-time worldwide information flows of Dow Jones 
Telerate, almost 50% of Dow Jones' total business is in various 
forms of electronic publishing. Dow Jones delivers business news in 
every form, time, and place: newspapers, magazines, radio, 
television, wire services, databases, CD-ROMs, personal 
computers, workstations, and digital feeds.

Dow Jones has been providing information to businesses and 
investors for over 100 years. This experience is reflected in every 
decision made about the design of its services and the information 
provided. "But it's not just the experience that matters," says Mr. 
Andrews. "Those just entering the online business market have 
many lessons to learn.

"They will experiment, and many of those experiments will fail. We 
have seen what works and what doesn't, through personal 
experience, and we have made adjustments. The lessons we have 
learned about what business people want is so deeply ingrained that 
it is part of our corporate culture. It drives everything we do, from 
the creation of our services to the selection of news and information 
contained inside."

Ms. Ottman concurs: "The bottom line is that business people want 
answers to their questions, quickly and efficiently. They do not want 
to be teased with superficial content or irritated by time-wasters 
such as hard-to-find and poorly organized data."

"The new release of Dow Jones News/Retrieval is backed by one of 
the largest, most respected editorial organizations in the world," 
says Mr. Andrews. "Dow Jones has over 1,000 editors and reporters 
working on stories as they unfold. Here in the Business Information 
Services division, a dedicated editorial team works on prioritizing, 
indexing, rewriting, and editing the stories that are incorporated into 
News/Retrieval. We like to think of these editors as our 
'intelligence engine,' working 24 hours a day on behalf of our 
subscribers. The new Dow Jones News/Retrieval puts the power of 
this intelligence engine into the hands of anyone with a computer, a 
modem, and a business question."
<center>
###
</center>
CustomClips is a service of Dow Jones News/Retrieval. Dow Jones 
News/Retrieval, The Wall Street Journal, CustomClips, Dow Jones 
News Service, and World Equities Report are registered trademarks 
or service marks of Dow Jones & Company, Inc. All other products 
mentioned are the trademarks of their respective companies.




</pre>

<hr>

<a href="../latest.html">Back to the main Dow Jones in the News page.</a>
<hr>
<H4>We welcome feedback or questions about the <A 
HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A 
HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4>





</blockquote>

<pre>


</pre>
 
				
				<center>
					<a href="../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../bizpubs/index.html">Newspapers</a> |
					<a href="../clipping/index.html">Alert Services</a> |
					<a href="../online-lib/index.html">Research</a>  |
					<a href="../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../index.html">Home</a> 

				</font>
				
				
				</center>
				

</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-86</DOCNO>
<DOCOLDNO>IA028-000307-B014-76</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/releas18.html 143.131.194.4 19970114051634 text/html 4999
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:20:46 GMT
Last-modified: Thursday, 23-May-96 18:34:33 GMT
Content-length: 4808
Content-type: text/html
</DOCHDR>
<html>
<head><title>PR Pages</title></head>


<body  background="../images/bgddj.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td>
<td>
<p>

<br>

<blockquote>

<center>

MEDIA ADVISORY<p>

<b>DOW JONES' MASSIVE ONLINE BUSINESS RESOURCE DOUBLES INTERNATIONAL PUBLICATIONS OFFERING WITH QUEST ECONOMICS DATABASE 

<p>Easy Access To Internationally Recognized Quest Economic Database, Provides In-Depth Global Economic Material Via Dow Jones News/Retrieval
</b></center>

<pre>
PRINCETON, N.J., May 7, 1996Dow Jones 
News/Retrieval, the leading online business resource, 
has expanded its coverage of global economic information 
with the addition of the internationally acclaimed Quest 
Economics Database.  Quest is a compilation of more than 
1,000 in-depth economic reports on more than 240 
countries and geographic regions.
	"This is another step in our commitment to add 
new, valuable content to Dow Jones News/Retrieval," 
said Josephine K. Ottman, director of product marketing, 
Dow Jones Business Information Services.  "Tracking 
economic trends and reviewing analyses and forecasts on 
a global level are a substantial part of many of our 
subscribers' business days.  The information from Quest, 
combined with the current economic selections on Dow 
Jones, will be key to our subscribers remaining 
competitive in a highly volatile global marketplace."
	The Quest Economics Database features 90 respected 
sources of economic forecasts and country reports written 
by top international banking institutions.  In addition, 
Quest includes reviews and surveys from the economic 
research departments of banks based in the United 
Kingdom and Europe, financial institutions, government 
agencies and economic research organizations.  
	Quest complements the current selection of 
economic sources on Dow Jones, providing a unique 
international perspective on economic trends that may 
not be available in most U.S.-based publications.  It also 
provides in-depth information that complements other 
international publications also available on Dow Jones, 
including The Economist and Financial Times. Economic 
reports in Quest are divided into sections; subscribers can 
retrieve pertinent parts or full documents. 
	Dow Jones News/Retrieval is the leading provider 
of online business and financial information, including 
more than 3,000 text publications and more than 400 other 
sources of business and financial data.  It is the only 
online service to offer same-day access to the full text of 
The Wall Street Journal, The New York Times, Los 
Angeles Times  and Financial Times.  In all, Dow Jones 
News/Retrieval makes available a total of 48 of the top 50 
U.S. newspapers.
	Dow Jones Business Information Services is the 
electronic publishing arm of Dow Jones & Company, Inc. 
that provides business and financial news and 
information products to corporations and consumers 
through a variety of electronic media: computer, 
telephone, facsimile and radio.
	Dow Jones also publishes The Wall Street Journal 
and its international editions, Barron's magazine and 
other periodicals, electronic business information 
services, including those of Dow Jones Telerate and Dow 
Jones Financial News Service, and the Ottaway group of 
community newspapers. Dow Jones produces business 
television programming internationally and video news 
delivered to desktop computers.
	More information on Dow Jones and its products 
can be found on the Internet's World Wide Web at 
http://bis.dowjones.com. 
<center>###</center>
Contact:
Maggie Landis				Michael Bayer, Alys Reynders
Dow Jones BIS				Miller/Shandwick Technologies
609-520-4679				617-536-0470
maggie.landis@cor.dowjones.com	mbayer@millercom.com

</pre>

<hr>

<a href="../latest.html">Back to the main Dow Jones in the News page.</a>
<hr>
<H4>We welcome feedback or questions about the <A 
HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A 
HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4>





</blockquote>

<pre>


</pre>
 
				
				<center>
					<a href="../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../bizpubs/index.html">Newspapers</a> |
					<a href="../clipping/index.html">Alert Services</a> |
					<a href="../online-lib/index.html">Research</a>  |
					<a href="../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../index.html">Home</a> 

				</font>
				
				
				</center>
				

</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-87</DOCNO>
<DOCOLDNO>IA028-000307-B014-107</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/releas17.html 143.131.194.4 19970114051704 text/html 4201
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:21:13 GMT
Last-modified: Thursday, 23-May-96 18:34:33 GMT
Content-length: 4010
Content-type: text/html
</DOCHDR>
<html>
<head><title>PR Pages</title></head>


<body  background="../images/bgddj.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td>
<td>
<p>

<br>

<blockquote>

<center>

MEDIA ADVISORY<p>

<b>THE WALL STREET JOURNAL INTERACTIVE EDITION'S FIRST WEEK BRINGS STRONG READER INTEREST, HEAVY TRAFFIC

<p>Expansion of Availability Already in Place With More to Come
</b></center>

<pre>
Princeton, N.J., May 6, 1996The Wall Street Journal 
Interactive Edition's first week of availability on the 
World Wide Web drew unprecedented interest, tripling 
the number of expected registrations.
	The Wall Street Journal Interactive Edition is the 
first complete interactive resource for up-to-the-minute 
business news, analysis and financial information, 
produced by a dedicated 24-hour staff at The Wall Street 
Journal newsroom.  The Interactive Edition can be found 
at http://wsj.com.
	Due to the heavy demand for The Journal's 
expanded news effort, some readers found access to the 
Interactive Edition difficult.  In response, the Interactive 
Edition has already doubled its original communications 
capability and added new server hardware, and still 
further improvements in availability will be evident in 
the next week.  Access to the Interactive Edition remains 
free until July 31 for anyone registering for access before 
May 31.  Nearly 400,000 readers are currently registered.
	"We're delighted at the favorable reaction so far to 
what we feel is the leading business news site on the 
Internet," said Tom Baker, business director, The Wall 
Street Journal Interactive Edition.  "We're working day 
and night to improve access so that all interested readers 
can come into the publication and see for themselves."
	At the same time, the Interactive Edition 
announced three new advertisersBarclays Bank, T. Rowe 
Price and Smith Barneyjoining the two dozen companies 
already announced at the April 29 launch.  
	Dow Jones Business Information Services, the 
electronic publishing arm of Dow Jones & Company, Inc., 
provides business and financial news and information 
products including The Wall Street Journal Interactive 
Edition and Dow Jones News/Retrieval to corporations, 
consumers and private investors through a variety of 
electronic media: computer, telephone, facsimile and 
radio. 
	Dow Jones also publishes The Wall Street Journal 
and its international editions, Barron's magazine and 
other periodicals, electronic information services, 
including those of Dow Jones Telerate and Dow Jones 
Financial News Services, and the Ottaway group of 
community newspapers. Dow Jones also produces 
business television programming internationally and 
video news delivered to desktop computers.  
<center>###</center>
Contact:
Maggie Landis				Michael Bayer, Alys Reynders
Dow Jones BIS				Miller/Shandwick Technologies
609-520-4679				617-536-0470
maggie.landis@cor.dowjones.com	mbayer@millercom.com

</pre>

<hr>

<a href="../latest.html">Back to the main Dow Jones in the News page.</a>
<hr>
<H4>We welcome feedback or questions about the <A 
HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A 
HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4>





</blockquote>

<pre>


</pre>
 
				
				<center>
					<a href="../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../bizpubs/index.html">Newspapers</a> |
					<a href="../clipping/index.html">Alert Services</a> |
					<a href="../online-lib/index.html">Research</a>  |
					<a href="../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../index.html">Home</a> 

				</font>
				
				
				</center>
				

</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-88</DOCNO>
<DOCOLDNO>IA028-000307-B014-143</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/releas16.html 143.131.194.4 19970114051719 text/html 28560
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:21:28 GMT
Last-modified: Thursday, 23-May-96 18:34:32 GMT
Content-length: 28368
Content-type: text/html
</DOCHDR>
<html>
<head><title>PR Pages</title></head>


<body  background="../images/bgddj.gif">

<TABLE width=400 BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td>
<td>
<p>

<br>

<blockquote>

<center>
MEDIA ADVISORY<p>
<b>The Wall Street Journal Interactive Edition Debuts Today 
on the World Wide Web
<p>World's Leading Business Publication Seizes Leadership in Web Publishing; 
Among First to Seek Subscription Revenues, Offer Personalized News
</b></center>
<pre>


For Immediate Release

The Wall Street Journal Interactive Edition Debuts Today on the 
World Wide Web

World's Leading Business Publication Seizes Leadership in Web 
Publishing; Among First to Seek Subscription Revenues, Offer 
Personalized News

NEW YORK, N.Y., April 29, 1996 -- The Wall Street Journal 
today launched The Wall Street Journal Interactive Edition, the 
industry's first complete interactive resource for up-to-the-minute 
business news, analysis and financial information.  The Wall Street 
Journal Interactive Edition is available on the World Wide Web at 
http://wsj.com.

"Today's launch of the Interactive Edition represents a commitment to 
interactive publishing that is unmatched in the industry," said Peter R. 
Kann, chairman of Dow Jones & Company, Inc. and publisher of 
The Wall Street Journal.  "Our goal is to serve a global electronic 
business audience as broad as The Wall Street Journal's print 
readership.  With the Interactive Edition, we feel we've established a 
new market standard for the dynamic delivery of business and 
financial news and information to business professionals." 

Produced by a dedicated 24-hour staff of more than 30 editors and 
other news professionals in The Journal's New York newsroom, the 
Interactive Edition provides continuously updated coverage of the full 
spectrum of business, including corporate news, financial markets, 
personal finance, technology, law and marketing.  In addition to the 
stories from the daily print editions of The Journal, the Interactive 
Edition adds its own non-stop, breaking coverage of news from more 
than 1,000 Dow Jones reporters from around the world and enhances 
stories with in-depth background information and supporting 
documents, resulting in the Web's most robust site for business.

"We know that The Wall Street Journal name means integrity and 
reliability to readers throughout the world," said Paul Steiger, 
managing editor of The Wall Street Journal.  "That same high 
standard of journalistic excellence is at the core of the Interactive 
Edition."

The Interactive Edition builds on the success of Money & Investing 
Update, a version of the product introduced in July 1995.  Money & 
Investing Update, for the first time, offered select front page stories 
and the third section of The Journal to readers via the Web, and was 
continuously updated throughout the day.  Available free of charge, 
the Update quickly became one of the Web's most popular sites for 
business, with more than 350,000 registered subscribers and an 
average of seven million hits per week.

Among First in Web Market With Subscription Revenue Model

The Interactive Edition is among the industry's first Web publishing 
efforts to seek subscription revenue from readers.  While readers who 
register before May 31 will have free access through July 31, regular 
subscription rates thereafter will be $49 annually, with subscribers to 
any edition of the print Wall Street Journal paying a lower rate of $29 
annually.

"With our interactive publishing efforts so far, we've proven that it's 
possible to expand the audience for Wall Street Journal content," said 
Neil Budde, editor of the Interactive Edition.  "With the power of The 
Wall Street Journal name behind it, we trust that serious business 
professionals in every part of the world will find reason to make the 
Interactive Edition part of their daily business lives."

Dow Jones' respected editorial judgment and unmatched market 
analysis give readers a strategic business advantage.  Unlike many 
other on-line newspapers, where updates are pulled unedited from 
third-party wire services, Interactive Edition editors work around the 
clock to identify and tailor the most relevant and business-critical 
information from their own reporters around the world.  This 
provides instant access to news from European and Asian markets 
and early availability of the next day's stories from The Journal's print 
edition.  The Interactive Edition also includes new sections devoted to 
continuously updated sports and weather, news not traditionally 
included in the print edition.

New Tools for the Business Community

In addition to its expanded depth of business coverage, the Interactive 
Edition offers a new Personal Journal component to allow readers to 
manage their time more efficiently by tracking only the news that is 
most important to them.  With Personal Journal, subscribers can 
design their own personal view of the day's news, and can monitor 
their personalized investment portfolio with the click of a button.  

The Interactive Edition also offers a wide array of integrated resources 
to provide perspective and background on the news.  Key among 
these are Company Briefing Books, which deliver comprehensive, 
graphical reports on more than 9,000 public companies around the 
world.  As company names appear within text, a click of a button will 
access extensive corporate news and financial information, including a 
one-year stock performance chart. 

Readers of the Interactive Edition can search a fourteen-day full-text 
archive of The Journal.  This archive will be significantly expanded by 
the end of 1996 to include access to the advanced research capabilities 
of Dow Jones News/Retrieval, one of the world's largest on-line 
sources of business information.

"Our readers recognize that the Interactive Edition is not simply an 
on-line newspaper," said Tom Baker, business director, The Wall 
Street Journal Interactive Edition.  "The interactive newsroom will 
never be closed, so our readers worldwide can be assured that their 
news and analysis is the most current available.  In addition, the 
Interactive Edition's unmatched depth of content, interactive research 
features, and personalized view of the news all provide a strategic 
business advantage to a new breed of business reader."

A Proven Venue for the New Age of Advertising

"While the Internet has exploded in so many directions, it's difficult 
for on-line advertisers to reach those users with the most critical 
business interests," said Stephanie Miller, advertising manager, The 
Wall Street Journal Interactive Edition.  "The market prominence and 
editorial personality of The Wall Street Journal deliver the credibility 
and comfort that advertisers need. Our readers are serious about 
business, so they want more from an interactive newspaper than just 
headlines and news briefs.  No matter what the medium, our brand 
name is the most powerful in business news, and that gives our 
advertisers an audience with more loyalty and purchasing influence 
than almost any other site on the Web today."  

The Interactive Edition is supported by more than 20 charter 
advertisers.  The growing list includes Bell Atlantic, Charles Schwab 
& Co. Inc., Corestates Bank, The Dreyfus Corp., EDS, Fidelity 
Investments, General Motors' Cadillac Motor Car Division, Hewlett 
Packard, Lexus, Lombard Institutional Brokerage Inc., Nortel, Nynex 
Interactive Yellow Pages, Oracle Corp., Sun Microsystems, Toyota, 
Vanguard Corp. and Wells Fargo.

The Interactive Edition is published using server technologies from 
Netscape Communications Corp., EDS, IDD Information Services, 
Verity, Inc., and Dow Jones itself.  News content for the Interactive 
Edition is supplemented by The Journal's print resources, Dow Jones 
News Service, and frequently with audio and video enhancements 
from the Dow Jones Investor Network, Dow Jones Radio report, 
and other services.

About Dow Jones

The Interactive Edition is published by The Wall Street Journal and 
Dow Jones Business Information Services, Princeton, N.J., the 
electronic publishing arm of Dow Jones & Company, Inc. that 
provides business and financial news and information products, 
including Dow Jones News/Retrieval, to corporations, consumers and 
private investors through a variety of electronic media: computer, 
telephone, facsimile and radio.  

Dow Jones & Company, Inc. also publishes the print version of The 
Wall Street Journal and its international editions, Barron's magazine 
and other periodicals, electronic information services, including those 
of Dow Jones Telerate and Dow Jones Financial News Services, and 
the Ottaway group of community newspapers.  Dow Jones also 
produces business television programming internationally and video 
news delivered to desktop computers.  Additional information on 
Dow Jones and its products can be found at http://bis.dowjones.com.

#   #   #   # 

The Wall Street Journal, Barron's, The Wall Street Journal Interactive 
Edition, Dow Jones News/Retrieval, Dow Jones News Service, and 
Dow Jones Investor Network are registered marks of Dow Jones & 
Company, Inc. 

Press contacts:

Stephanie Graves/Michael Bayer	Maggie Landis, (609) 520-
4679Miller/Shandwick Technologies		Paul Bell, (609) 520-
4108(617) 536-0470				Dow Jones BIS 
sgraves@miller.shandwick.com 
	maggie.landis@cor.dowjones.commbayer@miller.shandwick.
com   	paul.bell@cor.dowjones.com      

#   #   #   # 

Product Backgrounder

	Dow Jones & Company has always led the market for 
electronic media.  In the late nineteenth century, Dow Jones developed 
the world's first electric ticker to deliver reports from Dow Jones 
News Service.  In the 1970's, Dow Jones launched one of the 
industry's first successful database publishing efforts, called Dow 
Jones News/Retrieval.  And in 1996, The Wall Street Journal 
Interactive Edition debuted on the World Wide Web, heralding a new 
age in the delivery of time-critical business news and analysis to 
readers around the globe.  	The Wall Street Journal Interactive 
Edition (the Interactive Edition) has become the nation's first business 
newspaper to deliver continuously updated news and editorial via the 
Web, building upon more than a century of leadership in business 
news reporting and analysis.  The product was developed to provide 
several distinct advantages to customers searching for a next-
generation business news solution:  more robust data than a print 
newspaper; a more integrated global perspective; access to highly 
focused, personalized news and investment data; and most 
importantly, a serious business tool that can actually provide a 
competitive advantage for readers by providing critical business 
information. 

Evolution of Interactive News	The market for electronic news and 
information exploded in the 1990's as a result of the open computing 
movement.  Commercial service providers like America Online, 
CompuServe, and Prodigy dominated the market by delivering 
content from third party print sources, and later the World Wide Web 
created a new open communications medium that sent countless 
publishers scrambling to develop Web sites that would deliver their 
proprietary content to the fast- expanding electronic community.
	As this market evolved, however, Dow Jones and The Wall 
Street Journal identified a new opportunity:  to be the provider of 
useful on-line news for serious business professionals and investors, 
easily accessible via the Web.  The company targeted this void as a 
strategic business opportunity, and sought to develop the first broad-
scale electronic business product that would deliver The Journal's 
superior editorial perspective and content to a highly interactive 
environment.  While the audience for an interactive edition would 
differ from The Journal's traditional readership, Dow Jones 
maintained its belief that editorial judgment and integrity, not just 
technology or massive quantities of content, would be the key to 
success on-line, just as it always has been in the print world.

Measuring the News Market	One of the first challenges facing the 
Interactive Edition team was to conceptualize an interactive newspaper 
that would reflect the unmatched journalistic standards of The Wall 
Street Journal for an electronic audience.  The Interactive Edition 
development team, consisting of Neil Budde, editor, Tom Baker, 
business director, and Susan Cayne, technical director, conducted 
intensive market research and identified the key attributes that would 
make up the ideal interactive business news product:

* Timeliness -- up-to-the-minute coverage of global business news 24 
hours a day, seven days a week; * Personalization -- customization of 
news and investment data for personal relevance all in one place;* 
Natural Interface -- familiar newspaper format, intuitive navigation;* 
Trusted Quality -- news and analysis from the world's most credible 
business news publisher;* Robust Content -- In-depth analysis, 
archives, content not available in the print edition

	As a result of these findings, the Interactive Edition team 
naturally concluded that the Interactive staff should be seamlessly 
integrated with The Journal's print edition staff, not only 
geographically, but operationally as well.  Leveraging the editorial 
resources and procedures of both the print and electronic editions 
would ensure the highest quality Wall Street Journal content 
regardless of the medium.

Designing a News Delivery Solution	At the time the team members 
were developing the Interactive Edition, they were faced with several 
delivery options.  They could have designed a proprietary client 
software, or have "rented space" from a third-party service provider.  
As development of the Interactive Edition proceeded, however, it 
became obvious that the newborn World Wide Web would provide 
the open, transparent infrastructure upon which Dow Jones could 
develop a uniform client/server solution that could be accessed easily 
from all corners of the globe.  Although the team still developed a 
variety of proprietary publishing applications, the straightforward 
Web infrastructure allowed them to focus their efforts more seriously 
on the product's content and value to its readers.  

The Interactive Edition uses Netscape Communications Publishing 
System to provide basic server functions and to manage customer 
access and security.  The site also uses custom technology developed 
exclusively for the Interactive Edition both internally and with a 
variety of partners, including editing systems from EDS, financial 
data tools and servers from IDD Information Systems, and text 
searching from Verity, Inc.  The site itself is located at Dow Jones 
Business Information Systems headquarters near Princeton, N.J., 
although news and editorial operations take place in The Wall Street 
Journal's New York newsroom.

Launching the First Phase

An intense development schedule culminated in "phase one" of The 
Wall Street Journal Interactive Edition, called Money & Investing 
Update (the Update).  This interactive version of The Wall Street 
Journal's third section, Money & Investing, was launched in July 
1995 as a beta product.  For the first time on the Web, the Update 
delivered continuously updated business news from around the world 
in a comfortable, intuitive Web environment.

In September 1995, the Interactive Edition team added a new level of 
analysis and research capabilities to the Update through Briefing 
Books, hyperlinks that furnish detailed corporate and financial 
information, including one-year stock performance graphs, on any of 
more than 9,000 public companies mentioned within articles.  By 
enabling readers to "dig deeper" behind the story, the Update's 
Briefing Books added another business advantage to the subscriber's 
experience. 

In order to attract business executives who may not be familiar with 
the World Wide Web, Dow Jones introduced Netscape Navigator for 
The Wall Street Journal in November 1995.  Developed along with 
Internet leader Netscape Communications, the product featured a 
custom interface, instant access to the Update site and automatic 
registration of the Netscape software and third-party Internet access 
account.  This provided a one-stop solution for Internet access and 
navigation while optimizing the business relevance of the Internet for 
busy professionals. 

With a staff of 30 full-time dedicated editors, the Update quickly 
became the Web's most popular business site.  Cited by Netscape's 
Marc Andreessen as one of his favorite spots on the Web, the Update 
registered nearly 350,000 subscribers in the first nine months of 
operation and generated more than seven million site visits per 
business week.  At the time of the Interactive Edition launch, 
subscriber demographics were measured as follows:

* Median subscriber age was 38;* 90 percent of subscribers were 
male;* 90 percent of readers resided in the US;* Top-ranking 
professions were executive management, finance, engineering and 
consultants/analysts;* 45 percent of subscribers were also regular 
readers of the print edition;* 47 percent of subscribers had made ten 
or more investment transactions in the past year; four percent had 
made 100 or more.

A Next-Generation Advertising Venue

The Update earned its reputation as an attractive advertising venue for 
organizations targeting serious business readers, combining 
impressive traffic figures and audience demographics with the most 
powerful brand name in business news.  The Update was supported 
by 13 charter advertisers, including Cadillac Motor Car Division, The 
Dreyfus Corp., EDS, Fidelity Investments, Hewlett Packard, 
Lombard Institutional Brokerage Inc., Nortel, Oracle Corp., Charles 
Schwab & Co. Inc., Sun Microsystems, Tandy Corp., Toyota, and 
Wells Fargo.	The market prominence and editorial credibility of The 
Wall Street Journal supplied the comfort level that advertisers needed.  
In addition, the timeliness of news -- stories updated minute by 
minute -- ensured multiple daily hits and a higher number of 
advertising impressions.  Similarly, the Briefing Books research 
information attracted professionals interested in deeper analysis,  
further expanding the reader base and advertising forum. 

The Update's charter advertisers measured their success through 
reach, frequency and reader visits to their own Web sites.  The 
Interactive Edition provides third party verification of return rate data, 
measuring the ratio between readers simply viewing an ad and 
actually clicking to visit that advertiser's site.  Using this method, the 
average rate of return for charter advertisers was nearly five percent.  

The Final Product

After enjoying the market's overwhelming response to the Update, 
Dow Jones launched the full-text Wall Street Journal Interactive 
Edition in April 1996.  The Interactive Edition provides subscribers 
with an interactive version of The Wall Street Journal print edition, 
extending The Update's coverage beyond the markets to include 
politics, economics, technology news, marketing, updated sports and 
weather reports, and an expanded editorial page.  The Interactive 
Edition also offers a complete archive of the past 14 days of The 
Journal.  With the Interactive Edition, readers can truly read their 
Journal in a whole new way; they can see stories as they unfold 
throughout the day, and can dig deeper into those stories to understand 
the broader market context.

The Interactive Edition also includes the new Personal Journal section, 
which lets subscribers create their own personal view of the day's top 
business stories.  With Personal Journal, subscribers can get faster 
access to the stories and columns from The Wall Street Journal that 
are most important to them.  The Personal Journal feature also allows 
readers to build and track a customized investment portfolio.	The 
Interactive Edition team's first concern continues to be the quality and 
value of its content, aimed at giving readers a competitive advantage 
through time-critical business news and analysis.  The Interactive 
Edition provides this advantage in three ways:

Depth of Data
	News, analysis and editorial perspective from the world's 
premier business news source
	Briefing Book analysis on 9,000 companies  
	Archives of the past two weeks of Wall Street Journal news 
and editorialValue of Data
	News updates around the clock and from around the globe - 
The Interactive Edition readers get the full story first
	Personal Journal customized news and investment portfolio 
Ease of Use
	Transparent Web access from anywhere in the world 
	Two-way electronic exchange with staff editors
	Custom browser and one-step Internet access package 
available

Business Model Based on Quality 

The Interactive Edition represents a landmark for Web commerce.  
With a unique subscription model, The Interactive Edition has 
become one of the first newspapers to seek subscription revenues 
from an interactive edition.  Charter subscribers are offered three 
months of free access.  Annual subscriptions run $29 for print edition 
subscribers and $49 for non-print subscribers.  There is a two-week 
trial period for all new subscribers.  

This model represents Dow Jones' commitment to the World Wide 
Web as a viable next-generation publishing channel, and for the first 
time provides delivery of critical business content on the Internet.  The 
Interactive Edition has reached out to an untapped market, obtaining a 
new audience for The Journal newsroom, one that is mature, affluent, 
and will recognize high quality.  

Similarly, advertising support for The Interactive Edition testified to 
the product's appeal to a highly qualified audience and the powerful 
brand name of the nation's most prominent business news publisher.  
New advertisers, including AT&T, Apple Computer, Digital 
Equipment Corporation, E-Trade Corporation, Lexus, MCI, Nynex 
Interactive Yellow Pages, and Siemens, all joined the list of 
organizations wishing to reach the "new frontier" of serious readers of 
electronic media.

The Team Behind the News

Dow Jones has assembled some of the most forward-thinking 
journalism and technology professionals to create The Interactive 
Edition every day.  The Interactive Edition newsroom operates around 
the clock during the business week, and this spring, will expand to 24-
hour, 7-day-a-week coverage.  The Interactive Edition team includes a 
staff of editors, designers, programmers and business managers.
	The Interactive Edition staff is solely dedicated to the 
Interactive Edition.  While their news gathering and production 
processes are distinctly different from those of their print edition 
counterparts, they share access to news resources and participate in 
The Journal's editorial planning sessions on a regular basis.  

Neil Budde, EditorAs a key member of the original Interactive 
Edition development team, Neil now oversees the "new team" of over 
30 dedicated Interactive Edition professionals.  Neil maintains 
responsibility for the editorial direction and design of the Interactive 
Edition, as well as its relationship to the print edition and other Dow 
Jones news media.  Formerly, Neil was deputy editorial director for 
Dow Jones News/Retrieval, the leading business news archiving 
product, where he managed a 75-member editorial department.  He 
has also worked as an editor at USA Today and the Louisville 
Courier-Journal.

Rich Jaroslovsky, Managing EditorAs managing editor, Rich is 
responsible for organizing the Interactive Edition's daily news 
operations, overseeing the writing, editing, enhancement and 
compiling of news from around the globe.  As an award-winning 
journalist, Rich leverages his experience from The Journal's print 
edition, where he was White House correspondent and national 
political editor in the Washington bureau.  He also oversaw The Wall 
Street Journal/NBC News public opinion polls.

Jennifer Edson, Creative DirectorJennifer provides the overall design, 
interface and "look and feel"  for the Interactive Edition. The 
challenges presented by the newness of the medium and the rapidly 
changing technology draw upon Jennifer's expertise in multimedia 
design and corporate communications. Well prepared to tackle what it 
takes to make the Interactive Edition attractive and easy to use, 
Jennifer has been a consultant, designer and multimedia producer 
since 1989. She has worked for clients in a variety of industries such 
as advertising, entertainment, fashion, banking and financial services.

Ken Ficara, WebmasterAs the Webmaster for the Interactive Edition, 
Ken is responsible for providing editors with the tools and technical 
assistance needed to produce the daily edition and expand the content 
of the publication, and for staying abreast of new technologies that can 
be useful to editors and readers alike.  Also, he works with systems 
developers and designers to ensure that editorial goals are met.  Ken 
began his career with Dow Jones in 1990, and most recently was a 
project manager for development of on-line news products and 
Internet development within Business Information Services' Editorial 
group. 

Tom Baker, Business DirectorAs another key member of the original 
Interactive Edition development team, Tom is currently responsible 
for all business and marketing operations for the product.  With 13 
years of experience at Dow Jones, Tom has managed a variety of 
marketing and research areas for the print edition.  He has also been a 
reporter for Forbes and marketing director for Carnegie Hall in New 
York.

Stephanie Miller, Advertising ManagerStephanie works with the 
business, editorial and technical teams to ensure that the Interactive 
Edition delivers results to advertisers.  This includes tailoring creative 
ad programs to meet the unique needs of each advertiser, providing 
solid tracking and measurement, and leveraging interactive Web 
technology to support advertising programs.  Previously, Stephanie 
was Vice President, Management Supervisor of The Tierney Group, 
the largest strategic marketing communications consultancy in the 
mid-Atlantic US, where she developed and implemented corporate 
identity, product marketing, and public affairs communications 
programs for Fortune 100 corporations.  She has also worked as 
marketing director for The Greater Philadelphia Chamber of 
Commerce and the CBS affiliate, then WCAU-TV10, in Philadelphia.

Susan Cayne, Technical DirectorSusan, a 16-year veteran of electronic 
publishing at Dow Jones, continues to lead the Interactive Edition's 
technical development with a staff of 20 dedicated systems and 
network professionals.  Susan is responsible for the architecture, 
design, implementation, deployment and support of the Interactive 
Edition systems and networks.  Formerly a Project Manager and 
Programmer for Dow Jones News/Retrieval, Susan also helped to 
design the technology infrastructure behind Personal Journal, the 
customized electronic publication, launched by Dow Jones BIS in 
early 1995.



</pre>

<hr>

<a href="../latest.html">Back to the main Dow Jones in the News page.</a>
<hr>
<H4>We welcome feedback or questions about the <A 
HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A 
HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4>





</blockquote>

<pre>


</pre>
 
				
				<center>
					<a href="../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../bizpubs/index.html">Newspapers</a> |
					<a href="../clipping/index.html">Alert Services</a> |
					<a href="../online-lib/index.html">Research</a>  |
					<a href="../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../latest.html">DJ In The News</a>  |
						<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../index.html">Home</a> 

				</font>
				
				
				</center>
				

</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-89</DOCNO>
<DOCOLDNO>IA028-000307-B014-182</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/releas13.html 143.131.194.4 19970114051745 text/html 6992
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:21:53 GMT
Last-modified: Thursday, 23-May-96 18:34:31 GMT
Content-length: 6801
Content-type: text/html
</DOCHDR>
<html>
<head><title>PR Pages</title></head>


<body  background="../images/bgddj.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td>
<td>
<p>

<br>

<blockquote>

<center>

MEDIA ADVISORY<p>

<b>DOW JONES AND W.W. NORTON INTRODUCE FIRST-OF-ITS-KIND WORLD WIDE WEB
LEARNING RESOURCE
<p>Economics in the News is first site to combine news with textbook analysis</b></center>

<pre>
PRINCETON, NJ, February 27, 1996 -- Dow Jones Business Information Services,
in conjunction with W.W. Norton & Company, the publisher of trade and college
books, announced a new web site, Economics in the News, available today on
the World Wide Web at http://www.wwnorton.com/wsj.
 This new Internet site, the first of its kind, offers the academic community
a unique teaching resource that marries current worldwide news with economic
analysis.  Economics in the News presents the full text of a wide range of
articles written by Wall Street Journalr reporters, with annotations,
analyses, and descriptive graphics provided by a team of W.W. Norton's
distinguished economics authors.
 "Professors have always used The Wall Street Journal to make the world of
business understandable to students," said Josephine Ottman, director of
product marketing, Dow Jones Business Information Services. "Now, using
Economics in the News, professors can easily and clearly show students how
theories they learn in class relate to real-life business situations."
   Economics in the News currently contains more than 70 annotated articles
drawn from recent issues of The Wall Street Journal.  New articles will be
posted regularly, filling a need highlighted by Hal R. Varian, professor of
economics and dean of the School of Information Management and Systems at the
University of California at Berkeley, a Norton textbook author, and the
creator of the Economics in the News concept.
 "Everyone who teaches economics would like to use more current events in the
classroom, but the difficulty of locating, preparing, and distributing good
material has been a barrier to the widespread use of news items," noted
Professor Varian.  "The new technology offered by the World Wide Web has
allowed us to solve these problems by providing quick and efficient access to
selected Wall Street Journal news stories along with links back to the Norton
textbook explanations.  We think that this service will make coursework more
exciting and relevant for students."
 W. Drake McFeely, president of W.W. Norton & Company, commented, "The Wall
Street Journal and Norton are the perfect match to offer Economics in the
News.  Norton has a distinguished line of economics books and decades of
experience with anthologies.  We know how to make texts useful in the
classroom.  The Wall Street Journal is, of course, the preeminent source of
current information in the business and economics classroom. Economics in the
News is, in a sense, a mini-anthology that will help students find the
analytic line in news articles."
  Analysis of the articles in Economics in the News is provided by Jan Gerson
and Erik Hurst,  both of the economics department at the University of
Michigan, in conjunction with textbooks by Joseph Stiglitz of Stanford
University and Hal Varian.  All are noted throughout the academic community
for their published works, academic excellence and commitment to the learning
process. 
  Access to Economics in the News is free and links will be provided to
additional Dow Jones sites, such as the Money & Investing UpdateSM, and to
other Norton sites. 
 This latest Web initiative extends Dow Jones' long-standing commitment to
the academic community.  The company provides a broad range of educational
and research resources through:
* Dow Jones News/Retrievalr, a leading electronic library of business news
and information available at reduced rates to academic institutions;
* Money & Investing Update, the first interactive edition of The Wall Street
Journal on the World Wide Web;
* The Wall Street Journal and Barron'sr Newspaper in Education Program, a
service providing college students with these publications at reduced rates
when they are used in the classroom;
* The Wall Street Journal Classroom Edition, a tabloid newspaper for
secondary school students using stories drawn from The Wall Street Journal.


About W.W. Norton

 W.W. Norton & Company, Inc., the oldest and largest publishing house owned
wholly by its employees, has been recognized for decades for its
distinguished publishing programs in the trade and college areas.  Norton's
economics list features such titles as Joseph E. Stiglitz's Economics  and
 Economics of the Public Sector; Hal Varian's Intermediate Microeconomics and
Microeconomic Analysis; Robert E. Hall and John B. Taylor's Macroeconomics;
and Edwin Mansfield's Microeconomics, Applied Microeconomics, and Managerial
Economics.
 More information about W.W. Norton & Company can be found at
<a href="http://www.wwnorton.com">http://www.wwnorton.com</a>.

About Dow Jones

 Dow Jones Business Information Services is the electronic publishing arm of
Dow Jones & Company, Inc. that provides business and financial news and
information products, including Dow Jones News/Retrievalr, to corporations,
consumers and private investors through a variety of electronic media:
computer, telephone, facsimile and radio.
 Dow Jones also publishes The Wall Street Journalr and its international
editions, Barron'sr magazine and other periodicals, electronic information
services, including Dow Jones Telerate and Dow Jones Financial News Services,
and the Ottaway group of community newspapers.  Dow Jones also produces
business television programming internationally and video news delivered to
desktop computers.
</pre>

<hr>

<a href="../latest.html">Back to the main Dow Jones in the News page.</a>
<hr>
<H4>We welcome feedback or questions about the <A 
HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A 
HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4>





</blockquote>

<pre>


</pre>
 
				
				<center>
					<a href="../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../bizpubs/index.html">Newspapers</a> |
					<a href="../clipping/index.html">Alert Services</a> |
					<a href="../online-lib/index.html">Research</a>  |
					<a href="../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../index.html">Home</a> 

				</font>
				
				
				</center>
				

</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-90</DOCNO>
<DOCOLDNO>IA028-000307-B014-212</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/release1.html 143.131.194.4 19970114051836 text/html 4681
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:22:20 GMT
Last-modified: Thursday, 23-May-96 18:34:34 GMT
Content-length: 4490
Content-type: text/html
</DOCHDR>
<html>
<head><title>PR Pages</title></head>


<body  background="../images/bgddj.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td>
<td>
<p>

<br>


<blockquote>

<center>

MEDIA ADVISORY<p>

<b>Dow Jones' Massive Investor Research Service is Now Easily Accessible to

Canadian Private Investors for Less Than U.S. $1.00 Per Day</b></center>

<pre>

PRINCETON, N.J., February 23, 1996-Dow Jones Business Information Services

announced today that the massive online private investor research service-Dow

Jones News/Retrieval<font size=2>&#174;</FONT>-Private Investor Edition-is now available in major

metropolitan areas across Canada.  Canadian investors who require premier

global financial news and data to perform technical and fundamental analysis

can now access the service for less than U.S. $1.00 per day-only U.S. $29.95

per month.



 The service sports a new, easy-to-use software interface that customers can

use to quickly perform investment research and create custom portfolios of

stocks, bonds and mutual funds.  Dow Jones Private Investor Edition software

links investors to:

* Exclusive full-text articles from The Wall Street Journal<font size=2>&#174;</FONT> and Barron's<font size=2>&#174;</FONT>; 

* Business articles from the top U.S. and Canadian newspapers including  the

Los Angeles Times as well as hundreds of other publications;

* Full-text articles from the Financial Times and otherwise hard-to-find

 international news;

* Market news from seven exclusive Dow Jones newswires and eight other

 sources, including the New York Times News Service, the Canada  NewsWire,

and Canadian Corporate News;

* Current stock and mutual fund quotes and daily historical quotes going

 back a full year; 

* Two years of historical weekly stock quotes;

* Company financial data including security snapshots, earnings per share,

 earnings estimates, P/E ratio and yield; 

* Abstracts of analysts' research reports.



 Customers receive eight hours of access per month, from 7:01 p.m. to 6 a.m.

local time Monday through Friday, and all day Saturday and Sunday.  Customers

can access the Private Investor Edition outside these hours for an additional

charge.  Access to other information services are also available at their

normal rates to subscribers.



 To request the new software or to get more information, contact Dow Jones

Customer Service at 1-800-522-3567.


About Dow Jones

 Dow Jones Business Information Services is the electronic publishing arm of

Dow Jones & Company, Inc. that provides business and financial news and

information products to corporations, consumers and private investors through

a variety of electronic media: computer, telephone, facsimile and radio.

 Dow Jones also publishes The Wall Street Journal and its international

editions, Barron's magazine and other periodicals, electronic information

services, including Dow Jones Telerater and Dow Jones Financial News

Services, and the Ottaway group of community newspapers.


Dow Jones News/Retrieval, The Wall Street Journal and Barron's are registered

trademarks of Dow Jones & Company, Inc.  All other products mentioned are the

trademarks of their respective companies.



Release:  95-11



Contact:  Kris LeBoutillier   609-520-4638

   Wendell Wood Collins  609-520-4685

    or         <a href="mailto:dow.jonesPR@cor.dowjones.com">dow.jonesPR@cor.dowjones.com</a>.

</pre>

<hr>

<a href="../latest.html">Back to the main Dow Jones in the News page.</a>
<hr>
<H4>We welcome feedback or questions about the <A 
HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A 
HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4>





</blockquote>

<pre>


</pre>
 
				
				<center>
					<a href="../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../bizpubs/index.html">Newspapers</a> |
					<a href="../clipping/index.html">Alert Services</a> |
					<a href="../online-lib/index.html">Research</a>  |
					<a href="../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../index.html">Home</a> 

				</font>
				
				
				</center>
				

</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-91</DOCNO>
<DOCOLDNO>IA028-000307-B014-244</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/release7.html 143.131.194.4 19970114051912 text/html 5130
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:23:25 GMT
Last-modified: Thursday, 23-May-96 18:34:36 GMT
Content-length: 4939
Content-type: text/html
</DOCHDR>
<html>
<head><title>PR Pages</title></head>


<body  background="../images/bgddj.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td>
<td>
<p>

<br>


<blockquote>

<center>

MEDIA ADVISORY<p>

<b>Top Business News Now Directly Available On New Compaq PCs
<p>Dow Jones To Provide Preinstalled Software For Personal Journal<font size=2>&#174;</FONT> On New Compaq PCs</b></center>

<pre>

 Princeton, N.J., January 29, 1996-New Compaq<font size=2>&#174;</FONT> PC owners will now have direct

access to the top business information from The Wall Street Journal<font size=2>&#174;</FONT>.  Dow

Jones Business Information Services today announced that software for

Personal Journal<font size=2>&#174;</FONT> will be preinstalled on new Compaq Presario PCs. 



 Published in a familiar, newspaper-like format, Personal Journal is a

continuously updated, customizable electronic newspaper that provides a

quick, concise read of the business news that matters most to busy

professionals.  Personal Journal provides access to articles and news briefs

published in The Wall Street Journal each day, plus wire stories, stock

quotes, worldwide weather and sports.



 "Expert coverage of the day's business news from Wall Street Journal editors

and reporters can now be quickly accessed by new Compaq computer owners,"

said Tom Baker, business director, Business Information Services.  "By

pre-installing Personal Journal on its new line of desktop computers, Compaq

has increased its PCs' value by adding the perfect complement for the busy

'work at home' professional."



 In addition, subscribers can customize their Personal News profile to track

news on up to 25 companies or columns from The Wall Street Journal.  The

Personal Portfolio feature tracks quotes on up to 25 stocks and mutual funds.



 Thanks to the Personal Delivery function, readers can schedule automatic

delivery of their daily edition and updates, each business day, at the most

convenient time.  Readers can also request that the day's edition and quotes

be printed automatically on their personal computer printer.



 Distribution of the computers will be through Compaq-approved value-added

resellers, distributors and retail outlets in the U.S. and Canada.

 Those interested in subscribing to Personal Journal may call 1-800-291-9382,

ext. 888.  All new subscribers receive one download per day for 10 business

days at no charge.  


About Dow Jones

 Dow Jones Business Information Services is the electronic publishing arm of

Dow Jones & Company, Inc. that provides business and financial news and

information products, including Dow Jones News/Retrieval<font size=2>&#174;</FONT>, to corporations

and other consumers through a variety of electronic media: computer,

telephone, facsimile and radio.



 Dow Jones publishes The Wall Street Journal<font size=2>&#174;</FONT> and its international editions,

Barron's<font size=2>&#174;</FONT> magazine and other periodicals, electronic information services,

including Telerate<font size=2>&#174;</FONT>, real-time financial information to the international

business community, Dow Jones News Service<font size=2>&#174;</FONT> and other business news wires and

the Ottaway group of community newspapers.  Dow Jones also produces business

television programming internationally and video news delivered to desktop

computers.




 For access to Personal Journal software and subscriber information, go to

World Wide Web address: <A HREF="http://bis.dowjones.com/bizpubs/wsj-personal.html">http://bis.dowjones.com/bizpubs/wsj-personal.html</A> 



Personal Journal, The Wall Street Journal, Dow Jones News/Retrieval,

Barron's, Telerate and Dow Jones News Service are registered trademarks or

service marks of Dow Jones & Co., Inc.  All other products mentioned are

trademarks of their respective companies.
</pre>

<hr>

<a href="../latest.html">Back to the main Dow Jones in the News page.</a>
<hr>
<H4>We welcome feedback or questions about the <A 
HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A 
HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4>





</blockquote>

<pre>


</pre>
 
				
				<center>
					<a href="../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../bizpubs/index.html">Newspapers</a> |
					<a href="../clipping/index.html">Alert Services</a> |
					<a href="../online-lib/index.html">Research</a>  |
					<a href="../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../index.html">Home</a> 

				</font>
				
				
				</center>
				

</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-92</DOCNO>
<DOCOLDNO>IA028-000307-B014-289</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/release4.html 143.131.194.4 19970114051927 text/html 6522
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:23:39 GMT
Last-modified: Thursday, 23-May-96 18:34:35 GMT
Content-length: 6331
Content-type: text/html
</DOCHDR>
<html>
<head><title>PR Pages</title></head>


<body  background="../images/bgddj.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td>
<td>
<p>

<br>

<blockquote>

<center>

MEDIA ADVISORY<p>

<b>Exclusive Global Business Publications Added To Dowvision<font size=2>&#174;</FONT> News Service
<p>Most Popular Direct-to-the-Desktop News Service

Provides International News Over a Variety of Enterprise Networks </b></center>

<pre>

PRINCETON, N.J., January 23, 1996-Dow Jones Business Information Services

(BIS) announced today that DowVision<font size=2>&#174;</FONT>, the most widely read electronic source

of business and financial news for corporate enterprises, will add four more

widely respected Dow Jones publications on an exclusive basis: The Wall

Street Journal Europe<font size=2>&#174;</FONT>, The Asian Wall Street Journal<font size=2>&#174;</FONT>, Barron's<font size=2>&#174;</FONT> and the Far

Eastern Economic Review<font size=2>&#174;</FONT>.



 In addition to these publications, DowVision is the only service that

broadcasts the world's premiere business newspapers-The Wall Street Journal<font size=2>&#174;</FONT>,

The New York Times, the Financial Times and the Los Angeles Times-with the

Dow Jones newswires and press release wires, directly to corporate desktops.



 "Our customers are decision makers at top companies-both in the U.S. and

abroad-who demand high-quality information from sources they can trust," said

Clare Hart, director of corporate news products.  "And they want that

information in whatever computing environment they use.  DowVision is

uniquely positioned to provide businesspeople with a service that's delivered

directly to 'wherever they live,' whether that's in Lotus<font size=2>&#174;</FONT> Notes<font size=2>&#174;</FONT>, e-mail,

Windows<font size=2>&#174;</FONT>, Mac<font size=2>&#174;</FONT> or the Internet."



 The new publications make DowVision the richest source of international news

broadcast directly to corporate desktops.  In addition to the new content,

DowVision customers have access to the following Dow Jones wires: Dow Jones

International News Service; the European Corporate Report; the Economic

Report; the World Equities Report; the International Petroleum Report;

the Foreign Exchange Report, and the Bankers Report.  The Japan Economic

Newswire is also a source of English-language wire news from Kyodo News

International.



 DowVision customers also get international news the instant corporations

make it public through the press release wires.  In addition to PR Newswire

and Business Wire, DowVision provides Canada NewsWiresm and Canadian

Corporate Newssm.



 "Our business is around-the-globe," says Len Lynch, the partner in charge of

internal applications development for Arthur Andersen.  "Any news that we

broadcast on AA OnLine, our Notes-based knowledge sharing system, must be

relevant to our professionals in Singapore as well as Chicago.  The Dow Jones

international content provides our people with the information they need to

help our clients succeed."



The Additional Dow Jones International News Sources

 The full text of the following publications has been added to DowVision:

* The Wall Street Journal Europe, published five times a week in Brussels,

has earned a strong reputation for in-depth analytical coverage of the

European Union and topics of special interest to European business people;

* The Asian Wall Street Journal, published in Hong Kong, is the premier

English-language daily focused on business, political, and economic interests

throughout Asia;

* Far Eastern Economic Review, published weekly, offers superb coverage and

analysis of business and political issues in Asia;

* Barron's is known for its in-depth, sophisticated news reports and analyses

of the financial markets in the United States and around the world.


About Dow Jones

 Business Information Services is the electronic publishing arm of Dow Jones

& Company, Inc. that provides business news and information products,

including Dow Jones News/Retrieval<font size=2>&#174;</FONT>, to corporations, consumers and private

 investors through a variety of electronic media: computer, telephone,

facsimile and radio.



 Dow Jones publishes The Wall Street Journal<font size=2>&#174;</FONT> and its international 

editions, Barron's<font size=2>&#174;</FONT> magazine and other periodicals, 

electronic business information services including Telerate<font size=2>&#174;</FONT>, a provider of 

real-time financial information to the international business community, Dow Jones 

News Services and other business newswires and the Ottaway group of community 

newspapers.  Dow Jones also produces business television programming internationally 

and video news delivered to desktop computers.
<p>

DowVision, The Wall Street Journal, The Wall Street Journal Europe, The Asian

Wall Street Journal, Barron's, Far Eastern Economic Review, Dow Jones

International News Service, Dow Jones European Corporate Report, World

Equities Report, Dow Jones News/Retrieval and Telerate are trademarks or

service marks of Dow Jones & Co., Inc.  All other products mentioned are the

trademarks of their respective companies.

</pre>

<hr>

<a href="../latest.html">Back to the main Dow Jones in the News page.</a>
<hr>
<H4>We welcome feedback or questions about the <A 
HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A 
HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4>





</blockquote>

<pre>


</pre>
 
				
				<center>
					<a href="../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../bizpubs/index.html">Newspapers</a> |
					<a href="../clipping/index.html">Alert Services</a> |
					<a href="../online-lib/index.html">Research</a>  |
					<a href="../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../index.html">Home</a> 

				</font>
				
				
				</center>
				

</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-93</DOCNO>
<DOCOLDNO>IA028-000307-B014-323</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/release8.html 143.131.194.4 19970114051953 text/html 5212
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:23:55 GMT
Last-modified: Thursday, 23-May-96 18:34:37 GMT
Content-length: 5021
Content-type: text/html
</DOCHDR>
<html>
<head><title>PR Pages</title></head>


<body  background="../images/bgddj.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td>
<td>
<p>

<br>


<blockquote>

<center>

MEDIA ADVISORY<p>

<b>Personal Journal Software Now Available Through the Internet 
<p>First Electronic Edition of The Wall Street Journal Ready To Be Downloaded From Dow Jones' Home Page</b></center>

<pre>

Princeton, NJ, January 5, 1996 -- Dow Jones Business Information Services

today announced that Personal Journal<font size=2>&#174;</FONT> software is now downloadable from the

Dow Jones Business Information Services home page at

<A HREF="http://bis.dowjones.com/bizpubs/wsj-personal.html">http://bis.dowjones.com/bizpubs/wsj-personal.html</A>.

 Those accessing the Dow Jones home page can also view Personal Journal

sample screens and obtain information on becoming a subscriber.  After

downloading the Windows software and registering with Dow Jones, subscribers

can start using Personal Journal immediately.



 Published in a familiar, newspaper-like format, Personal Journal is a

continuously updated, customizable electronic newspaper that provides a

quick, concise read of the business news that matters most to busy

professionals.  



 Personal Journal provides access to articles and news briefs published in

The Wall Street Journal each day, plus wire stories, stock quotes, worldwide

weather and sports.



 In addition, subscribers can customize their Personal News profile

to track news on up to 25 companies or columns from The Wall Street Journal.



 The Personal Portfolio feature tracks quotes on up to 25 stocks and mutual

funds. 



 Thanks to the Personal Delivery function, readers can schedule automatic

delivery of their daily edition and updates, each business day, at the most

convenient time.  Readers can also request that the day's edition be printed

automatically on their personal computer printer.



 "Business professionals are looking for trusted sources of business news and

information, made available quickly and conveniently.  Personal Journal

provides that," said Tom Baker, business director, Dow Jones Business

Information Services.  "Now it's easy for the millions of people 'surfing the

net' to see for themselves how they can get immediate access to the business

insight of Wall Street Journal editors delivered directly to their PC's via

Personal Journal -- anytime or anywhere."



 Subscriptions cost $12.95 per month for one edition of Personal Journal each

business day; updates are 50 cents each.  Interested subscribers without Web

access can call 1-800-291-9382, extension 824, to order the software directly

from Dow Jones.  There is a shipping and handling charge of $4.95.


About Dow Jones

 Dow Jones Business Information Services is the electronic publishing arm of

Dow Jones & Company, Inc. that provides business news and information

products, including Dow Jones News/Retrieval<font size=2>&#174;</FONT>, to corporations, consumers and

private investors through a variety of electronic media: computer, telephone,

facsimile and radio.

 Dow Jones publishes The Wall Street Journal<font size=2>&#174;</FONT> and its international editions,

Barron's<font size=2>&#174;</FONT> magazine and other periodicals, electronic information services,

including Dow Jones Telerate and Dow Jones Financial News Services and the

Ottaway group of community newspapers.


 For access to Personal Journal software and subscriber information, go to

World Wide Web address: <A HREF="http://bis.dowjones.com/bizpubs/wsj-personal.html">http://bis.dowjones.com/bizpubs/wsj-personal.html</A>
 or call Personal Journal Customer Service at 1-800-291-9382, or e-mail
Dow Jones at<a href="mailto:personal.journal@nrs.dowjones.com">personal.journal@nrs.dowjones.com</a>.    



Personal Journal, The Wall Street Journal and Barron's are registered

trademarks of Dow Jones and Company, Inc.
</pre>

<hr>

<a href="../latest.html">Back to the main Dow Jones in the News page.</a>
<hr>
<H4>We welcome feedback or questions about the <A 
HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A 
HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4>





</blockquote>

<pre>


</pre>
 
				
				<center>
					<a href="../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../bizpubs/index.html">Newspapers</a> |
					<a href="../clipping/index.html">Alert Services</a> |
					<a href="../online-lib/index.html">Research</a>  |
					<a href="../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../index.html">Home</a> 

				</font>
				
				
				</center>
				

</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-94</DOCNO>
<DOCOLDNO>IA028-000307-B015-4</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/releas11.html 143.131.194.4 19970114052046 text/html 4776
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:24:52 GMT
Last-modified: Thursday, 23-May-96 18:34:30 GMT
Content-length: 4585
Content-type: text/html
</DOCHDR>
<html>
<head><title>PR Pages</title></head>


<body  background="../images/bgddj.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td>
<td>
<p>

<br>


<blockquote>

<center>

MEDIA ADVISORY<p>

<b>DOW JONES ANNOUNCES NEWS/RETRIEVALr FOR MACINTOSHx 
<p>Now Macintosh owners can easily tap the world's most useful business library, containing more than 47 million documents from an unmatched selection of top news sources.</b></center>

<pre>
PRINCETON, N.J., December 20, 1995 - Dow Jones Business Information Services
announced today the first Macintosh software for "point and click" access to
the world's most useful business library, Dow Jones News/Retrieval. The
Macintosh software dramatically increases the ease with which News/Retrieval
subscribers can navigate the massive business library and locate relevant
information. 
 Recently expanded, Dow Jones News/Retrieval is the only online service to
offer same-day access to the combination of the full text of The Wall Street
Journal,r The New York Times, the Los Angeles Times, and the Financial Times.
 With 67% more publications added over the last year, News/Retrieval now
offers more than 47 million documents from more than 3,400 sources, including
top wire services, unmatched in-depth financial resources, and a wide
selection of leading business and trade publications.  
      "Today's professionals need answers to difficult questions at a
moment's notice," said Greg Gerdy, director of research products, Dow Jones
Business Information Services.  "And we know that the professionals who use
Macintosh computers look online for answers.  MacWorld recently reported that
'Macs are used for the major commercial online services at about twice the
proportion of their installed base' of 7 - 9% of the business market. We're
pleased to offer our new software for easy Macintosh access to the most
useful online business library available."
   The Macintosh software was developed with Trax Softworks, Inc., as part of
a multi-year agreement between the two companies.  Dow Jones and Trax also
developed Windows software for News/Retrieval, introduced earlier this year.
 The Macintosh software is available now. To request the new software or to
get more information, contact Dow Jones Customer Service at 1-800-522-3567,
extension 52.
      Dow Jones News/Retrieval is the premier provider of online business and
financial information, including almost 3,000 text publications and more than
400 other sources of business and financial data. 
      Dow Jones Business Information Services is the electronic publishing
arm of Dow Jones & Company, Inc., that provides business and financial news
and information products to corporations, consumers and private investors
through a variety of electronic media: computer, telephone, facsimile and
radio.
      Dow Jones also publishes The Wall Street Journal and its international
editions, Barron'sr magazine and other periodicals, electronic information
services, including Dow Jones Telerate and Dow Jones Financial News Services,
and the Ottaway group of community newspapers.
      Trax Softworks, based in Culver City, CA, specializes in developing
software products for corporate customers. Trax developed CypressTM, an
interface for News/Retrieval, on which the new Macintosh interface is based. 

Dow Jones News/Retrieval, The Wall Street Journal and Barron's are registered
marks of Dow Jones & Company, Inc.  All other products mentioned are the
trademarks of their respective owners.
</pre>

<hr>

<a href="../latest.html">Back to the main Dow Jones in the News page.</a>
<hr>
<H4>We welcome feedback or questions about the <A 
HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A 
HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4>





</blockquote>

<pre>


</pre>
 
				
				<center>
					<a href="../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../bizpubs/index.html">Newspapers</a> |
					<a href="../clipping/index.html">Alert Services</a> |
					<a href="../online-lib/index.html">Research</a>  |
					<a href="../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../index.html">Home</a> 

				</font>
				
				
				</center>
				

</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-95</DOCNO>
<DOCOLDNO>IA028-000307-B015-35</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/releas15.html 143.131.194.4 19970114052134 text/html 7803
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:25:20 GMT
Last-modified: Thursday, 23-May-96 18:34:32 GMT
Content-length: 7612
Content-type: text/html
</DOCHDR>
<html>
<head><title>PR Pages</title></head>


<body  background="../images/bgddj.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td>
<td>
<p>

<br>

<blockquote>

<center>

MEDIA ADVISORY<p>

<b>The Wall Street Journal Announces Customized Netscape Navigator Offering
One-Step Access to Leading Internet News Source
<p>Joint Effort Creates Single Package Combining Web Navigation Software,
Service Provider, and Direct Link to the Journal's Money & Investing Update
</b></center>

<pre>
PRINCETON, NJ, November 27, 1995 -- The Wall Street Journal today introduced
Netscape Navigatorx for The Wall Street Journalr, a one-step innovative
Internet solution for business professionals.  Developed jointly with
Netscape Communications Corp. and offering access through a leading service
provider, Netscape Navigator for The Wall Street Journal simplifies the
Internet set-up and connection process and directly links to the premier
business news site on the World Wide Web.

Netscape Navigator for The Wall Street Journal combines in one step the
set-up of an Internet account through NETCOMx or a service provider of the
customer's choice; automatic registration of the navigator software; and
automatic connection to The Wall Street Journal's Money & Investing Update.
 Customers will also enjoy an advanced navigating environment from Netscape,
a premier provider of open Internet software.

Upon registration, Netscape Navigator for The Wall Street Journal
automatically links the customer to Money & Investing Update (The Update),
one of the most popular business publications on the World Wide Web,
featuring continually updated business and markets news from a dedicated
24-hour Wall Street Journal newsroom.  In addition, Netscape Navigator for
The Wall Street Journal is optimized for viewing The Update with a customized
toolbar and easy-to-use pull-down menus.  Netscape Navigator for The Wall
Street Journal also provides a gateway for customers to explore all the
Internet has to offer. 

"For more than a century, The Wall Street Journal has met the information
needs of business, and today, Money & Investing Update is meeting these needs
in a whole new way," said Tom Baker, business director of The Wall Street
Journal Interactive Edition.  "Now, we are giving business professionals an
easy, one-step solution to explore not only Money & Investing Update, but all
that the Internet can offer.  With the simplest navigation tools available,
we have made accessing the Web as easy as walking to the newsstand."  

"We are proud to be working with The Wall Street Journal to help bring
businesspeople onto the Internet," said Mike Homer, vice president of
marketing of Netscape.  "Our joint effort to remove some of the mystery of
the Web has resulted in a complete package that combines access, navigation
and a leading information source.  This package will help bring the business
benefits of the Web to a host of new users."

Availability and Pricing
Netscape Navigator for The Wall Street Journal is available for $39.95
directly from The Wall Street Journal by calling 1-800-538-9692, ext. 6300.
 Upon installation, Internet access can be arranged through NETCOM, a leading
nationwide Internet service provider, at $19.95 per month for 40 hours of
prime-time connect time or through another service provider of the customer's
preference.  Access to The Update is currently free of charge.  

About Money & Investing Update
Money & Investing Update is one of the most popular business publications on
the World Wide Web, featuring continually updated business and markets news
from a dedicated 24-hour Wall Street Journal newsroom.  Customers may access
The Update at: http://update.wsj.com.

Produced by a team of Wall Street Journal editors dedicated to interactive
publishing, Money & Investing Update was launched on July 11, 1995 and
quickly became one of the Web's most popular sources for continuously updated
business news.  The Update now has more than 150,000 registered readers
worldwide. 

In early 1996, Money & Investing Update will expand to encompass the full
scope of The Wall Street Journal's coverage, plus sports and customized
personal sections, evolving into a complete interactive edition of The
Journal.  Charter advertisers in The Update are Cadillac Motor Car Division,
The Dreyfus Corporation, EDS, Fidelity Investments, Hewlett Packard, Lombard
Institutional Brokerage Inc., Nortel, Oracle Corporation, Charles Schwab &
Co. Inc., Sun Microsystems, Tandy Corporation, Toyota, and Wells Fargo.  New
advertising opportunities are now available for early 1996. 

About Dow Jones
Money & Investing Update is published by The Wall Street Journal and Dow
Jones Business Information Services (BIS). BIS is the electronic publishing
arm of Dow Jones & Company, Inc. that provides business and financial news
and information products to corporations and consumers through a variety of
electronic media:  computer, telephone, facsimile and radio. 

Dow Jones publishes The Wall Street Journal and its international editions;
Barron's magazine and other periodicals; electronic business information
services, including Dow Jones Telerate, a provider of real-time financial
information to the international business community, Dow Jones News Service
and other business newswires; and the Ottaway group of community newspapers.
Dow Jones also produces business television programming internationally and
video news delivered to desktop computers.

About Netscape
Netscape Communications Corporation is a premier provider of open software to
enable people and companies to exchange information and conduct commerce over
the Internet and other global networks. The company was founded in April 1994
by Dr. James H. Clark, founder of Silicon Graphics, Inc., a Fortune 500
computer systems company; and Marc Andreessen, creator of the NCSA Mosaic
research prototype for the Internet. Traded on Nasdaq under the symbol
"NSCP", Netscape Communications Corporation is based in Mountain View,
California.

The Wall Street Journal is a trademark of Dow Jones & Co., Inc.; Money &
Investing Update is a service mark of Dow Jones & Co., Inc.; Netscape and
Netscape Navigator are registered trademarks of Netscape Communications;
NETCOM is a trademark of NETCOM Online Communication Services, Inc.

Press contacts:

Lisa Gilbert/Michael Bayer 
Miller/Shandwick Technologies   
(617) 536-0470  
lgilbert@millercom.com
mbayer@millercom.com

Maggie Landis 
Dow Jones BIS 
(609) 520-4679
maggie.landis@cor.dowjones.com
</pre>

<hr>

<a href="../latest.html">Back to the main Dow Jones in the News page.</a>
<hr>
<H4>We welcome feedback or questions about the <A 
HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A 
HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4>





</blockquote>

<pre>


</pre>
 
				
				<center>
					<a href="../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../bizpubs/index.html">Newspapers</a> |
					<a href="../clipping/index.html">Alert Services</a> |
					<a href="../online-lib/index.html">Research</a>  |
					<a href="../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../index.html">Home</a> 

				</font>
				
				
				</center>
				

</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-96</DOCNO>
<DOCOLDNO>IA028-000307-B015-81</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/releas12.html 143.131.194.4 19970114052156 text/html 5530
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:26:03 GMT
Last-modified: Thursday, 23-May-96 18:34:31 GMT
Content-length: 5339
Content-type: text/html
</DOCHDR>
<html>
<head><title>PR Pages</title></head>


<body  background="../images/bgddj.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td>
<td>
<p>

<br>

<blockquote>

<center>

MEDIA ADVISORY<p>

<b>'THE WORLD'S MOST USEFUL ONLINE BUSINESS LIBRARY'
ADDS  FULL-TEXT ARCHIVES OF THE NEW YORK TIMES
</b></center>

<pre>
PRINCETON, N.J. -- October  31, 1995 -- Subscribers to the massive Dow Jones
online business library, Dow Jones News/Retrieval,r will have access to the
archival full-text databases of The New York Times as of January 1996, thanks
to an agreement between Dow Jones & Company, Inc. and The New York Times
Information Services Group. 
 The agreement was announced today by James A. Cutie, president of The New
York Times Information Services Group, and Dorothea Coccoli Palsho, president
of Dow Jones Business Information Services. 
  The agreement gives Dow Jones Business Information Services' North American
subscribers access to the full text of the most recent 90 days of The New
York Times. In addition, North American customers can also tap into
collections of articles organized by topic, dating back to 1980. This new
agreement represents an expansion of an existing relationship between the two
companies; subscribers to Dow Jones online services have had access to
day-of-publication articles from The New York Times News Service since March
1994. 
  The agreement also stipulates that Dow Jones subscribers outside of North
America will be able to access the entire archive dating back to 1980. Both
North American and overseas customers will have access to abstracts of
articles dating back to 1969.  
Dow Jones & Company is totally committed to continuing to make Dow Jones
News/Retrieval the world's most useful online business library. "With so many
changes taking place in today's business world, and what seems to be an
ever-increasing flood of information, our customers tell us that they are
more interested than ever in the quality of the news and information they
receive," said Ms. Palsho.  "The sheer number of subjects now researched by
business people dictates that we must continually add content, but we are
also very selective. The New York Times is a well-respected publication, and
we are excited that we are now able to give our subscribers greater access to
its editorial resources."
  As a result of this agreement, The New York Times archive will be available
to subscribers of Dow Jones News/Retrieval; DowVision,r a service that
broadcasts news over corporate networks to individual desktops; and Dow Jones
CustomClips,r an electronic clipping service that delivers industry and trade
publications to a variety of electronic environments.  The New York Times
Information Services Group, a division of The New York Times Company,
develops new markets for the company's news and information, including
applications that use new and emerging technologies. The group includes NYT
Business Information Services, which produces the Times' archival databases
and the Times Index; NYT Custom Publishing; New Business Development; NYT New
Media/New Products; The New York Times News Service and The New York Times
Syndicate; NYT Specialized Publications, publisher of TimesFax; licensee and
database marketing and various services on the World Wide Web.

 Dow Jones Business Information Services is the electronic publishing arm of
Dow Jones & Company, Inc.  that provides business and financial news and
information products to corporations and consumers through a variety of
electronic media: computer, telephone, facsimile and radio. 
 Dow Jones publishes The Wall Street Journal and its international editions,
Barron's magazine and other periodicals, electronic business information
services, including Dow Jones Telerate, a provider of real-time financial
information to the international business community, Dow Jones News Service
and other business newswires and the Ottaway group of community newspapers.
Dow Jones produces business television programming internationally and video
news delivered to desktop computers.

Dow Jones News/Retrieval, The Wall Street Journal, DowVision, and CustomClips
are registered trademarks of Dow Jones & Company, Inc.  CustomClips is a
service of Dow Jones News/Retrieval. 

</pre>

<hr>

<a href="../latest.html">Back to the main Dow Jones in the News page.</a>
<hr>
<H4>We welcome feedback or questions about the <A 
HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A 
HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4>





</blockquote>

<pre>


</pre>
 
				
				<center>
					<a href="../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../bizpubs/index.html">Newspapers</a> |
					<a href="../clipping/index.html">Alert Services</a> |
					<a href="../online-lib/index.html">Research</a>  |
					<a href="../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |

					<a href="../index.html">Home</a> 

				</font>
				
				
				</center>
				

</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-97</DOCNO>
<DOCOLDNO>IA028-000307-B015-113</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/releas10.html 143.131.194.4 19970114052226 text/html 7309
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:26:24 GMT
Last-modified: Thursday, 23-May-96 18:34:30 GMT
Content-length: 7118
Content-type: text/html
</DOCHDR>
<html>
<head><title>PR Pages</title></head>


<body  background="../images/bgddj.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td>
<td>
<p>

<br>


<blockquote>

<center>

MEDIA ADVISORY<p>

<b>MASSIVE ONLINE BUSINESS LIBRARY BOOSTED BY OVER 65 PERCENT
<p>
Dow Jones News/Retrieval Now Contains Over 45 Million Documents</b></center>

<pre>
PRINCETON, N.J. -- October  30, 1995 -- As part of its quest to continue to
provide the world's most useful business library,  Dow Jones Business
Information Services has increased the content of the Dow Jones
News/Retrieval Text Library by 67.5%. Additions include hundreds of leading
trade publications from Information Access Company; influential government
publications from the Federal Document Clearing House; and hundreds of
international articles, through a relationship with the Financial Times for
FT McCarthy.
 "In addition to boosting our content, we have set very high goals for both
the quality and quantity of our content," says Dorothea Coccoli Palsho,
president of Dow Jones Business Information Services. "We are well aware that
today's business people want to be able to research a subject quickly and
efficiently, but at the same time, they want the quality of analysis that can
only come from the world's top journalistic sources. Toward that end, we are
the only business news library to offer the combination of The Wall Street
Journal,r The New York Times News Service and the Financial Times. Overall,
we carry 42 of the top 50 U.S. newspapers. In addition to general business
news, we now have a plethora of industry and trade publications for anyone
who needs to keep up with-or simply understand-specific markets. 
 "Dow Jones continues to comb the publishing world for prime sources of
business and financial information as it strengthens its interactive Text
Library," Ms. Palsho continued.  "More announcements are on the way." 

New Content: Trade Publications
 Through an agreement with Information Access Company (IAC), Dow Jones
News/Retrieval now offers access to the IAC Trade and Industry Index,x which
consists of the most widely read publications in a number of industries. This
new resource offers respected and wide-ranging publications such as the
American Journal of Psychology, British Medical Journal, Brookings Review,
Columbia Journal of World Business, Journal of Marketing Research, McKinsey
Quarterly, National Review, Sloan Management Review, Tax Advisor and Whole
Earth Review. 
 The Dow Jones News/Retrieval Text Library now also includes the IAC Industry
Express SM a full-text collection of trade and industry periodicals, which
makes computer, electronic and telecommunications news available at or near
the time of their publication. This area of the News/Retrieval Text Library
will grow as new publications from the pharmaceuticals, biotechnology and
health care industries are added.  Current titles  will include Biotech
Patent News, Chemical Week, Computer Retail Week, FCC Report and Industry
Week.
 In addition, the News/Retrieval Text Library offers the complete PROMT
database from IAC, with more than 1,100 sources offering international
coverage of companies, products, markets and applied technologies.
 With the addition of these IAC trade titles, Dow Jones News/Retrieval is now
the premier site for business coverage of  the computer, energy,
pharmaceutical and healthcare industries.

New Content: Government Resources
 The Federal Document Clearing House (FDCH) provides complete coverage of
developments in the federal government, including news conferences,
congressional hearings, White House meetings, speeches and briefings. FDCH
material is gathered from several sources, including Congressional testimony,
Regulatory Intelligence Database, General Accounting Office reports, white
papers, and Congressional and Washington transcripts. 

 "The new content from the Federal Document Clearing House gives our
subscribers access to valuable federal testimony and analysis," says Gregory
P. Gerdy, director of enterprise products. "Today's changing regulatory
climate makes it necessary for business people to have access to such
publications, so they can adjust to changes as they occur."

New Content: International Articles
 FT McCarthy content consists of company, industry and market news culled
from major European newspapers and business magazines by the FT Information
staff.  "Those doing business internationally-which includes almost everyone
these days-appreciate the full-text international articles provided by this
resource," says Mr. Gerdy. The FT McCarthy service is used extensively by
bankers, analysts, and business development managers.
 FT McCarthy sources include: The Daily Telegraph, The Guardian, The
European, The Herald, Evening Standard, Irish Independent, The Sunday
Telegraph, Lloyds List, The Scotsman, Yorkshire Post and Daily Mail.  The
full text of the Financial Times has been available on Dow Jones
News/Retrieval since March 1995.

 About Dow Jones
 Dow Jones Business Information Services is the electronic publishing arm of
Dow Jones & Company, Inc. Business Information Services provides business and
financial news and information products to corporations and consumers through
a variety of electronic media: computer, telephone, facsimile and radio. 
 Dow Jones publishes The Wall Street Journal and its international editions,
Barron's magazine and other periodicals, electronic business information
services, including Dow Jones Telerate, a provider of real-time financial
information to the international business community, Dow Jones News Service
and other business newswires and the Ottaway group of community newspapers.
Dow Jones produces business and television programming internationally and
video news delivered to desktop computers.

Dow Jones News/Retrieval and The Wall Street Journal are registered
trademarks of Dow Jones & Company, Inc. IAC Trade and Industry Index is a
trademark and IAC Industry Express is a service mark of Information Access
Company.  

</pre>

<hr>

<a href="../latest.html">Back to the main Dow Jones in the News page.</a>
<hr>
<H4>We welcome feedback or questions about the <A 
HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A 
HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4>





</blockquote>

<pre>


</pre>
 
				
				<center>
					<a href="../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../bizpubs/index.html">Newspapers</a> |
					<a href="../clipping/index.html">Alert Services</a> |
					<a href="../online-lib/index.html">Research</a>  |
					<a href="../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../index.html">Home</a> 

				</font>
				
				
				</center>
				

</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-98</DOCNO>
<DOCOLDNO>IA028-000307-B015-155</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/releas14.html 143.131.194.4 19970114052307 text/html 5453
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:27:04 GMT
Last-modified: Thursday, 23-May-96 18:34:31 GMT
Content-length: 5262
Content-type: text/html
</DOCHDR>
<html>
<head><title>PR Pages</title></head>


<body  background="../images/bgddj.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td>
<td>
<p>

<br>

<blockquote>

<center>

MEDIA ADVISORY<p>

<b>The Wall Street Journal Premiers 24-Hour News Reporting  in Money & Investing Update
<p>Registers More than 100,000 Users on World Wide Web Sites</b></center>

<pre>
NEW YORK, October 18, 1995 -- In the wake of rapid market acceptance and
overwhelming customer response, The Wall Street Journal today announced the
addition of 24-hour news reporting to Money & Investing Update, Dow Jones'
continually updated business news publication on the World Wide Web.
 In addition, Money & Investing Update also announced that it has registered
more than 100,000 users at its site since the publication's launch on July
11, making it one of the Web's busiest and fastest-growing sources for
business news.  The Update is currently available free of charge at 
<a href="http://update.wsj.com">http://update.wsj.com</a>.
 With 24-hour coverage during the business week, Update readers can now
follow key business stories and market indicators as news breaks around the
globe.  "Our readers make up a broad international audience, and by updating
the publication throughout the night with news and analysis of foreign
markets, we can give readers a measurable business advantage no matter what
their time zone or location," said Neil Budde, editor of the Money &
Investing Update.
 The overnight monitoring of international markets means that Money &
Investing Update readers will frequently have access to stories in advance of
their appearance in other print, broadcast or online media. For example,
during the Update's first week of 24-hour operation, a major story was
announced at midday in Tokyo: Daiwa Bank's surprise disclosure on September
26 of $1.1 billion of trading losses. The story was initially reported to
Update readers before1:00 a.m. (ET), with further updates throughout the
night as additional news became available.

More Information in Money & Investing Update's Briefing Books
 In addition, the editors of the Update announced today that the background
reports in the Company Briefing Books -- highly graphical compilations of
financial data, stock charts and recent news -- have been expanded to include
a roster of the company's officers, the address and phone number of its
headquarters and in-depth information about each company's products and
operations.  
 Briefing Books on approximately 10,000 companies are available by direct
hyperlinks from significant mentions of a company in an Update story or table
or by simply by entering a stock symbol or company name.
 Upcoming features of Money & Investing Update will include: stock quotes and
financial data; an archive of past Wall Street Journal articles; and the
ability to access the Update through a customized browser from Dow Jones.
 Charter advertisers in the Update include Cadillac Motor Car Division, The
Dreyfus Corporation, EDS, Fidelity Investments, Hewlett-Packard, Lombard
Institutional Brokerage Inc., Nortel, Oracle Corporation, Charles Schwab &
Co. Inc., Sun Microsystems, Tandy Corporation, Toyota, and Wells Fargo. 
About Dow Jones
 Money & Investing Update is published by The Wall Street Journal and Dow
Jones Business Information Services (BIS).  BIS, the electronic publishing
arm of Dow Jones & Company, Inc., provides business and financial news and
information products to corporations and consumers through a variety of
electronic media: computer, telephone, facsimile and radio.
 Dow Jones also publishes The Wall Street Journal and its international
editions, Barron'sr magazine and other periodicals, electronic business
information services, including Dow Jones Telerate, a provider of real-time
financial information to the international business community, Dow Jones News
Service and other business newswires and the Ottaway group of community
newspapers.  Dow Jones also produces business television programming
internationally and video news delivered to desktop computers.
Interested customers may access the Update at <a href="http://update.wsj.com">http://update.wsj.com</a>.

</pre>

<hr>

<a href="../latest.html">Back to the main Dow Jones in the News page.</a>
<hr>
<H4>We welcome feedback or questions about the <A 
HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A 
HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4>





</blockquote>

<pre>


</pre>
 
				
				<center>
					<a href="../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../bizpubs/index.html">Newspapers</a> |
					<a href="../clipping/index.html">Alert Services</a> |
					<a href="../online-lib/index.html">Research</a>  |
					<a href="../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../index.html">Home</a> 

				</font>
				
				
				</center>
				

</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-99</DOCNO>
<DOCOLDNO>IA028-000307-B015-194</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/release9.html 143.131.194.4 19970114052401 text/html 5026
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:27:47 GMT
Last-modified: Thursday, 23-May-96 18:34:37 GMT
Content-length: 4835
Content-type: text/html
</DOCHDR>
<html>
<head><title>PR Pages</title></head>


<body  background="../images/bgddj.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td>
<td>
<p>

<br>

<blockquote>

<center>

MEDIA ADVISORY<p>

<b>Now Personal Journal Delivers Itself Whenever You Want It
<p>New Version of Electronic, Customizable Edition of The Wall Street Journal Now Available With Automatic "Personal Delivery " Feature</b></center>

<pre>

Princeton, NJ, September 20, 1995 -- Dow Jones Business Information Services

today announced the availability of Personal Journalr 2.0, a new version of

the customizable, electronic edition of The Wall Street Journalr, featuring

"Personal Delivery" -- an autodialer that delivers Personal Journal directly

to subscribers' PCs, ready to read, anytime they want.



 "Customers told us they wanted their favorite Wall Street Journal editorial,

delivered to them automatically," said Josephine Ottman, director of product

marketing, Dow Jones Business Information Services.  "We responded with more

news choices and with Personal Delivery.  Personal Journal can now be

delivered automatically to subscribers' PCs whenever they want."



 Published in a familiar, newspaper-like format, Personal Journal is a

continuously updated electronic newspaper that provides a quick, concise read

of the day's business news.  Personal Journal was originally introduced in

March of 1995.



 In addition, readers can now select up to 25 favorite Wall Street Journal

columns or company news articles for daily delivery.  "Personal Journal

subscribers wanted more of the trusted business analysis that only Dow Jones'

editors and reporters can deliver," said Karyn Greco, product manager,

Personal Journal.  "Version 2.0 satisfies this request."



Version 2.0

 The Personal Delivery feature allows the reader to schedule the delivery

time of their Personal Journal seven days a week.  Readers can also request

that the day's edition be printed automatically on their personal printer.  



 Subscribers can also track 25 stock and mutual funds quotes in the Personal

Portfolio section of Personal Journal.  The Markets section includes many key

market indicators including the NASDAQ composite index, Dow Jones Industrials

and the S&P 500.



Subscribe To Personal Journal

 After installing the Windows software and registering with Dow Jones,

subscribers can start using Personal Journal immediately.  Subscriptions cost

$12.95 per month for one edition of Personal Journal each business day;

additional updates are 50 cents each.  Subscribers must have a modem with a

speed of 9,600 baud or higher.  Subscribers can use a local telephone number,

or an 800 number for an additional fee, for access to Personal Journal. 



 Those who wish to subscribe to Personal Journal can call 1-800-291-9382,

extension 888, to order the software directly from Dow Jones, and pay only a

shipping and handling charge of $4.95.


About Dow Jones

 Business Information Services is the electronic publishing arm of Dow Jones

& Company, Inc. that provides business news and information products,

including Dow Jones News/Retrievalr, to corporations, consumers and private

investors through a variety of electronic media: computer, telephone,

facsimile and radio.



 Dow Jones publishes The Wall Street Journalr and its international editions,

Barron'sr magazine and other periodicals, electronic information services,

including Dow Jones Telerate and Dow Jones Financial News Services and the

Ottaway group of community newspapers.


 For further information, please call Personal Journal Customer Service at

1-800-291-9382 or e-mail Dow Jones at <a href="mailto:personal.journal@nrs.dowjones.com">personal.journal@nrs.dowjones.com</a>.  
</pre>

<hr>

<a href="../latest.html">Back to the main Dow Jones in the News page.</a>
<hr>
<H4>We welcome feedback or questions about the <A 
HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A 
HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4>





</blockquote>

<pre>


</pre>
 
				
				<center>
					<a href="../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../bizpubs/index.html">Newspapers</a> |
					<a href="../clipping/index.html">Alert Services</a> |
					<a href="../online-lib/index.html">Research</a>  |
					<a href="../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../index.html">Home</a> 

				</font>
				
				
				</center>
				

</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-100</DOCNO>
<DOCOLDNO>IA028-000307-B015-229</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/release5.html 143.131.194.4 19970114052426 text/html 5989
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:28:38 GMT
Last-modified: Thursday, 23-May-96 18:34:35 GMT
Content-length: 5798
Content-type: text/html
</DOCHDR>
<html>
<head><title>PR Pages</title></head>


<body  background="../images/bgddj.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td>
<td>
<p>

<br>

<blockquote>

<center>

MEDIA ADVISORY<p>

<b>World Wide Web's First Continually Updated Market News Publication Now Offers
Detailed Company Background Reports</b></center>

<pre>

Princeton, NJ, September 19, 1995 -- The Wall Street Journal's Money &

Investing Update today introduced Company Briefing Books, a major enhancement

designed to provide businesspeople and investors with a rich,

up-to-the-minute background report on almost any company in the news.

 Briefing Books are highly graphical compilations of financial data, stock

charts, and recent news, available on more than 6,500 U.S. and international

companies.  They include news from The Wall Street Journal and Dow Jones

newswires, as well as extensive company performance data and background from

other leading information sources.

 Money & Investing Update editors will now include direct hyperlinks to

Briefing Books from nearly every significant mention of a company in an

Update story or table.  In addition, readers can ask for a Briefing Book on a

company of their choice at any time, simply by entering a stock symbol or

company name.  The Update is located on the World Wide Web at the URL

<a href="http://update.wsj.com">http://update.wsj.com</a>.

About Briefing Books

 Company Briefing Books include five sections, which readers can navigate

using a toolbar that appears at the top of every page.  "Our goal is to

provide a quick, yet comprehensive picture of a company to anyone in

business, whether they're preparing for a meeting, exploring an investment,

or just want more background on the news," said Neil Budde, editor of the

Money & Investment Update.  The Briefing Books five sections are as follows:



x   Company Background includes an updated overview of the company's business

and history.

x   The Financial Overview includes a two-year chart of quarterly earnings; a

five-year chart of annual earnings; tables listing five-year trends in

revenues, net income and dividends; and key balance-sheet figures and ratios.

x   The Stock Performance section features a graph of the stock's high, low,

close and volume over the past 200 days; a three-year chart of monthly

prices; a five-year picture of the stock's total return vs. its industry; and

basic measures such as 52-week high and low, yield, price-earnings ratio, and

other data.

x   Company News includes the full text of up to 18 stories on the company

from the past six months of The Wall Street Journal, the Dow Jones News

Service, and the AP/Dow Jones newswire.  The news stories provided are

constantly updated throughout the day.

x   A Press Releases section provides up to 18 items from the last six months

of the company's public announcements.


About Money & Investing Update

 Money & Investing Update is the first online publication to offer

continually updated news and analysis of the world's financial markets. 

 Produced by a team of Wall Street Journal editors dedicated to interactive

publishing, Money & Investing Update was launched on July 11, 1995 and

quickly became a major source for on-line business news.  The Update now has

more than 70,000 registered readers worldwide. 

 By early 1996, Money & Investing Update will expand its focus beyond the

markets to encompass the full scope of The Wall Street Journal's coverage,

evolving into a more complete interactive edition of The Journal. 

 Money & Investing Update will continue to be available for the next few

months at no charge.  Upcoming features will include: stock quotes and

financial data; expanded coverage around the clock; and the ability to access

the Update through customized software from Dow Jones.  

 Charter advertisers in the Update include Cadillac Motor Car Division, The

Dreyfus Corporation, EDS, Fidelity Investments, Hewlett Packard, Lombard

Institutional Brokerage Inc., Nortel, Oracle Corporation, Charles Schwab &

Co. Inc., Sun Microsystems, Tandy Corporation, Toyota, and Wells Fargo. 


About Dow Jones

 Dow Jones Business Information Services, the electronic publishing arm of

Dow Jones & Company, Inc., provides business and financial news and

information products to corporations and consumers through a variety of

electronic media: computer, telephone, facsimile and radio.

 Dow Jones also publishes The Wall Street Journal and its international

editions, Barron's<font size=2>&#174;</FONT> magazine and the Ottaway group of community newspapers.  

Interested customers may access the Update at <a href="http://update.wsj.com">http://update.wsj.com</a>. 
</pre>

<hr>

<a href="../latest.html">Back to the main Dow Jones in the News page.</a>
<hr>
<H4>We welcome feedback or questions about the <A 
HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A 
HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4>





</blockquote>

<pre>


</pre>
 
				
				<center>
					<a href="../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../bizpubs/index.html">Newspapers</a> |
					<a href="../clipping/index.html">Alert Services</a> |
					<a href="../online-lib/index.html">Research</a>  |
					<a href="../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../index.html">Home</a> 

				</font>
				
				
				</center>
				

</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-101</DOCNO>
<DOCOLDNO>IA028-000307-B015-267</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/release3.html 143.131.194.4 19970114052452 text/html 6361
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:29:00 GMT
Last-modified: Thursday, 23-May-96 18:34:35 GMT
Content-length: 6170
Content-type: text/html
</DOCHDR>
<html>
<head><title>PR Pages</title></head>


<body  background="../images/bgddj.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td>
<td>
<p>

<br>


<blockquote>

<center>

MEDIA ADVISORY<p>

<b>Dow Jones Introduces 

CustomClips<font size=2>&#174;</FONT> for Lotus Notes<font size=2>&#174;</FONT> and Desktop Data Inc.'s Newsedge<font size=2>&#174;</FONT>
<p>Provides Coverage of Critical News and Information Throughout the Day

For Companies Using Groupware</b></center>

<pre>

 BOSTON, MASS., August 29, 1995 -- Dow Jones Business Information Services

announced at the Lotus Notes Symposium the introduction of Dow Jones'

CustomClips<font size=2>&#174;</FONT> for Groupware -- a service of Dow Jones News/Retrieval.

 CustomClips provides automatic delivery of customized and targeted business

news coverage to enterprise users of Lotus Notes<font size=2>&#174;</FONT>, the leading platform for

developing and deploying groupware applications, and users of NewsEDGE<font size=2>&#174;</FONT> from

Desktop Data, Inc.



 CustomClips is a powerful information tool that allows Lotus Notes and

NewsEDGE customers to track breaking news from approximately 1,000 news

sources -- including The Wall Street Journal and Dow Jones newswires

exclusively, and Dow Jones News/Retrieval's text library and business

newswires.  



 Dow Jones' editors also have created a broad list of topics on more than 100

industries designed to monitor issues of great customer interest such as

research and development, product introductions, pricing changes or late

breaking business deals.  



 With CustomClips for Lotus Notes, selected stories that match a customer's

profile are e-mailed to the customer's database and automatically converted

to the Lotus Notes format using software from Dow Jones.  



 "Through CustomClips for Groupware, Dow Jones has created the premier

news-monitoring product for workgroups," said Josephine K. Ottman, director

of product marketing.  "Customers get high-quality business information that

lets them monitor competition better, follow new industry or product

developments, and stay up-to-date on market strategies directly through their

PCs.  Companies can immediately act on information instead of spending time

searching for it."



Targeted Information Only Dow Jones Can Deliver

 To help customers maximize the full potential of CustomClips, a Dow Jones

representative works directly with the customer using a "Topic Selection

Worksheet" to create a specific profile that captures all the relevant news

relating to a wide range of industries.  The profile enables a breaking

newswire story to be delivered to the corporate Groupware server minutes

after it becomes available -- making it an invaluable tool to key decision

makers and analysts.



 In addition to exclusive content from The Wall Street Journal and Dow Jones'

premier newswires including Dow Jones International News Service, users

receive articles from top U.S. newspapers, plus an extensive library of

local, regional and major international business and industry publications.



 "CustomClips for Lotus Notes provides new incentives for companies to

incorporate industry awareness into their daily communications," said Jeff

Papows, vice president, Lotus' Communications Products Group.  "With Lotus

Notes technology and Dow Jones news delivery expertise, timely news is

accessible seamlessly and effortlessly to companies world-wide."



 Updated throughout the day, stories are delivered directly to enterprise

Lotus Notes databases using Lotus Development's world-wide Lotus Notes

Network, WorldCom or directly through the Internet.  



 "With the availability of CustomClips, NewsEDGE customers will have the

ability to electronically monitor and access hundreds of additional

information sources," said Don McLagan, president, Desktop Data, Inc.



 "NewsEDGE customers in all industries, organizations and functions will be

delighted with the extended information coverage this provides."
<p>

About Dow Jones

 Dow Jones Business Information Services is the electronic publishing 

arm of Dow Jones & Company, Inc. which provides business news and 

information products to corporations, consumers and private investors through

a variety of electronic media: computer, telephone, facsimile and radio.



 Dow Jones also publishes The Wall Street Journal and its international

editions, Barron'sr magazine and other periodicals, electronic information

services, including Dow Jones Telerate and Financial News Services, and the

Ottaway community newspapers.
<p>

About Desktop Data, Inc.

 Desktop Data, Inc. is the leading independent provider of customized

real-time news and information delivered to knowledge workers over their

organizations' local area networks.  The company's NewsEDGEr service

currently delivers up to 488 news and information sources to 297 leading

corporate, financial and government institutions, representing approximately

60,000 authorized users.  Desktop Data is headquartered in Waltham,

Massachusetts.

</pre>

<hr>

<a href="../latest.html">Back to the main Dow Jones in the News page.</a>
<hr>
<H4>We welcome feedback or questions about the <A 
HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A 
HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4>





</blockquote>

<pre>


</pre>
 
				
				<center>
					<a href="../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../bizpubs/index.html">Newspapers</a> |
					<a href="../clipping/index.html">Alert Services</a> |
					<a href="../online-lib/index.html">Research</a>  |
					<a href="../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../index.html">Home</a> 

				</font>
				
				
				</center>
				

</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-102</DOCNO>
<DOCOLDNO>IA028-000307-B015-300</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/release2.html 143.131.194.4 19970114052522 text/html 6713
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:29:17 GMT
Last-modified: Thursday, 23-May-96 18:34:34 GMT
Content-length: 6522
Content-type: text/html
</DOCHDR>
<html>
<head><title>PR Pages</title></head>


<body  background="../images/bgddj.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td>
<td>
<p>

<br>


<blockquote>

<center>

MEDIA ADVISORY<p>

<b>INTRODUCING DOW JONES 

NEWS/RETRIEVAL--PRIVATE INVESTOR EDITION 
<p>Improved Version of Market Monitor and Tradeline Access Plan Features New,

Easy-To-Use Software</b></center>

<pre>

 PRINCETON, NJ  (June 14, 1995) Dow Jones Business Information Services

today announced improvements to its two services designed specifically for

private investors -- Dow Jones News/Retrieval<font size=2>&#174;</FONT>-Private Investor Edition and

Dow Jones News/Retrieval-Technical Analyst Edition.



 News/Retrieval-Private Investor Edition is a new, improved version of Dow

Jones Market Monitor, the most comprehensive online source of business and

financial information for the private investor who needs extensive news,

quotes and company data to make investment decisions.  



 News/Retrieval-Technical Analyst Edition, the improved version of Dow Jones

Tradeline Access Plan (TAP), is the most comprehensive source of in-depth

historical pricing data for investors who chart stock price movement.



 With the introduction of Dow Jones News/Retrieval-Private Investor Edition,

customers now have point-and-click access to hundreds of comprehensive

business and financial sources, daily and one-year historical quotes,

forecasts and analysis.  Using the new easy-to-use Windows or

soon-to-be-released Mac software, customers can create custom portfolios of

stocks, bonds and mutual funds and quickly perform investment research.  



 The Technical Analyst Edition now features Dow Jones Enhanced Current Quotes

as its source for the latest end-of-day quote information, plus access to

Tradeline's 20 years of historical pricing on over 150,000 securities, and

special technical analyst reports, all at the reduced price of $39.95 per

month.  



 "I rely on Dow Jones to provide me with the financial information to manage

my personal portfolio," said Barbara Robb, a Dow Jones customer from Chicago,

Illinois.  "It's crucial to get the day's closing information on stocks,

mutual funds and economic data from the wire services.  I haven't been able

to find a comparable service for the price."  



 "With Dow Jones, investors have access to the same sources financial

professionals use," said Josephine K. Ottman, director of product marketing,

Dow Jones Business Information Services.  "Our new software makes it easy to

get data investors need, and the flat monthly fee makes the cost predictable

and affordable.  Plus, customers can download data to a spreadsheet or to

popular investment software packages for further analysis."
<p>

About Dow Jones

 Dow Jones Business Information Services is the electronic publishing 

arm of Dow Jones & Company, Inc. that provides business news and 

information products to corporations, consumers and private investors through

a variety of electronic media: computer, telephone, facsimile and radio.

 Dow Jones also publishes The Wall Street Journal<font size=2>&#174;</FONT> and its international

editions, Barron's<font size=2>&#174;</FONT> magazine and other periodicals, electronic information

services, including Dow Jones Telerate and Financial News Services and the

Ottaway group of community newspapers.



More Information About Dow Jones Private Investor Services

The Private Investor Edition: An Unbeatable Value

 Subscribers can tap into high-quality comprehensive sources including:

* Full-text articles from The Wall Street Journal and Barron's and  hundreds

of other publications.

* Exclusive market news from five Dow Jones newswires and same-day

 newspapers, including The New York Times News Service and the  Financial

Times.

* A year's worth of daily mutual fund quotes; security snapshots,  including

earnings per share, P/E ratio, yield and more.

* Weekly stock quotes, back two years; hard-to-find international news;  and

abstracts of analysts' research reports.



 Cost for this service remains only $29.95 per month, the lowest price

available for a service of this kind.  The monthly fee offers users eight

hours a month access from 7:01 p.m. to 6 a.m. local time Monday through

Friday and all day Saturday and Sunday.  Customers can access the Private

Investor Edition outside these hours for an additional fee.  Additional

information sources are also available for an extra charge.

The Technical Analyst Edition: The Affordable Historical Pricing Source



 News/Retrieval-Technical Analyst Edition provides five hours access to the

Tradeline securities system, the largest historical pricing and performance

source available with daily prices on over 150,000 securities, plus five

hours of access to Dow Jones Enhanced Current Quotes -- all at a reduced

monthly fee of $39.95.



 Technical analysts who want to supplement their analysis with in-depth news

and company information can also subscribe to the Technical Analyst Gold

Edition, which encompasses the hundreds of sources available in the Private

Investor Edition in addition to the extensive pricing data from Tradeline.



 For the reduced rate of $59.95, subscribers receive eight hours access to

Private Investor Edition plus five hours access to the Tradeline security

system.  



To order software, contact Private Investor sales at 1/800-815-5100.
</pre>

<hr>

<a href="../latest.html">Back to the main Dow Jones in the News page.</a>
<hr>
<H4>We welcome feedback or questions about the <A 
HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A 
HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4>





</blockquote>

<pre>


</pre>
 
				
				<center>
					<a href="../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../bizpubs/index.html">Newspapers</a> |
					<a href="../clipping/index.html">Alert Services</a> |
					<a href="../online-lib/index.html">Research</a>  |
					<a href="../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../index.html">Home</a> 

				</font>
				
				
				</center>
				

</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-103</DOCNO>
<DOCOLDNO>IA028-000307-B015-345</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/release6.html 143.131.194.4 19970114052544 text/html 4935
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:29:49 GMT
Last-modified: Thursday, 23-May-96 18:34:36 GMT
Content-length: 4744
Content-type: text/html
</DOCHDR>
<html>
<head><title>PR Pages</title></head>


<body  background="../images/bgddj.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td>
<td>
<p>

<br>


<blockquote>

<center>

MEDIA ADVISORY<p>

<b>Dow Jones Introduces CD-ROM for Retirement Planning
<p>Interactive, multimedia program offers customized financial guidelines plus
new information from Wall Street Journal reporters and financial experts</b></center>

<pre>

PRINCETON, N.J. -- Dow Jones Business Information Services today introduced

Plan Aheadx for Your Financial Future from The Wall Street Journal. This new

CD-ROM is an interactive, multimedia guide for people aged 25 - 50 to map out

their retirement strategies in a knowledgeable and  enjoyable way.

 Plan Ahead for Your Financial Future was designed to help people create

long-range financial plans and develop manageable and realistic strategies

for saving and investing to reach those goals.  It offers original material

from Wall Street Journal reporters and expert analysis from money management

professionals, plus interactive worksheets and video commentary. 

 Individuals enter their personal retirement goals and current financial

situation into the worksheets.  From this information, Plan Ahead for Your

Financial Future provides customized savings and planning suggestions and

guidelines, provided by a "live" narrator (on video) and colorful, useful

charts and graphs. 

  Users may follow the game-board structure that leads them through the

process of creating a financial plan from beginning to end, or simply

point-and-click on those areas that are most important to them. 



 Plan Ahead offers segments such as:

* Your Retirement Goals

* Where Are You Now?

* Investing for Retirement

* Tax-Deferred Savings

* Retirement Income

* Other Life Goals

* Your Retirement Plan

 As users' financial situations change, they can easily review and revise

their goals and strategies.

 "Everybody looks forward to retirement, but few people look forward to

planning for it. And with concerns about the availability of Social Security

and company pension funds in the coming years, retirement planning often is

 an intimidating and overwhelming process," said Ronnie Fielding, assistant

director of Dow Jones Private Investor Products.  

 "That's why Dow Jones developed Plan Ahead for Your Financial Future: to

provide an interactive, easy-to-use product to help individuals identify

their retirement goals and determine a realistic savings and investing plan.

 With Plan Ahead, retirement planning can be an enjoyable experience," Ms.

Fielding said.

 Plan Ahead for Your Financial Future is available for $39.95 from Dow Jones

at 1-800-522-3567, ext. 319.  It is a Windows product, requiring standard

multimedia PC specifications: a 486 computer or higher with 8 megabytes of

RAM, CD-ROM drive, sound capabilities and video card with 256 colors.

 Plan Ahead for Your Financial Future utilizes ActiveBook and

ActiveInformation software, trademarked products of Vertigo Development

Group, Inc., Cambridge, Mass.


 Plan Ahead for Your Financial Future is a product of Dow Jones Business

Information Services, which provides business and financial news and

information products to corporations and consumers through a variety of

electronic media: computer, telephone, facsimile and radio.  Dow Jones

Business Information Services is a part of the Information Services group of

Dow Jones & Company, Inc., which includes Dow Jones Telerate and Dow Jones

Financial News Services.  Dow Jones also publishes The Wall Street Journal

and its international editions, Barron's and community newspapers.
</pre>

<hr>

<a href="../latest.html">Back to the main Dow Jones in the News page.</a>
<hr>
<H4>We welcome feedback or questions about the <A 
HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A 
HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4>





</blockquote>

<pre>


</pre>
 
				
				<center>
					<a href="../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../bizpubs/index.html">Newspapers</a> |
					<a href="../clipping/index.html">Alert Services</a> |
					<a href="../online-lib/index.html">Research</a>  |
					<a href="../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../index.html">Home</a> 

				</font>
				
				
				</center>
				

</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-104</DOCNO>
<DOCOLDNO>IA028-000307-B016-26</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/relcat1.html 143.131.194.4 19970114052557 text/html 4646
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:30:08 GMT
Last-modified: Monday, 16-Sep-96 14:34:44 GMT
Content-length: 4457
Content-type: text/html
</DOCHDR>
<html><head><title>PR Pages</title></head><body bgcolor="#ffffff" background="../images/bgddj.gif"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td><td><p><br><CENTER>	<H3><FONT SIZE=+2>N</FONT>ewspapers</H3><HR SIZE=4></CENTER><blockquote><p><STRONG> Aug. 16, 1996</STRONG> -  <A HREF="/press/releas31.html">Dow Jones Personal Journal To Be Preinstalled On New Line of Toshiba Notebook Computers</A><P><STRONG> Aug. 13, 1996</STRONG> - <A HREF="/press/releas29.html">The Wall Street Journal Interactive Edition  Announces Technology & Marketing Alliance with Microsoft</A><P><STRONG> July 29, 1996</STRONG> - <A HREF="/press/releas28.html">The Wall Street Journal Interactive Edition Introduces E-Mart</A><P><STRONG> July 23, 1996</STRONG> -  <A HREF="/press/releas27.html">Dow Jones Announces Distribution Agreement with Day-Timer Technologies; Personal Journal Now Included On Day-Timers CD-ROM</A><P><STRONG> July 22, 1996</STRONG> -<A HREF="/press/releas26.html">Photographer Annie Leibovitz Teams With The Wall Street Journal for First Internet Venture; Olympics Photos Appear on Journal's Interactive Edition</A><P><STRONG> July 1, 1996</STRONG> - <A HREF="/press/releas22.html">Dow Jones and U.S. Robotics Announce Distribution Agreement For Personal Journal</A><P><STRONG> June 24, 1996</STRONG> - <A HREF="/press/releas23.html">The Wall Street Journal Interactive Edition Registers 500,000th Reader</A><P><STRONG> May 29, 1996</STRONG> -<A HREF="/press/releas20.html">Dow Jones Systems Engineers Win Sun Microsystems' Java Cup Contest</A><P><STRONG>May 6, 1996</STRONG> - <A HREF="releas17.html">The Wall Street Journal Interactive Edition's First Week Brings Strong Reader Interest, Heavy Traffic</A><p><STRONG>April 29, 1996</STRONG> - <A HREF="releas16.html">The Wall Street Journal Interactive Edition Debuts Today on the World Wide Web</A><p><STRONG>February 27, 1996</STRONG> - <A HREF="releas13.html">Dow Jones and W.W. Norton introduce first-of-its-kind World Wide Web learning resource</A><p><STRONG>January 29, 1996</STRONG> - <A HREF="release7.html">Top Business News Now Directly Available On New Compaq PCs</A><p><STRONG>January 5, 1996</STRONG> - <A HREF="release8.htm">Personal Journal Software Now Available Through the Internet</A><p> <STRONG>November 27, 1995 </STRONG>  - <A HREF="releas15.html"> The Wall Street Journal Announces Customized Netscape Navigator Offering One-Step Access to Leading Internet News Source</a><p><STRONG>October 18, 1995</STRONG> - <A HREF="releas14.html"> The Wall Street Journal Premiers 24-Hour News Reporting in Money & Investing Update</a><p> <STRONG>September 20, 1995</STRONG> - <A HREF="release9.html">Now Personal Journal Delivers Itself Whenever You Want It</A><p> <STRONG>September 19, 1995</STRONG> - <A HREF="release5.html">The Wall Street Journal Enhances Money & Investing Update with Briefing Books</A><hr><CENTER><H4>Press releases organized by product line:</H4></CENTER> <p><p><A HREF="relcat2.html">Clipping, Tracking & Alert Services</A><p><A HREF="relcat3.html">Online Research Service</A><p><A HREF="relcat4.html">Personal Finance & Investing</A><p><br><a href="../latest.html">Back to the main Dow Jones in the News page.</a><hr><H4>We welcome feedback or questions about the <A HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4></blockquote><pre></pre> 								<center>					<a href="../toolbar.gif.map">								<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>					<BR>									<font size=2>					<a href="../bizpubs/index.html">Newspapers</a> |					<a href="../clipping/index.html">Alert Services</a> |					<a href="../online-lib/index.html">Research</a>  |					<a href="../pers-finance/index.html">Personal Finance</a>  |  					<a href="../latest.html">DJ In The News</a>  |					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |					<a href="../index.html">Home</a> 				</font>												</center>				</TD></tr></TABLE></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-105</DOCNO>
<DOCOLDNO>IA028-000307-B016-64</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/relcat2.html 143.131.194.4 19970114052648 text/html 2482
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:30:39 GMT
Last-modified: Wednesday, 09-Oct-96 14:22:40 GMT
Content-length: 2290
Content-type: text/html
</DOCHDR>
<html><head><title>PR Pages</title></head><body bgcolor="#ffffff" background="../images/bgddj.gif"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td><td><p><br><CENTER>	<H3><FONT SIZE=+2>C</FONT>lipping, Tracking & Alert Services</H3><HR SIZE=4></CENTER><blockquote><STRONG> Oct. 1, 1996</STRONG> - <A HREF="/press/releas36.html">Dow Jones' DowVision&#174 to Expand Daily Newspaper Coverage</A><P><STRONG> Sept. 19, 1996</STRONG> - <A HREF="/press/releas35.html">Dow Jones' DowVision&#174 toProvide Customized News and Information to Cadence Design</A><P><STRONG>August 29, 1995</STRONG> - <A HREF="release3.htm">Dow Jones Introduces CustomClips<font size=2>&#174;</FONT> for Lotus Notes<font size=2>&#174;</FONT> and Desktop Data Inc.'s Newsedge<font size=2>&#174;</FONT></A><p><STRONG>June 14, 1995 </STRONG> - <A HREF="release2.htm">Improved Version of Market Monitor and Tradeline Access Plan Features New, Easy-To-Use Software</A><hr><CENTER><H4>Press releases organized by product line:</H4></CENTER> <p><A HREF="relcat1.html">Newspapers</a><p><p><A HREF="relcat3.html">Online Research Service</A><p><A HREF="relcat4.html">Personal Finance & Investing</A><p><br><a href="../latest.html">Back to the main Dow Jones in the News page.</a><hr><H4>We welcome feedback or questions about the <A HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4></blockquote><pre></pre> 								<center>					<a href="../toolbar.gif.map">								<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>					<BR>									<font size=2>					<a href="../bizpubs/index.html">Newspapers</a> |					<a href="../clipping/index.html">Alert Services</a> |					<a href="../online-lib/index.html">Research</a>  |					<a href="../pers-finance/index.html">Personal Finance</a>  |  					<a href="../latest.html">DJ In The News</a>  |					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |					<a href="../index.html">Home</a> 				</font>												</center>				</TD></tr></TABLE></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-106</DOCNO>
<DOCOLDNO>IA028-000307-B016-98</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/relcat3.html 143.131.194.4 19970114052700 text/html 3267
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:31:10 GMT
Last-modified: Wednesday, 18-Sep-96 13:51:31 GMT
Content-length: 3075
Content-type: text/html
</DOCHDR>
<html><head><title>PR Pages</title></head><body bgcolor="#ffffff" background="../images/bgddj.gif"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td><td><p><br><CENTER>	<H3><FONT SIZE=+2>O</FONT>nline Research Service</H3><HR SIZE=4></CENTER><blockquote><br><STRONG> Sept. 16, 1996</STRONG> - <A HREF="/press/releas34.html">Same Day Full Text of The Washington Post Available Through Dow Jones Business Information Services</A><P><STRONG> Aug. 19, 1996</STRONG> - <A HREF="/press/releas32.html">Dow Jones News/Retrieval Now Available to Visitors of New Science, Industry and Business Library</A><P><STRONG> Aug. 12, 1996</STRONG> - <A HREF="/press/releas30.html">Dow Jones News/Retrieval Provides Continuously Updated News on Election Campaigns</A><P><STRONG> June 7, 1996</STRONG> -  <A HREF="/press/releas21.html">Dow Jones Establishes National Alliance Program For Professional Researchers</A><P><STRONG> May 14, 1996</STRONG><BR> <A HREF="press/releas19.html">Dow Jones Extends Leadership As Business Information Publisher; Sets New Industry Standard With Transformed Business Online Service</A><p><STRONG> May 7, 1996</STRONG> - <A HREF="releas18.html">Dow Jones' Massive Online Business Resource Doubles International Publications Offering With Quest Economics Database </A><p><STRONG>December 20, 1995</STRONG> -  <A HREF="releas11.htm">Dow Jones announces News/Retrieval for Macintosh</a><p><STRONG>October  31, 1995</STRONG>  - <A HREF="releas12.htm"> 'The world's most useful online business library' adds  full-text archives of the New York Times</A><p><STRONG>October  30, 1995</STRONG> - <A HREF="releas10.htm"> Massive online business library boosted by over 65 percent</A><hr><CENTER><H4>Press releases organized by product line:</H4></CENTER> <p><A HREF="relcat1.html">Newspapers</a><p><A HREF="relcat2.html">Clipping, Tracking & Alert Services</A><p><p><A HREF="relcat4.html">Personal Finance & Investing</A><p><br><a href="../latest.html">Back to the main Dow Jones in the News page.</a><hr><H4>We welcome feedback or questions about the <A HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4></blockquote><pre></pre> 								<center>					<a href="../toolbar.gif.map">								<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>					<BR>									<font size=2>					<a href="../bizpubs/index.html">Newspapers</a> |					<a href="../clipping/index.html">Alert Services</a> |					<a href="../online-lib/index.html">Research</a>  |					<a href="../pers-finance/index.html">Personal Finance</a>  |  					<a href="../latest.html">DJ In The News</a>  |					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |					<a href="../index.html">Home</a> 				</font>												</center>				</TD></tr></TABLE></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-107</DOCNO>
<DOCOLDNO>IA028-000307-B016-139</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/press/relcat4.html 143.131.194.4 19970114052714 text/html 1929
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:31:25 GMT
Last-modified: Thursday, 23-May-96 18:34:30 GMT
Content-length: 1738
Content-type: text/html
</DOCHDR>
<html>
<head><title>PR Pages</title></head>


<body bgcolor="#ffffff" background="../images/bgddj.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80 valign=top ><img SRC="../images/trsp.gif">  
<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../images/dowj.gif"></td>
<td>
<p>

<br>
<CENTER>	



<H3>
<FONT SIZE=+2>P</FONT>ersonal Finance & Investing
</H3>
<HR SIZE=4>
</CENTER>



<blockquote>
<b>June 14, 1995</b><p>

<A HREF="release2.htm">Improved Version of Market Monitor and Tradeline Access Plan Features New, Easy-To-Use Software</A>



<hr>
<CENTER><H4>Press releases organized by product line:</H4></CENTER> <p>
<A HREF="relcat1.html">Newspapers</a><p>
<A HREF="relcat2.html">Clipping, Tracking & Alert Services</A><p>
<A HREF="relcat3.html">Online Research Service</A><p>

<br>
<a href="../latest.html">Back to the main Dow Jones in the News page.</a>
<hr>
<H4>We welcome feedback or questions about the <A 
HREF="mailto:maggie.landis@cor.dowjones.com">press releases</a> or <A 
HREF="mailto:webmaster@bis.dowjones.com">the site</a>. </H4>





</blockquote>

<pre>


</pre>
 
				
				<center>
					<a href="../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../bizpubs/index.html">Newspapers</a> |
					<a href="../clipping/index.html">Alert Services</a> |
					<a href="../online-lib/index.html">Research</a>  |
					<a href="../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../index.html">Home</a> 

				</font>
				
				
				</center>
				

</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-108</DOCNO>
<DOCOLDNO>IA028-000307-B016-174</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/bizpubs/toolbar.gif.map 143.131.194.4 19970114052742 text/html 321
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:31:36 GMT
Content-type: text/html
Content-length: 180
</DOCHDR>
<TITLE>Imagemap Error</TITLE><H1>Imagemap Error</H1>Your client did not send any coordinates. Either your client doesn't support imagemap or the map file was not accessed as a map.
</DOC>
<DOC>
<DOCNO>WT18-B31-109</DOCNO>
<DOCOLDNO>IA028-000307-B016-207</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/pers-finance/mainpage.map 143.131.194.4 19970114052822 text/html 321
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:32:18 GMT
Content-type: text/html
Content-length: 180
</DOCHDR>
<TITLE>Imagemap Error</TITLE><H1>Imagemap Error</H1>Your client did not send any coordinates. Either your client doesn't support imagemap or the map file was not accessed as a map.
</DOC>
<DOC>
<DOCNO>WT18-B31-110</DOCNO>
<DOCOLDNO>IA028-000307-B016-315</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/custom-clips/publications/computers.html 143.131.194.4 19970114053008 text/html 6672
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:34:04 GMT
Last-modified: Wednesday, 29-May-96 14:59:51 GMT
Content-length: 6480
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>

<body bgcolor="#ffffff" background="../../images/bgdcc.gif">


<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td valign=top width=80>  
	<a href="../../index.html">
   <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../../images/lrgcosclip.gif"></a>
    <br>  
    <img SRC="../../../images/trsp.gif"></td> 
<td>

<br>

<CENTER><H2>
Computers/Computer Technology
</H2></CENTER>

<HR SIZE=4>
<P>
<blockquote>
<font size=4>			

<BR>
					

<BR>
					
		
		<P>
		<A NAME="A-C"></a>
		<B>A-C</B> 
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<A HREF="#D-M">D-M</A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<A HREF="#N-Z">N-Z</A>
		<bR>			
		
		
				<br>

<em>
				Advanced Imaging
				<BR>
				Advanced Intelligent Network News	
				<BR>
				AI Expert	
				<BR>
				America's Network	
				<BR>
				Audiotex Update	
				<BR>
				Automatic I.D. News	
				<BR>
				Automatic Merchandiser	
				<BR>
				Automation	
				<BR>
				Bank Systems & Technology	
				<BR>
				Bank Technology News	
				<BR>
				Business Computing Brief
				<BR>
				C/C++ Users Journal	
				<BR>
				CAD/CAM Update	
				<BR>
				CADalyst	
				<BR>
				Canadian Electronics	
				<BR>
				Cellular Business	
				<BR>
				Cellular Marketing	
				<BR>
				Comline Daily News Computers	
				<BR>
				Comline Daily News Electronics	
				<BR>
				Computer Conference Analysis Newsletter	
				<BR>
				Computer Aided Engineering	
				<BR>
				Computer Business Review
				<BR>
				Computer Dealer News	
				<BR>
				Computer Finance	
				<BR>
				Computer Gaming World	
				<BR>
				Computer Graphics World	
				<BR>
				Computer Life	
				<BR>
				Computer Protocols	
				<BR>
				Computer Shopper	
				<BR>
				Computer Telephony	
				<BR>
				Computer Workstations	
				<BR>
				Computergram International	
				<BR>
				Computers in Libraries	
				<BR>
				ComputerWorld	
				<BR>
				Computergram International
				<BR>
				Computing Canada	
				<BR>
				Consumer Electronics</EM>	
					<BR>

		<BR>				
		<A NAME="D-M"></a>


<A HREF="#A-C">A-C</A>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<B>D-M</B>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<A HREF="#N-Z">N-Z</A>



		<BR>
    <BR>



			<EM>	Data Based Advisor	
				<BR>
				Data Broadcasting News	
				<BR>
				Data Channels	
				<BR>
				Data Storage Report	
				<BR>
				DataTrends Report on DEC
				<BR>
				Database Searcher	
				<BR>
				DBMS	
				<BR>
				DEC Professional	
				<BR>
				Digital Media	
				<BR>
				Digital Systems Journal	
				<BR>
				Document Imaging Report	
				<BR>
				Dr. Dobb's Journal	
				<BR>
				Edge Work-Group Computing Report	
				<BR>
				EDI News
				<BR>
				Electronic Buyers' News
				<BR>
				Electronic Claims Processing Report	
				<BR>
				Electronic Engineering Times
				<BR>
				Electronic Learning	
				<BR>
				Electronic Messaging News	
				<BR>
				Electronic News	
				<BR>
				En Route Technology
				<BR>
				Electronics Design	
				<BR>
				Electronics Now	
				<BR>
				Electronics Times	
				<BR>
				En Route Technology	
				<BR>
				European R&D Initiative in Communications Report
				<BR>
				Enterprise Systems Journal	
				<BR>
				FCC Report
				<BR>
				Fujitsu Weekly
	
				<BR>
				Geo Info Systems	
				<BR>
				Government Computer News	
				<BR>
				GUI Program News	
				<BR>
				Health Management Technology	
				<BR>
				Hewlett-Packard Journal	
				<BR>
				Home Office Computing	
				<BR>
				HP Professional	
				<BR>
				Imaging Update	
				<BR>
				INTERNETWORK	
				<BR>
				ISDN News	
				<BR>
				LAN Product News
				<BR>
				LAN Magazine	
				<BR>
				LAN Product News	
				<BR>
				Laser Focus World	
				<BR>
				Library Software Review	
				<BR>
				Local Competition Report
				<BR>
				MacUser
				<BR>
				MacWEEK	
				<BR>
				Mainframe Computing	
				<BR>
				Modem User News
				<BR>
				Managing Office Technology	
				<BR>
				Microprocessor Report	
				<BR>
				Microsoft Systems Journal	
				<BR>
				Microwave Journal	
				<BR>
				Microwaves & RF	
				<BR>
				MIDRANGE Systems	
				<BR>
				MIS Quarterly	
				<BR>
				Modem User News</EM>	
								
		<BR>
		<BR>	
			
		<A NAME="N-Z"></a>
		<A HREF="#A-C">A-C</A>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<A HREF="#D-M">D-M</A>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<B>N-Z</B>


		<BR>

<BR>
				<EM>
				NetGuide
				<BR>
				Network Management Systems & Strategies
				<BR>
				Network VAR
				<BR>
				Networks Update	
				<BR>
				Newsbytes News Network	
				<BR>
				Novell News	
				<BR>
				Office Equipment and Products	
				<BR>
				Online Libraries & Microcomputers	
				<BR>
				Optical Memory News	
				<BR>
				PC Business Products
				<BR>
				PC Magazine	
				<BR>
				PC User	
				<BR>
				PC Week	
				<BR>
				PC Computing	
				<BR>
				PCS News	
				<BR>
				Productivity Software	
				<BR>
				Records Management Quarterly
				<BR>
				Report on IBM	
				<BR>
				Semiconductor Industry & Business Survey	
				<BR>
				Sensor Business Digest	
				<BR>
				Seybold Report on Desktop Publishing	
				<BR>
				Seybold Report on Publishing Systems	
				<BR>
				SMT Trends	
				<BR>
				Soft-letter	
				<BR>
				Software Futures	
				<BR>
				Software Industry Report	
				<BR>
				Software Magazine	
				<BR>
				Solid State Technology	
				<BR>
				Superconductor Week	
				<BR>
				Technical Communication	
				<BR>
				Technology & Learning	
				<BR>
				Technology Review	
				<BR>
				Telecommunications	
				<BR>
				Telecommuting Review:  the Gordon Report	
				<BR>
				Teleconnect	
				<BR>
				Toshiba Weekly
				<BR>
				UNIX News	
				<BR>
				UNIX Review	
				<BR>
				UNIX Update	
				<BR>
				Voice Technology News
				<BR>
				Windows Sources	
				<BR>
				Windows-DOS Developer's Journal</em>	
			
			

</font>
</blockquote>


<BR>
		<pre>
		
		
			</pre>
			<CENTER>Back To 
			<A HREF="publications.html">Publications</A>
			
			
					<a href="../../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../../bizpubs/index.html">Newspapers</a> |
					<a href="../../../clipping/index.html">Alert Services</a> |
					<a href="../../../online-lib/index.html">Research</a>   |
					<a href="../../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../../index.html">Home</a> 

				</font>
				
				</center>
				




</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-111</DOCNO>
<DOCOLDNO>IA028-000307-B016-345</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/custom-clips/publications/communications.html 143.131.194.4 19970114053034 text/html 2868
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:34:31 GMT
Last-modified: Wednesday, 29-May-96 14:59:51 GMT
Content-length: 2676
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>

<body bgcolor="#ffffff" background="../../images/bgdcc.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td valign=top width=80>  
	<a href="../../index.html">
   <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../../images/lrgcosclip.gif"></a>
    <br>  
    <img SRC="../../../images/trsp.gif"></td> 
<td>

<br>


<CENTER><H2>
Communications
</H2></CENTER>

<HR SIZE=4>
<P>
<blockquote>
<font size=4>
					
					
		
		<P>
		<br>
		<br>	
		
		
				<em>
				411 Newsletter
				<BR>
				Advanced Wireless Communications	
				<BR>
				Asia-Pacific Telecoms Analyst	
				<BR>
				Broadband Networking News	
				<BR>
				Common Carrier Week	
				<BR>
				Communication World	
				<BR>
				Communications Daily	
				<BR>
				Communications International	
				<BR>
				Communications News	
				<BR>
				Communications Standards News	
				<BR>
				Global Communications	
				<BR>
				Information Law Alert: A Voorhees Report	
				<BR>
				Inside Telecom	
				<BR>
				Land Mobile Radio News	
				<BR>
				Mobile Communications	
				<BR>
				Mobile Data Report	
				<BR>
				Mobile Phone News	
				<BR>
				Mobile Satellite Reports	
				<BR>
				RBOC Update	
				<BR>
				Report on AT&T	
				<BR>
				Satellite Communications	
				<BR>
				Satellite News	
				<BR>
				Satellite Week	
				<BR>
				Satnews	
				<BR>
				State Telephone Regulation Report	
				<BR>
				Telco Business Report	
				<BR>
				Tele-Service News	
				<BR>
				Telecom Markets	
				<BR>
				Telecommunications Alert	
				<BR>
				Telecomworldwire	
				<BR>
				Telemedia News & Views	
				<BR>
				Telephone IP News	
				<BR>
				Telephony	
				<BR>
				Wall Street Network News	
				<BR>
				Washington Telecom News	
				<BR>
				Wireless Business and Finance	
				<BR>
				Wireless Data News	
				<BR>
				Worldwide Telecom</em>	
<P>
					
</font>
</blockquote>		
			
		





<BR>
		<pre>
		
		
			</pre>
			
			<CENTER>Back To 
			<A HREF="publications.html">Publications</A>
			
			
			<br>					<a href="../../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../../bizpubs/index.html">Newspapers</a> |
					<a href="../../../clipping/index.html">Alert Services</a> |
					<a href="../../../online-lib/index.html">Research</a>   |
					<a href="../../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../../index.html">Home</a> 

				</font>
				
				
				</center>
				




</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-112</DOCNO>
<DOCOLDNO>IA028-000307-B016-373</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/custom-clips/publications/construct.html 143.131.194.4 19970114053048 text/html 2068
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:34:55 GMT
Last-modified: Wednesday, 29-May-96 14:59:51 GMT
Content-length: 1876
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>

<body bgcolor="#ffffff" background="../../images/bgdcc.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td valign=top width=80>  
	<a href="../../index.html">
   <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../../images/lrgcosclip.gif"></a>
    <br>  
    <img SRC="../../../images/trsp.gif"></td> 
<td>

<br>

<CENTER><H2>
Construction
</H2></CENTER>

<HR SIZE=4>
<P>
<blockquote>
<font size=4>
					
					
		
		<P>
	


<br><em>

Appraisal Journal	
<BR>
Asbestos & Lead Abatement Report	
<BR>
Carpet and Floorcovering News	
<BR>
Chilton's Hardware Age	
<BR>
Concrete Products	
<BR>
Construction Review	
<BR>
Contractor	
<BR>
Custom Builder	
<BR>
Design Quarterly	
<BR>
DIY Week	
<BR>
Electrical Construction & Maintenance	
<BR>
European Adhesives and Sealants	
<BR>
Flooring	
<BR>
Glass	
<BR>
Glass International
<BR>
Heating, Piping & Air Conditioning
<BR>
National Real Estate Investor
<BR>
Progressive Architecture
<BR>
Real Estate Economics
<BR>
World Tunnelling and Subsurface Excavation</em>



</font>
</blockquote>


<BR>
			
		<pre>
		
		
		
		</pre>
			
			<CENTER>Back To 
			<A HREF="publications.html">Publications</A>
			
			
			
			<br>
				
				<a href="../../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../../bizpubs/index.html">Newspapers</a> |
					<a href="../../../clipping/index.html">Alert Services</a> |
					<a href="../../../online-lib/index.html">Research</a>   |
					<a href="../../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../../index.html">Home</a> 

				</font>
			
				
				</center>
				




</TD></tr>
</TABLE>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT18-B31-113</DOCNO>
<DOCOLDNO>IA028-000307-B016-419</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/custom-clips/publications/energy.html 143.131.194.4 19970114053152 text/html 3234
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:35:36 GMT
Last-modified: Wednesday, 29-May-96 14:59:52 GMT
Content-length: 3042
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>

<body bgcolor="#ffffff" background="../../images/bgdcc.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td valign=top width=80>  
	<a href="../../index.html">
   <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../../images/lrgcosclip.gif"></a>
    <br>  
    <img SRC="../../../images/trsp.gif"></td> 
<td>

<br>



<CENTER><H2>
Energy
</H2></CENTER>

<HR SIZE=4>
<P>
<blockquote>
<font size=4>
					
					
		
		<P>
	






<br>

<br><em>
			21st Century Fuels	
			<BR>
			APS Diplomat Operations in Oil Diplomacy	
			<BR>
			APS Review Downstream Trends
			<BR>
			APS Review Gas Market Trends
			<BR>
			APS Review Oil Market Trends
			<BR>
			Asian Electricity Conference
			<BR>
			Coal
			<BR>
			Coal & Synfuels Technology
			<BR>
			Coal Outlook	
			<BR>
			Coal UK	
			<BR>
			East European Energy Report	
			<BR>
			EC Energy Monthly	
			<BR>
			Electric Light & Power	
			<BR>
			Energy Alert	
			<BR>
			Energy Economist
			<BR>
			Energy Report	
			<BR>
			Energy User News	
			<BR>
			European Energy Report
			<BR>
			European Power News	
			<BR>
			Gas Daily	
			<BR>
			Gas Transactions Report	
			<BR>
			Gas World International	
			<BR>
			GRID Gas Research Institute Digest	
			<BR>
			Hydrocarbon Processing	
			<BR>
			Improved Recovery Week
			<BR>
			International Coal Report	
			<BR>
			International Gas Report	
			<BR>
			Latin American Energy Alert	
			<BR>
			Mining Journal	
			<BR>
			National Petroleum News	
			<BR>
			North Sea Letter	
			<BR>
			North Sea Rig Forecast	
			<BR>
			Octane Week	
			<BR>
			Oil and Gas Interest Newsletter	
			<BR>
			OPECNA News Service	
			<BR>
			Oxy-Fuel News	
			<BR>
			Petroleum Finance Week
			<BR>
			Petroleum Economist	
			<BR>
			Petroleum Independent	
			<BR>
			Pipe Line and Gas Industry	
			<BR>
			Pipe Line Industry	
			<BR>
			Pipeline & Gas Journal	
			<BR>
			Pipeline and Utilities Construction	
			<BR>
			Power Asia	
			<BR>
			Power Electronics Daily	
			<BR>
			Power Engineering	
			<BR>
			Power Europe	
			<BR>
			Power UK
			<BR>
			UK Gas Report	
			<BR>
			Utility Reporter Fuels Energy & Power	
			<BR>
			World Oil	
			<BR>
			World Rig Forecast	
			<BR>
			Worldwide Energy</em>	
</font>
</blockquote>


<BR>
			
		<pre>
		
		
		
		</pre>
			
			<CENTER>Back To 
			<A HREF="publications.html">Publications</A>
			
			
			<br>
				
				<a href="../../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../../bizpubs/index.html">Newspapers</a> |
					<a href="../../../clipping/index.html">Alert Services</a> |
					<a href="../../../online-lib/index.html">Research</a>   |
					<a href="../../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../../index.html">Home</a> 

				</font>
		
				</center>
				




</TD></tr>
</TABLE>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT18-B31-114</DOCNO>
<DOCOLDNO>IA028-000307-B016-452</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/custom-clips/publications/environment.html 143.131.194.4 19970114053226 text/html 2940
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:36:33 GMT
Last-modified: Wednesday, 29-May-96 14:59:52 GMT
Content-length: 2748
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>

<body bgcolor="#ffffff" background="../../images/bgdcc.gif">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td valign=top width=80>  
	<a href="../../index.html">
   <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../../images/lrgcosclip.gif"></a>
    <br>  
    <img SRC="../../../images/trsp.gif"></td> 
<td>

<br>



<CENTER><H2>
Environment
</H2></CENTER>

<HR SIZE=4>
<P>
<blockquote>
<font size=4>


<br>

			<br><em>
			Alternative Energy Digests	
			<BR>
			Alternative Energy Network Online Today	
			<BR>
			Audubon
			<BR>
			Clean Air Network Online Today
			<BR>
			Conservationist	
			<BR>
			Corps Report	
			<BR>
			Defense Cleanup	
			<BR>
			Development Bulletin	
			<BR>
			E	
			<BR>
			E&P Environment	
			<BR>
			Environment Bulletin	
			<BR>
			Environment Business	
			<BR>
			Environment Watch Latin America	
			<BR>
			Environmental Action Magazine	
			<BR>
			Environmental Liability Report	
			<BR>
			Environmental Solutions	
			<BR>
			Environmental Watch Western Europe
			<BR>
			Environmental Problems & Remediation
			<BR>
			Global Environmental Change Report
			<BR>
			Global Warming Network Online Today	
			<BR>
			Industrial Environment
			<BR>
			Industrial Health & Hazards Update
			<BR>
			International Wildlife	
			<BR>
			Louisiana Industry Environmental Advisor	
			<BR>
			New Jersey Industry Environmental Advisor
			<BR>
			Municipal & Industrial Water & Pollution Control	
			<BR>
			National Wildlife	
			<BR>
			Ohio Industry Environmental Advisor	
			<BR>
			Oil Spill Intelligence Report	
			<BR>
			Ozone Depletion Network Online Today	
			<BR>
			Parks & Recreation	
			<BR>
			Plants Sites & Parks	
			<BR>
			Recycling Coordinator	
			<BR>
			Superfund Week
			<BR>
			Texas Industry Environmental Advisor	
			<BR>
			Waste Information Digests	
			<BR>
			Water Briefing	
			<BR>
			Whole Earth Review	
			<BR>
			World Wastes</em>	

</font>
</blockquote>


<BR>
			
		<pre>
		
		
		
		</pre>
		<CENTER>Back To 
			<A HREF="publications.html">Publications</A>
			
			
			<br>
				
				<a href="../../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../../bizpubs/index.html">Newspapers</a> |
					<a href="../../../clipping/index.html">Alert Services</a> |
					<a href="../../../online-lib/index.html">Research</a>   |
					<a href="../../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../../index.html">Home</a> 

				</font>

				
				</center>
				




</TD></tr>
</TABLE>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT18-B31-115</DOCNO>
<DOCOLDNO>IA028-000307-B017-36</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/custom-clips/publications/financial.html 143.131.194.4 19970114053240 text/html 6444
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:36:51 GMT
Last-modified: Wednesday, 29-May-96 14:59:52 GMT
Content-length: 6252
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>

<body bgcolor="#ffffff" background="../../images/bgdcc.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td valign=top width=80>  
	<a href="../../index.html">
	<IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../../images/lrgcosclip.gif"></a>
    <br>  
    <img SRC="../../../images/trsp.gif"></td> 
<td>

<br>



<CENTER><H2>
Financial
</H2></CENTER>

<HR SIZE=4>
<P>
<blockquote>
<font size=4>
	<br>
	<br>				
	<P>
	
		
		
		<A NAME="A-E"></a>
		<B>A-E</B>
		&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
		<A HREF="#F-Z">F-Z</A>
		<bR>			
	<P>	
				<em>ABA Banking Journal	
				<BR>
				Accounting & Finance	
				<BR>
				Accounting Today	
				<BR>
				American Banker	
				<BR>
				American Banker's Washington Watch	
				<BR>
				Asset Sales Report
				<BR>
				Bank Automation News
				<BR>
				Bank Loan Report	
				<BR>
				Bank Mutual Fund Report	
				<BR>
				Bank Network News
				<BR>
				Best's Review -- Life-Health Insurance Edition	
				<BR>
				Best's Review -- Property-Casualty Insurance Edition
				<BR>
				Bond Buyer
				<BR>
				Bond Buyers Public Finance Watch	
				<BR>
				Business Conference and Management Reports
				<BR>
				Business Insurance
				<BR>
				Business Insurance Managed Care	
				<BR>
				Buyouts	
				<BR>
				California Public Finance
				<BR>
				Canadian Banker	
				<BR>
				Card News
				<BR>
				Card Systems	
				<BR>
				CardFAX
				<BR>
				CDA -- Investnet Insider's Chronicle	
				<BR>
				CFO Alert	
				<BR>
				CIMA Letter	
				<BR>
				Comline Daily News Financial Markets
				<BR>
				Commercial Mortgage Alert
				<BR>
				Commercial Policy Guide	
				<BR>
				Corporate Cashflow Magazine	
				<BR>
				Corporate EFT Report	
				<BR>
				Corporate Money	
				<BR>
				Credit Card News
				<BR>
				Credit Card Management	
				<BR>
				Credit Risk Management Report	
				<BR>
				Credit Union Executive	
				<BR>
				Defense Counsel Journal	
				<BR>
				East European Insurance Report	
				<BR>
				EFT Report	
				<BR>
				European Savings Markets</em>	


			
		<BR>
		<BR>				
		<A NAME="F-Z"></a>
		<A HREF="#A-E">A-E</A>
		&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
		<B>F-Z</B>
		
		
		<BR>
		
		<BR><em>
					Federal & State Insurance Week	
					<BR>
					Federal Reserve Bank of New York Economic Policy Review
					<BR>
					Federal Reserve Bank of New York Quarterly Review
					<BR>
					Federal Reserve Bank of St. Louis Review	
					<BR>
					Federal Reserve Bulletin	
					<BR>
					Finance & Development	
					<BR>
					Finance East Europe	
					<BR>
					Financial Planning	
					<BR>
					Financial Regulation Report
					<BR>
					Financial Review	
					<BR>
					Financial Services Report
					<BR>
					Financial World	
					<BR>
					Futurist
					<BR>
					Going Public: The IPO Reporter	
					<BR>
					High Yield Report
					<BR>
					Indonesian Investment Highlights	
					<BR>
					Inside Market Data	
					<BR>
					Institutional Investor	
					<BR>
					Insurance in the EC and Switzerland Management Report
					<BR>
					International Banking Regulator	
					<BR>
					International Market Alert
					<BR>
					International Monetary Fund Staff Papers	
					<BR>
					International Trade Finance
					<BR>
					Investment Dealers' Digest	
					<BR>
					Journal of Financial Research	
					<BR>
					Journal of Portfolio Management	
					<BR>
					Journal of Post-Keynesian Economics	
					<BR>
					Journal of Retail Banking	
					<BR>
					Journal of Risk and Insurance	
					<BR>
					Kiplinger's Personal Finance Magazine	
					<BR>
					LDC Debt Report	
					<BR>
					Liability Week	
					<BR>
					Liquidation Alert
					<BR>
					Lloyd's List International	
					<BR>
					Management Accounting (USA)	
					<BR>
					Manager's Magazine	
					<BR>
					Mergers & Acquisitions	
					<BR>
					Mergers & Acquisitions Report	
					<BR>
					Money Laundering Alert	
					<BR>
					Money Tonight	
					<BR>
					Mortgage Banking	
					<BR>
					Mortgage Marketplace	
					<BR>
					Mortgage-backed Securities Letter	
					<BR>
					Mutual Fund Investor	
					<BR>
					National Underwriter Life & Health-Financial Services Edition
					<BR>
					National Underwriter Property & Casualty-Risk & 
					<BR>
					Benefits Management
					<BR>
					Offshore Outlook	
					<BR>
					Ohio-CPA Journal
					<BR>
					Outlook	
					<BR>
					Pension World	
					<BR>
					Pensions & Investments	
					<BR>
					Personal Policy Guide	
					<BR>
					POS News	
					<BR>
					Practical Accountant	
					<BR>
					Private Placement Reporter	
					<BR>
					Privatisation International	
					<BR>
					Public Finance Quarterly	
					<BR>
					Quarterly Journal of Business and Economics
					<BR>
					Risk Management	
					<BR>
					Savings & Community Banker
					<BR>
					SmartMoney	
					<BR>
					Social Security Bulletin
					<BR>
					Statistical Bulletin-Metropolitan Life Insurance Company
					<BR>
					Tax Adviser	
					<BR>
					Thrift Regulator	
					<BR>
					Trading Systems Technology	
					<BR>
					Treasury Manager's Report	
					<BR>
					Trusts & Estates	
					<BR>
					US Banker	
					<BR>
					Wall Street & Technology	
					<BR>
					Washington Watch	
					<BR>
					Weekly International Market Alert	
					<BR>
					World Accounting Report	
					<BR>
					World Corporate Insurance Report
					<BR>
					World Insurance Report	
					<BR>
					World Policy Guide
					<BR>
					World Tax Report</em>
</font>
</blockquote>
<BR>
		


<BR>
		<pre>
		
		
		
		</pre>
			
			<CENTER>Back To 
			<A HREF="publications.html">Publications</A>
			
			
			<br>
			
			
				<a href="../../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../../bizpubs/index.html">Newspapers</a> |
					<a href="../../../clipping/index.html">Alert Services</a> |
					<a href="../../../online-lib/index.html">Research</a>   |
					<a href="../../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../../index.html">Home</a> 

				</font>

				
				</center>
				




</TD></tr>
</TABLE>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT18-B31-116</DOCNO>
<DOCOLDNO>IA028-000307-B017-72</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/custom-clips/publications/food.html 143.131.194.4 19970114053301 text/html 3830
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:37:02 GMT
Last-modified: Wednesday, 29-May-96 14:59:52 GMT
Content-length: 3638
Content-type: text/html
</DOCHDR>
7<html>
<head><title>Dow Jones</title></head>

<body bgcolor="#ffffff" background="../../images/bgdcc.gif">


<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td valign=top width=80>  
	<a href="../../index.html">
   <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../../images/lrgcosclip.gif"></a>
    <br>  
    <img SRC="../../../images/trsp.gif"></td> 
<td>

<br>







<CENTER><H2>
Food Processing 

</H2></CENTER>

<HR SIZE=4>
<P>
<blockquote>
<font size=4>
	<br>
	<br>				
	<P>
	<em>
	
					AgExporter	
				<BR>
					Agribusiness Worldwide	
					<BR>
					Agricultural Research	
					<BR>
					American Journal of Agricultural Economics	
					<BR>
					Arizona Farmer-Stockman
					<BR>
					Beverage Industry	
					<BR>
					Candy Industry	
					<BR>
					Chilton's Food Engineering	
					<BR>
					Cornell Hotel & Restaurant Administration Quarterly	
					<BR>
					Dairy Industries International	
					<BR>
					Emerging Food R&D Report	
					<BR>
					Fertilizer International	
					<BR>
					Food Engineering International	
					<BR>
					Food Labeling News	
					<BR>
					Food Manufacture International	
					<BR>
					Foodbyte News
					<BR>
					Food Service Distributor	
					<BR>
					Food Trade Review	
					<BR>
					Foodbyte News	
					<BR>
					Frozen & Chilled Foods	
					<BR>
					Grain: World Markets & Trade	
					<BR>
					Grocer	
					<BR>
					Hospitality Design
					<BR>
					ID: The Voice of Foodservice Distribution	
					<BR>
					Idaho Farmer	
					<BR>
					Inland Farmer	
					<BR>
					Montana Farmer
					<BR>
					Livestock, Dairy and Poultry	
					<BR>
					Lodging Hospitality	
					<BR>
					Nation's Restaurant News	
					<BR>
					Oilseeds: World Markets and Trade	
					<BR>
					Pacific Farmer-Stockman
					<BR>
					Pest Control	
					<BR>
					Product Alert	
					<BR>
					Progressive Grocer	
					<BR>
					Quick Frozen Foods International	
					<BR>
					Research Studies - USDA ERS Wheat	
					<BR>
					Research Studies - USDA FAS World	
					<BR>
					Restaurant Business	
					<BR>
					Restaurant Hospitality	
					<BR>
					Situation and Outlook Report, Cotton	
					<BR>
					Situation and Outlook Report, Feed	
					<BR>
					Situation and Outlook Report, Former	
					<BR>
					Situation and Outlook Report, Fruit	
					<BR>
					Situation and Outlook Report, Sugar	
					<BR>
					Situation and Outlook Report, Tobacco	
					<BR>
					Situation and Outlook Report, Vegetables	
					<BR>
					Situation and Outlook Report, Wheat	
					<BR>
					Snack Food	
					<BR>
					Supermarket News	
					<BR>
					Tea & Coffee Trade Journal	
					<BR>
					U.S. Distribution Journal	
					<BR>
					Utah Farmer
					<BR>
					Washington Beverage Insight	
					<BR>
					Western Beef Producer	
					<BR>
					Wine Business Insider	
					<BR>
					World Tobacco</em>

			
		
	
</font>
</blockquote>
<BR>
		


<BR>
		<pre>
		
		
		
			</pre>
			<CENTER>Back To 
			<A HREF="publications.html">Publications</A>
			
			<br>
				
				<a href="../../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../../bizpubs/index.html">Newspapers</a> |
					<a href="../../../clipping/index.html">Alert Services</a> |
					<a href="../../../online-lib/index.html">Research</a>   |
					<a href="../../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../../index.html">Home</a> 

				</font>

				
				</center>
				




</TD></tr>
</TABLE>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT18-B31-117</DOCNO>
<DOCOLDNO>IA028-000307-B017-100</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/custom-clips/publications/pharma.html 143.131.194.4 19970114053318 text/html 7406
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:37:27 GMT
Last-modified: Wednesday, 29-May-96 14:59:54 GMT
Content-length: 7214
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>

<body bgcolor="#ffffff" background="../../images/bgdcc.gif">


<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td valign=top width=80>  
	<a href="../../index.html">
   <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../../images/lrgcosclip.gif"></a>
    <br>  
    <img SRC="../../../images/trsp.gif"></td> 
<td>

<br>

<center>

<H2>
Pharmaceutical/Medical/Health 
</H2></CENTER>

<HR SIZE=4>
<P>
<blockquote>
<font size=4>
	<br>
	<br>				
	<P>
				<A NAME="A-C"></A>
					<B>A-C</B> 
					&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
					<A HREF="#D-J">D-J</A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
					<A HREF="#M-Z">M-Z</A>
							<bR>			
							
							
									<br>
		
				<em>Accent on Living	
			<BR>
			Accountability News for Health Care Managers	
			<BR>
			Addiction Letter
			<BR>
			Age and Age-ing	
			<BR>
			Aging	
			<BR>
			AIDS Alert	
			<BR>
			AIDS Weekly	
			<BR>
			Alcohol Health & Research World	
			<BR>
			Alcoholism & Drug Abuse Week	
			<BR>
			American Druggist	
			<BR>
			American Fitness	
			<BR>
			American Journal of Sports Medicine	
			<BR>
			American Rehabilitation	
			<BR>
			Antiviral Agents Bulletin	
			<BR>
			Automated Medical Payments News	
			<BR>
			BBI Newsletter
			<BR>
			Back Letter	
			<BR>
			Beauty Counter	
			<BR>
			Behavioral Health Management	
			<BR>
			Better Nutrition for Today's Living	
			<BR>
			Bioindex
			<BR>
			BioScience	
			<BR>
			Biotech Business	
			<BR>
			Biotech Equipment Update
			<BR>
			Biotech Financial Reports	
			<BR>
			Biotech Patent News	
			<BR>
			Bioventure View	
			<BR>
			Blood Weekly	
			<BR>
			British Journal of Psychology	
			<BR>
			Brown University Child and Adolescent Behavior Letter
			<BR>
			Brown University Digest of Addiction Theory and Application
			<BR>
			Brown University Long-Term Care Quality Letter	
			<BR>
			BT Catalyst	
			<BR>
			Bulletin of the World Health Organization	
			<BR>
			Business & Health	
			<BR>
			Canadian Occupational Health & Safety News
			<BR>
			Cancer Biotechnology Weekly
			<BR>
			Chest	
			<BR>
			Child Health Alert	
			<BR>
			Children Today	
			<BR>
			Clinical Diabetes	
			<BR>
			Comline Daily News Biotechnology and Medical
			<BR>
			Cosmetic Insiders' Report
			<BR>
			Community Pharmacy	
			<BR>
			Complete Directory for People with Chronic Illness	
			<BR>
			Consultant	
			<BR>
			Cosmetics & Toiletries Manufacturers	
			<BR>
			Cosmetic Insiders' Report	CTD News
			<BR>
			Cosmetics International	
			<BR>
			CTD News</EM>	
							<BR>
		
				<BR>				
				<A NAME="D-J"></A>
				<A HREF="#A-C">A-C</A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
			<B>D-J</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
			<A HREF="#M-Z">M-Z</A>
		
				<BR>
		    <BR>
		
		
		
					<EM>
			Dermatology Times	
			<BR>
			Diabetes	
			<BR>
			Diabetes Forecast	
			<BR>
			Diabetes in the News	
			<BR>
			Drug & Cosmetic Industry	
			<BR>
			Drug Detection Report	
			<BR>
			Drug Resistance Weekly
			<BR>
			Drug Store News	
			<BR>
			Drug Topics	
			<BR>
			Environmental Nutrition	
			<BR>
			Exceptional Children	
			<BR>
			Exceptional Parent	
			<BR>
			Executive Health's Good Health Report	
			<BR>
			FDA Consumer	
			<BR>
			FDA Enforcement Report	
			<BR>
			Food & Nutrition	
			<BR>
			Generations
			<BR>
			Hasting's Center Report	
			<BR>
			Health Alliance Alert	
			<BR>
			Health Care PR and Marketing News	
			<BR>
			Health Care Strategic Management	
			<BR>
			Health Industry Today	
			<BR>
			Health Legislation & Regulation	
			<BR>
			Health News	
			<BR>
			Health News & Review	
			<BR>
			Health Works
			<BR>
			Healthcare Financial Management	
			<BR>
			Healthcare Financial Ventures Report
			<BR>
			Healthcare Technology & Business Opportunities
			<BR>
			HealthFacts	
			<BR>
			Hospital & Health Services Administration	
			<BR>
			Hospital Materials Management	
			<BR>
			In Vivo	
			<BR>
			Independent Living Provider	
			<BR>
			Infectious Disease Weekly	
			<BR>
			Information Management Strategies for Healthcare Executives
			<BR>
			Inside Health Care Reform
			<BR>
			Inside MS	
			<BR>
			Issues in Law & Medicine	
			<BR>
			Journal of Occupational and Organizational Psychology
			<BR>
			Journal of Rehabilitation	
			<BR>
			Journal of School Health	
			<BR>
			Journal of the American Dietetic Association</EM>	
							<BR>
		
				<BR>				
				<A NAME="M-Z"></A>
			
		<A HREF="#A-C">A-C</A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
		<A HREF="#D-J">D-J</A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
		<B>M-Z</B>
		
				<BR>
		    <BR>
		
		
		
					<EM>
			Managed Care Week	
			<BR>
			Medical Center News	
			<BR>
			Medical Device Approval Letter	
			<BR>
			Medical Economics	
			<BR>
			Medical Laboratory Observer	
			<BR>
			Medical Outcomes & Guidelines Alert	
			<BR>
			Medical Update	
			<BR>
			Medical Utilization Management	
			<BR>
			Medicine	
			<BR>
			Medicine & Health	
			<BR>
			Modern Healthcare
			<BR>
			Mortality Weekly Report	
			<BR>
			NCHAF Newsletter	
			<BR>
			Network News	
			<BR>
			New Drug Buyer	
			<BR>
			Newsletter -- People's Medical Society	
			<BR>
			Nursing Homes	
			<BR>
			Nursing Homes and Senior Citizen Care	
			<BR>
			Nutrition Action Healthletter	
			<BR>
			Nutrition Forum	
			<BR>
			OTC Business News
			<BR>
			Occupational Hazards	
			<BR>
			Ophthalmology Times	
			<BR>
			Ostomy Quarterly	
			<BR>
			Parents Magazine	
			<BR>
			Patient Care	
			<BR>
			Pharma Japan	
			<BR>
			Pharmaceutical and Health Industries in East Europe
			<BR>
			Pharmaceutical Business News	
			<BR>
			Pharmaceutical Executive	
			<BR>
			Pharmaceutical Manufacturing Review	
			<BR>
			Physical Therapy	
			<BR>
			Physician Executive	
			<BR>
			Population Reports	
			<BR>
			Prevention	
			<BR>
			Public Health Reports	
			<BR>
			Real Living with Multiple Sclerosis	
			<BR>
			Report on Long Term Care 	
			<BR>
			RN	
			<BR>
			Science News	
			<BR>
			Soap, Perfumery & Cosmetics	
			<BR>
			TB Weekly	
			<BR>
			Total Health	
			<BR>
			Transplant News	
			<BR>
			Tufts University Diet & Nutrition Letter	
			<BR>
			Urology Times	
			<BR>
			Vaccine Weekly	
			<BR>
			Vegetarian Times	
			<BR>
			Vibrant Life	
			<BR>
			Warning Letter Bulletin	
			<BR>
			Weight Watchers Magazine	
			<BR>
			Western Journal of Medicine	
			<BR>
			Women's Sports & Fitness	
			<BR>
			World Health	
			<BR>
			Worldwide Biotech	
			<BR>
			WRF Report</EM>	
			
			
		
	
</font>
</blockquote>
<BR>
		


<BR>
		<pre>
		
		
			</pre><CENTER>Back To 
			<A HREF="publications.html">Publications</A>
			
			
			<br>
				
				<a href="../../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../../bizpubs/index.html">Newspapers</a> |
					<a href="../../../clipping/index.html">Alert Services</a> |
					<a href="../../../online-lib/index.html">Research</a>   |
					<a href="../../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../../index.html">Home</a> 

				</font>

				</center>
				




</TD></tr>
</TABLE>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT18-B31-118</DOCNO>
<DOCOLDNO>IA028-000307-B017-131</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/custom-clips/publications/industechn.html 143.131.194.4 19970114053345 text/html 4505
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:37:42 GMT
Last-modified: Wednesday, 29-May-96 14:59:53 GMT
Content-length: 4313
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>

<body bgcolor="#ffffff" background="../../images/bgdcc.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td valign=top width=80>  
	<a href="../../index.html">
   <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../../images/lrgcosclip.gif"></a>
    <br>  
    <img SRC="../../../images/trsp.gif"></td> 
<td>

<br>


<CENTER><H2>
Industrial/Technology
</H2></CENTER>

<HR SIZE=4>
<P>
<blockquote>
<font size=4>
	<br>
	<br>				
	<P>
					
		
		<A NAME="A-J"></A>
		<B>A-J</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<A HREF="#L-Z">L-Z</A>
		<BR>			

			<BR>
<em>
Adhesives Age	
<BR>
Air Conditioning, Heating & Refrigeration News
<BR>
Aluminum Today	
<BR>
American Forests	
<BR>
American Machinists	
<BR>
American Metal Market	
<BR>
American Paint & Coating Journal	
<BR>
Appliance Manufacturer	
<BR>
Assembly	
<BR>
Boating Industry
<BR>
Boxboard Containers	
<BR>
British Plastics & Rubber	
<BR>
Canadian Mining Journal	
<BR>
Canadian Plastics	
<BR>
Ceramic Industry	
<BR>
Chemical Marketing Reporter	
<BR>
Chemical Monitor	
<BR>
Chemical Week
<BR>
China Chemical Reporter	
<BR>
Coatings Magazine	
<BR>
Comline Daily News Chemicals and New Materials
<BR>
Comline Daily News Industrial Automation
<BR>
Composites & Adhesives Newsletter
<BR>
Composites News:  Infrastructure	
<BR>
Control and Instrumentation	
<BR>
Diesel Process Engines & Drives	
<BR>
Electro Manufacturing	
<BR>
Engineer	
<BR>
Equipment & Materials Update	
<BR>
European Rubber Journal	
<BR>
Food, Cosmetics & Drug Packaging	
<BR>
Foundry Management & Technology	
<BR>
Hydraulics & Pneumatics	
<BR>
Industrial Paint & Powder	
<BR>
Industrial Specialties News	
<BR>
Innovator's Digest
<BR>
Instrument Business Outlook
<BR>
International Journal of Purchasing and Materials Management
<BR>
Journal of Coatings Technology</EM>



			<BR>
		<BR>				
		<A NAME="L-Z"></A>
		
		<A HREF="#A-J">A-J</A>
		&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
		<B>L-Z</B>
		
		<BR>
					
						<BR>
<EM>
Leather	
<BR>
Leather and Footwear Asia	
<BR>
Machine Design	
<BR>
Maglev News	
<BR>
Manufacturing Automation	
<BR>
Metalworking Insiders' Report
<BR>
Manufacturing Chemist	
<BR>
Material Handling Engineering	
<BR>
Mechanical Engineering	
<BR>
Metal Heat Treating	
<BR>
Metallurgia	
<BR>
Metals Industry News	
<BR>
Metalworking Insiders' Report	
<BR>
Mine Regulation Reporter	
<BR>
Mining Magazine	
<BR>
Modern Casting	
<BR>
Modern Paint & Coatings	
<BR>
Modern Power Systems	
<BR>
NDT Update	
<BR>
New Technology Week
<BR>
New Steel	
<BR>
Nitrogen	
<BR>
Nonwovens Industry	
<BR>
Packaging	
<BR>
Packaging Technology & Engineering	
<BR>
Packaging Week	
<BR>
Paint & Ink International	
<BR>
Paint & Resin	
<BR>
Paper, Film & Foil Converter	
<BR>
Paperboard Packaging	
<BR>
PIMA	
<BR>
Plastics Compounding	
<BR>
Plastics Engineering	
<BR>
Plastics News	
<BR>
Plastics World	
<BR>
Polymers & Rubber Asia	
<BR>
Precision Toolmaker	
<BR>
Process Engineering	
<BR>
Pulp & Paper	
<BR>
Rubber & Plastics News	
<BR>
Rubber & Plastics News II	
<BR>
Rubber World	
<BR>
Security Technology News
<BR>
Soap-Cosmetics-Chemical Specialties	
<BR>
Specialty Chemicals	
<BR>
Sulphur	
<BR>
Surface Modification Technology News	
<BR>
Technology Access Report	
<BR>
Technology Alert	
<BR>
Technology Transfer Week
<BR>
Testing Technology	
<BR>
Textile World	
<BR>
Tooling & Production	
<BR>
Urethanes Technology	
<BR>
Washington Technology
<BR>
Welding Review International	
<BR>
Wood Technology	
<BR>
World Mining Equipment	
<BR>
World Paper	</em>


			
		
	
</font>
</blockquote>
<BR>
		


<BR>
		<pre>
		
		
			</pre><CENTER>Back To 
			<A HREF="publications.html">Publications</A>
			
			<br>
				<a href="../../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../../bizpubs/index.html">Newspapers</a> |
					<a href="../../../clipping/index.html">Alert Services</a> |
					<a href="../../../online-lib/index.html">Research</a>   |
					<a href="../../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../../index.html">Home</a> 

				</font>

				
				</center>
				




</TD></tr>
</TABLE>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT18-B31-119</DOCNO>
<DOCOLDNO>IA028-000307-B017-171</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/custom-clips/publications/media.html 143.131.194.4 19970114053434 text/html 6062
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:38:39 GMT
Last-modified: Wednesday, 29-May-96 14:59:54 GMT
Content-length: 5870
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>

<body bgcolor="#ffffff" background="../../images/bgdcc.gif">


<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td valign=top width=80>  
	<a href="../../index.html">
   <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../../images/lrgcosclip.gif"></a>
    <br>  
    <img SRC="../../../images/trsp.gif"></td> 
<td>

<br>

<center>

<H2>
Media
</H2></CENTER>

<HR SIZE=4>
<P>
<blockquote>
<font size=4>
	<br>
	<br>				
	<P>

		<A NAME="A-H"></A>
		<B>A-H</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<A HREF="#I-Z">I-Z</A>
			<BR>
		
		
					<P><EM>
					Advertising Age	
					<BR>
					ADWEEK Eastern Edition
					<BR>
					ADWEEK Midwest Edition	
					<BR>
					ADWEEK New England Advertising Week	
					<BR>
					ADWEEK Southeast Edition	
					<BR>
					ADWEEK Southwest Edition	
					<BR>
					ADWEEK Western Advertising News	
					<BR>
					ADWEEK's Marketing Week	
					<BR>
					American Demographics	
					<BR>
					American Libraries	
					<BR>
					American Printer	
					<BR>
					American Record Guide	
					<BR>
					Amusement Business	
					<BR>
					Audio Week	
					<BR>
					Back Stage
					<BR>
					Baseball Weekly
					<BR>
					Before Your Eyes
					<BR>
					Billboard
					<BR>
					BPI Wire News
					<BR>
					Brand Strategy
					<BR>
					Brandweek
					<BR>
					Brandweek Superbrands	
					<BR>
					Business Marketing	
					<BR>
					Business Publisher	
					<BR>
					CableFAX	
					<BR>
					Campaign	
					<BR>
					Catalog Age	
					<BR>
					CD Computing News	
					<BR>
					CD ROM Databases	
					<BR>
					Computers in Libraries	
					<BR>
					Consumer Multimedia Report
					<BR>
					Daisy Fuentes	
					<BR>
					Delaney Report	
					<BR>
					Document Delivery World	
					<BR>
					Electronic Media	
					<BR>
					Entertainment Marketing Letter
					<BR>
					Euromarketing	
					<BR>
					European Media Business & Finance
					<BR>
					Film Comment	
					<BR>
					Film Quarterly	
					<BR>
					HDTV Report
					<BR>
					Hollywood Reporter Special Issue</EM>	
					<BR>


		<BR>				
		<A NAME="I-Z"></A>
		
		<A HREF="#A-H">A-H</A>
		&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
		<B>I-Z</B>
		
		
		<BR>
		
			<BR><EM>				
					Information Advisor	
					<BR>
					Information Networks	
					<BR>
					Information Technology & Libraries	
					<BR>
					Information Today	
					<BR>
					Inside Media	
					<BR>
					Interactive Content	
					<BR>
					Interactive Facts
					<BR>
					Interactive Marketing News
					<BR>
					Interactive Video News
					<BR>
					International Gaming and Wagering Business	
					<BR>
					International Journal of Advertising	
					<BR>
					Internet Business News	
					<BR>
					Journal of Advertising	
					<BR>
					Journal of Advertising Research	
					<BR>
					Legal Publisher	
					<BR>
					Library Technology Reports	
					<BR>
					Library Trends	
					<BR>
					Link-Up
					<BR>
					Market Asia Pacific	
					<BR>
					Market Latin America
					<BR>
					Marketing	
					<BR>
					Marketing Computers	
					<BR>
					Marketing To Women	
					<BR>
					Media Conference and Management Reports
					<BR>
					Med Ad News	
					<BR>
					Media Industry Newsletter
					<BR>
					Media Monitor
					<BR>
					MediaSource	
					<BR>
					Mediaweek	
					<BR>
					Medical Marketing & Media	
					<BR>
					Mother Jones	
					<BR>
					Multichannel News	
					<BR>
					Multimedia & Videodisc Monitor	
					<BR>
					Multimedia Publisher	
					<BR>
					Multimedia Week
					<BR>
					Music & Copyright	
					<BR>
					Music & Media
					<BR>
					Music Trades	
					<BR>
					Music Week	
					<BR>
					Musician	
					<BR>
					Nova - PBS (Transcripts)
					<BR>
					One to One	
					<BR>
					Online Newsletter	
					<BR>
					Online Product News	
					<BR>
					Photographic Trade News	
					<BR>
					Potentials in Marketing
					<BR>
					Precision Marketing	
					<BR>
					Printing Impressions	
					<BR>
					Printing News East	
					<BR>
					Promo	
					<BR>
					Promo Magazine's SourceBook	
					<BR>
					ProSound News Europe	
					<BR>
					Public Broadcasting Report	
					<BR>
					Public Relations Journal	
					<BR>
					Public Relations Review	
					<BR>
					Response TV	
					<BR>
					RQ	
					<BR>
					Sales & Marketing Management	
					<BR>
					Satellite TV Finance
					<BR>
					Satellite TV News
					<BR>
					Screen Digest	
					<BR>
					Screen Finance	
					<BR>
					Searcher	
					<BR>
					SHOOT	
					<BR>
					Special Libraries
					<BR>
					STN
					<BR>
					Tape-Disc Business	
					<BR>
					Target Marketing	
					<BR>
					Television Digest	
					<BR>
					The Quill	
					<BR>
					Tom Synder	
					<BR>
					Travel Weekly
					<BR>
					USA Weekend	
					<BR>
					Video Business	
					<BR>
					Video Magazine	
					<BR>
					Video Review	
					<BR>
					Video Store	
					<BR>
					Video Technology News	
					<BR>
					Video Week
					<BR>
					Warren's Cable Regulation Monitor
					<BR>
					Worldwide Databases	
					<BR>
					Worldwide Videotex Update
					<BR>
					Writer's Digest</EM>



			
		
	
</font>
</blockquote>
<BR>
		


<BR>
		<pre>
		
		
			</pre>
			
			<CENTER>
			Back To <A HREF="publications.html">Publications</A>
			
			<br>
				<a href="../../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../../bizpubs/index.html">Newspapers</a> |
					<a href="../../../clipping/index.html">Alert Services</a> |
					<a href="../../../online-lib/index.html">Research</a>   |
					<a href="../../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../../index.html">Home</a> 

				</font>

				
				</center>
				




</TD></tr>
</TABLE>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT18-B31-120</DOCNO>
<DOCOLDNO>IA028-000307-B017-207</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/custom-clips/publications/retail.html 143.131.194.4 19970114053510 text/html 2651
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:39:13 GMT
Last-modified: Wednesday, 29-May-96 14:59:55 GMT
Content-length: 2459
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>

<body bgcolor="#ffffff" background="../../images/bgdcc.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td valign=top width=80>  
	<a href="../../index.html">
   <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../../images/lrgcosclip.gif"></a>
    <br>  
    <img SRC="../../../images/trsp.gif"></td> 
<td>

<br>

<CENTER><H2>
Retail
</H2></CENTER>

<HR SIZE=4>
<P>
<blockquote>
<font size=4>
					
	
					<BR>
					
					<BR><EM>
			American Marketplace
			<BR>
			Appliance	
			<BR>
			Atlanta Business Chronicle
			<BR>
			Audrey Gostlin's Inside Fashion
			<BR>
			Bangor Daily News   Bangor, ME
			<BR>
			Chain Store Age Executive Fax	
			<BR>
			Chain Store Age Executive with Shopping Center Age	
			<BR>
			Children's Business	
			<BR>
			Cleveland County
			<BR>
			Colorado Springs Gazette Telegraph	
			<BR>
			Daily News Record	
			<BR>
			Dallas Business Journal
			<BR>
			Dealer News	
			<BR>
			Dealerscope Merchandising	
			<BR>
			Discount Store News	
			<BR>
			Footwear News	
			<BR>
			Gifts & Decorative Accessories	
			<BR>
			Greensboro News & Record	
			<BR>
			HFN: The Weekly Newspaper for Home Furnishing Network
			<BR>
			Housewares (UK)	
			<BR>
			Houston Business Journal
			<BR>
			International Journal of Retail & Distribution Management
			<BR>
			Journal of Consumer Affairs	
			<BR>
			Journal of Consumer Research	
			<BR>
			Journal of Retailing
			<BR>
			National Home Center News
			<BR>
			Non-Foods Merchandising
			<BR>
			Party & Paper Retailer
			<BR>
			Retail Store Image
			<BR>
			Shopping Center WorldSporting Goods Business
			<BR>
			Units</EM>


			
		
	
</font>
</blockquote>
<BR>
		


		<pre>
		
		
		
			</pre><CENTER>Back To 
			<A HREF="publications.html">Publications</A>
			
			<br>
				
				<a href="../../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../../bizpubs/index.html">Newspapers</a> |
					<a href="../../../clipping/index.html">Alert Services</a> |
					<a href="../../../online-lib/index.html">Research</a>   |
					<a href="../../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../../index.html">Home</a> 

				</font>

				</center>
				




</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-121</DOCNO>
<DOCOLDNO>IA028-000307-B017-246</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/custom-clips/publications/transp.html 143.131.194.4 19970114053531 text/html 3468
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:39:35 GMT
Last-modified: Wednesday, 29-May-96 14:59:56 GMT
Content-length: 3276
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>

<body bgcolor="#ffffff" background="../../images/bgdcc.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td valign=top width=80>  
	<a href="../../index.html">
   <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../../images/lrgcosclip.gif"></a>
    <br>  
    <img SRC="../../../images/trsp.gif"></td> 
<td>

<br>


<CENTER><H2>
Transportation
</H2></CENTER>

<HR SIZE=4>
<P>
<blockquote>
<font size=4>
					
	
					<BR>
					
					<BR>
<P><em>
				Aftermarket Business	
				<BR>
				Air Cargo Report
				<BR>
				Air Cargo World	
				<BR>
				Air Safety Week	
				<BR>
				Air Transport World	
				<BR>
				Aircraft Value News	
				<BR>
				Airline Financial News	
				<BR>
				Airline Marketing News	
				<BR>
				Airports International	
				<BR>
				Armed Forces Newswire Service
				<BR>
				Asian Aviation News
				<BR>
				Automotive Engineering
				<BR>
				Automotive Industries	
				<BR>
				Automotive Marketing
				<BR>
				Automotive News	
				<BR>
				Autoparts Report
				<BR>
				AutoWeek	
				<BR>
				BMD Monitor	
				<BR>
				Comline Daily News Transportation
				<BR>
				Commercial Carrier Journal	
				<BR>
				Commuter Regional Airline News	
				<BR>
				Commuter Regional Airline News International
				<BR>
				Dealer Business	
				<BR>
				Defense & Aerospace Electronics	
				<BR>
				Defense Conversion	
				<BR>
				Defense Daily	
				<BR>
				Defense Electronics	
				<BR>
				Global Positioning and Navigation News	
				<BR>
				High Speed Transport News	
				<BR>
				Implement & Tractor	
				<BR>
				Inside IVHS	
				<BR>
				Intelligent Highway
				<BR>
				Interavia Business & Technology	
				<BR>
				Japan Transportation Scan
				<BR>
				Journal of Electronic Defence	
				<BR>
				Marine Log	
				<BR>
				Mass Transit	
				<BR>
				Military Robotics	
				<BR>
				Modern Tire Dealer	
				<BR>
				Motor Age	
				<BR>
				Motor Trend	
				<BR>
				Navy News & Undersea Technolgy	
				<BR>
				Periscope-Daily Defense News Capsules
				<BR>
				Public Roads	
				<BR>
				Railway Age	
				<BR>
				Space Business News	
				<BR>
				Space Station News
				<BR>
				Tactical Technology	
				<BR>
				The Weekly of Business Aviation
				<BR>
				Tire Business	
				<BR>
				Traffic Management	
				<BR>
				Traffic World	
				<BR>
				Transportation Journal	
				<BR>
				U.S. Rail News	
				<BR>
				Ward's Auto World
				<BR>
				World Airline News	
				<BR>
				World Airport Week	</em>


			
		
	
</font>
</blockquote>
<BR>
		


		<pre>
		
		
			</pre><CENTER>Back To 
			<A HREF="publications.html">Publications</A>
			
			<br>		
				<a href="../../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../../bizpubs/index.html">Newspapers</a> |
					<a href="../../../clipping/index.html">Alert Services</a> |
					<a href="../../../online-lib/index.html">Research</a>   |
					<a href="../../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../../index.html">Home</a> 

				</font>

				</center>
				




</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-122</DOCNO>
<DOCOLDNO>IA028-000307-B017-279</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/custom-clips/publications/political.html 143.131.194.4 19970114053558 text/html 2522
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:39:58 GMT
Last-modified: Wednesday, 29-May-96 14:59:55 GMT
Content-length: 2330
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>

<body bgcolor="#ffffff" background="../../images/bgdcc.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td valign=top width=80>  
	<a href="../../index.html">
   <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../../images/lrgcosclip.gif"></a>
    <br>  
    <img SRC="../../../images/trsp.gif"></td> 
<td>

<br>

<center>

<H2>
Political
</H2></CENTER>

<HR SIZE=4>
<P>
<blockquote>
<font size=4>
					
	
					<BR>
					
					<BR><EM>
					Antitrust Freedom of Information Log	
					<BR>
					Common Cause Magazine	
					<BR>
					Congressional Research Report	
					<BR>
					Evans-Novak Political Report
					<BR>
					Federal News Service Congressional Hearing Testimonies
					<BR>
					Federal News Service Daybook	
					<BR>
					Federal News Service Washington Package	
					<BR>
					Foreign Affairs	
					<BR>
					FTC Freedom of Information Log	
					<BR>
					FTC Watch
					<BR>
					General Accounting Office Reports & Testimony	
					<BR>
					Nation	
					<BR>
					National Review	
					<BR>
					National Tax Journal	
					<BR>
					New Leader	
					<BR>
					New Perspectives Quarterly	
					<BR>
					New Republic	
					<BR>
					Reason	
					<BR>
					Spectrum: the Journal of State Government	
					<BR>
					The Progressive	
					<BR>
					U.S. Newswire	
					<BR>
					US Department of State Dispatch
					<BR>
					UNESCO Courier	
					<BR>
					US Department of State Dispatch	
					<BR>
					Vital Speeches	
					<BR>
					Washington Monthly	
					</EM>


			
		
	
</font>
</blockquote>
<BR>
		
		<pre>
			
			
			</pre><CENTER>Back To 
			<A HREF="publications.html">Publications</A>
			
			<br>
				<a href="../../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../../bizpubs/index.html">Newspapers</a> |
					<a href="../../../clipping/index.html">Alert Services</a> |
					<a href="../../../online-lib/index.html">Research</a>   |
					<a href="../../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../../index.html">Home</a> 

				</font>

				</center>
				




</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-123</DOCNO>
<DOCOLDNO>IA028-000307-B017-319</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/custom-clips/publications/localnews.html 143.131.194.4 19970114053620 text/html 6322
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:40:25 GMT
Last-modified: Wednesday, 29-May-96 14:59:54 GMT
Content-length: 6130
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>

<body bgcolor="#ffffff" background="../../images/bgdcc.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td valign=top width=80>  
	<a href="../../index.html">
   <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../../images/lrgcosclip.gif"></a>
    <br>  
    <img SRC="../../../images/trsp.gif"></td> 
<td>

<br>

<CENTER><H2>
Local Newspapers
</H2></CENTER>

<HR SIZE=4>
<P>


<blockquote>
<font size=4>
	<br>
	<br>				
	<P></A>
		<A NAME="A-S"></A>
		<B>A-S</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<A HREF="#T-Z">T-Z</A>
		<BR>
		<BR><EM>
		
				Allentown Morning Call	
				<BR>
				Anchorage Daily News	
				<BR>
				Arizona Daily Star	
				<BR>
				Austin American-Statesman	
				<BR>
				Capital District Business Review
				<BR>
				Charleston Newspapers	
				<BR>
				Dayton Daily News
				<BR>
				Evansville Business Journal
				<BR>
				Evansville Courier
				<BR>
				Grand Rapids Business Journal
				<BR>
				Grand Rapids Press	
				<BR>
				Herald
				<BR>
				Herald Independent
				<BR>
				Independent 	
				<BR>
				Indianapolis Business Journal
				<BR>
				Knoxville News-Sentinel 
				<BR>
				Lancaster New Era	
				<BR>
				Lancaster New Era   Lancaster, PA
				<BR>
				Los Angeles Daily News	
				<BR>
				Memphis Business Journal Post-Journal
				<BR>
				Minority Markets Alert	
				<BR>
				Nashville Banner	
				<BR>
				Oklahoma County	
				<BR>
				Peoria Journal Star	
				<BR>
				Press Democrat
				<BR>
				Reading Eagle, Reading Times
				<BR>
				Record Northern New Jersey
				<BR>
				Research Alert	
				<BR>
				Roanoke Times & World News
				<BR>
				San Antonio Express-News	
				<BR>
				San Diego Daily Transcript	
				<BR>
				San Francisco Examiner	
				<BR>
				Seattle Post-Intelligencer	
				<BR>
				Sheboygan Press
				<BR>
				Shooting Industry	
				<BR>
				Shopper Report	
				<BR>
				St. Louis Business Journal	
				<BR>
				Star Ledger
				<BR>
				State Journal</EM>
				
				
				
				<BR>
		<BR>				
		<A NAME="T-Z"></A>
		<A HREF="#A-S">A-S</A>
		&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
		<B>T-Z</B>
		
		
		<BR>	
				<BR><em>
				Telegram & Gazette	
				<BR>
				The Business Journal-San Jose	
				<BR>
				The Cincinnati Enquirer	
				<BR>
				The Cincinnati Post	
				<BR>
				The Columbus Dispatch	
				<BR>
				The Commercial Appeal 	
				<BR>
				The Courier-Journal  Louisville, KY	
				<BR>
				The CPA Journal	
				<BR>
				The Credit Union Accountant	
				<BR>
				The Daily Oklahoman	
				<BR>
				The Daily Reporter   Milwaukee, WI	
				<BR>
				The Daily Telegraph - London	
				<BR>
				The Daily Texan	
				<BR>
				The Dallas Morning News	
				<BR>
				The Denver Business Journal	
				<BR>
				The Des Moines Register	
				<BR>
				The Detroit News	
				<BR>
				The Edmonton Journal	
				<BR>
				The Energy Journal	
				<BR>
				The Evansville Courier	
				<BR>
				The Financial Post	
				<BR>
				The Financial Times	
				<BR>
				The Florida Times Union	
				<BR>
				The Food Institute Report	
				<BR>
				The Fort Worth Star-Telegram	
				<BR>
				The Free China Journal	
				<BR>
				The Fresno Bee	
				<BR>
				The Futurist	
				<BR>
				The Grand Rapids Press	
				<BR>
				The Greater Baton Rouge Business Report	
				<BR>
				The Guarantor	
				<BR>
				The Harrisburg Patriot	
				<BR>
				The Hartford Courant	
				<BR>
				The Herald 	
				<BR>
				The Hollywood Reporter	
				<BR>
				The Indianapolis Star	
				<BR>
				The Insurance Accountant	
				<BR>
				The Insurance Regulator	
				<BR>
				The Investment Reporter	
				<BR>
				The Jerusalem Post	
				<BR>
				The Journal of Commerce	
				<BR>
				The Lancet	
				<BR>
				The Las Vegas Review-Journal	
				<BR>
				The Logistics and Transportation Review	
				<BR>
				The Los Angeles Business Journal	
				<BR>
				The Miami Herald 	
				<BR>
				The Milwaukee Journal	
				<BR>
				The NCUA Watch	
				<BR>
				The New Orleans Times-Picayune	
				<BR>
				The News & Observer   Raleigh, NC	
				<BR>
				The News Tribune   Tacoma, WA	
				<BR>
				The Oil and Gas Journal	
				<BR>
				The Oil Daily	
				<BR>
				The Omaha World-Herald	
				<BR>
				The Orange County Register	
				<BR>
				The Ottawa Citizen	
				<BR>
				The Pantagraph   	
				<BR>
				The Patriot Ledger	
				<BR>
				The PCNetter	
				<BR>
				The Philadelphia Inquirer 	
				<BR>
				The Plain Dealer  	
				<BR>
				The Post-Standard  	
				<BR>
				The Press-Enterprise	
				<BR>
				The Quality Executive	
				<BR>
				The Record   	
				<BR>
				The Report on Microsoft	
				<BR>
				The Richmond Times-Dispatch	
				<BR>
				The Sacramento Bee	
				<BR>
				The Salt Lake Tribune	
				<BR>
				The San Francisco Chronicle	
				<BR>
				The Seattle Times	
				<BR>
				The Spokesman-Review	
				<BR>
				The Sporting News	
				<BR>
				The State Journal-Register	
				<BR>
				The Straits Times	
				<BR>
				The Sunday Times	
				<BR>
				The Tennessean-Nashville	
				<BR>
				The Times of London	
				<BR>
				The Toronto Star	
				<BR>
				The Tucson Citizen	
				<BR>
				The Virginian-Pilot and The Ledger-Star	
				<BR>
				The Westchester County Business Journal	
				<BR>
				Thin Film/Diamond Technology News	
				<BR>
				Thousand Oaks Star & News Chronicle	
				<BR>
				Tulsa County	
				<BR>
				Tulsa World	
				<BR>
				York Daily Record</EM>
	
</font>
</blockquote>
<BR>
		


		<pre>
		
		
			</pre><CENTER>Back To 
			<A HREF="publications.html">Publications</A>
			
			<br>
				
				<a href="../../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../../bizpubs/index.html">Newspapers</a> |
					<a href="../../../clipping/index.html">Alert Services</a> |
					<a href="../../../online-lib/index.html">Research</a>   |
					<a href="../../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../../index.html">Home</a> 

				</font>

				
				</center>
				




</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-124</DOCNO>
<DOCOLDNO>IA028-000307-B018-3</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/custom-clips/publications/majornews.html 143.131.194.4 19970114053701 text/html 1936
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:41:03 GMT
Last-modified: Wednesday, 29-May-96 14:59:54 GMT
Content-length: 1744
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>

<body bgcolor="#ffffff" background="../../images/bgdcc.gif">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td valign=top width=80>  
	<a href="../../index.html">
   <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../../images/lrgcosclip.gif"></a>
    <br>  
    <img SRC="../../../images/trsp.gif"></td> 
<td>

<br>


<CENTER><H2>
Major National Newspapers
</H2></CENTER>

<HR SIZE=4>
<P>
<blockquote>
<font size=4>
	<br>
	<br>				
	<EM>
				Atlanta Constitution
				<BR>
				Boston Herald	
				<BR>
				Buffalo News	
				<BR>
				Chicago Sun-Times	
				<BR>
				Christian Science Monitor
				<BR>
				Denver Post	
				<BR>
				Insight Magazine	
				<BR>
				Los Angeles Times
				<BR>
				Newsday	
				<BR>
				Rocky Mountain News	
				<BR>
				St. Louis Post-Dispatch	
				<BR>
				St. Petersburg Times
				<BR>
				Star-Tribune
				<BR>
				Sun-Sentinel
				<BR>
				Tampa Tribune</EM>

			
		
	
</font>
</blockquote>
<BR>
	

		<pre>
		
		
		
			</pre><CENTER>Back To 
			<A HREF="publications.html">Publications</A>
			
			<br>
				
				<a href="../../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../../bizpubs/index.html">Newspapers</a> |
					<a href="../../../clipping/index.html">Alert Services</a> |
					<a href="../../../online-lib/index.html">Research</a>   |
					<a href="../../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../../index.html">Home</a> 

				</font>

				
				</center>
				




</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-125</DOCNO>
<DOCOLDNO>IA028-000307-B018-36</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/custom-clips/publications/generalbus.html 143.131.194.4 19970114053729 text/html 6570
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:41:35 GMT
Last-modified: Wednesday, 29-May-96 14:59:53 GMT
Content-length: 6378
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>

<body bgcolor="#ffffff" background="../../images/bgdcc.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td valign=top width=80>  
	<a href="../../index.html">
   <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../../images/lrgcosclip.gif"></a>
    <br>  
    <img SRC="../../../images/trsp.gif"></td> 
<td>

<br>



<CENTER><H2>
General Business Publications
</H2></CENTER>

<HR SIZE=4>
<P>
<blockquote>
<font size=4>
	<A NAME="#A-I"></A>
		<B>A-I</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<A HREF="#J-Z">J-Z</A>
		<BR>			

			<BR>			
						<EM>
					Academy of Management Journal	
					<BR>
					Academy of Management Review	
					<BR>
					Across the Board	
					<BR>
					Administration & Society	
					<BR>
					Administrative Science Quarterly	
					<BR>
					American City & County	
					<BR>
					American Economist	
					<BR>
					American Review of Public Administration	
					<BR>
					Association Management	
					<BR>
					Atlantic Economic Journal	
					<BR>
					Berkeley Journal of Employment and Labor Law	
					<BR>
					Black Enterprise	
					<BR>
					Brookings Review	
					<BR>
					Business America	
					<BR>
					Business Communications Quarterly	
					<BR>
					Business Forum	
					<BR>
					Business Horizons	
					<BR>
					Business Journal	
					<BR>
					Business North Carolina	
					<BR>
					Business Perspectives	
					<BR>
					Business Quarterly	
					<BR>
					California Business	
					<BR>
					California Management Review	
					<BR>
					Challenge	
					<BR>
					Chief Executive (U.S.)	
					<BR>
					CIS Economics & Foreign Trade	
					<BR>
					Colorado Business Magazine	
					<BR>
					Columbia Journal of World Business	
					<BR>
					Commerce Business Daily	
					<BR>
					Compensation and Benefits Review	
					<BR>
					Corporate Board	
					<BR>
					Directors & Boards	
					<BR>
					Economic Commentary (Cleveland)	
					<BR>
					Economic Indicators	
					<BR>
					Economic Perspectives	
					<BR>
					Economic Quarterly	
					<BR>
					Employee Relations Law Journal	
					<BR>
					Employment Relations Today	
					<BR>
					Entrepreneurship: Theory and Practice	
					<BR>
					Europe - Unification Conference	
					<BR>
					European Venture Capital Journal	
					<BR>
					Forecast	
					<BR>
					Growth & Change	
					<BR>
					Hotel & Motel Management	
					<BR>
					HR Focus	
					<BR>
					Inc.	
					<BR>
					Industrial and Labor Relations Review	
					<BR>
					Industrial Relations (Canadian)	
					<BR>
					Industry Week	
					<BR>
					Inside Business	
					<BR>
					Inter Press Service	
					<BR>
					International Studies of Management & Organization	
					<BR>
					International Trade Forum</EM>	
					
					
					
						
			<BR>
		<BR>				
		<A NAME="J-Z"></A>
		<A HREF="#A-I">A-I</A>
		&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
		<B>J-Z</B>
		
		<BR>
					
						<BR>
					
					
					<EM>Journal of Business	
					<BR>
					Journal of Business Strategy	
					<BR>
					Journal of Development Studies	
					<BR>
					Journal of Human Resources	
					<BR>
					Journal of International Business Studies	
					<BR>
					Journal of Management	
					<BR>
					Journal of Socio-Economics	
					<BR>
					Journal of the American Planning Association	
					<BR>
					Journal of the American Statistical Association	
					<BR>
					Land Economics	
					<BR>
					Law and Policy in International Business	
					<BR>
					Licensing Letter	
					<BR>
					Lloyd's Bank Annual Review	
					<BR>
					Los Angeles Business Journal	
					<BR>
					M2 Presswire	
					<BR>
					Management Matters	
					<BR>
					Management Quarterly	
					<BR>
					Management Review	
					<BR>
					McKinsey Quarterly	
					<BR>
					Meetings & Conventions	
					<BR>
					Mid-Atlantic Journal of Business	
					<BR>
					Monthly Labor Review	
					<BR>
					Nation's Restaurant News	
					<BR>
					National Institute Economic Review	
					<BR>
					National Productivity Review	
					<BR>
					New England Economic Review	
					<BR>
					Newsweek	
					<BR>
					Occupational Outlook Quarterly	
					<BR>
					OECD Observer	
					<BR>
					Organizational Dynamics	
					<BR>
					Oxford Economic Papers	
					<BR>
					People Management	
					<BR>
					Personnel Journal	
					<BR>
					Planning	
					<BR>
					Public Management	
					<BR>
					Public Manager: The New Bureaucrat	
					<BR>
					Public Personnel Management	
					<BR>
					Public Works	
					<BR>
					Quarterly Review of Economics and Finance	
					<BR>
					Research Studies - Frost & Sullivan	
					<BR>
					Research Studies - Market Assessment	
					<BR>
					Research Studies - Maxtech International	
					<BR>
					Research Studies - Megatech Resources	
					<BR>
					Review of Black Political Economy	
					<BR>
					Review of Business	
					<BR>
					Review of Financial Economics	
					<BR>
					SAM Advanced Management Journal	
					<BR>
					School and College	
					<BR>
					Security Management	
					<BR>
					Set-Aside Alert	
					<BR>
					Sloan Management Review	
					<BR>
					Southern Economic Journal	
					<BR>
					Southwest Journal of Business & Economics	
					<BR>
					SRA Journal	
					<BR>
					Supervisory Management	
					<BR>
					Survey of Current Business	
					<BR>
					Texas Business Review	
					<BR>
					Training	
					<BR>
					Training & Development	
					<BR>
					U.S. Industrial Outlook	
					<BR>
					UK Venture Capital Journal	
					<BR>
					Venture Capital Journal	
					<BR>
					Work & Family Newsbrief	
					<BR>
					World Economic Outlook</EM>		
					
		
	
</font>
</blockquote>
					
<BR>
	

		<pre>
		
		
		
		</pre>
			
			<CENTER>Back To 
			<A HREF="publications.html">Publications</A>
			
			<br>
				<a href="../../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../../bizpubs/index.html">Newspapers</a> |
					<a href="../../../clipping/index.html">Alert Services</a> |
					<a href="../../../online-lib/index.html">Research</a>   |
					<a href="../../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../../index.html">Home</a> 

				</font>


				
				</center>
				




</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-126</DOCNO>
<DOCOLDNO>IA028-000307-B018-71</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/custom-clips/publications/international.html 143.131.194.4 19970114053754 text/html 4013
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:41:58 GMT
Last-modified: Wednesday, 29-May-96 14:59:53 GMT
Content-length: 3821
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>

<body bgcolor="#ffffff" background="../../images/bgdcc.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td valign=top width=80>  
	<a href="../../index.html">
   <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../../images/lrgcosclip.gif"></a>
    <br>  
    <img SRC="../../../images/trsp.gif"></td> 
<td>

<br>



<CENTER><H2>
International
</H2></CENTER>

<HR SIZE=4>
<P>
<blockquote>
<font size=4>
	<br>
	<br>				
					<EM>
						
					Access Czech Republic Business Bulletin	
					<BR>
					AFX News	
					<BR>
					Agence France-Presse	
					<BR>
					APS Diplomat Fate of the Arabian Peninsula	
					<BR>
					APS Diplomat News Service	
					<BR>
					APS Diplomat Recorder	
					<BR>
					APS Diplomat Redrawing the Islamic Map	
					<BR>
					APS Diplomat Strategic Balance in the Middle East	
					<BR>
					Asian Century Business Report	
					<BR>
					Beijing Weekend	
					<BR>
					BizEkon News	
					<BR>
					Brazil Service	
					<BR>
					Budapest Sun	
					<BR>
					Business Europa	
					<BR>
					Business Times (Singapore)	
					<BR>
					Business Weekly	
					<BR>
					Calgary Herald	
					<BR>
					Canadian Geographic	
					<BR>
					Caribbean Update	
					<BR>
					Central European Business Guide	
					<BR>
					China Business Review	
					<BR>
					China Daily	
					<BR>
					East European Business Law	
					<BR>
					East European Markets	
					<BR>
					Economic Record	
					<BR>
					EFTA News	
					<BR>
					German Business Scope	
					<BR>
					History Today	
					<BR>
					India Business Intelligence	
					<BR>
					Indonesian Commercial Newsletter	
					<BR>
					International Herald Tribune	
					<BR>
					Irish Times	
					<BR>
					Israel Business Today	
					<BR>
					Israel Faxx	
					<BR>
					Japan Economic Newswire	
					<BR>
					Japan Weekly Monitor	
					<BR>
					JEI Report	
					<BR>
					Korea Economic Daily	
					<BR>
					Kremlin Package	
					<BR>
					Lagniappe Quarterly Monitor	
					<BR>
					Market Europe	
					<BR>
					Mexico Business Monthly	
					<BR>
					Mexico Service	
					<BR>
					Micronesian Investment Quarterly	
					<BR>
					Mid East Business Digest	
					<BR>
					Mid-East Newswire	
					<BR>
					Montreal Gazette	
					<BR>
					New Statesman & Society	
					<BR>
					Ottawa Citizen	
					<BR>
					Reforma	
					<BR>
					RusLegisline	
					<BR>
					Russia Express Contracts	
					<BR>
					Russia Express News	
					<BR>
					Russia Express-Perestroika: Executive Briefing	
					<BR>
					Russian Life	
					<BR>
					Russian Press Digest	
					<BR>
					Saturday Night	
					<BR>
					Singapore Company Research Reports	
					<BR>
					South China Morning Post	
					<BR>
					Southern Africa Business Intelligence	
					<BR>
					Swedish Economy	
					<BR>
					SwissBusiness	
					<BR>
					Vancouver Sun	
					<BR>
					Vietnam Investment Review	
					<BR>
					Week in Germany	
					<BR>
					Windsor Star	
					<BR>
					Xinhua News Agency - CEIS</EM>	
				
		</font>
	
</font>
</blockquote>
				

<BR>
	

		<pre>
		
		
		
			</pre><CENTER>Back To 
			<A HREF="publications.html">Publications</A>
			
			<br>
				<a href="../../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../../bizpubs/index.html">Newspapers</a> |
					<a href="../../../clipping/index.html">Alert Services</a> |
					<a href="../../../online-lib/index.html">Research</a>   |
					<a href="../../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../../index.html">Home</a> 

				</font>

				
				</center>
				




</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-127</DOCNO>
<DOCOLDNO>IA028-000307-B018-103</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/custom-clips/publications/business.html 143.131.194.4 19970114053824 text/html 2095
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:42:32 GMT
Last-modified: Wednesday, 29-May-96 14:59:51 GMT
Content-length: 1903
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>

<body bgcolor="#ffffff" background="../../images/bgdcc.gif">
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td valign=top width=80>  
	<a href="../../index.html">
   <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../../images/lrgcosclip.gif"></a>
    <br>  
    <img SRC="../../../images/trsp.gif"></td> 
<td>

<br>



<CENTER><H2>
Business Publications

</H2></CENTER>
<HR SIZE=4>
<P>
<blockquote>
<font size=4>
	<br>
	<br>				
			
				<EM>
				Asian Wall Street Journal<font size=3>&#174;</FONT>	
				<BR>
				Barron's	
				<BR>
				Canadian Business	
				<BR>
				Capital Markets Report	
				<BR>
				Dow Jones International News	
				<BR>
				Dow Jones News Service	
				<BR>
				Dow Jones News Service - Ticker
				<BR>
				Far Eastern Economic Review	
				<BR>
				Forbes
				<BR>
				Investor's Business Daily	
				<BR>
				Professional Investor Report	
				<BR>
				The Wall Street Journal<font size=3>&#174;</FONT>	
				<BR>
				The Wall Street Journal<font size=3>&#174;</FONT> Europe	
				<BR>
				The Wall Street Transcript
				<BR>
				The Washington Times</EM>
</font>
				
		
	

</blockquote>
			

<pre>
		
		
		
</pre>
<CENTER>Back To 
			<A HREF="publications.html">Publications</A>	

			<a href="../../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../../bizpubs/index.html">Newspapers</a> |
					<a href="../../../clipping/index.html">Alert Services</a> |
					<a href="../../../online-lib/index.html">Research</a>   |
					<a href="../../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../../index.html">Home</a> 

				</font>

				</center>
				




</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-128</DOCNO>
<DOCOLDNO>IA028-000307-B018-135</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/custom-clips/publications/press.html 143.131.194.4 19970114053855 text/html 1647
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:42:44 GMT
Last-modified: Wednesday, 29-May-96 14:59:55 GMT
Content-length: 1455
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>

<body bgcolor="#ffffff" background="../../images/bgdcc.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td valign=top width=80>  
	<a href="../../index.html">
   <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../../images/lrgcosclip.gif"></a>
    <br>  
    <img SRC="../../../images/trsp.gif"></td> 
<td>

<br>


<CENTER><H2>
Press Releases
</H2></CENTER>

<HR SIZE=4>
<P>
<blockquote>
<font size=4>
	<br>
	<br>				
			<EM>
					Business Wire	
					<BR>
					Government Economic Data	
					<BR>
					Canada NewsWire	
					<BR>
					Canadian Corporate News	
					<BR>
					PR Newswire
			</EM>
				
		
	
</font>
</blockquote>
			

		<pre>
		
		
		
		</pre><CENTER>Back To 
			<A HREF="publications.html">Publications</A>
			
			
			<br>
				
				<a href="../../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../../bizpubs/index.html">Newspapers</a> |
					<a href="../../../clipping/index.html">Alert Services</a> |
					<a href="../../../online-lib/index.html">Research</a>   |
					<a href="../../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../../index.html">Home</a> 

				</font>


				
				</center>
				




</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-129</DOCNO>
<DOCOLDNO>IA028-000307-B018-162</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/custom-clips/publications/general.html 143.131.194.4 19970114053935 text/html 3973
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:43:44 GMT
Last-modified: Wednesday, 29-May-96 14:59:53 GMT
Content-length: 3781
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>

<body bgcolor="#ffffff" background="../../images/bgdcc.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td valign=top width=80>  
	<a href="../../index.html">
   <IMG WIDTH=65 HEIGHT=65 BORDER=0 SRC="../../images/lrgcosclip.gif"></a> 
    <img SRC="../../../images/trsp.gif"></td> 
<td>

<br>


<CENTER>
<H2>
General
</H2></CENTER>

<HR SIZE=4>
<P>
<blockquote>
<font size=4>
	<br>
	<br>				
	<P>
					
		
		<A NAME="A-G"></a>
		<B>A-G</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<A HREF="#H-Z">H-Z</A>
		<BR>			

			<BR>			
	<EM>
				Country Living	
			<BR>
			Accent on Living	
			<BR>
			African American Review	
			<BR>
			America	
			<BR>
			American Artist	
			<BR>
			American Heritage	
			<BR>
			American School & University	
			<BR>
			American Visions	
			<BR>
			Backpacker	
			<BR>
			Bicycling	
			<BR>
			Business Travel News	
			<BR>
			Camping Magazine	
			<BR>
			Canadian Review of Sociology and Anthropology	
			<BR>
			Chicago	
			<BR>
			Christianity Today	
			<BR>
			Colonial Homes	
			<BR>
			Country Journal	
			<BR>
			Countryside & Small Stock Journal	
			<BR>
			Crafts 'n Things	
			<BR>
			Daedalus	
			<BR>
			Dance Magazine	
			<BR>
			Discover	
			<BR>
			DownBeat	
			<BR>
			Early American Life	
			<BR>
			Endless Vacation - Resort Condominiums International
			<BR>
			Family Circle	
			<BR>
			Field & Stream (West)	
			<BR>
			Florida Trend	
			<BR>
			Focus	
			<BR>
			Georgia Trend	
			<BR>
			Golf Magazine	
			<BR>
			Golf Pro	
			<BR>
			Good Housekeeping	
			<BR>
			Guitar Player</EM>	
			
			
				
			<BR>
		<BR>				
		<A NAME="H-Z"></a>
		<A HREF="#A-G">A-G</A>
		&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
		<B>H-Z</B>
		<BR>
					
						<BR>
			
			
			<EM>Harper's Bazaar	
			<BR>
			Harper's Magazine	
			<BR>
			Hispanic	
			<BR>
			Home Book Magazine	
			<BR>
			Home Fashions Magazine	
			<BR>
			Home Mechanix	
			<BR>
			Horticulture	
			<BR>
			Hot Rod	
			<BR>
			House Beautiful	
			<BR>
			McCall's	
			<BR>
			Motor Boating & Sailing	
			<BR>
			National Catholic Reporter	
			<BR>
			National Forum	
			<BR>
			Off Road	
			<BR>
			Organic Gardening	
			<BR>
			Organizational Studies	
			<BR>
			Outdoor Life	
			<BR>
			Palaestra	
			<BR>
			Performing Arts & Entertainment in Canada	
			<BR>
			Petersen's Photographic	
			<BR>
			Popular Mechanics	
			<BR>
			Popular Science	
			<BR>
			Runner's World	
			<BR>
			Scholastic Update	
			<BR>
			Science World	
			<BR>
			Skeptical Inquirer	
			<BR>
			Skiing	
			<BR>
			Skin Diver	
			<BR>
			Smithsonian	
			<BR>
			Society	
			<BR>
			Sport	
			<BR>
			Sports Afield	
			<BR>
			SportStyle	
			<BR>
			Stamps	
			<BR>
			Tikkun	
			<BR>
			Tour and Travel News	
			<BR>
			Town & Country Monthly	
			<BR>
			Transpacific	
			<BR>
			Travel Agent	
			<BR>
			Travel Trade Gazette Europe	
			<BR>
			Travel Trade Gazette UK & Ireland	
			<BR>
			U.S. Catholic	
			<BR>
			Yachting	
			<BR>
			Youth Markets Alert	</EM>
		
	
</font>
</blockquote>
			
			

		<pre>
		
			
			</pre><CENTER>Back To 
			<A HREF="publications.html">Publications</A>
			<BR>						<a href="../../../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../../../bizpubs/index.html">Newspapers</a> |
					<a href="../../../clipping/index.html">Alert Services</a> |
					<a href="../../../online-lib/index.html">Research</a>   |
					<a href="../../../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../../../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../../../index.html">Home</a> 


				</font>
				
				
				
				</center>
				




</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-130</DOCNO>
<DOCOLDNO>IA028-000307-B019-35</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/online-lib/djnrcontact.html 143.131.194.4 19970114054321 text/html 4922
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:47:30 GMT
Last-modified: Thursday, 13-Jun-96 21:04:11 GMT
Content-length: 4731
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>
<body bgcolor="#ffffff" background="images/bgdonlin.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80
valign=top><a href="index.html"><IMG valign=top WIDTH=65 HEIGHT=65 BORDER=0 SRC="images/lrgonlinres.gif"></a><br><img
SRC="../images/trsp.gif"></td><td>
		

<CENTER>
<IMG WIDTH=199 HEIGHT=59 BORDER=0 SRC="images/djnr-logo.gif">
<p>
<h2>
Contact
</CENTER>
</H2>




<HR SIZE=4>
<P>



<blockquote>


<IMG WIDTH=132 HEIGHT=39 BORDER=0 SRC="images/djnr-logosm.gif">


<P>

Just fill in the blanks below and a Dow Jones representative will respond promptly!

<br>

<FORM  METHOD="POST" ACTION="/cgi-bin/lead.cgi">
<INPUT NAME="Formtype" VALUE="lead_form" TYPE="hidden" size=10>


<table>
<tr><td>
	<b>Name:</b>
</td><td>
	 <INPUT TYPE ="text" NAME="name" maxlength= 30 SIZE =30>
</td></tr><tr><td>
	<b>Company Name:</b>
</td><td>
	<INPUT TYPE ="text" NAME="CompanyName" maxlength= 50 SIZE =30>
</td></tr><tr><td>
	<b>Street Address:</b>
</td><td>
     <INPUT TYPE ="text" NAME="Address1"  maxlength= 40 SIZE =30>
</td></tr><tr><td>
</td><td>
     <INPUT TYPE ="text" NAME="Address2"  maxlength=40 SIZE =30> 
</td></tr><tr><td>
	<b>City:</b>
</td><td>                 
	<INPUT TYPE ="text"NAME="City"  maxlength= 30 SIZE =30>
</td></tr><tr><td>
	<b>State:</b>
</td><td>               
	<INPUT TYPE ="text"NAME="State"  maxlength= 30 SIZE =30> 
</td></tr><tr><td> 						  
	<b>Zip/Postal Code:</b>
</td><td>
   <INPUT TYPE ="text"NAME="Zip"maxlength= 30 SIZE =30> 
</td></tr><tr><td>
<b>Country:</b>
</td><td>
<INPUT TYPE="text" NAME="Country" maxlength=30 SIZE=30>
</td></tr>
</table>


<b>What product are you interested in?</B><br>
<Select Name ="Interested">
<OPTION SELECTED>Dow Jones News/Retrieval
<option> Dow Jones Custom Clips
<Option>DowVision
<option>All of them
</select>
<p>


<b>How would you describe your profession?</B> 
<Select Name ="Profession">
<br>
<OPTION SELECTED>Choose From List
<Option>Attorney/Counsel
<Option>Communications/Public Relations
<Option>Consultant/Analyst
<Option>Engineering
<option>Finance
<option>Human Resources/Training
<option>Executive Management
<option>Marketing/Advertising
<option>Money/Portfolio Management
<option>Product Management/Development
<option>Programming
<option>Research
<option>Sales (includes Brokerage)
<option>Strategy/Business Development
<option>Student<option>Systems Development
<option>Other
</Select>
 <P>


<B>What is your organization's primary business activity?</b>
<BR>
<Select Name = "Industry" >
<Option Selected>Choose From List
<Option>Accounting
<Option>Banking
<Option>Communications/Publishing/Entertainment <option>Computers/Software/Systems
<Option>Education/Schools
<Option>Financial Services/Securities
<Option>Health Care/Hospitals
<Option>Importing/Trade
<Option>Insurance
<Option>Legal
<Option>Manufacturing
<Option>Nonprofit/Government/Associations
<OPtion>Packaged Goods/Food
<Option>Pharmaceuticals
<Option>Real Estate
<Option>Retailing
<Option>Transportation
</Select>

<P>

<table>
<tr><td>
	<b>Phone Number: </b>
</td><td>
    <INPUT TYPE = "text" NAME="Phone"  maxlength= 30 SIZE =30>
</td></tr><tr><td>
	<b>Fax Number:</b>
</td><td>
    <INPUT TYPE ="text"NAME="FAX"  maxlength= 30 SIZE =30>
</td></tr><tr><td>
<b>E-Mail: </b>
</td><td>
    <INPUT TYPE = "text" NAME="email"  maxlength= 30 SIZE =30>
</td></tr>
</table>

<P>

<STRONG>I'm interested in:</STRONG><dl>
<DT><INPUT TYPE = "checkbox" Name="interested" Value="Financial_Info" >Financial Information
<BR>
<DT><INPUT TYPE = "checkbox" Name="interested" Value="News_as_it_happens" >News as it happens
<BR>
<DT><INPUT TYPE = "checkbox" Name="interested" Value="Company_and_Industry_info" >Company and Industry Information
<BR>
<DT><INPUT TYPE = "checkbox" Name="interested" Value="Search_newspapers_publications" >Search Newspapers and Publications
<BR>
<DT><INPUT TYPE = "checkbox" Name="interested" Value="All_above" >All of the above

<pre>
</pre>

<CENTER><P><INPUT TYPE="submit" VALUE="Send Info"> <INPUT TYPE="reset" VALUE =
"Clear"></CENTER>

</form>


 <BR>
<pre>




</pre>
 
				<center>
				<a href="../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../bizpubs/index.html">Newspapers</a> |
					<a href="../clipping/index.html">Alert Services</a> |
					<a href="../online-lib/index.html">Research</a>   |
					<a href="../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../index.html">Home</a> 

				</font>


				</center>
				
</TD></tr>
</TABLE>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-131</DOCNO>
<DOCOLDNO>IA028-000307-B019-64</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/online-lib/price.html 143.131.194.4 19970114054337 text/html 11164
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:47:44 GMT
Last-modified: Monday, 19-Aug-96 18:22:11 GMT
Content-length: 10974
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>Dow Jones News/Retrieval</TITLE><META NAME="AUTHOR" CONTENT="Kathryn Doyle"><META NAME="GENERATOR" CONTENT="Internet Assistant for Microsoft Word 2.0z"></HEAD><BODY bgcolor="#ffffff" background="images/bgdonlin.gif"><P><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><TD width=80  valign=top><A href="index.html"><IMG valign=top WIDTH=65 HEIGHT=65 BORDER=0 SRC="images/lrgonlinres.gif"> </A><BR><B><IMG SRC="../images/trsp.gif"></B> </TD><TD width=500><TD><CENTER><IMG WIDTH=199 HEIGHT=59 BORDER=0 SRC="images/djnr-logo.gif"> </CENTER><P><CENTER><B>Fast Answers to Tough Questions.</B> </CENTER><HR><H2>U.S. Standard Pricing Plan </H2><P>Click <A HREF="canprice.html">Canadian price schedule</A> for standard Canadian pricing. Outside of the U.S. and Canada, prices for News/Retrieval vary. To locate a contact for more information, <A href="outsideus.html">click here</A>.<H3>Current News </H3><BLOCKQUOTE>This Just In<A NAME="DDE_LINK1">&#174;</A>: $2.95 per access </BLOCKQUOTE><BLOCKQUOTE>Search Newswires and Newspapers: $2.95 per access/$2.95 per article </BLOCKQUOTE><H3>Search News and Articles </H3><BLOCKQUOTE>Publications Library: FREE searching/FREE headlines. $2.95 per article; $2.00 per lead or key word paragraph; $1.00 per citation </BLOCKQUOTE><H3>Track News and Articles </H3><BLOCKQUOTE>Dow Jones CustomClips&#174;: FREE headlines; $2.95 per article; $19.95 per month, per folder </BLOCKQUOTE><H3>Company and Industry Data </H3><BLOCKQUOTE><B>(The following prices listed are per report) </B></BLOCKQUOTE><H4>Get Information on a Company </H4><BLOCKQUOTE>Dow Jones Financial Snapshot: $2.95 </BLOCKQUOTE><BLOCKQUOTE>Dow Jones Financial Profile: $4.95 </BLOCKQUOTE><BLOCKQUOTE>Dow Jones Company Report: $49.95<BR></BLOCKQUOTE><H4>Screen for Companies </H4><BLOCKQUOTE>Screening: FREE </BLOCKQUOTE><BLOCKQUOTE>Screening List: $4.95<BR></BLOCKQUOTE><BLOCKQUOTE>Compare Companies and Industries: $4.95<BR></BLOCKQUOTE><H4>Corporate Ownership Watch </H4><BLOCKQUOTE>Daily Register/Insider Reports: $9.95 </BLOCKQUOTE><BLOCKQUOTE>Company Search: $29.95<BR></BLOCKQUOTE><BLOCKQUOTE>Disclosure Reports (per company): $19.95<BR></BLOCKQUOTE><H4>Dun's Financial Records PLUS </H4><BLOCKQUOTE>History &amp; Ops: $39.95 </BLOCKQUOTE><BLOCKQUOTE>Company Profile: $69.95 </BLOCKQUOTE><BLOCKQUOTE>Financial Records: $109.95 </BLOCKQUOTE><BLOCKQUOTE>All: $129.95<BR></BLOCKQUOTE><H4>D&amp;B Dun's Market Identifiers </H4><BLOCKQUOTE>Summary: $5.95 </BLOCKQUOTE><BLOCKQUOTE>Full: $6.95 </BLOCKQUOTE><BLOCKQUOTE>Company Structure/Employees/Sales: $4.95 </BLOCKQUOTE><BLOCKQUOTE>Telemarketing: $2.95 </BLOCKQUOTE><BLOCKQUOTE>Establishment ID: $1.25 </BLOCKQUOTE><BLOCKQUOTE>Corporate Snapshot: $1.95 </BLOCKQUOTE><BLOCKQUOTE>Corporate - Global: $49.95<BR></BLOCKQUOTE><B>Media General Financial Services</B>: $4.95 <P></P><B>Standard &amp; Poor's Profiles &amp; Estimates</B>: $6.95 <P></P><B>Saudi 1000</B>: $4.95 <P></P><B>Worldwide Corporate Reports</B>: $19.95<P></P><B>(The following prices listed are per page) </B><P></P><B>Corporate Canada Online</B>: $4.50<P></P> <B>Investext Analysts' Reports</B>: $6.75 <P></P><B>Nikkei Telecom Japan News &amp; Retrieval</B>: $4.50 <P></P><B>SEC Full-Text Filings</B>: $4.50 <P></P><B>Zacks Corporate Earnings Estimates</B>: $3.50 <P></P><H3>Quotes and Market Data </H3><BLOCKQUOTE>Portfolio: FREE </BLOCKQUOTE><BLOCKQUOTE>Symbols: FREE </BLOCKQUOTE><BLOCKQUOTE>Current Quotes: $.15 per quote </BLOCKQUOTE><BLOCKQUOTE>Real-Time Quotes (exchange fees apply): $.15 per quote </BLOCKQUOTE><BLOCKQUOTE>Historical Equities Quotes*: $.15 </BLOCKQUOTE><BLOCKQUOTE>Historical Dow Jones Averages: $.15 </BLOCKQUOTE><BLOCKQUOTE>Quotes on Commodities, Futures &amp; Indexes: $.15 </BLOCKQUOTE><BLOCKQUOTE><I>*Date ranges provided in 12-quote increments<BR></I></BLOCKQUOTE><H4>Tradeline (Note: Int'l refers to Tradeline International data) </H4><BLOCKQUOTE>Screening Report </BLOCKQUOTE><BLOCKQUOTE>screening list: $4.95 U.S./$4.95 Int'l </BLOCKQUOTE><BLOCKQUOTE>per issue listed: $.50 U.S./$.50 Int'l </BLOCKQUOTE><BLOCKQUOTE>additional data item: $.15 U.S./$.15 Int'l </BLOCKQUOTE><BLOCKQUOTE>Price History Report/Data Download </BLOCKQUOTE><BLOCKQUOTE>per day/wk/mo/qtr/yr: $.25 U.S./$.50 Int'l </BLOCKQUOTE><BLOCKQUOTE>Dividend and Capitalization Report </BLOCKQUOTE><BLOCKQUOTE>per event: $.50 U.S./$.50 Int'l </BLOCKQUOTE><BLOCKQUOTE>Security Snapshot </BLOCKQUOTE><BLOCKQUOTE>per issue: $2.95 U.S./$3.95 Int'l </BLOCKQUOTE><BLOCKQUOTE>Analytics (U.S. only) </BLOCKQUOTE><BLOCKQUOTE>per report: $1.00 </BLOCKQUOTE><BLOCKQUOTE>per line: $.50 </BLOCKQUOTE><BLOCKQUOTE>Stock Exchange Report (Int'l only) </BLOCKQUOTE><BLOCKQUOTE>per report: $4.50 </BLOCKQUOTE><BLOCKQUOTE>Exchange Rate Report (Int'l only) </BLOCKQUOTE><BLOCKQUOTE>per daily value report: $.50 </BLOCKQUOTE><BLOCKQUOTE>Issue Directory </BLOCKQUOTE><BLOCKQUOTE>per issue: $.25 U.S./$.50 Int'l </BLOCKQUOTE><BLOCKQUOTE>per cross reference: $1.95 Int'l <BR></BLOCKQUOTE><BLOCKQUOTE><B>(The following prices are per page)</B> </BLOCKQUOTE><BLOCKQUOTE><B>Innovest Technical Analysis Reports</B>: $2.95 </BLOCKQUOTE><BLOCKQUOTE><B>Mutual Funds Performance Reports</B>: $2.95 <P></P><B>MMS Weekly Surveys</B>: $2.95 <P></P><B>Wall $treet Week Transcripts Online</B>: $2.95<P></P><H3>Career and Travel </H3><BLOCKQUOTE>(<B>The following prices are per page) </B></BLOCKQUOTE><BLOCKQUOTE>Academic American Encyclopedia: $1.95 </BLOCKQUOTE><BLOCKQUOTE>Official Airline Guide: $2.95 </BLOCKQUOTE><BLOCKQUOTE>Peterson's College Selection Service/School: $1.95 </BLOCKQUOTE><BLOCKQUOTE>Career Information from the <I>National Business Employment Weekly</I>: $1.95<BR></BLOCKQUOTE><H3>Other Fees </H3><BLOCKQUOTE>MCI Mailbox: $35.00/year </BLOCKQUOTE><BLOCKQUOTE>One-time start-up: $29.95 </BLOCKQUOTE><BLOCKQUOTE>Annual: $29.95/individual account or $49.95/unlimited accounts within an organization<BR></BLOCKQUOTE><H3>Additional Terminal Mode Sources </H3><BLOCKQUOTE><B>(The following prices are per page) </B></BLOCKQUOTE><BLOCKQUOTE>Capital Markets Report: $4.50 </BLOCKQUOTE><BLOCKQUOTE>Company: $4.50 </BLOCKQUOTE><BLOCKQUOTE>Dow Jones International News Service&reg;: $4.50 </BLOCKQUOTE><BLOCKQUOTE>Dow Jones News Service&reg;: $4.50 </BLOCKQUOTE><BLOCKQUOTE>Federal Filings&reg;: $4.50 </BLOCKQUOTE><BLOCKQUOTE>Industry: $4.50 </BLOCKQUOTE><BLOCKQUOTE>Professional Investor Report: $4.50 </BLOCKQUOTE><BLOCKQUOTE>Release: $4.50 </BLOCKQUOTE><BLOCKQUOTE>TextM: $4.50 </BLOCKQUOTE><BLOCKQUOTE>Track (News): $4.50 </BLOCKQUOTE><BLOCKQUOTE>Track: $10.00/month/profile </BLOCKQUOTE><BLOCKQUOTE>Exchange Fees (for RTQ): $11.50 per month </BLOCKQUOTE><H3>Other things you need to know: </H3><UL><LI>Prices are billed and payable in U.S. dollars.<LI>Information charges and fees may be tax deductible. Consult your tax advisor for further details.<LI>These prices, terms and conditions are effective as of the date below, are subject to change and do not include applicable federal, state and local taxes.<LI>Dow Jones News/Retrieval is available 24 hours a day, 7 days a week.<LI>Prices are effective June 17, 1996.<LI>Use of the service is subject to your acceptance of the terms in the Subscription Agreement. </UL><H3>Definitions </H3><UL><LI>Headlines: These contain source name, date, single-line headline, word count, source code.<LI>Citations in the Publications Library: These contain everything in a headline plus accession number and, if available, section name, page number, column, edition and byline. Any combination of field codes incurs a citation charge, unless the request includes <STRONG>lp</STRONG>, <STRONG>td</STRONG> or <STRONG>tx</STRONG>. In those cases, the appropriate fee (for a lead paragraph or the full article) will apply.<LI>Key Word Paragraph (KWIC): A key word paragraph includes up to 50 lines of text surrounding the key words in your search statement.<LI>Access fees: These are incurred each time you enter the Current News area and request information. In This Just In, the fee is incurred once you click on one of the news interest areas (Business, World Wide, Sports, Weather). Once you have selected an area, you may look at any and all stories at no extra charge. In Search Newswires and Newspapers, the fee is incurred once you enter a search request, such as a company symbol or other selection. You may then enter as many search requests and view as many headlines as you like at no extra charge.<LI>Page: Approximately one printed page (assuming 10 point type) or 3000 characters or about 425 words. In certain sources, such as Investext, page indicators are not equivalent to a billing page.<LI>Quotes: In most cases, includes open, high, low and closing prices. In Quotes on Commodities, Futures &amp; Selected Indexes, a futures price is per quoted contract. In Historical Quotes, date ranges are provided in 12-quote increments. </UL><P><FONT SIZE=2></FONT><HR><P>Access News/Retrieval&#174; today! Download our <A HREF="/downl1.html" >Windows software</A>, and then call 1-800-369-7466 ext. 159 to set up your account and to receive your password. Macintosh users may call that number to receive the software and set up their accounts. <BR><BR>Outside of the U.S. and Canada, <A href="outsideus.html">click here</A> for ordering information. <P></P><A href="djnrcontact.html">Click here</A> if you'd like a Dow Jones representative to call you. <P></P><A HREF="/bissales.htm" >Click here</A> for a list of sales offices. <PRE><FONT SIZE=2>                </FONT></PRE><P><CENTER><A href="../toolbar.gif.map"><IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></A> <BR><A href="../bizpubs/index.html">Newspapers</A><FONT SIZE=2> | <A href="../clipping/index.html">Alert Services</A> | <A href="../online-lib/index.html">Research</A> | <A href="../pers-finance/index.html">Personal Finance</A> | <A href="../latest.html">DJ In The News</A> | <A href="mailto:webmaster@nrs.dowjones.com">Write Us</A> | <A href="../index.html">Home</A> </FONT></CENTER></TD></TR></TABLE><P></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-132</DOCNO>
<DOCOLDNO>IA028-000307-B019-107</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/online-lib/canprice.html 143.131.194.4 19970114054348 text/html 11096
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:47:57 GMT
Last-modified: Monday, 19-Aug-96 18:21:45 GMT
Content-length: 10906
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>Dow Jones News/Retrieval</TITLE><META NAME="AUTHOR" CONTENT="Kathryn Doyle"><META NAME="GENERATOR" CONTENT="Internet Assistant for Microsoft Word 2.0z"></HEAD><BODY bgcolor="#ffffff" background="images/bgdonlin.gif"><P><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><TD width=80  valign=top><A href="index.html"><IMG valign=top WIDTH=65 HEIGHT=65 BORDER=0 SRC="images/lrgonlinres.gif"> </A><BR><B><IMG SRC="../images/trsp.gif"></B> </TD><TD width=500><TD><CENTER><IMG WIDTH=199 HEIGHT=59 BORDER=0 SRC="images/djnr-logo.gif"> </CENTER><P><CENTER><B>Fast Answers to Tough Questions.</B> </CENTER><HR><H2>Canadian Standard Pricing Plan </H2><P>To locate a contact for more information on pricing in areas beyond the U.S. and Canada, <A href="outsideus.html">click here</A>.<H3>Current News </H3><BLOCKQUOTE>This Just In&#174;: $3.95 per access </BLOCKQUOTE><BLOCKQUOTE>Search Newswires and Newspapers: $3.95 per access/$3.95 per article </BLOCKQUOTE><H3>Search News and Articles </H3><BLOCKQUOTE>Publications Library: FREE searching/FREE headlines. $3.95 per article; $2.50 per lead or key word paragraph; $1.50 per citation </BLOCKQUOTE><H3>Track News and Articles </H3><BLOCKQUOTE>Dow Jones CustomClips&#174;: FREE headlines; $3.95 per article; $24.95 per month, per folder </BLOCKQUOTE><H3>Company and Industry Data </H3><BLOCKQUOTE><B>(The following prices listed are per report) </B></BLOCKQUOTE><H4>Get Information on a Company </H4><BLOCKQUOTE>Dow Jones Financial Snapshot: $3.95 </BLOCKQUOTE><BLOCKQUOTE>Dow Jones Financial Profile: $6.95 </BLOCKQUOTE><BLOCKQUOTE>Dow Jones Company Report: $64.95<BR></BLOCKQUOTE><H4>Screen for Companies </H4><BLOCKQUOTE>Screening: FREE </BLOCKQUOTE><BLOCKQUOTE>Screening List: $6.95<BR></BLOCKQUOTE><BLOCKQUOTE>Compare Companies and Industries: $6.95<BR></BLOCKQUOTE><H4>Corporate Ownership Watch </H4><BLOCKQUOTE>Daily Register/Insider Reports: $12.95 </BLOCKQUOTE><BLOCKQUOTE>Company Search: $39.95<BR></BLOCKQUOTE><BLOCKQUOTE>Disclosure Reports (per company): $26.95<BR></BLOCKQUOTE><H4>Dun's Financial Records PLUS (not part of free-time offers) </H4><BLOCKQUOTE>History &amp; Ops: $59.95 </BLOCKQUOTE><BLOCKQUOTE>Company Profile: $89.95 </BLOCKQUOTE><BLOCKQUOTE>Financial Records: $149.95 </BLOCKQUOTE><BLOCKQUOTE>All: $169.95<BR></BLOCKQUOTE><H4>D&amp;B Dun's Market Identifiers (not part of free-time offers) </H4><BLOCKQUOTE>Summary: $7.95 </BLOCKQUOTE><BLOCKQUOTE>Full: $8.95 </BLOCKQUOTE><BLOCKQUOTE>Company Structure/Employees/Sales: $6.95 </BLOCKQUOTE><BLOCKQUOTE>Telemarketing: $3.95 </BLOCKQUOTE><BLOCKQUOTE>Establishment ID: $1.95 </BLOCKQUOTE><BLOCKQUOTE>Corporate Snapshot: $2.50 </BLOCKQUOTE><BLOCKQUOTE>Corporate - Global: $69.95<BR></BLOCKQUOTE><B>Media General Financial Services</B>: $6.95 <P></P><B>Standard &amp; Poor's Profiles &amp; Estimates</B>: $8.95 <P></P><B>Saudi 1000</B>: $4.95 <P></P><B>Worldwide Corporate Reports</B>: $29.95<P></P><B>(The following prices listed are per page)</B> <P></P><B>Corporate Canada Online</B>: $5.95 <P></P><B>Investext Analysts' Reports</B>: $8.95 (not part of free-time offers) <P></P><B>Nikkei Telecom Japan News &amp; Retrieval</B>: $5.95 <P></P><B>SEC Full-Text Filings</B>: $5.95 <P></P><B>Zacks Corporate Earnings Estimates</B>: $4.95 <P></P><H3>Quotes and Market Data </H3><BLOCKQUOTE>Portfolio: FREE </BLOCKQUOTE><BLOCKQUOTE>Symbols: FREE </BLOCKQUOTE><BLOCKQUOTE>Current Quotes: $.20 per quote </BLOCKQUOTE><BLOCKQUOTE>Real-Time Quotes (exchange fees apply): $.20 per quote </BLOCKQUOTE><BLOCKQUOTE>Historical Equities Quotes*: $.20 </BLOCKQUOTE><BLOCKQUOTE>Historical Dow Jones Averages: $.20 </BLOCKQUOTE><BLOCKQUOTE>Quotes on Commodities, Futures &amp; Indexes: $.20 </BLOCKQUOTE><BLOCKQUOTE><I>*Date ranges provided in 12-quote increments<BR></I></BLOCKQUOTE><H4>Tradeline (Note: Int'l refers to Tradeline International data) </H4><BLOCKQUOTE>Screening Report </BLOCKQUOTE><BLOCKQUOTE>screening list: $6.50 U.S./$6.50 Int'l </BLOCKQUOTE><BLOCKQUOTE>per issue listed: $.75 U.S./$.75 Int'l </BLOCKQUOTE><BLOCKQUOTE>additional data item: $.20 U.S./$.20 Int'l </BLOCKQUOTE><BLOCKQUOTE>Price History Report/Data Download </BLOCKQUOTE><BLOCKQUOTE>per day/wk/mo/qtr/yr: $.35 U.S./$.75 Int'l </BLOCKQUOTE><BLOCKQUOTE>Dividend and Capitalization Report </BLOCKQUOTE><BLOCKQUOTE>per event: $.75 U.S./$.75 Int'l </BLOCKQUOTE><BLOCKQUOTE>Security Snapshot </BLOCKQUOTE><BLOCKQUOTE>per issue: $3.95 U.S./$4.95 Int'l </BLOCKQUOTE><BLOCKQUOTE>Analytics (U.S. only) </BLOCKQUOTE><BLOCKQUOTE>per report: $1.50 </BLOCKQUOTE><BLOCKQUOTE>per line: $.75 </BLOCKQUOTE><BLOCKQUOTE>Stock Exchange Report (Int'l only) </BLOCKQUOTE><BLOCKQUOTE>per report: $5.95 </BLOCKQUOTE><BLOCKQUOTE>Exchange Rate Report (Int'l only) </BLOCKQUOTE><BLOCKQUOTE>per daily value report: $.75 </BLOCKQUOTE><BLOCKQUOTE>Issue Directory </BLOCKQUOTE><BLOCKQUOTE>per issue: $.35 U.S./$.75 Int'l </BLOCKQUOTE><BLOCKQUOTE>per cross reference: $2.95 Int'l <BR></BLOCKQUOTE><B>(The following prices are per page)</B> <P></P><B>Innovest Technical Analysis Reports</B>: $3.95 <P></P><B>Mutual Funds Performance Reports</B>: $3.95 <P></P><B>MMS Weekly Surveys</B>: $3.95 <P></P><B>Wall $treet Week Transcripts Online</B>: $3.95<P></P><H3>Career and Travel </H3><BLOCKQUOTE><B>(The following prices are per page)</B> </BLOCKQUOTE><BLOCKQUOTE>Academic American Encyclopedia: $2.50 </BLOCKQUOTE><BLOCKQUOTE>Official Airline Guide: $3.95 </BLOCKQUOTE><BLOCKQUOTE>Peterson's College Selection Service/School: $2.50 </BLOCKQUOTE><BLOCKQUOTE>Career Information from the <I>National Business Employment Weekly</I>: $2.50<BR></BLOCKQUOTE><H3>Other Fees </H3><BLOCKQUOTE>MCI Mailbox: $35.00/year </BLOCKQUOTE><BLOCKQUOTE>One-time start-up: $39.95 </BLOCKQUOTE><BLOCKQUOTE>Annual: $39.95/individual account or $69.95/unlimited accounts within an organization<BR><BR></BLOCKQUOTE><H3>Additional Terminal Mode Sources </H3><BLOCKQUOTE>(The following prices are per page) </BLOCKQUOTE><BLOCKQUOTE>Capital Markets Report: $5.95 </BLOCKQUOTE><BLOCKQUOTE>Company: $5.95 </BLOCKQUOTE><BLOCKQUOTE>Dow Jones International News Service&reg;: $5.95 </BLOCKQUOTE><BLOCKQUOTE>Dow Jones News Service&reg;: $5.95 </BLOCKQUOTE><BLOCKQUOTE>Federal Filings: $5.95 </BLOCKQUOTE><BLOCKQUOTE>Industry: $5.95 </BLOCKQUOTE><BLOCKQUOTE>Professional Investor Report: $5.95 </BLOCKQUOTE><BLOCKQUOTE>Release: $5.95 </BLOCKQUOTE><BLOCKQUOTE>TextM: $5.95 </BLOCKQUOTE><BLOCKQUOTE>Track (News): $5.95 </BLOCKQUOTE><BLOCKQUOTE>Track: $10.00/month/profile </BLOCKQUOTE><BLOCKQUOTE>Exchange Fees (for RTQ): $14.50 per month </BLOCKQUOTE><H3>Other things you need to know: </H3><UL><LI>Prices are billed and payable in Canadian dollars.<LI>Information charges and fees may be tax deductible. Consult your tax advisor for further details.<LI>These prices, terms and conditions are effective as of the date below, are subject to change and do not include applicable federal, state and local taxes.<LI>Dow Jones News/Retrieval is available 24 hours a day, 7 days a week.<LI>Prices are effective June 17, 1996.<LI>Use of the service is subject to your acceptance of the terms in the Subscription Agreement. </UL><H3>Definitions </H3><UL><LI>Headlines: These contain source name, date, single-line headline, word count, source code.<LI>Citations in the Publications Library: These contain everything in a headline plus accession number and, if available, section name, page number, column, edition and byline. Any combination of field codes incurs a citation charge, unless the request includes <STRONG>lp</STRONG>, <STRONG>td</STRONG> or <STRONG>tx</STRONG>. In those cases, the appropriate fee (for a lead paragraph or the full article) will apply.<LI>Key Word Paragraph (KWIC): A key word paragraph includes up to 50 lines of text surrounding the key words in your search statement.<LI>Access fees: These are incurred each time you enter the Current News area and request information. In This Just In, the fee is incurred once you click on one of the news interest areas (Business, World Wide, Sports, Weather). Once you have selected an area, you may look at any and all stories at no extra charge. In Search Newswires and Newspapers, the fee is incurred once you enter a search request, such as a company symbol or other selection. You may then enter as many search requests and view as many headlines as you like at no extra charge.<LI>Page: Approximately one printed page (assuming 10 point type) or 3000 characters or about 425 words. In certain sources, such as Investext, page indicators are not equivalent to a billing page.<LI>Quotes: In most cases, includes open, high, low and closing prices. In Quotes on Commodities, Futures &amp; Selected Indexes, a futures price is per quoted contract. In Historical Quotes, date ranges are provided in 12-quote increments. </UL><P><FONT SIZE=2></FONT><HR><P>Access News/Retrieval&#174; today! Download our <A HREF="/downl1.html" >Windows software</A>, and then call 1-800-369-7466 ext. 159 to set up your account and to receive your password. Macintosh users may call that number to receive the software and set up their accounts. <BR><BR>Outside of the U.S. and Canada, <A href="outsideus.html">click here</A> for ordering information. <BR><P></P><A href="djnrcontact.html">Click here</A> if you'd like a Dow Jones representative to call you. <BR><P></P><A HREF="/bissales.html" >Click here</A> for a list of sales offices. <P></P><PRE><FONT SIZE=2>      </FONT></PRE><P><CENTER><A href="../toolbar.gif.map"><IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></A> <BR><A href="../bizpubs/index.html">Newspapers</A><FONT SIZE=2> | <A href="../clipping/index.html">Alert Services</A> | <A href="../online-lib/index.html">Research</A> | <A href="../pers-finance/index.html">Personal Finance</A> | <A href="../latest.html">DJ In The News</A> | <A href="mailto:webmaster@nrs.dowjones.com">Write Us</A> | <A href="../index.html">Home</A> </FONT></CENTER></TD></TR></TABLE><P></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-133</DOCNO>
<DOCOLDNO>IA028-000307-B019-191</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/online-lib/currnews.html 143.131.194.4 19970114054445 text/html 5247
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:48:54 GMT
Last-modified: Thursday, 11-Jul-96 13:41:14 GMT
Content-length: 5056
Content-type: text/html
</DOCHDR>
<HTML>

<HEAD>

<TITLE>Dow Jones News/Retrieval</TITLE>

<META NAME="AUTHOR" CONTENT="Kathryn Doyle">
<META NAME="GENERATOR" CONTENT="Internet Assistant for Microsoft Word 2.0z">
</HEAD>
<BODY bgcolor="#ffffff" background="images/bgdonlin.gif">

<P>
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><TD width=80  valign=top><A href="index.html"><IMG valign=top WIDTH=65 HEIGHT=65 BORDER=0 SRC="images/lrgonlinres.gif"></A> 
<BR>
<B><IMG SRC="../images/trsp.gif"></B> 
</TD>
<TD width=500>
<TD><CENTER><IMG BORDER=0 SRC="images/djnr-logo.gif"> </CENTER>
<H2><CENTER>Current News 
</CENTER></H2>

<HR>

<P>
<B>A Quick Summary:</B> <BR>
This Just In&#174; gives you the top stories of the day on business and world events as selected by Dow Jones business editors. You also get news from six top industries, and sports and weather forecasts.
<P>
You can also use Search Newswires and Newspapers to tap into the most respected newspapers and exclusive Dow Jones newswires. You can search by company name, symbol, subject, industry, region, or any combination of these--it's up to you. And the software will guide you every step of the way. Whether you're looking for a Front Page of current highlights or specifics on a company, industry or Dow Jones topic, This Just In&#174; delivers.
<P>
Dow Jones is the only service that combines the same-day full text of The Wall Street Journal<EM><FONT SIZE=2>&#174;</FONT>, The New York Times, Washington Post, Financial Times,</EM> and <EM>Los Angeles Times.</EM> Dow Jones is your window to more than 9,000 items coming in from newswires and newspapers every day
<P>
<B>The Specifics:</B> <BR>
The Current News area is a compilation of in-depth sources: <BR>

<UL>
<LI><B>Dow Jones Business Newswires</B> - This comprehensive source delivers breaking news, press releases, and analysts' reports. It provides concise, accurate reporting on business, financial and economic news from across the U.S. and around the world, plus full-text press releases from companies and government organizations. There are also summaries of recent analyst reports from Investext<FONT SIZE=2>&#174;</FONT> and same-day local business news from leading U.S. and Canadian newspapers. What's more, you'll also access same-day newspaper articles from <EM>The Wall Street Journal<FONT SIZE=2>&#174;</FONT>, The New York Times</EM> News Service, and the <EM>Los Angeles Times, </EM>Electronic Edition.
<LI><B>Business and Financial Report -</B> Here, the day's top business and financial news and statistics are culled from the Dow Jones News Service, Professional Investor Report and Capital Markets Report newswires, <EM>The Wall Street Journal<FONT SIZE=2>&#174;</FONT></EM> and other news sources and continuously updated by Dow Jones writers and editors. This is the information that's included when you select the Front Pages in the This Just In section. You'll get the latest major developments on companies, industries and domestic and international economies, as well as current market activity, with closing figures updated by 6:00 p.m. (ET). 
<LI><B>Dow Jones News -</B> This is an exclusive source of in-depth coverage of companies, industries, the stock market and the general economy, with a special focus on the U.S. and Canada. As Dow Jones News reporters and <EM>Wall Street Journal<FONT SIZE=2>&#174;</FONT> </EM>reporters gather breaking news, it is sent directly to the Ticker's offices and distributed over this wire. It's as fast as news gets! 
<LI><B>News/Retrieval<FONT SIZE=2>&#174;</FONT> World Report<FONT SIZE=2>(SM)</FONT> -</B> This is your source for continuously updated national and international news. A team of Dow Jones editors monitors the Associated Press newswire, Dow Jones' newswires and various broadcast media to create concise, information-packed global news items. With the World Report, you'll be aware of the world's headlines before tomorrow's newspaper hits your doorstep.
<LI><B>Sports</B> - Here's where you can get up-to-date in a flash on major sports activities. Choose the Front Page, which delivers the latest headlines or Scores and Standings, a compilation of professional and major college activity.
<LI><B>Weather </B>- A Front Page delivers important weather updates. You can also get U.S. and non-U.S. forecasts from Accu-Weather Inc.&#174;<BR>

</UL>

<P>
<CENTER>Click <A HREF="price.html">pricing information</A> for standard pricing information. </CENTER>
<P>
<CENTER>Back To <A HREF="overview.html">Source Overview</A> </CENTER>
<P>
<CENTER><A href="../toolbar.gif.map"><IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></A> 
<BR>
<A href="../bizpubs/index.html">Newspapers</A><FONT SIZE=2> | <A href="../clipping/index.html">Alert Services</A> | <A href="../online-lib/index.html">Research</A> | <A href="../pers-finance/index.html">Personal Finance</A> | <A href="../latest.html">DJ In The News</A> | <A href="mailto:webmaster@nrs.dowjones.com">Write Us</A> | <A href="../index.html">Home</A> </FONT></CENTER>
</TD></TR>

</TABLE>

<P>

</BODY>

</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-134</DOCNO>
<DOCOLDNO>IA028-000307-B019-218</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/online-lib/srchnews.html 143.131.194.4 19970114054458 text/html 4476
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:49:05 GMT
Last-modified: Wednesday, 21-Aug-96 15:45:39 GMT
Content-length: 4284
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>Dow Jones News/Retrieval</TITLE><META NAME="AUTHOR" CONTENT="Kathryn Doyle"><META NAME="GENERATOR" CONTENT="Internet Assistant for Microsoft Word 2.0z"></HEAD><BODY bgcolor="#ffffff" background="images/bgdonlin.gif"><P><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><TD width=80  valign=top><A href="index.html"><IMG valign=top WIDTH=65 HEIGHT=65 BORDER=0 SRC="images/lrgonlinres.gif"></A> <BR><B><IMG SRC="../images/trsp.gif"></B> </TD><TD width=500><TD><CENTER><IMG BORDER=0 SRC="images/djnr-logo.gif"> </CENTER><H2><CENTER>Search News and Articles </CENTER></H2><HR><P><B>A Quick Summary:</B> <BR>With just one search statement, you can search in seconds through the entire Dow Jones Publications Library--an amazing resource of more than 60 million documents and more than 3,400 carefully selected trade and business publications -- including 48 of the top 50 newspapers.<P>Use the Publications Library to find information on just about any subject, region, industry, company or person.<P>Highlight the articles you need in hundreds of national, regional, and local newspapers. Plus top business publications such as<I> Business Week, Fortune</I> and <I>Forbes</I>. You'll discover critical information in trade publications covering everything from farming to pharmaceuticals, bits to banking and mining to marketing.<P>You'll uncover important nuggets in leading international publications, including such favorites as the global editions of <I>The Wall Street Journal, </I>Quest Economic Reports and FT McCarthy's numerous European sources.<P>Just use the easy setup screens to construct a powerful search and to decide which sources you want to include.<P><B>The Specifics:</B> <BR>With more than 3,400 sources in all, it's a good bet that many of the publications you rely on for news and information--or wish you could--are included online here for your convenience. Sources are grouped into the following categories. For a complete list, click <A HREF="http:/online-lib/text-lib/index.html">Source List</A>. <BR><UL><LI><B>Top Sources - </B>Includes <I>The Wall Street Journal, Barron's, Dow Jones News Service, the Financial Times, The New York Times, The Washington Post, </I>and the <I>Los Angeles Times</I>.<LI><B>Major News Sources</B> - Includes several of the publications in Top Sources plus the Associated Press, the <I>Chicago Tribune, Newsday, Newsweek, Time, U.S. News &amp; World Report, USA TODAY</I> and more.<LI><B>Major Business Sources -</B> <I>Barron's, Business Week, The Wall Street Journal, Forbes, Fortune, Investor's Business Daily, Far Eastern Economic Review</I> and more.<LI><B>Wires - </B>A wide array of exclusive global coverage from the Dow Jones newswires.<LI><B>Top 50 U.S. Newspapers </B><LI><B>Media Transcripts </B>- 48 Hours, 60 Minutes. All Things Considered, Meet the Press, Washington Week in Review, to name a few. In all, transcripts from more than 70 shows are available here.<LI><B>Dow Jones Publications </B>- <I>American Demographics, Marketing Tools</I>, the global editions of <I>The Wall Street Journal</I>, all newswires, <I>SmartMoney</I>, and much more.<LI><B>Press Release Wires</B> - PR Newswire, Business Wire, Canada NewsWire, Canadian Corporate News and Government Economic Data.<LI><B>Other Wires</B> - Newswires from around the world including Japan Economic Newswire, Thomson News Service and the Xinhua News Agency - CEIS. <BR><BR></UL><P><CENTER>Click <A HREF="price.html">pricing information</A> for standard pricing information. </CENTER><P><CENTER>Back To <A HREF="overview.html">Source Overview</A></CENTER><P><CENTER><A href="../toolbar.gif.map"><IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></A> <BR><A href="../bizpubs/index.html">Newspapers</A><FONT SIZE=2> | <A href="../clipping/index.html">Alert Services</A> | <A href="../online-lib/index.html">Research</A> | <A href="../pers-finance/index.html">Personal Finance</A> | <A href="../latest.html">DJ In The News</A> | <A href="mailto:webmaster@nrs.dowjones.com">Write Us</A> | <A href="../index.html">Home</A> </FONT></CENTER></TD></TR></TABLE><P></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-135</DOCNO>
<DOCOLDNO>IA028-000307-B019-250</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/online-lib/track.html 143.131.194.4 19970114054557 text/html 4634
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:49:35 GMT
Last-modified: Thursday, 11-Jul-96 13:41:17 GMT
Content-length: 4443
Content-type: text/html
</DOCHDR>
<HTML>

<HEAD>

<TITLE>Dow Jones News/Retrieval</TITLE>

<META NAME="AUTHOR" CONTENT="Kathryn Doyle">
<META NAME="GENERATOR" CONTENT="Internet Assistant for Microsoft Word 2.0z">
</HEAD>

<BODY bgcolor="#ffffff" background="images/bgdonlin.gif">

<P>
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><TD width=80  valign=top><A href="index.html"><IMG valign=top WIDTH=65 HEIGHT=65 BORDER=0 SRC="images/lrgonlinres.gif"></A> 
<BR>
<B><IMG SRC="../images/trsp.gif"></B> 
</TD>
<TD width=500>
<TD><CENTER><IMG BORDER=0 SRC="images/djnr-logo.gif"> </CENTER>
<H2><CENTER>Track News and Articles 
</CENTER></H2>

<HR>

<P>
<B>A Quick Summary:</B> <BR>
One of the most powerful customized news services on the market today is Dow Jones CustomClips&#174;. All you have to do is set up clip folders--a process that takes just a few minutes. After that, you'll automatically receive news and information from the sources you choose. (Click <A HREF="http://bis.dowjones.com/clipping/custom-clips/publications/publications.html">source list</A> for the complete list of what's available.) Even delivery is flexible. Your news can be delivered to online folders within the software or you can choose to have it forwarded directly to your electronic mailbox.
<P>
You'll also find added value in our exclusive pre-created topics. Think of these as &quot;instant searches,&quot; written by expert editors at Dow Jones. These topics were set up to automatically deliver news on industries and the companies within those industries. Our topic searches were carefully constructed and tested extensively. The end result: Well-defined, on-target topics, that we guarantee deliver pertinent and important news direct to your desktop. Choose from any of 1,000 clip topics. You'll discover critical information in trade publications covering everything from farming to pharmaceuticals, bits to banking and mining to marketing.<BR>

<P>
<B>The Specifics:</B> <BR>
With 2,600 sources in all, it's a good bet that many of the publications you rely on for news and information are included online here for your convenience. Sources are grouped into the following categories. For a complete list, Click <A HREF="http://bis.dowjones.com/clipping/custom-clips/publications/publications.html">source list</A>. <BR>

<UL>
<LI><B>Top Sources - </B>Includes <I>The Wall Street Journal, Barron's</I>, Dow Jones News Service<I>, The Washington Post,</I> the<I> Financial Times, The New York Times, The Washington Post, </I>and the <I>Los Angeles Times</I>.
<LI><B>Major News Sources</B> - Includes several of the publications in Top Sources plus the Associated Press, the <I>Chicago Tribune, Newsday, Newsweek, Time, U.S. News &amp; World Report, USA TODAY</I> and more. 
<LI><B>Major Business Sources -</B> <I>Barron's, Business Week, The Wall Street Journal, Forbes, Fortune, Investor's Business Daily, Far Eastern Economic Review</I> and more. 
<LI><B>Wires - </B>A wide array of exclusive global coverage from the Dow Jones newswires. 
<LI><B>Top 50 U.S. Newspapers </B>
<LI><B>Media Transcripts </B>- 48 Hours, 60 Minutes. All Things Considered, Meet the Press, Washington Week in Review, to name a few. In all, transcripts from more than 70 shows are available here.
<LI><B>Dow Jones Publications </B>- <I>American Demographics, Marketing Tools</I>, the global editions of <I>The Wall Street Journal</I>, all newswires, <I>SmartMoney</I>, and much more.
<LI><B>Press Release Wires</B> - PR Newswire, Business Wire, Canada NewsWire, Canadian Corporate News and Government Economic Data.
<LI><B>Other Wires</B> - Newswires from around the world including Japan Economic Newswire, Thomson News Service and the Xinhua News Agency - CEIS. <BR>

</UL>

<P>
<CENTER>Click <A HREF="price.html">pricing information</A> for standard pricing information. </CENTER>
<P>
<CENTER>Back To <A HREF="overview.html">Source Overview</A></CENTER>
<P>
<CENTER><A href="../toolbar.gif.map"><IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></A> 
<BR>
<A href="../bizpubs/index.html">Newspapers</A><FONT SIZE=2> | <A href="../clipping/index.html">Alert Services</A> | <A href="../online-lib/index.html">Research</A> | <A href="../pers-finance/index.html">Personal Finance</A> | <A href="../latest.html">DJ In The News</A> | <A href="mailto:webmaster@nrs.dowjones.com">Write Us</A> | <A href="../index.html">Home</A> </FONT></CENTER>
</TD></TR>

</TABLE>

<P>

</BODY>

</HTML>


</DOC>
<DOC>
<DOCNO>WT18-B31-136</DOCNO>
<DOCOLDNO>IA028-000307-B019-282</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/online-lib/company.html 143.131.194.4 19970114054615 text/html 5155
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:50:23 GMT
Last-modified: Thursday, 11-Jul-96 13:41:13 GMT
Content-length: 4964
Content-type: text/html
</DOCHDR>
<HTML>

<HEAD>

<TITLE>Dow Jones News/Retrieval</TITLE>

<META NAME="AUTHOR" CONTENT="Kathryn Doyle">
<META NAME="GENERATOR" CONTENT="Internet Assistant for Microsoft Word 2.0z">
</HEAD>

<BODY bgcolor="#ffffff" background="images/bgdonlin.gif">

<P>
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><TD width=80  valign=top><A href="index.html"><IMG valign=top WIDTH=65 HEIGHT=65 BORDER=0 SRC="images/lrgonlinres.gif"></A> 
<BR>
<B><IMG SRC="../images/trsp.gif"></B> 
</TD>
<TD width=500>
<TD><CENTER><IMG BORDER=0 SRC="images/djnr-logo.gif"> </CENTER>
<H2><CENTER>Company and Industry Data 
</CENTER></H2>

<HR>

<P>
<B>A Quick Summary:</B> <BR>
Use this area of News/Retrieval to screen public companies that meet the criteria you specify, including earnings, profits, price/earnings ratio, price/book value, and more. Select from three types of reports for just the amount of information you need.
<P>
Access information on more than 10 million private and public companies, located anywhere on the globe. Data direct from SEC filings reveal income statements, balance sheets, and ownership information, plus in-depth fundamentals, and annual reports. Reports and profiles from such trusted services as Standard &amp; Poor's, Dun &amp; Bradstreet, Media General, Nikkei Telecom Japan News &amp; Retrieval, Investext and Disclosure provide details and analysis critical to making good decision.
<P>
Scan reports, in seconds, on insider transactions for more than 10,000 companies. Compare individual company performance with that of an industry as a whole. Read analyses of market conditions from more than 350 brokerage and investment firms, and technical reports and forecasts from major economists, traders and money dealers. <BR>

<P>
<B>The Specifics:</B> <BR>
Enter in a company name or symbol then choose from three kinds of reports: A Financial Snapshot, which offers a weekly, top-level summary of a company's performance; a Financial Profile, which expands that Snapshot into more detail; or a Company Report, which offers a customizable, comprehensive look at a company. Or create a list of companies that meet your needs by using the extensive Screen for Companies feature. You can create comparison reports on companies and industries or companies vs. their industries.
<P>
Data for these reports come from these respected sources:
<UL>
<LI><B>Investext Analysts' Reports</B>: Research reports by investment firms on companies and industries.
<LI><B>Dun's Financial Records PLUS</B>: In-depth financial, historical, and operational reports for public and private companies.
<LI><B>SEC Full-Text Filings</B>: Full text of 10Ks, 10Qs, annual reports, proxy filings, and 20Fs for more than 6500 companies listed on the New York, American, or Nasdaq Exchanges.
<LI><B>Disclosure Reports Derived from SEC Filings</B>: Detailed business and financial information from 10K and 10Q extracts on publicly held companies.
<LI><B>D&amp;B Dun's Market Identifiers</B>: Company and market identification data on public and private companies.
<LI><B>Corporate Ownership Watch</B>: Insider transactions of more than 80,000 individuals and 8000 companies.
<LI><B>Zack's Corporate Earnings Estimates</B>: Consensus of securities analysts on earnings-per-share estimates for companies and forecasts for industries.
<LI><B>Media General Financial Services</B>: Comparative price, volume, and fundamental data on companies and industries.
<LI><B>Standard &amp; Poor's Profiles and Estimates</B>: Profiles of 4700 companies, including dividend and market figures and outlook.
<LI><B>Corporate Canada Online</B>: Business news and financial market information on public, private, and government-owned Canadian companies.
<LI><B>Nikkei Telecom Japan News &amp; Retrieval</B>: Japan's largest news source of financial news and corporate information covering Japanese business, the economy, markets, and other political developments.
<LI><B>Worldwide Corporate Reports</B>: Comprehensive information on companies from around the world.
<LI><B>Saudi 1000</B>: Profiles of the top 1000 Saudi Arabian companies, including background, financial data, and other company information. can locate get a report by entering a company name. <BR>
<BR>

</UL>

<P>
<CENTER>Click <A HREF="price.html">pricing information</A> for standard pricing information. </CENTER>
<P>
<CENTER>Back To <A HREF="overview.html">Source Overview</A></CENTER>
<P>
<CENTER><A href="../toolbar.gif.map"><IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></A> 
<BR>
<A href="../bizpubs/index.html">Newspapers</A><FONT SIZE=2> | <A href="../clipping/index.html">Alert Services</A> | <A href="../online-lib/index.html">Research</A> | <A href="../pers-finance/index.html">Personal Finance</A> | <A href="../latest.html">DJ In The News</A> | <A href="mailto:webmaster@nrs.dowjones.com">Write Us</A> | <A href="../index.html">Home</A> </FONT></CENTER>
</TD></TR>

</TABLE>

<P>

</BODY>

</HTML>

</DOC>
<DOC>
<DOCNO>WT18-B31-137</DOCNO>
<DOCOLDNO>IA028-000307-B019-310</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/online-lib/quotes.html 143.131.194.4 19970114054707 text/html 4289
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:50:56 GMT
Last-modified: Thursday, 11-Jul-96 13:41:16 GMT
Content-length: 4098
Content-type: text/html
</DOCHDR>
<HTML>

<HEAD>

<TITLE>Dow Jones News/Retrieval</TITLE>

<META NAME="AUTHOR" CONTENT="Kathryn Doyle">
<META NAME="GENERATOR" CONTENT="Internet Assistant for Microsoft Word 2.0z">
</HEAD>

<BODY bgcolor="#ffffff" background="images/bgdonlin.gif">
<P>
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><TD width=80  valign=top><A href="index.html"><IMG valign=top WIDTH=65 HEIGHT=65 BORDER=0 SRC="images/lrgonlinres.gif"></A> 
<BR>
<B><IMG SRC="../images/trsp.gif"></B> 
</TD>
<TD width=500>
<TD><CENTER><IMG BORDER=0 SRC="images/djnr-logo.gif"> </CENTER>
<H2><CENTER>Quotes &amp; Market Data 
</CENTER></H2>

<HR>

<P>
<B>A Quick Summary:</B> <BR>
Dow Jones has been satisfying business customers and investors with relevant and reliable market information for more than 100 years. No one else can match Dow Jones for the accuracy of real-time, current and historical stock quotes and average from every major exchange.
<P>
Want to see where the market has been? Access up to 25 years of historical information on stocks, bonds, mutual funds, and foreign exchange rates.
<P>
You can build custom portfolios in seconds, then use them to monitor your investments. You can enter your holdings, check current prices, and be alerted to news as it happens. Only Dow Jones gives you such a smooth link between your investments and the latest news about them.
<P>
<B>The Specifics:</B> <BR>
Create a portfolio, find out what it's worth, then link instantly to breaking news on the issues you've included. Tap into technical and fundamental opinions, or perform original analysis using quotes, ratios and other market data. Sources for the Quotes &amp; Market Data area include:
<UL>
<LI><B>Current Quotes</B>: Quotes on stocks, bonds, mutual funds, U.S. Treasury issues, and options. stock quotes are enhanced with news alerts. Quotes are delayed 20 minutes during trading hours.
<LI><B>Real Time Quotes</B>: Real time stock quotes on common and preferred stocks on the New York, American, Pacific, Midwest, and Nasdaq Stock Exchanges.
<LI><B>Current and Historical Quotes</B>: Current and Historical quotes for commodities and financial futures traded on major North American exchanges, plus daily values for more than 100 selected indexes.
<LI><B>Historical Quotes</B>: Daily high, low, close, and volume for stocks for the past year, and monthly and quarterly stock price summaries.
<LI><B>Tradeline Global Security Pricing and Analysis</B>: Historical information on stocks, bonds, mutual funds, government securities, foreign-exchange rates, options, and indexes - includes both U.S. and global coverage. Tradeline includes screening and reporting features.
<LI><B>Historical Dow Jones Averages</B>: Daily summaries of the Dow Jones Averages back to 1982 and 12-day trading period summaries back one year.
<LI><B>Innovest Technical Analysis Reports</B>: Daily technical opinions on stocks traded on the New York and American exchanges plus over-the-counter issues.
<LI><B>Mutual Funds Performance Report</B>: Comprehensive performance statistics, assets, and background information on mutual funds.
<LI><B>MMS Weekly Market Analysis</B>: Weekly snapshot of expectations from top economists and traders for the world's equity, currency, and debt markets.
<LI><B>Wall $treet Week Online</B>: The four most recent transcripts of this popular PBS television program. <BR>

</UL>

<P>
<CENTER>Click <A HREF="price.html">Pricing Information</A> for standard pricing information. </CENTER>
<P>
<CENTER>Back To <A HREF="overview.html">Source Overview</A></CENTER>
<P>
<CENTER><A href="../toolbar.gif.map"><IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></A> 
<BR>
<A href="../bizpubs/index.html">Newspapers</A><FONT SIZE=2> | <A href="../clipping/index.html">Alert Services</A> | <A href="../online-lib/index.html">Research</A> | <A href="../pers-finance/index.html">Personal Finance</A> | <A href="../latest.html">DJ In The News</A> | <A href="mailto:webmaster@nrs.dowjones.com">Write Us</A> | <A href="../index.html">Home</A> </FONT></CENTER>
</TD></TR>

</TABLE>

<P>

</BODY>

</HTML>


</DOC>
<DOC>
<DOCNO>WT18-B31-138</DOCNO>
<DOCOLDNO>IA028-000307-B019-353</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/online-lib/career.html 143.131.194.4 19970114054730 text/html 2727
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:51:37 GMT
Last-modified: Thursday, 11-Jul-96 13:41:12 GMT
Content-length: 2536
Content-type: text/html
</DOCHDR>
<HTML>

<HEAD>

<TITLE>Dow Jones News/Retrieval</TITLE>

<META NAME="AUTHOR" CONTENT="Kathryn Doyle">
<META NAME="GENERATOR" CONTENT="Internet Assistant for Microsoft Word 2.0z">
</HEAD>
<BODY bgcolor="#ffffff" background="images/bgdonlin.gif">

<P>
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><TD width=80  valign=top><A href="index.html"><IMG valign=top WIDTH=65 HEIGHT=65 BORDER=0 SRC="images/lrgonlinres.gif"></A> 
<BR>
<B><IMG SRC="../images/trsp.gif"></B> 
</TD>
<TD width=500>
<TD><CENTER><IMG BORDER=0 SRC="images/djnr-logo.gif"> </CENTER>
<H2><CENTER>Career and Travel 
</CENTER></H2>

<HR>

<P>
<B>A Quick Summary:</B> <BR>
Plan your next trip with the popular OAG travel guide. Tap into career management advice from<I> The National Business Employment Weekly</I>&#174;. You can even get profiles on institutes of higher education through a college selection service, or profiles of people, places and things in the 32,000 article online encyclopedia.
<P>
<B>The Specifics:</B> <BR>
Select the service you want from the Career and Travel menu:
<UL>
<LI><I><B>National Business Employment Weekly</B></I><B>&#174;</B>: Provides timely articles on career management.
<LI><B>Academic American Encyclopedia</B>: A service of Grolier Inc. containing more than 33,000 articles in science and technology, the arts and humanities, the social sciences, geography, population statistics, and sports.
<LI><B>MCI Mail</B>: Access MCI Mail to transform your computer into an electronic post office.
<LI><B>Official Airline Guide</B>: Contains comprehensive information on worldwide flight schedules for more than 600 airlines.
<LI><B>Peterson's College Selection Service</B>: Provides capsule profiles of more than 3,000 colleges and universities in the U.S. and Canada. 
</UL>

<P>
<CENTER><A NAME="OLE_LINK2">Click </A><A HREF="price.html">pricing information</A> for standard pricing information. 
<BR>
</CENTER>
<P>
<CENTER>Back To <A HREF="overview.html">Source Overview</A></CENTER>
<P>
<CENTER><A href="../toolbar.gif.map"><IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></A> 
<BR>
<A href="../bizpubs/index.html">Newspapers</A><FONT SIZE=2> | <A href="../clipping/index.html">Alert Services</A> | <A href="../online-lib/index.html">Research</A> | <A href="../pers-finance/index.html">Personal Finance</A> | <A href="../latest.html">DJ In The News</A> | <A href="mailto:webmaster@nrs.dowjones.com">Write Us</A> | <A href="../index.html">Home</A> </FONT></CENTER>
</TD></TR>

</TABLE>

<P>

</BODY>

</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-139</DOCNO>
<DOCOLDNO>IA028-000307-B020-37</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/online-lib/signup.html 143.131.194.4 19970114054748 text/html 3184
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:51:55 GMT
Last-modified: Friday, 13-Sep-96 19:13:25 GMT
Content-length: 2995
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>Dow Jones News/Retrieval</TITLE><META NAME="AUTHOR" CONTENT="Kathryn Doyle"><META NAME="GENERATOR" CONTENT="Internet Assistant for Microsoft Word 2.0z"></HEAD><BODY bgcolor="#ffffff" background="images/bgdonlin.gif"><P><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><TD width=80  valign=top><A href="index.html"><IMG valign=top WIDTH=65 HEIGHT=65 BORDER=0 SRC="images/lrgonlinres.gif"></A> <BR><B><IMG SRC="../images/trsp.gif"></B> </TD><TD width=500><TD><CENTER><IMG BORDER=0 SRC="images/djnr-logo.gif"> </CENTER><H2><CENTER>How to Sign Up </CENTER></H2><HR><H2>Individuals&#133; </H2><P>If you're an individual and you're interested in signing up for News/Retrieval, you may:<UL><LI><A HREF="/downl1.html">Download</A> our Windows or <A HREF="/downlmac.html">Macintosh</A>software now. Then call 1-800-369-7466, ext. 159 (click <A HREF="outsideus.html">non-U.S. </A>for contact information outside the U.S. and Canada) to sign up for your account and get more information on your free 10 hours.<LI>If you want to connect via TCP/IP, you can do that, too. Or even a modem pool -- just call Customer Service at 609-452-1511 to see if we support your configuration.<LI>Be sure to check out the online <A HREF="price.html">price schedule</A>, which includes details and certain restrictions on the one-time, 10-hours free offer. </UL><P><FONT SIZE=2></FONT><HR><H2>Organizations&#133; </H2><P>If you're considering News/Retrieval for your organization, we offer a variety of flexible corporate price programs. And we'll work with you to ensure that News/Retrieval is configured for your LAN, WAN or modem pool. New/Retrieval also supports the TCP/IP communications protocol, allowing for a direct Internet link. Here's how you can get in touch with us for details:<UL><LI>Check out our online list of <A HREF="http://bis.dowjones.com/bissales.html">sales offices</A>.<LI>Fill out a <A HREF="http://bis.dowjones.com/online-lib/djnrcontact.html">brief form</A> if you'd like a representative to contact you. </UL><P><FONT SIZE=2></FONT><HR><H2>If you're not sure&#133; </H2><P>Click on the Write Us link at the bottom of the page and dash off an e-mail to our Webmaster. Your questions will be forwarded to the appropriate person. <HR><P><CENTER>Back To <A HREF="all.html">Tell Me More...</A></CENTER><P><CENTER><A href="../toolbar.gif.map"><IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></A> <BR><A href="../bizpubs/index.html">Newspapers</A><FONT SIZE=2> | <A href="../clipping/index.html">Alert Services</A> | <A href="../online-lib/index.html">Research</A> | <A href="../pers-finance/index.html">Personal Finance</A> | <A href="../latest.html">DJ In The News</A> | <A href="mailto:webmaster@nrs.dowjones.com">Write Us</A> | <A href="../index.html">Home</A> </FONT></CENTER></TD></TR></TABLE><P></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-140</DOCNO>
<DOCOLDNO>IA028-000307-B020-70</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/online-lib/cs.html 143.131.194.4 19970114054828 text/html 2391
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:52:14 GMT
Last-modified: Wednesday, 21-Aug-96 15:45:38 GMT
Content-length: 2199
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>Dow Jones News/Retrieval</TITLE><META NAME="AUTHOR" CONTENT="Kathryn Doyle"><META NAME="GENERATOR" CONTENT="Internet Assistant for Microsoft Word 2.0z"></HEAD><BODY bgcolor="#ffffff" background="images/bgdonlin.gif"><P><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><TD width=80  valign=top><A href="index.html"><IMG valign=top WIDTH=65 HEIGHT=65 BORDER=0 SRC="images/lrgonlinres.gif"></A> <BR><B><IMG SRC="../images/trsp.gif"></B> </TD><TD><CENTER><IMG BORDER=0 SRC="images/djnr-logo.gif"> </CENTER><H2><CENTER>Customer Service </CENTER></H2><HR><P><CENTER><STRONG>To order Dow Jones News/Retrieval call:</STRONG> </CENTER><P><CENTER>1-800-369-7466 ext. 159</CENTER><P><CENTER>24 hours a day, 7 days a week</CENTER><P><CENTER>(click <A HREF="outsideus.html">non-U.S.</A> for contact information outside the U.S. and Canada)</CENTER><P><CENTER><STRONG>Be sure to tell us if you've already <A HREF="/downl1.html"><B>downloaded</B></A> the free software.</STRONG> </CENTER><HR><P><CENTER><STRONG>If you're an existing customer or have questions about the service, call:</STRONG> </CENTER><P><CENTER>Dow Jones News/Retrieval Customer Service</CENTER><P><CENTER>1-800-369-7466</CENTER><P><CENTER>8 a.m.-Midnight ET, Monday-Friday</CENTER><P><CENTER>9 a.m.-6 p.m. ET, Saturdays</CENTER><P><CENTER>Closed Sundays and Holidays</CENTER><P><CENTER>E-mail address: <A HREF="mailto:djnr.support@wsj.dowjones.com">djnr.support@wsj.dowjones.com</A> </CENTER><P><CENTER>Back To <A HREF="all.html">Tell Me More...</A></CENTER><P><CENTER><A href="../toolbar.gif.map"><IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></A> <BR><A href="../bizpubs/index.html">Newspapers</A><FONT SIZE=2> | <A href="../clipping/index.html">Alert Services</A> | <A href="../online-lib/index.html">Research</A> | <A href="../pers-finance/index.html">Personal Finance</A> | <A href="../latest.html">DJ In The News</A> | <A href="mailto:webmaster@nrs.dowjones.com">Write Us</A> | <A href="../index.html">Home</A> </FONT></CENTER></TD></TR></TABLE><P></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-141</DOCNO>
<DOCOLDNO>IA028-000307-B020-101</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/online-lib/outsideus.html 143.131.194.4 19970114054844 text/html 3779
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:52:53 GMT
Last-modified: Monday, 09-Sep-96 19:53:18 GMT
Content-length: 3590
Content-type: text/html
</DOCHDR>
<HTML><head><title>Dow Jones News/Retrieval - BIS International</title><link rev=made href="mailto:wdoylenn@reach.com"><link rev=made href="mailto:mmccall@dowjones.co.uk"><link rev=made href="mailto:mduffnnn@reach.com"><link rev=made href="mailto:jsteven08@reach.com"></head><body bgcolor="#ffffff" background="images/bgdonlin.gif"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><td width=80valign=top><a href="index.html"><IMG valign=top WIDTH=65 HEIGHT=65 BORDER=0 SRC="images/lrgonlinres.gif"></a><br><imgSRC="../images/trsp.gif"></td><td>			<CENTER>	<H2>	<FONT SIZE=+3>D</FONT>OW	<FONT SIZE=+3>J</FONT>ONES	<FONT SIZE=+3>B</FONT>USINESS	<FONT SIZE=+3>I</FONT>NFORMATION	<FONT SIZE=+3>S</FONT>ERVICES	</H2>		<h2>International</h2>	<HR SIZE=4>		</CENTER>	<blockquote>												<p>				<b>International pricing for Dow Jones News/Retrieval<font size=2>&#174;</font></b> 		 		 <p>				Business Information Services-International markets and supports electronic				products of Dow Jones & Co. in all markets outside of the United States and				Canada. For corporate product sales information, please contact the regional				office nearest you. Inquiries for consumer products should be directed to our				head office.		<p>												<HR SIZE=2>				<b>Head Office:</b>		<p>						Dow Jones & Co.			<br>								Business Information Services-International, PO Box 300,				Princeton, NJ 08832 USA		<p>				Deputy Director, Dow Jones BIS International:							<br>								Rick Bremble, <a href="mailto:rick.bremble@cor.dowjones.com">rick.bremble@cor.dowjones.com</a>. Phone: (1)				609-520-4080 Fax: (1) 609-520-4068 						<p> 											<HR SIZE=2>					<b>Europe/Gulf Regional Office:</b>		<p>					10 Fleet Place, London EC4M 7RB ENGLAND 			<br>				European Sales & Marketing Manager:			<br>				Mary McCall, <a href="mailto:mmccall@dowjones.co.uk">mmccall@dowjones.co.uk</a>.				Phone: (44-171) 832-8078 Fax: (44-171) 832-9861 <p>				<HR SIZE=2>				<b>Asia /Pacific Sales Office:</b>				<p>								Times Square 42/F, NatWest Tower, 1 Matheson Street, Causeway Bay HONG KONG				<br>								Asia/Pacific Regional Account Manager: 							<br>							Mark Duff, <a href="mailto:mduffnnn@reach.com"> 				mduffnnn@reach.com</a>. Phone: (852) 2599-2222, 2599-2279 Fax: (852) 2599-2200, 2599-2499						<p>							<HR SIZE=2>					<b>Central/South America Sales Office:</b>						<p>						Central/South America Account Manager: 			<br>	John Stevens, <a href="mailto:jsteven08@reach.com">				jsteven08@reach.com</a>. Phone: (525) 280-62-09 Fax: (525) 280-61-09				</blockquote>												<pre>												</pre> 												<CENTER> Back To<B> <A HREF="index.html">Dow Jones						News/Retrieval&#174;.</A></B></center>														<center>				<a href="../toolbar.gif.map">								<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>					<BR>									<font size=2>					<a href="../bizpubs/index.html">Newspapers</a> |					<a href="../clipping/index.html">Alert Services</a> |					<a href="../online-lib/index.html">Research</a>   |					<a href="../pers-finance/index.html">Personal Finance</a>  |  					<a href="../latest.html">DJ In The News</a>  |					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |					<a href="../index.html">Home</a> 				</font>				</center></TD></tr></TABLE></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-142</DOCNO>
<DOCOLDNO>IA028-000307-B020-137</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/online-lib/access.html 143.131.194.4 19970114054918 text/html 2965
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:53:23 GMT
Last-modified: Friday, 13-Sep-96 19:13:23 GMT
Content-length: 2776
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>Dow Jones News/Retrieval</TITLE><META NAME="GENERATOR" CONTENT="Internet Assistant for Microsoft Word 2.0z"></HEAD><BODY bgcolor="#ffffff" background="images/bgdonlin.gif"><P><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><TD width=80  valign=top><A href="index.html"><IMG valign=top WIDTH=65 HEIGHT=65 BORDER=0 SRC="images/lrgonlinres.gif"></A> <BR><B><IMG SRC="../images/trsp.gif"></B></TD><TD width=500><TD><CENTER><IMG BORDER=0 SRC="images/djnr-logo.gif"> </CENTER><H2><CENTER>How to Access </CENTER></H2><HR SIZE=4><BR><BR><BR><H2>How can I access Dow Jones News/Retrieval<FONT SIZE=2>&#174;</FONT><FONT SIZE=5>? <BR></FONT></H2><P>Individuals and companies can access Dow Jones News/Retrieval<FONT SIZE=2>&#174;</FONT> in several ways. On an individual basis through a personal modem. Or in a workgroup through a modem pool. Larger companies can be outfitted for direct connections through LANs or WANs. News/Retrieval<FONT SIZE=2>&#174;</FONT> also supports the TCP/IP communications protocol, allowing for a direct Internet link.<P>If you're an individual and you're interested in signing up for News/Retrieval, you may:<UL><LI><A HREF="/downl1.html">Download</A> our Windows software or <A HREF="/downlmac.html"> Macintosh software</A> now. Then call 1-800-369-7466, ext. 159 (click <A HREF="outsideus.html">non-U.S.</A> for contact information outside the U.S. and Canada) to sign up for your account and get more information on your free 10 hours.<LI>Be sure to check out the online <A HREF="price.html">price schedule</A>. </UL><P>If you're considering News/Retrieval for your organization, we offer a variety of flexible corporate price programs and we'll work with you to configure your environment for News/Retrieval. Here's how you can get in touch with us for details:<UL><LI>Check out our online list of <A HREF="/bissales.html">sales offices</A>.<LI>Fill out a <A HREF="http://bis.dowjones.com/online-lib/djnrcontact.html">brief form</A> if you'd like a representative to contact you. <BR></UL><P><CENTER>Back To <A HREF="all.html">Tell Me More...</A> </CENTER><P><CENTER><A href="../toolbar.gif.map"><IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></A> <BR><A href="../bizpubs/index.html"><FONT SIZE=2>Newspapers</FONT></A><FONT SIZE=2> | <A href="../clipping/index.html">Alert Services</A> | <A href="../online-lib/index.html">Research</A> | <A href="../pers-finance/index.html">Personal Finance</A> | <A href="../latest.html">DJ In The News</A> | <A href="mailto:webmaster@nrs.dowjones.com">Write Us</A> | <A href="../index.html">Home</A> </FONT></CENTER></TD></TR></TABLE><P></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-143</DOCNO>
<DOCOLDNO>IA028-000307-B020-188</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/online-lib/apps.html 143.131.194.4 19970114054947 text/html 5727
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:53:55 GMT
Last-modified: Thursday, 11-Jul-96 13:41:34 GMT
Content-length: 5536
Content-type: text/html
</DOCHDR>
<HTML>

<HEAD>

<TITLE>Dow Jones News/Retrieval</TITLE>

<META NAME="AUTHOR" CONTENT="Kathryn Doyle">
<META NAME="GENERATOR" CONTENT="Internet Assistant for Microsoft Word 2.0z">
</HEAD>
<BODY bgcolor="#ffffff" background="images/bgdonlin.gif">

<P>
<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><TD width=80  valign=top><A href="index.html"><IMG valign=top WIDTH=65 HEIGHT=65 BORDER=0 SRC="images/lrgonlinres.gif"></A> 
<BR>
<B><IMG SRC="../images/trsp.gif"></B> 
</TD>
<TD width=500>
<TD><CENTER><IMG BORDER=0 SRC="images/djnr-logo.gif"> </CENTER>
<H2><CENTER>Applications 
</CENTER></H2>

<HR>
<BR>
<BR>
<BR>

<P>
To see just a few of the ways that Dow Jones News/Retrieval provides you with fast answers to your tough questions, click on your area of interest or scroll down to view them all.
<P>
<A HREF="#sales" >Sales</A>
<P>
<A HREF="#finance" >Finance</A>
<P>
<A HREF="#marketing" >Marketing</A>
<P>
<A HREF="#ip" >Information Professionals</A>
<P>
<A HREF="#rd" >Research &amp; Development</A>
<P>
<A HREF="#mis" >Management Information Systems</A> 

<HR>

<H2><A NAME="sales">Sales: A Snap with Dow Jones </A></H2>

<UL>
<LI>Keep track of your customers.
<LI>Find and research prospects.
<LI>Unravel your competitors' strategies.
<LI>Address your prospects' specific concerns using exclusive, in-depth information.
<LI>Spot trends that will improve your sales presentations.
<LI>Go into every sales call armed with news of new products, executive changes, financial outlooks and SEC filings. 
</UL>

<P>
<FONT SIZE=2></FONT>
<HR>

<H2><A NAME="finance">Finance: Confidence in your Decisions </A></H2>

<UL>
<LI>Evaluate your clients' and prospects' financial health using timely and reliable financial data.
<LI>Track private as well as public companies, using press releases, news, and editorial analysis.
<LI>Assess investments using current and historical stock quotes and corporate financials.
<LI>Monitor insider trading.
<LI>Check on mutual funds, corporate and foreign bonds, options, and U.S. Treasury issues.
<LI>Keep track of mergers and acquisitions that could affect your business.
<LI>Stay informed with top busines and industry news selected by Dow Jones editors. 
</UL>

<P>
<FONT SIZE=2></FONT>
<HR>

<H2><A NAME="marketing">Marketing: Develop Businesses with Assurance </A></H2>

<UL>
<LI>Track market share in your own industry and your customers' industries.
<LI>Uncover the latest trends before your competitors do.
<LI>Track national and local news about yor competitors.
<LI>Determine the source of your real competitive threats.
<LI>Assess which trends are most likely to affect your business.
<LI>Compare company releases with with subsequent coverage to determine the reliability of each message.
<LI>Keep track of investments or competitors using the portfolio feature. 
</UL>

<P>
<FONT SIZE=2></FONT>
<HR>

<H2><A NAME="ip">Information Professionals: Get Fast Results for Your Clients </A></H2>

<UL>
<LI>Answer quick-reference questions with continuously updated news.
<LI>Conduct in-depth research on companies, people and subjects.
<LI>Locate specific articles from<I> The Wall Street Journal, The New York Times, Financial Times, The Washington Post, Los Angeles Times</I> and more than 3,000 other publications.
<LI>Create comprehensive company reports from key statistical and text sources.
<LI>Provide clients with customized clip folders on topics that meet their precise information needs. 
</UL>

<P>
<FONT SIZE=2></FONT>
<HR>

<H2><A NAME="rd">R&amp;D: Create Products with Customers in Mind </A></H2>

<UL>
<LI>Monitor the pulse of public opinion to help predict emerging markets and market demands.
<LI>Be the first to identify the latest breakthroughs in materials and processes.
<LI>Analyze the activities and sales figures of your competitors.
<LI>Stay abreast of the latest actions of government agencies.
<LI>Track patent announcements and product approvals. 
</UL>

<P>
<FONT SIZE=2></FONT>
<HR>

<H2><A NAME="mis">MIS: Stay on Top of the Latest Developments </A></H2>

<UL>
<LI>Find out how other companies are deploying new technologies to increase their competitiveness.
<LI>Get the latest news on the world of standards committees.
<LI>Find out what happened when other companies developed or installed the technologies you're considering.
<LI>Access product reviews from top industry publications.
<LI>Be more confident in your systems strategy, based on trends you see in customer requirements and preferences.
<LI>Develop insight and the ability to quickly adapt your systems to new technologies because you saw them coming.
<LI>Put Dow Jones on every desktop in your organization and you will have given everyone in your company an intense competitive advantage. 
</UL>

<P>
<FONT SIZE=2></FONT>
<HR>


<P>
<CENTER>Back To <A HREF="all.html">Tell Me More...</A></CENTER>
<P>
<CENTER><A href="../toolbar.gif.map"><IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></A> 
<BR>
<A href="../bizpubs/index.html">Newspapers</A><FONT SIZE=2> | <A href="../clipping/index.html">Alert Services</A> | <A href="../online-lib/index.html">Research</A> | <A href="../pers-finance/index.html">Personal Finance</A> | <A href="../latest.html">DJ In The News</A> | <A href="mailto:webmaster@nrs.dowjones.com">Write Us</A> | <A href="../index.html">Home</A> </FONT></CENTER>
</TD></TR>

</TABLE>

<P>

</BODY>

</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-144</DOCNO>
<DOCOLDNO>IA028-000307-B020-224</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/online-lib/faqs.html 143.131.194.4 19970114055011 text/html 14473
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:54:11 GMT
Last-modified: Wednesday, 21-Aug-96 15:45:38 GMT
Content-length: 14280
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>Dow Jones News/Retrieval</TITLE><META NAME="AUTHOR" CONTENT="Kathryn Doyle"><META NAME="GENERATOR" CONTENT="Internet Assistant for Microsoft Word 2.0z"></HEAD><BODY bgcolor="#ffffff" background="images/bgdonlin.gif"><P><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><TD width=80  valign=top><A href="index.html"><IMG valign=top WIDTH=65 HEIGHT=65 BORDER=0 SRC="images/lrgonlinres.gif"></A> <BR><B><IMG SRC="../images/trsp.gif"></B> </TD><TD width=500><TD><CENTER><IMG BORDER=0 SRC="images/djnr-logo.gif"> </CENTER><H2><CENTER>Frequently Asked Questions </CENTER></H2><HR><H3>General Service Information </H3><P><A HREF="#great">So what's so great about the new News/Retrieval?</A><P><A HREF="#free">I haven't signed up yet for my 10 free hours. How do I get started?</A><P><A HREF="#mac">Is there a Macintosh version of the new software?</A><P><A HREF="#corporate">Do you offer corporate price plans?</A><P></P><HR><H3>Installation &amp; Setup </H3><P><A HREF="#help">How can I get assistance once I'm online?</A> <P><A HREF="#tcp">Can I connect via TCP/IP?</A> <P><A HREF="#pool">Can I configure the software to run on my organization's modem pool?</A> <P></P><HR><H3>Content &amp; Navigation </H3><P><A HREF="#pubs">Which publications can I search?</A> <P><A HREF="#clip">Do you offer a clipping service?</A> <P><A HREF="#portfolio">Can I create my own portfolio online?</A> <P><A HREF="#sameinfo">Will I get the same information in your Current News section that I get in my newspaper?</A> <P><A HREF="#cpheads">Can I continuously print news headlines?</A><P></P><HR><H3>Common Questions from Existing Customers </H3><P><A HREF="#install">When I install the new News/Retrieval (Windows v. 5.0), will it overwrite the earlier 3.2A version that I have on my PC?</A> <P><A HREF="#save">How do I save my local access number, password and other settings?</A> <P><A HREF="#new">What are the major enhancements this upgrade offers?</A> <P><A HREF="#existing">I've been using CustomClips for a while now. If I install the new software, what will happen to my existing news folders?</A> <P><A HREF="#findcc">How do I find my existing CustomClips news folders?</A> <P><A HREF="#text">Which area of the software includes //TEXT?</A> <P><A HREF="#print">How have you changed the print and capture features?</A> <P><A HREF="#customize">May I customize this new software?</A> <P><A HREF="#terminal" >I'm really familiar with your Terminal mode. Can I still use it with this new software?</A> <P></P><HR><H3>Pricing Questions </H3><P><A HREF="#bottom">What's the bottom line on your standard U.S. pricing plan?</A> <P><A HREF="#question">What if I have a pricing question once I'm online?</A> <P></P><HR><H3>General Service Information </H3><P><A NAME="great"><B>So what's so great about the new News/Retrieval?</B> </A><P>The new service includes a completely redesigned, sophisticated yet easy-to-use software interface based on Cypress&#153; front-end technology from Trax Softworks Inc. Regardless of your familiarity with online services, we believe you can work well with News/Retrieval for Windows v. 5.0. It allows you to navigate quickly and efficiently--whether you're conducting a simple search or a complex, Boolean one.<P>In addition, one of the important things we learned through extensive usability testing was that our own customers didn't realize the extent of our available content. In fact, users were surprised to learn that we offered more than 3,400 publications, reports on 10 million companies and quotes from every major financial exchange in the world--and then some. So our new software helps anyone who's interested get to the bottom of all that--and quickly locate the information that's relevant.<P>Finally, we've also revamped our pricing plans. Searching and headlines are now free and you'll pay just for the information you actually retrieve. For a complete U.S. price schedule plus contact information for non-U.S. pricing, click <A HREF="price.html">pricing</A>.<P><A NAME="free"><B>I haven't signed up for my 10 free hours yet. How do I get started?</B> </A><P>Check out <A HREF="signup.html">sign up information</A> for all the details.<P><A NAME="mac"><B>Is there a Macintosh version of the new software?</B> </A><P>We do offer Mac software for News/Retrieval, which you can order by calling Dow Jones at 1-800-369-7466 (click <A HREF="outsideus.html">non-U.S.</A> for contact information outside the U.S. and Canada). A Mac version of our new interface (v. 5.0) is scheduled for availability later this year.<P><A NAME="corporate"><B>Do you offer corporate price plans?</B></A><P>Of course! Plus we'll work with you to integrate News/Retrieval--and/or other BIS products as appropriate--into your organization's computing environment. E-mail <A HREF="mailto:djnr.sales@cor.dowjones.com">djnr.sales@cor.dowjones.com</A> or click <A HREF="/bissales.html">sales offices</A> to locate the contact nearest you. <HR><H3>Installation &amp; Setup </H3><P><A NAME="help"><B>How can I get assistance once I'm online?</B> </A><P>There are three ways to get help:<UL><LI>Access online help by making a selection from the Help menu in the software or clicking the question mark icon in the toolbar.<LI>Check out our free online newsletter, FYI, by choosing this selection from the Help menu in the software.<LI>Call Customer Service at 1-800-369-7466 for expert advice. Click <A HREF="cs.html">Customer Service </A>to learn more. </UL><P><A NAME="tcp"><B>Can I connect via TCP/IP?</B> </A><P>Yes. Just choose that option when you're going through the easy Setup process.<P><A NAME="pool"><B>Can I configure the software to run on my organization's modem pool?</B> </A><P>Yes. Just choose that option when you're going through the easy Setup process. If you have questions, contact Customer Service at 1-800-369-7466. <HR><H3>Content &amp; Navigation </H3><P><A NAME="pubs"><B>Which publications can I search?</B> </A><P>There are more than 3,400 of them, ranging from major global news sources such as <I>The Wall Street Journal</I> and <I>Financial Times</I> to industry, trade and other publications. Click <A HREF="overview.html">source list</A> to check out the complete list.<P><A NAME="clip"><B>Do you offer a clipping service?</B> </A><P>Yes--Dow Jones CustomClips. It's available in the Track News and Articles area of the software. CustomClips is easy to use and incredibly powerful. You just set up folders to track the information you want and decide which of the <A HREF="http://bis.dowjones.com/clipping/custom-clips/publications/publications.html">2,600 publications</A> you want searched automatically. For CustomClips pricing information, see the <A HREF="price.html">price schedule</A>.<P><A NAME="portfolio"><B>Can I create my own portfolio online?</B> </A><P>Of course. Choose Quotes and Market Data from the main menu. Then select the Portfolio Setup, Editing and Viewing button and follow the easy online instructions to create your own portfolio.<P><A NAME="sameinfo"><B>Will I get the same information in your Current News section that I get in my daily newspaper?</B> </A><P>Absolutely not. Unlike many online services, which offer unedited updates from national wire services, we have more than 1,000 reporters and editors on staff world-wide plus a U.S.-based team of interactive editors and writers, dedicated to prioritizing, indexing, rewriting and editing news exclusively for Dow Jones News/Retrieval.<P><A NAME="cpheads"><B>Can I continuously print news headlines?</B> </A><P>Sure! Just click the Print Articles button. When the print menu appears, select the &quot;Print As&quot; option and choose headlines from the resulting list. <HR><H3>Common Questions from Existing Customers </H3><P><A NAME="install"><B>When I install the new News/Retrieval (Windows v. 5.0) will it overwrite my earlier 3.2A version that I have on my PC?</B> </A><P>No. The new software won't overwrite any existing version of our software that it locates on your PC. Instead, it will make a copy of the setup information (e.g., local access number, password, etc.)--as long as you did not change the default directory when you originally installed it-- and install that information on the new version. In other words, you won't need to re-enter all this information! You may also free up space on your hard drive by deleting the old version.<P><A NAME="save"><B>How do I save my local access number, password and other settings?</B> </A><P>If you use the easy Setup Assistant, our step-by-step guide to installing and setting up News/Retrieval, you'll see a Done button on the last screen. To save your entire setup configuration, just click the button. Remember, if you had a previous version of the News/Retrieval software on your PC, all setup-related information is pre-installed for you; the Setup Assistant just offers you the chance to review and adjust your current settings as required.<P><A NAME="new"><B>What are the major enhancements this upgrade offers?</B> </A><P>They're too numerous to mention! Highlights include a completely redesigned interface that helps bring much of our &quot;hidden&quot; content to the surface, thus making it easier for you to expand your searching into areas you may not have even known we offered. We've added expanded portfolio capabilities, more content, easier customization features, better capturing, printing and saving functionality, a step-by-step Setup Assistant and much more. <A HREF="/downl1.html">Download now</A> and see for yourself.<P><A NAME="existing"><B>I've been using your CustomClips service for a while now. If I install the new software, what will happen to my existing news folders?</B> </A><P>The first time you connect to Dow Jones using the new version 5.0, your CLIP folders are retrieved for you--you don't need to re-key your searches or re-establish your folders.<P><A NAME="findcc"><B>How do I find my existing CustomClips folders?</B> </A><P>The first time you initiate a session with Dow Jones, your folder news will be delivered to your desktop. To then access your folders, select the Track News and Articles area from the main menu or click on the convenient dialog box that shows you your folders and how many new stories are included in each when you connect to Dow Jones. Each folder also then gets its own icon on the toolbar at the top of the screen.<P><A NAME="text"><B>Which area of the software includes //TEXT?</B> </A><P>You'll find //TEXT in the Search News and Articles tab. Check out the extensive search capabilities listed in the area. We're hoping you'll find it's more powerful--yet much easier to use--than ever before.<P><A NAME="print"><B>How have you changed the print and capture features?</B> </A><P>We've completely changed the way you print and capture information--largely based on your suggestions! Select Print or Save from the File menu at any time. Also watch for the easy-to-use Print and Save buttons that appear in various areas of the software. You'll find flexible options and presentation-ready printing.<P><A NAME="customize"><B>May I customize this new software?</B> </A><P>Please do! Create your own toolbar buttons for fast access to the areas that interest you most. Set up news clipping folders so that each time you sign on the news that you want is delivered direct to your desktop. And don't forget to set your preferences so that information is displayed the way you want it to be. Check out the software's online help for details.<P><A NAME="terminal"><B>I'm really familiar with your Terminal mode. Can I still use it with this new software?</B> </A><P>Sure. Select Terminal from the Tools menu. <HR><H3>Pricing Questions</H3><P><A NAME="bottom"><B>What's the bottom line on your standard U.S. pricing plan?</B> </A><P>It's a transaction-based plan, where both searching for information and article headlines are free--you pay just for the information you access. For example, individual articles in the Publications Library are priced at $2.95 per article. Experienced searchers who would rather view the lead paragraph or &quot;keyword-in-context&quot; paragraph pay $2.00 each. Citations are $1.00 each. Dow Jones CustomClips folders are $19.95 per month plus article charges. There is a one-time start up fee ($29.95) associated with Dow Jones News/Retrieval, and after the first year, an annual fee of $19.95. Company and Industry data provides company reports starting at $1.25 per report. Subscribers can screen to identify companies by 24 criteria, or search individual databases like Disclosure, where all reports on a given company are just $19.95. Click <A HREF="price.html">U.S. pricing</A> for a complete price schedule for the U.S. plus contact information for non-U.S. pricing.<P>Dow Jones also offers flat-fee enterprise site license pricing plans. Click <A HREF="/bissales.html">sales offices</A> to locate the office nearest you.<P><A NAME="question"><B>What if I have a question about pricing once I'm online?</B> </A><P>For fast access to the pricing for the area you're in, just click the $ icon in the upper-right corner of your screen. You'll get a page of information that details where you are and how much it costs. <HR><P><CENTER>Back To <A HREF="all.html">Tell Me More...</A></CENTER><P><CENTER><A href="../toolbar.gif.map"><IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></A> <BR><A href="../bizpubs/index.html">Newspapers</A><FONT SIZE=2> | <A href="../clipping/index.html">Alert Services</A> | <A href="../online-lib/index.html">Research</A> | <A href="../pers-finance/index.html">Personal Finance</A> | <A href="../latest.html">DJ In The News</A> | <A href="mailto:webmaster@nrs.dowjones.com">Write Us</A> | <A href="../index.html">Home</A> </FONT></CENTER></TD></TR></TABLE><P></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-145</DOCNO>
<DOCOLDNO>IA028-000307-B020-263</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/online-lib/customer-quotes.html 143.131.194.4 19970114055045 text/html 3105
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:54:38 GMT
Last-modified: Wednesday, 29-May-96 15:11:21 GMT
Content-length: 2913
Content-type: text/html
</DOCHDR>
<html>
<head><title>Dow Jones</title></head>
<body bgcolor="#ffffff" background="images/bgdonlin.gif">

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><td width=80
valign=top><a href="index.html"><IMG valign=top WIDTH=65 HEIGHT=65 BORDER=0 SRC="images/lrgonlinres.gif"></a><br><img
SRC="../images/trsp.gif"></td><td>
		



<CENTER>

<IMG WIDTH=132 HEIGHT=39 BORDER=0 SRC="images/djnr-logosm.gif">


</CENTER>
<HR SIZE=4>
<BR>
<blockquote>




<BR>
<B>What customers are saying... </B>

<P>



"News/Retrieval<font size=2>&#174;</FONT> puts us at least one day ahead of the competition.  
That's a big deal.  News/Retrieval<font size=2>&#174;</FONT> is a powerful business tool that truly pays for itself."
<BR>
<UL>
		-Tom Towers, American Bank Note </UL>

<P>

"I go online every morning.  I see everything first on the Newswires.  
And with Dow Jones CustomClips<font size=2>&#174;</FONT>, I get information on what I call a 
need-to-know-first basis.  CustomClips<font size=2>&#174;</FONT> leads me to the right prospects--I 
can pick up the phone and make a call with total confidence.  I'm prepared.  
I know where the key players, people and organizations are and what they're 
trying to do.  Many times I even know the ideas behind their plans...and I 
can call with a solution.  I read about it in the newspaper days after I find 
important information on News/Retrieval<font size=2>&#174;</FONT>."
<BR>
<UL>
		-Tony Rodriguez, Director of Sales and Marketing
<BR>
		Managed Health Reinsurance Area of Alden Health Management Services
<P></UL>

"News/Retrieval<font size=2>&#174;</FONT> gives us an incredible amount of information for prospecting 
and helps us see where companies stand relative to the type of business they're 
doing.  The Text Library is a mainstay for research and development.  It saves 
R&D time and money because everything is at our fingertips."
<BR><UL>
		-Rebecca White, Marketing Support Specialist
<BR>
		American Bankers Insurance Group </UL>
<P>


<BR>

<P>

<center>
See what the <a
href="..press-quotes.html">
<b>press</b></a> is saying about News/Retrieval<font size=2>&#174;</FONT> 
</center>

</blockquote>


<BR>
				<pre>
		
		
			</pre><center>Back To 
			<A HREF="all.html">Dow Jones News/Retrieval<font size=2>&#174;</FONT></A></CENTER>

				<center>
				<a href="../toolbar.gif.map">
			
					<IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></a>
					<BR>
					
				<font size=2>
					<a href="../bizpubs/index.html">Newspapers</a> |
					<a href="../clipping/index.html">Alert Services</a> |
					<a href="../online-lib/index.html">Research</a>   |
					<a href="../pers-finance/index.html">Personal Finance</a>  |  
					<a href="../latest.html">DJ In The News</a>  |
					<a href="mailto:webmaster@nrs.dowjones.com">Write Us</a>  |
					<a href="../index.html">Home</a> 

				</font>


				</center>
</TD></tr>
</TABLE>
</body>
</html>


</DOC>
<DOC>
<DOCNO>WT18-B31-146</DOCNO>
<DOCOLDNO>IA028-000307-B020-303</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/online-lib/press-quotes.html 143.131.194.4 19970114055056 text/html 3245
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:55:07 GMT
Last-modified: Monday, 09-Sep-96 19:55:41 GMT
Content-length: 3056
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>Dow Jones</TITLE><META NAME="GENERATOR" CONTENT="Internet Assistant for Microsoft Word 2.0z"></HEAD><BODY bgcolor="#ffffff" background="images/bgdonlin.gif"><P><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0><TR><TD width=80  valign=top><A href="index.html"><IMG valign=top WIDTH=65 HEIGHT=65 BORDER=0 SRC="images/lrgonlinres.gif"></A> <BR><B><IMG SRC="../images/trsp.gif"></B></TD><TD width=500><TD><CENTER><IMG WIDTH=132 HEIGHT=39 BORDER=0 SRC="images/djnr-logosm.gif"> </CENTER><HR SIZE=4><BR><BR><BR><BR><BLOCKQUOTE>&quot;Looking for one-stop shopping and a convenient pricing structure for business information? Dow Jones News/Retrieval service has been completely revamped, offering access via new Windows software to <I>The Wall Street Journal </I>and <I>New York Times</I>, plus over 3,000 publications and other business information sources.&quot; </BLOCKQUOTE><BLOCKQUOTE>-<EM>Online User</EM>, July/August 1996.<BR></BLOCKQUOTE><BLOCKQUOTE>&quot;[Dow Jones News/Retrieval's] straightforward interface works smoothly. It allows you to focus on getting the information and not worry about using the software...Results come back fast...when time is money, this service will pay for itself.&quot; </BLOCKQUOTE><BLOCKQUOTE>-<EM>InfoWorld</EM>,  June 1996.<BR></BLOCKQUOTE><BLOCKQUOTE>&quot;Dow Jones today announced a new version of the Dow Jones News/Retrieval online service. The highlight of its new feature is a transaction-based pricing structure...Dow Jones has made the service easier to navigate by organizing content in six sections.&quot; </BLOCKQUOTE><BLOCKQUOTE>-<EM>PC World Online</EM>, May 1996.<BR></BLOCKQUOTE><BLOCKQUOTE>&quot;The software provides examples of search strategies...a clear advantage of DJN/R over the competition. You can be quickly spoiled by the comprehensive, robust domestic coverage on Dow Jones News/Retrieval...it really doesn't get any better.&quot; </BLOCKQUOTE><BLOCKQUOTE>-<EM>Online User</EM>, September/October 1996.<BR></BLOCKQUOTE><BR><P><CENTER>See what <A href="customer-quotes.html"><B>customers</B></A> are saying about News/Retrieval<FONT SIZE=2>&#174;</FONT> <BR><BR></CENTER><PRE><FONT SIZE=2>                                        </FONT></PRE><P><CENTER>Back To <A HREF="all.html">Dow Jones News/Retrieval<FONT SIZE=2>&reg;</FONT></A> </CENTER><P><CENTER><A href="../toolbar.gif.map"><IMG WIDTH=430 HEIGHT=70 BORDER=0 SRC="../images/toolbar.gif" ISMAP></A> <BR><A href="../bizpubs/index.html"><FONT SIZE=2>Newspapers</FONT></A><FONT SIZE=2> | <A href="../clipping/index.html">Alert Services</A> | <A href="../online-lib/index.html">Research</A> | <A href="../pers-finance/index.html">Personal Finance</A> | <A href="../latest.html">DJ In The News</A> | <A href="mailto:webmaster@nrs.dowjones.com">Write Us</A> | <A href="../index.html">Home</A> </FONT></CENTER></TD></TR></TABLE><P></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-147</DOCNO>
<DOCOLDNO>IA028-000307-B020-340</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/pie/sftwre.map 143.131.194.4 19970114055134 text/html 321
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:55:31 GMT
Content-type: text/html
Content-length: 180
</DOCHDR>
<TITLE>Imagemap Error</TITLE><H1>Imagemap Error</H1>Your client did not send any coordinates. Either your client doesn't support imagemap or the map file was not accessed as a map.
</DOC>
<DOC>
<DOCNO>WT18-B31-148</DOCNO>
<DOCOLDNO>IA028-000307-B021-18</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/pie/wow.html 143.131.194.4 19970114055154 text/html 1329
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:56:01 GMT
Last-modified: Wednesday, 08-Jan-97 15:15:18 GMT
Content-length: 1137
Content-type: text/html
</DOCHDR>
<HTML><HEAD>   <TITLE>Window on WallStreet for Dow Jones</TITLE></HEAD><BODY TEXT="#000000" BGCOLOR="#FFFFFF" LINK="#0000FF" VLINK="#551A8B" ALINK="#0000FF"><H2><FONT COLOR="#5b0b5a"> Window on WallStreet&#153; for Dow Jones </FONT></H2><hr size=4><P>Make the most out of the data you access with Window on WallStreet<FONT SIZE=-2><SUP>TM</SUP></FONT>for Dow Jones. Turn the raw financial data you retrieve from DowJones into powerful charts and graphs that clearly indicate buy/sell signalsin just a few minutes. This special edition of the popular charting softwareis designed to work automatically with Dow Jones.</P><P>Window on WallStreet<SUP><FONT SIZE=-2>TM</FONT></SUP> for Dow Joneswill log onto Dow Jones, retrieve information on your entire portfolio,update that information, and convert the data into charts and graphs thatwill help you make more informed investment decisions. It can even be programmedfor automatic downloading.</P><P>Order NOW by calling 1-800-522-3567, ext. 385. Available for PCs only.</P><P><HR><CENTER><FONT SIZE=3><A HREF="rom.html">Home</A></FONT> </CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-149</DOCNO>
<DOCOLDNO>IA028-000307-B021-44</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/pie/nirvana.html 143.131.194.4 19970114055206 text/html 1230
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:56:15 GMT
Last-modified: Wednesday, 08-Jan-97 15:15:02 GMT
Content-length: 1038
Content-type: text/html
</DOCHDR>
<HTML><HEAD>   <TITLE>Nirvana Data Collector</TITLE></HEAD><BODY TEXT="#000000" BGCOLOR="#FFFFFF" LINK="#0000FF" VLINK="#551A8B" ALINK="#0000FF"><H2><FONT COLOR="#5b0b5a"> Nirvana Data Collector </FONT></H2><hr size=4><P>If you already have charting software and want to download your DowJones News/Retrieval&reg; data, Nirvana Data Collector is the product foryou! NDC works with MetaStock, Supercharts and other popular technicalanalysis programs. It updates multiple data directories and multiple datatypes from Dow Jones in one phone call. And it automatically detects errorsand adjusts prices for stock splits. You can even receive breaking newson your stocks from the <B><I>exclusive</I></B> Dow Jones Newswires witha simple click of your mouse!</P><P>The Nirvana Data Collector--a $99 value-- is just $29.95 for PrivateInvestor Edition subscribers. Available for PCsonly. Order by calling 1-800-522-3567, ext. 162. </P><P><HR><CENTER><FONT SIZE=3><A HREF="rom.html">Home</A></FONT></CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-150</DOCNO>
<DOCOLDNO>IA028-000307-B021-76</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/pie/plan.html 143.131.194.4 19970114055222 text/html 2353
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:56:31 GMT
Last-modified: Wednesday, 08-Jan-97 15:15:04 GMT
Content-length: 2161
Content-type: text/html
</DOCHDR>
<HTML><HEAD>   <TITLE>Plan Ahead for Your Financial Future</TITLE></HEAD><BODY TEXT="#000000" BGCOLOR="#FFFFFF" LINK="#0000FF" VLINK="#551A8B" ALINK="#0000FF" BACKGROUND="bgdfin.gif"><H2><FONT COLOR="#5b0b5a"> Plan Ahead&#153; for Your Financial Future. <BR>The best retirement planner on the market today. </FONT></H2><hr size=4><P><B>Do you want to retire as a millionaire? </B>Of course you do. Buthow? All you really need to know is how to save your hard-earned money.But who has the time to learn complex investment techniques? You do. Infact, Plan Ahead has made the whole process easy and fun. </P></UL><P>Plan Ahead for Your Financial Future is an interactive CD-ROM that easesyou into retirement planning by clearly explaining important retirementinvestment principles. </P><P><BR><B>Plan Ahead Makes Retirement Planning Easy</B> <BR>This CD-ROM is ideal for anyone who is just starting to think about savingfor retirement, but doesn't know how, or where, to begin. </P><P>Starting with the opening screen, you immediately focus on establishingyour retirement goals. You'll use interactive worksheets to find out ifyou're on track to a comfortable retirement. And you'll work at your ownspeed throughout the program. The entire program is designed to help yougain a better knowledge of retirement planning and create a plan that worksfor you! Throughout the entire process you'll get advice from experts inthe field. </P><P>Plus, as your life situation changes, you can easily update your worksheetsso that your retirement strategy will always be on-target. </P><P>At just $29.95, it could be your smallest, yet most important, retirementinvestment! </P><P><B>System requirements:</B> IBM-compatible, a CD-ROM drive, 486 processoror faster; 8 MB RAM; Super VGA, 256 colors; multimedia-compatible soundand video cards; DOS 6.0 or above; Windows<FONT SIZE=-1>&reg;</FONT> 3.1or above. </P><P><B>How to Order:</B> <BR>You can order by calling <B>1-800-522-3567, ext. 378</B>. Please, haveyour credit card ready. </P><P><HR><CENTER><FONT SIZE=3><A HREF="rom.html">Home</A></FONT></CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-151</DOCNO>
<DOCOLDNO>IA028-000307-B021-95</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/pie/coind.html 143.131.194.4 19970114055231 text/html 1137
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:56:42 GMT
Last-modified: Wednesday, 08-Jan-97 15:14:43 GMT
Content-length: 946
Content-type: text/html
</DOCHDR>
<HTML><HEAD>   <TITLE>Company &amp; Industry Data</TITLE></HEAD><BODY TEXT="#000000" BGCOLOR="#FFFFFF" LINK="#0000FF" VLINK="#551A8B" ALINK="#0000FF"><CENTER><IMG SRC="images/compdata.gif"></CENTER><P>Use our unique screening capabilities to identify a listof stocks that meet as many criteria as you choose. Select from over 6,000public companies. Then choose the <B>Compare Companies and Industries</B> featureto see how your choices stack up next to each other. Continue your researchby viewing timely income statements and balance sheets, along with detailedfinancial ratios and measures. And check our analysts' ratings and earningsforecasts before you buy or sell.</P><P><HR><CENTER><FONT SIZE=3><A HREF="downld.html">Download Now</A> | <A HREF="tour.html">Back To Tour</A> | <A HREF="index.html">Home</A></FONT><BR>Call <B>1-800-522-3567</B>, ext. 154 to subscribe, ext. 190 for more information.</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-152</DOCNO>
<DOCOLDNO>IA028-000307-B021-142</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/pie/search.html 143.131.194.4 19970114055320 text/html 1062
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:57:22 GMT
Last-modified: Wednesday, 08-Jan-97 15:15:11 GMT
Content-length: 871
Content-type: text/html
</DOCHDR>
<HTML><HEAD>   <TITLE>Search News &amp; Articles</TITLE></HEAD><BODY TEXT="#000000" BGCOLOR="#FFFFFF" LINK="#0000FF" VLINK="#551A8B" ALINK="#0000FF"><CENTER><IMG SRC="images/searchnews.gif"></CENTER><P>Research investment opportunities in a matter of secondswith a fast and easy search of the Dow Jones Private Investor PublicationsLibrary. You can access hundreds of business, financial and industry-specificpublications you trust, including the global editions of <I>The Wall StreetJournal&#174;, Barron's&#174;, Forbes, Fortune, The Economist, Institutional Investor,Bond Buyer</I> and more.</P><P><HR><CENTER><FONT SIZE=3><A HREF="downld.html">Download Now</A> | <A HREF="tour.html">Back To Tour</A> | <A HREF="index.html">Home</A><BR>Call <B>1-800-522-3567</B>, ext. 154 to subscribe, ext. 190 for more information.</FONT></CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-153</DOCNO>
<DOCOLDNO>IA028-000307-B021-171</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/pie/pubsources.html 143.131.194.4 19970114055404 text/html 15389
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:58:01 GMT
Last-modified: Wednesday, 08-Jan-97 15:15:07 GMT
Content-length: 15196
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN"><HTML><HEAD>   <TITLE>Publication Sources</TITLE>   <META NAME="GENERATOR" CONTENT="User-Agent: Mozilla/3.01Gold (Macintosh; I; PPC)"></HEAD><BODY TEXT="#000000" BGCOLOR="#FFFFFF" LINK="#0000FF" VLINK="#551A8B" ALINK="#0000FF"><A NAME="top"><H2><FONT COLOR="#5b0b5a">Publication Sources</FONT></H2><hr size=4></A><CENTER><TABLE BORDER=2 CELLSPACING=2 CELLPADDING=2 ><TR><TD><A HREF="#Major News:">Major News</A></TD><TD><A HREF="#Energy:">Energy</A></TD></TR><TR><TD><A HREF="#Regional Newspapers:">Regional Newspapers</A></TD><TD><A HREF="#Environment:">Environment</A></TD></TR><TR><TD><A HREF="#Business & Investing:">Business &amp; Investing</A></TD><TD><A HREF="#Financial Services:">Financial Services</A></TD></TR><TR><TD><A HREF="#Top International:">Top International</A></TD><TD><A HREF="#Food & Beverages:">Food &amp; Beverages</A></TD></TR><TR><TD><A HREF="#Chemicals & Industrial Technology:">Chemicals &amp; IndustrialTechnology</A></TD><TD><A HREF="#Health Biotechnology & Drugs:">Health Biotechnology &amp;Drugs</A></TD></TR><TR><TD><A HREF="#Computers Electronics & Telecommunications:">Computers Electronics&amp; Telecommunications</A></TD><TD><A HREF="#Media, Interactive & Online Services:">Media, Interactive&amp; Online Services</A></TD></TR><TR><TD><A HREF="#Construction & Real Estate:">Construction &amp; Real Estate</A></TD><TD><A HREF="#Retail:">Retail</A></TD></TR><TR><TD><A HREF="#Transportation:">Transportation</A></TD><TD></TD></TR><TR><TD></TD><TD></TD></TR><TR><TD WIDTH="40%"></TD><TD></TD></TR></TABLE></CENTER><CENTER><P><HR WIDTH="100%"></P></CENTER><CENTER><P><A NAME="Major News:"></A><B><FONT SIZE=+1>Major News:</FONT></B></P></CENTER><CENTER><TABLE BORDER=2 CELLSPACING=2 CELLPADDING=2 ><TR><TD>1. Dallas Morning News</TD><TD>7. Economist</TD></TR><TR><TD>2. Financial Times</TD><TD>8. Washington Post</TD></TR><TR><TD>3. Los Angeles Times</TD><TD>9. Wall Street Journal</TD></TR><TR><TD>4. Associated Press</TD><TD>10. USA Today</TD></TR><TR><TD>5. New York Times News Service</TD><TD>11. Newsweek</TD></TR><TR><TD>6. Chicago Tribune</TD><TD></TD></TR></TABLE><A HREF="#top">Back To Category List</A></CENTER><CENTER><P><HR WIDTH="100%"></P></CENTER><CENTER><P><A NAME="Regional Newspapers:"></A><B><FONT SIZE=+1>RegionalNewspapers:</FONT></B></P></CENTER><CENTER><TABLE BORDER=2 CELLSPACING=2 CELLPADDING=2 ><TR><TD>1. Boston Globe</TD><TD>12. St. Louis Post Dispatch</TD></TR><TR><TD>2. Charlotte Observer</TD><TD>13. Philadelphia Inquirer</TD></TR><TR><TD>3. Courier Journal Louisville</TD><TD>14. Pittsburgh Post Gazette</TD></TR><TR><TD>4. Arizona Republic</TD><TD>15. Orange County Register</TD></TR><TR><TD>5. Rocky Mountain News</TD><TD>16. Sacramento Bee</TD></TR><TR><TD>6. Detroit Free Press</TD><TD>17. Portland Oregonian</TD></TR><TR><TD>7. Indianapolis Star</TD><TD>18. Seattle Times</TD></TR><TR><TD>8. Kansas City Star</TD><TD>19. Houston Chronicle</TD></TR><TR><TD>9. Milwaukee Journal</TD><TD>20. New Orleans Times Picayune</TD></TR><TR><TD>10. Omaha World Herald</TD><TD>21. Atlanta Constitution</TD></TR><TR><TD>11. Plain Dealer Cleveland</TD><TD>22. Miami Herald</TD></TR></TABLE><A HREF="#top">Back To Category List</A></CENTER><P><HR WIDTH="100%"></P><CENTER><P><A NAME="Business & Investing:"></A><B><FONT SIZE=+1>Business&amp; Investing:</FONT></B></P></CENTER><CENTER><TABLE BORDER=2 CELLSPACING=2 CELLPADDING=2 ><TR><TD>1. Barron's</TD><TD>12. Dow Jones News Service</TD></TR><TR><TD>2. Investor's Business Daily</TD><TD>13. Capital Markets Report</TD></TR><TR><TD>3. Financial Times</TD><TD>14. Professional Investor Report</TD></TR><TR><TD>4. Forbes</TD><TD>15. Select Federal Filings</TD></TR><TR><TD>5. Fortune</TD><TD>16. Dow Jones Commodities Service</TD></TR><TR><TD>6. Wall Street Journal</TD><TD>17. Money Management Alert</TD></TR><TR><TD>7. SmartMoney</TD><TD>18. Business Wire</TD></TR><TR><TD>8. Going Public: IPO Reporter</TD><TD>19. Canada NewsWire</TD></TR><TR><TD>9. Institutional Investor</TD><TD>20. Canadian Corporate News</TD></TR><TR><TD>10. Kiplinger's Personal Finance</TD><TD>21. PR Newswire</TD></TR><TR><TD>11. Money</TD><TD></TD></TR></TABLE><A HREF="#top">Back To Category List</A></CENTER><P><HR WIDTH="100%"></P><CENTER><P><A NAME="Top International:"></A><B><FONT SIZE=+1>Top International:</FONT></B></P></CENTER><CENTER><TABLE BORDER=2 CELLSPACING=2 CELLPADDING=2 ><TR><TD>1. Wall Street Journal Europe</TD><TD>10. Agence France-Presse</TD></TR><TR><TD>2. Asian Wall Street Journal</TD><TD>11. Dow Jones International News</TD></TR><TR><TD>3. Financial Times</TD><TD>12. Dow Jones Australian/New Zealand Report</TD></TR><TR><TD>4. Mail on Sunday</TD><TD>13. Dow Jones Asian Equity Report</TD></TR><TR><TD>5. Japan Economic Newswire</TD><TD>14. Deutsche Presse</TD></TR><TR><TD>6. Marketing Week</TD><TD>15. Emerging Markets Report</TD></TR><TR><TD>7. Business Times (Malaysia)</TD><TD>16. Xinhua News Agency -CIS</TD></TR><TR><TD>8. Far Eastern Economic Review</TD><TD>17. South China Morning Post</TD></TR><TR><TD>9. AFX News</TD><TD></TD></TR></TABLE><A HREF="#top">Back To Category List</A></CENTER><P><HR WIDTH="100%"></P><CENTER><P><A NAME="Chemicals & Industrial Technology:"></A><B><FONT SIZE=+1>Chemicals&amp; Industrial Technology:</FONT></B></P></CENTER><CENTER><TABLE BORDER=2 CELLSPACING=2 CELLPADDING=2 ><TR><TD>1. Chemical Weekly</TD><TD>7. Packaging Week</TD></TR><TR><TD>2. Plastics &amp; Rubber Weekly</TD><TD>8. Rubber World</TD></TR><TR><TD>3. US Chemical Industry Statistical Handbook</TD><TD>9. Science</TD></TR><TR><TD>4. Air Conditioning, Heaging &amp; Refrigeration News</TD><TD>10. Security Technology News</TD></TR><TR><TD>5. Metals Industry News</TD><TD>11. Technology Transfer Week</TD></TR><TR><TD>6. New Technology Week</TD><TD>12. Textile World</TD></TR></TABLE><A HREF="#top">Back To Category List</A></CENTER><CENTER><P><HR WIDTH="100%"></P></CENTER><CENTER><P><A NAME="Computers Electronics & Telecommunications:"></A><B><FONT SIZE=+1>ComputersElectronics &amp; Telecommunications:</FONT></B></P></CENTER><CENTER><TABLE BORDER=2 CELLSPACING=2 CELLPADDING=2 ><TR><TD>1. Computer Reseller News</TD><TD>12. Release 1.0</TD></TR><TR><TD>2. Computer Retail Week</TD><TD>13. Soft-Letter</TD></TR><TR><TD>3. Computerworld</TD><TD>14. Cellular Business</TD></TR><TR><TD>4. Digital Media</TD><TD>15. Communications Daily</TD></TR><TR><TD>5. Information Week</TD><TD>16. Communications Week</TD></TR><TR><TD>6. InfoWorld</TD><TD>17. FCC Report</TD></TR><TR><TD>7. Interactive Age</TD><TD>18. PCS Week</TD></TR><TR><TD>8. MacWeek</TD><TD>19. Report on AT&amp;T</TD></TR><TR><TD>9. Network World</TD><TD>20. Satellite Week</TD></TR><TR><TD>10. PC Letter</TD><TD>21. Telephony</TD></TR><TR><TD>11. PC Week</TD><TD>22. Software Futures</TD></TR></TABLE><A HREF="#top">Back To Category List</A></CENTER><P><HR WIDTH="100%"></P><CENTER><P><A NAME="Construction & Real Estate:"></A><B><FONT SIZE=+1>Construction&amp; Real Estate:</FONT></B></P></CENTER><CENTER><TABLE BORDER=2 CELLSPACING=2 CELLPADDING=2 ><TR><TD>1. Builder</TD><TD>8. Real Estate Weekly</TD></TR><TR><TD>2. Buildings</TD><TD>9. DIY Week</TD></TR><TR><TD>3. Contractor</TD><TD>10. Progressive Architecture</TD></TR><TR><TD>4. Journal of Property Management</TD><TD>11. Appraisal Journal</TD></TR><TR><TD>5. Professional Builder</TD><TD>12. National Real Estate Investor</TD></TR><TR><TD>6. Real Estate Economics</TD><TD>13. Building Design and Construction</TD></TR><TR><TD>7. Real Estate Today</TD><TD></TD></TR></TABLE><A HREF="#top">Back To Category List</A></CENTER><P><HR WIDTH="100%"></P><CENTER><P><A NAME="Transportation:"></A><B><FONT SIZE=+1>Transportation:</FONT></B></P></CENTER><CENTER><TABLE BORDER=2 CELLSPACING=2 CELLPADDING=2 ><TR><TD>1. Automotive Engineering</TD><TD>10. Railway Age</TD></TR><TR><TD>2. Airline Financial News</TD><TD>11. Space News</TD></TR><TR><TD>3. Aviation Daily</TD><TD>12. Tire Business</TD></TR><TR><TD>4. Aviation Week &amp; Space Technology</TD><TD>13. Transportation and Distribution</TD></TR><TR><TD>5. Automotive News</TD><TD>14. Transportation Journal</TD></TR><TR><TD>6. Auto Week</TD><TD>15. Ward's Auto World</TD></TR><TR><TD>7. Defense News</TD><TD>16. Ward's Automotive International</TD></TR><TR><TD>8. Mass Transit</TD><TD>17. Ward's Automotive Reports</TD></TR><TR><TD>9. Motor Trend</TD><TD></TD></TR></TABLE><A HREF="#top">Back To Category List</A></CENTER><P><HR WIDTH="100%"></P><CENTER><P><A NAME="Energy:"></A><B><FONT SIZE=+1>Energy:</FONT></B></P></CENTER><CENTER><TABLE BORDER=2 CELLSPACING=2 CELLPADDING=2 ><TR><TD>1. Gas Daily</TD><TD>7. Energy Alert</TD></TR><TR><TD>2. Latin American Energy Alert</TD><TD>8. Energy Report</TD></TR><TR><TD>3. Oil and Gas Journal</TD><TD>9. Industrial Energy Bulletin</TD></TR><TR><TD>4. OPECNA News Service</TD><TD>10. World Oil</TD></TR><TR><TD>5. Petroleum Economist</TD><TD>11. Worldwide Energy</TD></TR><TR><TD>6. Petroleum Finance Week</TD><TD></TD></TR></TABLE><A HREF="#top">Back To Category List</A></CENTER><P><HR WIDTH="100%"></P><CENTER><P><A NAME="Environment:"></A><B><FONT SIZE=+1>Environment:</FONT></B></P></CENTER><CENTER><TABLE BORDER=2 CELLSPACING=2 CELLPADDING=2 ><TR><TD>1. Audubon</TD><TD>9. National Wildlife</TD></TR><TR><TD>2. Defense Cleanup</TD><TD>10. Nuclear Waste News</TD></TR><TR><TD>3. E</TD><TD>11. Recycling Today</TD></TR><TR><TD>4. Electric &amp; Hybrid Vehicles</TD><TD>12. Sierra</TD></TR><TR><TD>5. Electric Vehicles Energy Network</TD><TD>13. Sludge</TD></TR><TR><TD>6. Environment Business</TD><TD>14. Waste Age</TD></TR><TR><TD>7. Mother Earth News</TD><TD>15. Wilderness</TD></TR><TR><TD>8. National Parks</TD><TD></TD></TR></TABLE><A HREF="#top">Back To Category List</A></CENTER><P><HR WIDTH="100%"></P><CENTER><P><A NAME="Financial Services:"></A><B><FONT SIZE=+1>FinancialServices:</FONT></B></P></CENTER><CENTER><TABLE BORDER=2 CELLSPACING=2 CELLPADDING=2 ><TR><TD>1. American Banker</TD><TD>7. Bond Buyer</TD></TR><TR><TD>2. Bank Loan Report</TD><TD>8. Buyouts</TD></TR><TR><TD>3. Bank Technology News</TD><TD>9. Latin Finance</TD></TR><TR><TD>4. Banker</TD><TD>10. Pension Management</TD></TR><TR><TD>5. Best's Review-Life Health Insurance</TD><TD>11. Risk Management</TD></TR><TR><TD>6. Best's Review-Property Casualty Insurance</TD><TD>12. Securities Week</TD></TR></TABLE><A HREF="#top">Back To Category List</A></CENTER><P><HR WIDTH="100%"></P><CENTER><P><A NAME="Food & Beverages:"></A><B><FONT SIZE=+1>Food &amp;Beverages:</FONT></B></P></CENTER><CENTER><TABLE BORDER=2 CELLSPACING=2 CELLPADDING=2 ><TR><TD>1. Beverage World</TD><TD>8. Progressive Grocer</TD></TR><TR><TD>2. Dairy Foods</TD><TD>9. Supermarket News</TD></TR><TR><TD>3. Food Processing</TD><TD>10. Food &amp; Drink Weekly</TD></TR><TR><TD>4. Frozen Food Age</TD><TD>11. Emerging Food R&amp;D Report</TD></TR><TR><TD>5. Grocer</TD><TD>12. Feedstuffs</TD></TR><TR><TD>6. Milling &amp; Baking News</TD><TD>13. Food Manufacture</TD></TR><TR><TD>7. Prepared Foods</TD><TD></TD></TR></TABLE><A HREF="#top">Back To Category List</A></CENTER><P><HR WIDTH="100%"></P><CENTER><P><A NAME="Health Biotechnology & Drugs:"></A><B><FONT SIZE=+1>HealthBiotechnology &amp; Drugs:</FONT></B></P></CENTER><CENTER><TABLE BORDER=2 CELLSPACING=2 CELLPADDING=2 ><TR><TD>1. American Druggist</TD><TD>9. FDA EnforcementReport</TD></TR><TR><TD>2. Biomedical Market Newsletter</TD><TD>10. Genesis Report</TD></TR><TR><TD>3. Bioventure View</TD><TD>11. Genesis Report-RX</TD></TR><TR><TD>4. Bioworld Today</TD><TD>12. Marketletter</TD></TR><TR><TD>5. Cancer Biotechnology Weekly</TD><TD>13. Pharmaceutical Business News</TD></TR><TR><TD>6. Drug &amp; Cosmetic Industry</TD><TD>14. Pharmaceutical Executive</TD></TR><TR><TD>7. Drug News &amp; Perspectives</TD><TD>15. Science News</TD></TR><TR><TD>8. Drug Topics</TD><TD></TD></TR></TABLE><A HREF="#top">Back To Category List</A></CENTER><P><HR WIDTH="100%"></P><CENTER><P><A NAME="Media, Interactive & Online Services:"></A><B><FONT SIZE=+1>Media,Interactive &amp; Online Services:</FONT></B></P></CENTER><CENTER><TABLE BORDER=2 CELLSPACING=2 CELLPADDING=2 ><TR><TD>1. Electronic Information Report</TD><TD>8. Interactive Video News</TD></TR><TR><TD>2. Information Today</TD><TD>9. Backstage</TD></TR><TR><TD>3. Internet Business News</TD><TD>10. Billboard</TD></TR><TR><TD>4. Internet Week</TD><TD>11. Editor &amp; Publisher</TD></TR><TR><TD>5. Media Daily</TD><TD>12. Television Digest</TD></TR><TR><TD>6. Multimedia Business Report</TD><TD>13. Daily Variety</TD></TR><TR><TD>7. Multimedia Week</TD><TD>14. Variety</TD></TR></TABLE><A HREF="#top">Back To Category List</A></CENTER><P><HR WIDTH="100%"></P><CENTER><P><A NAME="Retail:"></A><B><FONT SIZE=+1>Retail:</FONT></B></P></CENTER><CENTER><TABLE BORDER=2 CELLSPACING=2 CELLPADDING=2 ><TR><TD>1. American Marketplace</TD><TD>15. Greetings Magazine</TD></TR><TR><TD>2. Appliance</TD><TD>16. International Journal of Retail &amp; Distribution Management</TD></TR><TR><TD>3. Automatic Merchandiser</TD><TD>17. Jeweler's Circular Keystone</TD></TR><TR><TD>4. Bobbin</TD><TD>18. Journal of Retailing</TD></TR><TR><TD>5. Chain Drug Review</TD><TD>19. Minority Markets Alert</TD></TR><TR><TD>6. Chain Store Age Executive Fax</TD><TD>20. National Home Center News </TD></TR><TR><TD>7. Chain Store Age Executive With Shopping Center Age</TD><TD>21. Party &amp; Paper Retailer</TD></TR><TR><TD>8. Children's Business</TD><TD>22. Research Alert</TD></TR><TR><TD>9. Daily News Record</TD><TD>23. Retail Store Image</TD></TR><TR><TD>10. Dealer News</TD><TD>24. Shopper Report</TD></TR><TR><TD>11. Discount Store News</TD><TD>25. Shopping Center World</TD></TR><TR><TD>12. Do-It-Yourself Retailing</TD><TD>26. Sporting Goods Business</TD></TR><TR><TD>13. Drug Store News</TD><TD>27. Stores</TD></TR><TR><TD>14. Gifts &amp; Accessories</TD><TD>28. Youth Markets Alert </TD></TR></TABLE><A HREF="#top">Back To Category List</A></CENTER><P><HR><CENTER><FONT SIZE=3><A HREF="downld.html">Download Now</A> | <A HREF="tour.html">Take A Tour</A> | <A HREF="index.html">Home</A><BR>Call <B>1-800-522-3567</B>, ext. 154 to subscribe, ext. 190 for more information.</FONT></CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-154</DOCNO>
<DOCOLDNO>IA028-000307-B021-198</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/pie/qandm.html 143.131.194.4 19970114055416 text/html 1195
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:58:24 GMT
Last-modified: Wednesday, 08-Jan-97 15:15:08 GMT
Content-length: 1003
Content-type: text/html
</DOCHDR>
<HTML><HEAD>   <TITLE>Quotes &amp; Market Data</TITLE></HEAD><BODY TEXT="#000000" BGCOLOR="#FFFFFF" LINK="#0000FF" VLINK="#551A8B" ALINK="#0000FF"><CENTER><IMG SRC="images/quotes.gif"></CENTER><P>No one else can match Dow Jones' exclusive monitoring system for ensuring the accuracy of the stock quotes and averages from major exchanges. In fact, Dow Jones has been satisfying investors with reliable market information for more than 100 years!</P><P>Stay on top of your investments with an all-new portfolio tracking feature.Simply enter your investment information, then see current prices, checkout gains, losses and portfolio values. You'll even receive news alertson your holdings! Being in control has never been easier. </P><P><HR><CENTER><FONT SIZE=3><A HREF="downld.html">Download Now</A> | <A HREF="tour.html">Back To Tour</A> | <A HREF="index.html">Home</A><BR>Call <B>1-800-522-3567</B>, ext. 154 to subscribe, ext. 190 for more information.</FONT></CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-155</DOCNO>
<DOCOLDNO>IA028-000307-B021-228</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/pie/resource.html 143.131.194.4 19970114055431 text/html 3048
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:58:41 GMT
Last-modified: Wednesday, 08-Jan-97 15:15:09 GMT
Content-length: 2856
Content-type: text/html
</DOCHDR>
<HTML><HEAD>   <TITLE>Resources</TITLE></HEAD><BODY TEXT="#000000" BGCOLOR="#FFFFFF" LINK="#0000FF" VLINK="#551A8B" ALINK="#0000FF"><H2><FONT COLOR="#5b0b5a">Resources</FONT></H2><hr size=4><P><B>Corporate Ownership Watch--</B>Insider trading activity on 8,000publicly-held companies and 80,000 individuals (officers, directors orowners of even 5% of a class of company stock.)</P><P><B>Zacks Corporate Earnings Estimates</B><SUP><FONT SIZE=-2>SM</FONT></SUP><B>--</B>Earnings-per-shareestimates and P/E ratio forecasts for 3,500 companies and 100 industries.</P><P><B>Media General Financial Services--</B>Financial and statistical informationon 6,200 companies and 180 industries. Useful for cross comparisons.</P><P><B>Standard &amp; Poor's Profiles and Estimates&reg;--</B>4,700 company financial profiles:dividend and market figures, earnings and estimates.</P><P><HR WIDTH="100%"></P><P><B>Enhanced Current Quotes</B><SUP><FONT SIZE=-2>SM</FONT></SUP><B>--</B>Quoteson issues traded on the New York, American Midwest, and Pacific exchanges;and NASDAQ listed issues for equities, options, bonds, mutual funds andtreasuries.</P><P><B>Historical Equities Quotes</B><SUP><FONT SIZE=-2>SM</FONT></SUP><B>--</B>Historicalpricing on stocks only (common, preferred, warrants and rights.) One yearof daily history, 17 months of monthly and 18 quarterly.</P><P><B>Snapshot Tradeline--</B>Provides a comprehensive snapshot of securityinformation and historical pricing for over 50,000 active and inactiveU.S. and Canadian issues.</P><P><B>Historical Dow Jones Averages&reg;--</B>Daily and historical pricingon the Dow Jones Averages; available back to May 24, 1982.</P><P><B>Quotes on Commodities, Futures and Selected Indexes</B><SUP><FONT SIZE=2>SM</FONT></SUP><B>--</B>Currentand historical quotes from major North American Exchanges on Commodities,Financial Futures, Dow Jones Industry Group and Equity Market Indexes, andthe Dow Jones World Stock Indexes. Also includes selected spot currenciesand spot oil prices and selected U.S. and International indices.</P><P><B>Innovest Technical Analysis Reports--</B>Price and volume analysisof more than 4,500 stocks trading on the New York and American exchanges,and the OTC.</P><P><B>Mutual Funds Performance Reports</B><SUP><FONT SIZE=-2>SM</FONT></SUP><B>--</B>Historicalperformance, assets and background information for 1,500 mutual funds.</P><P><B>Wall $treet Week</B><SUP><FONT size=2>SM</FONT></SUP><B> Transcripts Online--</B>Transcripts of the PBS program &#147;Wall$treet Week&#148;.</P><P><HR><CENTER><FONT SIZE=3><A HREF="downld.html">Download Now</A> | <A HREF="tour.html">Take A Tour</A> | <A HREF="index.html">Home</A><BR>Call <B>1-800-522-3567</B>, ext. 154 to subscribe, ext. 190 for more information.</FONT></CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-156</DOCNO>
<DOCOLDNO>IA028-000307-B021-257</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/pie/current.html 143.131.194.4 19970114055441 text/html 1309
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:58:50 GMT
Last-modified: Wednesday, 08-Jan-97 15:14:43 GMT
Content-length: 1117
Content-type: text/html
</DOCHDR>
<HTML><HEAD>   <TITLE>Current News</TITLE></HEAD><BODY TEXT="#000000" BGCOLOR="#FFFFFF" LINK="#0000FF" VLINK="#551A8B" ALINK="#0000FF"><CENTER><IMG SRC="images/current.gif"></CENTER><P>This Just In&#174; gives you top stories of the day on business and world events as selected by Dow Jones editors, plus sports and weather. The breadth of top quality news is vast -- Dow Jones is the only online service that combines the same-day full text editions of <I>The Wall Street Journal&#174;, The New York Times, Financial Times, Los Angeles Times, Barrons&#174;,</I> and <I>The Washington Post</I>...so you'll have a window to more than 9,000 news items coming in from newswires and newspapers each day. In addition, you'll be able to search newswires and newspapers by company name or symbol, industry, business, region, or by multiple selections. </P><P><HR><CENTER><FONT SIZE=3><A HREF="downld.html">Download Now</A> | <A HREF="tour.html">Back To Tour</A> | <A HREF="index.html">Home</A></FONT><BR>Call <B>1-800-522-3567</B>, ext. 154 to subscribe, ext. 190 for more information.</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-157</DOCNO>
<DOCOLDNO>IA028-000307-B022-23</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/pie/mainscreen.map 143.131.194.4 19970114055450 text/html 321
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:59:01 GMT
Content-type: text/html
Content-length: 180
</DOCHDR>
<TITLE>Imagemap Error</TITLE><H1>Imagemap Error</H1>Your client did not send any coordinates. Either your client doesn't support imagemap or the map file was not accessed as a map.
</DOC>
<DOC>
<DOCNO>WT18-B31-158</DOCNO>
<DOCOLDNO>IA028-000307-B022-56</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/pie/privinvst.map 143.131.194.4 19970114055514 text/html 321
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:59:22 GMT
Content-type: text/html
Content-length: 180
</DOCHDR>
<TITLE>Imagemap Error</TITLE><H1>Imagemap Error</H1>Your client did not send any coordinates. Either your client doesn't support imagemap or the map file was not accessed as a map.
</DOC>
<DOC>
<DOCNO>WT18-B31-159</DOCNO>
<DOCOLDNO>IA028-000307-B022-85</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/pie/tae.html 143.131.194.4 19970114055533 text/html 1355
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:59:41 GMT
Last-modified: Wednesday, 08-Jan-97 15:15:14 GMT
Content-length: 1163
Content-type: text/html
</DOCHDR>
<HTML><HEAD>   <TITLE>Technical Analyst Edition</TITLE></HEAD><BODY TEXT="#000000" BGCOLOR="#FFFFFF" LINK="#0000FF"VLINK="#551A8B" ALINK="#0000FF"><H2><FONT COLOR="#5b0b5a">Dow Jones News/Retrieval&#174; - -<BR>Technical Analyst Edition</FONT></H2><hr size=4>For just $39.95* per month, the Technical Analyst Edition is the onlineservice for investors who want to chart securities and rely on technicalindicators to make investment decisions. You'll get coverage of over 200,000 active and inactive U.S. and Canadian issues and 600 marketand industry indexes, as well as 25 years of pricing history for equities,U.S. Treasury Issues, stock and index options, market and industry indexes,corporate debt issues, interest rate issues and foreign exchange ratesfrom <I>Tradeline</I>.<P>* Restrictions apply. <B><A HREF="legal.html">See pricing, rulesand regulations.</A></B> </P><P><BR></P><P><HR><CENTER><FONT SIZE=3><A HREF="downld.html">Download Now</A> | <A HREF="tour.html">Take A Tour</A> | <A HREF="pie.html">Home</A><BR>Call <B>1-800-522-3567</B>, ext. 154 to subscribe, ext. 190 for more information.</FONT></CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-160</DOCNO>
<DOCOLDNO>IA028-000307-B022-119</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/pie/tag.html 143.131.194.4 19970114055615 text/html 1382
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 06:00:12 GMT
Last-modified: Wednesday, 08-Jan-97 15:15:14 GMT
Content-length: 1190
Content-type: text/html
</DOCHDR>
<HTML><HEAD>   <TITLE>Technical Analyst Gold Edition</TITLE></HEAD><BODY TEXT="#000000" BGCOLOR="#FFFFFF" LINK="#0000FF" VLINK="#551A8B" ALINK="#0000FF"><H2><FONT COLOR="#5b0b5a">Dow Jones News/Retrieval&#174; - -<BR>Technical Analyst Gold Edition</FONT></H2><hr size=4>With the Gold Edition, you'll get all the sources of Technical AnalystEdition, plus the news and research sources of the Private Investor Editionfor just $59.95* per month. <P>Screen the <I>Tradeline</I> database for securities that meet your uniqueinvestment criteria. Tap into Technical Analyst Report Cards. Locate detailedsummaries of events on important markets. Uncover past performance fora particular group of stocks with a profit/loss report. Use beta analysisreports to calculate a security's beta against an index you specify. <BR><P>* Restrictions apply. <B><A HREF="legal.html">See pricing, rulesand regulations.</A></B> <P><BR><P><HR><CENTER><FONT SIZE=3><A HREF="downld.html">Download Now</A> | <A HREF="tour.html">Take A Tour</A> | <A HREF="pie.html">Home</A><BR>Call <B>1-800-522-3567</B>, ext. 154 to subscribe, ext. 190 for more information.</FONT></CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-161</DOCNO>
<DOCOLDNO>IA027-000290-B040-115</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/ 143.131.194.4 19970114043339 text/html 3318
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 04:37:46 GMT
Last-modified: Wednesday, 08-Jan-97 22:12:50 GMT
Content-length: 3126
Content-type: text/html
</DOCHDR>
<html><head><title>Dow Jones BIS</title></head><BODY Background="images/lrgbkgd.jpg" TEXT="#ffffff" LINK="#99F300"VLINK="#99F300" ALINK="#ffffff" BGCOLOR="#000000">	<nobr>					<IMG BORDER=0 ALIGN=left SRC="images/mane2.gif">			<IMG WIDTH=338 HEIGHT=137 BORDER=0 SRC="images/djbis3.gif"></nobr><BR CLEAR="ALL"><HR SIZE=8><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=15 WIDTH=600><TR><TD  valign="top" WIDTH=200><P><FONT SIZE=+1>Each day, Dow Jones provides millions of business professionals withaccess to the accurate, in-depth information they need to stay aware and ahead ofthe competition.<p>You, too, can put the power of Dow Jones behind your business decisions. To findout how, just click on an area of interest.</FONT>		<p></TD> <TD VALIGN=TOP WIDTH=200>		<a href="bizpubs/wsj-interactive.html"> <IMG WIDTH=28 HEIGHT=28 BORDER=0		SRC="images/biz.jpg" align="left"></a><BR CLEAR=LEFT>		<a href="bizpubs/wsj-interactive.html">		<font size=4>Continually Updated Business News Publication</font></a><br>The daily electronic newspaper from Dow Jones andThe Wall Street Journal&#174;.		<FONT SIZE=2><UL><LI><a href="bizpubs/wsj-interactive.html">The Wall Street Journal<br> Interactive Edition&#174;</a></UL></FONT>		<HR>								<a href="clipping/index.html"> <IMG WIDTH=28 HEIGHT=28 BORDER=0		SRC="images/cclps.jpg"  align="left"></a><BR CLEAR=LEFT>				<a href="clipping/index.html">		<font size=4>Clipping, Tracking & Alert Services</font></a><br>		Services that help you stay on top of topics that matter to you 		and your enterprise. 		<FONT SIZE=2><UL><LI> <a href="dowvision/index.html"><I>All-new</I> DowVision&#174; <BR>from Dow Jones</a><LI> <a href="clipping/dowvision/index.html">DowVision&#174;</a><LI><a href="clipping/custom-clips/index.html">Dow Jones CustomClips&#174;</a></UL></FONT><HR>	<br><a href="http://www.dowjones.com">		<font size=4>Other Dow Jones Sites</font></a>  </TD><TD VALIGN=TOP WIDTH=200>					<a href="online-lib/index.html"> <IMG WIDTH=28 HEIGHT=28 BORDER=0		SRC="images/on-lin.jpg" align="left"></a><BR CLEAR=LEFT>				<a href="online-lib/index.html">		<font size=4>Online Research Service</font></a>		<BR> 		Fast answers to tough questions.		<FONT SIZE=2><UL><LI><a href="online-lib/index.html">Dow Jones News/Retrieval&#174;</a></UL></FONT><HR>					<a href="pie/private.html"> <IMG WIDTH=28 HEIGHT=28BORDER=0 SRC="images/perfin.jpg"  align="left"></a><BR CLEAR=LEFT>				<a href="pie/private.html">		<font size=4>Personal Finance & Investing</font></a> 		<BR>		Products and services that help you better manage your own finances.		<FONT SIZE=2><UL><LI> <a href="pie/index.html"><I>All-new</I> Dow Jones News/Retrieval: <BR>Private Investor Edition&#174;</a></UL></FONT><HR>			<a href="latest.html"> <IMG WIDTH=28 HEIGHT=28 BORDER=0SRC="images/djs.jpg"  align="left"></a><BR CLEAR=LEFT>				<a href="latest.html">		<font size=4>What's Going On at BIS</font></a> 		<BR> The latest developments at Dow Jones Business Information Services.</td></tr></table>							</body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-162</DOCNO>
<DOCOLDNO>IA028-000307-B018-192</DOCOLDNO>
<DOCHDR>
http://bis.dowjones.com:80/clipping/custom-clips/toolbar.gif.map 143.131.194.4 19970114053952 text/html 321
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Tuesday, 14-Jan-97 05:43:56 GMT
Content-type: text/html
Content-length: 180
</DOCHDR>
<TITLE>Imagemap Error</TITLE><H1>Imagemap Error</H1>Your client did not send any coordinates. Either your client doesn't support imagemap or the map file was not accessed as a map.
</DOC>
<DOC>
<DOCNO>WT18-B31-163</DOCNO>
<DOCOLDNO>IA093-001001-B043-279</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/ 199.29.141.24 19970121115042 text/html 4111
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:44:50 GMT
Server: NCSA/1.5.1
Content-type: text/html
</DOCHDR>
<HEAD><TITLE>Index of /</TITLE></HEAD><BODY>
<H1>Index of /</H1>
<PRE><IMG SRC="/icons/blank.xbm" ALT="     "> Name                   Last modified     Size  Description
<HR>
<A HREF="/"><IMG SRC="/icons/menu.xbm" ALT="[DIR]"></A> <A HREF="/">Parent Directory</A>       14-Jan-97 09:53      -  
<A NAME="996gsnap.html" HREF="996gsnap.html"><IMG SRC="/icons/text.gif" ALT="[TXT]"></A> <A NAME="996gsnap.html" HREF="996gsnap.html">996gsnap.html</A>          06-Sep-96 10:05     2K  Photographs picture soc>
<A NAME="a-t/" HREF="a-t/"><IMG SRC="/icons/menu.xbm" ALT="[DIR]"></A> <A NAME="a-t/" HREF="a-t/">a-t/</A>                   12-Jan-97 12:05      -  
<A NAME="aidsnyc/" HREF="aidsnyc/"><IMG SRC="/icons/menu.xbm" ALT="[DIR]"></A> <A NAME="aidsnyc/" HREF="aidsnyc/">aidsnyc/</A>               17-Jan-97 12:14      -  
<A NAME="catest.html" HREF="catest.html"><IMG SRC="/icons/text.gif" ALT="[TXT]"></A> <A NAME="catest.html" HREF="catest.html">catest.html</A>            27-Aug-96 10:58     1K  
<A NAME="database.html" HREF="database.html"><IMG SRC="/icons/text.gif" ALT="[TXT]"></A> <A NAME="database.html" HREF="database.html">database.html</A>          29-Apr-96 16:52     9K  Public Health and Medic>
<A NAME="docline/" HREF="docline/"><IMG SRC="/icons/menu.xbm" ALT="[DIR]"></A> <A NAME="docline/" HREF="docline/">docline/</A>               18-Jul-96 13:19      -  
<A NAME="gifs/" HREF="gifs/"><IMG SRC="/icons/menu.xbm" ALT="[DIR]"></A> <A NAME="gifs/" HREF="gifs/">gifs/</A>                  19-Nov-96 14:15      -  
<A NAME="health.html" HREF="health.html"><IMG SRC="/icons/text.gif" ALT="[TXT]"></A> <A NAME="health.html" HREF="health.html">health.html</A>            06-May-96 11:42     1K  American Library Associ>
<A NAME="index_old.html" HREF="index_old.html"><IMG SRC="/icons/text.gif" ALT="[TXT]"></A> <A NAME="index_old.html" HREF="index_old.html">index_old.html</A>         22-May-96 11:37     1K  American Library Associ>
<A NAME="links.html" HREF="links.html"><IMG SRC="/icons/text.gif" ALT="[TXT]"></A> <A NAME="links.html" HREF="links.html">links.html</A>             19-Mar-96 17:32    10K  ALA Conference 1996: pl>
<A NAME="natmed/" HREF="natmed/"><IMG SRC="/icons/menu.xbm" ALT="[DIR]"></A> <A NAME="natmed/" HREF="natmed/">natmed/</A>                08-Mar-96 13:16      -  
<A NAME="newsrch.html" HREF="newsrch.html"><IMG SRC="/icons/text.gif" ALT="[TXT]"></A> <A NAME="newsrch.html" HREF="newsrch.html">newsrch.html</A>           30-Apr-96 11:57     9K  Public Health Search Fo>
<A NAME="pubh/" HREF="pubh/"><IMG SRC="/icons/menu.xbm" ALT="[DIR]"></A> <A NAME="pubh/" HREF="pubh/">pubh/</A>                  23-Jul-96 16:54      -  
<A NAME="public_html/" HREF="public_html/"><IMG SRC="/icons/menu.xbm" ALT="[DIR]"></A> <A NAME="public_html/" HREF="public_html/">public_html/</A>           23-Sep-96 14:35      -  
<A NAME="srch.html" HREF="srch.html"><IMG SRC="/icons/text.gif" ALT="[TXT]"></A> <A NAME="srch.html" HREF="srch.html">srch.html</A>              29-Apr-96 14:38     1K  Public Health Search Fo>
<A NAME="talk.html" HREF="talk.html"><IMG SRC="/icons/text.gif" ALT="[TXT]"></A> <A NAME="talk.html" HREF="talk.html">talk.html</A>              19-Mar-96 17:33     6K  www.alanyc.org: talk sh>
<A NAME="testowa.html" HREF="testowa.html"><IMG SRC="/icons/text.gif" ALT="[TXT]"></A> <A NAME="testowa.html" HREF="testowa.html">testowa.html</A>           03-May-96 14:58     1K  
<A NAME="thread-images/" HREF="thread-images/"><IMG SRC="/icons/menu.xbm" ALT="[DIR]"></A> <A NAME="thread-images/" HREF="thread-images/">thread-images/</A>         19-Mar-96 14:51      -  
<A NAME="thread.html" HREF="thread.html"><IMG SRC="/icons/text.gif" ALT="[TXT]"></A> <A NAME="thread.html" HREF="thread.html">thread.html</A>            19-Mar-96 15:49     1K  Public Health Search Fo>
<A NAME="ttest.html" HREF="ttest.html"><IMG SRC="/icons/text.gif" ALT="[TXT]"></A> <A NAME="ttest.html" HREF="ttest.html">ttest.html</A>             04-Sep-96 16:56     1K  
</PRE></BODY>
</DOC>
<DOC>
<DOCNO>WT18-B31-164</DOCNO>
<DOCOLDNO>IA093-001001-B043-300</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/996gsnap.html 199.29.141.24 19970121115052 text/html 2996
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:45:00 GMT
Server: NCSA/1.5.1
Last-modified: Fri, 06 Sep 1996 15:05:30 GMT
Content-type: text/html
Content-length: 2813
</DOCHDR>
<html><head><title>Photographs picture society</title><br><br>

<body>
<body bgcolor="#FFFFFF">

<p>
<br>

<blockquote><center><h1>Photographs picture society</h1></center>
<p><font size="+2">A</font><font size="+1"> ceaseless tide of photographs
roll out of processing plants every day.  Millions upon millions of
snapshots as diverse as the people and places pictured in them.  What
does this tireless recording of our lives mean to our society?

<!-------  Net Editors: don't forget to change the art link--------!>

<img src="http://www.extraink.com/newissue/gifs/c-photo.gif" width=200
align=right><p>Until a few years ago, few gave much thought to the
phenomenon.  But lately, we've become more aware of the role photography
plays not only in our lives, but also in molding our perception of the
world around us. 

<p>According to Graham King in <i>Say 'Cheese'!  Looking at snapshots in
a new way</i>, (Dodd, Mead & Co.),  snapshots can posses the qualities
commonly looked for in a work of art.  "It is still possible, by luck,
discovery, observation, and interpretation, to make photographic history.
Unlike the well picked-over field of
art history, photographic masterpieces are constantly being turned up."
Colin Gordon, an teacher in Yorkshire, England bought 600 glass and film
negatives for five pounds (about $11 US) recording the life of a
middle-class Yorkshire family from the 1880s
to the 1920s.  It proved to be a gold mine of social and photographic
history, in addition to providing the foundation for the best seller <i>A
Richer Dust: Echoes from an Edwardian Album</i> (1978, Elm Tree Books,
London ).   
 <p> Although invented in 1829, the snapshot as we know it has been with
us a little more than a century.  The painfully stiff portraits from
those early days were the result of the subject being required to remain
immobile for a full minute or more.  Combined with the crippling posture
required of the photographer, it's little wonder early photographs were
considered major events. 
<p>	An entrepreneur named George Eastman moved photography from formal
portraits to casual snapshots that capture snippets of real life.  In
1888, Eastman produced the Kodak camera.  A box camera factory-loaded
with a roll of film for 100 circular pictures.  To get your photographs,
you returned the entire camera  to the factory where the film was
developed and the camera was again loaded with a fresh roll of film.
	<p>Today, a little more than a century later, photographs are an
important part of our lives and cameras have evolved, too.   The digital
camera instantly captures pictures to a PC and can be across the world
via modem in seconds.  That's a long way from the nine hours it took just
to develop the first photographs almost 150 years ago. <p>

<p>
</blockquote></body>
</html>

</DOC>
<DOC>
<DOCNO>WT18-B31-165</DOCNO>
<DOCOLDNO>IA093-001001-B043-321</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/a-t/ 199.29.141.24 19970121115100 text/html 4253
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:45:07 GMT
Server: NCSA/1.5.1
Last-modified: Sat, 18 Jan 1997 18:55:49 GMT
Content-type: text/html
Content-length: 4070
</DOCHDR>
<html>
<head>
<title>Able-Together</title>
</head>

<body background="gifs/stripe.gif" link="#ffffff" vlink="#4f9eaf"><font face="comic sans ms, century gothic">

<table cellpadding=0 cellspacing=0>
<tr>
<td><img src="gifs/ablelogo.gif"></td><td>&nbsp;&nbsp;</td><td><font face="comic sans ms, century gothic" color="#5959ab" size=+2>a forum for men with and without disabilities</font></td>
</tr><tr>
<td align=right><font face="comic sans ms, century gothic" size=+1><a href="about.html"><b>about A-T</b></a></font></td><td>&nbsp;&nbsp;</td><td><font face="comic sans ms, century gothic" color="#236b8e">who we are and what we do</font></td>
</tr><tr>
<td align=right><font face="comic sans ms, century gothic" size=+1><a href="guest.html">guestbook</a></font></td><td>&nbsp;&nbsp;</td><td><font face="comic sans ms, century gothic" color="#236b8e">guestbook, feedback, what youd like to see on the site</td>
</tr><tr>
<td align=right><font face="comic sans ms, century gothic" size=+1><a href="library.html">library</a></font></td><td>&nbsp;&nbsp;</td><td><font face="comic sans ms, century gothic" color="#236b8e">reviews, articles, newsletters, internet resources</font></td>
</tr><tr>
<td align=right><font face="comic sans ms, century gothic" size=+1><a href="new.html">what's new</a></font></td><td>&nbsp;&nbsp;</td><td><font face="comic sans ms, century gothic" color="#236b8e">guide to whats new on the site</font></td>
</tr><tr>
<td align=right><font face="comic sans ms, century gothic" size=+1><a href="bb.html">bulletin board</a></font></td><td>&nbsp;&nbsp;</td><td><font face="comic sans ms, century gothic" color="#236b8e">announcements, calendar of events, for sale/exchange/give it away</font></td>
</tr><tr>
<td align=right><font face="comic sans ms, century gothic" size=+1><a href="meeting.html">meeting place</a></font></td><td>&nbsp;&nbsp;</td><td><font face="comic sans ms, century gothic" color="#236b8e">personals - browse, add yours</font></td>
</tr><tr>
<td align=right><font face="comic sans ms, century gothic" size=+1><a href="resources.html">resources</a></font></td><td>&nbsp;&nbsp;</td><td><font face="comic sans ms, century gothic" color="#236b8e">what's out there and how to find it, online and off</font></td>
</tr><tr>
<td align=right><font face="comic sans ms, century gothic" size=+1><a href="people.html">people</a></font></td><td>&nbsp;&nbsp;</td><td><font face="comic sans ms, century gothic" color="#236b8e">personal web pages from men with disabilities</font></td>
</tr><tr>
<td align=right><font face="comic sans ms, century gothic" size=+1><a href="subscribe.html">subscribe</a></font></td><td>&nbsp;&nbsp;</td><td><font face="comic sans ms, century gothic" color="#236b8e">how to subscribe to A-T</font></td>
</tr><tr>
<td align=right><font face="comic sans ms, century gothic" size=+1><a href="gallery.html">gallery</a></font></td><td>&nbsp;&nbsp;</td><td><font face="comic sans ms, century gothic" color="#236b8e">images of men with disabilites</font></td>
</tr><tr>
<td align=right><font face="comic sans ms, century gothic" size=+1><a href="forums.html">forums</a></font></td><td>&nbsp;&nbsp;</td><td><font face="comic sans ms, century gothic" color="#236b8e">forums on topics of interest to men with disabilities</font></td>
</tr><tr>
<td align=right><font face="comic sans ms, century gothic" size=+1><a href="work.html">your work</a></font></td><td>&nbsp;&nbsp;</td><td><font face="comic sans ms, century gothic" color="#236b8e">your site/your work: poetry, photography, stories, essays, etc.</font></td>
</tr><tr>
<td align=right><font face="comic sans ms, century gothic" size=+1><a href="news.html">in the news</a></font></td><td>&nbsp;&nbsp;</td><td><font face="comic sans ms, century gothic" color="#236b8e">what's going on, action alerts</font></td>
</tr>
</table>
<p><p>
<table>
<tr>
<td align=center><font face="arial, helvetica" size=-1 color="#ffffff"><b>pages modified: 1/11/97 <br><a
href="mailto:blaine@well.com">blaine@well.com</a><br>
&#169 1997 A-T</b></font></td>
</tr>
</table>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-166</DOCNO>
<DOCOLDNO>IA093-001001-B043-338</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/ 199.29.141.24 19970121115107 text/html 6191
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:45:15 GMT
Server: NCSA/1.5.1
Last-modified: Mon, 20 Jan 1997 14:02:30 GMT
Content-type: text/html
Content-length: 6008
</DOCHDR>
<html>
<head>
<title>www.aidsnyc.org</title>
<meta name="description" content="A linked collection of pages from HIV/aIDS community based organizations in New York City.">
<meta name="keywords" content="HIV, AIDS, clinical trials,
opportunistic infections, treatments, housing, immigration, children, women, drugs">
</head>
<body background="gifs/strip.gif" width=1008 height=36 link="#8b2323" vlink="#696969">

<table width=100%>
<tr>
<td colspan=3><img src="gifs/newlogo.gif" alt="www.aidsnyc.org" width=368 height=55></td>
</tr><tr>
<td width=134>&nbsp;</td><td colspan=2><font face="comic sans ms">linked pages from community based organizations in New York City</font></td>
</tr><tr>
<td width=134>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
</tr><tr>
<td width=134><a href="Architext/aidsnycquery.html"><font face="comic sans ms" color="#ffffff" link="#ffffff" vlink="#ffffff">search</font></a></td><td align=center><font face="garamond"><a href="acqc/index.html"><b>AIDS Center of Queens County</b></a></font></td><td align=center><font face="garamond"><a href="aip/index.html"><b>AIDS in Prison Project</b></a></td>
</tr><tr>
<td width=134><a href="guide.html"><font face="comic sans ms" color="#ffffff" link="#ffffff" vlink="#ffffff">guide to sites</font></a></td><td align=center><font face="garamond"><a href="network/index.html"><b>AIDS Treatment Data Network</b></a></font></td><td align=center><font face="garamond"><a href="cwha/index.html"><b>Caribbean Women's Health Ass'n</b></a></font></td>
</tr><tr>
<td width=134><a href="new.html"><font face="comic sans ms" color="#ffffff" link="#ffffff" vlink="#ffffff">what's new</font></a></td><td align=center><font face="garamond"><a href="cdn/index.html"><b>Clinical Directors Network</b></a></font></td><td align=center><font face="garamond"><a href="berridge/index.html"><b>Coming Into View: Women &amp; Families</b></a></font></td>
</tr><tr>
<td width=134><a href="links.html"><font face="comic sans ms" color="#ffffff" link="#ffffff" vlink="#ffffff">links</font></a></td><td align=center><font face="garamond"><a href="cnews/index.html"><b>Consumer News</b></a></font></td><td align=center><font face="garamond"><a href="arrive/index.html"><b>Exponents Arrive</b></a></font></td>
</tr><tr>
<td width=134><a href="congress.html"><font face="comic sans ms" color="#ffffff" link="#ffffff" vlink="#ffffff">action alerts</font></a></td><td align=center><font face="garamond"><a href="fc/index.html"><b>The Family Center</b></a></font></td><td align=center><font face="garamond"><a href="glwd/index.html"><b>God's Love We Deliver</b></a></font></td>
</tr><tr>
<td width=134><a href="about.html"><font face="comic sans ms" color="#ffffff" link="#ffffff" vlink="#ffffff">about aidsnyc</font></a></td><td align=center><font face="garamond"><a href="heal/index.htm"><b>Health Education AIDS Liaison</b></a></font></td><td align=center><font face="garamond"><A HREF="http://www.liaac.org/index.html"><b>Long Island Assoc. for AIDS Care</b></A></font></td>
</tr><tr>
<td width=134><a href="docorder.html"><font face="comic sans ms" color="#ffffff" link="#ffffff" vlink="#ffffff">document order</font></a></td><td align=center><font face="garamond"><a href="momentum/index.html"><b>Momentum AIDS Project</b></a></font></td><td align=center><font face="garamond"><a href="natap/index.html"><b>Nat'l AIDS Treatment Advocacy Project</b></a></font></td>
</tr><tr>
<td width=134>&nbsp;</td><td align=center><font face="garamond"><a href="orphan/index.html"><b>The Orphan Project</b></a></font></td><td align=center><font face="garamond"><a href="ai/index.html"><b>NYS DOH AIDS Institute</b></a></font></td>
</tr><tr>
<td width=134 rowspan=2><a href="http://www.healthexplorer.com/"><img src="gifs/bestsite.gif" alt="health explorer bestsite" width=75 height=51></a></td><td align=center><font face="garamond"><a href="pwac/index.html"><b>People With AIDS Coalition/NY</b></a></font></td><td align=center><font face="garamond"><a href="pwahg/index.html"><b>PWA Health Group</b></a></font></td>
</tr><tr>
<td align=center><font face="garamond"><a href="siatf/index.html"><b>Staten Island AIDS Task Force</b></a></font></td><td align=center><font face="garamond"><a href="rtrp/index.html"><b>Real Treatments for Real People</b></a></font></td>
</tr><tr>
<td width=134>&nbsp;</td><td colspan=2 align=center><hr size=4 width=50% noshade></td>
</tr><tr>
<td width=134><font face="comic sans ms" size=-1 color="#ffffff" link="#ffffff" vlink="#ffffff">pages modified: <br><b>1/20/97</b> <br><a
href="mailto:hivinfo@nyam.org"><font color="#ffffff">www.aidsnyc.org</a></font></td>
<td colspan=2 align=center><b><a href="programs.html"><font face="garamond" color="#8b2323">other NYAM HIV/AIDS projects</a> | <a href="updates.html">Vancouver Updates</a> | <a href="retrov.html">Retroviruses Conference</a><br><font color="#000000">other NYC sites : <font color="#8b2323"><a href="http://www.actupny.org">ACT UP NY</a> | <a href="http://www.artistswithaids.org">The Estate Project</a> | <a href="http://www.gmhc.org/">GMHC</a> | <A HREF="http://www.housingworks.org/">Housing Works</A></font></b></td>
</tr><tr>
<td width=134>&nbsp;</td><td colspan=2 align=center><hr size=4 width=50% noshade></td>
</tr><tr valign=top>
<td width=134><font face="comic sans ms" color="#ffffff" size=-1>These pages made possible in part <br>by a grant from <a href="http://www.citibank.com"><img alt="Citibank" align=middle src="gifs/citibank.gif" border=0></a></font></td>
<td colspan=2><font face="comic sans ms" color="#000000" 
size=-1>www.aidsnyc.org is an open forum for various organizations and viewpoints. Inclusion of any group or organization on this site does not imply endorsement by the other member organizations or <a href="http://www.nyam.org/index.html">The New York Academy of Medicine</a>. This site designed and maintained by Joel Beard courtesy of the <a href="network/index.html">AIDS Treatment Data Network</a>. &#169; 1997</font></td>
</tr>
</table>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-167</DOCNO>
<DOCOLDNO>IA093-001001-B043-351</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/catest.html 199.29.141.24 19970121115114 text/html 369
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:45:22 GMT
Server: NCSA/1.5.1
Last-modified: Tue, 27 Aug 1996 15:58:25 GMT
Content-type: text/html
Content-length: 187
</DOCHDR>
<html>
<body>

<h1>Access the Online Catalog:</h1>

<a href="telnet://health.nyam.org">Telnet to health</a>
<p>
<a href="telnet://library.nyam.org">Rlogin to catalog</a>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-168</DOCNO>
<DOCOLDNO>IA093-001001-B043-366</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/database.html 199.29.141.24 19970121115125 text/html 9522
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:45:31 GMT
Server: NCSA/1.5.1
Last-modified: Mon, 29 Apr 1996 21:52:47 GMT
Content-type: text/html
Content-length: 9339
</DOCHDR>
<html>
<head>
<title>Public Health and Medicine: search page</title>
</head>

<body bgcolor="#ffffff" text="#7f00ff" link="#000000">

<h3 align=center><FONT SIZE=+3>P</FONT>UBLIC <FONT SIZE=+3>H</FONT>EALTH AND 
<FONT SIZE=+3>M</FONT>EDICINE:<br>
PARTNERING TO IMPROVE COMMUNITY HEALTH <br>IN THE 21st CENTURY</h3>

<hr size=3 noshade width=50% align=center>

<p align=center><a href="#search"><img src="gifs/search.gif" hspace=5>
</a><a href="#cite"><img src="gifs/cite.gif" hspace=5></a>
<img src="gifs/browse.gif" hspace=5 border=1><a href="index.html">
<img src="gifs/home.gif" hspace=5></a></p>

<hr size=3 noshade width=50% align=center>

<p><font size=+1><b><a name="search">Search</a> the database</b></font></p>

<form method="post" 
action="http://cues.nyam.org:8000/ows-bin/ph/owa/ph.phread">

<b>By Author and/or Title words and/or Year and/or Journal words</b></p>

<p><input name="active" type="radio" value=1> 
Author        : <input name="element_1" size=20>

<p><input name="active" type="radio" value=2> 
Title         : <input name="element_2" size=20> 

<p><input name="active" type="radio" value=3> 
Year          : <input name="element_3" size=20>

<p><input name="active" type="radio" value=4> 
Journal Words : <input name="element_4" size=20>

<P><input name="active" type="radio" value=5>
<b>by Abstract author</b>
<select name="element_5"> 
<option selected>Abramson, David
<option>Breslow, Lester
<option>Dunn, Kathel
<option>Fee, Elizabeth
<option>Glied, Sherry
<option>Hughes, Charles
<option>Kostelecky, Bonnie
<option>Lasker, Roz
<option>Lewis, Susan
<option>Miller, Russell
<option>Palica, Michael
<option>Prager, Dennis
<option>Reardon, Thomas
<option>Reiser, Stanley
<option>Warden, Gail
<option>Wasserman, Martin
</select> 

<P>
<b>by Major Subject "Controlled Vocabulary" terms</b><P>
<input name="active" type="radio" value=6> 
Subject term <input type="text" name="element_6" size="20">
or <input name="active" type="radio" value=7> 
<select name="element_7">
<option selected>Lung Cancer
<option>Epidemiology
<option>Disease
<option>Arthroscopy
</select>
<P>

<center><table><tr><td><INPUT TYPE="SUBMIT" VALUE="SEARCH"></td><td><br></td><td><INPUT TYPE="RESET" VALUE="CLEAR"></td></tr></table></center>

</form>

<hr size=3 noshade width=50% align=center>

<p align=center><a href="#search"><img src="gifs/search.gif" 
hspace=5></a><a href="#cite"><img src="gifs/cite.gif" hspace=5 border=1></a><img src="gifs/browse.gif" hspace=5><a href="index.html"><img src="gifs/home.gif" hspace=5></a></p>

<hr size=3 noshade width=50% align=center>

<p><font size=-1><b><a name="cite">Use</a> this form to enter citations for :</b> artwork, audiovisual materials, books, book sections, computer programs, conference proceedings, edited books, journal articles, magazine articles, maps, newspaper articles,


 patents, personal communications, reports, thesis, or web sites. Enter information into appropriate fields. </font></p>

<p><font size=-1>Use <a href="#case">this form</a> to enter a citation for a <b>case study</b> only.</font></p>

<form method="post">
<input name="BIBNO" type=hidden>
<input name="PHISIC" type=hidden>

<center><table width=100% cospec="50% 50%"><tr>
<td colspan=2><font size=-1><b>Author / Editor</b> (if edited book) <b>/ Reporter / Programmer</b> (if computer program) <b>/<br> Cartographer</b> (if map) <b>/ Artist</b> (if artwork) <b>/ URL </b>(if web site)</font><br><input type="text" name="AUTHOR" 


size="60"></td>
</tr>
<tr>
<td colspan=2width=50%><font size=-1><b>Title / Publication source </b>(if web site)</b></font><br><input type="text" name="TITLE" size="60"></td>
</tr>
<tr>
<td colspan=2><font size=-1><b>Journal / Series Title / Magazine / Newspaper / Conference name / <br>Academic Dpt. </b>(if thesis) <b>/ Publication source</b> (if patent) <b>/ Domaine</b> (if web site)</b></font><br><input type="text" name="SITLE" size="6


0"></td>
</tr>
<tr>
<td width=50%><font size=-1><b>Year</b></font><br><input type="text" name="YEAR" size="30" maxlength="4"></td>
<td><font size=-1><b>Editor / Series Editor / Access </b>(if web site)</b></font><br><input type="text" name="SAUTER" size="30"></td>
</tr>
<tr>
<td><font size=-1><b>Volume</b></font><br> <input type="text" name="VOLUME" size="30"></td>
<td><font size=-1><b>No. of volumes</b></font><br> <input type="text" name="NUMVOL" size="30"></td>
</tr>
<tr>
<td><font size=-1><b>City / Conference Location / Country</b> (if patent)</b></font><br><input type="text" name="PLACE" size="30"></td>
<td><font size=-1><b>Publisher / University / Assignee</b> (if patent)</b></font><br> <input type="text" name="PUBLISH:" size="30"></td>
</tr>
<tr>
<td><font size=-1><b>Issue</b></font><br> <input type="text" name="NUMBER" size="30"></td>
<td><font size=-1><b>Date </b>(month/day/year)<b> / Issue Date </b>(if newspaper)</b></font><br><input type="text" name="SDATE" size="30" maxlength="8"></td>
</tr>
<tr>
<td><font size=-1><b>Version </b>(if computer program) <b>/ Edition </b>(if map)</b></font><br><input type="text" name="EDITION" size="30"></td>
<td><font size=-1><b>Pages</b></font><br> <input type="text" name="PAGES" size="30"></td>
</tr>
<tr>
<td colspan=2><font size=-1><b>Type</b> (if personal communication / report / map / artwork / audiovisual material / web site)</b></font><br><input type="text" name="WORK" size="60"></td>
</tr>
<tr>
<td colspan=2><font size=-1><b>Case Study No.</b> (if known)</font><br><input type="text" name="STUN" size="60">
</tr>
<tr>
<td><input name="ABSNO" type=hidden>
<input name="BIBNO" type=hidden>
<font size=-1><b>Abstract author</b></font><br> <select name="AUTHOR"><option selected>Abramson, David
<option>Breslow, Lester
<option>Dunn, Kathel
<option>Fee, Elizabeth
<option>Glied, Sherry
<option>Hughes, Charles
<option>Kostelecky, Bonnie
<option>Lasker, Roz
<option>Lewis, Susan
<option>Miller, Russell
<option>Palica, Michael
<option>Prager, Dennis
<option>Reardon, Thomas
<option>Reiser, Stanley
<option>Warden, Gail
<option>Wasserman, Martin
</select></td>
<td><font size=-1><b>Major Subject "Controlled Vocabulary" terms</b></font><br><select name="SUBJECT"><option selected>Subject 1
<option>Subject  2
<option>Subject  3
<option>Subject  4
<option>Subject  5
</select></td>
</tr>
<tr>
<td align=center colspan=2><font size=-1><b>Abstract</b></font><br><textarea name="ABS" rows="5" cols="60"></textarea></td>
</tr>
<tr>
<td align=right><INPUT TYPE="SUBMIT" VALUE="SUBMIT"></td><td align=left><INPUT TYPE="RESET" VALUE="CLEAR"></td></tr>
</table></center>

</form>

<hr size=3 noshade width=50% align=center>

<p align=center><a href="#search"><img src="gifs/search.gif" hspace=5></a><a href="#cite"><img src="gifs/cite.gif" hspace=5 border=1></a><img src="gifs/browse.gif" hspace=5><a href="index.html"><img src="gifs/home.gif" hspace=5></a></p>

<hr size=3 noshade width=50% align=center>

<p><b><a name="case">Enter citation and abstract for Case study</a> only</b></p>

<p>Please fill in each field as completely as possible.</b></p>

<form method="post">
<input name="BIBNO" type=hidden>
<input name="PHISIC" type=hidden>

<center><table><tr>
<td align=right><b>Author</b> <input type="text" name="AUTHOR" size="20"></td>
<td align=right><b>Title</b> <input type="text" name="TITLE" size="20"></td>
</tr><tr>
<td align=right><b>Originator</b> <input type="text" name="SAUTER" size="20"></td>
<td align=right><b>Subject</b> <select name="SUBJECT"><option selected>Subject 1
<option>Subject  2
<option>Subject  3
<option>Subject  4
<option>Subject  5
</select></td>
</tr><tr>
<td align=right><b>Index terms</b> <input type="text" name="Index terms:" size="20"></td>
<td align=right><b>Date file created</b> <input type="text" name="SDATE" size="10"></td>
</tr><tr>
<td align=right><b>Description</b> <input type="text" name="Description:" size="20"></td>
<td align=right><b>Citations</b> <input type="text" name="STUN" size="20"></td>
</tr><tr>
<td align=right><b>Commentary</b> <input type="text" name="Commentary:" size="20"></td>
<td align=right><b>Abstract author</b> <input name="ABSNO" type=hidden>
<input name="BIBNO" type=hidden>
</b><select name="AUTHOR"><option selected>Abramson, David
<option>Breslow, Lester
<option>Dunn, Kathel
<option>Fee, Elizabeth
<option>Glied, Sherry
<option>Hughes, Charles
<option>Kostelecky, Bonnie
<option>Lasker, Roz
<option>Lewis, Susan
<option>Miller, Russell
<option>Palica, Michael
<option>Prager, Dennis
<option>Reardon, Thomas
<option>Reiser, Stanley
<option>Warden, Gail
<option>Wasserman, Martin
</select></td>
</tr>
<tr>
<td align=center colspan=2><b>Abstract</b><br><textarea name="ABS" rows=5 cols=60></textarea></td>
</tr>
<tr>
<td align=right><INPUT TYPE="SUBMIT" VALUE="SUBMIT"></td><td align=left><INPUT TYPE="RESET" VALUE="CLEAR"></td>
</tr></table></center>

</form>

<hr size=3 noshade width=50% align=center>

<p align=center><a href="#search"><img src="gifs/search.gif" hspace=5></a><a href="#cite"><img src="gifs/cite.gif" hspace=5 border=1></a><img src="gifs/browse.gif" hspace=5><a href="index.html"><img src="gifs/home.gif" hspace=5></a></p>

<hr size=3 noshade width=50% align=center>

<p align=center><a href="index.html"><img src="gifs/ref.gif" vspace=5></a><br>
<font size=-2>New York Academy of Medicine<br>
copyright &#169; 1996 NYAM<br>
Last modified: 4/29/96</p>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-169</DOCNO>
<DOCOLDNO>IA093-001001-B043-383</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/docline/ 199.29.141.24 19970121115138 text/html 1042
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:45:46 GMT
Server: NCSA/1.5.1
Last-modified: Wed, 20 Nov 1996 16:28:35 GMT
Content-type: text/html
Content-length: 860
</DOCHDR>
<html>
<head>
<title>NN/LM Middle Atlantic Region--Electronic Payment
System</title>
</head>

<body bgcolor="#ffffff">
<img src="hippox.gif">
<center>
<a href="http://www.nyam.org/">New York Academy of Medicine</a>
<p>
NN/LM Middle Atlantic Region
<br>
<h3>Electronic ILL Payment System</h3>
</center>
<p>
<hr>
<table>
<tr>
<td>
<form method=post action=
"http://cues.nyam.org:8080/ows-bin/docl/owa/docl.blibs">
<input type=image src="/gifs/browse.gif">
</td>
<td>
Browse the EPS<br> Membership List
</td>
</tr>
</table>
</form>
<hr>
Get Your Quarterly Report
<form method="POST"
action="http://cues.nyam.org:8080/ows-bin/docl/owa/docl.docread">
<pre><b>
LIBID:		<INPUT type="text" name="lib_no" size="6"><p>
Your Password:	<INPUT type="text" name="passwd" size="6"><P>
</b></pre>
Press here to submit:
<input type="submit" value="Submit Search">. <p>
</form>
</DOC>
<DOC>
<DOCNO>WT18-B31-170</DOCNO>
<DOCOLDNO>IA093-001001-B043-397</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/gifs/ 199.29.141.24 19970121115227 text/html 1614
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:46:12 GMT
Server: NCSA/1.5.1
Content-type: text/html
</DOCHDR>
<HEAD><TITLE>Index of /gifs/</TITLE></HEAD><BODY>
<H1>Index of /gifs/</H1>
<PRE><IMG SRC="/icons/blank.xbm" ALT="     "> Name                   Last modified     Size  Description
<HR>
<A HREF="/"><IMG SRC="/icons/menu.xbm" ALT="[DIR]"></A> <A HREF="/">Parent Directory</A>       12-Jan-97 12:04      -  
<A NAME="ala.gif" HREF="ala.gif"><IMG SRC="/icons/image.gif" ALT="[IMG]"></A> <A NAME="ala.gif" HREF="ala.gif">ala.gif</A>                23-Feb-96 12:07    42K  
<A NAME="att1.gif" HREF="att1.gif"><IMG SRC="/icons/image.gif" ALT="[IMG]"></A> <A NAME="att1.gif" HREF="att1.gif">att1.gif</A>               28-Aug-96 15:59   180K  
<A NAME="att2.gif" HREF="att2.gif"><IMG SRC="/icons/image.gif" ALT="[IMG]"></A> <A NAME="att2.gif" HREF="att2.gif">att2.gif</A>               28-Aug-96 15:59   179K  
<A NAME="browse.gif" HREF="browse.gif"><IMG SRC="/icons/image.gif" ALT="[IMG]"></A> <A NAME="browse.gif" HREF="browse.gif">browse.gif</A>             20-Nov-96 13:00     1K  
<A NAME="left.gif" HREF="left.gif"><IMG SRC="/icons/image.gif" ALT="[IMG]"></A> <A NAME="left.gif" HREF="left.gif">left.gif</A>               23-Feb-96 17:41     1K  
<A NAME="title.gif" HREF="title.gif"><IMG SRC="/icons/image.gif" ALT="[IMG]"></A> <A NAME="title.gif" HREF="title.gif">title.gif</A>              23-Feb-96 12:07     1K  
<A NAME="turqu.gif" HREF="turqu.gif"><IMG SRC="/icons/image.gif" ALT="[IMG]"></A> <A NAME="turqu.gif" HREF="turqu.gif">turqu.gif</A>              23-Feb-96 17:41     1K  
</PRE></BODY>
</DOC>
<DOC>
<DOCNO>WT18-B31-171</DOCNO>
<DOCOLDNO>IA093-001001-B043-408</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/health.html 199.29.141.24 19970121115237 text/html 1818
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:46:44 GMT
Server: NCSA/1.5.1
Last-modified: Mon, 06 May 1996 16:42:22 GMT
Content-type: text/html
Content-length: 1635
</DOCHDR>
<html>
<head>
<title>American Library Association: Annual Conference 1996</title>
</head>

<body bgcolor="#ffffff" background="gifs/ala.gif">

<center><table><tr><td><img src="gifs/title.gif"></td><td><img src="gifs/title.gif"></td><td><img src="gifs/title.gif"></td></tr></table></center>

<p align=center><font size=4><b>Welcome to the home page for the <br>American Library Association's <br>Annual Conference 1996<br><br>
New York City<br>
Conference Dates : July 4 - July 10<br>
Exhibit Date : July 6 - July 9</b></font></p>

<p align=center><b>Visit the <a href="links.html">links page</a> for suggestions of <br><br>what to do <br>where to eat <br>and how to get there<br><br>information about <br>theater tickets <br>tours and more</b><br><br>
<font size=-2><b>(updated 3/13/96)</b></font></p>

<p align=center><b>Comments? <br><a href="mailto:alanyc@nyam.org">Write us</a> - we'd like to hear from you.</b></p>

<hr size=5 width=50% align=center>

<p align=center><b><a href="http://www.ala.org"><img src="gifs/title.gif" hspace=5><br><font size=-1><b>American Library Association's main page</b></font></a></b></p>

<hr size=5 width=50% align=center>

<p align=center><font size=2><a href="mailto:alanyc@nyam.org">ALA Conference '96</a><br>
New York City<br>
last modified 3/13/96</font></p>

<center><table width=75% border=1><tr><td align=center><font size=-1><b>These pages are hosted on the <a href="http://www.nyam.org/">New York Academy of Medicine</a> server. The library is open Monday-Friday 9:00-5:00 with public access computers and a direct Internet connection.</b></font></td></table></center>

</body>
</html>

</DOC>
<DOC>
<DOCNO>WT18-B31-172</DOCNO>
<DOCOLDNO>IA093-001001-B043-427</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/index_old.html 199.29.141.24 19970121115249 text/html 1818
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:46:56 GMT
Server: NCSA/1.5.1
Last-modified: Wed, 22 May 1996 16:37:47 GMT
Content-type: text/html
Content-length: 1635
</DOCHDR>
<html>
<head>
<title>American Library Association: Annual Conference 1996</title>
</head>

<body bgcolor="#ffffff" background="gifs/ala.gif">

<center><table><tr><td><img src="gifs/title.gif"></td><td><img src="gifs/title.gif"></td><td><img src="gifs/title.gif"></td></tr></table></center>

<p align=center><font size=4><b>Welcome to the home page for the <br>American Library Association's <br>Annual Conference 1996<br><br>
New York City<br>
Conference Dates : July 4 - July 10<br>
Exhibit Date : July 6 - July 9</b></font></p>

<p align=center><b>Visit the <a href="links.html">links page</a> for suggestions of <br><br>what to do <br>where to eat <br>and how to get there<br><br>information about <br>theater tickets <br>tours and more</b><br><br>
<font size=-2><b>(updated 3/13/96)</b></font></p>

<p align=center><b>Comments? <br><a href="mailto:alanyc@nyam.org">Write us</a> - we'd like to hear from you.</b></p>

<hr size=5 width=50% align=center>

<p align=center><b><a href="http://www.ala.org"><img src="gifs/title.gif" hspace=5><br><font size=-1><b>American Library Association's main page</b></font></a></b></p>

<hr size=5 width=50% align=center>

<p align=center><font size=2><a href="mailto:alanyc@nyam.org">ALA Conference '96</a><br>
New York City<br>
last modified 3/13/96</font></p>

<center><table width=75% border=1><tr><td align=center><font size=-1><b>These pages are hosted on the <a href="http://www.nyam.org/">New York Academy of Medicine</a> server. The library is open Monday-Friday 9:00-5:00 with public access computers and a direct Internet connection.</b></font></td></table></center>

</body>
</html>

</DOC>
<DOC>
<DOCNO>WT18-B31-173</DOCNO>
<DOCOLDNO>IA093-001001-B044-17</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/links.html 199.29.141.24 19970121115306 text/html 11162
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:47:06 GMT
Server: NCSA/1.5.1
Last-modified: Tue, 19 Mar 1996 22:32:59 GMT
Content-type: text/html
Content-length: 10978
</DOCHDR>
<html>
<head>
<title>ALA Conference 1996: places of interest</title>
</head>

<body bgcolor="#ffffff">

<img src="gifs/turqu.gif" width=30 height=1850 align=left>
<img src="gifs/title.gif" align=left><br><br>

<h3>Links to places of interest in New York City</h3>

<center><table border=1 cellpadding=4 colspec="50% 50%">
<tr>
<th colspan=2>general guides on the web</th>
<p>
</tr>
<tr valign=top>
<td align=center width=50%><font size=2><a href="http://metrobeat.com:80/nyc/index.html">Explore New York</a> <br>Art galleries, music, comedy and cabaret, dance, movies, nightclubs and restaurants.</font></td>
<p>
<td align=center width=50%><font size=2><a href="http://www.mediabridge.com/nyc/transportation/subways/picker.html">Getting around</a> <br>An interactive map of the New York City subway system.</font></td>
<p>
</tr><tr valign=top>
<td align=center><font size=2><a href="http://www.mediabridge.com/nyc/">The Paperless Guide to New York City</a> <br>History and facts, general info, transportation, food and dining, shopping, site seeing, museums, current events, sports and fitness, media and entertainment.</font></td>
<p>
<td align=center><font size=2><a href="http://www.papermag.com">Paper Magazine</a> <br>PaperDaily, Stylin', The Guide, Hot Tips, WordUp and Current Issue.</font></td>
<p>
</tr><tr valign=top>
<td colspan=2 align=center><font size=-1><a href="http://www.hwwilson.com/newyork.html">New York by New Yorkers</a><br> from H.W.Wilson, a guide to the city for American Library Association conference goers.</font></td>
<p>
</tr><tr>
<th colspan=2>libraries</th>
<p>
</tr><tr valign=top>
<td align=center><font size=2><a href="http://www.nypl.org">New York Public Library's</a> links to catalogs, the research libraries, NOAH, and the branch libraries.</font></td>
<p>
<td align=center><font size=2><a href="http://www.metrobeat.com/nyc/locations/lda0087.html">Library for the Performing Arts</a> <br>Schedule of events, the exhibits, collections.</td>
</tr><tr valign=top>
<td align=center><font size=-1><a href="http://www.nyam.org/">New York Academy of Medicine</a> <br>Your host, with a huge collection of medical journals and reference materials, links to other medical libraries and resources.</font></td>
<p>
<td align=center><font size=-1><a href="http://www.nypl.org/research/sc/sc.html">The Schomburg Center </a> <br>Devoted to collecting, preserving and providing access to resources documenting the experiences of peoples of African descent throughout the world.</font></td></tr>
<p>
<tr>
<th colspan=2>restaurants</th>
<p>
</tr><tr valign=top>
<td align=center><font size=2><a href="http://metrobeat.com:80/nyc/mb/restaurants/section.html">Metrobeat's</a> selective guide to restaurants, arranged by neighborhood, type of food and price range.</font></td>
<p>
<td align=center><font size=2><a href="http://www.kerrymenu.com/Restaurants/NewYorkCity/index.html">Kerrymenu's</a> guide to restaurants includes menus, try <a href="http://www.kerrymenu.com/Restaurants/NewYorkCity/01l082.html">Le Cirque's.</a></font></td>
<p>
</tr><tr valign=top>
<td align=center><font size=-1><A HREF="http://pathfinder.com/@@ksBtsPEwHgAAQO@Y/Travel/Zagat/Dine/New+York+City/alphaSearch.html">Zagat's</A> ratings for selective New York City restaurants<br> by cuisine, food ranking, popularity and price.</font></td>
<p>
<td align=center><font size=-1><A HREF="http://www.nar.com/people/sib/foodfind.html">New York City Restaurant Finder</A> <br>Search by location and type of cuisine.</font></td>
<p>
</tr><tr valign=top>
<td align=center colspan=2><font size=-1><A HREF="http://www.nydining.com/">New York Dining Online</A><br> Menu browser and restaurant guide.</font></td>
<p>
</tr><tr>
<th colspan=2>museums</th>
<p>
</tr><tr valign=top>
<td align=center><font size=2><a href="http://artdirect.com/neast/nyc/museums/">ArtDirect's</a> listing of New York museums, some with links to descriptions of collections and current exhibits.</font></td>
<p>
<td align=center><font size=-1><A HREF="http://www.museumsny.com/">Museums New York</A> <br>Reviews of exhibits around New York. <a href="http://www.museumsny.com/features/barbie/index.html">Hey there, Barbie Doll!</a></font></td>
<p>
</tr><tr valign=top>
<td align=center><font size=2><a href="http://www.metmuseum.org/">The Metropolitan Museum of Art</a> <br>Maps of the floors with descriptions of the collections.</td>
<p>
<td align=center><font size=2><A HREF="http://www.netresource.com/mcny"><font size=-1>Museum of the City of New York</A> <br>Original cultural materials related to the history of New York City.</font></td>
<p>
</tr><tr valign=top>
<td align=center><font size=2><a href="http://www.metmuseum.org/htmlfile/gallery/cloister/cloister2.html">The Cloisters</a> <br>Medieval sculpture, the Unicorn tapestries, an herb garden, all at the northern tip of Manhattan.</font></td>
<p>
<td align=center><font size=2><a href="http://sigmar.artdirect.com/neast/nyc/museums/moma/">The Museum of Modern Art</a> <br>List of current exhibits and location.</font></td>
<p>
</tr><tr valign=top>
<td align=center><font size=-1><A HREF="http://www.echonyc.com/~whitney/">Whitney Museum of American
Art</A> <br>Current exhibits and programs. Graphics heavy, don't try it from home.</font></td>
<p>
<td align=center><font size=-1><A HREF="http://www.mtr.org/">Museum of Television and Radio</A> <br>An online tour, list of exhibits and screenings, and more.</font></td>
<p>
</tr><tr valign=top>
<td align=center><font size=-1><A
HREF="http://www.si.edu/organiza/museums/amerind/nmai/start.htm">National
Museum of the American Indian</A> <br>Exhibits covering the life, languages, literature, history, and arts of Native Americans.</font></td>
<p>
<td align=center><font size=-1><A HREF="http://www.westnet.com/intrepid/">Intrepid Sea, Air, Space Museum</A> <br>World War II, early aviation, undersea and space exploration exhibits.</font></td>
<p>
</tr>
<tr valign=top>
<td align=center><font size=-1><a href="http://artdirect.com/neast/nyc/museums/brook/">The Brooklyn Museum</a> <br>Hours, exhibits and how to get there.</font></td>
<p>
<td align=center><font size=-1><br></td></tr><p>
<tr>
<th colspan=2>theaters and concert halls</th>
<p>
</tr><tr valign=top>
<td align=center><font size=-1><a href="http://www.ticketmaster.com/directory/st_pages/ny.html#venue">Ticketmaster</a><br>Presents lists of theaters and events with seating charts; telephone numbers; credit card availability.</font></td>
<p>
<td align=center><font size=-1>Ticketmaster's <a href="http://www.ticketmaster.com/events/topacts/arts.top25acts.html">top 25 theater events</a>. Selection is based on the number of inquiries into the event database.(Does not say much for artistic quality).</font></td>
</tr><p><tr valign=top>
<td align=center><font size=-1><a href="http://artsnet.heinz.cmu.edu:80/OnBroadway/Off_Bway.html">On/Off Broadway</a> presents short annotations for theater on and off Broadway with information on obtaining day of performance discounted tickets (TDF). Also includes reviews with links provided by <a href="http://www.escape.com/~theanet/AisleSay.html">AisleSay</a>, the internet magazine of stage reviews and opinion.</font></td>
<p>
<td align=center><font size=-1><a href="http://www.cris.com/%7EShamstra/cabaret.html">Cabaret Hotline</a> features information on cabaret, jazz clubs, piano bars and comedy clubs. Gives club addresses, featured acts and credit card availability.</font></td>
</tr><p><tr valign=top>
<td align=center><font size=-1><a href="http://www.phyllisbroadway.com">Phyllis' Broadway</a> <br>Provides background information on current and future productions <br>with a "give my regards to Broadway" flavor.</font></td>
<p>
<td align=center><font size=2><a href="http://wheat.symgrp.com/playbill/html/home.html">Playbill Online</a> <br>Complete theater listings, on and off-Broadway, show times, ticket prices and nearby restaurants.</font></td>
<p>
</tr><tr>
<th colspan=2>tours</th>
<p>
</tr><tr valign=top>
<td align=center><font size=2><a href="http://www.epen.com/ny/index.html">American Siteseeing International</a> <br>Tours, maps, weather, coupons, facts and figures.</font></td>
<p>
<td align=center><font size=2><a href="http://www.mediaworks.com/nyat/nyatrates.html">New York Apple Tours</a> <br>Uptown and downtown loops, plus a combination of both tours, each ticket valid for two days.</font></td>
<p>
</tr><tr>
<th colspan=2>other sites of interest</th>
<p>
</tr><tr valign=top>
<td align=center><font size=2><a href="http://www.un.org/">The United Nations</a> <br>News, documents, departments, information resources, photos and <a href="http://www.un.org/Overview/Tours/">tours</a>.</font></td>
<p>
<td align=center><font size=2><a href="http://www.magicnet.net/~wwwlink/ny.html">New York Gay Link</a> <br>Community listings, restaurants, hotels.</font><td>
<p>
</tr>
<tr valign=top><td align=center><font size=-1><a href="http://info.rutgers.edu/Directories/Outside_Rolodex/Card.159.shtml">Ellis Island</a> <br>Ferry schedule to immigration museum and Statue of Liberty.</font></td>
<p>
<td align=center><font size=-1><a href="http://www.columbia.edu/cu/cerc/bronx_zoo/zoo2.html">Bronx Zoo</a></a> <br>Hours, directions, information from the Wildlife Conservation Society.</font></td></p></tr>
<tr valign=top><td colspan=2 align=center><font size=-1><a href="http://pathfinder.com/@@I9FqMGKV*AAAQHOj/vg/Gardens/NYBG/">New York Botanical Gardens</a> <br>A National Historic Landmark located in the Bronx. Education, research, events, plant info.</font></td><p></tr>
<tr valign=top>
<td align=center><font size=2><a href="http://www.panix.com/~bsteve/empwzep.html">The Empire State Building</a> <br>The one and only.</font></td>
<p>
<td align=center><font size=2><a href="http://www.cs.bsu.edu/homepages/vreddy/pics/liberty.html">The Statue of Liberty</a> <br>Not to be missed.</font></td>
<p>
</tr>
<tr><td colspan=2 align=center><font size=-1><a href="talk.html">Tickets to talk shows</a><br>Kathie Lee? Sally Jessy? Rolanda? All the information right here. <br>Plan ahead, because some are sold out months in advance.</font></td></tr>
<p>
<tr>
<th colspan=2>shopping</th>
<p>
</tr><tr valign=top>
<td align=center><font size=2><a href="http://www.tripod.com/living2/city_sketches/new_york/nyother.html">Shopping/Leisure</a> <br>Books, flea markets, live music, recorded music and more.</font></td>
<p>
<td align=center><font size=2><a href="http://www.mediabridge.com/nyc/shopping/">Mediabridge's shopping page</a> <br>Bookstores, clothing, cosmetics, department stores.</font></td>
</tr>
</table></center>

<p align=center><a href="index.html"><img src="gifs/left.gif" vspace=5><br>
<font size=2>ALA Conference Home Page</font></a></p>

<p align=center><img src="gifs/turqu.gif" width=400 height=2></p>

<p align=center><font size=-2><a href="mailto:alanyc@nyam.org">ALA Conference '96</a><br>
New York City<br>
last modified 3/19/96</font></p>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-174</DOCNO>
<DOCOLDNO>IA093-001001-B044-38</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/natmed/ 199.29.141.24 19970121115315 text/html 1608
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:47:23 GMT
Server: NCSA/1.5.1
Last-modified: Tue, 05 Mar 1996 21:34:32 GMT
Content-type: text/html
Content-length: 1425
</DOCHDR>
<html>
<head>
<title>National Medical Association</title>
</head>
<body background="gifs/logo2.gif" >
<p align=center><img src="gifs/name.gif"></p>
<hr size=4 align=center width=50% noshade>

<h5 align=center><a href="calendar.html">CALENDAR OF EVENTS</a></h5>
<h5 align=center><a href="policy.html">NMA POLICY COMPENDIUM</a></h5>
<h5 align=center><a href="articles.html">EDITORIAL ARTICLES AND PRESIDENTIAL STATEMENTS</a></h5>
<h5 align=center><a href="delnews.html">HOUSE OF DELEGATES NEWS</a></h5>
<h5 align=center><a href="member.html">NMA MEMBERSHIP APPLICATION</a></h5>
<h5 align=center><a href="http://www.slackinc.com/general/jnma/jnmahome.htm">JOURNAL LINK</a></h5>
<h5 align=center><a href="conven.html">101st ANNUAL CONVENTION</a><br>July 27-August 3, 1996 Chicago</h5>

<h5 align=center><a href="about.html">ABOUT THE NATIONAL MEDICAL ASSOCIATION</a></h5>

<hr size=4 align=center width=50% noshade>

<h5 align=center><a href="discuss.html">DISCUSSION GROUP FOR WEB PAGES</a></h5>

<hr size=4 align=center width=50% noshade>

<p align=center><b>e-mail : <a href="mailto:nma@www.natmed.org">nma@www.natmed.org</a><br>
1012 Tenth Street, NW<br>
Washington, DC 20001<br>
phone : (202) 347-1895</b></p>

<p align=center><img src="gifs/medical.gif" border=2 vspace=5><br><font size=-1><b><a href="mailto:nma@www.natmed.org">National Medical Association</a><br>
copyright &#169; 1996 NMA</b></font></p>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-175</DOCNO>
<DOCOLDNO>IA093-001001-B044-58</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/newsrch.html 199.29.141.24 19970121115329 text/html 10102
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:47:31 GMT
Server: NCSA/1.5.1
Last-modified: Tue, 30 Apr 1996 16:57:33 GMT
Content-type: text/html
Content-length: 9919
</DOCHDR>
<html>
<head>

<!--************* (1A) OLD SEARCH FORM ******************-->

<TITLE>Public Health Search Form</TITLE>
</head>
<body bgcolor="#ffffff" text="#7f00ff" link="#000000">

<H1>Public Health and Medicine Search Form</H1>
<I>This is only a test system</I>
<FORM METHOD="POST" ACTION="/cgi-bin/zgate">
<HR>
<input NAME="DBNAME" VALUE="ISEARCH" type="hidden">
<BR>
<INPUT NAME="ACTION" VALUE="SEARCH" TYPE="HIDDEN">
<INPUT NAME="RECSYNTAX" VALUE="1.2.840.10003.5.10" TYPE="HIDDEN">
<INPUT NAME="ESNAME" VALUE="B" TYPE="HIDDEN">
<INPUT NAME="TERM_1" SIZE="10">

<!-- ******************* (2A) OLD SEARCH NON-UNIQUE ************* -->

<SELECT NAME="USE_1">

<OPTION SELECTED VALUE="4">Title of the article
<OPTION VALUE="1010">Subject
<OPTION VALUE="1010">Keyword
<OPTION VALUE="1010">Full Text
<OPTION VALUE="1010">Abstract
<OPTION VALUE="1010">Panel
</SELECT>

<SELECT NAME="BOOLEAN_OP">
<OPTION SELECTED>AND
<OPTION>OR
</SELECT>

<INPUT NAME="TERM_2" SIZE="10">

<SELECT NAME="USE_2">
<OPTION SELECTED VALUE="4">Title of the article
<OPTION VALUE="1010">Subject
<OPTION VALUE="1010">Keyword
<OPTION VALUE="1010">Full Text
<OPTION VALUE="1010">Abstract
<OPTION VALUE="1010">Panel
</SELECT>

<BR>

<INPUT TYPE="SUBMIT" VALUE="Search">
</FORM>

<!-- ****************** (3A) END of OLD SEARCH FORM ************* -->

<hr>

<html>
<head>
<title>Public Health and Medicine: Add Article To Database</title>
</head>

<body bgcolor="#ffffff" text="#7f00ff" link="#000000">

<h3 align=center><FONT SIZE=+3>P</FONT>UBLIC <FONT SIZE=+3>H</FONT>EALTH AND <FONT SIZE=+3>M</FONT>EDICINE:<br>
PARTNERING TO IMPROVE COMMUNITY HEALTH <br>IN THE 21st CENTURY</h3>

<hr size=1 width=50% align=center>

<FORM METHOD=POST ACTION="/cgi-bin/phaddnew">

<center><table><tr>
<td align=right>Author:</td><td><INPUT TYPE="text" NAME="author" SIZE=40 MAXLENGTH=40></td>
</tr><tr>
<td align=right>Panel:</td><td><INPUT TYPE="text" NAME="panel" SIZE=40 MAXLENGTH=40></td>
</tr><tr>
<td align=right>Title:</td><td><INPUT TYPE="text" NAME="title" SIZE=40 MAXLENGTH=40></td>
</tr><tr>
<td align=right>Source:</td><td><INPUT TYPE="text" NAME="source" SIZE=40 MAXLENGTH=40></td>
</tr><tr>
<td align=right>Keyword:</td><td><INPUT TYPE="text" NAME="keyword" SIZE=40 MAXLENGTH=40></td>
</tr><tr>
<td align=right>Subject:</td><td><INPUT TYPE="text" NAME="subject" SIZE=40 MAXLENGTH=40></td>
</tr><tr>
<td align=right>Abstract:</td><td><br></td>
</tr><tr>
<td colspan=2><TEXTAREA NAME="abstract" ROWS=4 COLS=60></TEXTAREA></td>
</tr><tr>
<td colspan=2 align=center>

<INPUT TYPE=submit VALUE="POST">
<INPUT TYPE=reset VALUE="CLEAR"></td>

</tr>
</table></center>

</FORM></blockquote>
<p align=center><b>Note</b>: After you post, you will return to the home page</p>

<hr size=5 width=50% align=center>

<p align=center><a href="index.html"><img src="gifs/ref.gif" vspace=5></a><br>
<font size=-2>New York Academy of Medicine<br>
copyright &#169; 1996 NYAM<br>
Last modified: 4/9/96</p>

</body>
</html>


<!-- ******************** (1B) New Search Form ************************* -->

<html>
<head>
<title>Public Health and Medicine: search page</title>
</head>

<body bgcolor="#ffffff" text="#7f00ff" link="#000000">

<h3 align=center><FONT SIZE=+3>P</FONT>UBLIC <FONT SIZE=+3>H</FONT>EALTH AND 
<FONT SIZE=+3>M</FONT>EDICINE:<br>
PARTNERING TO IMPROVE COMMUNITY HEALTH <br>IN THE 21st CENTURY</h3>

<hr size=3 noshade width=50% align=center>

<p align=center><a href="#search"><img src="gifs/search.gif" hspace=5>
</a><a href="#cite"><img src="gifs/cite.gif" hspace=5></a>
<img src="gifs/browse.gif" hspace=5 border=1><a href="index.html">
<img src="gifs/home.gif" hspace=5></a></p>

<hr size=3 noshade width=50% align=center>

<p><font size=+1><b><a name="search">Search</a> the database</b></font></p>

<FORM METHOD="POST" ACTION="/cgi-bin/zgate">

<input NAME="DBNAME" VALUE="ISEARCH" type="hidden"><BR>
<INPUT NAME="ACTION" VALUE="SEARCH" TYPE="HIDDEN">
<INPUT NAME="RECSYNTAX" VALUE="1.2.840.10003.5.10" TYPE="HIDDEN">
<INPUT NAME="ESNAME" VALUE="B" TYPE="HIDDEN">
<INPUT NAME="TERM_1" SIZE="10">
<SELECT NAME="USE_1">

<b>Search by Key Fields</b></p>

<p><input name="active" type="radio" value=1> 
Author        : <input name="element_1" size=20>

<p><input name="active" type="radio" value=2> 
Title         : <input name="element_2" size=20> 

<p><input name="active" type="radio" value=3> 
Year          : <input name="element_3" size=20>

<p><input name="active" type="radio" value=4> 
Journal Words : <input name="element_4" size=20>

<P><input name="active" type="radio" value=5>
<b>by Abstract author</b>
<select name="element_5"> 
<option selected>Abramson, David
<option>Breslow, Lester
<option>Dunn, Kathel
<option>Fee, Elizabeth
<option>Glied, Sherry
<option>Hughes, Charles
<option>Kostelecky, Bonnie
<option>Lasker, Roz
<option>Lewis, Susan
<option>Miller, Russell
<option>Palica, Michael
<option>Prager, Dennis
<option>Reardon, Thomas
<option>Reiser, Stanley
<option>Warden, Gail
<option>Wasserman, Martin
</select> 

<P>
<b>by Major Subject "Controlled Vocabulary" terms</b><P>
<input name="active" type="radio" value=6> 
Subject term <input type="text" name="element_6" size="20">
or <input name="active" type="radio" value=7> 
<select name="element_7">
<option selected>Lung Cancer
<option>Epidemiology
<option>Disease
<option>Arthroscopy
</select>
<P>

<center><table><tr><td><INPUT TYPE="POST" 
VALUE="SEARCH"></td><td><br></td><td><INPUT TYPE="RESET" 
VALUE="CLEAR"></td></tr></table></center>

<!-- ******************** (2B) END OF SEARCH FORM *************** -->

</form>

<hr size=3 noshade width=50% align=center>

<p align=center><a href="#search"><img src="gifs/search.gif" 
hspace=5></a><a href="#cite"><img src="gifs/cite.gif" hspace=5 
border=1></a><img src="gifs/browse.gif" hspace=5><a href="index.html"><img src="gifs/home.gif" hspace=5></a></p>

<hr size=3 noshade width=50% align=center>

<p><font size=-1><b><a name="cite">Use</a> this form to enter citations 
for :</b> artwork, audiovisual materials, books, book sections, computer programs, conference proceedings, edited books, journal articles, magazine articles, maps, newspaper articles,

 patents, personal communications, reports, thesis, or web sites. Enter 
information into appropriate fields. </font></p>

<p><font size=-1>Use <a href="#case">this form</a> to enter a citation 
for a <b>case study</b> only.</font></p>

<FORM METHOD=POST ACTION="/cgi-bin/phaddnew">

<input name="BIBNO" type=hidden>
<input name="PHISIC" type=hidden>

<center><table width=100% cospec="50% 50%"><tr>
<td colspan=2><font size=-1><b>Author / Editor</b> (if edited book) <b>/ 
Reporter / Programmer</b> (if computer program) <b>/<br> 
Cartographer</b> (if map) <b>/ Artist</b> (if artwork) <b>/ URL </b>(if 
web site)</font><br><input type="text" name="AUTHOR" 


size="60"></td>
</tr>
<tr>
<td colspan=2width=50%><font size=-1><b>Title / Publication source 
</b>(if web site)</b></font><br><input type="text" name="TITLE" size="60"></td>
</tr>
<tr>
<td colspan=2><font size=-1><b>Journal / Series Title / Magazine / 
Newspaper / Conference name / <br>Academic Dpt. </b>(if thesis) <b>/ 
Publication source</b> (if patent) <b>/ Domaine</b> (if web 
site)</b></font><br><input type="text" name="SITLE" size="60"></td>
</tr>
<tr>
<td width=50%><font size=-1><b>Year</b></font><br><input type="text" 
name="YEAR" size="30" maxlength="4"></td>
<td><font size=-1><b>Editor / Series Editor / Access </b>(if web 
site)</b></font><br><input type="text" name="SAUTER" size="30"></td> </tr>
<tr>
<td><font size=-1><b>Volume</b></font><br> <input type="text" 
name="VOLUME" size="30"></td>
<td><font size=-1><b>No. of volumes</b></font><br> <input type="text" 
name="NUMVOL" size="30"></td> </tr>
<tr>
<td><font size=-1><b>City / Conference Location / Country</b> (if 
patent)</b></font><br><input type="text" name="PLACE" size="30"></td>
<td><font size=-1><b>Publisher / University / Assignee</b> (if 
patent)</b></font><br> <input type="text" name="PUBLISH:" size="30"></td>
</tr>
<tr>
<td><font size=-1><b>Issue</b></font><br> <input type="text" 
name="NUMBER" size="30"></td>
<td><font size=-1><b>Date </b>(month/day/year)<b> / Issue Date </b>(if 
newspaper)</b></font><br><input type="text" name="SDATE" size="30" 
maxlength="8"></td> </tr>
<tr>
<td><font size=-1><b>Version </b>(if computer program) <b>/ Edition 
</b>(if map)</b></font><br><input type="text" name="EDITION" size="30"></td>
<td><font size=-1><b>Pages</b></font><br> <input type="text" 
name="PAGES" size="30"></td> </tr>
<tr>
<td colspan=2><font size=-1><b>Type</b> (if personal communication / 
report / map / artwork / audiovisual material / web 
site)</b></font><br><input type="text" name="WORK" size="60"></td> </tr>
<tr>
<td colspan=2><font size=-1><b>Case Study No.</b> (if 
known)</font><br><input type="text" name="STUN" size="60"> </tr>
<tr>
<td><input name="ABSNO" type=hidden>
<input name="BIBNO" type=hidden>
<font size=-1><b>Abstract author</b></font><br> <select 
name="AUTHOR"><option selected>Abramson, David <option>Breslow, Lester
<option>Dunn, Kathel
<option>Fee, Elizabeth
<option>Glied, Sherry
<option>Hughes, Charles
<option>Kostelecky, Bonnie
<option>Lasker, Roz
<option>Lewis, Susan
<option>Miller, Russell
<option>Palica, Michael
<option>Prager, Dennis
<option>Reardon, Thomas
<option>Reiser, Stanley
<option>Warden, Gail
<option>Wasserman, Martin
</select></td>
<td><font size=-1><b>Major Subject "Controlled Vocabulary" 
terms</b></font><br><select name="SUBJECT"><option selected>Subject 1
<option>Subject  2
<option>Subject  3
<option>Subject  4
<option>Subject  5
</select></td>
</tr>
<tr>
<td align=center colspan=2><font 
size=-1><b>Abstract</b></font><br><textarea name="ABST" rows="5" 
cols="60"></textarea></td> </tr>
<tr>
<td align=right>


<INPUT TYPE="SUBMIT" VALUE="POST"></td><td 
align=left>
<INPUT TYPE="RESET" VALUE="CLEAR"></td></tr> </table></center>

</form>
</DOC>
<DOC>
<DOCNO>WT18-B31-176</DOCNO>
<DOCOLDNO>IA093-001001-B044-234</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/public_html/ 199.29.141.24 19970121115550 text/html 613
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:49:58 GMT
Server: NCSA/1.5.1
Content-type: text/html
</DOCHDR>
<HEAD><TITLE>Index of /public_html/</TITLE></HEAD><BODY>
<H1>Index of /public_html/</H1>
<PRE><IMG SRC="/icons/blank.xbm" ALT="     "> Name                   Last modified     Size  Description
<HR>
<A HREF="/"><IMG SRC="/icons/menu.xbm" ALT="[DIR]"></A> <A HREF="/">Parent Directory</A>       12-Jan-97 12:04      -  
<A NAME="cgraber/" HREF="cgraber/"><IMG SRC="/icons/menu.xbm" ALT="[DIR]"></A> <A NAME="cgraber/" HREF="cgraber/">cgraber/</A>               16-Sep-96 14:12      -  
</PRE></BODY>
</DOC>
<DOC>
<DOCNO>WT18-B31-177</DOCNO>
<DOCOLDNO>IA093-001001-B044-318</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/srch.html 199.29.141.24 19970121115738 text/html 1631
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:51:45 GMT
Server: NCSA/1.5.1
Last-modified: Mon, 29 Apr 1996 19:38:55 GMT
Content-type: text/html
Content-length: 1448
</DOCHDR>
<html>
<head>
<TITLE>Public Health Search Form</TITLE>
</head>
<body bgcolor="#ffffff" text="#7f00ff" link="#000000">

<H1>Public Health and Medicine Search Form</H1>
<I>This is only a test system</I>
<FORM METHOD="POST" ACTION="/cgi-bin/zgate">
<HR>
<input NAME="DBNAME" VALUE="ISEARCH" type="hidden">
<BR>
<INPUT NAME="ACTION" VALUE="SEARCH" TYPE="HIDDEN">
<INPUT NAME="RECSYNTAX" VALUE="1.2.840.10003.5.10" TYPE="HIDDEN">
<INPUT NAME="ESNAME" VALUE="B" TYPE="HIDDEN">
<INPUT NAME="TERM_1" SIZE="10">
<SELECT NAME="USE_1">
<OPTION SELECTED VALUE="4">Title of the article
<OPTION VALUE="1010">Subject
<OPTION VALUE="1010">Keyword
<OPTION VALUE="1010">Full Text
<OPTION VALUE="1010">Abstract
<OPTION VALUE="1010">Panel
</SELECT>
<SELECT NAME="BOOLEAN_OP">
<OPTION SELECTED>AND
<OPTION>OR
</SELECT>
<INPUT NAME="TERM_2" SIZE="10">
<SELECT NAME="USE_2">
<OPTION SELECTED VALUE="4">Title of the article
<OPTION VALUE="1010">Subject
<OPTION VALUE="1010">Keyword
<OPTION VALUE="1010">Full Text
<OPTION VALUE="1010">Abstract
<OPTION VALUE="1010">Panel
</SELECT>
<BR>
<INPUT TYPE="SUBMIT" VALUE="Search">
</FORM>
<hr>
You can also <a href="http://pubh.nyam.org/lasker/addnew.html">add an article</a> to the database.

<hr size=5 width=50% align=center>

<p align=center><a href="index.html"><img src="gifs/ref.gif" vspace=5></a><br>
<font size=-2>New York Academy of Medicine<br>
copyright &#169; 1996 NYAM<br>
Last modified: 4/10/96</p>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-178</DOCNO>
<DOCOLDNO>IA093-001001-B044-331</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/talk.html 199.29.141.24 19970121115746 text/html 7026
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:51:53 GMT
Server: NCSA/1.5.1
Last-modified: Tue, 19 Mar 1996 22:33:00 GMT
Content-type: text/html
Content-length: 6843
</DOCHDR>
<html>
<head>
<title>www.alanyc.org: talk show links</title>
</head>
<body bgcolor="#ffffff">

<img src="gifs/turqu.gif" width=30 height=2425 align=left>
<img src="gifs/title.gif" align=left><br><br>

<p><b><font SIZE=+2>TV Tickets for New York Shows</font></b></p>

<font size=-1>
<p align=center><img src="gifs/turqu.gif" width=400 height=2></p>

<p align=center><b><a 
HREF="http://baywatch.compuserve.com/aatv/bey/">Richard
Bey</a></b><br>
To become a guest, call:<br>
1-201-392-8499<br>
For complimentary tickets, send mail to:<br>
The Richard Bey Show<br>
9 Broadcast Plaza<br>
Secaucas, NJ 07096</p>

<p align=center><img src="gifs/turqu.gif" width=400 height=2></p>

<p align=center><b>CBS&nbsp;This Morning</b><br>
By phone: (212) 975-7000<br>
By fax: (212) 975-8181<br>
By mail: <br>
CBS This Morning Tickets<br>
524 W. 57th Street<br>
New York, NY 10019<br>

<p align=center><img src="gifs/turqu.gif" width=400 height=2></p>
<p align=center><b><a 
HREF="http://www.spe.sony.com/Pictures/tv/rickilake/ricki.html">Ricki Lake</a></b><br>
401 Fifth Avenue<br>
New York, NY 10016<br>
To be a guest on Ricki Lake, call:<br>
1-800-GO-RICKI (1-800-457-4354)<br>
or if in the New York area, call:<br>
1-212-889-7465</p>

<p align=center><img src="gifs/turqu.gif" width=400 height=2></p><br>

<p align=center><b><a HREF="http://www.cbs.com/lateshow/">The Late
Show with David Letterman</a></b><br>
David Letterman Tickets<br>
Ed Sullivan Theater<br>
1697 Broadway<br>
New York, NY 10019<br>
Standby Tickets. Available starting 12 noon at the
Ed Sullivan Theater box office, and given out on a first-come first-served basis. You must be at least sixteen years old.</p>

<p align=center><img src="gifs/turqu.gif" width=400 height=2></p><br>

<p align=center><b><a HREF="http://www.vpm.com/kmitchel/rush.htm">Rush
Limbaugh</a></b><br>
United Studios<br>
515 W. 57th Street<br>
New York, NY 10019<br>
212 397-7367</p>

<p align=center><img src="gifs/turqu.gif" width=400 height=2></p><br>

<p align=center><b><a 
HREF="http://www.nbc.com/entertainment/shows/conan/index.html">Late
Night with Conan O'Brien</a></b><br>
Mail Request. Same day tickets are always available<br>
Standby Tickets. Available starting 9 am at the page desk in the lobby of the G.E. building, and given out on a first-come first-served basis. You must be at least 16 years old. </p>

<p align=center><img src="gifs/turqu.gif" width=400 height=2></p><br>

<p align=center><b><a 
HREF="http://jhunix.hcf.jhu.edu/~quantum/maury.html">Maury
Povich</a></b><br>
For information on being a guest, call:<br>
1-800-593-2000<br>
For tickets, write to:<br>
Maury Povich Tickets<br>
221 W. 26th St.<br>
New York, New York 10001<br>
or call:<br>
1-212-989-3622</p>

<p align=center><img src="gifs/turqu.gif" width=400 height=2></p><br>

<p align=center><b><font COLOR="#FF0080"><a 
HREF="http://www.nbc6.nbc.com/sally.html">SallyJessy Raph&auml;el</a></font></b><br>
510 W. 57 Street<br>
New York, NY 10019<br>
(212) 582-1722<br>
Tickets<br>
(include # of tickets)<br>
P.O. Box 1400<br>
Radio City Station<br>
New York, NY 10101</p>

<p align=center><img src="gifs/turqu.gif" width=400 height=2></p><br>

<p align=center><b><a 
HREF="http://www.tvplex.com/TVplex/BuenaVista/RegisAndKathieLee/RegisAndKathieLeeG.html?GL=H">Live with Regis and Kathie Lee</a></b><br>
Mail Request.<br>
For tickets send a postcard with name, address and telephone number including the number of tickets you would like to receive. There is an 8-10 month wait for tickets. <br>
Live Tickets<br>
Ansonia Station<br>
P.O. Box 777<br>
New York, NY 10023-0777<br>
Standby Tickets. Available starting at 8am, and given out on a first-come first-served basis. </p>

<p align=center><img src="gifs/turqu.gif" width=400 height=2></p><br>

<p align=center><b>Geraldo</b><br>
CBS&nbsp;Television<br>
524 W. 57th Street<br>
New York, NY&nbsp;10019<br>
212 265-1283<br>
Tapings take place Tuesday through Thursday at 1pm and 3pm. For ticket requests for up to 10 people, call the above number or send a letter with a stamped, self-addressed envelope; expect a one-month wait. Standby tickets are sometimes available at 530 W. 57th Street, one hour before taping.<br>

<p align=center><img src="gifs/turqu.gif" width=400 height=2></p><br>

<p align=center><b><a 
HREF="http://www.nbc.com/entertainment/shows/snl/">Saturday
Night Live</a></b><br>
The legendary SNL show broadcasts out of the G.E. building at 30 Rockefeller Center. Tickets, available in August only, have already been sold for the season making standby tickets the only available option. <br>
Mail Request.<br>
Sold out for the season, see Standby tickets. <br>
<b>Standby Tickets</b><br>
Available starting 9:15 am at the G.E. building on the 49th Street side, and given out on a first-come first-served basis. Tickets are available for either
the dress-rehearsal or the live show, with the latter being more 
scarce.<br>
You must be at least 16 years old. </p>

<p align=center><img src="gifs/turqu.gif" width=400 height=2></p><br>

<p align=center><b>Rolonda Watts</b><br>
For show ideas and comments, send mail to:<br>
The Rolonda Show<br>
1456 E. 2nd Ave.<br>
Suite 202<br>
New York, New York<br>
To be a guest on the show, call:<br>
1-800-4RO-SHOW (1-800-476-7469)<br>
For ticket information, call:<br>
1-800-650-2060<br>
in New York, 212 650-2060</p>

<p align=center><img src="gifs/turqu.gif" width=400 height=2></p><br>

<p align=center><b><a HREF="http://www.kmsp.com/montel.html">Montel
Williams</a></b><br>
To be a guest, call:<br>
1-800-MONTEL2 (1-800-666-8352)<br>
For complimentary tickets, call: 1-212-560-3003<br>
For show ideas and comments, call: 1-900-933-3900<br>
75 cents per minute</p>

<p align=center><img src="gifs/turqu.gif" width=400 height=2></p><br>

<p align=center>Interested in being a guest? Try the <a 
HREF="http://ourworld.compuserve.com/homepages/ntsgr/">National
Talk Show Guest Registry.</a><br>
<br>
<i>Information taken in part from NYC&nbsp;Access,
ACCESSPRESS, 1994</i><br>
<br>
<i>and from</i><br>
<br>
<i><a 
HREF="http://www.cs.indiana.edu/hyplan/bodom/talkinfo.html">&quot;How
To Get In Contact With Talk Shows&quot;</a> </i></p></font>

<p align=center><img src="gifs/turqu.gif" width=400 height=2></p>

<center><table>
<tr>
<td align=center><a href="links.html"><img src="gifs/left.gif" vspace=5><br>
<font size=-1>Links</font></a></td>
<p>
<td><br></td>
<td align=center><a href="index.html"><img src="gifs/left.gif" vspace=5><br>
<font size=-1>Home</font></a></td></tr></table></center>

<p align=center><img src="gifs/turqu.gif" width=400 height=2></p>

<p align=center><font size=-2>Page compiled by <a href="mailto:kdun@nyam.org">Kathel Dunn</a><br>
<a href="mailto:alanyc@nyam.org">ALA Conference '96</a><br>
New York City<br>
last modified 3/1p/96</font></p>

</body>
</html>

</body>
</html>




</DOC>
<DOC>
<DOCNO>WT18-B31-179</DOCNO>
<DOCOLDNO>IA093-001001-B044-353</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/thread-images/ 199.29.141.24 19970121115759 text/html 5454
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:52:07 GMT
Server: NCSA/1.5.1
Content-type: text/html
</DOCHDR>
<HEAD><TITLE>Index of /thread-images/</TITLE></HEAD><BODY>
<H1>Index of /thread-images/</H1>
<PRE><IMG SRC="/icons/blank.xbm" ALT="     "> Name                   Last modified     Size  Description
<HR>
<A HREF="/"><IMG SRC="/icons/menu.xbm" ALT="[DIR]"></A> <A HREF="/">Parent Directory</A>       19-Mar-96 14:45      -  
<A NAME="approve.gif" HREF="approve.gif"><IMG SRC="/icons/image.gif" ALT="[IMG]"></A> <A NAME="approve.gif" HREF="approve.gif">approve.gif</A>            19-Mar-96 14:51     1K  
<A NAME="delete.gif" HREF="delete.gif"><IMG SRC="/icons/image.gif" ALT="[IMG]"></A> <A NAME="delete.gif" HREF="delete.gif">delete.gif</A>             19-Mar-96 14:51     1K  
<A NAME="delold.gif" HREF="delold.gif"><IMG SRC="/icons/image.gif" ALT="[IMG]"></A> <A NAME="delold.gif" HREF="delold.gif">delold.gif</A>             19-Mar-96 14:51     1K  
<A NAME="edit.gif" HREF="edit.gif"><IMG SRC="/icons/image.gif" ALT="[IMG]"></A> <A NAME="edit.gif" HREF="edit.gif">edit.gif</A>               19-Mar-96 14:51     1K  
<A NAME="grp-up.gif" HREF="grp-up.gif"><IMG SRC="/icons/image.gif" ALT="[IMG]"></A> <A NAME="grp-up.gif" HREF="grp-up.gif">grp-up.gif</A>             19-Mar-96 14:51     1K  
<A NAME="help.gif" HREF="help.gif"><IMG SRC="/icons/image.gif" ALT="[IMG]"></A> <A NAME="help.gif" HREF="help.gif">help.gif</A>               19-Mar-96 14:51     1K  
<A NAME="help.html" HREF="help.html"><IMG SRC="/icons/text.gif" ALT="[TXT]"></A> <A NAME="help.html" HREF="help.html">help.html</A>              19-Mar-96 14:51     7K   net.Thread Help
<A NAME="lessdet-gray.gif" HREF="lessdet-gray.gif"><IMG SRC="/icons/image.gif" ALT="[IMG]"></A> <A NAME="lessdet-gray.gif" HREF="lessdet-gray.gif">lessdet-gray.gif</A>       19-Mar-96 14:51     1K  
<A NAME="lessdet.gif" HREF="lessdet.gif"><IMG SRC="/icons/image.gif" ALT="[IMG]"></A> <A NAME="lessdet.gif" HREF="lessdet.gif">lessdet.gif</A>            19-Mar-96 14:51     1K  
<A NAME="logo.gif" HREF="logo.gif"><IMG SRC="/icons/image.gif" ALT="[IMG]"></A> <A NAME="logo.gif" HREF="logo.gif">logo.gif</A>               19-Mar-96 14:51     2K  
<A NAME="logout.gif" HREF="logout.gif"><IMG SRC="/icons/image.gif" ALT="[IMG]"></A> <A NAME="logout.gif" HREF="logout.gif">logout.gif</A>             19-Mar-96 14:51     1K  
<A NAME="moredet.gif" HREF="moredet.gif"><IMG SRC="/icons/image.gif" ALT="[IMG]"></A> <A NAME="moredet.gif" HREF="moredet.gif">moredet.gif</A>            19-Mar-96 14:51     1K  
<A NAME="msg-up.gif" HREF="msg-up.gif"><IMG SRC="/icons/image.gif" ALT="[IMG]"></A> <A NAME="msg-up.gif" HREF="msg-up.gif">msg-up.gif</A>             19-Mar-96 14:51     1K  
<A NAME="new.gif" HREF="new.gif"><IMG SRC="/icons/image.gif" ALT="[IMG]"></A> <A NAME="new.gif" HREF="new.gif">new.gif</A>                19-Mar-96 14:51     1K  
<A NAME="nextmsg-gray.gif" HREF="nextmsg-gray.gif"><IMG SRC="/icons/image.gif" ALT="[IMG]"></A> <A NAME="nextmsg-gray.gif" HREF="nextmsg-gray.gif">nextmsg-gray.gif</A>       19-Mar-96 14:51     1K  
<A NAME="nextmsg.gif" HREF="nextmsg.gif"><IMG SRC="/icons/image.gif" ALT="[IMG]"></A> <A NAME="nextmsg.gif" HREF="nextmsg.gif">nextmsg.gif</A>            19-Mar-96 14:51     1K  
<A NAME="post-gray.gif" HREF="post-gray.gif"><IMG SRC="/icons/image.gif" ALT="[IMG]"></A> <A NAME="post-gray.gif" HREF="post-gray.gif">post-gray.gif</A>          19-Mar-96 14:51     1K  
<A NAME="post.gif" HREF="post.gif"><IMG SRC="/icons/image.gif" ALT="[IMG]"></A> <A NAME="post.gif" HREF="post.gif">post.gif</A>               19-Mar-96 14:51     1K  
<A NAME="prevmsg-gray.gif" HREF="prevmsg-gray.gif"><IMG SRC="/icons/image.gif" ALT="[IMG]"></A> <A NAME="prevmsg-gray.gif" HREF="prevmsg-gray.gif">prevmsg-gray.gif</A>       19-Mar-96 14:51     1K  
<A NAME="prevmsg.gif" HREF="prevmsg.gif"><IMG SRC="/icons/image.gif" ALT="[IMG]"></A> <A NAME="prevmsg.gif" HREF="prevmsg.gif">prevmsg.gif</A>            19-Mar-96 14:51     1K  
<A NAME="purge.gif" HREF="purge.gif"><IMG SRC="/icons/image.gif" ALT="[IMG]"></A> <A NAME="purge.gif" HREF="purge.gif">purge.gif</A>              19-Mar-96 14:51     1K  
<A NAME="reject.gif" HREF="reject.gif"><IMG SRC="/icons/image.gif" ALT="[IMG]"></A> <A NAME="reject.gif" HREF="reject.gif">reject.gif</A>             19-Mar-96 14:51     1K  
<A NAME="reply.gif" HREF="reply.gif"><IMG SRC="/icons/image.gif" ALT="[IMG]"></A> <A NAME="reply.gif" HREF="reply.gif">reply.gif</A>              19-Mar-96 14:51     1K  
<A NAME="settings.gif" HREF="settings.gif"><IMG SRC="/icons/image.gif" ALT="[IMG]"></A> <A NAME="settings.gif" HREF="settings.gif">settings.gif</A>           19-Mar-96 14:51     1K  
<A NAME="thread-gray.gif" HREF="thread-gray.gif"><IMG SRC="/icons/image.gif" ALT="[IMG]"></A> <A NAME="thread-gray.gif" HREF="thread-gray.gif">thread-gray.gif</A>        19-Mar-96 14:51     1K  
<A NAME="thread.gif" HREF="thread.gif"><IMG SRC="/icons/image.gif" ALT="[IMG]"></A> <A NAME="thread.gif" HREF="thread.gif">thread.gif</A>             19-Mar-96 14:51     1K  
<A NAME="undelete.gif" HREF="undelete.gif"><IMG SRC="/icons/image.gif" ALT="[IMG]"></A> <A NAME="undelete.gif" HREF="undelete.gif">undelete.gif</A>           19-Mar-96 14:51     1K  
<A NAME="up-gray.gif" HREF="up-gray.gif"><IMG SRC="/icons/image.gif" ALT="[IMG]"></A> <A NAME="up-gray.gif" HREF="up-gray.gif">up-gray.gif</A>            19-Mar-96 14:51     1K  
</PRE></BODY>
</DOC>
<DOC>
<DOCNO>WT18-B31-180</DOCNO>
<DOCOLDNO>IA093-001001-B044-369</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/thread.html 199.29.141.24 19970121115812 text/html 418
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:52:14 GMT
Server: NCSA/1.5.1
Last-modified: Tue, 19 Mar 1996 20:49:09 GMT
Content-type: text/html
Content-length: 236
</DOCHDR>
<TITLE>Public Health Search Form</TITLE>
<H1>Public Health and Medicine Search Form</H1>
<I>This is only a test system</I>
<FORM METHOD="POST" ACTION="/cgi-bin/net.Thread.pl">
<HR>
<BR>
<INPUT TYPE="SUBMIT" VALUE="Search">
</FORM>
<hr>
</DOC>
<DOC>
<DOCNO>WT18-B31-181</DOCNO>
<DOCOLDNO>IA093-001001-B044-381</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/ttest.html 199.29.141.24 19970121115821 text/html 303
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:52:28 GMT
Server: NCSA/1.5.1
Last-modified: Wed, 04 Sep 1996 21:56:57 GMT
Content-type: text/html
Content-length: 121
</DOCHDR>
<html>
<body>

<a href="tn3270://cdappa">A Application</a>

<a href="tn3270://cdappb">B Application</a>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-182</DOCNO>
<DOCOLDNO>IA093-001001-B044-394</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/a-t/about.html 199.29.141.24 19970121115829 text/html 3595
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:52:37 GMT
Server: NCSA/1.5.1
Last-modified: Sat, 18 Jan 1997 18:55:42 GMT
Content-type: text/html
Content-length: 3412
</DOCHDR>
<html>
<head>
<title>About Able Together</title>
</head>
<body background="gifs/stripe.gif" link="#3232cd" vlink="#c0c0c0"><font face="comic sans ms, century gothic">

<table>
<tr valign=top>
<td align=center><a href="index.html"><img src="gifs/ablelogo.gif" border=0></a><br><font face="comic sans ms, century gothic" color="#ffffff" size=+2><b>about A-T</b></font><br><a href="index.html"><img src="gifs/home.gif" alt="Able-Together" border=0></a><br>
<a href="guest.html"><img src="gifs/guest.gif" alt="sign our guestbook!" border=0></a><br>
<a href="library.html"><img src="gifs/library.gif" alt="library" border=0></a><br>
<a href="new.html"><img src="gifs/new.gif" alt="what's new" border=0></a><br>
<a href="bb.html"><img src="gifs/bb.gif" alt="bulletin board" border=0></a><br>
<a href="meeting.html"><img src="gifs/meeting.gif" alt="meeting place" border=0></a><br>
<a href="resources.html"><img src="gifs/resources.gif" alt="resources on- and off-line" border=0></a><br>
<a href="people.html"><img src="gifs/people.gif" alt="people on the web" border=0></a><br>
<a href="subscribe.html"><img src="gifs/subscribe.gif" alt="subscribe to A-T!" border=0></a><br>
<a href="gallery.html"><img src="gifs/gallery.gif" alt="sexy pictures" border=0></a><br>
<a href="forums.html"><img src="gifs/forums.gif" alt="discussion forums" border=0></a><br>
<a href="work.html"><img src="gifs/work.gif" alt="your site/your work" border=0></a><br>
<a href="news.html"><img src="gifs/news.gif" alt="in the news" border=0></a><br><br><font face="arial, helvetica" size=-1 color="#ffffff"><b>pages modified: 1/11/97 <br><a
href="mailto:blaine@well.com">blaine@well.com</a><br>
&#169 1997 A-T</b></font></td>
<td><font face="comic sans ms, century gothic" color="#236b8e"><blockquote><p>Able Together is a quarterly international newsletter serving gay and bisexual disabled and disability-aware nondisabled men; A-T's Winter, Spring, Summer and Fall issues are published out of San Francisco, California at the end of the months of January, April, July and October. A-T has postal subscribers across the US and in Canada, the UK and elsewhere across the globe. You can buy A-T at certain gay/progressive bookstores across the US, and also in the UK.</p>

<p>You can <a href="subscribe.html">subscribe</a>! Your subscription for one year entitles you to a personal ad which will run for the length of your subscription.</p>

<p>Able-Together <i>is</i> its subscribers. Subscribers contribute letters, poems, opinions, artwork, articles &amp; bulletin board items, and help with outreach locally.We hope this web site will continue in the same tradition, and that you will contribute your work - photography, poems, fiction, reviews. And <a href="guest.html">let us know</a> what you'd like to see here, if you like what you see, and if you don't. <a href="forums.html">Forums</a> on subjects of interest to men with disabilites are another place to contribute you thoughts and voice your concerns.</p>

<p>Able-Together is co-edited by Michael Maurillo, who is spinal-injured, and Peter Hegedus, who is nondisabled; A-T seeks to bridge the gaps which our socialization has created from a perspective emphasizing the generation of positive feeling and experience in men's relationships. The contributing editor is Blaine Waterman and the Web Manager is Joel Beard.</p>
</blockquote></font>
</td>
</tr>
</table>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-183</DOCNO>
<DOCOLDNO>IA093-001001-B045-195</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/Architext/aidsnycquery.html 199.29.141.24 19970121120219 text/html 1679
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:56:27 GMT
Server: NCSA/1.5.1
Last-modified: Thu, 16 Jan 1997 01:33:50 GMT
Content-type: text/html
Content-length: 1496
</DOCHDR>
<html>
<head>
<title>www.aidsnyc.org: Architext Querying</title>
</head>
<body background="gifs/strip.gif" width=1008 height=36 link="#8b2323" vlink="#696969"><font face="arial, helvetica" size=-1>

<p align=center><font size=+2><a href="../index.html"><b>www.aidsnyc.org</b></a></font>

<p align=center><img src="../gifs/purple.gif" height=4 width=500  align=center alt=""></p>

<blockquote>
<FORM ACTION="/cgi-bin/aidsnycsearch.cgi" METHOD="POST">
<p>Enter
<ul>
<dt><INPUT TYPE="radio" NAME="mode" VALUE="concept" CHECKED> words describing a concept or
<dt><INPUT TYPE="radio" NAME="mode" VALUE="simple"> keywords you wish to find information about:</p>

<center><table><tr>
<td><TEXTAREA NAME="search" COLS=50 ROWS=3></TEXTAREA></td>
</tr><tr>
<td align=center><INPUT TYPE="image" NAME="SearchButton" BORDER=0 SRC="pictures/AT-search_button.gif">
<INPUT TYPE="hidden" NAME="sp" VALUE="sp"></td>
</tr></table></center>
</FORM>

<p> Documentation about <a href="/Architext/AT-queryhelp.html">making queries</a> is available.<p>

<p>If you plan on making multiple queries, you might wish to make a bookmark for this page.

</blockquote>

<p align=center><img src="../gifs/purple.gif" height=4 width=500  align=center alt=""></p>

<p align=center><a href="../index.html"><img src="../gifs/wturn.gif" vspace=5 vspace=5><br>
<b>www.aidsnyc.org</b></a></p>

<p align=center><b>last modified: 1/15/97<br>
write to: <a href="mailto:hivinfo@aidsnyc.org">hivinfo@aidsnyc.org</a></b></p>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-184</DOCNO>
<DOCOLDNO>IA093-001001-B045-210</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/acqc/index.html 199.29.141.24 19970121120226 text/html 4594
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:56:34 GMT
Server: NCSA/1.5.1
Last-modified: Wed, 08 Jan 1997 14:31:20 GMT
Content-type: text/html
Content-length: 4411
</DOCHDR>
<html>
<head>
<title>AIDS CENTER OF QUEENS COUNTY</title>
</head>

<body background="gifs/pad.gif"><font face="arial, helvetica" size=-1>


<p align=center><img src="gifs/logo.gif" alt="[logo]"></p>

<blockquote>

<p>The <b>AIDS Center of Queens County</b> (ACQC) provides comprehensive social services for Queens residents with HIV infection or AIDS, their families, partners and caregivers. Our services are provided in English or Spanish and include:</p>

<ul>
<li><b><A HREF="case.html">Case Management</A></b>:  Help with benefits, entitlements, advocacy and referral for services in the community.

<p>

<li><b>Clinical Services</b>:  The Counseling Center of Queens County was established by the AIDS Center of Queens County in 1995 to provise a comprehensive scope of outpatient mental health services that are sensitive to the diverse cultural, language and life style needs of residents of New York City.  Among the services offered to individuals, families and caregivers are: 
<br>
<ul>
<li>Assessment and Evaluation
<li>Crisis Intervention
<li>Problem-focused Intervention
<li>Individual, Family and Couples Therapy
<li>Short and Long Term Groups
</ul>
<br>
<li><b>Chemical Dependency Counseling</b> for HIV+ individuals and their families.
<p>
<li><b>Legal Services</b>:  Consultation on HIV and AIDS related legal issues.
<p>
<li><b> Volunteers</b> support the Agency's clients and paid staff.
<p>
<li><b>Information workshops</b> and seminars on a variety of HIV related topics. 
<p>
<li><b>Education about HIV/AIDS</b> for the Queens community is provided through formal presentations, in-service training, outreach and educational material.
</ul>

<p>To become a client of ACQC, please call for an intake appointment.  During this interview, we will discuss your needs and begin to provide you with our services.  Intake appointments are usually available within a few days of your call.</p>

<center><table width=90% cellpadding=6 colspecs="50% 50%">
<tr>
<td colspan=2>Call us at the office which is most convenient for you:</td>
</tr><p><tr valign=top>
<td>97-45 Queens Blvd, Suite 1220<br>
Rego Park, N.Y. 11374<br>
phone: (718) 896-2500<br>
fax:  (718) 275-2094<br>
e-Mail: <a href="mailto:76325.3422@compuserve.com">76325.3422@compuserve.com</a></td>
<p>
<td>175-61 Hillside Avenue, Suite 403<br>
Jamaica, N.Y. 11432<br>
phone:  (718) 739-2525<br>
fax: (718) 739-2552</td>
</tr><p><tr valign=top>
<td>21-17 Mott Ave., 5th Floor<br>
Far Rockaway, N.Y. 11691<br>
phone: (718) 868-8645<br>
fax: (718) 868-8436</td>
<p>
<td><b>Hearing Impaired Phone</b>:<br>
(718) 896-2985</td>
</tr></table></center>

<hr size=1 width=50% align=center noshade>
<ul>
<li><A HREF="holiday.html"><b>Annual holiday party - Join us!</b></A>
<p>
<li><a href="wills.html"><b>About Health Care Proxies and Living Wills</b></a> <font size=-1>(added 9/10/96)</font>
<p>
<li><a href="proxy.html"><b>Health Care Proxy for New York State</b></a>
<dt>ACQC provides this Health Care Proxy and Advanced Care Directive for New York State. You may print out a copy and fill in the required information. Having a Health Care Proxy in your files can help you be prepared for hospitalization, should it become necessary. A Proxy is the person you assign to make medical decisions for you, based on your wishes as defined in this document, should you be unable to make your wishes known. 
<p>
<dt>Each state has their own Health Care Proxy and Advanced Directive requirements. Please check the <a href="http://www.echonyc.com/~choice/">Choice in Dying</a> site for free downloadable state-specific advance directive packages.<font size=-1>(added 9/3/96)</font>
</ul>

<hr size=1 width=50% align=center noshade>
<p align=center><a href="../index.html"><img src="gifs/wturn.gif"><br>
<b>www.aidsnyc.org</b></a></p>
<hr size=1 width=50% align=center noshade>

<table width=90%>
<tr valign=top>
<td><font face="helvetica, arial" size=-1>ACQC<br>
copyright &#169; 1996 <br>
<a href="mailto:76325.3422@compuserve.com">76325.3422@compuserve.com</a><br>
Last modified: 10/29/96</font></td>
<p>
<td align=right><font face="helvetica, arial" size=-1>The ACQC site is part of <a href="../index.html"><b>www.aidsnyc.org</b></a>. <br>These pages are designed and maintained <br>by Joel Beard courtesy of the <br><a href="../network/index.html"><b>AIDS Treatment Data Network</b></a>.</font></td></tr>
</table>

</blockquote>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-185</DOCNO>
<DOCOLDNO>IA093-001001-B045-224</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/aip/index.html 199.29.141.24 19970121120241 text/html 1947
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:56:49 GMT
Server: NCSA/1.5.1
Last-modified: Wed, 08 Jan 1997 14:32:17 GMT
Content-type: text/html
Content-length: 1764
</DOCHDR>
<html>
<head>
<title>AIDS in Prison Project</title>
<meta name="description" content="The AIDS in Prison Project provides information and support for HIV+ prisoners, including discharge planning and referrals.">
<meta name="keywords" content="HIV, AIDS, prisoners, inmates, discharge, Spanish, referrals">
</head>
<body background="gifs/purple.gif" text="#ffffff" link="#ffffff" vlink="#4f9eaf"><font face="helvetica, arial" size=-1>

<center><table>
<tr>
<td><img src="gifs/aip.gif" align=left hspace=20 alt="[AIDS in Prison logo]"></td>
<td><font face="arial, helvetica" size=-1><b><a href="about.html">about the aids in prison project</a><br><br>
<a href="allia.html">alliance for inmates with aids</a><br><br>
<a href="cambio.html">cambios y alternativas</a> | <a href="changes.html">changes &amp; choices</a><br><br>
<a href="discharg.html">discharge planning</a><br><br>
<a href="facts.html">facts sheet</a><br><br>
<a href="well.html">LIVING-Well</a> | <a href="wellsp.html">en espa&ntilde;ol</a><br><br><a href="links.html">other resources</a><br><br>
<a href="osborne.html">other services of the osborne assocation</a></b>
</font></td></tr></table></center>
<table><tr><td><br><br></td></tr></table>
<table width=100%>
<tr valign=top>
<td><font size=-1 face="arial, helvetica"><b>pages modified: 11/24/96<br>
copyright &#169; 1966 <br>
<a href="mailto:osborne@aidsnyc.org">Osborne Association</a></b></font></td>
<td align=right><font size=-1 face="arial, helvetica"><b>The AIDS in Prison Project site is part of <a href="../index.html">www.aidsnyc.org</a>.<br>These pages are designed and maintained by Joel Beard <br>courtesy of the <a href="../network/index.html">AIDS Treatment Data Network</a>.</b></font></td>
</tr></table>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-186</DOCNO>
<DOCOLDNO>IA093-001001-B045-235</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/guide.html 199.29.141.24 19970121120249 text/html 7207
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:56:57 GMT
Server: NCSA/1.5.1
Last-modified: Wed, 08 Jan 1997 14:30:32 GMT
Content-type: text/html
Content-length: 7024
</DOCHDR>
<html>
<head>
<title>aidsnyc: guide to sites</title>
</head>

<body bgcolor="#ffffff" link="#8b2323" vlink="#696969"><font face="arial, helvetica">

<blockquote>

<p align=center><img src="gifs/purple.gif" height=4 width=500 alt=""></p>

<h3 align=center><a href="index.html">www.aidsnyc.org</a> provides a linked collection of information relevant to people living with HIV and AIDS from community based organizations in New York City. </h3>

<p><a href="new.html"><b>What's New</b></a> lists new pages/information added to www.aidsnyc.org with dates when they were installed on the server.</p>

<p><a href="congress.html"><b>Action Alerts</b></a> links to activist organization pages and e-mail to congress persons.</p>

<p><a href="updates.html"><b>Vancouver Updates</b></a> links to sites posting reports from the XI Internation AIDS Conference in Vancouver, July 7-12, 1996.</p>

<p>The <a href="acqc/index.html"><b>AIDS Center of Queens County (ACQC)</b></a> provides comprehensive social services for Queens residents with HIV infection or AIDS, their families, partners and caregivers. Services provided in English or Spanish.</p>

<p>The <a href="aip/index.html"><b>AIDS in Prison Project</b></a> established the first AIDS/HIV Clearinghouse and Free Bilingual Hotline for prisoners and former prisoners in 1992. Information on: AIDS/HIV prevention &amp; treatment, discharge planning, inmate support groups, and medical parole, as well as other services of the Osborne Assocation and Resource Links.</p>

<p>The <a href="network/index.html"><b>AIDS Treatment Data Network</b></a> site has information about clinical trials, drug descriptions, patient drug assistance programs, issues of their newsletter Treatment Review, a glossary of drugs, a glossary of opportunistic infections and more. A good source of information about treatments and clinical trials.</p>

<p><a href="cwha/index.html"><b>Caribbean Women's Health Association</b></a> programs include HIV/AIDS Education and Case Management, Comprehensive Immigration Services, Maternal Child Health Services and Substance Abuse Prevention.

<p>The <a href="cdn/index.html"><b>Clinical Directors Network</b></a> coordinates research and educational programs for member community health centers in New York, New Jersey, Puerto Rico and the Virgin Islands. The HIV/AIDS Program offers clinical trials in New York City and New Jersey, based in community health centers, that aim to improve the quality of health care for HIV+ patients.</p>

<p><a href="berridge/index.html"><b>Coming Into View: Women, Families &amp; AIDS</b></a> is a gallery of photographs by Mary Berridge.</p>

<p>The <a href="cnews/index.html"><b>Consumer Information &amp; Conflict Resolution Project</b></a> publishes a monthly newsletter, <b>Consumer News</b>, written by and for people living with HIV/AIDS. Includes information about supportive housing, advocacy, nutrition, case management, and more.</p>

<p><a href="arrive/index.html"><b>Exponents Arrive's</b></a> peer based programs create a sense of community among substance users to provide outreach, education and support. Exponents' advocates that former users play a role in the fight against AIDS and drug abuse.</p>

<p>The mission of <a href="fc/index.html"><b>The Family Center</b></a> is to strengthen children and their families as they move through the transitions caused by the loss of a parent. Descriptions of Programs, Publications, and Resources. <font size=-1>(added 11/18/96)</font></p>

<p><a href="glwd/index.html"><b>God's Love We Deliver</b></a> delivers hot meals to people homebound due to AIDS. Their site includes Eating Tips in English and Spanish, food guides in English, Spanish and French, and an Eating Modifications chart. <font size=-1>(added 7/5/96)</font></p>

<p><a href="heal/index.htm"><b>H.E.A.L.</b></a> Health Education Alternatives Liaison challenges the HIV/AIDS hypothesis and HIV-based treatment protocols. Information on non-toxic, natural and holistic approaches to recovering and maintaining health. <font size=-1>(added 9/8/96)</font></p>

<p>The <a href="momentum/index.html"><b>Momentum AIDS Project</b></a> is the only community-based organization that provides communal meals and supportive services to New Yorkers with HIV and their families. Facts sheets, nutrition information, volunteer program and more. <font size=-1>(added 10/16/96)</font></p>

<p>The <a href="natap/index.html"><b>National AIDS Treatments Advocacy Project</b></a> advocates for early access to promising treatements. Reports from conferences, FDA hearings, papers about protease inhibitor development and approval, viral load tests, and other drug approval procedures.</p>

<p>The <a href="ai/index.html"><b>New York State Department of Health AIDS Institute</b></a> distributes information about prevention and treatment to clinicians and people living with HIV and AIDS.</p>

<p><a href="orphan/index.html"><b>The Orphan Project</b></a> was established in 1991 to explore policy options to meet the needs of the entire spectrum of affected children -- from dying infants to healthy adolescents.</p>

<p>The <a href="pwac/index.html"><b>People With AIDS Coalition/New York</b></a> publishes their newsletter, PWAC/NY Newsline. Includes letters from prisoners living with HIV/AIDS, poems and personal articles about coping and grief, reviews of the latest drug approvals, and more.</p>

<p>The <a href="pwahg/index.html"><b>PWA Health Group</b></a>, a buyers club in New York, publishes information sheets about medications including thalidomide and SSKT, and their newsletter, Notes from the Underground.</p>

<p><a href="rtrp/index.html"><b>Real Treatments for Real People: Nutrition Index</b></a> provides information about buyers clubs, a guide to micronutrients, vitamins and nutrition, and important contact numbers.</p>

<p>The <a href="siatf/index.html"><b>Staten Island AIDS Task Force</b></a> is Staten Island's only HIV/AIDS organization, providing client services, a resource room, support groups, volunteer opportunities and more.</p>

<p align=center><img src="gifs/purple.gif" height=4 width=250  align=center alt=""></p>

<p align=center>www.aidsnyc.org is an <a href="about.html">HIV/AIDS Information Outreach Project</a> and is housed on the <a href="http://www.nyam.org/index.html">New York Academy of Medicine</a> server. Site designed and maintained by Joel Beard courtesy of the <a href="network/index.html">AIDS Treatment Data Network</a>. Please <a href="mailto:hivinfo@aidsnyc.org">write us</a> with any comments or questions.</p>

<p align=center><img src="gifs/purple.gif" height=4 width=500  align=center alt=""></p>

<p align=center><a href="index.html"><img src="gifs/wturn.gif" vspace=5 vspace=5><br>
<font size=-1><b>www.aidsnyc.org</b></font></a></p>

<p align=center><font size=-1>www.aidsnyc.org<br>
last modified: 11/24/96<br>
write to: <a href="mailto:hivinfo@nyam.org">hivinfo@nyam.org</a><br>
copyright &#169; 1996 www.aidsnyc.org</font></p>

</body>
</html>


</DOC>
<DOC>
<DOCNO>WT18-B31-187</DOCNO>
<DOCOLDNO>IA093-001001-B045-253</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/index.html 199.29.141.24 19970121120257 text/html 4315
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:57:05 GMT
Server: NCSA/1.5.1
Last-modified: Mon, 20 Jan 1997 18:52:47 GMT
Content-type: text/html
Content-length: 4132
</DOCHDR>
<html>
<head>
<title>AIDS Treatment Data Network</title>
<META  name="description" content="Simple Facts Sheets on treatments and opportunistic infections, directory of enrolling clinical trials, treatment newsletter and glossaries.">
<META  name="keywords" content="aids, clinical trials, opportunistic infections">
</head>
<body bgcolor="#ffffff" link="#00688b" vlink="#545454"><font face="century gothic, arial, helvetica" size=-1>

<center><table border=1 cellpadding=0 cellspacing=0 width=90%>
<tr>
<td rowspan=3 align=center><img border=0 width=209 height=96 src="gifs/logo1.gif" alt="[logo]"></td>
<p>
<td align=center><font face="century gothic, arial, helvetica" size=-1><b>information about treatments for HIV and AIDS</b></font></td>
<p>
<td align=center rowspan=3><font face="century gothic, arial, helvetica" size=+1 color="#0000ff">
<b>AIDS Treatment Data Network</b></font></td>
<p>
</tr>
<tr><td align=center><font face="century gothic, arial, helvetica" size=-1>
<a href="../Architext/aidsnycquery.html"><b>search www.aidsnyc.org</b></a></font></td>
<p>
</tr>
<tr><td align=center><font face="century gothic, arial, helvetica" size=-1>
<b><a href="lared/index.html">informaci&oacute;n en espa&ntilde;ol</a></b></font></td>
<p>
</tr>
<tr>
<td colspan=3 align=center><font face="century gothic, arial, helvetica" size=-1>
The Network is a non-profit community based organization providing <br>treatment counseling and referrals. Our nationwide toll-free number is (800) 734-7104.</font></td>
<p>
</table></center>

<p align=center><A HREF="trials.html"><b>directory of clinical trials</b></a> <br>(updated 12/22/96)</p>

<p align=center><a href="access/index.html"><b>the access project</b></a><br>
reporting on the availability of government and pharmaceutical sponsored <br>AIDS treatments nationwide, includes extensive <a href="access/drugs/index.html">drug index</a> with descriptions <br>
<a href="access/states/ny/drugs.html">New York State ADAP formulary</a> and <a href="access/states/ny/nutrit.html">nutrition supplements</a> restored as of December 1, 1996<br>
(updated 12/16/96)</p>

<p align=center><a href="sf.html"><b>simple facts sheets</b></A><br>(updated 1/20/97)</p>

<p align=center><a href="trs/trs.html"><b>Treatment Review</b></a> <br>(<a href="trs/23.html">new issue</a> added 12/17/96)</p>

<p align=center><a href="news.html"><b>in the news</b></A><br>
<a href="news.html#d4t">d4T/AZT combo in question</a> | <a href="news.html#agouron">Agouron protease inhibitor for children</a><br>
(updated 1/9/97)</p>

<p align=center><a href="phs/table.html"><b>PHS Guidelines</b></a> <br>US Public Health Service/Infectious Diseases Society of America <br>guidelines for the prevention of opportunistic infections</p>

<p align=center><A HREF="drugloss.html"><b>glossary of drugs</b> </a><br>(37K updated 12/16/96)</p>

<p align=center><A HREF="oisgloss.html"><b>glossary of opportunistic infections and conditions</b></A><br>(43K updated 12/2/96)</p>

<p align=center><A HREF="altx.html"><b>alternative treatments</b></A><br>
(updated 6/21/96)</p>

<p align=center><a HREF="links.html"><b>links to HIV/AIDS information on the Web</b></a><br>(updated 1/20/97)</p>

<p align=center><A HREF="member.html"><b>become a Network member</b></A></p>

<hr size=3 width=50% align=center noshade>

<p align=center><a href="tag/tag.html"><b>Treatment Action Group</b></a><br>(modified 7/2/96)</p>

<hr size=3 width=50% align=center noshade>

<table border=0 cellpadding=3 cellspacing=4 width=100%>
<tr>
<td><font size="-1" face="century gothic, arial, helvetica">Last modified: 1/20/97<br>
<a href="mailto:atdn@aidsnyc.org">atdn@aidsnyc.org</a></font></td>
<p>
<td align=center><a href="http://www.healthexplorer.com/"><img src="gifs/bestsite.gif" alt="health explorer bestsite" width=75 height=51></a></td>
<p>
<td align=right><font size=-1 face="century gothic, arial, helvetica">The Network site is part of <a href="../index.html">www.aidsnyc.org</a>. All pages designed <br>and maintained by Joel Beard. copyright &#169; 1996 1997 The Network </font></td>
<p>
</tr>
</table></center>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-188</DOCNO>
<DOCOLDNO>IA093-001001-B045-264</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/cwha/index.html 199.29.141.24 19970121120306 text/html 2219
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:57:14 GMT
Server: NCSA/1.5.1
Last-modified: Wed, 08 Jan 1997 14:37:45 GMT
Content-type: text/html
Content-length: 2036
</DOCHDR>
<html>
<head><title>Caribbean Women's Health Association</title>
</head>
<body bgcolor="#ffffff" text="#3232cd"><font face="arial, helvetica">

<img src="gifs/cwha.gif" border=4 vspace=8 align=left>

<hr size=4 width=50% align=center noshade>

<h5 align=center>COMMUNITY SERVICE CENTER<br>
SERVING<BR>
THE CARIBBEAN - AMERICAN<BR>
COMMUNITY<BR>
AND PROMOTING<BR>
HEALTH CARE SERVICES<BR>
FOR ALL</h5>

<hr size=4 width=50% align=center noshade>

<h5 align=center><a href="aids.html">HIV/AIDS PROGRAM</a></h5>
<h5 align=center><a href="child.html">MATERNAL CHILD HEALTH</a></h5>
<h5 align=center><a href="center.html">IMMIGRATION</a><BR><a href="espanol.html">en espa&ntilde;ol</a> | <a href="servicio.html">servicios</a></h5>
<h5 align=center><a href="about.html">ABOUT CWHA</a></h5>

<center><table border=1><tr valign=top>
<td align=center><font size=-1 face="arial, helvetica">2725 Church Avenue<br>
Brooklyn, N.Y. 11226<br>
Tel. (718) 826-2942<br>
Fax (718) 826-2948</font></td>
<p>
<td align=center><font size=-1 face="arial, helvetica">3312 Church Avenue<br>
Brooklyn, N.Y. 11203<br>
Tel. (718) 940-8386<br>
Fax (718) 940-8394</font></td>
<p>
<td align=center><font size=-1 face="arial, helvetica">1600 Central Avenue<br>
Far Rockaway, N.Y. 11691<br>
Tel. (718) 868-4746<br>
Fax# (718) 327-4173</font></td>
<p>
<td align=center><font size=-1 face="arial, helvetica">221-10 Jamaica Avenue<br>
Suite 202<br>
Queens Village, N.Y. 11428<br>
Tel. (718) 468-4454<br>
Fax (718) 468-5001</td>
</tr></table></center>

<p>

<table border=0 width=100%>
<tr>
<td><font size=-1 face="arial, helvetica">Page last modified: 4/17/96<br> &#169; 1996 CWHA <br>
<a href="mailto:hivinfo@aidnsyc.org">hivinfo@aidnsyc.org</a></font></td>
<td align=right><font size=-1 face="arial, helvetica">These pages are part of <a href="../index.html"><b>www.aidsnyc.org</b></a>. <br>These pages are designed and maintained by Joel Beard <br>courtesy of the <a href="../network/index.html"><b>AIDS Treatment Data Network</b></a>.</td>
</tr>
</tr></table></center>
</DOC>
<DOC>
<DOCNO>WT18-B31-189</DOCNO>
<DOCOLDNO>IA093-001001-B045-276</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/new.html 199.29.141.24 19970121120313 text/html 9644
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:57:21 GMT
Server: NCSA/1.5.1
Last-modified: Fri, 17 Jan 1997 17:14:53 GMT
Content-type: text/html
Content-length: 9461
</DOCHDR>
<html>
<head>
<title>www.aidsnyc.org: what's new</title>
</head>

<body bgcolor="#ffffff" link="#8b2323" vlink="#696969"><font face="arial, helvetica" size=-1>

<p align=center><img src="gifs/purple.gif" height=4 width=500  align=center alt=""></p>

<h2 align=center>What's new on <a href="index.html">www.aidsnyc.org</a>?</h2>

<blockquote>
<p><font size=-0><a href="index.html"><b>www.aidsnyc.org</b></a></font></p>
<ul>
<li>Links to reports from <a href="retrov.html">The 4th Conference on Retroviruses &amp; Opportunistic Infections</a>, January 22-26, Sheraton Washington Hotel (1/17/97)
<li><a href="docorder.html">Free document delivery services</a> from the HIV/AIDS Information Outreach Project. (12/31/96)
<li><a href="congress.html#pres">Presidential Advisory Council On HIV/AIDS PROGRESS REPORT</a> (7/15/96)
<li><a href="updates.html">Vancouver Updates</a> links to sites posting reports from the XI Int'l Conference on AIDS (7/5/96)
<li>a <a href="Architext/aidsnycquery.html">search engine</a> will return pages on all sites based on your request (6/27/96)
<li><a href="congress.html">Action Alerts page</a> and how to contact your representatives. (6/27/96)
</ul>

<p><font size=-0><a href="acqc/index.html"><b>AIDS Center of Queens County (ACQC)</b></a></font></p>
<ul>
<li><A HREF="acqc/holiday.html">Holiday invite</A> and description of <A HREF="acqc/case.html">case management services</A> (10/29/96)
<li><a href="acqc/proxy.html">Living Will &amp; Advanced Directive, New York State</a> (9/3/96)
<li><a href="acqc/wills.html">About health care proxies and living wills</a> (9/10/96)
</ul>

<p><font size=-0><a href="aip/index.html"><b>AIDS in Prison Project</b></a></font> (11/24/96)</p>

<p><font size=-0><a href="network/index.html"><b>AIDS Treatment Data Network</b></a></font></p>
<ul>
<li><a href="network/news.html#agouron">Agouron applies for FDA approval of protease inhibitor for children</a> (1/9/97)
<li>Trials for treatment of <a href="network/trials/crypto.html">cryptosporidiosis</a>, <a href="network/trials/micro.html">microsporidiosis</a>, <a href="network/trials/mac.html">MAC</a>, <a href="network/trials/neurop.html">neuropathy</a>, <a href="network/trials/pain.html">pain</a>, <a href="network/trials/pml.html">PML</a>, <a href="network/trials/tbtx.html">TB</a>, <a href="network/trials/wasting.html">wasting</a> and <a href="network/trials/wastprev.html">prevention of weight loss</a>, and treatment of HIV and opportunistic infections in <a href="network/trials/children.html">children</a> (12/22/96)
<li>Trials added for treatment of <A HREF="network/trials/anemia.html">anemia</A>, <A HREF="network/trials/hodlymph.html">Hodgkin's lymphoma</A> and <A HREF="network/trials/ks.html">KS</A> (12/21/96)
<li><a href="network/trs/23.html">Treatment Review Issue #23</a> with article describing combination treatments and study results (12/17/96)
<li>Trials added for <a href="network/trials/hiv.html">treatment of HIV</a> and <a href="network/trials/cmvret.html">CMV retinitis</a>. (12/16/96)
<li>Trials added for treatment of <a href="network/trials/thrush.html">thrush</a>, <a href="network/trials/cervical.html">cervical dysplasia</a>, <a href="network/trials/cmvret.html">CMV retinitis</a>, <a href="network/trials/crypto.html">cryptosporidiosis</a> and <a href="network/trials/cog.html">cognitive impairment</a> (12/12/96)
<li>Trials added for <a href="network/trials/hiv.html">HIV treatment</a> and <a href="network/trials/cmvprev.html">CMV prevention</a>, also <a href="network/trials/vaccines.html">vaccine study for HIV+ participants</a> (12/11/96)
<li>New <a href="network/trials/info.html">information gathering studies</a> (12/2/96)
<li>Changes, additions, deletions to <a href="network/drugloss.html">drug glossary</a> and <a href="network/oisgloss.html">glossary of opportunistic infections &amp; conditions</a> (12/2/96)
</ul>

<p><font size=-0><a href="cwha/index.html"><b>Caribbean Women's Health Association</b></a></font> (5/2/96)</p>

<p><font size=-0><a href="cdn/index.html"><b>Clinical Directors Network</b></a></font> (5/3/96)</p>

<p><font size=-0><a href="berridge/index.html"><b>Coming Into View: Women, Families &amp; AIDS</b></a></font></p>
<ul>
<li>photographs by Mary Berridge (3/29/96)
</ul>

<p><font size=-0><a href="cnews/index.html"><b>Consumer Information &amp; Conflict Resolution Project</b></a></font></p>
<ul>
<li><a href="cnews/conf/mediate.html">&quot;Successful Healthcare Conflict Resolution: Mediation &amp; Negotiation Training&quot;</a> conference description (added 1/15/97)
<li><a href="cnews/news/9701.html">January issue of Consumer News</a> (added 1/15/97)
<li><A HREF="cnews/news/9612.html">December issue of Consumer News</A> (added 12/21/96)
<li><a href="cnews/conf/ada.html">Mediation Training : Employment and the ADA</a> (12/16/96)
<li>Conference announcement <A HREF="cnews/conf/index.html">The 12th Annual Gay and Lesbian Addiction Studies</A> (10/31/96)
<li><A HREF="cnews/news/9610.html">October November double issue</A> (added 109/29/96)
<li><a href="cnews/news/9609.html#housing">Housing article</a> added to September issue (10/13/96)
<li>September issue of <a href="cnews/news/9609.html">Consumer News</a> (updated 9/10/96)
<li><a href="cnews/conf/index.html">Conference listings</a> (9/3/96)
</ul>

<p><font size=-0><a href="arrive/index.html"><b>Exponents Arrive </b></a></font> (added 8/1/96)</p>

<p><font size=-0><a href="fc/index.html"><b>The Family Center </b></a></font> (added 11/18/96)</p>

<ul>
<li><a href="fc/jobs.html">Job postings</a> - <a href="fc/jobs.html#data">data specialist</a> and <a href="fc/jobs.html#para">paralegal/entitlements referrals specialist</a> (11/20/96)
</ul>

<p><font size=-0><a href="glwd/index.html"><b>God's Love We Deliver</b></a></font></p>
<ul>
<li><a href="glwd/dev/mpconf.html">1996 AIDS Meals Providers Conference announcement</a> (8/15/96)
<li><a href="glwd/jobs/nas.html">New job postings</a> and <a href="glwd/master.html">master menu cycle</a> added (8/15/96)
<li><a href="glwd/pubs/ta.html">Technical Assistance Manual</a> description (8/14/96)
</ul>

<p><font size=-0><a href="heal/index.htm"><b>H.E.A.L. (Health Education AIDS Liason)</b></a></font> (added 8/5/96)</p>

<p><font size=-0><a href="momentum/index.html"><b>Momentum AIDS Project</b></a></font> (added 10/16/96)</p>
<ul>
<li>Article on <a href="momentum/herbal.html">New Age Herbalists</a> (1/8/97)
<li>Special Events updated (1/2/97)
<li><a href="momentum/special.html">Special Events announcements</a> and <a href="momentum/staffpro.html">Staff Profiles</a> (updated 11/12/96)
</ul>

<p><font size=-0><a href="natap/index.html"><b>National AIDS Treatment Advocacy Project</b></a></font></p>
<ul>
<li><a href="natap/drug/w94.html">141W94 Double Protease Inhibitor Study &amp; Brief Protease Therapy Discussion</a> (1/15/97)
<li><a href="natap/drug/vl.html">Access Programs to Viral Load Testing from Chiron and Roche</a> (1/15/97)
<li><a href="natap/conf/actgmeet.html">AIDS Clinical Trials Group (ACTG) Meeting of December 1996 in Washington, D.C.</a> -- Summary of Proceedings (1/9/97)
<li><a href="natap/drug/rtaztddc.html">Ritonavir plus AZT plus ddC</a> - abstract from <a href="natap/conf/index.html">Birmingham Conference</a> (1/8/97)
<li><a href="natap/drug/rtazt3tc.html">Ritonavir plus AZT plus 3TC</a> - abstract from <a href="natap/conf/index.html">Birmingham Conference</a> (1/8/97)
<li><a href="natap/drug/ritosaqu.html">Ritonavir plus saquinavir</a> - abstract from <a href="natap/conf/index.html">Birmingham Conference</a> (1/8/97)
</ul>

<p><font size=-0><a href="ai/index.html"><b>NYS DOH AIDS Institute</b></a></font></p>
<ul>
<dt><b>Note: AIDS Institute protocols are from August 1995</b>
<li><a href="ai/peds.html">HIV Medical Evaluation and Preventive Care for Children</a> (11/28/96)
<li><A HREF="ai/subs.html">Evaluation and Management of Substance Use</A> protocol (11/15/96)
<li><a href="ai/tb.html">Tuberculosis</a> and <a href="ai/nutrit.html">Nutrition</a> protocols (added 11/9/96)
</ul>

<p><font size=-0><a href="orphan/index.html"><b>The Orphan Project</b></a></font> (3/28/96)</p>
<ul>
<li>Description of <A HREF="orphan/index.html#crisis">Families in Crisis</A> and how to order (11/13/96)
</ul>

<p><font size=-0><a href="pwahg/index.html"><b>PWA Health Group</b></a></font> (4/9/96)</p>
<ul>
<li>Back issues <a href="pwahg/notes.html">#22-29 Notes from the Underground</a> (7/2/96)
<li><a href="pwahg/notas/notas1.html">Notas de la Clandestinidad</a> Junio 1996 Edici&oacute;n en espa&ntilde;ol 1 (6/22/96)
</ul>

<p><font size=-0><a href="rtrp/index.html"><b>Real Treatments for Real People: Nutrition Index</b></a></font></p>
<ul>
<li><a href="rtrp/nutrit.html">alternative nutrition index</a> for those not using Netscape  (8/5/96)
</ul>

<p><font size=-0><a href="siatf/index.html"><b>Staten Island AIDS Task Force</b></a></font> (11/23/96)</p>
<ul>
<li><a href="siatf/info.html">What's the buzz?</a> updated - oral sex and HIV (1/15/97)
</ul>
</blockquote>

<p align=center><img src="gifs/purple.gif" height=4 width=500  align=center alt=""></p>

<p align=center><a href="index.html"><img src="gifs/wturn.gif" vspace=5 vspace=5><br>
<font size=-1><b>www.aidsnyc.org</b></font></a></p>

<p align=center><font size=-1>last modified: 1/17/97<br>
write to: <a href="mailto:hivinfo@aidsnyc.org">hivinfo@aidsnyc.org</a><br>
copyright &#169; 1996 1997 www.aidsnyc.org</b></font></p>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-190</DOCNO>
<DOCOLDNO>IA093-001001-B046-5</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/cdn/index.html 199.29.141.24 19970121120322 text/html 2833
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:57:30 GMT
Server: NCSA/1.5.1
Last-modified: Wed, 08 Jan 1997 14:38:07 GMT
Content-type: text/html
Content-length: 2650
</DOCHDR>
<META  name="description" 
content="Clinical trials for HIV/AIDS and opportunistic infections in the New York City area.">
<META  name="keywords" content="aids, clinical trials, opportunistic infections"><html>
<head>
<title>Clinical Directors Network:  Community Health Centers HIV/AIDS Program</title>
</head>
<body bgcolor="#ffffff" text="#a62a2a" link="#6b8e23" vlink="#696969"><font face="arial, helvetica" size=-1>

<blockquote>

<p><img src="gifs/cdn1.gif" alt=" "><br>
<font size=7>C</font><font size=5>linical</font> <font size=7>D</font><font size=5>irectors</font> <font size=7>N</font><font size=5>etwork</font><br>
<font size=5>Community Health Centers HIV/AIDS Program</font><br>
<img src="gifs/bronze.gif" width=90% height=4 alt=" "></p>

<P><B><A href="studies.html">CLINICAL STUDIES</a></B><BR>
<FONT SIZE=-1>CDN coordinates several research studies at 8 community health centers<BR> in New York City and Newark, NJ, offering access to treatment options<BR> for people with HIV/AIDS in their primary care settings.</p>

<P><B><A href="cabs.html">COMMUNITY ADVISORY BOARDS</a></B><BR>
Community Advisory Boards (CABs) provide input on clinical research<BR>and treatment education in New York City and Newark, NJ. <BR>Be a part of decisions that affect the health of your community.<BR>Find out how you can join a CAB.</p>

<P><B><A href="mission.html">HIV/AIDS PROGRAM MISSION STATEMENT</a></B><BR>
Representing the interests of the HIV infected community.</p>

</blockquote>

<p align=center><img src="gifs/bronze.gif" width=75% height=4 alt=" "></p>
<p align=center><img src="gifs/bronze.gif" width=50% height=3 alt=" "></p>
<p align=center><img src="gifs/bronze.gif" width=25% height=2 alt=" "></p>

<p align=center><a href="mailto:cblum@aidsnyc.org">Clinical Directors Network<BR>
HIV/AIDS Program</a><BR>
8 West 19th Street, 8th floor<br>
New York, NY 10011<br>
Phone: (212) 255-3841<br>
Fax: (212) 255-5227</p>

<p align=center><a href="../index.html"><img src="gifs/wturn.gif" space=2 hspace=5 alt=" "><br><font size=2>www.aidsnyc.org</font></a></P>

<table border=1 cellpadding=3 cellspacing=4 width=100%>
<tr valign=top>
<td><font size=-1 face="arial, helvetica">Last modified 5/1/96<br>
<a href="mailto:cblum@aidsnyc.org">Clinical Directors Network</a><br>
copyright &#169; 1996 CDN</font></td>
<td align=right><font size=-1 face="arial, helvetica">The CDN site is part of <a href="../index.html"><b>www.aidsnyc.org</b></a>. <br>These pages are designed and maintained by Joel Beard <br>courtesy of the <a href="../network/index.html"><b>AIDS Treatment Data Network</b></a>.</font><td></tr></table>
</FONT>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT18-B31-191</DOCNO>
<DOCOLDNO>IA093-001001-B046-24</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/berridge/index.html 199.29.141.24 19970121120329 text/html 1209
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:57:37 GMT
Server: NCSA/1.5.1
Last-modified: Wed, 08 Jan 1997 14:38:53 GMT
Content-type: text/html
Content-length: 1026
</DOCHDR>
<html>
<head>
<title>Coming Into View: Women, Families and AIDS</title>
</head>
<body bgcolor="#ffffff" text="#0000ff" link="#000000" vlink="#70db93"><font face="arial, helvetica" size=-1>

<img src="gifs/berridge.gif" align=left hspace=5>

<p><font size=+2><b>COMING INTO VIEW:</b></font><br>
<font size=+1><b>WOMEN, FAMILIES &amp; AIDS</b></font></p>

<p><font size=+1><b>PHOTOGRAPHS BY<br>
MARY BERRIDGE</b></font></p>

<h4><a href="photos.html">THE PHOTOGRAPHS</a></h4>

<h4><a href="civ.html">ARTIST'S STATEMENT</a></h4>

<p>&#169; 1996 <a href="mailto:hivinfo@nyam.org">Mary Berridge</a><BR>
Last modified: 3/27/96</p>

<p><font size=-1><a href="../index.html">return to www.aidsnyc.org</a></font></p>

<hr width=80% align=left>

<br clear left>

<p><font size=-1>Coming Into View is part of <a href="../index.html"><b>www.aidsnyc.org</b></a>. These pages are designed and <br>maintained by Joel Beard courtesy of the <a href="../network/index.html"><b>AIDS Treatment Data Network</b></a>.</font></p>

</body>
</html>


</DOC>
<DOC>
<DOCNO>WT18-B31-192</DOCNO>
<DOCOLDNO>IA093-001001-B046-42</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/links.html 199.29.141.24 19970121120342 text/html 30631
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:57:46 GMT
Server: NCSA/1.5.1
Last-modified: Mon, 20 Jan 1997 14:02:40 GMT
Content-type: text/html
Content-length: 30447
</DOCHDR>
<html>
<head>
<title>HIV/AIDS: Links</TITLE>
</head>

<body bgcolor="#FFFFFF" TEXT="#000000" LINK="#4f9eaf" VLINK="#0080C0" 
ALINK="#FF0000"><font face="arial, helvetica" size="-1">

<H2 align=center>HIV/AIDS Information and Resources</H2>

<p align=center><img src="gifs/green.gif"  height=4  width=500  
align=center alt=""></p>

<p align=center><a href="#gov"><img src="gifs/gov.gif" alt="[governmental 
information resources]"></a><a href="#sci"><img src="gifs/sci.gif" 
alt="[scientific &amp; technical resources]"></a><a href="#aca"><img 
src="gifs/aca.gif" alt="[academic resources]"
></a><br><a href="#ref"><img src="gifs/ref.gif" alt="[reference 
materials"]></a><a href="#cul"><img src="gifs/cul.gif" alt="[cultural 
resources]"></a><a href="#com"><img src="gifs/com.gif" alt="[community 
resources]"></a></p>

<H3><a name="gov">Governmental </a>Information Resources</H3>

<ul>
<LI><A 
HREF="http://text.nlm.nih.gov/ftrs/dbaccess/ahcpr"><b>AHCPR 
Supported Guidelines - Online Version</b></A>
<dt>The Agency for Health Care Policy and Research, charged with 
supporting research designed to improve the quality of health care, reduce its cost, and broaden access to essential services.
<li><A HREF="http://www.cdc.gov"><b>Centers for Disease Control and 
Prevention (CDC)</b></A> 
<dt>Information about CDC efforts in the areas of diseases, health risks, 
travelers health as well as funding and employment opportunities.
<li><A HREF="http://www.cdc.gov/ncidod/EID/eid.htm"><b>CDC's Emerging 
Infectious Diseases</b></A>
<dt>Promoting the recognition of new and reemerging infectious diseases; 
intended for professionals in infectious diseases and related sciences.
<li><A HREF="ftp://ftp.cdc.gov"><b>CDC FTP server</b></A>
<dt>Will handle 50 users at a given time.
<li><A HREF="http://www.cdc.gov/nchstp/hiv_aids/dhap.htm"><b>CDC's 
HIV/AIDS Prevention</b></A>
<dt>Preventing HIV infection and reducing the incidence of HIV-related 
illness and death.
<li><A HREF="http://www.cdc.gov/epo/mmwr/mmwr.html"><b>CDC's Morbidity 
and Mortality Weekly Report</b></A>
<dt>Based on weekly reports to CDC by state health departments.
<LI><A HREF="gopher://cdcnac.aspensys.com:72/11/"><b>Centers for Disease Control and Prevention's National AIDS Clearinghouse</b></a>
<dt>Gopher server with connections to current AIDS informaton.
<li><A HREF="http://www.fedworld.gov"><b>FEDWORLD</b></A>
<dt>general information, services, Web sites and an index of U.S. 
government servers by subject category.
<li><A HREF="http://www.niaid.nih.gov"><b>NIAID Home Page</b></A>
<br>Working to develop new and improved ways to diagnose, treat and 
prevent infectious diseases and disorders of the immune system.
<li><A HREF="gopher://odie.niaid.nih.gov"><b>National Institute of 
Allergy and Infectious Diseases (NIAID) Gopher Server</b></A>
<dt>Links to the most up-to-date information resources, concentrating especially on research and reference tools.
<li><A HREF="http://www.nih.gov"><b>National Institutes of Health 
(NIH)</b></A>
<dt>News &amp; events, health information, grants &amp; contracts, 
scientific resources, and institutes &amp; offices.
<LI><A HREF="http://www.nlm.nih.gov"><b>National Library of Medicine's 
(NLM) HYPERDOC server</b></A>
<dt>Connects to NLM Services, Databases, Publications, Research 
Activities, Grants &amp; Contracts.
<li><A HREF="http://text.nlm.nih.gov/ftrs/dbaccess/hta"><b>NLM's Health 
Services/Technology Assessment Text</b></A>
<dt>Full text and help screens to aid in searching several HSTAT collections.
<li><a href="gopher://gopher.paho.org:70/11/info/AIDS"><b>Pan American 
Health Organization</b></a> 
<dt>Gopher page on AIDS/HIV and sexually transmitted diseases.
<li><A HREF="http://www.ssa.gov"><b>Social Security Administration On 
Line</b></A>
<dt>Agency information, benefit information, customer service standards, 
legislation, and rulings.
<li><A HREF="http://www.os.dhhs.gov"><b>U.S. Department of Health and 
Human Services - DHHS Resources Locator</b></A>
<dt>News &amp; public affairs, consumer information, policy information, and employee information.
<li><a href="http://www.fda.gov/"><b>U.S. Food and Drug Administration 
Home Page</b></a>
<dt>Information on FDA News, biologies, cosmetics, foreign 
language, foods, medical devices/ radiological health, field operations, human drugs, animal drugs, and toxicology.
<li><a href="gopher://gopher.cder.fda.gov"><b>U.S. FDA Gopher server</b></a>
<dt>Relevant information on using the server.
<li><A HREF="http://gpawww.who.ch/"><b>World Health Organization's Global (WHO) Programme on AIDS</b></A>
<dt>Links to <a href="http://www.unicef.org/"><b>UNICEF</b></a>, <a 
href="http://www.undp.org/"><b>United Nations Development 
Program</b></a>, <a 
href="http://www.unfpa.org/"><b>United Nations Population Fund</b></a>, 
<a 
href="http://www.who.org"><b>WHO</b></a>, <a 
href="http://www.worldbank.org/"><b>World Bank</b></a>, and <a 
href="http://www.unesco.org/"><b>UNESCO</b></a>.
</ul>

<p align=center><a href="#gov"><img src="gifs/gov.gif" alt="[governmental 
information resources]"></a><a href="#sci"><img src="gifs/sci.gif" 
alt="[scientific &amp; technical resources]"></a><a href="#aca"><img 
src="gifs/aca.gif" alt="[academic resources]"
></a><br><a href="#ref"><img src="gifs/ref.gif" alt="[reference 
materials"]></a><a href="#cul"><img src="gifs/cul.gif" alt="[cultural 
resources]"></a><a href="#com"><img src="gifs/com.gif" alt="[community 
resources]"></a></p>

<H3><a name="sci"></a>Scientific and Technical Resources</H3>

<ul>
<li><A HREF="http://app.cnidr.org/"><b>AIDS Patents Project</b></a>
<dt>Full text and images of international patents relating to AIDS.
<li><A 
HREF="http://www.netaxs.com/~aengel/JapanAIDSPatents/list.htm"><b>Japanese AIDS Patents</b></a>
<dt>Technical page concerning Japanese research into AIDS.
<li><A 
HREF="http://galen.med.virginia.edu/~pjb3s/ComplementaryHomePage.html"><b>Dr Bower's Complementary Medicine Home Page</A> </b>
<dt>Intended to catalog and assist in the research being carried out 
worldwide in alternative and complementary medicine.
<li><A 
HREF="http://hiv-web.lanl.gov"><b>HIV Sequence Database</b></a>
<dt>Genetic sequences of HIV-1, HIV-2, SIV and related animal retroviruses, as well as host cellular proteins.
<li><A 
HREF="http://www.ciesin.org/datasets/hivaids/hivaids-home.html"><b>HIV/AIDS Surveillance Database - CIESIN</b></a>
<dt>Information on the AIDS and on HIV infection in population groups in 
developing countries.
<li><A HREF="http://www.dungeon.com/home/cam/homeo.html"><b>Homeopathy 
Home Page</b></a>
<dt>Links to related available resources.
<li><A HREF="http://hpv-web.lanl.gov"><b>Human Papillomavirus Sequence 
Database</b></a>
<dt>Genetic sequences of papillomaviruses and related cellular 
proteins.
<li><A HREF="http://www.biochem.kth.se/MycDB.html"><b>MycDB, the 
Mycobacterium DataBase</b></a>
<dt>Mycobacterium database.
<li><A 
<li><A HREF="http://www.oxytherapy.com/"><b>Oxygen Therapy Home Page</b></a>
<dt>Oxygen therapies include the use of hydrogen peroxide, ozone therapy, 
hyperbaric oxygen, stabilized oxygen, and ionization.
<li><A HREF="http://www.maui.net:80/~drbill"><b>Natural Medicine for the 
Health Crisis</b></a>
<dt>Information on treating many disease conditions.
<li><A HREF="http://www.yahoo.com/Health/Alternative_Medicine"><b>Yahoo's 
Alternative Medicine Home Page</b></a>
<dt>Searchable engine.
</ul>

<p align=center><a href="#gov"><img src="gifs/gov.gif" alt="[governmental 
information resources]"></a><a href="#sci"><img src="gifs/sci.gif" 
alt="[scientific &amp; technical resources]"></a><a href="#aca"><img 
src="gifs/aca.gif" alt="[academic resources]"
></a><br><a href="#ref"><img src="gifs/ref.gif" alt="[reference 
materials"]></a><a href="#cul"><img src="gifs/cul.gif" alt="[cultural 
resources]"></a><a href="#com"><img src="gifs/com.gif" alt="[community 
resources]"></a></p>

<h3><a name="aca"></a>Academic Resources</h3>

<ul>
<li><a href="http://www-medlib.med.utah.edu/WebPath/AIDS.html"><b>AIDS 
Pathology</b></a> at WebPath: Internet Pathology Lab
<dt>University of Utah Health Sciences Center pathology lab.
<li><A HREF="http://bitmed.ucsd.edu/"><b>BITMed Simulation Server at 
UCSD</b></a>
<dt>Laboratory for Biological Informatics and Theoretical Medicine at the 
University of California, San Diego; simulations of biological, chemical 
and physical systems.
<li><A HREF="http://www.brown.edu/Research/TB-HIV_Lab/"><b>Brown 
University's TB/HIV Research Lab</b></a>
<dt>Also links to Brown's School of Medicine.
<li><a href="http://chanane.ucsf.edu/capsweb/"><b>Center for AIDS 
Prevention Studies</b></a> at the University of California, San Francisco
<dt>The Center for AIDS Prevention Studies (CAPS) at the University of 
California San Francisco  focuses on prevention of HIV.
<li><A HREF="http://cpmcnet.columbia.edu/"><b>Columbia-Presbyterian 
Medical Center</b></a>
<dt>CPMCnet is an informational resource serving the Health Sciences 
Division of Columbia University and the Presbyterian Hospital in New York City.
<li><A 
HREF="gopher://gopher.harvard.edu:70/11/.vine/providers/aids_institute"><b>Harvard AIDS Institute</b></a>
<dt>Harvard's AIDS gopher server.
<li><a href="http://www.med.harvard.edu/"><b>Harvard Medical Web Home 
Page</b></a>
<dt>Links to Harvard's Online Catalog, programs within Harvard's Medical 
School, and online publications by Harvard's Medical community.
<li><a href="http://www.NeoSoft.com/~hail/"><b>Houston AIDS Information Link</b></a>
<dt>A collaborative project to improve access to HIV/AIDS information for patients, health care providers and the affected community.
<li><a href="http://www.indiana.edu/~aids"><b>Indiana University and 
Purdue University's Rural Center for the Study and Promotion of HIV/STD 
Prevention</b></a>
<dt>The RPC develops and evaluates educational materials and approaches to HIV/STD. Best used with Netscape 1.1N Browser.
<li><A HREF="http://www.bocklabs.wisc.edu"><b>Institute for Molecular 
Virology at the University of Wisconsin</b></a>
<dt>Links to the Laboratory of Molecular Virology, Molecular Biology, and 
Microscopy Resources.  Best viewed using a Netscape 1.1N Browser.
<li><A HREF="http://www.interchg.ubc.ca/aids11/AIDS96.html"><b>XI 
International Conference on AIDS Home Page</b></a>
<dt>Conference annoucement- July 7th-July 12, 1996 in Vancouver, Canada, page is best viewed using Netscape 1.1.
<li><a href="http://www.bhs.mq.edu.au/nchsr.html"><b>National Centre in 
HIV Social Research</b></a> (Australia)
<dt>National Priority Program focusing on education and prevention for 
gay and homosexually active men.
<li><A HREF="http://www.med.nyu.edu/~akavia/hivaids.html"><b>NYU Medical Center AIDS Clinical Trials Unit</b></a>
<dt>Jump page to AIDS Clinical Trials Unit and other AIDS related URLs.
<li><a href="http://www.tulane.edu/~actgweb/"><b>Tulane University AIDS Clinical Trials Unit</b></a>
<dt>Protocols open for enrollment in the New Orleans area.
<li><A HREF="gopher://itsa.ucsf.edu"><b>UCSF Gopher</b></a>
<dt>University of California San Francisco's gopher server.
<li><a href="http://www.swmed.edu/home_pages/hivcrg"><b>University of Texas Southwestern Medical Center's HIV Clinical Research Group</b></a>
<dt>The HIVCRG performs clinical trials of newly developed HIV anti-retroviral drugs. Other studies
include treatment of diseases associated with or related to HIV infection. <font size="-2">(added 1/20/97)</font>
</ul>

<p align=center><a href="#gov"><img src="gifs/gov.gif" alt="[governmental 
information resources]"></a><a href="#sci"><img src="gifs/sci.gif" 
alt="[scientific &amp; technical resources]"></a><a href="#aca"><img 
src="gifs/aca.gif" alt="[academic resources]"
></a><br><a href="#ref"><img src="gifs/ref.gif" alt="[reference 
materials"]></a><a href="#cul"><img src="gifs/cul.gif" alt="[cultural 
resources]"></a><a href="#com"><img src="gifs/com.gif" alt="[community 
resources]"></a></p>

<H3><a name="ref"></a>Reference Materials</H3>
<ul>
<li><A HREF="http://www.actwin.com/aids/vl.html"><b>AIDS Virtual 
Library</b></a>
<dt>Social, political, and medical aspects of AIDS, HIV, and related issues.
<li><A HREF="http://www.cato.com/interweb/cato/biotech/"><b>Biotechnology 
Virtual Library</b></a>
<dt>Biotechnology, pharmaceutical development, genetic engineering, medical device development, and related fields such as pharmacology and toxicology.
<li><a href="http://www.libraries.wayne.edu/dcal/aids.html"><b>Detroit 
Community AIDS Library</b></a>
<dt>Gateway to HIV/AIDS Information for Detroit and Southeastern 
Michigan,  best when using Netscape 1.22 .
<li><A HREF="http://chanane.ucsf.edu/epidem/epidem.html"><b>Epidemiology 
Virtual Library</b></a>
<dt>Department of Epidemiology and biostatistics at the University of California San Francisco.
<li><a href="http://www.ama-assn.org/special/hiv/hivhome.htm"><b>JAMA 
HIV/AIDS Information Center</b></a>
<dt>Resources for physicians, other health professionals and the public.
<li><A HREF="http://www.ohsu.edu/cliniweb/wwwvl/"><b>Medicine Virtual 
Library</b></a>
<dt>Put together by Oregon Health Sciences University.
<li><A 
HREF="http://golgi.harvard.edu/biopages/micro.html"><b>Microbiology 
and Virology Virtual Library</b></a>
<dt>Put together by Harvard.
<li><A HREF="http://www.tiac.net/users/jtward/index.html"><b>Multimedia 
Medical Reference Library</b></a>
<dt>Searchable database that provides information on AIDS and other 
diseases. Page uses frames which may not be viewable on 
some browsers. May have to reload a few times to get it to run properly.
<li><A 
HREF="http://www.cpb.uokhsc.edu/pharmacy/pharmint.html"><b>Pharmacy 
Virtual Library</b></a>
<dt>Pharmacy related internet resources. 
<li><a href="http://pharminfo.com/"><b>PharmInfoNet Home Page</a> </b>
<dt>Pharmacy Information Network, a pharmaceutical information resource.
<li><A HREF="telnet://genrx@genrx.icsi.net"><b>Physician's GenRx</b></a>
<dt>Telnet site. May not work. There is a subscription site at<a 
href="http://www.genrx.com:80/"> <b>http://www.genrx.com:80/</b></a> You 
can preview for free. 
<li><a href="http://www.roxane.com"><b>Roxane Pain Institute</b></a>
<dt>Searchable database for Pain Institute's library, products, and 
lecture series.
<li><A HREF="http://www.safersex.org/"><b>Safer Sex Page</b></a>
<dt>Guides to safer sex, condom use and effectiveness, health information 
including HIV and birth control, and counselor information.
<li><a href="http://www.sciencemag.org/science/content/vol272/issue5270/"><b>Science Magazine</b></a> 
<dt>Special issue on AIDS, June 28, 1996, full text and summary articles.
<li><a href="http://cmm.info.nih.gov/modeling/drugbank.html"><b>The 
Three-Dimensional Drug Structure Data Bank</b></a>
<dt>Collection of investigational and approved therapeutic agents. Best used with a Netscape browser.
<li><A HREF="http://golgi.harvard.edu/biopages/"><b>World-Wide Web 
Virtual Library - Biosciences</b></a>
<dt>From Harvard University. Available in Spanish.
<li><A HREF="http://www.yahoo.com/yahoo/Health/Medicine/"><b>Yahoo's 
Health and Medicine Home Page</b></a>
<dt>Search engine.
</ul>

<p align=center><a href="#gov"><img src="gifs/gov.gif" alt="[governmental 
information resources]"></a><a href="#sci"><img src="gifs/sci.gif" 
alt="[scientific &amp; technical resources]"></a><a href="#aca"><img 
src="gifs/aca.gif" alt="[academic resources]"
></a><br><a href="#ref"><img src="gifs/ref.gif" alt="[reference 
materials"]></a><a href="#cul"><img src="gifs/cul.gif" alt="[cultural 
resources]"></a><a href="#com"><img src="gifs/com.gif" alt="[community 
resources]"></a></p>

<H3><a name="cul"></a>Cultural Resources</H3>

<ul>
<li><A 
HREF="gopher://ucsbuxa.ucsb.edu:3001/11/.Journals/.A/.AIDS"><b>AIDS 
Book Review Journal</b></a>
<dt>Gopher server.
<li><a href="http://www.thoughtport.com/AIDS/"><b>AIDS Mosaic</b></a>
<dt>To serve as a reminder of friends and that AIDS can be beat.
<li><a href="http://www.aidsride.org/"><b>AIDS Ride '96 Home Page</b></a>
<dt>Information about the five 1996 AIDS Rides taking place May-September 
1996.
<li><A 
HREF="http://artaids.dcs.qmw.ac.uk:8001/entrance/entrance.html"><b>ArtAIDS Link</b></a>
<dt>Contains a new gallery of work uploaded over the past year, from 
around the world. 
<li><a href="http://hwbbs.gbgm-umc.org/"><b>Computerized AIDS Ministries 
Bulletin Board Service</b></a>
<dt>Discussion of issues related to HIV/AIDS ministry. 
<li><A 
HREF="http://162.126.100.26/Images/vircit/glaidsho.htm"><b>CyberQueer 
Lounge</b></a>
<dt>Members only site. 
<li><a href="http://www.artistswithaids.org/"><b>Estate Project for 
Artists with AIDS</b></a>
<dt>Helps existing AIDS and arts service organizations by providing them with additional resources to help artists coping with AIDS. 
<li><A HREF="gopher://itsa.ucsf.edu/11/.i/.q/.d/"><b>Ben Gardiner's AIDS 
BBS database</b></a>
<dt>Gopher server.
<li><a href="http://florey.biosci.uq.oz.au/hiv/HIV_EMIR.html"><b>HIV 
Electronic Media Information Review</b></a>
<dt>Australian HIV Information Service, links to French, German, Italian, and Spanish language sites.
<li><a href="http://gbgm-umc.org/programs/hiv/aids.html"><b>HIV/AIDS 
Ministries Network</b></a>
<dt>A program of Health and Welfare Ministries, General Board of Global Ministries, and the United Methodist Church. 
<li><a 
href="http://www.positive.org/cps/jsy/jsy.html"><b>Just Say Yes: A Pro-sex, Safer Sex Guide for Teens</b></a>
<dt>Originally written by the Coalition for Positive Sexuality in Chicago, this pamphlet was written for distribution to high school students in the area .
<li><A HREF="http://cyberpark.com/kairos/welcome.htm"><b>KAIROS: Support for caregivers</b></a>
<dt>Resource center for the caregivers of HIV-affected persons. 
 <li><a href="http://www.interport.net/~kermit/livproof.html"><b>Living 
Proof: HIV and the Pursuit of Happiness</b></a>
<dt>Feature-length documentary of the "Living Proof" photography 
project that presents images of people living positively with HIV/AIDS. 
<li><a href="http://gaia.gn.apc.org/comsites/l&l/lov&liv.html"><b>Loving 
and Living exhibition</b></a>
<dt>Exhibition promoting positive images of love, optimism and hope for all people living with  HIV/AIDS. 
<li><a href="http://www.icomm.ca/~pfcda/"><b>Photography &amp; Friends United Against AIDS</b></a>
<dt>Canadian chapter, with a mandate to create and undertake projects of a photographic nature to raise funds to continue AIDS research, prevention, education and care programmes in Canada. <font size="-2">(added 1/15/97)</font>
<li><A HREF="http://www.serv.net/planet/ "><b>Positive Planet magazine</b></a>
<dt>Subscription magazine that features dating section for HIV positive 
people as well as interviews and feature stories.
<li><a href="http://plaza.interport.net/cats/david.html"><b>We See Face to Face: Homeless People with AIDS</b></a>
<dt>An exhibition of paintings by David F. Johnson.
<li><a href="http://www.outpr.com.au/wad.html"><b>World AIDS Awareness Week</b></a>
<dt>From New South Wales, Australia. Events in Sidney and all around NSW, updated weekly.
<li><a href="http://www.oneworld.org/textver/avert/worldaid.htm"><b>World AIDS Day 1996</b></a>
<dt>Links to relevant sites around the world and examples of events which will be happening in the UK.
</ul>

<p align=center><a href="#gov"><img src="gifs/gov.gif" alt="[governmental 
information resources]"></a><a href="#sci"><img src="gifs/sci.gif" 
alt="[scientific &amp; technical resources]"></a><a href="#aca"><img 
src="gifs/aca.gif" alt="[academic resources]"
></a><br><a href="#ref"><img src="gifs/ref.gif" alt="[reference 
materials"]></a><a href="#cul"><img src="gifs/cul.gif" alt="[cultural 
resources]"></a><a href="#com"><img src="gifs/com.gif" alt="[community 
resources]"></a></p>

<H3><a name="com"></a>Community Resources</H3>
<ul>
<li><a href="http://acupuncture.com/"><b>Acupuncture Home Page</b></a>
<dt>Information on traditional oriental therapies, consumer resources, 
practioner, and student resources.
<li><a href="http://www.aegis.com/"><b>AEGIS - AIDS Education Global Information System</b></a>
<dt>Headlines, news, library with vast searchable collection of articles, newsletters, etc. <font size="-2">(added 1/15/97)</font>
<li><a href="http://www.aac.org/"><b>AIDS Action Committee</b></a>
<dt>New England's oldest and largest provider of AIDS services, education and advocacy.
<li><a href="http://www.thebody.com/aac/aacix.html"><b>AIDS Action Council</b></a>
<dt>Articles about current research and action alerts.
<li><a href="http://SaferSM.org/SaferSM.html"><b>AIDS Committee 
of Toronto Safer SM Education</b></a>
<dt>Information about safe practices for SM. Best viewed using Netscape 
1.N or higher.
<li><A HREF="http://www.gus.com/care/apla/apla.html"><b>AIDS Project Los 
Angeles (APLA) Home Page</b></a>
<dt>Non-profit organization dedicated to supporting and maintaining the quality of life for persons affected by HIV.
<li><a href="http://www.altcare.com/welcome.html"><b>Alternative Care 
HomePage</b></a>
<dt>For people who wish to learn more about Alternative Health Care.
<li><a href="http://www.hivnet.ubc.ca/ctn.html"><b>Canadian HIV Trials 
Network</b></a>
<dt>Set up to increase the number of HIV clinical trials done in Canada and improve access to new treatments for Canadians with HIV. Available in French.
<li><a href="http://www.sfaf.org/beta.html"><b>BETA</b></a>, The Bulletin of Experimental Treatments for AIDS
<dt>Published quarterly (in May, June, September and December) by the <A HREF="http://www.sfaf.org/treat.html">Treatment Education and
Advocacy Department</A> of the <a href="http://www.sfaf.org/index.html">San Francisco AIDS Foundation</a>.
<li><a href="http://www.ip.net/candii"><b>The CANDII Program - The Children's Network Designed for Interfaith Involvement</b></a>
<dt>Interdenominational organization formed to serve the needs of children affected by HIV in Southeastern Virginia.
<li><b><a href="http://www.catie.ca/">CATIE - Community AIDS Treatment Information Exchange</a></b>
<dt>Canadian site providing information on treatment options including drugs, other medical treatments and complementary therapies. English and <a href="http://www.catie.ca/reseau.html">French</a>.
<li><a href="http://www.web-depot.com/users/cott/"><b>The Committee of 
Ten Thousand</b></a>
<dt>COTT is an advocacy group for people who have contracted HIV through blood products. 
<li><a href="http://www.ag.com/Condom/Country"><b>Condom Country</b></a>
<dt>Provides helpful information on condom use and allows you to order 
condoms from their catalog.
 <li><a href="http://www.infoex.co.uk/ie/index.html"><b>Crusaid 
HIV Information Exchange</b></a>
<dt>Forum for exchange of views on HIV and AIDS treatment, care and 
research for patients, clinic staff, GPs, the media and the general public. 
<li><a href="http://www.islandnet.com/~deathnet"><b>DeathNET</b></a>
<dt>An international archive specializing in all aspects of death and dying. Designed specifically for Netscape browser. For best viewing use Netscape 2.0. 
<li><a href="http://www.web-depot.com/hemophilia"><b>The Hemophilia Home Page</b></a>
<dt>Includes information on hemophilia &amp; AIDS.
 <li><a href="http://florey.biosci.uq.oz.au/hiv/AIDS-OZ.htm"><b>HIV/AIDS 
in Australia &amp; Pacific</b></a>
<dt>Information pertaining to HIV and AIDS in Australia.
<li><a href="http://www.nectec.or.th/users/craig/"><b>HIV/AIDS in 
Thailand</b></a>
<dt>Links to sites about HIV/AIDS in Thailand and Southeast Asia.
<li><a href="http://www.mcs.net/~flip/hiv.htm"><b>HIV/AIDS Resources for 
Filipinos</b></a> - from the <a 
href="http://pubweb.acns.nwu.edu/~flip/bakla.html"><b>Filipino Queer 
Resource Directory</b></a>
<dt>Information on AIDS in the Philipines.
<li><A HREF="http://carebase2.jri.org/infoweb/"><b>HIV Infoweb</b></a>
<dt>Links the online community with up-to-date information about HIV and AIDS treatments, information and other important resources.
<li><A HREF="http://gopher.hivnet.org"><b>HIVNET/GENA Information 
Server</b></a>
<dt>Gopher server concerning HIV and AIDS.
<li><a href="http://www.iapac.org/"><b>Internation Association of Physicians in AIDS Care</b></a>
<dt>Global strategies for development and faster approval of drugs, increased access, education and human rights. 
<li><a href="http://www.smartlink.net/~martinjh/"><b>Marty Howard's 
HIV/AIDS Home Page</b></a>
<dt>HIV/AIDS information resource. Sign up for <a
href="http://www.smartlink.net/~martinjh/maillist.html">newsgroups, listserves and newsletters</a>. 
<li><a href="http://www.execpc.com/~keephope/keephope.html"><b>Keep Hope Alive Home Page</b></a>
<dt>Information on  nutritional, bio-oxidative and alternative therapies for people with AIDS/HIV.
<li><a 
href="http://www.waverider.co.uk/~mysticm/lambda/lambda.html"><b>LambdaLink</b></a>
<dt>Information and links to homosexual resources on the Internet.
<li><A 
HREF="http://phymat.bham.ac.uk/LGB/general/positive.html"><b>Lesbian, 
Gay and Bisexual Guide to Great Britain's Positive Approaches to HIV and 
AIDS Home Page</b></a>
<dt>Safer sex guides for gays and lesbians.
 <li><a href="http://www.netfinder.com/spoonful/"><b>A Loving Spoonful, the Vancouver Meals Society</b></a>
<dt>Community based service which  provides meals to individuals with HIV/AIDS.
 <li><a 
href="http://www.medscape.com/home/medscape-AIDS/Medscape-AIDS.html"><b>Medscape's AIDS page</b></a>
<dt>Medscap features peer-reviewed articles, color graphics, self-assessment features, medical news, Medline Reviews, and links to Internet resources. Access is free but it does require a one-time registration.
<li><a href="http://www.hivnet.ch/migrants/"><b>Migrants contre le SIDA/HIV</b></a>
<dt>A monthly, independent newsletter in French and in English which focuses on grassroots activist efforts by refugee, migrant, and Black/Third World communities in Europe.
<li><a href="http://www.panix.com/~jscutero"><b>misc.health.aids 
Homepage</b></a>
<dt>Dedicated to a free and open exchange of ideas about AIDS. 
<li><a href="http://www.mssm.edu/peds/aids.html"><b>Mount Sinai Medical Center's Adolescent Health Center's Adolescent AIDS Prevention and Treatment Program</b></a>
<dt>Providing confidential comprehensive medical, mental health, family planning, and health education services to young people between the ages of 13-20.
<li><a href="http://www.users.interport.net/~clueless/nama1.html"><b>National Alliance of Methadone Advocates</b></a>
<dt>Committed to providing quality methadone maintenance treatment and educating professional and the public.
<li><a hREF="http://www.noah.cuny.edu"><b>NOAH: New York Online Access to Health</b></a>
<dt>Health information in both English and Spanish.
<li><A HREF="http://www.jaxnet.com/~nfan/text.htm"><b>Northeast Florida AIDS Network,Inc.</b></a>
<dt>Offers assistance in obtaining necessary medical, community, and social services.
<li><a href="http://www.projinf.org/"><b>Project Inform's Home Page</b></a>
<dt>Information on the diagnosis and treament of HIV for HIV infected individuals, their caretakers and their physicians.
<li><a href="http://www.gaypride.com/poh/"><b>Project Open 
Hand/Atlanta</b></a>
<dt>Prepares and delivers two freshly cooked, nutritious meals each day to people living with AIDS or HIV-related illnesses. 
<li><a href="http://www.well.com/user/hbp/poh/openhand.html"><b>Project 
Open Hand/San Francisco</b></a>
<dt>Provides comprehensive nutrition services to over 3,000 men, women, and children with symptomatic HIV and AIDS.
<li><A HREF="http://www.qrd.org/qrd/aids/"><b>Queer Resources Directory AIDS Page</A> </b>
<dt>HIV/AIDS related issues. Links to full text articles.
<li><a 
href="http://agora.rdrop.com/users/spyke/qrd/qrd-hiv-medical.html"><b>QRD HIV/AIDS Medical, Treatment and Support Information</b></a>
<dt>Contains facts, figures, and reports. Links to other AIDS related 
sites on the web.
 <li>Jeff Schwartz's <a 
href=" http://itec.sfsu.edu/aids/aids.html"><b>AIDS and HIV Resources 
Page</b></a>
<dt>Information source for teenagers  Awarded four stars by Magellan.
<li><a href="http://jeff.dca.udg.mx/sida/sida.html"><b>SIDA en Mexico - AIDS in Mexico</b></a>
<dt>Spanish page. Links to an information guide, organizations and 
publications.
<li><a 
href="http://www.hidwater.com/sisterlove/slhome.html"><b>SisterLove</a></b>
<dt>Established to increase the knowledge and practice of preventive health where women are at risk or already living with HIV/AIDS.
<li><A HREF="http://tin.ssc.plym.ac.uk/aids.html"><b>University of 
Plymouth (UK) Safer Sex, AIDS and HIV Internet Information</b></a>
<dt>Provides links to information on the Internet concerning HIV/AIDS. 
<li><a href="http://www.stopaids.org"><b>The Stop AIDS Project</b></a>
<dt>A four year old organization in San Francisco addressing gay and bisexual men and what they can do to stop AIDS. <font size="-2"><i>(added 6/24/96)</i></font>
<li><a href="http://www.thecure.org/home.html"><b>thecure.org</b></a>
<dt>The National Association of People With AIDS has action alerts, current issues and programs of NAPWA.
<li><A 
HREF="http://www.vicnet.net.au/vicnet/community/aidsline.html"><b>VICNET: Victoria's Network (Australia) AIDSLINE</b></a>
<dt>Telephone counselling, information and referral service on HIV, AIDS and all other sexually transmitted diseases.
<li><a href="http://www.ctv.es/USERS/fpardo/home.html"><b>VIH y SIDA</b></a>
<dt>Spanish language page of information worldwide.
</ul>

<p align=center><a href="#gov"><img src="gifs/gov.gif" alt="[governmental 
information resources]"></a><a href="#sci"><img src="gifs/sci.gif" 
alt="[scientific &amp; technical resources]"></a><a href="#aca"><img 
src="gifs/aca.gif" alt="[academic resources]"
></a><br><a href="#ref"><img src="gifs/ref.gif" alt="[reference 
materials"]></a><a href="#cul"><img src="gifs/cul.gif" alt="[cultural 
resources]"></a><a href="#com"><img src="gifs/com.gif" alt="[community 
resources]"></a></p>

<p align=center><img src="gifs/green.gif" height=4 width=500  
align=center alt=""></p>

<p align=center><a href="index.html"><img src="gifs/wturn.gif" 
align=middle vspace=5 alt=" "><br>www.aidsnyc.org</a></P>

<P><A 
HREF="mailto:hivinfo@aidsnyc.org">hivinfo@aidsnyc.org</A><dt>
Last modified 1/20/97<dt>
copyright  &#169; 1996 1997<dt>
www.aidsnyc.org</P>

</font>
</body>
</html> 


</DOC>
<DOC>
<DOCNO>WT18-B31-193</DOCNO>
<DOCOLDNO>IA093-001001-B046-58</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/cnews/index.html 199.29.141.24 19970121120350 text/html 2578
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:57:57 GMT
Server: NCSA/1.5.1
Last-modified: Wed, 15 Jan 1997 16:58:13 GMT
Content-type: text/html
Content-length: 2395
</DOCHDR>
<html> <head> <title>Consumer News</title> </head>
<body bgcolor="#ffffff" text="#a62a2a" link="#856363"><font face="arial, helvetica" size=-1>

<table width=100%>
<tr>
<td rowspan=3><img src="gifs/logo.gif" alt="[logo]"></td>

<td><a href="news/index.html"><img src="gifs/news.gif" alt="[newsletter]"></a></td>
<td><a href="conf/index.html"><img src="gifs/conf.gif"
alt="[conferences]"></a></td> </tr><tr> <td><a href="contacts/index.html"><img
src="gifs/contact.gif" alt="[contacts]"></a></td>

<td><a href="papers/das.html"><img src="gifs/papers.gif" alt="[position
papers]"></a></td> </tr><tr> <td colspan=2 align=center><a href="about.html"><img
src="gifs/about.gif" alt="[about consumer news]"></a></td> </tr> </table> 

<font size=-1>

<p><b>The Consumer Information and Conflict Resolution Project (CICRP)</b> is an alternative dispute resolution program for people living with AIDS that uses several tools to confront and resolve conflicts: information, intervention,mediation, conciliation, arbitration, facilitation, and consensus/colaborative problem solving. <a href="news/index.html"><b>Consumer News</b></a>, a monthly publication, is the primary instrument for disseminating information to people living with AIDS on current trends and practices. CICRP and Consumer News is an independent neutral organization dedicated to collaborative problem solving. The Consumer News web site brings to the electronic media the interactive processes that  encourage proactive, preventive approaches
to conflict resolution, empowering individuals and building community. </p> </font> 

<p align=center><b><a
href="news/index.html">newsletter</a> | <a href="conf/index.html">conferences</a> | <a
href="contacts/index.html">contacts</a> | <a href="papers/das.html">papers</a> | <a
href="about.html">about c-news</a></b></p>

<table width=100%> <tr valign=top>
<td><font face="arial, helvetica" size=-1>Consumer News<br> copyright &#169; 1996 1997<a
href="mailto:klowry@aidsnyc.org">Kenneth Lowry</a><br>
pages modified: 1/15/97</font></td>
<p>
<td align=right><font face="arial, helvetica" size=-1>The Consumer News
site is part of <a href="../index.html"><b>www.aidsnyc.org</a></b>. <br>These pages are designed and maintained by Joel Beard <br>courtesy of the <a href="../network/index.html"><b>AIDS Treatment Data Network</b></a>.</font></td></tr> </table></center>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-194</DOCNO>
<DOCOLDNO>IA093-001001-B046-81</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/arrive/index.html 199.29.141.24 19970121120408 text/html 18168
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:58:10 GMT
Server: NCSA/1.5.1
Last-modified: Wed, 08 Jan 1997 14:43:20 GMT
Content-type: text/html
Content-length: 17984
</DOCHDR>
<html>
<head><title>Arrive Exponents, Inc</title></head>
  
<body background="gifs/gold.gif" TEXT="#000000" LINK="#8e2323"  vlink="#9f5f9f" ALINK="#ff0000"><font face="arial, helvetica" size=-1>

<a name="home"><p><img src="gifs/arrive.gif" align=left alt="[logo]" hspace=5><font size=+2>EXPONENTS, INC.</font></a><br>

<b>151 West 26th Street, New York, New York 10001<br>
212/243-3434  <br>
Fax 212/243-3586</b></p>
<br clear left>

<p align=center><img  height="2" width="400" src="gifs/brick.gif"></p>
<blockquote>
<font size=-1>
<a name="mission"><p><b> EXPONENTS' mission</a> is to assist individuals and families through difficult transitions - from addiction to recovery, from incarceration to civilian life; from HIV negative to HIV positive, and from welfare to work. Exponents' peer based programs create a sense of community among substance users to provide outreach, education and support. Exponents' advocates that former users play a role in the fight against AIDS and drug abuse.</b></p>
<p align=center><img  height="2" width="400" src="gifs/brick.gif"></p>
</font>
</blockquote>

<center><table width="90%" cellpadding="4" cellspacing="2" border="1" colspecs="25% 25% 25% 25%">
<tr valign=top>
<td colspan="4" align=center><font size=-1 face="arial, helvetica"><b>EXPONENTS Inc., is the parent organization of four unique and interrelated <a href="#program">programs.</a> </b></font></td></tr>
<p>
<tr valign=top>
<td width=25%><font size=-1 face="arial, helvetica"><a href="#each">Each One Teach One</a></font></td>
<p>
<td width=25%><font size=-1 face="arial, helvetica">peer facilitated street outreach and HIV/substance abuse related presentations to community groups, prisons, adolescent group homes, halfway houses, and hospitals.</font></td>
<p>
<td width=25%><font size=-1 face="arial, helvetica"><a href="#second">A Second Chance</a></font></td>
<td width=25%><font size=-1 face="arial, helvetica">outreach and educational efforts in the correctional
    system; assisting inmates make successful transitions back into the
    community.</font></td></tr></p>
<p><tr valign=top>
<td><font size=-1 face="arial, helvetica"><a href="#cape">C.A.P.E.</a></font></td>
<td><font size=-1 face="arial, helvetica">a post-graduate training program consisting of over 50 workshops in skills enhancement and drug relapse prevention support services.</font></td></p>
<p><td><font size=-1 face="arial, helvetica"><a href="#arrive">Arrive </a></font></td>
<td><font size=-1 face="arial, helvetica">established in 1988, the program was one of the first initiatives in the U.S. to offer HIV education/prevention and communication skills for people with histories of substance use and incarceration. Using a peer model approach, ARRIVE improves the quality of life for people through life skills training and support services while enhancing recovery and stability through job preparation.</font></td></tr></p>
<p><tr valign=top>
<td colspan="2" align=center><font size=-1 face="arial, helvetica"><a href="#facts"> Important Facts about Exponent's Programs</a></font></td>
<td colspan="2" align=center><font size=-1 face="arial, helvetica"><a href="#director"> A Note from the Executive Director</a></font></td></tr></p>
</table></center>

<blockquote>
<font size=-1>

<h2 align=center><a name="program">Exponents Programs</a></h2>
     
<p>Exponents programs are funded by numerous state, city and other governmental sources. Throughout the year programs are evaluated through formal assessment processes and site visits. Exponents has received 'excellent' ratings 3 consecutive years, from NYC, Dept. of Health and 2 external evaluations have been completed. Comments directly from reports and evaluations:</p>
 
<p><i>"Students appear to emerge from ARRIVE not only somewhat better
    educated and better prepared for employment in the HIV and drug
    treatment service organizations, but also with a sense of self-worth and
    belonging." </i><br>---Brookdale Health Science Center report to MHRA, New York, 1995</p>

<p><i>"Exponents provides an essential step in the continuum of adjustment to
    and participation in society for those people disenfranchised and
    disconnected because of substance abuse and incarceration."</i><br>---Brookdale
    Health Science Center report to MHRA, New York, 1995</p>

<p><i>"ARRIVE participation significantly decreased certain sexual and drug-
    related risk behaviors and improved parolees' community adjustment."</i><br>
    ---Article; International Journal of the Addictions, 1994, National Development & Research
    Institutes, Inc.</p>

    <p><i>"ARRIVE's quality of services is reflected in their outstanding retention rate
    and waiting lists for services. The program provides a positive environment,
    fostering behavior change."</i><br>--- NYC/DoH, site visit report, 1995</p>
    
    <p><i>"Attending graduation was wonderful. It allowed me to more fully understand
    the impact the ARRIVE program has on the lives of clients and the excellent
    graduation rate is a tangible measure of the program's success."</i><br>--- MHRA, site visit
    report, 1995</p>
  
    
  <p>Organizations that fund and perform ongoing reports, or have evaluated
    Exponents' programs are:</p>
    
    <ul>
<li>NYC/Department of Health - Bureau of HIV Program Services
<li> Medical Health Research Associates, Inc., of NYC, HIV Care Services
<li>NY State Office of Alcohol and Substance Abuse Services NY State
<li>Department of Health - AIDS Institute National Development and
<li>Research, Inc., N.Y. Center on AIDS, Drugs, and Community Health -
<li>Brookdale School of Health Sciences, Hunter College, N.Y.
</ul>
<p align=center><img  height="4" width="400" src="gifs/brick.gif"></p>

<h4 align=center><a name="each">EACH ONE TEACH ONE</a></h4>
    
    <p>Each One Teach One - was established in the Spring of 1990 as
    a volunteer effort to help ensure that a message of hope
    returned to the communities ravaged by drug abuse and AIDS.
    Peer messengers deliver HIV/AIDS and substance use prevention
    and education to those most at risk and the public at large.
    Having received funding in March 1995 from NY State/AIDS
    Institute, the program has quadrupled its outreach efforts,
    combining peer worker training and public speaking.</p>
    
    <p>Each One Teach One - volunteers and peer educators reach over
    25,000 people a year through presentations at group homes,
    volunteer literacy programs, prisons, drug treatment centers,
    hospitals, homeless shelters, and alternative schools. The
    program also provides the opportunity to organize educational
    outreach to community leaders regarding issues affecting the
    lives of persons with AIDS and drug abuse problems.</p>

<p align=center><font color="#8e2323"><b><i>-------Your vision and insight have continued to be a blessing in my
    community and to all those in need of help.-------</i><br>
    --Debra Fraser-Howze, Executive Director,
     Black Leadership Commission on AIDS</b></font></p>

<h4 align=center><a name="second">A SECOND CHANCE</a><br>
    
    RIKERS ISLAND TRANSITIONAL PROGRAM</h4>
    
    <p>Chris M. is a former addict who spent time in prison. He is also
    infected with AIDS. Upon his release, Chris returned home to find his
    wife still using drugs. With the help of A Second Chance, Chris was
    placed in a drug free environment and attended the ARRIVE training
    to learn how to cope with living with the disease.</p>
    
    <p>Even before their release back into the community, drug and alcohol
    addicted and HIV positive inmates at Rikers Island Correctional Facility
    can begin to ease their transition back into everyday life.</p>
    
   <p> Part-time peer educators deliver over 50 AIDS and substance abuse
    trainings per year at the prison site. Two full time counselors do pre-
    release work and assist inmates to access medical, vocational, housing,
    and drug treatment services upon their release.</p>

 <p align=center><font color="#8e2323"><b><i>-------When my self-esteem was low, ARRIVE helped me to believe in myself. The
    program put structure in my life which in turn has made me a successful
    person in society today. l am now employed as a Community Liaison Worker.-------</i><br>
    Theresa, ARRIVE Graduate 1991</b></font></p>

 <h4 align=center><a name="cape">COMMUNITY AWARENESS AND PEER EMPOWERMENT<br>
                              C.A.P.E.</a></h4>
    
    <p>Robert A. had spent 15 years in the Arthur Kill State Prison, and 13
    years injecting drugs. Upon his release, he joined ARRI VE, stayed on
    afterwards as a volunteer, and attended CAPE's employment
    readiness trainings. Within six months, he was working full time for a
    research institute . Robert lives a drug and criminal free life and is
    the responsible father of two children.</p>
    
    <p>CAPE is the next level of training and education an ARRIVE graduate
    may choose to enter to further develop their skills. CAPE prepares
    graduates for peer counseling employment at hospitals, drug counseling
    centers, community based and public service organizations. Participants
    are taught facilitation, counseling, training, outreach, wellness, nutrition,
    parenting, stress management and coping skills. Current information
    about HIV/AIDS, tuberculosis, and other infectious diseases is
    discussed and integrated into the trainees' skill base.</p>
    
    <p>Program participants take part in meetings with senior staff to
    enhance their ability to facilitate support groups, and make
    presentations. In addition to basic program services, referral,
    counseling, and acupuncture services are available. All CAPE
    participants receive basic computer training and learn how to write a
    resume. Last year, 50% of the CAPE participants became employed
    in the AIDS and substance use fields before they finished the
    program.</p>

<p align=center><font color="#8e2323"><b><i>-------The way I look at it, ARRIVE saved my life. The information I needed to cope
    with this virus was there so I could take proper care of myself.-------</i><br>
    Juan, ARRIVE Graduate, Cycle 1, 1988</b></font></p>

 <h4 align=center><a name="arrive">ARRIVE <br>TRAINING AND SUPPORT 
    PROGRAM</a><br></h4>
    
<p>ARRIVE offers health, help and hope. It is a unique healing/learning
    community designed to combat AIDS and addiction through
    nurturing and education. ARRIVE provides an optimistic, supportive
    training environment where clients take an active role in their own
    education. ARRIVE believes in building bridges through 'user-
    friendly' outreach services. Using an harm reduction approach, the
    program accepts both active and recovering drug users into its non-
    judgmental and structured environment. ARRI VE's enriched
    curriculum motivates clients to charge negative behaviors while
    providing continuing support, AIDS education and employment
    training.</p>
    
    <p>Since 1988, ARRIVE has been educating and motivating high risk
    groups of individuals to seek appropriate treatment and conquer the
    threats they face. Dynamic trainers, gifted counselors and peer
    educators create a safe and nurturing environment. Many of the staff
    members are ax-addicts and exoffenders who are sensitive to the
    enormous task of recovery and stand as models of success working in
    society today. Through a structured insight-oriented training program,
    ARRIVE offers hope and vision to those who desire to work for
    change.</p>
    
    <p>Skills to prevent relapse into self destructive behaviors and improve
    self-worth, challenge participants' growth throughout the two month
    training. The program's communications and presentation classes help
    students to transform personal experience into marketable skills. Class
    topics include: addiction and depression, long-term survival skills,
    stress management/meditation and preventing infectious disease. A
    graduation is held at the end of the program to honor the students'
    achievements and to allow them to acknowledge their own growth
    and strength and share this with their families.</p>
    
    <p>Classes are held Monday, Tuesday, and Thursday from 2 - 4:30 PM
    and from 6:30 - 9 PM at 151 West 26th Street, 3rd Floor. For more
    information call (212) 243-3434.</p>
   
    <p align=center><font color="#8e2323"><b><i>-------ARRIVE is an excellent program that is active and has been successful in my
    District. It was instituted to provide services and training to parolees with
    substance abuse problems, a grossly underserved population.-------</i><br>
    The Honorable Charles R. Rangel<br>
     Congressman, New York</b></font></p>

<h4 align=center><a name="facts">IMPORTANT FACTS ABOUT EXPONENTS 
    PROGRAMS</a></h4>
    <ul>

<li> EXPONENTS Inc. is a 501 (c) (3) non-profit organization.

<li>A dedicated staff, innovative service methods and thousands of volunteer
    hours keep the cost of the ARRIVE training and support services at under
    $1,000 per student.
    
    <li> Prevention pays: It is estimated that over the course of their lives, persons
    living with HIV will incur medical costs of over $110,000. If ARRIVE prevents
    AIDS transmission in 10 individuals in one year, the financial savings would be
    equal to Exponents annual budget. If ARRIVE can help someone to stay out of
    the hospital for one day, the savings woul cover the entire cost of that
    individuals ARRIVE training. If ARRIVE helped someone to stay out of prison
    for one week, the savings would be more than the cost of their ARRIVE training.
    
    <li>In 1995, 923 substance users registered for ARRIVE's 24 class, 8 week
    trainings. 755 students were actually seated (capacity) and 81% completed
    program. Significantly, 53% were women, 61% were African American a' 32%
    were Hispanic. Upon completion, 288 graduates (44%) volunteered their
    services to the program.
    
   <li> At least 35% of all ARRIVE graduates entering the Program on public
    assistance, move from welfare to full or part time employment.
    
   <li> A recent survey indicates that virtually every graduate has referred at least
    one person to ARRIVE.
    
    <li> By the end of 1995, 4500 substance abusers and/or their family member have
    registered for ARRIVE. Not a single person has ever been coerced or mandated
    by the criminal justice system to enroll in the program.
    
   <li> Over 50% of CAPE participants find jobs in human services.
    
    <li>Staff and peer educators provide over 60,000 client contact hours yearly
    
    <li> Each year a network of over 200 health, human service and justice
    organizations refer clients to Exponents for training and support services.
    
   <li> Exponents has 16 full time staff members, 13 of which provide direct client
    service.
    
    <li> In 1995, 7,350 hours of volunteer services have been donated by
    program graduates to the community.
    
   <li> 8,000 people have attended outreach and education presentations since
    March of 1995.
    </ul>
<p align=center><img  height="4" width="400" src="gifs/brick.gif"></p>

<h4 align=center> <a name="director">FROM the EXECUTIVE DIRECTOR</a></h4>
    
    <p>When we began our work in 1988, AIDS related services for substance users were
    non-existent. It is gratifying that we have recently begun to recognize the
    importance of HIV prevention and care amongst drug users as they constitute the
    majority of new infections and new AIDS cases. In the last five years, our work
    has expanded to include the training of peer workers for service providers in the
    HIV field. In this manner, we feel that the impact of our work is even more far
    reaching. We are also gratified by the support and recognition by Exponents'
    clients and funders as they increasingly depend upon us to deliver effective and
    compassionate services. As more and more individuals seek entry to our
    programs, we reaffirm our commitment to them and to the general public, whose
    health we seek to maintain.</p>
    
    <p>Exponents' programs are driven by three principles. First, the programs are peer-
    oriented and rooted in therapeutic community philosophy of a community of
    former substance abusers helping other substance abusers. The programs seek to
    motivate substance users in the fight against AIDS by giving them a role to play.
    The second principle forming Exponents' programs is harm reduction. Exponents
    accepts active users and encourages positive, incremental changes in risk
    reduction behaviors. A third and related principle behind Exponents is of
    individual responsibility and empowerment. Program are insight-oriented in that
    they present information and opinions from many different substance abuse and
    medical treatment modalities and encourages self-discovery, individual choice
    and positive action.</p>
    
    <p>Howard Josepher, CSW<br>

    May, 1996</p>

</font>   
</blockquote>
<p align=center><img  height="4" width="400" src="gifs/brick.gif"></p>
<p align=center><a href="../index.html"><img src="gifs/wturn.gif" vspace=5 alt=" "><br><b>www.aidsnyc.org</b></font></a></P>

<table width=100%>
<tr valign=top>
<td><font size=-1 face="arial, helvetica">Last modified 8/1/96<br>
<a href="mailto:hivinfo@aidsnyc.org">Arrrive Exponents, Inc.</a><br>
copyright &#169; 1996</font></td>
<td align=right><font size=-1 face="helvetica, arrive">This site is part of <a href="../index.html">www.aidsnyc.org</a> and is designed <br>and maintained by Joel Beard courtesy of the <br><a href="../network/index.html">AIDS Treatment Data Network</a>.</font><td></tr></table>
</font>

</body>
</html>
    
    
         
                                 
</DOC>
<DOC>
<DOCNO>WT18-B31-195</DOCNO>
<DOCOLDNO>IA093-001001-B046-98</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/congress.html 199.29.141.24 19970121120443 text/html 2701
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:58:50 GMT
Server: NCSA/1.5.1
Last-modified: Fri, 20 Dec 1996 15:48:00 GMT
Content-type: text/html
Content-length: 2518
</DOCHDR>
<html>
<head>
<title>www.aidsnyc.org: access to Congress</title>
</head>
<body bgcolor="#ffffff" link="#8b2323" vlink="#696969"><font face="century gothic, arial, helvetica">

<p align=center><font size=+2><a

href="index.html"><b>www.aidsnyc.org</b></a></font>

<p align=center><img src="gifs/purple.gif" height=4 width=500  align=center alt=""></p>

<blockquote>

<p><b>This page provides ways of contacting your representatives. <a href="http://www.thecure.org/action.html">Action Alerts</a> are posted on the National Association of People With AIDS site. Check out the <a href="http://www.thebody.com/aac/aacix.html">AIDS Action Council</a> for articles on current research and action alerts. Alerts also posted on <a href="http://www.actupny.org">ACT UP New York</a>, see <a href="http://www.actupny.org/ADAPemergency.html">ADAP Emergency</a>.</b></p>

</blockquote>
<table width=100%><tr>
<th bgcolor="cdcdcd"><font face="helvetica, arial" color="#000000"><b><font color="#8b2323">NEW!</font> The <A HREF="http://www.housingworks.org/zap.htm">Housing Works Zap</A> page is designed so you can sign on to actions. </b></font></td></tr></table>

<blockquote><blockquote>
<ul>
<li> <A HREF="http://www.berkshire.net/~ifas/activist/"><b>The Electronic Activist</b></A> <dt>Educate your representatives via e-mail! 
<p> 
<li> <A HREF="http://www.geocities.com/CapitolHill/1007/"><b>Congressional E-Mail Addresses</i></A>
<p>
<li><form method=post action="http://www.voxpop.org/cgi-bin/Zipcodes/Fly.pl"><a href="http://www.stardot.com/zipper/"><b>Zipper</b></a>
<p>
<dt>Find your representative or senator with Stardot's <b><i>Zipper</i></b>
<br>
<br>
<code><b>Zip code:</b></code> <input type=text name="zip" size=10> <input type=submit value="search"> <br><br> <input type="radio" name="a" value="h" checked>representative <input type="radio" name="a" value="s">senators </form>
</ul>
</blockquote>
<p><b>This page is borrowed in part from the <a href="http://www.users.interport.net/~clueless/nama1.html">National Alliance of Methadone Advocates</a> page.</b></p>

</blockquote>

<p align=center><img src="gifs/purple.gif" height=4 width=500  align=center alt=""></p>

<p align=center><a href="index.html"><img src="gifs/wturn.gif" vspace=5 vspace=5><br> <font size=-1>www.aidsnyc.org</font></a></p>

<p align=center><font size=-1>last modified: 12/21/96<br> write to: <a href="mailto:hivinfo@aidsnyc.org">hivinfo@aidsnyc.org</a><br> copyright &#169; 1996 www.aidsnyc.org</b></font></p> 

</font>
</body> 
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-196</DOCNO>
<DOCOLDNO>IA093-001001-B046-115</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/fc/index.html 199.29.141.24 19970121120457 text/html 4226
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:58:58 GMT
Server: NCSA/1.5.1
Last-modified: Wed, 08 Jan 1997 14:43:35 GMT
Content-type: text/html
Content-length: 4043
</DOCHDR>
<html>
<head>
<title>Family Center</title>
</head>
<body background="gifs/gold.gif"><font face="arial, helvetica" size=-1>

<blockquote>

<img src="gifs/fc.gif" alt="logo" hspace=5 align=left><p><font size=+1><b><A HREF="programs.html">Programs</A><br>
<br>
<A HREF="pubs.html">Publications</A><br>
<br>
<a href="jobs.html">Job Postings</a><br>
<br>
<a href="events.html">Events</a></b></font></p>

<br clear=left>

<h3>PROBLEM</h3>

<p>As AIDS continues to claim lives nationwide, a rising number of children and adolescents are being left behind.  By the year 2001, 50,000 young people in New York City will lose at least one parent to the epidemic.  Most affected families live in economically disadvantaged communities.</p>

<h3>BACKGROUND</h3>

<p>In 1991, Barbara Draimin, DSW and colleagues at New York City's Department of Social Services began to explore the needs of healthy adolescents in families with AIDS.  They found that little had been done to prepare these youngsters for parental death, mourning or rebuilding their lives.  Without viable care plans and stigmatized by their association with HIV infection, surviving children were more anxious about being separated from their siblings and often forced into a series of temporary placements.</p>

<p>The Family Center, a program of the Medical and Health Research Association of New York City, Inc. (MHRA), was launched the following year with Barbara Draimin as its director.</p>

<h3>MISSION</h3>

<p>The mission of The Family Center is to strengthen children and their families as they move through the transitions caused by the loss of a parent.  The Center is guided by the beliefs that:</p>

<ul>
<li>Every child deserves an answer to the question:  "Who will take care of me?" 
<li>Children are served most effectively within the context of their families and their communities. 
<li>Changing the life of a child can change the face of the future.  
</ul>

<h3>GOALS</h3>

<p>The Family Center provides direct services, conducts research, disseminates information and leads advocacy efforts designed to:</p>

<ul>
<li>Assist seriously ill, HIV-infected parents to plan for the future of their children.
<li>Develop support structures such as a buddy program that ease a child's transition from one caregiver to another.
<li>Help new caregivers create an environment that fosters connection, stability, and love among all family members.
<li>Conduct research that documents the problems and strengths of families affected by AIDS and measures the effectiveness of model programs and services.
<li>Help children broaden their vision, enlarge their goals, and learn the skills necessary to avoid risky sexual behaviors and drug use.
<li>Establish a computer center for children to learn skills, network with one another, and become educated in computer science.
<li>Increase public awareness of the issue of orphaned children.
<li>Enhance communication among professionals working with families.
</ul>

</blockquote>

<p align=center><img src="gifs/purple.gif" width=50% height=4></p>

<center><table cellpadding=4>
<tr>
<td align=center><font size=-1 face="arial, helvetica">
<a href="programs.html"><img src="gifs/hands.gif" vspace=5><br>
<b>Programs</b></a></font></td>
<td align=center><font size=-1 face="arial, helvetica">
<a href="pubs.html"><img src="gifs/books.gif" vspace=5><br>
<b>Publications</b></a></font></td>
</tr>
</table></center>

<p align=center><img src="gifs/purple.gif" width=50% height=4></p>

<table width=100%>
<tr valign=top>
<td><font face="arial, helvetica" size=-1><a href="mailto:jsanchez@aidsnyc.org"><b>The Family Center</b></a><br>
copyright &#169; 1996 <br>
Last modified: 11/20/96</font></td>
<td align=right><font face="arial, helvetica" size=-1>The Family Center site is part of <a href="../index.html"><b>www.aidsnyc.org</b></a>. <br>These pages are designed and maintained by Joel Beard <br>courtesy of the <a href="../network/index.html"><b>AIDS Treatment Data Network</b></a>.</font></td>
</tr>
</table>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-197</DOCNO>
<DOCOLDNO>IA093-001001-B046-131</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/glwd/index.html 199.29.141.24 19970121120507 text/html 4015
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:59:14 GMT
Server: NCSA/1.5.1
Last-modified: Wed, 08 Jan 1997 14:43:56 GMT
Content-type: text/html
Content-length: 3832
</DOCHDR>
<META  name="description" 
content="Nutrition information, food guides in English, Spanish and Creole, and meals for home-bound people with HIV/AIDS.">
<META  name="keywords" content="HIV, AIDS, nutrition, food, diet, modifications">
<html>
<head>
<title>God's Love We Deliver</title>
</head>
<body bgcolor="#ffffff" text="#000000" link="#000000" vlink="#ff0000"><font face="arial, helvetcia" size=-1>

<p align=center><img src="gifs/line.gif"></p>

<table cellpadding=10><tr>
<td><img src="gifs/logo.gif" alt="[logo"]></td><td><font face="arial, helvetcia" size=-1><a href="fact.html">Fact Sheet</a> | <a href="amsp.html">Other AIDS Meal Service Providers in the US</a></font></td>
<p>
</tr><tr>
<td><img src="gifs/client.gif" alt="[client services]"></td><td><font face="arial, helvetcia" size=-1><a href="book1.html">Who are our clients</a> | Other Resources</font></td>
<p>
</tr><tr>
<td><img src="gifs/nutri.gif" alt="[nutrition information]"></td><td><font face="arial, helvetcia" size=-1><a href="tips6-94.html">Eating Tips - English |</a> <a href="spanish/tips-sp.html">Eating Tips - en espa&ntilde;ol</a> | <a href="guides/gen.html">Nutrition Guides</a> | <a href="mods.html">Dietary Modification List</a> | <A HREF="recipes.html">Recipes</A></font></td>
<p>
</tr><tr>
<td><img src="gifs/vol.gif" alt="[volunteer opportunities]"></td><td><font face="arial, helvetcia" size=-1><a href="vol/volopp4.html">Kitchen Opportunities</a> | Holiday Help | <a href="vol/nmdcflyr.html">Recruitment Flyer</a></font></td>
<p>
</tr><tr>
<td><img src="gifs/emp.gif" alt="[employment opportunities]"></td><td><font face="arial, helvetcia" size=-1><a href="jobs/nas.html">Nutrition Activities Scheduler</a> | <a href="jobs/deldir.html">Director of Delivery</a> | <a href="jobs/devasst.html">Development Associate</a> | <a href="jobs/dirprog.html">Director of Program and Community Relations</a> | <a href="jobs/janitor.html">Janitor/Handyperson</a></font></td>
<p>
</tr><tr>
<td><img src="gifs/spec.gif" alt="[special events]"></td><td><font face="arial, helvetcia" size=-1><a href="dev/mpconf.html">The 1996 AIDS Meals Providers Conference</a> | <a href="dev/rtdsue.html">Race to Deliver</a></font></td>
<p>
</tr><tr>
<td><img src="gifs/act.gif" alt="[activities]"></td><td><font face="arial, helvetcia" size=-1><a href="tiles.html">Memorial Tiles</a> | <a href="dev/dev.html#news">Newsletter</a> | <a href="dev/dev.html#shirt">T-shirt</a> | <a href="dev/dev.html#gifts">Holiday Gifts</a> | <a href="dev/dev.html#giving">Planned Giving</a> | <a href="dev/dev.html#wish">Wish List</a> | <a href="dev/dev.html#ways">Other Ways to Contribute</a></font></td>
<p>
</tr><tr>
<td><img src="gifs/pub.gif" alt="[publications]"></td><td><font face="arial, helvetcia" size=-1><a href="pubs/ta.html">TA Manual</a> |<a href="tips6-94.html">Eating Tips - English |</a>  <a href="spanish/tips-sp.html">Eating Tips - en espa&ntilde;ol</a> | <a href="pubs/book-sum.html">Food Guides</a></font></td>
<p>
</tr><tr>
<td><img src="gifs/kit.gif" alt="[kitchen]"></td><td><font face="arial, helvetcia" size=-1><a href="master.html">GLWD Menu Cycle</a></font></td>
<p>
</tr>
</table>

<p align=center><img src="gifs/line.gif"></p>

<p align=center><a href="../index.html"><img src="../gifs/wturn.gif" hspace=5 alt=" "><br>www.aidsnyc.org</font></a></P>

<table width=100%>
<tr>
<td><font face="arial, helvetcia" size=-1>Last modified 8/15/96<br>
<a href="mailto:glwd@aidsnyc.org">God's Love We Deliver</a><br>
copyright &#169; 1996 GLWD</font></td>
<td align=right><font face="arial, helvetcia" size=-1>The GLWD site is part of <a href="../index.html">www.aidsny.org</a>. <br>These pages are designed and maintained by Joel Beard <br>courtesy of the <a href="../network/index.html">AIDS Treatment Data Network</a>.</font><td></tr></table>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-198</DOCNO>
<DOCOLDNO>IA093-001001-B046-147</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/about.html 199.29.141.24 19970121120515 text/html 6090
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:59:23 GMT
Server: NCSA/1.5.1
Last-modified: Wed, 08 Jan 1997 14:30:43 GMT
Content-type: text/html
Content-length: 5907
</DOCHDR>
<html>
<head>
<title>About the HIV/AIDS Information Outreach Project</title>
</head>

<body bgcolor="#ffffff" link="#8b2323" vlink="#696969"><font face="arial, helvetica" size=-1>

<p align=center><img src="gifs/purple.gif" height=4 width=500  align=center alt=""></p>

<h2><img src="gifs/hippox.gif" align=left hspace=8 alt=" ">
About the HIV/AIDS <BR>Information Outreach Project<BR>
<FONT SIZE=-1>For community based organizations working with people affected by HIV/AIDS</FONT></h1>

<p align=center><img src="gifs/purple.gif" height=4 width=500  align=center alt=""></p>

<blockquote>
<h2 align=center><img hspace=5 src="gifs/star1.gif">Who are we?<img hspace=5 src="gifs/star1.gif"></h2>

<p>The HIV/AIDS Information Outreach Project is founded on the premise that information will support and strengthen those people affected by HIV/AIDS and those who work to provide for their needs.</P>

<P>The <a href="http://www.nyam.org/index.html">New York Academy of Medicine</a> is dedicated to improving the health of the public and, in particular, to addressing issues in urban health. The Academy is a leader in the field of public health, an independent voice to advance the well-being of all people.</P>

<P>The New York Academy of Medicine Library immediately responded to the HIV/AIDS epidemic by serving as a primary source of information to community-based organizations. With over 700,000 volumes and 2,000 journals, it is one of the largest medical libraries in the world. The <a href="http://www.nyam.org/library/about.html">Academy Library</a> maintains strong and important collections in areas associated with HIV/AIDS and has staff with expertise in HIV/AIDS information resources.</p>

<p align=center><img src="gifs/purple.gif" height=4 width=500  align=center alt=""></p>

<h2 align=center><img hspace=5 src="gifs/star1.gif">Who are you?<img hspace=5 src="gifs/star1.gif"></h2>

<UL>
<LI>Not for profit community-based organizations that respond to the needs of those whose lives have been affected by the HIV/AIDS epidemic.
<P>
<LI>An agency dealing with adolescents interested in designing a peer education program for at-risk youth.
<P>
<LI>The director of an AIDS service organization who needs help in identifying funding sources for treatment education.
<P>
<LI>A social worker whose client is a seropostive woman and needs information on the use of antiviral therapy to reduce the risk of transmission to the fetus.
<P>
<LI>A health care provider seeking information about the possible relationship between a weak heart muscle and HIV infection, to better serve a client.
<P>
<LI>A case manager enabling a family member to locate services for older persons living with AIDS.
<P>
</UL>
<P>In response to the HIV/AIDS epidemic, dozens of community-based organizations have been established to deliver supportive services to people living with AIDS and to their loved ones.</P>

<P>The Academy Library established the HIV/AIDS Information Outreach Project to assist these community-based organizations in providing vital services.</P>

<p align=center><img src="gifs/purple.gif" height=4 width=500  align=center alt=""></p>

<h2 align=center><img hspace=5 src="gifs/star1.gif">How can we help?<img hspace=5 src="gifs/star1.gif"></h2>

<P>The project will provide participating community-based organizations with:</P>
<UL>
<LI>Training in locating sources of HIV/AIDS information
<DT><i>Training and support for staff and clients in the use of electronic and print sources of information.</i>
<P>
<LI>Access to online databases
<DT><i>Access to the databases of the National Library of Medicine through Grateful Med, an easy to use front-end software.</i>
<P>
<LI>Research services
<DT><i>Including online searching, preparation of bibliographies and data retrieval.</i>
<P>
<LI>Internet assistance
<DT><i>Help in obtaining current research and in publishing your materials over the Internet.</i>
<P>
<LI>Computer hardware
<DT><i>Allowing participating organizations to borrow laptop comuters to provide on-site access to electronic resources.</i>
<P>
<LI>Access to published literature
<DT><i>Full-text of journal articles, technical reports and other publications delivered by fax or mail.</i>
<P>
</UL>
<H3 align=center>All services are free of charge.</h3>

<p align=center><img src="gifs/purple.gif" height=4 width=500  align=center alt=""></p>

<h2 align=center><img hspace=5 src="gifs/star1.gif">How to reach us?<img hspace=5 src="gifs/star1.gif"></H2>

<ADDRESS>
<p align=center><B>Write</B><BR>
HIV/AIDS Information Outreach Project<br>
New York Academy of Medicine Library<br>
1216 Fifth Avenue
<br>New York, NY 10029<BR><BR>
<B>Call, fax or e-mail</B><BR>
Phone: 212-822-7318<br>
Fax: 212-423-0266<br>
E-Mail: <a href="mailto:hivinfo@aidsnyc.org">hivinfo@aidsnyc.org</a></p>
</ADDRESS>

<P>The director of the community-based organization should call or write the Project. The organization will need to fill out a questionnaire and submit information about the services provided and the population served.</P>

</blockquote>

<p align=center><img src="gifs/purple.gif" height=4 width=500  align=center alt=""></p>

<P align=center><A HREF="index.html"><img hspace=5 align=center src="gifs/wturn.gif"><br><font size=-1>www.aidsnyc.org</A></font></P>

<p align=center><img src="gifs/purple.gif" height=4 width=500  align=center alt=""></p>

<P><img hspace=5 align=left src="gifs/hippox.gif" alt=" "><A HREF="mailto:hivinfo@aidsnyc.org">hivinfo@aidnyc.org</A><br>
Last modified 8/29/96<BR>
copyright  &#169; 1996<br>
The New York Academy of Medicine</P>

<BR CLEAR>
<H5 align=center>The HIV/AIDS Information Outreach Project is funded by the National Library of Medicine, the AT&T Foundation and the New York Academy of Medicine. Site designed and maintained by Joel Beard courtesy of the <br><a href="network/index.html">AIDS Treatment Data Network</a>.</H5>


</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-199</DOCNO>
<DOCOLDNO>IA093-001001-B046-165</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/heal/index.htm 199.29.141.24 19970121120530 text/html 1770
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:59:37 GMT
Server: NCSA/1.5.1
Last-modified: Mon, 02 Dec 1996 12:29:01 GMT
Content-type: text/html
Content-length: 1587
</DOCHDR>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>

<HEAD>

<META NAME="GENERATOR" CONTENT="Internet Assistant for Word 1.0Z">
<META NAME="AUTHOR" CONTENT="Edward Lieb">
</HEAD>
<BODY>

<H2>Welcome to HEAL - Health Education AIDS Liaison</H2>

<P>
HEAL is a non-profit, community based service organization founded
in New York City in 1982. The efforts of HEAL's president, Dr.
Michael Ellner, and HEAL's science advisor, Dr. Frank Buianouckas,
have inspired an international movement challenging the HIV/AIDS
hypothesis and HIV-based treatment protocols. Since 1985, HEAL
(NYC) has been the leading source for comprehensive information
on the many effective, non-toxic, natural and holistic approaches
to recovering and maintaining health. There are presently independent
HEAL chapters in Texas, New England, Minnesota, Detroit, Miami,
San Diego, Seattle, Vancouver, London, Buenos Aires and Australia.
<UL>
<LI><A HREF="interact.htm">The Interactive AIDS Test</A> - The
at-home AIDS test that could save your life! [UNDER CONSTRUCTION]
<LI><A HREF="main.htm">HIV/AIDS Information</A> - Links to various
articles about HIV and AIDS
<LI><A HREF="reading.htm">Recommended Reading</A> - List of books
and articles to read
<LI><A HREF="chapters.htm">HEAL Chapters Throughout the World</A>

<LI><A HREF="resource.htm">Other HEAL Resources</A> - Audio and
Video Tapes
<LI><A HREF="aidslink.htm">Links to Other Dissident AIDS Sites</A>

</UL>
<HR>

<ADDRESS>
This site brought to you by HEAL NY. 
</ADDRESS>

<ADDRESS>
Web page designed by Carlos E. Pereira. 
</ADDRESS>

</BODY>

</HTML>

</DOC>
<DOC>
<DOCNO>WT18-B31-200</DOCNO>
<DOCOLDNO>IA093-001001-B046-181</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/docorder.html 199.29.141.24 19970121120538 text/html 5561
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 11:59:46 GMT
Server: NCSA/1.5.1
Last-modified: Wed, 01 Jan 1997 00:06:27 GMT
Content-type: text/html
Content-length: 5378
</DOCHDR>
<html>
<head>
<title>www.aidsnyc.org: order a document online</title>
</head>
<body background="gifs/strip.gif" width=1008 height=36  link="#8b2323" vlink="#696969"><font face="garamond">

<table width=100%>
<tr>
<td colspan=2><img src="gifs/newlogo.gif" alt="www.aidsnyc.org" width=368 height=55></td>
</tr><tr valign=top>
<td width=134 rowspan=3 align=center><img src="gifs/order.gif" alt="order" width=38 height=217></td>
<td align=left><font face="comic sans ms" size=-1>The HIV/AIDS Information Outreach Project provides community based organizations with: access to online databases; access to the databases of the National Library of Medicine through Grateful Med, an easy to use front-end software; research services including online searching, preparation of bibliographies and data retrieval; and access to published literature with full-text of journal articles, technical reports and other publications delivered by fax or mail. All services are free of charge.</font></td>
</tr><tr>
<td align=left><font face="comic sans ms" size=-1>If you have questions about any of these services, please write the <a href="mailto:pwansor@aidsnyc.org">Project Director</a>. If you know the document(s) you would like, please fill in the order form below.</font></td>
</tr><tr>
<td align=center><hr size=4 width=60% noshade></td>
</tr></table>

<FORM METHOD="post" ACTION="mailto:pwansor@aidsnyc.org?subject=docorder" ENCTYPE="text/plain">
<br clear=left>
<table width=100%>
<tr>
<td width=134><font face=garamond color="#ffffff" size=+1><b>Your Name:</b></font></td><td><INPUT NAME="Name" size=50,1></td>
</tr><tr>
<td><font face=garamond color="#ffffff" size=+1><b>Organization:</b></font></td><td><INPUT SIZE=50,1 NAME="Organization"></td>
</tr><tr>
<td width=134><font face=garamond color="#ffffff" size=+1><b>Address:</b></font></td><td colspan=3><INPUT SIZE=50,1 NAME="Address1"></td>
</tr><tr>
<td width=134>&nbsp;</td><td><INPUT SIZE=50,1 NAME="Address2"></td>
</tr><tr>
<td width=134><font face=garamond color="#ffffff" size=+1><b>Phone:</b></font></td><td><INPUT SIZE=50,1 NAME="Phone"></td>
</tr><tr>
<td><font face=garamond color="#ffffff" size=+1><b>Fax number:</b></font></td><td><INPUT SIZE=50,1 NAME="Fax"></td>
</tr><tr>
<td width=134><font face=garamond color="#ffffff" size=+1><b>Email:</b></font></td><td><INPUT SIZE=50,1 NAME="Email"></td>
</tr><tr>
<td>&nbsp;</td><td align=left><font face="comic sans ms" size=-1>To order a copy of a specific document, please fill in as much information as you have about the item and click on the "Order Document" button.  You can continue to order more documents after pressing the "Order Document" button.</font></td></td>
</tr><tr>
<td><font face=garamond color="#ffffff" size=+1><b>Journal name:</b></font></td><td><INPUT SIZE=35 NAME="Title"></td>
</tr><tr>
<td><font face=garamond color="#ffffff" size=+1><b>Article Title:</b></font></td><td><INPUT SIZE=35 NAME="Article"></td>
</tr><tr>
<td><font face=garamond color="#ffffff" size=+1><b>Author:</b></font></td><td><INPUT SIZE=35 NAME="Author"></td>
</tr><tr>
<td><font face=garamond color="#ffffff" size=+1><b>Publisher:</b></font></td><td><INPUT SIZE=35 NAME="Publisher"></td>
</tr><tr>
<td><font face=garamond color="#ffffff" size=+1><b>ISSN/ISBN:</b></font></td><td><INPUT SIZE=35 NAME="ISSN/ISBN"></td>
</tr><tr>
<td><font face=garamond color="#ffffff" size=+1><b>Date:</b></font></td><td><INPUT SIZE=10 NAME="Date"></td>
</tr><tr>
<td><font face=garamond color="#ffffff" size=+1><b>Vol. number:</b></font></td><td><INPUT SIZE=10 NAME="Volume"></td>
</tr><tr>
<td><font face=garamond color="#ffffff" size=+1><b>Issue number:</b></font></td><td><INPUT SIZE=10 NAME="Issue"></td>
</tr><tr>
<td><font face=garamond color="#ffffff" size=+1><b>Page numbers:</b></font></td><td><INPUT SIZE=20 NAME="Pages"></td>
</tr><tr>
<td>&nbsp;</td><td align=center><font size=-1 face="comic sans ms">If the citation you have does not fit this format, please use the following space to enter the information.  You can also use this space to &quot;paste&quot; in a list of citations.</td>
</tr><tr>
<td>&nbsp;</td><td align=center><TEXTAREA NAME="Citation" ROWS=10 COLS=50> </TEXTAREA></td>
</tr><tr>
<td>&nbsp;</td><td align=center><font face="comic sans ms" size=-1>How do you prefer that this document be sent to you?  Choose one of the following options.</font></td>
</tr><tr>
<td>&nbsp;</td><td align=center><font face="comic sans ms" size=-1 color=#8b2323"><b><INPUT TYPE="radio" NAME=Deliver VALUE="Fax">Fax <INPUT TYPE="radio" NAME=Deliver VALUE="Firstclass">First Class Mail <INPUT TYPE="radio" NAME=Deliver VALUE="Pickup">I will pick up</b></font></td>
</tr><tr>
<td>&nbsp;</td><td align=center><INPUT TYPE="submit" VALUE="ORDER DOCUMENT">  <input type="reset" value="CLEAR ORDER FORM"></td>
</tr><tr>
<td width=134><font face="garamond" color="#ffffff">last modified: <b>12/31/96</b><br>
copyright &#169; 1996 www.aidsnyc.org</font></td>
<td align=center><font face="comic sans ms" size=-1><br><b><font color="#8b2323">Note</font>: When the browser says Done or the URL address location (at the top of the page) says  "<FONT COLOR="#8b2323">mailto:pwansor@aidsnyc.org</FONT>" your order has been successfully sent.  <br><A HREF="index.html">Return to www.aidsnyc.org.</a></b></font><br><br>
<hr size=4 width=60% noshade></td>
</tr>
</table>
</form>

</body>
</html>


</DOC>
<DOC>
<DOCNO>WT18-B31-201</DOCNO>
<DOCOLDNO>IA093-001001-B046-198</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/momentum/index.html 199.29.141.24 19970121120610 text/html 4031
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:00:16 GMT
Server: NCSA/1.5.1
Last-modified: Thu, 09 Jan 1997 01:08:04 GMT
Content-type: text/html
Content-length: 3848
</DOCHDR>
<html>
<head>
<title>Momentum AIDS Project</title>
</head>
<BODY BACKGROUND="gifs/1.gif"><FONT COLOR="#000000">
<P ALIGN=CENTER><img src="gifs/edwin.gif" alt="Momentum AIDS Project: Food and Family for People with HIV"></P><HR>

<P ALIGN=CENTER><b><BLOCKQUOTE>The Momentum AIDS Project is the only community-based organization that
provides communal meals and supportive services in a neighborhood setting to New Yorkers with HIV and their families. We provide meals, pantry bags, nutrition information, and counseling
for 1,500 people with HIV at eight sites in Manhattan, Queens, Brooklyn, and the Bronx.</BLOCKQUOTE></b></p>

<CENTER><table width=85% border=0 cellpadding=10 colspec="33% 33% 33%">

<TR><TD VALIGN=TOP><a href="about.html"><CENTER><IMG SRC="gifs/plate.gif" HEIGHT=100 WIDTH=100 ALIGN=TOP BORDER=0></CENTER><FONT SIZE=-1><P ALIGN=CENTER><B>Momentum AIDS Project Fact Sheet</B></P></FONT></a></TD>

<TD VALIGN=TOP><a href="fullserv.html"><CENTER><IMG SRC="gifs/plate.gif" HEIGHT=100 WIDTH=100 ALIGN=TOP BORDER=0></CENTER><FONT SIZE=-1><P ALIGN=CENTER><B>Client Services</B></P></FONT></A></TD>

<TD VALIGN=TOP><A HREF="volun.html"><CENTER><IMG SRC="gifs/plate.gif" HEIGHT=100 WIDTH=100 ALIGN=TOP BORDER=0></CENTER><FONT SIZE=-1><P ALIGN=CENTER><B>Volunteer Opportunities</B></P></FONT></A></TD></TR>

<TR><TD VALIGN=TOP><A HREF="helpus.html"><CENTER><IMG SRC="gifs/plate.gif" HEIGHT=100 WIDTH=100 ALIGN=TOP BORDER=0></CENTER><FONT SIZE=-1><P ALIGN=CENTER><B>Other Ways You Can Help Maintain
Momentum</B></P></FONT></A></TD>

<TD VALIGN=TOP><A HREF="refer.html"><CENTER><IMG SRC="gifs/plate.gif" HEIGHT=100 WIDTH=100 ALIGN=TOP BORDER=0></CENTER><FONT SIZE=-1><P ALIGN=CENTER><B>How to Become a Client or Refer Clients to Us</B></P></FONT></A></TD>

<TD VALIGN=TOP><A HREF="menu.html"><CENTER><IMG SRC="gifs/plate.gif" HEIGHT=100 WIDTH=100 ALIGN=TOP BORDER=0></CENTER><FONT SIZE=-1><P ALIGN=CENTER><B>Momentum Sites, Schedules, and Food Menus</B></P></FONT></A></TD></TR>
</TABLE></CENTER>



<P ALIGN=CENTER>


<IMG SRC="gifs/new2.gif" align=top hspace=5><A HREF="nutrition.html"><FONT SIZE=+1><B>Nutrition News</B></FONT></A><BR>
<A HREF="online.html"><B>Other Online Resources</B></A><BR>
<A HREF="other.html"><B>Other Places in NYC to Get Meals</B></A><BR>
<A HREF="special.html"><B>Special Events</B></A> (updated 1/2/97)<BR>
<A HREF="staffpro.html"><B>Meet Our Staff</B></A> (updated 12/12/96)<BR>
</P><P><TABLE><TR><TD>
<BLOCKQUOTE><B>Need some comprehensive information on how to start a meal program for people with HIV in your area?  Watch for our soon-to-released on-line <A HREF="faketech.html">Technical Assistance Manual</A>, coming March 1, 1997.</B></BLOCKQUOTE></TD></TR></TABLE>

</TABLE></CENTER>

<br clear=left>
<P>
<P>
<P>
<br>
<center><table border=6 padding=6 cellspacing=6 width=90%> 
<tr> <td><font size=-1><B>These pages are maintained by <a href="mailto:bmunisteri@aidsnyc.org">Ben Munisteri</a>. Last modified1/8/97 copyright &#169; 1997 Momentum</B></FONT></td>
<P> 
<td><FONT SIZE=-1><B>These pages are housed on the <A HREF="http://www.nyam.org/">New York Academy of Medicine</A> server as part of <a href="../index.html">www.aidsnyc.org</a> and are sponsored by the United Way of New York City/Strategic Alliance Fund.
</B></FONT></td>
<p>
<td><FONT SIZE=-1><B>You are visitor number<BR> <IMG SRC="http://asoftware.com/cgi-sys/Count.cgi?df=asoftw-bmuni" ALIGN=CENTER><BR> since 10/1/96, according to <a href="http://www.asoftware.com/countman.html">CountMan</A>.</B></FONT></TD> <p></tr> 
</table></center>
<P ALIGN=CENTER> <FONT SIZE=-1><B>The Momentum AIDS Project<br> 
155 West 23rd Street<br> 
New York, NY 10011<br>
Phone: (212) 691-8100<br>
Fax: (212) 691-2960</B></FONT><BR>
<A HREF="mailto:momentum@aidsnyc.org"><IMG SRC="gifs/plume.gif" border=0></A></P>
</body>
</html>




















</DOC>
<DOC>
<DOCNO>WT18-B31-202</DOCNO>
<DOCOLDNO>IA093-001001-B046-215</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/natap/index.html 199.29.141.24 19970121120618 text/html 1476
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:00:26 GMT
Server: NCSA/1.5.1
Last-modified: Wed, 15 Jan 1997 20:24:21 GMT
Content-type: text/html
Content-length: 1293
</DOCHDR>
<html>
<head>
<title>National AIDS Treatment Advocacy Project</title>
</head>

<body bgcolor="#ffffff">

<p align=center><a
href="../../Architext/aidsnycquery.html"><b>search www.aidsnyc.org</b></a></p>
<p align=center><img src="gifs/logo.gif" alt="[logo]"></p>

<blockquote><p><b>The National AIDS Treatment Advocacy Project advocates on treatment and policy issues for people with HIV and AIDS with drug companies, government officials (including FDA) and other treatment and policy advocates.</b></p></blockquote>

<p align=center><a href="papers/index.html"><img src="gifs/papers.gif" alt="[position papers"]></a><a href="drug/index.html"><img src="gifs/drug.gif" alt="[drug development]"></a><br>
<a href="conf/index.html"><img src="gifs/conf.gif" "[conference reports]"></a><a href="about.html"><img src="gifs/about.gif" "[about NATAP]"></a></p>

<table width=100%><tr valign=top>
<td>pages modified 1/15/97<br>
<a href="mailto:julev@aol.com">julev@aol.com</a><br>
copyright &#169; 1996 1997 natap</td>
<p>
<td align=right>The NATAP site is part of <a href="../index.html"><b>www.aidsnyc.org</b></a>.<br>These pages are designed and maintained by Joel Beard <br>courtesy of the <a href="../network/index.html"><b>AIDS Treatment Data Network</b></a>.</td>
</tr>
</table>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-203</DOCNO>
<DOCOLDNO>IA093-001001-B046-237</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/orphan/index.html 199.29.141.24 19970121120631 text/html 12084
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:00:38 GMT
Server: NCSA/1.5.1
Last-modified: Wed, 08 Jan 1997 14:44:37 GMT
Content-type: text/html
Content-length: 11900
</DOCHDR>
<html>
<head>
<title>The Orphan Project: Families and Children in the HIV Epidemic</title>
</head>
<body bgcolor="#ffffff" text="#000ff" link="#7093db"><font face="arial, helvetica" size=-1>

<img src="gifs/orphan.gif" alt="[logo]">
<blockquote>
<h2>The Orphan Project:<br>
<font size=+1>Families and Children in the HIV Epidemic</font></h2>

<p>As a result of the AIDS epidemic and its link to drug abuse, New York City is facing demands of caring for a particularly needy group of orphans: children whose parents or caregiving parent have died of AIDS or whose mothers or fathers are unable to function as parents because they are terminally ill.  By the year 2000, as many as 125,000 children and adolescents in the U.S. will have lost their mothers to AIDS.  About a third will be from New York City.</p>

<p>The Orphan Project was established in 1991 by its executive director, <a href="#levine">Carol Levine</a>, to explore policy options to meet the needs of the entire spectrum of affected children -- from dying infants to healthy adolescents.  There is no single solution, and each option has advantages and disadvantages.  Moreover, there are different potential roles for the public and the private sectors.  Of particular concern are issues concerning confidentiality and disclosure, custody and placement, and bereavement.  Most recently The Orphan Project is involved in providing guidance and research around the newly developed service of permanency planning, which assists terminally ill parents in identifying new guardians for their children and executing a legally binding custody plan.</p>

<p>In carrying out its work, The Orphan Project convenes meetings, publishes articles and reports, and develops collaborative work with direct service providers and family members.  Although New York City is its primary focus, The Orphan Project also collaborates with concerned individuals and organizations in other regions, and maintains a focus on global issues relating to orphans of the HIV/AIDS epidemic in the developing world.</p>

<P>The Orphan Project is funded through foundation grants and receives administrative and fiscal support services from the <a href="http://www.interport.net/~fcny">Fund for the City of New York</a>.</p>

<hr size=4 align=center width=50%>


<a href="#pubs"><h3>List of publications and materials</h3></a>
<h3>e-mail:  <a href="http://mailto:dsiegler@uhfnyc.org">The Orphan Project</h3></a>

<hr size=4 align=center width=50%>

<h3><a name="pubs">Publications</a> and materials</h3>

<p>The following materials are available free of charge from the Orphan Project:</p>

<ul>
<li>Carol Levine and David Michaels. <b>Estimates of the Number of Motherless Youth Orphaned by AIDS in the United States</b>, Journal of the American Medical Association  December 23/30, 1992; 268(24): 3456-3461.
<p>
<dt>This reprint contains the first epidemiological formula that estimates the number of youth in the United States who have been or will be left motherless by HIV/AIDS epidemic.  Between 72,000 and 125,000 children and adolescents will have lost their mothers to AIDS by the year 2000.  Includes comments on this growing population's needs.
<p>
<li>Carol Levine and Gary Stein.  <b>Orphans of the HIV Epidemic: Unmet Needs in Six U.S. Cities</b>  (New York:  The Orphan Project, 1994).
<p>
<dt>This 64-page report is based on a two-day conference with representatives from the six U.S. cities with the greatest numbers of youth left motherless by AIDS. These hardest-hit cities are New York, Newark, Miami, San Juan, Los Angeles, and Washington, DC.  Chapters include an Introduction, "Estimating the Number of Children and Adolescents Orphaned by HIV," "Assessing Service Needs," "Adopting Policies and Legal Standards," "Developing an Agenda for Research and Policy Analysis," and an appendix.
<p>
<dt><a href="http://cpn.journalism.wisc.edu/cpn/sections/topics/family-intergen/stories-studies/orphan_sixcities.html"><b>Executive summary of Orphans of the HIV Epidemic</b></a>
<p>
<li>Gary Stein, Carol Levine, Alice Herb.  <a href="http://cpn.journalism.wisc.edu/cpn/sections/topics/family-intergen/stories-studies/orphan_standby.html"><b>New York State's Standby Guardian Law: Recommendations for Amendments, Implementation, and Education</b></a>.  (New York: The Orphan Project, 16 June 1994).
<p>
<dt>White paper report that recommends changes to New York State's existing Standby Guardianship law, which enables terminally ill parents to appoint a guardian who assumes guardianship immediately upon the death of a parent.
<p>
<li>Carol Levine, Gary Stein, Barbara Draimin, Ivy Gamble.  <b>In Whose Care and Custody? Placements and Policies for Children Whose Parents Die of AIDS</b>.  (New York: The Orphan Project, 1994).
<p>
<dt>White paper report that reviews a sample of 43 closed case records and HRA procedures for following children after the death of the parent to see what custody arrangements, if any, were made prior to death.  Also analyzes the benefits and services lost when a parent dies and the benefits potentially available to a new guardian for the 
surviving children.
<p>
<li>The Orphan Project.  <b>Volunteer Opportunities</b>, September 1995.
<p>
<dt>List of the volunteer opportunities of New York agencies that provide permanency planning services to families with AIDS.

</ul>

<p align=right><a href="order.html">To order any of the above publications<img src="gifs/sright.gif" alt="" align=middle vspace=5 hspace=5></a></p>

<p>The following books from the Orphan Project are available from their respective publishers:</p>

<ul>
<li>Carol Levine, ed.  <b>A Death in the Family: Orphans of the HIV Epidemic</b>.  (New York: United Hospital Fund, 1993).  
<p>
<dt>Based on the nation's first conference about the orphans of the HIV/AIDS epidemic, this comprehensive guide describes the problem from the perspectives of epidemiology, law, mental health, program development, advocacy, and personal experience.  It presents policy options and service models, and includes a directory of 70 organizations in the New York City area that provide services to children, parents, and other affected family members.  For ordering information, call the United Hospital Fund's publication program at (212) 494-0700 or write to them at 350 5th Avenue, 23rd Floor, New York, NY  10118.
<p>
<li>Barbara O. Dane and Carol Levine, eds.  <b>AIDS and the New Orphans: Coping with Death</b>.  (Westport, CT: Greenwood Publishing Group, 1994).
<p>
<dt>In this book, experts on bereavement, developmental psychology, spirituality, minority communities, and new programs analyze this population of children and their needs.  Call the Greenwood Publishing Group at (203) 226-1502 or write to them at 88 Post Road West, P.O. Box 5007, Westport, CT  06881-5007.
<p>
<li><B><A name="crisis">Families</A> in Crisis: A Report of the Working Committee on HIV, Children, and Families</B>. (New York: Federation of Protestant Welfare Agencies, 1996).
<p>
<dt>In 1995, the New York State Legislature requested that the <A HREF="../ai/index.html">AIDS Institute</A> of the New York State Department of Health, in conjunction with other relevant agencies and service providers, produce a report on children orphaned by HIV/AIDS and a plan for comprehensive permanency planning in New York State. Substantial increases in the rates of HIV infection among women in New York State and a consequent near doubling of the estimated number of children and adolescents who will be orphaned by maternal HIV/AIDS death by the beginning of the century have vastly expanded the need for services. The Working Committee on HIV, Children, and Families was convened to develop this report and make recommendations. Chapters include an Executive Summary and an Introduction, "Estimated Number of Children and Adolescents Orphaned by Maternal HIV/AIDS Deaths in New York State," "Permanency Planning Experience and Service Need," " Review of Current Law and Regulations Concerning the Children of Parents with HIV/AIDS," "Recommendations of the Working Committee on HIV, Children, and Families," and a list of the members of the Working Committee. Appendices include a Plan for Pilot Demonstration Project, Regional Projections of Children Orphaned by HIV/AIDS, Services Potentially Available to Families Affected by HIV/AIDS, and Methodology for Projections Analysis. Copies of the report may be obtained by contacting: Federation of Protestant Welfare Agencies, 281 Park Avenue South, New York, NY 10010, Tel: (212) 777-4800, Fax: (212) 533-8792.      
</ul>

<p>Other materials (not produced by the Orphan Project):</p>

<ul>
<li>Shelley Geballe, Janice Gruendel, and Warren Andiman, eds.  <b>Forgotten Children of the AIDS Epidemic</b>.  (New Haven, CT: Yale University Press, 1995).
<p>
<li>The Family Center.  <b>A Gift for My Children</b>.  Videotape, 1995.  For information call the Family Center at (212) 766-4522.
<p>
<li>Gay Men's Health Crisis and South Brooklyn Legal Services.  <b>What About My Kids</b>.  Videotape.  For more information call South Brooklyn Legal Services at (718) 237-5546.

</ul>

<hr size=4 align=center width=50%>

<blockquote>
<h4><a name="levine">Carol</a> Levine</h4>

<p>Carol Levine is Executive Director of <b>The Orphan Project: Families and Children in the HIV Epidemic</b>, a research and policy development project analyzing the impact of the epidemic on children whose parents are ill with or have died of HIV/AIDS.  The Orphan Project, which is administered by the Fund for the City of New York, began in 1991 as the successor to the Citizens Commission on AIDS, of which Ms. Levine was also Executive Director.  Before joining the Commission in 1987, she was on the staff of the Hastings Center, a nonprofit research and educational institute in the field of medical ethics.  She was editor of the Hastings Center Report, and managing editor of IRB: A Review of Human Subjects Research.</p>

<p>Ms. Levine was a member of the White House Task Force on Health Care Reform.  She has been a consultant to many groups on AIDS including the World Health Organization, the World Council of Churches, the New York State AIDS Advisory Council, the Federal Office of Protection form research Risks, and has lectured and written extensively on medical ethics, family issues, and AIDS.  Among her books are Taking Sides: Controversial Issues in Biomedical Ethics (Dushkin, 6th ed., 1995), and A Death in the Family: Orphans of the HIV Epidemic (United Hospital Fund, 1993).  Her most recent book is AIDS and the New Orphans: Coping with Death, co-edited with Barbara Dane (Greenwood Publishing Group, 1994).</p>

<p>In 1993, Ms. Levine was one of 31 winners of MacArthur Fellowships awarded by the John D. and Catherine T. MacArthur Foundation.  In January 1995, Ms. Levine was one of four MacArthur Fellows invited to present their work at that Foundation's staff retreat.  In March 1994, Ms. Levine was named one of eight recipients of the Prudential Foundation Prize for Non-Profit Leadership.  In November 1994, Ms. Levine also received awards from the New York Council on Adoptable Children and the Church Avenue Merchants Block Association (CAMBA) in Brooklyn.</p>

</blockquote>

<p align=center><a href="../index.html"><img src="gifs/wturn.gif" hspace=5><br>
www.aidsnyc.org</a></p>
</blockquote>

<hr size=4 align=center width=50%>

<p align=center><a href="mailto:dsiegler@uhfnyc.org"><b>Dillan Seigler</b></a><br>
United Hospital Fund<br>
350 Fifth Avenue, 23rd floor<br>
New York, NY 10118<br>
modified: 11/13/96<br>
&#169 1996 The Orphan Project</p>

<p align=center>This site is part of <a href="../index.html"><b>www.aidsnyc.org</b></a>. These pages are designed and <br>maintained by Joel Beard courtesy of the <a href="../network/index.html"><b>AIDS Treatment Data Network</b></a>.</b></p>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-204</DOCNO>
<DOCOLDNO>IA093-001001-B046-247</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/ai/index.html 199.29.141.24 19970121120719 text/html 2276
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:01:09 GMT
Server: NCSA/1.5.1
Last-modified: Wed, 08 Jan 1997 14:44:53 GMT
Content-type: text/html
Content-length: 2093
</DOCHDR>
<html>
<HEAD>
<TITLE>NYS DOH AIDS Institute</TITLE>
</HEAD>

<BODY BACKGROUND="gifs/ai.gif" BGCOLOR="#ffffff"><font face="arial, helvetica" size=-1>

<h1 align=center><font size=+2>New York State Department of Health</font><br>
AIDS Institute<br><br>
<font size=3>Protocols dated July/August 1995</font></h1>

<ul>
<font size=+1>
<li><a href="letter.html"><B>Letter to Healthcare Professionals</B></a>
<p>
<LI><A HREF="subs.html"><B>Evaluation and Management of Substance Use</B></A>
<p>
<li><a href="adult.html"><B>HIV Medical Evaluation and Preventive Care for Adults</B></a>
<p>
<li><a href="peds.html"><b>HIV Medical Evaluation and Preventive Care for Children</b></a> <font size=-1>(added 11/28/96)</font>
<p>
<li><a href="women.html"><B>Healthcare Services for Women with HIV Infection</B></a>
<p>
<li><a href="adolesce.html"><B>HIV Medical Evaluation and Preventive Care for Adolescents</B></a>
<p>
<li><a href="nutrit.html"><b>Nutrition in HIV Infection</b></a> <font size=-1>(added 11/9/96)</font>
<p>
<li><A HREF="proph.html"><B>Prophylaxis of Opportunistic Infections in Adults and Children with HIV Infection</B></A> <font size=-1>(added 10/31/96)</font>
<p>
<li><a href="tb.html"><b>Tuberculosis Management for People with HIV Infection</b></a> <font size=-1>(added 11/9/96)</font>
<p>
<li><a href="about.html"><B>About the AIDS Institute</B></a>
</font>
</ul>

<p align=center><a href="../index.html"><img src="gifs/wturn.gif" vspace=5 vspace=5><br>
<b>www.aidsnyc.org</b></a></p>

<table border=1 cellpadding=4 cellspacing=4 width=100% colspecs="50% 50%">
<tr>
<td width=50%><font size=-1 face="arial, helvetica"><a href="mailto:bda01@health.state.ny.us">AIDS Institute</a><br>
copyright &#169; 1996<br>
Pages modified: 11/28/96</font></td>
<p>
<td width=50% align=right><font size=-1 face="arial, helvetica">This site is part of <a href="../index.html"><b>www.aidsnyc.org</b></a>. <br>Pages designed and maintained by Joel Beard <br>courtesy of the <a href="../network/index.html"><b>AIDS Treatment Data Network</b></a>.</font></td>
<p>
</tr>
</table></center>

</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT18-B31-205</DOCNO>
<DOCOLDNO>IA093-001001-B046-270</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/pwac/index.html 199.29.141.24 19970121120733 text/html 3427
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:01:41 GMT
Server: NCSA/1.5.1
Last-modified: Wed, 08 Jan 1997 14:45:32 GMT
Content-type: text/html
Content-length: 3244
</DOCHDR>
<html>
<head>
<title>People with AIDS Coalition/NY</title>
</head>
<body bgcolor="#ffffff"><font face="arial, helvetica" size=-1>

<p align=center><img src="gifs/pwac.gif"></p>

<h5 align=center>This is the first issue of PWAC/NY's <i>Newsline</i> available in electronic format. <br>The articles focus on issues of grief. If you would like to receive a printed copy, please <A HREF="mailto:hivinfo@nyam.org">write us</a>. <br>You can also download the <a href="zipped.html">zipped version</a> of the text.</h5>

<hr size=6 width=50% noshade align=center>

<a href="survive.html"><h4 align=center>surviving and thriving</h4></a><br>

<a href="letters.html"><h4 align=center>editorial policy/letters</h4></a><br>

<a href="editor.html"><h4 align=center>from the editor</h4></a><br>

<a href="grief.html"><h4 align=center>grief and healing</h4></a><br>

<a href="whirl.html"><h4 align=center>entering the whirlwind</h4></a><br>

<a href="plain.html"><h4 align=center>a funeral plainsong from a younger woman to an older woman</h4></a><br>

<a href="manage.html"><h4 align=center>managing grief in AIDS organizations</h4></a><br>

<a href="coping.html"><h4 align=center>coping after a lovers death</h4></a><br>

<a href="desert.html"><h4 align=center>grieving in the desert</h4></a><br>

<a href="well.html"><h4 align=center>well-infected</h4></a><br>

<a href="dirty.html"><h4 align=center>sounding off: dirty talk</h4></a><br>

<a href="walk.html"><h4 align=center>a very strong thing to feel</a><br>  the third annual ACE walkathon at the Bedford Hills correctional facility</h4><br>
<h4 align=center><font size=+3>P</font>risoners' <font size=+3>P</font>erspectives<br>
<a href="prison.html">why double bunking is a danger to our health</a><br>
<a href="miracle.html">miracle baby</a><br>
<a href="prislet.html">letters from prison</a></h4><br>

<a href="news.html"><h4 align=center>in the news</h4></a><br>

<a href="medical.html"><h4 align=center>medical matters</h4></a><br>

<a href="briefs.html"><h4 align=center>medical briefs</h4></a><br>

<a href="develop.html"><h4 align=center>PWAC NY development news</h4></a><br>

<a href="memor.html"><h4 align=center>memorials</h4></a><br>

<a href="announce.html"><h4 align=center>announcements</h4></a><br>

<a href="about.html"><h4 align=center>who we are</h4></a>

<hr size=6 width=50% noshade align=center><br>

<p align=center>Partial funding for Newsline is provided by the NYS AIDS Insititute, through a grant from the U.S. Public Health Service.</p>

<p align=center>PWAC/NY<br>
50 West 17th Street, 8th floor<br>
New York, NY 10011<br>
Administration: (212) 647-1415<br>
Fax: (212) 647-1419<br>
Hotline: (212) 647-1420 / (800) 828-3280</p>

<hr size=6 width=50% noshade align=center>

<P align=center>Last modified: 3/2/96<br>
PWAC/NY <A HREF="mailto:hivinfo@nyam.org">hivinfo@nyam.org</A><BR>
&#169; copyright 1995 PWAC/NY, Inc.</P>

<p align=center><a href="../index.html"><img align=middle vspace=5 src="gifs/wturn.gif"><br>www.aidsnyc.org</a></p>

<p align=center>This site is part of <a href="../index.html">www.aidsnyc.org</a>. Pages designed and maintained by <br>Joel Beard courtesy of the <a href="../network/index.html">AIDS Treatment Data Network</a>.</h5>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-206</DOCNO>
<DOCOLDNO>IA093-001001-B046-285</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/pwahg/index.html 199.29.141.24 19970121120741 text/html 3646
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:01:49 GMT
Server: NCSA/1.5.1
Last-modified: Wed, 08 Jan 1997 14:45:13 GMT
Content-type: text/html
Content-length: 3463
</DOCHDR>
<html>
<head>
<title>PWA Health Group</title>
</head>
<body bgcolor="#ffffff" link="#5c4033" vlink="#545454"><font face="arial, helvetica" size=-1>
<img src="gifs/pwa.gif">

<blockquote>
<p>The PWA (People With AIDS) Health Group was founded in 1987, and is primarily dedicated to providing access to promising or experimental treatments for HIV/AIDS, and to making more broadly accessible those few treatments already available. The PWA Health Group was founded by Thomas Hannan and Michael Callen, both PWAs, and their physician, Joseph Sonnabend MD, and is organized in New York State as People With AIDS Working for Health, Inc., a 501(c)3, not-for-profit corporation.</p>
</blockquote>

<img src="gifs/yell.gif" width=2 height=220 align=left alt="">

<blockquote>

<p><font size=3><b><a href="drugs.html">Info Sheets</a>:</b><br>
drug  descriptions, including side effects, dosing and results from clinical trials. <a href="info/crix.html">Crixivan availabilty</a> info sheet added 4/17/96 | <a href="info/norvir.html">Norvir dosing up schedule</a> added 5/23/96</font></p>

<p><font size=3><b><a href="notes.html">Notes from the Underground</a>:</b><br>published six times a year, reporting on issues pertaining to underground AIDS treatment and access. (<a href="notes/32.html">current issue</a> added 5/11/96)</i>.  <b><a href="notas/notas1.html">Notas de la Clandestinidad</a></b> Junio 1996 Edici&oacute;n en espa&ntilde;ol 1 (added 6/22/96).</font></p>

<font face="arial, helvetica" size=-1>

<p><font size=3><a href="drugs.html#order"><b>Order form/contributions</b></a></font></p>

<p><font size=3><a href="../rtrp/buyers.html"><b>Other buyers clubs around the country</b></a></font></p>

</blockquote>

<p><img src="gifs/yell.gif" height=2 width=400></p>

<p align=center>Executive Director Sally Cooper<br>
Deputy Director James Learned<br>
Office Manager Mark Niedzolkowski<br>
Accountant Mike Welch<br>
Editor Andy Young<br>
Women's Treatment Project Coordinator Lorna Gottesman</p>

<blockquote>
<img src="gifs/yell.gif" height=175 width=2 alt="" align=left><img src="gifs/yell.gif" height=2 width=400>

<p align=center>Board of Directors<br>
Jeff Birnbaum, MD | Gregg Bordowitz | John Falkenberg<br>
Gayann Hall, MD | Catherine Hanssens, Esq | Donald J. Huppert<br>
Michael Kasten | Michael Lange, MD | Gregory Mudd<br>
Joe Sonnabend, MD (Emeritus) | Harry Stahl, President | Gus Vianna<br>Telia Virgin | Steven Wilkinson</p>

<img src="gifs/yell.gif" height=2 width=400>

<p align=center>Founders<br>
Michael Callen | Thomas Hannan | Joe Sonnabend, MD</p>

<p align=center><a href="../index.html"><img src="gifs/wturn.gif" vspace=5><br>
www.aidsnyc.org</a></p>

<center><table border=1 cellpadding=3 cellspacing=4>
<tr>
<td rowspan=2><font face="arial, helvetica" size=-1>People with AIDS Working for Health, Inc. <br>
150 West 26th St, #201, New York, NY 10001<br>
tel (212) 255-0520 | fax (212) 255-2080<br>
<a href="mailto:pwahg@aidsnyc.org">pwahg@aidsnyc.org</a></font>
</td>
<p>
<td align=right><font size=-1 face="arial, helvetica">This site is part of <a href="../index.html"><b>www.aidsnyc.org</b></a>. <br>Pages designed and maintained by Joel Beard <br>courtesy of the <a href="../network/index.html"><b>AIDS Treatment Data Network</b></a>.</font></td>
<p>
</tr>
<tr><td><font size=-1 face="arial, helvetica">Last modified: 7/3/96 | copyright &#169; 1996 PWA Health Group</font></td></tr>
</table></center>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-207</DOCNO>
<DOCOLDNO>IA093-001001-B046-297</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/siatf/index.html 199.29.141.24 19970121120749 text/html 2209
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:01:57 GMT
Server: NCSA/1.5.1
Last-modified: Tue, 14 Jan 1997 18:14:46 GMT
Content-type: text/html
Content-length: 2026
</DOCHDR>
<html>
<head>
<title>Staten Island AIDS Task Force</title>
</head>
<body bgcolor="#ffffff" link="#8b1c62"><font face="ariel, helvetica">

<table>
<tr>
<td>
<img src="gifs/logo.gif" border=0 alt="logo"><br>
<img src="gifs/logo.gif" border=0 alt="logo"><br>
<img src="gifs/logo.gif" border=0 alt="logo"><br>
<img src="gifs/logo.gif" border=0 alt="logo"><br>
<img src="gifs/logo.gif" border=0 alt="logo"></td>

<td align=center><font face="arial, helvetica" size=+2 color="#8b1c62">Welcome to the<br>
Staten Island AIDS Task Force Homepage</font>
<font face="arial, helvetica">
<p align=center>Our mission - to develop a community of caring to help those living with HIV/AIDS and their family members, through support and advocacy, and to help the community stay healthy, through education and risk reduction.</p>

<p align=center>For more information about our programming or to ask questions regarding HIV prevention or treatment please see one of the following:</p>

<p align=center><b><a href="client.html">CLIENT SERVICES</a></b></p>

<p align=center><b><a href="educ.html">EDUCATION &amp; OUTREACH DEPARTMENT</a></b></p>

<p align=center><b><a href="programs.html">TRAINING PROGRAMS</a></b></p>

<p align=center><b><a href="volun.html">VOLUNTEER PROGRAMS</a></b></p>

<p align=center><b><a href="info.html">CURRENT INFO FROM OUR HIV/AIDS RESOURCES ROOM</a></b></p>

<p align=center>If you wish to speak to a live person <br>
please call our Helpline at<br>
(718) HIV CALL<br>
Helpline hours: M&amp;T 9AM-8PM  W&amp;F 9AM-6PM Th 9AM-9PM</p></td>
</tr><tr>
<td><a href="mailto:siatf@aidsnyc.org">siatf@aidsnyc.org</a><br>
copyright &#169; 1996 SIATF<br>
Last modified: 1/1/97</font></td>
<td nowrap align=right><font size=-1 face="ariel, helvetica">The SIATF site is part of <a href="../index.html"><b>www.aidsnyc.org</b></a>. <br>Pages designed and maintained by Joel Beard <br>courtesy of the <a href="../network/index.html"><b>AIDS Treatment Data Network</b></a>.</font></td>
<p>
</tr>
</table>

</font>
</body>
</html>


</DOC>
<DOC>
<DOCNO>WT18-B31-208</DOCNO>
<DOCOLDNO>IA093-001001-B046-315</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/rtrp/index.html 199.29.141.24 19970121120756 text/html 4266
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:02:04 GMT
Server: NCSA/1.5.1
Last-modified: Wed, 08 Jan 1997 14:46:12 GMT
Content-type: text/html
Content-length: 4083
</DOCHDR>
<html>
<head>
<title>ACT UP: AIDS Index to Treatments</title>
</head>
<body bgcolor="#ffffff"><font face="arial, helvetica" size=-1>

<p align=center><b><font size=6><a href="http://www.actupny.org">ACT UP</a> : R</font>eal <font size=6>T</font>reatments for <font size=6>R</font>eal <font size=6>P</font>eople</b><hr size=2 width=75% align=center></p>

<p align=center><font size=+3><b>AIDS Index to Treatments</b></font><br>
<b>version 15<br>
FOR PEOPLE LIVING WITH HIV/AIDS <br>AND THEIR ADVOCATES AND HEALTHCARE PROVIDERS</b><hr size=2 width=75% align=center></p>

<blockquote>

<p>Built for viewing with <a href="http://www.netscape.com/comprod/mirror/index.html">Netscape 2.0</a> as the format uses frames. The first part of the index available here is the <a href="nutrit/frame.html">Nutrition Index</a>. The complete index includes treatments for HIV and opportunistic infections and is available by <a href="mailto:gmc0@ix.netcom.com">request</a>.</p>

<ul>
<li><a href="nutrit/frame.html"><font size=4><b>Nutrition, micronutrients and vitamins</b></font></a>. Follow <a href="nutrit.html"><b>this link</b></a> if you are <b>not</b> using Netscape.
<p>
<li><a href="about.html"><font size=4><b>About the index</b></font></a> : how it was made, where the information came from, and how you can contribute.
<p>
<li><a href="numbers.html"><font size=4><b>Useful numbers</b></font></a> : <a href="numbers.html#news">newsletters and publications</a>, <a href="numbers.html#hot">hotlines and information sources</a>, <a href="numbers.html#resource">resource information</a>, <a href="numbers.html#bbs">computer bulletin boards</a>, <a href="numbers.html#pa">patient assistance programs</a>, and <a href="numbers.html#other">other useful numbers</a>, many with links to other web sites.
<p>
<li><a href="buyers.html"><font size=4><b>Buyer's Clubs</b></font></a> : contact numbers for buyer's clubs around the country.
</ul>

<hr size=2 width=50% align=center>

<h4>HOW TO USE THIS INDEX</h4>

<p>The left frame of the nutrition index lists topics. You can search the list for the topic that interests you (for example, vitamin C or water). Each topic links to a description in the right hand frame. Please <a href="mailto:gmc0@ix.netcom.com">write</a> and let me know if you're having difficulties using the index as formatted. Thanks.<p>

<center><table width=80% border=1><tr><td><font face="arial, helvetica" size=-1><b>Disclaimer</b>:  No endorsement is made for any product noted herein. Nothing written is intended to be prescriptive. Many of the treatments noted don't have a lot of data yet. Discuss any information provided herein with your primary care physician and/or pharmacist. Information provided is that of the author. It is intended as a guide and, where possible, cites for information sources are provided. The field is rapidly changing and information may be out-dated quickly; this is why this is an ongoing process.</font></td></tr></table></center>

<p align=center><a href="../index.html"><img src="gifs/wturn.gif" vspace=5><br>
<font size=-1>www.aidsnyc.org</font></a></p>

<center><table width=75% border=1><tr><td align=center><font face="arial, helvetica" size=-1>These pages are copyright protected. Permission is granted to copy and distribute material included here free of charge. No permission is granted to use the material herein for profit purposes or without author's consent. Information contained herein is for informational purposes only. Any treatment choices should be discussed with the primary care provider.</font></td></tr></table></center>

</blockquote>

<p align=center>ACT UP: Real Treatments for Real People<br>
Last modified: 3/29/96<br>
<A HREF="mailto:gmc0@ix.netcom.com">George Carter</A><br>
copyright &#169; 1996 G. Carter</P>

<hr size=2 width=25% align=center>

<p align=center>This site is part of <a href="../index.html"><b>www.aidsnyc.org</b></a>. All pages designed and maintained by <br>Joel Beard courtesy of the <a href="../network/index.html"><b>AIDS Treatment Data Network</b></a>.</p>

</font>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT18-B31-209</DOCNO>
<DOCOLDNO>IA093-001001-B046-326</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/programs.html 199.29.141.24 19970121120803 text/html 2317
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:02:11 GMT
Server: NCSA/1.5.1
Last-modified: Fri, 13 Sep 1996 15:44:40 GMT
Content-type: text/html
Content-length: 2134
</DOCHDR>
<html>
<head>
<title>NYAM: HIV/AIDS Programs</title>
</head>

<body bgcolor="#ffffff" link="#4f9eaf">

<img src="gifs/ribbon.gif" align=right>
<p><FONT SIZE=+2>Other HIV/AIDS Programs </FONT><BR><FONT SIZE=+1>of the <a href="http://www.nyam.org/index.html">New York Academy of Medicine</a></FONT></p>
<P>
<p><FONT SIZE=+2><a href="http://www.nyam.org/programs/index.html#special"><b>Office for Special Populations Projects</b></a></FONT><br>
<FONT SIZE=+1>Overseeing numerous HIV/AIDS programs including clinical research, investigation of cost-effective procedures, preventive measures, and access to immediate health care and social services.</FONT></p>
<P>
<p><a
href="http://www.nyam.org/programs/index.html#care"><FONT SIZE="+2"><B>HIV Care Grant</A></B></FONT><BR><FONT SIZE=+1>Strengthening communication among institutions, care providers and researchers; influencing development of related health policy.</FONT></p>
<P>
<p><a href="http://www.nyam.org/programs/index.html#profdev"><FONT SIZE="+2"><B>HIV Professional Development Project</a></B></FONT><BR><FONT SIZE=+1>Assuring adequate professional staffing for New York City's HIV care system.</FONT></p>
<P>
<p><a href="http://www.nyam.org/programs/index.html#hivprof"><FONT SIZE="+2"><B>HIV Professions</A></B></FONT><BR><FONT SIZE=+1>Newsletter of the HIV Professional Development Project. <BR>Articles about Academy initiatives, notes from the field, etc. </FONT></p>

<HR SIZE=3 WIDTH=50% ALIGN=CENTER>

<center><table><tr valign=top><td align=center><a href="index.html"><img align=center hspace=5 src="gifs/wturn.gif" alt=" "><br><font size=-1>www.aidsnyc.org</a></font></td><p><td align=center><a href="http://www.nyam.org/programs/index.html"><img align=center hspace=5 src="gifs/wspin.gif" alt=" "><br><font size=-1>Special Populations</a></font></td></tr></table></center>

<hr size=3 width=50% align=center>

<P><FONT SIZE=-2><img hspace=5  align=left src="gifs/hippox.gif" alt=" "><A HREF="mailto:hivinfo@nyam.org">hivinfo@nyam.org</A><br>
Last modified 4/23/96<BR>
copyright  &#169; 1996 <br>
The New York Academy of Medicine</P>
</FONT></p>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-210</DOCNO>
<DOCOLDNO>IA093-001001-B046-348</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/updates.html 199.29.141.24 19970121120811 text/html 2229
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:02:18 GMT
Server: NCSA/1.5.1
Last-modified: Wed, 28 Aug 1996 21:12:49 GMT
Content-type: text/html
Content-length: 2046
</DOCHDR>
<html>
<head>
<title>www.aidsnyc.org: Vancouver Updates</title>
</head>

<body bgcolor="#ffffff" link="#4f9eaf">

<p align=center><font size=+2><a href="index.html"><b>www.aidsnyc.org</b></a></font>

<p align=center><img src="gifs/purple.gif" height=4 width=500  align=center alt=""></p>

<blockquote>

<p align=center><A HREF="http://www.interchg.ubc.ca/aids11/aids96.html"><img src="gifs/vanc.gif"><br><b>XI 
International Conference on AIDS</a><br>
July 7-12, 1996 Vancouver, Canada</b></p>

<p><b>The following sites have updated information about the Vancouver conference:</b></p>

<ul><b>
<li><a href="http://sis.nlm.nih.gov/aidsabs.htm">Conference abstracts</a> available from searchable NIH database beginning Monday 7/8/96
<li><a href="http://www.actupny.org/Vancouver/Vanindex.html">ACT UP at Vancouver</a>
<li><a href="http://www.healthcg.com/conference/conference.html">Medical Education Collaborative and Healthcare Communications Group</a>
<li><a href="http://www.chisel.com">Video highlights</a> from the conference after downloading necessary software. 
<li><a href="natap/index.html">National AIDS Treatment Advocacy Project</a>
<li><a href="http://www.iapac.org/aidscan.html">International Association of Physicians in AIDS Care</a> beginning Monday July 8, 1996
<li><a href="http://www.ama-assn.org/special/hiv/xi-conf/aids11.htm">Journal of the American Medical Association</a>
<li><a href="http://www.immunet.org">Immunet</a>
</b>
</ul>

<p><b>Please <a href="mailto:hivinfo@aidsnyc.org">write us</a> if you know of a site that is posting information from the conference. Thank you.</p>


</blockquote>

<p align=center><img src="gifs/purple.gif" height=4 width=500  align=center alt=""></p>

<p align=center><a href="index.html"><img src="gifs/wturn.gif" vspace=5 vspace=5><br>
<font size=-1>www.aidsnyc.org</font></a></p>

<p align=center><font size=-1>last modified: 7/5/96<br>
write to: <a href="mailto:hivinfo@aidsnyc.org">hivinfo@aidsnyc.org</a><br>
copyright &#169; 1996 www.aidsnyc.org</b></font></p>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-211</DOCNO>
<DOCOLDNO>IA093-001001-B046-365</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/retrov.html 199.29.141.24 19970121120830 text/html 7159
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:02:30 GMT
Server: NCSA/1.5.1
Last-modified: Fri, 17 Jan 1997 18:48:58 GMT
Content-type: text/html
Content-length: 6976
</DOCHDR>
<html>
<head>
<title>www.aidsnyc.org: links to Retroviruses Conference</title>
</head>

<body bgcolor="#ffffff" link="#8b2323" vlink="#696969"><font face="arial, helvetica" size="-1">

<h3 align=center><a href="index.html">www.aidsnyc.org</a></h3>

<p align=center><img src="gifs/purple.gif" height=4 width=500  align=center alt=""></p>

<h2 align=center>4th Conference on Retroviruses &amp; Opportunistic Infections:<br> Where to Find Reporting on the Internet</h2>

<blockquote>

<p align=center>All information and text on this page courtesy of John James, <a href="http://www.immunet.org/atn/">AIDS Treatment News</a>. Published twice monthly. Subscription and Editorial Office:    P.O. Box 411256, San Francisco, CA 9414, 800/TREAT-1-2  toll-free U.S. and Canada, 415/255-0588 regular office number, fax: 415/255-4659, e-mail: <a href="mailto:aidsnews@aidsnews.org">aidsnews@aidsnews.org</a></p>

<p align=center><img src="gifs/purple.gif" height=4 width=500  align=center alt=""></p>

<p>The 4th Conference on Retroviruses and Opportunistic Infections will take place January 22-26 at the Sheraton Washington Hotel. Abstracts, reports (either daily, or after the conference), and audio feed and slide images, will be available through various sites on the Internet. You may want to check the following sites, which are accessible without charge, and from anywhere in the world.</p>

<ul>
<li><b>Audio feed, slides, and abstracts</b>: The conference organizers will broadcast (on the Internet) audio and slides of some of the major sessions of the conference, about 12 hours after the presentations. The equipment needed is a modem (with a DOS/Windows computer, either a 14.4 or 28.8 modem can be used; with a Macintosh, 28.8 is required), and a sound card. The system is optimized for either Netscape Navigator or Microsoft Internet Explorer, but other browsers may work as well. Users will see a picture of the presenter, with the slides changing with the talk as if one were in the room, and hear the audio (using RealAudio software, which can be downloaded through the site). There will also be a search engine to help skip ahead in a talk.
<p>
<dt>This system will be accessible through <a href="http://www.retroconference.org">www.retroconference.org</a>. The conference abstracts will be available through the same site; note that most abstracts were submitted months ago and have not been revised, but that the "late breaker" abstracts are new. (The "idsociety" Web address for the abstracts, which we published in our last issue, is being changed to the "retroconference" address, above; as we go to press on January 14, the "idsociety" address only has news and abstracts of LAST YEAR'S 1996 Retroviruses conference, and the "retroconference" address is not yet available. If you have problems connecting to the "retroconference" address, check the other sites for the latest information, or call AIDS TREATMENT NEWS.)
<p>
<dt>The conference organizers hope to broadcast the State of the Art talks, the two opening sessions, and one symposium each afternoon. It may not always be possible to get permission from the presenters, however, because medical journals often consider Internet distribution to be "publication," meaning that they will refuse to publish an article if the information has been released that way.
<p>
<dt>Check the "retroconference" site for the latest information.
<p>
<li>As we announced in our last issue, <b>Healthcare Communications Group</b> has organized 16 authors and writers to produce daily reports on the Retroviruses conference, to be available the following morning. Check their site at <a href="http://www.healthcg.com">http://www.healthcg.com</a> -- which already has useful pre- conference summaries on pathogenesis, viral markers, antiretrovirals, immunomodulation, TB/MAC, CMV, fungal infections, and AIDS-related cancers. A more direct URL is <a href="http://204.181.72.57:80/4thconf/">http://204.181.72.57:80/4thconf/</a>.
<p>
<li><b>The Body</b>, an organization which provides AIDS information on the Web, will publish reports by Ramon A. (Gabriel) Torres, M.D., Director of the AIDS Center at St. Vincent's Hospital in New York, and Andy Pavia, M.D., Director of Clinical Research for the University of Utah Health Sciences AIDS Center. Coverage will include a question and answer session with Drs. Torres and Pavia. The Web site is <a href="http://www.thebody.org">http://www.thebody.org</a>.
<p>
<li>The <b>International Association of Physicians in AIDS Care</b> will have daily reports by technical writers Mark Mascolini and David MacDougall, at <a href="http://www.thebody.org">http://www.iapac.org</a>.
<p>
<li>Extensive reports of the conference will be published on the <b>Critical Path AIDS Project</b> site, <a href="http://www.thebody.org">http://www.critpath.org</a>.
<p>
<li>Jules Levin will report on protease inhibitors on the <b>National AIDS Treatment Advocacy Project</b> site at <a href="natap/conf/index.html">http://www.aidsnyc.org/natap</a>.
<p>
<li>Also, there will be many wire service and other news-media reports on the Retroviruses conference. An excellent free source for most AIDS-related daily news is the AIDS list of <b>AEGIS</b> (AIDS Education Global Information System), run by Sister Mary Elizabeth in Southern California. You only need an email address to use this service; you do not need access to the World Wide Web. To subscribe, send email to: <a href="mailto:majordomo@global.org">majordomo@global.org</a>, with the message:
<p>
<p align=center>subscribe aids <br>end
<p>
<dt>Note: This service sends about 15 to 20 AIDS-related news reports per day (and probably more during the Retroviruses conference). If you want to reduce email traffic, you can have the messages collected into a digest, which is sent when it reaches 40,000 characters in size. To receive the digest, send email to: <a href="maito:majordomo@global.org">majordomo@global.org</a>, with the message:
<p>
<p align=center>subscribe aids-digest <br>end
<p>
For more information about this AIDS mailing list, send the message "info aids", or "info aids-digest" (without the quote marks) to: <a href="mailto:majordomo@global.org">majordomo@global.org</a>. Or see the AEGIS home page, <a href="http://www.aegis.com">http://www.aegis.com</a>.
<p>
<dt><b>Note</b>: By agreement with the International Association of Physicians in AIDS Care, AEGIS will also send to its AIDS mailing list the Retroviruses conference reports published on the <a href="http://www.iapac.org">http://www.iapac.org</a> Web site described above.

</blockquote>

<p align=center><img src="gifs/purple.gif" height=4 width=500  align=center alt=""></p>

<p align=center><a href="index.html"><img src="gifs/wturn.gif" vspace=5 vspace=5><br>
<font size=-1><b>www.aidsnyc.org</b></font></a></p>

<p align=center>last modified: 1/17/97<br>
write to: <a href="mailto:hivinfo@aidsnyc.org">hivinfo@aidsnyc.org</a></p>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-212</DOCNO>
<DOCOLDNO>IA093-001001-B047-201</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/natmed/calendar.html 199.29.141.24 19970121121220 text/html 6553
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:06:22 GMT
Server: NCSA/1.5.1
Last-modified: Tue, 05 Mar 1996 21:34:31 GMT
Content-type: text/html
Content-length: 6370
</DOCHDR>
<html>
<head>
<title>National Medical Association: Calendar</title>
</head>
<body bgcolor="#ffffff">
<p align=center><img alt="National Medical Association" src="gifs/name.gif">

<center><hr size=2 width=25% align=center noshade>
<font size=+3>calendar</font>
<hr size=3 width=25% align=center noshade></center>

<blockquote>
<font size=-1>
<p><b>March 1996<br>
National Nutrition Month</b></p>

<p><b>March or April 1996<br>
Region IV - NMA Annual Meeting</b>. Hosed by the Detroit Medical Society. Lonnie Joe, MD, President and mark Thurman, Region IV Chairman.</p>

<p><b>March 22-24, 1996<br>
Region III - NMA Annual Meeting</b>. Memphis, Tennessee. John T. McAdory, Region III Chairman.</p>

<p><b>March 23-26, 1996<br>
"Prevention 96 Conference: Prevention for All - Challenges, Opportunities, and Strategies."</b> Dallas, Texas. Sponsored by the American College of Preventive medicine and the Assocation of Teachers of Preventive medicine in collaboration with the Centers for Disease Control and Prevention and others. Reed Tuckson, MD, President of the Charles R. Drew University of Medicine and Science, will deliver the keynote address. For more information, call (202) 466-2569.</p>

<p><b>April 1996<br>
National Cancer Control Month</b></p>

<p><b>April 1, 1996<br>
Deadline for submission of candidates applications for NMA awards.</b> For more information, call (202) 347-1895.</p>

<p><b>April 1-7, 1996.<br>
Second National Public Health Week.</b> For more information, call (202) 789-5600.</p>

<p><b>April 4-7, 1996<br>
SNMA's 31st Annual Medical Education Conference.</b> Stouffers Renaissance Nashville Hotel, Nashville, Tennessee. "Changing Times: The Enterprising of Medicine and its Effects on Physicians of Color." For more information, call (800) 636-SNMA.</p>

<p><b>April 7, 1996<br>
World Health Day</b></p>

<p><b>April 17-21, 1996<br>
National Association for Equal Opportunity in Higher Education (NAFEO) 21st National Conference on Blacks in Higher Education.</b> The Washington Hilton &amp; Towers Hotel, Washington, DC. "Making a Difference." For more information, call (202) 543-9111.</p>

<p><b>April 18-21, 1996<br>
NMA Board of Trustees.</b> NMA Building, Washington, DC. For more information, call (202) 347-1895.</p>

<p><b>April 24-25, 1996<br>
Health Watch 1996 National Symposium.</b> New York Academy of medicine, New York, New York. Improving Health and Life Outcomes of African-Americans and Latino Adolescents." Includes Health Watch's Sixth Annual Awards Gala to be held April 24 at the Waldorf-Astoria Hotel. Norma J. Goodwin, MD, Founder and President. For more information, contact Anjean B. Carter, Symposium Coordinator, at (718) 434-5411.</p>

<p><b>May 1996<br>
National High Blood Pressure Education Month/Older Americans Month/National Physical Fitness and Sports Month</b></p>

<p><b>May 8, 1996<br>
World Red Cross Day</b></p>

<p><b>May 30-June 2, 1996<br>
Region II - NMA Annual Meeting.</b> Inner Harbor marriott, Baltimore, maryland. Willarda Edwards, MD Vice Chair. For more infomration, contact Jackie Peters, Coordinator, at (410) 523-5032.</p>

<p><b>May 31, 1996<br>
No Tobacco Day</b></p>

<p><b>June 6-17, 1996<br>
Association of Howard University Retirees.</b> Sponsors of an African-Brazillian Study Tour. For more information, contact James Hill at (202) 462-5155.</p>

<p><b>June 23-27, 1996<br>
AMA Annual Meeting.</b> Chicago Hyatt Regency, Chicago, Illinois. For more information, call (800) AMA-3211.</p>

<p><b>July 27-August 3, 1996<br>
The 101st Annual Convention of the NMA.</b> Hyatt Regency, Chicago, Illinois. For more information, call (202) 347-1895.</p>

<p><b>July 28-August 3, 1996<br>
5th Quadrennial Conference of the National Black Congress on Health Law and Economics.</b> Chicago, Illinois. ECHLE includes NMA, NDA, National Assocation of Black Nurses, National Bar Association, Chi Delta Mu Fraternitiy, Inc., National Podiatric Association, National Optometric Association, Association of Black Psychologists, Internation Assocation of Black Professional Firefighers, and the National Pharmaceutical Assocation. For information, contact Derrick A. Humphries, JD, at (202) 659-4020.</p>

<p><b>July 29-August 4, 1996<br>
Chi Delta Mu Grand Conclave.</b> Chicago Hilton Hotel, Chicago, Illinois. For more infomration, call (202) 842-1111.</p>

<p><b>September 1996<br>
National Cholesterol Education Month/National Sickle Cell Month.</b></p>

<p><b>October 1996<br>
W. Montague Cobb Day</b></p>

<p><b>October 17-20, 1996<br>
NMA Board of Trustees.</b> NMA Building, Washington, DC. For more information, call (202) 347-1895.</p>

<p><b>November 1996<br>
National Diabetes Month</b></p>

<p><b>December 8-11, 1996<br>
AMA Interim Meeting.</b> Marriott Marquis, Atlanta, Georgia. For information, call (800) AMA-3211.</p>

<p><b>April 1, 1997<br>
Deadline for submission of candidates applications for NMA awards.</b> For more information, call (202) 347-1895.</p>

<p><b>May 30-June 1, 1997<br>
Region 1 - NMA Annual Scientific Assembly.</b> Hilltop Inn, Poconos, Pennsylvania. For information, contact Eddie L. Hoover, MD, at (716) 898-5092.</p>

<p><b>June 22-26, 1997<br>
AMA Annual Meeting.</b> Chicago Hyatt Regency. For information, call (800) AMA-3211.</p>

<p><b>The 102nd Annual Convention of the NMA.</b> Honolulu, Hawaii.</p>

<p><b>December 4-7, 1997<br>
Chi Delta Mu Grand Conclave.</b> Marriott Castle Harbor Hotel, Tucker's Town, Bermuda. For more information, call (202) 842-1111.</p>

<p><b>December 7-10, 1997<br>
AMA Interim Meeting.</b> Loews Anatole. Dalls, Texas. For more information, call (800) AMA-3211.</p>

<hr size=3 width=25% align=center noshade>

<center><table border=1 width=50%><tr><td><font size=-1>The Calendar lists conventions, meetings, courses, and other events of interest to NMA members, or events concerning the NMA's mission. Send information about coming events for the Calendar to Theresa Greene Reed, MD, MPH, 11516 Patapsco Dr., Rockville, MD 20852; (301) 468-6830.</font></td></tr></table></center>

<hr size=3 width=25% align=center noshade>

<p align=center><a href="index.html"><img src="gifs/medical.gif" vspace=5><br>
<font size=-1>NMA Home Page</a></font></p>

<p align=center><font size=-1><a href="mailto:nma@www.natmed.org">National Medical Association</a><br>
copyright &#169; 1996 NMA</font></p>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-213</DOCNO>
<DOCOLDNO>IA093-001001-B047-215</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/natmed/policy.html 199.29.141.24 19970121121237 text/html 765
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:06:38 GMT
Server: NCSA/1.5.1
Last-modified: Tue, 05 Mar 1996 21:34:33 GMT
Content-type: text/html
Content-length: 583
</DOCHDR>
<html>
<head>
<title>National Medical Association: Policy</title>
</head>
<body background="gifs/logo2.gif" >
<p align=center><img src="gifs/name.gif"></p>

<center><hr size=2 width=25% align=center noshade>
<font size=+3>policy</font>
<hr size=3 width=25% align=center noshade></center>


<p align=center><a href="index.html"><img src="gifs/medical.gif" vspace=5><br>
<font size=-1><b>NMA Home Page</b></a></font></p>

<p align=center><font size=-1><a href="mailto:nma@www.natmed.org"><b>National Medical Association</a><br>
copyright &#169; 1996 NMA</b></font></p>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-214</DOCNO>
<DOCOLDNO>IA093-001001-B047-228</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/natmed/articles.html 199.29.141.24 19970121121246 text/html 6437
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:06:54 GMT
Server: NCSA/1.5.1
Last-modified: Wed, 06 Mar 1996 19:58:40 GMT
Content-type: text/html
Content-length: 6254
</DOCHDR>
<html>
<head>
<title>National Medical Association: Articles</title>
</head>
<body bgcolor="#ffffff" >
<p align=center><img src="gifs/name.gif"></p>

<center><hr size=2 width=75% align=center noshade>
<font size=+3>editorial articles &amp; presidential statements</font>
<hr size=3 width=75% align=center noshade></center>

<blockquote><h3>Superhighway: NMAs Access to the Internet</h3>

<font size=-1><a href="mailto:103323.54@compuserve.com">Winston S. Price, MD</a><br>
Brooklyn, New York</p>

<p>Now that the National Medical Association has reached its centennial, this becomes a time for reflection and looking toward the next hundred years. One of the most influential developments in recent history has been the emergence of computers. As technology develops, new innovations become part of the norm, much as the thermometer or magnetic resonance imaging have become to medicine.</p>

<p>One of the most far reaching and growing subsets of computing is the Internet. In simplest terms, the Internet is an interaction or interconnection between computer networks. The Internet is a process or an event. It is run by a set of agreements called protocols, between the thousands of computer networks of which it is composed. These agreements define how they will talk to each other and exchange information. It is these protocols and the information conduit they provide that give the Internet its identity.</p>

<p>The Internet provides a worldwide medium by which individuals are able to electronically share thoughts, resources, ideas, and knowledge. The precursor to the Internet was developed in the 1960s by the pentagon, who at the time was seeking to establish a holocaust-proof command an control system. What materialized was a network composed not of a typical hierarchical pyramid of systems, but a more flexible peer-to-peer interconnection in which no single system was in charge. Each element in the network was autonomous and independent.</p>

<p>Information was assembled into packets and addressed to the intended recipient. The packet then was cast adrift on the network with its address attached. It was up to the network to forward it in the general direction of its destination until it arrived. Once delivered, the package was disassembled and the original information restored.</p>

<p>In recent years, the number of users on the Internet has been increasing by 20% per month. Recent estimates of the size of the Internet range from 10,000,000 to 20,000,000 users worldwide. However, there is no practical way of finding out a more exact number, since people sign on at will.</p>

<p>For those who are busy in practice and are not computer literate, there are systems in libraries, universities, and government agencies where help can be sought to log on to the Internet to peruse the system through whatever means are provided for by the host computer.</p>

<p>One of the most popular means of accessing the internet is e-mail, or electronic mail. Internet e-mail will allow you to get and keep in touch with almost anyone, almost anywhere. The computer does not recognize distance and so any location in the world can be accessed in about the same time and with the same ease as any other. The possiblities in terms of patient care, diagnoses, and sharing research are unending using this means of communication.</p>

<P>When sending mail through the US Post Office, there are 5 parts to the address: name, address, city, state, and zip code. These can be seen as answers to two basic questions needed to properly deliver a letter: who does it go to, and where are they? Electronic mail needs answers to the same two questions in order to deliver messages or files. The mail delivery system must have all the information needed to navigate through this maze of networks to the precise mailbox you intend.</p>

<p>In the United States, there are several categories of systems connected to the Internet. Each of these have been given a three-letter abbreviation. The most commonly used is com, which stands for commercial systems. Outside the United States, these three-letter designations generally are replaced by a two-letter country code. These two- and three-letter codes for systems are called domains. All together, an e-mail address is basically, someone@somewhere.domain. The entire address following the @ symbol is technically called a Fully Qualified Domain Name, or FQDN. This just means that it represents a specific name of a specific system.</p>

<P>There are a growing number of private companies offering public Internet gateways. Since they are in business, there will be a charge. The charge varies from system to system. A basic account is generally between $10 and $35 a month on most systems. A lot of systems also are starting to charge a onetime installation fee. These typically run between $10 and $35.</p>

<p>If you are as comfortable with computers as you are with managed care, it is important not to be intimidated. There are several books on the market that deal with the Internet: <i>Riding the Internet Highway</i> by Sharon Fisher, New Riders Publishers, 1993; <i>The Internet Companion: A Beginnners Guide to Global Networking</i>, Tracy LaQuey, Addison-Wesley, 1993; <i>Internet - Getting Started</i>, PTR Prentic Hall, 1994.</p>

<p>It is also important to talk with people and find out what theyre using and where you can get it. With the change in medical care and technology, it is imperative that members of the National Medical Association be a part of the superhighway. Through the Public Affairs Committee, there is a plan to send information on resolutions and other pertinent issues on the Internet. In this way, millions of users will have exposure and access both to the Association and its position on key issues facing African Americans in the medical profession.</p>
</font>
<font size=-2>(Reprinted from the Journal of the National Medical Association, Vol. 88, No. 1)</i>


<p align=center><a href="index.html"><img src="gifs/medical.gif" vspace=5><br>
<font size=-1><b>NMA Home Page</b></a></font></p>

<p align=center><font size=-1><a href="mailto:nma@www.natmed.org"><b>National Medical Association</a><br>
copyright &#169; 1996 NMA</b></font></p>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-215</DOCNO>
<DOCOLDNO>IA093-001001-B047-240</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/natmed/delnews.html 199.29.141.24 19970121121253 text/html 797
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:07:01 GMT
Server: NCSA/1.5.1
Last-modified: Tue, 05 Mar 1996 21:34:31 GMT
Content-type: text/html
Content-length: 615
</DOCHDR>
<html>
<head>
<title>National Medical Association: House of Delegate News</title>
</head>
<body background="gifs/logo2.gif" >
<p align=center><img src="gifs/name.gif"></p>

<center><hr size=2 width=40% align=center noshade>
<font size=+3>house of delegate news</font>
<hr size=3 width=40% align=center noshade></center>


<p align=center><a href="index.html"><img src="gifs/medical.gif" vspace=5><br>
<font size=-1><b>NMA Home Page</b></a></font></p>

<p align=center><font size=-1><a href="mailto:nma@www.natmed.org"><b>National Medical Association</a><br>
copyright &#169; 1996 NMA</b></font></p>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-216</DOCNO>
<DOCOLDNO>IA093-001001-B047-253</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/natmed/member.html 199.29.141.24 19970121121302 text/html 7503
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:07:10 GMT
Server: NCSA/1.5.1
Last-modified: Tue, 05 Mar 1996 21:34:32 GMT
Content-type: text/html
Content-length: 7320
</DOCHDR>
<html>
<head>
<title>National Medical Association: membership application</title>
</head>
<body bgcolor="#ffffff">

<p align=center><img src="gifs/name.gif"></p>

<hr size=4 align=center width=50% noshade>

<h4 align=center>Membership Application</h4>

<ul><table width=75% cellspacing=0 border=1><tr><td><blockquote><font size=+1><u>Join NMA Today!</u></font>
<hr size=1 align=left width=75%>
<font size=-1><p>November 11, 1995 marked the 100th birthday of the National Medical Association. The NMA is as necessary now as it was in 1985 for enhanced publich recognition and to achieve our goals. The NMA needs the vitality, activity, and participation of every African-American physician...young, old, resident, fellow, academician, clinician...and medical student.</p>
<p>Working together, we can narrow the persistent gaps in health care, strengthen our practices and our communities, and ensure quality health care for all Amercans.</p>
<p>Join the NMA today to assure a year worthy of a continuous centennial celebration.</p>
<p align=right>--Yvonnecris Smith Veal, MD</p></blockquote></font></td></tr></table>
</ul>

<font size=-1>
<ul>
<li>Courtesy subscriptions to the monthly <b>Journal of the National Medical Association</b> and the quarterly <b>National Medical Association News</b>.
<li>Reduced member registration fees to the NMA's Annual Convention and Scientific Assembly.
<li>Educational programs for Category 1 credit in over 20 medical specialty areas at the NMA Annual Convention and Scientific Assembly, Regional Meetings, Consituent Association, and Component Society Meetings.
<li>Advocacy for health-care issues.
<li>Application for National Medical Association gold MasterCard.
</ul>

<center><table width=90% border=0 cellspacing=0 cellpadding=2><tr><th colspan=3 align=left><font size=-1>NATIONAL MEDICAL ASSOCIATION 1996 DUES SCHEDULE</font></th></tr>
<tr valign=top><td><font size=-1>Regular Members:</font></td>
<td><font size=-1>New Member Physicians applying for membership</font></td><td align=right><font size=-1>$395.00</font></td></tr>
<tr valign=bottom>
<td></td><td><font size=-1>New Physicians Payment Plan. Special payment plans are available upon request for new physicians.<br>First Year in Practice</font></td><td align=right><font size=-1>$140.00</font></td></tr>
<tr valign=top>
<td></td><td><font size=-1>Second Year in Practice</font></td><td align=right><font size=-1>$270.00</font></td></tr>
<tr valign=top>
<td><font size=-1>Military Members:</font></td><td><font size=-1>Physicians on active duty with military</font></td><td align=right><font size=-1>$205.00</font></td></tr>
<tr valign=bottom><td><font size=-1>Associate Members:</font></td><td><font size=-1>Doctoral level faculty at recognized medical education institutions.</font></td></td></td>
</tr>
<tr valign=bottom>
<td></td><td><font size=-1>Physician members of chartered medical societies of foreign countries engaged in medical missionary, educational, or similar work*</font></td><td align=right><font size=-1>$160.00</font></td></tr>
<tr valign=top>
<td><font size=-1>Residents/Fellows:</font></td><td></td><td align=right><font size=-1>$40.00</td></tr>
<tr valign=top>
<td><font size=-1>Medical Students:</font></td><td></td><td align=right><font size=-1>$20.00</font></td></tr>
<tr><td colspan=3><font size=-1>* Associate members may not vote or hold office. Please note that you must also pay your local constituent and/or component society dues, where applicable, for full membership in the NMA.</font></td></tr>
</tr></table></center>

<hr size=1>
<h4>NMA Membership Application : Personal Data</h4>

<font size=-1><b>Note</b>: You must have a forms-capable browser to submit this form online. Otherwise, you may print out this page and mail it in. Thank you.</font><p>

<form action="/cgi-bin/nmaform">

<input type="hidden" name="to" value="natmed@nyam.org">
<input type="hidden" name="body" value="materials">
<input type="hidden" name="sub" value="Member">
<input type="hidden" name="form_submitted" value="http://www.natmed.org/member.html">

<table border=0><tr valign=top>
<td width=34%><font size=-1><b>Last Name</b> <input name="lastname" size=15,1></font></td>
<td width=33%><font size=-1><b>First Name</b> <input name="firstname" size=14,1></font></td>
<td align=right width=33%><font size=-1><b>Middle</b> <input name="middle" size=15,1><br></font></td>
</tr><tr>
<td colspan=3><font size=-1><B>Home Address</B> <input name="street" size=30,1>
<B>City/State/Zip</B> <input name="citystatezip" size=20,1></font></td>
</tr><tr>
<td colspan=3><font size=-1><B>Business Address</B> <input name="bstreet" size=27,1>
<B>City/State/Zip</B> <input name="bcitystatezip" size=20,1></font></td>
</tr><tr>
<td colspan=3><font size=-1><B>Area Code/Home Phone</B> <input name="phone" size=14,1>
<B>Business</B> <input name="bphone" size=14,1>
<b>Fax</b> <input name="fax" size=14,1></font></td>
</tr></table>

<table border=0><tr><td colspan=2><font size=-1>Please indicate your mailing preference: Home <input type="checkbox" name="home"> Business <input type="checkbox" name="business"> e-mail address <input name="email" size=18,1></font></td>
</tr><tr>
<td colspec=50% align=left><font size=-1><input type="checkbox" name="male"> Male <input type="checkbox" name="female"> Female</font></td>
<td colspec=50% align=right><font size=-1>Date of birth <input name="dob" size=20,1></font></td></tr><tr>
<td colspan=2><font size=-1>Social Security # <input name="ss" size=21,1>  Board Certification <input name="bdcert" size=25,1></font></td>
</tr><tr>
<td colspan=2><font size=-1>Specialty <input name="special" size=22,1>  Medical School Attended <input name="school" size=24,1></font></td>
</tr><tr>
<td colspan=2 align=center><font size=-1><input type="checkbox" name="check">Dues Check Enclosed <input type="checkbox" name="card">Charge Dues to Credit Card  -- Dues are Tax Deductible.</td>
</tr><tr>
<td colspan=2><font size=-1>Credit Card Account Number <input name="account" size=20,1> Expiration Date <input name="date" size=20,1></font></td>
</tr><tr>
<td colspan=2><font size=-1>I authorize NMA to charge my <input type="checkbox" name="visa"> VISA <input type="checkbox" name="master"> MasterCard <input type="checkbox" name="Discover"> Discover <input type="checkbox" name="amex"> AMEX <input type="checkbox" name="diners"> Diners</font></td>
</tr><tr>
<td colspan=2><font size=-1>I hereby apply for membership in the National Medical Association, and do hereby agree to abide by the laws governing the organization.<br>
Signature: __________________________________________________________ Date__________ </font></td></tr></table>

<P>You can submit this form now, or print it out and mail with a check if you prefer to:</P>

<p align=center>National Medical Association<br>
PO Box 96610<BR>
Washington, DC 20077-7425<BR>
</BLOCKQUOTE>

<center><table><tr><td><input type="submit" value="SEND"></td><td><br></td><td><input type="reset" value="CLEAR"></td></tr></table></center>

</form></blockquote></font>

<p align=center><a href="index.html"><img src="gifs/medical.gif" vspace=5><br>
<font size=-1>NMA Home Page</a></font></p>

<p align=center><font size=-1><a href="mailto:nma@www.natmed.org">National Medical Association</a><br>
copyright &#169; 1996 NMA</font></p>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-217</DOCNO>
<DOCOLDNO>IA093-001001-B047-274</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/natmed/conven.html 199.29.141.24 19970121121318 text/html 841
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:07:24 GMT
Server: NCSA/1.5.1
Last-modified: Tue, 05 Mar 1996 21:34:31 GMT
Content-type: text/html
Content-length: 659
</DOCHDR>
<html>
<head>
<title>National Medical Association: 101st Annual Convention</title>
</head>
<body background="gifs/logo2.gif" >
<p align=center><img src="gifs/name.gif"></p>

<center><hr size=2 width=60% align=center noshade>
<font size=+3>101st annual convention</font><br>
<b>July 27-August 3, 1996 Chicago</b>
<hr size=3 width=60% align=center noshade></center>


<p align=center><a href="index.html"><img src="gifs/medical.gif" vspace=5><br>
<font size=-1><b>NMA Home Page</b></a></font></p>

<p align=center><font size=-1><a href="mailto:nma@www.natmed.org"><b>National Medical Association</a><br>
copyright &#169; 1996 NMA</b></font></p>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-218</DOCNO>
<DOCOLDNO>IA093-001001-B047-293</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/natmed/about.html 199.29.141.24 19970121121330 text/html 3919
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:07:34 GMT
Server: NCSA/1.5.1
Last-modified: Tue, 05 Mar 1996 21:34:30 GMT
Content-type: text/html
Content-length: 3736
</DOCHDR>
<html>
<head>
<title>About the National Medical Association</title>
</head>
<body bgcolor="#ffffff">
<img alt="National Medical Association" align=top src="gifs/name.gif"><img src="gifs/logo2.gif" align=left hspace=5 vspace=5><p>The mission of the National Medical Association (NMA) is to promote the science and art of medicine. The NMA also acts to influence society and its institutions, to encourage, to protect and to promote the betterment of the public health, and the quality of life for individuals and families. While throughout its history the National Medical Association has focused primarily on health issues related to African Americans and medically underserved populations, its principles, goals, initiaitives and philosophy encompass all sectors of the population.</p>

<p><img src="gifs/redball.gif" hspace=5>The National Medical Association (originally known as the National Association of Colored Physicians, Dentists and Pharmacists) was formed in Atlanta during the Cotton States Exposition in 1895. This orgnaizational meeting was held at the First Congregational Church in Atlanta, Georgia.</p>
<p><img src="gifs/redball.gif" hspace=5>The first president of the National Medical Association was Robert Fulton Boyd, D.D.S. of Nashville, Tennessee. Miles Vandahurst Lynk, M.D. of Jackson, Tennessee was the vice president.</p>
<p><img src="gifs/redball.gif" hspace=5>The second meeting of the National Medical Association was held at Meharry Medical College in Nashville, Tennessee in 1903. At this meeting, the name was changed to the National Medical Association.</p>
<p><img src="gifs/redball.gif" hspace=5>The first African American medical society, the Medico-Chirurgical Society of the District of Columbia, was formed in 1884. The Lone Star State Association was formed in Texas in 1886; the Georgia State Medical Association in 1893; the Palmetto State Medical Assocation in South Carolina in 1896; and, the Old North State Medical, Dental and Pharmaceutical Association in North Carolina in 1897. These later became NMA constituent associations. Today, there are 31 constituent assocations and 73 component societies which span the United States, Puerto Rico and the U.S. Virgin Islands.</p>
<p><img src="gifs/redball.gif" hspace=5>At its inception, the National Medical Association consisted of physicians, dentists and pharmacists and by 1912 the membership numbered more than 500. Today, the Association's membership database numbers 13,500 -- comprised of physicians in primary care, pediatrics, radiology, pathology, aerospace medicine, academic medicine, administration specialties and medical and surgical subspecialties.</p>
<p><img src="gifs/redball.gif" hspace=5><a href="http://www.slackinc.com/general/jnma/jnmahome.htm">The Journal of the National Medical Association</a>, founded in 1909, is the oldest medical magazine of any kind published under African American auspices.</p>
<p><img src="gifs/redball.gif" hspace=5>Since 1975, the National Medical Association has offered extensive continuing medical education programs to practicing physicians under the direction of William E. Matory, M.D. The NMA is approved by the Accreditation Council for Continuing Medical Education (ACCME) to provide Category 1 credit towards the Physicians' Achievement Award of the National Medical Association and the Physician's Recognition Award of the <a href="http://www.ama-assn.org/">American Medical Assocation</a>.</p>

<p align=center><a href="index.html"><img src="gifs/medical.gif" vspace=5><br>
<font size=-1>NMA Home Page</a></font></p>

<p align=center><font size=-1><a href="mailto:nma@www.natmed.org">National Medical Association</a><br>
copyright &#169; 1996 NMA</font></p>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-219</DOCNO>
<DOCOLDNO>IA093-001001-B047-314</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/natmed/discuss.html 199.29.141.24 19970121121340 text/html 1733
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:07:49 GMT
Server: NCSA/1.5.1
Last-modified: Tue, 12 Mar 1996 19:51:31 GMT
Content-type: text/html
Content-length: 1550
</DOCHDR>
<html>
<head>
<title>NMA: Web discussion</title>
</head>
<body bgcolor="#ffffff" >
<p align=center><img src="gifs/name.gif"></p>

<!--DISCUSSION-->

<center><hr size=2 width=40% align=center noshade>
<font size=+3>discussion group</font>
<hr size=3 width=40% align=center noshade></center>

<h3 align=center>comments and revisions for Web site pages</h3>
<p>Article submitted on March 5, 1996<br>
<!--LASTDATE--> Last post on: Tue Mar 12 14:51:30 EST 1996 

<HR><B>Joel Beard 
 <a HREF=mailto:jbeard@nyam.org>
		jbeard@nyam.org</A></b> Tue Mar 12 14:51:30 EST 1996
<P> my comments about the text
<!--POINTER-->

<hr size=1 width=50% align=center>

<blockquote>Post a response:
<br>
<FORM METHOD=POST
	ACTION="/cgi-bin/natmed.cgi/discuss.html">
Name: <INPUT TYPE="text" NAME="name" SIZE=25 MAXLENGTH=25>
<BR>
Email address: <INPUT TYPE="text" NAME="address" SIZE=30 MAXLENGTH=30>
<br>
Text:
<br>
<TEXTAREA ROWS=15 COLS=60 NAME="body"></TEXTAREA>
<br>
<center><table><tr><td><INPUT TYPE=submit VALUE="POST"></td><td><br></td><td><INPUT TYPE=reset VALUE="CLEAR"></td></tr></table></center>
</blockquote>
<p><b>Note</b>: after you post, you will return to the discussion page. Reload and you will see your post.</p>
</FORM>

<hr size=5 width=50% align=center>

<p align=center><a href="index.html"><img src="gifs/medical.gif" vspace=5><br>
<font size=-1><b>NMA Home Page</b></a></font></p>

<p align=center><font size=-1><a href="mailto:nma@www.natmed.org"><b>National Medical Association</a><br>
copyright &#169; 1996 NMA</b></font></p>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-220</DOCNO>
<DOCOLDNO>IA093-001001-B047-332</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/public_html/cgraber/ 199.29.141.24 19970121121358 text/html 1065
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:08:03 GMT
Server: NCSA/1.5.1
Content-type: text/html
</DOCHDR>
<HEAD><TITLE>Index of /public_html/cgraber/</TITLE></HEAD><BODY>
<H1>Index of /public_html/cgraber/</H1>
<PRE><IMG SRC="/icons/blank.xbm" ALT="     "> Name                   Last modified     Size  Description
<HR>
<A HREF="/public_html/"><IMG SRC="/icons/menu.xbm" ALT="[DIR]"></A> <A HREF="/public_html/">Parent Directory</A>       23-Sep-96 14:35      -  
<A NAME="PIOM.html" HREF="PIOM.html"><IMG SRC="/icons/text.gif" ALT="[TXT]"></A> <A NAME="PIOM.html" HREF="PIOM.html">PIOM.html</A>              16-Sep-96 14:11     1K  PIOM Library Orientatio>
<A NAME="POIM.html" HREF="POIM.html"><IMG SRC="/icons/text.gif" ALT="[TXT]"></A> <A NAME="POIM.html" HREF="POIM.html">POIM.html</A>              16-Sep-96 14:11     1K  POIM Library Orientatio>
<A NAME="POIM.html.save" HREF="POIM.html.save"><IMG SRC="/icons/text.gif" ALT="[TXT]"></A> <A NAME="POIM.html.save" HREF="POIM.html.save">POIM.html.save</A>         16-Sep-96 14:11     1K  
</PRE></BODY>
</DOC>
<DOC>
<DOCNO>WT18-B31-221</DOCNO>
<DOCOLDNO>IA093-001001-B047-488</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/thread-images/help.html 199.29.141.24 19970121121609 text/html 7589
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:10:15 GMT
Server: NCSA/1.5.1
Last-modified: Tue, 19 Mar 1996 19:51:41 GMT
Content-type: text/html
Content-length: 7406
</DOCHDR>
<html>

<head>
<Title> net.Thread Help</Title>
<head>

<body>

<h1 align = "center">net.Thread Help</h1>
<hr>
net.Thread is a thread-based discussion server that allows interactive
forums on World Wide Web sites. net.Thread combines the functionality
of a  USENET newsgroup with an easy to use graphical, hierarchical interface.


<hr>
<strong>Contents:</strong>
<ul>
<li> <a href="#login">Logging In</a>
<li> <a href="#navigating">Navigating the Discussion</a>
<li> <a href="#posting">Posting New Messages</a>
<li> <a href="#replying">Replying to Existing Messages</a> 
<li> <a href="#buttons">Button Reference</a>
</ul>

<hr>
<a name="login"></a>
<h2>Logging In</h2>

The net.Thread login form request three pieces of information:
<ul>
<li> Login Name
<li> Maximum Display Depth
<li> Last Login
</ul>

Your <strong>Login Name</strong> can be your real name, your email
address, or an alias.  No default login name is offered, although we
recommend that you be consistent with your login name so that all of
your posts originate from the same username. Note that you are not
required to enter a password with your username.<p>

The <strong>Maximum Display Depth</strong> specifies how much of the
hierarchy is visible at a time. The default setting is "3", meaning
that net.Thread will display the message hierarchy up to 3 levels
deep.  Beyond 3 levels, a note appears stating the number of replies
beneath the 3rd level message. The Maximum Display Depth can be set to
any integer greater than or equal to one.  Note that the display depth
can also be modified using the <a href="#depth+">Depth +</a> and <a
href="#depth-">Depth -</a> buttons.<p>

The <strong>Last Login</strong> field specifies the date of your last
login to this installation of net.Thread.  The default value is the
current date. Any messages which have been posted after to the Last
Login date will be marked as "<strong>NEW!</strong>".

<hr>

<a name="navigating"></a>
<h2>Navigating the Discussion</h2>
The net.Thread discussion hierarchy can be navigated by using:
<ul>
<li> Links to message Titles
<li> The <a href="#next">Next</a> and <a href="#previous">Previous</a> buttons
<li> The <a href="#thread">Thread</a> button
</ul>
Clicking on individual message titles is the easiest and fastest way to
navigate the discussion. When you click on a message title, the text
of the message is displayed, as well as it's parent and children
messages. To move to the top of the discussion area, click on the
topmost parent message. This message <em>always</em> represents the
discussion groups's root message.<p>

The <a href="#next">Next</a> button views the next message in the
thread hierarchy.  Similarly, the <a href="#previous">Previous</a>
button views the previous message in the thread hierarchy.  The Next
and Previous Buttons are useful for easily following specific
discussions.<p>

The <a href="#thread">Thread</a> button returns you to the top level
of the net.Thread installation.  From this "root" directory, all
discussion areas on the site are accessible.

<hr>

<a name="posting"></a>
<h2>Posting New Messages</h2>

To post a new message to the discussion, press the <a
href="#post">Post</a> button. The Post form will then appear, with
fields for entering the message Title, Sender, and Body.  The Title
and Body fields will be blank, and your Login Name will be the deafult
value in the Sender field.<p>

Type in the message title and body text. Beneath the body field are
three radio buttons which control how net.Thread will interpret the
body text.

<ul>
<li> <strong>Normal text</strong> automatically formats your post.  This
setting will display double-blank lines as HTML
paragraphs, words surrounded by asterisks as "strong"
(*strong* = <strong> strong </strong>), and words surrounded by
underscores as "emphasized" (_emphasized_ =
<em>emphasized</em>).
<li><strong>HTML</strong> assumes that HTML codes are already included in 
the message.
<li><strong>Preformat</strong> displays the message in a fixed-pitch font 
exactly as entered by the user.
</ul>

Beneath these radio buttons is the <strong>Preview</strong>
checkbox. The default button position allows you to preview your post
before it is actually posted in the discussion. This is particularly
useful for checking for typographical errors as well as "HTML" messages
which might not display as expected. If you need to change your
posting, use your browser's "Back" function to return to the Post
form.<p>

When you are ready to submit your post, press the
<strong>Post</strong> button.

<hr>

<a name="replying"></a>
<h2>Replying to Existing Messages</h2>

To respond to an existing message, press the <a
href="#reply">Reply</a> button while viewing the message text. The
Reply form is identical to the Post form in both function and
appearance. After previewing and submitting your reply, your message's
header information will appear indented beneath the original message
in the hierarchy.
<hr>

<a name="buttons"></a>
<h2 align="center">Button Reference</h2>
<hr>
This area gives brief explanations of each net.Thread button.
<hr>

<a name="post"></a>
<img src = "post.gif"><p>
<strong>Post</strong>: 
Creates a new message or group as a "child" of the currently viewed
group.  Note that the "Post" button is only available when viewing the
top level of a discussion forum.
<hr>

<a name="reply"></a>
<img src = "reply.gif"><p>
<strong>Reply</strong>:
Creates a new message as the next "child" of the currently viewed
message. Note that the "Reply" button is only available when viewing a
message.  The "Post" and "Reply" buttons appear under different
circumstances but function identically.

<hr>

<a name="next"></a>
<img src = "nextmsg.gif"><p>
<strong>Next</strong>:
Views the next message (goes down one message in the outline display)
from the message currently viewed. The "Next" button is only available
when a next message exists.
<hr>

<a name="previous"></a>
<img src = "prevmsg.gif"><p>
<strong>Previous</strong>:
Views the previous message (goes up one message in the outline
display) from the message currently viewed. The "Previous" button is
only available when a previous message exists.
<hr>

<a name="thread"></a>
<img src = "thread.gif"><p>
<strong>Thread</strong>:
Views the very top level of the site's thread hierarchy. Note that the "Thread" button is not available at the top level of the hierarchy.
<hr>

<a name="help"></a>
<img src = "help.gif"><p>
<strong>Help</strong>:
Views this help display.
<hr>

<a name="depth+"></a>
<img src = "moredet.gif"><p>
<strong>Depth +</strong>:
Increases the display depth (the number of levels of hierarchy shown
in the outline below the current message) by one unit. Note that the
"Depth +" button is only available when viewing a message or a
discussion forum.
<hr>

<a name="depth-"></a>
<img src = "lessdet.gif"><p>
<strong>Depth -</strong>:
Reduces the display depth (the number of levels of hierarchy shown in
the outline below the current message) by one unit. Note that the
"Depth -" button is only available when viewing a message or a
discussion forum.

<hr>

<a name="settings"></a>
<img src = "settings.gif"><p>
<strong>Settings</strong>:
Accesses the login screen so that the login name, display depth, and
last login date can be modified. After this procedure, net.Thread
returns to currently viewed message after settings are changed.
<hr>

</body>
</html>





</DOC>
<DOC>
<DOCNO>WT18-B31-222</DOCNO>
<DOCOLDNO>IA093-001001-B048-412</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/a-t/index.html 199.29.141.24 19970121122144 text/html 4253
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:15:38 GMT
Server: NCSA/1.5.1
Last-modified: Sat, 18 Jan 1997 18:55:49 GMT
Content-type: text/html
Content-length: 4070
</DOCHDR>
<html>
<head>
<title>Able-Together</title>
</head>

<body background="gifs/stripe.gif" link="#ffffff" vlink="#4f9eaf"><font face="comic sans ms, century gothic">

<table cellpadding=0 cellspacing=0>
<tr>
<td><img src="gifs/ablelogo.gif"></td><td>&nbsp;&nbsp;</td><td><font face="comic sans ms, century gothic" color="#5959ab" size=+2>a forum for men with and without disabilities</font></td>
</tr><tr>
<td align=right><font face="comic sans ms, century gothic" size=+1><a href="about.html"><b>about A-T</b></a></font></td><td>&nbsp;&nbsp;</td><td><font face="comic sans ms, century gothic" color="#236b8e">who we are and what we do</font></td>
</tr><tr>
<td align=right><font face="comic sans ms, century gothic" size=+1><a href="guest.html">guestbook</a></font></td><td>&nbsp;&nbsp;</td><td><font face="comic sans ms, century gothic" color="#236b8e">guestbook, feedback, what youd like to see on the site</td>
</tr><tr>
<td align=right><font face="comic sans ms, century gothic" size=+1><a href="library.html">library</a></font></td><td>&nbsp;&nbsp;</td><td><font face="comic sans ms, century gothic" color="#236b8e">reviews, articles, newsletters, internet resources</font></td>
</tr><tr>
<td align=right><font face="comic sans ms, century gothic" size=+1><a href="new.html">what's new</a></font></td><td>&nbsp;&nbsp;</td><td><font face="comic sans ms, century gothic" color="#236b8e">guide to whats new on the site</font></td>
</tr><tr>
<td align=right><font face="comic sans ms, century gothic" size=+1><a href="bb.html">bulletin board</a></font></td><td>&nbsp;&nbsp;</td><td><font face="comic sans ms, century gothic" color="#236b8e">announcements, calendar of events, for sale/exchange/give it away</font></td>
</tr><tr>
<td align=right><font face="comic sans ms, century gothic" size=+1><a href="meeting.html">meeting place</a></font></td><td>&nbsp;&nbsp;</td><td><font face="comic sans ms, century gothic" color="#236b8e">personals - browse, add yours</font></td>
</tr><tr>
<td align=right><font face="comic sans ms, century gothic" size=+1><a href="resources.html">resources</a></font></td><td>&nbsp;&nbsp;</td><td><font face="comic sans ms, century gothic" color="#236b8e">what's out there and how to find it, online and off</font></td>
</tr><tr>
<td align=right><font face="comic sans ms, century gothic" size=+1><a href="people.html">people</a></font></td><td>&nbsp;&nbsp;</td><td><font face="comic sans ms, century gothic" color="#236b8e">personal web pages from men with disabilities</font></td>
</tr><tr>
<td align=right><font face="comic sans ms, century gothic" size=+1><a href="subscribe.html">subscribe</a></font></td><td>&nbsp;&nbsp;</td><td><font face="comic sans ms, century gothic" color="#236b8e">how to subscribe to A-T</font></td>
</tr><tr>
<td align=right><font face="comic sans ms, century gothic" size=+1><a href="gallery.html">gallery</a></font></td><td>&nbsp;&nbsp;</td><td><font face="comic sans ms, century gothic" color="#236b8e">images of men with disabilites</font></td>
</tr><tr>
<td align=right><font face="comic sans ms, century gothic" size=+1><a href="forums.html">forums</a></font></td><td>&nbsp;&nbsp;</td><td><font face="comic sans ms, century gothic" color="#236b8e">forums on topics of interest to men with disabilities</font></td>
</tr><tr>
<td align=right><font face="comic sans ms, century gothic" size=+1><a href="work.html">your work</a></font></td><td>&nbsp;&nbsp;</td><td><font face="comic sans ms, century gothic" color="#236b8e">your site/your work: poetry, photography, stories, essays, etc.</font></td>
</tr><tr>
<td align=right><font face="comic sans ms, century gothic" size=+1><a href="news.html">in the news</a></font></td><td>&nbsp;&nbsp;</td><td><font face="comic sans ms, century gothic" color="#236b8e">what's going on, action alerts</font></td>
</tr>
</table>
<p><p>
<table>
<tr>
<td align=center><font face="arial, helvetica" size=-1 color="#ffffff"><b>pages modified: 1/11/97 <br><a
href="mailto:blaine@well.com">blaine@well.com</a><br>
&#169 1997 A-T</b></font></td>
</tr>
</table>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-223</DOCNO>
<DOCOLDNO>IA093-001001-B049-11</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/index.html 199.29.141.24 19970121122208 text/html 6191
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:16:09 GMT
Server: NCSA/1.5.1
Last-modified: Mon, 20 Jan 1997 14:02:30 GMT
Content-type: text/html
Content-length: 6008
</DOCHDR>
<html>
<head>
<title>www.aidsnyc.org</title>
<meta name="description" content="A linked collection of pages from HIV/aIDS community based organizations in New York City.">
<meta name="keywords" content="HIV, AIDS, clinical trials,
opportunistic infections, treatments, housing, immigration, children, women, drugs">
</head>
<body background="gifs/strip.gif" width=1008 height=36 link="#8b2323" vlink="#696969">

<table width=100%>
<tr>
<td colspan=3><img src="gifs/newlogo.gif" alt="www.aidsnyc.org" width=368 height=55></td>
</tr><tr>
<td width=134>&nbsp;</td><td colspan=2><font face="comic sans ms">linked pages from community based organizations in New York City</font></td>
</tr><tr>
<td width=134>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
</tr><tr>
<td width=134><a href="Architext/aidsnycquery.html"><font face="comic sans ms" color="#ffffff" link="#ffffff" vlink="#ffffff">search</font></a></td><td align=center><font face="garamond"><a href="acqc/index.html"><b>AIDS Center of Queens County</b></a></font></td><td align=center><font face="garamond"><a href="aip/index.html"><b>AIDS in Prison Project</b></a></td>
</tr><tr>
<td width=134><a href="guide.html"><font face="comic sans ms" color="#ffffff" link="#ffffff" vlink="#ffffff">guide to sites</font></a></td><td align=center><font face="garamond"><a href="network/index.html"><b>AIDS Treatment Data Network</b></a></font></td><td align=center><font face="garamond"><a href="cwha/index.html"><b>Caribbean Women's Health Ass'n</b></a></font></td>
</tr><tr>
<td width=134><a href="new.html"><font face="comic sans ms" color="#ffffff" link="#ffffff" vlink="#ffffff">what's new</font></a></td><td align=center><font face="garamond"><a href="cdn/index.html"><b>Clinical Directors Network</b></a></font></td><td align=center><font face="garamond"><a href="berridge/index.html"><b>Coming Into View: Women &amp; Families</b></a></font></td>
</tr><tr>
<td width=134><a href="links.html"><font face="comic sans ms" color="#ffffff" link="#ffffff" vlink="#ffffff">links</font></a></td><td align=center><font face="garamond"><a href="cnews/index.html"><b>Consumer News</b></a></font></td><td align=center><font face="garamond"><a href="arrive/index.html"><b>Exponents Arrive</b></a></font></td>
</tr><tr>
<td width=134><a href="congress.html"><font face="comic sans ms" color="#ffffff" link="#ffffff" vlink="#ffffff">action alerts</font></a></td><td align=center><font face="garamond"><a href="fc/index.html"><b>The Family Center</b></a></font></td><td align=center><font face="garamond"><a href="glwd/index.html"><b>God's Love We Deliver</b></a></font></td>
</tr><tr>
<td width=134><a href="about.html"><font face="comic sans ms" color="#ffffff" link="#ffffff" vlink="#ffffff">about aidsnyc</font></a></td><td align=center><font face="garamond"><a href="heal/index.htm"><b>Health Education AIDS Liaison</b></a></font></td><td align=center><font face="garamond"><A HREF="http://www.liaac.org/index.html"><b>Long Island Assoc. for AIDS Care</b></A></font></td>
</tr><tr>
<td width=134><a href="docorder.html"><font face="comic sans ms" color="#ffffff" link="#ffffff" vlink="#ffffff">document order</font></a></td><td align=center><font face="garamond"><a href="momentum/index.html"><b>Momentum AIDS Project</b></a></font></td><td align=center><font face="garamond"><a href="natap/index.html"><b>Nat'l AIDS Treatment Advocacy Project</b></a></font></td>
</tr><tr>
<td width=134>&nbsp;</td><td align=center><font face="garamond"><a href="orphan/index.html"><b>The Orphan Project</b></a></font></td><td align=center><font face="garamond"><a href="ai/index.html"><b>NYS DOH AIDS Institute</b></a></font></td>
</tr><tr>
<td width=134 rowspan=2><a href="http://www.healthexplorer.com/"><img src="gifs/bestsite.gif" alt="health explorer bestsite" width=75 height=51></a></td><td align=center><font face="garamond"><a href="pwac/index.html"><b>People With AIDS Coalition/NY</b></a></font></td><td align=center><font face="garamond"><a href="pwahg/index.html"><b>PWA Health Group</b></a></font></td>
</tr><tr>
<td align=center><font face="garamond"><a href="siatf/index.html"><b>Staten Island AIDS Task Force</b></a></font></td><td align=center><font face="garamond"><a href="rtrp/index.html"><b>Real Treatments for Real People</b></a></font></td>
</tr><tr>
<td width=134>&nbsp;</td><td colspan=2 align=center><hr size=4 width=50% noshade></td>
</tr><tr>
<td width=134><font face="comic sans ms" size=-1 color="#ffffff" link="#ffffff" vlink="#ffffff">pages modified: <br><b>1/20/97</b> <br><a
href="mailto:hivinfo@nyam.org"><font color="#ffffff">www.aidsnyc.org</a></font></td>
<td colspan=2 align=center><b><a href="programs.html"><font face="garamond" color="#8b2323">other NYAM HIV/AIDS projects</a> | <a href="updates.html">Vancouver Updates</a> | <a href="retrov.html">Retroviruses Conference</a><br><font color="#000000">other NYC sites : <font color="#8b2323"><a href="http://www.actupny.org">ACT UP NY</a> | <a href="http://www.artistswithaids.org">The Estate Project</a> | <a href="http://www.gmhc.org/">GMHC</a> | <A HREF="http://www.housingworks.org/">Housing Works</A></font></b></td>
</tr><tr>
<td width=134>&nbsp;</td><td colspan=2 align=center><hr size=4 width=50% noshade></td>
</tr><tr valign=top>
<td width=134><font face="comic sans ms" color="#ffffff" size=-1>These pages made possible in part <br>by a grant from <a href="http://www.citibank.com"><img alt="Citibank" align=middle src="gifs/citibank.gif" border=0></a></font></td>
<td colspan=2><font face="comic sans ms" color="#000000" 
size=-1>www.aidsnyc.org is an open forum for various organizations and viewpoints. Inclusion of any group or organization on this site does not imply endorsement by the other member organizations or <a href="http://www.nyam.org/index.html">The New York Academy of Medicine</a>. This site designed and maintained by Joel Beard courtesy of the <a href="network/index.html">AIDS Treatment Data Network</a>. &#169; 1997</font></td>
</tr>
</table>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-224</DOCNO>
<DOCOLDNO>IA093-001001-B049-60</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/acqc/case.html 199.29.141.24 19970121122233 text/html 7346
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:16:41 GMT
Server: NCSA/1.5.1
Last-modified: Tue, 29 Oct 1996 17:16:18 GMT
Content-type: text/html
Content-length: 7163
</DOCHDR>
<html><head><title>ACQC: Case Management Services</title></head><body background="gifs/pad.gif"><p align=center><img src="gifs/logox.gif" alt="[logo]"></p><h3 align=center>Case Management Services</h3><blockquote><p>A.C.Q.C. case managers assist people living with H.I.V. infection in coordinating the various services available to them.  The primary goal of each case manager is to be an advocate for those living with H.I.V.   They are experts in handling the red tape and bureaucracy that one encounters in "the system".  The services that case managers advocate for include the following:</p><ul><li><B>Medical Care</B><dt>Case managers make referrals to a wide variety of medical facilities, depending on the needs of each client.  These might be private practice physicians, hospital clinics, extended care facilities or home care providers.  Your case manager can also help you obtain dental care and pharmacy home delivery services.<p><li><B>Social Security</B><dt>Social Security Disability (S.S.D.) pays monthly checks to people who have a sufficient work history, have paid into the Social Security Program (F.I.C.A. taxes) and are now disabled. Your case manager can assist in filing paperwork for applying for S.S.D. or a reconsideration or appeal.<p><dt>Supplemental Security Income (S.S.I.) is a federal program run by the Social Security Administration.  It pays monthly checks to people who are disabled and have few assets, low income, but do not qualify for S.S.D. <p><li><B>New York State Disability</B><dt>NY State Disability (N.Y.S.D.) Is a short term benefit for people who have left or must leave their jobs due to illness or disability.  This plan is administered by your employer.  Some employers, especially in unionized shops, offer a higher level of benefits than the minimum required by New York State.<p><li><B>Public Assistance</B><dt>Public Assistance (Welfare or P.A.) Provides cash payments, Medicaid (Medical Assistance or M.A.), food stamps and rent payments for people with few assets and no income.  Higher rental assistance is available for those infected with H.I.V. (Enhanced Rent).  A special department within Public Assistance called the Division of A.I.D.S. Services (D.A.S.) provides both higher rent and higher cash payments for those with Center for Disease Control (C.D.C.) defined AIDS.<p><li><B>A.I.D.S. Health Insurance Program</B><dt>A.I.D.S. Health Insurance Program (A.H.I.P.) Pays health insurance premiums for certain persons living with A.I.D.S. or H.I.V. who have lost their jobs or can only work part time and would otherwise loose their health benefits.<p><li><B>A.I.D.S. Drug Assistance Plan</B><dt>A.I.D.S. Drug Assistance Plan (A.D.A.P. Plus) is a program administered by the New York State Department of Health's A.I.D.S.  Institute to provide medicine, clinic visits, lab tests and home care (Note: inpatient hospital care is NOT covered) for uninsured people living with H.I.V. in New York State regardless of their immigration status.  A.D.A.P. Plus can also help certain individuals cover Medicaid spend-downs or high insurance deductibles and copayments.<p><li><B>Legal Assistance</B><dt>While your case manager is NOT a lawyer, s/he can get  you an appointment with the A.C.Q.C. attorney to take care of legal matters such as health care proxies, permanency planning, child guardianship, wills, unfair collection practices and discrimination.  Referrals can also be made to outside attorneys specializing in areas such as immigration and housing.<p><li><B>Mental Health</B><dt>One's emotional state has a profound impact on one's health, just as one's physical state can deeply affect one's emotions.  Your case manager will help you get an appointment with a a certified counselor for individual counseling or support group or substance abuse counseling.  The A.C.Q.C.'s Counseling Center is fully licensed by the New York State Department of Health.<p><li><B>Transportation</B><dt>Getting around New York is not easy for those in the best of health.  When you have any serious illness this sometimes becomes a monumental task.  Your case manager can help you arrange transportation though the Red Cross ambulette service, Medicaid ambulette, NY Transit Authority Access-A-Ride or other emergency transportation.<p><li><B>Nutrition</B><dt>Good nutrition is essential in maintaining good health.  A.C.Q.C.'s team of case managers regularly schedule nutritional seminars and one-on-one sessions with a nutritionist.  Your case manager can provide you with access to our food pantry on an emergency basis.  <p><li><B>Buddy and Peer Support Programs</B><dt>A.C.Q.C.'s Buddy and Peer support programs provide emotional support and social contact for people living with A.I.D.S. who are limited in their ability to get out and socialize due to their health.  If you need this kind of support, your case manager can make arrangements for you to have a buddy assigned to you.  If you are well enough to get around and would like to visit someone to support them, you can be a Peer Volunteer.<p><li><B>Community Referrals</B><dt>Your case manager knows of a wide variety of other services available for you in the Queens and the Greater New York area.  You can be referred for home delivered meals, educational and vocational training, child related services, drug and alcohol detox and recovery programs and more.  Just discuss your needs and concerns with your A.C.Q.C. case manager.<p><li><B>Client Education</B><dt>Educational seminars are periodically sponsored by the case management department covering a wide variety of issues of concern to those affected and infected with H.I.V.  Once you are enrolled as a client you will receive a monthly update of seminars and other events planned for the upcoming months. Your case manager can also help you obtain literature on topics of concern, such as new treatment options and clinical trials.<p><li><B>Peer Education</B><dt>Your case manager will be happy to help you get involved in the Peer Education Department's various outreach programs.  Volunteers in these programs receive intensive training in A.I.D.S. and its prevention and participate in outreach projects to help educate the community at large.  There are programs are targeted at adolescents, women, Hispanics,  I.V. substance abusers, post-correctional, lesbian women,  gays and bisexual men as well as gay, lesbian and bisexual youth.</ul><p>To become a client of A.C.Q.C., please call for an intake interview.  These are generally scheduled at one of our three offices, but should you be unable to travel, a home intake can be arranged if necessary.  Please call the office closest to your residence to schedule your interview.  And be assured that all information you share with any A.C.Q.C. staff member or volunteer is kept strictly confidential.</p></blockquote><p align=center><a href="index.html"><img src="gifs/left.gif" vspace=8><br><font size=-1>ACQC</a><br>copyright &#169; 1996 <br><a href="mailto:hivinfo@aidsnyc.org">hivinfo@aidsnyc.org</a><br>Last modified: 10/29/96</font></p></body></html>
</DOC>
<DOC>
<DOCNO>WT18-B31-225</DOCNO>
<DOCOLDNO>IA093-001001-B049-85</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/acqc/holiday.html 199.29.141.24 19970121122243 text/html 1910
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:16:51 GMT
Server: NCSA/1.5.1
Last-modified: Tue, 29 Oct 1996 17:15:53 GMT
Content-type: text/html
Content-length: 1727
</DOCHDR>
<html><head><title>ACQC: Holiday Party</title></head><body background="gifs/pad.gif"><p align=center><img src="gifs/logox.gif" alt="[logo]"></p><h3 align=center>Annual Holiday Party - Join Us!</h3><blockquote><p>October 22, 1996</p><p>Dear Sir/Madam:</p><p>Do you know that there are 11,386 adults and 203 pediatric cases of AIDS in the borough of Queens?</p><p>The AIDS Center of Queens County (ACQC) is the largest and oldest community based not-for-profit agency in Queens providing comprehensive services to the HIV infected and affected families in this borough. Enclosed you will find a brochure about the services we provide.</p><p>This year we are hosting our annual holiday party on Thursday, December 19, 1996, from 5:00 to 8:00 P.M.,  at Samaritan Village  and would like to have gifts available for our clients and their children.</p><p>I am  writing to you to request donations for these families,  many of them receive income solely from social services.  Our agency would appreciate any contributions, or financial assistance to be received by December 10th.</p><p>We hope you  will be able to help us provide gifts to those who are in need during this holiday season.</p><p>Thank you for any consideration.  If you need to get in touch with me, I can be reached at (718) 896-2500.</p><p>Sincerely,<br><br>Rosemary Lopez, CSW<br>Deputy Executive Director of Case<br>Management Services</p></blockquote><p align=center><a href="index.html"><img src="gifs/left.gif" vspace=8><br><font size=-1>ACQC</a><br>copyright &#169; 1996 <br><a href="mailto:hivinfo@aidsnyc.org">hivinfo@aidsnyc.org</a><br>Last modified: 10/29/96</font></p></body></html>                          
</DOC>
<DOC>
<DOCNO>WT18-B31-226</DOCNO>
<DOCOLDNO>IA093-001002-B001-21</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/acqc/wills.html 199.29.141.24 19970121122254 text/html 4705
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:17:02 GMT
Server: NCSA/1.5.1
Last-modified: Thu, 12 Sep 1996 14:21:38 GMT
Content-type: text/html
Content-length: 4522
</DOCHDR>
<html>
<head>
<title>About Health Care Proxy/Living Wills</title>
</head>
<body background="gifs/pad.gif">

<h3 align=center>About Health Care Proxies and Living Wills</h3>

<blockquote>
<ul>
<li><a href="proxy.html"><b>New York State Health Care Proxy form to print out</b></a>
<li><a href="http://www.echonyc.com/~choice/"><b>Choice in Dying</b></a>: free downloadable state-specific advance directive packages.
</ul>
</blockquote>

<blockquote>

<p>A Health Care Proxy, though not required, is usually requested on admission by New York State hospitals. A Living Will is also not a required document, though it may be a good idea to have one in your files.</p>

<p>This information is provided so you can make a decision about what is right for you. It is also a good idea to give copies to the person you have appointed as your proxy agent, your doctor, and anyone else you want to know and understand decisions you have made about your health care.</p>

<p>A <a href="proxy.html">Health Care Proxy</a> form is a legal document which you fill out, sign, and have witnessed, appointing someone of your choice to make health care decisions for you if you are unable to make the decisions for yourself. A proxy is a person who is granted authority to act as an agent for you. You can appoint someone such as a family member, a friend, or a lover to be your Health Care Proxy. Appointing a Health Care Proxy is entirely voluntary. While it's not required, it's a good idea to have the proxy notarized. You can always change your mind and appoint someone else.</p>

<p>You don't need a lawyer to appoint a Health Care Proxy. You can use a standard form. The form and your rights are discussed clearly in the papers that come with the proxy. You will need two witnesses to sign their names below yours, which is a way of acknowledging that you made the decision to appoint a Health Care Proxy on your own.</p>

<p>In the proxy form, there are spaces to make your specific wishes known. You may choose not to have artificial nutrition or hydration (food and water) to continue your life if you are in a coma. The hospital cannot make the decision to remove these supports, but your Health Care Proxy, following your wishes, can. All hospitals, doctors and other health care facilities are legally required to honor the decisions made by your Health Care Proxy. You may appoint an alternate proxy, in case your first choice is not available to make decisions based on your wishes. Otherwise, health care providers will make treatment decisions for you that follow instructions you gave while you were still able to do so. Any instructions that you write on your Health Care Proxy form will guide health care providers if you are unable to inform them of your wishes.</p>

<p>The Health Care Proxy will be valid indefinitely unless you state otherwise. If you choose your wife or husband as your health care agent and you get divorced or legally separated, the appointment is automatically canceled. If you are in a nursing home or hospice, and wish to choose someone ho works there for your Health Care Proxy, there are special restrictions which you will have to discuss with the director or other management personnel. The person you appoint is not legally liable for treatment decisions made in good faith or for the costs of your care.</p>

<p>The Health Care Proxy is as useful for making decisions to receive or continue treatment as it is for making decisions to stop treatment. The person you appoint can interpret your wishes as medical circumstances change and can make decisions you could not have known would have to be made. If you complete a Health Care Proxy form, but also have a Living Will, the Living Will provides instructions for your health care agent, and will guide his or her decisions.</p>

<p>A Living Will is a document providing specific instructions about withholding treatment should you be unable to make your wishes known. A Living Will is generally used to declare wishes to refuse life-sustaining treatment under certain circumstances. The <a href="mailto:atdn@aidsnyc.org">Network</a> has a copy of a Living Will on file which they can send you, or they can give you a phone number to call and request one.</p>

</blockquote>

<p align=center><a href="index.html"><img src="gifs/left.gif"><br>
<font size=-1>ACQC</a><br>
copyright &#169; 1996 <br>
<a href="mailto:hivinfo@aidsnyc.org">hivinfo@aidsnyc.org</a><br>
Last modified: 9/12/96</font></p>

</body>
</html>                          
</DOC>
<DOC>
<DOCNO>WT18-B31-227</DOCNO>
<DOCOLDNO>IA093-001002-B001-50</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/acqc/proxy.html 199.29.141.24 19970121122315 text/html 8043
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:17:12 GMT
Server: NCSA/1.5.1
Last-modified: Tue, 10 Sep 1996 16:35:27 GMT
Content-type: text/html
Content-length: 7860
</DOCHDR>
<html>
<head>
<title>Health Care Proxy</title>
</head>
<body bgcolor="#ffffff">
<blockquote>


<h3 align=center>HEALTH CARE PROXY<br>
AND<br>
MEDICAL DIRECTIVE</h3>
<h4 align=center>New York State</h4>

<p>I, ___________________________________________  , residing at  ___________________________________________ , New York, desiring to designate a Health Care Agent and to state my wishes about my medical treatment, as permitted by New York law, hereby execute this Health Care Proxy and Medical Directive.  I expect my family, physicians and all those concerned with my care to regard themselves as legally and morally bound to honor my decisions and the decisions made by my Health Care Agent on my behalf under the authority I have conferred on my Health Care Agent below.</p>

<ol>
<li><b>Appointment of Health Care Agent</b>.
<dt>I appoint ________________________________________________ , currently residing at ________________________________________ , TELEPHONE (&nbsp;&nbsp;&nbsp;&nbsp;)__________, my Health Care Agent to act as provided in Section 2.
<p>
<dt>If for any reason the person I have here designated as my Health Care Agent is unable to act, I appoint  ____________________________________ , currently residing at  ________________________________________ , TELEPHONE (&nbsp;&nbsp;&nbsp;&nbsp;) __________ , my Health Care Agent.
<p>
<li><b>Authority of Health Care Agent</b>.
<dt>In the event I become unable to make my own health care decisions, I authorize my Health Care Agent to make health care decisions on my behalf, in accordance with my wishes, including (but not exclusively) decisions regarding my admission to and discharge from health care facilities, the administration of X-rays, tests, examinations, anesthetics, medical and surgical procedures, and decisions about life-sustaining procedures in accordance with Sections 3 and 4 below.  If my Health Care Agent shall not know my wishes (either because I have not initialed one or more of the circumstances or procedures listed in Sections 3 or 4) and cannot with reasonable diligence ascertain them, I authorize my Health Care Agent to make health care decisions on my behalf in accordance with my best interests.
<p>
<dt>I authorize, effective immediately, my Health Care Agent to visit me in any hospital, convalescent home, or other facility where I may be receiving treatment or care, and to consult with any physicians and other medical personnel who may treat me.  I direct that my Health Care Agent be given first priority, in any such visitation, and I instruct that my medical records, including, (but not exclusively) any confidential HIV-related information, be made available to my Health Care Agent as part of any such consultation.  If my Health Care Agent is not a member of my family, I direct that there be extended to my Health Care Agent all the rights and powers that any parent, spouse, or other relative of mine would have had if I had not signed this Health Care Proxy and Medical Directive.
<p>
<li>Wishes regarding the withholding or withdrawal of life-sustaining procedures.  I have initialed below my wishes regarding the withholding or withdrawal of life-sustaining procedures with respect to the following circumstances:
<p>
<dt>[Initial ONE OR MORE of the lines below]
<p>
<dt>______ It is my wish that the procedures initialed in Section 4 be withheld or withdrawn if, in the best judgment of my attending physician, I am permanently unconscious.
<p>
<dt>______ It is my wish that the procedures initialed in Section 4 be withheld or withdrawn if I have a condition that is likely to cause my death within a short period of time, whether or not such procedures are administered to me.
<p>
<dt>______ It is my wish that the procedures initialed in Section 4 be withheld or withdrawn if I have suffered a substantial and irreversible loss of mental functions.
<p>
<li>Life-sustaining procedures to be withheld or withdrawn in accordance with Section 3.  It is my wish that the procedures which I have initialed below shall be withheld or withdrawn from me under the circumstances I have initialed in Section 3:
<p>
<dt>[Initial each procedure to be withheld or withdrawn]
<p>
<dt>______ invasive diagnostic procedures

<dt>______ cardiopulmonary resuscitation

<dt>______ mechanical respiratory support

<dt>______ dialysis procedures

<dt>______ surgery

<dt>______ antibiotics

<dt>______ artificially administered nutrition

<dt>______ artificially administered hydration

<dt>______ any other extraordinary procedures or measures to sustain my life

<dt>______ I request that I be given appropriate treatment to relieve any pain that I may suffer due to the withholding or withdrawal of any life-sustaining treatment.
<p>
<dt>Notwithstanding the wishes I have expressed in Sections 3 and 4 above, it is my wish that life-sustaining procedures be administered to me if they are necessary to sustain my life for a reasonable period of time in order to enable ___________________________________ to be with me before my death.
<p>
<li>Other instructions or comments about care I do or do not want (i.e,  experimental treatments; preference to die at home; etc.)
<br>
<br>                                                                                                                   <br>
<br>
<br>
<br>
<br>
<li><b>Wishes to be honored in absence of Health Care Agent</b>.  
<dt>I understand that I have been diagnosed with an illness related to HIV infection.  If neither person I have designated in Section 1 to serve as my Health Care Agent is able and willing to so act, I direct that the life-sustaining procedures I have initialed in Section 4 be withheld or withdrawn under the circumstances I have initialed in Section 3.
<p>
<li><b>Release</b>.
<dt>As provided by New York State law, my Health Care Agent shall not be subject to any liability for making health care decisions in good faith under this Health Care Proxy and Medical Directive, nor shall any health care provider be subject to any liability or be deemed to have engaged in unprofessional conduct, for having honored in good faith the health care decisions made by my Health Care Agent under this Health Care Proxy and Medical Directive.
<p>
<dt>Any third party may act in reliance on a duly executed copy or facsimile of this Health Care Proxy and Medical Directive.  Nothing in this Health Care Proxy and Medical Directive shall rescind or otherwise invalidate any gift of all or part of my body I have made pursuant to the Uniform Anatomical Gifts Act.<p>
<li><b>Duration</b>.
<dt>The time period during which this Health Care Proxy and Medical Directive shall be effective, including  (but not exclusively) my authorization of the release of confidential HIV-related information to my Health Care Agent, shall begin immediately and will continue, unless I revoke it, for the duration of my life.
</ol>

<p>THIS HEALTH CARE PROXY AND MEDICAL DIRECTIVE, signed this ______ day of ________________ , 1996.</p>

<p>Each of the undersigned, being eighteen years of age or older, declares that the person who signed this document is personally known to me, that the same person signed this document in my presence, and appears to be of sound mind and acting willingly and free from duress.  None of the undersigned is appointed as Health Care Agent by this document.</p>


<p>____________________________________________________ , residing at ____________________________________________________________</p>

<p>____________________________________________________ , residing at ____________________________________________________________</p>

<p>____________________________________________________ , residing at ____________________________________________________________</p>
                           
</blockquote>

</body>
</html>                          
</DOC>
<DOC>
<DOCNO>WT18-B31-228</DOCNO>
<DOCOLDNO>IA093-001002-B001-74</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/aip/about.html 199.29.141.24 19970121122328 text/html 5673
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:17:36 GMT
Server: NCSA/1.5.1
Last-modified: Sun, 24 Nov 1996 16:03:37 GMT
Content-type: text/html
Content-length: 5490
</DOCHDR>
<html>
<head>
<title>About the AIDS in Prison Project</title>
</head>

<body background="gifs/stripe.gif" link="#9f5f9f"><font face="helvetica, arial" size=-1>

<blockquote>

<p><a href="index.html"><img src="gifs/aipx.gif" alt="logo" align=left hspace=5></a><br><font color="9f5f9f"><b>The AIDS in Prison Project was established in 1986, becoming one of the first organizations to recognize that prisons and jails were epicenters of HIV seroconversion and disease.</b></font><font face="helvetica, arial" size=-1></p>
<br clear left>
<p><b>Community Served</b><br>
In New York State prisons, correctional officials conservatively estimate that 8,300 prisoners are living with HIV. In the New York City jails, 22% of female inmates and 13% of male inmates are estimated to be HIV-positive, totaling approximately 2,500 inmates at any given time. Nationally, the rate of confirmed AIDS cases in federal and state prisons is more than 7 times higher than in the general U.S. population or almost 23,000 prisoners. Over one-third of all prisoner deaths are from AIDS-related causes.</p>

<p>The vast majority of prisoners living with AIDS/HIV survive their prison terms. By and large, they return to poor, inner-city communities of color, which have been the hardest hit by the AIDS epidemic. The AIDS in Prison Project looks toward a time when inmates leave their prison or jail linked to health care and educated in HIV-prevention and illness management.</p>

<p><b>AIDS/HIV Clearinghouse and Hotline Hotline</b><br>
<b>Hours</b>: Tu & Th, 3-8 p.m. <br>
<b>(212) 674-0800</b><br>
<b>Collect calls accepted from Prisoners</b></p>

<p>In the closed environment of a prison or jail, even highly motivated individuals face enormous obstacles to obtaining information on AIDS/HIV prevention, treatment and resources.</p>

<p>The AIDS in Prison Project established the first AIDS/HIV Clearinghouse and Free Bilingual Hotline for prisoners and former prisoners in 1992. Staff and peer counselors provide prisoners and former prisoners, their advocates, family members and friends with information on:</p>

<ul>
<li>AIDS/HIV prevention & treatment 
<li>Discharge planning 
<li>Inmate support groups 
<li>Medical parole
</ul>

<p>In addition, staff and peer counselors provide prisoners and former prisoners with:</p>

<ul>
<li>Placement in service organizations 
<li>Peer counseling 
<li>Medical advocacy
</ul>

<p>The Hotline accepts collect calls from all prisoners. Through the Clearinghouse, the Project mails HIV/AIDS-related information free of charge to anyone requesting it.</p>

<p><b>Public Policy &amp; Advocacy</b><br>
Since January 1992, the AIDS in Prison project's public policy and advocacy efforts have focused on:</p>

<ul>
<li>Discharge planning - the link between penal and community health care.
<li>Medical parole and compassionate release
<li>Access to appropriate medical care for prisoners
<li>Education of prison medical staff on the latest AIDS/HIV treatments and how best to apply them in the correctional setting
<li>Prisoner access to potentially life-saving clinical trials
</ul>

<p><b>Technical Assistance</b><br>
The AIDS in Prison Project offers substantive technical assistance to a wide range of clients, including:</p>

<ul>
<li>Community-based organizations 
<li>Churches 
<li>Prisoner activists 
<li>Court officials, including judges and attorneys
</ul>

<p>The Project responds to such questions as:</p>

<ul>
<li>How to establish and conduct an HIV support group in prison 
<li>How to obtain adequate medical treatment for detainees held in a county jail How to serve HIV- positive prisoners in community-based organizations
</ul>

<p>We look forward to a time when former prisoners bring not only their freedom, but also their health and health education back to their communities.</p>

<p>For a copy of the AIDS in Prison Project Discharge Planning Manual for Prisoners in New York City and State, send a check for $15.00 plus $3.00 shipping per manual to: AIDS in Prison Project, 135 East 15th Street, New York, NY 10003. Phone (212) 673-6633, Fax (212) 780-9878.</p>

<p>The Osborne Association is a non-profit criminal justice organization founded in 1931 to provide educational, vocational, and treatment services to defendants, prisoners, and their families.</p>

<p>The AIDS in Prison Project is funded by New York State Department of Health, AIDS Institute, Levi Straus Foundation, Aaron Diamond Foundation, Fund for the City of New York, and New York Community Trust.</p>

<p>EXECUTIVE OFFICE<br>
The Osborne Association<br>
135 East Fifteenth Street<br>
New York, New York 10003<br>
Tel: (212) 673-6633<br>
Fax: (212) 979-7652</p>

<P>Elizabeth Gaynes, Executive Director<br>
Steven Nesselroth, Project Director</p>

<p><b>AIDS in Prison Project<br>
<a href="facts.html">Facts Sheet</a> | <a href="discharg.html">Discharge Planning</a> | <a href="changes.html">Changes &amp; Choices</a> | <a href="allia.html">Alliance for Inmates with AIDS</a> | <a href="well.html">LIVING-Well</a> | <a href="links.html">Other Resources</a> | <a href="osborne.html">About the Osborne Association</a></b></p>

<p><a href="index.html"><img src="gifs/home.gif" vspace=5 alt="[button]"></a><br>
&nbsp;<a href="index.html"><b>Home</b></a></p>

<p>last mofidied: 11/7/96<br>
copyright &#169; 1966 <br>
<img align=top src="gifs/osborne.gif" alt="[osborne logo]"><a href="mailto:osborne@aidsnyc.org">Osborne Association</a></p>
</blockquote>

</font>
</body>
</html>


</DOC>
<DOC>
<DOCNO>WT18-B31-229</DOCNO>
<DOCOLDNO>IA093-001002-B001-91</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/aip/allia.html 199.29.141.24 19970121122335 text/html 3508
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:17:44 GMT
Server: NCSA/1.5.1
Last-modified: Sun, 24 Nov 1996 16:03:41 GMT
Content-type: text/html
Content-length: 3325
</DOCHDR>
<html>
<head>
<title>AllIA: Alliance for Inmates with AIDS</title>
</head>

<body background="gifs/stripe.gif" link="#9f5f9f"><font face="helvetica, arial" size=-1>

<blockquote>

<p><a href="index.html"><img src="gifs/aipx.gif" alt="logo" align=middle hspace=5></a><font size=+1 color="9f5f9f"><b>ALLIA: Alliance for Inmates with AIDS</b></font><font face="helvetica, arial" size=-1></p>

<p><font color="9f5f9f"><b>ALLIA</b></font><font face="helvetica, arial" size=-1> is a state-wide grassroots advocacy coalition committed to addressing the needs of prisoners and former prisoners living with AIDS/HIV. Formed under the leadership of the <a href="about.html">AIDS in Prison Project</a> in 1991, <font color="9f5f9f"><b>ALLIA</b></font><font face="helvetica, arial" size=-1> is now sponsored by the People With AIDS Coalition of New York (<a href="../pwac/index.html">PWAC/NY</a>) and coordinated by a team of co-chairs from the Osborne Association, PWAC/NY, the Latino Commission on AIDS and other dedicated members. <font color="9f5f9f"><b>ALLIA</b></font><font face="helvetica, arial" size=-1> embraces over 250 individual members and organizations, drawing its membership from churches, hospitals, former prisoners, drug treatment centers, housing organizations, legal clinics and activist organizations.</p>

<p><font color="9f5f9f"><b>ALLIA</b></font><font face="helvetica, arial" size=-1>'s current work includes:</p>

<ul>
<li>Holding bi-monthly planning meetings and skill-building workshops for its <li>members.
<li>Organizing meetings between advocates and prison and parole officials to discuss problems and seek solutions regarding the delivery of medical care to prisoners and follow-up services to parolees.
<li>Working groups focusing on such issues as dying in prison, medical parole and compassionate release, prisoners' access to clinical trials and the special needs of Latino prisoners.
<li>Studying the state correctional system's new regional medical units and managed care health maintenance organization.
</ul>

<p><font color="9f5f9f"><b>ALLIA</b></font><font face="helvetica, arial" size=-1> invites and encourages all interested persons to participate in <font color="9f5f9f"><b>ALLIA</b></font><font face="helvetica, arial" size=-1>'s activities and meetings. Call Mary Cotter of PWAC/NY at (212)647-1415 or write in care of PWAC/NY at 50 West 17th Street, 8th Floor, New York, NY 10011.</p>

<p>Read <font color="9f5f9f"><b><a href="../pwac/prislet.html">Letters from Prisoners</a></b></font><font face="helvetica, arial" size=-1> in PWAC/NY's Newsline.</p>
 
<p><b>AIDS in Prison Project<br>
<a href="about.html">About the AIDS in Prison Project</a> | <a href="facts.html">Facts Sheet</a> | <a href="changes.html">Changes &amp; Choices</a> | <a href="discharg.html">Discharge Planning</a> | <a href="well.html">LIVING-Well</a> | <a href="links.html">Other Resources</a> | <a href="osborne.html">About the Osborne Association</a></b></p>

<p><a href="index.html"><img src="gifs/home.gif" vspace=5 alt="[button]"></a><br>
&nbsp;<a href="index.html"><b>Home</b></a></p>

<p>last mofidied: 11/7/96<br>
copyright &#169; 1966 <br>
<img align=top src="gifs/osborne.gif" alt="[osborne logo]"><a href="mailto:osborne@aidsnyc.org">Osborne Association</a></p>
</blockquote>

</font>
</body>
</html>


</DOC>
<DOC>
<DOCNO>WT18-B31-230</DOCNO>
<DOCOLDNO>IA093-001002-B001-106</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/aip/cambio.html 199.29.141.24 19970121122402 text/html 19567
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:17:55 GMT
Server: NCSA/1.5.1
Last-modified: Sun, 24 Nov 1996 16:03:53 GMT
Content-type: text/html
Content-length: 19383
</DOCHDR>
<html>
<head>
<title>AIDS in Prison Project: cambios y alternativas</title>
</head>

<body background="gifs/stripe.gif" link="#9f5f9f"><font face="helvetica, arial" size=-1>

<blockquote>

<p><a href="index.html"><img src="gifs/aipx.gif" alt="logo" align=left hspace=5></a><br><font color="9f5f9f"><b>CAMBIOS Y ALTERNATIVAS</b><br>
Un Manual sobre el VIH/SIDA para Presidiarios en Pre-Excarcelaci&oacute;n y en Libertad Bajo Palabra</b></font><font face="helvetica, arial" size=-1><br>
<a href="osborne.html">La Asociaci&oacute;n Osborne</a> | Agosto de 1993</p>

<p><font color="9f5f9f"><b>TABLA DE CONTENIDO</b></font><font face="helvetica, arial" size=-1></p>

<ul>
<li><a href="#intro">Introducci&oacute;n: Cambios y Alternativas</a>
<li><a href="#living">LIVING-Well</a>
<br>
<li><a href="#whathiv">&#191;Qu&eacute; es la infecci&oacute;n del VIH?</a>
<li>&#191;C&oacute;mo el VIH afecta mi cuerpo?
<li>&#191;Qu&eacute; es el SIDA?
<li>&#191;C&oacute;mo contraigo el VIH?
<li>&#191;De d&oacute;nde viene el VIH?
<li>&#191;Qu&eacute; es la prueba de anticuerpos del VIH?
<li>&#191;Porqu&eacute; debo hacerme la prueba?
<li>Las opciones en la prueba de anticuerpos del VIH
<li>La confidencialidad
<li>La divulgaci&oacute;n y el derecho a la privacidad
<li>Despu&eacute;s de recibir el resultado de la prueba, &#191;qu&eacute; hago?
<li>&#191;Y si creo que tengo el virus (VIH)?
<li>&#191;C&oacute;mo puedo prevenir la transmisi&oacute;n del VIH, adquirirlo o ser reexpuesto?
<li>&#191;C&oacute;mo ponerse un cond&oacute;n de l&aacute;tex?
<li>&#191;C&oacute;mo usar un bloqueador vaginal?
<li>&#191;C&oacute;mo limpiar sus jeringuillas?
<li>Las relaciones sexuales no deseadas, &#191;qu&eacute; hacer?
<li>Las estrategias para vivir con el VIH
<li>Respuestas a las preguntas
<li>RECURSOS
</ul>

<p><font color="9f5f9f"><b><a name="intro">CAMBIOS</a> Y ALTERNATIVAS</b></font><font face="helvetica, arial" size=-1></p>

<p>El prop&oacute;sito de este manual es inspirarle a que usted efect&uacute;e los cambios y alternativas mas convenientes para vivir con el VIH, como individuos, en nuestras familias o en nuestras comunidades. </p>

<p>Nos han inspirado a escribir este manual los presidiarios y ex-presidiarios que han cambiado sus vidas y que han optado por tomar alternativas conscientes con respecto a su conducta para asegurarse de no infectarse con el VIH, ni de contagiar a otras personas con el virus. Tambi&eacute;n nos han inspirado presidiarios y ex-presidiarios que aunque tienen el VIH o el SIDA viven cada vez m&aacute;s saludables. Este manual se fundamenta en las alternativas que ellos han optado seguir y en los cambios que les han dado resultados. Lo aprendido por estas personas tambi&eacute;n puede ayudarle.</p>

<p>Usted ya ha hecho una buena selecci&oacute;n: usted est&aacute; leyendo sobre el VIH/SIDA. Este es un GRAN primer paso. Leer y pensar sobre el VIH puede resultar muy dif&iacute;cil, pero recuerde que el VIH y el SIDA afectan a todo el mundo. Es importante hablar sobre el SIDA y el VIH y enfrentarse a ellos directamente. Al abrir sus ojos y su coraz&oacute;n, al aprender a escuchar, usted puede salvar su vida y ayudar a otros a que vivan una vida mejor y m&aacute;s duradera. Usted tiene la ALTERNATIVA de planificar su vida para mantenerse saludable. (Usted podr&iacute;a tomar notas y hacer preguntas si no lo ha estado haciendo ya. Recuerde: La informaci&oacute;n es poder)</p>

<p>Este manual [<font color="9f5f9f"><b>CAMBIOS Y ALTERNATIVAS</b></font><font face="helvetica, arial" size=-1>] le presentar&aacute; algunos datos, ideas y estrategias para ayudarle a realizar algunos CAMBIOS en su vida si  usted est&aacute; en Libertad Bajo Palabra (on parole) o si aun no se la han concedido. Estas estrategias han funcionado para otros presidiarios y ex-presidiarios que viven con el VIH.</p>

<p>Una estrategia es un esquema, un m&eacute;todo, o plan que debe realizarse para lograr una meta. Eso es lo que hace falta para prevenir o sobrevivir al VIH.</p>

<p>Para ayudarle a entender la informaci&oacute;n de este manual hemos incluido algunas preguntas simples las cuales usted debe  contestar con s&iacute; o no. Las respuestas a estas preguntas se encuentran al final de este manual. Estas preguntas est&aacute;n dise&ntilde;adas para que usted compruebe lo que aprendi&oacute; despu&eacute;s de leer las distintas secciones de este manual. </p>

<p>(Si usted va a salir de la c&aacute;rcel, por favor pase esta informaci&oacute;n a sus amigos o deje el manual para que otros puedan aprender sobre el VIH y el SIDA)</p>

<p><font color="9f5f9f"><b>CAMBIOS Y ALTERNATIVAS</b></font><font face="helvetica, arial" size=-1> no trata sobre lo que es bueno o lo que es malo. No trata sobre lo que es correcto o lo que es incorrecto. En este manual no nos preocupa si es correcto o incorrecto endrogarse o si es bueno o malo tener relaciones sexuales.</p>

<p>Hay gente que se endroga. Hay gente que tiene relaciones sexuales. Quienes lo hacen no son malos ni est&aacute;n errados. Quienes no lo hacen no son buenos ni est&aacute;n correctos. Simplemente, los seres humanos hacemos estas cosas de muchas maneras y por varias razones.</p>

<p>Pero uno de los puntos de este manual es recordarle a usted que toda conducta tiene sus consecuencias.</p>

<ul>
<li>Algunas cosas que la gente hace tienen consecuencias indeseables.
<li>Algunas cosas que hacemos perjudican a otras personas.
<li>Algunas cosas que hacemos nos hacen da&ntilde;o.
<li>Algunas cosas que hacemos nos perjudican a nosotros(as) y a otras personas.
<li>Algunas cosas que hacemos nos llevan a la c&aacute;rcel.
<li>Algunas cosas que hacemos nos dan el VIH.
<li>Los cambios y alternativas que se hacen tambi&eacute;n tienen consecuencias.
<li>Algunas cosas que hacemos nos brindan lo que deseamos.
<li>Algunas cosas que hacemos ayudan a otras personas.
<li>Algunas cosas que hacemos nos ayudan a nosotros(as) mismos(as). 
<li>Algunas cosas que nosotros(as) hacemos nos capacitan a nosotros(as) y a los dem&aacute;s. 
<li>Algunas cosas nos ayudan a obtener Libertad Bajo Palabra.
<li>Algunas cosas evitan la propagaci&oacute;n del SIDA.
<li>Algunas cosas nos capacitan para vivir bien con el VIH.
</ul>

<p>En toda c&aacute;rcel, ya sea de m&aacute;xima, de mediana o de m&iacute;nima seguridad, los presidiarios tienen menos oportunidades para cambiar las circunstancias que los rodean de las que tienen las personas en la calle. Pero menos o poco es mejor que nada. En este preciso instante usted no podr&aacute; escoger qu&eacute; ropa ponerse o a d&oacute;nde ir. Pero usted puede decidir si va a terminar de leer este manual y si va a aprender sobre otros cambios y alternativas disponibles para usted ahora y en el futuro. </p>

<p>En este manual, no nos referimos a si usted debe o no debe consumir alcohol u otras drogas, o si usted debe o no tener relaciones sexuales. Queremos que usted sepa que si usted usa drogas (especialmente drogas intravenosas con agujas /instrumentos compartidos) o tiene relaciones sexuales sin ninguna protecci&oacute;n [Relaciones sexuales sin ninguna protecci&oacute;n: el intercambio de fluidos corporales (semen, secreciones vaginales y sangre menstrual) durante la relaci&oacute;n sexual] usted probablemente ser&aacute; infectado(a) con el VIH o contagiar&aacute; a otra persona. Si usted ya tiene el VIH, el usar drogas, o tener cierto tipo de contacto sexual tendr&aacute; un efecto negativo en la calidad y duraci&oacute;n de su vida. </p>

<p>Probablemente usted ha o&iacute;do datos estad&iacute;sticos sobre el SIDA. Algunos de estos datos muestran que el VIH y el SIDA tienen mucho que ver con las drogas  . Usted tambi&eacute;n ha escuchado hablar sobre "las cosas reales de la vida." El sexo tambi&eacute;n tiene que ver con el VIH y con el SIDA. </p>

<p>Veamos brevemente: Usted tambi&eacute;n ha o&iacute;do los "hechos reales". El SIDA tiene much&iacute;simo que ver con el acto sexual y con el uso de drogas. Para muchas personas es muy dif&iacute;cil hablar sobre relaciones sexuales. Tambi&eacute;n es muy dif&iacute;cil hablar de sexo a&uacute;n para las personas que pasan mucho tiempo pensando en el acto sexual, leyendo sobre &eacute;l, y manteniendo relaciones sexuales. (Y si usted piensa que es dif&iacute;cil hablar sobre este tema, trate de escribir un libro como este!) A pesar de todas las pel&iacute;culas, libros y programas de televisi&oacute;n que nos dicen que el acto sexual tiene que ver con el amor y el matrimonio, nosotros decimos que el sexo es solamente sexo. A la gente le gusta llamarle "hacer el amor". Pero si usted piensa en las palabras SEXO y AMOR, &eacute;stas tienen muy poco en com&uacute;n.</p>

<p><font color="9f5f9f"><b>EL SEXO</b></font><font face="helvetica, arial" size=-1>:  Preg&uacute;ntele a las personas c&oacute;mo le llaman: copulaci&oacute;n, procreaci&oacute;n, coito, joder, "dar bola", "meter", "hacer porquer&iacute;as". &#191;Qu&eacute; tiene el amor que ver con esto?</p>

<p><font color="9f5f9f"><b>AMOR</b></font><font face="helvetica, arial" size=-1>: Preg&uacute;ntele a las personas c&oacute;mo le llaman: afecto, cari&ntilde;o, ternura, familiaridad, comprensi&oacute;n, intimidad.
&#191;Qu&eacute; tiene el sexo que ver con esto?</p>

<p>La conexi&oacute;n es que algunas veces usted puede mantener relaciones sexuales con una persona que usted ama. Algunas personas piensan que usted se preocupar&iacute;a m&aacute;s por proteger del VIH a alguien a quien usted ama. Pero a lo mejor usted se preocupara menos de los riesgos con una persona que usted ama.</p>

<p>Si usted ama a una persona, posiblemente usted no quiera pensar en si el o ella ha tenido relaciones sexuales con otros hombres o mujeres. Si usted ama a una persona, posiblemente usted se sienta culpable o avergonzado al insistir que use alguna protecci&oacute;n, como es usar un cond&oacute;n de l&aacute;tex durante la penetraci&oacute;n vaginal o anal. Si usted ama a una persona, posiblemente no quiera decirle que usted ha usado drogas. Muchas prostitutas informan que ellas insisten en el uso de condones cuando les pagan por tener relaciones sexuales, pero que no los usan con sus amantes. A todos nos gusta pensar que la persona a quien amamos nos proteger&aacute;.</p>

<p>Esto es mucho m&aacute;s dif&iacute;cil para personas que salen de la c&aacute;rcel. Algunas personas piensan que si usted insiste en usar cond&oacute;n con su compa&ntilde;era(o) al llegar a su hogar despu&eacute;s de salir de la c&aacute;rcel, esto es porque usted no conf&iacute;a en ella o en el y en lo que el o ella hizo durante su ausencia. O que usted est&aacute; admitiendo que durante el per&iacute;odo de encarcelamiento usted estaba haciendo algo que pudo haberle contagiado con el VIH.</p>

<p>Excepto que en realidad esto no tiene nada que ver con la confianza o con el amor. Solamente significa que usted es lo suficientemente listo como para no poner en riesgo la vida de la persona que usted ama. Usted o su compa&ntilde;era(o) puede que sean VIH+ ( VIH positivo ) como resultado de algo de lo que ocurri&oacute; hace muchos a&ntilde;os, algo que usted ni siquiera se acuerda ahora.</p>

<p>Amar a alguien no los protege a ninguno de ustedes del VIH. El amor es amor y el sexo es sexo, y la protecci&oacute;n es protecci&oacute;n. La vida es m&aacute;s agradable y posiblemente m&aacute;s duradera cuando usted tiene estas tres cosas claras.</p>

<p>Algunos hechos son amargos en la vida. Todo tipo de droga (incluyendo el alcohol) ha tenido un gran impacto en la propagaci&oacute;n del SIDA. No solamente se ha probado que la gente transmite el VIH a trav&eacute;s de la sangre contaminada que pasa de una persona a otra al compartir agujas, jeringuillas (utensilios), pero tambi&eacute;n sabemos que las drogas debilitan su cuerpo (haci&eacute;ndolo m&aacute;s vulnerable a todo tipo de enfermedad) y su mente (cuando se est&aacute; endrogado la posibilidad de hacer cosas que propaguen el VIH es mayor, como no usar condones, o no hablar sobre las relaciones sexuales con su compa&ntilde;era(o).</p>

<p>Planifique con anticipaci&oacute;n. El planificar funciona. Usted lo sabe. Usted ha planificado su visita a la junta de Libertad Bajo Palabra, "la tabla"; usted tiene cartas y certificados. Usted probablemente se acuerda de cuando se le olvid&oacute; planificar y se meti&oacute; en problemas. Al aprender cosas nuevas, como simplemente leer este manual, usted se ha decidido a lidiar con cambios planific&aacute;ndolos.</p>

<p>Usted tiene ya algunos planes en mente sobre d&oacute;nde va a vivir despu&eacute;s de salir de la prisi&oacute;n, y de c&oacute;mo va a ganarse el dinero. A lo mejor usted tiene familia y est&aacute;n haciendo planes juntos.</p>

<p>Si usted est&aacute; limpio(a) (libre de drogas), &#191;Cu&aacute;les son los planes para mantenerse limpio(a)? La manera en que la gente vive ahora fuera de la c&aacute;rcel no es tan diferente de cuando usted fue sentenciado. Usted tal vez haya cambiado, pero las calles no. De alguna manera est&aacute;n peor. Hay menos empleos que antes, m&aacute;s desesperaci&oacute;n, y se vive de d&iacute;a a d&iacute;a. Esto causa mucha tensi&oacute;n y la tensi&oacute;n puede inducirle al uso de drogas si usted no est&aacute; preparado.</p>

<p>Pero: Si usted es VIH+ (VIH positivo), o piensa que posiblemente tenga el virus (virus de inmunodeficiencia humana), cu&aacute;les son sus estrategias para cuidar su salud?</p>

<blockquote>
<p><i>"Al salir de la c&aacute;rcel no sab&iacute;a exactamente qu&eacute; iba a pasar conmigo. Me sent&iacute; confuso porque ten&iacute;a m&aacute;s tensi&oacute;n en mi vida de la que yo necesitaba. Me refiero a la inseguridad de no saber qu&eacute; esperar despu&eacute;s de estar encarcelado por cierto tiempo. En la c&aacute;rcel no hay ning&uacute;n comit&eacute; o programa que me informe qu&eacute; tipo de trabajo o ayuda yo pod&iacute;a conseguir." <font color="9f5f9f"><b>Bob</b></i></font><font face="helvetica, arial" size=-1></p>
</blockquote>

<p>Si usted tiene el VIH, entonces, &#191;qu&eacute; tiene que ver eso con su situaci&oacute;n actual? &#191;En d&oacute;nde encuentra usted un m&eacute;dico o una cl&iacute;nica? &#191; C&oacute;mo encuentra usted dinero para pagar los medicamentos, y un lugar para vivir? Otros presidiarios y personas que est&aacute;n en Libertad Bajo Palabra y que est&aacute;n contagiados con el VIH ya han formulado respuestas a estas preguntas. Preguntas que funcionan!</p>

<p><font color="9f5f9f"><b>CAMBIOS Y ALTERNATIVAS</b></font><font face="helvetica, arial" size=-1> le dar&aacute; ideas sobre c&oacute;mo responder a estas y otras preguntas.</p>

<p><font color="9f5f9f"><b><a name="living">VIVIR</a>-Mejor</b></font><font face="helvetica, arial" size=-1>= mantenerse saludable con el VIH<br>
<font color="9f5f9f"><b>LIVING-Well</b></font><font face="helvetica, arial" size=-1>= Un programa de la Asociaci&oacute;n Osborne dise&ntilde;ado para ayudar a personas en Libertad Bajo Palabra, enfermas con el VIH, a lograr los <font color="9f5f9f"><b>CAMBIOS Y ALTERNATIVAS</b></font><font face="helvetica, arial" size=-1> necesarios para mantenerse saludable.

<p><font color="9f5f9f"><b>LIVING-Well</b></font><font face="helvetica, arial" size=-1> puede prestarle servicios a personas que est&aacute;n en Libertad Bajo Palabra y que viven en el Bronx, particularmente en las secciones de Hunts Point, Mott Haven y Tremont. En el futuro, LIVING-Well espera expandirse para poder prestarle servicios a m&aacute;s ex-presidiarios. LIVING-Well provee informaci&oacute;n y ayuda para localizar y conseguir cuidado m&eacute;dico, vivienda, ayuda econ&oacute;mica, trabajo y apoyo emocional.</p>

<blockquote>
<p><i>Despu&eacute;s de inyectarme drogas por a&ntilde;os, me limpi&eacute; y me he mantenido limpio. Yo us&eacute; drogas por cuatro a&ntilde;os y he estado limpio por ocho a&ntilde;os. Un amigo m&iacute;o muri&oacute; este a&ntilde;o de SIDA y fui a hacerme la prueba y me dijeron que soy VIH+. Me dijeron que mis c&eacute;lulas T4 estaban altas y que no me preocupara pero, &#191;qu&eacute; significa todo esto? <font color="9f5f9f"><b>Paco</b></font></i><font face="helvetica, arial" size=-1></p>
</blockquote>

<p>A continuaci&oacute;n, vamos a presentar los t&eacute;rminos que usaremos a lo largo de este manual.</p>

<p>VIH quiere decir virus de inmunodeficiencia humana. Es importante  saber que el SIDA y el VIH  no son la misma cosa. El VIH es una clase especial de virus que ataca el sistema inmunol&oacute;gico de su cuerpo. El VIH reduce su resistencia natural a infecciones y disminuye la capacidad de su cuerpo para combatir otras enfermedades. El SIDA se desarrolla cuando el cuerpo de una persona no puede combatir las infecciones. El SIDA es la etapa final de la infecci&oacute;n del VIH</p>

<ul>
<li><font color="9f5f9f"><b>VIRUS</b></font><font face="helvetica, arial" size=-1>: Microorganismo que causa <li>enfermedades.
<li><font color="9f5f9f"><b>INMUNIDAD</b></font><font face="helvetica, arial" size=-1>: Protecci&oacute;n contra enfermedades.
<li><font color="9f5f9f"><b>SISTEMA INMUNOLOGICO</b></font><font face="helvetica, arial" size=-1>: una cadena compleja de &oacute;rganos y c&eacute;lulas que protegen al cuerpo contra enfermedades.
</ul>

<p><font color="9f5f9f"><b><a name="whathiv">&#191;QUE</a> ES LA INFECCION DEL VIH?</b></font><font face="helvetica, arial" size=-1></p>

<p>La infecci&oacute;n del VIH significa que su cuerpo ha sido infectado por el virus de inmunodeficiencia humana (VIH). La mayor&iacute;a del mill&oacute;n de Estadounidenses que vive con el VIH viven su vida a plenitud, aunque muchas de estas personas no saben que est&aacute;n infectadas en este momento.</p>

<p>Se puede estar infectado con el VIH por varios a&ntilde;os y no mostrar ninguna enfermedad asociada con el SIDA y sin embargo una persona puede transmitir el VIH a otra persona. A medida que el VIH ataca al sistema inmunol&oacute;gico (sistema de defensa del organismo) el cuerpo se debilita y pierde su habilidad de protegerse de infecciones y c&aacute;nceres. Se dice entonces que la apersona tiene SIDA. El SIDA es la parte final de una enfermedad que comenz&oacute; con la infecci&oacute;n del VIH. Se dice que una persona tiene SIDA cuando tiene s&iacute;ntomas relacionados con la enfermedad del VIH.</p>

<p><font color="9f5f9f"><b><i>... ser&aacute; a&ntilde;adido texto adicional</i></b></font><font face="helvetica, arial" size=-1></p>

<p><b>AIDS in Prison Project<br>
<a href="about.html">About the AIDS in Prison Project</a> | <a href="facts.html">Facts Sheet</a> | <a href="discharg.html">Discharge Planning</a> | <a href="changes.html">Changes &amp; Choices</a> | <a href="allia.html">Alliance for Inmates with AIDS</a> | <a href="well.html">LIVING-Well</a> | <a href="links.html">Other Resources</a> | <a href="osborne.html">About the Osborne Association</a></b></p>

<p><a href="index.html"><img src="gifs/home.gif" vspace=5 alt="[button]"></a><br>
<font size=-1>&nbsp;<a href="index.html"><b>Home</b></a></font><font face="helvetica, arial" size=-1></p>

<p>last mofidied: 11/7/96<br>
copyright &#169; 1966 <br>
<img align=top src="gifs/osborne.gif" alt="[osborne logo]"><a href="mailto:osborne@aidsnyc.org">Osborne Association</a></p>
</blockquote>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-231</DOCNO>
<DOCOLDNO>IA093-001002-B001-132</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/aip/changes.html 199.29.141.24 19970121122414 text/html 15261
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:18:20 GMT
Server: NCSA/1.5.1
Last-modified: Sun, 24 Nov 1996 16:04:03 GMT
Content-type: text/html
Content-length: 15077
</DOCHDR>
<html>
<head>
<title>AIDS in Prison Project: changess &amp; choices</title>
</head>

<body background="gifs/stripe.gif" link="#9f5f9f"><font face="arial, helvetica" size=-1>

<blockquote>

<p><a href="index.html"><img src="gifs/aipx.gif" alt="logo" align=left hspace=5></a><br><font color="9f5f9f"><b>CHANGES AND CHOICES</b></font><br>
An HIV/AIDS Workbook for Prisoners in Pre-Release and Parolees<br>
<a href="osborne.html">The Osborne Association</a> | July 1993</p>
<br clear=left>

<p><font color="9f5f9f"><b>TABLE OF CONTENTS</b></font></p>

<ul>
<li><a href="#changes">INTRODUCTION:  Changes and Choices</a>      
<li><a href="#living">LIVING-WELL</a>         
<li><a href="#whathiv">What is HIV Infection?</a>        
<li>How Does HIV Affect My Body?       
<li>What is AIDS?         
<li>How Do I Get HIV?         
<li>Where Does HIV Come From?      
<li>What is the HIV Antibody Test?      
<li>Why Get Tested?        
<li>HIV Antibody Testing Options      
<li>Confidentiality 
<li>Disclosure and the Right to Privacy     
<li>After I Get My Test Result, Then What?     
<li>What if I Think I Have the Virus?        
<li>How Do I Prevent or Reduce the Risk of Infection or Re-Exposure?  
<li>How To Put On a Latex Condom      
<li>How To Use a Dental Dam       
<li>How To Clean My Works       
<li>Unwanted Sex - What To Do        
<li>Living With HIV        
<li>Answers to Questions       
<li>Resources          
</ul>

<p><font color="9f5f9f"><b><a name="changes">CHANGES</a> AND CHOICES</b></font></p>

<p>The purpose of this workbook is to inspire you to make the changes and choices we all need to make to LIVE with HIV (Human Immunodeficiency Virus), whether in ourselves, our families, or our communities.</p>

<p>We have been inspired by prisoners and former prisoners who have changed their lives and made choices about their actions to make sure they would not become infected with HIV or give the virus to anyone else. We are empowered by prisoners and former prisoners who are surviving, thriving, and LIVING WELL with HIV or AIDS. This book is based on choices they have made for themselves and changes that have worked for them. They may work for you.</p>

<p>You have already made one good choice: you are reading about HIV and AIDS. This is a BIG first step. Reading and thinking about HIV can be very hard, but remember that HIV affects everyone. It is important to speak about it and face it directly. By opening your ears, eyes and heart, you can save your life, and help others to live longer and better. You do have a CHOICE to plan on staying healthy. (You might think about taking notes and asking questions, if you are not already doing that. Information is power.)</p>

<p>CHANGES AND CHOICES will present some facts, ideas and strategies to help you get through some of the CHANGES in your life if you are paroled or if you are turned down. These strategies have worked for other prisoners and ex-prisoners living with HIV. A strategy is an approach, design, scheme, system, tactic, method, maneuver or plan. That's what it takes to prevent or live with HIV. </p>

<p>To better help you understand the information being provided, we have included some simple questions throughout the workbook to which you should answer yes or no. The answers to these questions are at the end of this workbook. (If you leave prison, please pass this information along to your friends, or leave the booklet behind for others to learn about HIV and AIDS!)</p>

<p>CHANGES AND CHOICES is not about what is good and what is bad. It is not about what is right and what is wrong. In this book we are not concerned about whether it is right or wrong to take drugs or whether it is good or bad to have sex. People do drugs. People have sex. We do those things for lots of reasons. We do those things in lots of ways. People who do them are not bad or wrong. People who don't do them are not good or right. </p>

<p>But one point of this workbook is to remind you that actions have results. </p>

<ul>
<li>Some things that people do have unwanted results. 
<li>Some things that we do hurt other people. 
<li>Some things that we do hurt ourselves. 
<li>Some things that we do hurt other people and ourselves. 
<li>Some things get us sent to prison.
<li>Some things give us HIV.
</ul>

<p>Changes and Choices in your actions also have results.</p>

<ul>
<li>Some things that we do get us what we want.
<li>Some things that we do help other people.
<li>Some things that we do help ourselves.
<li>Some things that we do empower ourselves and others.
<li>Some things help us get parole.
<li>Some things prevent the spread of HIV.
<li>Some things empower us to live well with HIV.
</ul>

<p>People in prisons have fewer choices than people in "the streets". There are maximum, medium and minimum security prisons. Prisoners have less ability to change their circumstances. But fewer and less does not mean none. Right now you may not get to choose what you wear and where you go. But you do get to choose whether you'll finish reading this and learn about other changes and choices available to you now and in the future. In this workbook, we are not talking about whether you should or should not use alcohol or other drugs or whether you should or should not have sex. </p>

<p>We would like you to know that if you use drugs (especially intravenous drugs with shared needles/works) or have unprotected sex [unprotected sex:  exchanging body fluids (semen) (cum) vaginal secretions and menstrual blood) during sex] you probably will become infected with HIV or give it to someone else. If you already have HIV, using drugs or having unprotected sex will have a negative effect on the quality and length of your life.</p>

<p>You have probably heard a lot of facts about HIV and AIDS.  Facts show that drugs have a lot to do with HIV. You already know the "facts of life". Sex also has a lot to do with HIV. Let's briefly look at the two.</p>

<p>Sex is hard for people to talk about. Even people who spend lots of time thinking about it, reading about it, and doing it have a hard time talking about it. (And if you think it's hard to talk about, try writing a book like this about it!) And despite all the movies and books and t.v. shows that tell us that sex has something to do with love and marriage, we say sex is just sex. People like to call it "making love." But if you think about the words SEX and LOVE, they may have very little in common. </p>

<p><font color="9f5f9f"><b>SEX</b></font>:  Ask people what they call it: copulation, procreation, intercourse, fucking, screwing, balling, banging, doing the nasty. What's love got to do with it?</p>

<p><font color="9f5f9f"><b>LOVE</b></font>: Ask people what they call it: affection, fondness, tenderness, familiarity, understanding, intimacy. What's sex got to do with it?</p>

<p>Love can sometimes be confusing when you have to make a decision about whether to have sex with someone you love who is HIV positive (HIV+ means being infected with HIV), or someone whose HIV status is unknown. Because you love someone, you won't want to think about whether he or she may have had sex with other men and women. Because you love someone, you might feel guilty or embarrassed about insisting on using a latex condom for anal, oral, or vaginal sex. Because you love someone, you may not want them to know you've used drugs. Many prostitutes report that they insist on using condoms when they're paid for sex, but don't use them with their lovers. We all want to believe that someone we love will protect us.</p>

<p>This is even more difficult for people who are coming out of prison. Some people think that if you insist on using a condom with your partner after you come home from prison, it means that you don't trust him or her and are suspicious of what he or she did while you were away. Or you're admitting that while in prison you were doing something that could have given you HIV. </p>

<p>But being careful doesn't mean anything about trust or about love. It just means you're too smart to take a chance with the life of someone you love. You or your partner may be HIV+ as a result of something that happened many years ago, that you don't even remember now. </p>

<p>Loving someone doesn't protect either of you from HIV. Love is love, sex is sex, and protection is protection. Life is nicer and possibly longer when you've got all three.</p>

<p>There are some sad facts of life. Drugs of all kinds (including alcohol) have had a big impact on the spread of HIV. Not only has it been proven that people can spread HIV through contaminated blood that goes from one person to another through sharing needles (works), but we also know that drugs break down your body (making it easier to get diseases) and run down your mind (when people are high they are much more likely to do things that spread HIV, like not using condoms, and not talking about sex with their partners). </p>

<p>Let's plan ahead. Planning ahead works. You know that. You have planned for your visit to the parole board; you have letters and certificates. You can probably remember times when you forgot to plan ahead and got into trouble. By learning new things, even just reading this workbook, you have given yourself the power to deal with change through planning for it.</p>

<P>You already have some plans in mind about where to live after release and how to make money. Maybe you have family and you are making these plans together.</p>

<p>If you are clean (off drugs), how do you plan to stay clean? Outside prison the way people live now is not so different than when you were sentenced. You may have changed, but the streets have not. In some ways they are worse. There are fewer jobs now than before, more desperation, and living is from day to day. This stress can easily lead to drug use if you are unprepared.</p>

<p><font color="9f5f9f"><b>But</b></font></p>

<p>If you are HIV+, or think that you may have the virus (HIV), what are your strategies for taking care of your health?</p>

<blockquote>
<p><i>"Upon being released I found myself in a state of confusion. I did not quite know what to do about my medical condition which added more stress to my life which I really did not need. What I am talking about is the feeling of insecurity and not knowing what to expect after being in for any amount of time. There isn't any Program Committee to tell me what kind of job they are assigning me. That happens in prison..." <font color="9f5f9f"><b>Bob</b></font></i></p>
</blockquote>

<p>If you are HIV+, then where does that fit into the picture? Where do you find a doctor or clinic? How do you find the money to pay for medicine and a place to live? Other prisoners and parolees who are HIV infected have already formed answers to these questions. Answers that work!</p>

<p><font color="9f5f9f"><b>CHANGES AND CHOICES</b></font> will give you some ideas about how to answer these questions and more.</p>

<p><font color="9f5f9f"><b><a name="living">LIVING</a>-Well</b></font> = staying healthy with HIV<br>
LIVING-Well = a program of the <a href="osborne.html">Osborne Association</a> designed to help parolees who have HIV to make the CHANGES AND CHOICES necessary to stay healthy. </p>

<p>LIVING-Well is able to serve parolees who live in the BRONX, in particular within the Hunts Point, Mott Haven and Tremont sections. In the future, LIVING-Well hopes to expand to be able to serve more former prisoners. LIVING-Well provides information and assistance in locating and accessing health care, a place to live, financial assistance, a job, and emotional support.</p>

<blockquote>
<p><i>"After shooting drugs for years, I got clean and stayed clean. I was down for four and have been clean for eight now. A friend died this year from AIDS and I went to get the test and they told me I was HIV+. They told me my T4 cells were high and not to worry, but what does this all mean?" <font color="9f5f9f"><b>Paco</b></font></i></p>
</blockquote>

<p>Let us go over some of the terms that we will use throughout this workbook.</p>

<ul>
<li>HIV stands for the Human Immunodeficiency Virus. It is important to know that AIDS and HIV are not the same thing. HIV is a special type of virus which attacks your body's immune system. HIV reduces your natural resistance to infections and lessens your body's abilities to fight off other illnesses. AIDS is the final stage of HIV infection.
<li>A VIRUS (vi-res) is a small micro-organism that causes disease.
<li>IMMUNITY (i-myoo-ni-te) means protection from disease.
<li>The IMMUNE SYSTEM is a complex network of organs and cells which protect the body from disease.
</ul>

<p><font color="9f5f9f"><b><a name="whathiv">WHAT</a> IS HIV INFECTION?</b></font></p>

<p>HIV INFECTION means that your body has been infected with the Human Immunodeficiency Virus (HIV). One is then said to be HIV positive (HIV+). Most of the one million people who live in the United States who are HIV+ are leading full lives, although many of them do not know that they are infected right now. </p>

<p>One can be infected with the virus and not have any symptoms (signs of illnesses). A person may have no symptoms for a long time, sometimes years, but can still pass the virus to someone else. HIV attacks the person's immune system. As the immune system becomes weakened, it loses it ability to protect the person from infections and cancers. The person may become ill. As the damage to the immune system becomes more severe, the person will be diagnosed with AIDS. AIDS is known to be the final stage of HIV infection. People with HIV disease have HIV-related symptoms or AIDS. Therefore, HIV disease is different from HIV infection where no symptoms are present.</p>

<p>HIV infection acts differently from person to person. Some people get symptoms immediately after being infected with HIV while others do not for many years. Symptoms and infections of HIV are also different for people who are HIV+. For example, women who are HIV+ or have AIDS can and often do have different infections than men. </p>

<p>HIV can damage your immune system in ways that may not make you feel sick but which are very serious.</p>

<p><font color="9f5f9f"><b><i>... more to be added</i></b></font></p>

<p><b>AIDS in Prison Project<br>
<a href="about.html">About the AIDS in Prison Project</a> | <a href="facts.html">Facts Sheet</a> | <a href="discharg.html">Discharge Planning</a> | <a href="allia.html">Alliance for Inmates with AIDS</a> | <a href="well.html">LIVING-Well</a> | <a href="links.html">Other Resources</a> | <a href="osborne.html">About the Osborne Association</a></b></p>

<p><a href="index.html"><img src="gifs/home.gif" vspace=5 alt="[button]"></a><br>
<font size=-1>&nbsp;<a href="index.html"><b>Home</b></a></font><font face="helvetica, arial" size=-1></p>

<p>last mofidied: 8/9/96<br>
copyright &#169; 1966 <br>
<img align=top src="gifs/osborne.gif" alt="[osborne logo]"><a href="mailto:osborne@aidsnyc.org">Osborne Association</a></p>
</blockquote>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-232</DOCNO>
<DOCOLDNO>IA093-001002-B001-147</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/aip/discharg.html 199.29.141.24 19970121122425 text/html 8380
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:18:33 GMT
Server: NCSA/1.5.1
Last-modified: Sun, 24 Nov 1996 16:04:11 GMT
Content-type: text/html
Content-length: 8197
</DOCHDR>
<html>
<head>
<title>AIDS in Prison Project: Discharge Planning</title>
</head>

<body background="gifs/stripe.gif" link="#9f5f9f"><font face="arial, helvetica" size=-1>

<blockquote>

<p><a href="index.html"><img src="gifs/aipx.gif" alt="logo" align=left hspace=5></a><br><font color="9f5f9f" size=+1>WHAT TO DO WHEN LEAVING PRISON <br>
IF YOU ARE HIV-POSITIVE</font><font face="helvetica, arial" size=-1><br><a href="#que"><font color="9f5f9f">en enspa&ntilde;ol</a></font><font face="helvetica, arial" size=-1></p>

<p>If you are an HIV-infected woman or man leaving prison, the return to community can be challenging and confusing. </p>

<p>If you are living with AIDS/HIV and will be going to the parole board within the next 9 to 12 months, the time to begin planning how to stay healthy, where to live, and how to support yourself is now.</p>

<p>This brochure shows some steps you can take to help yourself while you are still in prison.  It will also give you some tips for coping with those first days and weeks after you leave.</p>

<p align=center><font color="9f5f9f"><b>THE AIDS IN PRISON PROJECT<br>
IF YOU NEED HELP, CALL:<br>
The AIDS in Prison Project's AIDS/HIV Information Hotline<br>
Tuesdays and Thursdays<br>
3:00 to 8:00 p.m.<br>
(212) 674-0800</b><br>
<br>
English and Spanish spoken.<br>
All collect calls accepted.</font><font face="helvetica, arial" size=-1></p></p>

<p>A.  IF YOU ARE GOING TO YOUR PAROLE BOARD HEARING WITHIN THE NEXT 6 MONTHS:</p>

<ol>
<li><b>Begin planning where you are going to live. </b>
<br>
<dt>If you do not have an address, you can connect with housing agencies in the community by taking these steps:
<br>
<ul>
<li>Locate housing resources in the Pre-Release Center.
<li>Mail a request for information and referrals to:
<br>
<dt>The AIDS in Prison Project<br>
The Osborne Association<br>
135 East 15th Street<br>
New York, NY  10003
<br>
<li>Call :
<dt>The AIDS/HIV<br>
Information Hotline<br>
 at (212) 674-0800, <br>
on any Tuesday or Thursday, between 3:00 p.m. &amp; 8:00 p.m.<br>
English and Spanish spoken.<br>
Collect calls accepted.
</ul>
<br>
<li><b>Begin making sure you have identification in your file.</b> 

<dt>Identification means:
<p>
<ol>
	<li>A birth certificate, and
	<li> A social security card.
</ol>
<br>
<dt>Pre-Release Centers should have the application forms for a birth certificate, as well as waiver forms for the fee (if you were born in New York State).  There is a charge to receive a birth certificate from out of state.  The birth certificate will be mailed back to the facility and placed in your file.  This can take from 4 to 8 weeks.  
<br><br>
<dt>See your Institutional Parole Officer or someone at Pre-Release for more information.
<br><br>
<dt>To receive a birth certificate from Puerto Rico, mail a letter of request, along with a copy of a photo I.D., to:

<p align=center>Department of Health<br>
Commonwealth of Puerto Rico<br>
P. O. Box 11854, Fernandez Juncos Station<br>
San Juan, Puerto Rico  00910</p>

<dt>Enclose a money order for $2.00 payable to the Secretary of the Treasury. 
<p>
<dt>For birth certificates in other countries, see your Institutional Parole Officer or someone at Pre-Release.
<p>
<dt>Applications for social security cards, or to re-issue a lost or stolen card, can be made through the Pre-Release Center or the Parole Office.  Complete the form and send it to the Social Security Office indicated at Pre-Release.  (There is no charge.)  The card will be mailed back to your file in 4 to 6 weeks.
</ol>

<p><font size=+1 color="9f5f9f"><a name="que">QUE</a> HACER AL SALIR DE LA CARCEL<br>
SI USTED ES VIH POSITIVO</font><font face="helvetica, arial" size=-1></p>

<p>Si usted es un hombre o mujer que esta infectado(a) con el virus VIH, el retorno a la comunidad puede ser confuso y desafiante para usted.</p>

<p>Si usted tiene SIDA/VIH y va a presentarse ante la Junta de Parole (Parole Board), dentro de los pr&oacute;ximos 9 a 12 meses, ahora es el momento de planificar como mantenerse saludable, el lugar para vivir y el modo de subsistir.</p>

<p>Este folleto le ense&ntilde;a algunos de los pasos que puede tomar para ayudarse a si mismo(a) mientras que est&eacute; en la c&aacute;rcel.  Tambi&eacute;n le dar&aacute; informaci&oacute;n apropriada para arregl&aacute;rselas durante esos primeros d&iacute;as y semanas despu&eacute;s de que salga en libertad de la c&aacute;rcel.</p>

<p align=center><font color="9f5f9f">THE AIDS IN PRISON PROJECT<br>
SI NECESITA AYUDA, LLAME A:<br>
AIDS in Prison Project Hotline Sobre el SIDA/VIH<br>
Martes y Jueves<br>
de 3:00 a 8:00 p.m.<br>
(212) 674-0800<br>
<br>
Se habla Ingl&eacute;s y Espa&ntilde;ol.<br>
Se aceptan llamadas por cobrar.</font><font face="helvetica, arial" size=-1></p>

<p>A.  SI SE VA A PRESENTER A LA AUDIENCIA ANTE LA JUNTA DE PAROLE DENTRO  LOS PROXIMOS 6 MESES:</p>

<ol>
<li><b>Comience a planear adonde va a vivir.</b>
<dt>Si no tiene un lugar de residencia, se puede poner en contacto con las agencias de vivienda de la comunidad en la siguiente forma:
<ul>
<li>Localice los recursos de vivienda en las oficinas del "Pre-Release Center."
<li>Solicite por correo informaci&oacute;n y recomendaciones a:
<dt>The AIDS in Prison Project<br>
The Osborne Association<br>
135 East 15th Street<br>
New York, NY  10003
<li>Llame por tel&eacute;fono :
<dt>La L&iacute;nea Informativa ("Hotline") sobre el SIDA/VIH
 al (212) 674-0800, todos los martes y los jueves entre las 3:00 p.m. y 8:00 p.m.  <br>
Se habla Ingl&eacute;s y Espa&ntilde;ol.<br>
Se aceptan llamadas por cobrar.
</ul>
<p>
<li><b>Aseg&uacute;rese de que tiene identificaci&oacute;n en su expediente.</b> 
<dt>Identificaci&oacute;n quiere decir:
<p>
<ol>
<li>El Certificado de Nacimiento, y
<li>La Tarjeta del Seguro Social.
<p>
</ol>
<dt>Las oficinas del Pre-Release Center deben tener los formularios para solicitar el Certificado de Nacimiento y los formularios para evitar su costo (si usted naci&oacute; en el Estado de Nueva York).  Los certificados de nacimiento de otros estados tienen un costo adicionado.  El certificado de nacimiento ser&aacute; enviado directamente al centro de detenci&oacute;n y se pondr&aacute; en su expediente.  El tr&aacute;mite puede tomar de 4 a 8 semanas. 
<p>
<dt>Si desea m&aacute;s informaci&oacute;n, consulte con su oficial institucional de Parole o con alguien del Pre-Release Center.
<p>
<dt>Para recibir un certificado de nacimiento de Puerto Rico, solic&iacute;telo por carta junto con copia de una identificaci&oacute;n con retrato y m&aacute;ndela por correo a:

<p align=center>Department of  Health<br>
Commonwealth of Puerto Rico<br>
P. O. Box 11854, Fernandez Junco Station<br>
San Juan, Puerto Rico  00910</p>

<dt>Incluya una orden de pago (money order) de U.S. $2.00 pagable a la Secretaria del Tesoro.  
<p>
<dt>Para certificados de nacimiento de otros pa&iacute;ses, consulte con su oficial institucional de Parole o con alguien del Pre-Release Center.
<p>
<dt>Las solicitudes para obtener  tarjetas del Seguro Social, o para re-emitir una tarjeta perdida o robada, se pueden hacer a trav&eacute;s del Pre-Release Center o de la Oficina de Parole. Complete el formulario y env&iacute;elo a la oficina del Seguro Social indicada en el Pre-Release Center.  (Esto es gratis.)  La trajeta ser&aacute; enviada por correo directamente a su expediente dentro de 4 a 6 semanas.
</ol>
<p><b>AIDS in Prison Project<br>
<a href="about.html">About the AIDS in Prison Project</a> | <a href="facts.html">Facts Sheet</a> | <a href="changes.html">Changes &amp; Choices</a> | <a href="allia.html">Alliance for Inmates with AIDS</a> | <a href="well.html">LIVING-Well</a> | <a href="links.html">Other Resources</a> | <a href="osborne.html">About the Osborne Association</a></b></p>

<p><a href="index.html"><img src="gifs/home.gif" vspace=5 alt="[button]"></a><br>
<font size=-1>&nbsp;<a href="index.html"><b>Home</b></a></font><font face="helvetica, arial" size=-1></p>


<p>last mofidied: 11/7/96<br>
copyright &#169; 1966 <br>
<img align=top src="gifs/osborne.gif" alt="[osborne logo]"><a href="mailto:osborne@aidsnyc.org">Osborne Association</a></p>
</blockquote>

</font>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT18-B31-233</DOCNO>
<DOCOLDNO>IA093-001002-B001-166</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/aip/facts.html 199.29.141.24 19970121122438 text/html 5774
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:18:44 GMT
Server: NCSA/1.5.1
Last-modified: Sun, 24 Nov 1996 16:04:16 GMT
Content-type: text/html
Content-length: 5591
</DOCHDR>
<head>
<title>AIDS in Prison Project: facts sheet</title>
</head>

<body background="gifs/stripe.gif" link="#9f5f9f"><font face="helvetica, arial" size=-1>

<blockquote>

<p><a href="index.html"><img src="gifs/aipx.gif" alt="logo" align=left hspace=5></a><br><font color="9f5f9f" size=+1><b>FACTS SHEET<br><br><a href="#us">National</a> | <a href="#nys">New York State</a> | <a href="#nyc">New York City</a></b></font><font face="helvetica, arial" size=-1></p>

<p><font size=+1 color="9f5f9f"><a name="us"><b>United</a> States</b></font><font face="helvetica, arial" size=-1></p>

<ul>
<li>A record 1.46 million men and women are currently living behind bars in the United States.    Inmates of Federal, state, and local prisons and jails total approximately 0.37% of the population, yet they represent 4.6% of all AIDS cases in the United States reported to date.   Two percent of all adult and adolescent AIDS-related deaths occur behind bars.
<p>
<li>AIDS incidence (the number of new cases) among state and Federal prisoners is approximately 362 cases per 100,000 people, or 20 times the rate in the population at large. 
<p>
<li>AIDS rates in the United States increased by five percent between 1990 and 1992; rates in state and Federal prisons doubled during the same time. 
<p>
<li>Injection drug use is the leading risk factor for AIDS/HIV in prisons and jails throughout the country, and one-quarter of prisoners have used needles to inject drugs.   Nearly half of those prisoners who use illegal drugs have shared needles. 
<p>
<li>While women account for only 6% of the nation's prisoners, their numbers increased by 172% between 1986 and 1994 to a record 61,000.    Nearly one in three has been convicted of a drug offense, accounting for over half of the increase in the female inmate population.
<p>
<li>One-third of women in prison have used needles to inject drugs.  Over one-third report a history of sexual abuse, a factor that has been linked to behaviors that place women at increased risk of HIV infection. 
<p>
<li>Black and Latina women make up a disproportionate 60% of female inmates; 92% of women prisoners are under age 45.   According to the Centers for Disease Control, Black and Latina women of childbearing age are disproportionately at risk for AIDS/HIV, accounting for 75% of female AIDS cases in the United States, although they represent only 21% of all women. 
</ul>

<p align=center><img src="gifs/purple.gif" width=50% height=4>

<p><font size=+1 color="9f5f9f"><a name="nys"><b>New</a> York State</b></font><font face="helvetica, arial" size=-1></p>

<ul>
<li>New York State has more HIV positive inmates and more inmates with AIDS than any other state prison system. 
<p>
<li>A 1992 study by the New York State Department of Correctional Services found that 11.5% of men and over 20% of women entering State prisons tested positive for HIV. 
<p>
<li>Approximately 9,140 of the more than 66,000 prisoners in New York State are HIV positive  and over 2,600 State prisoners have been diagnosed with AIDS since surveillance reporting began.   
<p>
<li>Intravenous drug use is the risk factor for HIV transmission in over 90% of AIDS cases among New York State prisoners. 
<p>
<li>AIDS/HIV is now the leading cause of death in New York State prisons, accounting for 66% of inmate deaths and killing more people than all other causes combined. 
<p>
<li>In 1982 four prisoners died of AIDS; in 1993 the number of deaths attributed to AIDS was 224.  In all, over 1,600 people, or 62% of the known AIDS cases, have died behind New York State prison walls.  
<p>
<li>In 1986, 1991 and 1992, all deaths among women prisoners in New York State were attributed to AIDS. 
<p>
<li>Seventy-eight percent of deaths among Latino prisoners in New York State are attributed to AIDS, as are 62% of deaths among Black inmates and 39% among White inmates. 
<p>
<li>One-third of terminally ill prisoners who apply for early release under New York State's Medical Parole Law die before their applications are processed. 
</ul>

<p align=center><img src="gifs/purple.gif" width=50% height=4>

<p><font color="9f5f9f" size=+1><a name="nyc"><b>New</a> York City</b></font><font face="helvetica, arial" size=-1></p>
	
<ul>
<li>Approximately 100,000 men and women pass through the New York City jail system each year.  According to the New York City Department of Health, 2,600 of the 10,000 women prisoners are HIV-positive, as are 11,040 of the men. 
<p>
<li>Of the 8,000 inmates who voluntarily requested HIV-antibody testing in 1992, 22% of women and 13% of men were found to be HIV-positive. 
<p>
<li>Blinded epidemiologic surveys of new entrants to City jails have found rates of HIV infection as high as 16% for men and 26% for women. 
</ul>

<p align=center><img src="gifs/purple.gif" width=50% height=4>

<p><b>AIDS in Prison Project<br>
<a href="about.html">About the AIDS in Prison Project</a> | 
<a href="discharg.html">Discharge Planning</a> | <a href="changes.html">Changes &amp; Choices</a> | <a href="allia.html">Alliance for Inmates with AIDS</a> | <a href="well.html">LIVING-Well</a> | <a href="links.html">Other Resources</a> | <a href="osborne.html">About the Osborne Association</a></b></p>

<p><a href="index.html"><img src="gifs/home.gif" vspace=5 alt="[button]"></a><br>
<font size=-1>&nbsp;<a href="index.html"><b>Home</b></a></p>


<p>last mofidied: 11/7/96<br>
copyright &#169; 1966 <br>
<img align=top src="gifs/osborne.gif" alt="[osborne logo]"><a href="mailto:osborne@aidsnyc.org">Osborne Association</a></p>
</blockquote>

</font>
</body>
</html>


</DOC>
<DOC>
<DOCNO>WT18-B31-234</DOCNO>
<DOCOLDNO>IA093-001002-B001-190</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/aip/well.html 199.29.141.24 19970121122450 text/html 12960
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:18:57 GMT
Server: NCSA/1.5.1
Last-modified: Sun, 24 Nov 1996 16:04:37 GMT
Content-type: text/html
Content-length: 12776
</DOCHDR>
<html>
<head>
<title>Osborne Association: Living Well</title>
</head>

<body background="gifs/stripe.gif" link="#9f5f9f"><font face="helvetica, arial" size=-1>

<blockquote>

<p><b><a href="wellsp.html">en espa&ntilde;ol</a></b></p>

<p><a href="index.html"><img src="gifs/aipx.gif" alt="logo" align=left hspace=5><b><a href="about.html">About the AIDS in Prison Project</a> | <a href="facts.html">Facts Sheet</a> | <a href="discharg.html">Discharge Planning</a> | <a href="changes.html">Changes &amp; Choices</a> | <a href="allia.html">Alliance for Inmates with AIDS</a> | <a href="links.html">Other Resources</a> | <a href="osborne.html">About the Osborne Association</a></b></p>
<br clear=left>

<p><br><font size=+1 color="9f5f9f"><b>QUESTIONS AND ANSWERS ABOUT LIVING-Well</b></font><font face="helvetica, arial" size=-1></p>

<p><font color="9f5f9f"><b>WHAT IS LIVING-Well?</b></font><font face="helvetica, arial" size=-1></p>

<p>LIVING-Well is a service program, primarily for people from the South Bronx who are on parole or getting ready to leave prison. We provide HIV/AIDS education for parolees who are HIV positive, as well as for those who do not know their HIV status but want to remain healthy. We provide counseling for those considering an HIV test. For people on parole who need immediate care for HIV disease or AIDS, and meet certain eligibility requirements, LIVING-Well's case managers coordinate the many services needed by a person who wants to LIVE Well. </p>

<p><font color="9f5f9f"><b>WHO PROVIDES THESE SERVICES?</b></font><font face="helvetica, arial" size=-1></p>

<p>LIVING-Well is a program of THE OSBORNE ASSOCIATION, a nonprofit organization that has provided services to prisoners, former prisoners and their families for nearly 75 years. This program is staffed by case managers with training in social work and counseling, and familiarity with HIV/AIDS, chemical dependency, and the resources available for people with HIV. LIVING-Well is not a part of Parole.</p>

<p><font color="9f5f9f"><b>THE OSBORNE ASSOCIATION WAS ESTABLISHED AS A CRIMINAL JUSTICE ORGANIZATION.  WHY IS IT OFFERING HEALTH SERVICES?</b></font><font face="helvetica, arial" size=-1></p>

<p>HIV/AIDS is a reality in everyone's lives, and New York's prisons are at the center of the epidemic. More than 5,000 cases of AIDS have been reported among correctional inmates in the U.S. since the onset of the epidemic.   According to the US Department of Justice, in 1994 approximately 12% of the men and women in the NYS prison system are HIV positive. Whether we like it or not, whether we are living with HIV or not, nearly all of us have a relative or a friend who had or has HIV/AIDS. At this very moment, you may be afraid that you are positive and you don't really know what to do or where to start. Those organizations that serve the men and women coming out of prison must, and now do, include HIV services. </p>

<p><font color="9f5f9f"><b>WHAT IS THE PHILOSOPHY OF LIVING-Well?</b></font><font face="helvetica, arial" size=-1></p>

<p>LIVING-Well is about living. At LIVING-Well, we believe that HIV-related illness frequently can be handled if we challenge our life styles at the right time. Whether you go back to live with your friends or relatives or you live on your own, this is the right time. </p>

<p>We believe that the successful management of HIV requires CHANGES and CHOICES. (We have published a workbook called <a href="changes.html">Changes and Choices</a>, describing in detail the changes and choices that are needed to live well with HIV.)</p>

<p>People living with HIV have all made the CHOICE to make healthy CHANGES in their eating habits, self image, spirituality, exercise program, relationships and use of drugs and alcohol. </p>

<p><font color="9f5f9f"><b>WHAT IS CASE MANAGEMENT?</b></font><font face="helvetica, arial" size=-1></p>

<p>"Case Management" includes providing, referring, and coordinating all the different services a person infected with HIV needs to LIVE Well. A Case Manager coordinates medical and dental services, assists you in getting some form of economic assistance or entitlements, and helps you manage your particular needs including housing, drug rehabilitation, or mental health treatment. The LIVING-Well case managers ALSO escort clients to service providers, actively advocate for their clients and encourage their clients to adopt immune-enhancing lifestyles, including appropriate nutrition and exercise. </p>

<p><font color="9f5f9f"><b>I LIVE IN THE SOUTH BRONX, AND I'M ON PAROLE. WHAT CAN LIVING-Well DO FOR ME RIGHT NOW?</b></font><font face="helvetica, arial" size=-1></p>

<p>LIVING-Well staff is present at the Bronx Parole Bureaus every Tuesday and Wednesday from 9:00 to 1:00 p.m. If you tested positive for HIV, you want to remain as healthy as possible. We have orientation and counseling sessions which will strengthen life affirming activities. We encourage planning, caring for one's personal needs and inquiring about social services and medical treatment. Our clients are expected to participate actively in HIV/AIDS education sessions and special workshops provided by our staff. The content of our education and counseling sessions is based on the individual experience of each parolee rather than on the duplication of somebody else's experience. We offer special sessions for women.  Our program maintains the strictest respect for your need and right to confidentiality.</p>

<P><font color="9f5f9f"><b>DO YOU PROVIDE ANY SPECIAL SERVICES FOR WOMEN?</b></font><font face="helvetica, arial" size=-1></p>

<p>If you are a woman with HIV who is on parole and living anywhere in the Bronx, you are eligible for all of the Osborne Association's services. If you are pregnant, contact LIVING-Well immediately. We will coordinate the services you need, including prenatal care, medical treatment, entitlements, housing, and child care. We also offer HIV/AIDS education and weekly support groups to you, and support and counseling services to your family.</p>

<p><font color="9f5f9f"><b>DO YOU PROVIDE ANY SERVICES FOR MY PAROLE OFFICER?</b></font><font face="helvetica, arial" size=-1></p>

<p>Although we are not part of parole, we do provide some services AT the Bronx parole office, and our staff is always available to answer parole officers' questions about HIV and AIDS and to assist them in finding resources, referrals and services for people with HIV. We often encourage parole officers to refer appropriate clients to our case managers for more intensive services.</p>

<P><font color="9f5f9f"><b>I AM STILL IN PRISON. WHAT CAN YOU DO FOR ME?</b></font><font face="helvetica, arial" size=-1></p>

<p>The real question is," What can you do for yourself?" Prison is not the best place for people who want to take control of their lives, but one way to get some control is to get the best possible information. You can read as much as you can about HIV and attend any program that might provide information about HIV. Programs about substance abuse and family issues often include information about HIV transmission. Find out what HIV/AIDS literature is available in the library or through different organizations. Knowing the facts about HIV will help you start dealing with your fears about HIV/AIDS. </p>

<p>If you know you are HIV positive (HIV+), medical follow-up which includes blood tests and physical exams, is an important part of getting a handle on HIV. You must be informed to get what you want. Materials from LIVING-Well and other organizations will help you make some plans before you're released to your community. If you're HIV+ and in prison or out, other people with HIV, who you will meet in support groups will be a valuable source of information. </p>

<p>If you have not been tested and have had unprotected sex or shared works, you might consider taking an HIV test. Become informed about the difference between confidential and anonymous testing options. You will be counseled before and after the HIV test in whatever language you understand best. If you are positive, you may be able to get medications, treatments and other assistance that will help you to LIVE Well for a very long time.</p>

<p><font color="9f5f9f"><b>I AM ON PAROLE AND I AM HIV+ - OR AT LEAST I THINK I AM - BUT I DON'T COME FROM THE SOUTH BRONX. WHAT CAN YOU DO FOR ME?</b></font><font face="helvetica, arial" size=-1></p>

<p>You are more than welcome to attend our support groups (call 212-378-6590 for information about time and place) and learn about other resources available to you. Some of these resources include:</p>

<ul>
<li>BRONX AIDS TASK FORCE (212) 665-4906
<li>BROOKLYN AIDS TASK FORCE (718) 638-2437
<li>FORTUNE SOCIETY (212) 206-7070
<li>GAY MENS HEALTH CRISIS (212) 807-7660
<li>MINORITY TASK FORCE ON AIDS (212) 749-2816
<li>UPPER MANHATTAN TASK FORCE ON AIDS (212) 870-8152
<li>UPPER ROOM AIDS MINISTRY (212) 491-9000
<li>NYC DEPT. OF HEALTH AIDS HOTLINE (718) 485-8111
<li>CITY NOTIFICATION ASSIST PROGRAM (800) 828-0064
<li><a href="allia.html">ALLIANCE FOR INMATES</a> (212) 674-0800<a href="#1">*</a>
</ul>

<p><a name="1">*</a>Collect calls accepted Tuesdays and Thursdays 3pm - 8pm.</p>

<p><font color="9f5f9f"><b>WHAT OTHER SERVICES DOES THE OSBORNE ASSOCIATION PROVIDE FOR PAROLEES?</b></font><font face="helvetica, arial" size=-1></p>

<p>The Osborne Association operates El Rio, an outpatient substance abuse treatment program that includes acupuncture, relapse prevention, nutrition, and a wide variety of other services available through referral by your parole officer. Our Bureau of Vocational Placement works with people on parole to find jobs and training programs.</p>

<p><font color="9f5f9f"><b>HOW ARE CASES REFERRED TO LIVING-Well?</b></font><font face="helvetica, arial" size=-1></p>

<p>Most cases are referred by parole officers assigned to certain areas of the South Bronx. They will refer parolees whom they believe are at risk of HIV, or whom they know to be HIV+, for counseling, assistance with getting services, or case management. We will also consider parolees who contact us directly. We will NOT inform your parole officer or anyone else that you have contacted us unless you authorize us to do so. </p>

<p><font color="9f5f9f"><b>HOW CAN I CONTACT YOU?</b></font><font face="helvetica, arial" size=-1></p>

<p>LIVING-Well is located at 809 Westchester Avenue, Bronx, NY 10455, (212) 378-6590. Case managers also meet with clients and offer support groups at our Manhattan site, 135 East 15th Street, New York, NY 10003. You can also meet our staff at the Bronx parole office, where someone is available every Tuesday and Wednesday morning, 9:00 a.m. until 12:00 noon.</p>

<p><i>This brochure was prepared by LIVING-Well, a program of the Osborne Association, and is targeted to prisoners in pre-release programs and parolees in the State of New York. Funding for the development of this brochure was provided by The New York State Department of Health, AIDS Institute.</i></p>

<p><i>The Osborne Association is a non-profit criminal justice organization founded in 1933 to provide educational, vocational, treatment and support services to defendants, prisoners, ex-offenders, and their families. LIVING-Well is supported by the New York State Department of Health AIDS Institute, Ryan White CARE Act Title I Funds, as well as private grants and contributions. LIVING-Well receives no funding from the Division of Parole and is NOT a part of Parole. For more information about our HIV services, contact Dixon Valderruten, Program Director, LIVING-Well, 809 Westchester Avenue, Bronx, NY 10455 (212) 378-6590.</i></p>

<p align=center>The Osborne Association<br>
135 East Fifteenth Street<br>
New York, NY 10003<br>
(212) 673-6633<br>
Elizabeth Gaynes, Executive Director<br>
Ana Oliveira, Director of Program Services</p>

<p><b>AIDS in Prison Project<br>
<a href="about.html">About the AIDS in Prison Project</a> | <a href="facts.html">Facts Sheet</a> | <a href="discharg.html">Discharge Planning</a> | <a href="changes.html">Changes &amp; Choices</a> | <a href="allia.html">Alliance for Inmates with AIDS</a> | <a href="links.html">Other Resources</a> | <a href="osborne.html">About the Osborne Association</a></b></p>

<p><a href="index.html"><img src="gifs/home.gif" vspace=5 alt="[button]"></a><br>
&nbsp;<a href="index.html"><b>Home</b></a></p>

<p>last mofidied: 11/7/96<br>
copyright &#169; 1966 <br>
<img align=top src="gifs/osborne.gif" alt="[osborne logo]"><a href="mailto:osborne@aidsnyc.org">Osborne Association</a></p>

<p>The Osborne Association is a 501(c)(3) not for profit corporation. Your contribution is tax deductible to the extent provided by law.</p>

</blockquote>
</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-235</DOCNO>
<DOCOLDNO>IA093-001002-B001-213</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/aip/wellsp.html 199.29.141.24 19970121122457 text/html 15564
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:19:05 GMT
Server: NCSA/1.5.1
Last-modified: Sun, 24 Nov 1996 16:04:48 GMT
Content-type: text/html
Content-length: 15380
</DOCHDR>
<html>
<head>
<title>Osborne Association: Living Well - espa&ntilde;ol</title>
</head>

<body background="gifs/stripe.gif" link="#9f5f9f"><font face="helvetica, arial" size=-1>

<blockquote>

<p><a href="index.html"><img src="gifs/aipx.gif" alt="logo" align=left hspace=5><b>
<a href="about.html">About the AIDS in Prison Project</a> | <a href="facts.html">Facts Sheet</a> | <a href="discharg.html">Discharge Planning</a> | <a href="changes.html">Changes &amp; Choices</a> | <a href="allia.html">Alliance for Inmates with AIDS</a> | <a href="links.html">Other Resources</a> | <a href="osborne.html">About the Osborne Association</a></b></p>
<br clear=left>
<p><br><font size=+1 color="9f5f9f"><b>Preguntas &amp; Respuestas Sobre LIVING-Well</b></font><font face="helvetica, arial" size=-1></p>

<p><font color="9f5f9f"><b>&#191;Qu&eacute; es LIVING-Well?</b></font><font face="helvetica, arial" size=-1></p>

<p>LIVING-Well es uno de los programas de la ASOCIACION OSBORNE, una organizaci&oacute;n sin fines de lucro, que ha proveido servicios a presidiarios, ex-presidiarios y a sus familiares por casi 75 a&ntilde;os.  LIVING-Well asiste a las personas que viven en el Bronx y que se encuentran en Libertad Bajo Palabra (Division of Parole) o a punto de salir de la c&aacute;rcel.  LIVING-Well es un programa que cuenta con profesionales capacitados en trabajo social, consejer&iacute;a y salud, con &aacute;mplio conocimiento sobre el VIH y el SIDA, la drogadicci&oacute;n y el abuso de substancias qu&iacute;micas.</p>

<p>Para quienes est&eacute;n en Libertad Bajo Palabra prov&eacute;emos educaci&oacute;n completa sobre el VIH y el SIDA, damos consejer&iacute;a a personas que hayan dado positivo en la prueba del VIH y tambi&eacute;n coordinamos los servicios para quienes requieren asistencia immediata.  Asistimos a quienes desconocen su condici&oacute;n respecto al VIH pero quieren mantenerse saludables.  Los interesados deber&aacute;n cumplir con ciertos requisitos de elegibilidad.  LIVING-Well no hace parte de la Divisi&oacute;n de la Libertad Bajo Palabra (Division of Parole).</p>

<p><font color="9f5f9f"><b>La Asociaci&oacute;n Osborne se estableci&oacute; como una organizacion en pro de la justicia criminal. &#191;Por qu&eacute; ofrece sevicios de salud?</b></font><font face="helvetica, arial" size=-1></p>

<p>El VIH/SIDA es una realidad en la vida de todos nosotros, y las c&aacute;rceles de Nueva York tambi&eacute;n son parte de esta realidad.  Entre los presidiarios del sistema correccional en los Estados Unidos se han reportado mas de 5,000 casos de SIDA desde que se inicio la epidemia<sup><a href="#1">1</a></sup>.  Adem&aacute;s, de acuerdo con el Departamento de Justicia de los Estados Unidos, en 1994, 12% de los hombres y mujeres en el sistema carcelario de este estado eran VIH positivas.  Nos guste o no, vivamos con VIH o no, casi todos nosotros tenemos un familiar o un amigo que ha tenido o tiene VIH/SIDA.  En estos momentos, usted a lo mejor teme dar positivo en la prueba del VIH y realmente no sabe qu&eacute; hacer ni por d&oacute;nde empezar.  Aquellas organizaciones que ofrecen servicios a hobres y mujeres que salen de las c&aacute;rceles tienen que ofrecer servicios relacionados con el VIH.

<p><a name=1>1</a><i>Instituto Nacional de Justicia (National Institute of Justice), Boletin SIDA, septiembre de 1990.</i></p>

<p><font color="9f5f9f"><b>&#191;Cual es la filosof&iacute;a de LIVING-Well?</b></font><font face="helvetica, arial" size=-1></p>

<p>LIVING-Well es un programa que hace &eacute;nfasis en el vivir.  En LIVING-Well, creemos que la enfermedad asociada con el VIH puede ser sobrellevada si cambiamos nuestro estilo de vida.  Aquellas personas que viven con el VIH en forma saludable han optado por hacer cambios en sus h&aacute;bitos alimenticios, su auto-estima propia, su espiritualidad, su programa de ejercicios, en sus relaciones &iacute;ntimas y en el consumo de drogas y alcohol.  [Hemos publicado un manual con ese t&iacute;tulo (<a href="cambios.html">CHANGES and CHOICES</a>), en donde se describen m&aacute;s a fondo los cambios y las alternativas que le permitir&aacute;n vivir mejor, a pesar de tener un diagn&oacute;stico positivo del VIH].  En LIVING-Well mantenemos un estricto respeto a su derecho y su necesidad de confidencialidad.</p>

<p><font color="9f5f9f"><b>&#191;Qu&eacute; se entiende por "case mangement" o supervisi&oacute;n de casos?</b></font><font face="helvetica, arial" size=-1></p>

<p>En la supervisi&oacute;n de casos ("case management") se prov&eacute;en y coordinan todos los distintos servicios que una persona que es VIH+ (VIH positiva) necesita para VIVIR mejor.  Un supervisor de casos (trabajador social) eval&uacute;a y coordina los servicios m&eacute;dicos, que incluyen tratamiento dental y/o mental, y busca los programas para rehabilitaci&oacute;n de drogas.  El trabajador social tambi&eacute;n le ayuda a obtener vivienda.  Nuestros trabajadores sociales acompa&ntilde;an a sus clientes a las diferentes instituciones que proveen servicios e interceden por ellos.</p>

<p><font color="9f5f9f"><b>Vivo en el Bronx y estoy en libertad bajo palabra. &#191;Qu&eacute; es lo que LIVING-Well puede hacer por mi ahora?</b></font><font face="helvetica, arial" size=-1></p>

<p>Los trabajadores sociales de LIVING-Well estan pres&eacute;ntes en las oficinas de la Division de la Libertad Bajo Palabra en el Bronx los martes y miercoles de 9:00 a.m. a 1:00 p.m. y tambi&eacute;n los jueves de 9 a.m. - 12 p.m.  Si usted result&oacute; positivo en la prueba del VIH usted deber&aacute; conservarse lo m&aacute;s saludable posible.  Usted puede comunicarse con nuestros trabajadores sociales quienes le orientar&aacute;n y aconsejar&aacute;n lo que usted necesita hacer para mantenerse saludable.  Usted tambi&eacute;n ser&aacute; invitado a participar en sesiones educativas sobre el VIH/SIDA, las que adem&aacute;s incluyen informaci&oacute;n sobre nutrici&oacute;n, prevenci&oacute;n y abuso de drogas.</p>

<p><font color="9f5f9f"><b>&#191;Prov&eacute;en ustedes algunos servicios especiales para las mujeres?</b></font><font face="helvetica, arial" size=-1></p>

<p>Si.  Si usted es una mujer VIH positiva, que esta bajo Libertad Bajo Palabra y vive en cualquier &aacute;rea del Bronx, usted es elegible para recibir todos los servicios de la Asociaci&oacute;n Osborne.  Si usted est&aacute; en estado de embarazo, p&oacute;ngase en contacto con LIVING-Well inmediatamente.  Nosotros coordinamos los servicios que usted necesite, incluyendo cuidado prenatal, tratamiento m&eacute;dico, autorizaciones y servicios a los que tiene derecho, vivienda, y el cuido de ni&ntilde;os.  Le ofrecemos tambi&eacute;n educaci&oacute;n sobre VIH/SIDA y grupos de apoyo que se re&uacute;nen semanalmente, asi como servicios de apoyo y consejer&iacute;a para su familia.</p>

<p><font color="9f5f9f"><b>Estoy todavia en la prisi&oacute;n.  &#191;Qu&eacute; pueden hacer por mi? </b></font><font face="helvetica, arial" size=-1></p>

<p>La pregunta mas importante es "&#191;que puede hacer por usted mismo?"</p>
<ul>
<li>Usted debe informarse para obtener lo que desea.  El estar informado sobre el VIH le ayudar&aacute; a controlar el temor que pueda sentir hacia el VIH o el SIDA.  Usted puede leer lo m&aacute;s que pueda sobre el VIH y asistir a alg&uacute;n programa que le ofrezca informaci&oacute;n acerca de este virus.  Investigue qu&eacute; publicaciones sobre el VIH/SIDA est&aacute;n disponibles en la biblioteca.  Los materiales educativos publicados por LIVING-Well y otras organizaciones tambi&eacute;n le ayudar&aacute;n a hacer sus planes antes de que usted regrese a su comunidad.
<li>Si usted sabe que es VIH+ (VIH positivo) usted necesita cuidar de su salud.  Es decir, usted necesita escoger un m&eacute;dico y hacerse chequeos regularmente, hacerse ex&aacute;menes de sangre con frecuencia (incluyendo el conteo de sus c&eacute;lulas T4 y su carga viral).  Usted deber&aacute; discutir sus planes m&eacute;dicos con un m&eacute;dico, incluyendo las opciones a varios tratamientos a que usted tiene derecho.  Todas aquellas personas que pudiera conocer con el VIH en los diferentes grupos de apoyo tambi&eacute;n le ser&aacute;n una valiosa fuente de informaci&oacute;n.  En este momento usted puede empezar a conseguir sus documentos m&eacute;dicos y prescripciones para asegurar continuidad en su tratamiento m&eacute;dico.
<li>Si no se ha hecho la prueba del VIH y ha tenido relaciones sexuales sin protecci&oacute;n alguna o ha intercambiado agujas, jeringuillas u otros utensilios, usted deber&iacute;a considerar hacerse la prueba del VIH.  Inf&oacute;rmese en cuanta la diferencia entre una prueba confidencial y una an&oacute;nima.  Esta es una opci&oacute;n a la que usted tiene derecho.  Usted obtendr&aacute; asesoramiento antes y despu&eacute;s de la prueba del VIH en el idioma que usted entienda mejor.  Si usted es VIH positivo, usted podria obtener medicamentos y asistencia que lo ayudar&aacute;n a VIVIR mejor por largo tiempo.
</ul>

<p><font color="9f5f9f"><b>Estoy en Libertad Bajo Palabra y soy VIH positivo - o al menos eso es lo que yo creo - pero yo no vivo en el Bronx.  &#191;Qu&eacute; pueden hacer ustedes por mi?</b></font><font face="helvetica, arial" size=-1></p>

<p>Usted est&aacute; mas que invitado a asistir a nuestros grupos de apoyo (llame al 718-842-0500 para informaci&oacute;n sobre la hora y el lugar) y ent&eacute;rese de otros recursos disponibles para usted.  Algunos de estos recursos son:</p>
<ul>
<li>Bronx AIDS Services - (718) 295-5605
<li>Brooklyn AIDS Task Force - (718) 783-0883
<li>Fortune Society	- (212) 206-7070
<li>Gay Mens Health Crisis - (212) 807-7660
<li>Minority Task Force on AIDS - (212) 663-7772
<li>Upper Manhattan Task Force on AIDS - (212) 870-8152
<li>Harlem United Comm. AIDS Center - (212) 491-9000
<li>NYC Dept. of Health AIDS Hotline - (212) 447-8200
<li>City Notification Assist Program - (800) 828-0064
<li>Alliance for Inmates - (212) 647-1415
<li>AIDS in Prison Project Hotline - (212) 674-0800<sup><a href="#*">*</a></sup>
</ul>

<p><a name="*">*</a> (Se aceptan llamadas "collect" los martes y jueves entre las 3 y 8 de la noche.)</p>

<p><font color="9f5f9f"><b>&#191;Qu&eacute; otros servicios la Asociaci&oacute;n Osborne prov&eacute;e a los qu&eacute; estan en Libertad Bajo Palabra?</b></font><font face="helvetica, arial" size=-1></p>

<p>La Asociaci&oacute;n Osborne prov&eacute;e: tratamiento ambulatorio para la drogadicci&oacute;n (prevenci&oacute;n contra reca&iacute;das, grupo de apoyo y acupuntura), prove&eacute; asistencia legal, educacional y vocacional (preparaci&oacute;n para el GED y ayudamos a buscar empleo), prov&eacute;e servicios de salud, hacemos la prueba contra la tuberculosis y la prueba del VIH, tambi&eacute;n ofrecemos acupunctura y tratamiento natural (no tradicional) en base a hierbas para quienes tienen el VIH);  tambi&eacute;n ofrece otros servicios de apoyo como alimentaci&oacute;n completa, grupos de apoyo, actividades recreativas y reuniones basadas en los los principios de los Narc&oacute;ticos An&oacute;nimos).</p>

<p><font color="9f5f9f"><b>&#191;Prov&eacute;en ustedes algun servicio a los oficiales de Libertad Bajo Palabra?</b></font><font face="helvetica, arial" size=-1></p>

<p>Si.  LIVING-Well prove&eacute; servicios a la Division de la Libertad Bajo Palabra pero no hace parte de ella.  Nuestros empleados siempre est&aacute;n disponibles para contestar cualquier pregunta que los oficiales de la Divisi&oacute;n puedan tener acerca del VIH y el SIDA, o para proveerles asistencia en las &aacute;reas de recursos, referidos y servicios generales para personas con VIH.  A menudo sugerimos a los oficiales de la Divisi&oacute;n de la Libertad Bajo Palabra que refieran algunos de sus supervisados a nuestros trabajadores sociales para proveerles servicios m&aacute;s completos.</p>

<p><font color="9f5f9f"><b>&#191;C&oacute;mo es que las personas en Libertad Bajo Palabra son referidas a LIVING-Well?</b></font><font face="helvetica, arial" size=-1></p>

<p>La mayor&iacute;a de los casos son referidos por oficiales de la Division para la Libertad Bajo Palabra (Division of Parole) asignados a ciertas &aacute;reas del Bronx.  Aquellas personas que son consideradas de "alto riezgo" son referidos a nuestro programa donde reciben informacion y/o referidos.  Queien es son VIH+ y lo saben pueden ser admitidos en el programa si as&iacute; lo desean.  Nosotros tambi&eacute;n aceptamos en nuestro programa personas que est&eacute;n en Libertad Bajo Palabra y que nos contacten directamente.</p>

<p>A menos que usted nos lo autorize, nosotros NO LE INFORMAREMOS A NADIE, ni a&uacute;n a su oficial de Libertad Bajo Palabra, sobre su estado de salud.</p>

<p><font color="9f5f9f"><b>&#191;C&oacute;mo puedo ponerme en contacto con ustedes?</b></font><font face="helvetica, arial" size=-1></p>

<p>LIVING-Well est&aacute; localizado en el 809 Westchester Avenue, Bronx, NY 10455.  Nuestros trabajadores sociales se re&uacute;nen con sus clientes y ofrecen grupos de apoyo en las oficinas de Manhattan (135 East 15th Street, new York, NY 10003).  Adem&aacute;s, usted puede reunirse con los trabajadores sociales en las oficinas de la Divisi&oacute;n de Libertad Bajo Palabra (Division of Parole) en el Bronx, los martes y mi&eacute;rcoles de 9:00 a.m. a 1:00 p.m. y tami&eacute;n  los jueves de 9 a.m. -12 p.m.</p>

<p>Para m&aacute;s informaci&oacute;n acerca de los servicios del VIH/SIDA comunicese con Dicxon Valderruten, director del programa, al (718) 842-0500 ext.238 o escribir a las oficinas del programa.</p>

<p><i>LIVING-Well es financiado por el Instituto del SIDA del Departamento de Salud del estado de Nueva York, por los Fondos Ryan White Care Act, Titulo 1, y tambi&eacute;n por concesiones y donaciones privadas.  LIVING-Well no recibe fondos de la Divisi&oacute;n de la Libertad Bajo Palabra y tampoco hace parte de esta Divisi&oacute;n.</i></p>

<p align=center>The Osborne Association<br>
135 East Fifteenth Street, New York, NY 10003<br>
(212) 673-6633<br>
Elizabeth Gaynes, Executive Director</p>

<p><i>This brochure was prepared by LIVING-Well, a program of the Osborne Association, and is targeted to prisoners in pre-release programs and parolees in the State of New York.  Funding for the development of this brochure was provided by The New York State Department of Health, AIDS Institute.</i></p>

<p><b>AIDS in Prison Project<br>
<a href="about.html">About the AIDS in Prison Project</a> | <a href="facts.html">Facts Sheet</a> | <a href="discharg.html">Discharge Planning</a> | <a href="changes.html">Changes &amp; Choices</a> | <a href="allia.html">Alliance for Inmates with AIDS</a> | <a href="links.html">Other Resources</a> | <a href="osborne.html">About the Osborne Association</a></b></p>

<p><a href="index.html"><img src="gifs/home.gif" vspace=5 alt="[button]"></a><br>
&nbsp;<a href="index.html"><b>Home</b></a></p>

<p>last mofidied: 11/24/96<br>
copyright &#169; 1966 <br>
<img align=top src="gifs/osborne.gif" alt="[osborne logo]"><a href="mailto:osborne@aidsnyc.org">Osborne Association</a></p>

<p>The Osborne Association is a 501(c)(3) not for profit corporation. Your contribution is tax deductible to the extent provided by law.</p>

</blockquote>
</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-236</DOCNO>
<DOCOLDNO>IA093-001002-B001-253</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/aip/links.html 199.29.141.24 19970121122521 text/html 5416
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:19:27 GMT
Server: NCSA/1.5.1
Last-modified: Sun, 24 Nov 1996 16:04:24 GMT
Content-type: text/html
Content-length: 5233
</DOCHDR>
<html>
<head>
<title>AIDS in Prison Project: Resources</title>
</head>
<body background="gifs/stripe.gif" link="#9f5f9f"><font face="helvetica, arial" size=-1>

<ul><ul><ul><ul><ul>
<p><font size=+1><b><a href="index.html">AIDS in Prison Project</a></b></font></p>

<p><font size=+1><b>Resources on the Web</b></font></p>

<dt><a href="http://www.wco.com/~aerick/links.htm">Links in the Chain</a> has links to prison information and resources, corrections, education, health, international, journals and magazines, prisoners, prisoner support, religion, words and pictures, and other prison related sites.
<p>
<dt><a href="http://www.wco.com/~aerick/prison.html">The Other Side of the Wall</a> has articles, regular features and a reading list.
<p>
<dt><a href="http://mypage.direct.ca/b/berzerkr/links.htm">The Convict's Home Page</a> is a personal page from a 23 year old in Canada with links to information about prisons and tatooing.  
<p>
<dt><a href="http://clickshop.com/tame/nph-std/prisoner/links.tam?cart=96F25mnn.mqu&uu=221644">Other Prison Related Sites</a> includes Dead Man Talkin', columns from a prisoner on death row, and Death Row Inmates who need your help.
<p>
<dt><a href="http://www.strengthtech.com/">Strength Tech</a> posts information about the banning of weight lifting in prisons. 

<p><font size=3><b>Prisoner Activists Organizations</b></font></p>

<dt><b>ACE Out</b><br>
347 East 10th St., New York, NY 10009<br>
phone: (212) 353-3746
Peer support and discharge planning
<p>
<dt><a href="http://csde.aces.k12.ct.us/friends/ccsi/csusa/law/aclu.html"><b>ACLU National Prison Project</b></a><br>
1875 Connecticut Avenue, NW, Suite 410, Washington, DC 20009<br>
phone: (206) 523-4755, fax: (206) 523-1974, Email: <a href="mailto:ccsi@u.washington.edu">ccsi@u.washington.edu</a>
<p>
<dt><b><a href="allia.html">AllIA, the Alliance for Inmates with AIDS</a></b><br>
c/o <a href="../pwac/index.html">PWAC/NY</a><br>
50 West 17 Street, 8th floor <br>
New York, NY 10011<br>
phone: (212) 647-1415<br>
A grass-roots organization  working in collaboration with the AIDS in Prison Project.
<p>
<dt><a href="http://solar.rtd.utk.edu/oldfriends/ccsi/csusa/crime/amcorras.html"><b>American Correctional Assocation</b></a><br>
4380 Forbes Boulevard, Lanham, MD 20706-4322<br>
phone: (301) 918-1800, fax: (301) 918-1900<br>
Membership organization of correctional professionals, individuals, agencies and organizations.
<p>
<dt><b><a href="../arrive/index.html">Arrive Exponents</a></b><br>
151 West 26th Street, New York, NY 10001<br>
phone: (212) 243-3434, fax: (212) 243-3586<br>
Peer based programs to assist individuals and families through difficult transitions.
<p>
<dt><b>The Correctional Association of New York</b><br>
135 East 15th St.
New York, NY 10003<br>
phone:; (212) 254-5700, fax: (212) 473-2807<br>
The CA does policy work and is a prison "watchdog."
<p>
<dt><b>Fortune Society</b><br>
39 West 19th Street, New York, NY 10018<br>
phone: (212) 206-7070, fax: (212) 366-6323<br>
Case management, education/prevention, support, ATI referral, job preparation/placement.
<p>
<dt><b>HIV in Prison Project</b><br>
433 Jefferson Street, Oakland, CA  94607<br>
phone: (510) 834-5657 x 3150, fax: (510) 451-6998Bay)
<p>
<dt><b>HIV Law Project</b><br>
80 Fifth Avenue, Suite 1505, New York, NY 10011<br>
phone: (212) 722-8040<br>
Advocacy.
<p>
<dt><b>New York AIDS Coaltion</b><br>
150 West 26th Street, New York, NY 10001<br>
phone: (212) 675-7750<br>
Policy.
<p>
<dt><b>New York City Cimmission on Human Rights HIV Prison Project</b><br>
40 Rector Street, 10th floor, New York, NY 10016<br>
phone: (212) 306-7545, fax: (212) 306-7658<br>
AIDS discrimination.
<p>
<dt><b>Prisoners Legal Services</b><br>
105 Chambers Street, New York, NY 10007<br>
phone: (212) 513-7373<br>
Legal advocacy.
<p>
<dt><b>Prisoners Rights Project of the Legal Aid Society</b><br>
15 Park Row, 7th floor, New York, NY 10038<br>
phone: (212) 577-3550, 577-3990, fax: (212) 732-6003<br>
Legal advocacy.
<p>
<dt><b>PWA Rag published by Prisoners with AIDS Rights Advocacy Group</b><br>
PO Box 2161,
Jonesboro, GA 30327<br>
phone: (404) 946-9346<br>
A newsletter for PWAs in the Belly of the Beast. Provides an important
service with articles, treatment news, and prisoner resources. Donations (especially including postage stamps) are appreciated. 
<p>
<dt><b>Women's Prison Association</b><br>
110 2nd Ave.<br>
New York, NY<br>
phone: (212) 674-1163
</ul></ul></ul></ul></ul>

<blockquote>

<p><b>AIDS in Prison Project<br>
<a href="about.html">About the AIDS in Prison Project</a> | <a href="facts.html">Facts Sheet</a> | <a href="changes.html">Changes &amp; Choices</a> | <a href="allia.html">Alliance for Inmates with AIDS</a> | <a href="discharg.html">Discharge Planning</a> | <a href="well.html">LIVING-Well</a> | <a href="osborne.html">About the Osborne Association</a></b></p>

<p><a href="index.html"><img src="gifs/home.gif" vspace=5 alt="[button]"></a><br>
&nbsp;<a href="index.html"><b>Home</b></a></p>

<p>last mofidied: 11/7/96<br>
copyright &#169; 1966 <br>
<img align=top src="gifs/osborne.gif" alt="[osborne logo]"><a href="mailto:osborne@aidsnyc.org">Osborne Association</a></p>
</blockquote>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-237</DOCNO>
<DOCOLDNO>IA093-001002-B001-279</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/aip/osborne.html 199.29.141.24 19970121122537 text/html 6201
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:19:44 GMT
Server: NCSA/1.5.1
Last-modified: Sun, 24 Nov 1996 16:04:29 GMT
Content-type: text/html
Content-length: 6018
</DOCHDR>
<html>
<head>
<title>other services of the osborne association</title>
</head>

<body background="gifs/stripe.gif" link="#9f5f9f"><font="arial, helvetica" size=-1>

<blockquote>

<p><a href="index.html"><img src="gifs/aipx.gif" alt="logo" align=left hspace=5><b>
<a href="about.html">About the AIDS in Prison Project</a> | <a href="facts.html">Facts Sheet</a> | <a href="discharg.html">Discharge Planning</a> | <a href="changes.html">Changes &amp; Choices</a> | <a href="allia.html">Alliance for Inmates with AIDS</a> | <a href="well.html">LIVING-Well</a> | <a href="links.html">Other Resources</a></b></p>
<br clear=left>

<blockquote>

<p><br><font size=+1 color="9f5f9f"><b>Other Services of the Osborne Association</b></font><font face="helvetica, arial" size=-1></p>

<blockquote>

<p align=center><font color="9f5f9f"><b><i>"It is liberty alone that fits man for liberty."<br>Thomas Mott Osborne</i></b></font><font face="helvetica, arial" size=-1></p>

<ul><ul>In 1915, citizen Thomas Mott Osborne spent one week in Auburn prison disguised as prisoner Tom Brown, #33,333x. He lived just as the other inmates, and left Auburn prison committed to the goal of turning America's prisons from, "human scrap heaps into human repair shops."<br> 
<br>
First as warden of Sing Sing and later as founder of the Mutual Welfare League and the National Society of Penal Information, Mr. Osborne became known as the "pioneer and prophet of prison reform". After his death in 1931, the Osborne Association was established to continue his work.
</ul></ul>

<p>TODAY, the Osborne Association contributes to its founder's goal of a criminal justice system that "restores to society the largest number of intelligent, forceful honest citizens" by providing a wide range of services to prisoners, former prisoners and their families, serving more than 5,000 people each year through programs in the South Bronx, Brooklyn, Manhattan and Sing Sing Correctional Facility.</p>

<p align=center>THE OSBORNE ASSOCIATION<br>
135 East Fifteenth Street<br>
New York, NY 10003<br>
Telephone: (212) 673-6633<br>
Fax: (212) 979-7652</p>

</blockquote>

<p><font color="9f5f9f"><b>TREATMENT SERVICES</b></font><font face="helvetica, arial" size=-1></p>

<ul>
<li>El Rio (The River) is a licensed intensive outpatient treatment program established in the wake of the crack epidemic, using traditional counseling and 12-step techniques along with acupuncture and other holistic approaches to provide an effective alternative to prison. El Rio was designed as an alternative to incarceration and targets primarily jailbound defendants and has dedicated treatment slots available for offenders with HIV/AIDS.
<p>
<li>La Fuente (The Fountain) is a walk-in harm reduction program designed to decrease the negative consequences of drug use, such as HIV transmission, through engaging people in services and care including food; counseling and crisis intervention; acupuncture for reduction of craving/detox; and drug, health and HIV education. 
</ul>

<p><font color="9f5f9f"><b>HIV/AIDS SERVICES</b></font><font face="helvetica, arial" size=-1></p>

<ul>
<li><a href="well.html">LIVING-Well</a>, a model case management, education and outreach program for HIV+ parolees and their families, provides intensive case management, support groups, relapse prevention, counseling, referrals to primary health care, and family services.
<p>
<li><a href="about.html">The AIDS In Prison Project</a> operates the country's only Hotline for prisoners, accepting collect calls from prisoners and provides them with information and discharge planning. Project staff and volunteers provide on-site AIDS/HIV education to about 1,000 inmates and accept more than 2,500 collect calls each year. 
</ul>

<p><font color="9f5f9f"><b>LEGAL SERVICES, RESEARCH, AND ADVOCACY</b></font><font face="helvetica, arial" size=-1></p>

<ul>
<li>Assigned Counsel Services provides services for court-appointed lawyers, investigating mitigating circumstances and advocating individualized sentencing options, including treatment or community-based sanctions in appropriate cases.
<p>
<li>Research, Policy, and Advocacy  efforts are focused on the consequences of incarceration policies and practices. By using data collected in our programs about our clients and their needs, and studying policy on issues such as HIV/AIDS, drugs, and crime, we develop and recommend program and policy initiatives that foster the ability and opportunity for people to lead productive, crime-free lives.
</ul>

<p><font color="9f5f9f"><b>YOUTH AND FAMILY SERVICES</b></font><font face="helvetica, arial" size=-1></p>

<ul>
<li>FamilyWorks mends the ties that are broken when a family member is incarcerated, and to reduce the trauma for children left behind, through a parenting program and model children's visiting center for incarcerated fathers and their children at Sing Sing Correctional Facility.
<p>
<li>LEGIT  teaches youngsters brought to Brooklyn Family Court for selling drugs to channel their entrepreneurial skills into legitimate micro-enterprise, while providing educational and counseling support.
</ul>

</ul>

<p><b>AIDS in Prison Project<br>
<a href="about.html">About the AIDS in Prison Project</a> | <a href="facts.html">Facts Sheet</a> | <a href="discharg.html">Discharge Planning</a> | <a href="changes.html">Changes &amp; Choices</a> | <a href="allia.html">Alliance for Inmates with AIDS</a> | <a href="well.html">LIVING-Well</a> | <a href="links.html">Other Resources</a></b></p>

<p><a href="index.html"><img src="gifs/home.gif" vspace=5 alt="[button]"></a><br>
&nbsp;<a href="index.html"><b>Home</b></a></p>

<p>last mofidied: 11/24/96<br>
copyright &#169; 1966 <br>
<img align=top src="gifs/osborne.gif" alt="[osborne logo]"><a href="mailto:osborne@aidsnyc.org">Osborne Association</a></p>

<p>The Osborne Association is a 501(c)(3) not for profit corporation. Your contribution is tax deductible to the extent provided by law.</p>

</blockquote>
</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-238</DOCNO>
<DOCOLDNO>IA093-001002-B001-291</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/lared/index.html 199.29.141.24 19970121122544 text/html 6249
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:19:53 GMT
Server: NCSA/1.5.1
Last-modified: Wed, 03 Jul 1996 20:55:02 GMT
Content-type: text/html
Content-length: 6066
</DOCHDR>
<META  name="description" 
content="Informacion sobre tratamientos para el VIH y el SIDA. Estudios clinicos, hojas sueltas, glossarios.">
<META  name="keywords" content="VIH, SIDA, medicamentos, tratamientos, conditiones">
<html>
<head>
<title>La Red</title>
</head>

<body background="../gifs/blue_pap.gif" text="#000000">

<center><img src="../gifs/logo1.gif" alt="[logo]"></center>

<h1 align=center><FONT SIZE=6>L</font>a <FONT SIZE=6>R</font>ed de <FONT SIZE=6>I</font>nformaci&oacute;n sobre el <FONT SIZE=6>SIDA</font></h1>

<h3 align=center>Informaci&oacute;n sobre tratamientos para el VIH y el SIDA</h3>

<h5 align=center>La informaci&oacute;n presentada en estas p&aacute;ginas del WEB fue creada a trav&eacute;s del programa Netscape. Algunos accentos y caracteres no van a aperecer corectamente si Ud. usa otro programa hojeador que no sea Netscape. Si tiene dificultades en entender alguna informaci&oacute;n, puede llamar a la Red al (800) 734-7104.</h5>

<HR align=center size=3 width=50%>

<h2 align=center><a href="about.html">&#191;Qu&eacute; es La RED?</a></h2>

<H2 align=center><FONT SIZE=6>E</font>studios <FONT SIZE=6>C</font>l&iacute;nicos</H2>

<CENTER><TABLE BORDER=0 cellpadding=4 colspec="50% 50%">
<TR>
<TD colspan=2 align=center><h3><a href="hiv.html">Tratamientos contra VIH</a> <br><font size=-1><i>&Uacute;ltima revisi&oacute;n: 14/2/96</i></font></h3></TD>
<P>
</TR>
<TR>
<TD align=center><h3><a href="real.html">Estudios para recopilar informaci&oacute;n</a><br><font size=-1><i>&Uacute;ltima revisi&oacute;n: 19/2/96</i></font></h3></TD>
<P>
<TD align=center><h3><a href="vacunas.html">Estudios de vacunas</a></h3></TD>
<P>
</TR>
<TR>
<TD align=center colspan=2>
<a href="deberia.html"><h3 align=center>&#191;Deber&iacute;a Yo Participar en un Estudio Cl&iacute;nico sobre el SIDA?</a> <font size=-1><i>(50K)</i></font></h3> <a href="deberia.zip">Versi&oacute;n compacta</a> para leer fuera de la Internet</a>
</TABLE></CENTER>
 
<HR align=center size=3 width=50%>

<h2 align=center><FONT SIZE=6>H</font>ojas <FONT SIZE=6>S</font>ueltas</h2>

<CENTER><TABLE BORDER=0 cellpadding=4 width=100% colspec="33% 33% 33%">
<TR>
<TH colspan=3>Hojas con informaci&oacute;n b&aacute;sica sobre tratamientos y condiciones</TH>
<P>
</TR>
<TR valign=top>
<TD align=center width=33%><font size=-1><A HREF="simple/3tc.html"><b>3TC</b></A><BR> (<i>lamivudine</i>, lamivudina)</font> <br><font size=-2><i>&Uacute;ltima revisi&oacute;n: 11/12/95</i></font></TD>
<P>
<TD align=center width=33%><font size=-1><A HREF="simple/cripto.html"><b>criptosporidiosis</b></A></font></TD>
<p>
<TD align=center><font size=-1><A HREF="simple/d4t.html"><b>d4T</b></A><BR> (<i>stavudine, Zerit</i>, estavudina)</font></TD>
</tr>
<p>
<tr valign=top>
<TD align=center><font size=-1><A HREF="simple/ester.html"><b>los esteroides</b></A></font></TD
<P>
<td align=center><font size=-1><a href="simple/gan-o.html"><b>ganciclovir oral (cytovene)</b></a></font> <br><font size=-2><i>&Uacute;ltima revisi&oacute;n: 26/4/96</i></font></td>
<p>
<TD align=center><font size=-1><A HREF="simple/hongos.html"><b>hongos</b></A></font></TD>
</tr>
<p>
<tr valign=top>
<td align=center><font size=-1><a href="simple/passive.html"><b>inmunoterapia pasiva</b></a></font> <br></font size=-2><i>&Uacute;ltima revisi&oacute;n: 26/4/96</i></font></td>
<p>
<td align=center><font size=-1><a href="simple/implant.html"><b>implantes de ganciclovir contra retinitis de cmv</b></a></font> <br><font size=-2><i>&Uacute;ltima revisi&oacute;n: 26/4/96</i></font></td>
<p>
<td align=center><font size=-1><b><a href="simple/indi.html">indinavir (Crixivan, MK-639)</a></b> <br>inhibidores de proteasa de Merck</font><br> <font size=-2><i>&Uacute;ltima revisi&oacute;n: 25/5/96</i></font></td>
</tr>
<p>
<tr valign=top>
<td align=center><font size=-1><a href="simple/protease.html"><b>inhibidores de 
proteasa</b></a></font> <br><font size=-2><i>&Uacute;ltima 
revisi&oacute;n: 25/5/96</i></font></td>
<p>
<TD align=center><font size=-1><A HREF="simple/il2.html"><b>interleucina-2</b></A> (Il-2)</b></font> <br><font size=-2><i>&Uacute;ltima revisi&oacute;n: 26/4/96</i></font></TD>
<p>
<td align=center><font size=-1><a href="simple/nnrtis.html"><b>nevirapina, delavirdina, lovirida</b></a></font> <br><font size=-2><i>&Uacute;ltima revisi&oacute;n: 26/4/96</i></font></TD>
</tr>
<p>
<tr valign=top>
<td align=center><font size=-1><a href="simple/riton.html"><b>ritonavir (Norvir, ABT-538)</b></a> <br>inhibidores de proteasa de Abbott</font><br> <font size=-2><i>&Uacute;ltima revisi&oacute;n: 26/5/96</i></font></td>
<p>
<td align=center><font size=-1><a href="simple/saquin.html"><b>saquinavir (Invirase)</b></a> <br>inhibidores de proteasa de Hoffman-LaRoche</font> <br><font size=-2><i>&Uacute;ltima revisi&oacute;n: 26/5/96</i></font></TD>
<p>
<td align=center width=33%><a href="simple/combo.html"><font size=-1><b>terapia combinada</b></a></font> <br><font size=-2><i>&Uacute;ltima revisi&oacute;n: 26/4/96</i></font></td>
<p>
</tr><tr valign=top>
<td align=center><font size=-1><a href="simple/talid.html"><b>talidomida</b></a></font> <br><font size=-2><i>&Uacute;ltima revisi&oacute;n: 26/4/96</i></font></td>
<td><br></td><td><br></td>
</tr>
</TABLE></CENTER>

<HR align=center size=3 width=50%>

<h2 align=center><a href="programa.html">Programas de Acceso Extendido</a></h2>

<h2 align=center><a href="glosmed.html">Glosario de Medicamentos</a> <font size=-1><i>(50K)</i></font></h2>

<h2 align=center><a href="glosterm.html">Glosario de T&eacute;rminos</a> <font size=-1><i>(57K)</i></font></h2>

<hr size=3 width=50% align=center>

<p align=center><A HREF="../index.html"><img align=middle hspace=5 src="../gifs/return.gif" alt=" ">Para ir al &iacute;ndice del Network</A></p>

<HR align=center size=3 width=50%>

<ADDRESS>
<P><FONT SIZE="-1"><img align=left src="../gifs/logo.gif" alt="[logo]">&Uacute;ltima revisi&oacute;n: 3/7/96<BR>
The Network <A HREF="mailto:atdn@aidsnyc.org">atdn@naidsnyc.org</A><BR>
copyright &#169; 1996 The Network</FONT></P>
</ADDRESS>

</body>
</html>



</DOC>
<DOC>
<DOCNO>WT18-B31-239</DOCNO>
<DOCOLDNO>IA093-001002-B001-317</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/trials.html 199.29.141.24 19970121122557 text/html 3498
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:20:04 GMT
Server: NCSA/1.5.1
Last-modified: Thu, 16 Jan 1997 01:34:17 GMT
Content-type: text/html
Content-length: 3315
</DOCHDR>
<html>
<head>
<title>The Network: trials for CMV</title>
</head>
<body bgcolor="#ffffff" link="#00688b" vlink="#545454"><font face="century gothic, arial, helvetica" size=-1>

<blockquote>

<h2 align=center><a href="index.html">AIDS Treatment Data Network</a></h2>
<h2 align=center>Clinical Trials</h2>

<p align=center>Clinical trials are the way drugs are tested to see if they're safe and if they work. Clinical trials happen in several stages, or Phases. Phase I trials are done in a small number of people to make sure the drug is safe. Phase II trials are done in a larger number of people to see if the drug works. Phase III trials are done in a still larger group of people to continue to examine whether the drug is safe, what side effects it may have, and how well it works</p>

<P align=center>All clinical trials have inclusion and exclusion criteria. Inclusions are the things you must have in order to take part in the trial. Exclusions are the things you cannot have if you want to take part in the trial.</p>

<HR SIZE=3 WIDTH=50% ALIGN=CENTER noshade>

<p align=center><a href="shouldi.html"><b>Should I Join an AIDS Drug Trial?</b></A><font size=-2> (38K)</FONT></p>

<p align=center>This handbook describes the clinical trial process and lists many questions you might want to ask before joining a clinical trial. We will be happy to mail you the printed handbook as well as the Experimental Treatment Guide if you fill out the attached <A HREF="member.html">form</A> and send it back to us. <A HREF="shouldi.zip">Zipped version</A> for downloading.</p>

</blockquote>

<HR SIZE=3 WIDTH=50% ALIGN=CENTER noshade>

<p align=center><A HREF="trials/hiv.html"><b>trials of drugs to treat HIV</b></A><br><font size=-2> (updated 1/15/97)</font></p>

<p align=center><A HREF="trials/ois.html"><b>trials of drugs to treat opportunistic infections</b></A><br><font size=-2> (updated 12/22/96)</font></p>

<p align=center><A HREF="trials/children.html"><b>trials of drugs for treating children</b></A><br><font size=-2> (updated 1/15/97)</font></p>

<p align=center><A HREF="trials/women.html"><b>trials of drugs for treating pregnant women</b></A><br><font size=-2> (updated 10/6/95)</font></p>

<p align=center><A HREF="trials/info.html"><b>information gathering studies</b></A><br><font size=-2> (updated 12/2/96)</font></p>

<p align=center><A HREF="trials/vaccines.html"><b>vaccine trials</b></A><br>for HIV-negative and HIV+ participants<br><font size=-2> (updated 12/11/96)</font></p>

<HR SIZE=3 WIDTH=50% ALIGN=CENTER noshade>

<p align=center><a href="access/ind.html"><b>expanded access and compassionate use programs</b></a><br><font size=-2> (updated 1/15/97)</font></p>

<p align=center><a href="access/pa.html"><b>patient assistant programs</b></a><br><font size=-2> (updated 10/19/96)</font></p>

<p align=center><a href="phs/table.html"><b>PHS guidelines for prevention of opportunistic infections</b></a></p>

<HR SIZE=3 WIDTH=50% ALIGN=CENTER noshade>

<P ALIGN=CENTER><A HREF="index.html"><img src="gifs/return.gif" alt="[arrow]" hspace=5><br>to Network home page</A></P>

<hr size=3 align=center width=50% noshade>

<P align=center>Last modified: 1/15/97<BR>
<A HREF="mailto:atdn@aidsnyc.org">atdn@aidsnyc.org</A><BR>
copyright &#169; 1996 1997The Network</P>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-240</DOCNO>
<DOCOLDNO>IA093-001002-B001-338</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/access/index.html 199.29.141.24 19970121122624 text/html 7553
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:20:28 GMT
Server: NCSA/1.5.1
Last-modified: Thu, 16 Jan 1997 01:35:00 GMT
Content-type: text/html
Content-length: 7370
</DOCHDR>
<META  name="description" 
content="Access to AIDS drugs through pharmaceutical and government programs.">
<META  name="keywords" content="aids, drugs, compassionate use, expanded access, Medicaid, ADAP, investigational new drug">
<html>
<head>
<title>The Access Project</title>
</head>

<body bgcolor="#FFFFE8" text="#000000"><font size=-1 face="helvetica, arial">

<p align=center><img src="../gifs/access.gif" alt="[logo]"></p>

<h3 align=center>Accessing AIDS/HIV Treatments Nationwide<br> 
(800) 734-7104</h3>

<blockquote>

<p>The Access Project is an information clearinghouse. We collect and distribute information about medications available for HIV and AIDS through Medicaid, AIDS Drug Assistance Programs (ADAPs), and national pharmaceutical industry patient assistance/expanded access programs.</p>

<p>Programs are listed by state. The Access Project has information and contact numbers for all 50 states and the territories. Information includes: point of contact, eligibility &amp; pharmacies, medical criteria/dosages, care consortiums, which drugs are covered, and nutrition &amp; vitamins. States will be added to this Web site regularly. <font size=-2>(updated 10/26/96)</font></p>

<center><table width="90%" colspecs="20% 20% 20% 20% 20%">
<tr>
<td align=center bgcolor="#cdcdcd" width="20%"><font face="helvetica, arial" size=-1><a href="states/al/al.html"><b>Alabama</b></a></font></td>
<td align=center bgcolor="#eaeaae" width="20%"><font face="helvetica, arial" size=-1><a href="states/ak/ak.html"><b>Alaska</b></a></font></td>
<td align=center bgcolor="#cdcdcd" width="20%"><font face="helvetica, arial" size=-1><a href="states/as/medicaid.html"><b>American Samoa</b></a></font></td>
<td align=center bgcolor="#eaeaae" width="20%"><font face="helvetica, arial" size=-1><a href="states/az/az.html"><b>Arizona</b></a></font></td>
<td align=center bgcolor="#cdcdcd" width="20%"><font face="helvetica, arial" size=-1><a href="states/ca/ca.html"><b>California</b></a></font></td>
</tr><p><tr valign=top>
<td align=center bgcolor="#eaeaae"><font face="helvetica, arial" size=-1><a href="states/co/co.html"><b>Colorado</b></a></font></td>
<td align=center bgcolor="#cdcdcd"><font face="helvetica, arial" size=-1><a href="states/ct/ct.html"><b>Connecticut</b></a></font></td>
<td align=center bgcolor="#eaeaae"><font face="helvetica, arial" size=-1><a href="states/de/de.html"><b>Delaware</b></a></font></td>
<td align=center bgcolor="#cdcdcd"><font face="helvetica, arial" size=-1><a href="states/fl/fl.html"><b>Florida</b></a></font></td>
<td align=center bgcolor="#eaeaae"><font face="helvetica, arial" size=-1><a href="states/ga/ga.html"><b>Georgia</b></a></font></td>
</tr><p><tr valign=top>
<td align=center bgcolor="#cdcdcd"><font face="helvetica, arial" size=-1><a href="states/gu/gu.html"><b>Guam</b></a></font></td>
<td align=center bgcolor="#eaeaae"><font face="helvetica, arial" size=-1><a href="states/hi/hi.html"><b>Hawaii</b></a></font></td>
<td align=center bgcolor="#cdcdcd"><font face="helvetica, arial" size=-1><a href="states/id/id.html"><b>Idaho</b></a></font></td>
<td align=center bgcolor="#eaeaae"><font face="helvetica, arial" size=-1><a href="states/il/il.html"><b>Illinois</b></a></font></td>
<td align=center bgcolor="#cdcdcd"><font face="helvetica, arial" size=-1><a href="states/in/in.html"><b>Indiana</b></a></font></td>
</tr><p><tr valign=top>
<td align=center bgcolor="#eaeaae"><font face="helvetica, arial" size=-1><a href="states/ma/ma.html"><b>Massachusetts</b></a></font></td>
<td align=center bgcolor="#cdcdcd"><font face="helvetica, arial" size=-1><a href="states/md/md.html"><b>Maryland</b></a></font></td>
<td align=center bgcolor="#eaeaae"><font face="helvetica, arial" size=-1><a href="states/nj/nj.html"><b>New Jersey</b></a></font></td>
<td align=center bgcolor="#cdcdcd"><font face="helvetica, arial" size=-1><a href="states/ny/ny.html"><b>New York</b></a></font></td>
<td align=center bgcolor="#eaeaae"><font face="helvetica, arial" size=-1><a href="states/pa/pa.html"><b>Pennsylvania</b></a></font></td>
</tr><p><tr valign=top>
<td align=center bgcolor="#cdcdcd"><font face="helvetica, arial" size=-1><a href="states/tx/tx.html"><b>Texas</b></a></font></td>
<td align=center bgcolor="#eaeaae"><font face="helvetica, arial" size=-1><a href="states/dc/dc.html"><b>Washington DC</b></a></font></td>
<td align=center bgcolor="#cdcdcd"><font face="helvetica, arial" size=-1><a href="states/wa/wa.html"><b>Washington</b></a></font></td>
<td bgcolor="#eaeaae">&nbsp;</td><td bgcolor="#cdcdcd">&nbsp;</td>
</tr>
</table></center>

<p align=center><b><a href="states/ny/drugs.html">New York State ADAP formulary</a> and <a href="states/ny/nutrit.html">nutrition supplements</a> restored as of December 1, 1996</b></p>

<HR size=3 noshade width=50% align=center>

<p><a href="drugs/index.html"><font size=3><b>Drug Index</b></font></a>: Descriptions of drugs, including side effects, dosages and managing side effects, for treatments included in ADAP programs. <font size=-2>(updated 11/22/96)</font></p>

<p><a href="ind.html"><font size=3><b>Expanded Access and Compassionate Use Programs</b></font></a>: Drug companies sometimes make treatments available through special programs for people who have no other alternatives. <font size=-2>(Updated 1/15/97)</font></p>

<p><a href="pa.html"><font size=3><b>Patient Assistance Programs</b></font></a>: Programs that help people without government or private insurance afford necessary treatments. <font size=-2>(Updated 10/19/96)</font></p>

<p><a href="poverty.html"><font size=3><b>Federal poverty guidelines</b></font></a>: Federally defined income levels according to number of people in family. <font size=-2>(Updated 4/17/96 to current levels as of 4/1/96)</font></p>

<HR size=3 noshade width=50% align=center>

<p><a href="http://www.hcfa.gov/medicaid/medicaid.htm"><font size=3><b>General information about Medicaid</b>:</font></a> <font size=-1>from the Health Care Financing Administration, the Medicaid/Medicare Agency.</font> <font size=-2>(added 9/10/96)</font></p>

<HR size=3 noshade width=50% align=center>

<h4><a href="report.html">The Access Project Report</a> <font size=-1><i>(49K)</i></font></h4>

<p>This report summarizes the findings of the Access Project. Also available in a <a href="report.zip">zipped version</a> for downloading and reading offline. The text has been zipped in word processing format (Microsoft Word 6.0) rather than ascii text in order to preserve footnote and table formatting. Send <a href="mailto:atdn@nyam.org">e-mail</a> or call (800) 734-7104 if you would like to receive a copy by mail.</p>

<p>We would like to hear from you. Did you find this site useful? Did you find the information you were looking for? Is there more you would like to see here? Send us a <A HREF="mailto:atdn@nyam.org">note</a> or call (800) 734-7104.

<HR size=3 noshade width=50% align=center>

</blockquote>

<p align=center><a href="../index.html"><img hspace=5 alt=" " vspace=5 src="../gifs/return.gif"><br>To Network home page</a></p>

<HR size=3 noshade width=50% align=center>

<p><font size=-2><img hspace=5 align=left src="../gifs/logo.gif" alt="[logo]">Last modified: 1/15/97<br>
The Network <a href="mailto:atdn@aidsnyc.org">atdn@aidsnyc.org</a><br>
copyright &#169; 1996 1997 The Network</font></p>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-241</DOCNO>
<DOCOLDNO>IA093-001002-B002-274</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/access/drugs/index.html 199.29.141.24 19970121123122 text/html 18960
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:25:27 GMT
Server: NCSA/1.5.1
Last-modified: Fri, 17 Jan 1997 20:27:11 GMT
Content-type: text/html
Content-length: 18776
</DOCHDR>
<html>
<head>
<title>ADAP drugs</title>
</head>

<body bgcolor="#FFFFE8" text="#000000"><font face="arial, helvetica" size=-1>

<p align=center><img src="../../gifs/access.gif" alt="[logo]"></p>

<h1 align=center>Index of ADAP drugs</h1>

<p>Drugs are listed in alphabetical order by generic name. Brand names are also listed, so if you don't know the generic name, use the search function on your browser to find what you're looking for, i.e. brand name <a href="#atov">Mepron</a> is listed next to generic name <a href="#atov">atovaquone</a>.</p>

<center><table border=1 width=90%>
<tr>
<th>Drug name</th>
<th>Patient assistance</th>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="acyc.html">acyclovir</a> (Zovirax)</font></td>
<td align=center><font face="arial, helvetica" size=-1><a href="../pa/acyc.html">Yes</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="alph.html">alpha interferon</a> (Intron, Roferon)</font></td>
<td align=center><font face="arial, helvetica" size=-1><a href="../pa/alph-i.html">Intron</a>, <a href="../pa/alph-r.html">Roferon</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="amik.html">amikacin</a> (Amikin)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="amph.html">amphotericin B</a> (Fungizone)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="atov.html">atovaquone</a> <a name="atov">(Mepron)</a></font></td>
<td align=center><font face="arial, helvetica" size=-1><a href="../pa/atov.html">Yes</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="azit.html">azithromycin</a> (Zithromax)</font></td>
<td align=center><font face="arial, helvetica" size=-1><a href="../pa/azit.html">Yes</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="bleo.html">bleomycin</a> (Blenoxane)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="capr.html">capreomycin </a>(Capastat)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="cido.html">cidofovir</a> (Vistide, HPMPC)</font></td>
<td align=center><font face="arial, helvetica" size=-1><a href="../pa/cido.html">Yes</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="cipr.html">ciprofloxacin</a> (Cipro)</font></td>
<td align=center><font face="arial, helvetica" size=-1><a href="../pa/cipr.html">Yes</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="clar.html">clarithromycin</a> (Biaxin)</font></td>
<td align=center><font face="arial, helvetica" size=-1><a href="../pa/clar.html">Yes</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="clin.html">clindamycin</a> (Cleocin)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="clof.html">clofazimine</a> (Lamprene)</font></td>
<td align=center><font face="arial, helvetica" size=-1><a href="../pa/clof.html">Yes</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="clot.html">clotrimazole</a> (Gyne-Lotrimin, Lotrimin, Mycelex)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="cyclop.html">cyclophosphamide</a> (Cytoxan, Neosar)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="cyclos.html">cycloserine</a> (Seromycin)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="cypr.html">cyproheptadine hydrochloride</a> (Periactin)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="cyta.html">cytarabine </a> (Ara-C, cytosine arabinoside, Cytosar-U, Tarabine PFS)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="daps.html">dapsone </a>(DDS)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="dexa.html">dexamethasone </a>(Ak-Dex, Dalalone, Decadrol, Decadron, Decaject, Decameth, Dexacen, Dexasone, Dexon, Hexadrol, Mymethsone, Oradexon, Solurex)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="dida.html">didanosine </a>(ddI) <font size=-2>(updated 6/27/96)</font></td>
<td align=center><font face="arial, helvetica" size=-1><a href="../pa/dida.html">Yes</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="doxo.html">doxorubicin </a>(Adriamycin)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="dron.html">dronabinol </a>(Marinol)</font></td>
<td align=center><font face="arial, helvetica" size=-1><a href="../pa/dron.html">Yes</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="eryt.html">erythropoeitin</a> (EPO, Epogen, Eprex, Procrit, epoetin alfa)</font></td>
<td align=center><font face="arial, helvetica" size=-1><a href="../pa/eryt.html">Yes</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="etha.html">ethambutol</a> (Myambutol)</font></td>
<td align=center><font face="arial, helvetica" size=-1><a href="../pa/etha.html">Yes</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="ethi.html">ethionamide</a> (Trecator SC)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="etop.html">etoposide</a> (VP-16, Vepesid)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="filg.html">filgrastim</a> (G-CSF, Neupogen)</font></td>
<td align=center><font face="arial, helvetica" size=-1><a href="../pa/filg.html">Yes</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="fluc.html">fluconazole</a> (Diflucan)</font></td>
<td align=center><font face="arial, helvetica" size=-1><a href="../pa/fluc.html">Yes</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="flucy.html">flucytosine</a> (Ancobon, 5FC)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="fosc.html">foscarnet</a> (Foscavir, trisodium phosphonoformate)</font></td>
<td align=center><font face="arial, helvetica" size=-1><a href="../pa/fosc.html">Yes</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="ganc.html">ganciclovir</a> (Cytovene, DHPG)</font></td>
<td align=center><font face="arial, helvetica" size=-1><a href="../pa/ganc.html">Yes</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="../../simple/implants.html">ganciclovir implants</a> (Vitrasert)</font></td>
<td align=center><font face="arial, helvetica" size=-1><a href="../pa/gan-i.html">Yes</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="indi.html">indinavir</a> (Crixivan)</font> <font size=-2>(updated 11/22/96)</font></td>
<td align=center><font face="arial, helvetica" size=-1><a href="../pa/indi.html">Yes</a></font></td>
</tr>
<p>
<td align=center><font face="arial, helvetica" size=-1><a href="ison.html">isoniazid</a> (INH, Lanizid, Nydrazid)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="itra.html">itraconazole</a> (Sporonox)<br><font size=-1>(modified 10/19/96)</font></td>
<td align=center><font face="arial, helvetica" size=-1><a href="../pa/itra.html">Yes</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="ivig.html">IVIG</a> (Gamma globulin, immune globulin, <br>intravenous immunoglobulin, Gammagard)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="kana.html">kanamycin</a> (Kantrex)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="keto.html">ketoconazole</a> (Nizoral)</font></td>
<td align=center><font face="arial, helvetica" size=-1><a href="../pa/keto.html">Yes</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="lami.html">lamivudine</a> (Epivir, 3TC)</font></td><td align=center><font face="arial, helvetica" size=-1><a href="../pa/lami.html">Yes</a></font></td>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="leuc.html">leucovorin</a> Citrovorum, Wellcovorin, folinic acid)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1>lomustine (CCNU, CeeNU)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="mege.html">megestrol acetate </a> (Megace)</font></td>
<td align=center><font face="arial, helvetica" size=-1><a href="../pa/mege.html">Yes</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="meth.html">methotrexate</a> (Amethopetrin, Folex, Folex PFS)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="metr.html">metronidazole</a> (Flagyl, Metryl, Protostat, Satric, Neo-Tric)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="nyst.html">nystatin</a> (Mycostatin, Mykinac, Nilstat, Nystex, O-V Statin)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="octr.html">octreotide acetate</a> (Sandostatin)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</font></td>
</tr>
<p><tr>
<td align=center><font face="arial, helvetica" size=-1><a href="oflo.html">ofloxacin</a> (Floxin)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="para.html">para aminosalicyclic acid</a> (PAS)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="paro.html">paromomycin</a> (Humatin)</font></td>
<td align=center><font face="arial, helvetica" size=-1><a href="../pa/paro.html">Yes</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="pent.html">pentamidine</a> (aerosolized pentamidine, Nebupent, Pentam)</font></td>
<td align=center><font face="arial, helvetica" size=-1><a href="../pa/pent.html">Yes</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="pento.html">pentoxifyllline</a> (Trental)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="pred.html">prednisone</a> (Deltasone, Liquid Pred, Metocorten, Orasone, Panasol, Prednicen-M, Sterapred)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="prim.html">primaquine</a> (Primaquine Phosphate)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="proc.html">procarbazine</a> (Matulane)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="pyra.html">pyrazinamide</a> (PZA)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="pyri.html">pyrimethamine</a> (Daraprim, Fansidar)</font></td>
<td align=center><font face="arial, helvetica" size=-1><a href="../pa/pyri.html">Yes</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="rifa.html">rifabutin</a> (Ansamycin, Mycobutin)</font></td>
<td align=center><font face="arial, helvetica" size=-1><a href="../pa/rifa.html">Yes</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="rifam.html">rifampin</a> (RIF, Rifampicin, Rifadin, Rimactane)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="rito.html">ritonavir</a> (Norvir)</font></td>
<td align=center><font face="arial, helvetica" size=-1><a href="../pa/rito.html">Yes</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="saqu.html">saquinavir</a> (Invirase)</font></td>
<td align=center><font face="arial, helvetica" size=-1><a href="../pa/saqu.html">Yes</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="sarg.html">sargramostim</a>(Leukine, Prokine, GM-CSF)</font></td>
<td align=center><font face="arial, helvetica" size=-1><a href="../pa/sarg.html">Yes</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="stav.html">stavudine</a>(d4T, Zerit)</font></td>
<td align=center><font face="arial, helvetica" size=-1><a href="../pa/stav.html">Yes</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="stre.html">streptomycin</a> (Streptomycin sulfate)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="sulf.html">sulfadiazine</a> (Microsulfon)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="sulfa.html">sulfadoxine</a> (Fansidar)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="sulfam.html">sulfamethazine</a> (Triple Sulfa, Dayto Sulf, Gyne-Sulf, Sultrin, Trysul, VVS)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="sulfame.html">sulfamethoxazole</a> (Gantanol, Urobak)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="trim.html">trimethoprim</a> (Proloprim, Trimpex)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="tmp.html">TMP/SMX</a> (Bactrim, Septra)</font></td>
<td align=center><font face="arial, helvetica" size=-1><a href="../pa/tmp-b.html">Bactrim</a>, <a href="../pa/tmp-s.html">Septra</a></a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="trip.html">triple sulfa</a> (Dayto Sulf, Gyne-Sulf, Sultrin, Trysul, VVS)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="vinb.html">vinblastine</a> (Velban, Velsar)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="vinc.html">vincristine</a> (Oncovin, Vincasar PES, Vincrex)</font></td>
<td align=center><font face="arial, helvetica" size=-1>No</a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="zalc.html">zalcitabine</a> (ddC, Hivid, dideoxycytidine)</font></td>
<td align=center><font face="arial, helvetica" size=-1><a href="../pa/zalc.html">Yes</a></a></font></td>
</tr>
<p>
<tr>
<td align=center><font face="arial, helvetica" size=-1><a href="zido.html">zidovudine</a> (AZT, ZDV, Retrovir)</font></td>
<td align=center><font face="arial, helvetica" size=-1><a href="../pa/zido.html">Yes</a></a></font></td>
</tr>
<p>
</table>
</center>

<hr size=3 noshade width=50% align=center>

<h5>The drug descriptions on these pages are intended for informational purposes only. The Network does not promote or endorse the use of any specific treatment for any health-related condition. The medications described here can only be dispensed by a licensed health care professional. The information may have changed since these pages were updated, though every effort is made to keep these pages current. Please contact The Network at (800) 734-7104 to make sure you have the most up-to-date information.</h5>

<hr size=3 noshade width=50% align=center>

<p align=center><a href="../index.html"><img hspace=5 alt=" " align=middle src="../../gifs/return.gif">To Access Project home page</a></p>

<HR size=3 noshade width=50% align=center>

<P><FONT SIZE=-2><img hspace=5 align=left src="../../gifs/logo.gif" alt="[logo]">Last modified: 11/22/96<BR>
The Network <A HREF="mailto:atdn@nyam.org">atdn@nyam.org</A><BR>
copyright &#169; 1996 The Network</font></P>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-242</DOCNO>
<DOCOLDNO>IA093-001002-B002-292</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/access/states/ny/drugs.html 199.29.141.24 19970121123133 text/html 180
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:25:39 GMT
Server: NCSA/1.5.1
Last-modified: Fri, 17 Jan 1997 20:14:46 GMT
Content-type: text/html
Content-length: 0
</DOCHDR>
</DOC>
<DOC>
<DOCNO>WT18-B31-243</DOCNO>
<DOCOLDNO>IA093-001002-B002-310</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/access/states/ny/nutrit.html 199.29.141.24 19970121123148 text/html 3597
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:25:52 GMT
Server: NCSA/1.5.1
Last-modified: Mon, 25 Nov 1996 18:17:26 GMT
Content-type: text/html
Content-length: 3414
</DOCHDR>
<html>
<head>
<title>NY: nutrition component</title>
</head>

<body bgcolor="#FFFFE8" text="#000000">

<p align=center><a href="../../index.html"><img src="../../../gifs/access.gif" alt="[The Access Project]"></a></p>

<a href="ny.html"><h2 align=center>New York State</h2></a>
<h1 align=center>Nutrition and Vitamins</h1>

<center><table border=1 width=90% colspec="33% 33% 33%">
<tr>
<th colspan=3>Supplements available:</th>
</tr><p><tr valign=top>
<td align=center width="33%">Multiple Vitamins and Minerals</td>
<td align=center width="33%">Beta Carotene</td>
<td align=center width="33%">Vitamin B6 (Pyridoxine)</td>
</tr><p><tr valign=top>
<td align=center>Vitamin B12 (sublingual)</td>
<td align=center>Vitamin B12 (intramuscular)</td>
<td align=center>Vitamin C (ascorbic acid)</td>
</tr><p><tr valign=top>
<td align=center>Folate</td>
<td align=center>Folinic Acid (leucovorin)</td>
<td align=center>Iron</td>
</tr><p><tr valign=top>
<td align=center>Lactaid</td>
<td align=center>Magnesium Glutamate</td>
<td align=center>Selenium</td>
</tr><p><tr valign=top>
<td align=center>Zinc</td>
<td align=center>Ensure</td>
<td align=center>Ensure Plus</td>
</tr><p><tr valign=top>
<td align=center>Ensure with fiber</td>
<td align=center>Resource</td>
<td align=center>Resource Plus</td>
</tr><p><tr valign=top>
<td align=center>Sustacal</td>
<td align=center>Nutren</td>
<td align=center>Nutrement</td>
</tr><p><tr valign=top>
<td align=center>Carnation Instant Breakfast</td>
<td align=center>Meritene</td>
<td align=center>CitriSource</td>
</tr><p><tr valign=top>
<td align=center>Glucerna</td>
<td align=center>Advera</td>
<td align=center>Suplena</td>
</tr><p><tr valign=top>
<td align=center>Nepro</td>
<td align=center>Vivonex</td>
<td align=center>Lipisorb</td>
</tr><p><tr valign=top>
<td align=center>Peptamen</td>
<td align=center>Opti</td>
<td align=center>Pediasure</td>
<td><br></td>
</tr>
</table></center>

<h3 align=center>Nutrition notes:</h3>

<ul>
<li>Nutritional assessment and counseling available.
<li>For people with symptomatic HIV disease or AIDS 12 visits per year are allowed. For asymptomatic people with HIV, 4 visits a year are allowed.
<li>Maximum oral nutritional supplement allowance is 32 oz./day.
</ul>


<center><table border=0>
<tr>
<td align=center><a href="pharm.html"><img hspace=5 alt="[Eligibility & Pharmacies]" src="../../../gifs/elig.gif"></a> <a href="pharm.html#dose"><img hspace=5 alt="[Medical Criteria/Dosages]" src="../../../gifs/med.gif"></a> <a href="care.html"><img hspace=5 alt="[Care Consortiums]" src="../../../gifs/care.gif"></a> <a href="drugs.html"><img hspace=5 alt="[Which drugs are covered?]" src="../../../gifs/drugs.gif"></a> <a href="nutrit.html"><img hspace=5 alt="[Nutrition & Vitamins]" src="../../../gifs/nutrit.gif"></a></td>
</tr>
<p>
</table></center>

<HR size=3 width=50% align=center noshade>

<p align=center><a href="ny.html"><img hspace=5 alt=" " align=middle src="../../../gifs/left.gif">To NY State Contact page</a><a href="../../index.html"><img hspace=5 alt=" " align=middle src="../../../gifs/return.gif">To Access Project home page</a></p>

<HR size=3 width=50% align=center noshade>

<P><FONT SIZE=-2><img hspace=5 align=left src="../../../gifs/logo.gif" alt="[logo]">Last modified: 11/26/96<BR>
The Network <A HREF="mailto:atdn@nyam.org">atdn@nyam.org</A><BR>
copyright &#169; 1996 The Network</FONT></P>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-244</DOCNO>
<DOCOLDNO>IA093-001002-B002-330</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/sf.html 199.29.141.24 19970121123159 text/html 9361
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:26:05 GMT
Server: NCSA/1.5.1
Last-modified: Mon, 20 Jan 1997 18:53:00 GMT
Content-type: text/html
Content-length: 9178
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Simple Facts Sheets</TITLE>
</HEAD>
<BODY bgcolor=#ffffff><font face="helvetica, arial" size="-1">

<H2 align=center>Simple Facts Sheets</H2>

<p align=center>One page descriptions of treatments and conditions from <A HREF="index.html">The Network</A></p>

<center><table border=1 width=90% colspecs="33%, 33%, 33%"><tr>
<td colspan=3><font face="arial, helvetica" size="-1"><b>TREATMENTS</b></font></td>
<p>
</tr><tr valign=top>
<td width=33%><font face="arial, helvetica" size="-1"><b><A HREF="simple/three.html">3TC (lamivudine, Epivir)</b></A> <br>an antiretroviral in the same class of drugs as AZT</font> <br><font size="-2">(updated 8/21/96)</font></td>
<p>
<td width=33%><font face="arial, helvetica" size="-1"><b><A HREF="simple/steroids.html">anabolic steroids</a></b> <br>sythetic versions of a naturally occurring hormone used to treat weight loss</font> <br><font size="-2">(updated 8/27/96)</font></td>
<p>
<td width=33%><font face="arial, helvetica" size="-1"><b><a href="simple/cido.html">cidofovir (Vistide, HPMPC)</a></b><br>newly approved intravenous treatment for CMV retinitis</font><br><font size="-2">(updated 9/30/96)</font></td>
<p>
</tr><tr valign=top>
<td width=33%><font face="arial, helvetica" size="-1"><b><A HREF="simple/combo.html">combination therapy</a></b> <br><font face="arial, helvetica" size="-1">information from clinical trials about combination therapy with AZT, ddI and ddC, and protease inhibitors</font> <br><font size="-2">(updated 8/1/96)</font></td>
<p>
<td><font face="arial, helvetica" size="-1"><b><a href="simple/dida.html">didanosine (ddI, Videx)</a></b> <br>a nucleoside reverse transcriptase inhibitor</font> <br><font size="-2">(updated 6/27/96)</font></td>
<p>
<td><font face="arial, helvetica" size="-1"><b><a href="simple/dela.html">delavirdine (Rescriptor)</a></b><br>a non-nucleoside reverse transcriptase inhibitor</a></b></font><br><font size="-2">(updated 9/2/96)</font></td>
<p>
</tr><tr valign=top>
<td><font face="arial, helvetica" size="-1"><b><a href="simple/doxil.html">DOXIL</a></b> <br>a liposomal version of the anti-cancer drug doxorubacin for treating KS</font> <br><font size="-2">(added 12/5/95)</font></td>
<p>
<td><font face="arial, helvetica" size="-1"><b><A HREF="simple/stav.html">d4T (stavudine, Zerit)</a></b> <br>an antiretroviral in the same class of drugs as AZT, approved for people who can't take AZT</font> <br><font size="-2">(updated 9/6/96)</font></td>
<p>
<td><font face="arial, helvetica" size="-1"><b><A HREF="simple/implants.html">ganciclovir implants</a></b> <br>a treatment for CMV infection that is only in the eye</font><br><font size="-2">(updated 3/10/96)</font></td>
<p>
</tr><tr valign=top>
<td><font face="arial, helvetica" size="-1"><b><A HREF="simple/hyperth.html">hyperthermia</a></b> <br>an experimental treatment that involves heating the blood</font></td>
<p>
<td><font face="arial, helvetica" size="-1"><b><A HREF="simple/iltwo.html">IL-2</a></b> <br>a synthetic version of a naturally occuring messenger of the immune system, in studies as a treatment for HIV infection and KS</font> <br><font size="-2">(updated 11/13/96)</font></td>
<p>
<td><font face="arial, helvetica" size="-1"><b><a href="simple/indi.html">indinavir (Crixivan)</a></b> <br>protease inhibitor made by Merck</font> <br><font size="-2">(updated 11/22/96)</font></td>
<p>
</tr><tr valign=top>
<td><font face="arial, helvetica" size="-1"><b><a href="simple/daun.html">liposomal daunorubicin (DaunoXome)</a></b><br>newly approved treatment for KS</font> <br><font size="-2">(updated 5/8/96)</font></td>
<p>
<td><font face="arial, helvetica" size="-1"><b><a href="simple/nevi.html">nevirapine (Viramune)</a></b> <br>non-nucleoside reverse transcriptase inhibitor recently approved</font> <br><font size="-2">(updated 8/27/96)</font></td>
<p>
<td><font face="arial, helvetica" size="-1"><b><A HREF="simple/nnrtis.html">NNRTIs</a></b> <br><font size=2>non-nucleoside reverse transcriptase inhibitors, which work differently than the class <br>of drugs that includes AZT,  includes nevirapine and delavirdine <br><font size="-2">(updated 3/26/96)</font></td>
<p>
</tr><tr valign=top>
<td><font face="arial, helvetica" size="-1"><b><A HREF="simple/cytovene.html">oral ganciclovir</a></b> <br>pill form of the drug used to treat CMV</font> <br><font size="-2">(updated 7/2/96)</font></td>
<p>
<td><font face="arial, helvetica" size="-1"><b><A HREF="simple/passimm.html">passive immunotherapy</a></b> <br>an experimental form of treatment using blood with high levels of HIV antibodies</font></td>
<p>
<td><font face="arial, helvetica" size="-1"><b><A HREF="simple/protease.html">protease inhibitors</a></b> <br>a newer class of drugs being developed and studied by several drug companies</font> <br><font size="-2">(updated 8/1/96)</font></td>
<p>
</tr><tr valign=top>
<td><font face="arial, helvetica" size="-1"><b><a href="simple/riton.html">ritonavir (Norvir)</a></b> <br>Abbott's protease inhibitor, approved 3/1/96. See also <a href="simple/abbott.html">Letter from Abbott</a> sent to doctors 4/5/96 and <a href="../pwahg/info/norvir.html">Norvir dosing-up schedule</a></font> <br><font size="-2">(modified 5/25/96)</font></td>
<p>
<td><font face="arial, helvetica" size="-1"><b><a href="simple/saquin.html">saquinavir (Invirase)</a></b> <br>the protease inhibitor made by Hoffman LaRoche. Approved for prescription</font> <br><font size="-2">(updated 5/21/96)</font></td>
<p>
<td><font face="arial, helvetica" size="-1"><b><A HREF="simple/thalid.html">thalidomide</a></b> <br>a drug being studied for treating wasting and HIV infection. Used to treat aphthous ulcers</font></td>
</tr><tr valign=top>
<p>
<td><font face="arial, helvetica" size="-1"><b><a href="simple/zalc.html">zalcitabine (ddC, Hivid)</a></b> <br>a nucleoside reverse transcriptase inhibitor</font> <br><font size="-2">(added 3/10/96)</font></td>
<p>
<td><font face="arial, helvetica" size="-1"><b><a href="simple/zido.html">zidovudine (AZT, Retrovir)</a></b> <br>the first approved nucleoside reverse transcriptase inhibitor</font> <br><font size="-2">(added 3/10/96)</font></td>
<p>
<td><br></td>
</tr><tr>
<td colspan=3><font face="arial, helvetica" size="-1"><b>TESTS</font></td>
<p>
</tr><tr valign=top>
<td><font face="arial, helvetica" size="-1"><b><a href="simple/viral.html">viral load tests</a></b> <br>new tests for measuring the amount of virus in the blood. Recently FDA approved.</font>
<br><font size="-2">(modified 9/3/96)</font></td>
<p>
<td><br></td><td><br></td>
</tr><tr valign=top>
<td colspan=3><font face="arial, helvetica" size="-1"><b>CONDITIONS</font></td>
<p>
</tr><tr valign=top>
<td><font face="arial, helvetica" size="-1"><b><a href="simple/menin.html">cryptococcal meningitis</a></b> <br>a fungal infection that can cause swelling in the lining of the brain</font> <br><font size="-2">(added 6/10/96) <br><a href="phs/menin.html">PHS Guidelines</a></font></td>
<p>
<td><font face="arial, helvetica" size="-1"><b><A HREF="simple/crypto.html">cryptosporidiosis</a></b> <br>an intestinal infection, new treatments are being studied</font> <br><font size="-2">(modified 2/19/96)
<br><A HREF="phs/crypto.html">PHS Guidelines</A></font></td>
<p>
<td><font face="arial, helvetica" size="-1"><b><a href="simple/cmv.html">cytomegalovirus (CMV)</a></b><br>a viral infection that can cause disease in the eyes and the intestines as well as other parts of the body</font> <br><font size="-2">(updated 7/2/96) <br><a href="phs/cmv.html">PHS Guidelines</a></font></td>
<p>
</tr><tr valign=top>
<td><font face="arial, helvetica" size="-1"><b><A HREF="simple/fungal.html">fungal infections</a></b> <br>thrush and vaginal candidiasis are two kinds of fungal infections that HIV+ people can get</font> <br><font size="-2"><A HREF="phs/candi.html">PHS Guidelines</A></font></td>
<p>
<td><font face="arial, helvetica" size="-1"><b><a href="simple/hiv.html">HIV</a></b> <br>a description of the human immunodeficiency virus</font> <br><font size="-2">(added 12/14/95)</font></td>
<p>
<td><font face="arial, helvetica" size="-1"><b><A HREF="simple/ks.html">Kaposi's sarcoma</a></b> <br>a type of cancer that people with HIV infection can get</font> <br><font size="-2">(modified 4/17/96)</font></td>
<p>
</tr><tr valign=top>
<td><font face="arial, helvetica" size="-1"><b><A HREF="simple/mac.html">MAC</a></b> <br>a bacterial infection, Mycobacterium avium complex</font> <br><font size="-2">(updated 1/20/97) <br>HREF="phs/mac.html">PHS Guidelines</A></font></td>
<p>
<td><font face="arial, helvetica" size="-1"><b><a href="simple/pcp.html">PCP prevention</a></b> <br>pneumocystis carinii pneumonia</font> <br><font size="-2">(added 3/18/96) <br><a href="phs/pcp.html">PHS Guidelines</a></font></td>
<p>
<td><br></td>
</tr>
</table>

<P ALIGN=CENTER><A HREF="index.html"><img src="gifs/return.gif" alt="[arrow]"></p><p align=center>to Network home page</A></P>

<hr size=3 align=center width=50% noshade>

<P align=center><font size="-2">Last modified: 1/20/97<BR>
<A HREF="mailto:atdn@aidsnyc.org">atdn@aidsnyc.org</A><BR>
copyright &#169; 1996 1997 The Network</FONT></P>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-245</DOCNO>
<DOCOLDNO>IA093-001002-B002-345</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/trs/trs.html 199.29.141.24 19970121123208 text/html 8623
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:26:15 GMT
Server: NCSA/1.5.1
Last-modified: Thu, 19 Dec 1996 02:03:13 GMT
Content-type: text/html
Content-length: 8440
</DOCHDR>
<html>
<head>
<title>TR: index to issues </title>
</head>
<BODY bgcolor="#ffffff" link="#00688b" vlink="#545454"><font face="arial, helvetica" size=-1>

<h3 align=center><a href="../index.html">AIDS Treatment Data Network</a></h3>
<h2 align=center>Treatment Review <br><font size=3>index to issues</font></h2>

<blockquote>

<p><font size=3><a href="23.html"><b>Treatment Review #23</b></a></font><br>
Contents: New Ways to Treat HIV, Combination Treatment - Study Results, New York State ADAP Update, Combination Treatment - Other Options, Drugs that don't combine, Treatment Briefs, Drug Glossary and Technical Terms, Network Resources. <a href="zipped/23.zip">Zipped version</a> for downloading. <font size=-2>(added 12/17/96 - 55K)</font></p>

<p><font size=3><a href="22.html"><b>Treatment Review #22</b></a></font><br>
Contents: Protease Inhibitors and Drug Resistance, Community Forums Announced, Paying for Protease Inhibitors, NNRTIs - Another new class of anti-HIV drug, FDA Approves Viral Load Test!, MAC Treatment Warnings, Treatment Briefs. <a href="zipped/22.zip">Zipped version</a> for downloading.</p>

<p><font size=3><b><a href="21.html">Treatment Review #21</a></b></font><br>
Contents: New Treatments Approved, Combination Therapy, Saquinavir Facts Sheet, Ritonavir Facts Sheet, Indinavir Facts Sheet, Viral Load Testing, Treatment Briefs, Resources. <a href="zipped/21.zip">Zipped version</a> for downloading.</p>

<p><font size=3><b><a href="20.html">Treatment Review #20</a></b></font><br>
Contents: Combination Therapy Increases Survival; New Protease Inhibitor Studies; Treatment Briefs: Treatment for weight loss and AIDS? New anti-HIV drug being studie,; New cream for Kaposi's sarcoma, Herpes treatment for Kaposi's sarcoma, Less drug side effects for PCP? CMV drug approved; Young adults survey; Nitazoxanide for cryptosporidiosis, CMV treatment study, Preventing MAC infections increases survival, Protease for Kids! Imiquimod cream for genital warts; CMV drug approved; Network Resources : How to prevent and treat OIs, Spanish and English Internet resources, Eye care forum; About Treatment Review. <a href="zipped/20.zip">Zipped version</a> for downloading.</p>

<p><font size=3><b><A HREF="19.html">Treatment Review #19</a></b></font><br>
Contents: Background on Protease Inhibitors; August 11 Deadline for Protease Inhibitor; Another Protease Inhibitor Option; Treating CMV retinitis; Cidofovir (HPMPC); New Use For Foscarne; Albendazole Correction; $ for Young Adults Study; Dana Consortium; Expanded Access to 3TC; New Spanish language Experimental Treatment Guide; Our Internet Home Page; Good Doctors, Good Patients; Good Results for Stavudine (d4T); About Treatment Review. <a href="zipped/19.zip">Zipped version</a> for downloading.</p>

<p><font size=3><b><A HREF="18.html">Treatment Review #18</a></b></font><br>
Contents: Nutrition Study Pays; Vitamin E Drug; New Protease Inhibitor Studies; What We Know about anti-HIV drugs; Measuring the Virus; Interleukin-2 Studies; Anabolic Steroids; May 17th Meeting; PCP Prevention for Children; 3TC Expanded Access Update; Microsporidiosis; Fungal Infection Overview; For Investigational Use Only; Inflammation. <A HREF="zipped/18.zip">Zipped version</A> for downloading.</P>

<p><font size=3><b><A HREF="17.html">Treatment Review #17</a></b></font><br>
Contents: 3TC and AZT Combination; AZT and Children; New Protease Inhibitor Studies Enrolling; Does a Herpesvirus Cause KS; Asprin Study Stopped; What's in the Water; Oral DHPG for Prevention and Treatment; Herbal Medicines; Considering alternative treatments; Boxwood Study; Treatment Briefs: Foscarnet for KS; Tecogalen or IL-2 for KS; Thalidomide compassionate use; Il-2 for HIV; Studies for sexual or emotional depression; It's Time to Start a Fire by Ken Fornataro. <A HREF="zipped/17.zip">Zipped version</A> for downloading.</P>

<p><font size=3><b><A HREF="16.html">Treatment Review #16</A></b></font><br>
Contents: New information gathering study for KS; Gene transfer trial; Treatment for bowel syndrome; Your eyes and HIV; New drug for CMV in trials; Good results from eye implant study; Treatment for retinal detachments; Oral ganciclovir approved; Oral ganciclovir for maintenance; One person's story; Salasalate for HIV; Protein diet study; Nursing researchers and students; Network information. <A HREF="zipped/16.zip">Zipped version</A> for downloading.</P>

<p><font size=3><b><A HREF="15.html">Treatment Review #15</A></b></font><br>
Contents: MAC treatment and prevention; Human growth hormone; Chronic diarrhea; Flu shots; molluscum; Treatment for detached retinas; Sulfasalazine for HIV: possible anti-HIV treatment; Treatment at home; Information gathering studies: GYN care, male couples study, counseling and therapy; Weight loss and HIV; Thalidomide for wasting; Insulin-like growth factor for wasting; 3TC for HIV; Peptide T for dementia - new study open.<A HREF="zipped/15.zip">Zipped version</A> for downloading.</p>

<p><font size=3><b><A HREF="14.html">Treatment Review #14</A></b></font><br>
Contents: Drug trials and treatment studies: Oral ganciclovir, Gem91, IL-1 receptor, BV-ara-U, human growth hormone, Peptamen; Making a Difference by Marlene Diaz; Information gathering studies; Surrogate Markers; Side effects of treatments. <A HREF="zipped/14.zip">Zipped version</A> for downloading.</P>

<p><font size=3><b><A HREF="13.html">Treatment Review #13</A></b></font><br>
Contents: New Treatments: Zovirax, Zerit, famcyclovir, Zithromax, DHPG pills, valacyclovir; Diarrhea and cryptosporidiosis; A woman with AIDS speaks; 
One TB pill; Foscarnet cream study opens; Anti-oxidants; The T8 stimulator?; HPMPC; Carlo Mascarenhas; Alternatives: licorice root. <A HREF="zipped/13.zip">Zipped version</A> for downloading.</P>

<p><font size=3><b><A HREF="12.html">Treatment Review #12</A></b></font><br>
Contents: Protease inhibitor study opens in Philadelphia; Treatment Updates: hyperthermia, IVIG, Megace, d4T, NAC, Mepron, IL-12, Zovirax; Survival time; Herpes drug; Trental and hydrogen peroxide warnings; One person's treatments: an interview with Carlo; The alternative question; Skin disorder study; Women's treatment decisions; Echinacea and HIV. <A HREF="zipped/12.zip">Zipped version</A> for downloading.</P>

<p><font size=3><b><A HREF="11.html">Treatment Review #11</A></b></font><br>
Contents: Eye problems and rifabutin; IL-12 as HIV treatment?; St. John's wort herb - a possible anti-HIV pill; Memory and concentration study; Peptide T expanded access; SC-49483 for HIV; Red or purple spots - It might be something else; Report on possible side effects of AZT; IVIG recalled by pharmaceutical. <A HREF="zipped/11.zip">Zipped version</A> for downloading.</P>

<p><font size=3><b><A HREF="10.html">Treatment Review #10</a></b></font><br>
Contents: Getting the right message to the immune system; IL-2 studies for HIV, KS and TB; Making Treatment Decisions by Ken Fornataro; Substance Use and Abuse by Richard Haynes; MAC treatment guidelines; Interview with Carlo  Mascarenhas; Neutrexin for PCP; New hypericin study; Testing and counseling study; Diet and protein use study; G-CSF for low white blood cell count; In memory of Russ Bradley. <A HREF="zipped/10.zip">Zipped version</A> for downloading.</P></blockquote>

<HR SIZE=3 WIDTH=50% ALIGN=CENTER noshade>

<blockquote><p align=center><font size=2>If you don't have an unzip application, you can download shareware called <A HREF="http://wchat.on.ca/web/help/pkunzip.htm">pkunzip</A> for DOS, <A HREF="http://www.winzip.com/winzip/download.html">WinZip</A> for Windows, or <A HREF="http://www.awa.com/softlock/zipit/">Zipit</A> for Macs. Extract the zipped program onto your harddrive and associate the zip extension with the application both in your browser and on your harddrive. Then when you click on a zipped file to download, your harddrive will automatically unzip the file and you'll be able to read it with whatever text reader or word processing application you use.</p></blockquote>

<HR SIZE=3 WIDTH=50% ALIGN=CENTER noshade>

<P ALIGN=CENTER><A HREF="../index.html"><img src="../gifs/return.gif" alt="[arrow]"></p><p align=center>to Network homepage</A></P>

<hr size=3 align=center width=50% noshade>

<P align=center><FONT SIZE=-2>Last modified: 12/17/96<BR>
<A HREF="mailto:atdn@aidsnyc.org">atdn@aidsnyc.org</A><BR>
copyright &#169; 1996 The Network</font></P>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-246</DOCNO>
<DOCOLDNO>IA093-001002-B002-379</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/trs/23.html 199.29.141.24 19970121123226 text/html 57290
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:26:26 GMT
Server: NCSA/1.5.1
Last-modified: Sun, 22 Dec 1996 17:27:54 GMT
Content-type: text/html
Content-length: 57106
</DOCHDR>
<html>
<head>
<title>Treatment Review #23</title>
</head>
<body bgcolor=#ffffff link="#00688b" vlink="#545454"><font face="arial, helvetica" size=-1">

<h2 align=center>Treatment Review #23</h2>

<h3 align=center>December 1996</h3>

<blockquote>

<h3><font color="red">Happy Holidays!</font></h3>

<p>The Network wishes each and every one of you a safe and happy holiday season. Our next issue will review the success we have achieved in the last year. Just last week, for example, the <a href="../access/states/ny/drugs.html">New York State AIDS Drug Assistance Program (ADAP)</a> restored many treatments and services to residents of New York. The Network has been working hard to make this happen. Thanks to all of you who made a donation to The Network to make our work possible.</p>

<p>The Network does not accept promotional fees from any drug company or product marketer, nor do we ever sell advertising. This ensures that the information we provide is objective and free from bias. It also means that we greatly depend on donations and annual membership contributions - which are not required from anyone who cannot afford one - from professional and individual members. </p>

<DL compact>
<H4>Contents</h4>

<dt><a href="#new">New Ways to Treat HIV</a></dt>
<dd>Research has shown that certain combinations of anti-HIV drugs can reduce the amount of HIV in the blood to levels that can't be detected using current tests. Deciding what drug combination to take, and when to take it, is not an easy decision. There are both risks and benefits. To help in the decision making process, this issue of Treatment Review provides updated information from different combination therapy studies.</dd>
<dt><a href="#combo">Combination Treatment - Study Results</a></dt>
<dd>This is part one of a two part article. It looks at research studies of combinations of anti-HIV drugs that can reduce the amount of HIV in the blood to levels that can't be detected using current tests.</dd>
<dt><a href="#adap">New York State ADAP Update</a></dt>
<dd>New treatments are being added to ADAPs around the country, including New York State, thanks to advocacy by The Network and a coalition of many other organizations known as the ADAP Working Group.</dd>
<dt><a href="#combo2">Combination Treatment - Other Options</a></dt>
<dd>Many combinations of anti-HIV drugs have been shown to significantly reduce the levels of HIV in the body. This is the second part of our combination treatment article.</dd>
<dt><a href="#don't">Drugs that don't combine</a></dt>
<dd>Not all drugs combine well. Indinavir and ritonavir, for example, may not be a good combination because HIV becomes resistant to both of these drugs in the same way. Discuss your choices carefully with your care and support team.</dd>
<dt><a href="#briefs">Treatment Briefs</a></dt>
<dd>d4T for children, Medicaid and viral load testing, lobucavir for CMV, Abacavir for dementia, nelfinavir expanded access and children's study, Male Couples Project, human growth hormone approved, other treatments for wasting, zinc finger inhibitor.</dd>
<dt><a href="#gloss">Drug Glossary and Technical Terms</a></dt>
<dd>A description of all the drugs mentioned in our HIV treatment article, and explanations of some technical terms.</dd>
<dt><a href="#resources">Network Resources</a></dt>
<dd>The Network publishes The Experimental Treatment Guide, Treatment Review, Simple Fact Sheets and other materials in English and Spanish. We also have an Internet site at <a href="../index.html">http://www.aidsnyc.org/network</a>. Find out how to join The Network and support our work.</dd>
</dl>

<h3><font color="#0000ff"><a name="new">New</a> Ways to Treat HIV</font></h3>

<p>The decision about whether to take anti-HIV drugs, and which ones to take, is best made by an individual along with his or her healthcare provider. Finding a provider that is experienced in treating HIV is increasingly important as treatment choices become more complicated. Don't worry if all these different studies are too much to take in. Use this information for reference, and perhaps go over it later with your provider or support network. If you need help finding support services that can help you, or a healthcare provider that you can work with, call The Network and we'll assist you. You can also call us if you need more details on any of the drugs or studies mentioned in this article.</p>

<p>Recent scientific breakthroughs have completely changed the way HIV disease is treated. Studies have shown that it is possible to decrease the measurable activity of HIV in the blood to very low levels with combinations of drug treatments. Reducing HIV levels in this way seems to slow or perhaps even stop disease progression. It may also allow the immune system a chance to recover, at least partially, even if the T4 cell count has gotten very low.</p>

<p><b>Treatment Plans</b></br>
Unfortunately, there isn't one combination of anti-HIV treatments that works best for everyone. There are several different options that can work very well, and it's important to try and work out which option is best for you, depending on your situation.</p>

<p>For the first time, there are enough anti-HIV drugs available to make it worth considering long term treatment plans. Long term plans mean thinking about what drugs may work well now, and what the options would be if the effects of these drugs wear off due to drug resistance. This is the reason that we've listed "<a href="#options">Other Options</a>" after each of the different combination drug study reports.</p>

<p>Some people stay healthy and have very low levels of HIV in their body without any anti-HIV treatment. It is not yet known if combination anti-HIV treatment will benefit people in this situation. One treatment plan may be to wait for more information on the best way to use available drugs before starting treatment.</p>

<p>For people who may be experiencing signs of disease progression - increasing viral load, dropping T4 cell count, and/or symptoms of HIV disease - it is a good idea to discuss possible treatment plans with your healthcare provider.</p>

<p><b>Viral Load Tests</b><br>
There are now tests available that measure the amount of HIV in the blood. These tests are known as viral load tests. The viral load test helps someone with HIV decide if they need to start anti-HIV treatment, and how well it's working once they start.</p>

<p><b>The Ideal Goal of Treatment</b><br>
Many researchers now think that the ideal goal of anti-HIV treatment is to try and reduce the amount of HIV in the blood to very low levels. Recent studies have shown that it may take up to 4 months for an effective drug combination to do this. The only way to work out if a combination of anti-HIV treatments have achieved this goal is by measuring the amount of HIV in the blood using the viral load test. Currently available viral load tests can't measure less than 400 copies of HIV in a blood sample, so a number less than 400 is considered to be undetectable.</p>

<p>If viral load stays undetectable after repeated tests, researchers think that shows that HIV has been very effectively shut down in the body, and that it will be harder for the virus to get resistant to the treatments and cause illness and disease progression.</p>

<p>People that have taken anti-HIV drugs before may have a difficult time selecting a combination of treatments that effectively reduces HIV levels. Also, some people don't become undetectable even after taking a new drug combination. Reducing the level of HIV in the blood has been shown to improve health, even if the virus was not shut down completely. The problem is that HIV will probably get resistant to the effects of the treatments eventually.</p>

<p><b>The Resistance Problem</b><br>
HIV can get resistant to the effects of anti-HIV drugs. For HIV to become resistant to a drug, the virus needs to be able to reproduce in the body even though the drug is trying to stop it. That way, new viruses that get made have a chance to adapt and mutate so that the drug doesn't work at all. If HIV levels are reduced effectively by anti-HIV drugs, it is harder for the virus to make new copies of itself while the drugs are around. This makes it difficult for HIV to become resistant to the drugs.</p>

<p>This is why taking just one anti-HIV drug is no longer recommended by doctors. It's also why it's not a good idea to add one new drug to a two-drug combination to which you have already become resistant. This is because it doesn't change the fact that the virus is resistant to the other two drugs. The best choice seems to be to stop taking the drugs to which resistance has developed, and start a whole new combination of drugs to which your virus isn't resistant.</p>

<p>Some doctors still start people on two drug combinations such as AZT/3TC in the hope of keeping the viral load low for a while. The potential problem with this treatment option is that it may not be strong enough. Eventually, people become resistant to the AZT/3TC. This limits future treatment options, because you can no longer use these drugs as part of a treatment combination. There is still debate among researchers about these different approaches.</p>

<p><b>Interrupting Treatment</b><br>
If you are taking an effective combination treatment and need to stop (because of a side effect, for example), it is much better to stop all the anti-HIV drugs at once. Although the levels of HIV in the blood will probably go up when you stop treatment, the virus won't have had a chance to get resistant to any of the drugs; so they may work again if you restart treatment.</p>

<p><b>Side Effects</b><br>
Combination anti-HIV treatments may shut down the virus, but they can also have side effects. A drug that can't be taken because of side effects is not an effective drug. It's important to know what side effects to watch out for when taking any drug or drug combination, and to work with your healthcare provider to select treatments that are as easy as possible for you to take.</p>

<p><b>Undetectable Viral Load - Does It Make People Feel Better?</b><br>
Reducing the level of HIV in the body to very low levels may help prevent disease progression, but it may not always make people feel better if they are already sick. There may be damage that HIV has already caused, such as neuropathy, where the virus damages nerve endings. Conditions like neuropathy will still need to be diagnosed and treated if they are causing problems, regardless of how well anti-HIV treatment is working.</p>

<p>If your viral load is very low and you still feel ill, work with your healthcare provider to try and identify the problem. There may be problems due to drug side effects or drug interactions, or other conditions that have not been diagnosed and treated.</p>

<p>It is important to remember that reducing HIV to very low levels in the blood - sometimes referred to as "undetectable" if the viral load test being used doesn't measure below a certain number - may tell us very little about HIV in other areas of the body, such as the lymph glands, genital passages, and the brain. A low viral load does not mean that you shouldn't continue to practice safe sex, because semen and vaginal fluid may still be infectious.</p>

<p>It's also important to remember that even if your viral load has become undetectable, you should stay on any preventive medications that you may be taking, such as PCP or MAC prevention. Your immune system may not have recovered its ability to fight these infections despite the lower level of HIV in your blood.</p>

<h3><font color="#0000ff"><a name="combo">Combination</a> Treatment - Study Results</font></h3>

<p>There are two parts to this article. The first looks at research studies of combinations of anti-HIV drugs that seem to be able to reduce HIV levels very effectively. Research studies are also known as clinical trials. These studies are done to see how well new treatments work in people. Most of the studies included in this report are ongoing, because the idea of combination anti-HIV therapy is still new. If you'd like information about ongoing research studies contact The Network at (800) 734-7104.</p>

<p>The second part of this article looks at other drug combinations that have been shown to significantly lower the level of HIV in the blood, but not reduce it below measurable levels. Some of these combinations have also been shown to improve health and extend life. Now that the ideal goal of treatment is to reduce the activity of HIV as much as possible, these drug combinations may not be the best option, unless the viral load is not that high to start with. Researchers know that HIV will eventually get resistant to any drug combination that does not reduce viral activity effectively, and drug resistant HIV will limit future treatment options. Consider all the options carefully. Some options work far better when you haven't taken other anti-HIV drugs before.</p>

<p>For a full description of all the drugs mentioned in this article - including the many different names - see the <a href="#gloss">drug glossary</a>.</p>

<p>We've looked at the information from different combination treatment studies, made comments where appropriate, and asked some questions about the study results. These questions should help when making treatment decisions</p>

<ul>
<li>What were the side effects?
<li>At what stage of HIV disease were the participants?
<li>How many people left the study before it finished, and why did they leave?
<li>What was the anti-HIV effect? Did the treatments reduce levels of the virus, and for how long?
<li>What was the effect on the immune system?. Did it seem to recover?
<li>Had the people had previous treatment?. If they had, for how long on average, and which drugs?
<li>What other options would I have if these treatments stopped working?
</ul>

<p><font color="#0000ff"><b>AZT, 3TC and indinavir (Crixivan)</b></b></p>

<p><b>Side Effects</b>: The main side effects seen only in a few people in this study have been nausea and kidney stones. It is recommended that people taking indinavir drink 1.5 liters of water a day to try and prevent kidney stones. Indinavir has to be taken every 8 hours on an empty stomach, or with a small, low fat snack. An example of a snack is juice and a bowl of corn flakes with skim milk.</p>

<p><b>Stage of HIV</b>: People that received the triple combination started the study with an average T4 cell count of 143.</p>

<p><b>Left the Study</b>: In this study, 7 out of 97 left the study early. One person left the study because of mild nausea. Two left to use other treatments that were not permitted in this study. One left to treat his KS, which improved at the start of the study, but began to progress later on.</p>

<p><b>Anti-HIV Effect</b>: 26 people in this study have been followed for 36 weeks. 21 of the 26 have so little virus in their blood that it could not be found using the viral load test. 6 out of the 7 people that have now been on the combination for 48 weeks still have undetectable viral load.</p>

<p><b>The Immune System</b>: The average T4 cell count increase was 125. People that received the triple combination started the study with an average T4 cell count of 143. After 36 weeks their average T4 cell count had risen to 264.</p>

<p><b>Previous Treatment</b>: People in this study had already been taking AZT for an average of over two years, so it is likely that the strong anti-HIV effects of the triple combination were mainly due to people starting two new drugs (3TC and indinavir) at the same time. This is because HIV often gets resistant to the effects of AZT.</p>

<p><b>Other Options</b>: If this combination stops working because of drug resistance, there are various possible anti-HIV drug combinations that might be effective. However, there have not yet been any studies conducted in people who are resistant to AZT, 3TC and indinavir. Many researchers are concerned that getting resistant to the effects of one protease inhibitor may stop any other protease inhibitor from working.</p>

<p>Drugs that might be considered include new drugs called non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as nevirapine (Viramune) and delavirdine (Rescriptor). d4T (Zerit) and ddI (Videx) might also be used as part of a combination. Some doctors are trying a combination of the protease inhibitors saquinavir and ritonavir, although it is not yet known how well this will work if HIV has become resistant to indinavir. The experimental protease inhibitor nelfinavir (Viracept) is currently available through an expanded access program for people that aren't benefitting from approved protease inhibitors. It is not yet known whether nelfinavir will work against HIV that is resistant to other protease inhibitors. Several new anti-HIV drugs are also in clinical trials, such as 1592U89 (Abacavir), adefovir dipivoxil (PMEA), PMPA, F-ddA, DMP-266, or VX-478 (the Vertex protease inhibitor).</p>

<p><font color="#0000ff"><b>AZT, ddI (Videx), nevirapine (Viramune)</b></font></p>

<p><b>Comments</b>: This study started before results of studies combining AZT and 3TC were released. The combination of AZT and 3TC may have stronger anti-HIV effects than AZT and ddI, so a triple combination of AZT, 3TC and nevirapine may produce better results than those seen in this study. A study of AZT/3TC/nevirapine is ongoing at the moment.</p>

<p>Previous studies of nevirapine in people who had already taken anti-HIV drugs did not show very good results. HIV becomes resistant to the effects of nevirapine very quickly when the drug is used alone or in combination with just one other anti-HIV drug.</p>

<p><b>Side Effects</b>: The main side effects seen in this study were nausea, vomiting, diarrhea and rash.</p>

<p><b>Stage of HIV</b>: People started the study with an average T4 cell count of 387.</p>

<p><b>Left the Study</b>: Out of 51 people receiving the triple combination of AZT, ddI and nevirapine, 3 people left the study due to a rash they got from nevirapine. Several other people are reported to have stopped taking the ddI because of side effects, but they didn't leave the study.</p>

<p><b>Anti-HIV Effect</b>: Of the 34 people that have been followed for a year, approximately 20 people are reported as still having undetectable viral load in their blood.</p>

<p><b>The Immune System</b>: People started the study with an average T4 cell count of 387. After a year the average T4 cell count of the 34 people taking the triple combination had increased by 140 cells.</p>

<p><b>Previous Treatment</b>: No one in this study had taken any anti-HIV drugs before.</p>

<p><b>Other Options</b>: Drugs that may work against virus that is resistant to these treatments include d4T, 3TC, and any protease inhibitor (saquinavir, ritonavir, indinavir, nelfinavir). HIV that is resistant to nevirapine is likely to be resistant to other NNRTI drugs such as delavirdine, although this has not yet been studied in people.</p>

<p><font color="#0000ff"><b>NNRTIs</b></font></p>

<p>Some researchers are very encouraged by the results of the nevirapine study reported on here. Using NNRTI drugs like nevirapine as part of triple combination may be a good option for people starting HIV treatment for the first time. The chances of reducing HIV to undetectable levels using these treatments seems good. It also allows people time to learn more about protease inhibitors before they use them.</p>

<p>These drugs should never be used alone, as HIV becomes resistant to them very quickly. For a full description of the different NNRTI drugs see the <a href="#gloss">drug glossary</a>.</p>

<p><font color="#0000ff"><b>AZT, 3TC, nelfinavir (Viracept)</b></font></p>

<p><b>Comments</b>: Nelfinavir is an experimental protease inhibitor that is not yet available by prescription. It is expected to be approved by the Food and Drug Administration (FDA) in early 1997. Contact The Network for information about the Expanded Access program for this drug.</p>

<p><b>Side Effects</b>: The main side effect seen in this study has been diarrhea.</p>

<p><b>Stage of HIV</b>: People started the study with an average T4 cell count of 245.</p>

<p><b>Left the Study</b>: Only 1 person left this study out of the 12 that started. The reason for leaving was liver toxicity and diarrhea. This is a very small study so it's hard to know what would happen in a larger group of people.</p>

<p><b>Anti-HIV Effect</b>: After 16 weeks, all eleven people in the study had very low levels of HIV in their blood as measured by several different sensitive tests.</p>

<p><b>The Immune System</b>: The average T cell rise was 100. People started the study with an average T4 cell count of 245. After 16 weeks their average T4 cell count had risen to 345.</p>

<p><b>Previous Treatment</b>: No one in this study had taken any anti-HIV drugs before.</p>

<p><b>Other Options</b>: Researchers do not know for certain which drugs would work against HIV if it becomes resistant to AZT and 3TC - drugs that may work include nevirapine, delavirdine, d4T and ddI and experimental drugs such as 1592U89, F-ddA and DMP-266. According to very preliminary study results, it seems that the approved protease inhibitors (saquinavir, ritonavir and indinavir) would still work against HIV that had gotten resistant to nelfinavir.</p>

<p><font color="#0000ff"><b>AZT, ddC (HIVID), ritonavir (Norvir)</b></font></p>

<p><b>Side Effects</b>: The side effects seen in this study include nausea, diarrhea, facial numbness (paresthesia) and toxicity to the liver. The ritonavir being used in this study was a liquid formulation. It was hoped that the new pill form of ritonavir would have less side effects, but people report that ritonavir, even as a pill, is a very tough drug to take.</p>

<p><b>Stage of HIV</b>: People started the study with an average T4 cell count of 180.</p>

<p><b>Left the Study</b>: Out of 32 people that started the study, 15 people left early due to side effects. That's almost half of the people on the study. Most of these people dropped out because of side effects caused by ritonavir.</p>

<p><b>Anti-HIV Effect</b>: After 60 weeks, 9 of the 15 people that had made it that far had undetectable viral load in their blood.</p>

<p><b>The Immune System</b>: People started the study with an average T4 cell count of 180. After 60 weeks the average T4 cell count of the 17 people that stayed in the study that long was 338 - but so many people had dropped out that these 17 people may have had higher T4 cell counts to start with.</p>

<p><b>Previous Treatment</b>: No one in this study had taken any anti-HIV drugs before.</p>

<p><b>Other Options</b>: Drugs that may work against HIV that is resistant to these treatments include d4T, 3TC, ddI, nevirapine, delavirdine, and possibly other protease inhibitors. Several anti-HIV drugs that are currently experimental may also be effective.</p>

<p><font color="#0000ff"><b>AZT, 3TC, ritonavir</b></font></p>

<p><b>Comments</b>: This study was done in a very small number of people who had only been HIV infected for 90 days or less. This period is known as primary infection. This study is being done to see if it is possible to cure HIV infection in people that have recently become infected. How this combination works in people that have been infected for a long time is not known.</p>

<p>Several different tests will be done after people have been on the study for a year to see if there is still virus in their bodies. If it turns out that HIV has not been eliminated by the treatments, the long term effects of reducing the amount of HIV in the body so early in the course of infection will not be known for many years.</p>

<p><b>Side Effects</b>: The main side effects seen in this study were nausea, vomiting, diarrhea and paresthesias (numbing sensations on the skin).</p>

<p><b>Stage of HIV</b>: People in this study had been HIV infected for 90 days or less. This period is known as primary infection.</p>

<p><b>Left the Study</b>: Out of 12 people that started, 3 people left the study due to side effects or allergic reactions to ritonavir.</p>

<p><b>Anti-HIV Effect</b>: All 9 people still in the study have no virus in their blood as measured by several different sensitive tests. The length of time people have been in the study ranges from 3 to 10 months.</p>

<p><b>The Immune System</b>: Because the people in this study had only recently become HIV-infected, most had high T4 cell counts. The researchers looked at the ratio of T4 cells to T8 cells to see if the treatments had an effect on the immune system. The T4/T8 ratio is another way of measuring how well the immune system is doing. Most of the people in the study had an improvement in the T4/T8 cell ratio after treatment.</p>

<p><b>Previous Treatment</b>: No one in this study had ever taken any anti-HIV drugs before.</p>

<p><b>Other Options</b>: Drugs that might be considered include new drugs called non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as nevirapine (Viramune) and delavirdine (Rescriptor). d4T (Zerit) and ddI (Videx) might also be used as part of a combination. The experimental protease inhibitor nelfinavir (Viracept) is currently available through an expanded access program for people that aren't benefitting from approved protease inhibitors.</p>

<p><font color="#0000ff"><b>indinavir (Crixivan), AZT, ddI</b></font></p>

<p><b>Comments</b>: The combination of AZT, ddI and indinavir may not be as effective as AZT, 3TC and indinavir (see first study, above) against HIV. Indinavir and ddI are also difficult drugs to take in combination, because they need to be taken an hour apart, and they both have to be taken on an empty stomach.</p>

<p><b>Side Effects</b>: The main side effects experienced by people in these studies were gastrointestinal (stomach and digestive system) upset, nausea and headache. There has only been one case of kidney stones reported in this study so far.</p>

<p><b>Stage of HIV</b>: People started the study with an average T4 cell count of 150.</p>

<p><b>Left the Study</b>: Out of 78 people that started this study, 10 left early due to gastrointestinal side effects which were thought to be caused by ddI.</p>

<p><b>Anti-HIV Effect</b>: This study has been going on for six months. The 78 people in the study were divided into three groups. One group is taking a triple combination of AZT, ddI and indinavir. The second group is taking indinavir on its own. The third group is taking AZT and ddI. In the group taking the triple combination of AZT, ddI and indinavir, 60% of people have undetectable viral loads.</p>

<p><b>The Immune System</b>: People started the study with an average T4 cell count of 150. After 24 weeks, people on the triple combination had an average T4 cell increase of 110 cells.</p>

<p><b>Previous Treatment</b>: No one in these studies had taken anti-HIV drugs before.</p>

<p><b>Other Options</b>: It is not yet known whether any other protease inhibitors will work against HIV that is resistant to indinavir. The experimental protease inhibitor nelfinavir (Viracept) is currently available through an expanded access program for people that aren't benefitting from approved protease inhibitors. Drugs that may work against HIV that is resistant to AZT and ddI include d4T, 3TC, nevirapine, delavirdine and several experimental anti-HIV drugs that are currently in clinical trials.</p>

<p><font color="#0000ff"><b>saquinavir and ritonavir</b></font></p>

<p><b>Comments</b>: This study has not been going on for very long. It is the first study to test a combination of protease inhibitors. The anti-HIV effect of the combination seems strong, and may be an option for people whose virus is resistant to the effects of all the nucleoside analog anti-HIV drugs (AZT, ddI, ddC, d4T, 3TC). However, it would be a good idea for people to wait for more long-term information about this drug combination if they can.</p>

<p>People in this study have been divided into four groups. Group A is taking saquinavir 400 mg twice a day along with 400 mg of ritonavir twice a day. Group B is taking 400 mg of saquinavir twice a day and 600 mg of ritonavir twice a day (this is the standard dose of ritonavir). Group C is taking 400 mg of saquinavir three times a day and 400 mg of ritonavir three times a day. Group D is taking 600 mg of saquinavir twice a day and 600 mg of ritonavir twice a day. So far, information is available for groups A and B after 20 weeks on the study, and for groups C and D after 12 weeks on the study.</p>

<p><b>Side Effects</b>: People in this study have experienced many side effects. Out of 128 people starting the study, 99 experienced numbing sensations known as paresthesias, 98 had diarrhea and 57 had nausea. Other side effects included fatigue and elevated levels of substances in the blood called triglycerides. Increases in liver function tests, sometimes severe, have also been noted, particularly in patients with underlying hepatitis. For most people in the study, these side effects are reported to have gotten better or gone away after the first few weeks.</p>

<p><b>Stage of HIV</b>: The average T4 cell counts at the start of the study were 277 in Group A, 264 in Group B, 302 in Group C, and 251 in Group D.</p>

<p><b>Left the Study</b>: This study is ongoing. At the last report, out of 128 people that started, 12 people had left the study. Eight of the drop-outs were from Group C, who were receiving the drugs three times a day. This group has now had their dosing schedule changed to twice a day.</p>

<p><b>Anti-HIV Effect</b>: Most people in the study have had the levels of HIV in their bodies reduced to undetectable levels. Some people's levels of virus are not undetectable yet but are still going down.</p>

<p><b>The Immune System</b>: T4 cell counts have increased an average of 75 in Group A, 120 in Group B, 100 in Group C and 120 in Group D.</p>

<p><b>Previous Treatment</b>: People in this study were allowed to have taken nucleoside analog anti-HIV drugs (AZT, ddI, ddC, d4T, 3TC) before, but had to stop taking them before joining the study. No one in this study had taken protease inhibitors before.</p>

<p><b>Other Options</b>: The experimental protease inhibitor nelfinavir (Viracept) is currently available through an expanded access program for people that aren't benefitting from approved protease inhibitors. It is not yet known whether nelfinavir will work against HIV that is resistant to both saquinavir and ritonavir.</p>

<p><font color="#0000ff"><b>Protease inhibitor combinations - the future?</b></font></p>

<p>Researchers are hopeful that the new protease inhibitor nelfinavir (Viracept) may combine well with either saquinavir or indinavir. Early information about the safety and interactions of these drugs in HIV negative people is reported to be encouraging. Studies in people with HIV are planned. It is hoped that these combinations may work as well as the only protease inhibitor combination studied so far, ritonavir/saquinavir (described on this page), but with less side effects. The results of studies planned for next year will help show if this is true.</p>

<h3><font color="#0000ff"><a name="combo2">Part</a> 2 - Other Combinations</font></h3>

<p><b>ritonavir and AZT, ddI, ddC or d4T</b><br>
This study was an example of just adding one new drug to current treatment. Researchers no longer think that this is a good idea, because people in this study seemed to have gotten resistant to the effects of ritonavir after six months. The effects may have been longer lasting if people had changed their other anti-HIV treatments at the same time as starting ritonavir.</p>

<p>In this study in people with less than 100 T4 cells, ritonavir was found to help people live longer, and delay progression of disease. There were 1090 people in this study. The average T4 cell count was around 20. People were allowed to take AZT, ddI, ddC or d4T while on the study. One group of people added ritonavir to the medications they were taking, the second group got a placebo or dummy pill.</p>

<p>After an average of six months, 46 people taking the placebo had died compared to 26 people taking ritonavir. This means that for people taking ritonavir, the risk of death was greatly reduced - almost halved - compared to people taking the placebo. Eighteen percent of the participants on ritonavir discontinued because of side effects.</p>

<p><font color="#0000ff"><b>AZT/ddI</b></font><br>
This combination has been shown to improve health and extend life compared to AZT alone in people with less than 500 T4 cells. This effect was seen even if people had already been on AZT for a while. The improvements in health were linked to how well the drugs reduced viral load.</p>

<p><font color="#0000ff"><b>AZT/ddC</b></font><br>
This combination has been shown to improve health and extend life compared to AZT alone in people with less than 500 T4 cells. This effect was only seen in people who had never taken any anti-HIV drugs before. The combination of AZT and ddC did not seem to help people who had already been taking AZT. As with AZT and ddI, the improvements in health were linked to how well the drugs reduced viral load.</p>

<p><font color="#0000ff"><b>AZT/3TC</b></font><br>
This combination has been shown to greatly reduce viral load. Also, a large European trial of 3TC enrolled 1,892 people with T4 cells between 25 and 250. Participants in this study were already being treated with AZT, or AZT with ddI, or AZT with ddC. People were randomly divided into three groups. One group added 3TC to their current treatment. The second group added 3TC and an experimental drug called loviride. The third group added a placebo. The study was stopped after one year because people receiving 3TC had a 54% reduction in disease progression and death.</p>

<p><font color="#0000ff"><b>d4T/3TC</b></font><br>
This is a very popular combination therapy, but it has not been very well studied. Two small studies have shown that this combination can cause a greater than 90% drop in viral load within a few weeks. The long term effects of the combination on viral load are not yet known.</p>

<p><font color="#0000ff"><b>saquinavir/ddC</b></font><br>
A recent study compared the combination of saquinavir and ddC (trade name HIVID) to saquinavir or ddC taken alone. The average T4 cell count of people in the study was 160-180. Everyone had taken AZT for over a year before joining the study. This study found that the combination reduced the death rate by two thirds - after a year and a half there had been 28 deaths on ddC, 34 on saquinavir and 9 in the combination saquinavir/ddC group. The current thinking is that taking ddC or saquinavir by themselves is not a good idea, because the anti-HIV effects are so weak.</p>

<p><font color="#0000ff"><b>d4T/ddI</b></font><br>
An ongoing study has found that this combination may have strong anti-HIV effects. The viral load in people in this study was reduced by over 99%, and a few people have maintained this reduction for a year. Surprisingly, little peripheral neuropathy occurred in any of the doses tested. This combination has only been studied in people who have never taken anti-HIV drugs before.</p>

<p><font color="#0000ff"><b>ddI/hydroxyurea (Hydrea)</b></font><br>
Hydroxyurea is a cancer treatment that may help ddI work better. In a year long study in France, people taking the combination have had their viral load reduced by 90% or more. No major side effects have been seen so far. One study has suggested that taking ddI with hydroxyurea may work even if HIV has gotten resistant to the effects of ddI used alone. Two studies of the ddI/hydroxyurea combination have recently begun in the US. Call The Network for a referral.</p>

<p><font color="#0000ff"><b>delavirdine (Rescriptor) and AZT</b></font><br>
Delavirdine is an experimental anti-HIV drug in a class known as non-nucleoside reverse transcriptase inhibitors (NNRTIs). It is currently available through expanded access for people with less than 300 T4 cells. The main side effect is a rash. Delavirdine has been shown to reduce viral load in combination with AZT. A study combining delavirdine with AZT and 3TC is ongoing. New information on delavirdine is likely to be available soon.</p>

<h3><font color="#0000ff"><a name="don't">Drugs</a> that don't combine</font></h3>

<p>The combination of AZT and d4T should be used with caution. A recent study found that starting this combination caused an unexplained drop in T4 cell counts in people that had been taking AZT before. A note to physicians has been sent out about this study, call The Network for a copy.</p>

<p>The combination of ddI and ddC isn't thought to be a good idea because of side effects. Information on 3TC combined with ddI or ddC will be available soon, but these are not generally used in combination.</p>

<p>There are some drug combinations that can be very difficult to take due to the different schedules and food requirements of each drug. Taking ddI with a protease inhibitor, for example, may be especially difficult because you would have to take pills four or five times a day.</p>

<p>The combination of saquinavir and indinavir has not yet been studied, and there is a test tube study that suggests that these drugs may not work well together. Ritonavir and indinavir may not be a good combination because HIV becomes resistant to both of these drugs in the same way.</p>

<p>Recent information shows that nevirapine (Viramune) may lower the levels of protease inhibitors in the body. Delavirdine (Rescriptor) seems to increase the blood levels of the protease inhibitors saquinavir and indinavir. Call the Network for full information on these studies.</p>

<h3><font color="#0000ff"><a name="adap">Treatments</a> and Services added to NYS Program</font></h3>

<p>New treatments are available through <a href="../access/states/ny/ny.html">The New York State AIDS Drug Assistance Program (ADAP)</a> starting December 1, 1996. In addition, the viral load test (PCR) and other services have been added to ADAP Plus, and changes have been made to the home care services that are available. For more information contact The Network at (800)734-7104.</p>

<h3><font color="#0000ff"><a name="briefs">Treatment</a> Briefs</font></h3>

<p><b>d4T (Zerit) and Children</b><br>
A recent study comparing d4T to AZT in children has found that d4T seems to work just as well or slightly better. The children in this study were young, with an average age of just over a year old. The study concluded that d4T caused less neutropenia, a side effect of AZT that lowers the white blood cell count. The study also concluded that there was some evidence that d4T caused better weight gain, and that T4 cell counts were better maintained in children on d4T. The study was too small to notice any differences in disease progression.</p>

<p><b>Viral Load Testing and Medicaid</b><br>
Getting viral load tests covered in clinics in New York is still reported to be difficult for some people. Some clinics receive special reimbursement from Medicaid because they serve so many people with HIV and AIDS. For a while, New York State asked these clinics to use this extra money to cover viral load testing for their clients, even though it was not enough and would have broken the clinics' budget. People receiving care at these clinics could not get viral load testing covered, even though other people on Medicaid could. Iris Long, PhD, of ACT-UP New York has been working hard to get this issue resolved, but apparently there are still problems. If you are on Medicaid and having difficulty getting viral load tests covered, call The Network and let us know.</p>

<p><b>Lobucavir for CMV</b><br>
A new drug called lobucavir is being studied for the treatment of newly diagnosed CMV retinitis. CMV retinitis is an infection caused by a herpesvirus that people with low T4 cells can get. If untreated, the infection leads to blindness. Lobucavir is an antiviral drug that is active against many different herpesviruses, as well as HIV. In an early study, lobucavir reduced the amount of HIV in the blood by over 90%. Lobucavir is a pill that is taken 4 times a day. Call the Network if you'd like a referral to the study site.</p>

<p><b>The Experimental Treatment Guide</b><br>
The Network's Winter 1996/1997 edition of The Experimental Treatment Guide will be available in January. There are over 70 new studies listed. This directory is funded by The New York State Department of Health AIDS Institute. It is free of charge to any New York State resident. Call The Network at (800)734-7104 to request a copy, or to make sure you're on the mailing list.</p>

<p><b>Abacavir for Dementia</b><br>
Abacavir (1592U89) is a new anti-HIV drug that is being studied for the treatment of HIV-related dementia. Symptoms of dementia include muddled thinking, memory loss and personality changes. There are <a href="../trials/cog.html">two study sites</a> in New York, call The Network for a referral.</p>

<p><b>Nelfinavir Expanded Access</b><br>
Nelfinavir (trade name Viracept) is a protease inhibitor made by a company called Agouron. Nelfinavir is now available to people with under 50 T4 cells who either cannot take approved protease inhibitors because of side effects, or have not responded to treatment with approved protease inhibitors. Call Agouron at (800) 621-7111 for more information.</p>

<p><b>Nelfinavir for Children</b><br>
A clinical trial of the protease inhibitor nelfinavir (Viracept) has started for adolescents, children and newborns. The drug is available as a sprinkle for those too young to swallow pills. Call The Network for a referral.</p>

<p><b>Male Couples Project</b><br>
A project in New York is offering eight-week group workshops for male couples in which one partner is HIV positive and the other is HIV negative. The workshops, led by two facilitators, are aimed at reducing the stress faced by these couples in such areas as sustaining safer sex, developing better communication skills, planning for the future, and maintaining relationship satisfaction. The workshops are offered free of charge at sites throughout New York City. Eligible couples are men aged 22-55 who have been in a committed relationship for at least four months and are physically able to participate in the group. Call The Network for a referral.</p>

<p><b>Growth Hormone Approved</b><br>
A new treatment for HIV-related wasting has been approved for prescription. Human Growth Hormone (trade name Serostim) has been shown to improve lean body mass in early studies, when given for a 12 week period. Lean body mass is a measurement of important muscle tissue where energy is stored. People with wasting seem to lose this tissue rather than fat, and loss of lean body mass can be fatal. The US Food and Drug Administration (FDA) has requested that the company that makes Serostim conduct further studies to work out how best to use this drug, as not all studies using Serostim have shown clear benefits. Serostim is very expensive, and can cost up to $36,000 a year. Serostim is given by an injection under the skin. The company that makes the drug, Serono Laboratories, has set up a patient assistance program that can be reached at (800) 714-2437.</p>

<p><b>Other Treatments for Wasting</b><br>
Other treatments that may improve lean body mass in people with wasting are in clinical trials, such as anabolic steroids. Anabolic steroids are less expensive than human growth hormone. An anabolic steroid called oxandrolone is being studied for the treatment of wasting in both men and women with HIV. Oxandrolone is given as a pill. Call The Network for a referral, or for a full listing of current trials for wasting.</p>

<p><b>Zinc Finger Inhibitor for HIV</b><br>
Another new class of anti-HIV drugs known as zinc finger inhibitors are entering clinical trials. These drugs block part of HIV known as zinc fingers. Zinc fingers are a part of HIV that help assemble new viruses as they are leaving an infected cell. When the zinc fingers are blocked, HIV makes copies of itself that don't work and can't infect new cells.</p>

<p>A zinc finger inhibitor called CI-1012 is being studied at the National Institutes of Health (NIH) in Bethesda, Maryland. To participate in this study you must have a T4 cell count between 200 and 500, and must not be on any anti-HIV treatment, or willing to stop anti-HIV treatment before joining the study. As with most studies at the NIH, they will pay airfare for every visit except the first. Call the Network for more information and referrals.</p>

<h3><font color="#0000ff"><a name="gloss">Drug</a> Glossary</font></h3>

<p>This glossary lists our current information on approved and experimental anti-HIV drugs. For more information on any drug, including clinical trials of experimental drugs, call The Network.</p>
<dl compact>
<dt>3TC (lamivudine, Epivir): <dd>Approved nucleoside analog reverse transcriptase inhibitor. 3TC has also shown activity against the hepatitis B virus. Side effects can include headache, nausea, low white blood cells and rare cases of hair loss.
<dt>Abacavir (1592U89): <dd>Experimental nucleoside analog reverse transcriptase inhibitor. Similar to AZT but has stronger anti-HIV effects. Main side effects seen so far are rash and headache. This drug may become available by prescription in late 1997.
<dt>adefovir dipivoxil (PMEA): <dd>Experimental nucleotide analog antiviral drug. Effective against many different herpesviruses, as well as HIV. Now being studied in combination with other anti-HIV drugs. Dosing is one pill a day. This drug may become available by prescription in late 1997.
<dt>AZT (zidovudine, Retrovir): <dd>Approved nucleoside analog reverse transcriptase inhibitor. Long-term AZT use is associated with loss of muscle. Other side effects can be nausea, vomiting, anemia, low white blood cells, bone marrow damage, and headaches. Also approved for preventing transmission of HIV from mother to child.
<dt>d4T (stavudine, Zerit): <dd>Approved nucleoside analog reverse transcriptase inhibitor. Side effects can include nerve damage in the hands and feet (peripheral neuropathy), stomach upset, damage to the pancreas (pancreatitis) and liver damage.
<dt>ddC (zalcitabine, HIVID): <dd>Approved nucleoside analog reverse transcriptase inhibitor. Side effects can include peripheral neuropathy, pancreatitis, and sores in the mouth.
<dt>ddI (didanosine, Videx): <dd>Approved nucleoside analog reverse transcriptase inhibitor. Comes as chewable tablet or powder. Side effects can include peripheral neuropathy, pancreatitis, and diarrhea. ddI is coated in an antacid buffer that can effect the absorption of other drugs such as dapsone and indinavir.
<dt>delavirdine (Rescriptor): <dd>Experimental non-nucleoside reverse transcriptase inhibitor (NNRTI). The main side effect is a rash. This drug is currently available through an expanded access program and is likely to be approved for prescription early in 1997.
<dt>DMP266: <dd>Experimental non-nucleoside reverse transcriptase inhibitor (NNRTI). DMP-266 stays in the body for a long time and so is only taken once a day. Had strong anti-HIV effects in an early study. The drug is thought to have few side effects. If studies go well, this drug may become available by prescription in late 1997 or early in 1998.
<dt>F-ddA: <dd>Experimental nucleoside analog reverse transcriptase inhibitor. F-ddA is related to ddI, but is expected to be better absorbed and therefore does not have to be administered with buffers. The buffers in ddI pills can make the drug difficult to take. In the test tube, F-ddA is active against HIV that is resistant to ddI. This drug is only in the first phase of human studies.
<dt>fozivudine tidoxil: <dd>Experimental nucleoside analog reverse transcriptase inhibitor, similar to AZT. This drug is only in the first phase of human studies.
<dt>HBY-097: <dd>Experimental non-nucleoside reverse transcriptase inhibitor (NNRTI). In the laboratory, HIV that is resistant to HBY-097 does not reproduce as well as normal HIV. If studies go well, this drug may become available by prescription in late 1997 or early in 1998.
<dt>hydroxyurea (Hydrea): <dd>Approved anti-cancer drug being studied for the treatment of HIV infection in combination with ddI. May help ddI work better, even if HIV has gotten resistant to the effects of ddI alone. Side effects can be nausea, vomiting and bone marrow suppression.
<dt>indinavir (Crixivan): <dd>Approved protease inhibitor. Side effects can be nausea and kidney stones. If HIV becomes resistant to indinavir, other protease inhibitors may not work.
<dt>lobucavir: <dd>Experimental nucleoside analog antiviral drug. Effective against many different herpesvirus types, as well as HIV. Also being studied as a CMV treatment. If studies go well, this drug may become available by prescription in late 1997 or early in 1998.
<dt>nelfinavir (AG-1343, Viracept): <dd>Experimental protease inhibitor. The main side effect is diarrhea, which has been controlled with over the counter antidiarrheal medications when needed. This drug is currently available through an expanded access program and is expected to be approved for prescription in 1997.
<dt>nevirapine (Viramune): <dd>Approved non-nucleoside reverse transcriptase inhibitor (NNRTI). HIV develops resistance to this drug quickly, so it is approved for use in combination with nucleoside analog anti-HIV drugs. Not yet approved for use with protease inhibitors due to possible drug interactions. Possible side effect can be rash, which in some cases can be severe.
<dt>PMPA: <dd>Experimental nucleotide analog anti-HIV drug. May be more potent than nucleosides like AZT. Protected macaques from SIV ( a virus related to HIV) infection in animal studies. In Phase I studies in human beings.
<dt>ritonavir (Norvir): <dd>Approved protease inhibitor. Side effects can be nausea, diarrhea and numbing around the mouth. Also effects the absorption of many other drugs by the body due to its actions in the liver. There is a long list of drugs that can not be taken when taking ritonavir.
<dt>saquinavir (Invirase): <dd>Approved protease inhibitor. Few side effects, mainly stomach upset and gas. Not as well absorbed by the body as other protease inhibitors, which may make it easier for HIV to get resistant to saquinavir. HIV that is resistant to saquinavir may find it easier to resist the effects of other protease inhibitors. This is currently being studied in people.
<dt>VX-478 (141W94): <dd>Experimental protease inhibitor. Well tolerated in a small 4 week Phase I study, with the main side effect being a rash. Also had a strong anti-HIV effect. Larger studies are expected to begin in early 1997.
<p>
<dt><font color="#0000ff">Technical Terms</font>
<p>
<dt>nucleoside analog: <dd>An artificial copy of a nucleoside. Nucleosides are one of the building blocks of DNA, and DNA stores information necessary for creating any new living thing. Viruses make copies of themselves with DNA. Nucleoside analogs like AZT get into cells in the body and are mixed up with the virus' DNA as the virus tries to infect those cells. The nucleoside analog stops viral DNA from working properly. This prevents the cell from being infected, like throwing a wrench in the virus' genetic works. Nucleoside analogs may also sometimes inhibit production of human DNA in healthy cells, causing side effects. Non-nucleosides (NNRTIs) are drugs that inhibit the virus without using this mechanism.
<dt>nucleotide analog: <dd>An artificial copy of a nucleotide. Nucleotides work in the same way as nucleosides, but they have a slightly different chemical structure. This difference in structure is thought to make it easier for these drugs to get into cells in the body to protect them from infection by HIV.
<dt>reverse transcriptase inhibitors: <dd>Reverse transcriptase is a part of HIV required to infect cells in the body and make more virus. Drugs that inhibit reverse transcriptase stop HIV from infecting uninfected cells in the body. They do not help cells that have already been infected with the virus.
<dt>protease inhibitors: <dd>Protease inhibitors are non-nucleoside drugs that inhibit protease, an enzyme that HIV uses when it releases new virus from an infected cell. Unlike drugs that inhibit reverse transcriptase, protease inhibitors stop cells that are already infected from making new virus.
</dl>

<h3><font color="#0000ff"><a name="resources">About</a> Treatment Review</font></h3>

<p>The information in this review is not meant to replace the advice or care of a medical professional. Always discuss your treatment options with a trained health care provider. We don't manufacture, test, sell, advertise, or endorse any of these drugs or therapies.</p>

<p>Treatment Review is published six or more times a year. An annual membership contribution is requested from all Network participants, but is not mandatory. This donation greatly helps us run our day to day operations.</p>

<p>Treatment Review is written and edited by Ken Fornataro and Richard Jefferys, with the assistance of Stephen Rehberg, Eddy Gordon Berroa, Lizzie Nevrez, Mximo Seplveda, Marlene Daz, and many friends and colleagues. Special thanks go to Trip Gulick, MD and Mark Harrington.</p>

<p>If you want to copy, reproduce or excerpt this information, please give us a call at (800)734-7104. This helps us to keep track of where and how this information is being used. Treatment Review and other Network resources are available by E-mail, and are on the Internet. Drop us a line at <a href="mailto:atdn@aidsnyc.org">atdn@aidsnyc.org</a>.</p>

<p>The AIDS Treatment Data Network (The Network) is a not-for-profit, independent organization. We receive support for our work from individuals, foundations, government, and corporations. We appreciate and encourage contributions for our work.</p>

<p>Treatment Review is dedicated to Robert D. Farber, our friend, colleague, artist, teacher, brother, and sponsor. The Network offices are named in memory and honor of Robert. Special thanks also go to the Farber Family, and Fund for the City of New York.</p>

<p>The Network can be contacted by phone, by mail, fax, or e-mail. You can also visit our World Wide Web home page at http://www.aidsnyc.org/network. Our nationwide toll-free number is (800)734-7104. Our New York City number is (212)260-8868. If you have a computer and modem, our e-mail address is atdn@aidsnyc.org.<//p>

<p><b>Professional Membership</b><br>
Clinicians, industry representatives, academic and community researchers, service providers, organizations and other professionals are requested to make an annual membership contribution of $50.00. Members receive a subscription to Treatment Review, unlimited access to our Internet home page, and several other guides. If requested, members are listed in our resource providers databases as well.</p>

<p><b>Individual Membership</b><br>
Individual members receive up-to-the minute information about approved and experimental treatments, treatment counseling, referrals, and case management support. All of our informational resources and individualized counseling and referral services are available in both English and Spanish.</p>

<p> An optional $25.00 a year annual membership contribution is requested from individuals. People with AIDS and HIV are not required to make any contribution to receive services or materials, although contributions are greatly appreciated. All identifying information is kept strictly confidential. We do not share or rent our mailing lists, although we do occasionally mail out special announcements and other materials in sealed envelopes that do not include the words AIDS or HIV.</p>

<p>We're interested in hearing your comments, and suggestions of treatments you would like to see written about in Treatment Review.</p>

<p><b>Treatment Review</b><br>
Treatment Review is the newsletter of the AIDS Treatment Data Network. Each issue includes descriptions of approved, alternative, and experimental treatments, as well as announcements of seminars and forums on treatments and clinical trials. Published six or more times a year. $16.00. Publicado en Espa&ntilde;ol como Rese&ntilde;a de Tratamientos.</p>

<HR size=3 width=50% align=center noshade>

<p align=center><A HREF="trs.html"><img align=middle hspace=5 src="../gifs/left.gif" alt="">index of issues</A>
<A HREF="../index.html"><img align=middle hspace=5 src="../gifs/return.gif" alt="">Network home page</A></p>

</blockquote>

<HR size=3 width=50% align=center noshade>

<p align=center><font size=-2>Last modified: 12/23/96<BR>
<A HREF="mailto:atdn@aidsnyc.org">atdn@aidsnyc.org</A><BR>
copyright &#169; 1996 The Network</font></p>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-247</DOCNO>
<DOCOLDNO>IA093-001002-B002-396</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/news.html 199.29.141.24 19970121123237 text/html 21191
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:26:43 GMT
Server: NCSA/1.5.1
Last-modified: Thu, 16 Jan 1997 01:34:38 GMT
Content-type: text/html
Content-length: 21007
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Network: News</TITLE>
</HEAD>
<BODY bgcolor="#ffffff" link="#00688b" vlink="#545454"><font face="arial, helvetica" size=-1>

<H2 align=center>In the News</H2>

<H5 align=center>The <A HREF="index.html">Network</A> reports on information about treatments and research for HIV and AIDS <br>from newsletters, journals, newspapers and the Internet.</H5>

<p align=center><img src="gifs/line.gif" alt="[line]" width=50%></p>

<blockquote>

<h5><a name="agouron">January</a> 9, 1997</h5>

<p>"First Protease Inhibitor Drug Designed for HIV-Infected Children Is Due Soon"
Wall Street Journal (01/07/97) P. B6; Rundle, Rhonda L. A new <a href="simple/protease.html">protease inhibitor</a>, the first one to be formulated for and tested in children, will become available free of charge for children age 2 to 13 via a program offered by Agouron Pharmaceuticals.  Agouron has submitted its drug, Viracept, to the Food and Drug Administration for approval, seeking to market both a tablet for adults and a pediatric powder for children. <a href="../natap/drug/nelfped.html">Early trials of Viracept in children</a> have suggested that the drug offers benefits similar to those seen in <a href="trials/hiv.html#agex">adults</a>.  The three protease inhibitors being sold now have shown great benefit for adults, but have not been approved for <a href="trials/children.html#agex">children</a>.</p>

<p>PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 7 January 1997. A toll free information service will be available after January 7, 1997 for physicians, health care professionals and parents interested in the VIRACEPT Pediatric Expanded Access Program. 800-621-7111 is available Monday through Friday from 8:00 a.m. to 6:00 p.m. EST to answer calls. Calls placed before or after these hours will be returned during operating hotline hours.</p>

<h5><a name="d4t">November 27, 1996</h5>

<p>An internal memorandum from the AIDS Clinical Trials Group (ACTG) has entered circulation. It contains a warning about the <a href="simple/combo.html">combination</a> of the drugs <a href="simple/zido.html">AZT (Retrovir)</a> and <a href="simple/stav.html">d4T (Zerit)</a>. People taking this combination in a study known as ACTG 290 experienced significant unexplained drops in their T4 cell counts. People in this study had already been taking AZT for three years on average. Another study, known as ACTG 298, is looking at the combination of AZT and d4T in people who haven't taken anti-HIV drugs before. So far, in this study T4 cell counts are NOT dropping in people
receiving AZT/d4T. A note to physicians is being drafted by the ACTG, advising them to closely monitor the T4 cell count of anyone that is taking this combination."</p>

<h5><a name="dc">October</a> 12, 1996</h5>

<p><b>New Standards of Care in HIV Treatment</b>, October 18-19, 1996, Omni Shoreham Hotel, 2500 Calvert Street NW
Washington DC 20008, Sponsored by the DC CARE Consortium and the Mid-Atlantic AIDS Education and Training Center.</p>

<p>These two one day forums will present new infornation about the treatment of HIV. October 18 will be a Medical Forum intended for health professionals, with a registration fee of $25.00.</p>

<p>October 19 is a free Community Forum for people living with HIV and their service providers. Topics include "Practical Infornation about Antiretroviral Therapy," "The Role of Motivation, Nutrition and Complimentary Therapies in the Management of HIV Disease," and "Current Standards of Care in HIV Infection."</p>

<p>For more information about registering for this event, call Thom Martin, Special Projects, at RESCON, (703) 821-8205.</p>

<h5>September 30, 1996</h5>

<p>Agouron's protease inhibitor nelfinavir (Viracept) available to those who qualify through <a href="trials/hiv.html#agex">expanded access program</a>.

<h5><a name="medicaid">August</a> 29, 1996</h5>

<p>From the NYS Medicaid Office: <br>
ATTENTION:  Physicians, Clinics and Laboratories</p>

<p>"The Amplicor HIV-1 Monitor Test, which measures viral RNA using PCR amplification technology, has been approved by the FDA for the prognosis of HIV infected patients. Effective June 3, 1996 this "quantitative HIV RNA PCR test" is Medicaid reimbursable to appropriately certified labs when used in patient management to predict clinical outcomes, to predict risk of disease progression, and/or to provide information for a decision to initiate antiretroviral therapy or to change treatment regimes. </p>

<p>The Amplicor HIV-1 Monitor Test is not labeled for use as a screening test for HIV or as a diagnostic tool to confirm HIV infection, and is not reimbursable for these uses.</p>

<p>The MMIS procedure code to be used by clinical laboratories to claim reimbursement for the "quantitative HIV RNA PCR test" is 87179. This is to be billed withh 6 units as "times performed." The billing laboratory is responsible for assuring that the total amount requested does not exceed  their charge to the general public for the same test. The code listed above was appropriate at publication time of this article, but is subject to change based on fee schedule revision or other notification.</p>

<p>REMINDER: Medicaid policy restricts fee-for-service reimbursement to enrolled laboratories actually performing the test under NYS permit." <i>(<b>See also</b> <a href="simple/viral.html">viral load tests</a> and <a href="access/states/ny/medicaid.html">NYS Medicaid</a>.)</i> Other State Medicaid programs are being encouraged to develop local codes for viral load reimbursement until such time as a new CPT code has been allocated to the test.</p>

<h5><a name="soca">August</a> 14, 1996</h5>
<p>MOUNTAIN VIEW, Calif., Aug. 14 /PRNewswire/ -- Protein Design Labs, Inc. (PDL) (Nasdaq: PDLI) announced that the Studies of the Ocular Complications of AIDS (SOCA) group decided today to stop enrollment and treatment in the Phase II/III trial of PDL's PROTOVIR (TM) human anti-CMV antibody (MSL 109) as a supplemental treatment to primary treatment for CMV retinitis in patients with newly diagnosed or relapsed retinitis, based on lack of evidence of efficacy.</p>

<p>SOCA is an academic AIDS clinical research group supported by the National Eye Institute (NEI), a unit of the National Institutes of Health.</p>

<p>The study had enrolled 209 of the 325 patients planned for the study. Of those enrolled, approximately 40% were newly diagnosed with CMV retinitis and 60% had previously been diagnosed with, and treated for, CMV retinitis.</p>

<p>In making this decision, the SOCA investigators in the 15-center trial acted upon the recommendation of an independent data and safety monitoring board. The recommendation was based on the lack of evidence of efficacy of PROTOVIR for CMV retintis in this trial. The median time to progression was 65 days in the PROTOVIR group and 66 days in the placebo group.S</p>

<p>In the attached statement issued by SOCA to the participating centers, SOCA stated: "It also was observed that there was a higher mortality rate in the MSL 109-assigned group. The observed mortality difference was present only in patients with relapsed retinitis. No difference was observed in newly diagnosed patients. However, the meaning of this difference is unclear. It was noted that there was a lower than expected mortality rate in relapsed patients assigned to placebo."</p>

<p>PROTOVIR is also being tested in two other currently ongoing clinical trials, a Phase II study of the antibody in people with AIDS with newly diagnosed CMV retinitis that is being conducted by the AIDS Clinical Trial Group (ACTG) of the National Institute for Allergy and Infectious Diseases (NIAID) and a Phase II study being conducted by PDL for prevention of CMV infections in patients undergoing bone marrow transplantation. The Company is discussing the Impact of the SOCA decision on these trials with the relevant data and safety monitoring boards for these trials. The Company has received a preliminary indication that the ACTG intends to continue with that trial; however the ultimate impact of the SOCA action, if any, on the continuation or enrollment in the ACTG trial in CMV retinitis or the PDL-sponsored trial in bone marrow transplantation cannot be anticipated at this time.</p>

<p>The clinical centers are informing patients of the study results and of their treatment assignments. Follow up of patients will continue. Preparation of the study database is in progress for dissemination and publication of results.</p>

<h5><a name="pml">August</a> 1, 1996</h5>
<p><b>Ara C study stopped.</b> AIDS Clinical Trials Groups (ACTG) has stopped the trial for proven PML (progressive multifocal leukoencephalaopathy) that compares "maximum tolerated doses of anti retroviral treatment (with or with out protease or NNRTI's) to maximum tolerated antiretroviral treatment with IV administered ara-C, to intrathecal (directly to the brian through a shunt) ara-C with IV ara-C and maximum tolerated anti-retroviral treatment. The study, ACTG 243, accured 64 human beings with biopsy proven PML.</p>

<p>There was no difference in any of the arms in survival or in response to treatment. This means that no one lived longer and that no one improved and treatment with ara-C did NOT make a differnce and will probably NOT be recommended for treatment for PML. ara-C is an extremly bone marrow toxic cancer treatment. PML remains poorly understood. Some people, including some trial participants have remission of symptoms or stabization of symptoms with or with out any treament. There have been reports for years of individuals who seem to have responded to ara-C. However, there are more reports of people who died in the usual 1 to 4 months post diagnosis of PML.</p>

<p>The good thing about the study, though negative in result, is that it may have enough data about PCR teats for active JC virus in the Cerabral Spinal Fluid to find out if this is predictive of active PML disease. The results may also verify that MRI scans combined wiht a clinical picture can be used to diagnose PML, at least in people with low T cells. The ACTG is developing another trial with 9-amino campothecan (CPT-11), another cancer drug with action agaist JC Virus in the test tube. Pharmacia-Upjohn holds the patent. This would be a very small phase one trial. There is also a plan to develop an informational data base for PML to collect information about the potential use of protease inhibitors and NNRTI's (etc?) in PML. And to continue collecting information about JC virus levels in the CSF and some basic science information about the disease. <i>Matthew Chappell, ACT UP Golden Gate</i>.</p>

<h5><a name="clof">July</a> 28, 1996</h5>
<p>Dear CPCRA and ACTG Investigators:</p>

<p>FDA has just provided us with their recently completed results of an internal analysis on the data from Abbott study M93-069 "A Randomized Open-Label Study of the Tolerability and Efficacy of Clarithromycin and Ethambutol in Combination With or Without Clofazimine for the Treatment of dMAC in Patients With AIDS". This analysis included evaluation of microbiological, bacteriological, and clinical efficacy as well as a comparison of mortality stratified by baseline CFU. Conclusions from the FDA analysis are that:</p>

<ul>
<li>"Clofazimine adds no measurable bacteriological or clinical benefit to clarithromycin and ethambutol and may result in excessive mortality although the exact mechanism of this is not apparent. It is therefore unwarranted at this time to add Clofazimine to clarithromycin and ethambutol for the initial treatment of dMAC."
</ul>

<p>Given this new information the Division of AIDS recommends that investigators contact patients receiving Clofazimine therapy in CPCRA 027 and the salvage arm of ACTG 223 and advise them to discontinue Clofazimine.</p>

<p>DAIDS recognizes that M93-069 was a study of acute therapy for M. avium and the use of Clofazimine in ACTG 223 is limited to salvage therapy. However, given the lack of clinical and microbiological benefit and the potential increase in mortality DAIDS has concluded that the removal of Clofazimine from ACTG 223 is warranted. Patients on the salvage arm of ACTG 223 should be instructed to continue taking other study medications and additional therapy can be added at the discretion of the investigator pending further communication from the ACTG 223 team.</p>

<p>Although CPCRA 027 closes August 2nd, it is important that CPCRA investigators notify patients to stop Clofazimine therapy as soon as possible. CPCRA 027 patients may continue other study medications through August 2nd 1996. Further information will be disseminated as it becomes available. </p>

<h5><a name="clar">July</a> 28, 1996</h5>
<p><b>NIAID alert</b>: <a href="access/drugs/clar.html">clarithromycin (Biaxin)</a> should not be used at doses over 1000 mg a day, as doses higher than that have been associated with poor survival. Clarithromycin is used for prevention and treatment of <a href="simple/mac.html">MAC</a>.</p>

<h5><a name="nevi">June</a> 27, 1996</h5>
<p>"<b>Boehringer Viramune Drug Cleared as HIV Treatment</b>." Wall Street Journal (06/25/96) P. B6. <a href="simple/nevi.html">Viramune</a>, a new HIV drug made by Boehringer Ingelheim, is the first reverse transcriptase inhibitor to be approved by the Food and Drug Administration. The FDA cautioned that Viramune (nevirapine) should be combined with at least one other AIDS drug because HIV quickly becomes resistant to nevirapine when used alone. Studies showed that the drug was able to increase the efficacy of AZT in increasing CD4 cell counts.</p>

<p><b>Note</b>: Nevirapine will not be in pharmacies until August. by then, there will hopefully be more information from the XI International Conference on AIDS about nevirapine's safety and clinical effects (whether it has a good effect on a person's health).</p>

<p><b><a name="ddi">New</a> Flavor ddI Approved</b>. The Pink Sheet, June 3, 1996 "In Brief." New mandarin orange flavored tablets of <a href="simple/dida.html">ddI (didanosine, Videx)</a> were approved on Feb 27th and are now available. AWP (Average Wholesale Price) ranges from $23.26 for 25 mg 60s to $138.96 for 150 mg 60s. They are 35% smaller and softer than the original tablets and take half the time to disperse in water, about two minutes. BMS is also developing swallowable caplet and enteric-coated products to address gastrointestinal side effects associated with Videx.</p>

<h5><a name="cyclo">June</a> 22, 1996</h5>
<font size=-1><p>NEW YORK--(BUSINESS WIRE)--June 14, 1996--A small outbreak of a digestive illness caused by cyclospora, a parasite that city health officials believe may be harbored in strawberries shipped in from California, has resulted in at least 26 cases of illness in New Yorkers this week.</p>

<p>John Asher, M.D., medical director of the Jetti Katz Tropical Disease Lab, provides answers to commonly asked questions about the outbreak and how New Yorkers can protect themselves:</p>

<p>Q: What is cyclospora?</p>

<p>Dr. Asher: Cyclospora cayetanensis is a protozoan parasite that can cause diarrhea, nausea and fatigue, as well as cramping, weight loss, aching muscles and fever.</p>

<p>Q: How dangerous is it?</p>

<p>Dr. Asher: It is not usually fatal but its symptoms can be severe and can last a month or more. Anyone who believes he/she has been affected by it should see a doctor right away for accurate diagnosis and treatment.</p>
<P>Q: What is causing the current outbreak?</p>

<P>Dr. Asher: City health officials think it was caused by cyclospora in strawberries, perhaps in a shipment from California.</p>

<P>Q: What should I do to avoid getting sick? Will washing the berries make them safe?</p>

<p>Dr. Asher: No, washing is not enough since the organism may have burrowed into the berry. I recommend not eating strawberries until the city health department says it's safe to do so.</p>

<p>Q: What should I do if I think I have a case of the illness caused by cyclospora?</p>

<p>Dr. Asher: Accurate diagnosis is critical since cyclospora can easily be treated with Septra DS. If you think you have contracted cyclospora, see your doctor right away.</p>

<p>Q: Is cyclospora in other foods or in water?</p>

<p>Dr. Asher: There is no evidence of cyclospora contamination currently in any other food or in the city's water. Cyclospora has been found in the past in diarrhea outbreaks in Westchester and Florida, and in a few isolated cases in New York.</p>

<p><i>John Asher, M.D., an infectious disease specialist, began consulting with the laboratory in 1979 to study the relationship of the high rates of intestinal parasitic infections among HIV seropositive gay men. Dr. Asher is now president and medical director of Jetti Katz  Tropical Disease Laboratory, 212/472-3542 or 212/876-1492</i></p></font>

<h5><a name="pcr">June</a> 5, 1996</h5>
</p><font size=-1>VIRAL LOAD--FDA approves test June 3, 1996 from: <a href="../natap/pcr.html">National AIDS Treatment Advocacy Project</a>. See also <a href="simple/viral.html">viral load</a> Simple Facts Sheet.</font></p>

<h5><a name="saqu">May</a> 7, 1996</h5>
<font size=-1><p>(<i>ed. comment</i>) The following report from an Executive Summary from Hoffman-LaRoche shows the <a href="simple/combo.html">combination</a> of saquinavir/ddC compared to <a href="simple/zalc.html">ddC</a> or <a href="simple/saquin.html">saquinavir</a> alone cut the death rate more than two-thirds in study NV 14256. Other <a href="trials/hiv.html">combination studies</a> (<i><a href="../Architext/aidsnycquery.html">search</a> saquinavir</i>)  with saquinavir are ongoing.</p> 

<blockquote><b>NV 14256 Analysis of Clinical Endpoints</b><br>

NV14256 is a randomized, double blind comparison of zalcitabine (HIVID, ddC), saquinavir (Invirase, SQV) and the combination of saquinavir and ddC in 1086 HIV infected patients, with a CD4 lymphocyte count of 50-300 cells and with >/= 16 weeks of prior zidovudine (Retrovir, AZT) therapy. This is the final analysis of the primary clinical endpoints of the study, time to first AIDS-defining event or death, and the analysis of the secondary endpoint, survival alone. The analysis plan called for testing for the first hypothesis, the comparison of SQV + ddC to ddC, with testing for the second hypothesis, SQV vs. ddC only if the first is positive. Alpha level for significance is 0.05.</p>

<p>The patients in the intent to treat analysis (N=978) were balanced across the three treatment arms, with respect to sex, age, race, baseline viral load and baseline CD4 count (median baseline CD4 count 160-180 cells), and reason for discontinuing prior ZDV. The median duration of prior ZDV therapy was lower in the SQV + ddC group (68 weeks) than in the other groups (74-75 weeks).</p>

<p>Duration on initial treatment was shorter for patients on ddC, but duration of follow up was similar for all treatment arms (median 73-74 weeks). Slightly more patients in the SQV + ddC group than in the monotherapy arms completed the protocol, and discontinuations for protocol-mandated toxicity was highest in the ddC arm. Lost to follow up rates were low.</p>

<p>For the primary endpoint, time to first AIDS-defining event or death, there was a statistically significant benefit of combination SQV + ddC treatment over ddC treatment, with 85 endpoints on ddC, 77 on SQV and 46 on the combination arm (p=0.0002 by logrank test). There was no significant difference in the second hypothesis tested, the comparison of SQV to ddC.</p>

<p>For the secondary analysis of survival alone (time to death) there was also a statistically significant benefit of combination SQV + ddC treatment over ddC treatment, with 28 deaths on ddC, 34 on SQV, and 9 on the combination arm (p=0.002 by logrank test). There was no significant difference in the second hypothesis tested, the comparison of SQV to ddC.</p>

<p>A prior analysis of surrogate markers and safety in the first 423 patients out to week 48 established the safety profile of SQV + ddC and SQV compared to ddC. SQV was well tolerated alone and in combination, with no increase in ddC toxicities when used in combination. A full safety report from this study will be completed later in the year.</p>

<p>The final clinical endpoint analysis of this study clearly demonstrates, both for time to first AIDS-defining event or death, and survival alone, the clinical benefit of combination SQV + ddC over ddC. </p></blockquote>

</blockquote>

<p align=center><img src="gifs/line.gif" alt="[line]" width=50%></p>

<P ALIGN=CENTER><A HREF="index.html"><img src="gifs/return.gif" alt="[arrow]"></p><p align=center>to Network home page</A></P>

<p align=center><img src="gifs/line.gif" alt="[line]" width=50%></p>

<P align=center><FONT SIZE=-2>Last modified: 1/15/97<BR>
<A HREF="mailto:atdn@aidsnyc.org">atdn@aidsnyc.org</A><BR>
copyright &#169; 1996 1997 The Network</FONT></P>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-248</DOCNO>
<DOCOLDNO>IA093-001002-B002-415</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/phs/table.html 199.29.141.24 19970121123247 text/html 9261
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:26:54 GMT
Server: NCSA/1.5.1
Last-modified: Sat, 23 Nov 1996 22:46:56 GMT
Content-type: text/html
Content-length: 9078
</DOCHDR>
<html>
<head>
<title>PHS Guidelines</title>
</head>

<BODY bgcolor="#ffffff" TEXT="#000080" LINK="#0000FF" VLINK="#0080C0" ALINK="#FF0000"><font face="helvetica, arial" size=-1>

<H2 align=center>USPHS/IDSA Guidelines for prevention of opportunistic infections</H2>

<CENTER><TABLE Border=3 width=90%>
<TR>
<TH align=center colspan=2><font face="helvetica, arial" size=-1><a href="preface.html"><H3>About the Public Health Service Guidelines</H3></a>
Explains how the guide was written, and what the codes mean for treatment decisions between you and your doctor.</font></TH>
<P>
</TR>
<TR valign=top>

<TD width=50%><a href="pcp.html"><font face="helvetica, arial" size=-1><h4 align=center>Pneumocystis carinii pneumonia: PCP</A></H4>
<UL align=left>
<LI><A HREF="pcp.html#pcpexp">Prevention of exposure</A>
<LI><A HREF="pcp.html#pcprev">Prevention of disease</A>
<LI><A HREF="pcp.html#pcprec">Prevention of recurrence</A>
<LI><A HREF="pcp.html#pcped">Pediatric notes</A>
<LI><A HREF="pcp.html#pcpreg">Note regarding pregnancy</A>
</UL>
</font></td>

<P>

<TD width=50%><A HREF="toxo.html"><font face="helvetica, arial" size=-1><h4 align=center>toxoplasmosis</H4></A>
<UL align=left>
<LI><A HREF="toxo.html#toxprev">Prevention of exposure</A>
<LI><A HREF="toxo.html#toxdis">Prevention of disease</A>
<LI><A HREF="toxo.html#toxrec">Prevention of recurrence</A>
<LI><A HREF="toxo.html#toxped">Pediatric notes</A>
<LI><A HREF="toxo.html#toxpreg">Note regarding pregnancy</A>
</UL>
</font></td>
<P>
</TR>
<TR valign=top>

<TD><A HREF="crypto.html"><font face="helvetica, arial" size=-1><h4 align=center>cryptosporidiosis</H4></A>
<UL align=left>
<LI><A HREF="crypto.html#cryprev">Prevention of exposure</A>
<LI><A HREF="crypto.html#crypdis">Prevention of disease</A>
<LI><A HREF="crypto.html#cryprec">Prevention of recurrence</A>
<LI><A HREF="crypto.html#cryped">Pediatric notes</A>
</UL></font></td>

<P>

<TD><A HREF="micro.html"><font face="helvetica, arial" size=-1><h4 align=center>microsporidiosis</H4></A>
<UL align=left>
<LI><A HREF="micro.html#microprev">Prevention of exposure</A>
<LI><A HREF="micro.html#microdis">Prevention of disease</A>
<LI><A HREF="micro.html#microrec">Prevention of recurrence</A>
</UL>
</font></td>

<P>

</TR>
<TR valign=top>

<TD><A HREF="tb.html"><font face="helvetica, arial" size=-1><h4 align=center>tuberculosis: TB</H4></A>
<UL align=left>
<LI><A HREF="tb.html#tbprev">Prevention of exposure</A>
<LI><A HREF="tb.html#tbdis">Prevention of disease</A>
<LI><A HREF="tb.html#tbrec">Prevention of recurrence</A>
<LI><A HREF="tb.html#tbped">Pediatric notes</A>
<LI><A HREF="tb.html#tbpreg">Note regarding pregnancy</A>
</UL></font></td>

<P>

<TD><a href="mac.html"><font face="helvetica, arial" size=-1><h4 align=center>Mycobacterium avium complex: MAC</H4></A>
<UL align=left>
<LI><A HREF="mac.html#macprev">Prevention of exposure</A>
<LI><A HREF=" mac.html#macdis">Prevention of disease</A>
<LI><A HREF="mac.html#macrec">Prevention of recurrence</A>
<LI><A HREF="mac.html#macped">Pediatric notes</A>
<LI><A HREF="mac.html#macpreg">Note regarding pregnancy</A>
</UL></font></td>

<P>
</TR>

<TR align=top>

<TD><a href="bacresp.html"><font face="helvetica, arial" size=-1><h4 align=center>Bacterial respiratory infections</H4></A>
<UL align=left>
<LI><A HREF="bacresp.html#resprev">Prevention of exposure</A>
<LI><A HREF=" bacresp.html#resdis">Prevention of disease</A>
<LI><A HREF="bacresp.html#resrec">Prevention of recurrence</A>
<LI><A HREF="bacresp.html#resped">Pediatric notes</A>
<LI><A HREF="bacresp.html#respreg">Note regarding pregnancy</A>
</UL></font></td>

<P>

<TD><a href="bacent.html"><font face="helvetica, arial" size=-1><h4 align=center>Bacterial enteric infections</H4></A>
<UL align=left>
<LI><A HREF="bacent.html#resprev">Prevention of exposure</A>: <A HREF="bacent.html#entfood">food</A>, <A HREF="bacent.html#entpets">pets</A>, <A HREF="bacent.html#entrav">travel</A>
<LI><A HREF=" bacent.html#entdis">Prevention of disease</A>
<LI><A HREF="bacent.html#entrec">Prevention of recurrence</A>
<LI><A HREF="bacent.html#entped">Pediatric notes</A>
<LI><A HREF="bacent.html#entpreg">Note regarding pregnancy</A>
</UL></font></td>

<P>

</TR>

<TR valign=top>

<TD><a href="barton.html"><font face="helvetica, arial" size=-1><h4 align=center>Bartonella</H4></A>
<UL align=left>
<LI><A HREF="barton.html#barprev">Prevention of exposure</A>
<LI><A HREF="barton.html#bardis">Prevention of disease</A>
<LI><A HREF="barton.html#barec">Prevention of recurrence</A>
<LI><A HREF="barton.html#barped">Pediatric notes</A>
</UL></font></td>

<P>

<TD><a href="candi.html"><font face="helvetica, arial" size=-1><h4 align=center>candidiasis</H4></A>
<UL align=left>
<LI><A HREF="candi.html#canprev">Prevention of exposure</A>
<LI><A HREF="candi.html#candis">Prevention of disease</A>
<LI><A HREF="candi.html#canrec">Prevention of recurrence</A>
<LI><A HREF="candi.html#canped">Pediatric notes</A>
</UL></font></td>

<P>

</TR>

<TR valign=top>

<TD><a href="menin.html"><font face="helvetica, arial" size=-1><h4 align=center>Cryptococcosis</H4></A>
<UL align=left>
<LI><A HREF="menin.html#menprev">Prevention of exposure</A>
<LI><A HREF="menin.html#mendis">Prevention of disease</A>
<LI><A HREF="menin.html#menrec">Prevention of recurrence</A>
<LI><A HREF="menin.html#menped">Pediatric notes</A>
<LI><A HREF="menin.html#menpreg">Note regarding pregnancy</A>
</UL></font></td>

<P>

<TD><a href="histo.html"><font face="helvetica, arial" size=-1><h4 align=center>histoplasmosis</H4></A>
<UL align=left>
<LI><A HREF="histo.html#hisprev">Prevention of exposure</A>
<LI><A HREF="histo.html#hisdis">Prevention of disease</A>
<LI><A HREF="histo.html#hisrec">Prevention of recurrence</A>
<LI><A HREF="histo.html#hisped">Pediatric notes</A>
</UL></font></td>

<P>
</TR>
<TR valign=top>

<TD><a href="cocci.html"><font face="helvetica, arial" size=-1><h4 align=center>Coccidioidomycosis</H4></A>
<UL align=left>
<LI><A HREF="cocci.html#cocprev">Prevention of exposure</A>
<LI><A HREF="cocci.html#cocdis">Prevention of disease</A>
<LI><A HREF="cocci.html#cocrec">Prevention of recurrence</A>
<LI><A HREF="cocci.html#cocped">Pediatric notes</A>
</UL></font></td>

<P>

<TD><a href="cmv.html"><font face="helvetica, arial" size=-1><h4 align=center>Cytomegalovirus: CMV</H4></A>
<UL align=left>
<LI><A HREF="cmv.html#cmvprev">Prevention of exposure</A>
<LI><A HREF="cmv.html#cmvdis">Prevention of disease</A>
<LI><A HREF="cmv.html#cmvrec">Prevention of recurrence</A>
<LI><A HREF="cmv.html#cmvped">Pediatric notes</A>
</UL></font></td>
<P>
</TR>
<TR valign=top>

<TD><a href="simplex.html"><font face="helvetica, arial" size=-1><h4 align=center>Herpes simplex virus</H4></A>
<UL align=left>
<LI><A HREF="simplex.html#simprev">Prevention of exposure</A>
<LI><A HREF="simplex.html#simdis">Prevention of disease</A>
<LI><A HREF="simplex.html#simrec">Prevention of recurrence</A>
<LI><A HREF="simplex.html#simped">Pediatric notes</A>
<LI><A HREF="simplex.html#simpreg">Note regarding pregnancy</A>
</UL></font></td>

<P>

<TD><a href="zoster.html"><font face="helvetica, arial" size=-1><h4 align=center>Herpes zoster virus</H4></A>
<UL align=left>
<LI><A HREF="zoster.html#zosprev">Prevention of exposure</A>
<LI><A HREF="zoster.html#zosdis">Prevention of disease</A>
<LI><A HREF="zoster.html#zosrec">Prevention of recurrence</A>
<LI><A HREF="zoster.html#zospreg">Note regarding pregnancy</A>
</UL></font></td>

<P>

</TR>
<TR valign=top>

<TD><a href="hpv.html"><font face="helvetica, arial" size=-1><h4 align=center>Human papilloma virus</H4></A>
<UL align=left>
<LI><A HREF="hpv.html#hpvprev">Prevention of exposure</A>
<LI><A HREF="hpv.html#hpvdis">Prevention of disease</A>: <A HREF="hpv.html#women">women</A>, <A HREF="hpv.html#men">men</A>
<LI><A HREF="hpv.html#hpvrec">Prevention of recurrence</A>
<LI><A HREF="hpv.html#hpvped">Pediatric notes</A>
</UL></font></td>

<P>

<TD><font face="helvetica, arial" size=-1><h4 align=center><A HREF="notes.html">Notes</A> and <A HREF="notes.html#credits">Credits</A></H4>
All the footnotes and credits in one location with a mailform for requesting materials you'd like to pursue further.</font></td>

<P>

</TR>
<TR>

<TD colspan=2><a href="phs.zip"><font face="helvetica, arial" size=-1><h4 align=center>Zipped text for downloading</H4></A>
<P ALIGN=CENTER>If you need an unzip application, download <A HREF="file://ftp.farces.com/pub/visitors-center/software/ms-dos/compression/">pkunzip</A> for DOS, <BR><A HREF="http://www.winzip.com/winzip/download.html">WinZip</A> for Windows, or <A HREF="ftp://ftp.pht.com/pub/mac/umich/util/compression/">Zipit</A> for MACs.</P></font></td>
<P>
</TR>
</TABLE></CENTER>

<P align=center><A HREF="../index.html"><img align=middle hspace=5 src="../gifs/return.gif" alt="[arrow]">Back to Network home page</A></P>

<HR>

<P><FONT SIZE="-2"><img align=left src="../gifs/logo.gif" alt="[logo]" hsapce=5>Last modified: 8/8/95<BR>
The Network <A HREF="mailto:atdn@nyam.org">atdn@nyam.org</A><BR>
&#169; copyright 1995 The Network</FONT></P>

</font>
</body>
</html>








</DOC>
<DOC>
<DOCNO>WT18-B31-249</DOCNO>
<DOCOLDNO>IA093-001002-B002-441</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/drugloss.html 199.29.141.24 19970121123303 text/html 54161
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:27:03 GMT
Server: NCSA/1.5.1
Last-modified: Mon, 16 Dec 1996 22:05:21 GMT
Content-type: text/html
Content-length: 53977
</DOCHDR>
<html>
<head>
<title>Glossary: Drugs &amp; Treatments</title>
</head>

<body bgcolor="#ffffff" link="#00688b"><font face="arial, helvetica" size=-1>

<h3 align=center><a href="index.html">AIDS Treatment Data Network</a></h3>

<img align=left src="gifs/pillshot.gif" alt="[pill/shot]"><h2>Descriptions of drugs and treatments <br><font size=2>You can use your find function to search the glossary for the word you want. The binoculars icon in the Netscape toolbar does the same thing.</font></h2>

<p align=center><a href="#a"> A </a> | <a href="#b"> B </a> | <a href="#c"> C </a> | <a href="#d"> D </a> | <a href="#e"> E </a> | <a href="#f"> F </a> | <a href="#g"> G </a> | <a href="#h"> H </a> | <a href="#i"> I </a> | <a href="#j"> J </a> | <a href="#k"> K </a> | <a href="#l"> L </a> | <a href="#m"> M </a> | <a href="#n"> N </a> | <a href="#o"> O </a> | <a href="#p"> P </a> | <a href="#q"> Q </a> | <a href="#r"> R </a> | <a href="#s"> S </a> | <a href="#t"> T </a> | <a href="#u"> U </a> | <a href="#v"> V </a> | <a href="#w"> W </a> | <a href="#x"> X </a> | <a href="#y"> Y </a> | <a href="#z"> Z </a></p> 

<blockquote>

<dl compact> 

<dt><B><a name="a">A</a></B> 

<dt>abacavir (1592U89): 
<dd>Nucleoside analog reverse transcriptase inhibitor similar to AZT but thought to have stronger anti-HIV effects. Main side effects are rash and headache. In studies for the treatment of HIV and HIV-related dementia.

<dt>ABELCET: 
<dd>A liposomal preparation of <a href="#amph">amphotericin B</a>. A liposome is a tiny fat bubble that may help to direct drugs to diseased tissue. May have fewer side effects. Approved for the treatment of aspergillosis and other invasive fungal infections in people who can't take standard amphotericin B.

<dt>ABT-538 (ritonavir): 
<dd>See <a href="#rito">ritonavir.</a> 

<dt>ABV: 
<dd>This standard cancer chemotherapy treatment combines adriamycin, bleomycin and vincristine. It is given as an injection into the vein. 

<dt><a href="access/drugs/acyc.html">acyclovir (Zovirax)</a>: 
<dd>Approved for the treatment of herpes infections. Treatment is by mouth or injection. Acyclovir has few side effects. Stomach upset, headache or nausea are possible. Hair loss from prolonged use has been reported.

<dt><a name="adefovir">adefovir</a> dipivoxil (PMEA): 
<dd>A nucleotide analog. Effective against many different herpesvirus types, as well as HIV. Several studies in human beings are underway.

<dt>Adriamycin: 
<dd>See <a href="#doxorubicin">doxorubicin</a>. 

<dt>aerosolized pentamidine (Nebupent, Pneumo-pent): 
<dd>See <a href="#pentamidine">pentamidine</a>. 

<dt>AG-1343 (Viracept): 
<dd>See <a href=#nelfinavir>nelfinavir</a> 

<dt>albendazole: 
<dd>Being studied for the treatment of microsporidiosis. A pill. Side effects can include stomach upset, headaches and dizziness. Available from the <a href="../pwahg/info/albe.html">PWA Health Group</a> and other <a href="../rtrp/buyers.html">buyers clubs</a>. 

<dt>all-trans retinoic acid: 
<dd>The natural acid derivative of vitamin A. Has been shown to inhibit growth of cancer cells. Being studied for the treatment of KS. 

<dt><a name="alpha">alpha interferon</a> (Interferon alpha-2a, Roferon, Intron A): 
<dd>Approved as a treatment for KS. Given by injection. Side effects may include fevers, loss of white blood cells, flu-like symptoms and chills. Nausea is common. 

<dt><a name="alrt">ALRT</a> 1057. 
<dd>In studies in oral and topical form for the treatment of KS. Previous versions of this treatment were known as LGD 1057 and 9-cis-retinoic acid.  

<dt>Ambisome: 
<dd>Liposomal <a href="#amph">amphotericin B</a>. In studies for treatment of cryptococcal meningitis in children and adults. 

<dt>amikacin: 
<dd>An approved antibiotic. Being studied in combination with other drugs for the treatment of <a href="simple/mac.html">MAC</a>. Given by injection. Side effects include kidney damage. Another side effect can be hearing loss. 

<dt><a name="ami">amitriptyline</a> (Amitril, Elavil): 
<dd>For treatment of depression. Also used for peripheral neuropathy. 

<dt>Amphocil:
<dd>A liposomal preparation of <a href="#amph">amphotericin B</a>. A liposome is a tiny fat bubble that may help to direct drugs to diseased tissue. May have fewer side effects. Treatment for fungal infections. 

<dt>Amphotec (Amphocil): 
<dd>A liposomal preparation of amphotericin B. A liposome is a tiny fat bubble that may help to direct drugs to diseased tissue. May have fewer side effects. Approved for the treatment of aspergillosis in people who can't take standard amphotericin B.

<dt><a name="amph">amphotericin B (Fungizone)</a>: 
<dd>Antibiotic used to treat cryptococcal meningitis. Given intravenously. Strong side effects include fevers, chills, headache, anorexia, nausea, vomiting, diarrhea, kidney damage, and suppression of bone marrow production. An liquid version is now available that can be taken by mouth. A pill form is available from buyers' clubs.

<dt><a name="ana">anabolic steroids</a>: 
<dd>Known to increase muscle mass and weight. Use of steroids is still experimental in HIV, especially for long periods of time. Side effects in people with HIV are not yet known. 

<dt><a name="b4">anti-B4</a> blocked ricin: 
<dd>Treatment for lymphoma. Anti-B4 is a monoclonal antibody linked to a plant toxin (ricin). Blocking the ricin prevents it from binding to most cells, while the anti-B4 antibody targets the molecule to malignant B cells. Can affect the liver. Other side effects can be allergic reactions and weight gain. 

<dt>anti-B cell monoclonal antibody LL2s:
<dd><font size=2>Monoclonal antibodies are tumor-specific compounds that target diseased cells in the body with great precision. The monoclonal antibodies deliver radioisotope particles to the exact sites of infection, giving doctors a complete picture of how far a cancer has spread. 

<dt>anti-D: 
<dd>Anti-Rh antibodies. For the treatment of thrombocytopenia and low platelet count. Also known as Winrho. 

<dt>anti-TNF monoclonal antibody: 
<dd><font size=2>Drug that blocks TNF, sometimes called cachectin. TNF is a naturally occurring substance with many functions in the immune system. TNF levels are elevated in people with HIV infection and may contribute to progression of disease and wasting. 

<dt>AR-623 (tretinoin): 
<dd>A derivative of vitamin A. An intravenous drug being studied for KS. 

<dt><a name="ara-C">ara-C</a> (cytarabine): 
<dd>A cancer drug. Nausea and vomiting are the most common side effects. Sometimes used to treat PML. A recent study found no benefit to ara-C in the treatment of PML.

<dt>aspirin: 
<dd>Aspirin, or acetylsalicylic acid, has pain-relieving, fever-reducing, and anti-inflammatory activities. Aspirin is no longer being studied as a treatment for HIV disease. 

<dt><a name="atovaquone">atovaquone</a> (Mepron): 
<dd>Antibiotic approved for the treatment of mild to moderate PCP in people who can't take Bactrim/Septra. Experimental in the treatment of toxoplasmosis and microsporidiosis. Taken by mouth. Side effects can include headache, nausea, diarrhea, fever and rashes. Approved for treatment of mild to moderate PCP.

<dt><a name="azithromycin">azithromycin</a> (Zithromax): 
<dd>Antibiotic approved for the treatment of chlamydia and urinary tract infections, and for the treatment and prevention of MAC. Experimental in the treatment of toxoplasmosis and cryptosporidiosis. Side effects can be mild GI symptoms such as nausea and diarrhea, dizziness, sensitivity to sunlight, and hearing loss.

<dt><a href="simple/zido.html">AZT</a> (<a name="azt">zidovudine</a>, Retrovir): 
<dd>Nucleoside analog anti-HIV drug. AZT was the first drug approved for the treatment of AIDS. Recent studies show that it should not be used alone. AZT is now used in combination with the other anti-HIV drugs. Long-term AZT use is associated with loss of muscle. Other side effects can be nausea, anemia, white blood cell depression, mouth sores, bone marrow damage, and headaches. Also approved for preventing transmission of HIV from mother to child.

<dt><B><a name="b">B</a></B> 

<dt>B-4 blocked ricin: 
<dd>See <a href="#b4">anti-B4 blocked ricin</a> 

<dt>Bactrim: 
<dd>See <a href="#tmp">TMP/SMX</a> 

<dt>bDNA: 
<dd>See <a href="#dna">branched DNA assay</a>. 

<dt>Biaxin: 
<dd>See <a href="#clarithromycin">clarithromycin</a> 

<dt>bleomycin: 
<dd>An anti-cancer drug used for KS and lymphomas. The major side effect is suppression of bone marrow activity which can cause anemia. Other side effects can be fever, chills, and hair loss. 

<dt><a name="bovine">bovine</a> immunoglobulin concentrate (BIC, Sporidin-G): 
<dd>Experimental treatment for cryptosporidiosis. Made from antibodies derived from Cow's milk.

<dt><a name="dna">branched</a> DNA assay (bDNA): 
<dd>One of several new <a href="simple/viral.html">research tests</a> that measure the amount of HIV in the blood. The test uses a light-detecting system to find HIV RNA particles in a blood sample. The intensity of light generated by the captured particles is proportional to the amount of HIV present. 

<dt>Bucast: 
<dd>See <a href="#mdl">MDL 28574A</a>. 

<dt><a name="bv">BV</a>-ara-U: 
<dd>Antiviral with activity against herpes and varicella-zoster virus (VZV). Seems to be tolerated as well as acyclovir. Can have dangerous interactions with cancer drugs.

<dt>BW256U: 
<dd>See <a href="#valacyclovir">valacyclovir</a>. 

<dt><B><a name="c">C</a></B> 

<dt>CCNU (Lomustine): 
<dd>An anti-cancer drug being studied for the treatment of HIV associated lymphoma. 

<dt>capreomycin: 
<dd>Antibiotic used to treat MAC and TB. Side effects can include anorexia, thirst, excess urination, red blood cells in urine, anemia, hearing loss. 

<dt>ceftriaxone: 
<dd>Antibiotic which may be an effective treatment for neurosyphilis. Can be given outside of the hospital. Side effects can include diarrhea and liver problems. 

<dt>CHOP: 
<dd>CHOP: Combination of anti-cancer drugs that include cytoxan, <a href="#doxorubicin">doxorubicin</a> (hydroxydaunomycin hydrochloride), Oncovin, <a href="#prednisone">prednisone</a>. 

<dt>CI-1012: 
<dd>Anti-HIV zinc finger inhibitor currently in studies. Zinc fingers are a part of HIV that help assemble new viruses as they are leaving an infected cell. When the zinc fingers are blocked, HIV makes copies of itself that don't work and can't infect new cells. 

<dt><a name="cido">cidofovir</a> (Vistide, HPMPC): 
<dd>Newly approved intravenous <a href="simple/cmv.html">CMV</a> treatment. Infusions can be as far apart as every other week. Given with a drug called probenicid to try and avoid the major side effect, which is kidney damage. Also being studied in an intravitreal formulation. 

<dt><a name="cimetidine">cimetidine</a> (Tagamet): 
<dd>Approved for treatment of peptic (stomach) ulcers. 

<dt>ciprofloxacin (Cipro):
<dd>Antibiotic used in combination with other drugs to treat <a href="simple/mac.html">Mac</a>. When used as preventive medication, may reduce risk of intestinal infections. Nausea, diarrhea, vomiting, and  abdominal pain are the most frequent side effects. Bad taste in the mouth, restlessness, rash, sensitivity to sunlight and seizures are other possible side effects.

<dt>cisplatin (Platinol): 
<dd>Chemotherapy treatment for tumors. Kidney damage is the most serious side effect. 

<dt><a name="clarithromycin">clarithromycin</a> (Biaxin): 
<dd>Antibiotic approved for treatment and prevention of mycobacterium avium complex (MAC). Experimental in the treatment of toxoplasmosis and cryptosporidiosis. May have to be used in combination with other drugs. Infrequent side effects are diarrhea, nausea, and abnormal taste. Should NOT be used at doses higher than 1000 mg a day.

<dt>clindamycin: 
<dd>Antibiotic. Currently under investigation in combination with pyrimethamine for treatment and prevention of toxoplasmosis, and treatment of pneumocystis pneumonia (PCP). Side effects include diarrhea. IV administration can cause a bitter taste in the mouth. 

<dt>clofazimine: 
<dd>Approved for the treatment of Hansen's disease. Clofazimine has been studied as a treatment for MAC, but it did not work. Side effects can include gastrointestinal upset and rashes. Also, gradual skin discoloration.

<dt>clotrimazole troche (Mycelex): 
<dd>A slow-dissolving lozenge. For treatment of fungal infection in the mouth. Occasional side effects are nausea, dizziness, diarrhea and change in liver function. 

<dt><a name="corti">corticosteroid</a>: 
<dd>Corticosteroids include prednisone, corticosterone, cortisone, and aldosterone. Used for treatment of PCP. High dose corticosteroids are immunosuppressive and people with HIV infection should be cautious about taking them. 

<dt>Crixivan: 
<dd>See <a href="#indinavir">indinavir</a>. 

<dt>cyclophosphamide: 
<dd>Anti-cancer drug, intravenous or oral. Has immune suppressing effects. Under investigation for the treatment of HIV. Side effects can include blood damage and nausea. 

<dt>cycloserine: 
<dd>Antibiotic used to treat MAC and TB. Side effects can include nervous system symptoms, allergy, skin rash, and elevated liver function tests. Individuals with severe kidney impairment should not be given this drug. 

<dt>cysteamine: 
<dd>Used for treatment of a rare genetic kidney disease in children. May work with AZT in stopping HIV from reproducing.

<dt>cytarabine: 
<dd>See <a href="#ara-C">ara-C</a>. 

<dt>Cytovene: 
<dd>See <a href="#ganciclovir">ganciclovir</a>. 

<dt><B><a name="d">D</a></B> 

<dt><a name="d4t"><a href="simple/stav.html">d4T</a></a> (stavudine, Zerit): 
<dd>Approved nucleoside analog anti-HIV drug. Side effects can include nerve damage in the hands and feet, stomach upset, pancreatitis and liver damage.

<dt>dacarbazine: 
<dd>An anti-cancer drug often added to the combination of adriamycin, bleomycin and vincristine. Used for treating lymphomas. 

<dt>dapsone: 
<dd>Approved to treat Hansen's disease. Used for the treatment of Pneumocystis carinii pneumonia (PCP). Babies and adults who cannot take Bactrim because they get rashes, fevers, and other allergic reactions may respond better to dapsone. Also being used as prevention. Side effects can be anemia, and allergic reactions such as widespread rash and fever. In studies for prevention of PCP in children. 

<dt>daunorubicin: 
<dd>Being studied for the treatment of cancers such as leukemias, sarcomas, carcinomas, and lymphomas 

<dt>Daunoxome: 
<dd>Approved first-line treatment for advanced AIDS-related KS. Also approved for people who cannot take standard treatments. A liposome form of daunorubicin. A liposome is a tiny fat bubble that may help to direct drugs to diseased tissue. May have fewer side effects in treating KS. Given intravenously once every two weeks.

<dt><a name="ddc">ddC</a> (Hivid): 
<dd>Approved nucleoside analog anti-HIV drug. Side effects can include nerve damage in the hands and feet, pancreatitis, and sores in the mouth.

<dt><a href="simple/dida.html">ddI (<a name="ddi">Videx</a>)</a>: 
<dd>Approved nuclseoside analog anti-HIV drug. Comes as chewable tablet or powder. Side effects can include nerve damage in the hands and feet, damage to the pancreas, and diarrhea. Serious adverse reactions have been reported in people taking ddI at the same time as rifabutin and clofazimine. If you are taking IV pentamidine for PCP at the same time as ddI, there is an increased risk of pancreatitis.

<dt><a name="delavirdine">delavirdine</a> (U90): 
<dd>A non-nucleoside reverse transcriptase inhibitor (NNRTI). Reverse transcriptase is a part of HIV required to infect cells in the body and make more virus. NNRTIs stop the reverse transcriptase from working properly, like the nucleoside analog drugs. The main side effect is a rash.

<dt>dexamethasone: 
<dd>A steroid. May be effective in reducing cranial pressure that is a symptom of cryptococcal meningitis. Long term treatment can cause adrenal suppression.

<dt>Dexedrine: 
<dd>An amphetamine. Approved for treatment of narcolepsy and attention deficit disorder. In studies for treatment of fatigue associated with AIDS. 

<dt>dextromethorphan: 
<dd>Being studied for treatment of HIV encephalopahty (swelling of the brain) or dementia. Works against glutamate receptors in the brain which may be involved in duronal dysfunction in HIV infection. Generally well tolerated. Mild side effects are immediately reversible through dose reduction or discontinuation. 

<dt>DHPG: 
<dd>See <a href="#ganciclovir">ganciclovir</a>. 

<dt>didanosine: 
<dd>See <a href="#ddi">ddI</a>.

<dt>Diflucan: 
<dd>See <a href="#fluc">fluconazole</a>. 

<dt>DMP266: 
<dd>One of a new class of drugs called NNRTIs (non-nuceloside reverse transcriptase inhibitors) which include nevirapine and delavirdine. DMP-266 stays in the body for a long time and so is only taken once a day. Currently in studies in human beings.

<dt>Doxil: 
<dd>Approved KS treatment. Liposomal doxorubicin, an anti-cancer drug. A liposome is a tiny fat bubble that may help to direct drugs to diseased tissue. Drugs encapsulated in liposomes may have fewer side effects. 

<dt><a name="doxorubicin">doxorubicin</a> (Adriamycin): 
<dd>Approved drug for many types of cancers such as leukemias, sarcomas, carcinomas, and lymphomas. Can cause bone marrow suppression, mouth sores, and make your urine red. 

<dt><a name="dron">dronabinol</a> (Marinol): 
<dd>A synthetic version of the active chemical in marijuana. Approved for treatment of appetite loss or anorexia associated with weight loss in people with AIDS. Most frequent side effects are drowsiness, muddled thinking, and coordination impairment. 

<dt><B><a name="e">E</a></B> 

<dt>Elavil: 
<dd>See <a href="#ami">amitriptyline</a> 

<dt>Epivir: 
<dd>See <a href="#3tc">3TC</a>. 

<dt><a href="access/drugs/eryt.html">erythropoietin (EPO)</a>: 
<dd>Approved for the treatment of AZT-related anemia in people with HIV. May help treat other HIV-related anemias. Generally well tolerated. Side effects can include chest pain, swelling, fast heart beat, headache, and high blood pressure.

<dt>ethambutol (Myambutol): 
<dd>Oral drug used in combination with other drugs to treat tuberculosis. Used in combination with other drugs as a treatment for MAC. Side effects may include decreased or distorted vision, pain and swelling of joints, tingling burning pain, nausea, vomiting, headache, and mental confusion. 

<dt>etoposide (Vepesid): 
<dd>Approved drug for treatment of cancer of the testicles and small cell lung cancer. In studies for treatment of AIDS associated KS. May be useful for treating CNS lymphomas. It can be taken by mouth or injected into a vein. Side effects include blood damage, hair loss, nausea, loss of coordination, inflammation of the mouth, shortness of breath, and loss of appetite. 

<dt><B><a name="f">F</a></B> 

<dt>5-FU (flourouracil): 
<dd>A cream applied to the cervix and into the vagina for treatment and prevention of cervical cancer. Side effects can include burning and inflammation. 

<dt>famciclovir (Famvir): 
<dd>Approved for the treatment of herpes zoster virus (shingles). A pill formulation of the IV drug penciclovir. Side effects are minimal. In studies for zoster in people with HIV.

<dt>F-ddA: 
<dd>An experimental nucleoside analog anti-HIV drug. F-ddA is related to the approved anti-HIV drug ddI, but is expected to be better absorbed and therefore does not have to be administered with buffers. The buffers in ddI pills can make the drug difficult to take. In the test tube, F-ddA is active against HIV that is resistant to ddI.

<dt>fentanyl:
<dd>An opiate being studied in patch form for the treatment of chronic pain in people with AIDS. 

<dt>1592U89:
<dd>See <a href="#u89">U89</a>. 

<dt><a name="fluc">fluconazole</a> (Diflucan): 
<dd>Approved for the treatment of different types of fungal infections. Used to treat cryptococcal meningitis and thrush in the esophagus. Side effects can include stomach upset. Some doctors are starting people with low T4 cell counts on fluconazole or a related drug, itraconazole, as preventive treatment for fungal infections. 

<dt>flucytosine (5-FC, Ancobon): 
<dd><font size=2>Anti-fungal drug usually given with <a href="#amph">amphotericin B</a> in order to decrease the emergence of resistant strains. A pill. Side effects can include liver damage. 

<dt>foscarnet (Foscavir): 
<dd>Approved for treatment of CMV disease and acyclovir reistant herpes simplex infections.. Also inhibits other herpes viruses and HIV. Being studied for treatment of KS. Main side effect is kidney damage, which can be treated. The foscarnet your body gets rid of in urine can sometimes cause irritation. If sores occur, they will go away even with the continuation of foscarnet. 

<dt>fozivudine tidoxil: 
<dd>An experimental nucleoside analog anti-HIV drug, similar to AZT. In phase I studies.

<dt>Fungizone: 
<dd>see <a href="#amph">amphotericin B</a>. 

<dt><B><a name="g">G</a></B> 

<dt><a name="gamma">gamma </a>interferon (rIFN-gamma): 
<dd>Being studied in combination with AZT in children. An immunomodulator that has been shown to help children with severely compromised nonspecific immunity. Used to treat leprosy and may be useful for treatment of other mycobacterial infections. 

<dt><a name="ganciclovir">ganciclovir</a> (DHPG, Cytovene): 
<dd><font size=2>Approved for treatment of <a href="simple/cmv.html">CMV</a>. Given intravenously through a permanent catheter. <a href="simple/cytovene.html">Ganciclovir pills</a> are approved for maintenance treatment in some cases. Also approved for CMV prevention in some cases. Side effects include suppression of white blood cells, called neutropenia. You must discontinue <a href="simple/zalc.html">ddC</a> until you are stable on ganciclovir. 

<dt>G-CSF (Neupogen): 
<dd>Approved to treat neutropenia (a decrease in white blood cells) in people with cancer, although not yet in people with AIDS. Stimulates production of white blood cells. Side effects of G-CSF include nausea, bone pain and rash. 

<dt>GEM91: 
<dd>Belongs to a new category of drugs, called antisense drugs. May be able to target a specific disease without causing significant side effects. Antisense drugs work by interfering with the way viral proteins make more virus. Currently in Phase I studies in NYC for treating HIV infection. 

<dt>GM-CSF (sargramostim, Leukine, Prokine): 
<dd>Approved to treat neutropenia (a decrease in white blood cells) after bone marrow transplants, although not yet approved in people with AIDS. Side effects can include bone pain, rashes, and fever. Stimulates macrophages, which may be infected with HIV.

<dt><a name="gp120">gp120</a> vaccine: 
<dd>gp120 is a piece of protein on the outside of the HIV virus. By creating a vaccine with the shape of this protein, it is hoped that the immune system will begin or increase production of antibodies against the virus. Studies have found no benefit to this vaccine. 

<dt><a name="gp160">gp160</a> vaccine: 
<dd>gp160 is part of the outer envelope of the HIV virus. Researchers hope that the gp160 vaccine will stimulate the immune system to attack the virus, extending the symptom-free period. Studies so far have not found any benefit to this vaccine. 

<dt>growth factor, growth hormone: 
<dd>See <a href="#hgh">human growth hormone</a>. 

<dt><B><a name="h">H</a></B> 

<dt><a name="hby">HBY 097</a>: 
<dd><font size=2>An experimental anti-HIV drug in a class of drugs called non-nucleoside reverse transcriptase inhibitors. Other drugs in this class are <a href="#nevirapine">nevirapine</a> and <a href="#delavirdine">delavirdine</a>. Laboratory studies suggest that when HIV tries to resist the effects of this drug, the HIV becomes weaker and possibly less harmful to the body. <a href="oisgloss.html#neutropenia">Neutropenia</a> may be a side effect. 

<dt>HGH: 
<dd>See <a href="#hgh">human growth hormone</a>. 

<dt>Hivid: 
<dd>See <a href="#ddc">ddC</a> 

<dt>HIVIG: 
<dd>A type of passive immunotherapy which may help people with HIV. HIVIG is a sterile solution of concentrated antibodies. Differs from passive immunotherapies in which blood from an HIV+ person with high levels of antibodies is given to an HIV+ person with low levels of antibodies. HIVIG is being tested to see if it prevents transmission from mothers to newborns. Side effects may include headaches, low-grade fever, allergic reaction, and transient rashes. 

<dt>HPMPC: 
<dd>See <a href="#cido">cidofovir</a>. 

<dt><a name="hgh">human</a> growth hormone (Serostim, HGH, rHGH): 
<dd>Approved for the treatment of weight loss in people with AIDS. Growth factors and growth hormones are naturally occurring substances necessary for the growth of particular immune system cells.

<dt>Humatin: 
<dd>See <a href="#paro">paromomycin</a> 

<dt>Hycamtin: 
<dd>See <a href="#topotecan">topotecan</a>.

<dt>hydroxychloroquine (Plaquenil): 
<dd><font size=2>Used for many years to treat malaria, rheumatoid arthritis, and lupus, an automimmune disease. In the test tube, has shown anti-HIV activity. May correct HIV-related inflammation. Side effects are rare. 

<dt>hypericin: 
<dd>A substance in the herb St. John's Wort which has anti-HIV effects in the test tube. Human studies in the US were stopped due to severe reactions to sunlight seen in trial participants. Studies are ongoing in Thailand.

<dt><B><a name="i">I</a></B> 

<dt>IL-2: 
<dd>See <a href="#il2">interleukin-2</a>. 

<dt>IL-3: 
<dd>See <a href="#il3">interleukin-3</a>. 

<dt>IL-10: 
<dd>See <a href="#il10">interleukin-10</a>. 

<dt>IL-12: 
<dd>See <a href="#il12">interleukin-12</a>.

<dt>IM-862 nasal solution: 
<dd>Water peptide, administered intranasally. Has been shown in studies to strongly suppress growth of new blood vessels and has shown anti-cancer activity. In studies for the treatment of KS. 

<dt>imipramine (Tofranil): 
<dd><font size=2>Anti-depressant. Possible side effects include insomnia, numbness and tingling, tremors, seizures, dry mouth or blurred vision. 

<dt><a name="imiquimod">imiquimod</a>: 
<dd>A cream being studied for treatment of anal and genital warts. The cream causes the body to produce a substance called <a href="oisgloss.html#interferon">alpha-interferon</a>. In one study, this helped treat the warts in more than half the people that were using the cream. 

<dt><a name="indinavir">indinavir</a> (Crixivan, MK-639): 
<dd> Protease inhibitor made by Merck. <a href="simple/protease.html">Protease inhibitors</a> are non-nucleoside drugs that inhibit protease, an enzyme that HIV used to replicate. Studies have shown that it can greatly reduce the amount of HIV in the blood, particularly when combined with other anti-HIV drugs. Researchers recommend taking indinavir with at least one other nucleoside analog anti-HIV drug (AZT, ddI, ddC, d4T or 3TC). For the strongest anti-HIV effect indinavir should be taken with two nucleoside analogs. Side effects can be elevated liver function tests and kidney stones. 

<dt>interferons: 
<dd>Produced by the body during viral infections. See <a href="#alpha">alpha interferon</a>, <a href="#gamma">gamma interferon</a>.

<dt><a name="il2">interleukin 2</a> (IL-2): 
<dd>Controls the growth and function of many types of cells. Being studied in combination with AZT and other antivirals, also being studied for the treatment of KS. Side effects can be fever, chills, and overall sick feeling. 

<dt><a name="il3">interleukin-3</a> (IL-3): 
<dd>One of the messengers of the immune system. Stimulates red and white blood cells, as well as platelets. 

<dt><a name="il10">interleukin-10</a>: 
<dd> One of the chemical messengers of the immune system. Under study for HIV infection. Effects on the body are not yet known. 

<dt><a name="il12">interleukin-12</a>: 
<dd>One of the chemical messengers of the immune system. May stimulate cellular immunity. Caused severe side effects when given intravenously as a treatment for kidney cancer. Now being studied as an intramuscular shot for the treatment of HIV infection. 

<dt><a name="ig">intravenous</a> immunoglobulin (IVIG): 
<dd>A sterile solution of concentrated antibodies that is injected into a vein or muscle. Approved for the prevention of bacterial infections in children with HIV. Sometimes used to treat low platelet counts in people with AIDS.

<dt>Invirase (saquinavir): 
<dd>See <a href="#saqu">saquinavir</a>. 

<dt><a href="access/drugs/ison.html">isoniazid (INH)</a>: 
<dd>Oral and IV antibiotic used in combination with other drugs to treat and prevent active tuberculosis (TB). Side effects can include liver damage and neuropathy. 

<dt>isotretinoin (retinoic acid): 
<dd><font size=2>Reduces development of tumors in previously treated individuals. Side effects include inflammation of the skin and mucus membranes, and hepatitis. 

<dt><a name="itra">itraconazole</a> (Sporanox): 
<dd><font size=2>Antifungal drug being studied for a number of AIDS-related fungal infections including cryptococcal meningitis. Approved as treatment for histoplasmosis and blastomycosis. Taken by mouth. Side effects can include stomach upset, loss of potassium, and headache. 

<dt>IVIG: 
<dd>Approved for the prevention of bacterial infections in pediatric
HIV infection. See <a href="#ig">intravenous immunoglobulin</a>. 

<dt><B><a name="j">J</a></B> 

<dt><B><a name="k">K</a></B> 

<dt>ketoconazole (Nizoral): 
<dd>A prescription drug supplied in tablets and liquid. It is used for the treatment of systemic (throughout the body) fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomy-cosis, histoplasmosis, chromomycosis, and paracoccidioidomycsis. Side effects may include liver problems and the suppression of hormone production, including testosterone. 

<dt>KNI-272 (Kynostatin): 
<dt>Experimental anti-HIV protease inhibitor. In phase I studies in adults and children.

<dt><B><a name="l">L</a></B> 

<dt>L-735,524 (MK-639, Crixivan): 
<dd>See <a href="#indinavir">indinavir</a>. 

<dt>lamivudine: 
<dd>See <a href="#3tc">3TC</a>. 

<dt>L-carnitine (levocarnitine): 
<dd>A naturally occuring substance in the body used in metabolism and energy production. Also available as a supplement.

<dt><A NAME="leuc">leucovorin</A> calcium: 
<dd>A member of the vitamin B complex. Leucovorin is used to treat severe anemia. Leucovorin is used to reduce anemia in people taking dapsone, a preventive treatment for PCP, and to treat side effects of sulfa drugs taken to treat toxoplasmosis. Skin rash and itching are possible side effects. 

<dt>Levamisole: 
<dd>A prescription drug approved for use in colon cancer treatment. Being studied in children with HIV infection. May improve immune function. Rare side effects are nausea, vomiting, diarrhea, rash and flu-like symptoms. 

<dt>levofloxacin (ofloxacin): 
<dd>Used to treat lower respiratory infections. Has broad activity against bacterial infections. Common side effects include restlessness, nausea, diarrhea, vomiting and abdominal pain.

<dt>Lexipafant:
<dd>A platelet-activating factor antagonist. In studies for the treatment of HIV-associated dementia. 

<dt>liarozole: 
<dd>Experimental drug that stimulates the production of retinoic acid. Being studied as a treatment for Kaposi's sarcoma.

<dt>liposome-encapsulated amphotericin B: 
<dd>A liposome is a tiny fat bubble that may help to direct drugs to diseased tissue. Liposomal drugs may have fewer side effects. See <a href="#amph">amphotericin B</a>. 

<dt><B><a name="m">M</a></B> 

<dt>Marinol: 
<dd>See <a href="#dron">dronabinol</a> 

<dt>mBACOD: 
<dd>mBACOD stands for methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine and dexamethasone. Together with folinic acid and GM-CSF (to stimulate white blood cell production), they constitute standard treatment for AIDS-related lymphoma. Side effects can include nausea, vomiting, hair loss, and reduced numbers of white blood cells. 

<dt><a name="mdl">MDL</a> 28574: 
<dd>Currently in Phase I studies. In lab tests, MDL 28574 reduced the capacity of T4 cells to bind with cells chronically infected with HIV-1 which resulted in reduced virus production. 

<dt>Megace (megestrol acetate): 
<dd>Approved for treatment for weight loss and poor appetite. A female hormone. Rare side effects can include change in menstrual patterns, pain in chest, depression, swelling in hands and feet, brown spots on skin, increased body hair, increased breast tenderness, and high blood pressure.

<dt>memantine: 
<dd>Used in Europe since 1982 to treat Parkinson's disease. Being studied for the treatment of dementia in people with HIV.

<dt>Mepron: 
<dd>See <a href="#atovaquone">atovaquone</a> 

<dt>methadone: 
<dd>A prescription drug which effects the body similarly to morphine or heroin. Used as a substitute narcotic in the management of heroin addiction. 

<dt>methionine: 
<dd>Amino-acid necessary for the formation of myelin. In studies for treatment of a neurological disorder called myelopathy. 

<dt>methotrexate: 
<dd>Anti-cancer drug, intravenous or oral. Also used to treat psoriasis. Under study as a treatment for HIV. Side effects can include blood damage and nausea. Some drugs, such as anti-inflammatory agents and acyclovir, can increase the toxicity of methotrexate. 

<dt>mexiletine: 
<dd>Approved for the treatment of heart rhythm disorders. Being studied as a treatment for HIV-related neuropathy. Side effects can be GI distress and dizziness. 

<dt><a name="mgbg">MGBG</a> (metoguazone): 
<dd>Anti-tumor drug. Not approved for the treatment of any malignancy, but has demonstrated antitumor activity. Being studied for the treatment of non-Hodgkin's lymphoma. The compound is non-mylosuppressive and has excellent penetration of the blood brain barrier. Side effects of daily dosing produced severe mucositis, vasculitis, painful skin lesions and anorexia with significant weight loss. Prolonging the infusion produced severe diarrhea. 

<dt>MK-639 (L-735, Crixivan): 
<dd>See <a href="#indinavir">indinavir</a>. 

<dt><a name="mono">monoclonal</a> antibody: 
<dd>Copies of antibodies that target diseased cells in the body with precision. Side effects may include allergic reactions, fevers, chills, low blood pressure, and liver and kidney problems. Used as drug delivery systems for cancer treatments. 

<dt><a name="msl">MSL </a>109 (serivumab, Protovir): 
<dd>A monoclonal antibody (see <a href="#mono">above</a>) designed to target <a href="simple/cmv.html">CMV</a>. Early results are promising.

<dt>Mycobutin: 
<dd>See <a href="#rifa">rifabutin</a> 

<dt><B><a name="n">N</a></B> 

<dt>NAC (N-acetylcysteine)
<dd>A derivative of the naturally occurring amino acid cysteine. Used in liquid form in very high doses to treat Tylenol overdoses. In Europe, commonly used for bronchitis. Broken down by the body into cystein which is used to replace glutathion. People with AIDS can have low levels of cysteine. Being studied for the treatment of HIV infection in the gut.

<dt><a name="nelfinavir">nelfinavir</a> (AG-1343, Viracept): 
<dd>Protease inhibitor made by Agouron. Targets the protease enzyme of HIV. Early studies have shown that it can greatly reduce the amount of HIV in the blood.

<dt><A NAME="neutrexin">NeuTrexin</A>:
<dd>NeuTrexin: See <a href="#gluc">trimetrexate glucuronate</a>.

<dt><a name="nevirapine">nevirapine</a> (BI-RG-587, Viramune): 
<dd>Approved anti-HIV drug. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). HIV develops resistance to this drug quickly, so it is approved for use in combination with other anti-HIV drugs. Possible side effect can be rash.

<dt>nimodipine (Nimotop): 
<dd>A calcium channel blocker. A pill that may treat dementia by preventing the calcium channels from letting HIV enter into brain cells. Side effects can include decreased blood pressure. 

<dt>9-cis-retinoic acid: 
<dd>A possible treatment for KS. A natural acid derivative of vitamin A. In studies as a cream applied directly to KS lesions. Possible side effects include skin irritation so exposure to sun should be avoided. See <a href="#alrt">ALRT 1057</a>.

<dt><a name="ntz">nitazoxanide</a> (NTZ): 
<dd>Experimental antiparasitic drug in studies as a treatment for cryptosporidiosis. Showed promise in early studies in Mexico. The most common side effects are abdominal pain, nausea and diarrhea. Available from the PWA Health Group.

<dt>Norvir: 
<dd>See <a href="#rito">ritonavir</a>. 

<dt>NTZ: 
<dd>See <a href="#ntz">nitazoxanide</a>. 

<dt>nucleoside analog: 
<dd>An artificial copy of a nucleoside (the building blocks of DNA). When incorporated into the virus' DNA during viral replication the analog acts to prevent production of new virus. Nucleoside analogs can also inhibit production of DNA in healthy cells. Non-nucleosides are drugs that inhibit the virus without using this mechanism. 

<dt>nystatin (Mycostatin): 
<dd>A common topical treatment for thrush. Also used for the treatment of intestinal candidiasis. Has shown anti-HIV effect in the test tube and is being studied in an intravenous formulation for treatment of HIV infection. Side effects can include affecting taste, nausea, vomiting, diarrhea and stomach pain. 

<dt><B><a name="o">O</a></B> 

<dt>OK-B7: 
<dd>A monoclonal antibody being tested for lymphoma. See also <a href="#mono">monoclonal antibody</a>. 

<dt>OPC-14117: 
<dd> Antioxidant in studies for cognitive impairment. A vitamin E-like compound that may protect nerve cells from damage due to HIV infection. 

<dt>oxandrolone (Anavar): 
<dd>A steroid being studied to see if it can help people with AIDS gain weight and muscle strength. It is a pill. Side effects in men can include the development of breast tissue and low sperm counts. Side effects in women can include an interrupted menstrual cycle and the development of facial hair and a deeper voice. Side effects in both men and women can include water retention and liver damage. The effects of steroids in people who are HIV positive are not known. 

<dt><B><a name="p">P</a></B> 

<dt><a name="paro">paromomycin</a> (Humatin): 
<dd>An antibiotic used for the treatment of intestinal infections. May be a useful treatment for diarrhea caused by cryptosporidiosis infection. A pill. Side effects can include stomach upset and diarrhea. 

<dt>passive immunotherapy: 
<dd>A treatment where blood from an HIV+ donor with a high level of anti-HIV antibodies is given to an HIV+ person with fewer antibodies, in hopes that it will boost the immune response to infection. 

<dt>PCR: 
<dd>See <a href="#pcr">polymerase chain reaction assay</a>. 

<dt>penicillin G: 
<dd>Standard therapy for neurosyphilis. Must be given in a hospital setting. 

<dt><a name="pentamidine">pentamidine</a> (Pentam, Nebupent): 
<dd>Administered intravenously to treat PCP. Given in aerosol form as a prevention against PCP. Side effects of injected pentamidine can include low blood sugar, pancreatitis, and kidney disease. Side effects of inhaled pentamidine can include coughing and collapsed lung. There is an increased risk of getting PCP when only inhaled pentamidine is used. 

<dt><a name="pento">pentoxifylline</a> (Trental): 
<dd>Approved for the treatment of blood-clotting disorders in the elderly. May reduce levels of tumor necrosis factor (TNF) is the blood. Studies have not found benefits for people with AIDS. Headache, tremor, dizziness, bad digestion, nausea, and vomiting are the most common side effects. 

<dt>Peptide T: 
<dd>A drug intended to block HIV from entering cells. May be helpful for peripheral neuropathy as well. In studies for dementia. Available from buyers clubs. 

<dt>Pixy321: 
<dd>A combination of two naturally occurring cytokines, IL-3 and GM-CSF. In lab and animal tests, Pixy321 has been able to stimulate both neutrophil and platelet growth after high-dose radiation. 

<dt>PMEA (adefovir): 
<dd>See <a href="#adefovir">adefovir dipivoxil</a>.

<dt>PMPA:
<dd>A nucleotide analog. May be more potent than nucleosides like AZT. Protected macaque monkeys from SIV (a virus related to HIV) infection in animal studies. In Phase I studies in humans beings.

<dt>Pneumopent: 
<dd>See <a href="#pentamidine">aerosolized pentamidine</a> 

<dt><a name="pcr">polymerase</a> chain reaction sassay (PCR): 
<dd> One of several approved <a href="simple/viral.html">tests</a> that measure the amount of HIV in a blood sample. May help show how well an anti-HIV treatment is working. May also help people decide if they could benefit from anti-HIV treatment. 

<dt>polypophyrin: 
<dd>Used to make skin sensitive to light. 

<dt><a name="prednisone">prednisone</a>: 
<dd>A corticosteroid used to reduce inflammation. Taken by mouth. Side effects can include immune suppression, depression, euphoria, hypertension, nausea, and anorexia. 

<dt>procarbazine: 
<dd>An approved oral anti-cancer drug used primarily as part of a multi-drug treatment for Hodgkin's disease. Side effects can include mylosuppression, nausea, and vomiting, neuropathy, confusion and swelling. 

<dt>procysteine: 
<dd>Stimulates production of glutathione which may inhibit the replication of HIV. Many people with HIV have low levels of glutathione. Taken by mouth. Currently in clinical trials. 

<dt>proleukin (IL-2): 
<dd>Used for the treatment of kidney cancer. Being tested as a TB treatment. Also in combination studies for HIV infection and KS. <a name="protease">

<dt><a href="simple/protease.html">protease inhibitor</a></a>: 
<dd>Drug which stops protease from working. Protease is an enzyme needed for HIV replication. 

<dt>Protovir: 
<dd>See <a href="#msl">MSL-109</a>. 

<dt>Prozac (fluoxetine): 
<dd>A standard treatment for depression in non HIV-infected individuals. Side effects can include overstimulation, upset stomach, and headache. 

<dt>pyrazinamide (PZA): 
<dd>An oral anti-TB drug used in combination. Side effects can include liver damage, nausea, and rash. 

<dt><a name="pyridoxine">pyridoxine</a>: 
<dd>Form of vitamin B6 used with INH treatments for tuberculosis to help prevent side effect of peripheral neuropathy. 

<dt>pyrimethamine: 
<dd>An anti-protozoal drug. Standard treatment for toxoplasmosis in combination with sulfadiazine. Being studied as a prevention. Taken by mouth. Side effects can include bone-marrow damage and rashes. Folic acid deficiency can cause a painful burning tongue, loss of taste, and anemia. 

<dt><B><a name="q">Q</a></B> 

<dt><B><a name="r">R</a></B> 

<dt><a name="rhngf">recombinant</a> human nerve growth factor: 
<dd>In studies for treatment of HIV-associated peripheral neuropathy. May be able to reverse nerve damage. Animal studies have shown it also completely prevents nerve damage caused by toxic effects of certain cancer drugs.

<dt>Rescriptor: <dd>See <a href="#delavirdine">delavirdine</a>.

<dt>retinoids: 
<dd>A class of drugs which have shown encouraging results in the treatment of cancers and other conditions such as hairy leukoplakia and molluscum contagiosum. These drugs are a chemically created version of a substance found in Vitamin A. Like Vitamin A, retinoids can be very dangerous, and stay in the body for a very long time. Medical supervision is highly recommended. 

<dt>Retrovir: 
<dd>See <a href="#azt">AZT</a>. 

<dt>rhNGF:
<dd>Recombinant <a href="#rhngf">human nerve growth factor</a>. In studies for treatment of HIV-associated peripheral neuropathy.

<dt>rhu IL-1R: 
<dd>Binds to IL-1. Used in experimental treatments for KS. IL-1 is a cytokine produced in response to infection which may contribute to KS. 

<dt>ribavirin (Virazole): 
<dd>In lab studies, inhibits HIV replication. Test tube studies show it works better in combination with ddI. In early trials in humans, did not work. 

<dt><a name="rifa">rifabutin</a> (Mycobutin): 
<dd>Approved for preventing MAC in people with AIDS with less than 75 T4 cells. Recent studies have found it less effective than clarithromycin or azithromycin. Also used in combination with other drugs as a MAC treatment. Side effects can include kidney and liver damage, bone marrow suppression, rash, fever and GI distress. Urine, feces, saliva, sputum, sweat or tears may become red-orange to red-brown in color.

<dt>rifampin: 
<dd>TB treatment. Can be taken by mouth or injected into a vein. Side effects can include liver damage, and stomach upset.

<dt>rifapentine: 
<dd>An antibiotic. In studies for the treatment of MAC.

<dt><a name="rito">ritonavir</a>: 
<dd>Protease inhibitor made by Abbott. Studies have shown that it can greatly reduce the amount of HIV in the blood. It has also been shown to reduce disease progression and death in a study of people with under 100 T cells. Side effects can be nausea, diarrhea and numbing around the mouth. Also affects the absorption of many other drugs by the body due to its actions in the liver. 

<dt>RMP-7: 
<dd>A drug which allows substances to cross the blood-brain barrier. 

<dt>rPF4: 
<dd>Recombinant platelet factor 4. A synthetic version of a naturally occurring protein which inhibits blood vessel formation. Being studied for the treatment of KS. New blood vessel formation is believed to be important in the development of KS. 

<dt>r24 antibody: 
<dd>Copy of an antibody that attacks r24, which is a protein found on cells damaged by Hodgkin's disease. See also <a href="#mono">monoclonal antibody</a>. 

<dt><B><a name="s">S</a></B> 

<dt><a name="saqu">saquinavir</a>: 
<dd>(Invirase, Ro 31-9959) <a href="#protease">Protease inhibitor</a> made by Hoffman-La Roche. Well tolerated with almost no side effects. Not as well absorbed by the body as other protease inhibitors. Better antiviral activity in studies when combined with nucleoside analogs. 

<dt>Septra: 
<dd>See <a href="#tmp">TMP/SMX</a> 

<dt>serivumab: 
<dd>See <a href="#msl">MSL-109</a>. 

<dt>Sorivudine: 
<dd>See <a href="#bv">BV-ara-U</a>. 

<dt>sparfloxacin: 
<dd>An antibiotic that has shown activity against mycobacterium, the organisms which cause tuberculosis and MAC. Side effects from use in non-HIV infected people include hypersensitivity to sunlight and GI distress. 

<dt>Sporanox: 
<dd>See <a href="#itra">itraconazole</a>.

<dt>Sporidin-G: 
<dd>See <a href="#bovine">bovine immunoglobulin concentrate</a>.

<dt>stavudine: 
<dd>See <a href="#d4t">d4T</a>. 

<dt>streptomycin: 
<dd>Antibiotic used in combination with other drugs to treat TB. Side effects can include nausea, vomiting, dizziness, rash and fever. Loss of hearing has been seen following long-term use. Should not be used by anyone with kidney impairment. 

<dt>steroids: 
<dd>See <a href="#ana">anabolic steroids</a> or <a href="#corti">corticosteroids</a>. 

<dt>sulfadiazine: 
<dd>A sulfa drug used in the treatment of toxoplasmosis and meningitis. Sulfadiazine can produce toxic side effects which include bone marrow suppression. Because it is a sulfa drug, many people cannot tolerate it. The drug forms crystals in the kidneys, which can lead to blockage and kidney failure. 

<dt>sulfamethoxazole:
<dd>For people with HIV disease, this drug is usually given in a combination form for prevention of PCP. The combination form is trimethoprim/sulfamethoxazole, or TMP/SMX. As a single drug product, sulfamethoxazole is most commonly used to treat urinary tract infections.

<dt>sulfasalazine: 
<dd>Widely used for the treatment of inflammatory conditions such as ulcerative colitis and arthritis. Has been safely used in people with HIV disease complicated with arthritis. Comes in tablet form and is taken by mouth. The main side effects are headaches, nausea, vomiting and abdominal pain. 

<dt>Sustacal Plus: 
<dd>Nutritional supplement being studied as a treatment for weight loss. 

<dt><B><a name="t">T</a></B> 

<dt>Tagamet: 
<dd>See <a href="#cimetidine">cimetidine</a>

<dt>Targretin: 
<dd>See <A HREF="#alrt">ALRT 1057</A>. Activates retinoid receptors. Oral form in studies for treatment of KS. 

<dt>Taxol (paclitaxel): 
<dd>Anti-cancer treatment made from yew trees. Being studied for KS treatment. 

<dt><a name="3tc">3TC</a> (Epivir, lamivudine): 
<dd>Approved nucleoside analog anti-HIV drug. 3TC has also shown activity against the hepatitis-B virus (HBV). Side effects can include headache, nausea, low white blood cells and rare cases of hair loss.

<dt>testosterone: 
<dd>Male sex hormone. In trials for treatment of sexual dysfunction, weight loss and depression.

<dt><a href="simple/thalid.html">thalidomide</a>: 
<dd>Originally developed as a sleeping pill. Lab studies show that it has effect against HIV, TB and inflammatory conditions. May cause severe birth defects. In studies for treatment of HIV and wasting. Available through an Emergency IND program. 

<dt>thymic humoral factor (THF): 
<dd>A hormone found in thymuses of young calves. The most common side effect associated with administration of THF is pain upon injection. More uncommon are redness and/or swelling. 

<dt>thymopentin (TP-5): 
<dd>In lab tests, stimulates the thymus and production of T cells. Possible side effects include respiratory congestion, pain at injection, headache, and fatigue. 

<dt>TJ-9: 
<dd>A formulation of the herbal compound Sho-Saiko-To.

<dt>TLC D-99: 
<dd>A form of liposomal doxorubicin made by The Liposome Company. In study for treatment of KS. 

<dt><a name="tmp">TMP/SMX</a> (Bactrim, Septra): 
<dd>A drug combination effective at preventing and treating PCP pneumonia. May also prevent toxoplasmosis as well. Can cause allergies, typically fever, itchy rash, nausea, and vomiting. Neutropenia can also occur. 

<dt><a name="TNP-470">TNP-470</a>: 
<dd>Possible treatment for KS. An angiogenesis inhibitor, is tolerated in people with KS. TNP-470 prevents the growth and development of new blood vessels. New blood vessel formation is believed to be important in the development of KS. Possible toxicities are expected to be very mild, including diarrhea, anorexia, and nausea. 

<dt><a name]"topotecan">topotecan</a>: 
<dd>Approved treatment for ovarian cancer. Being studied for the treatment of PML.

<dt>total parenteral nutrition (TPN): 
<dd>Liquid food injected directly into the bloodstream through a vein. Used to treat malnourishment. 

<dt>Trental: 
<dd>See <a href="#pento">pentoxifylline</a> 

<dt>trifluridine: 
<dd>Used experimentally to treat acyclovir-resistant herpesvirus infections. 

<dt>trimethoprim (TMP): 
<dd>One component of Bactrim and Septra, drugs which are used to prevent PCP pneumonia in HIV+ individuals. Often used with leucovorin rescue, a B vitamin that helps prevent the blood cell damage these drugs can cause.

<dt><a name="gluc">Trimetrexate</a> glucuronate: 
<dd>Approved for treatment of moderate to severe PCP when Bactrim/Septra cannot be used. Used in combination with leucovorin which protects cells from drug toxicity.

<dt><B><a name="u">U</a></B> 

<dt><a name="u89">U89</a>: 
<dd>Reverse transcriptase inhibitor similar to AZT but thought to have fewer side effects. In Phase I/II studies. Resistance to treatment may also be slower to develop. In animal studies, crosses blood brain barrier and has synergy with AZT, ddI, ddC, 3TC and some protease inhibitors.

<dt>U90: 
<dd>See <a href="#delavirdine">delavirdine</a>. 

<dt><B><a name="v">V</a></B> 

<dt>vaccines: 
<dd>Vaccines are being tested as treatments for people who are HIV+. From all studies conducted to date, HIV vaccines appear to be safe in HIV+ people. At this time it is not known if they are effective treatments. The vaccine cannot give you HIV. See also <a href="#gp120">gp120</a>, <a href="#gp160">gp160</a>. 

<dt><a name="valacyclovir">valacyclovir</a>: 
<dd>An antiviral agent which is rapidly turned into acyclovir in the bloodstream. More absorbable by the body than oral acyclovir. 

<dt>Vaxsyn: 
<dd>An experimental HIV vaccine treatment using the gp 160 protein. 

<dt>Videx: 
<dd>See <a href="#ddi">ddI</a> 

<dt>VIMRxyn: 
<dd>A synthetic version of hypericin, an anti-HIV substance in the herb St. John's Wort. Studies are ongoing in Thailand.

<dt>vinblastine: 
<dd>Given intravenously in combination with other drugs for the treatment of KS. Can have many side effects, including suppression of bone marrow. 

<dt>vincristine (Oncovin): 
<dd>A drug sometimes used in the treatment of KS, thrombocytopenia, leukemias, lymphomas, and solid tumors. Can have many side effects, including reversible peripheral neuropathy. 

<dt>Viracept: 
<dd>Brand name for <a href="#protease">protease inhibitor</a> made by Agouron, also known as AG-1343. Approval expected in early 1997, expanded access in October 1996.

<dt>Viramune:
<dd>See <a href="#nevirapine">nevirapine</a>.

<dt>Vistide: 
<dd>See <a href="#cido">cidofovir</a>. 

<dt>vitamin B6: 
<dd>See <a href="#pyridoxine">pyridoxine</a>. 

<dt>VX-478: 
<dd>Experimental protease inhibitor made by Glaxo-Wellcome. Well tolerated in Phase I study. 

<dt><B><a name="w">W</a></b>

<dt>WinRho SD: 
<dd>Approved for the treatment of <A HREF="oisgloss.html#thrombo">ITP</A> in children with chronic or acute ITP, adults with chronic ITP and children and adults with ITP secondary to HIV infections. See <A HREF="#ig">immune globulin</A>. Not approved for patients whose spleen have been removed. 

<dt><b><a name="x">X</a></b> 

<dt><b><a name="y">Y</a></B> 

<dt><B><a name="z">Z</a></B> 

<dt>zalcitabine: 
<dd>See <a href="#ddc">ddC</a>. 

<dt>Zerit: 
<dd>See <a href="#d4t">d4T</a>. 

<dt>zidovudine: 
<dd>See <a href="#azt">AZT</a>.

<dt>Zithromax:
<dd>See <a href="#azithromycin">azithromycin</a>.

</dl>

</blockquote>

<HR SIZE=3 WIDTH=50% ALIGN=CENTER noshade>

<P ALIGN=CENTER><A HREF="index.html"><img src="gifs/return.gif" alt="[arrow]"></p><p align=center>to Network home page</A></P>

<hr size=3 align=center width=50% noshade>

<P align=center>Last modified: 12/16/96<BR> <A HREF="mailto:atdn@aidsnyc.org">atdn@aidsnyc.org</A><BR> copyright &#169; 1996 The Network</P>

</font>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-250</DOCNO>
<DOCOLDNO>IA093-001002-B003-19</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/oisgloss.html 199.29.141.24 19970121123314 text/html 49041
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:27:19 GMT
Server: NCSA/1.5.1
Last-modified: Mon, 02 Dec 1996 16:43:01 GMT
Content-type: text/html
Content-length: 48857
</DOCHDR>
<html>
<head>
<title>Glossary: Conditions & Symptoms</title>
</head>
<BODY bgcolor="#ffffff" link="#00688b" vlink="#545454"><font face="arial, helvetica" size=-1>

<h3 align=center><a href="index.html">AIDS Treatment Data Network</a></h3>
<img align=left src="gifs/pillbot.gif" alt="[pill/bottle]"><h2>Descriptions of opportunistic infections and conditions <br><font size=2>You can use your find function to search the glossary for the word you want. The binoculars icon in the Netscape toolbar does the same thing.</font></h2>

<CENTER><TABLE WIDTH=570 BORDER=0>
<TR>
<TD><font size=-1 face="arial, helvetica"><a href="#a">|A|</a> <a href="#b">|B|</a> <a href="#c">|C|</a> <a href="#d">|D|</a> <a href="#e">|E|</a> <a href="#f">|F|</a> <a href="#g">|G|</a> <a href="#h">|H|</a> <a href="#i">|I|</a> <a href="#j">|J|</a> <a href="#k">|K|</a> <a href="#l">|L|</a> <a href="#m">|M|</a> <a href="#n">|N|</a> <a href="#o">|O|</a> <a href="#p">|P|</a> <a href="#q">|Q|</a> <a href="#r">|R|</a> <a href="#s">|S|</a> <a href="#t">|T|</a> <a href="#u">|U|</a> <a href="#v">|V|</a> <a href="#w">|W|</a> <a href="#x">|X|</a> <a href="#y">|Y|</a> <a href="#z">|Z|</a></font></TD><P></TR></TABLE></CENTER>

<blockquote><DL COMPACT>

<DT><B><a name="a">A</a></B>

<DT>AIDS: <DD>The late stage of a disease caused by infection with the virus called 
HIV. There is a difference between being HIV-positive (HIV+) and having AIDS. 
<DT><a href="altx.html#acupuncture">acupuncture</a>: <DD>Therapy in which needles are applied to meridians (set points of the body). The precise disorder treated or the degree of anesthesia required determines the temperature of the needle used, the angle of insertion, the speed of insertion and withdrawal. 
<DT>acute: <DD>Rapid in onset; severe, life-threatening. The opposite of persistent, chronic, or long-term. 
<DT>adjuvant: <DD>Any substance which enhances the immune-stimulating properties of an antigen or the pharmacological effect of a drug. 
<DT>administration: <DD>This term refers to how a drug is taken. 
<DT>adverse reaction (side effect): <DD>Participants in clinical trials may have reactions to the experimental medicines. Toxic reactions are usually listed in the protocol and the participant's Informed Consent. However, some reactions may never have been reported before. Any amount of toxicity must be reported within 24 hours by telephone to the sponsor of the trial, who then must tell the FDA. A clinical trial can be stopped because of an adverse reaction. Approved drugs can also have side effects. All side effects that may be caused by an approved drug are listed on the labeling. 
<DT>aerosolized: <DD>A form of administration in which a drug, such as pentamidine, is turned into a fine spray or mist by a nebulizer. The drug is then inhaled. 
<DT>AIDS Clinical Testing Unit (ACTU): <DD>The sites where NIAID's AIDS drug clinical trials are performed. 
<DT>AIDS Clinical Trials Group (ACTG): <DD>The federal AIDS drug testing organization. 
<DT>alkaline phosphatase (alk phos): <DD>An enzyme measurement that indicates the health of the liver. 
<DT>allergy: <DD>An immediate or delayed immune reaction caused by a substance such as dust, a drug, or other foreign material that causes an allergic reaction amebiasis: Infection caused by a tiny animal parasite which lives in the human large intestine. 

<dt>Amplicor: 
<dd>See <a href="#pcr">polymerase chain reaction test</a>.

<DT>amylase: <DD>A class of enzymes (proteins). Amylase it is secreted by salivary glands and the pancreas to aid digestion of food. An increase in amylase levels may indicate pancreatitis. 
<DT>anabolic steroid: <DD> Naturally occurring hormones that help convert protein into muscle. Testosterone is an anabolic steroid. May be useful in treating wasting associated with AIDS. 
<DT>analgesic: <DD> Agent that reduces pain without reducing consciousness. Aspirin is an analgesic. 
<DT>analog (analogue): <DD>A chemical compound with a structure similar to that of another but differing from it in respect to a certain component; it may have a similar or opposite action metabolically. 
<DT><a name="anemia">anemia</a>: <DD>A condition which occurs if the blood cannot carry enough oxygen to nourish tissues. Common symptoms of anemia are fatigue, headache, and shortness of breath. Anemia may be caused by too few red blood cells or too little hemoglobin or both. 
<DT>anorexia: <DD>Prolonged loss of appetite that leads to significant weight loss. 
<DT>antagonist: <DD>A drug that prevents or reverses the action of another drug. 
<DT>antibacterial: <DD>A substance which stops or checks the growth of bacteria. 
<DT>antibodies: <DD>Proteins in the blood which recognize and block foreign substances. 
<DT>anticoagulant: <DD>A substance that delays or counteracts blood clotting. 
<DT>antifungal: <DD>A substance which kills or inhibits the growth of a fungus. 
<DT><a name="antigen">antigen</a>: <DD>A substance which, when introduced into the body, is capable of starting the production of a specific antibody by the immune system. 
<DT>anti-inflammatory: <DD>A substance which counteracts or suppresses inflammation. Swelling and redness are types of inflammation. There are two types of anti- inflammatory drugs: steroids, such as cortisone, and non-steroidal agents, such as aspirin. 
<DT>antioxidant: <DD>Substances that may prevent free radicals from causing damage. Molecules in the body that are oxidized can cause cell damage. Examples of antioxidants are vitamins A, C and E. 
<dt>antiretroviral: <DD>A substance that stops or suppresses the activity of a retrovirus such as HIV. AZT, ddC, ddI, d4T, 3TC, saquinavir, ritonavir, indinavir nevirapine, etc. are examples of antiretroviral drugs. 
<dt>antiviral: <DD>A type of substance or process which destroys a virus or suppresses its pathogenic action. 
<dt>ARC (AIDS Related Complex): <DD>HIV positive with symptoms. Usually called HIV disease. 
<dt>aspergillosis: <DD>A disease caused by a fungus. It can cause lesions of the skin, ear, orbit, nasal sinuses, lungs and sometimes the bones, meninges, heart, kidneys or spleen. Symptoms include fever, chills, difficulty breathing, and coughing up blood. If the infection reaches the brain, it may cause dementia. 
<dt>assay: <DD>A test 
<dt>asymptomatic: <DD>Infection without symptoms. Someone who is asymptomatic has antibodies to HIV but does not have any visible signs or symptoms of HIV infection. 
<dt>ataxia: <DD>Loss of muscle control leading to jerky or uncoordinated movements. 
<dt>atrophy: <DD>A wasting or decrease in size. 
<dt>attenuated virus: <DD>A weakened virus whose ability to infect or produce disease is potentially reduced. 
<dt>autoantibodies: <DD>Antibodies that mistakenly attack host cells. 
<dt>autoimmune disease: <DD>A disease which arises from and is 
directed against an individual's own tissues. 

<DT><B><a name="b">B</a></B> 

<dt>bDNA: 
<dd>See <a href="#bdna">branched DNA assay</a>.

<dt>B-lymphocytes (B-cells): <DD>One of the immune system cell types; B cells fight infection primarily by making antibodies. During infections, these cells are transformed into factories that make thousands of antibodies against a foreign substance. This transformation occurs through interactions with various types of T-cells and other components of the immune system. 
<dt>B symptoms: <DD>Fever, night sweats, weight loss. 
<dt>bacteria: <DD>A group of microscopic organisms that cause disease when they infect someone. 
<dt>baseline: <DD>The first or starting measurement. New measurements of blood values are compared to this starting value. 
<DT>bDNA: See <a href="#bdna">branched DNA</a> assay.
<dt>bilirubin: <DD>A reddish yellow pigment occurring in bile, blood, urine and gallstones. An elevated level is a fair indicator that something is wrong with the liver, pancreas, or bile ducts. The eyes often become yellow in color. Indicates the health status of the liver. 
<dt>bioavailability: <DD>The rate and extent to which a substance is absorbed and circulated in the body. 
<dt>biopsy: <DD>Removal and laboratory examination of tissue from the living body. In some cases a tiny piece of skin is cut off and examined. Other types of biopsy can be more serious, such as a brain biopsy, which is done very rarely. A biopsy is usually done to clearly determine the cause of an illness. 
<dt>blastomycosis: <DD>An infectious disease caused by a fungus, usually in the lungs. It can spread to the skin, bone or other tissues. 
<dt>blood brain barrier: <DD>A barrier between brain blood vessels and brain tissues. This barrier controls what goes into the brain. Some drugs cannot cross this barrier, making brain infections difficult to treat. 
<dt>bone marrow: <DD>Soft tissue located inside bones. This is where blood cells are formed. A bone marrow biopsy involves inserting a long needle into the center of a bone to remove a sample to see if an infection is growing in the bone marrow. 
<dt>bone marrow suppression: <DD>A condition that can be caused by certain drugs. It leads to a decrease in white blood cells, red blood cells, and platelets. This can lead to bleeding or infections. People taking medications known to cause bone marrow suppression should have frequent blood tests. 
<DT><a name="bdna">branched </a>DNA assay (bDNA): 
<DD>One of several new tests that measure the amount of HIV in the blood (commonly known as viral load). The test uses a light-detecting system to find HIV RNA particles in a blood sample. The intensity of light generated by the captured particles is proportional to the amount of HIV present.

<dt>bronchoscopy: <DD>Insertion of a thin flexible tube into the lungs through the nose or mouth. Often used as a diagnostic tool for PCP. 
<dt>buffered: <DD>Coated with a special substance which allows easier absorption by the stomach. Buffered drugs often prevent stomach upset. They may also help to avoid damage by stomach acids. 
<dt>Burkitt's lymphoma: <DD>A malignant cancer of the lymphatic system. Epstein-Barr virus has been isolated from Burkitt's lymphoma and is suspected as a causative agent. 

<DT><B><a name="c">C</a></B> 

<dt>cachexia: <DD>General ill health and malnutrition. A general weight loss and wasting occurring in the course of a chronic disease or emotional disturbance. 
<dt>cancer: <DD>A large group of diseases characterized by uncontrolled growth and spread of abnormal cells. 
<dt><a name="candi">candidiasis</a>: <DD>A <a href="simple/fungal.html">fungal infection</a>, often seen as white patches in the mouth called thrush. Can cause vaginal candidiasis and disease in other parts of the body. 
<dt>catheter: <DD>A device that allows drugs to be given on an ongoing basis. A catheter is put in the chest during a minor operation. 

<dt>CD4 (T4): 
<dd>A protein embedded in the outside of immune system cells called helper T-lymphocytes, or T cells. The protein allows scientists to identify helper T cells, also called T4 cells. The protein is also used by HIV to infect these cells. The number of T4 cells in a blood sample is used to measure the health of the immune system in people with HIV.

<dt>CD8 (T8): 
<dd>A protein embedded in the cell surface of suppressor T-lymphocytes. The protein allows scientists to identify suppressor T cells, also called T8 cells.

<dt>CDC: <DD>The Centers for Disease Control and Prevention. A federal health agency that is a branch of the Public Health Service. 
<dt>cell: <DD>The smallest independent unit of an organism. A cell is composed of cytoplasm and a nucleus, and is surrounded by a membrane or wall. 
<dt>central nervous system (CNS): <DD>The brain and spinal cord with their nerves and end organs that control voluntary acts. 
<dt>cervical dysplasia: <DD>Abnormal tissue development of the lower part of the uterus; may progress to cancer of the uterus. 
<dt>chemotherapy: <DD>The use of chemical agents in the treatment of a disease. 
<dt>chlamydia: <DD>A bacterial infection that can cause disease. Left untreated it can lead to cancer. 
<dt>chronic: <DD>Continuous or ongoing. 
<dt>CMV retinitis: <DD>A herpes infection in the eye which can cause blindness. It is common in people with AIDS. People with CMV retinitis must take treatment for the rest of their life. 
<dt>co-factor: <DD>Something that may also affect a disease. Hemophiliacs who have both herpes and HIV progress to AIDS faster than do hemophiliacs who do not have herpes. The herpes is said to be a co-factor in the progression to AIDS. 

<dt>cognitive impairment: 
<dd>Problems with memory and thinking. Can be caused by HIV. Sometimes used to describe a less severe form of dementia.

<DT>colitis: <DD>Inflammation of the colon, part of the intestines. 
<DT>combination therapy: <DD>The use of two or more drugs as treatment. Also, the use of two or more types of treatment in combination, alternately or together. 
<dt>comparison trial: <DD>A trial in which experimental drugs are tested against each other or against an approved drug. 
<dt>compassionate use IND: <DD>People who are seriously ill can have their doctor ask the drug company to give them an experimental drug they think will help them. Few drugs are available through this program, but they are usually free. 
<DT>complete blood count (CBC): <DD>Series of tests including cell counts, hematocrit, hemoglobin, and cell volume measurement. 
<DT>continuous infusion: <DD>Uninterrupted introduction of fluid other than blood into a vein. 
<DT>controlled trials: <DD>Trials in which one group gets the experimental drug and another group gets either a placebo or an approved drug therapy. Participants usually do not know which group they are in. 
<DT>CPCRA: <DD>Community Programs for Clinical Research on AIDS. Part of the NIH's Division of AIDS. 
<DT>creatinine: <DD>A protein found in muscles and blood and excreted by the kidneys in the urine. The level of creatinine in the blood and urine provides a measure of kidney function. 
<DT>crossover: <DD>A controlled drug trial in which, halfway through the study, the groups in the trial switch. That is, those taking the experimental drug are given the standard drug and vice versa. 
<DT>cryptococcal meningitis: <DD>A fungal infection of the brain and spinal cord. Symptoms include severe headache, dizziness, nausea, weight loss, vision disorders and mental deterioration. Meningitis with headache, blurred vision, confusion, dizziness, nausea, anorexia, depression, agitation or slurred speech are common symptoms. 
<DT><a href="simple/crypto.html">cryptosporidiosis</a>: <DD>An infection whose main symptom is prolonged diarrhea which leads to weight loss. All treatments for this illness are still experimental. 
<dt>cyclospora: <dd>an intestinal parasite that can cause severe diarrhea in people with AIDS. A recent outbreak was associated with contaminated North American strawberries.
<dt>cytokines: <DD>Proteins produced by white blood cells that act as chemical messengers between cells. CD8 (T-suppressor) cells release a cytokine that appears to block HIV replication in infected cells, at least until the advanced stage of HIV disease. 
<dt>cytomegalovirus: <DD>A virus related to the herpes family, CMV infections may occur without any symptoms or may result in mild flu-like symptoms of aching, fever, mild sore throat, weakness or enlarged lymph nodes. In AIDS, severe CMV infections can cause illnesses such as hepatitis, pneumonia, retinitis and colitis, leading in some cases to blindness, chronic diarrhea, and death. 
<dt>cytotoxic: <DD>Term used to describe something which damages cells. Also used as the name of a type of T-cell. 
<dt>cytotoxic T lymphocyte (CTL): <DD>A lymphocyte that is able to kill foreign cells that have been marked for destruction by the immune system. 

<DT><B><a name="d">D</a></B> 

<dt>dementia: <DD>Loss of memory and other intellectual functioning caused by HIV or another disease. 
<dt>dose: <DD>The amount of a drug that is given at one time. dose comparison: <DD>A trial that uses different amounts of the same drug. Sometimes the drug is tested against a placebo. 
<dt>dose escalation trial: <DD>In this type of trial, one or a few people, usually under a dozen, take a small amount of the drug. If it doesn't hurt them, one or a few more take a larger amount. This continues until the researchers find the largest amount of the drug that can be taken without immediate harm. 
<dt>dose ranging: <DD>A drug trial in which two or more doses of a given drug are being tested against each other in order to determine which dose works best and is the least harmful. 
<dt>double-blind: <DD>A type of drug trial in which people are divided into different groups. One group takes the experimental drug and other groups take different doses, the standard therapy, or placebo. Neither the researchers nor the person in the trial knows who is taking what until the trial is over. 

<DT><B><a name="e">E</a></B> 

<dt>encephalitis: <DD>Inflammation of the brain. Symptoms include headache, neck pain, fever, nausea, and vomiting. Nervous system problems may occur such as laziness, paralysis, weakness, and coma. Treatment includes antibiotics for infection, steroids to reduce brain swelling, medicine to control fever and headache, and prolonged bedrest. Several types of opportunistic infections can cause encephalitis. 
<dt>enzyme: <DD>Protein chemical that can accelerate a chemical reaction in the body. 
<dt>eosinophil: <DD>A type of white blood cell, called a granulocyte, that can digest microorganisms. 
<dt>Epstein-Barr virus (EBV): <DD>A herpes-like virus that causes one of the two kinds of mononucleosis (the other is caused by CMV). 
<dt>erythrocytes: <DD>Red blood cells whose primary function is to carry oxygen to cells. 
<dt>expanded access: <DD>Programs designed to make experimental drugs available on a wide basis to people who do not qualify for the drug trials or who live too far from a trial site. 
<dt>experimental drug: <DD>A drug that has not been approved for use as a treatment for a particular condition. 

<DT><B><a name="f">F</a></B> 

<dt>floaters: <DD>Floating dark spots within the field of vision. They can be caused by CMV retinitis, but also appear in some persons as a normal part of the aging process. An HIV-knowledgeable eye doctor can make a correct diagnosis. 
<dt>fungus: <DD>A general term used to denote a class of microbes including mushrooms, yeast, and molds. Fungi cause infections such as thrush, cryptococcal meningitis, and toxoplasmosis. 

<DT><B><a name="g">G</a></B> 

<dt>gamma globulin (IgG): <DD>The portion of the plasma that contains antibodies. 
<dt>gastroenteritis: <DD>Inflammation of the lining of the stomach and intestines. 
<dt>gamma globulins: <DD>A type of immunoglobulin (see below) made by plasma cells, which is able to resist infection by viruses and bacteria. Simple proteins found in blood serums which contain various molecules central to immune system function. 

<dt>gp120: 
<dd>gp120: A piece of HIV that can cause damage to the immune system and other parts of the body. gp120 is the foundation for several vaccines.

<dt>granulocytes: <DD>A cell type of the immune system filled with granules of toxic chemicals that enable them to digest microorganisms. Basophils, neutrophils, and eosonophils, are examples of granulocytes. 
<dt>granulocytopenia: <DD>An abnormally low number of granulocytes in the circulating blood that can lead to increased risk of severe bacterial infection. 
<dt>growth factors: <DD>A growth factor is responsible for regulating cell proliferation (rapid and repeated reproduction), function and differentiation. Different growth factors elicit different responses from different cell types, such as stimulating cell growth, enhancing cell survival, initiating cell migration and stimulating the secretion of tissue-specific hormones. 

<DT><B><a name="h">H</a></B> 

<dt>hairy leukoplakia: <DD>A whitish, slightly raised lesion that appears on the side of the cheeks, gums or tongue. Thought to be related to Epstein-Barr Virus infection. (OI) 

<dt>helper cell (T4 cells, CD4 cells): 
<dd>A subset of T cells that carry the T4 marker and are essential for turning on antibody production, activating cytotoxic T cells, and initiating other immune responses. The number of T4 cells in a blood sample is used to measure the health of the immune system in people with HIV.

<dt>hematocrit: <DD>The percentage of packed red blood cells in a given volume of blood. Normal ranges: <DD>women 37-43%, men 43-49%. 
<dt>hemoglobin: <DD>The protein in red-blood cells responsible for carrying oxygen. 
<dt>hemophilia: <DD>An inherited disease that prevents the normal clotting of blood. 
<dt>hepatitis B (HBV): <DD>A viral liver disease that can be acute or chronic and even life- threatening, particularly in people with poor immune resistance. 

<dt>hepatotoxic: 
<dd>Damaging to the liver.

<dt>herpes simplex virus I (HSV I): <DD>A virus which causes cold sores or fever blisters on the mouth or around the eyes and can be transmitted to the genital region. The latent virus can be reactivated by stress, trauma, other infections or suppression of the immune system. 
<dt>herpes simplex virus II (HSV II): <DD>A virus causing painful sores of the anus or genitals which may lie dormant in nerve tissue and can be reactivated to produce the symptoms. HSV II may be transmitted to a baby during birth. 

<dt>herpes zoster: 
Herpes zoster, also called shingles, consists of very painful blisters on the skin that follow nerve pathways.

<dt>Hickman catheter: <DD>A flexible, needle shaped tube which can be surgically placed in a large blood vessel and held in place for a long periods of time. 
<dt>histamine: <DD>A hormone/chemical transmitter involved in local immune responses, in regulating stomach acid production and in allergic reactions. 
<dt>histoplasmosis: <DD>A fungal infection that causes acute pneumonia, inflammation of the meninges, heart, peritoneum, adrenals, and all other organs of the body. Symptoms usually include fever, shortness of breath, cough, weight loss and physical exhaustion. 
<dt>HIV disease: <DD>A term used to describe a variety of symptoms and signs found in people who are HIV positive. These may include recurrent fevers, unexplained weight loss, swollen lymph nodes, and/or fungus infection of the mouth and throat. Also commonly described as symptomatic HIV infection. 
<dt>Hodgkin's disease: <DD>A progressive malignant cancer of the lymphatic system. Symptoms include lymphadenopathy, wasting, weakness, fever, itching, night sweats and anemia. This disease is treated with radiation and chemotherapy; newer combinations of anticancer drugs are being tried constantly with increasing success. 
<dt>hormone: <DD>A substance made by the body to influence a process. Testosterone, for example, is a hormone that makes people more aggressive and muscular. Most men have more of this hormone than women. 
<dt>hypersensitivity: <DD>A situation in which the body reacts with an exaggerated immune response to drugs or other substances. 

<DT><B><a name="i">I</a></B> 

<dt>IDU: <DD>An injection or intravenous drug user (IVDU). <dt>immune complex: <DD>A pair of immune system pieces. Immune complexes form when the immune system marks foreign objects so the body knows how to deal with them. 
<dt>immunity: <DD>A natural or acquired resistance to a specific disease. Immunity may be partial or complete; long lasting or temporary. 
<dt>immunization: <DD>To protect against disease by vaccination, usually with a weak form of the agent that causes illness. People are usually immunized against a disease by getting vaccinated, although having a disease one time usually prevents or "immunizes" you from getting it again. This may not always be true with people who are HIV positive. 
<dt>immunomodulators: <DD>Drugs hoped to strengthen the immune system and help the body fight off opportunistic infections or other diseases that attack people with AIDS. Not necessarily used to stimulate the immune system, which may be harmful. This includes two sub-groups: cytokines and "broad acting" immune modulators. Broad acting immune modulators are chemical transmitters/hormones in the body which regulate the immune system (i.e., endorphins), or act in a similar fashion. 
<dt>inclusion/exclusion criteria: <DD>The medical or other reasons why a person may or may not be allowed to enter a trial. For example, some trials do not allow pregnant women to join, others do not allow people to take certain drugs, and others exclude people with certain illnesses. Other trials may try to include pregnant or nursing women. 
<dt>IND or investigational new drug: <DD>The name given to an experimental drug after the FDA agrees that it can be tested in people. 
<dt>indication: <DD>Purpose for which a drug is intended; e.g. Pentamidine is indicated for PCP. 
<dt>inflammatory bowel disease (IBD): <DD>A disorder of the colon that causes stomach pain, constipation, and diarrhea. 
<dt>informed consent: <DD>Type of protection available to people considering entering a drug trial. Before entering the trial participants must sign a consent form that contains an explanation of a) why the research is being done; b) what researchers want to accomplish; c) what will be done during the trial and for how long; d) what risks are in the trial; e) what benefits can be expected from the trial; f) other treatments available; and g) the right to leave the trial at any time. 
<dt>infusion: <DD>The process of giving a substance (medication, food supplements, etc.) to an individual by injecting it into a vein. This procedure can either be a one-time event or continued over many hours, days or even months. 
<dt>inhibitor: <DD>In medicine, refers to a drug or chemical or substance that inhibits or blocks something from happening. 
<dt>Institutional Review Board (IRB): <DD>Every institution or hospital that conducts research involving human subjects must have an IRB that approves and periodically reviews the research. The IRB protects the rights of the people in the trial, determines who can participate in the trial, and whether the trial is ethical. 
<dt>interaction: <DD>Change in the body's response to one drug when another is taken. Interaction may increase the effect of one or both drugs, decrease the effect of one or both drugs, or cause toxicity. 
<DT><a name="interferon">interferon</a>: <DD>A substance that is produced when the body senses an infection with a virus. Interferon is released to coat uninfected cells so that they don't become infected. There are three main classes of interferon alpha, beta, and gamma. 
<dt>interleukin: <DD>A natural blood substance that helps immune system cells to communicate. 
<dt>intestinal malabsorption: <DD>A condition in which the nutrients found in food are not absorbed by the body. It can lead to malnutrition and weight loss. 
<dt>intralesional: <DD>Injected directly into a lesion. 
<dt>intrathecal: <DD>Injected into the fluid surrounding the spinal cord. 
<dt>intravenous (IV): <DD>Intravenous drugs are injected directly into the veins. 
<dt>intravitreal: <DD>In the eye. 
<dt>in vitro: <DD>(Latin for "in glass") An artificial environment created outside a living organism, e.g., a test tube or culture plate, used in experimental research to study a disease or process. 
<dt>in vivo: <DD>(Latin for "in life") Studies conducted within a living organism, e.g., animal or human studies. 
<dt>IRB: <DD>See Institutional Review Board. 

<DT><B><a name="j">J</a></B>

<DT><B><a name="k">K</a></B> 

<dt>Kaposi's sarcoma (KS): <DD>A cancer of the blood vessels that may occur in people with AIDS. Blood vessels which grow rapidly and cause pink to purple, painless spots on the skin. Kaposi's sarcoma (KS). Lesions may first appear on the feet or legs and on the soft palate of the mouth. They may also remain hidden in the internal organs. KS can also grow in other places such as the lungs. It can be accompanied by fever, enlarged lymph nodes and stomach problems. 
<dt>Karnofsky score: <DD>A measurement system for how you perform everyday tasks. If you can eat and get dressed by yourself then you probably have a high Karnofsky score. It goes down as you need more help in doing things. 
<dt>killer T cells: <DD>A class of immune system cells that function to kill cancer and virus- infected cells; also called "Natural Killer" cells. 

<DT><B><a name="l">L</a></B> 

<DT>latency: <DD>The period when an organism is in the body, but is not producing any ill effects. HIV is never really latent, although you may not have symptoms or feel bad. 
<dt>lesion: <DD>Any pathological or traumatic discontinuity of tissue, which may cause a loss of function (of the affected or surrounding tissue). 
<dt>leukocytes: <DD>All white blood cells. 
<dt>leukopenia: <DD>A lower than normal level of leukocytes in the blood. 
<dt>lymph glands: <DD>Small immune system centers that are located all over the body. Lymph glands protect the bloodstream from infection by filtering out infectious particles. 
<dt>lymphadenopathy: <DD>Swollen, firm and possibly tender lymph glands. The cause may range from a temporary infection such as the flu, HIV, mononucleosis, to lymphoma (cancer of the lymph nodes). 
<dt>lymphocytic interstitial pneumonia (LIP): <DD>A type of pneumonia that affects 35 to 40% of children with AIDS. Children with HIV who have LIP are diagnosed as having AIDS. 
<dt>lymphoma: <DD>A cancer of the cells that are responsible for normal immune function. A type of cancer that may include symptoms such as lymph-node swelling, weight loss, and fever. The type of treatment depends on the appearance of the lymphoma under the microscope as well as the extent of the spread of the lymphoma. Treatment can involve either radiotherapy or chemotherapy, or a combination of both. In most cases of Hodgkin's disease and about 50 percent of non-Hodgkin's lymphoma, treatment can result in a cure. 

<DT><B><a name="m">M</a></B> 

<dt>MAC: <dd>See <a href="#mac">mycobacterium avium complex</a>.
<dt>macrophage: <DD>A large immune system cell that roams through the blood looking for foreign matter. These cells also alert the rest of the immune system when help is needed. 
<dt>magnetic resonance imaging (MRI): <DD>A non-invasive diagnostic technique that can provide information on the form and function of internal tissue and organs of the body. 
<dt>maintenance therapy: <DD>Use of a treatment or treatments even after the disease has been brought under control. Unless maintenance therapy is used against PCP pneumonia, for example, the disease will probably occur again. 
<dt>malabsorption syndrome: <DD>Decreased intestinal absorption resulting in loss of appetite, muscle pain and weight loss. 
<dt>malignancy: <DD>A tumor or cancer. 
<dt>memory cells: <DD>T cells that have been exposed to specific <a href="#antigen">antigens</a> and are able thereafter to proliferate upon repeat exposure to the same antigens. 
<dt>meningitis: <DD>Inflammation of the brain and spinal cord that is usually caused by bacteria or a virus. 
<dt>microsporidiosis: <dd>An infection of the gut caused by a parasite. The main symptom is diarrhea.
<dt>molluscum contagiosum: <DD>A skin disease caused by a virus which causes small rounded tumors. They are persistent but have no other general symptoms 
<dt>monoclonal antibodies: <DD>Custom made immune system pieces that are used against one specific disease causing agent. 
<dt>MRI: <DD>See Magnetic Resonance Imaging. 
<dt>myalgia: <DD>Pain in one or more muscles. 
<DT><a name="mac">mycobacterium avium complex</a> (<a href="simple/mac.html">MAC</a>): <DD>A disease caused by an organism found in soil and dust particles. In PWAs, it can spread through the bloodstream to infect many parts of the body. Symptoms of MAC include prolonged wasting, fever, fatigue and enlarged spleen. It is usually found only in individuals who have T cells under l00. Though there is no cure, many different combinations of drugs are used to treat MAC. Also called MAI sometimes. 
<dt>mycosis: <DD>Any disease caused by a fungus. 
<dt>myelopathy: <DD>Neurologic disorder. Symptoms can be weakness of limbs, partial paralysis, inability to control legs, frequent urination and, in men, inability to get erections. 
<dt>myelosuppression: <DD>The suppression of bone marrow activity, which can cause anemia. Red blood cells, whose function is to transport oxygen to tissues and to remove their carbon dioxide waste, are constantly made in the bone marrow. A drug that damaged the bone marrow would cause loss of red blood cells. 

<DT><B><a name="n">N</a></B> 

<dt>natural killer cells: <DD>(NK cells) Large immune system cells that attack and destroy infected and cancer causing cells. They are known as 'natural' killers because they attack without any help from the rest of the immune system. 
<dt>neoplasm: <DD>An abnormal and uncontrolled growth of tissue; a tumor. 
<dt>neopterin: <DD>A substance produced by macrophages when they encounter a foreign substance such as a virus. Doctors sometimes measure neopterin to see whether the immune system is fighting HIV. 

<dt>nephropathy: 
<dd>Kidney disease.

<dt>nephrotoxic: 
<dd>Damaging to the kidneys.
 
<dt>neuropathy: <DD>Any abnormal, degenerative or inflammatory state of the peripheral nervous system. 
<dt><a name="neutropenia">neutropenia</a>: <DD>A low number of neutrophils in the blood. Neutrophils are a white blood cell important in defending the body against infections. 
<dt>neutrophil: <DD>A white blood cell which plays a central role in the immune system. Neutrophils are the immune system's main defense against bacterial infections. 
<dt>night sweats: <DD>Extreme sweating which happens during sleep. Night sweats are considered a symptom of HIV only when the body is drenched. Slight sweating is not a symptom. 
<dt>NK cells: <DD>See natural killer cells. 
<dt>non-Hodgkin's lymphoma (NHL): <DD>A rare B-cell lymphoma that is seen in AIDS. 

<DT><B><a name="o">O</a></B> 

<dt>off label: <DD>A drug prescribed for conditions other than those indicated on the label. 
<dt>open trial: <DD>A drug trial is "open" when doctors and participants know which drug is being administered, as opposed to a double blinded trial in which they do not know (some may receive a test drug or a placebo) until the trial is over. 
<dt>open-label: <DD>A type of drug trial in which researchers and participants know who is taking the experimental drug or the treatment being given. 
<dt>opportunistic infection (OI): <DD>Certain illnesses (such as PCP pneumonia) that people with AIDS can get and which can be life threatening. People with healthy immune systems do not usually get these illnesses, even though most people have the organisms that cause these illnesses in their body already. Only when the immune system is damaged can the organisms take advantage of the "opportunity" of this weakened state and cause damage. 
<dt>oral (po): <DD>Taken by mouth as a pill or liquid. 

<DT><B><a name="p">P</a></B> 

<dt>pancreatitis: 
<dd>The pancreas is an organ of the human body attached to the small intestine, just past the stomach. The pancreas produce natural chemicals that digest food. Pancreatitis is a potentially fatal swelling or infection of this organ. Pancreatitis causes severe stomach pain that goes right through to your back, and can be a side effect of some anti-HIV drugs.

<dt>pancreatotoxic: 
<dd>Damaging to the pancreas.

<dt>parallel track: <DD>A system of distributing experimental drugs to individuals who are unable to participate in ongoing clinical trials. 
<dt>parasite: <DD>An animal or plant that lives inside or upon another living animal or plant without extending any benefit to it in return. Parasites kill millions of people worldwide every year, although some parasites are harmless. The usual means of infection is through contaminated water or poor washing habits. Rimming can also spread parasites. 

<dt>PCR: 
<dd>See <a href="#pcr">polymerase chain reaction</a> assay.

<dt>peripheral neuropathy: 
<dd>A disorder of the nerves, usually involving the hands, feet, arms and legs. Symptoms may include numbness, a tingling or burning sensation, sharp pain, weakness and abnormal reflexes. In severe cases, paralysis may result. Can be a side effect of some drugs. This condition can often be successfully treated.

<dt>pharmacokinetics: 
<dd>The study of how much of a drug gets into the body and how long it stays there.

<dt>pharmacokinetic trials: <DD>Trials which study how the drug is absorbed by the body. People in these trials often have blood tests every few minutes or hours. These trials often require a short stay in the hospital. 

<dt>phase I study: <DD>The first step in human testing of a drug. Designed to evaluate toxicity at different dose levels. Takes place with a small number of participants. 
<dt>phase II study: <DD>FDA drug testing phase for effectiveness in humans. The stage at which drug effectiveness is established. Proceeds only if Phase I studies show toxicity to be within acceptable levels. Usually involves 50 to 300 volunteers. 
<dt>phase III study: <DD>FDA drug testing phase for extensive clinical trials in humans. Expansion of phase II study to 300 to 3000 volunteers. Designed to back up information gathered in Phase I and II testing. Also compares the drug to other agents, either alone or in combination. 

<dt>phenylketonuria: 
<dd>High levels of a substance in the body called phenylalanine.

<dt>placebo: <DD>A substance that has no effect on the body (often referred to as a sugar pill) that is given to one group in a placebo-controlled trial. In placebo-controlled drug studies, a placebo is given to one group of participants, while the drug being tested is given to another group. The results obtained in the two groups are then compared. 
<dt>placebo effect: <DD>A change that occurs when a placebo is taken. Although you may not actually be taking a real treatment you may still experience positive things because you want them to happen. The placebo effect usually wears off, although having a positive attitude may still be helpful in dealing with HIV. 
<dt>platelet: <DD>A blood cell that helps wounds to heal. Platelets also produce other helpful chemicals. HIV can decrease platelets and cause bleeding and other disease. A normal platelet count is between 200,000 to 300,000. 
<dt>PML: <DD>See progressive multifocal leukoencephalopathy. <dt>pneumocystis carinii pneumonia (PCP): <DD>It is a type of pneumonia caused by a fungus which grows rapidly in the lungs of people with AIDS. PCP pneumonia is the leading cause of death of people with AIDS, but it is both treatable and preventable. Anyone who is HIV positive should discuss when to take treatments that will prevent PCP with a doctor. 

<DT><a name="pcr">polymerase</a> chain reaction assay (Amplicor, PCR): 
<dd>An approved viral load test that measures the amount of HIV in a blood sample. The result provides information about the risk of disease progression. The test is also used to find out how well an anti-HIV treatment is working.

<dt>PPD: <DD>A test for tuberculosis. If you are PPD positive you have been exposed to tuberculosis. This does not mean that you have the disease, although everyone who is PPD positive must be treated to avoid getting a serious and contagious form of tuberculosis. 
<dt>progressive multifocal leukoencephalopathy (PML): <DD>A viral infection of the brain that causes memory loss, motor control problems and loss of strength. PML can lead to coma and death. 
<dt>prophylactic: <DD>A drug that helps to prevent a disease before it occurs. For example, Bactrim is a prophylactic treatment that prevents PCP pneumonia. 
<dt>prophylaxis: <DD>Taking a drug to prevent yourself from getting an illness. 

<dt>protease: 
<dd>A substance in the blood that breaks down proteins. HIV has a protease enzyme that it uses to make more virus. Sometimes spelled proteinase.

<DT>protein: <DD>Plants and animals are made of protein. Amino acids are the building blocks of protein. 
<DT>protocol: <DD>The plan for a clinical trial. A protocol explains why an experimental treatment is being studied and how it will be tested. A detailed plan which states a drug trial's rationale, purpose, drug dosages, length of treatment, how the drug is given, who may participate (inclusion/exclusion criteria). 
<dt>protozoa: <DD>A group of one celled animals, a few of which cause human disease. 
<dt>p24 antigen: <DD>A protein fragment of HIV. The p24 antigen test measures this fragment. A positive result for p24 antigen suggests that HIV is multiplying, although there is debate about this. 
<dt>PWA: <DD>Person with AIDS or people with AIDS. 

<DT><B><a name="q">Q</a></B>

<DT><B><a name="r">R</a></B>

<dt>radiation therapy: <DD>A treatment for cancer using radiation produced by a machine. 

<dt>renal failure: 
<dd>When the kidneys stop functioning properly due to infection. HIV can sometimes cause renal failure.

<dt>resistance: <DD>The ability of a disease to overcome a drug. For example, after long- term use of AZT, HIV can develop strains of virus in the body that are no longer suppressed by this particular drug, and therefore are said to be resistant to AZT. 
<dt>retina: <DD>Innermost covering of the eyeball on which the image is formed. 
<dt>retinitis: <DD>Inflammation of the retina, a part of the eye, which can be caused by cytomegalovirus (CMV) infection. If left untreated, CMV retinitis usually leads to blindness. 
<dt>retrovirus: <DD>Retroviruses are RNA viruses that transcribe their genetic material into DNA using an enzyme called reverse transcriptase. 
<dt>reverse transcriptase: <DD>An enzyme that is needed by HIV to get inside cells and make more of itself. 

<DT><B><a name="s">S</a></B> 

<dt>salvage therapy: <DD>Treatment for individuals who don't respond to or who can't take other treatments for a condition. 
<dt>sepsis: <DD>A serious condition caused by uncontrolled growth of bacteria in the blood. This condition can lead to septic shock. This involves a sudden drop in blood pressure, changes in heart rate and temperature. 
<dt>SGOT and SGPT: <DD>A blood test to see if the liver is damaged. 
<dt>shingles: <DD>See herpes zoster. 
<dt>short form written consent document: <DD>A form that been verbally explained to an individual entering the trial. A witness must be present when the trial is explained and this form is signed. 
<dt>side effects: <DD>The action or effect of a drug other than that desired. The term usually refers to undesired or negative effects, such as headache, skin irritation, or liver damage.  
<dt>sigmoidoscopy: <dd>A procedure during which a small piece of tissue is taken from the lower intestine.
<dt>spinal tap: <DD>See lumbar puncture. 
<dt>STD: <DD>A sexually transmitted disease.  

<dt>stomatitis: <DD>Swelling of the throat that is usually painful. Some drugs, such as ddC, may cause this condition.  
<dt>subcutaneous: <DD>Giving a drug by injecting it under the skin. 
<dt>suppressor T cells: <DD>T cells that turn other T cells off. 

<dt>surrogate markers: 
<dd>Laboratory tests that are used to measure disease progression. Different surrogate markers are being studied to see how well they measure the progress of HIV. The T4 cell count is a marker of how well the immune system is doing against HIV. Viral load is a new surrogate marker that seems to be able to measure disease progression better than the T4 cell count.

<dt>symptom: <DD>a sign that the body is going through a process. A fever is a symptom of the body fighting off an infection. A rash is a symptom that the immune system is reacting to something such as dust. 

<dt>synergism/synergistic: 
<dd>When one drug increases the effectiveness of another one, it is said to have synergism with that drug. This effect is greater than you would expect from just adding the two drugs together.

<dt>systemic: <DD>Affecting the whole body. 

<DT><B><a name="t">T</a></B> 

<dt>T cells: <DD>White blood cells that play an important part in the immune system. There are three different types of T cells, each of which has different subsets. The commonly measured T cells are helper T cells, killer T cells, and suppressor T cells.  

<dt>T-helper cell (T4 cell, CD4 cell): 
<dd>A subset of T cells. Physicians regularly measure T-helper cell counts in HIV positive people. The normal range for T-helper cells is 480-1800, but may vary.

<dt>T-killer cell (cytoxic T cells): <DD>A type of white-blood cell that kills foreign organisms after being activated by T-helper cells. 

<dt>T-suppressor cell (T8 cell, CD8 cell): 
<dd>A type of white blood cell that helps control the body's response to an infection.

<dt>thrombocytopenia: 
<dd>A condition in which platelets, a type of blood cell, fail to help blood clot. Treatment is either with drugs, removal of the spleen, or by platelet transfusion.

<dt>TNF: <DD>See tumor necrosis factor. 
<dt>thrush: <DD>See <a href="#candi">candidiasis</a>.
<dt>thymus: <DD>The organ of the body that trains T cells to be part of the immune system. 
<dt>toxic reaction: <DD>A poisonous or unwanted reaction to a vitamin, drug or other substance. A toxic side effect is when a helpful medicine also causes some damage to the blood or body. Toxicity is a measurement of how much damage may be caused.  
<dt>toxoplasmosis: <DD>An inflammation of the brain caused by toxoplasma gondii, a parasite. Frequently causes inflammation of the brain. It may also involve the heart, lung, adrenal glands, pancreas and testicles. This disease is usually mild but it can cause fever and swollen glands, as well as severe headaches. Fifty percent of Americans have been exposed to toxoplasma gondii at some point in their lives.  
<dt>transaminase: <DD>An enzyme measurement that indicates the health of the liver. 
<dt>transfusion: <DD>The process of giving blood, or parts of the blood from one person to another. 
<dt>triglycerides:
<dd>Fatty substances in the blood. High levels can indicate liver malfunction or pancreatitis. Low levels can indicate malnutrition.
<dt>Treatment IND: <DD>An FDA program that makes experimental drugs available to seriously ill people. Drug companies may charge for the drug, although most don't. 
<dt>tuberculosis (TB): <DD>An infection caused by Mycobacterium tuberculosis. Treatment consists of the administration of a combination of antibacterial drugs, usually for at least nine months.  
<dt>tumor necrosis factor (TNF): <DD>A protein produced by macrophages. By itself, TNF destroys cancer cells. TNF can cause fever, chills, fatigue, headache, and inflammation. TNF causes weight loss and probably helps HIV to grow.  

<DT><B><a name="u">U</a></B>

<DT><B><a name="v">V</a></B> 

<dt>vaccine: <DD>A shot or shots that prevent(s) a disease. Another kind of vaccine, treatment vaccines, are in development and being studied. Treatment vaccines may help fight HIV even after someone has been infected.  
<dt>vaginal candidiasis: <DD>Infection in the vagina with thrush. Presents with pain, itching, redness and white patches in the vaginal wall. Much more common and more difficult to treat in women with HIV infection. 
<dt>varicella virus: <DD>See herpes zoster virus. 
<dt>viremia: <DD>The presence of virus in the blood stream. 
<DT><a name="viral load">viral load</a>: <DD>The amount of measurable virus in the blood. Tests used to measure virus are <a href="#pcr">PCR</a> and <a href="#bdna">bDNA</a>.
<dt>virus: <DD>The smallest known infectious organism. A group of infectious agents characterized by their inability to reproduce outside of a living cell. They are unable to live or multiply outside of a host cell since most do not possess the means to synthesize protein.

<DT><B><a name="w">W</a></B>

<dt>wasting syndrome:
<DD>Severe weight loss involving depletion of muscle mass in people with AIDS and HIV positive individuals which can occur even in the absence of other infections. Unwanted weight loss of more than 10% of body weight plus either chronic diarrhea or chronic weakness and fever for more than 30 days. Treatment is required.

<dt>white blood cells: <DD>Part of the immune system that protects the body against foreign substances such as disease-producing microorganisms. 

<DT><B><a name="x">X</a> <a name="y">Y</a> <a name="z">Z</a></B>

</DL>

</blockquote>

<HR SIZE=3 WIDTH=50% ALIGN=CENTER noshade>

<P ALIGN=CENTER><A HREF="index.html"><img src="gifs/return.gif" alt="[arrow]"></p><p align=center>to Network home page</A></P>

<hr size=3 align=center width=50% noshade>

<P align=center><FONT SIZE=-2>Last modified: 12/2/96<BR>
<A HREF="mailto:atdn@nyam.org">atdn@nyam.org</A><BR>
copyright &#169; 1996 The Network</P>

</font>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT18-B31-251</DOCNO>
<DOCOLDNO>IA093-001002-B003-35</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/altx.html 199.29.141.24 19970121123333 text/html 10771
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:27:40 GMT
Server: NCSA/1.5.1
Last-modified: Sat, 23 Nov 1996 22:45:50 GMT
Content-type: text/html
Content-length: 10587
</DOCHDR>
<html>

<head>

<title>Network: Alternative treatments</title>

</head>

<BODY bgcolor="#ffffff" link="#00688b" vlink="#545454"><font face="arial, helvetica" size=-1>

<h2 align=center>Alternative Treatments</h2>

<blockquote><h5 align=center>This page will change frequently in response to questions received about alternative treatments. Send your questions using the e-mail address at the bottom of this page.</h5>

<p><font size=3><b><a name="alicin">Garlic</a> for <a href="simple/crypto.html">Cryptosporidiosis</a>?</b></font><br>
Results of a trial of garlic for the treatment of cryptosporidiosis have been announced. Cryptosporidiosis is an infection of the gut caused by a parasite called cryptosporidium, the main symptom is prolonged diarrhea which leads to weight loss. The trial was conducted by a community-based research organization called the AIDS ReSearch Alliance in California. The trial used a garlic concentrate called Allicin, which is available in the US in 30 mg glass vials that are imported from China. In this study, 30 mg of Allicin was mixed with 90cc of distilled water. This mixture was taken twice daily by participants.</p>

<p>Twenty people enrolled in the study. The only major side effect, as expected, was a strong garlic smell and taste. This side effect was a problem for about a third of the participants and led at least one person to drop out of the study. After six weeks, there were sixteen people remaining in the study. Ten of these people had less diarrhea and fewer watery stools, and had stable or increased body weight. The most significant finding of the study was that, in four out of eight people who chose to remain on the study for longer than eight weeks, stool tests have been repeatedly negative for the cryptosporidium parasite. The average T4 cell count of people in this study was less than 30, and most had tried and failed the standard cryptosporidiosis treatment, Humatin. Clearance of cryptosporidium has not been reported before in people with T4 cell counts this low.</p>

<p>AIDS ReSearch Alliance is planning a larger, phase II study of Allicin for the treatment of cryptosporidiosis. The AIDS ReSearch Alliance can be reached at (310) 358-2423 for more information.</p>

<p><font size=3><b><a href="http://www.bastyr.edu/research/recruit.html">Bastyr University AIDS Research Center</a></b></font></br>
The AIDS Research Center in Seattle is conducting a nationwide observational study. Anyone who uses alternative medicine as part of their treatment plan can participate. The Web site includes information about what is required of participants, confidentiality and contacts.</p>

<p><font size=3><b><a name="yoga">Yoga</a> for people living with HIV and AIDS</b></font></br>
<a href="http://www.yogagroup.org/yoga/default.html">The Yoga Group, Inc.</a> A group based in Denver, Colorado with free classes for people living with HIV and AIDS. The Web site includes information about yoga positions, articles, and contacts for other classes around the world.</p>

<p><font size=3><a name="acupuncture"><b>acupuncture</b></a></font></br>
Acupuncture is a branch of Traditional Chinese Medicine (TCM). As a result of thousands of years of observation and experimentation it was discovered that in all types of diseases, both physical and mental, certain points on the body become tender. These points, known as acupuncture points, flow through channels in the body called meridians. Each major organ of the body (such as the heart, lungs, or small intestine) lies on a meridian. According to the principles of acupuncture these channels allow energy (called Qi or Chi by the Chinese) to flow smoothly throughout the body, otherwise the organs which lie on these meridians may not function properly. Extremely thin, solid needles are inserted into the acupuncture points to normalize and redirect energy flow when there is a problem, creating a healing impact. Herbology, massage, diet, and exercise techniques are also part of TCM.</p>

<p>Research has demonstrated acupuncture's role in reducing fever, increasing antibody production, and increasing the body's overall resistance to disease. French researchers in the late 1970s demonstrated the ability of acupuncture to affect T and B-lymphocytes. The most well known effects of acupuncture are its ability to lessen pain and produce a calmer state of mind, two effects which are most likely related to its ability to increase the production of endorphins. Endorphins are a substance which the body produces to help regulate the immune system, especially in response to forms of stress such as a viral infection. They trigger transmitters which affect the spinal cord and brain, lessening the pain.</P> 

<p>As a practitioner in the field of TCM and acupuncture for over a decade, I have observed the positive impact which acupuncture can have. I have worked for the past nine years with many HIV+ individuals who have responded well to acupuncture, either with or without western medical treatments. Acupuncture can help to alleviate the side effects of toxic chemotherapeutic agents.</P>

<I>From an article by Jackie Haught, D.Ac., Dipl.Ac. (NCAA). More information on acupuncture, as well as referrals, can be found on <A HREF="http://www.Acupuncture.com">Acupuncture.com</I></A>. An excellent article appears in the September 1, 1995 issue of <a href="http://www.qrd.org/QRD/aids/atn/230-09.01.95">AIDS Treatment News</a>.</P>

<p><font size=3><img align=middle hspace=2 src="gifs/pestle.gif" alt="[pestle/mortar]"><A NAME="cat"><b>Cat's claw</b></A></font></br>
Uncaria tomentosa is an herb that grows wild in the highlands of the Peruvian Amazon. It has been used for hundreds, perhaps thousands, of years by the native Ashanica Indians for treatment of a wide range of health problems associated with the immune and digestive systems.</P>

<p>Ongoing research suggests that Uncaria tomentosa may be benficial in the treatment of cancer, arthritis, bursitis, rheumatism, genital herpes and herpes zoster, allergies, ulcers, systemic candidiasis, PMS and irregularities of the female cycle, environmental toxin poisoning, numerous bowel and intestinal disorders, organic depression, and those infected with HIV.</P> 

<p>Dr. Brent W. Davis, DC, who has been working with Uncaria tomentosa for a number of years, has referred to this herb as "The Opener of the Way" because of its remarkable ability to cleanse the entire intestinal tract and help patients suffering from many different stomach and bowel disorders including: Chrohn's disease, diverticulitis, leaky bowel syndrome, colitis, hemorrhoids, fistulas, gastritis, ulcers, parasites and intestinal flora imbalance. In its healing ability and benfit to the immune system, Uncaria tomentosa appears to have so many therapeutic applications that it far surpasses such well known herbs as Pau d'Arco, Echinacea, Golden Seal, Astragalus and Siberian Ginseng, as well as Reishi and Shitake mushrooms, and other natural products such as Citrus Seed Extract, Caprylic Acid and Shark Cartilage.</P>

<p><I>This information is from from an article dated May 1994 in The Townsend Letter for Doctors.</I></P>


<p><font size=3><A NAME="garlic"><b>garlic</b></A></font></br>
Garlic (Allium staivium), a member of the lily family, has been used for medicinal purposes from as early on as 3,000 BC. Allicin, a sulfur containing compound in garlic, is believed to be primarily responsible for most of the suggested benefits of garlic - along with the unique odor. Claims of garlic's effectiveness against AIDS-related OIs are based on test-tube studies that showed garlic was an anti-bacterial, and anti-fungal agent. There have been no studies as yet that have looked at garlic closely for its uses with immunomodulation.</P>

<p>Toxicity with garlic usage occurs when too much raw garlic is ingested. The high sulfur content can cause dermatitis; and colitis occurs by an overkill of the normal flora in the gut. In high doses, garlic also may inhibit blood clotting and interfere with proper thyroid function.</P>
<p><I>From Treatment Issues Special Winter Issue 93/94</I></P>

<p>Five people with cryptosprodiosis have already finished a small, uncontrolled trial of allicin, an oil derived from garlic, conducted by Search Alliance, a community-based research organization in Los Angeles. Participants received once a day a 5 ml solution that contained 2 ml of allicin and 3 ml of water. All five experienced a decrease in cryptosporidiosis symptoms. Five more people are still in the study and further enrollment is expected. </P>

<p><I>From CPS InfoPak Spring 1995. Read more about garlic on the <A HREF="http://www.panix.com/~jscutero/garlic.html">misc.health.aids pages</A>.</I></P>

<p><font size=3><b><img align=middle hspace=2 src="gifs/magnify.gif" alt="[magnify]">SPV-30</b></font></br>
SPV-30 is a natural herb product extracted from an evergreen tree and presently being used to reverse the declining level of CD4 lymphocytes in people with asymptomatic HIV.</P>
<p>
SPV-30 has been proven to be non-toxic and non-mutagenic. Studies of SPV-30 are being established in major US cities. Participants receive six months of free product in exchange for lab results every two months. For more information or to enroll in a study in your area, call David Stokes at (617) 424-9195 or send an <A HREF="m/ailto:Boston CDS@aol.com">e-mail request for info</A>.<P>

<p>A small phase I study in France demonstrated significant rises in CD4 cell counts in participants. However, all participants had more than 250 CD4 cells and no viral load measurements were taken.  Sally Cooper at the PWA Health Group in New York City was concerned at the possibility of an IL-2 type situation where stimulation of CD4 population without antiviral activity may actually increase viral load. The company that makes the product are, according to Sally, seemingly well intentioned but a little naive about HIV pathogenesis. SPV-30 can also now be bought from pharmacies in the city as a nutritional supplement.</P>
<p><I>See also the Clinical Trials page on <A HREF="trials/hiv.html">Treatments for HIV</A>.</I></p></blockquote>

<HR SIZE=3 WIDTH=50% ALIGN=CENTER noshade>

<P ALIGN=CENTER><A HREF="index.html"><img src="gifs/return.gif" alt="[arrow]"></p><p align=center>to Network home page</A></P>

<hr size=3 align=center width=50% noshade>

<P align=center><FONT SIZE=-2>Last modified: 6/21/96<BR>
<A HREF="mailto:atdn@nyam.org">atdn@nyam.org</A><BR>
copyright &#169; 1996 The Network</font></P>

</font>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT18-B31-252</DOCNO>
<DOCOLDNO>IA093-001002-B003-62</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/links.html 199.29.141.24 19970121123352 text/html 10833
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:27:59 GMT
Server: NCSA/1.5.1
Last-modified: Mon, 20 Jan 1997 14:03:25 GMT
Content-type: text/html
Content-length: 10649
</DOCHDR>
<html>
<head>
<title>Network Links</title>
</head>

<BODY bgcolor="#ffffff" link="#00688b" vlink="#545454"><font face="arial, helvetica" size="-1">

<h3 align=center><a href="index.html">AIDS Treatment Data Network</a></h3>
<h3 align=center>Links to other sources of HIV/AIDS information</h3>

<blockquote>

<DL>
<DT><A HREF="http://www.Acupuncture.com">Acupuncture.com</A>
<DD>Information on acupuncture, oriental and Chinese Medicine, herbology, Qi Gong, a practitioner referral list, and more.
<P>
<DT><A HREF="http://www.ircam.fr/solidarites/sida/index-e.html">AIDS and HIV - informations and resources</A>
<DD>Information and resources in French and English. Lots of links.
<p>
<dt><a href="www.actis.org">AIDS Clinical Trials Information Service</a> (ACTIS)
<dd>National information about clinical trials. Access to MedLine databases.
<p>
<DT><A HREF="http://www.gus.com/care/apla/apla.html">AIDS Project Los Angeles</A>
<DD>Support groups, advocacy, health tips and other links for the Los Angeles area.
<p>
<DT><A HREF="http://www.eyenet.org/public/faqs/aids_faq.html">American Academy of Ophthalmology</A>
<DD>Basic information about AIDS/HIV and the eye. No descriptions of treatments in <A HREF="trials/cmvret.html">clinical trials</A>.
<p>
<dt><a href="http://www.sfrefuge.org/Ark.html">The Ark of Refuge</a>
<dd>San Francisco organization promoting AIDS education in African-American Community and targeted high risk groups, includes housing and direct services.
<p>
<dt><a href="http://www.critpath.org/aric/">ARIC: AIDS Research Information Center</a>
<dd>is a private, non-profit AIDS medical information service offering current, medically accurate information on AIDS treatment and research in plain English to anyone who requests it. <font size="-1">(added 1/20/96)</font>
<p>
<dt><a href="http://www.bastyr.edu/research/recruit.html">Bastyr University AIDS Research Center</a>
<dd>The AIDS Research Center in Seattle is conducting a nationwide observational study. Anyone who uses alternative medicine as part of their treatment plan can participate.
<p>
<dt><a href="http://galen.library.ucsf.edu/aidstrials/">California AIDS Clinical Trials</a>
<dd>Forms for searching trials by condition, CD4 count and personal history. <font size=-2>(added 4/2/96)</font>
<p>
<DT><A HREF="http://unixg.ubc.ca:780/~fortin/Marcel.html">Canadian HIV Trials Network</A>. <DD>Information about clinical trials and other HIV-related resources in Canada. Also in <A HREF="http://unixg.ubc.ca:780/~fortin/French.html">french</A>
<p>
<DT><A HREF="gopher://cdcnac.aspensys.com:72/">CDC AIDS 
Daily</A>
<DD>Updates from the Centers for Disease Control taken from journals and other publications around the world. Ten one paragraph abstracts with references, posted to the Web each morning.
<p>
<DT><A HREF="http://www.critpath.org/critpath.htm">Critical Path Project</A>
<DD>A vast amount of valuable information on prevention, research, clinical trials, treatments, alternative treatments, services, and a searchable index. Includes <a href="www.critpath.org/actup/">ACT UP Philadelphia</a>'s HIV Adult Standard of Care.
<p>
<DT><A HREF="http://cyberzine.org/html/GLAIDS/glaidshomepage.html">CyberQueer Lounge</A>
<DD>Links to AIDS info including the Digital Quilt, as well as other links of interest to the lesbian, gay and transgendered community. Updated and added to often. Lots of political stuff.
<p>
<DT><A HREF="http://www.dejanews.com">DejaNews</A>
<DD>Excellent search engine that allows you to search newsgroups for articles by subject words, author and date. Submit the query filter form first to limit the newsgroups searched; for example: sci.med.aids, misc.health.aids.
<p>
<DT><A HREF="http://unixg.ubc.ca:780/~aids11/aids96.html">XI International Conference on AIDS</A>
<DD> The conference will be held July 7-12, 1996 in Vancouver. Frequently updated site with newsletter.
<p>
<DT><A HREF="http://gopher.hivnet.org:70/1/newsgroups">GENA Mailing List Archives</A>
<DD>Where you'll find many discussion groups about HIV/AIDS, including AIDS dialogue, AIDS drugs, AIDS and spirituality, AIDS drug trials, and women and HIV.
<p>
<dt><a href="http://www.gmhc.org/living/living.html">GMHC's Living with HIV or AIDS</a>
<dd>Information on medical care and treatment, nutrition, mental health and counseling services, support groups, financial concerns, legal concerns, alcohol and drug use, insurance, and emergency services.
<p>
<DT><A HREF="http://www.crl.com/~robbee/herbal.html">Herbal Resources</A> 
<DD>Links and downloadable information about herbs. Join the <A HREF="news:alt.folklore.herbs">alt.folklore.herbs</A> newsgroup for an ongoing discussion about herbs as treatments.
<p>
<DT><A HREF="http://www.aidsnyc.org/about.html">HIV/AIDS Information Outreach Project</A>
<DD>Links to government, scientific and technical information, academic and reference materials, cultural resources, community resources, and the resources of the New York Academy of Medicine. 
<p>
<DT><A HREF="http://florey.biosci.uq.oz.au/hiv/HIV_EMIR.html">HIV Electronic Information Media Review</A>
<DD>An electronic newsletter with a selection of information from all over the Internet, updated every two weeks. Also, Australian and Pacific information, clinical trials, and facts sheets on conditions and treatments.
<p>
<DT><A HREF="http://hivnet.org/">HIVNET/GENA Information Server</A>
<DD>Downloadable texts from mazagines, newsletters and other periodicals. A lot of good information, but some of the text files on conditions and treatments are very out-of-date, so be aware of the date at the bottom of each file. Links to other places with HIV/AIDS information on the Web.
<p>
<DT>HIV Sequence Database
<DD><A HREF="http://hiv-web.lanl.gov/hiv.html">Pictures of HIV</A> and <A HREF="http://hiv-web.lanl.gov/">scientific papers</A> on HIV gene sequences from the Los Alamos National Laboratory.
<p>
<dt><a href="http://www.prescript.com/infopack/">InfoPack Newsletter</a>
<dd>From Community Prescription Service. Articles on anemia, MAC prophylaxis. <font size=-2>(added 4/2/96)</font>
<p>
<DT><A HREF="http://www.infoex.co.uk/ie/index.html">The Information Exchange</A> 
<DD>UK site providing an important forum for exchange of views on HIV and Aids treatment, care and research for patients, clinic staff, GPs, the media and the general public. Excellent clinical trial information, including many treatments not yet being studied in the US. 
<p>
<dt><a href="http://www.ama-assn.org/special/hiv/hivhome.htm">JAMA HIV/AIDS Information Center</a>
<dd>The Journal of the American Medical Association's HIV/AIDS site. Excellent source for journal articles, abstracts, the CDC Daily, treatment guidelines, and more.
<p>
<DT><a href="http://www.actwin.com/cgi-bin/mfs/05/aids/jsyIndex.html?2#mfs">Just Say Yes</A>
<DD>Information about safer sex.
<p>
<DT><a href="http://www.libertynet.org:80/~fight/">Philadelphia Fight</a>
<DD>Philadelphia FIGHT is a Community-Based Research Initiative on AIDS in Philadelphia.  Founded in 1990, FIGHT is a consortium of physicians and people living with HIV who have joined together to test potential treatments for HIV/AIDS and its complications. 
<p>
<dt><a href="http://www.sageways.com/power">PoWeR: Program for Wellness Restoration</a> <dd> Information on approaches to preventing/reversing wasting syndrome in HIV disease. <font size="-2">(added 3/27/96)</font>
<p>
<dt><a href="http://www.projinf.org">Project Inform</a>
<dd><a href="http://www.projinf.org/fs/">Facts Sheets</a>, <a href="http://www.projinf.org/pub/dp_index.html">Discussion Papers</a>, <a href="http://www.projinf.org/hh/">Hotline Handouts</a>, and their newsletter <a href="http://www.projinf.org/pub/pip_index.html">PI Perspectives</a>.
<p>
<DT><A HREF="http://www.infoqueer.org/queer/quis">Queer Infoservers</A> <DD>Located at UC Berkeley. Health section with links to a variety of sources for HIV/AIDS and related info.
<p>
<DT><A HREF="http://www.casti.com/QRD/.html/QRD-home-page.html">Queer Resources Directory</A>
<DD>Massive archive of files relating to all things queer. Links to health and sexuality issues, including information on HIV/AIDS.
<p>
<DT><A HREF="http://www.indiana.edu/~aids">Rural Prevention Center</A>
<DD>Located at at Indiana University/Purdue, focusing on the promotion of preventing HIV and STDs in rural America.
<p>
<DT><A HREF="http://cornelius.ucsf.edu/~troyer/safesex.html">The Safer Sex Page</A>
<DD>Answers to some questions you may have with links to other pages.
<p>
<dt><a href="http://www.stopaids.org">The Stop AIDS Project</a>
<dd>A four year old organization in San Francisco addressing gay and bisexual men and what they can do to stop AIDS. <font size="-2">(added 1/27/96)</font>
<p>
<dt><a href="http://www.tulane.edu/~actgweb/">Tulane University AIDS Clinical Trials Unit</a>
<dd>Protocols open for enrollment in the New Orleans area. <font size=-2>(added 6/11/96)</font>
<p>
<DT><A HREF="http://www.phar.cam.ac.uk/DDG/hiv.html">The University of Cambridge</A>
<DD>has some pictures for downloading of HIV protease.
<p>
<dt><a href="http://www.swmed.edu/home_pages/hivcrg">University of Texas Southwestern Medical Center's HIV Clinical Research Group</a>
<dd>The HIVCRG performs clinical trials of newly developed HIV anti-retroviral drugs. Other studies
include treatment of diseases associated with or related to HIV infection. <font size="-2">(added 1/20/97)</font>
<p>
<DT><A HREF="http://www-medlib.med.utah.edu/WebPath/AIDS.html">WebPath</A>
<DD>The Internet Pathology Laboratory for Medical Education. Pictures of HIV, PCP, CMV and other infectious agents.
<p>
<DT><A href="http://www.yogagroup.org/yoga/default.html">The Yoga Group, Inc.</a>
<DD>A group based in Denver, Colorado with information about yoga for people living with HIV and AIDS, and links to other sites.
<p>
<DT><a href="http://www.critpath.org/wtp/">We the People</a>
<DD>The only Philadelphia-area organization created and run by and for people living with HIV disease and AIDS. Includes their monthly newspaper, Alive &amp; Kicking! and information about their weekly TV broadcast on health care in the age of AIDS: Positive Health. <font size="-2">(added 11/24/95)</font>
<p>
</DL>

</blockquote>

<HR SIZE=3 WIDTH=50% ALIGN=CENTER noshade>

<P ALIGN=CENTER><A HREF="index.html"><img src="gifs/return.gif" alt="[arrow]"></p><p align=center>to Network home page</A></font></P>

<hr size=3 align=center width=50% noshade>

<P align=center><FONT SIZE=-2>Last modified: 1/20/97<BR>
<A HREF="mailto:atdn@nyam.org">atdn@aidsnyc.org</A><BR>
copyright &#169; 1996 1997 The Network</FONT></P>

</font>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT18-B31-253</DOCNO>
<DOCOLDNO>IA093-001002-B003-80</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/member.html 199.29.141.24 19970121123400 text/html 5231
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:28:08 GMT
Server: NCSA/1.5.1
Last-modified: Wed, 08 Jan 1997 14:37:11 GMT
Content-type: text/html
Content-length: 5048
</DOCHDR>
<HTML>
<head>
<TITLE>The Network: Membership</TITLE>
</head>

<BODY bgcolor="#ffffff" link="#00688b" vlink="#545454"><font face="arial, helvetica" size=-1>

<center><table border=1 cellpadding=0 cellspacing=0 width=90% colspecs="10% 45% 45%">
<tr>
<td align=center rowspan=2 width="10%"><a href="index.html"><img src="gifs/logo1.gif" <img border=2 width=209 height=96 alt="[logo] "></a></td>
<p>
<td align=center width="45%" nowrap><font face="century gothic, arial, helvetica" size=-1><b>information about treatments <br>for HIV and AIDS</b></font></td>
<p>
<td align=center rowspan=2 bgcolor="#b0e2ff" width="45%"><font size=+1 color="#0000ff" face="century gothic, arial, helvetica" color="#00688b"><b>Network <br>Membership</b></font></td>
<p>
</tr>
<tr><td align=center nowrap><font face="century gothic, arial, helvetica" size=-1>Our membership list is confidential. <br>We do not sell or share our mailing lists.</font></td>
<p>
</tr>
<tr>
<td colspan=3 align=center><font face="century gothic, arial, helvetica" size=-1>To become a Network Member, fill out as much of the information below as you can and send the form to us using the button at the bottom of the page. If you'd like to make a donation for membership and materials, please print the form and mail it to us with your check.</font></td>
<p>
</table></center>
 
<form action="/cgi-bin/atdnfrm">
<input type="hidden" name="to" value="atdn@nyam.org">
<input type="hidden" name="from" value="jbeard@nyam.org">
<input type="hidden" name="body" value="materials">
<input type="hidden" name="sub" value="Member">
<input type="hidden" name="form_submitted" value="http://health.nyam.org:8000/public_html/network/member.html">
<br>

<center><table width=90%>
<tr>
<td align=right><font face="century gothic, arial, helvetica" size=-1><B>First Name</B> <br><input name="firstname" size=40,1></font></td>
<td align=left><font face="century gothic, arial, helvetica" size=-1><B>Last Name</B> <br><input name="lastname" size=40,1></font></td>
</tr><tr>
<td align=right><font face="century gothic, arial, helvetica" size=-1><B>Title</B> <br><input name="title" size=40,1></font></td>
<td align=left><font face="century gothic, arial, helvetica" size=-1><B>Affiliation</B> <br><input name="affiliation" size=40,1></font></td>
</tr><tr>
<td align=right><font face="century gothic, arial, helvetica" size=-1><B>Street Address</B> <br><input name="street" size=40,1></font></td>
<td align=left><font face="century gothic, arial, helvetica" size=-1><B>City/State/Zip</B> <br><input name="citystatezip" size=40,1></font></td>
</tr><tr>
<td align=right><font face="century gothic, arial, helvetica" size=-1><B>Phone (Include Area Code)</B> <br><input name="phone" size=40,1></font></td>
<td align=left><font face="century gothic, arial, helvetica" size=-1><B>E-mail Address</B> <br><input name="email" size=40,1></font></td>
</tr><tr>
<td colspan=2><font face="century gothic, arial, helvetica" size=-1>If you'd like to receive our publications by mail, please mark the appropriate check boxes below. All our publications are free of charge to anyone who can't afford them. Donations of any size are gratefully accepted.</font></td>
</tr><tr>
<td colspan=2><font face="century gothic, arial, helvetica" size=-1><DL>
<DT><INPUT TYPE="checkbox" NAME="TR"><B>Treatment Review ($16/yr)</B>
<DD>The Network's newsletter, published at least 6 times a year.

<DT><INPUT TYPE="checkbox" NAME="ETG"><B>The Experimental Treatment Guide ($10)</B>
<DD>A directory of clinical trials in the New York area, published 4 times a year.

<DT><INPUT TYPE="checkbox" NAME="ShouldI"><B>Should I Join an AIDS Drug Trial? ($1)</B>
<DD>A handbook exploring many of the issues surrounding being part of a clinical trial.
<DT><INPUT TYPE="checkbox" NAME="Spanish"><B>I would like to receive Spanish language materials.</B>
<DD>Treatment Review, Should I Join an AIDS Drug Trial? and The Experimental Treatment Guide are available in Spanish. 

</DL></font></td>
</tr><tr>
<td align=center colspan=2><font face="century gothic, arial, helvetica" size=-1><B>Comments or Suggestions</B></p>

<textarea name="suggestions" rows=5 cols=60></textarea></font></td>
</tr><tr>
<td align=center colspan=2><font face="century gothic, arial, helvetica" size=-1>You can submit this form now, or print it out and mail with a check if you prefer to:<br>
The Network<BR>
611 Broadway, Suite 613<BR>
New York, NY 10012</font></td>
</tr><tr>
<td align=center colspan=2><font face="century gothic, arial, helvetica" size=-1><input type="submit"   value="SEND">
<input type="reset" value="CLEAR"></font></td>
</tr>
</table></center>
</form>

<HR SIZE=3 WIDTH=50% ALIGN=CENTER noshade>

<P ALIGN=CENTER><A HREF="index.html"><img src="gifs/return.gif" alt="[arrow]"></p><p align=center>to Network home page</A></P>

<hr size=3 align=center width=50% noshade>

<P align=center><FONT SIZE=-2>Last modified: 1/8/97<BR>
<A HREF="mailto:atdn@nyam.org">atdn@nyam.org</A><BR>
copyright &#169; 1996 The Network</FONT></P>

</font>
</body>
</html>







</DOC>
<DOC>
<DOCNO>WT18-B31-254</DOCNO>
<DOCOLDNO>IA093-001002-B003-96</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/tag/tag.html 199.29.141.24 19970121123408 text/html 5313
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:28:16 GMT
Server: NCSA/1.5.1
Last-modified: Sun, 19 Jan 1997 16:59:03 GMT
Content-type: text/html
Content-length: 5130
</DOCHDR>
<html>
<head>
<title>TAG: Treatment Action Group</title>
</head>

<body background="gifs/stripe.gif" link="#2f2f4f" vlink="#696969"><font face="arial, helvetica" size="-1">

<p><img src="gifs/logo.gif" alt="Treatment Action Group" width=78 height=63 align=middle hspace=4><font size=+2>TAG : Treatment Action Group</font></p>

<blockquote>
<ul>
<p align=right>Founded in January, 1992, the Treatment Action Group, or TAG, is the first and only AIDS organization dedicated solely to advocating for larger and more efficient research efforts, both public and private, towards finding a cure for AIDS.</p>

<p align=right>TAG supports the work of approximately fifty treatment activists as they meet with researchers, pharmaceutical companies, and government officials, ensuring a voice for people living with HIV in the process of finding and accessing promising treatments.  TAG's treatment activists, most of whom are living with HIV, strive to develop the scientific and political expertise needed to transform policy.</p>

<p align=center><font size=+2>Tagline - A monthly paper of research and policy</font></p>
<ul>
<li><a href="9605.html">Volume 3  Issue 4 May 1996</a>
<dt>FDA Reviews Roche PCR Assay, Comparing Protease Inhibitors, 10 A&ntilde;os De Protesta, AIDS activism as religious cult, Random Gleanings, La Revisi&oacute;n del PCR, Notas de Todas Partes
</ul>

<p align=center><font size=+2>Policy papers and research reviews</font></p>

<ul>
<li><a href="icaac.zip"><b>TAG Does ICAAC</b></a> by Mark Harrington and Michael Marco
<dt>AIDS research highlights from the 35th Interscience Conference on Antimicrobial Agents &amp; Chemotherapy (ICAAC), San Francisco, California, <b>September 17-20, 1995</b>.
<li><a href="lymphoma.zip"><b>The Lymphoma Project Report</b></a> by Michael Marco
<dt>Current issues in the research and treatment of AIDS-associated lymphoma. Written for the 31st Annual Meeting American Society of Clinical Oncology Los Angeles, CA <b>May 20-23, 1995</b>. 
<li><a href="protease.zip"><b>Problems with Protease Inhibitor Development Plans</b></a>
<dt>Written for the National Task Force on AIDS Drug Development <b>February 23, 1995</b>, Washington, D.C. Discusses development and research of protease inhibitors with recommendations for future clinical trial design.
<li><a href="ks.zip"><b>The KS Project Report</b></a> by Michael Marco with Martin Majchrowicz
<dt>Current issues in research and treatment of Kaposi's sarcoma. Written for the eighteenth AIDS Clinical Trials Group Meeting Washington, D.C., <b>July 25,1994</b>.
<li><a href="basic.zip"><b>The Challenge Ahead</b></a> by Greg Gonzalves
<dt>36 basic scientists working in AIDS interviewed during <b>April and May 1993</b> discuss scientific issues, practical problems, and outline practical means of remedying the situation.
<li><a href="crisis.zip"><b>The Crisis in AIDS Research</b></a> by Mark Harrington
<dt>An overview of AIDS research, written in <b>1993</b>, with suggestions for changes in fundamental approaches to how the virus, treatments, and research goals are viewed.
<li><b>AIDS Research at the NIH: A Critical Review</b> by Gregg Gonsalves and Mark Harrington
<dt><a href="nih1.zip">Part I: Summary</a>. <a href="nih2.zip">Part II: The NIH, A User's Guide</a>. VIII International Conference on AIDS, Amsterdam, the Netherlands, <b>July 20, 1992</b>.
</ul>

<p align=center>Each of these papers is available in hard copy format by writing or calling TAG at the address and numbers below. Please note that all papers provided here are dated. While the information contained in them is important, treatment options have changed since the dates of their writing.</p>

<hr size=3 width=50% align=center noshade>

<p  align=right>TAG papers are provided here in zipped text-only format for downloading and reading with a text editor. If you don't have an unzip application, you can download shareware called <A HREF="http://wchat.on.ca/web/help/pkunzip.htm">pkunzip</A> for DOS, <A HREF="http://www.winzip.com/winzip/download.html">WinZip</A> for Windows, or <A HREF="http://www.awa.com/softlock/zipit/">Zipit</A> for Macs. Extract the zipped program onto your harddrive and associate the zip extension with the application both in your browser and on your harddrive. Then when you click on a zipped file to download, your harddrive will automatically unzip the file and you'll be able to read it with whatever text reader or word processing application you use.</p>

</ul>

<p align=center><a href="../index.html"><img src="../gifs/return.gif" vspace=5><br>Network home page</a></p>

<hr size=3 width=50% align=center noshade>

<P align=center>Last modified: 1/19/97<br>
<A HREF="mailto:spencerc@panix.com">Treatment Action Group</A><br>
200 East 10th Street, #60<br>
New York, NY 10003<br>
phone: (212) 260-0300<br>
fax: (212) 260-8561<br>
copyright &#169; 1996 1997 TAG</P>

<p align=center><font face="comic ms sans, century gothic">This site designed and maintained by Joel Beard courtesy of <br>Ken Fornataro and the <a href="../index.html">AIDS Treatment Data Network</a>.</font></p>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-255</DOCNO>
<DOCOLDNO>IA093-001002-B003-114</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/cwha/aids.html 199.29.141.24 19970121123416 text/html 1954
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:28:24 GMT
Server: NCSA/1.5.1
Last-modified: Wed, 10 Jul 1996 22:17:59 GMT
Content-type: text/html
Content-length: 1771
</DOCHDR>
<html>
<head><title>CWHA: HIV/AIDS Program</title>
</head>
<body bgcolor="#ffffff" text="#ff0000" alink="#8f8fbd">

<p align=center><a href="index.html"><img src="gifs/logo.gif"></a></p>
<hr size=3 width=50%>
<blockquote>
<p>The HIV/AIDS Program has four components:

<ul>
<li>The Peer Initiative Project
<li>The Adolescent Initiative
<li>The Women's Component
<li>The Case Management Component
</ul>

<p>The overall goal of the program is to provide HIV/AIDS prevention education. Our targeted population (Hispanics, Caribbean-American and Haitians) are met through interactive workshops, street outreach, one-to-one educational sessions and health fairs. The Case Management part of the program provides counseling to HIV+ individuals and their families.</p>

</blockquote>

<p align=center><font size=+1><b>Support Groups for PWA's and PWHIV</b></font><br>
<br>
<b>Brooklyn</b><br>
<br>
Saturdays at 1:00 p.m. to 2:00 p.m.<br>
<br>
at<br>
<br>
3312 Church Avenue<br>
(Between New York Avenue and 34th Street)<br>
Brooklyn, New York 11226<br>
<br>
<b>Call: (718) 940-8386</b></p>

<hr size=3 align=center width=50%>

<p align=center><b>Far Rockaway</b><br>
<br>
Mondays at 6:00 p.m. to 7:00 p.m.<br>
<br>
1600 Central Avenue<br>
(Across from Fire Department<br>
Far Rockaway, New York 11691<br>
<br>
<b>Call: (718) 868-4746</b><br>
<br>
<b>Contact Persons:</b><br>
Dr. Ady Turnier<br>
Elaine Reid, C.S.W.<br>
<br>
<b>HIV Counseling offered in Creole, Spanish and English</b></p>

<hr size=4 width=50% align=center noshade>

<p align=center><a href="index.html"><img src="gifs/palm.gif" border=2 vspace=5><br>
<font size=-1>CWHA home page</a><br>
modified 7/10/96<br>
&#169 1996 CWHA<br>
<a href="mailto:hivinfo@aidsnyc.org">hivinfo@aidsnyc.org</a></p>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-256</DOCNO>
<DOCOLDNO>IA093-001002-B003-130</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/cwha/child.html 199.29.141.24 19970121123425 text/html 2017
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:28:33 GMT
Server: NCSA/1.5.1
Last-modified: Thu, 02 May 1996 20:53:53 GMT
Content-type: text/html
Content-length: 1834
</DOCHDR>
<html>
<head><title>CWHA: Maternal Child Health</title>
</head>
<body bgcolor="#ffffff" text="#000000" alink="#8f8fbd">

<p align=center><a href="index.html"><img src="gifs/logo.gif"></a></p>

<p align=center><font size=+2 color="#ff0000">Maternal Child Health</font></p>

<blockquote>

<p>The Maternal Child Health Program provides outreach education, case management, child health and other social support services such as housing referral, food pantry, etc., to low income pregnant and parenting families in high risk neighborhoods to ensure that they gain early entrance and continuous participation inprimary and prevention health services. Approximately 2,000 families are served annualy. </p>

<p><b>Health Care Referral Services</b></p>
<ul>
<li>Prenatal Care
<li>Child Health
<li>Family Planning
<li>Immunization
<li>AIDS Education and Testing
<li>Lead Poisoning
<li>Communicable Diseases
<li>Adolescent Pregnancy Program
<li>Dental
</ul>

<p><b>Family and Social Support Referral Services</b></p>
<ul>
<li>Medicaid
<li>Public Assistance
</ul>

<p><b>Nutrition Referral Services</b></p>
<ul>
<li>W.I.C.
<li>Food Pantry
<li>Food Stamps
<li>Meals on Wheels
</ul>

<p><b>Substance Abuse Referral Services</b></p>
<ul>
<li>Alcohol
<li>Drugs
<li>Smoking
</ul>

<p><b>Other Referral Services</b></p>
<ul>
<li>Domestic Violence
<li>Day Care
<li>Senior Citizens
<li>Housing
<li>Legal Aid
<li>Mental Health Services
<li>Services for the disabled
<li><a href="center.html">Immigration Services</a> (<a href="espanol.html">en espa&ntilde;ol</a>)

<hr size=4 width=50% align=center noshade>

<p align=center><a href="index.html"><img src="gifs/palm.gif" border=2 vspace=5><br>
<font size=-1>CWHA home page</a><br>
modified 4/23/96<br>
&#169 1996 CWHA<br>
<a href="mailto:hivinfo@aidsnyc.org">hivinfo@aidsnyc.org</a></p>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-257</DOCNO>
<DOCOLDNO>IA093-001002-B003-143</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/cwha/center.html 199.29.141.24 19970121123432 text/html 2695
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:28:41 GMT
Server: NCSA/1.5.1
Last-modified: Thu, 02 May 1996 20:53:53 GMT
Content-type: text/html
Content-length: 2512
</DOCHDR>
<html>
<head><title>CWHA: Immigrant Service Center</title>
</head>
<body bgcolor="#ffffff" text="#000000" alink="#8f8fbd">

<a href="index.html"><img src="gifs/logo.gif" vspace=5 hspace=5 align=left></a>

<ul><font size=-1><p><a href="espanol.html">en espa&ntilde;ol</a></font></p>
<p><a href="#about"><font size=+1><b>About CWHA's Immigrant Service Center</a></b></font></p>
<p><a href="citizen.html"><font size=+1><b>Why become a citizen?</a></b></font></p>
<p><a href="asylum.html"><font size=+1><b>Find out what you need to know about asylum</a></b></font></p></ul>

<p><font size=+2><a name="about">CWHA's</a> Immigrant Service Center</font></p>

<p>The Caribbean Women's Health Association (CWHA) operates a non-profit Immigrant Service Center ("Center") which is accredited to represent cleints before the U.S. Immigration and Naturalization Services, The Immigration Court and the Board of Immigration Appeals.</p>

<p>The Center provides comprehensive, culturally senstitive dedicated immigration services designed to meet the special needs of immigrant clients, protect their rights, assist them in making positive adjustments and becoming self-sufficient productive members in their host communities. Emphasis is placed on high quality, low-cost legal services regardless of immigration status or ethnicity.</p>

The Center's multi-lingual, professional staff consisting of attorneys, immigration counselors and social workers who are uniquiely qualified to provide social support and immigration-related services, and represent clients at immigration hearings.</p>

The Center also conducts training seminars and operates a Speaker's Bureau with expert speakers on immigration related issues. It also serves as a citizenship test site for the Educational Testing Services.</p>

The Center works with CWHA's social support programs to connect families with housing, education, entitlements, employment, fmily support and health care services. Clients from over a hundred countries are served.</p>

If you want to know the alternatives for obtaining a Green Card or need professional assistance in immigration matters, call us to make an appointment for a free consultation session. We are here to help you.</p>

<hr size=4 width=50% align=center noshade>

<p align=center><a href="index.html"><img src="gifs/palm.gif" border=2 vspace=5><br>
<font size=-1>CWHA home page</a><br>
modified 4/17/96<br>
&#169 1996 CWHA<br>
<a href="mailto:hivinfo@aidsnyc.org">hivinfo@aidsnyc.org</a></p>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-258</DOCNO>
<DOCOLDNO>IA093-001002-B003-160</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/cwha/espanol.html 199.29.141.24 19970121123440 text/html 2206
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:28:47 GMT
Server: NCSA/1.5.1
Last-modified: Thu, 02 May 1996 20:53:54 GMT
Content-type: text/html
Content-length: 2023
</DOCHDR>
<html>
<head><title>CWHA: hazte ciudadano ahora</title>
</head>
<body bgcolor="#ffffff" text="#000000" alink="#8f8fbd">

<img src="gifs/us.gif" vspace=5 hspace=5 align=left>
<font size=-1>
<p><font size=+2 color="#ff0000">&#161;Hazte ciudadano ahora!</font></p>

<ul>
<li>Los ciudadanos pueden votar
<br>
<li>Pueden viajar libremente
<br>
<li>Pueden pedir por sus familiares
</ul>

<p>Si usted recibi&oacute; su "tarjeta verde" por la amnist&iacute;a, puede ser elegible para la ciudadan&iacute;a.</p>

<p align=center><font size=+1>NOSOTROS PODEMOS AYUDARLE A OBTENER SU CIUDADAN&Iacute;A</FONT></P>

<p align=center><font size=+1>&#161;LLAME AHORA!<BR> (718) 826-2942</font></p>

<p align=center><font size=+1><a href="servicio.html">SERVICIOS</a></font></p>

<P ALIGN=CENTER><b>ASOCIACI&Oacute;N DE SALUD DE MUJERES CARIBE&Ntilde;AS CENTRO DE SERVICIO DE INMIGRACI&Oacute;N</b></FONT></P>

<p><font size=-1><b>Acreditada por el Servicio de Inmigraci&oacute;n y Naturalizaci&oacute;n de los E.U. como entidad designada y calificada.</b></font></p>

<center><table><tr><td align=center><font size=-1>2725 Church Ave.<br>Brooklyn, New York 11226</font></td><td><br></td><td align=center><font size=-1>Lunes a Viernes 10:00 a.m.-6:00 p.m.<br>Sabado 11:00 a.m.-3:00 p.m.</font></td></tr><tr><td colspan=3 align=center><font size=-1>Entre las Avenidas Nostrand &amp; Rogers<br>No. 2 &amp; 5 Subway hasta Church Avenue</font></td></tr><tr><td align=center><font size=-1>Precios razonables</font></td><td><br></td><td><font size=-1>Hablamos frances y espa&ntilde;ol</font></td></tr><tr><td colspan=3 align=center><font size=-1>Ofrecemos Servicios Completos de inmigraci&oacute;n y confidencialidad total</font></td></tr></table></center>

<hr size=4 width=50% align=center noshade>

<p align=center><a href="index.html"><img src="gifs/palm.gif" border=2 vspace=5><br>
<font size=-1>CWHA home page</a><br>
modified 4/25/96<br>
&#169 1996 CWHA<br>
<a href="mailto:hivinfo@aidsnyc.org">hivinfo@aidsnyc.org</a></p>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-259</DOCNO>
<DOCOLDNO>IA093-001002-B003-179</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/cwha/servicio.html 199.29.141.24 19970121123449 text/html 6582
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:28:56 GMT
Server: NCSA/1.5.1
Last-modified: Thu, 02 May 1996 20:53:54 GMT
Content-type: text/html
Content-length: 6399
</DOCHDR>
<html>
<head><title>CWHA: servicios de inmigraci&oacute;n</title>
</head>
<body bgcolor="#ffffff" text="#ff0000" alink="#8f8fbd">

<p><a href="index.html"><img src="gifs/logo.gif" vspace=5 hspace=5 align=left></a><font size=+2>INMIGRANTES DE NUEVA YORK</font></p>

<p><font size=+1>Servicios de Inmigraci&oacute;n profesionales a bajo costo</font></p>

<hr size=4 align=center width=50%>

<p><b>El Centro de Servicios de Inmigraci&oacute;n de CWHA</b></p>

<p>La Asociaci&oacute;n de Salud de Mujeres Caribe&ntilde;as (CWHA) opera un Centro sin fines de lucro, el cu&aacute;l est&aacute; acreditado para representar clientes ante la Oficina de Inmigraci&oacute;n y Naturalizaci&oacute;n de los Estados Unidos de Am&eacute;rica; as&iacute; como ante la Corte de Inmigraci&oacute;n y la Junta de Apelaciones de Inmigraci&oacute;n.</p>

<p>El Centro cuenta con un personal altamente calificado, bilingue, abogados, consejeros de inmigraci&oacute;n y trabajadores sociales que estan dispuestos a ayudarle. Se ofrecen servicios confidenciales cubriendo las diversas necesidades que puedan tener los inmigrantes, protegiendo al mismo tiempo sus derechos, asisti&eacute;ndoles a ajustarse positivamente en esta sociedad para ser individuos m&aacute;s productivos e &uacute;tiles.</p>

<p>El costo legal es m&iacute;nimo, no importa el status legal del individuo. Entre la gama de servicios que se ofrecen dictamos seminarios, entrenamientos y damos el examen de la ciudadan&iacute;a.</p>

<p>El Centro opera con otros programas de apoyo para proveer consejer&iacute;a productiva y lograr as&iacute; resolver sus problemas de renta, educaci&oacute;n, trabajo, soporte familiar y cuidadados de salud. Clientes de cientos de Pa&iacute;ses son atendidos regularmente.</p>

<p>Si desea obtener informaci&oacute;n sobre las alternativas para obtener su "green card" o necesita asistencia profesional en asuntos de inmigraci&oacute;n, ll&aacute;menos para una consulta. Estamos para ayudarle.</p>

<p><font color="#000000"><b>Servicios Legales</b></font></p>

<p>Podemos ofrecerle la ayuda que usted necesita en todas estas &aacute;reas de inmigraci&oacute;n:</p>

<ul>
<li>Representaci&oacute;n en la Corte de Inmigraci&oacute;n;
<li>Solicitud de residencia permanente ("Tarjeta Verde");
<li>Autorizaci&oacute;n de Trabajo;
<li>Petici&oacute;n para familiares;
<li>Visa de Visitante;
<li>Solicitud de naturalizaci&oacute;n y ciudadan&iacute;a;
<li>Visa de estudiante;
<li>Reemplazo de documentos del INS;
<li>Extensi&oacute;n de visa;
<li>Asilo politico;
<li>Examen de la ciudadan&iacute;a;
<li>Traducci&oacute;n de documentos de inmigraci&oacute;n;
<li>Huellas digitales y fotograf&iacute;as;
<li>Visas de trabajo;
<li>Permiso de re-entrada;
<li>Representaci&oacute;n en procesos de deportaci&oacute;n y exclusi&oacute;n.
</ul>

<p><font color="#000000"><b>CWHA Le Ayudar&aacute; a Resolver sus Problemas de Inmigraci&oacute;n</b></font></p>

<p>Antes de integrarse c&oacute;modamente a la vida en los Estados Unidos, usted deber&aacute; resolver el tema de su estado legal con el Servicio de Inmigraci&oacute;n y Naturalizaci&oacute;n (INS). No importa cu&aacute;nto tiempo haya vivido en los Estados Unidos ni cual sea su estado legal, completar los complicados formularios y seguir los procedimientos correctos del INS es tan importante como confuso.</p>

<p><font color="#000000"><b>El Centro de Servicios para Inmigrantes de la Asociaci&oacute;n de Salud de Mujeres Caribe&ntilde;as (CWHA)</b></font> elimina la preocupaci&oacute;n, confusi&oacute;n y el alto costo de resolver los problemas de inmigraci&oacute;n, ya sean simples o complejos. Una agencia de servicios de inmigraci&oacute;n sin fines de lucro ha asistido en el reasentamiento de m&aacute;s de 100,000 inmigrantes durante los &uacute;ltimos 10 anos. El Centro ofrece servicios legales a bajo costo a los extranjeros, no importa a que grupo &eacute;tnico pertenezcan ni cual sea su estado legal. Somos un grupo dedicado de profesionales--abogados, asesores sobre asuntos de inmigraci&oacute;n y trabajadores sociales altamente calificados para ayudarle a resolver un amplia gama de asuntos legales y sociales.</p>

<center><table border=1 width=50%><tr><th><font size=+1 color="#000000">AVERIGUE LO QUE PODEMOS HACER POR USTED<BR><BR>OFRECEMOS SERVICIOS CONFIDENCIALES. CON NOSOTROS USTED OBTIENE RESULTADOS<font></th></tr></table></center>

<p><font color="#000000"><b>Asistencia con las solicitudes de Inmigraci&oacute;n</b></font></p>

<p>Le ayudaremos a completar sus solicitudes y las presentaremos al INS por usted. Adem&aacute;s le ofreceremos informaci&oacute;n sobre como completar todos los documentos que debe presentar junto a sus peticiones y solicitudes. Y nos aseguraremos de que usted est&eacute; debidamente preparado para sus entrevistas de inmigraci&oacute;n.</p>

<p><font color="#000000"><b>Representaci&oacute;n de procesos de inmigraci&oacute;n</b></font></p>

<p>Despu&eacute;s de completar sus solicitudes, lo acompa&ntilde;aremos a su entrevista en el Servicio de Inmigraci&oacute;n y Naturalizaci&oacute;n. Y si debe hacer frente a un proceso de exclusi&oacute;n o deportaci&oacute;n, nuestros profesionales legales lo representaran ante el juez para proteger sus derechos.</p>

<p><font color="#000000"><b>Servicios sociales integrales</b></font></p>

<p>Ad&eacute;mas de proveer representaci&oacute;n legal altamente calificada, CWHA combina asesoramiento sobre asuntos de inmigraci&oacute;n con servicios sociales. Enfocamos todos sus problemas desde un punto de vista integral, ya trav&eacute;s de nuestros ostros programas de servicios sociales y de salud para ayudarles con problemas sobre vivienda, empleo, educaci&oacute;n, familiares, con asesoramiento sobre sus derechos, e informaci&oacute;n de donde adquirir ayuda. Nuestro personal de trabajoadores sociales son altamente capacitados y tambi&eacute;n pueden ayudarle en situaciones de emergencia.</p>

<center><table border=1 width=70%><tr><th><font color="#000000">Si Quiere ser Voluntario, llame al (718) 826-2942<br>Todas las contribuciones son deducibles del "income tax"</font></th></table></center>

<p align=center><a href="index.html"><img src="gifs/palm.gif" border=2 vspace=5><br>
<font size=-1>CWHA home page</a><br>
modified 4/25/96<br>
&#169 1996 CWHA<br>
<a href="mailto:hivinfo@aidsnyc.org">hivinfo@aidsnyc.org</a></p>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-260</DOCNO>
<DOCOLDNO>IA093-001002-B003-198</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/cwha/about.html 199.29.141.24 19970121123500 text/html 2236
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:29:07 GMT
Server: NCSA/1.5.1
Last-modified: Thu, 02 May 1996 20:53:52 GMT
Content-type: text/html
Content-length: 2053
</DOCHDR>
<html>
<head><title>About the Caribbean Women's Health Association</title>
</head>
<body bgcolor="#ffffff" text="#ff0000" alink="#8f8fbd">

<img src="gifs/logo2.gif" vspace=5 hspace=5 align=left>

<p>The Caribbean Women's Health Association Inc. (CWHA), is a community based organization comprised of a membership association and four community service centers located in Brooklyn and Queens.</p>

<p>The mission of CWHA is to provide comprehensive, culturally sensitive health care, immigration and support services to a diverse constituency in central Brooklyn and Southern Queens.</p>

<p>Current operational programs include:</p>

<ul>
<li><a href="aids.html">HIV/AIDS Education and Case Management</a>
<br>
<li><a href="center.html">Comprehensive Immigration Services</a>
<br>
<li>Health Fairs
<br>
<li><a href="child.html">Maternal Child Health Services</a>
</ul>
<ul>
<li>Substance Abuse Prevention
<dt>Provides outreach, education and case management to persons at risk for substance abuse as well as those already involved in the behavior. The program serves 500 familes annually.
<br>
<li>College Internship Program
<dt>Provides a College Internship Program designed to enable interns to gain professional experience and skills that will enhance career development.
</ul>

<blockquote>
<p>CWHA is now at a pivotal point in history. The organization has built a solid reputation in service delivery and is viewed as a leader in addressing barriers to health, immigration and social services. On the strength of its reputation and capability, CWHA is in the process of developing and constructing a health center in partnership with University Hospital of Brooklyn. This facility will address the need for primary care in East Flatbush and Crown Heights.</p></blockquote>

<hr size=4 width=50% align=center noshade>

<p align=center><a href="index.html"><img src="gifs/palm.gif" border=2 vspace=5><br>
<font size=-1>CWHA home page</a><br>
modified 4/17/96<br>
&#169 1996 CWHA<br>
<a href="mailto:hivinfo@aidsnyc.org">hivinfo@aidsnyc.org</a></p>
</DOC>
<DOC>
<DOCNO>WT18-B31-261</DOCNO>
<DOCOLDNO>IA093-001002-B003-214</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/trials/crypto.html 199.29.141.24 19970121123520 text/html 7699
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:29:28 GMT
Server: NCSA/1.5.1
Last-modified: Sat, 21 Dec 1996 22:35:29 GMT
Content-type: text/html
Content-length: 7516
</DOCHDR>
<html>
<head>
<title>Trials: cryptosporidiosis</title>
</head>
<body bgcolor=#ffffff><font face="arial, helvetica" size=-1>

<h2 align=center>Trials for the treatment of <a href="../simple/crypto.html">cryptosporidiosis</a></h2>

<blockquote><h5 align=center>Contact numbers on these pages are for the New York area. Many of the trials are nationwide. For sites in your area, call the AIDS Clinical Trials Information Services (ACTIS) at 1-800-TRIALS-A.</h5>

<HR size=3 width=50% align=center noshade>

<p><a name="azithro">066-167S</a>. Drug: <B>azithromycin</B>. Azithromycin is available through a Treatment IND protocol for treatment of cryptosporidiosis for PWAs who have failed or are intolerant to conventional treatments. Side effects of IV azithromycin include nausea and abdominal pain. Oral azithromycin failed to show an effect on the frequency of bowel movements, parasite shedding in the stool or overall clinical response in a placebo-controlled study. You must be intolerant to prior standard anti-diarrhea antibiotic or other therapies for cryptosporidiosis with other causes of diarrhea excluded. Contact: Pfizer/Premier Research, (800) 742-3029.</p>

<p><a name="clarithro">COR-CLA</a>. Drug: <B>clarithromycin</B>. This trial will study clarithromycin for the treatment of cryptosporidiosis. All participants will be treated with clarithromycin at a dose of 500 mg twice a day for 3 weeks. If no response is seen, the dose will be raised to 1000 mg twice a day for 4 weeks. Contact: Rosemary Soave, MD, Cornell Medical College, New York, NY, (212) 746-6320. </p>

<p>COR-NTZm. Drug: <b>nitazoxanide (NTZ)</b>. This trial will study a drug called nitazoxanide (NTZ) for the treatment of microsporidiosis. Study participants will receive a dose of 2000 mg of NTZ per day for four weeks. If the infection does not respond, people can continue to take the drug for four more weeks at 3000mg per day. Evaluations will be required at weeks 1,2,4, 6 and 8 while taking the drug, followed by one to three visits after the drug is stopped. Both the participant and the doctor will know which treatment is being taken. To participate you must be HIV+, 18 years or older, with a diagnosis of microsporidial diarrhea.  If you have cryptosporidiosis as well, you are eligible. You cannot be pregnant or have an active intestinal infection other than microsporidiosis or cryptosporidiosis such as  salmonella, shigella, campylobacter, yersinia, giardia, E. histolytica, isospora, cyclospora, Mycobacterium avium complex, cytomegalovirus or clostridium difficile. The total time on study will be 5 to 11 weeks. Contact: Lawrence Davis, MD, Cornell Medical Center, New York, NY, (212) 746-6320; Rosemary Soave, MD, Cornell Medical Center, New York, NY, (212) 746-6320. <font size=-2>(added 10/8/96)</font></p>

<p>GG-10-09. Drug: <b>bovine immunoglobulin concentrate (sporidin-G)</b>. This trial will study BIC (bovine immunoglobulin concentrate) for the treatment of cryptosporidiosis and diarrhea. The participants will be divided into two groups. The first group will receive BIC. The second group will receive a placebo. Neither the participant nor the doctor will know which treatment is being given. After 28 days all the participants will be eligible to receive eight further weeks of BIC. To participate you must be HIV+ and 18  years or older with a <b>T4 cell count under 180</b>. You must have a diagnosis of cryptosporidiosis (by biopsy or identification of C.parvum oocysts in stool) with diarrhea for at least 10 days three weeks prior to study entry. You cannot be pregnant or nursing, have a diagnosis of CMV colitis or history of allergy to milk protein or primary  lactose intolerance (e.g. not able to tolerate one 8 oz. glass of milk per day), or presence in the stool of enteric pathogens other than C. parvum. You cannot have changed your anti-diarrheal therapy within 7 days of study entry, have ever participated in any bovine trial, or used laxatives or have a positive test on a laxative screen (danthron, bisacodyl, phenolphthalein) within 7 days of study entry. Total time on study is 28 days. Contact: Howard Grossman, MD, New York, NY, (212) 929-2629; Douglas Simon, MD, AECOM, Bronx, NY, (718) 918-5650. <font size=-2>(added 12/12/96)</font></p>

<p>SLR-THAL. Drug: <b><a href="../simple/thalid.html">thalidomide</a></b>. This trial will study thalidomide for the treatment of microsporidiosis and/or cryptosporidiosis.  Participants will be divided into two groups. One group will be treated with thalidomide. The other group will be treated with placebo. Neither the doctor nor the participant will know which treatment is being given. To participate you must be HIV+ and 18 years or older with a <b>T4 cell count under 200</b>. You must have biopsy and stool proven microsporidiosis or cryptosporidiosis and a history of average of 3 liquid bowel movements per day for 2 weeks prior to study entry. You cannot be pregnant or nursgin, or have evidence of CMV enteritis or colitis, or peripheral neuropathy. You cannot be taking Tenidap, appetite stimulants or treatment with pentoxifylline. Total time on study is 4 weeks. Contact: Glenda Winson, RN, St. Luke's/Roosevelt Hospital Center, New York, NY, (212) 523-3670. <font size=-2>(modified 12/22/96)</font></p>

<p><a name="umd">UMD</a>-95-009. Drug: <b>nitazoxanide (NTZ)</b>. This compassionate use program will study NTZ for the treatment of cryptosporidiosis. There is a limited enrollment of 30 people. People with over 200 T4 cells may qualify if they have had symptomatic cryptosporidiosis for at least 4 weeks. Treatment is for 14 days. An additional 14 days of treatment may be given at the physician's discretion. An additional months supply of drug is also available, but the total duration of NTZ treatment can not be more than 60 days. To participate, you must be over 15 years old with a <b>T4 cell count of under 200</b>. You must have a diagnosis of cryptosporidial diarrhea and have failed other therapies. If youre taking medications for prophylaxis or maintenance therapy of opportunistic infection, the dosage must be stable for at least two weeks prior to enrollment. If you have a history of or current intestinal infection with something other than cryptosporidiosis, you may not be allowed to participate. You may not be taking medications with anti-cryptosporidial or microsporidial activity. Contact: Sandy Faulkner, Unimed Pharmaceuticals, (800) 864-6330 x 3032. <font size=-2>(added 12/13/95)</font></p>

<p>The <a href="http://www.cdc.gov/ncidod/diseases/crypto/crypto.htm">CDC site</a> provides extensive information about crypto control and prevention. If you would like more information about water filters, you can read Multi-Pure's <A HREF="http://www.humboldt1.com/~pwn/">Pure Water Guide</A> and use the search index at the <A HREF="<A HREF="http://www.ansi.org/docs/home.html">American Standards</A> site for more information about filters and standards. </p>

</blockquote>

<HR size=3 width=50% align=center noshade>

<p align=center><A HREF="ois.html"><img align=middle hspace=5 src="../gifs/left.gif" alt=" ">trials for opportunistic infections</A><A HREF="../index.html"><img align=middle hspace=5 src="../gifs/return.gif" alt=" ">Network home page</A></p>

<HR size=3 width=50% align=center noshade>

<P align=center><FONT SIZE=-2>Last updated: 12/12/96<BR>
<A HREF="mailto:atdn@nyam.org">atdn@nyam.org</A><BR>
&#169; copyright 1996 The Network</FONT></P>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-262</DOCNO>
<DOCOLDNO>IA093-001002-B003-230</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/trials/micro.html 199.29.141.24 19970121123528 text/html 3947
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:29:37 GMT
Server: NCSA/1.5.1
Last-modified: Sat, 21 Dec 1996 22:35:35 GMT
Content-type: text/html
Content-length: 3764
</DOCHDR>
<html>
<head>
<title>Trials: microsporidiosis</title>
</head>
<body bgcolor=#ffffff><font face="arial, helvetica" size=-1>

<h2 align=center>Trials for the treatment of microsporidiosis</h2>
<blockquote><h5 align=center>Contact numbers on these pages are for the New York area. Many of the trials are nationwide. For sites in your area, call the AIDS Clinical Trials Information Services (ACTIS) at 1-800-TRIALS-A.</h5>

<HR size=3 width=50% align=center noshade>

<p>GHBA-659. Drug: <B>albendazole</B>. This trial will study albendazole for the treatment of microsporidiosis. Participants will be divided into two groups. One group will be treated with albendazole. The other group will be treated with placebo. Neither the doctor nor the participant will know which treatment is being given. After the 28 day double-blind period, all participants will receive open-label albendazole for 62 days. If you become hospitalized or have to remain in the hospital due to worsening diarrhea during the first 14 days of the study, you will be given open-label treatment. You must be 18 years or older with biopsy-proven microsporidiosis within 90 days of study entry and a history of average of 3 liquid bowel movements per day for 4 weeks prior to study entry. Contact: sites in New York and Washington DC. Call The Network at (800) 734-7104 or ACTIS at 1-800-TRIALS-A for referral.</P>  

<a name="skb">SKB-030</a>. Drug: <B>albendazole</B>. This compassionate use protocol provides albendazole for the treatment of intestinal microsporidiosis. Doctors should call (800) 877-7074 x 3909. They will be given a number to call at the FDA to obtain an IND number. Once that is complete, the pharmaceutical company will ship the drug directly to the physician. You must be 13 years or older with confirmed intestinal microsporidiosis. Contact: Betty Wagner, Smith Kline Beecham, (800) 877-7074 x 3909. <P>

<p>SLR-THAL. Drug: <b><a href="../simple/thalid.html">thalidomide</a></b>. This trial will study thalidomide for the treatment of microsporidiosis and/or cryptosporidiosis.  Participants will be divided into two groups. One group will be treated with thalidomide. The other group will be treated with placebo. Neither the doctor nor the participant will know which treatment is being given. To participate you must be HIV+ and 18 years or older with a <b>T4 cell count under 200</b>. You must have biopsy and stool proven microsporidiosis or cryptosporidiosis and a history of average of 3 liquid bowel movements per day for 2 weeks prior to study entry. You cannot be pregnant or nursgin, or have evidence of CMV enteritis or colitis, or peripheral neuropathy. You cannot be taking Tenidap, appetite stimulants or treatment with pentoxifylline. Total time on study is 4 weeks. Contact: Glenda Winson, RN, St. Luke's/Roosevelt Hospital Center, New York, NY, (212) 523-3670. <font size=-2>(modified 12/22/96)</font></p>

<p>If you would like more information about water filters, you can read Multi-Pure's <A HREF="http://www.humboldt1.com/~pwn/">Pure Water Guide</A> and use the search index at the <A HREF="<A HREF="http://www.ansi.org/docs/home.html">American Standards</A> site for more information about filters and standards. 
</P>

</blockquote>

<HR size=3 width=50% align=center noshade>

<p align=center><A HREF="ois.html"><img align=middle hspace=5 src="../gifs/left.gif" alt=" ">trials for opportunistic infections</A><A HREF="../index.html"><img align=middle hspace=5 src="../gifs/return.gif" alt=" ">Network home page</A></p>

<HR size=3 width=50% align=center noshade>

<P align=center><FONT SIZE=-2>Last updated: 12/22/96<BR>
<A HREF="mailto:atdn@aidsnyc.org">atdn@nyam.org</A><BR>
copyright &#169; 1996 The Network</FONT></P>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-263</DOCNO>
<DOCOLDNO>IA093-001002-B003-248</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/trials/mac.html 199.29.141.24 19970121123601 text/html 6651
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:29:59 GMT
Server: NCSA/1.5.1
Last-modified: Sat, 21 Dec 1996 22:35:32 GMT
Content-type: text/html
Content-length: 6468
</DOCHDR>
<html>
<head>
<title>Trials: MAC</title>
</head>
<body bgcolor=#ffffff><font face="arial, helvetica" size=-1>

<h2 align=center>Trials for the treatment of <I>mycobacterium avium complex</I> (<a href="../simple/mac.html">MAC</a>)</h2>

<blockquote>

<h5 align=center>Contact numbers on these pages are for the New York area. Many of the trials are nationwide. For sites in your area, call the AIDS Clinical Trials Information Services (ACTIS) at 1-800-TRIALS-A.</h5>

<HR size=3 width=50% align=center noshade>

<p><a name="066">066-162</a>. Drug: <B>azithromycin</B>. This compassionate use program provides azithromycin to people with MAC who have failed or are intolerant to existing treatments. Azithromycin is taken in pill form. The drug is provided free of charge. There is also a program for people who have mycobacterial infections other than MAC or TB. This program also provides azithromycin in intravenous form. Contact: Pfizer/Premier Research, (800) 742-3029. </P>

<p>94-0-236. Drug: <b><a href="../access/drugs/clar.html">clarithromycin</a>, <a href="../access/drugs/etha.html">ethambutol</a>, <a href="../access/drugs/filg.html">G-CSF</a></b>. This trial will study filgrastim (G-CSF) combined with clarithromycin and ethambutol for the treatment of MAC infection. Study participants will be randomly divided into two groups. The first group will receive filgrastim along with clarithromycin and ethambutol. The second group will receive a placebo along with clarithromycin and ethambutol. Neither the participants nor the doctor will know which treatment is being given.  Two bone marrow biopsies will be required during the study period. All patients who complete the 8 week study or who terminate early due to side effects may be eligible for open-label treatment with filgrastim with clarithromycin and ethambutol. To participate you must be HIV+ and 13 years or older with a diagnosis of disseminated MAC and less than 48 hours of any treatment for MAC. You cannot be pregnant or nursing. The study coordinator will go over with you other conditions and drugs not allowed while on study. Total time on study is 8 weeks. Contact: Pablo Colon, St. Vincent's Hospital, New York, NY, (212) 604-2684; Jane Courtless, George Washington Univ., Washington, DC, (202) 994-2417. <font size=-2>(added 12/22/96)</font></p>

<p>ACTG 223. Drug: <B>clarithromycin, ethambutol, rifabutin</B>. This trial will compare different treatments for MAC. Participants will be divided into three groups. One group will take clarithromycin and ethambutol. The second group will take clarithromycin and rifabutin. The third group will take all three study drugs. All study drugs are pills. Contact: sites in Buffalo, New York, Rochester and Philadelphia. Call The Network at (800) 734-7104 or ACTIS at 1-800-TRIALS-A for referral.</P>

<p>NYH-0018. Drug: rifapentine, <a href="../access/drugs/azit.html">azithromycin</a>, <a href="../access/drugs/clar.html">clarithromycin</a>, <a href="../access/drugs/etha.html">ethambutol</a>. This trial will study rifapentine (a derivative of rifamycin) in combination with one of three drugs proven to be active against <a href="../simple/mac.html">MAC</a> (azithromycin, clarithromycin or ethambutol). Participants will be divided into 3 groups with escalating dosages of rifapentine.  The first group will receive 300 mg/day of rifapentine with one of the 3 drugs listed above. The second group will receive 450 mg/day of rifapentine with one of the 3 drugs listed above.  The third group's dosage will be determined by the results of the first 2 groups, also with one of the other three drugs listed above. Participants will receive $500 when they finish the study. Both the participant and the doctor will know which treatment is being given. To participate, you must be HIV+, 18 years or older, with one positive MAC blood culture. You cannot be pregnant or nursing. You cannot have been treated for MAC for more than 21 days or have had episodes of uveitis, an eye infection. The study coordinator will go over with you drugs not allowed while on study. Total time on study is 7 weeks.  Contact: Sandi Sledz, RN, Cornell Medical Center, New York, NY, (212) 746-4393. <font size=-2>(added 10/8/96)</font></p>

<p>OYPR-0018. Drug: <b>rifapentine, <a href="../access/drugs/azit.html">azithromycin</a>, <a href="../access/drugs/clar.html">clarithromycin</a>, <a href="../access/drugs/etha.html">ethambutol</a></b>. This trial will study rifapentine for the treatment of MAC infection. Participants will be divided into 3 groups. The first group will receive 300 mg/day of rifapentine. The second group will receive 450 mg/day of rifapentine. The third group will receive rifapentine at a dosage determined by the results from the first 2 groups. After 21 days, participants will add a standard MAC treatment (azithromycin, clarithromycin or ethambutol) to their rifapentine. Two hospital stays of 2 nights each are schedule for day 1 and day 13 of the study. Participants may receive $500 compensation for their participation in the complete study. Both the doctor and the participant will know which treatment is being given. To participate you must be HIV+ and 18 years or older with one positive MAC blood culture and two or more MAC associated symptoms. A 5 day washout of any MAC prophylaxis is required. You cannot be pregnant or nursing, or have had any prior treatment for MAC for greater than 21 days. The study coordinator will go over with you other conditions and drugs not allowed while on study. Total time on study is seven weeks. Contact: Sandi Sledz, RN, Cornell Medical Center, New York, NY, (212) 746-4393; Trish Garton, Doctor's Office - G. Blick, MD, Greenwich, CT, (203) 622-1118; Kathy Opel, Anderson Clinical Research, Inc., Philadelphia, PA, (800) 711-5878; Monica Earnst. Anderson Clinical Research, Inc., Pittsburgh, PA, (800) 711-5878. <font size=-2>(added 12/22/96</font></p>

</blockquote>

<HR size=3 width=50% align=center noshade>

<p align=center><A HREF="ois.html"><img align=middle hspace=5 src="../gifs/left.gif" alt=" ">trials for opportunistic infections</A><A HREF="../index.html"><img align=middle hspace=5 src="../gifs/return.gif" alt=" ">Network home page</A></p>

<HR size=3 width=50% align=center noshade>

<P align=center><FONT SIZE=-2>Last updated: 11/22/96<BR>
<A HREF="mailto:atdn@nyam.org">atdn@nyam.org</A><BR>
copyright &#169; 1996 The Network</FONT></P>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-264</DOCNO>
<DOCOLDNO>IA093-001002-B003-259</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/trials/neurop.html 199.29.141.24 19970121123611 text/html 4792
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:30:18 GMT
Server: NCSA/1.5.1
Last-modified: Sat, 21 Dec 1996 22:35:40 GMT
Content-type: text/html
Content-length: 4609
</DOCHDR>
<html>
<head>
<title>Trials: peripheral neuropathy</title>
</head>
<body bgcolor=#ffffff><font face="arial, helvetica" size=-1>

<h2 align=center>Trials for the treatment of peripheral neuropathy</h2>
<blockquote><h5 align=center>Contact numbers on these pages are for the New York area. Many of the trials are nationwide. For sites in your area, call the AIDS Clinical Trials Information Services (ACTIS) at 1-800-TRIALS-A.</h5>

<HR size=3 width=50% align=center noshade>

<p>ACTG 242. Drug: <B>Elavil, mexilitine</B>. This trial will study the combination of Elavil (amitriptyline) and mexilitine for the treatment of HIV related neuropathy. Participants be divided according to which antiretroviral they've taken, either ddI, ddC or d4T, and how long they've taken it. Participants will be divided into three groups. One group will take amitriptyline with placebo. The second group will take mexilitine and placebo. The third group will take both study drugs. Neither the doctor nor the participant will know which treatment is being taken. Contact: sites in Buffalo, New York, Rochester, Syracuse, New Haven, Baltimore and Philadelphia. Call The Network at (800) 734-7104 or ACTIS at 1-800-TRIALS-A for referral.</P>

<p>ACTG 291. Drug: <b>nerve growth factor (rhNGF)</b>. This trial will study recombinant human nerve growth factor for the treatment of HIV-related peripheral neuropathy. Participants will be divided into three groups. The first two groups will be treated with recombinant human nerve growth factor at different doses. The third group will be treated with placebo. Follow-up after 18 weeks of treatment is for 28 days. During the follow-up period, participants will complete daily pain assessments, and have neurological measurements to monitor large and small nerve fiber dysfunction. Neither the participant nor the doctor will know which treatment is being taken. To participate, you must be HIV+, 18 years or older, with a diagnosis of predominantly sensory neuropathy. You must be either antiretroviral naive or on a stable dose for the past 8 weeks. You cannot be pregnant or nursing, or have other contributing cause for peripheral neuropathy. You cannot have had an opportunistic infection within the past 2 weeks other than oral thrush; oral, genital, or rectal herpes; or MAI bacteremia. You cannot have a current active malignancy, a major active psychiatric disorder, or any conditions, including dementia and myelopathy, that would interfere with patient evaluation. The study coordinator will go over with you drugs not allowed while on study. Total time on study is six and a half months. Contact: Laura Ponticello, RN, Cornell Medical Center, New York, NY, (212) 746-4177; Eileen Chusid, PhD, Mount Sinai Medical Center, New York, NY, (212) 241-0433; Carol Greisberger, RN, University of Rochester, Rochester, NY,  (716) 275-2740; Kay Carter, PA, Johns Hopkins, Baltimore, MD, (410) 955-1895; Becky Becker, RN, Johns Hopkins, Baltimore, MD, (410) 955-2898. <font size=-2>(modified 12/22/96)</font></p>

<p>CPCRA 022. Drug: <B>acupuncture, Elavil</B>. This trial will study acupuncture and Elavil (amitriptyline) for the treatment of peripheral neuropathy. Participants will be divided into two groups. One group will take amitriptyline and be given one of two kinds of acupuncture. Amitriptyline is a pill. The second group will be given acupuncture and take a placebo pill. Acupuncture will be given twice a week for six weeks, then once a week for two months. No one will know if the pill is amitriptyline or placebo. Participants will keep a daily pain diary during treatment and for the 4 weeks of post-treatment followup by choosing one word from a 13-word list of words describing pain. You must be 13 years or older with lower extremity peripheral neuropathy secondary to HIV infection. Contact: Cheryl Guity, RN, Harlem AIDS Treatment Group, New York, NY, (212) 939-2915; Deborah Winters, Infectious Disease Associates, Princeton, NJ, (609) 497-1068; Carol Graeber, PA-C, Philadelphia Fight, Philadelphia, PA, (215) 557-82675. </P>

</blockquote>

<HR size=3 width=50% align=center noshade>

<p align=center><A HREF="ois.html"><img align=middle hspace=5 src="../gifs/left.gif" alt=" ">trials for opportunistic infections</A><A HREF="../index.html"><img align=middle hspace=5 src="../gifs/return.gif" alt=" ">Network home page</A></p>

<HR size=3 width=50% align=center noshade>

<P align=center><FONT SIZE=-2>Last updated: 12/22/96<BR>
<A HREF="mailto:atdn@aidsnyc.org">atdn@nyam.org</A><BR>
copyright &#169; 1996 The Network</FONT></P>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-265</DOCNO>
<DOCOLDNO>IA093-001003-B002-108</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/trials/pain.html 199.29.141.24 19970121123620 text/html 2174
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:30:28 GMT
Server: NCSA/1.5.1
Last-modified: Sat, 21 Dec 1996 22:36:00 GMT
Content-type: text/html
Content-length: 1991
</DOCHDR>
<html>
<head>
<title>Trials: pain</title>
</head>
<body bgcolor=#fffff><font face="arial, helvetica" size=-1>

<h2 align=center>Trials for the treatment of chronic pain</h2>

<h5 align=center>Contact numbers on these pages are for the New York area. Many of the trials are nationwide. For sites in your area, call the AIDS Clinical Trials Information Services (ACTIS) at 1-800-TRIALS-A.</h5>

<HR size=3 width=50% align=center noshade>

<blockquote>

<p>DUR-Fen. Drug: <b>fentanyl patch</b>. This trial will study the Duragesic fentanyl patch (an opiate) for the treatment of chronic pain in people with AIDS.  All participants will receive the drug. All participants must be referred by a doctor.  Financial compensation is offered for those  participants who complete the study covering transportation and other expenses (up to $250). Both the participant and the doctor will know which treatment is being given. To participate, you must have AIDS and be 18 years or older, with chronic pain in 4 weeks prior to trial requiring opiate dosing with moderate pain control on stable opiate dosing. You cannot be pregnant or nursing. You cannot have an allergy to opioids, an active psychiatric disorder, active substance use, severe respiratory or cardiac disease, confusion, or disorientation. You cannot be taking ritonavir (Norvir). Total time on study is 14 days. Contact: Doctor's Office, Brooklyn, NY, (718) 625-4244. <font size=-2>(added 10/14/96)</font></p>

</blockquote>

<HR size=3 width=50% align=center noshade>

<p align=center><A HREF="ois.html"><img align=middle hspace=5 src="../gifs/left.gif" alt=" ">trials for opportunistic infections</A><A HREF="../index.html"><img align=middle hspace=5 src="../gifs/return.gif" alt=" ">Network home page</A></p>

<HR size=3 width=50% align=center noshade>

<P align=center><FONT SIZE=-2>Last updated: 10/14/96<BR>
<A HREF="mailto:atdn@nyam.org">atdn@nyam.org</A><BR>
copyright &#169; 1996 The Network</FONT></P>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-266</DOCNO>
<DOCOLDNO>IA093-001003-B002-122</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/trials/pml.html 199.29.141.24 19970121123634 text/html 2379
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:30:40 GMT
Server: NCSA/1.5.1
Last-modified: Sat, 21 Dec 1996 22:36:12 GMT
Content-type: text/html
Content-length: 2196
</DOCHDR>
<html>
<head>
<title>Trials: PML</title>
</head>
<body bgcolor=#ffffff><font face="arial, helvetica" size=-1>

<h2 align=center>Trials for the treatment of PML</h2>

<blockquote>

<h5 align=center>Contact numbers on these pages are for the New York area. Many of the trials are nationwide. For sites in your area, call the AIDS Clinical Trials Information Services (ACTIS) at 1-800-TRIALS-A.</h5>

<HR size=3 width=50% align=center noshade>

<p><b>Note</b>: ACTG 243, a study of ara-C for the treatment of PML, has ended. See <a href="../news.html#pml">In the News</a>. (8/1/96)</p>

<p>JHU-96-PML. Drug: <b>topotecan HCL (Hycamtin)</b>. This trial will study topotecan  for the treatment of PML (progressive multifocal leukoencephalopathy). Topotecan is given in cycles of 28 days. The first 21 days is a continuous intravenous infusion of topotecan followed by seven days without treatment. These cycles will be repeated indefinitely. Participants will be divided into two groups. The first group will be treated immediately with topotecan. The second group will be treated after an 8 week delay. Both the doctor and participant will know which treatment is being given. To participate you must be HIV+ and 18 years or older with biopsy proven PML. You must be on a stable antiretroviral therapy for 3 weeks prior to study and willing to have a central venous catheter inserted. You must have durable power of attorney. You cannot be pregnant or nursing. The study coordinator will go over with you other conditions and drugs not allowed while on study. Contact: Linda Apuzzo, Johns Hopkins, Baltimore, MD, (410) 614-1069. <font size=-2>(added 12/22/96)</font></p>

</blockquote>
  
<HR size=3 width=50% align=center noshade>

<p align=center><A HREF="ois.html"><img align=middle hspace=5 src="../gifs/left.gif" alt=" ">trials for opportunistic infections</A><A HREF="../index.html"><img align=middle hspace=5 src="../gifs/return.gif" alt=" ">Network home page</A></p>

<HR size=3 width=50% align=center noshade>

<P align=center><FONT SIZE=-2>Last updated: 12/22/96<BR>
<A HREF="mailto:atdn@nyam.org">atdn@nyam.org</A><BR>
copyright &#169; 1996 The Network</FONT></P>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-267</DOCNO>
<DOCOLDNO>IA093-001003-B002-138</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/trials/tbtx.html 199.29.141.24 19970121123646 text/html 2910
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:30:52 GMT
Server: NCSA/1.5.1
Last-modified: Sat, 21 Dec 1996 22:36:14 GMT
Content-type: text/html
Content-length: 2727
</DOCHDR>
<html>
<head>
<title>Trials: TB treatment</title>
</head>
<body bgcolor=#ffffff><font face="arial, helvetica" size=-1>

<h2 align=center>Trials of drugs for the treatment of TB</h2>

<blockquote>

<h5 align=center>Contact numbers on these pages are for the New York area. Many of the trials are nationwide. For sites in your area, call the AIDS Clinical Trials Information Services (ACTIS) at 1-800-TRIALS-A.</h5>

<HR size=3 width=50% align=center noshade>

<p>ACTG 309. Drug: <b><a href="../access/drugs/ison.html">INH</a>, <a href="../access/drugs/rifam.html">rifampin</a>, <a href="../access/drugs/etha.html">ethambutol</a> &amp; <a href="../access/drugs/pyra.html">pyrazinamide </a></b>. This trial will study the pharmacokinetics of four drugs used to treat TB (isoniazid, rifampin, ethambutol and pyrazinamide). Pharmacokinetics means the amount of drug that gets into the blood stream and how long it stays there. All participants will receive all four drugs. All drugs are pills. All participants will receive all four drugs on a daily basis until the first pharmacokinetic (PK)  tests are done. The first round of PK tests will be done between days 10 and 14.  After the first PK tests are done, then participants may take all four drugs either 3 or 2 times a week. A second round of PK tests will be done between weeks 5 and 6 of the study On the PK test days, participants will have blood drawn 2, 6 and 10 hours after taking the medications. To participate you must be HIV+ and 13 years or older with proven TB currently being treated with at least 2 of the following drugs:  INH, rifampin, ethambutol or pyrazinamide. You cannot be pregnant or nursing. Other disorders and conditions will be evaluated on a case-by-case basis. You cannot be taking p-aminosalicylic acid (PAS). Concurrent use of antacids, sucralfate, didanosine (ddI) and imidazoles are not allowed unless administered more than 2 hours from any anti-TB agents. Total time on study is 6 weeks. Contact: Eileen Chusid, PhD, Mount Sinai Medical Center, New York, NY, (212) 241-0433; Deborah Dunbar, NP, University of Pennsylvania Medical Center, Philadelphia, PA, (215) 349-8092. <font size=-2>(added 12/22/96)</font></p>

</blockquote>

<HR size=3 width=50% align=center noshade>

<p align=center><A HREF="ois.html"><img align=middle hspace=5 src="../gifs/left.gif" alt=" ">trials for opportunistic infections</A><A HREF="../index.html"><img align=middle hspace=5 src="../gifs/return.gif" alt=" ">Network home page</A></p>

<HR size=3 width=50% align=center noshade>

<P align=center><FONT SIZE=-2>Last updated: 11/22/96<BR>
<A HREF="mailto:atdn@nyam.org">atdn@nyam.org</A><BR>
copyright &#169; 1996 The Network</FONT></P>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-268</DOCNO>
<DOCOLDNO>IA093-001003-B002-152</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/trials/wasting.html 199.29.141.24 19970121123656 text/html 13591
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:31:03 GMT
Server: NCSA/1.5.1
Last-modified: Sat, 21 Dec 1996 22:36:20 GMT
Content-type: text/html
Content-length: 13407
</DOCHDR>
<html>
<head>
<title>Trials: wasting</title>
</head>
<body bgcolor=#ffffff><font face="arial, helvetica" size=-1>

<h2 align=center><img align=middle hspace=2 src="../gifs/pillbot.gif" alt="">Trials for the treatment of wasting</h2>

<blockquote>

<h5 align=center>Contact numbers on these pages are for the New York area. Many of the trials are nationwide. For sites in your area, call the AIDS Clinical Trials Information Services (ACTIS) at 1-800-TRIALS-A.</h5>

<HR size=3 width=50% align=center noshade>

<p>ACTG 313. Drug: <b>Megace oral suspension, testosterone</b>. This trial will study Megace and testosterone for the treatment of HIV associated weight loss. Participants will be divided into two groups. One group will receive Megace and testosterone. The second group will receive Megace and a placebo. Neither the doctor nor the participant will know which treatment is being given. Megace comes as a liquid. Both the testosterone and the placebo are given by intramuscular injection (a shot into the muscle). Participants who complete the double-blind phase of the study will be eligible to receive open label combination of Megace and testosterone for an additional 12 weeks. To participate you must be HIV+ and 18 years or older with weight loss greater than 10% of your body weight. You cannot be pregnant or nursing. Total time on study is 12 weeks. Contact: Deborah Dunbar, NP, University of Pennsylvania Medical Center, Phildalphia, PA, (215) 349-8092. <font size=-2>(added 12/22/96)</font></p>

<p>ACTG 329. Drug: <b>nandrolone decanoate</b>. This trial will study nandrolone decanoate for the treatment of weight loss associated with HIV infection in women. Participants will be divided into two groups. One group will receive nandrolone decanoate. The second group will receive a placebo. Both the nandrolone decanoate and placebo will be given by intramuscular injection (a shot into the muscle) every two weeks. Neither the doctor nor the participant will know which treatment is being given. All participants who successfully complete the first 12 weeks of the study will be eligible to receive open-label nandrolone decanoate for a further 12 weeks. To participate you must be an HIV+ woman with involuntary weight loss of greater than 5% of your body weight within the past 12 months. You cannot be pregnant or nursing. Deborah Dunbar, NP, University of Pennsylvania Medical Center, Philadelphia, PA, (215) 349-8092. <font size=-2>(added 12/22/96)</font></p>

<p><a name="cel">Cel</a>-SYN. Drug: <b><a href="../simple/thalid.html">thalidomide</a> (Synovir)</b>. Thalidomide is being studied as a treatment for weight loss or wasting. This program will provide thalidomide to people ineligible for ongoing clinical trials. The company that makes thalidomide, Celgene, has been allowed by the government to recover costs for the program. They will charge about $550 for a 12 week supply. There will be some drug available free of charge for those unable to pay or obtain reimbursement. If you and your doctor have difficulty obtaining thalidomide, you should call the PWA Health Group at (212) 255-0520 which is keeping records of access problems, and may be able to help. You can also call the Network toll-free at (800) 734-7104 and we will notify the PWA Health Group for you. To participate in this program, you must by HIV+, 18 years or older with profound involuntary weight loss of of more than 10% in the absence of a concurent illness other than HIV infection. You must be on a stable antiretroviral regimen (<a href="../access/drugs/zido.html">AZT</a>, <a href="../access/drugs/dida.html">ddI</a>, <a href="../access/drugs/zalc.html">ddC</a>, <a href="../access/drugs/stav.html">d4T</a> or <a href="../simple/three.html">3TC</a>) or no antiretroviral for one month. Coordinating center, Celgene Corporation, (800) 801-8328. <font size=-2>(updated 10/20/96)</font></p>

<p>COR-Nut. Drug: <b>Lipisorb, Sustacal Plus</b>. This trial will compare two kinds of liquid nutritional supplements for the treatment of wasting. The study will look for improvements in body weight, muscle mass and quality of life. Examples of improved quality of life may include reduced abdominal discomfort. Participants will be divided into two groups. One group will take 3 cans of Lipisorb a day. The second group will take 3 cans of Sustacal Plus a day. The supplements will be taken between meals, every day, for six months. Neither the doctor nor the participant will know which supplement is being taken. To participate in this study you must be HIV+, 18 years or older, with a <b>T4 cell count of under 100</b>. You must have watery diarrhea more than three times a day for the past three weeks or longer. You cannot have started a new antiretroviral within a month before beginning study, or be taking appetite stimulants, corticosteroids, anabolic agents, testosterone (except replacement dosage), thalidomide or ganciclovir. You do not have to be losing weight to join this study. Total time on study is 6 months. Contact: Tricia Sarracco, RN, Cornell Medical Center, New York, NY, (212) 746-4161. <font size=-2>(added 10/20/96)</font></p>

<p>CPM-TP. Drug: <b>testosterone patch</b>. This trial will study the effect of a patch that releases testosterone as a treatment for wasting associated with AIDS. Participants will be divided into two groups. One group will receive a supply of active patches. The second group will receive patches that aren't active. Neither the doctor nor the participant will know which treatment is being used. Participants must be male and 18 years or older with a diagnosis of AIDS and evidence of wasting. You cannot have MAC or have used steroids, Megace or Marinol in the past 3 weeks. The study coordinator will go over other drugs that aren't allowed. Total time on trial is 12 weeks. An additional 26 weeks of open treatment will be offered at no cost to participants who complete the study. Contact: Judith Rabkin, PhD, Columbia Presbyterian Medical Center, New York, NY, (212) 960-5762. <font size=-2>(added 11/24/95)</font></p>

<p>CRI-Nut. Drug: <b>Lipisorb, Sustacal Plus</b>. This trial will compare two kinds of liquid nutritional supplements. The study will look for improvements in body weight, muscle mass and quality of life. Examples of improved quality of life may include reduced abdominal discomfort. Participants will be divided into two groups. One group will take 3 cans of Lipisorb a day. The second group will take 3 cans of Sustacal Plus a day. The supplements will be taken between meals, ever day, for six months. You do not have to be losing weight to join this study. To participate you must be 18 years or older with a <b>T4 cell count under 100</b>. You cannot have watery diarrhea more than three times a day for the past three weeks or longer. You must not have started a new antiretroviral within a month before beginning the study, or be taking appetitie stimulants, steroids, thalidomide or ganciclovir. Contact: Connie Abelardo, CRIA, New York, NY (212) 924-3934. <font size=-2>(added 2/16/96)</font>

<p>FDA 025C. Drug: <B>Megace oral suspension</B>. This trial will study Megace in an oral form for the treatment of weight loss associated with HIV infection in women. Participants will be treated with two different doses in order to compare weight gain, appetite, and other parameters at 12 and 24 weeks. Participants will be started at one dose and, if they have not gained 5 pounds or had appetitie improvement to good or excellent, the dose will be increased. All participants will be evaluated every four weeks. Both the participant and doctor will know which treatment is being given. Contact: Steve Crook, PA-C, Doctor's office, Greenwich, CT, (203) 622-1118; Laurie Andrews, RN, Yale Univ. Medical College, New Haven, CT, (203) 785-3557; Bennetta Bynum, Georgetown University, Washington DC, (202) 687-1079.</p>

<p>NYS-TestMet. Drug: <b>testosterone, Met-Rx (nutritional supplement)</b>. This trial will study testosterone and Met-Rx (a high protein, nutritional supplement) as treatment for wasting in HIV+ men. Participants will be divided into three groups. One group will receive Met-Rx and placebo injection. The second group will receive testosterone with a standard nutritional supplement, and the third group will receive Met-Rx and testosterone. Neither the doctor nor the participant will know which treatment is being given. Testosterone or  placebo are given by injection every two weeks. Met-Rx and/or other nutritional supplement are taken daily in liquid form.  All groups will have open-label treatment available to them for an additional 10 weeks. To participate in this study you must be HIV+, male, 19 years or older, with a <b>T4 cell count of under 400</b>. You must have abnormally low testosterone levels and evidence of loss of muscle mass (BIA). You cannot currently be taking steroids (within 3 weeks of study) or other anti-depression treatments. Total time on study is 4 months. Contact: Judith Rabkin, PhD, New York State Psychiatric Institute, New York, NY, (212) 960-5762. <font size=-2>(added 10/20/96)</font></p>

<p>OXN-95-002. Drug: <b>oxandrolone</b>. This trial will study the safety and efficacy of oxandrolone for the treatment of wasting in HIV infected men. Oxandrolone is an <a href="../simple/steroids.html">anabolic steroid</a> with fewer masculinizing effects than other drugs in this category. Oxandrolone is approved in doses up to 20mg/day to promote weight gain in patients with severe weight loss caused by extensive surgery, chronic infections or severe trauma. This study will determine if similar of higher doses can cause weight gain in HIV-infected men. The participants will be divided into four groups. The first 3 groups will receive escalating doses of oxandrolone (20mg, 40mg or 80mg/day). The fourth group will be treated with placebo. Neither the doctor nor the participant will know which treatment is being given. There is a $10 compensation per visit ($80 maximum) plus transportation tokens. To participate in this study you must be HIV+, male and 18 years or older. You must have documented 10-20% unintentional weight loss. If youre taking antiretroviral therapy, you must be on a stable dose for 6 weeks before starting the study. You cannot have pre-existing liver disease, malabsorption syndrome, or eating disorders. You cannot be taking Megace, appetitie stimulants, other anabolic steroids (eg. testosterone) or growth hormone. Total time on study is 12 weeks. Contact: Gloria Howard-Mello, MD, CRIA, New York, NY, (212) 924-3934, Glenda Winson, RN, St. Luke's/Roosevelt Hospital Center, New York, NY, (212) 523-3670, Doctor's Office, New York, NY, (212) 986-3330. <font size=-2>(added 10/20/96)</font></p>

<p>OXN-95-007. Drug: <b>oxandrolone</b>. This trial will study oxandrolone for the treatment of wasting in HIV infected women. Oxandrolone is an <a href="../simple/steroids.html">anabolic steroid</a> with fewer masculinizing effects than other drugs in this category. The participants will be divided into three groups. The first 2 groups will receive escalating doses of oxandrolone. The third group will be treated with placebo. Neither the doctor nor the participant will know which treatment is being given. To participate in this study you must be HIV+, female and 18 years or older. You must have documented 10-20% unintentional weight loss. If youre taking antiretroviral therapy, you must be on a stable dose for 6 weeks before starting the study. You cannot have pre-existing liver disease, malabsorption syndrome, or eating disorders. You cannot be taking Megace, appetitie stimulants, other anabolic steroids (eg. testosterone) or growth hormone. Total time on study is 12 weeks. Contact: Glenda Winson, RN, St. Luke's/Roosevelt Hospital Center, New York, NY, (212) 523-3670. <font size=-2>(added 10/20/96)</font></p>

<p><A NAME=hgh>Ser-HGH</A>. Drug: <B>Serostim (growth hormone)</B>. This expanded access program will provide Serostim to individuals who have experienced substantial unintentional weight loss and have failed or are intolerant to Megace and Marinol. Call the number below for information packets on how to obtain the drug. Serostim is given by subcutaneous injection. The program allows the company to charge for the drug. It can cost $150 per day for the initial treatment, though it may later be possible to reduce the dose. Serono has hired a reimbursement agency to help participants get paid by their insurance companies, and will provide some drug without charge to those unable to pay. The recommended dose is 6 mg daily for 12 weeks. Dosing schedule and cost of maintenance treatment following the first 12 weeks of treatment is not known. You must have failed or be intolerant to Megace and Marinol. Contact: Serono Laboratories, (800) 714-2437. </p>    

</blockquote>

<HR size=3 width=50% align=center noshade>

<p align=center><A HREF="ois.html"><img align=middle hspace=5 src="../gifs/left.gif" alt=" ">trials for opportunistic infections</A><A HREF="../index.html"><img align=middle hspace=5 src="../gifs/return.gif" alt=" ">Network home page</A></p>

<HR size=3 width=50% align=center noshade>

<P align=center><FONT SIZE=-2>Last updated: 12/22/96<BR>
<A HREF="mailto:atdn@nyam.org">atdn@nyam.org</A><BR>
copyright &#169; 1996 The Network</FONT></P>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-269</DOCNO>
<DOCOLDNO>IA093-001003-B002-165</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/trials/wastprev.html 199.29.141.24 19970121123711 text/html 2874
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:31:17 GMT
Server: NCSA/1.5.1
Last-modified: Sat, 21 Dec 1996 22:36:33 GMT
Content-type: text/html
Content-length: 2691
</DOCHDR>
<html>
<head>
<title>Trials: weight loss prevention</title>
</head>
<body bgcolor=#ffffff><font face="arial, helvetica" size=-1>

<h2 align=center><img align=middle hspace=2 src="../gifs/pillbot.gif" alt="">Trials for the prevention of weight loss</h2>

<blockquote>

<h5 align=center>Contact numbers on these pages are for the New York area. Many of the trials are nationwide. For sites in your area, call the AIDS Clinical Trials Information Services (ACTIS) at 1-800-TRIALS-A.</h5>

<HR size=3 width=50% align=center noshade>

<p>CPCRA 038. Drug: <b>Peptamen, NuBasics, multivitamins and mineral supplement</b>. This trial will study multivitamins with minerals and two different nutritional supplements for the prevention of weight loss. The two nutritional supplements studied are Peptamen and NuBasics. Participants will be divided into three groups. The first group will take only multivitamin/mineral supplements. The second group will take multivitamin/mineral supplements plus Peptamen. The third group will take multivitamin/mineral supplements plus NuBasics. The study will be last for 4 months with a 4 month period of follow-up. Nutritional supplements are liquids. Multivitamins and minerals are pills. Participants that complete the 4 month follow-up will be offered a 30 day supply of multivitamin/minerals and the nutritional supplement of their choice. To participate you must be HIV+ and 13  years or older with a <b>T4 cell count under 200</b>. You must have had less than 5% weight loss during the 3-6 months prior to study entry. You cannot be pregnant or nursing. The study coordinator will go over with you conditions and treatments not allowed while on study. Total time on study is 4 months. Contact: Cheryl Guity, RN, Harlem AIDS Treatment Group, New York, NY, (212) 939-2930; Luis Fuentes, Harlem AIDS Treatment Group, New York, NY, (212) 939-4170; Norma Santos, RN, Atlantic City Medical Center, Atlantic City, NJ, (609) 441-2178; Debbie Winters/Helen Ferlazzo, Infectious Disease Associates, Somerville, NJ, (908) 725-2522; ; Wendie Lubin/Nancy Relly, NJCRI, Newark, NJ, (201) 483-3444 x23. <font size=-2>(added 12/22/96)</font></pP

</blockquote>

<HR size=3 width=50% align=center noshade>

<p align=center><A HREF="ois.html"><img align=middle hspace=5 src="../gifs/left.gif" alt=" ">trials for opportunistic infections</A><A HREF="../index.html"><img align=middle hspace=5 src="../gifs/return.gif" alt=" ">Network home page</A></p>

<HR size=3 width=50% align=center noshade>

<P align=center><FONT SIZE=-2>Last updated: 12/22/96<BR>
<A HREF="mailto:atdn@nyam.org">atdn@nyam.org</A><BR>
copyright &#169; 1996 The Network</FONT></P>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-270</DOCNO>
<DOCOLDNO>IA093-001003-B002-183</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/trials/children.html 199.29.141.24 19970121123724 text/html 25081
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:31:27 GMT
Server: NCSA/1.5.1
Last-modified: Thu, 16 Jan 1997 01:35:39 GMT
Content-type: text/html
Content-length: 24897
</DOCHDR>
<html>
<head>
<title>Trials: children</title>
</head>

<body bgcolor=#ffffff><font face="arial, helvetica" size="-1">

<h2 align=center>Trials for children with HIV infection</h2>

<blockquote>

<h5 align=center>Contact numbers on these pages are for the New York area. Many of the trials are nationwide. For sites in your area, call the AIDS Clinical Trials Information Services (ACTIS) at 1-800-TRIALS-A.</h5>

<HR size=3 align=center width=50% noshade>

<p>93-C-207. Drug: <b>cyclophosphamide, methotrexate, cytarabine, G-CSF</b>. This study is being done at the National Cancer Institute in Bethesda, MD. The NCI will pay for airfare for every visit except the first. This study is for the treatment of non-Hodgkins lymphoma and is open to both HIV infected children and those children with a congenital immunodeficiency. For HIV-infected children, antiretroviral therapy (AZT and ddI) will be added to their treatment. Participants with brain lymphomas will also be treated with radiation therapy. If there is a relapse or persistent disease at the end of the study, ifosfamide and cytarabine will be added. To participate the child must be 3 months to 18 years old with acquired or congenital immunodeficiency. The child must have proven B-cell non-Hodgkins lymphoma or have failed a trial of alpha-interferon/IVIG and be sufficiently stable to go on chemotherapy. The study coordinator will go over with you conditions and drugs not allowed while on study. Contact: Susan Sandelli, RN, National Cancer Institute, Bethesda, MD, (301) 402-1391. <font size=-2>(added 12/22/96)</font></p>

<p>95-C-172. Drug: <b>Salk vaccine (Remune)</b>. This study is being done at the National Cancer Institute in Bethesda, MD. The NCI will pay for airfare for every visit except the first. This trial will study a therapeutic vaccine called Remune for the treatment of HIV infection in children. All children who have not been immunized for Hepatitis B or who have no history of Hepatitis B will also receive the Hepatitis B vaccine. To participate the child must be HIV+ and 3 months to 18 years old. T4 cell count requirement varies with age. The child must be asymptomatic or have mild symptoms, with normal to moderate immune suppression. The study coordinator will go over with you conditions and drugs not allowed while on study. Total time on study is 24 weeks. Contact: Susan Sandelli, RN, National Cancer Institute, Bethesda, MD, (301) 402-1391. <font size=-2>(added 12/22/96)</font></p>

<p>96-C-0041. Drug: <b>itraconazole oral solution</b>. This study is being done at the National Cancer Institute in Bethesda, MD. The NCI will pay for airfare for every visit except the first. This trial will study itraconazole oral solution for the treatment of candidiasis (thrush) in children. All study participants will receive itraconazole oral solution for 15 days. Participants who benefit from the treatment can receive itraconazole oral solution for an additional five months. To participate you must be HIV+ and 6 months to 18 years old with culture proven candida in oropharynx and clinically overt oropharyngeal candidiasis. You cannot be pregnant or nursing, or have a history of allergy to itraconazole or other azoles. Any use of itraconazole within two weeks of study is not allowed. Any use of terfenadine, astemizole, cisapride, rifampin, rifabutin, cyclosporin, phenytoin and phenobarbital is not allowed while on study. Total time on study is 15 days. Contact: Maureen McEvoy, National Cancer Institute, Bethesda, MD, (301) 496-7396. <font size=-2>(added 12/22/96)</font></p>

<p>96-C-COM. Drug: <b><a href="../simple/indi.html">indinavir (Crixivan)</a>, <a href="../simple/zido.html">AZT</a>, <a href="../simple/three.html">3TC</a></b>. This study is being done at the National Cancer Institute in Bethesda, MD. The NCI will pay for airfare for every visit except the first. This trial will study the protease inhibitor indinavir, AZT and 3TC for the treatment of HIV infection in children. Participants will receive all three drugs unless they have a history of intolerance to AZT or 3TC. Participants with a history of intolerance to AZT will receive indinavir with 3TC. Participants with a history of intolerance to 3TC will receive indinavir with AZT. To participate the child must be HIV+ and 6 months to 21 years old. <b>T4 cell count requirements varies with age</b>. The child must be able to swallow capsules and have a history of toxicity or intolerance to prior antiretroviral therapy. Both the participant and the doctor will know which treatment is being given. Total time on study is 24 weeks. Contact: Susan Sandelli, RN, National Cancer Institute, Bethesda, MD, (301) 402-1391. <font size=-2>(added 12/22/96)</font></p>

<P>ACTG 179. Drug: <b>dapsone</B>. This trial will study different doses of dapsone to prevent PCP pneumonia in children who have already had PCP even though they have been treated with other medications for prevention. The  drug is in liquid form taken either once a day or once a week. The child can take a pill form if the syrup is not tolerated. The child must be 1 month to 12 years old and have had a previous episode of PCP and be at risk of another, with a known intolerance to Bactrim. Contact: sites in New York, Rochester, Newark, Paterson and Philadelphia. Call The Network at (800) 734-7104 or ACTIS at 1-800-TRIALS-A for referral.</P>

<P>ACTG 225. Drug: <B>measles vaccine</B>. This trial will study a measles vaccine for the prevention of measles in infants with HIV. Infants will be divided into two groups. The first group will be treated a measles vaccine at 6 months and a vaccine for measles, mumps and rubella at 12 months of age. The second group will be treated with the vaccine for measles, mumps and rubella only at 12 months of age. Infants will be followed for 24 months after their last vaccination. Infants must be between 6 and 7 months old and the mothers must be HIV+. Contact: sites in Great Neck, New York, Rochester, Syracuse, Valahala, Patterson and Philadelphia. Call The Network at (800) 734-7104 or ACTIS at 1-800-TRIALS-A for referral.</P>
 
<P>ACTG 226. Drug: <B>oral ganciclovir</B>. This trial will study oral ganciclovir for the treatment of CMV in children and adolescents with low T4 cell counts. After a single intravenous dose of ganciclovir, participants will be treated with one of four doses in either pill or syrup form. Both the doctor and participant will know which treatment is being given. You must be 2 weeks to 20 years old with a T4 cell count of under 150 and documented CMV infection. You may not have lost sight in one eye with evidence of CMV infection in the other. Contact: sites in New York, Newark and Philadelphia. Call The Network at (800) 734-7104 or ACTIS at 1-800-TRIALS-A for referral.</P> 

<P>ACTG 230. Drug: <b>gp120 vaccine</B>. This trial will study a vaccine for the treatment of HIV infection in infants less than 3 days old born to HIV+ women. Participants will be divided into three groups. One group will be given the vaccine at 0, 4, 12 and 20 weeks. The second group will be given vaccine at 0, 4, 8 and 20 weeks. The third group will be given placebo. Both vaccine and placebo are given by shots. Neither the infant's mother nor the doctor will know which treatment the infant is getting. Contact: sites in New York, Rochester, Syracuse, Baltimore, Patterson, and Philadelphia. Call The Network at (800) 734-7104 or ACTIS at 1-800-TRIALS-A for referral.</P> 

<p><a name="245">ACTG 245</a>. Drug: <b><a href="../simple/nevi.html">nevirapine</a> (Viramune), AZT, ddI</b>. This trial will study combination treatment for HIV infection in children and adolescents.  Participants will be divided into three groups.  One group will take AZT, ddI and nevaripine.  The second group will take ddI and AZT.  The third group will take ddI and nevaripine.  Children who cannot take pills will take the study drugs in oral solutions.  Neither the doctor nor the participant will know which treatment is being given. To participate, you must be HIV+ and between 6 months and 20 years old with at least 24 weeks prior antiretroviral therapy. You may not have a history of clinical pancreatitis or be getting acute treatment for a serious opportunistic infection within 2 weeks of study entry. Other drugs are not allowed which the study coordinator will go over with you. Total time on study is 48 weeks. Contact: sites in Albany, the Bronx, Brooklyn, Great Neck, New Hyde Park, New York, Rochester, Stony Brook, Syracuse, Valhalla, Phildadelphia. Call the Network at 1-800-734-7104 or ACTIS at 1-800-TRIALS-A for referral.</p>

<P>ACTG 254. Drug: <B>atovaquone, azithromycin, Bactrim</B>. This trial will compare different drugs for the prevention of PCP in children and adolescents. Participants will be divided into two groups. The first group will take Bactrim. The second group will take atovaquone and azithromycin in combination. Neither the participant nor the doctor will know which treatment is being taken. Participants can change treatment if serious side effects occur. If a bacterial infection or PCP breakthrough occurs, participants will change to the alternative treatment. Clinic visists are every 4 weeks for the first 4 months, then every 8 weeks. Contact: sites in New York, Great Neck, Rochester, Stony Brook, Syracuse, Valhalla, Baltimore and Philadelphia. Call The Network at (800) 734-7104 or ACTIS at 1-800-TRIALS-A for referral.</P>

<p>ACTG 265. Drug: <b>Varivax (varicella vaccine for chickenpox)</b>. This trial will study a chickenpox vaccine in HIV-infected children. All children will receive vaccine at study entry and again at week 12 of the study. If a participant does not respond to the vaccine, a booster will be given 13 months after study entry. To participate the child must be HIV+ and 1 to 8 years old, asymptomatic or mildly symptomatic for HIV/AIDS. Total time on study is 39 months. Contact: Babette Tang, MD, Columbia Presbyterian Medical Center, New York, NY, (212) 305-7222; Sandra Deygoo, New York University Medical Center, New York, NY, (212) 263-6426; Michelle Davi, SUNY at Stony Brook, Stony Brook, NY (516) 444-1313; Carol Vincent, RN, Children's Hospital, Philadelphia, PA,  (215) 590-2262. <font size=-2>(added 12/22/96)</font></p>

<p><a name="273">ACTG </a>273. Drug: <b>HIVIG</b>. This trial will study HIVIG for the treatment of HIV infection in children. Participants will be randomly divided into three groups. Each group will receive HIVIG by intravenous infusion once every four weeks for six months, at one of three dose levels. All participants will be followed for 3 months after the last infusion. To participate in this study the child must be HIV+, between 2 and 12 years old, and with a <b>T4 cell count of more than 200 if 2 to 5 years old or more than 100 if over 5 years old</b>. The child must have been on antiretroviral therapy for at least 6 months, with no change in regimen for at least 3 months prior to study entry. The child may not have a history of severe reaction to IVIG, or severe diarrhea, nephrotic syndrome, or other protein-losing state that requires large doses of IVIG. Current IVIG treatment or IVIG within the past 60 days is not allowed. Total time on study is 6 months. Contact: sites in Washington DC, New York, Great Neck, Brooklyn, Albany, Rochester, Philadelphia, and Newark. Call the Network at 1-800-734-7104 or ACTIS at 1-800-TRIALSA for referral. <font size=-2>(added 7/2/96)</font></p>

<p>ACTG 274. Drug: <b>ddI, ribavirin</b>. This trial will study the safety of ribavirin and ddI for the treatment of HIV infection in children. Participants will be divided into two groups. One group will take ddI alone for four week, followed by a combination of ddI and ribavirin. The second group will take ddI and ribavirin in combination. Both groups will take prescription antiretrovirals for four weeks after the study medications are stopped. To participate the child must be 3 months to 12 years old. T4 cell count requirement varies according to age. The child may not have taken ddI or oral ribavirin, and other drugs which the study coordinator will go over with you. Contact: Patrice Edwards-Cihak, Bronx Lebanon, Bronx, NY (718) 960-1010; Connie Colter, PNP, Schneider Children's Hospital, New Hyde Park, NY (718) 470-7000; Babette Tan, MD, Columbia University, New York, NY (212) 305-7222. <font size=-2>(added 2/16/96)</font></p>

<P>ACTG 300. Drug: <B>3TC, AZT, ddI</B>. This trial will study AZT, 3TC and ddI for the treatment of HIV infection in children. Participants will be divided into three groups. The first group will be treated with 3TC and AZT. The second group will take ddI alone. The third group will take ddI and AZT. All participants take study drugs twice a day. Clinic visits are once a month. Neither the participant nor the doctor will know which treatment is being given. Follow-up after the treatment part of the trial is over is for up to three years. Participants must be between 90 days and 15 years old and not have had more than 56 days of antiretroviral treatment. You cannot have a current diagnosis of a malignancy. Contact: sites in Albany, Great Neck, New Hyde Park, New York, Syracuse, Valhalla and Paterson. Call The Network at (800) 734-7104 or ACTIS at 1-800-TRIALS-A for referral.</P>

<p>ACTG 327. Drug: <b><a href="../simple/stav.html">d4T</a>, <a href="../simple/dida.html">ddI</a>, <a href="../simple/zido.html">AZT</a></b>. This trial will compare d4T alone to d4T and ddI or d4T and AZT for the treatment of HIV infection in children. The participants will be divided into 3 groups. The first group will receive d4T and ddI.  The second group will receive d4T and placebo. The third group will receive d4T and ddI. Neither the doctor nor the participant will know which treatment is being given. All drugs will be taken orally either in tablet or liquid form depending on the weight of the child. To participate the child must be HIV+ and between 6 months and 10 years old, with a minimum of 26 weeks of AZT monotherapy experience immediately prior to study or participation in ACTG 240. The child cannot have an active acute opportunistic infection requiring therapy, intractable diarrhea or vomiting. The child cannot have ever taken ddI or d4T for more than 6 weeks. The study coordinator will go over with you other drugs not allowed while on study. Total time on study is 48 weeks. Contact: sites in Great Neck, Hyde Park, the Bronx, Brooklyn, New York, Rochester, Newark, Washington DC, Philadephia, PA. Call the Network at (800) 734-7100 or ACTIS at (800) TRIALS-A for referral. <font size=-2>(modified 12/22/96)</font></p>

<p>AG 524. Drug: <b>nelfinavir (Viracept)</b>. This trial will study a protease inhibitor called nelfinavir for the treatment of HIV infection in children and infants. Study participants will be divided into four groups based on age. Group 1 will include children 7 to 13 years old. Group 2 will include children 2 to 7 years old. Group 3 will include children 3 months to 2 years old. Group 4 will include newborns that are less than 3 months old.  All groups will receive nelfinavir. All groups will also receive antiretroviral nucleoside analog reverse transcriptase inhibitors (AZT, ddI, ddC, d4T or 3TC). Nelfinavir is formulated in two ways. One formulation is a powder and mixed with either milk or formula. The second formulation is the standard pill form. After the first 6 weeks of the study, participants can choose to receive nelfinavir for an additional 6 months. To participate the child must be HIV+ and 3 months to 13 year old or an infected or exposed infant if younger than 3 months. The study coordinator will go over with you conditions and drugs not allowed while on study. Total time on study is six weeks. Contact: Patrice Edwards-Cihak MPH, Bronx Lebanon Hospital Center, Bronx, NY, (718) 960-1010. <font size=-2>(added 12/22/96)</font></p>

<p>ACTG 292. Drug: <b>pneumococcal vaccine</b>. This trial will study a pneumococcal vaccine for children. Participants will be divided into two groups. One group will receive the vaccine at the beginning of the study, with boosters at months 2 and 4. The final booster will be given at 15 months of age. The second group will receive a placebo. Both the vaccine and placebo are given by intramuscular injection (a shot into the muscle). To participate the child must be HIV+ and 2-6 months old with a birth weight of at least 3.75 lbs. The study coordinator will go over with you conditions and drugs not allowed while on study. Total time on study is 24 months. Contact: sites in Great Neck, New York, Stony Brook, Rochester, Syracuse, Newark. Call the Network at (800) 734-7104 or ACTIS at (800) TRIALS-A for referral. <font size=-2>(added 12/22/96)</font></p>

<p><a name="agex">AG-EX</a>. Drug: <b><a href="../../natap/drug/nelfped.html">nelfinavir (Viracept)</a></b>. This expanded access program provides Viracept, a <a href="../simple/protease.html">protease inhibitor</a>, the first one to be formulated for and tested in children, free of charge for children age 2 to 13 via a program offered by Agouron Pharmaceuticals. The toll free information service will be available after January 7, 1997 for physicians, health care professionals and parents interested in the VIRACEPT Pediatric Expanded Access Program Monday through Friday from 8:00 a.m. to 6:00 p.m. EST. Calls placed before or after these hours will be returned during operating hotline hours. Contact: (800) 621-7111. <font size=-2>(added 1/15/97)</font></p>

<p>FDA 255A. Drug: <b>sorivudine</b>. This trial will study an antiviral called sorivudine, also known as <a href="../drugloss.html#bv">BV-ara-U</a>,  for the treatment of varicella-zoster infection in children. Zoster infection causes chicken pox in children and shingles in adults. To participate, the child must be HIV+,  2 to 17 years old, and have documented zoster infection within 7 days of study entry. The child must have failed or be intolerant of acyclovir or foscarnet therapy. The child must not have taken 5-flucytosine, 5-fluorouracil, high-dose prednisone, or probenecid within 4 weeks prior to study entry. Participation is through the child's doctor. The doctor can call Bristol-Myers Squibb at (203) 284-7658. <font size=-2>(added 3/20/96)</font></p>

<P>NCI 47. Drug: <B>amphotericin B lipid complex</B>. This study is being done at the National Cancer Institute in Bethesda, MD. The NCI will pay for airfare for every visit except the first. The trial will study amphotericin B lipid complex (ABLC) for the treatment of candida infections of the spleen and liver in children and adolescents being treated for cancer. All participants will be given ABLC. The drug is injected into a vein. Follow-up is for six months after completing treatment. You must be 2-18 years old with candida infection in the liver or spleen. Contact: Thomas Walsh, MD, National Cancer Institute, Bethesda, MD, (301) 496-7371.</P>

<P>NCI 93-C-207. Drug: <B>cyclophosphamide, methotrexate, cytarabine, G-CSF</B> This study is being done at the National Cancer Institute in Bethesda, MD. The NIH will pay for airfare for every visit except the first. This trial will study a combination of drugs for the treatment of non-Hodgkin's lymphoma in children with HIV infection. All participants will receive the same treatment. The treatment will be 3 cycles of chemotherapy with G-CSF. AZT and ddI will also be given. Participants with brain lymphomas will also be treated with radiation therapy. If there is a relapse or persistent disease at the end of the study, ifosfamide and cytarabine will be added. You must be 3 months to 18 years old with proven B-cell non-Hodgkin's lymphoma. Contact: Susan Sandelli, RN, National Cancer Institute, Bethesda, MD, (301) 402-1391.</p>

<P>NCI-95-PB1. Drug: <B>all-trans-retinoic acid, alpha interferon</B>. This study is being done at the National Cancer Institute in Bethesda, MD. The NCI will pay for airfare for every visit except the first. This study is primarily for HIV infected children, but children with lymphomproliferative disorders caused by other immune deficiencies may also be eligible. The study is in two parts. The first part is an observation period. The second part is the combination of treatments listed above. All children with HIV infection must also receive approved antiretroviral therapy. Children will be seen at the beginning of the study, then 12 weeks before starting treatment. Tissue biopsy is required at entry and after 12 weeks of treatment and may require hospitalization. To participate in this study you must have lymphoproliferative disorder (severe and/or progressive lymphadenopathy with hypergammaglobulinemia or diffuse infiltrative lymphocystosis syndrome or polyclonal B-cell  LPD or LPD with histology compatible with non-Hodgkins lymphoma but following non-aggressive course. You must be under 18 years old, and can be HIV+ or HIV-. You may not be pregnant or nursing, critically ill or clinically unstable. Total time on study is six months. Contact: Susan Sandelli, RN, National Cancer Institute, Bethesda, MD, (301) 402-1391.</P>

<P>NCI-95-PB2. Drug: <B>levamisole, AZT, ddI</B>. This study is being done and the National Cancer Institute in Bethesda, MD. The NCI will pay for airfare for every visit except the first. This trial will study levamisole in combination with AZT and ddI for the treatment of HIV infection in children and adolescents. For the first eight weeks of the study, all participants will take AZT and ddI in combination. After eight weeks, all participants will begin taking levamisole.  All participants will be required to stay in the hospital for the first week of levamisole therapy. All drugs in this trial are pills. The dose of levamisole will be increased gradually throughout the study. To participate in this study, you must be HIV+, 2 to 21 years old with progressive weight loss and failure or intolerance to prior antiretroviral therapy. You may not be pregnant or nursing, or have an active opportunistic infection requiring treatment at time of entry. Contact: Susan Sandelli, RN, National Cancer Institute, Bethesda, MD, (301) 402-1391.</P>

<P>NCI-95-PB3. Drug: <B>IL-2, AZT, ddI</B>. This study is being done and the National Cancer Institute in Bethesda, MD. The NCI will pay for airfare for every visit except the first. This trial will study IL-2 in combination with AZT and ddI for the treatment of HIV infection in children and adolescents. For the first eight weeks of the study, all participants will take AZT and ddI in combination. After eight weeks, all participants will begin taking IL-2. All participants will be required to stay in the hospital for the first IL-2 cycle. A cycle of IL-2 lasts for five days and will take place once every other month. Both AZT and ddI are pills. IL-2 will be given through an IV. All participants will take the study drugs. To participate in this study you must be HIV+ and 2 to 21 years old with progressive weight loss. You may not have had previous therapy with IL-2. Contact: Susan Sandelli, RN, National Cancer Institute, Bethesda, MD, (301) 402-1391.</P>

<P><a name="riton">NCI-95-PB5</a>. Drug: <B>protease inhibitor (ritonavir, ABT-538), AZT, ddI</B>. This study is being done and the National Cancer Institute in Bethesda, MD. The NCI will pay for airfare for every visit except the first. This trial will study the safety of ritonavir (ABT-538) protease inhibitor alone and in combination with AZT and 3TC. The first two weeks of the study are an evaluation period - no drug will be give. After two weeks, all participants will begin taking one of four doses of ritonavir. After twelve weeks, participants who do not have a history of AZT or ddI intolerance will be given these two drugs.  Participants with prior AZT or 3TC intolerance will only continue to take ritonavir. To participate in this study you must be HIV+, 6 months to 21 years old, and with a history of toxicity or intolerance to prior antiretroviral therapy. You may not have a  history of severe recurrent or persistent diarrhea, a family history of kidney stones, or be pregnant or nursing. Total time on study is 6 months. Contact: Susan Sandelli, RN, National Cancer Institute, Bethesda, MD, (301) 402-1391.</P>

</blockquote>

<HR size=3 width=50% align=center noshade>

<p align=center><A HREF="../trials.html"><img align=middle hspace=5 src="../gifs/left.gif" alt="arrow">trials page</A><A HREF="../index.html"><img align=middle hspace=5 src="../gifs/return.gif" alt="arrow">Network home page</A></p>

<HR size=3 width=50% align=center noshade>

<P align=center><FONT SIZE=-2>Last updated: 1/15/97<BR>
<A HREF="mailto:atdn@nyam.org">atdn@nyam.org</A><BR>
copyright &#169; 1996 1997 The Network</FONT></P>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-271</DOCNO>
<DOCOLDNO>IA093-001003-B002-196</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/trials/anemia.html 199.29.141.24 19970121123733 text/html 2228
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:31:42 GMT
Server: NCSA/1.5.1
Last-modified: Fri, 20 Dec 1996 21:35:18 GMT
Content-type: text/html
Content-length: 2045
</DOCHDR>
<html>
<head>
<title>Trials: anemia</title>
</head>

<body bgcolor=#ffffff><font face="arial, helvetica" size=-1>

<h2 align=center>Trials for treatment HIV-related anemia</h2>

<blockquote><h5 align=center>Contact numbers on these pages are for the New York area. Many of the trials are nationwide. For sites in your area, call the AIDS Clinical Trials Information Services (ACTIS) at 1-800-TRIALS-A.</h5>

<HR size=3 width=50% align=center noshade>

<font size=-1>

<p>PR95-29-015. Drug: <b><A HREF="../access/drugs/eryt.html">Procrit (erythropoietin)</A></b>. This trial will study the effect of Procrit (erythropoetin) on HIV related anemia. Anemia is a condition due to a low number of red blood cells. Erythropoetin is a natural hormone secreted by the kidneys that acts on the bone marrow to stimulate production of red blood cells. All participants will receive Procrit by injection under the skin, 3 times a week for 4 months. To participate you must be HIV+ and 18 years or older. If you are taking AZT, the dose should be less than 4,200 mg per week. You cannot be pregnant or nursing, have HIV related dementia, a history of hematologic disease, uncontrolled hypertension or seizure disorder, current substance abuser, or anemia attributable to causes other than HIV. You cannot have ever taken epoetin alfa. Contact: Carmella Romnes, Albany Medical College, Albany, NY, (518) 262-6759; Trish Garton, Doctor's Office - G. Blick, MD, Greenwich, CT, (203) 622-1118. <font size=-2>(added 12/21/96)</font></p>

</blockquote>

<HR size=3 width=50% align=center noshade>

<p align=center><A HREF="ois.html"><img align=middle hspace=5 src="../gifs/left.gif" alt=" ">trials for opportunistic infections</A><A HREF="../index.html"><img align=middle hspace=5 src="../gifs/return.gif" alt=" ">Network home page</A></p>

<HR size=3 width=50% align=center noshade>

<P align=center><FONT SIZE=-2>Last updated: 12/21/96<BR>
<A HREF="mailto:atdn@nyam.org">atdn@nyam.org</A><BR>
copyright &#169; 1996 The Network</FONT></P>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-272</DOCNO>
<DOCOLDNO>IA093-001003-B002-212</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/trials/hodlymph.html 199.29.141.24 19970121123740 text/html 2481
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:31:49 GMT
Server: NCSA/1.5.1
Last-modified: Fri, 20 Dec 1996 21:35:21 GMT
Content-type: text/html
Content-length: 2298
</DOCHDR>
<html>
<head>
<title>Trials: Hodgkin's lymphoma</title>
</head>
<body bgcolor=#ffffff><font face="arial, helvetica" size=-1>

<h2 align=center>Trials the treatment of Hodgkin's lymphoma</h2>

<blockquote>

<h5 align=center>Contact numbers on these pages are for the New York area. Many of the trials are nationwide. For sites in your area, call the AIDS Clinical Trials Information Services (ACTIS) at 1-800-TRIALS-A.</h5>

<HR size=3 width=50% align=center noshade>

<p>ACTG 149. Drug: <b>ABVD, G-CSF</b>. This trial will study G-CSF plus ABVD for the treatment of Hodgkin's lymphoma. ABVD is adriamycin, bleomycin vinblastine and dacarbazine. Participants are treated in 28 day cycles. Treatment with ABVD is on days 1 and 15 of each cycle. G-CSF is given on days 2 through 14, and then 16 through 28 of each cycle. All participants receive 4 cycles of treatment and are then restaged. Participants who have disease progression after the first 4 cycles will stop treatment. Participants with a complete response receive two more cycles of treatment. Participants with a partial response receive two more cycles and are then restaged again. At that point if they have a complete response, they will receive two more cycles. If there is no complete response, treatment is stopped. Minimum time on study is 4 months. To participate you must be HIV+ and 12 years or older with Hodgkin's disease. You must be on PCP prophylaxis. You cannot be pregnant or nursing. You cannot be taking any antiretroviral therapy within 2 weeks of study entry. The study coordinator will go over with you other conditions and drugs not allowed while on study. Contact: Eileen Chusid, PhD, Mount Sinai Medical Center, New York, NY, (212) 241-0433. <font size=-2>(modified 12/21/96)</font></p>

</blockquote>

<HR size=3 width=50% align=center noshade>

<p align=center><A HREF="ois.html"><img align=middle hspace=5 src="../gifs/left.gif" alt=" ">trials for opportunistic infections</A><A HREF="../index.html"><img align=middle hspace=5 src="../gifs/return.gif" alt=" ">Network home page</A></p>

<HR size=3 width=50% align=center noshade>

<P align=center><FONT SIZE=-2>Last updated: 12/21/96<BR>
<A HREF="mailto:atdn@nyam.org">atdn@nyam.org</A><BR>
copyright &#169; 1996 The Network</FONT></P>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-273</DOCNO>
<DOCOLDNO>IA093-001003-B002-221</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/trials/ks.html 199.29.141.24 19970121123808 text/html 14819
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:31:56 GMT
Server: NCSA/1.5.1
Last-modified: Fri, 20 Dec 1996 21:35:26 GMT
Content-type: text/html
Content-length: 14635
</DOCHDR>
<html>
<head>
<title>Trials: KS</title>
</head>

<body bgcolor=#ffffff><font size=-1 face="arial, helvetica">

<h2 align=center>Trials for the treatment of Kaposi's sarcoma</h2>

<blockquote>

<h5 align=center>Contact numbers on these pages are for the New York area. Many of the trials are nationwide. For sites in your area, call the AIDS Clinical Trials Information Services (ACTIS) at 1-800-TRIALS-A.</h5>

<HR size=3 width=50% align=center noshade>

<p>94CE32-0656. Drug: <B>TLC D-99</B>. This trial will study TLC D-99 for the treatment of Kaposi's sarcoma. TLC D-99 is a form of liposomal doxorubicin made by The Liposome Company. Participants will be treated with one of two doses of TLC D-99 every two weeks. No one will receive more than six treatments. Participants who respond favorably to treatment may enroll in an open-label study at the conclusion of this trial. Two months after the last treatment, cardiac evaluations and other tests will be repeated. You must be 18 years or older with a clinical diagnosis of Kaposi's sarcoma with at least 5 measurable cutaneous lesions that have not been previously radiated and one of the following: 10 cutaneous lesions; or development of 6 or more cutaneous lesions within the prior month; or documented visceral disease, including oral lesions. You may not be pregnant or nursing. You may not have visceral disease including oral lesions with no cutaneous lesions, or an active opportunistic infection requiring myelotoxic therapy, such as ganciclovir. The study coordinator will go over with you drugs that are not allowed while on the study. Contact: Pat Amsler, Albany Medical College, Albany, NY, (518) 262-6759; Eileen Chusid, PhD, Mount Sinai Medical Center, New York, NY, (212) 241-0433.</p>

<p>95FOS33. Drug: <B>foscarnet</B>. This trial will study foscarnet for the treatment of early KS.  Because research has connected a type of herpes virus to KS, the antiviral activity of foscarnet is being studied as a treatment.  This study is seeking participants with early KS -- for no longer than six months, and with no prior treatment for KS.  All participants in the study will be given foscarnet.  Participants in the study will be given foscarnet twice a day for two weeks and then stop for two weeks.  This cycle will happen three times.  All treatment will be self-administered at home.  A home care service will provide regular visits to monitor the IV and  provide instructions.  Eight visits will also be required to the study site. To participate you must be HIV+ and 18 years or older with a <B>T4 cell count over 50</B>. You must have a diagnosis of KS (by biopsy) within six months of study entry. The insertion of a Central Venous Catheter for foscarnet infusions is required. The study coordinator will go over with you other conditions and drugs not allowed while on study. Total time on study is 6 months. Contact: Lorrie Jondreau, New York University Medical Center, New York, NY, (212) 263-5244; Linda Thompson, Astra Pharmaceuticals, Nationwide, (800) 257-3261. <font size=-2>(modified 12/21/96)</font></p>

<p>96-C-0004A. Drug: <b><a href="../simple/thalid.html">thalidomide</a></b>. This study is being done at the National Cancer Institute in Bethesda, MD. The NCI will pay for airfare for every visit except the first. This trial will study oral thalidomide for the treatment of Kaposi's sarcoma. Everyone in the study will receive thalidomide at doses up to 1000mg a day. The treatment period can be extended for up to one year if people are responding to the therapy. To participate you must be HIV+, 18 years or older with biopsy proven KS with evidence of progression during the two months prior to study. You must have at least 5 measurable lesions that have never received locally administered therapy. You may not have pulmonary or other potentially acutely life-threatening KS, or actively bleeding or critically located KS lesions. The study coordinator will go over other treatments and conditions not allowed with you. Total time on study drug is 6 months. Contact: Tino Merced-Galindez, RN, National Cancer Institute, Bethesda, MD, (800) 772-5464 x 562. <font size=-2>(added 3/26/96)</font></p>

<p>ACTG 206. Drug: <B>alpha interferon, ddI</B>. This trial will study alpha interferon in combination with ddI for the treatment of KS. Participants will be divided into two groups. The alpha interferon will be given in two different doses. The alpha interferon is given as a shot. ddI is a pill. The alpha interferon is given once a day, the ddI is taken twice a day. Treatment can continue for up to one year. You must be 18 years or older with a T4 cell count of over 100. You cannot have pulmonary KS. Contact: sites in Albany, Buffalo, New York, Syracuse and New Haven. Call The Network at (800) 734-7104 or ACTIS at 1-800-TRIALS-A for referral.</p>

<p>ACTG 215. Drug: <B>TNP-470</B>. The trial will study TNP-470 at different doses for the treatment of Kaposi's sarcoma. The drug is injected into a vein. The infusion takes 1 hour. Participants may be inpatients or outpatients. Treatment will be once a week for 24 weeks. You must be 12 years or older with cutaneous disease with 5 or more measurable lesions and no evidence of visceral KS. Contact: sites in Albany, New York and Syracuse. Call The Network at (800) 734-7104 or ACTIS at 1-800-TRIALS-A for referral.</p>

<p>ACTG 269. Drug: <B>low dose etoposide</B>. This trial will study low-dose etoposide for the treatment of KS. All participants will take etoposide in pill form. Participants will take 50 mg daily on days 1 through 7 every 2 weeks for a minimum of 2 cycles. Dose will be raised in later cycles if participant achieves partial or complete response with no toxicity. Both the doctor and the participant will know which treatment is being given. Participants continue on therapy until stable disease or complete response is achieved, or disease progression occurs. You must be 12 years or older with biopsy proven KS that has relapsed or progressed following non-investigational systemic chemotherapy with at least two agents. Contact: sites in Albany, Buffalo, New York and New Haven. Call The Network at (800) 734-7104 or ACTIS at 1-800-TRIALS-A for referral.</p>

<p><a name="ds9321">DS 93-21</a>. Drug: <B>low dose <a href="../simple/iltwo.html">Il-2</a></B>. This trial will study low-dose IL-2 for treatment of KS or non-Hodgkin's lymphoma. IL-2 is given by shot. Participants will be given IL-2 every day for one to three months. You will be taught to give yourself the injections under the skin at home. The first dose will be given in the clinic and you will be watched for 6 hours by one of the study nurses and blood tests will be done. Every 2 weeks you will return to the clinic for an injection and another 6 hour period. You will be asked to keep a daily journal at home, recording weight, temperature and any side effects you may experience. At the end of the study, a special blood test called a leukapharesis will be done, in which white blood cells are drawn through a catheter, taking approximately one hour. You must be 18 years or older with biopsy proven KS or biopsy proven lymphoma, disease in stable or partial remission and, if on antiretroviral therapy, on stable dose for at least 1 month prior to entry. Contact: Margaret Gould, RN, Rosewell Park Cancer Institute, Buffalo, NY, (716) 845-8965. <p>

<p>DS 95-30. Drug: <b>AR-623 (Tretinoin IV)</b>. This trial will study AR-623 for the treatment of KS. AR-623 is given intravenously over 30-60 minutes. Participants will be divided into two groups at the beginning of the study. The first group will receive AR-623 once a week. The second group will receive AR-623 three times a week. After 12 weeks the two groups will be evaluated to see which dosing schedule was most effective. Treatment will then continue using the most effective dosing schedule. Total time on study can be as long as two years. To participate you must be 18 years or older with biopsy-proven KS. You cannot have symptomatic or documented internal KS, diabetes, or an acute AIDS-defining OI (excluding thrush) three weeks prior to study drug administration. The study coordinator will go over drugs not allowed while on the study. Contact: Margaret Gould, RN, Center for HIV-Related Cancers, Buffalo, NY (800) 685-6825. <font size=1>(added 2/16/96</font></p>

<p>L1057T-28. Drug: <b>oral ALRT 1057</b>. This trial will study ALRT 1057 in oral capsules for the treatment of KS. The study will test the safety and efficacy in escalating dosages starting at 60mg/day and increasing every 2 weeks by 40mg/day.  Previous versions of this treatment were known as LGD 1057 and 9-cis-retinoic acid.  After 16 weeks, participants can receive open-label ALRT 1057 for as long as the treatment is judged to be of benefit. Both the doctor and participant will know which treatment is being taken. To participate you must be HIV+, 18 years or older, with biopsy proven KS. The lesions must not have received any prior topical or local therapy within 60 days of study entry. You must be on current approved anti-retroviral therapy for 6 weeks prior to study and, if female, have a negative pregnancy test within prior 7 days. You cannot be pregnant or nursing, or have a serious illness or infeciton including MAC, PCP, toxoplasmosis and cryptococcal meningitis. The study coordinator will go over with you drugs not allowed while on study. Total time on study is 16 weeks. Contact: Stone Blacka, Anderson Clinical Research, New York, NY, (212) 973-1156. <font size=-2>(added 10/8/96)</font></p>

<p><a name="L1057T">L1057T</a>-31. Drug: <b> ALRT 1057 topical gel</b>. This trial will study a topical gel called ALRT 1057 for the treatment of KS on the skin. Previous versions of this treatment were known as LGD 1057 and 9-cis-retinoic acid. Study participants will be randomly assigned to receive either ALRT 1057 or a placebo gel. Neither the doctor nor the participant will know which treatment is being given. The gel is applied three times a day for two weeks, then four times a day for the remainder of the study. After 12 weeks, participants can receive open-label ALRT 1057 for as long as the treatment is judged to be of benefit. To participate you must be HIV+ and 18 years or older. You must have biopsy proven KS with a minimum of 6 lesions on the skin, including at least 3 raised lesions present for at least 30 days OR lesions of at least 10 mm to which the study drug can be self-applied. The lesions must not have been treated with any topical or local therapy within 60 days of study entry. You cannot be pregnant or nursing or have a known sensitivity to retinoid class drugs. The study coordinator will go over with you drugs not allowed while on study. Total time on study is 12 weeks. Contact: Eileen Chusid, PhD, Mount Sinai Medical Center, New York, NY, (212) 241-8903; Lorrie Jondreau, New York University Medical Center, New York, NY, (212) 263-5244; Margaret Gould, RN, Center for HIV-Related Malignancies, Buffalo, NY, (716) 845-3221; Jane Rosen, Baltimore Trials, Baltimore, MD, (410) 328-3588; Frank Hijek, Anderson Clinical Research, Pittsburgh, PA, (800) 711-5878. <font size=-2>(added 10/8/96)</font></p>

<p>L1069T-21. Drug: <B>LGD1069 (Targretin)</B>. This trial will study LGD1069 for the treatment of KS. Different doses of the drug will be given to see if they are safe.  After 16 weeks, participants can receive open-label LGD1069 if they are benefiting from the treatment. To participate you must be HIV+ and 18 years or older with a T4 cell count over 200. You must have a negative pregnancy test within prior 7 days, and have biopsy proven KS with a minimum of 6 lesions on the skin, including at least 3 raised lesions present for at least 30 days OR a lesion of at least 10 mm, and these KS "index" lesions must not have received any prior topical or local therapy within 60 days of study entry. You must be on current approved anti-retroviral therapy for 6 weeks prior to study entry. You cannot be pregnant or nursing. The study coordinator will go over with you other conditions and drugs not allowed while on study. Total time on study is 16 weeks. Contact: Alice Bouchet, Hershey Medical Center, Hershey, PA, (717) 531-7488; Alex Seymour, Anderson Clinical Research, Inc., Washington DC, (800) 711-5878; Doug Jackson, Doctor's Office:  Mahmoud Mustafa, MD, Washington, DC, (202) 331-3888. <font size=-2>(modified 10/8/96)</font></p>

<p>MB 298. Drug: <B>TNP-470</B>. This study is being done at the National Cancer Institute in Bethesda, MD. The NCI will pay for airfare for every visit except the first. This trial will study TNP-470 at different doses for the treatment of Kaposi's sarcoma. The drug is injected into a vein. The infusion takes 1 hour. Treatment will be  every other day for 6 to 18 weeks. You must stay in the area while participating in the trial. You must be 18 years or older with cutaneous disease with 5 or more measurable lesions and no evidence of visceral KS. Contact: Kathleen Wyvill, RN, National Cancer Institute, Bethesda, MD, (301) 496-8959. </p>

<p>NYH-IM862. Drug: <b>IM-862 nasal solution</b>. This trial will study IM-862 (a peptide) administered intranasally (through the nose) for the treatment of KS.  The study will be divided into 2 groups.  The first group will receive IM-862 for 10 consecutive, then wait 20 days.  This cycle will be complete 3 times.  The second group will receive IM-862 for 5 consecutive days, then wait for 10 days.  This cycle will be completed 6 times. Both the participant and doctor will know which treatment is being taken. To participate you must be HIV+, 18 years or older, with biopsy proven KS with 5 or more lesions but not internal KS. You cannot be pregnant or nursing or have an acute infection within 2 weeks of study. The study coordinator will go over other treatments and conditions not allowed while on study. Total time on study is 12 weeks. Sandi Sledz, RN, Cornell Medical Center, New York, NY, (212) 746-4393. <font size=-2>(added 10/8/96)</font></p>

</blockquote>

<HR size=3 width=50% align=center noshade>

<p align=center><A HREF="ois.html"><img align=middle hspace=5 src="../gifs/left.gif" alt=" ">trials for opportunistic infections</A><A HREF="../index.html"><img align=middle hspace=5 src="../gifs/return.gif" alt=" ">Network home page</A></p>

<HR size=3 width=50% align=center noshade>

<P align=center><FONT SIZE=-2>Last updated: 12/21/96<BR>
<A HREF="mailto:atdn@aidsnyc.org">atdn@aidsnyc.org</A><BR>
copyright &#169; 1996 The Network</FONT></P>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-274</DOCNO>
<DOCOLDNO>IA093-001003-B002-261</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/trials/hiv.html 199.29.141.24 19970121123838 text/html 74650
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:32:36 GMT
Server: NCSA/1.5.1
Last-modified: Thu, 16 Jan 1997 01:36:28 GMT
Content-type: text/html
Content-length: 74466
</DOCHDR>
<html>
<head>
<title>Trials for HIV</title>
</head>

<body bgcolor="#ffffff" link="#00688b"><font size=-1 face="helvetica, arial">

<blockquote>

<h2><img align=middle hspace=3 vspace=3 src="../gifs/3bot.gif" alt="[bottles]">Trials of drugs for treating HIV</h2>

<h5 align=center>Contact numbers on these pages are for the New York area. Many of the trials are nationwide. For sites in your area, call the AIDS Clinical Trials Information Services (ACTIS) at 1-800-TRIALS-A.</h5>

<HR size=3 width=50% align=center noshade>

<p>506. Drug: <b>nelfinavir (Viracept), d4T</b>. This trial will study a protease inhibitor in combination with d4T for the treatment of HIV infection. The protease inhibitor is made by Agouron and is called nelfinavir (trade name Viracept). Participants will be divided into three groups. The first group will be given nelfinavir in combination with  d4T. The second group will be given a different dose of nelfinavir in combination with d4T. The third group will take d4T alone. Neither the doctor nor the participant will know which treatment is being given.To participate you must be HIV+ and 13 years or older with a <b>T4 cell count over 50</b>. You must use double barrier contraception. You cannot have acute hepatitis or pancreatitis, neuropathy, or acute opportunistic infection at study entry. You cannot have ever taken a protease inhibitor. You cannot be taking oral contraceptives. The study coordinator will go over with you other conditions and drugs not allowed. Total time on study is 24 weeks. Contact: Mary Hedrick, North Shore University Hospital, Manhasset, NY, (516) 562-4280. <font size=-2>(updated 11/25/96)</font><p>

<p>1193-219. Drug: <B>Il-2</B>. This trial will study subcutaneous injections of IL-2 for the treatment of HIV infection. All participants will be treated with IL-2. Participants will be taught to give themselves shots and will take IL-2 daily. All participants must remain on current antiretroviral for the length of the study. Antiretroviral can be AZT, ddI, ddC, d4T or 3TC, alone or in combination. Clinic visits for weekly physicals and labs are required. You must be 18 years or older with a <B>T4 cell count of 200 to 500</B>. You must be on antiretroviral therapy for more than one month. Contact: Elizabeth Jacobson, MD, New York Hospital/Cornell, New York, NY, (212) 746-4464. </P>

<p><a name="93i205">93-I-205</a>. Drug: <B>Il-2</B>. This study is being done at the National Institutes of Health in Bethesda, MD. The NIH will pay for airfare for every visit except the first. This trial will study subcutaneous injections of IL-2 for the treatment of HIV infection. All participants will be treated with IL-2 twice a day for a five day period, either every month or every other month. Dose varies between treatment groups. Participants will be hospitalized for the first week of treatment. Following treatments can be done on an outpatient basis. Please note that, due to the volume of calls, it may be several weeks before the study coordinator gets back to you, but your name will go on the list and your call will be answered in the order in which it was received. You must be 18 years or older with a <B>T4 cell count of over 500</B>. You must have been taking an approved antiretroviral for at least 6 weeks before starting the study. Total time on study is 6 months. Contact: Doreen Chaitt, RN, National Institutes of Health, Bethesda, MD, (800) 772-5464 x 312. </P>  

<p>94-332ME. Drug: <B>hydroxychloroquine, AZT</B>. This trial will study the combination of hydroxychloroquine and AZT for the treatment of HIV. Participants will be divided into two groups. One group will take both drugs. The other group will take AZT alone. Neither the doctor nor the participant will know which treatment is being given. You must be 18 years or older with a <B>T4 cell count of 200 to 500</B>. Total time on study is 4 months. Contact: Kurt Sperber, MD, Mount Sinai Hospital, New York, NY, (212) 241-0764. </P>

<p><a name="95-C-0192A">95-C-0192A</a> . Drug: <b>F-ddA</b>. This study is being done at the National Cancer Institute in Bethesda, MD. The NCI will pay for airfare for every visit except the first. This trial will study a nucleoside analog called 2'-B-fluoro-2', 3'-didoxyadenosine, known as F-ddA, for the treatment of HIV infection. F-ddA is related to the approved anti-HIV drug <a href="../simple/dida.html">ddI</a>, but is expected to be better absorbed and therefore does not have to be administered with buffers. The buffers in ddI pills can make the drug difficult to take. In the test tube, F-ddA is active against ddI resistant HIV. Study participants will be hospitalized for the first three days, but the remainder of the study will be done on an outpatient basis. It is possible that the study will be extended up to 12-16 weeks. To participate you must HIV+, 18 years or older, with a <b>T4 cell count between 100 and 400</b>. You cannot have a history of cardiac disease or abnormality, a history of pancreatitis (grade 2) or current grade 2 peripheral neuropathy. You must discontinue any antiretroviral therapy for at least 3 weeks before study entry. If you are receiving acute treatment for a serious infection or AIDS-defining opportunistic infection,  the treatment must be completed 14 days prior to study entry. Cytotoxic chemotherapies, steroids, interferon, immunomodulating agents or any investigational drugs are not allowed. Contact: Jill Lietzau, RN, National Cancer Institute, Bethesda, MD, (800) 772-5464 x 508. <font size=-2>(added 5/4/96)</font></p>

<p>96-HG-0051. Drug: <b>receptor cell therapy for twins (gene therapy)</b>. This study is being done at the National Institutes of Health in Bethesda, MD. The NIH will pay for airfare for every visit except the first. This trial will study a treatment using blood from an HIV-negative identical twin that is treated and then given to the HIV+ identical twin. Healthy CD4+ lymphocytes (T4 cells) will be obtained from the HIV-negative twins by a blood cell donation called apheresis. All donor cells will be genetically engineered to include a signal gene (for monitoring) and some also to randomly include two anti-HIV genes. The altered cells will then be given to the HIV+ twins through infusion, an intravenous treatment done as an outpatient. After infusion the twin getting the treatment will be monitored weekly for 12 weeks. Apheresis, cell-processing and transfer can be done up to 4 times. To participate you must be identical twins, one HIV+ and one HIV-negative, and 13 years or older. The HIV+ twin must have a <b>T4 cell count over 50</b> and be healthy enough to take care of him or herself and travel. If the T4 cell count is under 500, he or she must be able to take an approved or expanded access antiretroviral or combination since there may be a burst of viral activity following infusion with the treated blood from the HIV-negative twin. You cannot be pregnant. The study coordinator will go over with you conditions and medications not allowed while on study. Total time on study is 1 year. Contact: Christine Bechtel, RN, National Inst. of Health, Bethesda, MD, (800) 772-5464 x 401. <font size=-2>(added 12/11/96)</font></p>

<p>A1455-048. Drug: <b>AZT, 3TC, d4T</b>. This trial will study combinations of AZT, 3TC and d4T for the treatment of HIV infection. Participants will be divided into four groups. One group will take AZT and 3TC. The second group will take 3TC and placebo. The third group will take 3TC and d4T. The fourth group will take 3TC and placebo. Neither the doctor nor the participant will know which treatment is being given. To participate you must be HIV+ and 18 years or older with a <b>viral load of greather than 10,000</b>. You must have been taking AZT at more than 300 mg per day for at least 1 month before starting the study. You cannot be pregnant or nursing, have a new AIDS diagnosis or active opportunistic infection requiring therapy. The study coordinator will go over with you other drugs not allowed before starting study. Total time on study is 6 months. Contact: Ruth Tenzler, SUNY at Stony Brook, Stony Brook , NY, (516) 444-1658.<font size=-2>(added 11/23/96)</font></p>

<p>ACR-96-BMS-1. Drug: <b><a href="../simple/stav.html">d4T</a></b>. This trial will study d4T for the treatment of HIV infection. All participants will be treated with d4T for 8 weeks with the option of continuing therapy for an additional 8 weeks. The dose of d4T will be based on your weight. The study drug is a pill. Both the participant and the doctor will know which treatment is being given. To participate you must be HIV+ and 18 years or older with a <b>T4 cell count of between 100 and 500</b>. You may not have taken any anti-HIV nucleoside treatment, such as <a href="../simple/zido.html">AZT</a>, <a href="../simple/dida.html">ddI</a>, <a href="../simple/zalc.html">ddC</a>, <a href="../simple/three.html">3TC</a>, <a href="../simple/stav.html">d4T</a>, or <a href="../simple/protease.html">protease inhibitors</a> for more than 7 days. If you have taken any for less than 7 days, you must have stopped them at least 1 month before starting the study. You may not be pregnant or nursing, or be taking any treatment for an acute opportunistic infection. The study coordinator will go over with you other drugs not allowed. Total time on study is 16 weeks. Contact: Monica Earnst, Anderson Clinical Research, Inc., Pittsburgh, PA, (800) 711-5878. <font size=-2>(added 11/18/96)</font></p>

<p>ACR-96-BMS-6. Drug: <b><a href="../simple/indi.html">indinavir (Crixivan)</a>, <a href="../simple/zido.html">AZT</a>, <a href="../simple/three.html">3TC</a>, <a href="../simple/stav.html">d4T</a>, <a href="../simple/dida.html">ddI</a></b>. This trial will compare the protease inhibitor indinavir (Crixivan) in combination with AZT and 3TC to the combination of indinavir with d4T and ddI for the treatment of HIV infection. All of the study drugs are pills. Both the participant and the doctor will know which treatment is being given. Participants will be divided into two groups. The first group will take AZT, 3TC and indinavir. The second group will take d4T, ddI and indinavir. To participate you must be HIV+ and 18 years or older with a <b>T4 cell count between 200 and 700</b>. Your viral load must be more than 10,000. You may not have taken any antiretroviral treatment before starting the study except AZT or ddI for less than 4 weeks. Total time on study is 48 weeks. You may not be pregnant or nursing. The study coordinator will go over with you other drugs not allowed while on study. Contact: Alex Seymour, Anderson Clinical Research, Inc., Washington, DC, (800) 711-5878. <font size=-2>(added 11/18/96)</font></p>

<p>ACR-96-IMM-3. Drug: <b><a href="../access/drugs/sarg.html">GM-CSF</a></b>. This trial will study GM-CSF for the treatment of advanced HIV infection. Participants will be randomly divided into two groups. The first group will receive GM-CSF. The second group will receive placebo. Both GM-CSF and placebo will be given by an injection under the skin three times a week. Neither participants nor doctors will know which treatment is being given. To participate you must be HIV+ and 18 years or older with a <b>T4 cell count under 100</b>. Those applying with fewer than 50 T4 cells automatically qualify, and those with fewer than 100 T4 cells but with a history of an AIDS-defining illness may be qualified for this trial. You must have been taking an approved antiretroviral or combination for at least 28 days before study entry. You cannot be pregnant or nursing or have a history of allergies to yeast derived GM-CSF The study coordinator will go over with you drugs not allowed. Total time on study is 6 to 12 months. Contact: Stone Blacka, Anderson Clinical Research, Inc., New York, NY, (800) 711-5878; Monica Earnst, Anderson Clinical Research, Inc., Pittsburgh, PA, (800) 711-5878; Alex Seymour, Anderson Clinical Research, Inc., Washington, DC, (800) 711-5878. <font size=-2>(added 11/24/96)</font></p>

<p><a name="248">ACTG 248</a>. Drug: <B>IL-2, AZT, ddI, ddC, d4T</B>. This trial will study the combination of IL-2 and current antiretroviral for the treatment of HIV infection. Participants will be divided into two groups. Everyone will take their current antiretroviral treatment. The first group will also be given shots of IL-2. After 24 weeks, the second group will be given shots of IL-2 and the first group will take only their antiretroviral. Everyone will know which treatment is being given. When getting IL-2, participants will visit the clinic every 2 to 4 weeks. The NYU study site is asking that doctors refer potential participants by fax with relevant information to (212) 263-8264. You must be 18 years or older with a <B>T4 cell count of 300 to 700</B>. You must have been on a stable antiretroviral treatment for 3 months. Contact: sites in New York, New Haven and Philadelphai. Call The Network at (800) 734-7104 or ACTIS at 1-800-TRIALS-A for referral.</P>

<p>ACTG 267. Drug: <B><a href="../simple/thalid.html">thalidomide</a></B>. This trial will study thalidomide for the treatment of HIV. Participants will be divided into 3 groups. The first two groups will take thalidomide at different doses. The third group will take placebo. Neither the participant nor the doctor will know which treatment is being given. Participants will make weekly clinic visits. Total time on study is 16 weeks. You must be 18 years or older with a <B>T4 cell count of 200 to 500</B>.  For 4 weeks before study entry and until 4 weeks after end of treatment, women must use both hormonal and barrier forms of birth control and men must use condoms. Contact: sites in New York and Philadelphia. Call The Network at (800) 734-7104 or ACTIS at 1-800-TRIALS-A for referral. <B>Note</B>: <A HREF="../simple/thalid.html">Thalidomide</A> is now available through an expanded access program.</P> 

<p>ACTG 276. Drug: <B>AZT, ddI</B>. This trial will study the combination of AZT and ddI for the treatment of early HIV infection. Participants will be divided into 6 groups. The first group will take AZT alone. The second group will take AZT for 16 weeks and then switch to ddI for 16 weeks. The third group will take AZT for 16 weeks and then add ddI for 16 weeks. The fourth group will take ddI for 16 weeks and switch to AZT for 16 weeks. The fifth group will take AZT and ddI for 32 weeks. The sixth group will take placebo. Neither the doctor nor the participant will know which treatment is being given. Clinic visits are required every other week for the first month and then once a month for the rest of the study. You must have a <B>T4 cell count of over 550</B>. You may not have ever taken an antiretroviral. Contact: Eileen Chusid, PhD, Mount Sinai Medical Center, New York, NY, (212) 241-0433; Mary Ann Kiernan, MPH, NYU Medical Center, New York, NY, (212) 263-6545.</P> 

<p>ACTG 290. Drug: <b>d4T, ddI, AZT.</b> This trial will study d4T, ddI and AZT for the treatment of HIV infection. Participants will be divided into four groups.  One group will take d4T. The second group will take ddI.  The third group will take d4T and AZT. The fourth group will take AZT and ddI.  The three study drugs are pills. Both the doctor and person in the study will know whether they are taking ddI or d4T.  Neither the doctor or person in the trial will know whether AZT is being given. To participate you must be HIV+ and 12 years or older with a <b>T4 cell count between 300 and 600.</b> You must have taken AZT for more than 24 weeks with a minimum of 12 weeks of AZT alone just before starting the study. You cannot have acute or chronic pancreatitis, a current malignancy requiring systemic chemotherapy or an active acute opportunistic infection. You cannot have ever taken ddI, ddC or d4T. Other anti-HIV treatments must have been discontinued for at least one month. Contact: Holly Ingelfinger-Lopez, RN, Erie County Medical Center /SUNY, Buffalo, NY, (716) 898-3158; Michelle Lewis, Erie County Medical Center/SUNY, Buffalo, NY, (716) 898-3932; Mohan Ramnarine, MD, Kings County Hospital, Brooklyn, NY, (718) 467-4446; Carol Greisberger, RN, University of Rochester, Rochester, NY, (716) 275-2740; Susan Zamer, Children's Hospital of Washington DC, Washington, DC, (202) 884-3682. <font size=-2>(modified 11/23/96)</font></p>

<p>ACTG 298. Drug: <b>AZT, 3TC, d4T</b>. This trial will study AZT, 3TC and d4T alone and in combination for the treatment of HIV infection. Participants will be divided into three groups. One group will take AZT and 3TC. The second group will take d4T alone. The third group will take a combination of AZT and d4T. Neither the doctor nor the participant will know which treatment is being given. To participate you must be HIV+ and 12 years or older with a <b>T4 cell count between 300 and 600</b>. You cannot be pregnant or have an AIDS diagnosis or active opportunistic infection. You cannot have taken any antiretroviral treatment within 90 days or other anti-HIV drugs within 30 days before starting the study. The study coordinator will go over with you other drugs not allowed. Total time on study is 48 weeks. Contact: Peter Berg&eacute;, PA, Beth Israel Medical Center, New York, NY, (212) 420-4519; Ron Farinella, RN, Beth Israel Medical Center, New York, NY, (212) 420-4519; Eileen Chusid, PhD, Mount Sinai Medical Center, New York, NY, (212) 241-0433; Sandra Deygoo, New York University Medical Center, New York, NY, (212) 263-6426. <font size=-2>(modified 11/23/96)</font></p>

<p>ACTG 307. Drug: <b>hydroxyurea, ddI</b>. This trial will study hydroxyurea and ddI for the treatment of HIV infection. Study participants will be divided into three groups. The first group will take ddI with a placebo. After 12 weeks hydroxyurea will be added to their treatment. The second group will take hydroxyurea with a ddI placebo. After 4 weeks, ddI will be added to their treatment. The third group will take hydroxyurea with ddI. Hydroxyurea will be given at a dose of either 1,000 mg or 1,500 mg a day. To participate you must be HIV+ and 18 years or older with a <b>T4 cell count between 200 and 500</b>. You cannot be pregnant or nursing. You cannot have taken any antiretroviral within 14 days or ever have taken hydroxyurea. The study coordinator will go over with you other drugs and treatments not allowed. Total time on study is 24 weeks. Contact: Eileen Chusid, PhD, Mount Sinai Medical Center, New York, NY, (212) 241-0433; Margie Vasquez, RN, New York University Medical Center, New York, NY, (212) 263-8174; Deborah Dunbar, NP, University of Pennsylvania Medical Center, Philadelphia, PA, (215) 349-8092. <font size=-2>(modified 12/2/96)</font></p>

<p><a name="320">ACTG</a> 320. Drug: <b>protease inhibitor (<a href="../simple/indi.html">indinavir, Crixivan</a>), AZT, 3TC</b>. This trial will study a protease inhibitor called indinavir (trade name Crixivan, formerly known as MK-639) in combination with AZT and 3TC for the treatment of HIV infection. Participants will be randomly divided into two groups. The first group will take AZT, 3TC and Crixivan. The second group will take only AZT and 3TC. Neither the participant nor the doctor will know which treatment is being given. Participants will have the option to change from AZT to d4T because of AZT intolerance at any time during the study or after 24 weeks because of disease progression. Participants who experience a new opportunistic infection will be offered open-label Crixivan. To participate you must be 18 years or older with a <b>T4 cell count under 200</b>. You must have had at least 6 months of cumulative AZT therapy and have taken ddI, ddC or d4T. You cannot have taken a protease inhibitor of had more than 3 weeks of treatment with 3TC. Other drugs are not allowed which the study coordinator will go over with you. All study drugs are pills. Total time on study is 48 weeks. Contact: sites in the Bronx, Buffalo, New York, Rochester, Syracuse and Philadelphia. Call The Network at (800) 734-7104 or ACTIS at 1-800-TRIALS-A for referral. <font size=-2>(added 2/14/96)</font></p>

<p><a name="ACTG 333">ACTG 333</a>. Drug: <b><a href="../simple/saquin.html">saquinavir (Invirase)</a>, <a href="../simple/indi.html">indinavir (Crixivan)</a></b>. This trial will study the anti-HIV effect of switching from the hard capsule formulation of the drug saquinavir (trade name Invirase) to either the new soft gelatin capsule, or indinavir (Crixivan). Everyone in the study must have been taking saquinavir for at least a year. Participants will be randomly divided into three groups. One group will continue to take the hard capsule saquinavir for 8 weeks and then switch to indinavir. The second group will take the new soft gel capsule formulation of saquinavir. The third group will take indinavir. Participants can continue to take any other approved nucleoside analog anti-HIV treatment (AZT, ddI, ddC, d4T, 3TC). Participants who don't respond to their assigned treatment by week 8 will be allowed to switch to a different group. To participate in this study, you must be HIV+, 18 years or older, and have been taking saquinavir in the hard capsule formulation at 1800 mg/day for more than 1 year. You cannot be pregnant or nursing. You must have been on the same antiretroviral treatment for the past two months. The study coordinator will go over with you drugs not allowed while on study. Total time on study is 24 weeks. Contact: Ron Farinella, RN, Beth Israel Medical Center, New York, NY, (212) 420-4519; Vicki Rosenwald, RN, New York University Medical Center, New York, NY, (212) 263-7523; Margaret Granville, RN, St. Vincent's Hospital, New York, NY, (212) 741-0576. <font size=-2>(added 9/30/96)</font></p>

<p><a name="AG-525">AG-525</a>. Drug: <b>nelfinavir (Viracept)</b>. This trial will study a <a href="../simple/protease.html">protease inhibitor</a> called <a href="../../natap/drug/nelf2.html">nelfinavir</a> for the treatment of HIV infection. Participants will be randomly divided into two groups. One group will add nelfinavir to their current nucleoside analog (AZT, ddI, ddC, d4T, 3TC) anti-HIV therapy. The second group will change their current nucleoside analog anti-HIV therapy and also add nelfinavir to their treatment. The decision about which nucleoside analog treatment to use will be made by the participant and their primary care provider. Both the participant and doctor will know which treatment is being taken. To participate you must be HIV+, 18 years or older with a <b>T4 cell count of under 100</b>. You must have been taking for more than 1 month AZT, ddI, or d4T monotherapy or AZT/3TC, AZT/ddC, AZT/ddI, d4T/3TC, d4T/ddI, d4T/AZT combination therapy. You cannot be pregnant or nursing, have acute hepatitis, pancreatitis or opportunistic infection. You cannot have ever taken a protease inhibitor. Total time on study is 12 months. Contact: Tricia Sarracco, RN, Cornell Medical Center, New York, NY, (212) 746-4161. <font size=-2>(added 9/30/96)</font></p>

<p><a name="agex">AG-EX</a>. Drug: <b><a href="../../natap/drug/nelf2.html">nelfinavir (Viracept)</a></b>. This program will make the protease inhibitor nelfinavir (trade name Viracept) available to people with advanced HIV infection. Providers and patients can call the number below for enrollment information. To participate you must be HIV+ and 13 years or older with a <b>T4 cell count under 100</b>. Pregnant women will be considered on a case-by-case basis. You may not have prior treatment with nelvinaivr and terfenadine (Seldane), astemizole (Hismanal), cisapride (Propulsid), and rifampin are not allowed while on study. Contact: Program Coordinator, Agouron Pharmaceuticals, Nationwide, (800) 621-7111. <b>For children</b>: a toll free information service will be available after January 7, 1997 for physicians, health care professionals and parents interested in the VIRACEPT Pediatric Expanded Access Program. 800-621-7111 is available Monday through Friday from 8:00 a.m. to 6:00 p.m. EST to answer calls. Calls placed before or after these hours will be returned during operating hotline hours.<font size=-2>(modified 1/15/97)</font></p>

<P>BI 1038. Drug: <B>nevirapine, AZT</b>. This trial will compare the combination of nevirapine and AZT to AZT alone. Participants will be divided into two groups. One group will take nevirapine and AZT. The second group will take AZT. Neither the doctor nor the person on the study will know which treatment is being taken. Both study drugs are pills. After 6 months, everyone will be on open-label nevirapine. You must be 18 years or older with a <b>T4 cell count of 200 to 500</b>. You cannot have ever taken ddI or ddC. Contact: Steve Crook, PA-C, Doctor's Office, Greenwich, CT, (203) 622-1118; Pat Costello, RN, St. Vincent's Hospital , New York, NY, (212) 620-0144. </P>

<p>BMS 001. Drug: <b>indinavir (Crixivan), AZT, 3TC, d4T</b>. This trial will study a protease inhibitor called <a href="../simple/indi.html">indinavir (Crixivan)</a> in combination with AZT and 3TC compared to indinavir in combination with d4T and 3TC for the treatment of HIV infection. Participants will be divided into two groups. The first group will take AZT, 3TC and indinavir. The second group will take d4T, 3TC and indinavir. Both the participant and the doctor will know which treatment is being given. To participate you must be HIV+ and 16 years or older with a <b>T4 cell count between 200 and 700</b>. You must have less than 4 weeks of antiretroviral therapy with a 2 week washout before study entry. You cannot be pregnant or nursing, or have an acute AIDS-defining illness requiring prescription therapy within 30 days of study entry. The study coordinator will go over with you other conditions and drugs not allowed. Total time on study is 48 weeks. Contact: Richard Hutt, RN, New York University Medical Center, New York, NY, (212) 562-4439. <font size=-2>(added 12/16/96)</font></p>

<p>CAB 02. Drug: <B>sulfasalazine</B>. This trial will study sulfasalazine to see if it can improve T4 cell counts in people with HIV infection.  Participants will be divided into two groups. The first group will be treated with sulfasalazine. The second group will be treated with placebo. Neither the participant nor the doctor will know which treatment is being given. Both study drug and placebo are pills. Everyone will take two pills a day for the first four days. The dosage will be increased by one pill daily for the following 4 days to a total of four pills daily in divided doses. Clinic visits are required once a week for the first two weeks and then every other week. Total time on study is 16 weeks. You must be 18 years or older with a <B>T4 cell count of 200 to 700</B>. If you're taking AZT or other antiretroviral you must be on stable dose for 4 months and continue treatment during study period. Time on study is 16 weeks. Contact: Eddy Disla, MD, Cabrini Medical Center, New York, NY, (212) 995-6996. </P>  

<p><a href="http://www.aidsnyc.org/cdn/amfar07.html">CBCT 07</a>. Drug: <b>hydroxyurea, ddI</b>. This trial will study the combination of hydroxyurea and ddI for the treatment of HIV infection. Participants will be divided into two groups. One group will take hydroxurea and ddI in combination. The second group will take ddI alone for 12 weeks and then add hydroxyurea for the remaining 12 weeks. All participants will know which treatment is being given. To participate you must be HIV+ and 18 years or older with a <b>T4 cell count between 50 and 600 and bDNA viral load over 10,000</b>. You cannot have taken ddI for more than one week. You cannot be pregnant or nursing or have an active acute infection requiring treatment. The study coordinator will go over with you drugs not allowed. Contact: Cori Blum, H.E.L.P./Project Samaritan, Bronx, NY, (212) 255.3841 x 37; Colleen Dowling, RN, Sunset Park Family Health Center, Brooklyn, NY, (718) 630-8232; Tricia Sarracco, RN, Cornell Medical Center, New York, NY, (212) 746-4161; Cori Blum, Gouverneur Hospital, New York, NY, (212) 238-8188; Margaret Granville, RN, St. Vincent's Hospital, New York, NY, (212) 741-0576. 
<font size=-2>(updated 11/24/96)</font></p>

<p><a href="../../cdn/08summ.html">CBCT 08</a>. Drug: <b>3TC &amp; stable antiretroviral regimen</b>. This trial will compare bDNA (viral load) levels in individuals who are adding 3TC to a stable antiretroviral therapy (other than AZT used alone or those using protease inhibitors).  bDNA levels will be checked at baseline (beginning of study) and again in weeks 4, 8 and 12; then every 8 weeks for the remainder of the study year. Any vaccination during the first 12 weeks of this study is <b>strongly</b> discouraged. To participate in this study you must be HIV+, 18 years or older, with a <b>T4 cell count of between 50 and 600</b>. You must have a viral load of greater than or equal to 10,000 copies using the bDNA test, and 8 weeks of antiretrovial therapy (except AZT monotherapy or protease inhibitors). You cannot have ever taken 3TC, or been vaccinated within 45 days prior to beginning the study. This is an observational study and both the participant and the doctor will know what treatment is being taken. Total time on study is 52 weeks. Contact: sites in Brooklyn, the Bronx, New York and Newark. Please call the Network at 1-800-734-7104 or ACTIS at 1-800-TRIALSA for referral. <font size=-2>(added 5/8/96)</font></p>

<p><a name="CNAA 2003">CNAA 2003</a>. Drug: <b><a href="../../natap/drug/u89.html">abacavir (1592U89)</a>, AZT, 3TC, ddI, d4T</b>. This trial will study 1592U89 (abacavir) for the treatment of HIV infection. Participants will be divided into four groups, depending on which anti-HIV drugs they have taken in the past. The first group will receive abacavir and AZT.  The second group will receive abacavir with AZT and 3TC.  The third group will receive abacavir with ddI.  The fourth group will receive abacavir with d4T. Both the doctor and the participant will know which treatment is being given. To participate, you must be HIV+, 13 years or older with a <b>T4 cell count over 100 and viral load greater than 30,000</b>. You cannot be pregnant or nursing, have a history of lymphoma or an active AIDS-defining opportunistic infection. The study coordinator will go over with you drugs not allowed while on study. Total time on study is 24 weeks. Contact: Gwen Constantini, Beth Israel Medical Center, New York, NY, (212) 420-4519.<font size=-2>(added 9/30/96)</font></p>

<p>CPCRA 039. Drug: <b>adefovir dipivoxil (bis-POM PMEA,) L-carnitine supplement</b>. This trial will study adefovir dipivoxil for the treatment of advanced HIV infection. The trial will also study whether adefovir can prevent CMV infections in people who are at risk for developing CMV disease. Participants will be divided into two groups. One group will be treated with a daily dose of oral adefovir dipivoxil (120 mg) plus an L-carnitine supplement. L-carnitine is naturally occurring substance in the body used in metabolism and energy production. The second group will take the L-carnitine supplement alone. Neither the doctor nor the participant will know which treatment is being given. To participate you must be HIV+ and 13 years or older with a <b>T4 cell count under 100</b>. You cannot be pregnant or nursing or have a history of CMV in your organs or active CMV disease at study entry. You cannot have taken foscarnet within 60 days of study entry. Total time on study is 20 months. Contact: Norma Santos, RN, Atlantic City Medical Center, Atlantic City, NJ,  (609) 441-2178; Wendie Lubin/Nancy Relly, NJCRI, (201) 483-3444 x23. <font size=-2>(added 12/11/96)</font></p>

<p>CPCRA 041. Drug: <b><a href="../simple/indi.html">indinavir (Crixivan)</a></b>. This trial will study indinavir (Crixivan) for the treatment of HIV infection. Participants will be divided into two groups. One group will receive indinavir in addition to their current antiretroviral therapy. The second group will receive a placebo in addition to their current antiretroviral therapy. Neither the doctor nor the participant will know which treatment is being given. If a participant experiences disease progression open-label indinavir will be offered. To participate you must be HIV+, and 16 years or older with a <b>T4 cell count between 200 and 500 and viral load of more than 10,000</b>. You cannot be pregnant or nursing or have a serious opportunistic infection or any illness causing fever with temperature higher than 101.3&#176;F within 3 days of study entry. You cannot have taken <a href="../simple/saquin.html">saquinavir</a> for more than 14 days and you cannot have taken any other <a href="../simple/protease.html">protease inhibitor</a>. You cannot be taking nonnucleoside reverse transcriptase inhibitors such as delavirdine and nevirapine during the study. Total time on study is 12 months. Contact: Norma Santos, RN, Atlantic City Medical Center, Atlantic City, NY, (609) 441-2178; Wendie Lubin/Nancy Relly, NJCRI, Newark, NJ, (201) 483-3444 x 23. <font size=-2>(added 11/25/96)</font></p>

<p>CPCRA 042. Drug: <b><a href="../../natap/drug/nelf2.html">nelfinavir (Viracept)</a>, <a href="../simple/riton.html">ritonavir (Norvir)</a></b>. This trial will study compare nelfinavir (Viracept) to ritonavir (Norvir) for the treatment of HIV infection. Participants will be divided into two groups. One group will take nelfinavir with other nucleoside analog antiretroviral treatments (AZT, ddI, ddC, d4T, 3TC). The second group will take ritonavir with other antiretroviral treatments. The choice of nucleoside analog treatments will be left to the study participant and their doctor. Persons that are not on other antiretroviral treatments may participate in this study if their doctor agrees. Participants will be allowed to switch study protease inhibitors in the event of disease progression or if they can't take their assigned protease inhibitor because of side effects. Both the participant and the doctor will know which treatment is being given. To participate you must be HIV+ and 13 years or older with a <b>T4 cell count under 100</b>. You cannot be pregnant or nursing. The study coordinator will go over medications, and infections and conditions not allowed while on study. Total time on study is 18 months. Contact: Norma Santos, RN, Atlantic City Medical Center, Atlantic City, NJ, (609) 441-2178; Wendie Lubin/Nancy Relly; NJCRI, Newark, NJ,  (201) 483-3444 x23. <font size=-2>(added 12/11/96)</font></p>

<p><a name="CRI-RIT">CRI-RIT</a>. Drug: <b>protease inhibitor (<a href="../simple/riton.html">ritonavir, Norvir)</a>, <a href="../simple/zido.html">AZT</a>, <a href="../simple/three.html">3TC</a></b>. This trial will study the long-term effectiveness of a combination of ritonavir with AZT and 3TC for people who have recently become HIV-infected.  Ritonavir is a protease inhibitor.  AZT and 3TC are both nucleoside analogues. To participate in this study you must be 18 years or older with documented new HIV infection (i.e., a previous negative  HIV-1 antibody within six months of screening). Both the participant and doctor will know which treatment is being taken. Total time on study is 12 months. Contact: Gloria Howard-Mello, MD, CRIA, New York, NY, (212) 924-3934. <font size=-2>(added 9/30/96)</font></p>

<p>DATRI 013. Drug: <b>methotrexate</b>. This trial will study methotrexate for the treatment of HIV infection. Participants will be randomly assigned to take 5 or 10 mg/wk for 12 weeks with 8 weeks of follow-up. All participants will know which dose they are taking. To reduce possible side effects, all participants will receive folic acid supplements once a day. To participate you must be 18 years or older with a <b>T4 cell count over 350</b>. You may not have had an AIDS-defining illness in the past 60 days or a previous diagnosis of cancer, or herpes infection that requred medication. You cannot be positive for TB, hepatitis B or C, or have taken any antiretrovirals within the past six months. The study drug is a pill. Total time on study is 12 weeks. Contact: Connie Abelardo, CRIA, New York, NY (212) 924-3934. <font size=-2>(added 2/14/96)</font></p>

<p>DATRI 022. Drug: <b>low dose oral alpha-interferon</b>. This trial will study three preparations of low dose oral alpha-interferon as a treatment for HIV infection. Low dose oral alpha-interferon is sometimes known as <a href="http://www.noah.cuny.edu/illness/aids/gmhc/gmhi84.html">Kemron</a> (search "kemron"). The preparations used in this study are Alferon LDO, Veldona and Ferimmune. The trial will also study responses to the drugs based upon sex, race and use of other antiretrovirals. Participants will be randomly divided into four groups. One group will receive Alferon LDO alone. The second group will receive Alferon LDO with Veldona. The third group will receive Alferon LDO with Ferimmune. The fourth group will receive three placebos. Neither the doctor nor the participant will know which treatment is being given. To participate in this trial you must be HIV+ with a <b>T4 cell count between 50 and 350</b>. You must be 13 years or older, and if on antiretrovirals you must be on a stable dose for 6 months prior to study entry. You cannot have taken oral alpha-interferon or other immune-based treatment within the past month, or therapy for any acute disease within the past week. Total time on study drug is six months. Contacts: Angela Crespo, office of Barbara Justice, MD, New York, NY, (212) 926-8557; Kathleen O'Keefe, Westchester County Medical Center, Valhalla, NY, (914) 285-7400; Beth Kaniefski, Univ. of PA Medical Center, Philadelphia, PA, (215)-662-2473; Kimothy Jones, Abundant Life Clinic, Washington, DC, (202) 397-4000. <font size=-2>(added 2/14/96)</font></p>

<p>DMP266-004. Drug: <b>DMP266, AZT, 3TC</b>. This trial will study DMP266 in combination with AZT and 3TC for the treatment of HIV infection. DMP266 is one of a new class of drugs called NNRTIs (non-nuceloside reverse transcriptase inhibitors). All participants will be given AZT and 3TC for 8 weeks. After 8 weeks, participants will be divided into three groups. One group will take AZT, 3TC and 400mg of DMP266. The second group will take AZT, 3TC and 600 mg of DMP266. The third group will take AZT, 3TC and a placebo. Neither the doctor nor the participant will know which treatment is being given. To participate you must be HIV+ and 18 years or older with a <b>T4 cell count between 100 and 500 and viral load greater than 5,000</b>. You cannot be pregnant or nursing, or have recurrent diarrhea or vomiting lasting more than 4 days within 3 months of study. Total time on study is 12 weeks. You cannot have taken any NNRTI, protease inhibitor or antiretroviral other than AZT or 3TC. The study coordinator will go over with you other drugs not allowed while on study. Ruth Tenzler, SUNY at Stony Brook, Stony Brook, NY, (516) 444-1658; Jane Courtless, George Washington University, Washington, DC, (202) 994-2417. <font size=-2>(added 11/23/96)</font></p>

<p>DMP266-005. Drug: <b>DMP266, AZT, 3TC</b>. This trial will study DMP266 in combination with AZT and 3TC for the treatment of HIV infection. DMP266 is one of a new class of drugs called NNRTIs (non-nuceloside reverse transcriptase inhibitors). Participants will be divided into four groups. One group will take AZT, 3TC and 200mg of DMP266. Thesecond group will take AZT, 3TC and 400 mg of DMP266. The third group will take AZT, 3TC and 600 mg of DMP266. The fourth group will take AZT, 3TC and a placebo for 12 weeks, and will then add one of the 3 dosages of DMP266 for the remaining 12 weeks of the study.  Neither the doctor nor the participant will know which treatment is being given. To participate you must be HIV+ and 13 years or older with a <b>T4 cell count between 50 and 500 and viral load greater than 20,000</b>. You cannot be pregnant or nursing or have recurrent diarrhea or vomiting lasting more than 4 days within 3 months of study. You cannot have ever taken any antiretroviral therapy. The study coordinator will go over with you other drugs not allowed. Total time on study is 24 weeks. Contact: Ruth Tenzler SUNY at Stony Brook, Stony Brook, NY, (516) 444-1658. <font size=-2>(added 11/23/96)</font></p>

<p><a name="229">FDA</a> 229D. Drug: <b>saquinavir AZT, ddI, ddC, 3TC, d4T</b>. This trial will study a new formulation of the protease inhibitor saquinavir in combination with antiretrovirals. To participate you must be 13 years or older, HIV+ and have taken antiretrovirals for less than 4 weeks and a protease inhibitor for less than 2 weeks. Both the participant and the doctor will know which treatment is being given. Contact: Gwen Constantini, Beth Israel Medical Center, New York, NY, (212) 420-4519. <font size=-2>(added 9/23/96)</font></p>

<p>FDA 237A. Drug: <B>935U83</B>. This trial will study a new antiretroviral called 935U83 for the treatment of HIV infection. Participants will be randomized to different doses of the study drug. Treatment is every 8 hours for 12 weeks. You may not have taken any other antiretrovirals within 6 months before starting this study. The study drug is a pill. Both the participant and doctor will know which treatment is being given. You must be 13 years or older and have a <B>T4 cell count of 200 to 500</B>. Contact: Karen Gammon, Georgetown University, Washington DC, (202) 687-1079.</P>

<P>GS 94-405. Drug: <B>PMEA, AZT</B>. This study is being done at the National Cancer Institute in Bethesda, MD. The NCI will pay for airfare for every visit except the first. The trial will study the combination of bis-POM PMEA and AZT for the treatment of HIV infection. PMEA is a type of drug similar to AZT. It is effective against herpesvirsuses and CMV as well as HIV. PMEA is injected into a vein. AZT is a pill. bis-POM PMEA will be taken daily 2 minutes after taking the morning dose of AZT. 500 mgs of AZT will be taken as follows: 200 mg in the morning, 100 mg in the afternoon and 200 mg in the evening. You must be 18 years or older with a <B>T4 cell count of 100 to 500</B>. You must be allready taking and tolerating 500 mgs AZT per day for at least 4 weeks before the study Total time on study is 12 weeks. Contact: Florentino Merced, RN, National Cancer Institute, Bethesda, MD, (301) 496-5489. </P>

<p>GS-96-408. Drug: <b>adefovir dipivoxil (bis-POM PMEA)</b>. This trial will study adefovir dipivoxil (bis-POM PMEA) for the treatment of HIV infection. Study participants will be randomly divided into two groups. One group will add adefovir and a single L-carnitine supplement to their current approved anti-HIV therapy. The second group will add a placebo and the L-carnitine supplement to their current approved ant-HIV therapy. For the first 24 weeks of the study, neither the doctor nor the study participant will know which treatment is being given. After the first 24 weeks, all study participants will receive open label adefovir. Study visits are required every 4 weeks for the first 24 weeks and then every 8 weeks for the remaining 24 weeks. Adefovir is a pill that is taken once a day. To participate in this trial you must be HIV+, 13 years or older, with a <b>T4 cell count of between 200 and 500</b>, and HIV RNA &gt; 5,000 within 14 days prior to study entry. You must be tolerating treatment with approved antiretroviral therapies (<a href="../simple/zido.html">AZT</a>, <a href="../simple/dida.html">ddI</a>, <a href="../simple/zalc.html">ddC</a>, <a href="../simple/stav.html">d4T</a>, <a href="../simple/three.html">3TC</a>, <a href="../simple/saquin.html">saquinavir</a>, <a href="../simple/riton.html">ritonavir</a>, <a href="../simple/indi.html">indinavir</a>) for at least 8 weeks prior to study, and willing to continue this therapy for at least 24 weeks. Pregnant women and nursing mothers are not allowed. You may not have had an AIDS-defining event within 2 months of study entry, or active serious infections other than HIV requiring IV antibiotic or antiviral therapy. Total time on study is 48 weeks. Contact: Carol MacDonald, RN, Albany Medical College, Albany, NY, (518) 262-6323; Peg Lankford, Institute for Clinical Research, Washington DC, (202) 745-8000 x 5007. <font size=-2>(added 6/26/96)</font></p>

<p>GS-96-701. Drug: <b>PMPA</b>. This trial will study a drug called PMPA for the treatment of HIV infection. Participants will be into two groups. The first and largest group will receive PMPA. The second group will receive placebo. Neither the doctors nor the participants will know which treatment is being given. Both PMPA and placebo will be given by intravenous infusion. Participants will be paid for taking part in this trial. To participate you must be HIV+ and 18 years or older with a <b>T4 cell count over over 200</b>. You may not be pregnant or nursing, have hepatitis B or C or an active serious infection other than HIV requiring IV antibiotic or antiviral therapy. You may not be taking any antiretrovirals, including <a href="../simple/zido.html">AZT</a>, <a href="../simple/three.html">3TC</a>, <a href="../simple/dida.html">ddI</a>, <a href="../simple/zalc.html">ddC</a>, <a href="../simple/stav.html">d4T</a> or other anti-HIV drugs. The study coordinator will go over with you other drugs that are not allowed while on study. Total time on study is 14 days. Contact: Elizabeth Cornell, Johns Hopkins, Baltimore, MD, (410) 955-7703; Donna Brown, Johns Hopkins, Baltimore, MD, (410) 955-3422. <font size=-2>(added 11/18/96)</font></p>

<P>HBY097/2001. Drug: <b><a href="../drugloss.html#hby">HBY 097</a>, <a href="../simple/zido.html">AZT</a></b>. This trial will study the safety and anti-HIV effects of a new drug called HBY 097. HBY 097 is one of a class of anti-HIV drugs called <a href="../simple/nnrtis.html">non-nucleoside reverse transcriptase inhibitors</a>. Other drugs in this class are <a href="../simple/dela.html">delavirdine</a> and <a href="../simple/nevi.html">nevirapine</a>. There will be three different doses of HBY 097 used in this study. Study participants will be divided into three groups. One group of will receive their assigned dose of HBY 097 alone. A second group will take their assigned dose of HBY 097 and AZT. Neither the doctor nor the person taking part in the study will know which treatment is being taken. After 12 weeks, participants will be able to receive open-label HBY-097. Waivers on previous antiretroviral therapy, T4 count and viral load requirements will be considered on a case-by-case basis. To participate you must be HIV+, 18 years or older with a <b>T4 cell count between 200 and 500 and viral load greater than 10,000</b>. You must be asymptomatic or mildly symptomatic. You cannot have taken antiretrovirals for more than 4 weeks. You cannot have a past or current history of an AIDS-defining event or be pregnant or nursing. You cannot have ever taken HBY 097. The study coordinator will go over with you other drugs not allowed. Total time on study is 12 weeks. Contact: Janet Forcht, RN, New York University Medical Center, New York, NY, (212) 263-8724; Sharon Boone, Georgetown University, Washington DC, (202) 687-7387; Irene Scanlon, Georgetown University, Washington DC, (202) 687-1079. <font size=-2>(updated 11/24/96)</font></p>

<p>IP#1100.1090. Drug: <b><a href="../simple/nevi.html">nevirapine (Viramune)</a>, <a href="../simple/three.html">3TC</a></b>. This trial will study nevirapine and 3TC for the treatment of HIV infection. For this study all participants must be on stable nucleoside analog (AZT, ddI, ddC or d4T) treatment for four weeks before joining the study. Participants will then be divided into two groups. One group will add nevirapine and 3TC to their current nucleoside analog treatment. The second group will add 3TC and a placebo to their current nucleoside analog treatment. Neither the doctor nor the participant will know which treatment is being given. To participate you must be HIV+ and 13 years or older with a <b>T4 cell count under 200</b>. You cannot be pregnant or nursing. The study coordinator will go over with you drugs not allowed while on study. Total time on study is 24 months. Sites in New York, New Brunswick, Princeton, Somerville, Pittsburgh. Call the Network at (800) 734-7100 or ACTIS at (800) TRIALS-A for referral. <font size=-2>(added 12/11/96)</font></p>

<p>MF4314. Drug: <b>fozivudine tidoxi</b>l. This trial will study fozivudine tidoxil for the treatment of HIV infection. Participants will be divided into two groups. One group will receive different doses of fozivudine tidoxil. The second group will receive placebo. Neither the doctor nor the participant will know which treatment is being given. To participate you must be HIV+ and 18 years or older with a <b>bDNA viral load of more than 10,000</b>. You cannot be pregnant or nursing, have an active medical problem or opportunistic infection requiring therapy, or have gotten a blood transfusion within 2 weeks of study entry. You cannot have taken any prior anti-HIV treatment. The study coordinator will go over with you other drugs not allowed. Total time on study is 4 weeks. Contact: Kathy Opel , Anderson Clinical Research, Inc., Philadelphia, PA, (800) 711-5878. <font size=-2>(added 11/25/96)</font></p>

<p>MMD-MDL. Drug: <B>MDL 28,574A, AZT</B>. This trial will study MDL 28,574A for the treatment of HIV infection. Participants will be divided into two groups. The first group will take the study drug for 12 weeks at different doses. At the end of 12 weeks, AZT will be added. The second group will take placebo for 12 weeks, at the end of which AZT will be added. Neither the participant nor the doctor will know which treatment is being given. In lab tests, MDL 28574 reduced the capacity of T4 cells to bind with cells chronically infected with HIV-1 which resulted in reduced virus production. You must be 18 years or older with a <B>T4 cell count of 100 to 500</B>. If you're taking AZT or another antiretroviral, it must be for less than 6 months. You must be able to tolerate 600 mg of AZT per day. Total time on study is 6 months. Contact: sites in Rochester, Stony Brook, Stony Brook, Newark and Washington DC. Call The Network at (800) 734-7104 or ACTIS at 1-800-TRIALS-A for referral.</P> 

<p>MRK-037. Drug: <B>protease inhibitor (<a href="../simple/indi.html">MK-639</a>), <a href="../simple/stav.html">d4T</a></B>. This trial will study a protease inhibitor alone and in combination with d4T for the treatment of HIV infection. The protease inhibitor in this study is made by Merck, and is called MK-639 (was L-735,524). Participants will be divided into three groups. The first group will take the protease inhibitor and d4T. The second group will take the protease inhibitor alone. The third group will take d4T alone. Neither the participant nor the doctor will know which treatment is being given. You must be 18 years or older with a <B>T4 cell count of 50 to 500</B>. You must have taken AZT for at least 6 months at any time and do a 2 week washout of any antiretroviral before starting the study. You may not have ever taken d4T or a protease inhibitor. You cannot have preexisting neuropathy, a diagnosis of visceral KS, or cutaneous or palatal KS treated with immunosuppressive therapy, or a current diagnosis of acute hepatitis due to any cause. Total time on study is one year. Contact: sites in New York, Stony Brook, Philadelphia and Washington DC. Call The Network at (800) 734-7104 or ACTIS at 1-800-TRIALS-A for referral. <B>Note: </B>This trial is full but still accepting names for a waiting list. <font size=-2>(updated 8/18/95)</font>.</P>

<p>MRK-039. Drug: <B>protease inhibitor (<a href="../simple/indi.html">MK-639</a>), <a href="../simple/three.html">3TC</a>, <a href="../simple/zido.html">AZT</a></B>. This trial will study 3 different drugs in combination and alone for the treatment of HIV infection. The drugs are MK-639, AZT and 3TC. Participants will be divided into four groups. The first group will take AZT and 3TC. The second group will take the protease inhibitor. The third group will take all three study drugs together.  The fourth group will be participants who can't take AZT, have used AZT for less than six months, or have taken 3TC before.  This fourth group will receive open label protease inhibitor. The protease inhibitor in this study is made by Merck, and called MK-639 (was L-735,524). You must be 18 years or older with a <B>T4 cell count of under 50</B>. You must have taken and tolerated AZT for more than 6 months at the standard dose to be eligible for groups 1-3. You must be intolerant of AZT, or have taken AZT for less than six months, or have had prior 3TC to be eligible for open label MK-639. You may not have ever taken any protease inhibitors. Contact: sites in New York, Stony Brook and Philadephia. Call The Network at (800) 734-7104 or ACTIS at 1-800-TRIALS-A for referral. <B>Note: </B>This trial is full but still accepting names for a waiting list. <font size=-2>(added 8/18/95)</font>.</P>

<p>MRK-042. Drug: <b><a href="../simple/indi.html">indinavir (Crixivan)</a>, <a href="../simple/zido.html">AZT</a>, <a href="../simple/three.html">3TC</a></b>. This trial will study a protease inhibitor called indinavir (trade name Crixivan, formerly known as MK-639) in combination with AZT and 3TC for the treatment of primary HIV infection. Primary infection is when a person is first infected with HIV. Study participants will be divided into three groups.  The first group will take AZT, 3TC and Crixivan.  The second group will take only AZT and 3TC.  The third group will take Crixivan alone.  Neither the participant nor the doctor will know which treatment will be given. Total time on study is one year. To participate you must be HIV+ and 18 years or older. The study coordinator will go over other requirements with you. Contact: Richard Hutt, RN, New York University Medical Center, New York, NY, (212) 263-8477. <font size=-2>(added 11/25/96)</font></p>

<p><a name="94c40">NCI 94 C-40</a>. Drug: <B>protease inhibitor (kynostatin, KNI-272)</B>. This study is being done at the National Cancer Institute in Bethesda, MD. The NCI will pay for airfare for every visit except the first. This trial will study a protease inhibitor called kynostatin. The treatment will be given intravenously. All participants will be given a single fixed intravenous dose, followed by an oral dose during a period of no food, and a second oral dose after eating. Participants are in the hospital for the first 3 days and return for out-patient follow-up after 1 week. In the second stage of this study, participants will be given the drug orally 4 times a day for 4 weeks. Both the participant and the doctor will know which treatment is being given. You must be 18 years or older with a <B>T4 cell count of 100 to 400</B>. You must be off all antiretrovirals for 3 weeks before starting study. Contact: Kathleen Wyvill, RN, National Cancer Institute, Bethesda, MD, (301) 496-8959. </P>

<p>NIH-BL-DONOR. Drug: <b>blood donation</b>. This study is being done at the National Institutes of Health in Bethesda, MD. The NIH will pay for airfare for every visit except the first. This trial will enroll HIV positive volunteers to donate blood and/or white blood cells for use in several ongoing studies. The first volunteers will have blood drawn and a physical exam (approximately 90 minutes). Qualified candidates will then be scheduled for the blood donation. Participants will be paid. To participate you must be HIV+, 18 years or older with a <b>T4 cell count of over 200</b>. You may not be pregnant or nursing, have drug or alcohol dependence, or psychiatric illness. You may not be taking any medications that might interfere with blood clotting, such as heparin or coumadin. Total time on study is 1 day. Contact: Linda Ehler, RN, National Institutes of Health, Bethesda, MD, (301) 496-1471. <font size=-2>(added 11/18/96)</font></p>

<p>NIH-CI1012. Drug: <b>CI-1012</b>. This study is being done at the National Institutes of Health in Bethesda, MD. The NIH will pay for airfare for every visit except the first. This trial will study a zinc finger inhibitor called CI-1012 for the treatment of HIV infection. Zinc fingers are a part of HIV that help assemble new viruses as they are leaving an infected cell. When the zinc fingers are blocked, HIV makes copies of itself that don't work and can't infect new cells. Participants in this study will receive increasing doses of CI-1012 for two weeks. Hospital admission is required on the first and thirteenth day of the study. Daily clinic visits are required for the 12 days in between these hospital admissions. Follow-up visits will be required one week and four weeks after the last dose of CI-1012 is given. To participate you must be HIV+ and 17 years or older with a <b>T4 cell count between 200 and 500</b>. You cannot have a prior history of allergies to sulfa drugs. You cannot be taking antiretroviral therapy or if you are you must be willing to stop for 4 weeks prior to study and wait 1 week after the study before starting again. You cannot be pregnant or nursing. The study coordinator will go over with you other drugs not allowed while on study. Contact: Diane M. Rock, RN, National Inst. of Health, Bethesda, MD, (800) 772-5464 x 312. <font size=-2>(added 12/16/96)</font></p>

<p>NIH-rhuil-10. Drug: <b>IL-10 (interleukin-10)</b>. This study is being done at the National Institutes of Health in Bethesda, MD. The NIH will pay for airfare for every visit except the first. This trial will study the effects of IL-10 on immune function and the activity of HIV in the body. Participants will be divided into four groups. Three groups will be HIV positive, one group will be HIV negative volunteers. Inpatient admission will be required for 3 nights and 2 days. An intravenous line will be put in for 24 hours. All participants will receive 1-4 infusions of IL-10. Follow up visits will be required up to 21 days after the IL-10 infusions. Both the doctor and the participant will know which treatment is being given. To participate you must be 18 years or older. If you are HIV+ you must have a <b>T4 cell count over 200</b>. You cannot be pregnant or nursing or have a history of an AIDS-defining illness. You cannot have smoked within six months of study entry. You cannot be taking pentoxyfilline, and alcohol and caffeine are not allowed during the study. Total time on study is 21 days. Contact: Linda Ehler, RN, National Inst. of Health, Bethesda, MD, (301) 496-1471. <font size=-2>(updated 11/25/96)</font></p>

<p>NIH-SUL. Drug: <B>Sulfasim (CI-0694)</B>. This study is being done at the National Institutes of Health in Bethesda, MD. The NIH will pay for airfare for every visit except the first. This trial will study a drug that may help eliminate side effects from medications containing sulfamethoxazole like Bactrim or Septra.  Participants will be divided into two groups. One group will be given a single shot of Sulfasim. The second group will be given a single shot of placebo. Skin tests for allergy will be done first. Participants will be in the hospital for the injection followed by at least 24 hours of safety monitoring. Clinic visits for blood tests will be daily for 7 days, then at 2 weeks and at one month. You must be 18 years or older with a <B>T4 cell count of over 200</B>. Total time on study is one month. Contact: Betsey Herpin, RN, National Institutes of Health, Bethesda, MD, (800) 772-5464 x 304. </P>

<p><a name="14182">NV 14182</a>.  Drug: <b>protease inhibitor (<a 
href="../simple/saquin.html">saquinavir</a>)</b>. This trial will study a new soft gelatin capsule formulation of a protease inhibitor called saquinavir. Saquinavir is made by Hoffman-LaRohce. Participants in this study will be divided randomly into two groups. The first group will consist of two-thirds of the total participants. This group will add the new soft gelatin formulation of saquinavir to their current approved antiretroviral therapy. The other participants will add a placebo to their current approved antiretroviral therapy. Neither the participant nor the doctor will know which treatment is being given. To participate you must be 13 years or older with a <b>T4 cell count of under 500</b>. You cannot have an active opportunistic infection and any acute therapy must be completed within 14 days of study entry. You cannot have any prior use of saquinavir. Previous use of other protease inhibitors is allowed with a 5 day washout. The study drug is a pill. Total time on study is 16 weeks. Contact: David Kaufman, MD, New York, NY (212) 620-0144; Pablo Colon, St. Vincent's Hospital, New York, NY (212) 604-2684. <font size=-2>(added 2/14/96)</font></p>

<p>NV 15182. Drug: <a href="../simple/saquin.html"><b>saquinavir (Invirase)</b></a>. This trial will study a new soft gelatin capsule formulation of a protease inhibitor called saquinavir. Participants in this study will be divided into two groups. The first group will add the new soft gelatin formulation of saquinavir to their current approved antiretroviral therapy. The second group will take their approved antiretroviral therapy alone. Neither the participant nor the doctor will know which treatment is being given. To participate you must be HIV+ and 13 years or older with a <b>T4 cell count under 500</b>. You cannot be pregnant or nursing. You cannot have an active opportunistic infection and any acute therapy must be completed 14 days before study entry. You cannot have ever taken saquinavir. If you have taken another protease inhibitor, a 5 day wash-out is required before starting the study. Total time on study is 16 weeks. Contact: Doctor's Office - D. Kaufman, MD,  (212) 620-0144. <font size=-2>(added 12/11/96)</font></p>

<p><a name="NV 15355">NV 15355</a>. Drug: <b>protease inhibitor (<a href="../simple/saquin.html">saquinavir, Invirase</a>)</b>. This trial will study two formulations of the protease inhibitor saquinavir.  Either the new soft gelatin capsule formulation or the hard capsule formulation will be administered in combination with the participants prescribed anti-retroviral therapyParticipants in this study will be divided into two groups. The first group will  add the new soft gelatin formulation of saquinavir to their current approved antiretroviral therapy. The second group will add the hard capsule formulation of saquinavir to their current approved antiretroviral therapy. To participate you must be HIV+ and 13 years or older. You cannot be pregnant or nursing, or have an active opportunistic infection. You cannot have ever taken saquinavir. If youve taken other protease inhibitors, a 5 day washout is required. Both the participant and the doctor will know which treatment is being taken. Total time on study is 16 weeks. Contact: Gwen Constantin, Beth Israel Medical Center, New York, NY, (212) 420-4519. <font size=-2>(added 9/30/96)</font></p>

<p><a name="NYH 0296-220">NYH 0296-220</a>. Drug: <b><a href="../simple/indi.html">indinavir (Crixivan)</a>, <a href="../simple/iltwo.html">IL-2</a>, <a href="../simple/zido.html">AZT</a>, <a href="../simple/three.html">3TC</a></b>. This trial will study IL-2 for the treatment of HIV infection. Participants will be divided into two groups. One group will receive indinavir, AZT, 3TC and IL-2. IL-2 is given by an injection under the skin. Participants in this group will be taught to give themselves the injections and will take IL-2 daily. The second group will receive indinavir, AZT and 3TC. All participants will know which treatment they are getting. Monthly clinic visits are required to monitor T4 cell count and viral load. To participate you must be HIV+ and 18 years or older with a <b>T4 cell count over 500</b>. You cannot have ever taken an antiretroviral. You cannot be pregnant or nursing. The study coordinator will go over other conditions and drugs not allowed. Call one of the 3 doctors listed here. A package will be mailed to those interested describing the study. Those still interested will be scheduled for more detailed screening. Subjects will be considered based on initial phone contact order. Total time on study is 12 months. Contact: Mary Lind Veloso, MD, Cornell Medical Center, New York, NY, (212) 746-4464; Roger Emert, MD, Cornell Medical Center, New York, NY, (212) 746-4464; Elizabeth Jacobson, MD, Cornell Medical Center, New York, NY, (212) 746-4464. <font size=-2>(updated 11/25/96)</font></p>

<p><a name="NYH 1193-219">NYH 1193-219</a>. Drug: <b>protease inhibitor (<a href="../simple/indi.html">indinavir, Crixivan</a>), <a href="../simple/iltwo.html">IL-2</a>, <a href="../simple/zido.html">AZT</a>, <a href="../simple/three.html">3TC</a></b>. This trial will study IL-2 for the treatment of HIV infection. IL-2 is given by an injection under the skin. Participants will be taught to give themselves shots and will take IL-2 daily. All participants must take indinavir, AZT and 3TC for the length of the study. Monthly clinic visits are required to monitor T4 cell count and viral load. Both the participant and the doctor will know which treatment is being given. To participate you must be HIV+ and 18 years or older with a <b>T4 cell count between 200 and 500</b>. You cannot be pregnant or nursing. The study coordinator will go over other conditions and drugs not allowed. Call one of the 3 doctors listed here. A package will be mailed to those interested describing the study. Those still interested will be scheduled for more detailed screening. Subjects will be considered based on initial phone contact order. Total time on study is 12 months. Contact: Mary Lind Veloso, MD, Cornell Medical Center, New York, NY, (212) 746-4464; Roger Emert, MD, Cornell Medical Center, New York, NY, (212) 746-4464; Elizabeth Jacobson, MD, Cornell Medical Center, New York, NY, (212) 746-4464. <font size=-2>(updated 11/25/96)</font></p>

<p>NYU-GEM. Drug: <B>GEM91</B>. This trial will study a new antisense drug called GEM91 for the treatment of HIV infection. Participants will be divided into two groups. One group will be treated with one of three doses of GEM91. The second group will be treated with placebo. Both study drug and placebo are given by continuous intravenous infusion. Neither the participant nor the doctor will know which treatment is being given. A two week stay in the hospital at the beginning of the trial is required. Participants will be paid $100 per day in the hospital. Weekly follow-up visits are required for the last three weeks of the study. You must be 18 years or older with a <B>T4 cell count of 200 to 500</B>. Total time on study is 7 weeks. Contact: Sandra Sledz, RN, Cornell Medical Center, New York, NY, (212) 746-4393. </P>

<p>PATH-1. Drug: <B>passive immunotherapy</B>. Passive immunotherapy is hyperimmune antibody-rich plasma pooled from healthy HIV+ asymptomatic donors. PI is administered monthly, intravenously in the Study center to reduce or prevent disease progression and to reduce HIV viremia, increase T4 cells, and increase neutralizing antibodies against hIV and other infections. Participant must provide donor. Cost is $900 per month. Reimbursement is possible from insurance companies for visits and labs. Your <B>T4 cell count must be over 200</B>. Steve Crook, PA-C, Doctor's Office, Greenwich, CT, (203) 622-1118. </P>

<p><a name="pu">PU</a>-DLV-EX. Drug: <b><a href="../simple/dela.html">delavirdine</a> (Rescriptor)</b>. This program will provide delavirdine (trade name Rescriptor) to people who are failing their current anti-HIV therapy. Delavirdine is one of a class of anti-HIV drugs called non-nucleoside reverse transcriptase inhibitors (NNRTI's). To participate you must be HIV+ with a <b>T4 cell count of under 300</b>. You must be 13 years or older, failing current therapy, and taking at least one other anti-HIV drug. You may not be taking other investigational drugs, <a href="../access/drugs/rifam.html">rifampin</a>, <a href="../access/drugs/rifa.html">rifabutin</a> and other drugs which the study coordinator will go over with you. Contact: Pharmacia/Upjohn Program Coordinator, (800) 779-0070. <font size=-2>(added 4/1/96)</font></p>

<p>SLR-NAC . Drug: <b>NAC</b>. This trial will study the effect of NAC (nacetyl cysteine) on HIV in the gut. The trial will include two sigmoidoscopies, which is when a small piece of tissue is taken from the lower intestine. Participants will be paid $100 for each sigmoidoscopy. Participants will be divided into two groups. One group will receive NAC. The second group will take a placebo. Neither the participants nor the doctors will know which treatment is being given. To participate you must be HIV+ and 18 years or older with a <b>T4 cell count over 200</b>. You cannot be pregnant or nursing. You cannot change your antiretroviral treatment within 8 weeks of study entry, and you cannot be taking NAC or any other amino acid supplement. Total time on study is 1 month. Contact: Ellen Engelson, St. Luke's/Roosevelt Hospital Center, New York, NY, (212) 523-2041. <font size=-2>(added 11/25/96)</font></p>

<p>SLR-rhIL-12. Drug: <b>IL-12</b>. This trial will study interleukin 12 (IL-12) for the treatment of HIV infection. IL-12 is given subcutaneously, which means by an injection under the skin. Treatment will be given twice a week for twelve weeks. Three quarters of the study participants will receive IL-12. One quarter of participants will receive placebo. Neither the doctor nor the participant will know which treatment is being given. To participate in this study you must be at least 18 years old and on stable antiretroviral <a href="../simple/combo.html">combination therapy</a> for at least six weeks before starting study. You must agree to use adequate contraception while on study and have a <b>T4 cell count of between 100 and 500.</b> You may not have any AIDS defining opportunistic infections, other than minor conditions such as <a href="../simple/fungal.html">oral or vaginal candidiasis</a>, localized <a href="../simple/ks.html">Kaposi's sarcoma</a>, cervical  carcinoma in situ, resolved herpes simplex infection, resolved herpes zoster or resolved PCP. The study nurse will go over other conditions and treatments not allowed. Total time on study is 12 weeks. Contact: Julie Rivera, RN,St. Luke's/Roosevelt - West 59 Street, New York, NY, (212) 523-6723. <font size=-2>(added 12/31/95)</font></p>

<p>TP-5. Drug: <B>thymopentin, AZT, ddI, ddC</B>. This trial will study thymopentin and its effects on the immune system. Those who join the study will receive either shots of thymopentin or shots of placebo. Shots will be given three times a week. Participants can give themselves shots at home if they learn how to do it. The drug is injected under the skin. Neither the doctor nor the person in the study will know which treatment is being given. Participants will also receive antiretroviral therapy with AZT, ddI, d4T or 3TC. Participants will have two screening blood tests within 3 weeks, then visits monthly for the first 6 months and every 2 months after that. Total time on study is 2 years. You must be 18 years or older with a <B>T4 cell count of 100 to 400</B>. You must have been taking AZT at a stable dose for at least 6 months. If taking ddI, ddC, d4T or 3TC you must have been taking and tolerating the treatment for at least 4 weeks. Time on study is 2 years. Contact: New York, Stony Brook, Greenwich and Philadelphia. Call The Network at (800) 734-7104 or ACTIS at 1-800-TRIALS-A for referral.</P>

<p><a name="021">UP 021</a>. Drug: <b>delavirdine, AZT, 3TC</b>. This trial was previously comparing delavirdine (U90) to AZT for the treatment of HIV infection. Recent delavirdine study results have led the drug company to change the study. People joining the study now will be divided into two groups. One group will receive AZT and 3TC. The second group will receive AZT, 3TC and delavirdine. Neither the doctor nor the participant will know which treatment is being given. To participate you must be 14 years or older with a <b>T4 cell count of 200 to 500</b>. You must have had less than six months of AZT and a 21 day washout of AZT is required before study entry. You cannot have a history of peripheral neuropathy or pancreatitis. Other drugs are not allowed which the study coordinator will go over with you. Total time on study is two years. Contact: sites in Albany, Buffalo, New York, Rochester, Stony Brook, Washington DC, Hershey and Philadelphia. Call The Network at (800) 734-7104 or ACTIS at 1-800-TRIALS-A for referral. <font size=-2>(added 2/14/96)</font></p>

<p>VIR-001. Drug: <b>nevirapine, 3TC</b>. This trial will compare the combination of nevirapine, 3TC and nucleoside analog therapy to 3TC and nucleoside analog therapy in preventing AIDS progression events or death. Nucleoside analog therapy includes one or more of the following drugs: AZT, ddI, ddC and d4T. For this study all participants must be on stable nucleoside analog therapy for four weeks before joining the study. Eligible participants will then be divided into two groups. One group will add nevirapine and 3TC to their current nucleoside analog therapy. The second group will add 3TC and a placebo to their current nucleoside analog therapy. Neither the doctor nor the person on the study will know if nevirapine is being taken. All study drugs are pills. To participate you must be 13 years or older with a <b>T4 cell count under 200</b>. You cannot have ever taken a non-nucleotide reverse transcriptase inhibitor (<a href="../simple/nnrtis.html">NNRTI</a>) or 3TC. Total time on study is 24 months. Contact: David Kaufman, MD, New York, NY (212) 620-0144. <font size=-2>(added 2/14/96)</font></p>

</blockquote>

<HR size=3 width=50% align=center noshade>

<P align=center><A HREF="../trials.html"><img align=middle hspace=5 src="../gifs/left.gif" alt=" ">trials page</A>
<A HREF="../index.html"><img align=middle hspace=5 src="../gifs/return.gif" alt=" ]">Network home page</A></P>

<HR size=3 width=50% align=center noshade>

<P align=center>Last modified: 1/15/97<BR>
<A HREF="mailto:atdn@nyam.org">atdn@aidsnyc.org</A><BR>
copyright &#169; 1996 1997 The Network</P>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-275</DOCNO>
<DOCOLDNO>IA093-001003-B002-275</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/trials/cmvret.html 199.29.141.24 19970121123848 text/html 11266
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:32:56 GMT
Server: NCSA/1.5.1
Last-modified: Mon, 16 Dec 1996 23:08:19 GMT
Content-type: text/html
Content-length: 11082
</DOCHDR>
<html>
<head>
<title>Trials: CMV retinitis</title>
</head>

<body bgcolor=#ffffff><font face="arial, helvetica" size=-1>

<h2 align=center>Trials for the treatment of CMV retinitis</h2>

<blockquote>

<h5 align=center>Contact numbers on these pages are for the New York area. Many of the trials are nationwide. For sites in your area, call the AIDS Clinical Trials Information Services (ACTIS) at 1-800-TRIALS-A.</h5>

<HR size=3 width=50% align=center noshade>

<P>ACTG 266. Drug: <B>MSL 109</B>. This trial will study MSL 109 in combination with either foscarnet or ganciclovir for the treatment of CMV retinitis. MSL 109 is a drug made from antibodies the body makes to fight CMV infection. All participants will be treated with either ganciclovir or foscarnet at the beginning of the study. Both drugs are given by IV.  Both the doctor and the participant in the trial will know which drug is being given. Participants will also be given MSL 109 or placebo by IV once every two weeks. Neither the doctor nor the participant will know whether MSL 109 or placebo is being given. After the first 14 days of treatment, doses of ganciclovir and foscarnet will be reduced to maintenance dose. Participants who are taking foscarnet will continue to take the drug by IV. Participants being treated with ganciclovir will take the drug in pill form. Treatment with MSL 109 or placebo will be continued every 2 weeks. Total time on study is 11 months. To participate in this study you must be HIV+, 13 years or older,  and have CMV retinitis. You may not be pregnant or nursing, or have retinal detachment or other opportunistic infection in the eye. You may not have taken ganciclovir or foscarnet for non-CMV infections within 6 months of study, be taking IV or oral acyclovir, or be on chemotherapy for an active malignancy. Contacts: Laurie Andrews, RN, Yale University Medical College, New Haven, CT, (203) 785-3557; Mykyelle Crawford, RN, Columbia Presbyterian Medical Center, New York, NY, (212) 305-6356; Carol Greisberger, RN, University of Rochester, Rochester, NY, (716) 275-2740; Deborah Dunbar, NP, Hospital of the University of Pennsylvania, Philadelphia, PA, (215) 349-8092. <b>Note:</b> Enrollment in MSL 109 studies has been stopped by an independent monitoring board due to lack of efficacy. Please see <a href="../news.html#soca">In the News</a>.</P>

<p>ACTG 278. Drug: <B>oral ganciclovir, IV ganciclovir</B>. This trial will study alternating oral and intravenous ganciclovir on a fixed schedule for the treatment of CMV retinitis. All participants will be treated with induction dose ganciclovir through a temporary catheter for 2 weeks. Following induction, maintenance treatment is oral ganciclovir three times a day for 3 weeks. After that, all participants are treated with intravenous ganciclovir at a single dose per day for one week. Participants will be treated for four cycles. Both the participant and the doctor will know the treatment being given. You must be 18 years or older and experiencing your first episode of CMV retinitis. You may not have retinal detachment in the eye being evaluated or uncontrolled diarrhea or nausea. You may not be taking preventive treatment for CMV, have a prior history of any treatment for CMV retinitis, or have taken ganciclovir or foscarnet for more than 4 months at any time and/or within 4 weeks of study entry. Contact: Phyllis Ristau, RN, St. Clare's Hospital, New York, NY, (212) 459-8662.</P>

<p>BMS-LOB. Drug: <b>lobucavir</b>. This trial will study lobucavir for the treatment of newly diagnosed, non sight-threatening CMV retinitis. Participants will be divided into two groups. The first group will take lobucavir. The second group will receive a placebo. Neither the doctor nor the participant will know which treatment is being given. Participants will have eye examinations every two weeks to closely monitor for any disease progression. If progression occurs participants will be treated according to best medical judgment with open-label lobucavir as an option. After the first eight weeks of the study, eye exams will be done every four weeks. After people have been on the study for 24 weeks, eye exams will be done every 12 weeks. To participate you must be HIV+ and 18 years or older with nwly diagnosed peripheral CMV retinitis. You cannot be pregnant or nursing, or have CMV outside the eye. Prior or current use of any anti-CMV drugs except when used for prevention is not allowed. You cannot be taking diuretics or IV pentamidine. Contact: Adrienne Addessi, RN, New York University Medical Center, New York, NY, (212) 263-8473. <font size=-2>(added 12/16/96)</font></p>

<p><a name="2304">GANS2304</a>. Drug: <B>IV ganciclovir, oral ganciclovir, implant</B>. This trial will compare three different treatments for CMV retinitis. Participants will be divided into three groups. The first group will be treated with standard IV ganciclovir. The second group will be treated with an intravitreal (in the eye) ganciclovir implant along with oral ganciclovir. The third group will be treated with an intravitreal ganciclovir implant plus placebo. The two groups receiving the implant and oral ganciclovir or placebo will be double-blinded. The ganciclovir implant is designed to release ganciclovir into the eye over a period of 6 to 8 months and then can be replaced. Participants who develop CMV disease in other parts of their body must go off the study but may receive an implant and oral ganciclovir. Clinic visits will be every 2 weeks. You must be 13 years or older with CMV retinitis in one eye only for less than 6 months. Contact: Claudette Lajam, Doctor's office, New York, NY, (212) 737-7400; Richard Hutt, RN, Doctor's office, New York, NY, (212) 561-4439; Cari O'Leary, RN, New York Hospital/Cornell, New York, NY, (212) 746-2493. </P>

<p>GANS-ITV. Drug: <b>ganciclovir (intravitreal)</b>. This trial will study intravitreal (shots into the eye) injections of ganciclovir for the treatment of CMV retinitis for patients who have failed, relapsed or had disease progression while on other treatment for CMV retinitis. Participants will receive an intravitreal injection twice per week for three weeks. Both the participant and the doctor will know which treatment is being given. To participate you must be HIV+ and have failed conventional CMV therapy. Total time on study is 3 weeks. Contact: Michael Stern, Doctor's Office - R. Leiberman, MD, (212) 737-7400. <font size=-2>(added 12/12/96)</font></p>

<p>GS-96-503. Drug: <b>cidofovir</b>. This trial will study intraocular (shots into the eye) injections of cidofovir for the treatment of CMV retinitis in people who have failed, relasped or had disease progression while on standard treatment (ganciclovir or foscarnet). Failure of prior treatment is defined as CMV progression while receiving at least 4 weeks of therapy on ganciclovir or foscarnet either by intraocular  injection,  implant or systemic therapy (at least 2 weeks of which was at IV induction dose). Both the participant and the doctor will know which treatment is being given. To participate you must be HIV+ and 13 years or older with relapsing CMV retinitis despite treatment with standard therapies. You cannot be pregnant or nursing, have hemophilia or be blind. You cannot have previously used cidofovir or had a ganciclovir intravitreal implant unless it was removed. You cannot take other anti-CMV treatments while on study. Contact: Julie Rivera, RN, St. Luke's/Roosevelt Hospital Center, New York, NY, (212) 523-6743; Mary Heneghan, Doctor's office - Alan Palestine, MD, Washington, DC, (202) 833-1328. <font size=-2>(added 12/12/96)</font></p>

<p>ISIS 2922-CS2. Drug: <B>ISIS 2922</B>. This trial will study ISIS 2922 for the treatment of CMV retinitis. Participants will be divided into two groups. One group will be treated with the study drug. The other group will not be treated until disease progression is observed. Participants must have newly diagnosed CMV retinitis that does not immediately threaten their vision. The study drug is administered by injection into the globe of the eye once a week for three weeks, and then once every other week. Each participant will be followed for approximately 20 weeks. Participants can continue treatment after the end of the study. You must be 18 years or older with newly diagnosed CMV retinitis in one eye. Contact: Mike Stern, Doctor's office, New York, NY, (212) 737-7400. </P>

<p</>>ISIS 2922-CS3. Drug: <B>ISIS 2922, IV ganciclovir, oral ganciclovir</B>. This trial will compare the combination of ISIS 2922 and oral ganciclovir to the combination of IV ganciclovir and oral ganciclovir for the treatment of CMV retinitis. Participants must have CMV retinitis that has progressed at least once while being treated with ganciclovir or foscarnet. Participants will be divided into two groups. The first group will be treated with both drugs for three weeks, and then with ISIS 2922 alone. The second group will be treated with oral ganciclovir. ISIS 2922 will be administered by injection into the globe of the eye once per week for three weeks and then once every other week. Ganciclovir is taken in pill form. Participants will be followed for approximately 20 weeks and will be offered the opportunity to continue therapy with ISIS 2922 after this period. You must be 18 years or older with CMV retinitis in one or both eyes that has progressed at least once while being treated with ganciclovir or foscarnet. Contact: Mike Stern, Doctor's office, New York, NY, (212) 737-7400. </P> 

<p>ISIS 2922-CS9. Drug: <b>ISIS 2922</b>. This tril will study two dose regimens of ISIS 2922 for the treatment of advanced CMV retinitis. ISIS 2922 is given by injection into the eye. Participants will be divided into two groups. One group will receive ISIS 2922 on days 1, 8 and 15 of the study, follwed by a maintenance dose of ISIS 2922 every other week. The second group will receive ISIS 2922 on days 1 and 15 of the study, followed by a maintenance dose every fourth week. Everyone that responds to ISIS 2922 can continue to receive treatment indefinitely. Participants may also take oral ganciclovir during the study. To participate you must have unilateral or bilateral CMV retinitis and have received more than two induction courses of IV anti-CMV therapy. You cannot have ganciclovir implants or be on systemic anti-CMV therapy other than oral ganciclovir. Contact: Mike Stern, Doctor's office, New York, NY (212) 737-7400. <font size=-2>added 2/16/96</font></p>

</blockquote>

<HR size=3 width=50% align=center noshade>

<p align=center><A HREF="ois.html"><img align=middle hspace=5 src="../gifs/left.gif" alt=" ">trials for opportunistic infections</A><A HREF="../index.html"><img align=middle hspace=5 src="../gifs/return.gif" alt=" ">Network home page</A></p>

<HR size=3 width=50% align=center noshade>

<P align=center><FONT SIZE=-2>Last updated: 12/16/96<BR>
<A HREF="mailto:atdn@aidsnyc.org">atdn@aidsnyc.org</A><BR>
copyright &#169; 1996 The Network</FONT></P>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-276</DOCNO>
<DOCOLDNO>IA093-001003-B002-286</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/trials/thrush.html 199.29.141.24 19970121123857 text/html 6494
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:33:04 GMT
Server: NCSA/1.5.1
Last-modified: Thu, 12 Dec 1996 20:46:01 GMT
Content-type: text/html
Content-length: 6311
</DOCHDR>
<html>
<head>
<title>Trials: thrush</title>
</head>
<body bgcolor=#ffffff><font face="arial, helvetica" size=-1>

<h2 align=center>Trials for the treatment of thrush</h2>
<blockquote><h5 align=center>Contact numbers on these pages are for the New York area. Many of the trials are nationwide. For sites in your area, call the AIDS Clinical Trials Information Services (ACTIS) at 1-800-TRIALS-A.</h5>

<HR size=3 width=50% align=center noshade>

<font size=-1><p>ACTG 295. Drug: <b>amphotericin B oral suspension</b>. This trial will study an oral suspension form of amphotericin B for the treatment of oral thrush that doesn't respond to fluconazole treatment. Oral suspension means that the drug is swished around in the mouth and then swallowed. All participants in the trial will be treated with oral suspension amphotericin B four times a day for 14 days. Participants who demonstrate successful treatment with oral suspension amphotericin B will then be treated with the drug twice a day. This is called a maintenance dose. Participants who do not demonstrate a response from the treatment will continue to use oral suspension amphotericin B for another 14 days. Participants who do worse on amphotericin B will discontinue the study. To participate in this study you must be HIV+, 13 years or older, with oral candidiasis (thrush) documented by a KOH smear and culture and no significant clearing of oral thrush after use of fluconazole, either IV or oral, for at least 14 consecutive days.  Failure must have occurred in the 3 months prior to trial entry. You may not have esophageal candidiasis, active cryptococcal meningitis or disseminated histoplasmosis requiring therapy. Some drugs are not allowed which the study coordinator will go over with you. Contact: Wendie Lubin, RN, Beth Israel Medical Center, New York, NY, (212) 420-4519; Mary Ann Kiernan, NYU Medical Center, New York, NY, (212) 263-6565, Laurie DiDonato, Montefiore Hospital, Bronx, NY, (718) 920-5344. <font size=1><i>added 11/8/95</i></font></p>

<p>IP#001.0009. Drug: <b><a href="../access/drugs/sarg.html">GM-CSF</a>, <a href="../access/drugs/fluc.html">fluconazole</a></b>. This trial will study GM-CSF with fluconazole for the treatment of <a href="../simple/fungal.html">oral thrush</a> that is not responding to standard treatment with fluconazole. Participants will be randomly divided into two groups. One group will receive high-dose fluconazole and GM-CSF. The second group will receive high-dose fluconazole alone. Fluconazole is given as a pill taken once a day. GM-CSF is given by injection under the skin once a day. Participants taking fluconazole alone who do not respond to treatment after 14 days can add GM-CSF for a further 14 days. Participants who have a response to treatment after 14 days will be able to remain on the study -  those that were in the fluconazole and GM-CSF group will stop taking fluconazole but continue to receive GM-CSF twice a week for 10 weeks. Participants who were taking fluconazole alone will stop treatment and be followed for 10 weeks. To participate in this study you must be HIV+, 18 years or older, with confirmed oral thrush that's failed treatment with at least 14 days of fluconazole at equal to or more than 200 mg/day in the month prior to joining the study. You must have been taking an approved antretroviral treatment(s) for at least a week before starting GM-CSF. You cannot be pregnant or nursing. You cannot have significant, uncontrolled cardiovascular disease, including congestive heart failure, unstable angina, myocardial infarction or cerebrovascular accident within past six months, or uncontrolled arrhythmias. The study coordinator will go over with you drugs not allowed while on study. Total time on study is 14 days. Contact: Pablo Colon, St. Vincent's Hospital, New York, NY, (212) 604-2684; David Shepp, MD, North Shore University Hospital, Manhasset, NY, (516) 562-4280. <font size=-2><i>(added 10/14/96)</i></font></p>

<p>ITR-USA-94. Drug: <B>itraconazole oral solution</B>. This trial will study itraconazole oral solution for the treatment of oral thrush that is not responsive to fluconazole treatment. All participants who qualify will be treated with oral solution itraconazole twice a day. Everyone will know which treatment they are getting. Total time on study includes a six week follow-up. You must be 18 years or older with oral thrush (oropharyngeal candidiasis) resistant to fluconazole at 200 mg/day for 14 days. You cannot have esophageal candidiasis. Contact: Becky Becker, RN, Johns Hopkins University Hospital, Baltimore, MD, (410) 955-2898; Lillie Dungo, RN, St. Michael's Hospital, Newark, NJ, (201) 877-2915; Nancy Pietroski, PharmD, Pennsylvania Hospital, Philadelphia, PA, (215) 925-8010. </P>

<p>ITR-USA-109. Drug: <b>itraconazole oral solution</b>. This trial will study itraconazole oral solution for the treatment of candidiasis (thrush) in the mouth or throat that is not responsive to fluconazole treatment. All participants who qualify will be treated with oral solution itraconazole once a day by swishing and swallowing the liquid for 6 weeks.  After 6 weeks, participants will be put on a maintenance dose given 3 times a week. Everyone will know which treatment they are getting. To participate you must be 13 years or older with candidiasis of the mouth or throat that has been resistant to fluconazole at 200 mg/day for 14 days. You cannot be pregnant women or nursing, have significant hepatic abnormalities or yypersensitivity to imidazole or azole compounds, or be taking systemic or oral antifungal agents . Total time on study is 6 weeks. Contact: Trish Garton, Doctor's Office - G. Blick, MD, Greenwich, CT, (203) 622-1118. <font size=-2>(added 12/12/96)</font></p>


</font>
</blockquote>


<HR size=3 width=50% align=center noshade>

<p align=center><A HREF="ois.html"><img align=middle hspace=5 src="../gifs/left.gif" alt=" ">trials for opportunistic infections</A><A HREF="../index.html"><img align=middle hspace=5 src="../gifs/return.gif" alt=" ">Network home page</A></p>

<HR size=3 width=50% align=center noshade>

<P align=center><FONT SIZE=-2>Last updated: 12/12/96<BR>
<A HREF="mailto:atdn@aidsnyc.org">atdn@nyam.org</A><BR>
copyright &#169; 1996 The Network</FONT></P>

<font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-277</DOCNO>
<DOCOLDNO>IA093-001003-B002-303</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/trials/cervical.html 199.29.141.24 19970121123907 text/html 2847
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:33:14 GMT
Server: NCSA/1.5.1
Last-modified: Thu, 12 Dec 1996 20:45:31 GMT
Content-type: text/html
Content-length: 2664
</DOCHDR>
<html>
<head>
<title>Trials: cervical dysplasia</title>
</head>
<body bgcolor=#ffffff><font face="arial, helvetica" size=-1>
<h2 align=center>Trials for the treatment of cervical dysplasia</h2>
<blockquote><h5 align=center>Contact numbers on these pages are for the New York area. Many of the trials are nationwide. For sites in your area, call the AIDS Clinical Trials Information Services (ACTIS) at 1-800-TRIALS-A.</h5>
<HR size=3 width=50% align=center noshade>

<P>ACTG 200. Drug: <B>5-FU</B>. This trial will study an ointment called 5-FU (fluorouracil) for women who have already been treated for cervical dysplasia. The study will compare 5-FU to regular monitoring. Participants will be divided into two groups. Women in the first group will apply 5-FU cream directly to the vagina twice a week for six months. Women in the second group will be monitored but will not apply the cream. You must be 12 years or older with a diagnosisi of cervical dysplasia with ablative therapy within the past 8 weeks. Treatment is for 6 months. Contact: sites in New York, Albany, Buffalo, Rochester, Washington DC, Baltimore and Newark. Call The Network at (800) 734-7104 or ACTIS at 1-800-TRIALS-A for referral.</P>

<p>ACTG 293. Drug: <b>oral isotretinoin</b>. This trial will study oral isotretinoin for the treatment of cervical dysplasia. Participants will be randomly divided into two groups. One group will receive oral isotretinoin for 6 months. The second group will receive regular observation for 6 months. All study participants will then be followed for an additional 12 months. Both the participant and doctor will know which treatment is being given. To participate you must be HIV+ and 13 years or older with Grade 1 CIN. You must have a negative pregnancy test within 7 days of study entry. The study coordinator will go over with you conditions and treatments not allowed while on study. Total time on study is 6 months. Contact: sites in the Bronx, Brooklyn, New York, Syracuse, Baltimore and Philadelphia. Call the Network at (800) 734-7104 or ACTIS at (800) TRIALS-A for referral. <font size=-2>(added 12/12/96)</font></p>

</blockquote>

<HR size=3 width=50% align=center noshade>

<p align=center><A HREF="ois.html"><img align=middle hspace=5 src="../gifs/left.gif" alt=" ">trials for opportunistic infections</A><A HREF="../index.html"><img align=middle hspace=5 src="../gifs/return.gif" alt=" ">Network home page</A></p>

<HR size=3 width=50% align=center noshade>

<P align=center><FONT SIZE=1>Last updated: 12/12/96<BR>
<A HREF="mailto:atdn@nyam.org">atdn@nyam.org</A><BR>
copyright &#169; 1996 The Network</FONT></P>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-278</DOCNO>
<DOCOLDNO>IA093-001003-B002-314</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/trials/cog.html 199.29.141.24 19970121123915 text/html 4997
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:33:23 GMT
Server: NCSA/1.5.1
Last-modified: Thu, 12 Dec 1996 20:45:43 GMT
Content-type: text/html
Content-length: 4814
</DOCHDR>
<html>
<head>
<title>Trials: dementia</title>
</head>
<body bgcolor=#ffffff><font face="arial, helvetica" size=-1>

<h2 align=center>Trials for the treatment of cognitive impairment</h2>

<blockquote>

<p>96-316NE. Drug: <b><a href="../../natap/drug/u89.html">1592U89</a></b>. This trial will study 1592U89 for the treatment of HIV dementia.  Symptoms of dementia include memory, concentration and thinking problems. Participants will be divided in to two main groups: those taking AZT and those not taking AZT.  Then participants will be further divided into two sub-groups.  The first sub-group in each section will receive the medication 1592U89; the second sub-group in each section will receive a placebo.  Neither the doctor nor the participants will know which group is receiving 1592U89 and which the placebo.  A stipend is paid participants for transportation to the site. To participate in this study you must be HIV+, 18 years or older, with a <b>T4 cell count of under 300</b>. You must be having problems with short-term memory and feeling slowed down, and be on a stable anti-retroviral treatment during past 8 weeks. You cannot be pregnant or nursing or have severe psychiatric illness, dementia, physical debilitation or history of central nervous system opportunistic infections or neoplasms. You cannot have had pancreatitis or hepatitis within 6 months. You cannot have taken any investigational drugs with 90 days of study, be participating in other drug studies, taking nerve growth factor, d4T or some other drugs which the study coordinator will go over with you. Total time on study is 12 weeks. Ronda Friedman-Clouse, RN, Columbia Presbyterian Medical Center, New York, NY, (212) 960-2230; Jessica Moise, Mount Sinai Medical Center, New York, NY, (212) 241-0784. <font size=-2>(added 9/30/96)</font></p>

<p>ACTG 301. Drug: <b>memantine</b>. This trial will study memantine for the treatment of HIV dementia. The participants will be divided into two groups. The first group will receive memantine along with their antiretroviral therapy.  The second group will receive a placebo along with their antiretroviral therapy.  Neither the participants nor the doctors will know which treatment is being given.  After the 16 weeks there will follow a 4 week washout period. Following the washout all participants will be given the opportunity to receive memantine for 12 weeks. To participate you must be HIV+ and 18 years or older with a diagnosis of AIDS dementia complex. You must be on stable FDA-approved antiretroviral therapy for more than 8 weeks prior to study entry and willing to continue during study. You cannot be pregnant or nursing or have an AIDS-defining infection requiring therapy other than prophylaxis. The study coordinator will go over with you other conditions and treatments not allowed while on study. Total time on study is 16 weeks. Contact: Deborah Dunbar, NP, University of Pennsylvania Medical Center, Philadelphia, PA, (215) 349-8092. <font size=-1>(added 12/12/96)</font></p>

<p>Dana-DTA . Drug: <b>lexipafant</b>. This trial will study lexipafant for the treatment of HIV dementia. Symptoms of dementia include memory, concentration and thinking problems. Participants will be divided in to two  groups.  The first group will receive lexipafant; the second group will receive a placebo.  Neither the doctor nor the participants will know which group is receiving lexipafant and which the placebo.  After 10 weeks, an open-label follow-up phase will be offered to both groups.  A stipend is paid participants for transportation to the site. To participate in this study you must be HIV+ and 18 years or older. You must be having problems with short-term memory and feeling slowed down, and be on a stable anti-retroviral treatment during past 6 weeks. You cannot be pregnant or nursing or have severe psychiatric illness, dementia, physical debilitation or history of central nervous system opportunistic infections or neoplasms. You cannot have had pancreatitis or hepatitis within 6 months. You cannot have taken any investigational drugs with 30 days of study. Total time on study is 10 weeks. Ronda Friedman-Clouse, RN, Columbia Presbyterian Medical Center, New York, NY, (212) 960-2230. <font size=-2>(added 9/30/96)</font></p>

</blockquote>

<HR size=3 width=50% align=center noshade>

<p align=center><A HREF="ois.html"><img align=middle hspace=5 src="../gifs/left.gif" alt=" ">trials for opportunistic infections</A><A HREF="../index.html"><img align=middle hspace=5 src="../gifs/return.gif" alt=" ">Network home page</A></p>

<HR size=3 width=50% align=center noshade>

<P align=center><FONT SIZE=-2>Last updated: 12/12/96<BR>
<A HREF="mailto:atdn@nyam.org">atdn@nyam.org</A><BR>
copyright &#169; 1996 The Network</FONT></P>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-279</DOCNO>
<DOCOLDNO>IA093-001003-B002-332</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/trials/cmvprev.html 199.29.141.24 19970121123925 text/html 2345
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:33:31 GMT
Server: NCSA/1.5.1
Last-modified: Wed, 11 Dec 1996 17:57:30 GMT
Content-type: text/html
Content-length: 2162
</DOCHDR>
<html>
<head>
<title>Trials: CMV prevention</title>
</head>
<body bgcolor=#ffffff><font face="arial, helvetica" size=-1>

<h2 align=center>Trials for prevention of CMV</h2>

<blockquote>

<h5 align=center>Contact numbers on these pages are for the New York area. Many of the trials are nationwide. For sites in your area, call the AIDS Clinical Trials Information Services (ACTIS) at 1-800-TRIALS-A.</h5>

<HR size=3 width=50% align=center noshade>

<p>CPCRA 039. Drug: <b>adefovir dipivoxil (bis-POM PMEA,) L-carnitine supplement</b>. This trial will study adefovir dipivoxil for the treatment of advanced HIV infection. The trial will also study whether adefovir can prevent CMV infections in people who are at risk for developing CMV disease. Participants will be divided into two groups. One group will be treated with a daily dose of oral adefovir dipivoxil (120 mg) plus an L-carnitine supplement. L-carnitine is naturally occurring substance in the body used in metabolism and energy production. The second group will take the L-carnitine supplement alone. Neither the doctor nor the participant will know which treatment is being given. To participate you must be HIV+ and 13 years or older with a <b>T4 cell count under 100</b>. You cannot be pregnant or nursing or have a history of CMV in your organs or active CMV disease at study entry. You cannot have taken foscarnet within 60 days of study entry. Total time on study is 20 months. Contact: Norma Santos, RN, Atlantic City Medical Center, Atlantic City, NJ,  (609) 441-2178; Wendie Lubin/Nancy Relly, NJCRI, (201) 483-3444 x23. <font size=-2>(added 12/11/96)</font></p>

</blockquote>

<HR size=3 width=50% align=center noshade>

<p align=center><A HREF="ois.html"><img align=middle hspace=5 src="../gifs/left.gif" alt=" ">trials for opportunistic infections</A><A HREF="../index.html"><img align=middle hspace=5 src="../gifs/return.gif" alt=" ">Network home page</A></p>

<HR size=3 width=50% align=center noshade>

<P align=center><FONT SIZE=-2>Last updated: 12/11/96<BR>
<A HREF="mailto:atdn@nyam.org">atdn@nyam.org</A><BR>
copyright &#169; 1996 The Network</FONT></P>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-280</DOCNO>
<DOCOLDNO>IA093-001003-B002-345</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/trials/vaccines.html 199.29.141.24 19970121123951 text/html 5771
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:33:58 GMT
Server: NCSA/1.5.1
Last-modified: Wed, 11 Dec 1996 17:56:07 GMT
Content-type: text/html
Content-length: 5588
</DOCHDR>
<html>
<head>
<title>Trials: vaccines</title>
</head>

<body bgcolor=#fffff><font face="arial, helvetica" size=-1>

<h2 align=center><img align=middle hspace=2 src="../gifs/pillshot.gif" alt="[pill/shot]">Vaccine Trials</H2>

<blockquote>

<h5 align=center>Contact numbers on these pages are for the New York area. Many of the trials are 
nationwide. For sites in your area, call the AIDS Clinical Trials Information Services (ACTIS) at 1-800-TRIALS-A.</h5>

<P align=center>Read more about progress in the development of vaccines in an <A HREF="killen.html">interview with Jack Killen, M.D.</A>, director of NIAID's Division of AIDS (DAIDS). This interview is from NIAID AIDS Agenda.</P>

<HR size=3 width=50% align=center noshade>

<h4>For HIV-negative participants<br>
<font size=2>Vaccines that are meant to prevent infection have to be tested in people who are HIV-negative.</font></h4>

<p>AVEG 019: This trial is studying an HIV vaccine called p17/p24:Ty-VLP. Copies of pieces of two internal HIV proteins, p17 and p24, are incorporated with a yeast protein (Ty) that helps them assemple into virus-like particles (VLPs). In ongoing small studies in humans, the vaccine so far appears to be safe. In the first part of the trial, participants will be divided into two groups. One group will receive the vaccine in intramuscular injections at the beginning of the study, at two months, and at six months with booster shots at 10 and 11 months. The second group will be treated with a placebo and booster doses at the same times. Participants are healthy, HIV-1 seronegative, adult volunteers without identifiable higher risk behavior for HIV-1 infection, as determined by a comprehensive screening questionnaire. The vaccine will be given by injection, by pill, and rectally. Total time on study is 18 months. Shirley Erb, RN, University of Rochester, Rochester, NY (716) 275-5744. </p>

<p>AVEG 022: This trial will study the safety and immunogenicity of an oral vaccine in people who are HIV-negative. Participants are healthy, HIV-1 uninfected, adult volunteers 18 to 60 years of age who have no identifiable high-risk behavior for HIV infection. Shirley Erb, RN, University of Rochester, Rochester, NY (716) 275-5744; Jack Lambert, MD, Johns Hopkins University Hospital, Baltimore, MD (410) 955-1622. </p>

<p>AVEG 023: This trial will study an intramuscular vaccine followed by an oral booster in people who are HIV-negative. The main goal is to find out if giving an intramuscular injection before giving oral booster doses works better than treatments being studied in other trials. Participants are healthy, HIV-1 uninfected, adult volunteers 18 to 60 years of age who have no identifiable high-risk behavior for HIV infection. Total time on study is 14 months. Contact: Shirley Erb, RN, University of Rochester, Rochester, NY (716) 275-5744.</p>

<h4>For HIV+ participants<br>
<font size=2>A newer kind of vaccine is a treatment vaccine, meant to boost or restore immune function in people who are HIV+. </font></h4>

<p>MAS-96-Gp120. Drug: <b>gp120 with two monoclonal antibodies</b>. This trial will study the gp120 vaccine with two monoclonal antibodies (AD-439 and AD-519) for the treatment of HIV infection. Participants will be divided into two groups. The first group will receive the Gp120 vaccine with monoclonal antibodies. The second group will receive a placebo. Both study drugs and placebo are administered by injection and will be given every three weeks. Neither the participant nor the doctor will know which treatment is being given. To participate you must be HIV+ and 18 years or older with a <b>T4 cell count between 50 and 300</b>. You must have been on stable use of antiviral medications at least 4 weeks prior to study and must remain stable during 6 months of study. You cannot be pregnant or nursing, or be taking any investigational medications. Total time on study is 6 months. Contact: Betsy Ruiz, RN, Bronx VA Medical Center, Bronx, NY, (718) 584-9000 x 5860. <font size=-2>(added 11/24/96)</font></p>

<p>MB 345. Drug: <b>vaccines</b>. This study is being done at the National Cancer Institute in Bethesda, MD. The NCI will pay for airfare for every visit except the first. This trial will study two peptide vaccines for the treatment of HIV infection. Participants will be divided into three groups. The first two groups will receive one vaccine and the third group will be treated with both vaccines. Clinic visits are once every 3 months. Participants will be monitored for up to two hours following each vaccination. Both the participant and doctor will know which treatment is being given. To participate you must be HIV+ and 18 years or older with a <b>T4 cell count over 500</b>. You cannot be pregnant or have ever had an AIDS defining opportunistic infection. The study coordinator will go over with you other conditions and medications not allowed while on study. Total time on study is 1 year. Contact: Tino Merced-Galindez, RN, National Cancer Institute, Bethesda, MD, (800) 772-5464 x 562. <font size=-2>(modified 12/11/96)</font></p>

<HR size=3 width=50% align=center noshade>

<p align=center><A HREF="../trials.html"><img align=middle hspace=5 src="../gifs/left.gif" alt=" ">trials page</A><A HREF="../index.html"><img align=middle hspace=5 src="../gifs/return.gif" alt=" ">Network home page</A></p>

<HR size=3 width=50% align=center noshade>

<P align=center><FONT SIZE=-2>Last updated: 12/11/96<BR>
<A HREF="mailto:atdn@nyam.org">atdn@nyam.org</A><BR>
copyright &#169; 1996 The Network</FONT></P>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-281</DOCNO>
<DOCOLDNO>IA093-001003-B002-359</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/network/trials/info.html 199.29.141.24 19970121124000 text/html 10247
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:34:07 GMT
Server: NCSA/1.5.1
Last-modified: Mon, 02 Dec 1996 20:34:40 GMT
Content-type: text/html
Content-length: 10063
</DOCHDR>
<html>
<head>
<title>Information Gathering Studies </title>
</head>
<body bgcolor=#ffffff><font face="ariel, helvetica" size=-1>

<blockquote>

<h2><img align=left vspace=2 hspace=5 src="../gifs/check.gif" alt="[pencil]">Information gathering studies</h2>

<p align=center>Some trials don't test new drugs, but are information gathering studies. You can contribute data about your health status to an information gathering study that may provide ongoing clinic visits and regular monitoring.</p>

<h5 align=center>Contact numbers on these pages are for the New York area. Many of the trials are nationwide. For sites in your area, call the AIDS Clinical Trials Information Services (ACTIS) at 1-800-TRIALS-A.</h5>

<hr size=3 align=center width=50% noshade>

<p>94-10: <b>CD4 Gamma-2 Imaging Trial</B>. This study will use a fusion protein and imaging to look at viral load. It's difficult to measure the amount of virus in your body during a good part of the history of the disease. The trial uses a new technology that makes specific proteins by fusing genes. This fusion protein attaches to cells infected with HIV. The gamma 2 can be traced with scans to see if tissues infected with HIV can be imaged. This could aid in monitoring treatment with antiretrovirals. Because of the small amount of radioiodine used, the researchers don't anticipate toxicities. Participants will be given one injection and return at 24 hours, 48 hours and 1 week later for the imaging scan. Monthly follow-up visits to the clinic will be for four months. David Straus, MD, Memorial Sloan Kettering, New York, NY (212) 639-8365.</p>

<p>ACTG 219: <b>Pediatric Outcomes Protocol</b>. This information gathering study follows children who have been enrolled in clinical trials. Various sites, call The Network for information. </p>

<p>ACTG 220: <b>Pre-enrollment protocol for HIV+ adolescents</b>. This information gathering study follows HIV+ adolescents with clinic visits every three months. The study gathers information about adolescents to see what the similarities and differences are  compared to adults and children. This information will be used to design trials that are more specific to adolescents' needs. Participants are given information about drug trials, and taking part in this study gives them practice in being part of a research protocol with very few requirements. At clinic visits participants are monitored for signs and symptoms of disease, and given a list of drug trials for which they might be eligible to see whether or not they want to enroll. To participate you must be HIV+, 13-21 years old, and not currently 
enrolled in a clinical trial. Various sites, call The Network for information.</p>

<p>ACTG 255: <b>Maternal AZT-resistant HIV Transmission</b>. This study will investigate maternal-fetal transmission of HIV that is resistant AZT. You must have had at least 6 months of AZT treatment to be in this study, and have been pregnant for 20-36 weeks. Various sites, call The Network for information.<font size=-2>(added 12/2/96)</font></p>

<p>Col-MCP: <b>Male Couples Project</b>. This Couple Project offers eight-week group workshops for male couples in which one person is HIV+ and the other is not. The workshops, led by two facilitators, are aimed at reducing the distress faced by these couples in such areas as sustaining safer sex, developing better communication skills, planning for the future, and generally maintaining relationship satisfaction. The workshops are offered free of charge at sites throughout New York City. Eligible couples will be men of mixed HIV status, ages, 22-55, who have been in a committed relationship for at least four months and are physically able to participate in the group. Contact: Raymond A. Smith, New York State Psychiatric Institute, New York, NY, (212) 740-3505. <font size=-2>(added 12/2/96)</font></p>

<p>Cor-MFT: <b>Maternal-Fetal Transmission of HIV-1</b>. This information gathering study is looking at transmission of virus from HIV+ mothers to new babies. This study focuses on mother-infant pairs and in particular the type of T-cell that is infected with HIV when the virus is first transmitted. One blood sample from the mother is required. From the babies repeated blood samples are taken over the first and second years of life, up to six samples per year if possible. One blood sample needs to be collected in the first 2 weeks of life. Any HIV+ mother and her child can be included regardless of whether they are on other studies and regardless of the treatment protocol. Usually informed consent is obtained prior to birth from the mother. Consent can also be obtained immediately after birth allowing collection of the critical initial baby sample during the first 2 weeks of life. The only excluded patients are those where either mother or baby will not be available for future follow up and repeat samples. Contact: Cornell University Medical College, New York, NY, David Posnett, MD (212) 746-6488.</p>

<p><a name="msk-adu">MSK-ADU</a>. <b>Older Adults Living With HIV</b>. This information gathering study will look at what life is like for men and women 50 and older living with HIV/AIDS.  Participants will have two meetings with an interviewer for approximately 2 or 2 1/2 hours each meeting.  All interviews are strictly confidential.  Participants will be compensated for their time and reimbursed for travel expenses. To participate you must be HIV+ and 50 years or older. Contact: Karolynn Siegel, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, (212) 434-5135. <font size=-2>(added 9/30/96)</font></p>

<p>MSK-AZT: <b>Attitudes to AZT Use During Pregnancy</b>. This information gathering study is looking to interview HIV-positive women who are pregnant or considering pregnancy. The study will ask questions about attitudes concerning the uses, risks and benefits of AZT during pregnancy and in newborns. Participants will be asked to take part in a single 2-2.5 hour confidential interview. You will be compensated $25.00 for your time and reimbursed for your travel. Interviewers speak English and Spanish. Contact: Karolynn Siegel, MD at Memorial Sloan Kettering, New York, NY (212) 434-5115. <font size=-2>(added 12/2/96)</font></p>

<p>MSK-TDM: <b>Women Living With HIV</b>. Memorial Sloan Kettering is looking for volunteers to participate in an NIH funded psycho-social study of treatment decision making of women who are HIV positive. Participants are paid $30 for their time and travel and the interview is strictly confidential. The interview is approximately 2 hours. A second study, starting in June, will be for women with AIDS. Participants will be seen for 3 visits, and paid $25 per visit for their time and travel. Babysitting costs will be reimbursed at $7.50/hr. Hablomos espanol. Eileen Gorey, RN, Memorial Sloan Kettering, New York, NY (212) 639-3654.</p>

<p>Network 438: <b>MRI Imaging Spectroscopy</b>. Participants in this study will have an MRI screening and neuropsychological testing every six months for 2-3 years. All participants in the study will be paid $45.00 each time the tests are done. The study will look at changes in the concentration of certain biochemical substances in the brains of people who are HIV+, as well as in people who are HIV-negative and at risk of HIV infection. The HIV-negative participants will serve as the control group. Karen Willis, RN, Albany Medical College, New York, NY (518) 262-6713.</p>

<p>SVH-CIN: <b>Routine Gynecological Care for HIV+ Women</b>. This information gathering study will collect clinical data from the routine gynecological care provided to women with HIV infection. The study hopes to more clearly define the relationship between the degree of immunosuprression with the risk for cervical intraepithelial neoplasia (CIN) and cervical cancer. Participants will be followed for 
a minimum of 24 months. Mary Jo Hoyt, NP, St. Vincent's Hospital, New York, NY (212) 647-1709.</p>

<p>TLC-NYC: <B>Teams Linking Care</B>. This research project focuses on improving the health and quality of life of HIV+ young adults. Becoming involved includes meeting in small groups with others living with HIV or AIDS, as well as meeting individually for interviews every three months. TLC pays you $20 each time you complete an interview and $10 for each group session you attend. The three parts of the group meetings are: Staying Healthy, Acting Safe, and Keeping Up. Each series is 12 two hour group sessions held weekly with a three month break between series. Groups have 6-12 members and two co-facilitators. You must be between 14 and 23 years old to participate. Younger people will also be considered. Groups are conducted in Spanish and English. Sites in LA, San Francisco and NY. Contact: Whitney Wright, TLC Project Coordinator, New York, NY, (212) 946-1050.</p> 

<p>Vincent 01: <b>Sexual Functioning Study</b>. This study looks at sexual functioning in HIV+ people. Given that individuals are living longer with HIV due to gains in treatments, it is important to look at the quality of the longer life. Human sexuality is an integral part of health and well-being. Early identification and treatment of sexual problems may help individuals have improved mood and life satisfaction, improved partner relationships, and decreased overall sexual suffering. Participation in this study involves answering a questionnaire. To participate you must be 18 years or older and HIV+. Gayle Newshan, NP, St. Vincent's Hospital, New York, NY (212) 647-1709.</p>

</blockquote>

<HR size=3 width=50% align=center noshade>

<P align=center><A HREF="../trials.html"><img align=middle hspace=5 src="../gifs/left.gif" alt="[arrow]">trials page</A>
<A HREF="../index.html"><img align=middle hspace=5 src="../gifs/return.gif" alt="[arrow]">Network home page</A></P>

<HR size=3 width=50% align=center noshade> 

<P align=center><FONT SIZE="-2">Last updated: 12/2/96<BR>
<A HREF="mailto:atdn@nyam.org">atdn@nyam.org</A><BR>
copyright &#169; 1996 The Network</P>

</font>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT18-B31-282</DOCNO>
<DOCOLDNO>IA093-001003-B002-377</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/cnews/conf/mediate.html 199.29.141.24 19970121124025 text/html 11707
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:34:17 GMT
Server: NCSA/1.5.1
Last-modified: Wed, 15 Jan 1997 16:58:36 GMT
Content-type: text/html
Content-length: 11523
</DOCHDR>
<html>
<head>
<title>Sprint '97 Mediation Training - Center for Medical Ethics & Mediation</title>
</head>

<body bgcolor="#FFFFFF"><font face="arial, helvetica" size=-1>

<blockquote>
    <p align="center"><a href="../index.html"><font size="2"
    face="arial, helvetica">home</font></a><font size="2"
    face="arial, helvetica"> | </font><a
    href="../news/index.html"><font size="2"
    face="arial, helvetica">newsletter</font></a><font size="2"
    face="arial, helvetica"> | </font><a
    href="../contacts/index.html"><font size="2"
    face="arial, helvetica">contacts</font></a><font size="2"
    face="arial, helvetica">| </font><a href="../papers/das.html"><font
    size="2" face="arial, helvetica">papers</font></a><font
    size="2" face="arial, helvetica"> | </font><a
    href="index.html"><font size="2" face="arial, helvetica">conferences</font></a><font
    size="2" face="arial, helvetica"> | </font><a
    href="../about.html"><font size="2" face="arial, helvetica">about
    consumer news</font></a></p>
    <p align="center"><font size="2" face="arial, helvetica"><img
    src="../gifs/bronze.gif" width="50%" height="4"></font></p>

    <p align="center"><font color="#008000" size="5"><strong>The
    Center for Medical Ethics &amp; Mediation<br>
    Announces Spring 1997</strong></font></p>
    <p align="center"><font color="#FF8040" size="4"><strong>Three
    Day Mediation Certificate Program </strong></font></p>
    <p align="center"><font size="4"><em>&quot;Successful
    Healthcare Conflict Resolution:<br>
    Mediation &amp; Negotiation Training&quot; </em></font></p>

    <p align="left">This training is designed exclusively for
    healthcare practitioners, administrators and attorneys
    committed to creating the conflict-positive healthcare
    environment. The focus of the course addresses critical
    issues such as medical ethics, non-compliant patients,
    malpractice, HMO grievance cases and risk management.</p>
    <p align="left">Methods of instruction include: didactic
    presentations, large and small group simulations, and 6
    supervised mock mediation practice sessions.</p>
    <p align="left">Learning objectives for this certificate
    course address the following:</p>
    <ul>
        <li><p align="left">Understand how to manage healthcare
            conflict more cost effectively.</p>
        </li>
        <li><p align="left">Master the three stages of mediation
            during supervised practice sessions.</p>
        </li>
        <li><p align="left">Facilitate active communications
            between hostile parties.</p>
        </li>
        <li><p align="left">Appreciate how genders and
            individuals approach negotiation.</p>
        </li>
        <li><p align="left">Systematically analyze a clinical
            ethics case according to JCAHO standards.</p>
        </li>
    </ul>
    <p align="center"><font size="4"><strong><br>
    FACULTY<br>
    </strong></font><font color="#008000"><strong>Mileva Saulo,
    Ed.D., R.N</strong></font><strong>.</strong> - University of
    Southern California, Department of Nursing<br>
    <font color="#008000"><strong>Steven M. Kuriga, P.A.-C., M.S.</strong></font>
    - Administrator, Mission Hills Medical Group<br>
    <font color="#008000"><strong>Robert J. Wagener, M.A., M.Div.</strong></font>
    - USCD Medical Center Ethics Committee</p>
    <p align="center"><font size="4"><strong><br>
    DATE - TIME - PLACE<br>
    </strong></font><font color="#FF8040"><strong>March 7th
    through 9th, 1997, 8:00 a.m. to 5:00 p.m.<br>
    </strong></font>Quality Resort Hotel - Mission Valley, San
    Diego, CA<br>
    Lodging at the remodeled Quality Resort Hotel ($49 + tax per
    night) can be Arranged by calling:<br>
    <font color="#808000" size="5"><strong>1-800-362-7871</strong></font></p>
    <p align="center"><font size="4"><strong><br>
    TUITION<br>
    </strong></font>Early Bird Registration - $375 - On or Before
    February 20, 1997<br>
    Late Registration $450 - Payment at the Door<br>
    (Includes: Certificate of Completion, training materials, and
    one networking luncheon)</p>
    <p align="center">Please print <img src="../gifs/printer.gif"
    width="25" height="20"> the following form:</p>
    <hr size="4" width="75%" color="#008000">
    <p align="center"><font color="#008000"><em><strong>Registration
    </strong></em></font></p>
    <p align="left">Name.____________________________________
    Telephone (_____)_______________</p>
    <p align="left"><br>
    Address________________________ City_________________
    State____ Zip__________</p>
    <p align="left"><br>
    <font size="2"><em>____ Yes, I want to take advantage of the
    Early Registration - Enclosed is My Check for $____________</em></font></p>
    <p align="left"><font size="2"><em>____ Yes, hold my place
    for this training with a Partial Payment - Payment at the
    door $______________</em></font></p>
    <p align="left"><font size="2"><em>____ Yes, we want to take
    advantage of &quot;Send Three &amp; get One Free&quot;
    Offer.) Please tell me how?</em></font></p>
    <p align="center">Make Check Payable <img
    src="../gifs/letter.gif" width="33" height="24"> and Return
    To:</p>
    <p align="center"><strong>The Center for Medical Ethics &amp;
    Mediation<br>
    1081 Camino del Rio South, Suite 106<br>
    San Diego, CA 92108-3545</strong></p>
    <div align="center"><center><table border="2"
    cellpadding="10" cellspacing="4" width="75%"
    bordercolor="#FFFF00" bordercolordark="#808080"
    bordercolorlight="#FFFF00">
        <tr>
            <td><font face="arial, helvetica" size="-1">This workshop is specifically
            designed for healthcare professionals. &#149; The
            challenges experienced in today&#146;s rapidly
            changing healthcare service requires an ethical and
            conflict-positive environment. &#149; If you are
            looking to acquire skills that are relevant to these
            challenges, then this is the best investment for your
            time and energy. &#149; If your organization is
            preparing for a JCAHO Survey, then do not miss this
            opportunity to learn from other seasoned
            professionals and educators. &#149; Recently, the
            Third Report of the Pew Health Professions Commission
            customer satisfaction and management of ethical
            issues as top priorities for revitalizing the health
            professions for the 21rst Century. &#149; Register
            today!</font></td>
        </tr>
    </table>
    </center></div>
    <p align="center"><font size="4"><strong>Workshop Faculty</strong></font></p>
    <p align="left"><font color="#008000"><strong>Robert J.
    Wagener, M.A., M.Div</strong>.</font> - Is the President and
    Founder of the Center for Medical Ethics and Mediation. He is
    a seasoned clinical ethicist, bringing nearly 20 years of
    experience to his present position. He serves as a consultant
    for the Ethics Committees for UCSD Medical Center: UCSD Home
    Care, Vencor Hospital &amp; San Diego Hospice. Recent
    publications include a co-authored article: &quot;The impact
    of Mediation Training of Healthcare Manager&#146;s Management
    of Conflict,&quot; a follow up study of San Diego
    Children&#146;s Hospital &amp; Health Center professional
    mediation training in May 1995. Robert is listed on panels
    for the San Diego and Las Vegas Office of the American
    Arbitration Association, and he has mediated over 500 cases,
    many in the San Diego Superior and Municipal Courts. Recent
    large corporate trainings conducted by Robert include:
    PacifiCare of California and Kaiser Permanente of Southern
    California.</p>
    <p align="left"><font color="#008000"><strong>Steven M.
    Kuriga, P.A.-C., M.S.</strong></font> - Is the Administrator
    of Mission Hills Medical Group in San Diego and familiar with
    managed care conflicts. He is currently on the Editorial
    Advisory Boards of both the Medical-Legal Practice Advisor
    and the Work-Comp Advisor publications. Steve has extensive
    training in mediation and healthcare negotiation and recently
    returned to San Diego from the Advanced Program in Health
    Care Negotiation and Conflict Resolution at the Harvard
    School of Public Health.</p>
    <p align="left"><font color="#008000"><strong>Mileva Saulo,
    Ed.D. R.N.</strong></font> - Is Assistant Professor and
    Director of the Graduate Nursing Program at the University of
    Southern California, Department of Nursing, Administration
    and Case management. Recent publications include a
    co-authored article: <a href="../news/9612.htm#conflict">&quot;How
    Good Case Managers Make Tough Choices: Ethics and
    Mediation,&quot;</a> (the Journal of Care Management, The
    Official Journal of the Case Management Society of America),
    February and April, 1996.</p>

    <p align="center"><font size="-2"><em>This certificate meets
    the 1991 California Dispute Resolution Program Act:<br>
    Statutes and Regulations (Section 3622)</em></font></p>
    <p align="left"><font size="-2">Contact Hours:<br>
    This activity approved, for 14.0 contact hours: California
    Board of Registered Nurses. Provider numbers 10539 and MCLE
    credit by the State Bar of California. This activity conforms
    to the standards for approved education activities prescribed
    by the rules and regulations of the State Bar of California
    governing minimum legal education. In case of non-attendance
    by registrants, a $35 registration fee will be withheld; a
    full refund, will be made in case of cancellation by
    provider.<br>
    <br>
    </font></p>
</blockquote>

<blockquote>
    <p align="center"><font size="2" face="arial, helvetica"><img
    src="../gifs/bronze.gif" width="50%" height="4"></font></p>
</blockquote>

<p align="center"><a href="../news/index.html"><font size="2"
face="arial, helvetica">newsletter</font></a><font size="2"
face="arial, helvetica"> | </font><a
href="../contacts/index.html"><font size="2"
face="arial, helvetica">contacts</font></a><font size="2"
face="arial, helvetica">| </font><a href="../papers/das.html"><font
size="2" face="arial, helvetica">papers</font></a><font size="2"
face="arial, helvetica"> | </font><a href="index.html"><font
size="2" face="arial, helvetica">conferences</font></a><font
size="2" face="arial, helvetica"> | </font><a
href="../about.html"><font size="2" face="arial, helvetica">about
consumer news</font></a></p>

<p align="center"><a href="../index.html"><font size="2"
face="arial, helvetica"><img src="../gifs/sleft.gif" vspace="5"
width="36" height="32"><br>
CNews Home Page</font></a></p>

<p align="center"><font size="2" face="arial, helvetica"><img
src="../gifs/bronze.gif" width="50%" height="4"></font></p>

<p align="center"><font size="2" face="arial, helvetica">Consumer
News<br>
P.O. Box 41<br>
Cooper Station<br>
New York, NY 10026-0041<br>
</font><font size="2" face="Arial">Last modified: <!--webbot
bot="Timestamp" startspan s-type="REGENERATED"
s-format="%m/%d/%y" -->01/14/97<!--webbot bot="Timestamp"
i-checksum="13750" endspan --><br>
</font><a href="mailto:cnews@aidsnyc.org"><font size="2"
face="arial, helvetica">cnews@aidsnyc.org</font></a><font
size="2" face="arial, helvetica"><br>
copyright  1997 Consumer News</font></p>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-283</DOCNO>
<DOCOLDNO>IA093-001003-B003-10</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/cnews/news/9701.html 199.29.141.24 19970121124053 text/html 106010
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:34:55 GMT
Server: NCSA/1.5.1
Last-modified: Sat, 18 Jan 1997 13:27:45 GMT
Content-type: text/html
Content-length: 105825
</DOCHDR>
<html>
<head>
<title>Consumer News: January 1997</title>
</head>

<body bgcolor="#FFFFFF" text="#A62A2A" link="#856363">

    <p><a href="index.html"><img src="../gifs/ban1.gif"
    alt="[logo]" width="528" height="99"> </a></p>

<blockquote>

    <p><font color="#008000" face="arial, helvetica"><b>VOL. 2 NO. 1
    JANUARY 1997</b></font><b> </b></p>
    <p><font size="-1" face="arial, helvetica"><b>Contents:<br>
    </b></font><a href="#health_care"><font size="-1" face="arial, helvetica"><b>AIDS-Related
    Kaposi's Sarcoma</b></font></a><font size="-1" face="arial, helvetica"> <br>
    <b>- </b></font><a href="#health_care_pathogenesis"><font
    size="-1" face="arial, helvetica"><b>Pathogenesis</b></font></a><font
    size="-1" face="arial, helvetica"> <br>
    - </font><a href="#health_care_clinical_findings"><font
    size="-1" face="arial, helvetica"><b>Clinical Findings</b></font></a><font
    size="-1" face="arial, helvetica"> <br>
    - </font><a href="#health_care_pathology"><font size="-1"
    face="arial, helvetica"><b>Pathology</b></font></a><font size="-1"
    face="arial, helvetica"><br>
    <b>- </b></font><a href="#health_care_clinical_staging"><font
    size="-1" face="arial, helvetica"><b>Clinical Staging</b></font></a><font
    size="-1" face="arial, helvetica"> <br>
    - </font><a href="#health_care_treatment"><font size="-1"
    face="arial, helvetica"><b>Treatment</b></font></a><font size="-1"
    face="arial, helvetica"><br>
    </font><a href="#conflict_resolution"><font size="-1"
    face="arial, helvetica"><b>Ethics &amp; Epidiency On The Line? When in
    Doubt. . .</b></font></a><font size="-1" face="arial, helvetica"> <br>
    </font><a href="#nutrition"><font size="-1" face="arial, helvetica"><b>All
    Grains Are Not Created Equal</b></font></a><font size="-1"
    face="arial, helvetica"> <br>
    </font><a href="#lifestyles"><font size="-1" face="arial, helvetica"><b>A
    Mother's Diary of Her Son's Struggle with AIDS - Part 5</b></font></a><font
    size="-1" face="arial, helvetica"> <br>
    </font><a href="#book_review"><font size="-1" face="arial, helvetica"><b>Fair
    Division: From Cake-Cutting to Dispute Resolution<br>
    </b></font></a><a href="#entertainment"><font size="-1"
    face="arial, helvetica"><b>Worth Reviewing<br>
    </b></font></a><a href="#notices"><font size="-1" face="arial, helvetica"><b>Notices</b></font></a><font
    size="-1" face="arial, helvetica"><b><br>
    <br>
    <br>
    </b></font></p>
    <p><a name="health_care"><font color="#000000" face="arial, helvetica"><i>Feature
    - Health Care<br>
    </i><b>AIDS-RELATED KAPOSI'S SARCOMA</b></font></a> </p>
    <p><font size="-1" face="arial, helvetica"><i>By Miguel Sanchez, M.D.</i></font></p>
    <p><font size="-1" face="arial, helvetica">Kaposi's sarcoma is a
    multicentric, malignant neoplasia suspected to be derived of
    virally-transformed microvascular tissue. The disease was
    reported in 1872 by the Hungarian physician, Moritz Kaposi<sup>1*</sup>,
    who described indolent-growing vascular tumors in elderly men
    from Eastern European and Mediterranean backgrounds, often of
    Jewish descent. The lesions often remained confined to the
    skin of the lower extremities and patients rarely died from
    this &quot;classic&quot; form of Kaposi's sarcoma. In the
    late 1950's, the occurrence of Kaposi's sarcoma in younger
    adults from Central Africa was recognized and epidemiologic
    studies subsequently showed high prevalences in some
    countries in Central Africa<sup>2</sup>. In these patients,
    nodular, florid and infiltrative forms were reported, as well
    as a lymphadenopathic form in children and young adults<sup>3</sup>.
    In the 1970's the disease was found to develop in some
    patients receiving organ transplants who were treated with
    potent immunosuppressive drugs. Notably, in some of these
    cases, the tumors regressed spontaneously when the doses of
    immunosuppressive agents were lowered or discontinued<sup>4</sup>.</font>
    </p>
    <p><font size="-1" face="arial, helvetica">In 1981, Dr. Alvin
    Friedman-Kien from New York University published his landmark
    report describing disseminated Kaposi's sarcoma in
    immunocompromised gay men. These were the earliest reported
    cases of AIDS<sup>5</sup>.</font> </p>
    <p><font size="-1" face="arial, helvetica"><img src="../gifs/sanchez.jpg"
    alt="Photo of Dr. Michael Sanchez" align="left" hspace="10"
    vspace="1" width="186" height="296"></font><font size="-1"
    face="arial, helvetica">The predominance of Kaposi's sarcoma in gay men
    was recognized early in the AIDS epidemic, at which time it
    was the initial presentation in approximately half of men who
    became infected through sex with other men, but in only 4&#37; of
    AIDS cases acquired by intravenous drug use <sup>6</sup>.
    However, the proportion declined to 30&#37; between 1984 and 1987
    and continued to fall, possibly as a result of more
    widespread use of safer sex protection or more effective
    viral suppression by antiviral drug regimens<sup>7</sup>. <br>
    </font></p>
    <p><a name="health_care_pathogenesis"><font size="-1"
    face="arial, helvetica"><b>Pathogenesis</b></font></a> </p>
    <p><font size="-1" face="arial, helvetica">Kaposi's sarcoma is an
    infectious disease caused by the human herpesvirus 8 (HH-8),
    also known as Kaposi's sarcoma-herpes virus (KSHV)<sup> 7 1/2</sup>.
    This recent discovery is of monumental significance since
    antiviral agents can now be developed to eradicate or at
    least cease replication of the virus. The virus is present as
    an intact latent genome in Kaposi's sarcoma tissue, but
    replicates in the peripheral blood mononuclear cell of the
    patients (8 1/2). Expression of viral RNA has been found by
    the polymerase chain reaction (PCR) technique in 89.7&#37; of 29
    specimens of fresh Kaposi's sarcoma tissue<sup>8</sup>. In
    one study, HH-8 was detected with a nested PCR technique in
    64&#37; of HIV-infected gay men and 23&#37; of HIV-uninfected healthy
    men. Over 5 years, 43&#37; of men concomitantly infected with HIV
    and HH-8 developed Kaposi's sarcoma<sup>9</sup>. In another
    study, six of eleven (55&#37;) HIV-infected patients with HH-8 in
    their peripheral blood mononuclear cells developed
    clinically-evident Kaposi's sarcoma within 30 months<sup>10</sup>.
    However, the absence of detectable virus in white blood cells
    does not completely exclude future development of Kaposi's
    sarcoma, possibly because current testing is not sensitive
    enough. Approximately 9&#37; of patients with Kaposi's sarcoma
    test negative for HH-8<sup>9,10</sup>. The virus is rarely
    detected in throat swabs and sputum, but is commonly found in
    semen<sup>11</sup>. It appears to be sexually transmitted and
    anal intercourse may be a highly risky form of transmission.
    Notably, some HIV-seronegative gay men have developed
    epidemic Kaposi's sarcoma<sup>12</sup>. HIV-infected women
    rarely develop Kaposi's sarcoma, implying that vaginal or
    oral transmission is uncommon or that female sex hormones,
    such as <b>human chorionic gonadotropin</b>, suppress
    development of lesions<sup>14</sup>. Vertical transmission
    from mother to child has been reported<sup>14 1/2</sup>. The
    virus has also been found in body-cavity-based lymphomas,
    Castleman tumors and rarely in vascular proliferative lesions
    (15-15 4/8). The mechanisms by which vascular proliferation
    is induced or stimulated is not yet known. One possible
    inducer is <b>platelet activating factor</b>, which is
    produced and secreted by Kaposi's sarcoma cells. The cells
    also have receptors and high-affinity-binding-sites for this
    chemokine which can activate vascular endothelial cells and
    induce angiogenesis<sup>16</sup>. Another implicated agent is
    <b>interleukin-6</b> which is copiously produced by the tumor
    cells and in turn stimulates the tumor to grow<sup>17</sup>.
    Also, <b>Oncostatin M</b>, which is produced by activated T
    cells, is the most potent stimulator of Kaposi's sarcoma cell
    proliferation known to date and has been shown to cause
    vascular smooth muscle cells to change into spindle cells
    that resemble those of Kaposi's sarcoma<sup>18</sup>. Other
    implicated endothelial growth factors include basic
    fibroblast growth factor, interleukin-1, and tumor necrosis
    factor<sup>19-22</sup>.</font> </p>
    <p><font size="-1" face="arial, helvetica">HIV may directly influence the
    development of Kaposi's sarcoma. Male mice transgenic for the
    <b>tat gene </b>of the HIV virus develop Kaposi's
    sarcoma-like tumors with spindle cells that produce
    interleukin-6<sup>23</sup>. Although the origin of the
    spindle cells that are charachteristic of Kaposi's sarcoma
    has not yet been determined, the evidence deeply implicates
    the endothelial cells which line blood vesels<sup>23.5</sup>.</font><font
    face="arial, helvetica"> </font></p>
    <p><font size="-1" face="arial, helvetica">The following chart adapted
    from a report by Gallo and his colleagues illustrates a
    possible mechanism through which viruses and cytokines
    interact to cause Kaposi's sarcoma<sup>24</sup>. </font></p>
    <div align="center"><center><table border="1" width="80%">
        <tr>
            <td align="center">&nbsp;</td>
            <td align="center" width="14%">&nbsp;</td>
            <td align="center" width="14%"><font size="-1"
            face="arial, helvetica">Tat, IFN-gamma </font></td>
            <td align="center" width="14%">&nbsp;</td>
            <td align="center" width="14%">&nbsp;</td>
            <td align="center" width="14%">&nbsp;</td>
            <td align="center" width="15%">&nbsp;</td>
            <td align="center" width="15%">&nbsp;</td>
        </tr>
        <tr>
            <td align="center">&nbsp;</td>
            <td align="center" width="14%">&nbsp;</td>
            <td align="center" width="14%">&nbsp;</td>
            <td align="center" width="14%">&nbsp;</td>
            <td align="center" width="14%"><font size="-1"
            face="arial, helvetica">Fibroblast</font><font size="-1"> </font></td>
            <td align="center" width="14%">&nbsp;</td>
            <td align="center" width="15%">&nbsp;</td>
            <td align="center" width="15%">&nbsp;</td>
        </tr>
        <tr>
            <td align="center">&nbsp;</td>
            <td align="center" width="14%"><font size="-1"
            face="arial, helvetica">Lymphocytes</font></td>
            <td align="center" width="14%">&nbsp;</td>
            <td align="center" width="14%"><font size="-1"
            face="arial, helvetica">growth factor </font></td>
            <td align="center" width="14%">&nbsp;</td>
            <td align="center" width="14%"><font size="-1"
            face="arial, helvetica">Neoangiogenesis</font></td>
            <td align="center" width="15%">&nbsp;</td>
            <td align="center" width="15%">&nbsp;</td>
        </tr>
        <tr>
            <td align="center"><font size="-1" face="arial, helvetica"><b>HIV</b></font></td>
            <td align="center" width="14%">&nbsp;</td>
            <td align="center" width="14%"><font size="-1"
            face="arial, helvetica">Oncostatin M </font></td>
            <td align="center" width="14%"><font size="-1"
            face="arial, helvetica">Spindle cells</font></td>
            <td align="center" width="14%"><font size="-1"
            face="arial, helvetica">IL-6 </font></td>
            <td align="center" width="14%"><font size="-1"
            face="arial, helvetica">Spindle cell</font><font size="-1"> </font></td>
            <td align="center" width="15%">&nbsp;</td>
            <td align="center" width="15%">&nbsp;</td>
        </tr>
        <tr>
            <td align="center">&nbsp;</td>
            <td align="center">&nbsp;</td>
            <td align="center">&nbsp;</td>
            <td align="center">&nbsp;</td>
            <td align="center">&nbsp;</td>
            <td align="center">&nbsp;</td>
            <td align="center">&nbsp;</td>
            <td align="center"><font size="-1" face="arial, helvetica">proliferation</font></td>
        </tr>
        <tr>
            <td align="center">&nbsp;</td>
            <td align="center"><font size="-1" face="arial, helvetica">Macrophages</font></td>
            <td align="center"><font size="-1" face="arial, helvetica">IL-1,
            TNF</font></td>
            <td align="center"><font size="-1" face="arial, helvetica">FGF</font></td>
            <td align="center">&nbsp;</td>
            <td align="center">&nbsp;</td>
            <td align="center"><font size="-1" face="arial, helvetica">Fibroblast
            and</font><font size="-1"> </font></td>
            <td align="center">&nbsp;</td>
        </tr>
        <tr>
            <td align="center">&nbsp;</td>
            <td align="center">&nbsp;</td>
            <td align="center">&nbsp;</td>
            <td align="center">&nbsp;</td>
            <td align="center"><font size="-1" face="arial, helvetica">PGDF<br>
            TGF</font></td>
            <td align="center">&nbsp;</td>
            <td align="center">&nbsp;</td>
            <td align="center"><font size="-1" face="arial, helvetica">endothelial
            cell</font><font size="-1"> </font></td>
        </tr>
        <tr>
            <td align="center">&nbsp;</td>
            <td align="center">&nbsp;</td>
            <td align="center">&nbsp;</td>
            <td align="center">&nbsp;</td>
            <td align="center"><font size="-1" face="arial, helvetica">IL-6</font></td>
            <td align="center">&nbsp;</td>
            <td align="center">&nbsp;</td>
            <td align="center"><font size="-1" face="arial, helvetica">proliferation</font><font
            size="-1"> </font></td>
        </tr>
    </table>
    </center></div><p><a name="health_care_clinical_findings"><font
    size="-1" face="arial, helvetica"><b>Clinical Findings</b></font></a>
    </p>
    <p><font size="-1" face="arial, helvetica">The course of
    &quot;epidemic&quot; Kaposi's sarcoma is rather
    unpredictable. A single or few lesions may remain unchanged
    for months or years or even disappear, but the disease is
    more frequently aggressive.</font><font face="arial, helvetica"> </font></p>
    <p><font size="-1" face="arial, helvetica">The <b>skin</b> is the most
    commonly affected organ. The earliest clinically evident
    lesion is a flat, non-palpable, well-demarcated, cyanotic,
    pink <i>macule or patch</i>. While initially the lesion may
    blanch under direct pressure, it soon becomes nonblanchable.
    The neoplasm, subsequently, grows horizontally and vertically
    becoming thicker and raised and developing into a palpable <i>plaque</i>
    measuring from 0.5 to 3 cm in diameter. The color is red to
    dark purple, except in dark-skinned individuals, in whom the
    lesions are usually dark brown. Early plaques may be soft and
    have a spongy feel but eventually become firm and hard. The
    tumors are not usually painful, but large skin lesions may
    become tender specially in the soles, impairing ambulation.
    On the trunk, the tumors are often oval and follow skin lines
    so that they appear to be distributed along oblique lines.
    Edema is common in lesions of the feet and periorbital areas.</font>
    </p>
    <p><font size="-1" face="arial, helvetica">In some lesions, the vertical
    growth approximates the width resulting in <i>nodules</i>. If
    the lesion is contained below the skin surface, it is
    referred to as a <i>subcutaneous nodule</i>. The <i>nodular
    form</i> of Kaposi's sarcoma is characterized by one or more
    nodules that vary in size from millimeters to centimeters. In
    the <i>florid</i> form, the lesions are large, exophytic and
    vegetating, may necrose and may involve underlying tissue
    including bone. In the <i>infiltrative</i> form, the lesions
    spread aggressively through the skin and into underlying
    tissues. The <i>lymphadenopathic</i> form affects primarily
    peripheral lymph nodes and other lymphatic tissue.</font><font
    face="arial, helvetica"> </font></p>
    <p><font size="-1" face="arial, helvetica">Involvement of other organs is
    frequent. In one report 29&#37; of AIDS patients were found to
    have asymptomatic and unsuspected internal tumors, mostly
    involving the lymph nodes and gastrointestinal tract,
    although no lesions were present in their skin (28), and in
    another report, 90&#37; of autopsied AIDS patients were found to
    have internal organ involvement (28.5).</font><font
    face="arial, helvetica"> </font></p>
    <p><font size="-1" face="arial, helvetica">Oral lesions are common. The
    oral mucosa is the initial site in 10 to 15&#37; of cases<sup>25</sup>.
    The lesions may bleed or become painful, specially if they
    ulcerate or infiltrate the gingiva. Soft palate and
    pharyngeal lesions may cause obstruction. Many of these
    patients have lesions in other areas of the <b>gastrointestinal
    tract</b>. Involvement of the <b>gastrointestinal tract </b>has
    been reported in up to 40&#37; of Kaposi's sarcoma patients with
    asyptomatic cutaneous tumors<sup>26</sup>. A combination of
    symptoms that may include early satiety, obstipation,
    diarrhea, malabsorption and fecal incontinence may develop,
    but more commonly the lesions produce minor or no symptoms
    and rarely ulcerate, become infected, cause hemorrhage or
    obstruct the bowel.</font><font face="arial, helvetica"> </font></p>
    <p><font size="-1" face="arial, helvetica"><b>Lymph node</b> involvement<b>
    </b>has been reported in 30 to 95&#37; of cases<sup>27</sup>. The
    tumor-infiltrated nodes become enlarged but are usually
    asymptomatic. However, in some cases infiltration of the
    lymphatics and lymph nodes cause obstruction of the lymphatic
    flow resulting in swelling of the face or extremities and
    eventually gross lymphedema. Severe lymphedema, resulting in
    fibrotic, nonpitting gross swelling of the extremities and
    even pelvis, genitalia and lower abdomen, is a disabling and
    life-threatening complication<sup>29</sup>.</font> </p>
    <p><font size="-1" face="arial, helvetica"><b>Pulmonary </b>involvement
    develops in about 30&#37; of cases and is the cause of death in
    about 25&#37; of these patients<sup>30</sup>. Without treatment
    the median survival is between two and six months, therefore,
    aggressive treatment with systemic chemotherapy is
    recommended<sup>31</sup>.</font> </p>
    <p><font size="-1" face="arial, helvetica">Unlike involvement of other
    organs which is frequently asymptomatic, pulmonary Kaposi's
    sarcoma usually produces symptoms, such as cough,
    bronchospasm, dyspnea and respiratory failure leading to
    death. The more common radiologic findings are diffuse
    interstitial infiltrates, hilar adenopathy (in about half the
    cases), pleural effusions and a reticular-nodular pattern (in
    a third)<sup> 32</sup>. A gallium scan helps to differentiate
    Kaposi's sarcoma from opportunistic infections, since the
    tumors do not absorb radioactive gallium and fluoresce, but
    bronchoscopy is the definitive diagnostic procedure. Biopsies
    respiratory tract lesions are avoided because of the risk of
    profuse bleeding. In general, the lungs are not involved
    until the malignancy is advanced, but involvement is common
    when more than fifty skin lesions are present<sup>33</sup>.
    It has been suggested that the presence of a tumor on the tip
    of the nose is associated with increased risk of pulmonary
    disease<sup>34</sup>.</font> </p>
    <p><font size="-1" face="arial, helvetica">Involvement of the spleen,
    bone marrow, bones, liver or brain is unusual and of other
    organs rarer still<sup>35</sup>. <br>
    </font></p>
    <p><a name="health_care_pathology"><font size="-1"
    face="arial, helvetica"><b>Pathology</b></font></a> </p>
    <p><font size="-1" face="arial, helvetica">A biopsy is indicated to
    exclude bacillary angiomatosis, benign or malignant
    fibrohistiocytomas, arteriovenous malformations, angiomas and
    other vascular or infectious lesions that may resemble
    Kaposi's sarcoma. The clinical diagnosis is confirmed by a
    small (3-4 mm) tissue biopsy. The expertise of a pathologist
    experienced in diagnosing skin lesions is critical specially
    in early lesions where the findings may be subtle. Well
    developed tumors are composed of spindle-shaped cells,
    aggregates of blood vessels, jagged vascular spaces channels
    lined with large endothelial cells, extravasated red blood
    cells and an infiltrate composed predominantly of mononuclear
    cells<sup>36</sup>.<br>
    </font></p>
    <p><a name="health_care_clinical_staging"><font size="-1"
    face="arial, helvetica"><b>Clinical Staging</b></font></a> </p>
    <p><font size="-1" face="arial, helvetica">A clinical staging system has
    been devised, which is primarily helpful to randomize cases
    in clinical research studies<sup>37</sup>. It should be noted
    that the presence of internal organ involvement other than
    the lung does not alone worsen the prognosis.<br>
    </font></p>
    <div align="center"><center><table border="0" width="100%">
        <tr>
            <td valign="top" width="20%"><font size="-1"
            face="arial, helvetica"><i>TUMOR<br>
            EXTENT</i></font><font face="arial, helvetica"> </font></td>
            <td valign="top" width="17%;"><font size="-1"
            face="arial, helvetica">Stage I <br>
            Stage II<br>
            Stage III<br>
            Stage IV</font><font face="arial, helvetica"> </font></td>
            <td valign="top" width="429"><font size="-1"
            face="arial, helvetica">&lt; 10 lesions in the skin or limited
            to 1 anatomic area <br>
            &gt; 10 skin lesions or present in more than 1
            anatomic area<br>
            Generalized mucocutaneous with lymph node involvement<br>
            Internal organ involvement</font><font face="arial, helvetica"> </font></td>
        </tr>
        <tr>
            <td valign="top" width="135"><br>
            </td>
            <td valign="top" width="163">&nbsp;</td>
            <td valign="top" width="429">&nbsp;</td>
        </tr>
        <tr>
            <td valign="top" width="135"><font size="-1"
            face="arial, helvetica"><i>SYMPTOMATIC</i></font><font
            face="arial, helvetica"> </font></td>
            <td valign="top" colspan="2" width="592"><font
            size="-1" face="arial, helvetica">A - Asymptomatic<br>
            B - Systemic signs such as weight loss and fever</font><font
            face="arial, helvetica"> </font></td>
        </tr>
    </table>
    </center></div><p><a name="health_care_treatment"><font
    size="-1" face="arial, helvetica"><b>Treatment</b></font></a> </p>
    <p><font size="-1" face="arial, helvetica">Even in the <b>disseminated</b>
    cases, Kaposi's sarcoma is usually not the primary cause of
    death in AIDS patients<sup>38</sup>. Although more therapies
    are available, the survival of patients with Kaposi's sarcoma
    has not changed significantly since it was first reported.
    Because most AIDS patients do not die of complications of
    Kaposi's sarcoma, treatment, with the exception of cases with
    pulmonary involvement, does not significantly improve
    survival<sup>35</sup>. The most valuable predictor of
    survival is the absolute CD<sub>4</sub> lymphocyte count and
    only 30&#37; of patients with counts below 100 cells/ml survive
    for one year<sup>39</sup>. However, treatment markedly
    improves morbidity, disability and disfigurement. Local
    therapies are more effective when tumors are small and
    limited to the skin. A recent comparison of local therapies
    concluded that based on success rate, cost and convenience,
    cryotherapy, intralesional chemotherapy and radiation had
    advantages over surgical excision and laser surgery<sup>40</sup>.
    <br>
    </font></p>
    <p><a name="health_care_surgery"><font size="-1" face="arial, helvetica"><b>Surgery</b></font></a>
    </p>
    <p><font size="-1" face="arial, helvetica"><i>Excision</i> under local
    anesthesia is an option when tumors are small to medium size,
    and few in numbers<sup>41</sup>. However margins must be
    obtained to avoid recurrences and in order to close the wound
    with stitches a larger amount of skin beyond the wound must
    be excised. Sutures are removed in 5 to 7 days on the face
    and 10-14 days on the rest of the body. Alternately, the
    tumor can be scooped out and the wound can be left open to
    granulate, but closure will require several weeks depending
    on the wound size and area of the body.</font> </p>
    <p><font size="-1" face="arial, helvetica">A <i>CO</i><sub><i>2</i></sub><i>
    laser </i>beam destroys the tumor leaving an open wound that
    will heal slowly. Its use has been limited by clinicians'
    concern that tissue evaporation by this laser creates a plume
    that contains infectious HIV and HSV-8 viral particles. There
    are no reports of transmission of either one of these viruses
    through the plume, but facial and intranasal human
    papillomavirus infection in physicians and nurses who ablated
    warts by this method has been well documented<sup>42</sup>.</font>
    </p>
    <p><font size="-1" face="arial, helvetica">The <i>pulse dye laser</i>
    which is selective for vascular lesions improve appearance
    temporarily, but tumors recur within 3 months<sup>43</sup>.</font>
    </p>
    <p><font size="-1" face="arial, helvetica"><i>Photodynamic therapy</i> is
    a still investigational but potentially effective technique
    in which a porphyrin derivative, such as Photofrin, becomes
    concentrated into the tumor following intravenous injection<sup>44</sup>.
    The tumor is then treated with a l70 or 120 J/cm<sub>2</sub>
    dose of 630 nm wavelength laser light that is absorbed by the
    dye, causing destruction of the tumor. Response rates are
    higher for small tumors in the head and neck area. Patients
    often note that the extent of the wound is larger than
    anticipated and are disappointed with the resulting cosmetic
    appearance of the scar and long-lasting pigmentation<sup>44</sup>.</font>
    </p>
    <p><font size="-1" face="arial, helvetica"><i>Cryotherapy </i>with liquid
    nitrogen spray destroys tissue by freezing, resulting in
    destruction of small, flat tumors and cosmetic improvement of
    thicker tumors by creating superficial scarring that
    camouflages<sup>45</sup>. However unless a brisk immunologic
    reaction associated with the injury destroys the deeper
    portion of the tumor, regrowth becomes visible within a few
    months. The procedure produces stinging which is tolerated
    for several seconds. If longer duration of freezing is
    required, the lesion should be locally anesthetized.
    Freeze-thaw cycles are repeated at least once. The freezing
    time depends on the size and depth of the tumor but is at
    least seven seconds per cycle.<br>
    </font></p>
    <p><font size="-1" face="arial, helvetica"><b>Local Chemotherapy</b></font>
    </p>
    <p><font size="-1" face="arial, helvetica">Chemotherapeutic agents may be
    administered into the lesion. The advantage of <i>intralesional
    chemotherapy</i> is that the medication is injected right
    into the tumor so small amounts are needed and systemic
    effects are almost always absent. However, this method is
    only an option when a small number of isolated lesions are
    present in the skin or oral mucosa. Complications are local
    and consist of pain, irritation, blistering and ulceration.
    The most commonly-used agent used is vinblastine, which is
    injected in small amounts with a very fine 30-gage needle
    into the surface of the tumor<sup>46</sup>. In order to avoid
    severe adverse effects, concentrations of .01 - .02 mg/ml for
    lesions on the face, genitalia, oral mucosa and distal
    extremities and .02-.03 mg/ml for lesions on other skin areas
    are recommended. If side effects are bearable, the
    concentration may be increased by .01 mg/ml per treatment up
    to .06 mg/ml. A total of 1.5 mg per treatment may be injected
    into the lesions without concern of systemic toxicity. Enough
    medication is injected superficially into the dermis to
    produce blanching. Deeper injections cause subcutaneous
    inflammation with excessive scarring. It is important to
    inject evenly throughout the lesion and not to concentrate on
    the center of the lesion or annular lesions will remain.
    Injections are repeated every 2 weeks until there is only
    pigmentation and no clinical evidence of tumor. High
    responses are obtained and even when remissions persist for
    several months, retreatment is effective<sup>47</sup>. In
    oropharyngeal and laryngeal lesions injected with .01 or .02
    mg/ml every 4 to 5 weeks until resolution or stabilization of
    lesions, complete regression was achieved in 62&#37; (16
    lesions), 20&#37; to 50&#37; reduction in size in 15&#37; (4 lesions),
    less than 20&#37; reduction in 12&#37; (3 lesions), no response in 8&#37;
    (2 lesions) and continued growth in 4&#37; (1 lesion). Eleven
    patients complained of pain unrelieved by acetaminophen and
    five had ulcerations<sup>48</sup>.</font> </p>
    <p><font size="-1" face="arial, helvetica">Vinblastine, a closely-related
    chemotherapeutic agent, has been administered successfully by
    <i>iontophoresis</i>, a process in which the medication is
    dissolved in water and added into a machine that produces a
    current that promotes absorption<sup>49</sup>. However,
    commercially-available machines are not adequate for
    treatment of most body areas.</font> </p>
    <p><font size="-1" face="arial, helvetica">Combinations of <i>cryotherapy
    and intralesional vinblastine </i>may accelerate resolution
    compared to either treatment alone, and may result in
    improved cosmetic appearance.</font> </p>
    <p><font size="-1" face="arial, helvetica"><i>Intralesional bleomycin </i>is
    less frequently used but in one study of 13 patients with 134
    lesions, 43&#37; of the lesions had complete responses and 44&#37;
    had partial response. Only one patient complained of pain and
    the lesions healed with hypopigmentation. As usual, small,
    flat lesions responded best and responses did not correlate
    with CD<sub>4</sub> counts<sup>50</sup>. On the other round,
    a combination of bleomycin-dimethyl sulfoxide applied
    topically was not effective<sup>51</sup>.</font> </p>
    <p><font size="-1" face="arial, helvetica"><i>Intralesional injections of
    3&#37; sodium tetradecyl sulfate, a sclerosing agent, </i>eradicated
    all 15 oral mucosal tumors in 12 patients and decreased the
    size of an additional 12 lesions in 12 other patients by 80&#37;.
    Even a single treatment may be effective. After 18 months no
    regrowth was present. Pain, ulceration and scarring are
    complications but responses are obtained within 2 to 3 weeks<sup>52</sup>.</font>
    </p>
    <p><font size="-1" face="arial, helvetica"><i>Intralesional injections of
    interferon-alfa </i>in doses between 3 to 5 million units
    three times a week improve the treated lesions and, through a
    systemic effect, the non-injected lesions as well<sup>53-55</sup>.
    Smaller doses have been used but their effectiveness remains
    undetermined.</font> </p>
    <p><font size="-1" face="arial, helvetica">The number of patients treated
    with <i>intralesional recombinant granulocytes-macrophage
    colony stimulating factor</i> (GM-CSF) is too small for
    conclusion<sup>56</sup>. The agent appears promising but it
    is investigational and expensive.</font> </p>
    <p><font size="-1" face="arial, helvetica">Topical <i>9-cis retinoic acid
    gel</i> in a 0.1&#37; concentration is an investigation treatment
    which is convenient and promising for small, flat lesions and
    may have a role as adjunctive treatment in thicker lesions.
    The gel is applied three to four times daily directly to the
    lesions and responses are observed in approximately 6 weeks.
    In one study treatment produced a partial (at least 50&#37; of
    treated lesions became flat) or complete (all treated lesions
    became flat) remission in 30&#37; of patients<sup>57</sup>.
    Various degrees of irritation with a combination of erythema,
    edema, blistering, exfoliation and excoriations are common.
    The mechanism of action may be inhibition of interleukin-6
    receptor alpha chain expression, causing a diminished
    response by the tumor to IL-6, a cytokine which is secreted
    by Kaposi's sarcoma cells and acts as an autocrine growth
    factor. Superficial flat lesions have the best response.<br>
    </font></p>
    <p><font size="-1" face="arial, helvetica"><b>Radiotherapy</b></font>
    </p>
    <p><font size="-1" face="arial, helvetica">Kaposi's sarcoma is very
    radiosensitive and local treatment with even a single or
    fractionated 800 cGy dose produced high rates of local
    palliation<sup>58</sup>. Doses of 15 to 30 Gy local field
    irradiation achieved complete remission in 85&#37; of treated
    lesions<sup>59</sup>. In a recent report of 594 lesions in 65
    patients, complete remission was achieved in 86.5&#37; and
    reduction in size or pain palliation in another 13.5&#37;. After
    2 to 9 months, only 2.4&#37; of successfully treated lesions had
    relapsed<sup>60</sup>. The dose of radiation should be
    adequately fractionized over several treatments in order to
    decrease the severity of inflammation due to acute
    radio-dermatitis. Doses of 15.2 Gy for oral lesions, 20 Gy
    for lesions on the conjunctiva eyelids, lips, hands, feet,
    penis and perianal region, and 30 Gy for other cutaneous
    sites have been found effective with acceptable tolerance (61
    1/2). Acral lesions in the hands, feet and genitals are
    specially prone to radiodermatitis. In black patients
    pigmentation may be pronounced and considered by some
    patients cosmetically unacceptable. Pigmentation in light
    skin patients is less and lightens over time. The scarring
    produced by radiation tends to worsen after approximately ten
    years and the skin can become not only hypopigmented but
    thin, atrophic and even ulcerated. These are important
    considerations now that advances in the treatment of HIV
    infection continue to prolong survival. Radiotherapy of
    lesions in mucosal surfaces, such as the mouth, has a high
    rate of severe mucositis and exacerbation of oral infection.<br>
    </font></p>
    <p><font size="-1" face="arial, helvetica"><b>Systemic Treatments</b></font>
    </p>
    <p><font size="-1" face="arial, helvetica">Systemic chemotherapy and
    interferon are the treatments of choice when the tumors are
    disseminated, rapidly progressive, diffusely infiltrative,
    cause symptomatic internal organ disease, involve lung or
    brain, result in lymphedema that is unresponsive to radiation
    or cause intraoral or pharyngeal pain and discomfort and are
    unresectable. Systemic chemotherapy and interferon can
    /result in bone marrow suppression with neutropenia, which
    predisposes to the development of opportunistic infections.
    These and other systemic treatments also may impair hepatic
    or renal function which intensifies the toxicities of
    antiretroviral and prophylactic agents<sup>61</sup>.<br>
    </font></p>
    <p><font size="-1" face="arial, helvetica"><b>Interferon</b></font>
    </p>
    <p><font size="-1" face="arial, helvetica">High doses of interferon alfa
    in the range of 20 to 36 million units daily achieve 17&#37;
    complete response, 26&#37; partial response, and 16&#37; minor or
    stable response. Doses less than 20 million units daily
    induce complete, partial and minor or stable responses in 2&#37;,
    5&#37; and 20&#37; of cases, respectively<sup>62</sup>. Interferon
    efficacy is greater in patients with CD<sub>4</sub>
    lymphocyte counts greater than 200 cells/ml. Response rates
    of over 45&#37; have been achieved in patients with high CD<sub>4</sub>
    counts (62.5).</font> </p>
    <p><font size="-1" face="arial, helvetica">Doses as low as 3 million
    units three times a week may be effective when antiretroviral
    agents such as zidovudine are added. While some patients with
    CD<sub>4</sub> counts below 250 mg/mm<sup>2</sup> may
    respond, remissions are confined to patients with CD<sub>4</sub>
    counts higher than 250 cells/mL<sup>2 65</sup>. High dose
    treatment is highly intolerable. Flu-like symptoms, such as
    fever, chills, myalgias, diarrhea, headache, fatigue and
    weight loss occur to some degree in all patients and can be
    debilitating. Pretreatment with aspirin or ibuprofen
    diminishes the severity of these symptoms. Many patients
    develop tachyphylaxis during the first weeks of therapy, but
    some never do. Depression, abnormal liver function, anemia,
    transient neutropenia, abdominal pain, paresthesias, skin
    tachycardia, hypotension, and ulceration at the injection
    site are other adverse effects. <br>
    </font></p>
    <p><font size="-1" face="arial, helvetica"><b>Systemic chemotherapy</b></font>
    </p>
    <p><font size="-1" face="arial, helvetica">Systemic chemotherapy should
    be reserved for patients with advanced disease not only
    because of the adverse effects associated with it but also
    because patients eventually become refractory to the
    treatment regimens. Bleomycin is the most common
    non-liposomally encapsulated agent used singly. At a dose of
    10-15 mg/m<sup>2</sup> every 2 weeks, responses of up to 50&#37;
    have been reported <sup>64</sup>. It is a good option in
    patients with myelo-suppression. In these patients,
    vincristine at a dose of 2 mg weekly is an alternative and
    responses between 20 and 50&#37; have been achieved <sup>65</sup>.
    Vincristine can cause peripheral neuropathy which is a
    potential adverse effect of other medications that patients
    may be taking (ddC, thalidomide, Dapsone and others).
    However, one study using ddC and a regimen that included
    vincristine, did not find higher numbers of neuropathy. The
    closely related vinblastine has similar effectiveness at a
    dose of 0.05 to 0.1 mg/kg/week and is not so neurotoxic, but
    can cause myelosuppression<sup>66</sup>. Since both drugs
    have similar modes of action, toxicities associated with each
    can be diminished by alternating vincristine and vinblastine
    on alternate weeks<sup>67</sup>. The combination of
    vincristine (2 mg weekly) and bleomycin (10 mg/m<sup>2</sup>
    every 2 weeks) is more effective than either drug alone with
    response rates of up to 100&#37; and is tolerated by granulory
    topenic patients<sup>68</sup>.</font> </p>
    <p><font size="-1" face="arial, helvetica">Etoposide (VP-16) can be given
    orally at a dose of 50 mg daily with a response rate of up to
    75&#37;, however, its acceptability is hampered by the resulting
    alopecia<sup>69</sup>.</font> </p>
    <p><font size="-1" face="arial, helvetica">Doxorubicin is considered to
    be the most active chemotherapeutic agent against Kaposi's
    sarcoma and is administered intravenously every two weeks at
    a dose of 20 mg/m<sup>2 70</sup>. The combination of
    adriamycin (doxorubicin), vincristine and bleomycin (AVB) is
    the treatment by which the newer chemotherapeutic agents have
    been measured<sup>71</sup>. Toxicity is significant and
    concurrent administration of growth factors to stimulate
    production of white and red blood cells may be necessary.
    Other agents used include dactinomycin, dacarbazine,
    teniposide, and epirubicin<sup>72</sup>. Doxorubicin attached
    to microscopic globules of fat called liposomes (Doxil), is
    highly concentrated after intravenous injection by the
    growing tumor, possibly due to leakage through its
    inefficient blood vessels. As a result, 5 to 11 times greater
    concentrations of the drug are achieved into the lesions and
    the half life of the drug is increased five-fold, enhancing
    effectiveness, and decreasing toxicity, since other tissues
    do not take up liposomes so readily<sup>73</sup>. The overall
    response to the AVB combination is about 60&#37;<sup>74</sup>
    while the overall response rate to liposomally-encapsulated
    doxorubicin nears 100&#37;<sup>75</sup>.</font> </p>
    <p><font size="-1" face="arial, helvetica">In one clinical trial
    involving severely immunocompromised patients (median CD<sub>4</sub>
    counts of 13.5 cells/mm<sup>3</sup>) with extensive,
    progressive Kaposi's sarcoma treated with liposomal
    doxorubicin, 43.2&#37; had a partial response, 55.9&#37; were stable
    and only one patient had disease progression compared to 110
    patients receiving the combination doxorubicin (in
    nonliposomal form), bleomycin and vincristine in whom 24.5&#37;
    had a partial response, 67.3&#37; were stable and 6 patients had
    progression of their disease (3 patients left the study)<sup>76</sup>.
    In another study in which 8 patients were treated with a dose
    of 20 mg/m<sup>2</sup> monthly for 6 months and 10 mg/m<sup>2</sup>
    thereafter, clinical complete remissions were seen in 5
    patients and partial responses in 3. While relapses occurred
    following discontinuation of therapy, partial responses were
    again obtained with retreatment<sup>77</sup>.</font> </p>
    <p><font size="-1" face="arial, helvetica">As Doxil,
    liposomally-encapsulated daunorubicine (Daunoxome) is also
    effective in patients who have become refractory to other
    chemotherapeutic agents, possibly by overcoming P.
    glycoprotein-associated drug resistance. At doses of 40 mg/m<sup>2</sup>
    escalated to 60 mg/m<sup>2</sup>, if no response occurs,
    response rates of 80&#37; are achieved<sup>78</sup>. The dosing
    of doxorubicin has been limited by toxicity of heart muscle
    when the total cumulative dose approaches 550 mg/ml, or even
    less if patients risk factors for heart disease or have been
    treated with certain chemotherapeutic agents<sup>79</sup>.
    While the liposomally-encapsulated forms of doxorubicin and
    donorubicin produce less nausea, alopecia, and fatigue,
    myelosuppression remains a significant problem. Other serious
    adverse effects include neutropenia<sup>80</sup>.</font> </p>
    <p><font size="-1" face="arial, helvetica"><i>Paclitaxil</i>, an
    inhibitor of microtubule assembly, that stabilizes
    microtubule polymerase, produced partial responses with
    remissions of approximately two months in 18 patients with
    advanced disease<sup>81</sup>. Remarkable improvement in some
    severe cases have been reported. Neutropenia, cutaneous
    eruptions, fever and eosinophilia are encountered as adverse
    effects. Chemotherapy has been enhanced by the concommitant
    use of human granulocyte-monocyte colony stimulating factor
    (Gy-CSF), which protect patients from developing dangerous
    levels of neutropenia (81 1/2).</font> </p>
    <p><font size="-1" face="arial, helvetica"><i>Oral 9-cis retinoic acid</i>
    is being evaluated alone and in combination with
    interferon-alfa. The initial dose of 60 mg/m<sup>2</sup>/d is
    gradually raised to 140 mg/m<sup>2</sup>/d over 5 weeks.
    Partial remissions in 4 and minor response or stabilization
    in 10 patients were obtained in one study<sup>82</sup>. The
    most frequent major side effect is headache, which may be
    accompanied by skin flushing. Practically all patients
    complain of dry skin, lips, eye and nose.
    Hypertriglyceridemia, hypercalcemia, liver tests elevations
    and, rarely, rhabdomyolysis may occur. Intermittent all trans
    retinoic acid administered every other week in combination
    with interferon alfa-2a is currently being evaluated, but in
    the doses previously administered has not been promising
    (82.5).<br>
    </font></p>
    <p><font size="-1" face="arial, helvetica"><b>Human chorionic
    gonadotropin (HCG)</b></font> </p>
    <p><font size="-1" face="arial, helvetica">Intramuscular injections of
    HCG above 150,000 IU three times a week have resulted in
    significant tumor regression in treated patients.
    Unfortunately this investigational treatment is inordinately
    expensive, costing upwards of $36,00 annually (82 8/9).<br>
    </font></p>
    <p><font size="-1" face="arial, helvetica"><b>Antiviral agents</b></font>
    </p>
    <p><font size="-1" face="arial, helvetica">The nuleotide inhibitors
    appear to have no direct significant activity against
    Kaposi's sarcoma, although rarely, cases of tumor regression
    are observed when therapy with these agents is instituted
    presumably due to the resulting improvement in immune
    function and decreased HIV viral loads. This response may
    explain why zidovudine improves the effectiveness of lower
    doses of interferon. In this manner they may also enhance the
    effectiveness of chemotherapy. Zidovudine, however, is
    myelosuppressive and may have to be substituted for another
    antiretroviral agent in some cases.</font> </p>
    <p><font size="-1" face="arial, helvetica">Patients on the intravenous
    antiherpetic agent, <i>foscarnet </i>have been reported to
    have a 70&#37; reduced risk of developing Kaposi's sarcoma.
    Remissions have been reported in some patients with early
    disease. However, HH-8 continues to be detected in peripheral
    blood mononuclear cells during foscarnet therapy<sup>82</sup>.
    In an open-label study, 3 out of 5 patients had remission
    that lasted over one year following foscarnet treatment. The
    results of larger studies are pending, but the data must be
    interepreted cautiously as some of the responders were being
    simultaneously treated with antiviral regimens that included
    protease inhibitors. Treatment with injections of <i>immunoglobulin</i>,
    which has been reported to have some activity in classic
    Kaposi's sarcoma, may be reconsidered because of its
    antiviral properties<sup>83</sup>. While regressions have
    been reported in some patients after starting treatment with
    zidovudine and other antiretroviral agents, these cases are
    not common. However, clinicians have noted significant tumor
    regressions and remissions in some patients after initiation
    of treatment with antiviral regimens that include protease
    inhibitors. <br>
    </font></p>
    <p><font size="-1" face="arial, helvetica"><b>Extracorporeal Perfusion
    Hyperthermia</b></font> </p>
    <p><font size="-1" face="arial, helvetica">Raising the core body
    temperature to 42 degrees Celsius for one hour with
    extracorporeal perfusion and ex vivo blood heating to 49
    degrees C was found to cause tumor regression that persisted
    for at least four months in approximately half of treated
    patients. However, complications include death from cardiac
    arryhtmias and cdentral nervous system hemorrhage and
    intravascular coagulopathy (83.5).<br>
    </font></p>
    <p><font size="-1" face="arial, helvetica"><b>Other Treatments</b></font>
    </p>
    <p><font size="-1" face="arial, helvetica">The search for agents which
    inhibit formation of blood vessels (antiagniogenesis therapy)
    has been intense. Such agents include<i> TNP-470</i>, a
    fumagillin analogue and pentosan polysulfate, a B-FGF
    inhibitor, which so far have been ineffective in the doses
    administered<sup>84-84.5</sup>. Other agents at early stages
    of investigation include <i>suramin, pentosan polysulfate
    (which inhibits B-FGF), antiestrogens</i>, <i>protein kinase</i>
    <i>and</i> <i>tyrosine kinase inhibitors</i>,<i> recombinant</i>
    <i>platelet factor 4</i>, <i>carboxyaminoimidazole</i>, <i>sulfated
    polysaccharide-peptidoglycan compounds </i>(86) and <i>metalloproteinase
    inhibitors</i><sup>85-88</sup>. Early clinical trials are
    also being conducted to evaluate reduce tumor growth by
    inhibiting cytokines, such as<i> basic fibroblast growth
    factor</i>,<i> oncostatin-M</i>, <i>interleukin-6 </i>and <i>tumor
    necrosis factor</i><sup>89-91</sup>. <i>Interleukin-4</i>, <i>platelet
    factor 4</i>, <i>pentoxifylline</i> and <i>TAT antagonists</i>
    may inhibit growth through their mitogenic action on Kaposi's
    sarcoma cells<sup>92,93</sup>. Optimism cannot be mustered
    from the results using the combination of interleukin 2 and
    interferon alfa (82 3/4) Infusions of<i> activated autologous
    CD8 T-cells and interleukin-2</i> resulted in partial
    regression in 2 patients but this highly investigational
    treatment is expensive, difficult to administer and toxic<sup>94</sup>.
    Data from studies using infusions of recombinant fusion toxin
    DAB486IL-2 are preliminary (94.5).<br>
    </font></p>
    <p><font size="-1" face="arial, helvetica"><b>Psychosocial effects</b></font>
    </p>
    <p><font size="-1" face="arial, helvetica">A major consequence of
    Kaposi's sarcoma is disfigurement. I have treated patients
    with facial lesions who had not attended a social function
    for months and had become recluse and depressed.
    Disfigurement is particularly devastating to gay men who may
    socialize in an environment in which youthfulness and
    attractiveness are highly valued. It is not appropriate to
    appraise a patient's reaction to the illness through the
    caregiver's values. It is more fruitful to understand the
    resulting emotional impact in terms of the magnitude by which
    the actual or perceived physical disfigurement or disability
    alters the patient's life. Even when patients feel well and
    are living active and productive lives, the lesions are
    stigmata which constantly remind patients and alert others of
    the underlying HIV infection. Social alienation and
    occupational discriminations with possible reduction in
    career status or loss of employment are often feared and
    commonly actualized. If anxiolytics or antidepressants are
    warranted, they should be prescribed, together with
    individual or group psychotherapy.<br>
    </font></p>
    <p><font size="-1" face="arial, helvetica"><b>Cosmetic Camouflage</b></font>
    </p>
    <p><font size="-1" face="arial, helvetica">Even successful treatment may
    leave temporary or permanent pigmentation and scarring, but
    cosmetics can be successfully used to camouflage the lesions.
    A moisturizer to the skin helps to apply the cosmetics more
    evenly. Application of a green foundation to red or purple
    lesions will counteract these colors. On top of the green
    foundation, another coat of foundation or powder, with a
    shade close to the patient's skin color, is evenly applied
    with a cosmetic sponge. The wider available camouflage
    cosmetics are Dermablend and Covermark. These are sold in
    several department stores, where a salesperson is usually
    available to provide on-hand instruction. Some persons may
    need to purchase two different shades in order to better
    simulate their skin color. Cosmetics by Fay Mendelsohn and
    Dermage are available only from the companies through
    mail-order. The Fay Mendelssohn powders blend well into the
    skin and are easy to apply. If cosmetics are applied to the
    beard area, the person must have closely shaved or the
    appearance will be bumpy and uneven.<br>
    </font></p>
    <p><font size="-1" face="arial, helvetica"><b>Conclusion</b></font>
    </p>
    <p><font size="-1" face="arial, helvetica">Presently, AIDS-related
    Kaposi's sarcoma is a chronic disease which requires
    different treatments at different stages of its course. It is
    important to be followed by physicians who are experienced in
    the available treatment modalities and who remain updated on
    the more recent advances and new investigational therapies. A
    recent study of general internists and family practitioners
    found that only 26&#37; of physicians detected and correctly
    diagnosed Kaposi's sarcoma despite being directed by the
    patients' histories to the affected body sites. Even the
    local modalities require experience and a finesse of
    technique in order to achieve optimal cosmetic results.</font>
    </p>
    <p><font size="-1" face="arial, helvetica">At Bellevue Hospital Center,
    we have established a special multidisciplinary clinic for
    the treatment of Kaposi's sarcoma which is staffed by a team
    of experienced virologists, dermatologists, oncologists,
    radiation oncologists, nurses and social workers. Every
    patient is evaluated by the entire team, which then discusses
    all aspects of the case before presenting the findings and
    recommendations to the patient. All approved, as well as new
    investigational treatments, are used so that patients can
    receive the most current and potentially effective treatment
    available. </font></p>
    <p><font size="-1" face="arial, helvetica">In our opinion, this is a
    unique model and ideal approach to the treatment of Kaposi's
    sarcoma.<br>
    </font></p>
    <p><font size="-2" face="arial, helvetica"><i>Miguel Sanchez, M.D. is an
    Assistant Professor at New York University's Department of
    Dermatology and directs the Dermatology Department at
    Bellevue Hospital Center. His area of subspecialization is
    cutaneous infectious disease. In 1983 he began the earliest
    specialty clinic for the treatment of HIV-related skin
    disease and in 1995 co-developed the muiltidisciplinary
    Karposi's sarcoma clinic. He has authored or co-authored over
    forty scientific publications and is currently the principal
    investigator of a major grant to educate primary care
    physicians about HIV infection. Recently he was a member of
    the advisory panel to the American Medical Association's
    Physician Guide to HIV Prevention and co-wrote the American
    Academy of Dermatology's treatment guidelines of care for
    cutaneous manifestation of HIV infection.<br>
    <br>
    <br>
    </i>* References (all footnotes in this article) are
    available upon request. Please e-mail request to </font><a
    href="mailto:cnews@aidsnyc.org"><font size="-2" face="arial, helvetica">Consumer
    News</font></a><font size="-2" face="arial, helvetica">.<br>
    <br>
    </font></p>
    <p><a name="conflict_resolution"><font color="#000000"
    face="arial, helvetica"><i>Confict Resolution <br>
    </i><b>Ethics &amp; Epidiency On The Line? When in Doubt. . .</b></font></a>
    </p>
    <p><font size="-1" face="arial, helvetica"><b>Questions to consider</b></font>
    </p>
<ul>
<li><font size="-1" face="arial, helvetica">What if I knew there would be
    a full audit of every decision we've made two years from now?</font>
  <li><font size="-1" face="arial, helvetica">What are the likely
    consequences of our decisions one year down the road? Three
    years down the road?</font>
<li><font size="-1" face="arial, helvetica">How will this decision effect
    our clients trust in us?</font>
<li><font size="-1" face="arial, helvetica">How many times have similar
    outcomes happened in the past and why?</font> 
<li><font size="-1" face="arial, helvetica">What if we had 10 times as
    much time in which to make the decision? Would I reccommend
    the same thing?</font> 
</ul>
<p><font size="-1" face="arial, helvetica"><b>Questions to break the
    self-interest zone</b></font></p>
<ul> 
<li><font size="-1" face="arial, helvetica">What is my intention?</font> 
<li><font size="-1" face="arial, helvetica">Have I invited and tolerated
    dissent?</font>
<li><font size="-1" face="arial, helvetica">What have I omitted from my
    analysis?</font>
<li><font size="-1" face="arial, helvetica">Have I listened to other
    opinions? Can I tolerate hearing them directly, or only
    filtered through company communication channels?</font> 
<li><font size="-1" face="arial, helvetica">Did we address the facts?
    Precisely what value are we creating?</font>
<li><font size="-1" face="arial, helvetica">At whose expense are we
    creating value?</font>
<li><font size="-1" face="arial, helvetica">Are our decisions or behaviors
    having a negative impact on the relationships involved?</font>
<li><font size="-1" face="arial, helvetica">Are we rewarding
    egodominant, relationshipdestroying attitudes in others?</font>
<li><font size="-1" face="arial, helvetica">What if we get caught?</font>
</ul>
<p><font size="-2" face="arial, helvetica"><b>Adapted from: Good
    Intentions Aside: A Managers's Guide to Resolving Ethical
    Problems. Laura L. Nash, (1993). Reprinted from Pontis
    Seasonal Bulletin Vol. 4, No. 3 Fall 1996. </b></font><a
    href="../conf/mediate.html"><font size="-2" face="arial, helvetica"><b>The
    Center for Medical Ethics Mediation</b></font></a><font
    size="-2" face="arial, helvetica"><b>, 181 Camino del Rio South, Suite
    106, San Diego, CA. 92108-3545. <br>
    </b></font><font size="-1" face="arial, helvetica"></font></p>

    <p align="center"><a name="nutrition"><font color="#000000"
    face="arial, helvetica"><b><i>Nutrition<br>
    </i></b></font><font color="#800000" size="5" face="arial, helvetica"><b><i>A</i></b></font><font
    color="#800000" face="arial, helvetica"><b><i>LL </i></b></font><font
    color="#800000" size="5" face="arial, helvetica"><b><i>G</i></b></font><font
    color="#800000" face="arial, helvetica"><b><i>RAINS </i></b></font><font
    color="#800000" size="5" face="arial, helvetica"><b><i>A</i></b></font><font
    color="#800000" face="arial, helvetica"><b><i>RE </i></b></font><font
    color="#800000" size="5" face="arial, helvetica"><b><i>N</i></b></font><font
    color="#800000" face="arial, helvetica"><b><i>OT </i></b></font><font
    color="#800000" size="5" face="arial, helvetica"><b><i>C</i></b></font><font
    color="#800000" face="arial, helvetica"><b><i>REATED </i></b></font><font
    color="#800000" size="5" face="arial, helvetica"><b><i>E</i></b></font><font
    color="#800000" face="arial, helvetica"><b><i>QUAL</i></b></font> </a></p>
    <p><font size="-2" face="arial, helvetica">By Cori Wolf</font> </p>
    <p><font size="-1" face="arial, helvetica">The United States Department
    of Agriculture's Food Guide Pyramid recommends that people
    consume six to eleven servings from the bread, grain, and
    cereal group each day. Nutrition professionals recommend that
    at least 3 of these servings be from whole-grains; the slogan
    &quot;Three Are Key&quot; is catching on like wildfire. You
    may be asking yourself... &quot;What is a whole
    grain?&quot;.... &quot;Why are whole grains are so
    important?&quot; ..... &quot;How do I know if I am eating
    whole grains?&quot;</font> </p>
    <p><font size="-1" face="arial, helvetica">First its necessary to
    understand why some grains are whole-grains and why others
    are not. Before grains are milled or refined they are all
    whole; they contain all the original components of a grain:
    the inner layer of germ, the middle layer called the
    endosperm, and the outer bran layer. When a grain is refined
    or milled the germ and bran layers are often removed and the
    starchy endosperm is what remains. For example, white rice
    and white bread only contain the endosperm.</font> </p>
    <p><font size="-1" face="arial, helvetica">Whole-grains are important
    because they are important dietary sources of antioxidants,
    phytochemicals, and fiber. Antioxidants such as vitamin E and
    selenium are important because they protect the body from
    cell damaging free radicals. Vitamin E interacts with free
    radicals making them more stable, thus reducing the damage it
    can do to your body's cells. Selenium is a cofactor for the
    enzyme glutathione peroxidase, this enzyme complex breaks
    down peroxides, which tend to become free radicals, and
    prevents the peroxides from damaging cell membranes and
    causing cell death. Whole-grains also supply zinc, B6, copper
    and iron. Deficiencies in these nutrients have been shown to
    impair the immune system.</font> </p>
    <p><font size="-1" face="arial, helvetica">Phytochemicals are a
    relatively new and hot topic. They are found in plant foods
    and grains but are not nutrients. Although they have no
    nutritive value, they are proposed to have great health
    benefits. There are thousands of phytochemicals in fruits,
    vegetables, legumes, and whole-grains, many of which have yet
    to be found. Two phytochemical found in whole-grains are
    phenols and phytates. Phenols which are found in oats may
    decrease the incidence of cancer and heart disease, as well
    as decrease oxidative stress, and phytates, which are
    abundant in whole grains, may prevent tumor growth.</font> </p>
    <p><font size="-1" face="arial, helvetica">Fiber has been well researched
    and the findings indicate that insoluble fiber has health
    benefits such as regularity, and increased protection against
    colon and rectal cancers. In addition, lignins, an insoluble
    fiber that is found in whole-grains, is thought to act as an
    antioxidant, and may decrease the incidence of colon and
    breast cancer. Soluble fiber has health benefits too. Soluble
    fiber decreases cholesterol, and helps to normalize blood
    sugar in diabetics by slowing absorption. Fiber may also
    prevent gut atrophy by providing energy and nutrients to the
    gut when metabolized to short chain fatty acids.</font> </p>
    <p><font size="-1" face="arial, helvetica">When grains are refined or
    milled they lose most of these valuable substances.</font> </p>
    <p><font size="-1" face="arial, helvetica">Therefore, when choosing your
    foods be a wise consumer and read the labels. When buying
    breakfast cereals look for &quot;whole-grain&quot; written on
    the package and check the ingredients to see if
    &quot;whole-grain&quot; is written before these grains: oats,
    barley, wheat, corn and rice. For example, look for
    whole-grain oats. When buying bread look for whole wheat
    bread. Also check that whole-grain flour is the first
    ingredient because whole-grain bread is not required to be
    100&#37; whole-grain. If several flours are listed in the
    ingredients the majority of them should be whole-grain flour.
    Brown rice is the only whole-grain rice, so buy brown rice as
    often as possible. Most pastas are not whole-grain pasta, but
    if you do see it on the shelves in your local supermarket or
    health food store be sure to buy it. Be adventurous and try
    other whole grains such as couscous, millet, kasha, cornmeal
    bulgur, and quinoa.</font> </p>
    <p><font size="-1" face="arial, helvetica">You are in charge of what food
    you put into your body so next time you are doing your food
    shopping read the labels and choose foods that will benefit
    your immune system and help prevent disease. Treat your body
    right and start increasing your whole-grain intake because
    all grains are not created equal.</font> </p>
    <p><font size="-2" face="arial, helvetica"><i>Cori Wolf MS, RD/CDN is a
    registered dietitian specializing in HIV nutrition. As the
    Nutritionist at the Comprehensive Care Center at Beth Israel
    Medical Center she provides nutrition counseling and
    education to people living with HIV and AIDS.</i></font> </p>
    <p><font size="-2" face="arial, helvetica"><i>The HIV Comprehensive Care
    Center is a group practice of HIV specialists providing a
    full continuum of care to patients with HIV related disease
    and AIDS. For more information call (212) 844-1800.<br>
    <br>
    <br>
    <br>
    </i></font></p>
    <p><a name="lifestyles"><font color="#000000" face="arial, helvetica"><i>Lifestyles
    <br>
    </i><b>A Mother's Diary of Her Son's Struggle with AIDS -
    Part 5</b></font></a> </p>
    <p><font size="-2" face="arial, helvetica">By Anna Nimos</font> </p>
    <p><font size="-1" face="arial, helvetica">Johnnie, a friend of Marc's
    who has a tattoo on his arm stating that he is HIV positive,
    offered to stay with a friend so that Marc's Father, Luis and
    his wife Carmen would have a place to stay. Luis and Carmen
    came over for several hours each morning and afternoon and
    evening. At one point when Bev was looking pretty worn out,
    they suggested that Bev spend the night at Johnny's apartment
    with Carmen, so she could get a good night's sleep and that
    Luis would sleep on the couch in Marc's room. Leon and I were
    sleeping in the bed in the living room. In the middle of the
    night I heard Marc calling, &quot;Mom.&quot; I went into the
    room and asked him what he wanted. He said he needed the
    urinal. I turned on the lights and held the bottle for him.
    Luis never woke up. It was just like it was when the kids
    were little. I always woke up at the slightest peep from one
    of the kids and he slept through. I woke him up and told him
    to get in bed with Leon and I stayed on the couch next to
    Marc the rest of the night. It never occurred to me that
    telling my ex-husband to sleep with my husband was a little
    unusual, but both of them took it in stride. </font></p>
    <p><font size="-1" face="arial, helvetica">Charlie was good at
    visualizations. He had taught me to do visualizations with
    Marc to reduce his nausea. The next morning, Charlie did a
    visualization with Marc of Mexico. I knew I could do a better
    one because I had really been there and besides, I had some
    ideas. I had been taking my breaks at a little Mexican
    restaurant just a few blocks away where I was becoming quite
    attached to their Marguerites and quesadillos. I had gotten
    to know the proprietress, a large Mexican woman with bleached
    hair, who liked to sit at my table with me sometimes and
    converse in Spanish. I asked her if I could borrow one of the
    tapes of Mexican music she always played in the restaurant.
    When I told her why I wanted it, she gave me three and told
    me to keep them as long as I needed them. </font></p>
    <p><font size="-1" face="arial, helvetica">The sun had started to shine
    more and more - a sign of spring in Seattle, I guess. It
    would shine in the window on to Marc's bed and sometimes it
    would get so warm we would have to pull the shades. On March
    23, the day we were to leave for Mexico, it was beautiful,
    about 75 degrees. I opened the windows wide and let the sun
    beat in on Marc's poor emaciated body. I put on the tape of
    Mexican music and I did such a detailed and beautiful
    visualization of our trip to Mexico that I almost believed it
    myself. Marc loved it and asked for it again several times.
    Bev loved it too and sat in on all of them until the time she
    got the giggles at one of my improvisations when the man
    upstairs flushed the toiled and the pipes made this loud
    rumbling noise. I worked the noise in by talking about a
    truck rumbling by full of chicken crates. </font></p>
    <p><font size="-1" face="arial, helvetica">Will was on tour and the
    promoters were giving him a hard time about canceling shows
    but he canceled several anyway and arrived in Seattle the
    same day Luis and Carmen arrived. </font></p>
    <p><font size="-1" face="arial, helvetica">The next few days were
    actually fun - Will, who could not deal with the throat pump
    or stand to see Marc in pain, played all of Marc's and his
    old time favorite records - Earth Wind and Fire, the
    Commodores, etc., ran out to get Marc any kind of food he
    mentioned having a taste for - Ethiopian, Mexican, Jolly
    Ranchers, popcycles. Marc couldn't swallow, but he could
    taste so he would mull it around in his mouth and spit it
    into a napkin. Will couldn't handle that either, but I was
    really proud of him. I could tell that this was very hard for
    him because he went to two or three AA meetings a day, and he
    spent his nights with a woman he knew who probably helped him
    forget for a few hours, but he did not turn to alcohol or
    drugs. And when he couldn't be there for Marc, at least he
    was there for us. </font></p>
    <p><font size="-1" face="arial, helvetica">Marc sort of held court during
    this time. Many of his friends and enemies came by or called.
    Without exception, he made his peace with everyone and let
    each know that he appreciated their involvement in the
    political struggles they had been engaged in, even if they
    had not seen eye to eye. </font></p>
    <p><font size="-1" face="arial, helvetica">Marc and Will planned the
    music he wanted Will to tape for his memorial service and
    told him when to play it - like in the beginning as people
    were gathering and then a special song or two between
    speakers, and at the end as people were leaving. He wanted
    some old songs of the Commodores and Earth Wind and Fire. I
    especially remember &quot;I'm easy, easy like Sunday
    morning&quot; because Marc had him play that a lot the next
    few days. </font></p>
    <p><font size="-1" face="arial, helvetica">Nancy Nystrom made a batch of
    cheese enchiladas - the best I ever tasted and even though
    they were terrible for my cholesterol and gave me heart burn,
    they were all I ate for several days. </font></p>
    <p><font size="-1" face="arial, helvetica">Marc kept complaining about
    his feet and legs and I used up all the charcoal things we
    got from the acupuncture clinic trying to apply heat to the
    soles of his feet. I went to the clinic to get some more and
    ran into Shad, the acupuncturist who usually treated Marc. I
    told her Marc was too sick to come and she offered to come by
    the house after the clinic closed. She came by about 2 p.m.
    and gently talked to Marc for a long time and then gave him
    his needles. Then she offered to give anyone else who wanted
    a treatment for stress. Everyone but Bev had a needle or two
    in their ears and she gave me a special one in the middle of
    my forehead. Soon a peaceful mood settled over everyone, even
    Bev. It was like the whole atmosphere in the apartment
    changed. When the physical therapist came to rub Marc's feet,
    she said she felt so good there that she didn't want to
    leave. I realized it was the same feeling I got when I would
    go with Marc to the clinic - somehow the vibrations released
    by the needles permeated the whole apartment. </font></p>
    <p><font size="-1" face="arial, helvetica">During this time, the house
    was full of his friends and family. One day some of the women
    were talking in the living room and somehow the subject of
    the &quot;G spot&quot; came up. I was adamant that I did not
    believe in it (and I still don't). I thought for sure it was
    some male fantasy (straight male fantasy, I mean). But most
    of the women in the room were lesbians and they seemed to
    have an open mind on the subject. Tracy mentioned a
    documentary video for rent at this sex shop, so we told her
    to get it. It was such a weird thing to do. We watched this
    purely pornographic - I think - video in the format of a
    documentary - watching women find their &quot;G spot&quot;
    and ejaculate and we argued whether or not it was real or
    fake, pornographic or educational, and we laughed our heads
    off. Leon was the only man in the room and he didn't know
    whether to stay or leave. Somehow Bev wasn't bothered by
    Leon's presence but she kept saying, &quot;If dad walks in,
    you have to turn this off immediately!&quot; </font></p>
    <p><font size="-1" face="arial, helvetica">So we had another moment of
    lightness, maybe hysteria, followed by the most serious time
    we had yet to face. Marc wanted to talk to us about assisted
    suicide before he got to the point he couldn't talk any more.
    He called in Heather, the nurse who had brought Marc the tea
    for his mouth ulcer. We hadn't seen much of her after that,
    but apparently Marc had asked her to be on his care team for
    the main reason that she had experience planning assisted
    suicide. Marc was in the tub and she and I and Tracy and
    Jennifer sat on the toilet and on the floor and around the
    tub and she told us what we needed to know; but one thing she
    made perfectly clear was that, as a nurse, she could not
    actually be involved. &quot;Yeah, right. Where were you all
    these months? And now you pop up and tell us how to help Marc
    die, but you're not willing to stick your neck out,&quot; I
    thought. I really resented her, but I kept it to myself. I'm
    glad, because in retrospect, what she was doing was exactly
    what Marc wanted her to do, and she probably had to keep some
    distance in order to do it. </font></p>
    <p><font size="-1" face="arial, helvetica">The next day Allison came over
    with her &quot;stash&quot; of Seconal for Marc and a book
    titled ------- that explained how to do it, listing the
    toxicity of various drugs, how to prepare them, how to ingest
    them. They thought the best way to go with Marc was to empty
    the Seconal capsules into a small amount of water and cook
    the mixture until it dissolved and then inject it into Marc's
    catheter at the same time giving him all of the Adivan we had
    and turning up his morphine as high as it would go. </font></p>
    <p><font size="-1" face="arial, helvetica">I was committed to helping
    Marc die if that was how he wanted to end his life, but I had
    a lot of questions and Heather and Allison didn't have the
    answers. For example, what if they did an autopsy on Marc and
    found this drug that had not been prescribed? Could we be
    accused of murder? What if the Seconal didn't dissolve and it
    plugged up his veins or burned his veins? I talked to Dr.
    Panther who said she could only talk hypothetically, but she
    felt the morphine we had was enough, but she advised that we
    should not send his body to her for study if he did decide to
    take the Seconal. She referred me to a man who worked with an
    organization affiliated with the Hemlock Society called the
    &quot;Foundation for Compassionate Dying.&quot; I called him
    and set up a meeting for him with the whole family - Leon,
    Bev, Will, Luis and Carmen. I wasn't going to do this alone
    if I could help it. </font></p>
    <p><font size="-1" face="arial, helvetica">As it turned out Ralph was a
    minister, but not a typical one. He believed in the right of
    the individual to determine how and when. He knew Allison and
    told us that she only began to be at peace since she had
    acquired her &quot;stash.&quot; Just knowing she could end
    her suffering whenever she chose, gave her the strength to go
    on, he said. Offering her stash to Marc was a true act of
    love. However, he told us we really didn't need it. He told
    us how to remove the leftover morphine and store it when the
    nurse hooked up a new pack - sometimes leaving as much as a
    third of the pack to be thrown away. He also showed us how to
    override the safety control on the computerized drip so that
    we could increase the dosage as high as we wanted too. </font></p>
    <p><font size="-1" face="arial, helvetica">The thing that comforted me
    most was that he said we should let Marc know we were ready
    to assist him and work out a clear signal for him to let us
    know when he was ready. He had gone into Marc's room before
    our meeting and Marc and he realized they knew each other.
    Marc seemed happy to see him. From that brief meeting, he
    told us he felt that Marc had a very short time left and that
    just knowing he had that option might be all he needed to let
    go and die without assistance. He also told us that the
    hospitals and the law looked the other way in situations like
    Marc's, and that there would be no investigation. We all
    agreed that we would help Marc die if that's what he really
    wanted and we talked about ways of sharing the burden
    (guilt?) like each of us shooting syringes of morphine into
    his catheter. </font></p>
    <p><font size="-1" face="arial, helvetica">The next morning I told Marc
    we were ready to assist him and asked if he was ready. He
    said no, not yet. I called Allison and told her she could
    have her stash back, that we had decided to use morphine and
    Adivan. I thanked her and told her I understood what offering
    Marc her &quot;insurance&quot; had meant. I felt very close
    to her. </font></p>
    <p><font size="-1" face="arial, helvetica">Up to that point, Marc had
    kept close control of his morphine. I controlled the pack but
    I only increased the dosage with his permission. Often he was
    in pain but didn't want me to give him the extra balis that I
    could by just hitting the button. Even with his caution, the
    dosage continued to gradually increase in amount and the time
    between the balises and regular computerized injections of
    morphine decreased. He wanted to stay awake a lot during the
    day so he could say good-by to the many friends who were
    stopping by. He especially wanted to find Dan, who was his
    last lover, but we couldn't find him. Dan had AIDS too and we
    don't know if he died or what happened to him. </font></p>
    <p><font size="-1" face="arial, helvetica">Marc's tongue and lips became
    more and more paralyzed and his speech was slurred to the
    point only Bev could understand him and she stayed near to
    translate on the phone or to his friends. We had bought a
    baby training cup to help him drink but that had quit working
    several days ago. His eyelids became paralyzed. They would
    not stay open by themselves and also would not close all the
    way. To keep them moist and comfortable we taped them closed
    when he slept. When he was awake, he held one eye open with
    his hand. When that became difficult for him, we would tape
    one lid up. Without the ability to blink, his eye would
    become dry so we had to let it close every few minutes and we
    also had eye drops. Finally we found some eye salve that made
    a film over his eyes that lasted through the night so we
    didn't need to continue to tape his eyes shut at night and we
    could tape it open for longer than a few minutes. Marc had
    several accidents at night because he was so doped up so we
    bought depends and pads to keep him dry and comfortable while
    he was sleeping. </font></p>
    <p><font size="-1" face="arial, helvetica">I again asked Marc if he
    wanted to talk about saying good-by and he again said no. He
    even seemed a little irritated with me for asking. I knew he
    was very close to loosing his ability to tell us what he
    wanted to do and I was afraid I would manipulate him past
    that point. I expressed this concern to Allison, and she said
    she felt Marc had made the decision not to have us help him
    die. She said once he knew we would help him, he probably
    relaxed and decided he could do it on his own. </font></p>
    <p><font size="-1" face="arial, helvetica">Charlie, the hospice nurse
    came by every day. On one of those days he gave me a paper
    that described what to look for when a person was ready to
    die. It said that the heart beat and breathing would slow
    down and blood pressure would drop. It also mentioned that
    when people are close to death, they would not be swallowing
    much and saliva would stay in the back of their throat,
    causing a rattle when they breath, referred to as a death
    rattle. Because Marc's throat was paralyzed, he had been
    rattling for several weeks. We used a pump to clear his air
    passage way, but it was getting harder and harder to do,
    especially because we didn't want to wake him and he was
    sleeping a lot. As far as his vital signs were concerned,
    Marc's heartbeat, breathing and blood pressure remained
    strong, so I felt that he still had time. That's why I
    encouraged Will to do the show that had already been booked
    on Saturday in Detroit. He would be back in less than 24
    hours and it would appease his booking agent, who was getting
    nasty and implying that he must be back on drugs, since he
    had canceled the last two shows. Will dedicated that show to
    Marc, his brother who had AIDS. </font></p>
    <p><font size="-1" face="arial, helvetica">On April 2nd Marc slept most
    of the day and the rattle in his throat was worse and had
    begun to really get to me. I felt like I had something in my
    throat and couldn't clear it. Contz sensed how stressed out I
    was and invited Leon and me over to his lover's house for
    dinner. Terry came by to stay with Bev and Luis and Carmen. </font></p>
    <p><font size="-1" face="arial, helvetica">It was a relief not to be able
    to hear Marc's labored breathing but still I couldn't relax
    even after two glasses of wine. As soon as it was polite to
    do so, I asked Contz to take us home. </font></p>
    <p><font size="-1" face="arial, helvetica">Luis and Carmen had retired to
    Johnnie 's for the night. Bev and Terry were watching TV.
    Marc's breathing hadn't changed. I injected his meds into his
    catheter, put salve in his eyes and kissed him. He didn't
    wake up. It was raining out and Terry asked if he could spend
    the night and walk home in the morning. He said he'd sleep on
    the couch in Marc's room so Bev could get some rest. Bev and
    I went to sleep on the bed in the living room. Leon slept on
    the floor in Marc's sleeping bag. Even though we were not in
    the room with Marc, we could hear every rattling breath
    through the monitor. He was breathing was very slow. </font></p>
    <p><font size="-1" face="arial, helvetica">Several hours later I woke up
    and listened for Marc's breathing. He was breathing fast and
    shallow but there was no rattling at all. I thought,
    &quot;good, he's breathing easier.&quot; Just then Bev, who
    was awake and listening as well, said, &quot;Mom, Marc sounds
    better.&quot; Then we both turned over and went back to
    sleep. A little later, I don't know how long, I woke up with
    a start. Everything was still. I didn't hear Marc breathing!
    I jumped out of bed and headed for Marc's room. Terry
    collided with me in the hall. &quot;I think you ought to
    check Marc,&quot; he said. </font></p>
    <p><font size="-1" face="arial, helvetica">I flew into the room and
    turned on the light. Marc's mouth was open. He wasn't
    breathing. His eyes were half closed, half open. One hand was
    propped awkwardly under his chin. I knew Marc was gone, but I
    took his face in my hands and kissed him all over his face,
    telling him I loved him. His face already felt different. I
    took his hand and it was cool and felt unreal. I remembered
    all the movies I'd seen and I gently reached up and closed
    his eyes, but they slowly opened again. I put my hand under
    his chin and closed his mouth, but when I took my hand away,
    it opened again. I went out and told Bev, Leon and Terry that
    Marc was dead. Dead. We all held each other but I don't think
    we cried just then.</font> </p>
    <p align="center"><font size="-1" face="arial, helvetica">MARC NIMOS</font>
    </p>
    <p align="center"><font size="-1" face="arial, helvetica">OCTOBER 24,
    1960 - APRIL 3, 1994</font> </p>
    <p><font size="-1" face="arial, helvetica">I thought I was finished but I
    want to write about the day he died; how we prepared him for
    his friends to see him; who came; what they brought; what
    they did; the last visitor and then when the finally came and
    took his body to Washington University and then to the
    crematorium.</font></p>

<p><a name="book_review"><font color="#000000" size="3"
    face="arial, helvetica"><b>Book Review<br>
    </b></font><font color="#000000" size="4" face="arial, helvetica"><b><b>Fair
    Division: From Cake-Cutting to Dispute Resolution</b></b></font></a></p>
    <p><font size="-1" face="arial, helvetica"><b>By James B. Boskey </b></font></p>
    <p><font size="-1" face="arial, helvetica"><b>Brams, Steven J. and
    Taylor, Alan., Cambridge University Press, 40 West 20th St.,
    New York, NY 10011-4211 (286pp $54.95(c) $18.95 p) 1996.</b></font></p>
    <p><font size="-1" face="arial, helvetica">The issues of fair division
    are fundamental to the field of dispute resolution, and
    everybody in the field is familiar with many of the classic
    examples from the biblical story of Solomon dividing the baby
    to the problem of how to divide a piece of cake and its many
    solutions. Most of the fair division concepts with which we
    are familiar are effective, but they have been identified
    only bay ad hoc means, and some of them may well be less fair
    the they appear.</font></p>
    <p><font size="-1" face="arial, helvetica">Brams and Taylor&#146;s
    approach to the problem of fair division from a rigorous
    mathematical viewpoint, seeking clear algorithm for effective
    division and clarifying the advantages and defects of various
    accepted process. Despite the intimidating sound of this
    approach and chapter titles, such as &quot;Proportionality of
    n&gt;2: the divisible case&quot; that similarly suggest that
    the material will be unintelligible to mere mortals, it turns
    out that the authors write clearly without demanding any
    great level of numeracy, and generally make the ideas they
    are presenting readily accessible to the interested reader.</font></p>
    <p><font size="-1" face="arial, helvetica">The problem of fair division
    is one which negotiators and neutrals deal every day. The
    fundamental issue in many circumstances is to create an
    &quot;envy free&quot; division where each party feels that he
    or she has gotten at least a proportional, and usually
    greater than proportional, share of the pie. This book
    suggests a wide range of means for accomplishing this many of
    which are likely not to have occurred to those who have made
    a serious study of the field.</font></p>
    <p><font size="-1" face="arial, helvetica">Amongst the interesting
    insights that the authors bring is a clarification of the
    reasons that envy free solutions are not necessarily parieto
    optimal. We have been encouraged in recent years, by the work
    of Howard Raiffa amongst others, to seek post settlement
    settlements that enhance the quality of agreed solutions.
    This book offers, inter. alia., one of the clearer
    explanations of why this is possible and implies means of
    encouraging such joint profit maximization after fair
    division is achieved.</font></p>
    <p><font size="-1" face="arial, helvetica">Some of the problems addressed
    here are not ones that have been, at least me, usually
    thought of as falling under the fair division rubric. The
    discussion of auctions and elections as a means of
    accomplishing fair division will be of special value to those
    in the public and complex dispute sectors, although some of
    the ideas can used in bilateral disputes as well.</font></p>
    <p><font size="-2" face="arial, helvetica"><b>James B. Boskey, Professor
    of Law, Seton Hall University is Editor of the Alternative
    Newsletter on Dispute Resolution. <br>
    </b></font><font size="-1" face="arial, helvetica"><br>
    <br>
    </font></p>
    <p><font color="#000000" size="4" face="arial, helvetica"><b><i><br>
    </i></b></font><a name="entertainment"><font color="#000000"
    size="3" face="arial, helvetica"><i>Entertainment<br>
    </i></font><font color="#000000" size="4" face="arial, helvetica"><b><i>WORTH
    RE-VIEWING</i></b></font><font size="4"> </font></a></p>
    <p><font size="-2" face="arial, helvetica"><b>By R J DeMasi</b></font></p>
    <p align="center"><font color="#000000" size="-1" face="arial, helvetica">I
    want to tell ya 'bout:</font></p>
    <div align="center"><center><table border="0" width="75%">
        <tr>
            <td valign="top" width="33%"><p align="center"><font
            size="-1" face="arial, helvetica"><i>Videos</i> </font></p>
            </td>
            <td valign="top" width="33%"><p align="center"><font
            size="-1" face="arial, helvetica"><i>Lost Prints/Footage</i> </font></p>
            </td>
            <td valign="top" width="33%"><p align="center"><font
            size="-1" face="arial, helvetica"><i>L Box Editions</i> </font></p>
            </td>
        </tr>
        <tr>
            <td valign="top" width="33%"><p align="center"><font
            size="-1" face="arial, helvetica"><i>Films</i> </font></p>
            </td>
            <td valign="top" width="33%"><p align="center"><font
            size="-1" face="arial, helvetica"><i>Restorations</i> </font></p>
            </td>
            <td valign="top" width="33%"><p align="center"><font
            size="-1" face="arial, helvetica"><i>Mini-Series</i> </font></p>
            </td>
        </tr>
        <tr>
            <td valign="top" width="33%"><p align="center"><font
            size="-1" face="arial, helvetica"><i>Documentaries</i> </font></p>
            </td>
            <td valign="top" width="33%"><p align="center"><font
            size="-1" face="arial, helvetica"><i>Colorizations</i> </font></p>
            </td>
            <td valign="top" width="33%"><p align="center"><font
            size="-1" face="arial, helvetica"><i>Concerts</i> </font></p>
            </td>
        </tr>
    </table>
    </center></div><p align="center"><font color="#000000"
    size="-1" face="arial, helvetica"><b>My Review:</b></font></p>
    <div align="center"><center><table border="0" width="80%">
        <tr>
            <td valign="top" width="30%"><font size="-1"
            face="arial, helvetica">Name: </font></td>
            <td valign="top" width="409"><font color="#FF0000"
            size="4" face="arial, helvetica"><b>Days of Heaven </b></font></td>
        </tr>
        <tr>
            <td valign="top" width="30%"><font size="-1"
            face="arial, helvetica">Year Released: </font></td>
            <td valign="top" width="409"><font color="#000000"
            size="3" face="arial, helvetica"><b>1978 </b></font></td>
        </tr>
        <tr>
            <td valign="top" width="30%"><font size="-1"
            face="arial, helvetica">Rating as of Release: </font></td>
            <td valign="top" width="409"><font color="#000000"
            size="3" face="arial, helvetica"><b>*** 1/2</b></font><font
            color="#000000" size="4"><b> </b></font></td>
        </tr>
        <tr>
            <td valign="top" width="30%"><font size="-1"
            face="arial, helvetica">Color/Tone: </font></td>
            <td valign="top" width="409"><font size="-1"
            face="arial, helvetica">Color </font></td>
        </tr>
        <tr>
            <td valign="top" width="30%"><font size="-1"
            face="arial, helvetica">Length Released: </font></td>
            <td valign="top" width="409"><font size="-1"
            face="arial, helvetica">95 Minutes </font></td>
        </tr>
        <tr>
            <td valign="top" width="30%"><font size="-1"
            face="arial, helvetica">Director: </font></td>
            <td valign="top" width="409"><font size="-1"
            face="arial, helvetica">Terrence Malik </font></td>
        </tr>
        <tr>
            <td valign="top" width="30%"><font size="-1"
            face="arial, helvetica">Cast: </font></td>
            <td valign="top" width="409"><font size="-1"
            face="arial, helvetica">Richard Gere, Brooke Adams, Sam Shepard,
            Linda Manz, Robert Wilke, Jackie Shultz and Stuart
            Margolin </font></td>
        </tr>
        <tr>
            <td valign="top" width="30%"><font size="-1"
            face="arial, helvetica">Special Note: </font></td>
            <td valign="top" width="409"><font size="-1"
            face="arial, helvetica">I've seen the original 128 minute
            version just recently (on video ), probably a rare
            find. </font></td>
        </tr>
    </table>
    </center></div><p align="center"><font color="#000000"
    size="-1" face="arial, helvetica"><b>My View:</b></font></p>
    <p><font size="-1" face="arial, helvetica">This depression era tale
    features both Richard Gere and Sam Shepard in one of their
    earliest films. </font></p>
    <p><font size="-1" face="arial, helvetica">Although low-key and
    slow-paced, this flick is a mesmerizing visual treat. Lush
    wheat fields dominate scenes of vagrant farm workers eking
    out a life in America during poor and desperate times. Here,
    we meet those brought together by such circumstances,
    particularly three vagabond workers whose only survival is
    traveling the country, mounting trains with hordes of
    laborers such as themselves. They are taken to farms in the
    middle of a still young America where they work for farm
    owners and their strawbosses. Two of the trio are young
    lovers ( Richard Gere and Brooke Adams ) who have found each
    other in the midst of this terrible background. They claim to
    all to be brother and sister ( and Gere tries to dispel any
    other thoughts as is witnessed by a food throwing fight with
    another worker who has caught on.) Gere oozes effective
    strength and brawl qualities which is also shown in an
    earlier scene. The actor always seems to excel in 'loose
    cannon' characterizations, really a master at 'chip on the
    shoulder' attitudes. </font></p>
    <p><font size="-1" face="arial, helvetica">The third in the close knit
    triad of characters is the eleven or twelve year old sister
    of Gere's. She (Linda Manz) is the surprisingly insightful
    narrator of the piece. In her 'grown up fast and tough'
    lingo, and continually puffing cigarettes whenever she can
    get them, Ms. Manz tells the tale from her perspective, with
    poignant bluntness, underscoring the hopelessness of their
    situation. </font></p>
    <p><font size="-1" face="arial, helvetica">Through their travels, the
    three come upon a farm owner (Sam Shepard) who, in short
    order, falls in love and marries Gere's companion. Gere (it
    seems their names were not prominent enough in the dialogue
    for me to easily remember) has, actually, given his secret
    approval to the Adams' character, agreeing to the alliance
    since he has given great to the balance of their prospects as
    opposed to what he considers to be Shepard's frail health and
    his land holdings which would naturally be his wife's should
    anything happen to him. All their interaction's with the
    farmer smack of their conning him, and he is, mostly naive,
    and honestly in love with the woman. Ms. Adams' is effective
    in showing the woman to be caught in a web and handles it
    with almost a smug confusion and searching attitudes leading
    to one realization. She is probably in love with both men. </font></p>
    <p><font size="-1" face="arial, helvetica">Enough said for laying the
    framework for this artistically well handled and physically
    beautiful film. I leave the rest for you to enjoy. There is a
    locust swarm, the ruination of the crops and a blazingly
    destructive fire, visually crackling and intense to cap the
    events. And there is quite a bit more story before the
    ending. </font></p>
    <p><font size="-1" face="arial, helvetica">I've recently seen the long
    version (found in video bargain pile, as I find most the more
    odd and interesting pieces which I add to my library). It is
    two hours and eight minutes. </font></p>
    <p><font size="-1" face="arial, helvetica">To my recollection, this
    version was never actually released. Although I liked the
    original 95 minute version which I saw on the big screen, I
    do remember that that edit clipped a lot of the narrative
    flow into 'not so sure why that happened?' story movements.
    The visual beauty was, however, consistent and dominating. It
    breathed perfect atmosphere into the story. That's what I
    remembered, and it's still there. The Cinematographer, quite
    deservedly, won an Academy Award. Good Viewing in either
    version. RJD<br>
    </font></p>
    <p><font size="-1" face="arial, helvetica"><b>Commentary:</b>
    Hi, Film Addicts! Since this is the first printing of my
    criticisms and comments about the film medium, I thought I
    might tell you a bit about myself. I am continually
    fascinated by our American legacy of everything put on film,
    especially since and because of which, we can all have access
    via videos. The plethora of culture given us through words
    and images is a continuum of greater understanding we can
    have for the asking, of who we were, who we are and who we
    hope to be. </font></p>
    <p><font size="-1" face="arial, helvetica">I'm constantly looking for any
    variations of classic films not generally available, and
    especially of thise not yet recognized as classic. I
    constantly look for the different productions, treatments and
    edits that may be in circulation but overlooked, somewhere.
    It's quite a coup to find them, (without paying a pretty
    penny to a video research service, although this has its
    place for hard finds). Do stay in touch with this column. <i>I'm,
    always interested in other film buffs who have discovered or
    happened upon, or are simply looking like me for lost prints,</i>
    <i>versions longer or shorter than those released, original
    color toning done in the thirties and forties, as well as
    films simply hard to find. In many cases just sharing the
    knowledge of the existence of some of these items will be
    rewarding for all concerned. RJ DeMasi<br>
    <br>
    <br>
    <br>
    <br>
    </i></font><a name="notices"><font color="#000000"
    face="arial, helvetica"><i>Notices</i></font> </a></p>
    <p><font size="-1" face="arial, helvetica">Consumer News can
    be found at: A Different Light Bookstore, AIDS Service Center
    of Lower Manhattan, Bellevue, Hospital Center, Bellvue
    Hospital Center, Beth Israel Medical Center-Comprehensive
    Care Center, Bronx AIDS Services, DAS Centers, Federation of
    Protestant Welfare Agencies, Federation of Puerto Rican
    Communities, Fort Green HIV Project, Gay Activists Alliance
    of New Jersey, Gay Men's Health Crisis, Harlem United, The
    Lesbian and Gay Community Services Center, The New York
    Public Library, North Central Bronx Hospital, Project
    Hospitality, The Queens Borough Public Library, South Bronx
    Action Group, Veterans Administration Medical Center
    Manhattan, and on the Internet at this web site you are
    currently viewing.</font></p>
    <p><font size="-1" face="arial, helvetica"><b>Win $100.00 -
    Care partners wanted for study on AIDS</b><br>
    Gay males who are currently caring for a partner with AIDS
    wanted for a study by Columbia University doctoral student.
    Its purpose is to design interventions which will help care
    partners cope with the complex and at times overwhelming
    tasks which caring for a partner with AIDS can entail. The
    first 75 participants will be entered in a lottery to win one
    $100.00 prize. For more information, please call: (718)
    237-4248 or E-mail </font><a
    href="mailto:gene.thegak.koski@worldnet.att.net"><font
    size="-1" face="arial, helvetica">gene.thegak.koski@worldnet.att.net</font></a><font
    size="-1" face="arial, helvetica"> </font></p>
    <p><a href="../conf/mediate.html"><font color="#804000"
    size="-1" face="arial, helvetica"><b>&quot;Successful Healthcare
    Conflict Resolution: Mediation &amp; Negotiation
    Training&quot;</b></font></a><font color="#804000"
    size="-1" face="arial, helvetica"> <br>
    March 7-9, 1997, Mission Valley, San Diego, CA. The Center
    for Medical Ethics &amp; Mediation, Spring 1997 Three Day
    Mediation Certificate Program</font></p>
    <p><a href="../conf/index.html"><font size="-1"
    face="arial, helvetica"><b>The 12th Annual Gay and Lesbian
    Addiction Studies</b></font></a><font size="-1"
    face="arial, helvetica"><br>
    Union Theological Seminary, 3041 Broadway at 121st St. in New
    York City Friday, April 11th, 1997 9:00 a.m. - to 5:00 p.m.
    Reconstructing Recovery: Healing Technologies for the 21st
    Century New Considerations and Approaches to the Substance
    Abuse Recovery Process. For more information contact the
    G.L.A.S. Conference Planning Committee c/o NYC Office of Gay
    &amp; Lesbian Health Concerns, 125 Worth St., Box 67, New
    York 10013, (212) 788 -4399.</font></p>
    <p><a href="../conf/ada.html"><font size="-1"
    face="arial, helvetica"><b>Mediation Training : Employment
    and the ADA</b></font></a><font size="-1"
    face="arial, helvetica">. Sunday, April 27, 1997, Arlington,
    VA, Tuesday, April 29, 1997, Newark, NJ. </font></p>
    <p><font size="-1" face="arial, helvetica"><b>Substance
    abuse therapy</b><br>
    Paul Matwiow, M.Div, CAC Pshychotherapist. Early Recovery
    Group for Gay Lesbian Bi and Trans Persons Thursday 6-7:30
    p.m. Beginning January 16th. (212) 349-2429 </font></p>
    <p><font size="-1" face="arial, helvetica"><b>Jobs &amp; Job
    Training</b><br>
    Consumer Information and Conflict Resolution Project (CICRP),
    is accepting resumes for several positions: Administrative
    Assistant, Financial Officer, Computer Specialist, Senior
    Editor, and Webmaster.</font></p>
    <p><font size="-1" face="arial, helvetica"><b>FROST'D is
    Seeking Volunteers</b><br>
    The mission of Foundation for Research on Sexually
    Transmitted Diseases (FROST'D) is helping homeless women
    whose activities on the street have put them at risk for HIV
    infection. FROST'D has a medical Center, two transitional
    housing programs, for people who are HIV positive and a court
    project for individuals charged with prostitution or various
    drug charges. 212-924-3733</font></p>
    <p><font size="-1" face="arial, helvetica"><b>Young
    People 14 to 21<br>
    </b>Out of School? In trouble? Homeless? Just Troubled?
    Join the Henry Street Settlement's Adolescents Against
    HIV/AIDS (A.A.H.A), Theater project. Stipend and Social
    Services are provided. Call, Rachel Beck, CSW: 212-254-3100.</font></p>
    <p><font size="-1" face="arial, helvetica"><b>GMHC Job
    Line</b>: 212/337-1910. Current job openings at GMHC
    updated weekly.</font></p>
    <p><font size="-1" face="arial, helvetica"><b>Multitasking
    Systems of NY, Inc. (MTS)</b>. 38 East 29th Street,
    Ninth Floor, New York, NY 10016. 212-679-8234.</font></p>
    <p><font size="-1" face="arial, helvetica"><b>Volunteers,
    Writers, Artists, Photographers</b> wanted for this
    publication. PWAs are encouraged to submit works for
    publication by Consumer News. Submit a sample of your work
    to: Consumer News, P.O. 41, Cooper Station, New York, NY
    10276-0041. Materials cannot be returned. No phone calls
    please.</font></p>
    <p><font size="-1" face="arial, helvetica"><b>Volunteers</b>
    wanted for Consumer information and Conflict Resolution
    Project, (CICRP). 212-387-0824.</font></p>
</blockquote>

<hr width="50%">

<p align="center"><a href="index.html"><img
src="../gifs/sleft.gif" alt="Back to Consumer News" vspace="5"
width="36" height="32"> <br>
<font size="-1" face="arial, helvetica">Consumer News Index</font></a></p>

<hr width="50%">

<p align="center"><a href="../index.html"><font size="-1">Consumer
News Home Page</font></a></p>

<p align="center"><font size="-1">P.O. Box 41<br>
Cooper Station<br>
New York, New York 10026-0041<br>
</font><font size="-1" face="arial, helvetica">Last modified: <!--webbot
bot="Timestamp" startspan s-type="REGENERATED"
s-format="%%d/%y" -->01/18/97<!--webbot bot="Timestamp"
i-checksum="13750" endspan --> </font></p>

<p align="center"><a href="mailto:cnews@aidsnyc.org"><font
size="-1">cnews@aidsnyc.org</font></a><font size="-1"> </font></p>

<p align="center"><font size="-1">copyright  1997 Kenneth Lowry</font></p>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-284</DOCNO>
<DOCOLDNO>IA093-001003-B003-31</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/cnews/news/9612.html 199.29.141.24 19970121124109 text/html 108481
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:35:12 GMT
Server: NCSA/1.5.1
Last-modified: Sun, 22 Dec 1996 17:31:52 GMT
Content-type: text/html
Content-length: 108296
</DOCHDR>
<html>
<head>
<title>Consumer News: December 1996</title>
</head>

<body bgcolor="#ffffff" text="#a62a2a" link="#856363"><font face="arial, helvetica" size=-1>

<p><a href="index.html"><img src="../gifs/ban1.gif" alt="[logo]"></a></p>

<h3>Vol. 1 No. 12 December 1996</h3>

<blockquote>

<p><b>Contents:<br>
<A HREF="#mc">Managed care and the current AIDS service delivery system: examining core values</A><br>
<A HREF="#conflict">How good case managers make tough choices: Ethics and Mediation, Part 2</A><br>
<A HREF="#housing">CUNY DRC and CICRP Facilitate Forum to Consider Public Policy on Housing for People Livng with AIDS</A><br>
<A HREF="#hud">A New Office at HUD Will Be the Focal Point for Department Policies Affecting People with Disabilities</A><br>
<A HREF="#health">Neurological disorders and people with HIV &amp; AIDS</A><br>
<A HREF="#nutrition">New age herbalists</A><br>
<A HREF="#recipe">Friendship bread recipe</A><br>
<a href="#entertainment">Entertainment: Metropolitan Museum of Art</a><br>
<a href="#books">Books: Tales from the Dragon Cave: Peace Making Stories for Everyone</a><br>
<a href="#lifestyles">Lifestyles: A Mother's Diary . . .Part-4</a><br>
<a href="#briefs">Consumer Briefs</a><br>
<a href="#editorial">Editorial</a><br>
<a href="#oped">OpEd: NATAF</a><br>
<a href="#notices">Notices</a></b></p>

<p><b><A NAME="mc">OpEd Feature</A></b></p>

<p><b>MANAGED CARE AND THE CURRENT AIDS SERVICE DELIVERY SYSTEM: EXAMINING CORE VALUES</b></p>

<p>AIDS advocates and providers must understand the values that are inherent in their own service delivery system and the managed care system and where those values collide/conflict to carry out core functions such as:</p>
<ul>
<li>assist consumers to participate in the managed care system as informed, aggressive consumers;
<li>advocate for reforms of the managed care system;
<li>assist clients to get the highest level of care out of the managed care system; 
<li>support clients through grievance and dispute resolution systems within the managed care system;
<li>engage in responsible decision making about the way their agency delivers/accesses services;
<li>engage in responsible decision making with consumers, Board of Directors, staff and volunteers about the future of their agency's mission and status as an independent entity;
<li>engage in responsible decision making about how and why to "get ready" for managed care;
<li>navigate changes in funding and service delivery cultures while maintaining consumer, staff and volunteer morale;
<li>advocate to maintain HIV/AIDS services that are fundamental and valued by consumers;
<li>effect changes in public policy as the managed care system becomes subject to challenge and change.
</ul>

<p>VALUES OF THE AIDS SERVICE DELIVERY SYSTEM</p>

<ol>
<li>create unlimited access to a wide array of medical and social services;
<li>advocate to break down barriers to access and utilization ("gatebuster" role);
<li>empower consumers to make treatment/service decisions and obtain these treatment/services choices "at will";
<li>promote consumer confidentiality;
<li>advocate for and create service systems where none existed (i.e. AIDS housing, needle exchange, harm reduction services, prevention and education);
<li>support programmatic/fiscal risk by encouraging development of "controversial program/services (i.e. needle exchange, peer education/outreach, experimental treatment information and access);
<li>develop new service options outside of traditional licensing and regulatory arenas (i.e. harm reduction services, supportive scatter site housing etc.);
<li>oppose institutionalization of homeless people with HIV/AIDS by demanding and creating supportive housing and other non-institutional housing options that are separate from the healthcare system;    
<li>advocate for access to homecare and ancillary services to enable frail consumers to remain in their own homes, if they choose, through death;
<li>advocate for funding that supports the actual cost of service delivery;
<li>advocate for flexible funding streams that can be "piggybacked" to enhance services/access (i.e. Ryan White funding, HOPWA, etc.);
<li>advocate for programs/services that are "cost effective" but more costly than minimum standard programs (i.e. supportive housing vs. shelter care)
<li>prioritize development of and access to care/services over cost analysis and program evaluation;
<li>support development of numerous "boutique" (i.e. single purpose agency) providers;
<li>develop services that are culturally/linguistically appropriate and support the creation of agencies/programs whose mission is to primarily serve subpopulations of the epidemic (i.e. people of color, adolescents, gay men, women, ex-offenders etc.)   
<li>oppose cutbacks or limitations in entitlements;
<li>accept non-traditional definitions of "family" in eligibility determination (i.e. gay/lesbian couples and domestic partners);
<li>advocate for speedy development of and access to experimental treatments regardless of cost;
<li>reward providers for maximizing consumer access and utilization;
<li>reward providers for 100% spending of contract/grant funds to provide services.
<li>support fragmented as well as coordinated service delivery;
</ol>

<p><b>VALUES OF THE MANAGED CARE DELIVERY SYSTEM</b></p> 
<ul>
<li>A. control cost of healthcare delivery system; 
<li>B. control utilization of "high end" services such as inpatient care, non-emergency use of emergency room services, laboratory and diagnostic services;
<li>C. manage and limit patient treatment choices through use of a "gatekeeper" system;
<li>D. reward providers who control utilization;
<li>E. promote less than 100% spend down of funding by allowing providers to keep "savings"; 
<li>F. utilize/promote only licensed and accredited services/providers;
<li>G. promote "one stop" shopping for services/care from agencies with vast service capacity or corporately unified consortia of agencies that are organized on a geographic basis;
<li>H. discourage boutique agency service delivery; 
<li>I. require unit of service cost analysis;
<li>J. promote patient identification and tracking;
<li>K. limit funding to a capitated medicaid premium that is based on less than 100% of the actuarial determination of the unit based cost;
<li>L. prioritize quality assurance in current delivery system over development of new programs/systems;
<li>M. promote use of medical care model;
<li>N. limit "risk" programmatic/fiscal risk 
<li>O. highly regard fiscal considerations in the determination of care choices; 
<li>P. discourage care/service delivery on a "subpopulation" basis.
<li>Q. promote maximum coordination of services; discourage fragmentation.
<li>R. discourage experimental treatment/programs;
<li>S. define "family" in traditional legal terms;
</ul>

<p><b>CHALLENGES FOR AIDS SERVICE PROVIDERS</b></p>

<ul>
<li>Compare/contrast agency's mission/values vs. managed care system mission/values;
<li>Determine extent to which managed system is/is not compatible with agency's mission/values;
<li>Analyze current funding streams to determine how they will be affected by managed care system;
<li>Analyze how agency's current service delivery system will be affected by managed care;
<li>Determine "vulnerability" of each service component;
<li>Determine whether there will be service "carve outs" in the managed care system;
<li>Determine extent to which managed care system is an "opportunity" or "threat" to existing programs; 
<li>Develop a strategy to address how the agency will position itself and its programs in the new/changing environment;
<li>Collaborate with other agencies to develop advocacy strategies;
<li>Participate in managed care seminars, conferences, planning groups;
<li>Educate Board of Directors, staff, volunteers and clients about how managed care will affect them;
<li>However you decide to "get ready" maintain the spirit, commitment, daring, courage and vision the AIDS community was created with. 
</ul>

<p><i>copyright 1996 Regina Quattrochi</i><br>
Regina Quattrochi Esq. is Executive Director of Bailey Holt House</p>

<p><b><A NAME="conflict">Conflict</A> Resolution</b></p>

<p><b>HOW GOOD CASE MANAGERS MAKE TOUGH CHOICES: Ethics and Mediation, Part 2</b><br>
<i>By Mileva Saulo, EdD, RN, and Robert J. Wagener, MA, MDiv.</i></p>

<p>Mediation is gaining in importance as a process for addressing patient grievances and related ethical issues.  In Part 2 of their discussion on mediation and ethics, (see <A HREF="9610.html">Oct.-Nov.Vol.1 Nos.10-11 Part 1</A>) the authors present a typical case and outline the mediation process and how it can lead to successful conflict resolution. These articles are printed in their entirety on the Consumer News web page, www.aidsnyc.org/cnews</p>

<p><i>Reprinted with permission from Saulo, M. and Wagener, R. How good case managers make tough choices: Ethics and Mediation, J of Care Manage. 2(2):10-16 35-38</i></p>

<p>The printed page is a one-dimensional form of communication that presents a challenge in bringing to life the complex interactions that make mediation an effective and interactive process.  The methods used in mediation training are primarily experiential.  Thus, to make this article as close as possible to reality, we are using a case study as a management learning1 tool and invite you, the reader, to experience it as your own.  After the initial case presentation, the mediation process is outlined, followed by an explanation of the case manger's "tool chest" of ethics analysis and values clarification, which are used to guide and manage the matter, and resolve the case.  As you study the case, begin to ask questions such as:</p>

<ul>
<li>What are the issues from each participant's perspective?
<li>What emotions are implicitly and explicitly expressed?
<li>What do these persons have in common?
</ul>

<p><b>CASE REPORT</b><br>
Jill, a 31-year-old California female, is considered by MediCal standards to be "disabled," due to morbid obesity.  She is 5 feet 7 inches tall and last week, during a routine office visit, was weighed at 288 lbs.  Her left leg was injured (tendons and cartilage) 2 years ago in a workplace accident.  The combination of the injury and the depression that followed being house-bound after the accident has contributed to a major weight gain.  There is a family history of obesity and eight family members are 50-75 lbs over weight.</p>

<p>Sixteen months ago, Jill was well enough to attend a local weight-loss clinic that combined a program of physical exercise with behavior modification.  Panic attacks brought on by the exercise required prescribed medications to control symptoms.  Jill was able to continue with the program and her weight dropped to about 212 lbs.  Although this was the best weight reduction ever attained, she remained 75 lbs over the ideal weight recommended by her physician.</p>

<p>Six months ago, Jill's weight began to fluctuate and she became depressed and discouraged by yet another weight gain.  While at a support group meeting, she was told by another attendee about Roux-en-Y surgery "for people like us."  This gastric by-pass surgery has been greatly perfected over the last 5 years and is now considered safe and the therapy of choice for morbid obesity.</p>

<p>Jill consulted her physician who considered her a good candidate for surgery and recommended that the procedure be done immediately.  When reviewed by the HMO insurance company, the claim was denied.  When queried about the denial, the case manager was only at liberty to state that the applicant did not meet the criteria for this type of surgery.</p>

<p>Angered by the denial, Jill, with the full support of her physician, submitted an appeal.  After consultation with the corporate Medical Director and legal counsel, the case manager informed Jill that the matter had been referred to mediation.</p>

<p><b>A "tool chest" for Case Managers</b><br>
In Part 1 of this article,2 we suggested that in today's health care system the case manager needs additional skills that complement existing skills and abilities.  These skills form a "tool chest" for providing quality patient care management and were identified as:</p>

<ul>
<li>Ethical case analysis: The ability to identify and address ethical dilemmas and utilize ethical principles.
<li>Values history assessment: The window into the client's (patient's) decision-making pathway.
<li>Mediation: A collaborative problem-solving process, which is client-centered, and a commitment to improve positive communication between participant/parties in a dispute.
</ul>

<p>Case managers learn how to apply these tools proportionate to the needs of each case (full application of all three tools is not always essential) and to choose the ones that best suit the needs of the case.  For most case managers, the challenge is in learning how to maintain an appropriate balance among the multiple roles and responsibilitiesthe legitimate needs of the client, the expectations of society, and the relationships with treating physicians or provider groups.</p>

<p><b>Overview of the Mediation Process</b><br>
Mediation has gained importance as a fair process for addressing patient grievances and related ethical issues.<sup>3</sup>  In this process, involved parties, assisted by trained neutral (impartial) person(s), systematically isolate issues or concerns.  The aim is to develop options, consider alternatives, and reach consensus that addresses case needs.  The process of mediation creates a safe and rational environment where conflict can be addressed and managed constructively.  Unlike a court of law, mediation is not a fault-finding process overly concerned with the details of the past to fix or establish blame.  Rather, it is an interactive process dependent on the good faith efforts of all participants to manage issues or concerns with a focus on present and future problem-solving responsibility.  Finally, mediation offers a way to transform the character of the dispute so that the relationships of the individual disputants are not only salvaged but strengthened.</p>

<p><b>Opening The Mediation</b><br>
The mediator's responsibility is to establish the "tone" for what the participants hope to achieve with the mediation.  Even when the mediator prepares for the session by reading briefs filed by the parties, the success of the mediation hinges on procedural fairness and the building of a level playing field.  In other words, the mediator establishes a safe and rational environment that fosters understanding among and between the participants.  In their seminal work, Fisher and Ury<sup>4</sup> state:</p>

<p>"The ability to see the situation as the other side sees it, as difficult as it may be, is one of the most important skills a negotiator (disputant) can possess.  It is not enough to know that they see things differently.  If you want to influence them, you also need to understand empathetically the power of their point of view and to feel the emotional force with which they believe it."</p>

<p>It is wise to internalize this insight from experts in the field of conflict resolution and negotiation.  Participants attending a mediationor any negotiationneed to discover that strongly held differences can be managed, and much is gained from understanding the opposition's point of view.  Acknowledging understanding, however, does not signify agreement with the other party's position.</p>

<p><b>Stage 1: Introduction and Narratives</b><br>
After participants are identified and seated, the mediator opens the session by stating his/er role and identifying any bias (preserving the parties' right of informed consent) to the mediation.  By identifying biases and any potential conflict of interest, the mediator exhibits fidelity to the role of a neutral.  Participants often select their mediator from a biographical card, which describes the mediator's expertise and associations.</p>

<p>Typically, the mediator proceeds to explain the role of the neutral.  For example: "My job as your mediator is not to tell who is right or wrong.  I am impartial, since I have no stake in the outcome of this mediation.  I will not take sides or make decisions.  I am here to assist you in talking about the issue(s) and working together, in good faith, to reach a solution(s) acceptable to each of you."  He/she then explains the mediation process and ground rules to be utilized during the session.</p>

<p><b>Stage 1 - Introduction and Narratives</b></p>
<ul>
<li>Mediator requests participants to briefly address all key concerns, speaking directly to the mediator.
<li>Participants recess for a brief period while the mediator constructs and issue agenda.
</ul>

<p><b>Stage 2 - Exploring the Issues</b></p>
<ul>
<li>Mediator guides participants in a direct exchange regarding all issues on the agenda.
<li>Mediator may call for private meetings (caucuses) to explore issues more fully, thereby reducing participants' vulnerability.
</ul>

<p><b>Stage 3 - Decision-Making</b></p>
<ul>
<li>Mediator assists parties in brainstorming options, determines objective criteria by which options will be selected, and builds a SMART agreement for settlement.
</ul>

<p><b>Fig 2.  Ground rules</b></p>

<ul>
<li>Everyone has an opportunity to speak without interruption.  Participants agree that when there is disagreement about what is being said, they will write down their thoughts and address them when it's their time to speak.
<li>Participants agree to treat each other with respectcivilitymeaning that only one person speaks at a time, there will be no name calling, and there is agreement on how to handle beeper/emergency calls or other pressing business.
<li>All agree they are attending in good faith, which means working together to reach a settlement.
<li>Participants agree that the Civil Code regarding confidentiality applies to the mediation and to review at the close of the session the details released to those individuals not attending the session.
</ul>

<p>Procedural fairness is vital to the process and essential to the overall success of the mediation. The mediator's credibility and impartiality is established by evenhanded application of the ground rules and steps in the process.  The mediator who lives up to the promise of impartiality fulfills the ethical principle of role fidelity.</p>

<p>The legal concept of confidentiality is another important aspect of the mediation process.  Many states provide protection in the Civil Code section against the discovery of information that can be used later in a court of law, and it is important to be fully informed of your state code(s) related to mediation.  Privacy, apart from the legal concept of confidentiality, is also important to the process.  Thus, the mediator needs to inform participants that things may be said and done during mediation that probably should be left at the negotiation table.  Only later in the process will participants decide what, if anything, will be shared outside.  Many meditations end with the participants indicating to outsiders that the matter was mediated and settled.  In this manner, mediation creates a safe zone protected by Civil Code for settlement discussions.</p>

<p>Mediating the case of Jill and her HMO insurance company requires the mediator to: preserve the balance of power between the participants; assist the participants in "saving face" through the use of private breakout sessions, or caucuses; and develop an atmosphere where participants view each other as collaborative problem solvers rather than one that encourages an "enemy" image.  After laying the foundation for mediation, the mediator requests that participants tell their stories.  Each is given a block of time to identify their key concerns and what they hope to accomplish in the mediation session.</p>

<p>To expedite the information gathered during Stage 1, the mediator may want to organize the data using the Case Analysis Grid (Fig 3).5  Since participants cannot be relied upon to present their stories in an organized, coherent fashion, this case analysis grid assists in managing large amounts of information and in clarifying and identifying issues and dilemmasand neglected factors.  It also helps in identifying missing data, and serves as a point of reference for determining how important this missing data is to resolution of the problem.</p>

<p><b>Fig 3.  Case analysis grid*</b></p>

<center><table width=80% colspecs="50% 50%" border=1>
<tr>
<th width=50%><font face="arial, helvetica" size=-1>Clinical Indicators</font></th><th width=50%><font face="arial, helvetica" size=-1>Patient Concerns</font></th>
</tr><tr>
<td><font face="arial, helvetica" size=-1><ul>
<li>Medical diagnosis and prognosis
<li>Treatment goals
<li>Treatment standards/criteria 
<li>HMO medical criteria</ul></font></td>
<td><font size=-1 face="arial, helvetica"><ul>
<li>Patient values (competency, Advance directive, DNR order, Surrogates)
<li>Informed options
<li>Emotional component
<li>Cultural component, including spiritual</ul></font></td>
</tr><tr>
<th width=50%><font face="arial, helvetica" size=-1>Quality-of-Life Issues</font></th><th width=50%><font face="arial, helvetica" size=-1>Contextual Factors</font></th>
</tr><tr>
<td><font face="arial, helvetica" size=-1><ul>
<li>Plan member values
<li>Family and significant other values
<li>Previous health history
<li>Treatment benefits/burdens
<li>Health care team values</ul></font></td><td><font face="arial, helvetica" size=-1><ul><li>Legal system
<li>Medical system
<li>Family system
<li>Administrative policy
<li>Insurance contract</ul></font></td>
</tr><tr>
<td colspan=2><font face="arial, helvetica" size=-1> *  Adapted from Jonson A. Slegier M. Winslade WJ Clinical Ethics 3rd ed.  New York, NY: McGraw-Hill, Inc., 1992</font></td></tr>
</table></center>

<p><b>Participants Tell Their Stories</b><br>
The following narratives are typical of those heard by mediators.  In this case, the mediator also has a mediation brief from the (absent) corporate Medical Director.</p>

<p>Patient Jill:  "I am furious with this company because they are not willing to give me a chance at having a normal life.  I have tried for 20 years to control my weight with pills, liquid diets, exercise, and recently, attendance at a weight -loss clinic.  The best I have ever done is the loss of 50 lbs and this was very hard work.  I want to know if this company is just waiting for me to have a heart attack?  Like I really enjoy the thought of having surgery!  I am not willing to leave this meeting without approval of the surgery, or some program resulting in surgery.  If denied again, I will take my case to court."</p>

<p>Insurance Company Case Manager (attending with limited settlement authority but with the corporate Medical Director on telephone standby): "I am here today in order to mange this situation and reconsider why Jill should be given care for which she does not qualify at this time.  I am also here to press for other and safer options.  I want to make sure she fully understands the severity of the Roux-en-Y surgery, even though her physician recommended it.  I would like to see this case settled so that Jill can get on with her life."</p>

<p>Jill's Physician (attending in support of her): "I have treated Jill for 10 years for various conditions related to her workplace injury, weight control, and the usual illnesses.  I have researched the Roux-en-Y procedure and know that it has been greatly perfected and is now very successful for treating patients with her diagnosis; the statistical evidence shows that 80% of those treated have a favorable result within 6 months (weight loss of 100 lbs or more), 15% have good results within 6 months (weight loss of 75 lbs or more), and about 5 to 6% have a poor outcome (weight loss does not change significantly).  I have discussed the benefits and risks associated with the treatment with Jill.  In my opinion, this is the only means for her to gain control over her weight.  Although she does not meet all the criteria, she is at high risk for a major health-related problem (heart attack, strike, diabetes) within the next 3 to 5 years.  Therefore, the Roux-en-Y surgery should be approved now, rather than later when she is in a higher risk situation."</p>

<p>Corporate Medical Director (unable to attend, but had provided a written brief to the mediator): "I have reviewed this case thoroughly and Jill does not meet the medical criteria established for the Roux-en-Y procedure.  The criteria are as follows: 1) the patient must be morbidly obese; 2) the condition must be life-threatening; 3) there must be a demonstrated failure to lose weight; and, 4) there must be attending psychological issues.  Unfortunately, she only meets three of the four criteria.  Since her condition is not immediately life threatening, she does not meet the second criterion.  I am additionally concerned about her panic attacks, since the aftercare from the Roux-en-Y surgery is combined with exercise in order to obtain maximum weight control.  I therefore recommend that at this time Jill be treated with the safer liquid protein fast.  I have witnessed patients progressing very well with this less invasive approach to weight control.</p>

<p>The case manager is authorized to disclose the reason for current denial and to encourage Jill's cooperation with participation in the less invasive approach.  I am also directing our case manager to make sure that Jill has seriously considered all the risks involved.  I will be available by telephone on the day of the mediation if you need my opinion or approval for any settlement arrived at during the session.</p>

<p>Unless the participants want to add new information during Stage 1, the mediator summarized the narratives for accuracy and adjourns the session for a brief break.  During this recess the mediator reviews notes made during the meeting in order to build an issues agenda for the second stage of the mediation process.  This agenda is comprised of three parts: 1) relevant content issuesthese may include medical, contractual, legal, ethical values, and communication issues: 2) emotional concernsthese include all charged feelings that either hinder settlement possibilities or assist in determining their urgency; and 3) common positivesthese include identifying some positive things that help participants shift the focus from further conflict to exploring mutual interests and problem solving (fig 4).</p>

<p><b>Fig 4.  Mediator's issue agenda</b></p>

<p>Relevant Content Issue(s) | Emotional Concern(s) Common Positive(s)</p>

<ul>
<li>Contractual issues:
<dt>What does this insurance contract cover?
<dt>Where is the contract?
<li>Clarify medical terminology.
<li>Identify ethical dilemmas such as autonomy, justice, and beneficence.
<li>Legal implications, if any, regarding MediCal standard and the American Disability Act.
<li>Criteria for denial of claim and how they were established.
<li>Medical prognosis including short- and long-range health risks.
<li>Treating MD's diagnosis and rationale for recommending Roux-en-Y surgery over protein fast.
<li>Risks and benefits of surgery as reflected in medical literature.
<li>Patient's anger at the denial resulting in a threat of court action.
<li>Insurance company's frustration with patient's unreasonable position and the real risk of surgery.
<li>Treating MD's frustration in being unable to provide patient with the best care available.
<li>General feeling by all participants of "being stuck" in the previous negotiation process.
<li>Patient's desire to live a more normal life, to be accepted, and to not be ridiculed.
<li>A general consensus that medical care is necessary.
<li>Appropriate care should be initiated as soon as possible.
<li>Participant's desire to explore and manage the matter, without further outside intervention.
<li>Participants agree to work in good faith to seek a reasonable solution to the conflict.
</ul>

<p><b>Stage 2:  Exploring The Issues</b><br>
When participants return to the mediation table, the mediator reassures them that all important issues put before mediation will be appropriately addressed.  Sufficient time is spent with the mediator stating his/her understanding of the issues agenda and seeking the participants' agreement to the agenda.  Agreeing to the agenda is as essential to a successful outcome as agreeing to abide by the ground rules and the process itself.  Once participants agree to the agenda, the mediator may want to acknowledge that progress is being made.</p>

<p>Working backwards, the mediator begins with the common positives, since it is important to start with and area of common interest.  This establishes a new and more positive atmosphere and helps to move the participants from positions to interests and from areas of dispute to agreement.  In Stage 2, participants speak directly to each other.  In Jill's case, we would suggest that the mediator expedite the process by stating the common positive(s).  For example, "I have noticed several common themes among all of your concerns expressed her today.  It is important to identify them.  First, there is a general consensus that Jill needs medical care.  Second, it appears, all of you agree that this care must be initiated soon.  Finally, everyone appears eager to manage this situation here, rather than taking the matter to outside decision makers."  These are all important common positives with which to begin the next stage of mediation.  The mediator reviews the remaining agenda, usually in conjunction with participants, and makes a decision as to what should be addressed next.</p>

<p>The mediator must be concerned with balancing power so that Jill is not viewed as just another anonymous plan member and so that she understands that the corporate Medical Director, who has not met her, may not fully comprehend the impact of obesity on her life.  The mediator continues to preserve a balance of power around the negotiation table, since many lay participants may come to mediation without much knowledge concerning their diagnosis, medical terminology, or how the criteria for treatment are established.  In addition, some professionals involved in the mediation process may have a bias toward assertive clients and lack empathy because they have never had a face-to-face meeting.  Thus, attempts are made during the second stage to "humanize" the situation by using culturally sensitive communication skills to not only balance power, but to clarify emotions and identify misperceptions of understandings.</p>

<p>In preparing for this stage, the mediator recalls the participants' narratives, for example, "During the break, I made a note that the parties expressed a need for further clarification regarding such terms as normal life, medical criteria for denial, morbid obesity, and appropriate level of care.  Am I correct?"  "Are there any other terms or statements that need to be clarified."  It is important to seek clarification for all such questions as Jill's, " I want to know if this company is just waiting for me to have a heart attack?"  Equally important is that Jill appreciates the seriousness of the Roux-en-Y surgery, a concern expressed in the mediation brief submitted by the corporate Medical Director.  In either case, it is highly unlikely that participants will not be reassured by the nature of answers to these questions.</p>

<p>Underlying Jill's query is a more fundamental concernthe need for legitimization of the seriousness of her diagnosis and the desire to regain control of her life.  The mediator's task is to unmask these underlying concerns, interests, or needs, so that participants can formulate options that satisfy these concerns.  Carefully moving participants with strongly held positions to a safe assessment of those positions allows them to negotiate a settlement in good faith without lossing face.</p>

<p>During this stage, participants speak directly to each other rather than to the mediator.  To clarify particular points, the mediator often selects the best suited participant to speak directly to anotheer.  Prior to adding any new information, the mediator asks the participant receiving the information to paraphrase what was communicated.  This technique monitors the feedback and makes certain that participants are working with the same set of data and assumptions.  Many conflicts, begun as the result of poor or inadequate communication, are compounded and grow when the communication process breaks down.  Building common understanding through improved communication is a key ingredient to a successfully mediated settlemten.</p>

<p>Skilled mediators use a variety of communication techniques to facilitate dialogue (Fig 5).  For example, the mediator may ask Jill to tell the Medical Director (now in attendance via the speaker telephone) what her life is like weighing 288 lbs.  She may discuss the sneers and name calling and the inconveniences she endures daily, such as not being able to buy clothing off the rack, or to get into movie and airplane seats, or the lack of intimacy in her life.</p>

<p><b>Fig 5.  CARES SKILLS*</b></p>

<p><b>Tools to enhance communication effectiveness</b></p>

<p><b>Clarification</b>: Used to gather more information, help participants see other points of view, or enable the speaker to reevaluate his/her own perspective.  Skills used are: asking open-ended questions, restating content and asking speaker for further clarification.</p>

<p><b>Active Listening</b>: Used to develop rapport by communicating the listener's understanding of the subjective and emotional content of a message.  Skills used are: paying attention to body language, maintaining appropriate level of eye and body contact, sensitivity to cross-cultural issues, waiting for corrective feedback or acknowledgment that mediator understands, and allowing for constructive periods of silence.</p>

<p><b>Reframing</b>: Used to change the tone of a message from negative to neutral.  The listener rephrases a statement made by a particpant so that another participant may "hear" it better.  Skills used are: neutralizing language that is negative, threatening, blaming, or offensive; interpreting content/concern in an impartial or consturctive vein; and refocusing communication from past to future behavioral changes.</p>

<p><b>Empathizing</b>: used to show that the listener understands how the speaker feels.  Acknowledging emotions may include enabling the speaker to continue despite tears or other strong emotions.  Skills used are: reflecting back speaker's feelings and observing that emotions are clues to strongly held beliefs, values, or principles of the speaker.</p>

<p><b>Summarizing</b>: Used to review progress or to pull important ideas, facts and feelings together.  For tracking, it may be useful to note what has been accomplished and what needs to be done to move forward.  Skills used are: restating major ideas, including feelings, and listing points of agreement already reached.</p>

<p><i>* Used with permission, Designates Clarification, Active Listening, Reframing, Empathizing, Summarizing.  CARES skills represents the original work of faculty member Linda Daniels, MD. JD, and remains the exclusive property of The Center for Medical Ethics and Mediation.  Except for its inclusion in a review, no part may be reproduced without the expressed permission of the Center.</i></p>

<p>The mediator asks the corporate Medical Director to paraphrase what he/she heard and to speak to Jill about the risk of surgery, concerns about the panic attacks, and the anesthesiologist's concern about postoperative problems.  With such guided exchanges, "hardened positions" often soften.  In addition, as participants move from positions to interests, solutions begin to emerge.  At this stage, the mediator tests to see if participants are ready to proceed to the next phase of mediation, the generating of options for settlement.  Before moving to Stage 3, all important questions or concerns expressed by participants during the first stage in the mediation process are fully explored.  This review may unlock some important new information or dispel an unintended misconception.</p>

<p>As indicated earlier, the case manager's "tool chest" for mediation includes the skills of ethical analysis and values clarification.  It may be helpful to organize data collection using the Case Analysis Grid (Fig 3).  Several ethical issues may emerge; the seriousness of the medical diagnosis and the physician's opinion; the importance of the patient's choice of preferred treatment: and, the insurance company's concern that resources be spent wisely and according to existing standards.  At least three ethical principles come into play: 1) the principle of physician beneficence; 2) patient autonomy; and 3) justice as related to the allocation of resources.</p>

<p>In Jill's case, the dilemma appears to be in the tension between her right to select and initiate a course of action related to taking control of her health (autonomy); the Medical Director's clinical knowledge about the aggressiveness and risks (beneficence) associated with the Roux-en-Y surgery; and the health plan's duty to inform the patient of those risks.  Finally, decisions need to be fair and must be made according to some clinically acceptable standard (justice).  Although these principles are abstractions of important values in the health care field, they involve real people deadlocked because of strongly held positions.</p>

<p>Some may argue that another justice issue applies to the organizational level.  In today's managed care environment, making decisions that are good for the patient must be balanced with the health of the organization and other plan members.  The Medical Director of a managed care organization is aware that medical groups, under capitated agreements, assume both the health care and financial risks attendant to providing care, especially care that falls outside of established guidelines.  As suggested in <A HREF="9610.html#conflict">Part 1</A> of this article, values should serve as a window into those factors that drive the decision-making process.  Emotions often complicate problems, and what often appears as irrational to one observer is frequently caused by ignorance of what lies behind the other values and why.</p>

<p>For example, the Medical Director may appear beneficent, a traditionalist as described by Massey.<sup>6</sup>  Perhaps the Medical Director is viewed as controlling for selecting a course of action that protects Jill, since it makes no medical sense to subject a patient to risk, especially when the efficacy of a less invasive action is well known and highly successful.  On the other hand, according to Massey, Jill is a "challenger"; one who prized her autonomy and right to make choices and knows that society makes value judgements about obese people.  It is to be expected that she questions the denial of treatment.  The mediator's role is to be sure that such areas are fully explored and to understand these areas so that solutions will arise out of addressing mutual interests and concerns, and not as a reaction to strongly held positions.</p>

<p>Attorney Gerry Spence, counsel for the now famous Karen Silkwood case (plutonium poisoning), recently addressed why attention to the emotions is so important in negotiations.</p>

<p>"A winning argument is possible only when, speaking out of our authority, we address the authority of the other...most of us do not tell much of the truth about ourselves.  We hold back our hurt, our anger, our deep dread.  We fear to reveal our fear, our joy, our jealousy, our hunger, our ideas, our insecurities ourselves. Credibility comes out of the bonedeeper yetout of the marrow."</p>

<p>Ultimately, it is important to the credibility and outcome of the mediation of Jill's case that both the Medical Director and the case manager hear and understand the frustration behind her statement  "give me a chance at having a normal life."  Equally important is that Jill hears and understands that the insurance company is not attempting to abandon her, but wants to use its resources wisely and safely for the benefit of its clients.  Veteran dispute resolution trainers.  Ury, Brett, and Goldberg8 wrote about the importance of acknowledging and dealing with emotions in mediation.</p>

<p>"Before disputants can effectively begin the process of reconciling interests, they may need to vent their emotions.  Rarely are emotions absent from disputes.  Emotions often generate disputes, and disputes, in turn, often generate emotions.  Properly designed, mediation can meet some of the same needs for emotional venting served by fighting."</p>

<p>Mediators understand that emotions acknowledged around a negotiation table clearly signal the participant's values.  The more vulneralbe the particpants become to each other in a safe environment, the better the chance for successful mediation ending in a collaborative settlement agreement.</p>

<p><b>Stage 3: Decision Making</b><br>
Once participants are talking openly and exploring the depth of interests, concerns, and needs brought to the mediation table, possible solutions to the conflict usually begin to emerge.  At this point, the mediator again enters into the process to guide participants toward a specific, measurable, achievable, realistic, and timed (SMART) agreement.  Brainstorming solutions is important to the final outcome.  Also important is evaluating the possible solutions against criteria established by the participants (e.g., timeliness, policies, legalities, ethical principles, medical standards, fairness, positive outcome, safety) that allows them to build an agreement that will endure the test of time.  Finally, many agreements are signed by the participants as a symbol of their commitment.  It has been our experience however, that signing an agreement is usually not necessary when the agreement truly originated with the participants.</p>

<p>Mediators neither order participants to settle nor make suggestions when participants become stuck in the brainstorming phase of mediation.  It is important to remember that the participants, not the mediator, must live out the consequences of their decisions.  In the case report presented, the outcomes reached may well be:</p>
<ol>
<li>Jill agrees to have a fasting blood sugar and blood urea nitrogen tomorrow
<li>Jill's physician agrees to order protein supplement as soon s lab results are availableno later than 3 days.
<li>Jill agrees to a psychiatric consultation to deal with anxiety attacks associated with exercise.
<li>Jill agrees to begin a supervised protein supplement program and continue until the anesthesiologist certifies that she is not at risk for postoperative respiratory problems.
<li>Jill's physician agrees to make a psychiatric referral tomorrow.
<li>Medical Director of the health care group agrees to a second mediation to review the psychologist and anesthesiologist assessments of risk in 2 months.
<li>Medical Director agrees to Roux-en-Y procudure when the psychologist and anesthesiologist indicate that risk is now minimized.
<li>All participants agree to hold this agreement in confidence
</ol>

<p>In the space of this article it is naturally impossible to move through the entire mediation processoften, cases take several hours and several meetings to resolve fully.</p>

<p><b>Additional Applications of "Tool Chest" Skills</b><br>
An inherent part of the work of case managers is critical thinking, involving inquiry and data gathering, and the evaluation of the information and data that lead to tentative conclusions.  Since readers of this article are professionals who are highly proficient in using problem-solving techniques, we recommend that these skills in this new "tool Chest" supplement what they already know and do, and that skills can be applied everyday.</p>

<p><b>How to Apply the Mediation Process to Small Meetings or Conference Telephone Calls</b></p>

<p><b>Stage 1Introduction and Narratives</b></p>
<ul>
<li>Outline purpose of the meeting and address time constraints.  Ask participants to address an issue agenda, and have all parties agree to the agenda.
</ul>

<p><b>Stage 2Exploring the Issues</b></p>

<ul>
<li>Guide participants in direct interchange regarding all of the issues on the agenda.
<li>Call for private individualized conversation to explore issues more fully.
</ul>

<p><b>Stage 3Decision Making</b></p>

<ul>
<li>Assist parties in brainstorming options, determining objective criteria to selection options, and building a SMART agreement for settlement.
</ul>

<p><b>Case Manager Application of Mediation Principles:</b><br>
<p><b>Ground rules</b>: The guidelines of civility, good faith, and one person speaking at a time are helpful for small meetings or telephone conference calls and facilitate mutual respect.  Other ground rules may include time management and special needs to be considered, such as the need for individuals to respond to beepers, emergency calls, or other pressing business.</p>

<p><b>Neutrality</b>: It may be impossible to be totally neutral.  However, the case manager shows neutrality or impartiality by facilitating joint problem solving, resisting premature settlement when parties are not ready and allowing participants to have a fair share of time to tell their story.</p>

<p><b>Balance of power</b>: Members of health plans and their families may be intimidated by professionals with titles.  Power, however, can be equalized by everyone being addressed in the same manner.  In informal settings, first names may be used.  Or, if a person prefers a professional title (e.g., Dr., Nurse, Mr., Ms., Mrs.), then all participants are addressed in a formal manner.  Balance of power is achieved when no one participant is allowed to dominate a conversation or meeting.  The case manager may control this by saying, "I want to be sure that I have heard from everyone.  I noticed that one of the participants has not as yet spoken.  Is there anything that you would like me to know?"</p>

<p><b>Setting an agenda</b>: time is a precious resource and not to be wasted.  Setting an agenda for a telephone communication, conference call, or meeting is always helpful in focusing participants' energies and commitment.</p>

<p><b>Conclusion</b><br>
Although this discussion presents the mediation process in a "fast forward" fashion, it demonstrates how applying the principles of mediation and its attendant skills can resolve simple to complex conflicts among plan members and their families, providers, and health care administrators.  The "tools" of ethical analysis and the values history can be used within the context of mediation.  The example of Jill and her HMO insurance provider serves to demonstrate how the case manager uses those tools to enhance effective resolution of conflict.  Mediation serves as:</p>
<ul>
<li>A cost-effective process with a high degree of success in improving communication among participants, which, in turn, contributes to realistic problem solving.
<li>A creative open environment in which values related to the issue(s) can be fully explored, thereby creating a "narrative ethic."
<li>An arena where parties can fully participate and share in the decision-making process, one that is necessary in today's managed care marketplace.
<li>A nonadversarial, patient-centered focus for creative, collaborative decision making.
</ul>
<p>The "tool chest" of ethical analysis, values clarification, and mediation provide the case manager with mechanisms for asking the right questions and a format for resolving conflicts.  This approach keeps the control of the conflict with the relevant parties rather than with outsiders.  Bush and Folger,9 suggest that through mediation people find ways to avoid giving in to the pressure to act in a destructive way.  While overcoming the pressures involved in making difficult choices, people discover new capacities for good and find new ways to deal with life's problems and each other.</p>

<p><i>Meleva Saulo is Director of the Graduate Nursing Program and a Faculty Member of the Nursing Administration and Case Management Department of the University of Southern California in Las Angeles. Robert J. Wagener is President of the Center for Medical Ethics and Mediation in San Diego, California.</i></p>

<p><b><A NAME="housing">Housing</A></b></p>

<p><b>CUNY DRC and CICRP Facilitate Forum to Consider Public Policy 
on Housing for People Living with AIDS</b><br>
By Kenneth Lowry</p>

<p>Directors of housing agencies that service consumers who are active or recovering substance abusers living with AIDS and mental illness express the need for a consensus position on policy and service provision to such clients.  In response to this concern, the Consumer Information and Conflict Resolution Project (CICRP) in partnership with City University of New York, Dispute Resolution Consortium (CUNY DRC) has convened a group of concerned professionals from several disciplines in a collaborative problem solving effort to articulate these concerns, explore alternatives, and determine a course of action. The group's first meeting identified this position among the housing providers and health care professionals who work with this population: substance abuse is the most significant obstacle to successfully housing and stabilizing the physical and mental health of PWAs. The group found that there was no city-wide policy that adequately addressed the needs of clients who present with all three diagnoses.</p>

<p>The Mayor's Office of AIDS Policy of City of New York has asked this group to serve in an advisory capacity for the restructuring of Scatter Site Housing Policy. Public and private service providers, in cooperation with government, need to foster the development of good working relationships among themselves, and to ensure that effective high-quality plans are consistent with their historical record of service to the AIDS community.  Other circumstances require the necessity for neutral, and sometimes prestigious, auspices under which these groups can be convened to insure productive, equitable meetings.  The roles of the neutral facilitator and support staff are to plan and facilitate the meetings, clarify goals, and support the development of a consensus.  CICRP and CUNY/DRC will make available to all interested parties a consensus position which addresses options for public and private agencies that can effectively work for clients who present with all three diagnoses.</p>

<p>The Collaborative Problem Soling Forum will call experts from the fields of mental health, substance abuse, law, criminal justice, law enforcement, legislative law, real estate, community boards and AIDS, and people living with AIDS, to inform the group, and examine current practices and trends. The Collaborative Problem Solving Forum is convened by: Kenneth W. Lowry, Executive Director, CICRP. The sessions are facilitated by Maria Volpe, Ph.D. Professor of Sociology at John J. College of Criminal Justice and Director, CUNY DRC, and president International Society of Professionals In Dispute Resolution, and Allen J. Zerkin, J.D., Adjunct Assistant Professor at New York University's Wagner School of Public Service and Chair of New York State Forum on Conflict and Consensus.  Peter Maida, Ph.D. JD, Key Bridge Foundation is the consultant on the Americans with disabilities Act. To participate and for more information contact The Conflict Resolution Project (CICRP), at: 212-387-0824 or  E-mail: <A HREF="mailto:cnews.aidsnyc.org">cnews.aidsnyc.org</A>.</p>

<p><b><a name="hud">A </a>New Office at HUD Will Be the Focal Point for Department Policies Affecting People with Disabilities</b><br>
By David Voss</p>

<p>Tuesday, November 12, 1996<br>
The Office on Disability Policy will advise Secretary Henry G. Cisneros on all housing issues dealing with people with disabilities and will propose changes to Department rules or policies that negatively affect them.  Thea Spires, director of the Office, is the Department's main liaison to groups representing people with disabilities.</p>

<p>An Office task force is reviewing HUD programs and policies to gauge their impact on people with disabilities.  The review seeks to ensure that people with disabilities have equal access to the full range of housing opportunities in communities.</p>

<p>Other task forces are working on home ownership issues and on bringing together people with disabilities who live in HUD housing and the developers who build it.</p>

<p>This past summer, HUD held forums in Boston, Chicago, Denver, Houston, Philadelphia, and San Francisco called "Choice, Access, and Communities" to hear directly from people with disabilities about what they want and need in HUD's housing programs.</p>

<p>For more information on the Office on Disability Policy, call Thea Spires at 401-7991 or send her an E-Mail message at <A HREF="mailto:thea_spires@hud.gov">thea_spires@hud.gov</A></p>

<p>For more information on HUD programs and what's new at HUD, visit HUD's Home Page on the World Wide Web at <A HREF="http://www.hud.gov/">http://www.hud.gov/</A>. Community Connections Support line 1-800-998-9999 or TDD: 1-800-483-2209.

<p><i>David Voss is the HOPWA Admnistrator in the HUD Office of HIV/AIDS Housing</i></p>

<p><b><A NAME="health">Healthcare</A></b></p>

<p><b>NEUROLOGICAL DISORDERS AND PEOPLE WITH HIV &amp; AIDS</b><br>
By Michele L. Krukin, OTR/L</p>

<p>People with HIV and AIDS are frequently diagnosed with disorders affecting their nervous systems. Both the central nervous system (brain and spinal cord) and peripheral nervous system (all other nerves) are affected by a plethora of devastating ailments with varying degrees of severity.  Studies suggest that 50 to 66% of people with HIV and AIDS contend with these disorders,  the most common of which are distal polyneuropathies - disease processes involving the body's distal nerves - or nerves of the arms and legs.  Distal polyneuropathies result from diverse causes including immunological mechanisms, increased infectious states, nutritional deficits, toxic factors (i.e., neurotoxic drugs used to combat the virus and opportunistic infections), and metabolic factors (i.e., body's inability to absorb  vitamin B12). Polyneuropathies can present at any stage of HIV and AIDS, with studies suggesting they are usually more severe in the later stages.  Sensory and motor deficits are the primary symptoms.  Examples of these include a person's decreased ability or inability to detect sensory stimuli and to adequately control movements of the arms and/or legs.  Pain may also be present.   These problems frequently hinder people in carrying out their  activities of daily living (ADLs) such as dressing and bathing.  A person's job and other daily life tasks such as child care, cooking, and shopping are also negatively influenced.  Some of the more common polyneuropathies affecting people with HIV or AIDS are:</p>

<p><b>Distal Symmetrical Polyneuropathy (DSP)</b> -  DSP usually attacks the feet first, where people note a persistent burning sensation.  Symptoms are symmetrical and include impaired reflexes and sensation in the feet, weakness, and muscle atrophy - or muscle wasting- in the feet.  The hands are usually affected in later stages of  the disease.</p>

<p><b>Inflammatory Demyelinating Polyneuropathy (IDP)</b> -  This is essentially Guillian-Barre disease, which is present in the non-HIV/AIDS population where it is often precipitated by a viral infection, viral immunizations, and surgical procedures.  Clinical manifestations include sensory deficits, mild symmetrical paralysis of the legs and/or arms to full quadriplegia. Reflexes are impaired. The respiratory and cardiovascular systems may be affected.</p>
 
<p><b>Multiple Myelopathy (MM)</b> - People with MM usually have asymmetrical involvement of the nerves, as opposed to the symmetrical imvolvement in DSP and IDP, and more peripheral nerve involvement (parts of the body closer to the trunk) are affected.  Reflexes are usually intact.
Progressive Radiculopathy -  Usually occurs in people with AIDS or those in the later stages of HIV.  Symptoms include abnormal sensations such as tingling, burning, or pricking in the feet followed by progressive motor loss and lack of reflexes in the legs, sensory loss that ascends up the body, and eventually urinary retention.  Pain in the lower body is common.  The upper body usually is not involved until late in the course of polyradiculopathy.</p>

<p>Medical treatments for distal polyneuropathies vary widely and include plasmapheresis and immunosuppressive therapy. Spontaneous remission is also not uncommon, especially with people in the earlier stages of HIV. Anyone with neurological symptoms should see a doctor immediately, as early diagnosis and treatment can lead to an improved prognosis.   Patients with these disorders can also benefit from rehabilitative therapies, such as occupational and physical therapy, which can facilitate a person's recovery and help compensate for sensory loss, impaired motor control and coordination, and functional deficits.  Some suggestions for people with sensory and motor loss include:</p>

<ul>
<li>Use your eyes to compensate for lack of sensation.  For instance, always look before putting your hands into a drawer to avoid being cut by sharp objects.
<li>Test water temperature with the elbow or upper arm, not the fingertips or toes, as these areas are usually the first to have sensation impaired and will be inaccurate.  Burns could result.
<li>Show increased care with cutting foods and other items as cuts will not be easily noticed because of sensory loss and may heal poorly due to poor immune status.
<li>Always wear clean socks and check shoes for  pebbles, etc. before placing foot in shoe to avoid abrasions and blisters on the feet which could heal slowly and lead to increased infection secondary to impaired immune status. 
<li>Do not go barefoot to avoid cuts on the feet.
<li>If you have a lack of motor control and lack of coordination, rearrange counters and closets to avoid excessive reaching.  This prevents falls and injuries from dropped items.  
<li>Show greater care around stove tops, irons, and other extremely hot and cold surfaces.
<li>Wear warm gloves and footwear in cold weather to avoid frostbite.
</ul>

<p>Polyneuropathies are recognized as common disorders which inflict people with HIV and AIDS, as well as people with other non-HIV and AIDS related diseases such as diabetes and multiple sclerosis.  Research into these nervous system disorders continues to grow along with other research devoted to HIV and AIDS.  As with other diseases, early diagnosis and treatment can lead to much better outcomes for a person.  Education is extremely important for people with polyneuropathies because the multiple problems and consequences (i.e., burns, cuts, and blisters) arising from sensory loss and motor loss can be avoided.</p>
  
<p>People with HIV and AIDS contend daily with a multitude of physical, emotional , and psychological ailments.  The fact that physical disorders such as polyneuropathy compound the emotional, spiritual, and mental well being of a person require health care workers as well as their clients to treat the condition as thoroughly and as quickly as possible.  This is especially true with distal polyneuropathies where early education is often a prime component to the success of  treatment.</p>

<p><i>Michele Krukin, MS is an occupational therapist at the New York Veterans' Administration Medical Center.</i></p>

<p><b><A NAME="nutrition">Nutrition</A></b></p>

<p><b>"NEW AGE HERBALISTS"</b></p>

<p>Often when we "discover" something new and exciting, we think of it as new to the world, not just to ourselves.  We may even consider it revolutionary in its importance. People who discover herbal therapy for the first time frequently have this reaction. In fact, the use of plants as medicines is as old as civilization itself.  It is found in different cultures on every continent on this planet.  the Egyptians sealed medicinal herbs with their mummified pharaohs to guarantee their health on their journey to the other world.  In India, AYMEDIC medicine has been in constant use for thousands of years. The Chinese have books about medicinal herbs that predate the Christian calendar by 2,000 years. When the Europeans set sail to discover the New World, they carried with them their collection of herbal remedies.  When they arrived here in America, they found the land populated by Native American nations, each with its own version of herbal treatments.  Herbs and herbal treatments are mentioned frequently in both the Bible and the Koran.</p>
 
<p>Before the development of modern medicine, herbal remedies were one type of treatment used by people around the globe.  Similar discoveries were made about the healing properties of certain plants by cultures that had no contact with each other.  For example, garlic was used by the Arabs, Babylonians, Chinese, Egyptians, Greeks, Hindus, and Romans to treat intestinal disorders, gas, worms, respiratory infections, skin diseases, wounds, scorpion and snake bites among other ills.  Today garlic is being investigated for use against cryptosporidium.  The oldest antiseptics were a combination of herbs and flowers used before their active ingredients were understood.</p>

<p>Many ancient people believed that medicinal plants were effective because they protected people against witchcraft and the Evil Eye.  A plant called wild angelica or the Holy Plant was cultivated because it was considered the best defense against witchcraft. Wolfsbane and garlic were used to keep vampires away.</p>
 
<p>Even as we learn to separate superstition from the effective use of an herb, we must remember that our understanding or lack thereof will not help or hinder the effectiveness of a particular substance. Quinine made from cinchona tree bark was used by Native Americans to combat malaria long before the Spanish explorers arrived in South America.  As recently as the 1980's, it was still used to fight malaria, especially the strains that have become resistant to the synthetic anti-malarial drugs.  Probably the most famous example of a remedy being used effectively without understanding why was the British use of lime and lemons to prevent scurvy among their sailors during long sea voyages.  It could be argued that this simple remedy was a major contribution to the British ability to dominate the world's oceans and set up its colonial empire.</p>

<p>In the US today, very little investigation is being done to determine which herbs or herbal products are effective in the fight against infectious disease.  There are thousands of herbs and herbal products on the market.  In the absence of objective research, our task is to learn how to sort out the effective herbal medicines from the "witchcraft".  In our society witchcraft goes by the name of profiteering.  You can easily find an example of this witchcraft by looking through new age or holistic magazines in any health food store.  The magazines are usually free.  They exist by selling advertising space to manufacturers, just like any mainstream publication.  The point of the advertising is simple: get people to buy the product.  There is nothing holistic or new age about that.  What is different is the types of code words used in these ads.  Typical statements include ..."youthing," "reversing the aging process," "boosting the immune system." "Becoming centerrd or grounded, and "tonifying" certain organs, often the liver. The Spanish explorer Ponce de Leon began looking for the Fountain of Youth in 1513.  He did not find it, so the search continues.  My personal favorite is a vegetable preparation that is presented as "Brain and Body Superfuel, turbocharged with vitamins and minerals."  For a moment I thought they were talking about steamed vegetables with rice and beans.</p>

<p>If you want to use this ancient therapy to see if it can work for you, your first task is to educate yourself.  Have realistic goals about what you want to learn so that you don't try to understand ayurvedic, Chinese, African and European herbalism in a month.  It took thousands of years for these treatments to develop.  You can't master them in a crash course. You might want to find a study group with people who have goals similar to your own.  If one does not exist in your area, start one.  All you need is one other person and you have a group.</p>

<p>Beware of claims that sound too good.  The claims will be good, the medication won't.  Look out for code phrases like secrets of the Ming dynasty, elixir of the emperors, ancient cure unearthed and smuggled into the US.  Conspiracy theories are very appealing because they trigger an excitement in our lives.  They allow us to become part of the good guys searching for the truth. the bad guys are trying to keep us from finding it, and we can join in the crusade to defeat them.  Bear in mind that if this "secret elixir" is found in 10,000 health food stores from coast to coast, it is not much of a secret.  On the other hand, if this magic bullet works it won't be hard to find countless people who have been cured.  I am sure they will be happy to talk about their success. Unfortunately, most of the time the magic part is how fast the emperor's elixir increases the manufacturer's bank account.</p>

<p>Try to find out about the area, culture or country that the particular therapy comes from.  How is the health of the people there? Do they use the treatments that are credited to them?  Where are their experts and practitioners trained?  If an "expert" or practitioner is someone who read the literature wrapped around the medicine bottle 10 minutes before you did, you are in trouble.</p>
 
<p>Don't be fooled by titles.  An expert in one field is just as much of a layman as you are in another area that neither on of you has studied.  Choose an area that has measurable success.  The chinese herbalists, for example, have a system worth looking into.  Herbal.medicine in china today is no an alternative therapy, it is mainstream.  A lot of research has been done on the immune system
and specific herbal therapies.  There is a great deal of information available and practitioners are trained well.  Much of this information is available on the Internet.</p>

<p>It would be a good idea if you could talk about your search with your health care provider.  She/He may know more about herbalism than you think, or may be able to help you find a good practitioner.  In any case, you should always tell you provider about all the medications of any type that you are taking.  You may be embarrassed or uncomfortable about telling one practitioner that you are trying what you may think is a competing form of medicine.  Don't be.  If someone's feelings are hurt that is unfortunate and unpleasant, but what you are trying to avoid is an unhealthy or even dangerous combination of drugs, herbs and food.  If you cannot speak openly with your practitioner, then you should think about finding a new one.  Where your health is concerned you should leave no stone unturned.</p>

<p>In order for any therapy to work effectively, the person using it must eat well.  Both the quality and the quantity of the food  must be at least adequate.  There is a wide range of what constitutes good nutrition and each person must find a comfortable  place in that range.  But vegetables and whole grains must have a place.  The chinese placed brown rice at the center of their daily eating plan.  Vegetables and other plants like seaweed were added next.  Finally animal products were used to complete the picture.</p>
 
<p>Many other Asian cultures also adopted this eating style.  Here in the US, we seem to prefer eating in the opposite direction, even though we know the value of eating brown rice and other whole grains and vegetables.  The American Cancer Society encourages us to eat less meat, reduce fat intake, and eat more vegetables.  The USDA food pyramid also reflects this way of eating.  Unfortunately, we don't see this way of eating as a form of herbal therapy.  We still think of eating as separate from any kind of medicine.  We can recognize the special healing properties of plants when we call them herbs, but not when we call them vegetables and grains.</p>

<p>Eating well is as important as any form of medicine.  Here is an example of the long-range consequences of an inadequate diet.  I will use calories as an example, since most people understand the need for calories very well.  If you need 2500 calories every day to fight the good fight against your illness and you get only 90% or 2250 calories each day, than every 10 days you have lost the equivalent of one whole day of eating (10 x 250 = 2500).  If you continue eating at 90% of your needs for one month, you will lose 3 days worth of calories.  After one year of this regimen, it is as though you haven't eaten for 36 days, more than 5 weeks.  This means the lose of 5 weeks worth of energy, vitamins, minerals, phytochemical, protein and fiber.  Where is you body getting the nutrients it needs to continue its work of living and fighting off infection?  It is actually consuming itself.  The process that is going on is a form of slow starvation.  The less you eat the faster the decline.  The potential damage to your immune system from this loss cannot be made up by any medication from the east or west.</p>

<p>Do not fall into the trap of thinking that medicine, supplements, or meal substitutes can take the place of real food. Whatever type of medicine you decide to use, make sure you put it into a body that is well nourished.  Remember, eat you vegetables every day.</p>

<p><b><A NAME="recipe">FRIENDSHIP BREAD RECIPE</A></b></p>

<p><b>Hint</b>: This is wonderful little tea bread that is made with sourdough starter. You make the bread and give the starter and the recipe to a friend. Note, only use glass or plastic containers to store and mix in.</p>

<p>Mix a Sour Dough Starter and place it in the container:<br>
day 1 - do nothing<br>
day 2 - do nothing<br>
day 3 - stir with a wooden spoon<br>
day 4 - do nothing<br>
day 5 - do nothing<br>
day 6 - add 1 cup flour, 1 cup sugar, and 1 cup milk, stir with a wooden spoon.<br>
day 7 - do nothing<br>
day 8 - stir with a wooden spoon<br>
day 9 - do nothing<br>
day 10 - add 1 cup flour, 1 cup sugar, and 1 cup milk - stir with a wooden
spoon.  Take 3 cups of starter and put 1 cup into three separate containers
(to give away).</p>

<p>THE REST OF THE BATTER YOU USE FOR YOUR BREAD<br>
to the batter you add<br>
3/4 cup oil<br>
1/2 cup milk<br>
3 eggs<br>
1 teaspoon vanilla<br>
mix well using a wooden spoon</p>

<p>IN A SEPARATE BOWL COMBINE<br>
2 cups of flour<br>
1 cup of sugar<br>
1 1/2 teaspoon of baking powder<br>
6 oz of instant vanilla pudding<br>
2 teaspoons of cinnamon<br>
1/2 teaspoon of salt<br>
1/2 teaspoon of baking soda<br>
1 cup of nuts (optional)</p>

<p>mix well and add gradually to the batter</p>

<p>GREASE 2 BREAD PANS AND COAT SIDES WITH SUGAR AND CINNAMON<br>
add the batter<br>
bake at 325 degrees for 1 hour</p>

<p>ENJOY!!!  THE BATTER IN THE THREE SEPARATE CONTAINERS IS FOR YOUR FRIENDS.</p>

<p><b><A NAME="entertainment">ENTERTAINMENT</A></b></p>

<p><B>Metropolitan Museum of Art</B> <A HREF="http://www.metmuseum.org/htmlfile/calm_a/m_apg04.html">http://www.metmuseum.org/htmlfile/calm_a/m_apg04.html</A></p>

<p>Queen Nefertiti and the Royal Women: Images of Beauty from Ancient Egypt<br>
Through February 2,1997<br>
Special Exhibitions Galleries, 1st floor, adjacent to Greek and Roman Galleries</p>

<p>The royal sculptors of Amarna, particularly artists from the workshop of the master sculptor Thutmose, produced some of the most exquisite and individual images of royal women from ancient Egypt. This international loan exhibition focuses on about a dozen masterpieces from this time-sculptures representing Queen Nefertiti, her daughters, and other women of the royal family from childhood through adulthood and old age. Representations of these women in feliefs accompany the masterpieces.</p>

<p><i>Made possible in part by Lewis B. and Dorothy Cullman.</i></p>

<p><font color="#008000"><B>Annual Christmas Tree and Neapolitan Baroque Cr&ecirc;che</B></font><br>
November 30, 1996-January 5,1997<br>
Medieval Art, 1st floor</p>

<p>The Museum's long holiday tradition continues with the annual presentation of its Christmas tree, combining the customs of elaborate and densely populated 18th-century Neapolitan Nativity displays and candlelit northern European Christmas trees. Recorded Christmas music adds to the enjoyment of the holiday presentation. Lighting ceremony Friday and Saturday evenings at 7:00.</p>

<p><i>Made possible by The Loretta Hines Howard Trust. </i></p>

<p><b>Enduring Rhythms: African Musical Instruments and the Americas</b><br>
Through March 30,1997<br>
Arts of Africa, Oceania, and the Americas, 1st floor, The Michael C. Rockefeller Wing</p>

<p>The exhibition explores how a rich heritage of African musical instruments and musical stylebrought and preserved by Africans sold into slaveryhas been transformed over 5 centuries throughout the Western hemisphere.</p>

<p><b><a name="books">BOOKS</a></b></p>

<p><b>Tales from the Dragon Cave: Peace Making Stories for Everyone</b><br>
By James B. Boskey<br>
Williams, Arlene. Tales from the Dragon Cave: Peacemaking Stories for Everyone, Waking Light Press, PO Box 1329, Sparks, NV 89432 (160pp $15.00 1995)</p>

<p>The art of the storyteller is a subtle one, and this is especially true when the stories that are told are designed to teach as well as entertain, and especially true when they must reach an audience of any age. In tales from the Dragon Cave, Arlene Williams establishes herself as a master of the art, with stories that balance reality and fantasy, entertainment and education, and sophistication and clarity n a way that will appeal to listeners and readers of any age, from the youngest toddler through  the "grumpiest old man." While many of the stories have an oriental tone to them, they are in fact universal in their themes and especially effective in the manner in which they draw all within scope rather than excluding those who have not yet learned the lessons that they teach.</p>

<p>Publicity for this suggests that the target audience in children from age two to six, but, with the possible exception of teens who might reject some of the fantasy elements, it is difficult to conceive of an audience that would not be entranced and educated by these stories. The dragons f the stories are powerful but wise, and the humans and other characters are able to learn from them ways to improve their lives.</p>

<p>The stories are grouped to present four basic themes. The first is self-respect, and it is demonstrated through tales that show that this is something that all may have, but that must be earned through conscious effort not by mere chance. The contrast is nicely pointed up by the way in which the characters learn from their errors and grow in contrast. This is especially nicely managed in the person of the centaur mistress who at first appears evil, but is shown to be able to grow in understanding herself. The second theme is of the importance of words and the manner in which they are spoken.  Two stories focus on the nature of friendship and the power of language, while the third combines these with an introduction to the use of the "talking stick" as a peacemaking and maintaining device . The third group of stories teaches cooperation and the way that it can multiply the individuals strength, while the final theme presented is the search for win-win solutions and techniques of problem solving. It also reemphasizes the fact that wisdom is a substitute for magic in finding such solutions.</p>

<p>In addition to the stories, Williams also provides n each section of the book simple projects that children can undertake to reinforce the lessons of the stories. These would be of special value in the classroom setting, but they could also be used, by parents or group leaders working with children in other settings.</p>

<p>This is a wonderful book as the stories are delightful, informative and exceptionally well designed for either oral telling or reading. I would suggest that they could easily form the basis for an elementary school conflict resolution unit, serve as a text for a storyteller at a fair or carnival, or provide a healthy and enjoyable library reader session.</p>

<p><i>James B. Boskey, Professor of Law, Seton Hall Unversity is Editor of The Alternative Newsletter, A resource, Newletter on Dispute Resolution.</i></p>

<p><b><a name="lifestyles">LIFESTYLES</a></b></p>

<p><b>A Mother's Diary . . .Part-4</b><br> 
By Anna Nimos</p>

<p>On Wednesday, we walked to the video store  three blocks away.  Just as we were leaving the store, we ran into Tracy, who was amazed to see Marc so far from home.  She offered us a ride, but Marc said he felt pretty good and would prefer to walk.  About a block from home, Marc thought he was going to loose control of his bowels.  The morphine kept Marc constipated and we were always trying different remedies for this.  They usually didn't work, but this time Marc thought it had. He was very upset at the thought of soiling himself on the street and he started walking very fast but taking little steps. He had his arm over my shoulder and we were both shuffling along in double time when Marc said in a panic "Oh my God!  I shit my pants!" We could both smell it, but I assured him no one could tell and we should slow down and walk the last block and a half as calmly as we could. When we got home, Marc went into the bathroom and discovered it had only been gas, but the whole incident unnerved him and he told me he didn't feel safe walking any more.</p>

<p>The next day we took a taxi to the post office down town to check Marc's PO box and to go across the street to this dirty little coffee shop where mostly homeless and other down-and-out people hung out.  The shop served an apricot Danish which he had been craving.  When we got out of the taxi, Marc fell.  He kept saying, "My legs won't go right."  He was very unsteady and had to lean heavily on me.  I noticed people were making a lot of room on the sidewalk for us, like they didn't want to get too near us.  We went straight to the coffee shop and found a table by the window.  I got Marc's coffee and Danish and left him there while I went across the street to get his mail.   When I came back, Marc was sort of panicked and said he felt nauseated and wanted to get home as soon as he could.  I went out and flagged down a cab.  Then I went back in and walked Marc out to the cab.  It seemed like a very long walk across the sidewalk to the cab.  He did better from the cab to his apartment.  I think it was because he didn't feel so pressured since no one was around.</p>

<p>The day after that, Marc started swallowing air whenever he swallowed, which caused him to burp a lot.  This bothered him and he called the neurologist.  She seemed quite alarmed and asked him to come in the following day (a day early) for his spinal tap.  The following day he complained that his legs "wouldn't go right" and he could hardly keep his balance.  He began to get nauseated again and he asked for a wheel chair when we got to the hospital.  He carried a towel with him and vomited into it several times.</p>

<p>After the neurologist examined him, she told him that the chemo was not working and she would not be giving him more.  She told him very forthrightly that the tumor in his brain was growing rapidly and the pressure on his brain would gradually  in the next two or three weeks  shut down all of his functions.  It was already paralyzing his esophagus and that in a short time he would not be able to swallow and speech and walking would become difficult and then impossible.  Then she said since there was nothing else she could do for Marc, we should go over to see Dr. Abolaphia and he would help us make arrangements for hospice care or hospitalization.</p>

<p>She called me aside to see if I had any questions.  I asked her about medication.  She said she would recommend a morphine drip, Adivan and Dexamethazone  all intravenously.  That's all he would need.  I asked her about hydration, and she told me it would be easier on Marc not to hydrate him any more.  I didn't question this.</p>

<p>Marc wanted to die at home and Dr. Abolaphia helped us arrange for hospice care.  He  discussed with Marc the advantages and disadvantages of intravenous feeding.  In a nutshell, he didn't think it would make much difference, but it would require Marc to be hospitalized.  He thought the tumor would "shut his system down before he starved to death."  These were such hard things to hear, but Marc listened carefully and asked many questions  especially about the morphine pack Dr. Abolaphia had ordered for pain management.  How to use it.  When to increase the dose.  Could he over-dose?  Could he take it on the plane? Would he be able to go into Mexico with it and his other medications?  That's when I realized Marc still intended to make the trip to Mexico.</p>

<p>We got the apartment set up.  We put a hospital bed in Marc's room and we moved the couch in there and moved his bed into the living room. We got a wheelchair and a portable toilet. We bought a room monitor so we could hear what was going on in Marc's room from the living room and vise versa.   Marc was very uncomfortable during these days.  He felt the bed was too high and wanted me to try to lower it to the level his bed had been (i.e., a mattress and box springs on the floor) but there was no way.   He had trouble sleeping and the doctor prescribed Halcyon.  It helped, but we found the Adivan worked better.</p>

<p>That night I dreamed that I found all these electric buttons under Marc's bed and I pushed one and found it lowered the bed like Marc wanted it.  I pushed another one and it was an eject button that flipped the mattress up, throwing Marc out of the bed and across the room.  When I told Marc about the dream, he got the giggles. He had me tell the dream several times to visitors and the more horrified their reaction, the more we laughed.</p>

<p>Marc could barely walk and I realized soon he would need to be carried and I could no longer handle the situation by myself with the help of periodic visits from his care team and the hospice nurses.  We needed at least two of us there at all times.</p>

<p>Thanks to the leave transfer program at work, my leave was covered by leave donations from my co-workers, but Beth and Louis's jobs weren't so flexible, so I had been telling them not to come out until it was absolutely necessary.  But the time had come and I called them and asked them to come.</p>

<p>When I told Marc that Beth and Louis were coming, he became angry because he thought I had taken it upon myself to cancel the trip to Mexico.  I explained that I could not get him to Mexico by myself. We would have to take a wheel chair, the IV rack in addition to luggage  if we were still going.  He was adamant that we were. He was sure that if he could just feel the warm sun on his body, it would be worth any amount of trouble it took to get there.  I continued to make arrangements to go to Mexico.  We changed Beth and Louis's tickets to leave from Seattle.  We got the travel agent to change hotels so we could be in one with access to the beach by wheelchair. We found a hospice nurse willing to make the trip with us for a modest cost and made hotel and plane reservations for her. I even found out what to do in the event Marc died in Mexico.  But this trip frightened me more than anything we had been through.  (I made a desperate call to Gerry, wondering if we could use his jet.  He and my imagination helped me through the most agonizing times on that issue.)</p>

<p>Beth and Louis arrived the next day  March 21st.  Marc could still walk, but only with one of us on each side.  We had to lift him into the tub and onto the toilet.  Since he couldn't swallow, the saliva was collecting in his throat and his breathing was congested. The doctor ordered a patch to dry up his saliva and a pump to suck the saliva out of his throat.  I was worried about how Beryle would react to all of this but she plunged in like she had been doing it all her life.  There was nothing she couldn't or wouldn't do for her brother  from sucking saliva out of his throat to holding the jar for him to urinate in. Marc was having trouble sleeping and she went out and bought a special blind that was designed to keep out the light and put it up on the window in his room.  Then she hung towels around the edges to make the room pitch black.  Marc's hair had come in a lot and he had a ragged beard, so she shaved his face.  From the time she arrived, she insisted on sleeping in Marc's room almost every night.</p>

<p>Leon was as usual, unshakable and instinctively knew what to do for Marc to make him comfortable or for me to get me through.  We did everything we could to make Marc comfortable.   We bought an eggshell foam rubber bed liner and we lined the backside of his bed with pillows.  We put pillows between his legs and between the bottom of his feet and the foot of the bed.  Marc had lost so much weight that he was literally skin and bones.  Any part of his body was subject to a painful bed sore if it rested against a hard surface for very long  that included his knees resting against each other.</p>

<p>By the next day Marc could no longer walk.  Beryle or Leon carried him back and forth from his bed to the tub or the toilet.  Marc's legs were becoming paralyzed and he complained that they "felt funny."  He wanted Leon to rub and move his feet and legs a lot and took five or six hot baths a day.  In addition to his general discomfort, he was experiencing bouts of nausea and he thought a joint would help.  Leon rolled one for him, but by this time his throat had become paralyzed and he could not pucker his lips to suck on a joint, so Leon would take a drag and blow it into his mouth.  It seemed to calm his stomach and ease his discomfort.</p>

<p>We moved Marc from his hospital bed to the lazyboy chair in the living room to the bathtub, but he couldn't get comfortable. Several times he had very painful attacks of burning nerve pain on the surface of his skin like shingles.  The only thing that seemed to help was a joint, but even that wasn't working consistently.</p>

<p>The hospice nurse said she thought his electrolytes were out of balance and asked me when I had given him his last hydration.  I told her what the neurologist had said about hydration and that I hadn't given him any in two days.</p>

<p>She told me there were different schools of thought on hydration and called Dr. Abolaphia, who then talked to me.   He said he thought that hydration would not prolong Marc's suffering and that he would be more comfortable on hydration.  Withholding hydration from Marc never felt right to me and I gladly put him on round-the-clock hydration.  It helped and he became much more comfortable, but he continued to ask Leon for a joint a few times after that.</p>

<p>I've mentioned the marijuana because I didn't know what a common thread it was among care-givers.  Two days after Marc died, one of his friends took me to a support group for mothers who were caring for or who had cared for their sons with AIDS.  A major portion of that meeting was taken up discussing how and where to get medicinal (uncontaminated) marijuana and sharing how to use it.  One mother, older than I and quite frail looking, had her money stolen when she had been attempting to purchase Marijuana in an alley.</p>

<p>Another had paid a ridiculous price because she didn't know the going rate.  These mothers had been literally risking their lives to buy a drug that could bring a little comfort and a measure of well-being to their dying sons.  I was struck with the full realization of the risk Marc's friends and Leon had been taking to keep us supplied  and I will be ever grateful to them.  How tragic, cruel and ironic it seemed to add to the stress and fear of a grieving loved one or a very sick person, by forcing them to take their lives in their hands as well as risk arrest to get marijuana, when other more potent drugs, such as morphine were readily available.</p>

<p>It was March 22nd and Marc still insisted he could make the trip to Mexico.  We were supposed to leave the next day.  That morning Carl, one of the nurses that had been coming to the house since the beginning, called.  He had been on vacation to New Mexico and had caught a cold due to the change in climate which had forced him to stay away from Marc another week, but he said he was coming over that afternoon and wanted me to bring him up to date.  In the process, I conveyed my concern about Marc's determination to make the trip to Mexico.
"Do you want me to talk to him about it?" he offered and I said, "Please, I just can't tell him he can't go.  He has to make the decision himself."</p>

<p>Carl was the sweetest, most gentle heterosexual man I have ever met  next to Leon.  He always got on his knees when talking or taking care of Marc.  While he was checking Marc's vital signs, he talked to him about the trip to Mexico and his physical ability to travel and withstand the shock of a different climate and new germs.  After Carl left, Marc told me he didn't think he was strong enough to make the trip and asked me to cancel our tickets and try to get some of the money back.  He asked me to call Marc's Father and his wife and Will and have them come to Seattle instead of Mexico. They arrived in Seattle two days later on the 24th of March.</p>

<p><b><a name="briefs">CONSUMER BRIEFS</a></b></p>

<p><b>METRO:</b><br>
AIDS advocates are concerned that Hispanic AIDS Forum, The city's oldest and largest Latin AIDS service organization may go under.  The Village Voice reports that a nine month payroll crisis, Finings and the resignation of a dozen staff members has put the agency's future in jeopardy...</p>

,p>According to the New York Times, PROMESA, another agency with ties to the Latino community is being investigated by the city's department of investigation.  So far the audit has turned up $289,000 in unaccounted for public funds. Readers may remember the contract execution-style shooting of the agency's bookkeeper when she discovered discrepancies in PROMESA'S books.  PROMESA operates a therapeutic drug rehabilitation program in the Bronx.  It also operates Casa PROMESA, a residential program for AIDS patients with substance abuse problems...</p>

<p>The New York Times published two upbeat reports about minority AIDS prevention.  The first feature New York Harm Reduction Educators, a needle exchange program servicing Harlem and the Bronx. According to research from the chemical dependency Institute at Beth Israel Medical Center, such programs (there are six legal ones in New York) have halved the number of new HIV cases amongst intravenous drug users.  The second story concerned the Greater Brownsville Youth Council, a Brooklyn based agency that hires young people to educate their peers in the streets and giant housing projects that dominate Brownsville.  Peer counseling and condom distribution teams are often caught in the middle.  On one hand , threatened and mugged at gun point by angry drug dealers and on the other hand threatened with arrest and frisked for weapons by the police teams that saturate high crime neighborhoods...</p>

<p><b>NATION:</b><br>
Laurie Garrett, Newsday's trenchant reporter on the AIDS beat, wrote that despite possible changes in the Clinton Administration personnel there will not be dramatic changes in policy.  Increase emphasis and spending on vaccine development is likely.  Currently only one percent of all AIDS research dollars globally have gone to such research.  She also reported that the administration continues to anger many scientists and activists over it's failure to allocate federal money for needle exchange programs.  Despite the efficacy of such initiatives...</p>

<p>The successful passage of propositions to legalize marijuana for Medical use for PWA's and those with other painful, chronic illnesses in California and Arizona has unleashed a barrage of criticism.  A.M. Rosenthal (New York Times Columnist) Joseph Calfiano (President of The National Center on Addiction and Substance Abuse), General Barry McCaffray (Director of U.S. drug policy) and countless spokespersons at The Justice Department suggest that the public is being brain-washed by a small group with a stealth plan agenda to legislate the legalization of drugs, period...</p>

<p>Some churches affiliated with the Christian Coalition have found a new way to celebrate Halloween. The original Allhallow's Eve, the evening before All Saints' Day and All Souls' Day, a religious holiday whose traditions can be traced back to the Druids who believed that Saman, the lord of the devils, called forth evil spirits. At the Abundant Life Christian Center in Arvada, Colorado, visitors get a 30 minute trip into Hell House led by a "demon tour guide".  In the first room they witness a young homosexual who has died of AIDS lying in a casket...</p>

<p>Readers of Consumer News's February issue will remember the lead article on AIDS in the black community.  The recent forum at Harvard underlined our disquiet as speaker after speaker re-iterated the urgency of dealing with the epidemic facing African Americans.  Frustration was voiced at the inactivity of black leaders and it was noted that neither the NAACP or Congressional Black Caucus thought it important enough to send their big guns to the forum...</p>

<p><b><a name="editorial">Editorial</a></b><br>
Consumer News will begin its second year of publication.Thank you for your continued support. We have been fortunate to have had many fine articles from scholars, consumers and service providers. We strive to present information that will help you in your struggle with AIDS. This is not political paper with an agenda dedicated advocacy, although advocates submit articles that we print. Consumer News is meant to be upbeat and provide information that will be of benefit to you and other experts on AIDS.  We have much to look forward to in the coming months. Of note are upcoming articles by noted physicians Miguel Sanchez, MD, of Bellevue and New York University Medical Centers on Kaposis sarcoma, and Natalie Roche, MD, ObGyn of Beth Israel Medical Center on, HIV disease and Women's Health. We are also looking forward to conflict resolution articles by Larry Ray, Esq. of the National Association of Community Mediation and Peter Maida, Ph.D. JD of the Key Bridge Foundation on the Americans with Disabilities Act and the Justice Department.</p>

<p>In order to continue to make this Newsletter available to people living with AIDS free of charge, we have begun to sell advertising space. Although we expect be responsible in this endeavor, we do not endorse the products that are advertised and recommend that you do what good consumers do, shop carefully, buy from reputable companies and spend your money wisely. See you in 1997. </p>

<p><b><a name="oped">OpEd</a></b></p>

<p><b>NATAF</b><br>
by Tim Baros</p>

<p>I recently attended the National AIDS Treatment Advocates Forum (NATAF) in Washington D.C., sponsored by the National Minority AIDS Council.</p>

<p>NATAF has two main goals.  The first is to create a setting to train new treatment advocates and those interested in becoming treatment advocates.  The second is to provide experienced treatment advocates with an opportunity to be updated on various advocacy issues  and to discuss advocates with an opportunity to be updated on various advocacy issues and to discuss advocacy strategies with their peers.</p>

<p>Did you ever wonder what happened to all of those ACT-UP activists who marched in the streets early on in the HIV epidemic?  Who chained themselves to the desks of drug company officials?  Who took over the Food &amp; Drug Administration in 1988?  Well, these people are now directors or employees of agencies/coalitions/community organizations working full-time to assist people living with HIV and AIDS.</p>

<p>Many of these people attended NATAF, people from numerous AIDS organizations all over the country, including Act Up Golden Gate, AIDS Action Baltimore, AIDS Project Los Angeles, American Foundation for AIDS Research, Broadway Cares/Equity Fights AIDS, Gay Men's Health Crisis, Latino Commission on AIDS, Project Inform, Red+ Hot Organization and Treatment Action Group.  The Forum was also attended by advocacies, educators, employees and case-workers of HIV/ AIDS organizations.</p>

<p>At NATAF, I Met the "Stars" of HIV/AIDS Treatment and Advocacy.</p>

<p>I attended a "Basic Science 101" session with Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases.  Dr. Fauci provided participants with a basic understanding of HIV immune pathogeneses and T-Cell function.  It was quite a thrill to be able to ask questions to one of the most knowledgeable people in HIV/AIDS research.</p>

<p>Dr. Lark Lands gave a presentation on alternative therapies.  Dr. Lands is a health educator and author, a wonderful, warm, and very intelligent woman who has used her research expertise to do extensive investigations in the area of health enhancement.  Dr. Lands has worked with hundreds of people living with HIV and has spent the last decade compiling information on a total, aggressive, integrated approach to HIV infection.</p>

<p>Jeff Getty was a presenter of a session on Immune-based therapies.  Earlier this year Getty received Baboon bone marrow, and although his immune system "did not take" to the new bone marrow, Jeff appears to be doing very well and looks good.</p>

<p>I also met Dawn Averitt-Doherty of Atlanta's Women's Information Service & Exchange who was one of six panelists on the Vancouver Tele-conference had in July.  She made such an impression on me then and made more of an impression on me at NATAF.  Dawn found out that she was HIV infected at age 19, and for the next four years she listened to her doctor and did what he told her.  It wasn't until three years ago that she decided to learn more about HIV and has since become one of the leading women's HIV treatment advocates.</p>

<p>The National Council for International Health and Jairo Pedraza of the Global Network of People with AIDS presented "Promoting Access to Treatment and Care in Developing Countries." Jairo gave a compassionate plea for the availability of drugs and Medical care for HIV-infected people all over the world.  Two women spoke of their experiences in treating HIV-infected people in third world countries where the only medication they had to give their AIDS patients was aspirin.  These women would see their patients die a slow and painful death and all they could do was to be at their side and hold their hands.</p>

<p>The Caucus of Community Representatives to Research Programs was for anyone serving as a community representative for an AIDS clinical research program.  The caucus provided an opportunity for members of Community Advisory Boards of various research programs to meet their counterparts and discuss issues of common concern...issues such as increasing effectiveness and power within the program, sharing information about ongoing AIDS research, and supporting each other in community advocacy work.</p>

<p>Sally Cooper of New York's PWA Health Group led the Women's Treatment Advocacy session, which provided a basic overview of women-specific issues.  Topics included the need for more women-specific treatment information and materials, access and policy issues relevant to women.</p>

<p>Attendees in policy and Legislation 101 learned how decisions made by the U.S. Congress and numerous federal agencies have a tremendous impact on AIDS research and treatment.  Scott Sanders of AMFAR and Ann Donnelly of Project Inform provided descriptions of the structure and operations of Congress and relevant agencies and focused on mechanisms for public involvement.  A dialogue with both Washington-based and community-based advocates identified obstacles and provided successful strategies for individual and organizational involvement in Federal-level policy issues.</p>

<p>Participants in one session - Treatment Advocacy for Case Managers - were presented with a patient's Medical history and current clinical condition.  They were then asked to come up with an analysis of problems and gaps in the patient's current treatment regimen, and a more appropriate treatment plan was proposed for the patient.</p>

<p>New treatment advocates were given the opportunity to clarify questions with experienced treatment advocates they had regarding how to take what was learned at NATAF in applying this new knowledge in their own community.</p>

<p>NATAF culminated in its final session - AIDS Treatment Activism: The Vision and The Work.  All NATAF attendees were given the chance to give their ideas on the development of an action plan for the future and the importance of community organizing, grassroots mobilization and mentoring in HIV/AIDS treatment advocacy.</p>

<p>What intrigued me most about this forum was not how much I learned but how many people from all over the country, of different ages and of different races, are fighting HIV...either fighting HIV personally or professionally.  These people are on the front lines of this disease, fighting battles with a deaf government, fighting battles with the profit-conscious pharmaceutical companies, and fighting battles with people from the bigger cities to the small communities...ignorant people in the hills of Kentucky who "just don't get it."</p>

<p>To summarize, I thought I knew a lot about HIV and AIDS going into NATAF, but now I realize I knew less than what I thought I did.  NATAF gave me a chance to be able to question and converse with key people in the country who work in HIV/AIDS treatment and advocacy.</p>

<p><i>Tim Baros is a freelance writer.</i></p>

<p><b><a name="notices">NOTICES</a></b></p>

<p>Consumer News can be found at: A Different Light Bookstore, AIDS Service Center of Lower Manhattan, Bellevue, Hospital Center, Bellvue Hospital Center, Beth Israel Medical Center-Comprehensive Care Center, Bronx AIDS Services, DAS Centers, Federation of Protestant Welfare Agencies, Federation of Puerto Rican Communities, Fort Green HIV Project, Gay Activists Alliance of New Jersey, Gay Men's Health Crisis, Harlem United, The Lesbian and Gay Community Services Center, The New York Public Library, North Central Bronx Hospital, Project Hospitality, The Queens Borough Public Library, South Bronx Action Group, Veterans Administration Medical Center Manhattan, and on the Internet at <a href="www.aidsnyc.org/cnews">www.aidsnyc.org/cnews</a>.</p>

<p><b>Win $100.00 - Care partners wanted for study on AIDS</b><br>
Gay males who are currently caring for a partner with AIDS wanted for a study by Columbia University doctoral student. Its purpose is to design interventions which will help care partners cope with the complex and at times overwhelming tasks which caring for a partner with AIDS can entail. The first 75 participants will be entered in a lottery to win one $100.00 prize. For more information, please call: (718) 237-4248 or E-mail <a href="mailto:gene.thegak.koski@worldnet.att.net">gene.thegak.koski@worldnet.att.net</a> 

<p><b><a href="../conf/index.html">The 12th Annual Gay and Lesbian Addiction Studies</a></b><br>
Union Theological Seminary, 3041 Broadway at 121st St. in New York City Friday, April 11th, 1997  9:00 a.m. - to 5:00 p.m. Reconstructing Recovery: Healing Technologies for the 21st Century New Considerations and Approaches to the Substance Abuse Recovery Process. For more information contact the G.L.A.S. Conference Planning Committee c/o NYC Office of Gay & Lesbian Health Concerns, 125 Worth St., Box 67, New York 10013, (212) 788 -4399.</p>

<p><b><a href="../conf/ada.html">Mediation Training : Employment and the ADA</a></b>. Sunday, April 27, 1997, Arlington, VA, Tuesday, April 29, 1997, Newark, NJ. </p>

<p>HIV Planning Council: Tuesday Dec.3rd. 3.00 P.M. to 5.00 P.M., 52 Chambers Street, Room 201. PWA Support Group: Saturday Dec.14 11A.M. -12NOON, GMCH, 129 West 20st., Rm. 4A PWA Advisory Group: Sat Dec.14 12.00 NOON -2.00 A.M. GMCH, 129 West 20st., Rm.4A. HIV Planning Council: Tuesday Dec.3rd. 3.00 P.M. to 5.00 P.M., 52 Chambers Street, Room 201.
Positive Kids: Healthy Kids, Parents and care givers of HIV Positive Children are Invited to a Parents Forum on Saturday, November 16, 1996 at: 10:30 a.m. - 4:00 p.m. at PWAC NY 50 West 17th St. 8th Floor New York, New York Between 6th and 5th Aves. Guest Speakers, Parent Panel, Nutrition, Latest Medicines(treatments and tests), Alternative Therapies, Disclosure, Ect. Brunch and Baby-Sitting Provided, To Register call: Ms. Sharon Favors 212-647-1415. Ms. Emily Gordon 212-627-3390. 800-341-1880</p>

<p>Paul Matwiow, M.Div, CAC Pshychotherapist: Substance abuse therapy. Early Recovery Group for Gay Lesbian Bi and Trans Persons Thursday 6-7:30 p.m. Beginning January 16th.  (212) 349-2429 </p>

<p>HIV Positive and Body Positive and the Brooklyn VA HIV positive Drop in Center, Wednesdays, 6:00 p.m. to 7:30 p.m. Brooklyn Veterans, Health Center 40 Flatbush Ave Ext. (25 Chapel St.)  Brooklyn New York. For ore information call: Steve Koblick (718) 439-4337.</p>

<p><b>Jobs and Job Training</b><br>
Consumer Information and Conflict Resolution Project (CICRP), is accepting resumes for several positions: Administrative Assistant, Financial Officer, Computer Specialist, Senior Editor, and Webmaster.</p>

<p><b>FROST'D is Seeking Volunteers</b><br>
The mission of Foundation for Research on Sexually Transmitted Diseases (FROST'D) is helping homeless women whose activities on the street have put them at risk for HIV infection. FROST'D has a medical Center, two transitional housing programs, for people who are HIV positive and a court project for individuals charged with prostitution or various drug charges. 212-924-3733</p>

<p>Young People 14 to 21 out of School? In trouble? Homeless? Just Troubled? Join the Henry Street Settlement's Adolescents Against HIV/AIDS (A.A.H.A), Theater project. Stipend and Social Services are provided. Call, Rachel Beck, CSW: 212-254-3100.</p>

<p>GMHC Job Line: 212/337-1910. Current job openings at GMHC updated weekly.</p>

<p>Multitasking Systems of NY, Inc. (MTS). 38 East 29th Street, Ninth Floor, New York, NY 10016. 212-679-8234.</p>

<p>Volunteers, Writers, Artists, Photographers wanted for this publication. PWAs are encouraged to submit works for publication by Consumer News. Submit a sample of your work to: Consumer News, P.O. 41, Cooper Station, New York, NY 10276-0041. Materials cannot be returned. No phone calls please.</p>

<p>Volunteers wanted for Consumer information and Conflict Resolution Project, (CICRP). 212-387-0824.</p>

<hr size=2 width=50% align=center>

<p align=center><a href="index.html"><img src="../gifs/sleft.gif" vspace=5><br>
Consumer News index</a></p>

<hr size=2 width=50% align=center>

<p align=center><a href="../index.html">Consumer News</a><br> P.O. Box
41<br> Cooper Station<br> New York, New York 10026-0041<br> Last modified:
12/23/96<br> <a href="mailto:cnews@aidsnyc.org">cnews@aidsnyc.org</a><br>
copyright &#169; 1996 Kenneth Lowry</p>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-285</DOCNO>
<DOCOLDNO>IA093-001003-B003-47</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/cnews/conf/ada.html 199.29.141.24 19970121124121 text/html 8401
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:35:27 GMT
Server: NCSA/1.5.1
Last-modified: Tue, 17 Dec 1996 00:20:28 GMT
Content-type: text/html
Content-length: 8218
</DOCHDR>
<html>
<head>
<title>Mediation Training : Employment and the ADA</title>
</head>

<body bgcolor="#ffffff" text="#a62a2a" link="#856363"><font size=-1 face="arial, helvetica">
<blockquote>

<p align=center><a href="../index.html">home</a> | <a href="../news/index.html">newsletter</a> | <a
href="../contacts/index.html">contacts</a>| <a href="../papers/das.html">papers</a> | <a href="index.html">conferences</a> |
<a href="../about.html">about consumer news</a></p>

<p align=center><img src="../gifs/bronze.gif" width=50% height=4></p>

<h2 align=center>Mediation Training : Employment and the ADA</h2>

<p align=center><b>Full day advanced training for experienced mediators on Title I of the <a href="gopher://wiretap.spies.com/00/Gov/disable.act">Americans with Disabilities Act</a></b></p>

<p align=center><b>Two Convenient Trainings</b></p>

<p align=center><b>Cost: $150.00 per each Training</b></p>

<center><table><tr>
<td align=center><font face="arial, helvetica" size=-1><b>Sunday, April 27, 1997<br>
Quality Hotel/Courthouse Plaza<br>
Arlington, VA</b></font></td>
<p>
<td align=center><font face="arial, helvetica" size=-1><b>Tuesday, April 29, 1997<br>
Holiday  Inn/North<br>
Newark. NJ</b></font></td>
</tr>
</table></center>

<p><b>Sponsored By The Mediation Training and Information Center for the ADA and funded through a grant from William and Flora Hewlet Foundation.</b></p>

<p align=center><b>Space is Limited Register Early</b></p>

<p align=center><img src="../gifs/bronze.gif" width=50% height=4></p>

<h3 align=center>Registration</h3>

<p>Name____________________________________________________</p>
<p>Organization________________________________________________</p>
<p>Address___________________________________________________</p>
<p>City,_____________________________State,_________Zip_________</p>
<p>Previous Mediation Training</p>
<p>_______________________________________________</p>
<p>_______________________________________________</p>
<p>_______________________________________________</p>

<p>check the training you will be attending:</p>
<p>____ Arlington, VA ____ Newark, NJ</p>
<p>Print this form and send it with $150.00  (checks payable to Key Bridge Foundation) to:</p>

<p align=center><b>The Mediation Training and Information Center for the ADA</b><br>
1117 North 19th Street, Suite 903 <br>
Arlington, VA 22209  </p>

<p>Please List Needed Accommodations:</p>
<p>________________________________________________</p>
<p>________________________________________________</p>

<p align=center><img src="../gifs/bronze.gif" width=50% height=4></p>

<p align=center>Mediation Training : Employment and the ADA</p>

<p>For experienced Mediators who would like to utilize their mediation skills n resolving disputes arising from Title I of the Americans With Disabilities Act (ADA). Title I is specific to issues regarding employment.</p>

<center><table border=1 width=70%>
<tr>
<th colspan=2><font face="arial, helvetica" size=-1>Training Agenda</font></th>
</tr>
 <td><font face="arial, helvetica" size=-1>8:15 am</font><td><font face="arial, helvetica" size=-1>Registration and Continental Breakfast</font></td>
</tr><tr>
<td><font face="arial, helvetica" size=-1>8:45 am</font><td><font face="arial, helvetica" size=-1>Introductions and Opening Statements</font></td>
</tr><tr>
<td><font face="arial, helvetica" size=-1>9:00 am</font><td><font face="arial, helvetica" size=-1>Mediator's Overview of Title I of the ADA</font></td>
</tr><tr>
<td><font face="arial, helvetica" size=-1>10:15 am</font><td><font face="arial, helvetica" size=-1>Break</font></td>
</tr><tr>
<td><font face="arial, helvetica" size=-1>10:30 am</font><td><font face="arial, helvetica" size=-1>Mediator's Overview (contd.)</font></td>
</tr><tr>
<td><font face="arial, helvetica" size=-1>11:30 am</font><td><font face="arial, helvetica" size=-1>Demonstration - Mediating a Title I ADA Complaint</font></td>
</tr><tr>
<td><font face="arial, helvetica" size=-1>12:00 pm</font><td><font face="arial, helvetica" size=-1>Lunch</font></td>
</tr><tr>
<td><font face="arial, helvetica" size=-1>1:00 pm</font><td><font face="arial, helvetica" size=-1>Role Plays, Analysis, Discussion about Title of the ADA as it relates to each role play situation</font></td>
</tr><tr>
<td><font face="arial, helvetica" size=-1>3:00 pm</font><td><font face="arial, helvetica" size=-1>Break</font></td>
</tr><tr>
<td><font face="arial, helvetica" size=-1>3:15 pm</font><td><font face="arial, helvetica" size=-1>Role Plays, Analysis, Discussion (contd.)</font></td>
</tr><tr>
<td><font face="arial, helvetica" size=-1>5:30 pm</font><td><font face="arial, helvetica" size=-1>Close of Training
</tr>
</table></center>

<p><b>Trainers</b></p>
<ul>
<li><b>Peter Maida, Ph.D., J.D.</b>
<dt>Dr. Peter Maida has been a mediator and trainer for 17 years. He has been training mediators how to use mediation to resolve disagreements about the implementation of the ADA since its passage. He was on the second Qualifications Commission of the Society of Professionals in Dispute Resolution and is currently a Board Member of the Academy of Family Mediators. Dr. Maida has written a number of articles discussing the use of mediation to resolve disagreements about the implementation of the ADA.
<p>
<li><b>Sy DuBow, Esq.</b><dt>Sy Dubow was the Legal of the National Center for Law and Deafness at, Gallaudet University from 1975 untill 1996. He pl;ayed amn active role throughout the legislative process in the passage of the  ADA. He also provided comments and testimony to the EEOC and DOJ regarding their ADA regulations.  He has been the Director of a project promoting voluntary compliance with the ADA and provides technical assistance to public accommodations, state and local governments, employers, and individuals with disabilities.  Mr. Dubow is a trained mediator and has trained mediators about the ADA.
<p>
<li><b>Marilyn Golden</b>
<dt>Marilyn Golden is a Policy Analyst with the Disability Rights Education and Defense Fund in Berkeley, California. She was a member of a small group that directed the developement of the ADA and part of a larger coalition that lobied for its passage. She has educated policy makers and Members of Congress about the ADA. Directing a large contract with two federal agencies, EEOC and DOJ, she has trained a network of 400 people with disabilities throughout the U.S. to be specialsts on the ADA. Ms. Golden has been trained as a mediator and has trained mediators about the ADA.
</ul>

<center><table width=50% colspecs="50% 50%">
<tr>
<th colspan=2><font face="arial, helvetica" size=-1>For Overnight acccomodations contact:</font></th>
</tr><tr>
<td width=50%><font face="arial, helvetica" size=-1>Arlington: Quatily Hotel<br>
703-524-4000</font></td>
<p>
<td width=50% align=right><font face="arial, helvetica" size=-1>Newark: Holiday Inn/North<br>
201-589-1000</font></td>
</tr><tr>
<th colspan=2><font face="arial, helvetica" size=-1>For further information contact</font></th>
</tr><tr valign=top>
<td><font face="arial, helvetica" size=-1>1-800-346-7643<br>
703-528-1667<br>
<a href="mailto:KeyBfound@aol.com">KeyBfound@aol.com</a></font></td>
<p>
<td align=right><font face="arial, helvetica" size=-1>For HIV/AIDS Sensitivity Training Information for Mediators contact <a href="mailto:cnews@aidsnyc.org">cnews@aidsnyc.org</a></font></td>
</tr>
</table></center>

<p align=center><img src="../gifs/bronze.gif" width=50% height=4></p>

</blockquote>

<p align=center><a href="../news/index.html">newsletter</a> | <a
href="../contacts/index.html">contacts</a>| <a href="../papers/das.html">papers</a> | <a href="index.html">conferences</a> |
<a href="../about.html">about consumer news</a></p>

<p align=center><a href="../index.html"><img src="../gifs/sleft.gif"
vspace=5><br> <font size=-1>CNews Home Page</font></a></p>

<p align=center><img src="../gifs/bronze.gif" width=50% height=4></p>

<p align=center><a href="index.html">Consumer News</a><br> P.O. Box
41<br> Cooper Station<br> New York, New York 10026-0041<br> Last modified:
12/16/96<br> <a href="mailto:cnews@aidsnyc.org">cnews@aidsnyc.org</a><br>
copyright &#169; 1996 Consumer News</p>

</font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-286</DOCNO>
<DOCOLDNO>IA093-001003-B003-60</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/cnews/conf/index.html 199.29.141.24 19970121124128 text/html 7839
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:35:36 GMT
Server: NCSA/1.5.1
Last-modified: Wed, 15 Jan 1997 16:58:26 GMT
Content-type: text/html
Content-length: 7656
</DOCHDR>
<html>
<head>
<title>Consumer News: conferences</title>
</head>

<body bgcolor="#FFFFFF" text="#A62A2A" link="#856363">

<p><a href="../index.html"><font size="2" face="arial, helvetica"><img
src="../gifs/logo.gif" alt="[logo]" width="305" height="116"></font></a><a
href="../../Architext/aidsnycquery.html"><font size="2"
face="arial, helvetica"><br>
<b>search www.aidsnyc.org</b></font></a></p>

<blockquote>
    <p><font size="2" face="arial, helvetica">This page lists
    conferences both directly sponsored by the Consumer
    Information and Conflict Resolution Project, and links to
    pages describing conferences of interest to the community. If
    you know of a conference that is appropriate for this page,
    please </font><a href="mailto:cnews@aidsnyc.org"><font
    size="2" face="arial, helvetica">contact us</font></a><font
    size="2" face="arial, helvetica">.</font></p>
    <p align="center"><font size="2" face="arial, helvetica"><img
    src="../gifs/bronze.gif" width="50%" height="4"></font></p>
    <ul>
        <li><p align="left"><font color="#804000" size="2"
            face="Arial">March 7-9, 1997, Mission Valley, San
            Diego, CA. The Center for Medical Ethics &amp;
            Mediation, Spring 1997 Three Day Mediation
            Certificate Program, </font><a href="mediate.html"><font
            color="#804000" size="2" face="Arial"><strong>&quot;Successful
            Healthcare Conflict Resolution: Mediation &amp;
            Negotiation Training&quot;</strong></font></a><font
            color="#804000" size="2" face="Arial"> </font></p>
        </li>
        <li><p align="left"><font color="#804000" size="2"
            face="arial, helvetica">Sunday, April 27, 1997,
            Arlington, VA, Tuesday, April 29, 1997, Newark, NJ. </font><a
            href="ada.html"><font color="#804000" size="2"
            face="arial, helvetica"><b>Mediation Training :
            Employment and the ADA</b></font></a></p>
        </li>
        <li><font color="#804000" size="2"
            face="arial, helvetica">June 3-7, 1</font><font
            size="2" face="arial, helvetica">997 San Francisco,
            CA. <b>Association of Family and Conciliation Courts
            Annual Conference and Second World Conference on
            Family Law and the Rights of the Child</b>. Contact:
            AFCC, 329 W. Wilson St., Madison, WI 53703. 608-251
            4001</font></li>
    </ul>
    <ul>
        <li><font size="2" face="arial, helvetica">July 15-19,
            1997, Cape Cod, MA. <b>Academy of Family Mediators
            Annual Conference</b>, Academy of Family Mediators, 4
            Militia Dr., Lexington, MA 02173. 617-674-2663. Fax:
            (617) 674-2690. </font></li>
    </ul>
    <p align="center"><font size="2" face="arial, helvetica"><img
    src="../gifs/bronze.gif" width="50%" height="4"></font></p>
    <p align="center"><font size="2" face="arial, helvetica"><b>The
    12th Annual Gay and Lesbian Addiction Studies</b><br>
    To Be Held at Union Theological Seminary<br>
    3041 Broadway at 121st St. in New York City<br>
    Friday, April 11th, 1997 9:00 a.m. - to 5:00 p.m.</font></p>
    <p align="center"><font size="2" face="arial, helvetica">Theme:<br>
    <b>Reconstructing Recovery:<br>
    Healing Technologies for the 21st Century<br>
    New Considerations &amp; Approaches to the Substance Abuse
    Recovery Process</b></font></p>
    <p align="center"><font size="2" face="arial, helvetica">Keynote
    Speaker:<br>
    <b>Michael Picucci, Ph.D., Nacac II</b><br>
    Author of<br>
    Complete Recovery: An Expanded Model of Community Healing</font></p>
    <p align="center"><font size="2" face="arial, helvetica">Registration
    materials will be mailed in February 1997</font></p>
    <p align="center"><font size="2" face="arial, helvetica">For
    more information contact the<br>
    G.L.A.S. Conference Planning Committee<br>
    c/o NYC Office of Gay &amp; Lesbian Health Concerns<br>
    125 Worth St., Box 67, New York 10013<br>
    (212) 788 -4399</font></p>
    <p align="center"><font size="2" face="arial, helvetica"><img
    src="../gifs/bronze.gif" width="50%" height="4"></font></p>
    <ul>
        <li><font size="2" face="arial, helvetica"><b>Second
            International Conference on Nutrition and HIV
            Infection</b> </font><dl>
                <dt><font size="2" face="arial, helvetica">April
                    23-25, 1997, Cannes, FR - France </font></dt>
                <dt><font size="2" face="arial, helvetica">Contact:
                    Dr. Thierry Saint Marc, Pavillon P - Hopital
                    E. Herriot - 69437 Lyon Cedex 03 - France,
                    (33) 72.11.01.95, FAX: (33) 72.33.00.44 </font></dt>
                <dd><font size="2" face="arial, helvetica"></font>&nbsp;</dd>
            </dl>
        </li>
        <li><a href="http://www.ias.se"><font size="2"
            face="arial, helvetica"><b>12th International
            Conference on AIDS</b></font></a><font size="2"
            face="arial, helvetica"> </font><dl>
                <dt><font size="2" face="arial, helvetica">June
                    28-July 3, 1998, Geneva, SW - Switzerland </font></dt>
                <dt><font size="2" face="arial, helvetica">Contact:
                    Conference Secretariat, 12th International
                    Conference on AIDS, Congrex(Sweden)AB, Box
                    5619, S-114 86 Stockholm, Sweden<br>
                    +46 8 612 69 00 FAX: +46 8 612 62 96<br>
                    Internet email: </font><a
                    href="mailto:aids98@congrex.se"><font
                    size="2" face="arial, helvetica">aids98@congrex.se</font></a><font
                    size="2" face="arial, helvetica"><br>
                    World Wide Web home page: </font><a
                    href="http://www.ias.se"><font size="2"
                    face="arial, helvetica">http://www.ias.se</font></a><font
                    size="2" face="arial, helvetica"> </font></dt>
            </dl>
        </li>
    </ul>
    <p align="center"><font size="2" face="arial, helvetica"><img
    src="../gifs/bronze.gif" width="50%" height="4"></font></p>
</blockquote>

<p align="center"><a href="../news/index.html"><font size="2"
face="arial, helvetica">newsletter</font></a><font size="2"
face="arial, helvetica"> | </font><a
href="../contacts/index.html"><font size="2"
face="arial, helvetica">contacts</font></a><font size="2"
face="arial, helvetica">| </font><a href="../papers/das.html"><font
size="2" face="arial, helvetica">papers</font></a><font size="2"
face="arial, helvetica"> | </font><a href="../about.html"><font
size="2" face="arial, helvetica">about consumer news</font></a></p>

<p align="center"><a href="../index.html"><font size="2"
face="arial, helvetica"><img src="../gifs/sleft.gif" vspace="5"
width="36" height="32"><br>
CNews Home Page</font></a></p>

<p align="center"><font size="2" face="arial, helvetica"><img
src="../gifs/bronze.gif" width="50%" height="4"></font></p>

<p align="center"><font size="2" face="arial, helvetica">Consumer
News<br>
P.O. Box 41<br>
Cooper Station<br>
New York, New York 10026-0041<br>
</font><font size="2" face="Arial">Last modified: <!--webbot
bot="Timestamp" startspan s-type="REGENERATED"
s-format="%m/%d/%y" -->01/14/97<!--webbot bot="Timestamp"
i-checksum="13750" endspan --><br>
</font><a href="mailto:cnews@aidsnyc.org"><font size="2"
face="arial, helvetica">cnews@aidsnyc.org</font></a><font
size="2" face="arial, helvetica"><br>
copyright  1996 Consumer News</font></p>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B31-287</DOCNO>
<DOCOLDNO>IA093-001003-B003-84</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/cnews/news/9610.html 199.29.141.24 19970121124142 text/html 111430
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:35:44 GMT
Server: NCSA/1.5.1
Last-modified: Mon, 11 Nov 1996 13:15:23 GMT
Content-type: text/html
Content-length: 111245
</DOCHDR>
<html>
<head>
<title>Consumer News: October November 1996</title>
</head>

<body bgcolor="#ffffff" text="#a62a2a" link="#856363">

<p><a href="index.html"><img src="../gifs/ban1.gif" alt="[logo]"></a></p>

<h3>Vol. 1  No. 10 October November 1996</h3>

<blockquote>
<font size=-1>
<p><b>Contents:</b><br>
<A HREF="#hud">HUD Secretary Henry G. Cisneros' Directive on HIV/AIDS</A><br>
<A HREF="#conflict">How Good Case Managers Make Tough Choices: Ethics and Mediation</A><br>
<A HREF="#housing">MODEL HIV/AIDS PROJECTS</A>: Community Partnerships for Housing Assistance and Related Services<br>
<A HREF="#health">The Interplay of Alcohol Use and HIV - Challenge to the Mental Health Professional</A><br>
<A HREF="#nutrit">Recipe: Cream of Mushroom Soup</A><br>
<A HREF="#enter">Entertainment</A>: Boys Choirs in Concert, the Cloisters, the Museum of Modern Art<br>
<A HREF="#books">Books</A>: The Art of Meditation<br>
<A HREF="#life">Lifestyles</A>: A Mother's Diary of Her Son's Struggle With AIDS -- Part Three<br>
<A HREF="#briefs">Consumer Briefs</A>: Metro, Nation, State<br>
<A HREF="#edit">Editorial</A> - A Cultural Perspective<br>
<A HREF="#oped">Op-Ed</A>: DAAIR<br>
<A HREF="#notices">Notices</A>: Jobs and Job Training
</p>

<hr size=4 width=50% align=center>

<p><a name="hud"><b>HUD</a> Secretary Henry G. Cisneros' Directive on HIV/AIDS</b><br>
The following are excerpts of Secretary Cisneros's Directive on HIV/AIDS.<br>
<i>By Henry G. Cisneros</i></p>

<p>Over the past two years, I have been meeting with people with HIV infection and people with AIDS, as well as with providers of housing for these populations. These productive discussions have assisted me in further understanding the unique obstacles faced by many people with HIV infection and AIDS, and their families, in securing housing and related services. I am writing to make you aware of the programs and protections the Department offers people with HIV infection or AIDS, and to clarify the qualification of HIV or AIDS as a disability.</p>

<P>Awareness of the housing, services, and protections that exist for persons with AIDS is essential for maintaining HUD's active role in ensuring safe affordable and available housing for persons with AIDS or HIV infection.</p>

<p><b>Protection from Discrimination: The Office of Fair Housing and Equal Opportunity</b><br>
Persons with HIV infection and persons with AIDS are protected from discrimination under civil rights laws. It is illegal to discriminate against a person because of a real or perceived disability.</p>
 
<p>HUD stands ready to investigate cases where individuals with AIDS or HIV infection, or individuals perceived to have AIDS or HIV infection, have been subjected to discrimination in housing, If they have not already done so, local Offices of Fair Housing and Equal Opportunity will contact AIDS service organizations in their areas to explain the procedures for reporting cases of discrimination.</p>

<p>The Office of Fair Housing and Equal Opportunity (FHEO) assists people in understanding their rights under the Fair Housing Act and other provisions.   If persons with AIDS or HIV infection believe they have been discriminated against, or have questions, FHEO's Office of Investigation will discuss this matter in a confidential manner and will take immediate action when it is required to prevent homelessness or other serious harm. FHEO will work with the Department of Justice to apply all pertinent measures (e.g. temporary restraining orders, injunctive relief) to facilitate prompt resolution if conciliation and other means of dispute resolution are not successful.</p>

<p>Field Offices are directed to make appropriate referrals to FHEO in one of its ten Enforcement Centers and other agencies (i.e. State Attorneys General offices) to meet the needs of consumers living with HIV infection and AIDS.</p>

<p>You may contact the FHEO Office of Investigations at 1-800 -669-9777, via any HUD Office or at Headquarters at 202-708-0836. The Federal Information Relay Service TDD umber is 1-800-877-8339.</p>

<p><b>Targeted Assistance: Housing Opportunities For Persons With AIDS</b><br>
The HOPWA program makes grants to local communities, states and non-profit organizations to benefit clients and their families who are low-income where the client has a HIV positive status or a diagnosis of AIDS. HOPWA funds may be used for a wide range of housing, social services, program planning; and development costs. These include, but are not limited to, the acquisition, rehabilitation or new construction of housing units, costs for facility operations, rental assistance and short-term payments to prevent homelessness. HOPWA funds may be used for supportive services, such as health care and mental health services, chemical dependency treatment, nutritional services, case management, assistance with daily living, and other services.</p>

<p><b>Other HUD Programs That May Be Used To Assist Persons With HIV Or AIDS</b><br>
While HOPWA provides housing specific to the needs of people with HIV/AIDS, it is not the only HUD program that serves this population. People living with HIV/AIDS who meet the program requirements (e.g. low-income, homelessness, etc.) are eligible for any HUD programs for which they might otherwise qualify. Examples of these programs include Public Housing, Assisted Housing programs, Section 8 vouchers/certificates, and the Continuum of Care Homeless Assistance programs (Shelter Plus Care, Supportive Housing, and Section 8 SRO Mod Rehab.</p>

<p><b>Your HIV/AIDS Resource: HUD'S Office of HIV/AIDS Housing</b><br>
Last year in an effort to emphasize our commitment to address the housing and service needs of the growing number of persons living with HIV/AIDS, I created an Office of HIV/AIDS Housing within the Community Planning and Development (CPD) division of HUD. You should consider this office a resource in HUD to support efforts to respond to the needs of persons living with HIV/AIDS in our communities. In addition to managing the HOPWA program, This office works internally in HUD to ensure that housing concerns are not forgotten in our government's efforts to assist persons living with HIV/AIDS. Also I have asked the staff the Office of HIV/AIDS Housing to serve as HUD's link to the National AIDS Policy Office and other Federal Departments addressing HIV/AIDS issues to ensure that Housing concerns are not forgotten in our government's efforts to assist person's living with HIV/AIDS.</p>

<p align=center>Office of HIV/AIDS Housing<br> 
U.S. Department of Housing and Urban Development<br>
451 7th Street S.W., Room 7154<br>
Washington, D.C. 20401<br>
Phone: (202) 708-1934<br>
TDD: 1-800-887-8339<br>
Fax: (202) 708 1744</p>

<p><i>Information on HOPWA and Other HUD programs is also available on the HUD Home Page on the World Wide Web at <A HREF="http://www.hud.gov">www.hud.gov</A> and from Community Connections Support line at 1-800 998-9999 or TDD-1800-483-2209</i></p>
	
<p><b><A NAME="conflict">Conflict</A> Resolution</b></p>

<p><b>How Good Case Managers Make Tough Choices: Ethics and Mediation</b><br>
<i>By Mileva Saulo, Ed.D., RN, and Robert J. Wagener, MA, M.Div.</i></p>

<p><i>Maintaining a balance between the multiple roles and responsibilities of case managers is a delicate task.  Often, competing values result in conflicts that defy easy resolution.  Ethical principles, values, and the mediation process can serve as a type of `tool chest' to help case managers resolve ethical conflicts.. The  first part of this article provides an overview of some of these processes and issues, and is continued on our web page. Part II in the next issue, will provide examples of applying the basic information in the 'tool chest' for resolution of an ethical issue or conflict. These articles are printed in their entirety on the Consumer News web page, www.aidsnyc.org/cnews</i></p>

<p>Reprinted with permission from Saulo, M. and Wagener,RJ. How good case managers make tough choices: Ethics and Mediation, <I>J of Care Manage</I>. 2(2):10-16, 35-38.</p> 

<p>The health care environment in which many case managers were educated is gone and will not return.  Changes in medical technology, organizational structures, payment mechanisms, financial resources, and societal expectations have created complex issues and challenges.  In this constantly changing environment, the case manager or care coordinator has been regarded as one member of the health care team who will coordinate care and advocate for clients and families, while still addressing issues of cost effectiveness and quality of care. <sup>1</sup></p>

<p>Over the years, multiple roles have been attributed to case managers, including that of facilitator, liaison, coordinator/gatekeeper, broker, educator, negotiator, monitor, reporter, and patient advocate.<sup>2</sup>  While acting in these capacities, and trying to balance issues of quality of care and cost, case managers have also had to deal with complex internal and external relationships.  Although these multiple roles are a framework for managing the complex situations that arise as patients and families struggle to cope with catastrophic illnesses, case managers are increasingly faced with problems that arise from conflicting values, treatment goals, and desired outcomes.  Often, the ethical issues raised by these conflicts have no ready answers.  Common sense suggests that conflict resolution might emerge out of skilled use of dialogue, inquiry, and problem solving, and through effective communication.  Basic nursing education programs provide limited skills in conflict management and negotiation.  Those skills needed to manage conflict can be learned<sup>3</sup>; a growing body of literature deals with applying these skills to the health care environment.</p>

<p>This article will appear in two parts.  Part I, in this issue, provides and overview of the mediation process, clinical ethics, ethical issues in a managed care environment, and ethical reasoning.  A case study approach in Part II will show how the skills outlined in the following discussion can "help good case managers to make tough choices."  These acquired skills are applicable irrespective of setting or model of case management.</p>

<p><b>Ethical Issues in Health Care - Setting the Tone</b><br>
The ethical issues in health care today are greater than simply those related to refusal of or withdrawal of life support.  Youngberg<sup>4</sup> identifies additional dilemmas: the use of aggressive treatment given to preterm, very-low-birth-weight infants who may survive but face life with multiple lifelong physical and mental problems; requests for costly treatments with questionable efficacy for patients whose insurance does not cover such benefit; and issues related to access to care, rationing of care, and patient selection of procedures (such as organ transplant) [or combination drug therapies], where demand may exceed supply or where costs may be prohibitive.  Gillies<sup>5</sup> identified other issues; responses to requests for assisted suicide; obtaining patient's informed consent for care, treatment orders, and measures (for example, DNR orders, withholding/withdrawing nutrition and fluids); the need to balance the patients' need for confidentiality and privacy against society's need for protection from unreasonable risk; and the need to protect the rights of patients who participate in random trials of experimental treatments.</p>

<p>In addition, it is imperative to note the conflicts created by the managed care environment and long-term care.  Browdie<sup>6</sup> and Kane<sup>7</sup> suggest that additional ethical dilemmas are created when the case manager acts as both client advocate and gatekeeper.  Similar concerns are raised about physicians in managed care environments who must balance the interest of one patient with those of others.  Conflicts also develop when the physician must balance the needs of patients with their own financial interests and cost-containment measures.<sup>8</sup></p>

<p>Other conflicts for case managers are raised in a study by Wetle on the ethical issues in the case management of frail older persons.<sup>9</sup>  Here, there is potential conflict between the case manager and client families, agencies, other professional disciplines, employers, and the larger service system.</p>

<p>Conflicts can arise concerning who will make treatment decisions, who is the client, communication gaps, "turf battles," ageism, rationing, fragmentation, the rights and responsibilities of involved parties, who knows the client's wishes, and appropriate levels of care.<sup>9</sup>  Since all these ethical issues and conflicts will be a part of the health care environment for the foreseeable future, the challenge is to find manageable ways to understand the bases for the conflicts and then to work in partnership with all involved parties to find collaborative, rather than competitive, solutions.  One such collaborative model is developed based on the case manager as mediator.</p>

<p><b>Mediation-An overview</b><br>
The State of Pennsylvania has made the case manager the mediator so that a client's needs can be met on their own terms while making finite dollars last.  "This was the only way to guarantee that somebody who cares, and is not in a position to financially profit from the decision to serve, will be the one who is making the decisions about the client's care."<sup>6</sup>  The following discussion of mediation in case management-to be followed in detail in Part II of this article shows the relevance of values, ethical principles, and ethical theory to ethical decision making in case management.  Look upon this knowledge and the skills as a "tool chest" for case managers.</p>

<p>Mediation as a problem-solving intervention has long been used in labor-management disputes,<sup>10</sup> and is gaining prominence in psychology, psychiatry, law, and social work.<sup>11-13</sup>  The benefits of such an integrative, collaborative-rather than positional, competitive-approach to problem solving and negotiation is well established.<sup>14</sup>  Mediation is gaining importance as a process for health care professionals and ethics committees of institutions to use in resolving ethical issues.<sup>15-17</sup>  Certainly, this is a promising avenue for helping health care organizations in meeting the Joint Commission on Accreditation of Healthcare Organizations standards requiring that institutions have a mechanism in place not only to identify ethical issues but to educate consumers and providers in finding new ways to resolve contemporary bioethical concerns and issues.</p>

<p>Mediation is an interactive process in which the parties, with the assistance of a neutral person(s), systematically isolate individual issues or concerns to consider alternatives, develop options, and reach a consensus that addresses all the needs of the involved parties.  Unlike litigation, this process emphasizes that the parties involved in the conflict are responsible for making decisions.  Essentially, this is a self-empowering process.  Mediators attempt to create safe and rational environments where conflict can be addressed and managed constructively.  Mediation focuses on how the involved parties will resolve the conflict rather than dwelling on personal histories.  Recently, Bush and Folger<sup>18</sup> suggested that mediation offers more than the benefits of collaborative problem solving: It can offer involved parties the means to transform the negotiating positions of the individual disputants so that relationships are not only salvaged but strengthened.  This is a particularly relevant point when looking at the importance of strengthening the ongoing relationship between health care consumers, providers, and payors.</p>

<p>The mediator serves as a neutral third party in a three-stage process: (1) introduction and narratives, (2) exploring the issues, and (3) decision making.  In health care this process provides participants with an opportunity to share values, goals, means, hopes, dreams, and fears surrounding a particular illness or event.  Guided by the process and/or mediation, participants develop and reach agreement with their own unique resolution.  Thus, a part of the mediators "tool chest" is a working knowledge of ethical  principles, values formation, and history-all a basis for ethical decision making.</p>

<p><b>Ethical Principles Guiding Case Management Practice</b><br>
Health care professionals have long been guided by ethical codes of conduct.  The recently circulated draft of CMSA's <i>Proposed Statement Regarding Ethical Case Management Practice</I> outlines the principles for ethical case management.  This draft statement recognizes that although case managers emerge from a variety of health care disciplines, they continue to follow the code of ethics of their original profession.  Irrespective of the original profession, those who have entered the field of case management are guided by the principles of autonomy, beneficence, nonmaleficence, justice, and veracity (Table 1).<sup>19</sup>  Two other principles are fidelity and privacy.  Fidelity means faithfulness and promise-keeping, while privacy is an extension of autonomy and the right to be protected against any form of intrusive contact from others.<sup>20</sup>  All these moral principles guide behavior in the clinical setting and general health care environment.</p>

<p align=center><b>TABLE 1.  ETHICAL PRINCIPLES</b></p>

<p align=center><i>Autonomy</i>: "a form of personal liberty of action when the individual determines his or her own course of action in accordance with a plan chosen by himself or herself"</p>

<p align=center><i>Beneficence</i>: "the obligation or duty to promote good, to further a person's legitimate interests, and to actively prevent or remove harm"</p>

<p align=center><i>Nonmaleficence</i>: "refraining from doing harm to others"</p>

<p align=center><i>Justice</i>: "maintenance of what is right and fair,/i></p>

<p align=center><i>Distributive justice</i>: "deals with the moral basis for dissemination of goods and evils, burdens and benefits"</p>

<p align=center><i>Veracity</i>: "truth telling"</p>

<p>A review of these principles shows that the principles themselves can, and often do, conflict with each other.  For example, allocating scarce resources to one client in the name of autonomy, may mean that equally scarce resources will be unavailable to others.  Thus, a conflict is created between autonomy and justice.  On a clinical level, an RN may have to perform painful treatments while treating a severely underweight newborn in the NICU, setting up a conflict between "doing good" and "doing harm."  A timely example for a case manager is a pregnant woman, who asks in the name of privacy and autonomy (the right of the individual to make his or her own health care decisions), that HIV status be kept from her partner.  In the name of fidelity you hold it confidential, however, you are then conflicted between competing principles-fidelity to your patient and veracity (truth telling) and autonomy.  This is the proverbial "being caught between a rock and a hard place."</p>

<p>Another set of conflicts for case managers has emerged from the research and training under way at The Center for Medical Ethics and Mediation in San Diego, California.  Here, numerous training workshops have been conducted for health care professionals, including case managers and ethics committees.  Some conflicts to emerge include:</p>

<ul>
<li>Advocacy for client versus profit motive
<li>Confidentiality versus computerized information systems and electronic communication
<li>Scarce resources allocation versus quality care
<li>Professional clinical decision making versus treatment decisions by non-health care professionals
</ul>

<p>The perspective of Rushworth J. Kidder, an English professor and former journalist, sheds some light on these tensions and conflicts.  Kidder teaches ethics in corporate settings and takes a journalistic rather than an academic approach when describing ethical principles.  He presents a new paradigm of ethical principles, one derived from countless interviews and workshops with people in business and industry.</p> 

<p>Since making "right vs. right" choices is so common in our everyday experience, Kidder believes these types of choices can stand as models, patterns, or paradigms.<sup>21</sup> They are:</p>

<ul>
<li>Truth vs. loyalty
<li>Individual vs. community
<li>Short term vs. long term
<li>Justice vs. mercy
</ul>

<p>Take note of the different language Kidder uses.  These are terms most people understand; he avoids the mystery of philosophical terms.  According to Kidder, the ability to frame ethical dilemmas in terms of these four paradigms helps to cut through the mystery, complexity, and confusion in the analysis stage of problem solving.  In other words, these paradigms help the inquirer to cut to the heart of the matter.  While there is no guarantee that naming a conflict will resolve it, using simple terms helps to separate right vs. right vs. wrong.  By understanding traditional ethical language and setting forth principles in everyday terminology Kidder has provided case manger with a valuable tool.</p>

<p><b>Values-A Cornerstone for Action</b><br>
Conflicting values are often encountered while managing cases.  "Values are the lived sources of meaning for a person, and they actively constitute a person's history as they are put into words."<sup>22</sup>  If the prevailing ethical principle of autonomy is used, the case managers must work with, understand, and respect their clients' value systems.  In return, health care providers may ask that patients reciprocate by working with, understanding, and respecting the value system of care providers, care organizations, and payors Values are action oriented and give direction and meaning to life.  As general guides to specific behavior, they do not exist separately and independently but originate in an individual's consciousness and are expressed in behavior.  Values theorists agree that values are identified and clarified in a three-phase process: choosing, prizing, and acting.</p>

<p><i>Choosing</i>.  Choices are made freely, from alternatives, after the consequences of each alternative are considered, and complement other values.  This is the logical, critical, creative thinking part of the development of moral judgment.</p>

<p><i>Prizing</i>.  A person cherishes, is happy with, and willingly affirms the choice.  This is the emotional expression of values whereby the individual experiences positive self-esteem.</p>

<p><i>Acting</i>.  This is the behavioral component of the process.  An individual not only chooses a value and prizes it, but reflects the chosen value in behavior.<sup>23</sup></p>

<p>In this three-stage process, an individual affirms the choice, makes it part of their behavior and repeats the choice consistently.  This value system (organization of beliefs)which governs a person's mode of conduct, shapes decision making and perceptions and serves as a "filter" for governing how we rule information in or out.</p>

<p>According to Masssey,<sup>23</sup> core values are formed by the age of 10 years, and we change them only when we are confronted with significant emotional events.  He says that "you are what you are because of where you were when."  Put another way, values reflect time, events, and history and vary according to experience and culture.  Massey identifies four broad categories of world-view value differences, and classifies groups simply as: traditionalists, in-betweeners, challengers, and synthesizers.</p>

<p><i>Traditionalists</i>.  Values were shaped by the events of the 1920s to 1940s-a period when family structure was extended and identified roles were still in place.  Values in this group include patriotism, a recognition of authority, and legitimate chains of command.  Scarcity was common in these postdepression and World-War generations.  This led to a view of materialism based on the concept that "doing without as we grow up is important to us."  The Protestant work ethic, the traditional family, assigned roles, and the values of the "establishment" are all important to this group.  Their world view is characterized as "The Right Way."</p>

<p><i>In-betweeners</i>.  Values were shaped by the events of the late 1940s and 1950s.  This group is caught between the traditionalist and the highly individualized values embraced in the mid 1960s-colloquially called "The Organization Man" and "Take-This-Job-and-Shove-It" generations respectively.  In-betweeners maintain some traditional values, but shift between conforming and experimenting.  They were eager consumers of "how to........." books.  They function as a bridge between the traditionalists and the challengers and their work view is characterized as "The Good Way."</p>

<p><i>Challengers</i>.  Values were shaped by the events of the early 1960s through the mid-1970s.  This group is the product of wealth and power.  Just as scarcity was the valued materialism of the traditionalists, this group tends to take material possessions for granted, and appears to devalue a work of abundance.  This group challenged standards and authority.  They are very individualistic, demanding participation and personal consideration in the workplace.  Their work view is characterized as "My Way."</p>

<p><i>Synthesizers</i>.  Values were shaped by the events of the late 1970s to today.  This group appears to have borrowed something from each of the three preceding groups.  Synthesizers are more conservative than challengers, yet more cynical and skeptical than either traditionalists or in-betweeners.  The future appears to hold less for them in both a qualitative and quantitative sense.  They view "the system" as both problem and solution.  Synthesizers appear to accept the role of adapting to change by creating new systems to both provide and sustain.  Their world view is characterized as "The Correct Way."</p>

<p>It is essential that case managers involved in resolving differences understand these major shifts in values among groups, especially since changes will continue in culturally diverse populations.  An examination of the shifting paradigms in medicine and health over the last 50 years leads to a better understanding of the impact of differences among value groups (Table 2)<sup>24</sup>

<p>Case managers serve as mediators who "bridge the gap" between clients and providers who value both the old and new paradigms.  One prerequisite of this role is active-listening skills, because if conflict is to be resolved, case managers must be attentive to differences in values and bring theses differences to the surface for conscious consideration.</p>

<center><table>
<tr>
<th colspan=2><font size=-1>TABLE 2.  SHIFTING PARADIGMS OF MEDICINE AND HEALTH</font></th>
</tr>
<tr valign=top>
<th><font size=-1>Old Paradigm of Medicine</font></th><th><font size=-1>New Paradigm of Health</font></th>
</tr>
<tr valign=top>
<td><font size=-1><ul>
<li>Treatment of symptoms			       
<li>Primary intervention with drugs and surgery; emphasis on treatment and cure
<li>The patient as the dependent; the professional as the authority		         
<li>The body and mind are separate entities
<li>Health care insurance client chooses physician and hospital; cost is irrelevant in treatment options</font></td>
<td>
<font size=-1>
<ul>
<li>Search for patterns and causes
<li>Combination of invasive and noninvasive technology; emphasis on healthy lifestyle
<li>Patient as autonomous; the professional as therapeutic partner
<li>Body, mind, spirit are viewed as a continuum
<li>Health care is viewd as a business; access depends upon having insurance
<li>Physician choice is limtied; quality and cost-effectiveness are regularly scrutinized
</ul></font>
</td>
</tr>
</table></center>

<p><i>Adapted from Ferguson M. The Aquarian Conspiracy: Personal and Social Transformation in the 1080s.  Boston: Houghton Mifflin: 1980:246-248.</i></p>

<p><b>Values and Catastrophic Illness</b><br>
An understanding of the patient's values is very important when working with clients and families faces with important treatment decisions that accompany catastrophic illness.  Courts have used patients' values (expressed either verbally or in written form such as an advanced directive) as a baseline for inferring choices and decisions when persons are unable to speak for themselves.<sup>25</sup></p>

<p>A "values history" is one way to learn more about the patient's values, particularly as they relate to chosen and/or rejected treatments, or in advance directives.<sup>26</sup>  Thus, the case manager becomes an "alert listener" for the values of client, family, and provider regarding such issues as:</p>

<ul>
<li>Receipt of information
<li>Decisional authority and patterns
<li>Factors related to avoidance of pain and suffering
<li>Quality of life consistent with a life pattern
<li>Burden of patient to family and friends
<li>Preserving (not depleting) economic resources
<li>Prolongation of life at any cost<sup>25,26,28,29</sup>
</ul>

<p><b>Ethical Decision Making</b><br>
Building the foundation for ethical decision making begins with understanding ethical principles, paradigms, and values.</p>

<p>"You reader, whoever you are, are not a complete beginner in this subject.  You already have some idea of what `good' and `bad,' `right' and `wrong' mean, and you know some acts to be right, others wrong, some things to be good and some bad.  Now these are precisely the topics with which Ethics as a subject of systematic study deals."<sup>27</sup></p>

<p>The foundation of ethics is reflection.  Ethical inquiry begins by asking better questions.  In making tough choices and arriving at a tentative decision, case managers differentiate between "right vs. wrong" decisions, or moral and legal temptations, as opposed to "right vs. right," decisions, or ethical dilemmas.  Kidder<sup>21</sup> suggests subjecting tentative decision to three basic tests: "Stench," "Front Page," and "Mom."  Does it smell?  Would you want to read about your decision on the front page of a national newspaper?  Would you want your mother to know what you have done?  Answering "yes" to any of these questions is definitely a "right vs. wrong" decision and not an ethical dilemma.</p>

<p><b>Ethical Theories</b><br>
For purposes of this descussion, we assume that ethical principles and theories which serve to guide tthical decision making were addressed during a case manager's training in his or her original profession.  What follows is an examination of the basic features and weaknesses of rules-based or deontology (moral obligation or commitment) and ends-based theories.  In addition, we will look at a third theory, the narriative or discursive approach that we believe is needed in today's health care environment-one that is more applicable to clinical practice and the mediation process.</p>

<p><b>Rules-based theory</b>.-According to this ethical theory, the goodness of an act depends on the act's agreement with a fundamental duty or obligation to another human being.  Although rules-based decision makers may consider the unfavorable outcome of their decision, the anticipated negative outcome does not govern their final decision.  In other words, the rules win out.  Rules are usually applied as absolutes and not usually considered in contect.  When viewed as absolutes, rules often inflict harm.</p>

<p>This model has two major difficulties.  First, it is increasingly difficult to establish a consensus regarding rules in our pluralistic society.  Second, in the rush of the clinical setting, this cognitive process ignores the interpersonal dimension of conflict by leaving the patient out of the discussion.</p>

<p><b>Ends-based theory</b>.-This theory is also called outcomes thinking.  It is referred to as utilitarian, teleological, or consequential ethics.  Here, the goodness of an act is determined by its consequences and is sometimes generalized as "do whatever produces the greatest good for the greatest number."  This approach is typical in public policy decisions and is used in cost-benefit analysis when questions such as, "Who will be hurt"? Are asked.  The principal limitation of this approach is the criticism that one cannot always speculate on the "greatest good" without speculating on probable futures.  Critics ask, "Who defines the best possible result?"  "Who selects the solution that produces the most benefit over the greatest range?"</p>

<p>Both ethical theories are formulated on basic principles, values, and ideals governing moral behavior.  Rules-based thinking suggests questions around norms of obligation: "What is right or obligatory?"  "What am I to do?" it also suggests questions around values: "What are the ethical qualities of a good person?"  In contrast, ends-based thinking suggests questions such as "What are the goods we should cherish or the ends that we should seek?"<sup>30-31</sup></p>

<p>Although abstract theories are effective in purely academic discussions, applying them in a clinical situation is difficult, since they fail to allow for the expressed values of the patient.  Thus, in an analytical discuttion, the subjective component of nay clinical situation is lost.</p>

<p><b>Narrative ethics</b>.-Burrell and Hauerwass <sup>32</sup>suggest that narrative ethics is an alternative to the normative, abstract theories of deontology ant teleology (design or purpose in natural phenomena).  Normative ethics frees moral behavior from the context of the agent's beliefs, dispositions, and character.  Where is the patient's voice in the discussion of rules, rights, obligations, risk/benefit analysis?  In a normative framework, the patient is lost in the ethical quandary, and finding a solution becomes the object of the inquiry.  By concentrating on the decision, the case manager fails to adequately formulate a solution that arises out of the discourse, stories, or narratives of the involved parties.  "What we need to do is develop the reflective capacity to analyze those stories, so that we better understand how they function."<sup>32</sup></p>

<p>Narrative ethics enhances the oportunities for suggestions, solutions, and resolution.  The parties seek to engage in collaborative problem solving and mutually seek closure to their values conflict.  During mediation, the case manager uses knowledge of ethical principles (ethical theory) to help the involved parties analyze and define the conflict.  The "real story" emerges from the narratives of each party during the opening phase of mediation.  Different perspectives, values, and goals are heard directly by all parties during these narratives, rather than "filtered" throught third parties such as attorneys, bioethicists, or health care providers.</p>

<p><b>Conclusion</b><br>
We recognize the diverse areas in which case managers practice and the wide range of issues with which they cope on a daily basis.  We believe that the principles outlined in this article cut across the diversity of practice settings and the issues unique to each setting.  Conflicts are complex and involve differences in goals, means, values, and ethics; often, they are laden with emotion.  Mediation provides a framework in which these differences are isolated and examined.  It is a process that builds on small agreements, searches for mutual interests, and fosters collaboration that results in solutions that meet the needs of all parties.  It is an application of ethics to the clinical setting that is practical, rather than theoretical.</p>

<p>Clinical ethics is not about definitions, footnotes, philosophers, and dusty arguments.  "It's about inner impulses, judgments, and duties of people like you and me."<sup>21</sup>  This is not to dismiss philosophical inquiry as irrelevant, but instead to acknowledge that "for ethics to be practical and applicable it must be understood as the stuff of daily life."<sup>21</sup></p>

<p>In the clinical setting, a case manager's common sense, intuition, and reflection provide the raw material that gives life to ethical principles.  The process of decision making is enhanced by understanding ethics, contemporary ethical issues in health care, values, and mediation as an integrative problem-solving process.  Ethical thinkers are catalysts.  The moral viewpoint, gently added to a difficult situation, has an uncanny way of stimulating and transforming the decision making process.</p>

<p><I>article references <A NAME="mailto:cnews@aidsnyc.org">upon request</A></I></p>

<p><i>Meleva Saulo is Director of the Graduate Nursing Program 
and a Faculty Member of the Nursing Administration and Case Management Department of the University of Southern California in Las Angeles. Robert J. Wagener is President of the Center for Medical Ethics and Mediation in San Diego, California.</i></p>

<p><b><A NAME="housing">Housing</A></b></p>
	
<p><b>MODEL HIV/AIDS PROJECTS<br>
Community Partnerships for Housing Assistance and Related Services</b><br>
<i>By Fred Karnas Ph.D.</i></p>

<p>Earlier this fall, Housing and Urban Development Secretary Henry G. Cisneros announced $17.1 million in grants to 19 community-based programs addressing the housing needs of low-income Americans with HIV/AIDS.  The grants were made under the competitive portion of HUD's $171 million Housing Opportunities for Persons with AIDS (HOPWA) 1996 program.</p>

<p>"We know that for many people with HIV/AIDS adequate housing can mean the difference between life and death," Cisneros said.  "People with AIDS who lose their housing often die within six months.  That is why these grants are so critical.  They serve people when they're most vulnerable, with limited resources, often with less than ideal family and medical support systems."</p>

<p>Cisneros said that this year's grant process, with 140 applications for limited funding requesting almost $130 million in assistance, was very competitive.  After consideration of all applications, the Department selected proposals from 12 non-profit organizations, one State agency, and six local governments.  The 19 projects will be carrying out activities in 12 States and one project is for nation-wide activities with additional sites to be selected.</p>

<p>Eight of the grants were awarded under the HIV Multiple Diagnoses Initiative (MDI) which targets assistance to low-income persons living with HIV/AIDS who also have chronic alcohol and/or drug abuse problems and/or serious mental illness.  Under MDI, HUD assistance was offered in conjunction with the Department of Health and Human Services (HHS) to improve the integration of health care and other services with housing assistance.</p>

<p>In announcing the MDI awards, Cisneros said, "Clearly it is a significant challenge to escape homelessness, but if you are homeless with a severe disability, the obstacles are almost insurmountable.  This collaboration will more efficiently use existing HUD and HHS resources to assist some of this country's most vulnerable citizens."</p>

<p>"We have learned that to reach homeless persons with HIV and a multiplicity of other problems, we must provide integrated services, housing, and health care.  These innovative programs we are funding today will save lives and provide models for addressing this difficult problem," said HHS Secretary, Donna Shalala.</p>

<p>The HUD/HHS initiative is designed to address the needs of the most difficult to reach homeless population: persons with multiple diagnoses.</p>

<p>Additionally, nine of the 1996 HOPWA competitive grants were awarded to innovative projects serving as models for providing housing assistance and supportive services to the HIV/AIDS community, under the Special Projects of National Significance (SPNS) category.  Two other grants were for development of long-term comprehensive strategies for providing assistance in areas of the country that do not receive HOPWA grants by formula allocation.</p>

<p>The 19 selected applications indicate that 15,736 persons will be directly assisted during the operating period of these projects (up to three years), including: 4,995 persons with HIV/AIDS will receive some form of housing assistance; 1,659 additional family member will receive some form of housing assistance; and 9,082 additional persons with HIV/AIDS will benefit from supportive services.</p>

<p>The 19 applications propose the following aggregate uses of HOPWA funds: $5.8 million for Supportive services (34.1%); $3.8 million for housing development (acquisition, rehab, lease, new construction and operating costs for facilities) (22.4%); $3.2 million for rental assistance and short-term payments (18.7 %); $1.6 million for program development (technical assistance, information and resource development) (9.6%); $1.1 million for grant administration (6.5%); $0.8 million for MDI program evaluation and dissemination (4.7%); and $0.7 million for a reverse mortgage SPNS project (4.1%).</p>

<p>These applicants have pledged $45.7 million in other funds and resources as leveraging in support of their applications, including over 178,000 hours of volunteer time.</p>

<p>In the New York area, HOPWA grants are being made to the following five local organizations:</p>

<ul>
<li>Catholic Community Services for a MDI of $755,692 that will support "Operation Link," a housing services program in Jersey City that will reach out and "link" services to the "hardest to reach" homeless clients-those with HIV/AIDS and a severe mental illness and/or an addiction to alcohol and other drugs.
<p>
<li>United Bronx Parents, Inc., for a MDI project "Casita Esperanza" in the Bronx for $1,130,000, a culturally sensitive, one-stop service center and low-demand emergency and transitional housing program.
<p>
<li>The Actors' Fund of America for SPNS grant for $750,000 to support the Aurora project to provide 60 units of permanent, supportive housing for low-income persons with HIV/AIDS on the West Side of Manhattan.
<p>
<li>Bailey House, Inc., for a SPNS vocational rehabilitation program for persons with HIV/AIDS in New York City and nine other sites to be selected nation-wide for $717,268.
<p>
<li>Housing &amp; Services, Inc., for a MDI "Share Project" to be operated by their South Florida office to assist homeless persons with HIV/AIDS through activities in Miami, Florida for $1,090,000.
</ul>

<center><table border=1 width=90%>
<tr>
<th colspan=4><font size=-1>HOPWA 1996 Awards in the Metropolitan New York City Area</font></th>
</tr><tr>
<th><font size=-1>Grant Recipient</font></th><th><font size=-1>Type</font></th><th><font size=-1>Project Location</font></th><th><font size=-1>Amount
</tr><tr>
<td><font size=-1>Catholic Community Services</font></td><td><font size=-1>MDI</font></td><td><font size=-1>Jersey City, New Jersey</font></td><td><font size=-1>$755,692</font></td>
</tr><tr>
<td><font size=-1>United Bronx Parents, Inc.</font></td><td><font size=-1>MDI</font></td><td><font size=-1>New York City</font></td><td><font size=-1>$1,130,000</font></td>
</tr><tr>
<td><font size=-1>The Actors' Fund of America</font></td><td><font size=-1>SPNS</font></td><td><font size=-1>New York City</font></td><td><font size=-1>$750,000</font></td>
</tr><tr>
<td><font size=-1>Bailey House, Inc.</font></td><td><font size=-1>SPNS</font></td><td><font size=-1>New York City and other sites to be selected nationwide</font></td><td><font size=-1>$717,268</font></td>
</tr><tr>
<td><font size=-1>Housing &amp; Services Inc. (by their South Florida office)</font></td><td><font size=-1>MDI</font></td><td><font size=-1>Miami, Florida</font></td><td><font size=-1>$1,090,000</font></td>
</tr>
</table></center>

<p>United Bronx Parents, Inc. will use a MDI grant to establish "Casita Esperanza," a culturally sensitive, one-stop service center and low-demand emergency and transitional housing program.  The project will provide 12 emergency and 30 transitional beds to a total of 340 homeless single men and women with HIV/AIDS and chronic substance abuse problems who are entering or recently discharged fro inpatient detoxification services or are awaiting residential treatment placements.  The project fills a service gap identified in the New York State Consolidated Plan.  The program will engage participants through a continuum of ongoing low-threshold/recovery readiness counseling.  HIV services and contemporary substance abuse treatment approaches that are especially designed to handle the various stages of recovery, including relapse.</p>

<p>With low-demand entry requirements as an attraction, participants will then be offered life skills training including risk-reduction counseling, HIV education, and self-care.  Case managers will assist with obtaining entitlement benefits and accessing all proper mental health, primary care, and a full range of supportive services.  Transitional housing support will continue for up to five months and a housing counselor will aid in developing a plan for permanent housing with continued case management and supportive services.  As part of its information dissemination activities, the grantee will develop a technical assistance publication for organizations interested in replicating the project.</p>

<p>Catholic Community Services will receive MDI funds for a program by Catholic Community Services, "Operation Link," a housing services program in Jersey City that will reach out and "link" services to the "hardest to reach" homeless clients-those with HIV/AIDS and a severe mental illness and/or an addiction to alcohol and other drugs.  The program will be operated by a team of social service providers including Let's Celebrate and Jersey City Medical Center's Medical and Social Services for the Homeless. (MASSH) as well as Catholic Community Services.  This project will support leasing, operating and rehabilitation costs for a drop-in center and transitional and permanent housing facilities and related supportive services.</p>

<p>The CCS Operation Link goal is to demonstrate that the traditionally undeserved population can be effectively linked to a broad continuum of housing services designed to meet their special needs.  Five highly integrated graduated housing components are designed to move the target population from the streets to permanent housing: (1) an Assertive Mobile Outreach unit (AMO); (2) a No/Low Demand Drop-In Center; (3) a supported Transitional Housing Facility; (4) a Permanent Housing Facility; and (5) support from a staff of experienced behavior health and social service professionals and a team of specially trained Operation Link "Peers."</p>

<p>The support will help clients navigate the social service system and achieve a more stable, healthy, and independent lifestyle.  During its three years of operation, Link will provide services to up to 600 homeless persons, 75 of whom will receive direct housing placements.  It is anticipated that up to 30 will be women and children who will be provided with further specialized Link services.  Catholic Community Services is a non-sectarian, nonprofit social services corporation.</p>

<p>Under the Actors' Fund of America proposal, a Special Project of National Significance grant wil support the "Aurora" project to provide 60 units of permanent, supportive housing for low-income persons with HIV/AIDS on the West Side of Manhattan.  The Fund has acquired the Aurora, a 30-story apartment building on West 57th Street in New York City, and has converted it into an affordable, supportiv housing residence by utilizing private equity contributed through the sale of low-income housing tax credits.  The 178 bedroom units in the building's 98 apartments will provide shared housing for approximaely 190 people from three populaitons: people with HIV/AIDS, the elderly, and low-income working people.  In this congregate living environment, HOPWA-eligible residents will receive social and supportive services provided on-site by Actor's Fund social workers.  Over a three year period, the Aurora will be home to 222 people, including and estimated 95 persons living with HIV/AIDS and three family members who have a special need for stable, affordable housing.  An additional 200 persons with HIV/AIDS are expected to benefit from services.  As one of the City's largest residences which provides permanent housing for people with AIDS, the project is a pioneering effort at integrated and shared housing.</p>

<p>The Actors' Fund grant will provide funds for expanding on-site supportive services, operating costs, and technical assistance in managing this newly rehabilitated apartment building to provide shared units of permanent independent living.  The location of the Aurora apartment project on the West Side of Manhattan expands the amount and availability of affordable, supportive housing and allows many clients to remain in their neighborhood in proximity to their existing health care and other providers and networks.  The Fund has affiliated with St. Lukes'-Roosevelt Hospital and the Visiting Nurse Service of New York for the on-site provision of medical services. The fund's volunteer initiative will assist clients with "buddy" services and offer other educational and social activities.  Over $15 million of additional financial and volunteer contributions have been committed to this project in connection with the acquisition of the building through the use of Federal low-income tax credits and over $34 million in private equity.  The project also involves components to assist residents who are elderly or are low-income, disabled, and/or underemployed.</p>

<p>A nation-wide project will be undertaken by Bailey House, Inc., which currently operates a vocational/educational program for people living with AIDS in New York.  This national technical assistance grant will provide funds to test and replicate a Vocational/Educational Program Development Technical Assistance Project for persons living with HIV and AIDS.  Bailey House will work with the World Institute on Disability (WID) of Oakland, California, to develop supportive housing programs that challenge existing ideas about AIDS, disability, and employment.  The initiative responds to PWAs who are living longer, healthier lives by promoting greater independence and productivity by expanding the use of vocational/education programs by AIDS housing providers.  As a condition on site selections, no more than ten percent of these program funds will be used in the New York City EMSA.</p>

<p>The Bailey House project will identify participating agencies from a range of rural to urban settings, employment markets, and client characteristics and needs for technical assistance and program development support. The project proposes five stages: needs assessments, training, model development and implementation, monitoring and evaluation, and dissemination and replication. Over 150 clients are expected to be assisted by the project directly over three years.  In addition, participating organizations will have improved capacity and skills to help develop other similar efforts.  The project will issue training materials, a curriculum for technical assistance, adapt materials based on the WID's Vocational Rehabilitation and HIV/AIDS: A Resource and Training Manual and adapt policies and procedures based on the existing Bailey Housing model for participating supportive housing providers.</p>

<p>Housing and Services, Inc., (of South Florida) (HSI) will undertake the "Share Project," the first coordinated assistance program for multiply diagnosed homeless persons in Dade County, Florida.  An estimated 250 persons living with HIV/AIDS and their families will benefit fro supportive services and program development support designed to increase their access to appropriate care, including treatment for chronic substance abuse and/or serious mental illness.  The activities will be managed by the Miami office of this New York based non-profit housing provider in coordination with local Florida organizations.  The Share Project will involve specialized outreach efforts by Camillus Health Concerns and discharge planning for client transition from inpatient care by Jackson Memorial Hospital.  HSI will provide assistance to housing providers on developing and operating supportive housing programs, including the publication of an annual housing services guide for distribution to clients and providers, seminars on property management, and service design for programs serving special needs populations, leveraging predevelopement loans, business plans and other program development tools and tracking systems on client outcomes.  The activities will be coordinated with other supportive services provided by Dade County Homeless Trust, a public-private partnership on housing and services planning.  The proposed activities are consistent with the Metropolitan Dade County Consolidated Plan.</p>

<p>The HOPWA program provides funding for housing and services for low-income persons living with HIV/AIDS and their families.  Ninety percent of the annual appropriation is allocated by formula to eligible metropolitan areas and States based on the number of reported cases of AIDS in the area and incidence in the population.  In FY 1996, 49 metropolitan areas and 27 States qualify for formula grants and a total of $153.9 million has been allocated.  Communities which receive funds under the Department's affordable housing and community development programs, including recipients of HOPWA formula allocations, are involved in the Consolidated Planning process, that involves citizen participation in assessing needs, creating a strategic plan and detailing the use of federal and other resources.  Area plans should identify the unmet housing needs of persons living with HIV/AIDS and may use resources to address those needs.  In addition, ten percent of the total HOPWA appropriations is awarded by national competition as described above.</p>

<p>HOPWA funds may be used for a wide range of housing, social services and program planning and development costs, including, but not limited to, the acquisition, rehabilitation, or new construction of housing units, costs for facility operations, rental assistance and short-term payments to prevent homelessness.  HOPWA funds may be used also for supportive services, such as health care and mental health services, chemical dependency treatment, nutritional services, case management, assistance with daily living, and other services and for program development.</p>

<p>For More Information: Contact the HUD State or area Office or the Office of HIV/AIDS Housing, U.S. Department of Housing and Urban Development, 451 Seventh Street, SW, Room 7154, Washington, D.C.  20410, or phone (202) 708-1934; TTY 1-800-887-8339, FAX: (202) 708-1744.</p>

<p>Information on HUD programs and area consolidated plans is available on the HUD HOME Page on the World Web at <A HREF="http://www.hud.gov/home.html">http://www.hud.gov/home.html</A> and from Community Connections at 1-800-998-9999, by TTY at 1-800-483-2209, and email at <A HREF="mailto:amcom@aspensys.com">amcom@aspensys.com</A></p>

<p><i>Fred Karnas is Director of The United States Department of Urban Development, Office of HIV/AIDS Housing</i></p>

<blockquote>
<hr size=4 width=50% noshade>
<p><b>"A winning argument is possible only when, speaking out of our authority, we address the authority of the other...most of us do not tell much of the truth about ourselves.  We hold back our hurt, our anger, our deep dread.  We fear to reveal our fear, our joy, our jealousy, our hunger, our ideas, our insecurities ourselves. Credibility comes out of the bone-deeper yet-out of the marrow."<br>
Gerry Spence. How to Argue and Win Every Time.</b></p>
<hr size=4 width=50% noshade>
</blockquote>

<p><b><A NAME="health">Health</A> Care</b></p>

<p><b>The Interplay of Alcohol Use and HIV - Challenge to the Mental Health Professional</b><br>                                                
<i>BY PAUL MATWIOW, M.Div, CAC</i></p>
                    
<p>It is incumbent upon mental health practitioners to play a pivotal role in the prevention of HIV infection.  Providers who work with alcohol and substance abusers are called upon to address with their clients the multilayered interrelationship between their alcohol/drug use and HIV.  This article focuses on the interrelationship specifically between the two chronic and progressive diseases of alcoholism and HIV and  focuses on four topics: 1) the correlation between alcohol use and increased risk for initial HIV infection, 2) the importance of abstinence from alcohol for the HIV+ alcohol abuser, 3) the interplay between emotional issues relative to seropositive status and continued drinking or abstinence, and 4) the challenge this dynamic interplay presents to the clinician working with HIV+ alcoholics with the goal of dual relapse prevention (alcohol relapse prevention, and prevention of relapse into sexual activities at high risk for HIV transmission).</p>

<p><b>Correlation Between Alcohol Use and High-risk Sexual Behaviors</b><br>
Studies to date have explored the relationship between alcohol use and sexual behaviors at high-risk for HIV transmission.  Most have researched specific subgroup populations, finding a significant correlation between alcohol use and high-risk behaviors in those subgroups.1  Significantly, Shillington and colleagues (1995) found a significant correlation between heavy drinking and high-risk behavior, not in subgroups but in the general population.2  The studies show not a causal relationship, but a correlative relationship between drinking and risky sex.  They suggest that beyond the disinhibiting effects of alcohol on behavior and despite being knowledgeable of safer sex and HIV, other conjoining biological and psychosocial factors play a part in the determination of people to engage in risky behaviors.</p>

<p>Research seeking to identify these conjoining factors has led to a number of competing hypotheses that seek to explain the drinking/risky behavior connection relative to these factors.  Ostrow (1986) has labeled these competing hypotheses: the "disinhibition," "aphrodisiac," "personality," "social context," and "multifactorial" hypotheses.3  The disinhibition hypothesis proposes that the effect of alcohol permits the drinker to act out high-risk sexual desires and attribute them to the alcohol, thus avoiding personal responsibility, i.e., being inebriated serves as an acceptable excuse for risky sexual behaviors.  The aphrodisiac hypothesis suggests that in spite of the fact that alcohol is a depressant, the drinker's belief that alcohol will enhance sexual arousal leads to alcohol use during sexual activity with a resulting lapse into high-risk behaviors in spite of safer sex knowledge.4  The personality hypothesis proposes the possibility of a yet unidentified constellation of personality characteristics and emotional needs that demand the concurrent use of alcohol and participation in high-risk sexual activity; whereas the social context hypothesis proposes that certain subgroups, e.g., the gay male community, have learned to combine high-risk sex and alcohol use, and this combination over time becomes so reinforced that the behavior becomes difficult to change.  The multifactorial hypothesis proposes a complex interrelationship between a myriad of both known and as yet unknown determinants.</p>
  
<p>Each client will present with his/her own unique combination of determinants. To be effective it is imperative that clinicians working with the alcohol abusing clients and public health developing HIV prevention education programs recognize and address these multi-variate determinants, which comprise the drinking/high risk sexual  behavior dynamic.</p> 

<p><b>Benefits of Abstinence from Alcohol for the Alcoholic HIV+ Person</b><br>
Addressing the interplay between drinking and risky behavior is central in working with the HIV+ person who has a diagnosis of alcohol abuse or dependency.  It is important for the HIV+ alcoholic client to remain abstinent from alcohol for both public and personal health reasons.  Notwithstanding the responsibility to one's sexual partner, alcohol-impaired judgment interfacing with any number of conjoining factors can lead the HIV+ alcoholic to lapse into sexual behaviors that put both partner and self at risk.   Not only is the concern for the increased risk of transmitting the virus to an uninfected partner, but it is equally imperative that the HIV+ person not be reinfected with HIV, increasing the viral load that the immune system must contend with and possibly introducing additional strains of HIV into the body.</p>

<p><b>The Interplay of Alcohol Use and HIV</b><br>
Proper nutrition is essential for the HIV+ person. alcoholics.5  The negative effects of drinking on eating habits and on gastrointestinal and liver functions can result in both an inadequate intake and absorption of nutrients; indeed there exists a high rate of malnutrition among alcoholics.   Malnutrition negatively impacts the immune system; alcoholics, particularly those with liver dysfunction, suffer high rates of infection.6  For the seropositive alcoholic whose immune system is already compromised from HIV and for whom warding off opportunistic infections is vital, drinking is a formula for disaster.</p>  

<p>Committed to maintaining the health of the HIV + alcoholic client and to preventing the transmission of HIV, it is essential for providers to help the HIV + alcoholic to attain and subsequently maintain abstinence from alcohol. It is important to remember that the process of going from active alcohol use to abstinence is an emotional, physical and spiritual process which involves changing behaviors. This process must be recognized, honored and worked within a time oriented manner, respecting and working with the clients resistances and present abilities. Current harm reduction approaches fully recognize and respect these realities and challenges.</p>

<p><b>The Psychodynamic Interplay Between Seropositive Status and Abstinence From or Continued Use of Alcohol</b><br>
Alcohol is an alluring elixir helping the drinker to avoid uncomfortable issues and feelings and quickly providing temporary pleasure and relief from stress. The efficacy of alcohol's positive effects prompts a continuing reenactment of drinking behavior and over time there ensues a progressively deepening emotional and possibly physical dependence on alcohol.  The alcoholic in early recovery is faced with the daunting challenge of facing issues and feelings full force without the relief provided by alcohol.  Attempting to meet this challenge without alternative coping skills or a solid sober support network firmly in place, the abstinent alcoholic can easily become overwhelmed and seek relief by returning to drink.</p>

<p>The HIV+ alcoholic is doubly challenged for she/he has to cope with a whole additional layer of stressful therapeutic issues relative to being seropositive.  Not only are the nature of these issues stressful, but the client operates within an awareness that one's life span is likely to be foreshortened-adding a powerful element of urgency and imminence to daily living.7  The alcoholic's shame and guilt over the negative effects of his/her drinking can be compounded by the shame, guilt and fear over actual and anticipated negative effects of HIV on self and significant others.  Additionally, these feelings can be exacerbated by the multiple social disenfranchisement which the HIV+ alcoholic experiences; prevailing negative societal attitudes toward alcoholics and toward persons with HIV can become internalized and guilt and shame arise from being both alcoholic and HIV+.</p>

<p>Concurrently, the HIV+ alcoholic may be wrestling with issues of grief relative to past lost opportunities due to alcohol use and lost long-term future opportunities due to HIV.  Coming face-to-face with his/her own mortality gives rise to profound physical and existential concerns.  The client is grappling with frightening possibilities: debilitating illness, the loss of control over his/her body and life, abandonment by friends and loved ones, and death.  Primal existential and spiritual questions can weigh heavily on the client.  Overwhelmed by feelings of anxiety, anger, fear, guilt, shame, depression, and hopelessness, the HIV+ alcoholic can easily relapse into drinking.  With that comes an increased likelihood of the resumption of risky sexual behaviors. One HIV+ alcoholic that I worked with stated, "I'm feeling so stressed out; sex is the only place I can find escape and pleasure, but I need to get high in order to forget about AIDS for the escape and pleasure to happen.  Besides I don't know how long I have to live so I'm going  to enjoy myself while I can."</p>

<p>HIV+ alcoholics are at greater risk for an alcohol relapse due to the added dimension of the overwhelming stress of being seropositive.  It is imperative that the issues relative to HIV are acknowledged and addressed by both the client and provider.  Indeed, abstinence or continued drinking, and the consequential implications for the health of the drinker and for prevention of HIV transmission, will depend on if, when, and to what degree the HIV+ alcoholic is able to acknowledge and come to terms with emotional issues relative to seropositive status.</p>

<p><b>Challenges for Clinicians Working With HIV+ Alcoholics</b><br>
The HIV+ alcoholic can become overwhelmed by a flood of emotional issues about being HIV+ and relapse to alcohol use and correlative high-risk sexual behaviors.  Conversely, the intense emotional and existential issues that arise can serve as the catalyst for profound emotional and spiritual growth.  The challenge to the provider is to help the HIV+ alcoholic to use his or her circumstances as an opportunity for growth rather than as a rationalization and/or justification for destructive behaviors.  The provider is confronted with helping each client to find the delicate balance between respecting his and her need to resist addressing emotionally laden HIV-related issues, while simultaneously not colluding with the client in a dangerous pact of silence due to the provider's own counter-transferential feelings (e.g., overprotection and/or unresolved issues relative to HIV).</p>

<p>A collusion of silence may lead to a relapse of drinking.  As suppressed and repressed emotions progressively gather more momentum and force with the client perceiving no healthy alternative outlets he/she may seek solace once again in alcohol.  Once drinking begins and behavior is disinhibited, the alcoholic can seek further enhancement of pleasure and escape found in sex.  The affirmation of being sexually desired by another serves as an additional powerful lure for the HIV+ alcoholic, who because of having both alcoholism and HIV has experienced a multiple stigmatization and disenfranchisement.</p>

<p>Colluding in a pact of silence with the client may also prevent the client from accessing proper medical care and from planning for possible future health-care needs.  Important decisions regarding insurance issues, treatment options, health-care proxies, and living wills are all the best made with unrushed, thoughtful foresight.  Silence also can impede the client from accessing the emotional support and sense of connectedness available through the many social services and support organizations for HIV+ persons.  Studies have shown that hope is positively correlated with the amounts of perceived social supports one has available.<sup>8</sup></p>

<p>Colluding with the HIV+ alcoholic client in not addressing HIV-related issues, disallows the person the opportunity of fully coming to terms with his/her HIV and from wrestling with the existential questions of life and death.  The wrestling holds out the potential for extraordinary emotional and spiritual growth and for a life lived to its fullest potential.  Thus, in terms of preventing alcohol relapse, maintaining safer sex practices, obtaining adequate medical care and emotional support, and tapping into potentials for profound emotional and spiritual growth, the provider, who is attuned to the interplay between alcoholism and HIV, can help the client address HIV-related issues.  However, this is a time-oriented process and providers need to be respectful of the client's cues and be patient with the client's process.  As the length of time the client remains sober increases, his/her ego strength increases, the relationship with the provider deepens, and a solid, sober support network of significant persons develops, the client may be willing and able to address HIV issues.  Then again maybe not; and this is the crux of the challenge to the providers; to respect the client's boundaries while not colluding in a way that will be harmful to the person or to others.</p>

<p><I>article references <A NAME="mailto:cnews@aidsnyc.org">upon request</A></I></p>

<center><table border=1>
<tr><td><font size=-1><p>Paul Matwiow, M.Div., CAC<br> 
Alcohol and Substance Abuse Counseling<br>
Private Practice (212) 349-2429</font></td>
</tr>
</table></center>

<p><i>Paul Matwiow received his Master of Divinity in psychology from Union Theological Seminary. He received a certificate in spiritual direction from General Theological Seminary. He is a NYS certified alcoholism counselor and has worked with HIV+ substance abusers both as a counselor and Chaplin.  He has developed and implemented  imp substance abuse treatment programs for gay, lesbian, bisexual and trans persons. He is on the staff at the Center for Christian Spirituality at the General Theological Seminary.</i></p>

<p><b><A NAME="nutrit">Nutrition</A></b></p>

<p><b>Recipe</b><br>
Soups are a good solid food meant  to warm and nourish. In France good restaurants are distinguished by their soups. If the soup isn't good, the rest of the food probably isn't either.  Here is why. Soups are made with stocks, the life blood of haute cuisine, the bases for not only soup, but to make or enrich demiglace, sauces, jus, court bouillons, fumets, and more. For this reason good restaurants make stocks and soups daily. . . from fresh ingredients.  Many restaurants try to achieve the same results by using canned, paste, or powdered stocks, or base. While other restaurants simply open a can. All of these preparations have a place in American cooking. I will present the classic way here, but you can substitute cannned stock, chicken or buillon cubes.</p>

<p align=center><b>Cream of Mushroom Soup<br>
Poultry Stock</b></p>

<p>3-4  lbs of chicken or turkey backs, necks, and wings blanched for five minutes- discard the water. Or, start with the carcass from a roasted bird. Cover with 3-4 quarts of cold water, and simmer uncovered for about 20 -30 mins.</p>

<center><table width=90% colspecs="50% 50%">
<tr valign=top>
<td width=50%><font size=-1><i>Wash and Add</i><br>
1 onion skins and all<br> 
2 ribs of celery<br>
1 carrot with skin<br>
<br>
<i>Add</i><br>
1  bay leaf<br>
1 Tbsp. of fresh thyme<br>
6 cloves<br>
1/4 bunch of parsley<br>
4-peppercorns<br>
<br>
A scum will form on the top, remove this and simmer about three hours. Strain, cool, cover and refrigerate. Discard the trash (the vegetables, skin, and bones left in the strainer).<br>
<br>
Add 1/2 lb of mushrooms washed and cut in 1/4s.<br>
1 medium onion, peeled and quartered.<br> 
sauteed in 1 Tbsp. of butter.</font><td>
<p>
<td width=50%><font size=-1><i>Add</i><br>
4 cups of chicken stock<br> 
bring to boil and simmer ten minutes<br>
strain and puree the vegetables<br> 
<br>
<i>Veloute</i><br>
roux : melt in 2 Tbsp. butter in a skillet, add 1 1/2 Tbsp. flour stirring constantly over high heat for 5-7 mins or untill the mixture smells like "burnt cookies."<br>
<br>
Remove Stock from heat and<br>
Add roux to<br>
hot strained stock<br> 
Stir until thickened over medium heat<br>
<br>
Add pureed vegetables and 1/2 lb sliced mushrooms<br> 
Simmer 10 mins<br> 
Stir in 1/2 to 1 cup of heavy cream and heat until hot.<br> 
Serve with whole wheat sourdough bread.</font></td>
</tr>
</table></center>

<p><b><A NAME="enter">Entertainment</A></b></p>

<p><b>Boys Choirs In Concert</b><br>
The choirs of men and boys of<br>
Trinity Church on the Green, New Haven<br>
St. Peter's Church, Philadelphia<br>
Grace Church in New York<br>
present<br>
AN ALL MOZART PROGRAM<br>
Coronation Mass, K.317<br>
Laudate Dominum from Vesperae Solennes de Confessore. K.339<br>
Exsultate, Jubilate, K165, Arlene Travis, soprano</p>

<p>Saturday 9, November 1996 at 7:30 PM<br>
Grace Chuirch 802 Broadway At Tenth Street Tickets, $10.00 available at the parish office and at Readers 35 East Tenth Street.</p>

<p><b><A HREF="http://www.metmuseum.org/htmlfile/gallery/cloister/cloister.html">The Cloisters</A></b><br> 
The Cloisters, the branch of The Metropolitan Museum of Art for medieval art, incorporates sections of European cloisters, a chapter house, chapels, and other architectural elements, both domestic and religious, all dating from the 12th through the 15th century. The Cloisters Collection includes spectacular medieval sculptures, the famed Unicorn Tapestries, exquisite illuminated
manuscripts, splendid goldsmiths' work, and glorious stained glass. Other highlights include the beautiful herb garden.

<p>Hours: Tuesday-Sunday 9:30-4:45 (November-February); 9:30-5:15 (March-October). Highlights Tours of the Collection for individual visitors: Tuesday-Friday at 3:00; Sunday at 12:00. Garden tours for individual visitors at 1:00, Tuesday-Sunday. All group visits require advance reservations. For information call (212) 650-2280.</p>

<p>Admission: Free to Members of the <A HREF="http://www.metmuseum.org">Metropolitan Museum</A>. Suggested contribution same as Main Building, includes admission to both on the same day.</p>

<p>Directions: Subway: IND A train to 190th Street and Overlook Terrace and take No. 4 bus (Fort Tryon Park- The Cloisters). Bus: No 4 Madison Avenue (Fort Tryon Park-The Cloisters). Car: Henry Hudson Parkway north to first exit after George Washington Bridge.</p>

<p>Accessibility: Limited access for mobility impaired visitors. Call (212) 923-3700 or check at entrance upon arrival.</p>

<p>Saturdays at The Cloisters at 12:00 and 2:00<br>
Free with Museum admission. No advance reservations necessary, but due to limited gallery space, organized groups of 10 or more cannot be accommodated.</p>

<p>Saturday Gallery Workshops for children (ages 4-12) and their adult friends. Free with Museum admission. Workshop materials provided. Meet in the Main Hall at 1:00.</p>

<p><b><A HREF="http://www.moma.org ">MUSEUM OF MODERN ART</A></b><br>
First Retrospective in 20 Years Features Late Work Exhibited for the First Time<br> 
Jasper Johns: A Retrospective<br>
October 20, 1996-January 21, 1997</p>

<p>The most comprehensive survey ever held of perhaps the most  influential artist of the postwar era opens at The Museum of Modern Art on October 20, 1996. Jasper Johns: A Retrospective,  the first in-depth study of the artist's work in nearly 20 years, presents four decades of achievement, from the early paintings of flags and targets that stunned the art world to the recent densely layered canvases that probe the whole of his career. Until now, nearly half of the artist's work has never been treated by a retrospective.</p>

<p><b><A NAME="books">Books</A></b><br>
<i>By James B. Boskey</i></p>

<p>The Art of Mediation<br> 
Bennett, Mark and Herman, Michele --National Institute for Trial Advocacy, 1602 North Ironwood, South Bend, IN 46635 (337pp $29.95 1996)</p>

<p>As increasing numbers of mediation training manuals have appeared over the past several years, I have become increasingly picky in my reviews about their quality and coverage. It is with real pleasure, therefor, that I am able to give my wholehearted recommendation to Mark Bennett's and Michelle Hermann's manual, The Art of Mediation, which they have developed at the University of New Mexico Law School and which NITA has adopted for its training.</p>

<p>The Art is a generalized mediation training manual, focusing on the basic skills needed to be effective in any area of mediation, rather than focusing on a mediation of any specific class of disputes. As such it is most useful, by itself, for training for community mediation, but it can easily be supplemented with information about peculiar characteristics of mediation of specific types of disputes. One impressive feature of The ART is the way in which the authors steer between the shoals of different approaches to mediation. They recognize where there are different views on particular approaches to mediation, provide their student/reader with information about all views, but take sides only where it is necessary, in their view, for mediation to be effective.</p>

<p>The primary text is contained in four chapters. The first introduces the concept of mediation and places it in context among dispute resolving mechanisms. It also addresses the roles and functions of the mediator. The second deals with the stages of mediation. The authors adopt a seven stage model that focuses heavily on issue identification and individual issue resolution. They deal with the complexity of mediation and the fact that no model will reflect fully the pattern of decision making in any given case.</p>

<p>The third chapter deals with generalized and cross-cutting mediation themes. Amongst those addressed are communication skills, values and feelings, power balancing, use of caucuses, and ethical issues. The final chapter deals with practical issues in the establishment of a mediation practice including a further look at mediation ethics in a business context. Appendices pride forms, checklists, and a bibliography as well as seven role plays of varying complexity for use in the training.</p>

<p>This book is well written and clearly organized, making effective use of appropriate graphics and font variations to encourage focus an points of importance. A valuable contribution to the training literature.</p>

<p><i>James B. Boskey, Professor of Law, Seton Hall University is Editor of  The Alternative Newsletter, A Resource Newsletter on Dispute Resolution.</i></p>   

<blockquote>
<hr size=4 width=50% align=center>
<p><b>"I believe that in our constant search for security we can never gain any peace of mind until we secure our soul.  And this I do believe, above all espescially in my times of greater discouragment, that I must believe - -that I must believe in my fellow men --that I must believe in myself --that I must believe in God --if life is to have any meaning."<br>
Margaret Chase Smith</b></p>
<hr size=4 width=50% align=center>
</blockquote>

<p><b><A NAME="life">Lifestyles</A></b></p>

<p><b>A Mother's Diary of Her Son's Struggle With AIDS -- Part Three</b><br>
<i>By Anna Nimos</i></p>

<p>We bought presents for each other.  I got Marc an orange juice maker, because he liked fresh squeezed juice.  I got Will some African prints for his new house.  Marc got me a long-sleeved undershirt and a fancy scarf from the Banana Republic.  Will got me two vests.  Will had sent me a blank check and had me get Marc a TV set and VCR to entertain us as we anticipated spending more time in the house.  On Christmas day, Gwen and Trish came over with small gifts for everyone including Will.  Then they took us to Gwen's mom's for Christmas dinner.  They (Gwen's mom and her mother's sister, Gwen's brother and his wife and daughter and Gwen's son and his wife) all knew Marc from before.  We had a traditional Christmas dinner.  After dinner, we played a game of Jenga, which involves balancing little blocks of wood on each other.  Marc's hands were shaking too much for him to play, so we all stopped, pretending it was a boring game anyway.  That Marc's hands were shaking so bad he couldn't stack the pieces made us all so sad, but we all stuffed it.
We had a few good weeks after that.  We went to the movies and we rented movies.  We saw the Joy Luck Club twice because Marc loved it.  We also saw a bunch of really strange videos he called "camp" films (they were pretty raunchy) and we saw a bunch of foreign films that Will knew about.  One that I'll never forget was a Chinese film called "Raising the Led Lantern," a study of women's oppression carried to the full extreme.</p>

<p>We continued to go to the acupuncture clinic on Tuesdays.  I got used to seeing the same young men.  Most of them healthy looking at first, with better-than-average builds, stylish haircuts and attractive clothes.  Marc knew them all.  Then we wouldn't see someone for a while and we'd hear he was in the hospital, or was not doing well.  A few times we heard one of them had died.  It was the life Marc had been living for several years now.  He'd make a friend at one March on Washington and at the next one, his friend would not be there.  He lived every day with loss - loss of his friends and allies in the gay/AIDS movement and loss of his own health.</p>

<p>Almost every night Casius and Jan came over to eat with us or we went to the beautiful old house Jan's partner owned and Jan fixed us dinner or we went to Casius's apartment and Casius fixed dinner.</p>

<p>Bill and Shad came to visit Marc from December 30th to January 3rd so I took the opportunity to visit Connie, (Marc's grandmother) who was going through chemo and radiation for cancer of the bladder.  She was doing very well compared to Marc.  I came back to Seattle for a few days and then on January 10th, my ex-husband, Marc's father, and his wife came to stay with Marc and I went home for two weeks.</p>

<p>In the airport and on the plane I kept looking at young people, and sometimes older people, and thinking fondly that they might be gay.  I was drawn to them and wished I could sit next to them or talk to them.  People who looked really straight seemed boring and even hostile.  "Probably homophobic, "I thought," or even members of the Christian Right, homophobic and myopically condemning people with AIDS to God's punishment."  I not only missed Marc terribly, but I also missed his community.</p>

<p>I came back to Seattle on January 27th to be with Marc when he went back in for chemo the third time.  I was glad to be back with Marc and his friends; it felt like home.</p>

<p>The neuropathy continued to plague Marc's foot and lower leg, and he had started to rely on the rainstick I got him for his birthday as a cane.  In addition to helping him walk, it was a great conversation piece.  It gave nurses, doctors, friends and casual acquaintances something besides his health to talk to him about.  I thought it also made him look handsome and unique as he walked down the street with his rainstick.</p>

<p>Again the chemo went well and Marc continued to improve.  Dr. Abolaphia agreed to put off the next chemo session so that we could make a trip to Mexico that Marc had been talking about for a long time.  I helped him plan it.  Marc's father and his wife, Bev and Tao, Bill, Larry and Marc and I were scheduled to fly in from different points and meet in Los Cabos on March 23rd.  Thanks to the money My brother Dan offered, we would all be able to stay together in a villa on the beach.</p>

<p>Marc had been without chemo long enough that his hair had started to grow back.  he said he felt well enough to take care of himself with help from his friends for the next few weeks and wanted me to go home, so I returned home on February 19th.  We all planned to meet in Los Cabos on March 23rd and then I would come back with Marc to Seattle to stay with him while he went through his fourth chemo treatment.</p>

<p>I had the same experience of culture shock on my way home, only this time it was more intense.  I found I was identifying so much with the gay community, I wanted to somehow stay in it.  It was very much the same feeling I had when we came back from Mississippi after the summer as a civil rights worker.  I had become so emerged in the Black struggle, that I actually felt more Black than White.  My world had broadened, and I never felt right in all-White circles again.  Now I identified so much with the gay struggle and the fight they were waging against AIDS, I felt more gay than straight and I didn't feel right unless I was around gay people.</p>

<p>Leaving the plane in DC, I was behind a young man who had a button on his backpack with a pink cross on it that said:  "Quit Crucifying Queers!"  When I got the opportunity, I said, "I like your button."  He smiled and I guess took me as a supporter and we talked all the way to the baggage claim about the church's position on homosexuality.  When his luggage came out, he gave me his button (he said he had more) and hugged me good-bye.  I felt like I had met a kindred spirit.</p>

<p>A few days after I got home, Marc started vomiting.  I talked to him every day on the phone and every day he sounded worse but he kept telling me he didn't think I needed to come out.  Finally, Nancy and Gwen called me and told me they thought Marc was in real trouble and that they thought I should come back out whether he wanted me to or not.  I wanted to go so much, but I just felt I couldn't unless he said it was okay.  Miraculously, the next day he told me he thought I should come back to Seattle and then I could fly with him to Mexico.  The day after that, March 3rd, I arrived in Seattle.</p>

<p>Marc had been vomiting for seven days.  He had a little mountain of clear plastic bags full of green liquid on the floor by the bed.  From that evidence, I knew he had been alone for a while and simply vomited into a bag and tied it in a knot when he got nauseated.  He was too sick to get up.  The sight of those bags wrenched my heart very much the way the refrigerator full of little brown bags full of untouched molding meals did the first time I arrived in Seattle.</p>

<p>Marc was weak and dehydrated and so very tired of being nauseated.  He told me he was "ready."  He was wearing an eye patch because he was having double vision.  He consented to an MRI the day I came back and the next morning he agreed to go into the hospital, partly because he was so dehydrated and he was hoping they could stop his vomiting.  The hospital gave him a transfusion and started him on an IV for hydration and put Compozine in it as well for the vomiting.  But Marc had been taking Compozine for days and it wasn't working.</p>

<p>The University of Washington sent over the film from the MRI and it revealed some "enhancement" at the stem of his brain, where the nausea center is located.  A neurologist was brought into the picture and she gave Marc Dexamethazone, an anti-inflammatory used for brain tumors; his nausea stopped within an hour.  Within 24 hours he had us getting him Mexican food from a nearby restaurant and he deemed his improvement a "miracle" and began talking again about his trip to Mexico.</p>

<p>It was also during this hospital stay that Marc gave me and Jennifer his plan for his memorial service.  He wanted his body to go to the University of Washington for AIDS research, but before we had them pick it up, he wanted to "lay-in-state" for a day at home and wanted us to let all of his friends know so they could come by if they wanted to and say good-bye and take something of his with them to remember him.  (He had already taped a long list of personal items he wanted to go to certain people - his record collection to Will, his DJ-ing equipment to a young black brother who was trying to break into that scene, his medicine bag to Leon, his speakers and stereo to Larry, etc.)</p>

<p>Then he gave us a list of people and the subject he wanted them to address at his memorial.  For example, he wanted Leon to talk about his tenant organizing in DC, Jennifer to discuss his organizing activities for the April March in Washington, Allison to talk about his political action at the World AIDS Conference in San Francisco where the cop had deliberately crushed his ankle and his work on the Gay Pride demonstrations at the Republican Convention in Texas, Nancy to tell about his political action in Seattle, Comrade Jim to talk about his work in the Party, Ms. Jones about his work with Mothers Against Police Brutality, Will to talk about their relationship, Tim (his uncle) to talk about his organizing style, Terry about the formation of Act-Up Seattle, Will to write and read his Eulogy and me to talk about Marc as a child.</p>

<p>He got a kick out of reminiscing about these times and we had fun planning this event.  He wanted us to fly Comrade Pam out from DC to sing "Harriet Tubman" and he wanted Thunder Cloud to drum for him.  He wanted Gwen, who was in seminary, to chair the program, but he asked me to be sure and remind her not to get religious on him.  He wanted the tone to be like an upbeat political rally or a Party program - no praying.  For that very reason he didn't want an open microphone.  True to his need to control, he wanted to control how his service went.  He even told us where he wanted the service (in the same funeral home where Bruce Lee's service was held) and who he wanted to do the flowers and the color scheme for the event.</p>

<p>After the service, he wanted Paula to have a big party at her house with lots and lots of food and booze and he wanted Will to do the music for the service and the party.</p>

<p>Dr. Abolaphia came in in the midst of our laughing and note-taking and told Marc that all indications were that the lymphoma had gone to his brain and was forming a tumor there, but the only way they could tell for sure was to do a spinal tap and remove some spinal fluid to test.  The fluid would have to be replaced and he wanted Marc to allow him to replace it with chemo since that would be the only treatment for Marc if the fluid tests showed that a tumor was indeed forming in Marc's brain and it would save an extra puncture.
Marc did not want a spinal tap - partly because he was just plain afraid and partly because a friend of his, Alison (you may remember her; she spoke at his service) who has AIDS and had gone through this particular "invasive procedure," swore it wasn't worth it and if she had it to do over again, she would not do it.  The reason he finally decided to do it was that Dr. Abolaphia told him that there was a chance that he could make the trip to Mexico if he underwent the chemo treatment to the spinal fluid.  Otherwise, he felt he would not last long enough to go to Mexico and he felt the vomiting would surely return.</p>

<p>The neurologist did the first spinal tap in the hospital.  I knew how bad Marc wanted to go to Mexico, because as terrified as he was of the procedure, he went ahead with it.  He told the doctor how scared he was and she ordered him a "cocktail" of tranquilizers, including Adivan in his IV.  Soon Marc was coasting off into another world and he began talking of being in a jungle with vivid flowers and birds.  I wished I had some of what Marc had because my anxiety was almost out of control.  I felt obligated to stay by his side, hold his hand and watch everything.  And the more I watched the more my heart hammered in my chest and the more I thought I might faint.</p>

<p>The fluid she drew was the color of urine and it was supposed to be clear like water.  From the color of the spinal fluid, it was no surprise to the doctors that the lab work indicated that the lymphoma had invaded Marc's brain and central nervous system.  Three days later they did another and this time the spinal fluid was clear instead of yellow and the lab work showed the lymphoma was responding to the chemo.  Three days after that he had another and the tests continued to be very positive.  Dr. Abolaphia really gave Marc a lot of hope that he would feel well enough to make the trip to Mexico.
After his last visit to the hospital, Dr. Panther arranged for Marc to get intravenous hydration at home.  I hooked him up to two bags of hydration a day so that he wouldn't get dehydrated again.  Marc also taught me how to take care of his catheter - clean it and replace the bandage.  He had been doing it himself until then, but he decided I should learn how to do it in case he was unable to do it himself.  He was an exciting teacher, demanding that I follow the protocol exactly so that the catheter would not become infected.</p>

<p>Marc was strong enough during this time to walk two blocks to and from the acupuncture clinic on Tuesday.  The last time I had been to the clinic, I noticed one man who had been absent for a long time was back.  He looked very thin and weak.  There were two women there, who I had not seen before.  They looked anarexic and tired, as though they were nearing the end of their battle with AIDS.  This time I was aware that others might notice that now Marc looked like he, too, was nearing the end of his battle.</p>

<p>I was usually the only friend or care-giver there, but this time, there were two young mothers there.  One had an eleven-year-old son, very thin and listless, leaning against her waiting for his turn.  The other had two rosy-cheeked teenagers, maybe 14 and 16, dressed in the latest baggy denims and plaid flannel shirts, with baseball caps on sideways.  I couldn't believe they were sick, but from the way they talked about their night sweats, I knew they had AIDS too.</p>

<p>It was not the sick boys so much, as the mothers, patient and strong, who undid me.  I had to wait for Marc outside.  When he came out, he caught me with tears streaming down my face.</p>


<p><b><A NAME="briefs">Consumer</A> Briefs</b></p>

<p><b>Metro</b><br>
Source: <A HREF="http://www.usatoday.com">USA Today</A> (10/16/96) P. 9A<br>
Abstract: A survey of 625 New Jerseyans found that 92 percent support government aid for people who have a health problem for which they are not responsible, such as those who contract HIV through blood transfusions.  Only 53 percent of those polled thought that people who contracted HIV through unsafe sex should be eligible for government aid, however...</p>

<p><b>State</b><br>
Authors: Dao, James<br>
Source: New York Times (10/16/96) P. B5 <A HREF="http://www.nytimes.com">www.nytimes.com</A>
Abstract: The New York State Court of Appeals announced a decision Tuesday that significantly extends the protection of people with HIV from discrimination by doctors and dentists.  The court ruled that the state's Human Rights Law, which prohibits discrimination in employment, housing, and public accommodations, should be interpreted to cover the offices of doctors and dentists, as well as any place that provides "conveniences and services to the public."  The court was considering two cases in which people charged that they had been denied dental services because they had tested positive for HIV or had been exposed to the virus...</p>

<p><b>Nation</b><br>
Source: The Washington Post <A HREF="http://www.washingtonpost.com">www.washingtonpost.com</A>
Friday, October 11 1996; Page A03<br>
Abstract:House Majority Leader Richard K. Armey (R-Tex.) said, of a harm reduction program in Los Angeles,"Any federal program that condones illegal drug use is ill-conceived and must be changed, "It is never compassionate to condone illegal drug use, especially with taxpayer dollars."Congressional Republicans are attacking a pilot program in Los Angeles that will provide federally funded housing for people with AIDS, but will not eject people for using illegal drugs, even if they do so within the facility itself. Such a program, they argue, appears to conflict with long-stated Department of Housing and Urban Development policies requiring expulsion for any drug use in public or assisted housing.The criticism of the program comes as conservatives have been attempting to portray the Clinton administration as being soft on drugs and unable to produce an effective policy for combating what appears to be increasing drug use nationwide, particularly among teenagers.</p>

<p>The  House Banking Committee's Housing Sub-Committee press office said "We are questioning the NOFA, in order to determine if  it means there is change in HUD's policy." When asked if  this to determine whether to reevaluate the funds that are approriated to HOPWA, "Yes," was the answer. Said HUD's  Dr. Fred Karnas, when Consumer News contacted the Office of AIDS Housing for comment, "We are making it clear that HUD has a zero tolerance rule for illegal activities, including drug use, in our programs.  However, we recognize that relapse is a part of recovery and our programs should have policies for addressing relapse issues that minimize the chance of persons with HIV/AIDS and substance abuse problems ending up back on the street."</p>

<p>You can express your views on this issue by writing to the House Subcommitte on
Housing (<a href="http://www.voxpop.org:80/netgrams/">http://www.voxpop.org:80/netgrams/</a>). </p>

<p>Authors: Sbarbaro, John<br>
Source: <A HREF="http://interactive.wsj.com/std_regchoice.html">Wall Street Journal</A> (10/16/96) P. A21<br>
Abstract: A combined strategy is needed to fight the spread of HIV and Tuberculosis (TB), contends Dr. John Sbarbaro, Medical Adviser to the Global TB Education Fund, in a letter to the editor in the Wall Street Journal.  He notes that TB causes the most AIDS-related deaths worldwide, and that treating AIDS patients effectively for TB could prevent nearly 4 million TB cases and increase the lives of people with HIV by an average of two years.Without such precautions, Sbarbaro says, people infected with HIV and TB will die earlier than necessary, and TB will continue to spread to the general population.. .</p>

<p>Authors: Squires, Sally<br>
Source: Washington Post--Health (10/15/96) P. 7 <A HREF="http://www.washingtonpost.com">www.washingtonpost.com</A><br>
Abstract: The Centers for Disease Control and Prevention (CDC) predicts that this year's influenza season is likely to be a bad one, with the advent of at least one strain of flu virus that has been linked to severe symptoms.  The CDC therefore recommends that people in high-risk groups--including the elderly; people infected with HIV; those receiving cancer therapy; and children and adults with chronic health conditions--become vaccinated against the virus.

<p><b>Kemped Out: HUD and HIV</b><br> 
Author: by Mark Schoofs<br>
Source: Village Voice (10/29/96) P.8 <A HREF="http://www.villagevoice.com">www.villagevoice.com</A><br>  
Abstract:The GOP trumpets Jack Kemp's compassion for America's downtrodden and praise his innovations in public housing. But AIDS advocates charge that Kemp slammed the door on poor people
with HIV.</p>

<p>Under Kemp's watch in 1990, the Department of Housing and Urban Development refused to classify AIDS as a disability, effectively barring people with the disease from important federal shelter programs for the handicapped. HUD's reasoning is documented in legal memos submitted during conngressional hearings: HIV killed too quickly to qualify as ''an impairment which is expected to be of long-continued and indefinite duration.''...</p>

<p><b><A NAME="edit">Editorial</A></b></p>

<p><b>AIDS - A Cultural Perspective</b><br>
Consumer News posed this question to both campaigns, "What can we expect of housing for People with AIDS under a Clinton / Dole Presidency in the next four years?" HUD responded with the Secretary's directive. The Dole press office didn't bother responding.</p> 

<p>Inner-city neighborhoods where affordable housing for the elderly poor, the disabled and other low income people is frequently plagued by high rates of crime and drug activity, fueled by poverty. These neighborhoods are often places where there is little common unity, where people live isolated from each other. The conditions are fertile ground for destructive defensive behavior. Still, there are practical reasons for distancing oneself from strangers, the least of which is privacy. Safety and the need to protect one's identity and personal integrity are reason enough for this isolation. The pervasiveness of substance abuse, alcoholism, joblessness and other neighborhood problems undermine social organization and foster crime, gang violence,  and drug trafficking which highlights the fear that is the sum part of this peoples experience.</p> 

<p>People in these neighborhoods must learn to live with diseases that thrive among the poor, the uninformed, and those who have lost hope. By and large there is a cultural aspect to illness. An epileptic seizure presents different images requiring different cautions in Manhattan than it does in Scarsdale particularly when the patient leaves with a token instead of car keys. When we begin to examine HIV disease in a cultural perspective, the prognosis is modified by environmental factors, social organization, self-esteem, values and ethics as well as medical treatment. "Culture, may be defined as the sharing of modes of behavior and outlook within a community. The study of culture involves an analysis of how culture is transmitted from generation to generation and the way it is sustained through social interaction in the community. To act according to ones culture is--either through forms of nonverbal action, including engaging in or refraining from certain conduct, or in the verbal expression of opinions or attitudes concerning norms, values or beliefs--is to follow one's inclinations as they have been developed by influence or learning from other members of the community that one belongs to or identifies with," William Julius Wilson states in <i>When Work Disappears-- The World of the New Urban Poor</i>.</p>

<p>Confused cultural values prevent an entire group of men from practicing safe sex and worse, from seeking medical intervention. In Afro American, Latino, and Gay ghetto/communities, sexual prowess, multiple conquests, and having babies are valued. For many, promiscuity proves they are men, "real men and women." That they are attractive, stylish, somebody and, oddly enough, adult or grown among their peers (Kenneth B Clark, <i>Dark Ghetto</i>). This cavalier attitude about sex in this time of AIDS impacts upon the wider community in much the same way as substance abuse. Whether you measure its costs in dollars or lives, it is expensive. Nevertheless, we can vote for candidates who propose aggressive AIDS policies and real remedies for jobs, housing, and health care. Then, begin to address and prevent this toxic mix of poverty, muddled values, and deadly disease.</p> 


<p><b><A NAME="oped">Op-Ed</A></b></p>

<p><b>DAAIR</b><br>
<i>By John Bingham</i></p>

<p>O.K.  You're lucky enough to be on triple combination (protease plus two nukes) and you're feeling pretty good.  You're viral load is very low or undetectable.  You even think of the "C" word (cure) once in awhile but you know that's uncharted territory.  What you do know is that both researchers and doctors are now talking openly about the necessity of  remaining on triple to quadruple antiviral drug combinations for anywhere from two to five years, possibly longer.  Possibly forever.  The length of time on these drugs is still very controversial and based on extremely speculative theories about the length of time necessary to clear HIV from your body while remaining at undetectable levels of viral load. To these multiple antivirals, you can add numerous other prophylactic drugs for persons who once had below 200 CD4 cells. Deep down you know these theories are the ultimate crap shoot.  To expect a human being to tolerate -and respond favorably to- so many drugs at once for so long a period is unprecedented in medical history.  There is simply no other disease in the short history of western medicine where so many drugs have been thrown at one person for such long periods of time.  You're going to need help maximizing the benefits of these drug combinations, many with known substantial long term toxicities.  You're going to have to offset pharmaceutical drug toxicities and to aid the body in detoxification.  If you're thinking cure, and you're thinking of living a normal lifespan, you're going to have to lessen-or eliminate-the possibility of side effects.  More importantly, it just simply flat out may allow you to take life-extending therapies for substantially longer periods of time.  And this time could ultimately add up to a normal life span.  So let's talk about one specific drug. We don't have the space to do more.  For more in-depth free information on these suggestions please refer to the Personal HIV Nutritional Protocols section in the 125+ page DAAIR Membership Outreach Pack (MOP).   You can get it by calling 212/725-6994.</p>

<p>AZT (which as anyone knows means Always Zero Tolerance) is chronic chemotherapy, and-no matter what anyone else says-a lousy drug with substantial side effects and cumulative toxicities.  Other "nukes" like ddI, ddC, 3TC also have significant toxicities. In particular, AZT targets the bone marrow as well as the cells' energy factories called mitochondria.  This results in low blood cells counts, anemia, and muscle wasting.  Astragalus, coenzyme Q 10, and carnitine or acetyl-carnitine are all particularly 
protective in both these structures and are strongly suggested for anyone using AZT for any length of time.  Also, vitamin E has been shown to increase AZT's ability to penetrate virally infected cells and to lessen bone marrow toxicity in laboratory conditions.  If you are beginning AZT chronic therapy with already low blood cell counts, you may want to think about using the Chinese herbal combination called Marrow Plus. And remember that alpha lipoic acid (Thioctic acid) has a proven track record for lowering liver enzyme levels in persons sensitive to pharmaceutical drugs.  Using non-toxic treatments to lessen drug toxicities and to aid the body in detoxification just makes common good sense.  Think it over.</p>

<p><i>John Bingham is Executive Director of DAAIR</i></p> 

<p><b><A NAME="notices">Notices</A></b></p>

<p><b>Are You Caring For A Partner with AIDS? You can win $100</b><br>
If you are a gay male who is currently caring for a partner with AIDS, you are invited to participate in a study which will look at your experience as a care partner. Its purpose is to design interventions which will help care partners cope with the complex and at times overwhelming tasks which caring for a partner with AIDS can entail. 
Participation is strictly confidential and would require answering a questionnaire which would be mailed to you. This study is being carried out by a gay male doctoral student at Columbia University. As a token of my appreciation I am entering the first 75 participants in a lottery to win $100.</p>

<p>If you are interested in receiving a questionnaire or more information, please contact <a href="mailto:gene.thegak.koski@worldnet.att.net">gene.thegak.koski@worldnet.att.net</a><p>

<p> Your participation will help in providing support for the often unrecognized hero in the fight against this illness. </p>

<p><b>Consumer News</b> begins to accept advertsing with this issue. E-mail <A HREF="mailto:cnews@aidsnyc.org">Consumer News</A> for information</p>  

<p><b>Jobs and Job Training</b><p>

<p><b>Clinical Supervisor<br>
McBurney House</b>:<br>
 To provide team leadership in assessing and developing resident's re-housing readiness, stabilization, and re-housing plans. Provide Clinical and Administrative Supervision to five re-housing specialists as the program is expanded from 50 to 75 residents. Share, with the Project , in the management of McBurney House transitional housing project. Master's in Psychology/Counseling or Masters in Social Work with three years supervisory experience in residential, or treatment with AIDS/addiction-affected populations. Well grounded in Clinical case management, group process, supervision, and organizational development. Spanish/English. Resume to: <a href="mailto:facetoface_dfjohnson@msn.com">Mr. David Johnson, Project Director</a>. McBurney YMCA, 215 West 23rd Street, New York, NY. 10011. 212/741-8330 Fax: 212/741-9515 Apply by Sept. 23rd, 1996</p>

<p><b>FROST'D is Seeking Volunteers</b><br>
The mission of Foundation for research on Sexually Transmitted Diseases (FROST'D) is helping homeless women whose activities on the street have put them at risk for HIV infection. FROST'D has a medical Center, two transitional housing programs, for people who are HIV positive and a court project for individuals charged with prostitution or various drug charges. 212-924-3733</p>

<p><b>Young People 14 to 21 out of School? In trouble? Homeless? Just Troubled?</b> Join the Henry Street Settlement's Adolescents Against HIV/AIDS (A.A.H.A), Theater project. Stipend and Social Services are provided. Call, Rachel Beck, CSW: 212-254-3100.</p>

<p><b>GMHC Job Line</b>: 212/337-1910. Current job openings at GMHC updated weekly.</p>

<p><b>Multitasking Systems of NY, Inc. (MTS)</b>. 38 East 29th Street, Ninth Floor, New York, NY 10016. 212-679-8234.</p>

<p><b>Volunteers, Writers, Artists, Photographers</b> wanted for this publication. PWAs are encouraged to submit works for publication by Consumer News. Submit a sample of your work to: Consumer News, P.O. 41, Cooper Station, New York, NY 10276-0041. Materials cannot be returned. No phone calls please.</p>

<p>Volunteers wanted for <b>Consumer information and Conflict Resolution Project, (CICRP)</b>. 212-387-0824.</p>

<hr size=2 width=50% align=center>

<p><b>Consumer News</b> can be found at: A Different Light Bookstore, AIDS Service Center of Lower Manhattan, Bellevue, Hospital Center, Beth Israel Medical Center-Comprehensive Care Center,Bronx AIDS Services, DAS Centers, Federation of Protestant Welfare Agencies, Federation of Puerto Rican Communities, Gay Activists Alliance of New Jersey, Gay Men's Health Crisis, Harlem United, The Lesbian and Gay Community Services Center, The New York Public Library, North Central Bronx Hospital Project Hospitality, The Queens Borough Public Library, South Bronx Action Group, Veterans Administration Medical Center Manhattan, and on the Internet at www.aidsnyc.org/cnews.</p>

<p align=center><a href="index.html"><img src="../gifs/sleft.gif" vspace=5><br>
<font size=-1>Consumer News index</font></a></p>

<hr size=2 width=50% align=center>

<p align=center><font size=2><a href="../index.html">Consumer News</a><br> P.O. Box
41<br> Cooper Station<br> New York, New York 10026-0041<br> Last modified:
11/11/96<br> <a href="mailto:cnews@aidsnyc.org">cnews@aidsnyc.org</a><br>
copyright &#169; 1996 Kenneth Lowry</p>

</body>
</html>
 
</DOC>
<DOC>
<DOCNO>WT18-B31-288</DOCNO>
<DOCOLDNO>IA093-001003-B003-103</DOCOLDNO>
<DOCHDR>
http://health.nyam.org:80/aidsnyc/cnews/news/9609.html 199.29.141.24 19970121124156 text/html 72362
HTTP/1.0 200 Document follows
Date: Tue, 21 Jan 1997 12:36:00 GMT
Server: NCSA/1.5.1
Last-modified: Sun, 13 Oct 1996 19:58:23 GMT
Content-type: text/html
Content-length: 72178
</DOCHDR>
<html>
<head>
<title>Consumer News: September 1996</title>
</head>

<body bgcolor="#ffffff" text="#a62a2a" link="#856363">

<p><a href="index.html"><img src="../gifs/ban1.gif" alt="[logo]"></a></p>

<h3>Vol. 1  No. 9 September 1996</h3>


<table border=1><tr><td>"<b>There are few misfortunes in this world you cannot turn into <br>personal triumphs if you have the skills.</b>"<br>
South African President, Nelson Mandela</td></tr></table>

<blockquote>
<font size=-1>
<p><b>Contents:</b><br>
<i><a
href="#conflict">Conflict Resolution: People with AIDS: Self-Identifying at the Workplace<br>
<a href="#housing">Housing</a><br>
<a href="#health">Health Care: Holistic Approach To Managing HIV/AIDS</a><br>
<a href="#nutrit">Nutrition: How to Change your Eating Habits</a><br>
<a href="#recipe">Recipe: Rice and Peas/Jamaican Style</a><br>
<a href="#life">Lifesyles: A Mother's Diary Of Her Son's Struggle with AIDS: The Last Year - Part 2</a><br>
<a href="#enter">Entertainment: the Brooklyn Botanical Garden</a><br>
<a href="#books">Books: The Mediation Process</a><br>
<a href="#briefs">Consumer Briefs</a><br>
<a href="#edit">Editorial: The conundrum of equality in legal and social status</a><br>
<a href="#oped">Op-Ed</a><br>
<a href="#letters">Letters to the Editor</a><br>
<a href="#jobs">Jobs &amp; Job Training</a><br>
</i></p>

<p><a name="conflict"><b>Conflict</a> Resolution: PEOPLE WITH AIDS: SELF-IDENTIFYING AT THE WORKPLACE</b><br>
<i>by Judy Cohen</i></p>

<p>As an <a href="gopher://trace.wisc.edu/00/ftp/PUB/TEXT/ADA_INFO/LAW_TEXT/ADA.TXT">Americans with Disabilities Act (ADA)</a> consultant, I am often asked whether people with disabilities should tell their employer that they have a disability. There is no simple answer. The decision to disclose is a personal one. The decision to disclose involves strategizing based on the circumstances of each particular case. The decision involves risks. It can mean the difference between having a job or losing a job, being accepted or being stigmatized by one's co-workers, and preserving or jeopardizing one's health.</p>

<p>This article addresses the issue of disclosure in terms of obtaining a reasonable accommodation. A reasonable accommodation is a change in a job or in a work environment that enables a qualified individual with a disability to perform the essential functions of the job or to enjoy the privileges and benefits of the job equal to those of other employees.</p>

<p>In order to be entitled to a reasonable accommodation under the Americans with Disabilities Act, the employee must self-identify as having a disability. (AIDS is considered a disability under the ADA, as is HIV, even if it is asymptomatic.) The employer is not required to accommodate an unknown disability. If you have trouble doing your job due to fatigue, for example, and you do not disclose, the employer may not be obligated to accommodate you and you will probably not be protected.</p>

<p>Once you self-identify, you do have some legal protection, since discrimination against people with disabilities is prohibited under the ADA. However, such discrimination (e.g., you start getting poor work performance evaluations even though your performance is good) may be difficult to prove. ADA complaints filed through government enforcement agencies such as the EEOC (Equal Employment Opportunity Commission) and lawsuits take a long time. The outcome of your case cannot be predicted. Do not count on your theoretical legal rights as absolute protection. </p>

<p><b>To disclose or not to disclose ...</b><br>
In order to make the best decision about whether to disclose, employees with AIDS need to analyze a whole set of information. </p>

<ul>
<li>Judge the potential reaction of the supervisor. 
<dt>Is your immediate supervisor likely to be sympathetic? If not, you may want to approach a higher level supervisor or any trustworthy potential ally in the supervisory or administrative staff for guidance and support. [See Gulf Grinding Co. Inc. (filed February 1995, U.S. District Court for the Southern District of Texas, National Disability Law Reporter Volume 6/Number 4) where a suit filed by an employee with AIDS contends that after he self-identified and requested reasonable accommodations to continue working, the owner allegedly told 32 employees of his status and asked them to vote on whether the employee should be permitted to return.] 

<li>Learn the provisions for confidentiality at your work place. 
<dt>Under the ADA, disability-related documentation must be maintained in separate medical files and be treated as confidential. The employer may not disclose this confidential information to anyone except the immediate supervisor, emergency personnel on a need to know basis, and government agencies for purposes of affirmative action and other documentation. However, if proper protections are not in place, breaches of confidentiality may occur. Find out who has access to your medical files. Get a feel for confidentiality in the work place culture.

<li>Get a sense of what co-workers reactions will be. 
<dt>What are their attitudes about AIDS? (Again, see Gulf Grinding Co. Inc. where 13 of the employees allegedly voted "no".) How they might react to a co-worker having a reasonable accommodation?

<li>Find out what support systems are available. 
<dt>Is a reasonable accommodation request procedure in place? If there is a union, look at its history in dealing with ADA and AIDS issues. Do you trust your union representative to deal with this issue appropriately and confidentially? If you are not sure, find an ally in the union who can advise you. 

<li>Urge an ally in the administration to provide training in AIDS Awareness for supervisors and employees and in ADA for managerial staff so that they understand their obligations under the ADA. This training can lay the groundwork for a safe environment in which to self-identify.

</ul>

<p><b>If you decide to disclose ...</b><br>
Where the disability is not obvious, the employer is entitled to request documentation of the nature and severity of the disability. The employee is not required to provide the actual diagnosis (e.g., AIDS). For example, it may be sufficient for the doctor to write that you have a medical condition which limits your ability to ______, and for which you are receiving medical care.</p>

<p>This documentation serves a dual purpose. First, it provides the employer with proof that the person really has a disability. Second, it is the first building block in designing a reasonable accommodation, and it can have a significant impact on the reasonable accommodation that is eventually designed. For that reason you need to be sure that it describes your functional limitations that impact on your ability to do specific aspects of your job (e.g., due to fatigue [employee] needs a five-minute break each hour; due to incontinence, [employee] needs an office near a bathroom; due to medical therapy appointments, [employee] needs a flexible schedule for six weeks).</p>

<p>To be most helpful, the medical documentation should address the actual job functions which an accommodation can enable you to perform, as well as those job functions which you cannot perform. In the latter case, the reasonable accommodation being requested is "job restructuring"; that is, assigning a job function to another employee or job classification. </p>

<p>The ADA calls for the process of designing a reasonable accommodation to be interactive. That means that you, the employee, are included in the process. You may also involve an advocate such as a union representative or a vocational rehabilitation counselor in these discussions.</p>

<p>The employer should come prepared with a description of your job functions or duties. You should be prepared to discuss your limitations (e.g., can't work early in the morning due to medication, inability to travel as frequently as before, prefer not to deal with the public). </p>

<p>Also, if either you or the employer is not sure how to proceed in designing the reasonable accommodation, or if there is a dispute about the reasonable accommodation, consider having the session mediated by a skilled neutral mediator with ADA and/or AIDS expertise. </p>

<p>Once you and your employer agree on what the job functions are and on what your limitations are, you can work together to identify potential accommodations which would be effective in enabling you to do your job.</p>

<p>The employer should consider your preference, but is free to select any reasonable accommodation, as long as it is effective.</p>

<p><b>It's an on-going process ...</b><br>
The process of disclosing at the workplace starts before you disclose and continues after the disclosure. Lay the groundwork for your disclosure by seeing that there is a culture of equal access at your workplace. This starts with developing relationships with people who have other disabilities, and continues as you develop allies at the workplace and at your union if you have one. Find the most effective way to suggest that the company provide training and other ways of enlightening co-workers and supervisory staff. A reasonable accommodation will be most effective if you feel comfortable and if the work environment is accepting. In most cases, you can play an active role in making this happen.</p>

<p><b>Mediating Reasonable Accommodations for Employees with AIDS</b><br>
In mediation, a neutral person -- the mediator -- functions not as judge, but as a facilitator. She hears both parties' presentations of the facts and background, and she guides them in a process toward resolving the dispute.</p>

<p>The mediated agreement is based on the facts of the particular case. Each situation is unique in terms of the work place, the employee and his health status, the job in question, the supervisor's attitude, relationship with co-workers, etc.</p>

<p>The mediator does not impose a solution; she assists the parties in collaborating in the design of their own solution. Because the parties agree to resolve their disagreement by working together, the process helps preserve the relationship, and helps the parties establish a productive method for working out future issues that may arise.</p>

<p>In a recent case, an employee with AIDS needed reasonable accommodations to be able to do his job. Through a mediator, the employee conveyed that dealing with clients was exhausting him; he wanted his job restricted to paperwork. He also asked for a loosening of time and attendance rules. Management wanted to do the right thing, but was afraid to violate time and attendance rules and civil service job descriptions at this public agency. Partly because he was a long term-employee (and possibly because they recognized that his health would probably not permit him to work much longer), management ultimately agreed to alter his job duties so that he did paper work exclusively (a move that delighted his co-workers whose paperwork burden he lessened, and who preferred the face-to-face with clients). Management also agreed to loosen up on the time and attendance rules, so that if he couldn't work or came in late because of illness, he would not be penalized. Although these reasonable accommodations may have been permissible under the ADA, management felt uncomfortable "bending" the rules, so this agreement was not put in writing. Because of the level of trust between the parties -- enhanced no doubt by the mediation process -- a written agreement was not necessary.</p>

<p>In another case, an employee with AIDS had extra duties assigned to him by his supervisor who was not sympathetic to the fact that the extra work was affecting his health and who refused to discuss reasonable accommodations with him. Bypassing the supervisor, a conference call/"mediation session" was set up with upper management. Through this process, the employee was able to get a relocation as a reasonable accommodation, which achieved a few things: a new supervisor who was sympathetic, co-workers who happened to know this employee and that he was sick and who accepted him, a location closer to his home which lessened the travel strain, job duties in conformity with his actual job title, and an agreement that reasonable accommodations could be re-negotiated if his health deteriorated.</p>

<p>Mediation can be helpful even when a straight-forward reasonable accommodation is not the issue. If you are having trouble working due to declining health, but need to keep your job for the health benefits, a mediator may be able to negotiate a way for you to maintain your benefits. If you believe you have been discriminated against, the employer may be willing to pay a financial settlement for you to not return to work. In these cases, a mediator may use private caucuses to negotiate a solution that is acceptable to both parties.</p>

<p>Your reasonable accommodation case does not have to be a full-blown dispute in order to benefit from mediation. A mediator with expertise in this area can step in from time the request is made to keep the process on a productive track.</p>

<p><i>Judy Cohen, Executive Director of Access Resources, is a mediator, specializing in the employment regulations of the Americans with Disabilities Act. As a mediator, she is certified through the NYS Court System, and she is a member of the U.S. Department of Justice ADA mediation project. Access Resources also provides training in ADA and in Disability Awareness. </i></p>

<p><b><a name="housing">Housing</a></b><br>
<i>By K.Lowry</i></p>

<p>As we enter this election season, we hear the rhetorical refrains of politicians blaming each other for the rise in drug use, as if it were that simple. The pundits proclaim that "Just say no" created an atmosphere where drugs were not in vogue for young people. Black caucus members talk about housing, education and jobs as a panacea for substance abuse. The truth is that it is a very complicated problem that plagues all the citizens of this land, including people with AIDS. </p>

<p>Let me outline a couple of scenarios that speak to this problem. </p>

<p>A person with a recent history of substance abuse is placed in an apartment or hotel that is located in an area that is known for drug activity and crime. When she attempts to leave or enter her home, dealers with bargains and addicts looking for a fix or an easy mark meet her. Frequently others meet him who have not yet come to grips with their own addiction. When he goes to his ASO, or the corner Bodega, or has a visit from a case manager, or a home attendant, he may have to interact with drug abusing workers who still manage to do their jobs for now. How long will it before the seduction is complete? How long will it be before she enters the depths of active addiction where she may not have face the future of a life without hope? After all he did not expect to live this long, not without hope, not without any clear idea of a purpose to live.</p>

<p>These are questions that service providers and PWAs alike are asking. Who suffers if the dealers remain on the block? Clearly it is not the job of ASOs, or the cities protect its clients or citizens from the throws of addiction, or, is it. I want to be the first in our community to applaud the City for doing its part in this venue. Walk through the East Village and Alphabet City and look at the number of closed businesses with police notices on the doors. </p>

<p>What importance do we assign to those who work with tools instead of words? The focus of education in the United States is college. If a student is in a college preparatory program in secondary school, a fast track to the University, he or she can count on jobs throughout their life. Here they reward academic achievement and the ability to follow through, not excellence. Compare the wages of people who have worked as long to perfect their craft to the salaries of college graduates. We pay little attention to the people who keep the city running.</p>

<p>If the promise of the current drug therapies is realized there will be one less reason to escape to the euphoria of substance abuse. The promise will carry with it the responsibility of caring for ourselves, of giving back to the world that which we have learned. Regardless of the tales told about the problems, PWAs are among the most motivated people I know. The lessons that we learn now are survival tools of our future with the much promised "manageable AIDS." </p>

<P>Dr. Werner Rhode, a Philosophy scholar, defining mans relationship to grace and sin explained, "It's like this. Imagine it is your birthday, and everyone has gathered to celebrate. They all are having a great time, singing and dancing, all, --except you. You have taken your chair and sitting in the middle of the floor, with everyone wishing you well declare, I won't have a good time . . . I won't.'That is sin, the refusal to accept the gift of grace that is yours from birth." Whether you subscribe to a theology as fact or mythology there are lessons here.</p>

<p>Bernie Siegel told us: to take charge of our healing, of the power of love, to meditate and visualize the way we want our immune systems to respond. Lawrence LeShan told us to mobilize our immune systems by realizing dreams, relieving psychic pain, and healing our alienated souls with zest and happiness. Tullia Forlani Kidde urged us all to reach down deep inside and pull to the surface that which makes us whole, which can empower us. I insist we take a proactive, preventive approach to managing conflicts, to relieving stress. These messages remind us of our responsibility to ourselves, that hope springs from the way we respect ourselves, that healing is within our grasp. </p>

<p>So, in spite of all the problems and complaints, ASOs, the City, and countless others do what they do to make housing secure and the environment safe. Don't be caught sitting in the middle of the floor. Help yourself to a large slice of life.</p>

<p><a name="health"><b>Health</a> Care</b></p>

<p><b>Holistic Approach To Managing HIV/AIDS</b><br>
<i>George M. Carter</i></p>

<p>On August 7, I had the opportunity to see Dr. Lawrence LeShan, Tullia Forlani Kidde and Dr. Bernie Siegel at Hunter College. They were talking about the non-physical side of life. Personally, I have my own ideas about spirituality and I recognize the importance of these ideas. But I must confess. Part of me just thinks, geez, what a crock of feel-good mumbo jumbo that doesn't mean squat. That's my cynical side. And I think a little cynicism doesn't hurt. A lot of people make money hand over fist offering little more than pablum and thin hope. And Siegel is indeed one who often gets exorbitant sums of money to give his talks. This talk was practically a giveaway. And while the auditorium was nearly filled, it was hardly capacity. This was surprising. Yet, considering that many people with HIV (and their providers) need to work daily whether at a job or just to stay alive, 
in some ways it is not all that surprising after all.</p>

<p>Still, addressing the needs of the heart and the soul MUST be a part of life--whether living with HIV or not. People too often take their lives for granted, perhaps only truly recognizing their own mortality when faced with a diagnosis like HIV or cancer. And while that recognition makes nights alone painful and frightening, a whole new way of looking at your life arrives. What I liked about the presentations was that it provided some simple, hands on tools one can use to address these issues that are the very core of our individual existence.</p>

<p>While the new combinations of nukes (like AZT, 3TC, d4T, etc.) and protease inhibitors are offering new hope for many (that can afford them) they aren't the cure. At the same time, we must ALWAYS remember that HIV infection is NOT a death sentence. The chances of developing AIDS and dying too young are far too high. We have to remember that the drugs are only part of the picture. Diet and nutritional supplements are important. And a lot of the issues raised at this conference are--this is what is meant by "holistic." Addressing the needs of the body, the mind and the spirit. I raise this point because too often people say "this is the way that counts" or "just do the drugs" or what have you. This is not true! It is the balance you strike between these various approaches that is what counts.</p>

<p>Dr. LeShan started out in the 50s to address these many issues of facing mortality by people with cancer. He noted that their research had not looked at people with HIV/AIDS, but it is pretty obvious that some of the techniques he offers can be helpful. One idea was to sit down and spend some time just writing down what you want from your life. Just for you. He emphasized this wasn't meant to be an exercise in selfishness but rather a way to address the things you really want to do. Then set aside a time, perhaps every Wednesday afternoon where you pursued that activity. For me, it has been playing the violin--an activity that is fraught with difficulties and teaches me a lot about humility! But gives me a great joy. It is something that has always been meaningful to me. Each of us must seek within and find that joy in life. It could be as simple as taking a walk and enjoying the remarkable panoply of colors and sounds and smells we so very often ignore.</p>

<p>Tullia Kidde discussed her most remarkable struggle from a serious cancer diagnosis in the 70s. She movingly discussed the physical anguish, the despair and fear she went through. And how she hung on. She noted that at the time there weren't any support groups (that she knew about). Ultimately, we all undergo our struggles alone. But to the extent that we can listen to other people's experience and share our experience with others, this can empower us. Tullia had with her several men and women with HIV who told wonderful stories. Not just feel-good or delusional crap, but meaningful ways of shaping their lives.</p>

<p>Dr. Siegel is a true performance artist. He is a surgeon and talked about how medical schools train the empathy right out of you. One can understand that to feel anguish every time a patient suffers or dies would make being a doctor a living hell. But the downside is that physicians too often do not address these primary issues or worse, discount them as meaningless to health.</p>

<p>One of the exercises he offered was for you to draw a picture of yourself. Of your family. Your loved ones. A lot of information can be revealed by the pictures. To the extent that they may illuminate your 
life and help you decide what is important to you, this can be very helpful. A support group at Dr. Siegel's ECaP 300 Plaza Middlesex, Middletown, CT 06457 phone: (203) 343-5950, Fax: (203) 343-5956 may help in interpreting these pictures.</p>

<p>What does all this mean? Are these just exercises in mental masturbation? (There's my cynical side again!!) I don't think so. I think what addressing these issues does is helps us re-assess what the really important things are in life. Is sticking a needle filled with dope in my arm the way I want to live? Is living for the kids 100% of the time really that good for the kids if you lose yourself? Is that job all there is to life? Is there more to this existence then the struggle to survive? I think a lot of us avoid these questions. They sometimes can leave us adrift. But just think about what turns you on, what makes you engage in life. And follow that. It may be a false start; trust yourself. But don't confuse the struggle and frustration and effort that might be involved in realizing a dream with a bad 
choice! It's the journey that counts.</p>

<p>The next hard part is your friends and family. Dr. Siegel pointed out how very often the people closest to you, even when they may have been saying "stop smoking," or providing all kinds of sensible advice may be your biggest saboteurs. "Oh, c'mon. It's a special occasion. One little drink..." Or if you are starting to follow your dreams, they will interrupt you and not understand your making changes. People HATE change, it seems. But there are ways to firmly but gently incorporate these changes, day by day. No one ever said it would be easy. But it truly can be remarkable.</p>

<p>None of this is meant as a panacea. One of the points Siegel made was that information without inspiration doesn't go very far. We all know about using condoms for safe sex, but we must WANT to use them. Just being told to do so is not the same. Being told your diet is important doesn't mean jack until you decide that you are going to take control. And indeed, there are many studies that indicate that people who take their own life in their hands do better.</p>

<p>The scientist in me wants to quantify all of this; how much does it help? Can we assess it by quality of life measures and put numbers on it? But when it comes right down to it, that's the wrong question. The real question stands before us. As the saying has it, this isn't a dress rehearsal. Where shall you take this journey? </p>

<p>For more information: Contact: ECaP 300 Plaza Middlesex, Middletown, CT 06457, phone: (203) 343-5950, Fax: (203) 343-5956</p>

<p><b><a name="nutrit">Nutrition</a></b></p>
	
<p><b>How to Change your Eating Habits</b></p>

<p>As I wrote in last month's column, we know that nutrition education, in the form of nutrition counseling, works.  When people get accurate information about how and what to eat, they do better. I also pointed out getting that information can be troublesome, because of the problems with the nutrition business.  Using good source of information such as the Momentum AIDS Project, Gay Men's Health Crisis and <a href="../../glwd/index.html">God's Love We Deliver</a> can help a person get over that hurdle.  The next step is putting that information to work by eating properly.  The struggle to do that has two parts. One side requires a person to identify bad habits and other negative factors and cut them out.  The other side, shows the need for filling the newly created gaps with good habits.  Imagine wanting to fill a glass with orange juice.  If the glass is already filled with soda you have to empty it out, before you can add the orange juice If your morning meal consists of Twinkies, cola and cigarettes, you won't have room for oatmeal, eggs, fruit or any other nutritious foods.  Changing one's eating habits or eating style requires first of all a very strong desire .  Life itself is a serves of changes.  The point is to direct that change in order to get more positive results.</p>

<p>There are many factors that can motivate people to change their eating habits.  Moving into a new culture and wanting to become a part of it, looking better in a bathing suit, being sexier, improving athletic performance or trying to become healthier are just a few examples.  People who get diabetes, heart conditions, high blood pressure or other illnesses are often motivated to make positive changes in their eating habits in order to improve their chances of gaining control over their illnesses  HIV disease can be such a motivator. Remember, there are always choices to make.  Some will be better, others worse. </p>

<p>A strong desire to change is a great motivator, but a person needs other tools to make the changes.  These tools include enough money for food, access to good cooking facilities every day, a adequate meal program that keeps one from isolation and clear water.  If you give someone a bunch of broccoli, a bag of rice, a bag of beans, a freshly killed, organic, free range chicken and he or she doesn't have a kitchen to cook in, these good foods have less nutritional value uneaten than eating a bag of chips and a soda.  Along with kitchen facilities a stove, a sink with both hot and cold water a refrigerator and freezer and enough pats, pans, dishes and utensils the person must have good enough cooking skills to know what to do.
Having good enough cooking skills means several things.  One has to know various recipes or be able to read them in a cookbook.  Are you literate? Do you have a cookbook? Does your kitchen have the supplies necessary to complete a recipe, for example, salt, sugar, spices, oil, vinegar, onions, garlic, hot sauce, soy sauce and butter?</p>

<p>If a person can't read or doesn't have the skills or equipment to begin the change, than he or she needs  to be able to get help with both literacy and cooking skills. If one doesn't get help, frustration can kill the desire to change.</p>

<p>Low literacy, or illiteracy also interferes with a person's shopping ability. If you can't read labels you can't make the best choices.  Watching T.V. enters the picture here, since the most recognizable products, though not necessarily the best ones, will be those most easily identified in the store.  I am writing about shopping as if it were an activity, like breathing.  We all do it about the same all the time. This is not the case.  Some neighborhoods or areas are much better to shop in than others.  In poorer neighborhoods in New York City it is difficult to find fresh vegetables.  Last Year I was at a health fair in the South Bronx.  I needed a broccoli for a demonstration and I hadn't brought one.  My assumption was that I would buy one in the neighborhood so that I could tell visitors to my booth that I bought it locally.  It was a good lesson for me. I went to 8 small stores before I found one that had fresh produce.  The other 7 had no fresh or frozen vegetables.  All they had were canned vegetables-peas, carrots, corn and beans. A good supermarket was a train ride away, a ride that would add three dollars to your grocery bill if you lived in that neighborhood and needed to shop elsewhere in order to change your diet.</p>

<p>We must also remember that gender plays a role here.  In our society girls not boys are taught how to cook as a function of their growing into maturity.  As a result many men don't know how to cook and they don't have a history of cooking to draw from.  A woman may not know particular recipes, but she may remember how her mother prepared a certain dish.  Men in homosexual or heterosexual relationships may be able to relay on their partners for help with shopping and cooking while working to change their eating habits, but gay or straight single men may have to go it alone.  Women who were not taught cooking skills have similar problem to overcome.</p>

<p>The question we rarely ask when we talk about diet change is, "What do your friends and family eat?" What they eat exerts as much influence as what you eat when you want to change your eating habits.  I say this because eating is not merely talking in nutrients.  The definition of nutrition is "a source of nutrients  culturally defined". </p>

<p>The culturally defined part is what is most difficult to change.  If we could make fruits, vegetables and whole grains look and taste like Big Macs, french fries and a cake, and make sure they had all the vitamins, minerals. fibers, phytochemicals, protein and carbohydrates of the original produce, many of our education problems would be solved.  It would be difficult if not impossible for most people to eat completely differently from the people they live with.  This does not mean that you should eat alone rather than serve two kinds of meals when you eat with friends and family.  It doesn't mean that you should give up on the idea of changing your eating habits.  Except for the increase in calories, and supplements, most of the dietary changes that a person with HIV who is asymptomatic should make would be beneficial.  Everyone would benefit from an increase in green leaf and vegetables.  Cutting down on junk food and not eating on the run would be better for everyone.  Pure water is better for everyone and practicing food safety cuts down on the flulike symptoms that accompany food poisoning, especially during the warmer months.  Even though people with HIV need additional protein, the amount of protein that Americans eat exceeds even those recommendations.  Hopefully, following an HIV diet and increasing the amount of vegetables will result in a overall reduction in the amount of protein you eat, and perhaps happier healthier kidneys.  Take your friends and family on this road to better health.  It will help everyone.</p>

<p>To be realistic about these changes means that we have to face the fact that these things take time and often are not successful.  Since it is critically important for HIV infected people to make positive dietary changes and be able to learn while eating well, you should find a support network as soon as possible.  Going to congregate meal programs for people with HIV has many advantages.   The meals are prepared especially for people with HIV.  The participants exchange the latest information on many subjects, including HIV nutrition.  Very often there are nutrition counselors present who can answer questions about your eating habits.  Many of the participants have taken giant steps in how thy care for themselves and as a result are good examples.  Perhaps most important is sharing the sense of excitement and optimism about all the new information and therapies starting to develop.  Finally, you will find that change is possible and that you have taken the right path to achieve that change.</p>

<p><b><a name="recipe">Recipe</a></b>: <font color="#ff0000">Rice and Peas/Jamaican Style</b></font></p>

<font size=-1>
<p><b>Hint</b>: You can subsitute canned coconut and beans which will cut the cooking time in half. The ground coconut is used twice to retrieve enough milk to cook the rice and beans. This is discarded.</p>

<center><table border=1 width=80% cellpadding=6 colspecs="40% 60%">
<tr valign=top>
<td width="40%"><font size=-1>2 cups of  red kidney beans<br>
4 cups of long grain rice<br>
2 ham hocks, smoked<br>
3 T butter<br>
1 coconut cut and blend<br>
1/4 cup celery leaves<br>
1 carrot grated<br>
1 t thyme<br>
1 medium onion diced<br>
2 garlic cloves<br>
hot pepper to taste (omit if you an oral infection)</font></td>
<p>
<td width="60%"><font size=-1>Preparing the coconut<br> 
Blend: Put coconut in a blender or food processor with water, about &#189; a blender full. Pass the contents through a strainer and squeeze the milk out of the "trash." Put the trash in the blender and repeat the process.<br>
<br>
Soak the beans overnight. Drain them and add all the ingredients except the rice and butter.  Cook everything together in a large pot until the beans are done about hour. Remove the ham hocks. Add the rice and butter add enough coconut milk (from the trash) to cover,  boil and mix with a fork. Cover and simmer for about 45 minutes or until the rice is done.</font></td>
</table></center>

<p><b><a name="life">Lifestyles</a></b></p>

<p><b>A Mother's Diary Of Her Son's Struggle with AIDS: The Last Year - Part 2</b><br>
<i>By Anna Nimos</i></p>

<p><i>(Editorial Note: the first part of this two part article is in the <a href="9608.html#life">August Issue</a> of Consumer News.)</i></p>

<p>One of the few things Marc could eat was popsicles and we made sure he got as many as he wanted.  Whenever the nurses looked in his mouth, his tongue was always orange or purple.  Once one of the nurses mistook his purple tongue for dehydration until I explained.</p>

<p>I spent most of the day and evening with Marc during his first visit to the hospital.  I didnt know how sick Marc was but later I learned he didnt remember much about the days he spent in the hospital during his first chemo therapy session.  He was just too sick.  But two things he was completely aware of were his vitamins and other supplements recommended by the Bastier Clinic of Alternative Medicine and the amount of time he was in the hospital.</p>

<p>Dr. Abolaphia told him it would take four days to administer the chemo. However, due to tests and other things, they didnt start the chemo until late in the evening of the first day he arrived, and they had some problems with his veins collapsing, so it took an extra day before all the bags were finished.  Marc was furious about the delay.  He felt it was some scheme the hospital had to keep him longer than necessary.  He complained about this vociferously to anyone that would listen.</p>

<p>Finally, on the fifth day the bags were finished and he started check out procedures.  It was on Sunday.  The nurses went over his medications with us. Marc insisted on knowing what each pill was for and asked a lot of coherent questions.  Each pill had two names  i.e., Diazepam and Valium.  He had Compozine suppositories for nausea.  Pills to build up his system.  Little purple morphine pills for pain.  Prophylactic (Zorvirax) pills to ward off Herpes. Doxipin for sleeping and a mood elevator.  Orange capsules to soften his stool.  Pink square pills called Megace for his appetite. The check-out nurse told us what to expect.  That his immune system and red blood cells would be at their lowest in ten days to two weeks.  To expect a lot of fatigue and nausea.  Not to do anything to stress his already weak immune system  i.e., dont get chilled or over tired but try to walk a little each day.  Sleep a lot.  Eat a lot  very important to build weight back up.  Dont worry about cholesterol  eat as much fat and rich food as possible.  Marc asked about getting his teeth cleaned.  (He had an appointment in about ten days.)  The nurse advised against it.  "Let it wait." she said.  Then he mentioned it to the doctor who looked incredulous and asked why would he want to do that?  Marc said because he didnt want to loose his teeth to gum disease.  The doctor shook his head and said, "Well, at least wait until your blood work indicates that your system has recovered from the chemo."</p>

<p>Then more delays before he could check out.  It seems that a blood test they gave him that morning revealed that he had picked up a staff infection in the line they had put into the artery.  They wanted to keep him 24 more hours to give him a broad-scope antibiotic through an IV.  Marc refused and left the hospital against the supervising doctors orders.</p>

<p>Dr. Abolaphia and Dr. Panther were both out of town at seminars.  The supervising physician put him on an oral antibiotic and said if it didnt kill the staff infection in two weeks, the staff infection would kill him.</p>

<p>I agreed with the doctors that Marc should stay another 24 hours because they told me the staff infection was more likely to kill him than the cancer in the next few days.  Marc was furious at me that I had sided with the doctors.</p>

<p>He made it clear that his support team was to do just that  support him in any and all decisions he made about his health because he was in control and our job was to see that he remained in control even if it shortened the little time he had left.</p>

<p>When  we got home, he called a meeting of his care team.  He said there had been a break down in the commitment of his care team to be his advocate at all times.  He pointed to Paula who had tried to talk him into having an MRI and spinal tap that the hospital wanted him to have before I got there.  He pointed to me and said how disappointed he had been that I took the side of the doctors when he wanted to leave the hospital and they wanted him to stay.  He wanted to have each of us reaffirm our roles as advocates against the "medical establishment" he so distrusted or resign from his team.  He wanted us to assure him that we would support him if he refused certain tests or medication or treatments and keep him supplied with his alternative medicines (vitamins, herbs and marijuana for his nausea and appetite).  "I may not always make the best medical decisions, but I will be the one to make them, and when I do, I want you to support me," he said.  We all agreed that we would.</p>

<p>From this encounter it seemed that Paula, Gwen and I were leaning more towards listening to the doctors (we were the older part of the team).  Jane and Tracy were advocates against "invasive" procedures and for alternative medicine and suspicious of "the medical establishment."  The others were somewhere in the middle.  But I concluded, whatever our personal biases were regarding treatment, everyone really was 100% on Marcs side and we all understood his need for control.</p>

<p>I had no philosophical disagreement with Marcs desire to be in control of his medical treatment or his death  that was almost a family tradition didnt we all support Dads living will?</p>

<p>Marc had moved into his current apartment only weeks before I arrived and he had been too sick to unpack anything but his stereo and record collection.  With everything else in boxes, the apartment was not a comfortable place.  As soon as Marc came home, I began, under his direction, to unpack his boxes and put up his nick-knacks and pictures.  Within a week or so the apartment took on a cozy atmosphere and a reflection of who Marc was.  I let the air out of the mattress and put it away.  I slept on the couch, which was actually very comfortable.</p>

<p>I approached Marcs care with a motivation bordering on fanaticism.  The doctors had said Marc had to gain at least eight pounds before they would give him his next chemo.  My job was to feed him and make sure he took his medicine.  Between the vitamins and herbs he was taking from his alternative medicine advisors and the other medications, it was a challenge just keeping all the pills straight.  But I used every pill as an excuse to give Marc a small portion of food.  And I cooked everything I could think of that Marc had liked as a child and teenager when he was living at home  roast beef and potatoes and gravy, apple pie, macaroni and cheese, pumpkin pie with whip cream, oatmeal and raisins, home fries, bacon and eggs, muffins, waffles, pancakes, pork roast, lasagna, roast chicken and dressing, creamed hamburger on mashed potatoes, and on and on.</p>

<p>Every day brought something new to deal with.  First it was a painful ulcer in his mouth.  Nothing seemed to help and it interfered with his eating.  Fern, who was a nurse and an herbalist and part of Marcs care team, brought him various teas for the ulcer, but they didnt seem to help either.  (When I returned to Seattle a year after Marcs death, Jane told me Fern was a witch who had contacted Marc after his death and reported that he was happy but was waiting for Allison  a friend of his with AIDS  before he moved to the next level of his next journey.)</p>

<p>Marc had been having trouble with neuropathy for almost a year.  It would come and go.  After we got the mouth ulcer under control, the neuropathy started acting up again.  The sole of his left foot hurt and the pain was moving up to his shin.  Sometimes his fingers tingled.  Marc said the only treatment that had any effect on his neuropathy was acupuncture, so every Tuesday we walked up the street to the free Kang Wan acupuncture clinic.</p>

<p>It was a bare room with about fifteen portable cots and four or five acupuncturists.  Most of the cots were full, with young men waiting to be treated; some being treated; some with needles in them.  There was usually at least one person waiting for a cot.  Before giving the needles, the acupuncturist spent time talking to each one about his appetite, sleep, energy level, diarrhea, night sweats, pain and other symptoms.</p>

<p>Marc usually lucked out and got Shad; she was his favorite and you could tell  she liked him a lot.  She seemed so quiet and strong and compassionate.  Actually every one in there had a very peaceful aura about them and I always felt so peaceful sitting there waiting for Marc.</p>

<p>In addition to the acupuncture, Shad lit these charcoal sticks that looked like black crayons and moved them around near the soles of his feet.  She gave me some and showed me how to use them between visits to relieve the pain in his foot.  The acupuncture helped these symptoms, but more than that, it relaxed him and put him in a good mood.  For some reason, it put me in a good mood, too.  Marc used to say it improved the quality of his life.</p>

<p>It was common folk knowledge that Marijuana gave you the "munchies" and was good for nausea, so Marcs friends kept him supplied with "medicinal marijuana."  Marc had quit smoking marijuana for fun when he first learned he was HIV+ as part of his positive immunity program.  Now he used it for his appetite and nausea, but he didnt smoke it.  He drank a cup of Marijuana tea before meals if he wasnt feeling hungry, and I sprinkled it liberally in my spaghetti sauce and some other dishes.  My cooking, the Megace and the Marijuana, worked and Marc gained ten pounds over the next three weeks.</p>

<p>I abandoned my vegetarian life style and started eating whatever I cooked for Marc, causing me to gain ten pounds, too.</p>

<p>True to expectations, Marcs hair started to fall out  not just the hair on his head but his facial hair, his eyebrows, his chest and leg hair.  Two or three times a day I rolled a tape lint collector over his body to collect his hair.  Marcs whole body became as soft and smooth and hairless as a babys.</p>

<p>In the midst of my feeding frenzy and hair collecting came that damn dentist appointment.  Ten days after Marc left the hospital, he went to have his teeth cleaned!  The staff infection was still not under control.  I tried to convince him not to go with reason, threats, anger and tears, but nothing worked.  He was determined to do it and there was no stopping him.  He took a cab to the dentist alone and I walked the rainy streets of Seattle in a rage of tears.</p>

<p>God, I was pissed off!  I had worked so hard to build him up and now he was throwing it all away out of sheer stubbornness.  If he wasnt going to let me take care of him, then I might just as well go home.  I just could not understand why he felt so strongly about getting his teeth cleaned.  (Later he told me he did not remember his discussion about it with the doctor but I think what was really going on was a battle of wills.  I think he had to get it straight between us who was calling the shots, while he was still strong enough to fight, because later he would not be able to fight and he wanted me to carry out his wishes, even if I didnt agree with them.)</p>

<p>During my long walk in the dreary Seattle mist, I finally reached the conclusion that Marc was going to die of this terrible disease, in a few days or weeks or months and that maybe there was something more important to him than extending the time  maybe even more important than managing his pain and that was controlling what little he had control over.  I decided I would let him make the decisions and I would not fight with him again over what he decided to do in the short time he had left.</p>

<p>In spite of the teeth cleaning; in spite of leaving the hospital with the staff infection, Marc survived.  On the 14th day his blood test revealed that the staph infection was gone, but he was so anemic that they gave him a transfusion.  After that he began to feel better  good enough that the doctor felt it safe to give him a general anesthetic and do the surgery required so they could put a permanent catheter in his chest for future chemo treatments.  He went into surgery and then stayed in the hospital four more days to get his second chemo treatment.  It went well.</p>

<p>December 16th was the run-off for the union elections.  I was in a run-off for president of the Local against Tim Coward, a guy I was beginning to detest for his deceit and his unfounded personal attacks on me, but I barely focused on reports from the Local and my supporters efforts to keep on campaigning for me in my absence.  In fact, I had forgotten about the run-off until Ernie called that evening and told me I had lost.  I didnt care  at least I didnt feel anything.  When I told Marc, he surprised me by bursting
into tears and cursing my opposition and the people who voted for them.</p>

<p>I cried then too, but I wasnt crying over the elections although I wanted Marc to think I was. I was crying because I knew how much I would miss Marcs understanding, support, empathy and criticism of my involvement in the Union and other political activities. Who else but Marc would cry for me when it was not politically correct for me to cry for myself?</p>

<p>The tumor was shrinking. Much of the pain was gone. We put up a Christmas tree and Will (Marcs brother), came to spend Christmas with us.</p>

<p><b><a name="enter">Entertainment</a></b><br>
<i>By CN Staff</i></p>

<p><b><font color="#00ff00">BROOKLYN BOTANIC GARDEN</font></b><br>
<font size=-1>
The Brooklyn Botanic Garden is located at 900 Washington Avenue, open Tuesday through Sunday and easily accessible by public transportation. By public transportation. By subway take the 2 or 3 to Eastern Parkway/Brooklyn Museum or the D to Prospect Park. By bus use the B41, B47, B48 or B71. The standard adult admission (17 and over) is $3; the fee for adults (65 and over) and students with valid ID is $1.50; and the fee for children (6 to 16) is $0.50. Children (5 and under), all school groups, Community Pas holders and Garden Members are admitted free.  Every Tuesday (except holidays) the Garden is open free of charge to all. For more information, call 718-622-4433.</p>

<center><table width=90% border=1 cellpadding=6 colspecs="40% 60%">
<tr>
<td width="40%"><font size=-1>Sept. 21 - Oct. 27</font></td><td width="60%"><font size=-1>Chili Pepper Art Exhibition</font></td>
</tr><p><tr>
<td colspan=2><font size=-1>From September 21 through October 27, the Steinhardt Conservatory Gallery will be filled with bright oil painting of chili peppers by Marcy Wasserman.  More than a dozen pieces will be on display as the Garden gets ready for its 4th annual Chili Pepper Fiesta on Sunday, October 6. Hours: 10 a.m. to 5:30 p.m. until October 7. After October 7, hours are 10 a.m. to 4:30 p.m.; free with paid admission to the Garden.</font></td>
</tr><p><tr>
<td><font size=-1>October 6</font></td><td><font size=-1>Chili Pepper Fiesta</font></td>
</tr><p><tr>
<td colspan=2><font size=-1>In celebration of the Chili Peppers international appeal, the BBG will host a multi cultural Fiesta of music, dance, art and food. Fiesta events, highlighting the cultural diversity of this distinguished pepper, will make for a full day of family activities. There will be performances by Thai and Peruvian music and dance groups, and puppet show, and of course, strolling Mariachis.  And, no Fiesta would be complete without food. A variety of foods will be available for sale so you can taste the fiery impact that the chili has had on the cuisines of Mexico, South America, Thailand, China, India, the Caribbean and our own Southwest. Hours: 10 a.m. to 6 p.m.; For more details about this event, try calling out dedicated "HOT!" line at 718-622-4433, ext. 423.</font></td>
</tr><p><tr valign=top>
<td><font size=-1>October 7</font></td><td><font size=-1>Hours change
8 a.m. - 4:30 p.m. (Tues-Fri); 10 a.m. - 4:30 p.m. (Sat & Sun); Closed on Mondays.</font></td>
</tr><p><tr valign=top>
<td><font size=-1>October 19 - 27</font></td><td><font size=-1>Bonsai Exhibit</font></td>
</tr><p><tr>
<td colspan=2><font size=-1>Check out these unique trees at this special exhibition in the Gardens Steinhardt Conservatory. More than 50 specimens from local clubs will be on display. Hours; 10 a.m. to 4 p.m.; free with paid admission to the Garden.</font></td>
</tr><p><tr>
<td><font size=-1>October 20</font></td><td><font size=-1>Bonsai Tour and Symposium</font></td>
</tr><p><tr>
<td colspan=2><font size=-1>Tour of the C.V. Starr Bonsai Museum at BBG followed by a special Bonsai Symposium complete with lectures, demonstrations and tours with Chase Rosade and BBG Bonsai Curator Rober Mahler. Tour begins at 1 p.m. and Symposium begins at 2:30 p.m. free with paid admission to the Garden.</font></td>
</tr><p><tr valign=top>
<td><font size=-1>Mid-October through November</font></td><td><font size=-1>Fall Foliage</font></td>
</tr><p><tr>
<td colspan=2><font size=-1>Throughout the fall, the Brooklyn Botanic Garden is a great place to view nature at its best. The garden is ablaze with color during the fall foliage season. From deep reds, to yellows and golden browns the colors here are more magnificent than those you would need to spend hours driving to see. We are close, we are beautiful, and we are a great place at which to spend the day</font></td>
</tr><p><tr valign=top>
<td><font size=-1>Nov. 2 - Dec. 1</font></td><td><font size=-1>Leafscape Art Exhibit by Katia Peeva</font></td>
</tr><p><tr>
<td colspan=2><font size=-1>A mixed media art exhibit well timed for the season. Hours: 10 a.m. to 4 p.m.; free with paid admission to the Garden.</font></td>
</tr>
</table></center>

<p><b><a name="books">Books</a></b><br>
<i>by James B. Boskey</i></p>

<p>Moore, Christopher W., <b>The Mediation Process</b> (2d), Jossey-Bass Publishers, 350 Sansome St., San Francisco, CA 94104-9825 (450pp $29.95 1996)</p>

<p>The first edition of Chris Moores, <b>The Mediation Process</b>, has been recognized as one of the fundamental works in the field defining the nature of mediation and the manner in which it should be practiced. In this second edition, Moore has built on that solid foundation, drawing on his own and experience in mediation to further elaborate the process and to identify some best practice models that should be considered by anyone working in the field.</p>

<p>In theory, <b>The Mediation Process</b> is simply a manual on how to be an effective mediator. From that viewpoint it is one of the most effective such volumes available, providing a clear and well focused image of the mediation process including a recognition of many of the different approaches that may need to be adopted in light of variations in parties and subject matter.</p>

<p>What Moore offers, however, is in fact far more than merely just another manual. His comprehensive knowledge of the mediation and negotiation literature is reflected not only in the eighteen pages of references collected in the back of the book, but in the extensive citations that support, elaborate, and even question or provide alternative interpretations to the text. This is, then, a book for scholarship as well as one of technique, providing an understanding of the richness of the field and the range of approaches that it comprehends.</p>

<p>The layout of the book has not changed radically from the first edition. The sixteen chapters are divided into four parts. The first part defines the four parts. The first part defines the subject matter-looking at conflict management in general and providing an overview of the mediation process at work. The second part deals with the premediation and entry stages of the process, looking at initial contact between the mediator and the parties, development of mediation strategies, collection of background information, and building trust in the process and the mediator. The third section focuses on the mediation process: management of the mediation session, agenda setting, uncovering hidden issues and generation options. Finally the fourth section address the closing stages of the process: assessment of settlement options, final bargaining, and development of the formal agreement. Two final chapters deal with special problem areas and mediation ethics and standards, although the last chapter is almost moot to my mind as the questions have been so well incorporated into the general discussion.
In sum, Chris Moore has maintained his status as one of the best informed and most informative writers on mediation practice. This is a book for anyone in the field.</p>

<p><i>James B. Boskey, Professor of Law, Seton Hall Law School, is Editor of the Alternative Newsletter, The ADR Resource on Dispute Resolution.</i></p>

<p><b><a name="briefs">Consumer</a> Briefs</b><br>
<i>By CN Staff</i></p>

<p><b>Metro</b><br>
Controversy swirled around a series of fundraisers last month. The Morning Party, and annual Fire Island Pines beach dance benefit for G.M.H.C., came under fire by some in the AIDS Community who believe it has evolved into a drug-fest that promotes unsafe sex. A series of articles in the New York press stated that the agency was a target of criticism because it had failed to sever ties with the event despite being fully aware of rampant drug use. LGNY noted the irony- "an intoxicating combination of muscles, sex, drugs and alcohol with the proceeds in part-going to G.M.H.Cs Substance Abuse Counseling and Education (SUCE) program." The press coverage intensified when one party goer collapsed from an overdose on the dance floor- a dozen others were treated in the on-site medical tent. Dr. Howard Grossman, a board member, stated that G.M.H.C had distributed fliers warning of the dangers of drug use.</p>

<p>Controversy of another kind surrounds AIDS Service Centers upcoming fundraiser at Stellas Bar. Proceeds from the affair will be shared by Community Research Initiative on AIDS (CRIA). Stellas is notorious for its hustlers.</p>

<p>PWAs were asked to join in an action which was designed to disrupt President Bill Clintons birthday fundraiser at Radio City Music Hall by Housing Works and Republican hecklers.</p>

<p>The New York Public Library, with funding from the National Library of Medicine and a private donor has established permanent AIDS Information Special Projects at three branch libraries. Increased reference materials, Consumer News, additional copies of popular titles, videos and access to the Internet will be available at the Francis Martin Reginal Branch on University Avenue in the Bronx (718-295-5287), The George Bruce Branch on 125th St. in Harlem (212-6629727) and St. George Central Library on Staten Island (718-442-8560).</p>

<p>Minority Task Force on AIDS got the go-ahead to build a 25 unit family residence in Harlem. The project will be funded by a one million dollar grant from HUD. It will be built adjacent to a residence for single persons that the task force opened years ago.</p>

<p><b>STATE</b><br>
NY State health officials are generally happy with the announced Federal Governments terms under which they can move more than 3.5 million Medicaid recipients into managed care. The plan is predicted to be in place by the end of the year. Washington insists on a slower time-table for enrolling AIDS/ HIV patients into special needs plans... President Clinton has asked Congress to give an additional sixty-five million to he States to fund new treatments such as protease inhibitors. New York State may expect an extra ten million for is <a href="../../network/access/states/ny/ny.html">Aids Drug Assistance Program (ADAP)</a>.</p>

<p><b>NATION</b><br>
The Republican Convention in San Diego reprised Mary Fisher as its featured AIDS speaker. At the Democrat Convention in Chicago, Christopher Reeves spoke eloquently about research initiatives for all disabling illnesses including AIDS The cast of the Broadway smash-hit musical, RENT, entertained the delegates with its story of HIV+ bohemians in the East Village--but as with the moving Mary Fisher, this did not rate a Prime Time slot.</p>

<p>The new Welfare Reform bill will have an impact on a particularly vulnerable group of PWAs. Undocumented aliens those deemed illegal because they entered the U.S.A. without a Visa, or overstayed a Visa in many States may lose Medicaid and public assistance. Legal aliens may also lose Social Security.</p>

<p><b><a name="edit">Editorial</a></b></p>

<p><b>The conundrum of equality in legal and social status</b><br>
The Americans with Disabilities Act of 1990 (ADA) is the first comprehensive civil rights law to prohibit discrimination against people with disabilities on the basis of disability. It covers employment, all services of state and local governments privately owned and public places, publicly funded agencies, telecommunication, and transportation. The Act seeks to level the playing field by accommodating disabled people with tools to assure equality in housing, and the workplace.</p>

<p>What does equality mean for housing and social adjustment for a person with AIDS.  What kinds of accommodations are reasonable  in order to have equality. When do these become impositions or obfuscate the boundaries that define independence and individuality. Does a PWA choose a congregate housing program where, she will get the special services she requires and, emphasize her differences and stigmatize her. Or, does he enter into an independent living arrangement that facilitates his integration or mainstreams him into the community and in so doing, become insensitive to his special difference, Or, do they opt for scatter site which provides supportive services when needed, thus stigmatizing them by assigning a relationship that obligates programs, and tax dollars.. The soon to be released and published on www.aidsnyc.org for public scrutiny New York State Housing for Individuals and Families Living with HIV/AIDS, sets standards that bring to mind these questions.</p>

<p>The rights of people with AIDS (PWA) to nondiscrimination are covered by the ADA. The ADA assures you that you have a right to equal opportunity to participate in and benefit from programs, services, and activities enjoyed by others. Accommodations are made on the basis of individual need, related to the way(s) in which a person's disability substantially limits major life activities-such as caring for one's self, performing manual tasks, walking, seeing or hearing.</p>

<p>People with disabilities live in an environment in which they do not fit. The world was built, not for the disabled, but for the "normal" and does not take  into account the ability of those who are different to negotiate this environment The ADA is testament to the great conscience of America, establishing the relationships that are critical to setting and respecting boundaries and include and embrace you by distributing the burdens associated with your disabilities, throughout the community.</p>

<p><b><a name="oped">OP</a> ED</b><br>
<i>By Andrew Stern</i></p>

When I was 17 years and 10 months old, I registered to vote for the first time. You see, I just couldn't wait until my 18th birthday to know that I could play a role in the democratic process. Simply by signing my name, walking through a curtain, pulling a handle and pushing little red levers down -- I would have a voice in my government. I honestly believed that I could change the world by voting, that I was making a real difference, that my vote really mattered.</p>

<p>There have been many elections since I stepped into a voting booth for the first time. While not quite the same idealist I was those many years ago, I still consider voting to be critically important. In fact, years of fighting the AIDS epidemic has demonstrated to me that voting is an even greater imperative. Why? Because I have seen too many people I love and care about beaten down by the harsh bureaucracies of DAS and EVR. Because I have seen still others live in fear of losing the basic Medicare or Medicaid benefits which they depend upon for their survival. And because I have felt what it is like to be denied basic civil liberties by a homophobic and hate-mongering section of our society. I know that there are many people who have been so let down by the system, so disenfranchised from their government, that voting appears little more than a waste of time and energy. But I also know that if we are not a part of the solution we are most certainly a part of the problem.</p>

</p>It is a given that politicians respond to those who use the power to vote them in and out of office. The Conservative Right and so-called "Moral" Majority have shown us the powerful influence a voting block can have over our elected officials. If the AIDS community is to make a genuine difference in how our politicians respond to the epidemic, we must first acknowledge that many of the communities which AIDS has devastated are the same communities whose polling places are noticeably quiet on Election Day. As agencies, we must take to the streets and begin registering our staff, clients, volunteers and donors. We must provide candidate comparisons and teach our people how to use a voting booth. And we must store their names, addresses and phone numbers in our data bases, so that we can remind them when the polls are open and the importance of getting there. As individuals, we must accept personal responsibility by registering to vote, educating ourselves, getting to the polls, and taking our family and friends along with us.</p>

<p>This year we will be electing our President. Make no mistake -- for people living with AIDS, a Clinton Presidency will look different from a Dole Presidency, which will look different still from a Perot Presidency. But next year we will be electing our Mayor, and the year after that our Governor and one of our U.S. Senators. It is incumbent on all of us to establish goals that look well beyond this November. I challenge every eligible voter to become a part of the solution by getting to the polls on Tuesday, November 5. Next year, I challenge everyone to register one other member of our community and see to it that they get to the polls as well. And so real change begins.</p>

<b><a href="mailto:cnews@aidsnyc.org">Letters to the Editor</a></b>

<p><a name="letters">To</a> the Editor:<br>
I wanted to thank you for letting me know about the lecture and workshop given by Dr. Lawrence LeShan, Tulia Forlani Kidde and Dr. Bernie Siegel which I was fortunate to be able to attend on August 7, 1996. All three speakers were absolutely wonderful. Dr. LeShan fielded questions from the audience brilliantly and Tulia Forlani Kiddes "Meditation" was a special gift.</p>

<p>In all fairness, however, I must tell you that the highlight of the day (and perhaps the year!) was listening to Dr. Bernie Siegel. I admit that I have been a loyal fan of his since I first read "Love, Medicine and Miracles", but even this predisposition could not have prepared me for what I was to experience that day.</p>

<p>The range of emotions that surfaced during Dr. Siegels lecture included grief, sadness, anger and a profound sense of being loved. I know this may sound strange, but as he spoke I had a reverie of the joy and pain my lover of 19 years and I experienced during the struggle we shared prior to his death due to AIDS, which has yet to incapacitate me. The agony and the helplessness that resurfaced were almost intolerable, yet Dr. Siegel was able to somehow also help me rekindle the sense of relief and acceptance that washed over me when just one month before his grisly death, on what would have been our 19th anniversary, my dear Joe "forgave" me and told me he loved me. I may have remembered that moment but I had completely forgotten how important it was and how fortunate it made me feel in spite of (or maybe because of) the circumstances.</p>

<p>Please accept my personal thank you and share it with all of the presenters, and of course, particularly with Dr. Siegel. You can let him know that we have at least one thing in common, my parents love me, too, and they let me know it often.</p>

<p align=right>August 13, 1996, JK, Manhattan</p>

<p><a name="jobs"><b>Jobs</a> &amp; Job Training</b></p>

<p><b>Bereavement Counselor/Chaplain Opportunity</b><br>
BAILEY-HOLT HOUSE RESIDENCE FOR PWAS</p>

<p>A part-time bereavement counselor/chaplain is needed to provide emotional and spiritual counseling and support to residents who live at Bailey-Holt House, a 44 room congregate residence. Qualified candidates will possess strong commitment, comfort and experience with persons diverse in culture, religion, racial-ethnic background and lifestyle. Fulfillment of theological and educational requirements of candidate's faith group required. Experience of three years with a population of substance abuse, mental illness and HIV disease. Bilingual (Spanish/English) skills are preferred; clinical-pastoral education a plus. Hours of a work-17  hours a week. Salary-high teens. Please send resume by September 30th with salary history to: Bereavement Counselor/Chaplain Search,. Bailey House, Inc., 275 Seventh Avenue, 12th Floor, New York, NY 10001.</p>

<p><b>Clinical Supervisor<br>
McBurney House</b>:<br>
 To provide team leadership in assessing and developing resident's re-housing readiness, stabilization, and re-housing plans. Provide Clinical and Administrative Supervision to five re-housing specialists as the program is expanded from 50 to 75 residents. Share, with the Project , in the management of McBurney House transitional housing project. Master's in Psychology/Counseling or Masters in Social Work with three years supervisory experience in residential, or treatment with AIDS/addiction-affected populations. Well grounded in Clinical case management, group process, supervision, and organizational development. Spanish/English. Resume to: <a href="mailto:facetoface_dfjohnson@msn.com">Mr. David Johnson, Project Director</a>. McBurney YMCA, 215 West 23rd Street, New York, NY. 10011. 212/741-8330 Fax: 212/741-9515 Apply by Sept. 23rd, 1996</p>

<p><b>Health Care Coordinator<br>
McBurney House</b></br>
Supervise health services, health education, and referrals for primary health care for all residents in cooperation with the support team. Develop program initiatives that address two specific health concerns within the residential program: tuberculosis and substacnes use, misuse, and abuse. Duties: Provide an initial medical intake on all residents in the project to establish a base line and assess level of understanindg regarding HIV and other health concerns. Maintain medical records and monitro medications. Work with other staff in establishing, maintaining and referring for primary health care. Participate in weely team meetings. Initiate links ot hte community. Oversee the work of the substance abuse counselor and a recovery program. Arrange for educational presentations for staff and residents. Requirements: New York State registered Nurse. And/or experience in community medicine, public health, addiction and HIV infection/AIDS. Bi-lingual (Spanish/English) helpful. Resume to: <a href="mailto:facetoface_dfjohnson@msn.com">Mr. David Johnson</a>, Project Director. McBurney YMCA, 215 West 23rd Street, New York, NY. 10011. 212/741-8330 Fax: 212/741-9515</p>

<p><i><b>McBurney House</b> is a seventy-five person transitional housing program with supportive services for HIV infected adults.</i></p>

<hr size=2 width=50% align=center>

<p><b>Consumer News</b> can be found at: A Different Light Bookstore, AIDS Service Center of Lower Manhattan, Bellevue, Hospital Center, Beth Israel Medical Center-Comprehensive Care Center,Bronx AIDS Services, DAS Centers, Federation of Protestant Welfare Agencies, Federation of Puerto Rican Communities, Gay Activists Alliance of New Jersey, Gay Men's Health Crisis, Harlem United, The Lesbian and Gay Community Services Center, The New York Public Library, North Central Bronx Hospital Project Hospitality, The Queens Borough Public Library, South Bronx Action Group, Veterans Administration Medical Center Manhattan, and on the Internet at www.aidsnyc.org/cnews.</p>

<p align=center><a href="index.html"><img src="../gifs/sleft.gif" vspace=5><br>
<font size=-1>Consumer News index</font></a></p>

<hr size=2 width=50% align=center>

<p align=center><font size=2><a href="../index.html">Consumer News</a><br> P.O. Box
41<br> Cooper Station<br> New York, New York 10026-0041<br> Last modified:
10/13/96<br> <a href="mailto:cnews@aidsnyc.org">cnews@aidsnyc.org</a><br>
copyright &#169; 1996 Ken Lowry</p>

</body>
</html>


</DOC>
